PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Andersen, HS; Iversen, LF; Jeppesen, CB; Branner, S; Norris, K; Rasmussen, HB; Moller, KB; Moller, NPH				Andersen, HS; Iversen, LF; Jeppesen, CB; Branner, S; Norris, K; Rasmussen, HB; Moller, KB; Moller, NPH			2-(Oxalylamino)-benzoic acid is a general, competitive inhibitor of protein-tyrosine phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTENT INHIBITION; CRYSTAL-STRUCTURE; 1B; PEPTIDES; MECHANISM; DESIGN; SITE; DEPHOSPHORYLATION; ALENDRONATE; MIMETICS	Protein-tyrosine phosphatases (PTPs) are critically involved in regulation of signal transduction processes. Members of this class of enzymes are considered attractive therapeutic targets in several disease states, e.g. diabetes, cancer, and inflammation. However, most reported PTP inhibitors have been phosphorus-containing compounds, tight binding inhibitors, and/or inhibitors that covalently modify the enzymes. We therefore embarked on identifying a general, reversible, competitive PTP inhibitor that could be used as a common scaffold for lead optimization for specific PTPs, We here report the identification of 2-(oxalylamino)-benzoic acid (OBA) as a classical competitive inhibitor of several PTPs, X-ray crystallography of PTP1B complexed with OBA and related non-phosphate low molecular weight derivatives reveals that the binding mode of these molecules to a large extent mimics that of the natural substrate including hydrogen bonding to the PTP signature motif, In addition, binding of OBA to the active site of PTP1B creates a unique arrangement involving Asp(181), Lys(120), and Tyr(46). PTP inhibitors are essential tools in elucidating the biological function of specific PTPs and they may eventually be developed into selective drug candidates, The unique enzyme kinetic features and the low molecular weight of OBA makes it an ideal starting point for further optimization.	Novo Nordisk AS, Signal Transduct, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, Medchem Res 1, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, Prot Chem, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, New Lead Discovery, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, Diabet Biol, DK-2880 Bagsvaerd, Denmark	Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk	Andersen, HS (corresponding author), Novo Nordisk AS, Signal Transduct, Bldg 6A1-086,Novo Alle, DK-2880 Bagsvaerd, Denmark.	hsa@novo.dk; nphm@novo.dk		Jeppesen, Claus Bekker/0000-0003-2878-4348				Akamatsu M, 1997, BIOORGAN MED CHEM, V5, P157, DOI 10.1016/S0968-0896(96)00195-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; Beaulieu PL, 1999, J MED CHEM, V42, P1757, DOI 10.1021/jm980676t; Burke TR, 1998, BIOPOLYMERS, V47, P225, DOI 10.1002/(SICI)1097-0282(1998)47:3<225::AID-BIP3>3.0.CO;2-O; Burke TR, 1996, J MED CHEM, V39, P1021, DOI 10.1021/jm950621g; Burke TR, 1996, BIOCHEMISTRY-US, V35, P15989, DOI 10.1021/bi961256d; Burke TR, 1998, TETRAHEDRON, V54, P9981, DOI 10.1016/S0040-4020(98)00590-0; BURKE TR, 1994, BIOCHEM BIOPH RES CO, V204, P129, DOI 10.1006/bbrc.1994.2435; CHEN L, 1995, BIOCHEM BIOPH RES CO, V216, P976, DOI 10.1006/bbrc.1995.2716; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; Desmarais S, 1998, ARCH BIOCHEM BIOPHYS, V354, P225, DOI 10.1006/abbi.1998.0691; Drake PG, 1998, MOL CELL BIOCHEM, V182, P79, DOI 10.1023/A:1006808100755; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Groves MR, 1998, BIOCHEMISTRY-US, V37, P17773, DOI 10.1021/bi9816958; HIRIYANNA KT, 1995, EXP CELL RES, V216, P21, DOI 10.1006/excr.1995.1003; HIRIYANNA KT, 1994, ANAL BIOCHEM, V223, P51, DOI 10.1006/abio.1994.1545; HOPPE E, 1994, EUR J BIOCHEM, V223, P1069, DOI 10.1111/j.1432-1033.1994.tb19085.x; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Kole HK, 1996, J BIOL CHEM, V271, P14302, DOI 10.1074/jbc.271.24.14302; KOLE HK, 1995, BIOCHEM BIOPH RES CO, V209, P817, DOI 10.1006/bbrc.1995.1573; KOLE HK, 1995, BIOCHEM J, V311, P1025, DOI 10.1042/bj3111025; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LIOTTA AS, 1994, J BIOL CHEM, V269, P22996; Murakami H, 1997, BONE, V20, P399, DOI 10.1016/S8756-3282(97)00025-2; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; POSNER BI, 1994, J BIOL CHEM, V269, P4596; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P3068, DOI 10.1073/pnas.93.7.3068; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; Showalter HDH, 1996, J ORG CHEM, V61, P1155, DOI 10.1021/jo951790b; Skorey K, 1997, J BIOL CHEM, V272, P22472, DOI 10.1074/jbc.272.36.22472; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Taing M, 1999, BIOCHEMISTRY-US, V38, P3793, DOI 10.1021/bi9813781; Yao ZJ, 1998, BIOORGAN MED CHEM, V6, P1799, DOI 10.1016/S0968-0896(98)00140-0; Zhang ZY, 1997, CURR TOP CELL REGUL, V35, P21, DOI 10.1016/S0070-2137(97)80002-7; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624	42	127	138	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7101	7108		10.1074/jbc.275.10.7101	http://dx.doi.org/10.1074/jbc.275.10.7101			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702277	hybrid			2022-12-27	WOS:000085809600057
J	Kwan, HY; Huang, Y; Yao, XQ				Kwan, HY; Huang, Y; Yao, XQ			Store-operated calcium entry in vascular endothelial cells is inhibited by cGMP via a protein kinase G-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CA2+ ENTRY; INTRACELLULAR CALCIUM; ENDOPLASMIC-RETICULUM; SMOOTH-MUSCLE; DEPLETION; INFLUX; CHANNELS; THAPSIGARGIN; PROSTACYCLIN; ACTIVATION	Store-operated Ca2+ entry in vascular endothelial cells not only serves to refill the intracellular Ca2+ stores, but also acts to stimulate the synthesis of nitric oxide, a key vasodilatory factor. In this study, we examined the role of cGMP in regulating the store-operated Ca2+ entry in aortic endothelial cells. Cyclopiazonic acid (CPA) and thapsigargin, two selective inhibitors of endoplasmic reticulum Ca2+-ATPase, were used to induce store-operated Ca2+ entry. 8-Bromo-cGMP, an activator of protein kinase G, inhibited the CPA- or thapsigargin-induced Ca2+ entry in a concentration-dependent manner. An inhibitor of protein kinase G, KT5823 (1 mu M) or H-8 (10 mu M), abolished the inhibitory action of 8-bromo-cGMP and resumed Ca2+ entry. Addition of S-nitroso-N-acetylpenicillamine (a nitric oxide donor) or dipyridamole (a cGMP phosphodiesterase inhibitor) during CPA treatment elevated cellular cGMP levels, stimulated protein kinase G activity, and at the same time reduced Ca2+ influx due to CPA. Patch clamp study confirmed the existence of a CPA-activated Ca2+- permeable channel sensitive to cGMP inhibition. These results suggest that cGMP via a protein kinase G-dependent mechanism may play a key role in the regulation of the store-operated Ca2+ entry in vascular endothelial cells.	Chinese Univ Hong Kong, Fac Med, Dept Physiol, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong	Yao, XQ (corresponding author), Chinese Univ Hong Kong, Fac Med, Dept Physiol, Shatin, Hong Kong, Peoples R China.		Yao, Xiaoqiang/I-5413-2016; Huang, Yu/K-2866-2017	Yao, Xiaoqiang/0000-0002-0687-8186; Huang, Yu/0000-0002-1277-6784; KWAN, Hiu Yee/0000-0002-6088-7323				ADAMS DJ, 1989, FASEB J, V3, P2389, DOI 10.1096/fasebj.3.12.2477294; BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BALLIGAD JL, 1997, ARTERIOSCLER THROMB, V17, P1845; BEEBE SJ, 1986, ENZYMES, V17, P43; Bian XP, 1996, CELL CALCIUM, V19, P351, DOI 10.1016/S0143-4160(96)90075-5; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BISCHOF G, 1995, CELL CALCIUM, V17, P250, DOI 10.1016/0143-4160(95)90071-3; CABELLO OA, 1993, BIOCHEM J, V295, P357, DOI 10.1042/bj2950357; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FISCUS RR, 1984, BIOCHIM BIOPHYS ACTA, V805, P382, DOI 10.1016/0167-4889(84)90022-3; FISCUS RR, 1988, METHOD ENZYMOL, V159, P150; GILON P, 1995, BIOCHEM J, V311, P645; GRIDER JR, 1993, AM J PHYSIOL, V264, pG334, DOI 10.1152/ajpgi.1993.264.2.G334; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIMMEL HM, 1993, HYPERTENSION, V21, P112, DOI 10.1161/01.HYP.21.1.112; JENNER S, 1994, BIOCHEM J, V303, P337, DOI 10.1042/bj3030337; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCKHOFF A, 1988, BRIT J PHARMACOL, V95, P189; MONCADA S, 1991, PHARMACOL REV, V43, P108; Murphy MP, 1999, BBA-BIOENERGETICS, V1411, P401, DOI 10.1016/S0005-2728(99)00029-8; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PASYK E, 1995, AM J PHYSIOL-HEART C, V268, pH138, DOI 10.1152/ajpheart.1995.268.1.H138; PEARSON JD, 1978, BIOCHEM J, V170, P265, DOI 10.1042/bj1700265; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SCHILLING WP, 1992, BIOCHEM J, V284, P521, DOI 10.1042/bj2840521; Sharma NR, 1996, AM J PHYSIOL-HEART C, V270, pH267, DOI 10.1152/ajpheart.1996.270.1.H267; SOUTHAM E, 1991, NEUROSCI LETT, V130, P107, DOI 10.1016/0304-3940(91)90239-P; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC920, DOI 10.1152/ajpcell.1994.267.4.C920; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; WEISHAAR RE, 1986, BIOCHEM PHARMACOL, V35, P787, DOI 10.1016/0006-2952(86)90247-9; WHITE DG, 1989, BRIT J PHARMACOL, V97, P683, DOI 10.1111/j.1476-5381.1989.tb12004.x; WINEGAR BD, 1991, J GEN PHYSIOL, V97, P351, DOI 10.1085/jgp.97.2.351; XU X, 1994, J BIOL CHEM, V269, P12645; Yao XQ, 1996, J CLIN INVEST, V97, P2525, DOI 10.1172/JCI118700; Yao XQ, 1999, LIFE SCI, V65, P55, DOI 10.1016/S0024-3205(99)00218-0; ZHANG H, 1994, EUR J PHARMACOL, V251, P119, DOI 10.1016/0014-2999(94)90391-3	39	82	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6758	6763		10.1074/jbc.275.10.6758	http://dx.doi.org/10.1074/jbc.275.10.6758			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702231	hybrid			2022-12-27	WOS:000085809600011
J	Muradov, KG; Artemyev, NO				Muradov, KG; Artemyev, NO			Loss of the effector function in a transducin-alpha mutant associated with Nougaret night blindness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECESSIVE RETINITIS-PIGMENTOSA; ROD CGMP PHOSPHODIESTERASE; HETEROZYGOUS MISSENSE MUTATION; GUANINE-NUCLEOTIDE-BINDING; G-PROTEIN; ADP-RIBOSYLATION; PERTUSSIS TOXIN; GTPASE ACTIVITY; RHODOPSIN GENE; BETA-SUBUNIT	A missense mutation, G38D, was found in the rod transducin a subunit (G alpha(t)) in individuals with the Nougaret form of dominant stationary night blindness. To elucidate the mechanism of Nougaret night blindness, we have examined the key functional properties of the mutant transducin, Our data show that the G38D mutation does not alter the interaction between G alpha(t) and G beta gamma(t) or activation of transducin by photoexcited rhodopsin (R*). The mutant G alpha(t) has only a modestly (similar to 2.5-fold) reduced k(cat) value for GTP hydrolysis. The GTPase activity of G alpha(t)G38D can be accelerated by photoreceptor regulator of G protein signaling, RGS9. Analysis of the G alpha(t)G38D interaction with cGMP phosphodiesterase revealed marked impairment of the mutant effector function. G alpha(t)G38D completely fails to bind the inhibitory PDE gamma subunit and activate the enzyme. Altogether, our results demonstrate a novel molecular mechanism in dominant stationary night blindness. In contrast to known forms of the disease caused by constitutive activation of the visual cascade, the Nougaret form has its origin in attenuated visual signaling due to loss of effector function by transducin G38D mutant.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Artemyev, NO (corresponding author), Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA.			Artemyev, Nikolai/0000-0002-5266-6854	NEI NIH HHS [EY-10843] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; Artemyev NO, 1997, BIOCHEMISTRY-US, V36, P4188, DOI 10.1021/bi963002y; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Baylor D, 1996, P NATL ACAD SCI USA, V93, P560, DOI 10.1073/pnas.93.2.560; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; Chen CK, 1999, P NATL ACAD SCI USA, V96, P3718, DOI 10.1073/pnas.96.7.3718; Dryja TP, 1999, INVEST OPHTH VIS SCI, V40, P1859; DRYJA TP, 1993, NAT GENET, V4, P280, DOI 10.1038/ng0793-280; DRYJA TP, 1995, P NATL ACAD SCI USA, V92, P10177, DOI 10.1073/pnas.92.22.10177; Dryja TP, 1996, NAT GENET, V13, P358, DOI 10.1038/ng0796-358; DRYJA TP, 1991, P NATL ACAD SCI USA, V88, P9370, DOI 10.1073/pnas.88.20.9370; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; GAL A, 1994, NAT GENET, V7, P64, DOI 10.1038/ng0594-64; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; HUANG SH, 1995, NAT GENET, V11, P468, DOI 10.1038/ng1295-468; KLEUSS C, 1987, J CHROMATOGR, V407, P281, DOI 10.1016/S0021-9673(01)92625-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Li QB, 1997, J BIOL CHEM, V272, P21673, DOI 10.1074/jbc.272.35.21673; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MCLAUGHLIN ME, 1995, P NATL ACAD SCI USA, V92, P3249, DOI 10.1073/pnas.92.8.3249; Natochin M, 1998, J BIOL CHEM, V273, P21808, DOI 10.1074/jbc.273.34.21808; Natochin M, 1997, J BIOL CHEM, V272, P17444, DOI 10.1074/jbc.272.28.17444; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Raw AS, 1997, BIOCHEMISTRY-US, V36, P15660, DOI 10.1021/bi971912p; Sandberg MA, 1998, ARCH OPHTHALMOL-CHIC, V116, P867, DOI 10.1001/archopht.116.7.867; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SIEVING PA, 1995, P NATL ACAD SCI USA, V92, P880, DOI 10.1073/pnas.92.3.880; Skiba NP, 1999, J BIOL CHEM, V274, P8770, DOI 10.1074/jbc.274.13.8770; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VANDOP C, 1984, J BIOL CHEM, V259, P23; WATKINS PA, 1985, J BIOL CHEM, V260, P3478; WEST RE, 1985, J BIOL CHEM, V260, P4428; Yamamoto S, 1997, NAT GENET, V15, P175, DOI 10.1038/ng0297-175; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	44	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6969	6974		10.1074/jbc.275.10.6969	http://dx.doi.org/10.1074/jbc.275.10.6969			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702259	hybrid			2022-12-27	WOS:000085809600039
J	Yan, XZ; Xue, H; Liu, HZ; Hang, J; Wong, JTF; Zhu, G				Yan, XZ; Xue, H; Liu, HZ; Hang, J; Wong, JTF; Zhu, G			NMR studies of Bacillus subtilis tRNA(Trp) hyperexpressed in Escherichia coli - Assignment of imino proton signals and determination of thermal stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; TWO-DIMENSIONAL NMR; NUCLEAR-MAGNETIC-RESONANCE; PHENYLALANINE TRANSFER-RNA; CRYSTAL-STRUCTURE; TRANSFER RNA(TRP); 3-DIMENSIONAL STRUCTURE; TRANSFER RNAFMET; RESOLUTION; ASP	N-15-Labeled Bacillus subtilis tRNA(Trp) wild type and a series of mutants were hyperexpressed in Escherichia coli and purified for NMR studies with the use of two-dimensional nuclear Overhauser effect spectroscopy (NOESY) and heteronuclear single quantum correlation (HSQC) and three-dimensional NOESY-HSQC techniques, These made possible chemical shift assignments of imino protons and determination of the thermal stability of the tRNATrp molecules. Almost all of the imino protons in the helical regions and the tertiary base pairs were assigned, except three imino protons of the AU base pairs whose peaks were not clearly observed. Several base triplets found in the crystal structure of tRNA were observed in the present study as well. These studies also revealed two components of tRNA(Trp), which could not be separated by high pressure liquid chromatography, corresponding to s(4)U and U at position 8 of the tRNA(Trp), as indicated by two different, sets of peaks for the T psi C and D arms. The modification at position 8 altered the local conformation of the core region of the tRNA Thermal unfolding experiments showed that the unfolding process is cooperative in the presence of a high concentration of magnesium ions and that the component corresponding to the s(4)U8 is more stable than the U8 component, thus providing evidence that the thiolation of U8 stabilizes the tertiary structure of tRNA.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Zhu, G (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.	gzhu@ust.hk		Wong, J. Tze-Fei/0000-0001-8539-8537				AMANO M, 1992, EUR J BIOCHEM, V210, P671, DOI 10.1111/j.1432-1033.1992.tb17468.x; CHOI BS, 1983, BIOCHEMISTRY-US, V25, P1529; DAVIS DR, 1986, J BIOL CHEM, V261, P3584; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; EMILSSON V, 1992, NUCLEIC ACIDS RES, V20, P4499, DOI 10.1093/nar/20.17.4499; GIEGE R, 1977, J MOL BIOL, V115, P91, DOI 10.1016/0022-2836(77)90248-0; GRIFFEY RH, 1983, P NATL ACAD SCI-BIOL, V80, P5895, DOI 10.1073/pnas.80.19.5895; GRIFFEY RH, 1986, J BIOL CHEM, V261, P2074; GRIFFEY RH, 1985, J BIOL CHEM, V260, P9734; HARE DR, 1985, BIOCHEMISTRY-US, V24, P4300, DOI 10.1021/bi00337a008; HARE DR, 1982, BIOCHEMISTRY-US, V21, P5129, DOI 10.1021/bi00264a004; HOLLEY RW, 1965, SCIENCE, V147, P1462, DOI 10.1126/science.147.3664.1462; IKEMURA T, 1985, MOL BIOL EVOL, V2, P13; JOHNSTON PD, 1978, NUCLEIC ACIDS RES, V5, P3913, DOI 10.1093/nar/5.10.3913; KAN LS, 1977, BIOCHEMISTRY-US, V16, P3143, DOI 10.1021/bi00633a017; KASTRUP RV, 1975, BIOCHEMISTRY-US, V14, P3612, DOI 10.1021/bi00687a015; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KIM SH, 1973, SCIENCE, V179, P285, DOI 10.1126/science.179.4070.285; MATSUGI J, 1992, NUCLEIC ACIDS RES, V20, P3514, DOI 10.1093/nar/20.13.3514; MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0; NIIMI T, 1993, BIOCHIMIE, V75, P1109, DOI 10.1016/0300-9084(93)90010-P; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; REID BR, 1981, ANNU REV BIOCHEM, V50, P969, DOI 10.1146/annurev.bi.50.070181.004541; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROY S, 1982, BIOCHEMISTRY-US, V21, P6081, DOI 10.1021/bi00267a009; ROY S, 1981, NUCLEIC ACIDS RES, V9, P7073, DOI 10.1093/nar/9.24.7073; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SANCHEZ V, 1980, P NATL ACAD SCI-BIOL, V77, P5659, DOI 10.1073/pnas.77.10.5659; SCHEVITZ RW, 1979, NATURE, V278, P188, DOI 10.1038/278188a0; SCHIMMEL P, 1989, BIOCHEMISTRY-US, V28, P2747, DOI 10.1021/bi00433a001; SCHIMMEL PR, 1980, ANNU REV BIOPHYS BIO, V9, P181, DOI 10.1146/annurev.bb.09.060180.001145; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Steinberg S, 1996, RNA, V2, P84; WALLIS NG, 1995, BIOCHEMISTRY-US, V34, P7668, DOI 10.1021/bi00023a013; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; WOO NH, 1980, NATURE, V286, P346, DOI 10.1038/286346a0; XUE H, 1993, NUCLEIC ACIDS RES, V21, P2479, DOI 10.1093/nar/21.10.2479; XUE H, 1993, J CHROMATOGR-BIOMED, V613, P247, DOI 10.1016/0378-4347(93)80139-U; XUE H, 1993, J BIOL CHEM, V268, P9316; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; ZHU G, 1990, J MAGN RESON, V90, P405, DOI 10.1016/0022-2364(90)90150-8	43	10	10	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6712	6716		10.1074/jbc.275.10.6712	http://dx.doi.org/10.1074/jbc.275.10.6712			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702225	hybrid			2022-12-27	WOS:000085809600005
J	Nunomura, W; Takakuwa, Y; Parra, M; Conboy, JG; Mohandas, N				Nunomura, W; Takakuwa, Y; Parra, M; Conboy, JG; Mohandas, N			Ca2+-dependent and Ca2+-independent calmodulin binding sites in erythrocyte protein 4.1 - Implications for regulation of protein 4.1 interactions with transmembrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECTRIN-ACTIN BINDING; MEMBRANE CA2+ PUMP; PLASMA-MEMBRANE; SKELETAL PROTEIN-4.1; OPTICAL BIOSENSOR; RESONANT MIRROR; DOMAIN; PURIFICATION; MODULATION; ADDUCIN	In vitro protein binding assays identified two distinct calmodulin (CaM) binding sites within the NH2-terminal 30-kDa domain of erythrocyte protein 4.1 (4.1R): a Ca2+- independent binding site (A(264)KKLWKVCVEHHTFFRL) and a Ca2+-dependent binding site (A(181)KKLSMYGVDLHKAKDL). Synthetic peptides corresponding to these sequences bound CaM in vitro; conversely, deletion of these peptides from a 30-kDa construct reduced binding to CaM. Thus, 4.1R is a unique CaM-binding protein in that it has distinct Ca2+-dependent and Ca2+-independent high affinity CaM binding sites. CaM bound to 4.1R at a stoichiometry of 1:1 both in the presence and absence of Ca2+, implying that one CaM molecule binds to two distinct sites in the same molecule of 4.1R Interactions of 4.1R with membrane proteins such as band 3 is regulated by Ca2+ and CaM. While the intrinsic affinity of the 30-kDa domain for the cytoplasmic tail of erythrocyte membrane band 3 was not altered by elimination of one or both CaM binding sites, the ability of Cd2+/CaM to down-regulate 4.1R-band 3 interaction was abrogated by such deletions. Thus, regulation of protein 4.1 binding to membrane proteins by Ca2+ and CaM requires binding of CaM to both Ca2+-independent and Ca2+-dependent sites in protein 4.1.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Tokyo Womens Med Univ, Sch Med, Dept Biochem, Tokyo 1628666, Japan	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Tokyo Women's Medical University	Mohandas, N (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Mail Stop 74-157,1 Cyclotron Rd, Berkeley, CA 94720 USA.				NIDDK NIH HHS [DK 32094, DK 26263] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026263, P01DK032094, R37DK026263] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; An XL, 1996, J BIOL CHEM, V271, P33187, DOI 10.1074/jbc.271.52.33187; ANDERSON JP, 1987, J BIOL CHEM, V262, P6365; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; COHEN CM, 1992, SEMIN HEMATOL, V29, P244; CONBOY JG, 1991, J BIOL CHEM, V266, P8273; CONBOY JG, 1993, SEMIN HEMATOL, V30, P58; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; CUSH R, 1993, BIOSENS BIOELECTRON, V8, P347, DOI 10.1016/0956-5663(93)80073-X; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DISCHER D, 1993, J BIOL CHEM, V268, P7186; FILOTEO AG, 1992, J BIOL CHEM, V267, P11800; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GEORGE AJT, 1995, J IMMUNOL METHODS, V183, P51, DOI 10.1016/0022-1759(95)00031-5; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HUSAIN A, 1985, BIOCHEM INT, V10, P1; JONS T, 1992, EMBO J, V11, P2863, DOI 10.1002/j.1460-2075.1992.tb05354.x; KARAS M, 1987, INT J MASS SPECTRUM, V78, P58; KESSLER F, 1992, BIOCHEMISTRY-US, V31, P11785, DOI 10.1021/bi00162a016; Kuhlman PA, 1996, J BIOL CHEM, V271, P7986, DOI 10.1074/jbc.271.14.7986; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LARSEN FL, 1979, SCIENCE, V204, P306, DOI 10.1126/science.155309; LETO TL, 1984, J BIOL CHEM, V259, P4603; LOMBARDO CR, 1994, BBA-BIOMEMBRANES, V1196, P139, DOI 10.1016/0005-2736(94)00233-9; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; MISCHE SM, 1987, J CELL BIOL, V105, P2837, DOI 10.1083/jcb.105.6.2837; Nunomura W, 1997, J BIOL CHEM, V272, P30322, DOI 10.1074/jbc.272.48.30322; PARRA M, 1998, GENOMICS, V31, P145; PASTERNACK GR, 1985, J BIOL CHEM, V260, P3676; SCARAMUZZINO DA, 1993, P NATL ACAD SCI USA, V90, P3398, DOI 10.1073/pnas.90.8.3398; SCHISCHMANOFF PO, 1995, J BIOL CHEM, V270, P21243, DOI 10.1074/jbc.270.36.21243; SOBUE K, 1981, BIOCHEM BIOPH RES CO, V100, P1063, DOI 10.1016/0006-291X(81)91931-8; TAKAKUWA Y, 1988, J CLIN INVEST, V82, P394, DOI 10.1172/JCI113611; Tanaka K, 1988, RAPID COMMUN MASS SP, V2, P151, DOI [10.1002/RCM.1290020802, DOI 10.1002/RCM.1290020802, 10.1002/rcm.1290020802]; TANAKA T, 1991, J BIOL CHEM, V266, P1134; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; VOGEL HJ, 1994, BIOCHEM CELL BIOL, V72, P357, DOI 10.1139/o94-049; VORHERR T, 1992, BIOCHEMISTRY-US, V31, P8245, DOI 10.1021/bi00150a018; Walensky LD, 1999, J NEUROSCI, V19, P6457; WATTS HJ, 1994, ANAL CHEM, V66, P2465, DOI 10.1021/ac00087a010; Zhou N, 1997, BIOCHEMISTRY-US, V36, P2817, DOI 10.1021/bi9625713	43	56	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6360	6367		10.1074/jbc.275.9.6360	http://dx.doi.org/10.1074/jbc.275.9.6360			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692436	hybrid			2022-12-27	WOS:000085654400048
J	Orozco, BM; Kong, LJ; Batts, LA; Elledge, S; Hanley-Bowdoin, L				Orozco, BM; Kong, LJ; Batts, LA; Elledge, S; Hanley-Bowdoin, L			The multifunctional character of a geminivirus replication protein is reflected by its complex oligomerization properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLDEN MOSAIC-VIRUS; TRANSGENIC TOBACCO PLANTS; LEAF CURL GEMINIVIRUS; DNA-REPLICATION; REP PROTEIN; TRANSCRIPTIONAL REGULATION; TETRAMERIZATION DOMAIN; FUNCTIONAL DOMAINS; TUMOR-SUPPRESSOR; GENETIC-ANALYSIS	Tomato golden mosaic virus (TGMV), a member of the geminivirus family, encodes one essential replication protein, AL1, and recruits the rest of the DNA replication apparatus from its plant host. TGMV AL1 is an oligomeric protein that binds double-stranded DNA and catalyzes cleavage and ligation of single-stranded DNA. The oligomerization domain, which is required for DNA binding, maps to a region that displays strong sequence and structural homology to other geminivirus Rep proteins. To assess the importance of conserved residues, we generated a series of site-directed mutations and analyzed their impact on AL1 function in vitro and in vivo. Two-hybrid experiments revealed that mutation of amino acids 157-159 inhibited AL1-AL1 interactions, whereas mutations at nearby residues reduced complex stability. Changes at positions 157-159 also disrupted interaction between the full-length mutant protein and a glutathione S-transferase-AL1 oligomerization domain fusion in insect cells. The mutations had no detectable effect on oligomerization when both proteins contained full-length AL1 sequences, indicating that AL1 complexes can be stabilized by amino acids outside of the oligomerization domain. Nearly all of the oligomerization domain mutants were inhibited or severely attenuated in their ability to support AL1-directed viral DNA replication. In contrast, the same mutants were enhanced for AL1-mediated transcriptional repression. The replication-defective AL1 mutants also interfered with replication of a TGMV A DNA encoding wild type AL1, Full-length mutant AL1 was more effective in the interference assays than truncated proteins containing the oligomerization domain. Together, these results suggested that different AL1 complexes mediate viral replication and transcriptional regulation and that replication interference involves multiple domains of the AL1 protein.	N Carolina State Univ, Dept Biochem, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Orozco, BM (corresponding author), N Carolina State Univ, Dept Biochem, Box 7622, Raleigh, NC 27695 USA.			Hanley-Bowdoin, Linda/0000-0001-7999-8595				Ach RA, 1997, MOL CELL BIOL, V17, P5077, DOI 10.1128/MCB.17.9.5077; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Brunetti A, 1997, MOL PLANT MICROBE IN, V10, P571, DOI 10.1094/MPMI.1997.10.5.571; Chene P, 1999, J MOL BIOL, V288, P883, DOI 10.1006/jmbi.1999.2734; Cooper CS, 1998, VIROLOGY, V241, P312, DOI 10.1006/viro.1997.8941; DESBIEZ C, 1995, P NATL ACAD SCI USA, V92, P5640, DOI 10.1073/pnas.92.12.5640; EAGLE PA, 1994, PLANT CELL, V6, P1157, DOI 10.1105/tpc.6.8.1157; Eagle PA, 1997, J VIROL, V71, P6947, DOI 10.1128/JVI.71.9.6947-6955.1997; ELMER JS, 1988, NUCLEIC ACIDS RES, V16, P7043, DOI 10.1093/nar/16.14.7043; FONTES EPB, 1992, PLANT CELL, V4, P597, DOI 10.1105/tpc.4.5.597; FONTES EPB, 1994, J BIOL CHEM, V269, P8459; FONTES EPB, 1994, PLANT CELL, V6, P405, DOI 10.1105/tpc.6.3.405; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GEITZ D, 1992, NUCLEIC ACIDS RES, V20, P1425; Hanley-Bowdoin L, 1999, CRIT REV PLANT SCI, V18, P71, DOI 10.1016/S0735-2689(99)00383-4; HANLEYBOWDOIN L, 1990, P NATL ACAD SCI USA, V87, P1446, DOI 10.1073/pnas.87.4.1446; HANLEYBOWDOIN L, 1989, PLANT CELL, V1, P1057, DOI 10.1105/tpc.1.11.1057; Hanson SF, 1999, PHYTOPATHOLOGY, V89, P480, DOI 10.1094/PHYTO.1999.89.6.480; HANSON SF, 1995, VIROLOGY, V211, P1, DOI 10.1006/viro.1995.1373; Harlow E., 1988, ANTIBODIES LAB MANUA; Harris SF, 1999, SCIENCE, V284, P1673, DOI 10.1126/science.284.5420.1673; HEYRAUD F, 1993, EMBO J, V12, P4445, DOI 10.1002/j.1460-2075.1993.tb06130.x; HEYRAUDNITSCHKE F, 1995, NUCLEIC ACIDS RES, V23, P910, DOI 10.1093/nar/23.6.910; Horvath GV, 1998, PLANT MOL BIOL, V38, P699, DOI 10.1023/A:1006076316887; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P482; LAUFS J, 1995, P NATL ACAD SCI USA, V92, P3879, DOI 10.1073/pnas.92.9.3879; Laufs J, 1995, FEBS LETT, V377, P258, DOI 10.1016/0014-5793(95)01355-5; LAZAROWITZ SG, 1992, PLANT CELL, V4, P799, DOI 10.1105/tpc.4.7.799; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; McLure KG, 1999, EMBO J, V18, P763, DOI 10.1093/emboj/18.3.763; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAGAR S, 1995, PLANT CELL, V7, P705, DOI 10.1105/tpc.7.6.705; Noris E, 1996, VIROLOGY, V224, P130, DOI 10.1006/viro.1996.0514; Orozco BM, 1998, J BIOL CHEM, V273, P24448, DOI 10.1074/jbc.273.38.24448; Orozco BM, 1998, VIROLOGY, V242, P346, DOI 10.1006/viro.1997.9013; Orozco BM, 1996, J VIROL, V70, P148, DOI 10.1128/JVI.70.1.148-158.1996; Orozco BM, 1997, J BIOL CHEM, V272, P9840; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Ponten A, 1997, J VIROL, V71, P2591, DOI 10.1128/JVI.71.4.2591-2599.1997; Pujol A, 1997, J VIROL, V71, P7393, DOI 10.1128/JVI.71.10.7393-7403.1997; Sangare A, 1999, MOL BREEDING, V5, P95, DOI 10.1023/A:1009611403565; SAUNDERS K, 1991, NUCLEIC ACIDS RES, V19, P2325, DOI 10.1093/nar/19.9.2325; Sedman J, 1998, J VIROL, V72, P6893, DOI 10.1128/JVI.72.8.6893-6897.1998; Settlage SB, 1996, J VIROL, V70, P6790, DOI 10.1128/JVI.70.10.6790-6795.1996; Sherman F, 1986, LAB COURSE MANUAL ME; Shirra MK, 1998, J BIOL CHEM, V273, P19260, DOI 10.1074/jbc.273.30.19260; STENGER DC, 1991, P NATL ACAD SCI USA, V88, P8029, DOI 10.1073/pnas.88.18.8029; SUNTER G, 1990, VIROLOGY, V179, P69, DOI 10.1016/0042-6822(90)90275-V; SUNTER G, 1989, VIROLOGY, V170, P243, DOI 10.1016/0042-6822(89)90372-3; SUNTER G, 1989, VIROLOGY, V173, P647, DOI 10.1016/0042-6822(89)90577-1; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; Weisshart K, 1999, J VIROL, V73, P2201, DOI 10.1128/JVI.73.3.2201-2211.1999; Yasugi T, 1997, J VIROL, V71, P891, DOI 10.1128/JVI.71.2.891-899.1997	56	62	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6114	6122		10.1074/jbc.275.9.6114	http://dx.doi.org/10.1074/jbc.275.9.6114			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692401	hybrid			2022-12-27	WOS:000085654400013
J	Baneres, JL; Roquet, F; Martin, A; Parello, J				Baneres, JL; Roquet, F; Martin, A; Parello, J			A minimized human integrin alpha(5)beta(1) that retains ligand recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; AMINO-ACID-SEQUENCE; CRYSTAL-STRUCTURE DETERMINATION; DEPENDENT ADHESION SITE; PIKE 4.10 PARVALBUMIN; I-DOMAIN; HUMAN FIBRONECTIN; CATION-BINDING; STRUCTURE PREDICTION; ESCHERICHIA-COLI	Two isolated recombinant fragments from human integrin alpha(5)beta(1) encompassing the FG-GAP repeats III to VII of alpha(5) and the insertion-type domain from beta(1), respectively, are structurally well defined in solution, based on CD evidence. Divalent cation binding induces a conformational adaptation that is achieved by Ca2+ or Mg2+ (or Mn2+) with alpha(5) and only by Mg2+ (or Mn2+) with beta(1). Mn2+ bound to beta(1) is highly hydrated (similar to 3 water molecules), based on water NMR relaxation, in agreement with a metal ion-dependent adhesion site-type metal coordination. Each fragment saturated with Mg2+ (or Mn2+) binds a recombinant fibronectin ligand in an RGD-dependent manner. A conformational rearrangement is induced on the fibronectin ligand upon binding to the alpha(5), but not to the beta(1) fragment, based on CD, Ligand binding results in metal ion displacement from beta(1). Both alpha(5) and beta(1) fragments form a stable heterodimer (alpha(5)beta(1) mini-integrin) that retains ligand recognition to form a 1:1:1 ternary complex, in the presence of Mg2+, and induces a specific conformational adaptation of the fibronectin ligand, A two-site model for RGD binding to both alpha and beta integrin components is inferred from our data using low molecular weight RGD mimetics.	CNRS, UPRESA 5074, Fac Pharm, F-34060 Montpellier 2, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Baneres, JL (corresponding author), CNRS, UPRESA 5074, Fac Pharm, 15 Av Ch Flahault, F-34060 Montpellier 2, France.	baneres@pharma.univ-montp1.fr			NATIONAL CANCER INSTITUTE [P01CA028896] Funding Source: NIH RePORTER; NCI NIH HHS [5PO1CA28896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andersson M, 1997, PROTEIN SCI, V6, P1139, DOI 10.1002/pro.5560060602; AOTA S, 1994, J BIOL CHEM, V269, P24756; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; Baneres JL, 1998, J BIOL CHEM, V273, P24744, DOI 10.1074/jbc.273.38.24744; BEUGELMANSVERRIER M, 1976, TETRAHEDRON LETT, P361; BLANCUZZI Y, 1993, BIOCHEMISTRY-US, V32, P1302, DOI 10.1021/bi00056a015; BLOEMBERGEN N, 1961, J CHEM PHYS, V34, P842, DOI 10.1063/1.1731684; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; Cao ZJ, 1998, J BIOL CHEM, V273, P31670, DOI 10.1074/jbc.273.48.31670; CAVE A, 1979, BIOCHIMIE, V61, P755, DOI 10.1016/S0300-9084(79)80270-9; Cierniewski CS, 1999, J BIOL CHEM, V274, P16923, DOI 10.1074/jbc.274.24.16923; Copie V, 1998, J MOL BIOL, V277, P663; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; DAURES MF, 1977, THESIS U MONTPELLIER; DECLERCQ JP, 1991, J MOL BIOL, V220, P1017, DOI 10.1016/0022-2836(91)90369-H; DECLERCQ JP, 1988, J MOL BIOL, V202, P349, DOI 10.1016/0022-2836(88)90464-0; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; Dickeson SK, 1998, BIOCHEMISTRY-US, V37, P11280, DOI 10.1021/bi9727848; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; DWEK RA, 1973, NUCL MAGNETIC RESONA, P247; EDWARDS JG, 1988, J CELL SCI, V89, P507; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; FITZGERALD LA, 1985, J BIOL CHEM, V260, P1366; GAILIT J, 1988, J BIOL CHEM, V263, P12927; Garnier J, 1996, METHOD ENZYMOL, V266, P540; GEOURJEON P, 1993, PROTEIN ENG, V6, P383; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; Griggs DW, 1998, J BIOL CHEM, V273, P22113, DOI 10.1074/jbc.273.34.22113; GULINO D, 1992, J BIOL CHEM, V267, P1001; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAWASAKI H, 1994, PROTEIN PROFILE, V1, P343; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; Lin ECK, 1997, J BIOL CHEM, V272, P14236, DOI 10.1074/jbc.272.22.14236; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; Lombardo A, 1996, PROTEIN SCI, V5, P1934, DOI 10.1002/pro.5560050922; LOSTER K, 1995, J CHROMATOGR A, V711, P187, DOI 10.1016/0021-9673(95)00208-5; MARTIN SR, 1986, BIOCHEM J, V238, P485, DOI 10.1042/bj2380485; McKay BS, 1996, J BIOL CHEM, V271, P30544, DOI 10.1074/jbc.271.48.30544; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; Mould AP, 1998, J BIOL CHEM, V273, P25664, DOI 10.1074/jbc.273.40.25664; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; Oxvig C, 1999, P NATL ACAD SCI USA, V96, P2215, DOI 10.1073/pnas.96.5.2215; PARELLO J, 1978, FEBS LETT, V87, P191, DOI 10.1016/0014-5793(78)80329-9; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RIVAS GA, 1991, BIOCHEM J, V276, P35, DOI 10.1042/bj2760035; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SALUNKE DM, 1981, INT J PEPT PROT RES, V18, P348; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; Smith J.W., 1994, INTEGRINS MOL BIOL R, P1; SPEICHER DW, 1989, TECHNIQUES PROTEIN C, V1, P24; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; SWAIN AL, 1989, J BIOL CHEM, V264, P16620; THOMAS JO, 1989, METHOD ENZYMOL, V170, P549; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; VANDERWE.DR, 1971, FEBS LETT, V14, P333, DOI 10.1016/0014-5793(71)80294-6; Venyaminov S. Y., 1996, CIRCULAR DICHROISM C; Weber G, 1992, PROTEIN INTERACTIONS, P271; Woody RW, 1996, CIRCULAR DICHROISM C, P109; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328	77	41	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5888	5903		10.1074/jbc.275.8.5888	http://dx.doi.org/10.1074/jbc.275.8.5888			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681581	hybrid			2022-12-27	WOS:000085474500088
J	Chaillan-Huntington, C; Braslavsky, CV; Kuhlmann, J; Stewart, M				Chaillan-Huntington, C; Braslavsky, CV; Kuhlmann, J; Stewart, M			Dissecting the interactions between NTF2, RanGDP, and the nucleoporin XFXFG repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRANSPORT FACTOR-2; PORE COMPLEX; PROTEIN IMPORT; FACTOR P10; GDP-RAN; P62	We have used a range of complementary biochemical and biophysical methods to investigate the interactions between nuclear transport factor 2 (NTF2), the Ras family GTPase Ran, and XFXFG nucleoporin repeats that are crucial for nuclear trafficking. Microcalorimetry, microtiter plate binding, and fluorescence quenching in solution are all consistent with the binding constant for the NTF2-RanGDP interaction being in the 100 nM range, whereas the interaction between NTF2 and XFXFG repeat-containing nucleoporins such as Nsp1p is in the 1 mu M range. Although the accumulation of NTF2 at the nuclear envelope is enhanced by RanGDP, we show that Ran binding does not alter the affinity of NTF2 for nucleoporins nor does the binding of nucleoporins alter the affinity of NTF2 for RanGDP, These results indicate that, instead, Ran increases the binding of NTF2 to nucleoporins by another mechanism, most probably by Ran itself binding to nucleoporins and NTF2 binding to this nuclear pore-associated Ran.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	MRC Laboratory Molecular Biology; Max Planck Society	Stewart, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	ms@mrc-lmb.cam.ac.uk						Bayliss R, 1999, J MOL BIOL, V293, P579, DOI 10.1006/jmbi.1999.3166; BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.biophys.14.1.131; Berrios M, 1998, METHOD CELL BIOL, V53, P3; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; Bullock TL, 1996, J MOL BIOL, V260, P422, DOI 10.1006/jmbi.1996.0411; Clarkson WD, 1997, J MOL BIOL, V272, P716, DOI 10.1006/jmbi.1997.1255; Clarkson WD, 1996, J MOL BIOL, V263, P517, DOI 10.1006/jmbi.1996.0594; Corbett AH, 1996, J BIOL CHEM, V271, P18477, DOI 10.1074/jbc.271.31.18477; DELBOCCIO G, 1991, J BIOL CHEM, V266, P13777; Feldherr C, 1998, J CELL SCI, V111, P1889; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; GROTE M, 1995, J CELL SCI, V108, P2963; HAUGLAND RP, 1996, HDB FLUORESCENT PROB, P47; Kent HM, 1999, J MOL BIOL, V289, P565, DOI 10.1006/jmbi.1999.2775; Kent HM, 1996, J STRUCT BIOL, V116, P326, DOI 10.1006/jsbi.1996.0049; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; Paschal BM, 1997, J BIOL CHEM, V272, P21534, DOI 10.1074/jbc.272.34.21534; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Smith A, 1998, CURR BIOL, V8, P1403, DOI 10.1016/S0960-9822(98)00023-2; Stewart M, 1999, NAT STRUCT BIOL, V6, P301, DOI 10.1038/7529; Stewart M, 1998, J MOL BIOL, V277, P635, DOI 10.1006/jmbi.1997.1602; Yamada M, 1998, CURR BIOL, V8, P1339, DOI 10.1016/S0960-9822(07)00566-0; Yaseen NR, 1999, P NATL ACAD SCI USA, V96, P5516, DOI 10.1073/pnas.96.10.5516	27	59	59	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5874	5879		10.1074/jbc.275.8.5874	http://dx.doi.org/10.1074/jbc.275.8.5874			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681579	hybrid			2022-12-27	WOS:000085474500086
J	Huang, WP; Scott, SV; Kim, J; Klionsky, DJ				Huang, WP; Scott, SV; Kim, J; Klionsky, DJ			The itinerary of a vesicle component, Aut7p/Cvt5p, terminates in the yeast vacuole via the autophagy/Cvt pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TARGETING PATHWAY; SACCHAROMYCES-CEREVISIAE; AMINOPEPTIDASE-I; CYTOPLASM; MUTANTS; TRANSPORT; DELIVERY; MEMBRANE	Aminopeptidase I (API) is delivered to the yeast vacuole by one of two alternative pathways, cytoplasm to vacuole targeting (Cvt) or autophagy, depending on nutrient conditions, Genetic, morphological, and biochemical studies indicate that the two pathways share many of the same molecular components. The Cvt pathway functions during vegetative growth, while autophagy is induced during starvation. Both pathways involve the formation of cytosolic vesicles that fuse with the vacuole, In either case, the mechanism of vesicle formation is not known. Autophagic uptake displays a greater capacity for cytosolic protein sequestration. This suggests the involvement of an inducible protein(s) that allows the vesicle-forming machinery to adapt to the increased degradative needs of the cell. We have analyzed the biosynthesis of Aut7p, a protein required for both pathways. We find Aut7p expression is induced by nitrogen starvation. Aut7p is degraded by a process dependent on both proteinase A and Cvt/autophagy components. Protease accessibility assays demonstrate that Aut7p is located within vesicles in strains defective in vesicle delivery or breakdown. Finally, the aut7/cvt5 mutant accumulates precursor API at a stage prior to vesicle completion. These data suggest that Aut7p is induced during autophagy and delivered to the vacuole together with precursor API by Cvt/autophagic vesicles.	Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA	University of California System; University of California Davis	Klionsky, DJ (corresponding author), Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA.			HUANG, WEI-PANG/0000-0001-8410-6555	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053396] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53396] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; BAUM P, 1978, P NATL ACAD SCI USA, V75, P4962, DOI 10.1073/pnas.75.10.4962; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Coligan JE, 1995, CURRENT PROTOCOLS PR; Gerhardt B, 1998, J BIOL CHEM, V273, P15818, DOI 10.1074/jbc.273.25.15818; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; HARLOW E, 1999, USING ANTIBODIES LAB, P61; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kim J, 1997, J CELL BIOL, V137, P609, DOI 10.1083/jcb.137.3.609; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Klionsky DJ, 1998, J BIOL CHEM, V273, P10807, DOI 10.1074/jbc.273.18.10807; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; Matsuura A, 1997, GENE, V192, P245, DOI 10.1016/S0378-1119(97)00084-X; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; MORANO KA, 1994, J CELL SCI, V107, P2813; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; Scott SV, 1995, J CELL BIOL, V131, P1727, DOI 10.1083/jcb.131.6.1727; Scott SV, 1998, CURR OPIN CELL BIOL, V10, P523, DOI 10.1016/S0955-0674(98)80068-9; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Wurmser AE, 1998, EMBO J, V17, P4930, DOI 10.1093/emboj/17.17.4930	31	191	202	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5845	5851		10.1074/jbc.275.8.5845	http://dx.doi.org/10.1074/jbc.275.8.5845			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681575	hybrid, Green Submitted			2022-12-27	WOS:000085474500082
J	Nakamura, J; La, DK; Swenberg, JA				Nakamura, J; La, DK; Swenberg, JA			5 '-nicked apurinic/apyrimidinic sites are resistant to beta-elimination by beta-polymerase and are persistent in human cultured cells after oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE LYASE; APURINIC SITES; DNA; REPAIR; ENDONUCLEASE; EXCISION; DAMAGE; 8-OXOGUANINE; RADICALS; CLONING	Genomic DNA is continuously exposed to oxidative stress. Whereas reactive oxygen species (ROS) preferentially react with bases in DNA, free radicals also abstract hydrogen atoms from deoxyribose, resulting in the formation of apurinic/apyrimidinic (AP) sites and strand breaks. We recently reported high steady-state levels of AP sites in rat tissues and human liver DNA (Nakamura, J., and Swenberg, J. A. (1999) Cancer Res. 59, 2522-2526), These AP sites were predominantly cleaved 5' to the lesion. We hypothesized that these endogenous AP sites were derived from oxidative stress. In this investigation, AP sites induced by ROS were quantitated and characterized. A combination of H2O2 and FeSO4 induced significant numbers of AP sites in calf thymus DNA, which were predominantly cleaved 5' to the AP sites (75%) of total aldehydic AP sites). An increase in the number of 5'-AP sites was also detected in human cultured cells exposed to H2O2, and these 5'-AP sites were persistent during the post-exposure period. beta-Elimination by DNA beta-polymerase efficiently excised 5'-regular AP sites, but not 5'-AP sites, in DNA from cells exposed to H2O2. These results suggest that 5'-oxidized AP sites induced by ROS are not efficiently repaired by the mammalian short patch base excision repair pathway.	Univ N Carolina, Dept Environm Sci & Engn, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Swenberg, JA (corresponding author), Univ N Carolina, Dept Environm Sci & Engn, Chapel Hill, NC 27599 USA.	james_swenberg@unc.edu		Nakamura, Jun/0000-0002-1756-7199	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES005948] Funding Source: NIH RePORTER; NIEHS NIH HHS [P42-ES05948] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; Cadet J, 1999, MUTAT RES-FUND MOL M, V424, P9, DOI 10.1016/S0027-5107(99)00004-4; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; Henle ES, 1999, J BIOL CHEM, V274, P962, DOI 10.1074/jbc.274.2.962; Hofer T, 1998, CHEM RES TOXICOL, V11, P882, DOI 10.1021/tx980041x; Jackson AL, 1998, P NATL ACAD SCI USA, V95, P12468, DOI 10.1073/pnas.95.21.12468; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; LAFLEUR MVM, 1981, INT J RADIAT BIOL, V39, P113, DOI 10.1080/09553008114550131; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3618, DOI 10.1021/bi00769a019; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Nakamura J, 1999, CANCER RES, V59, P2522; Nakamura J, 1998, CANCER RES, V58, P222; Pogozelski WK, 1998, CHEM REV, V98, P1089, DOI 10.1021/cr960437i; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; VONSONNTAG C, 1987, CHEM BASIS RAD BIOL, P238; Xu YJ, 1998, J BIOL CHEM, V273, P28837, DOI 10.1074/jbc.273.44.28837	28	92	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5323	5328		10.1074/jbc.275.8.5323	http://dx.doi.org/10.1074/jbc.275.8.5323			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681505	hybrid, Green Published			2022-12-27	WOS:000085474500012
J	Saloheimo, A; Aro, N; Ilmen, M; Penttila, M				Saloheimo, A; Aro, N; Ilmen, M; Penttila, M			Isolation of the ace1 gene encoding a Cys(2)-His(2) transcription factor involved in regulation of activity of the cellulase promoter cbh1 of Trichoderma reesei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSOR; ZINC-FINGER PROTEIN; SACCHAROMYCES-CEREVISIAE; CELLOBIOHYDROLASE-II; ASPERGILLUS-NIGER; ENDOGLUCANASE GENE; CRYSTAL-STRUCTURE; CATALYTIC CORE; EXPRESSION; YEAST	A genetic selection method was developed for the cloning of positive-acting transcriptional regulatory genes in Saccharomyces cerevisiae. The method was applied for the isolation of activators of Trichoderma re reesei (Hypocrea jecorina) cellulase genes. Activator genes were isolated from a T. reesei expression cDNA library on the basis of the ability of their translation products to activate transcription from the full-length T. reesei cbh1 promoter coupled to the S. cerevisiae HIS3 gene and to support the growth of the yeast colonies in the absence of histidine. Among the clones obtained was the ace1 gene encoding a novel polypeptide, ACEI, that contains three zinc finger motifs of Cys(2)-His(2) type. Possible ACEI homologues were found among expressed sequence tags of Aspergillus and Neurospora. The ability of ACEI to bind to the cbh1 promoter was further confirmed in the yeast one-hybrid system. In vitro binding and gel mobility shift assays revealed several binding sites for the ACEI protein in the cbh1 promoter. Disruption of the ace1 gene in T. reesei resulted in retarded growth of the fungus on a cellulose-containing medium, on which cellulases are normally highly expressed.	VTT Biotechnol, FIN-02044 Espoo, Finland	VTT Technical Research Center Finland	Ilmen, M (corresponding author), VTT Biotechnol, Tietotie 2,POB 15000, FIN-02044 Espoo, Finland.		Penttilä, Merja E/A-4710-2013	Penttila, Merja/0000-0002-6929-1032				ADAMS TH, 1988, CELL, V54, P353, DOI 10.1016/0092-8674(88)90198-5; AHN JH, 1995, MOL GEN GENET, V246, P529, DOI 10.1007/BF00298959; BAILEY MJ, 1981, ENZYME MICROB TECH, V3, P153, DOI 10.1016/0141-0229(81)90076-4; Bohm S, 1997, NUCLEIC ACIDS RES, V25, P2464, DOI 10.1093/nar/25.12.2464; BREITWIESER W, 1993, YEAST, V9, P551, DOI 10.1002/yea.320090512; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COVITZ PA, 1991, GENE DEV, V5, P1982, DOI 10.1101/gad.5.11.1982; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DIVNE C, 1994, SCIENCE, V265, P524, DOI 10.1126/science.8036495; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HenriqueSilva F, 1996, BIOCHEM BIOPH RES CO, V228, P229, DOI 10.1006/bbrc.1996.1646; Ilmen M, 1996, MOL GEN GENET, V251, P451, DOI 10.1007/s004380050189; Ilmen M, 1997, APPL ENVIRON MICROB, V63, P1298; Ilmen M, 1996, MOL GEN GENET, V253, P303, DOI 10.1007/s004380050326; Kleywegt GJ, 1997, J MOL BIOL, V272, P383, DOI 10.1006/jmbi.1997.1243; Koivula A, 1996, PROTEIN ENG, V9, P691, DOI 10.1093/protein/9.8.691; Kubicek CP, 1998, TRICHODERMA GLIOCLAD, V1, P49; Lambert M, 1997, MOL CELL BIOL, V17, P3966, DOI 10.1128/MCB.17.7.3966; MANDELS M, 1971, APPL MICROBIOL, V21, P152, DOI 10.1128/AEM.21.1.152-154.1971; MANTYLA AL, 1992, CURR GENET, V21, P471, DOI 10.1007/BF00351657; MargollesClark E, 1997, J BIOTECHNOL, V57, P167, DOI 10.1016/S0168-1656(97)00097-7; Montenecourt B. S. ., 1979, ACS SYM SER, V181, P289, DOI DOI 10.1021/BA-1979-0181.CH014; NEVALAINEN KMH, 1978, APPL ENVIRON MICROB, V35, P11, DOI 10.1128/AEM.35.1.11-16.1978; PENTTILA M, 1987, GENE, V61, P155, DOI 10.1016/0378-1119(87)90110-7; PENTTILA ME, 1984, MOL GEN GENET, V194, P494, DOI 10.1007/BF00425564; RAEDER U, 1985, LETT APPL MICROBIOL, V1, P17, DOI 10.1111/j.1472-765X.1985.tb01479.x; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; SALOHEIMO A, 1994, MOL MICROBIOL, V13, P219, DOI 10.1111/j.1365-2958.1994.tb00417.x; Sambrook J., 2002, MOL CLONING LAB MANU; SHERMAN F, 1991, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; STALBRAND H, 1995, APPL ENVIRON MICROB, V61, P1090; STRAUSS J, 1995, FEBS LETT, V376, P103, DOI 10.1016/0014-5793(95)01255-5; SU SSY, 1993, NUCLEIC ACIDS RES, V21, P3789, DOI 10.1093/nar/21.16.3789; Takashima S, 1996, BIOSCI BIOTECH BIOCH, V60, P173, DOI 10.1271/bbb.60.173; TILBURN J, 1995, EMBO J, V14, P779, DOI 10.1002/j.1460-2075.1995.tb07056.x; van Peij NNME, 1998, MOL MICROBIOL, V27, P131, DOI 10.1046/j.1365-2958.1998.00666.x; van Peij NNME, 1998, APPL ENVIRON MICROB, V64, P3615; Zeilinger S, 1998, J BIOL CHEM, V273, P34463, DOI 10.1074/jbc.273.51.34463	41	146	174	2	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5817	5825		10.1074/jbc.275.8.5817	http://dx.doi.org/10.1074/jbc.275.8.5817			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681571	hybrid			2022-12-27	WOS:000085474500078
J	Vogel, W; Brakebusch, C; Fassler, R; Alves, F; Ruggiero, F; Pawson, T				Vogel, W; Brakebusch, C; Fassler, R; Alves, F; Ruggiero, F; Pawson, T			Discoidin domain receptor 1 is activated independently of beta(1) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASES; COLLAGEN RECEPTORS; STEM-CELLS; EXPRESSION; DIFFERENTIATION; ADHESION; BINDING; MIGRATION; MEMBERS; FAMILY	Various types of collagen have been identified as potential ligands for the two mammalian discoidin domain receptor (DDR) tyrosine kinases, DDR1 and DDR2, It is presently unclear whether collagen-induced DDR receptor activation, which occurs with very slow kinetics, involves additional proteins with kinase activity or membrane-anchored proteins serving as coreceptors. In particular, the role of the collagen-binding integrins alpha(1)beta(1) or alpha(2)beta(1) in the DDR activation process is undefined. Here, we provide three lines of evidence suggesting that DDR1 signaling is distinct from integrin activation. First we demonstrate that the enzymatic activity of DDR1 is essential for receptor tyrosine phosphorylation, Collagen-induced DDR receptor autophosphorylation can be blocked either by a dominant negative mutant or by a preparation of recombinant extracellular domain, Second, we show DDR1 signals independent of the epidermal growth factor (EGF) receptor. In cells that endogenously express both DDR1 and the EGF receptor, stimulation with EGF does not induce DDR activation. Third, we detected full DDR1 activation after collagen stimulation in cells that have been treated with blocking antibodies for alpha(2)beta(1) integrin or in cells with a targeted deletion of the beta(1) integrin gene. Finally, we show that overexpression of dominant negative DDR1 in the myoblast cell line C2C12 blocks cellular differentiation and the formation of myofibers.	Mt Sinai Hosp, Programme Mol Biol & Canc, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Lund Univ, Dept Expt Pathol, S-22185 Lund, Sweden; Univ Gottingen, Dept Hematol & Oncol, D-37075 Gottingen, Germany; CNRS, Inst Biol & Chim Prot, F-69367 Lyon, France; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Lund University; University of Gottingen; Centre National de la Recherche Scientifique (CNRS); University of Toronto	Vogel, W (corresponding author), Goethe Univ Frankfurt, Biomed Res Inst, Georg Speyer Haus,Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.	W.Vogel@em.uni-frankfurt.de	Pawson, Tony J/E-4578-2013	RUGGIERO, Florence/0000-0003-2915-5359; Brakebusch, Cord/0000-0002-9342-1634				ALVES F, 1995, ONCOGENE, V10, P609; Baumgartner S, 1998, PROTEIN SCI, V7, P1626, DOI 10.1002/pro.5560070717; Brugge JS, 1998, NAT GENET, V19, P309, DOI 10.1038/1189; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; Delacoux F, 1998, J BIOL CHEM, V273, P15069, DOI 10.1074/jbc.273.24.15069; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; Haq M, 1998, J AM SOC NEPHROL, V9, P614; Hirsch E, 1996, NATURE, V380, P171, DOI 10.1038/380171a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KEELY PJ, 1995, J CELL SCI, V108, P595; KUHN K, 1997, INTEGRIN LIGAND INTE; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; NANDAN D, 1990, J CELL BIOL, V110, P1673, DOI 10.1083/jcb.110.5.1673; Pozzi M, 1998, J CELL BIOL, V142, P587; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; SAITOH O, 1992, EXP CELL RES, V200, P70, DOI 10.1016/S0014-4827(05)80072-2; SANTORO SA, 1994, METHOD ENZYMOL, V245, P147; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schlessinger J, 1997, CELL, V91, P869, DOI 10.1016/S0092-8674(00)80477-8; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Vogel W, 1999, FASEB J, V13, pS77, DOI 10.1096/fasebj.13.9001.s77; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227	25	124	133	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5779	5784		10.1074/jbc.275.8.5779	http://dx.doi.org/10.1074/jbc.275.8.5779			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681566	hybrid			2022-12-27	WOS:000085474500073
J	Wang, ZG; Ackerman, SH				Wang, ZG; Ackerman, SH			The assembly factor Atp11p binds to the beta-subunit of the mitochondrial F-1-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MITOCHONDRIA; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SHUTTLE VECTORS; F1-ATPASE; PROTEIN; GENE; SYNTHASE; IDENTIFICATION; DISRUPTION	Atp11p is a protein of Saccharomyces cerevisiae required for the assembly of the F-1 component of the mitochondrial F1F0-ATP synthase. This study presents evidence that Atp11p binds selectively to the beta-subunit of F-1. Under conditions in which avidin-Sepharose beads specifically adsorbed biotinylated Atp11p from yeast mitochondrial extracts, the F-1 beta-subunit coprecipitated with the tagged Atp11p protein. Binding interactions between Atp11p and the entire beta-subunit of F-1 or fragments of the beta-subunit were also revealed by a yeast two-hybrid screen: Atp11p bound to a region of the nucleotide-binding domain of the beta-subunit located between Gly(114) and Leu(318). Certain elements of this sequence that would be accessible to Atp11p in the free beta-subunit make contact with adjacent alpha-subunits in the assembled enzyme. This observation suggests that the alpha-subunits may exchange for bound Atp11p during the process of F-1 assembly.	Wayne State Univ, Sch Med, Dept Surg, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Ackerman, SH (corresponding author), Wayne State Univ, Sch Med, Dept Surg, Detroit, MI 48201 USA.	sackerm@med.wayne.edu						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ACKERMAN SH, 1992, J BIOL CHEM, V267, P7386; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BOWMAN S, 1991, J BIOL CHEM, V266, P7517; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BURNS DJ, 1986, J BIOL CHEM, V261, P2066; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIRAUD MF, 1994, EUR J BIOCHEM, V222, P851, DOI 10.1111/j.1432-1033.1994.tb18932.x; GUELIN E, 1993, J BIOL CHEM, V268, P161; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miller J.H., 1972, EXPT MOL GENETICS; PAUL MF, 1994, J BIOL CHEM, V269, P26158; PENEFSKY HS, 1991, ADV ENZYMOL RELAT AR, V64, P173; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SIKORSKI RS, 1989, GENETICS, V122, P19; TAKEDA M, 1985, J BIOL CHEM, V260, P5458; TAKEDA M, 1986, J BIOL CHEM, V261, P5126; Wang ZG, 1999, FEBS LETT, V452, P305, DOI 10.1016/S0014-5793(99)00676-6; Wang ZG, 1996, J BIOL CHEM, V271, P4887; WHITE M, 1995, ARCH BIOCHEM BIOPHYS, V319, P299, DOI 10.1006/abbi.1995.1296	28	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5767	5772		10.1074/jbc.275.8.5767	http://dx.doi.org/10.1074/jbc.275.8.5767			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681564	hybrid			2022-12-27	WOS:000085474500071
J	Liu, JW; Ahlborn, TE; Briggs, MR; Kraemer, FB				Liu, JW; Ahlborn, TE; Briggs, MR; Kraemer, FB			Identification of a novel sterol-independent regulatory element in the human low density lipoprotein receptor promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOSTATIN-M; LDL RECEPTOR; HEPG2 CELLS; TRANSCRIPTIONAL ACTIVATION; GENE-TRANSCRIPTION; PROTEIN; SEQUENCE; SP1; REPRESSION; EXPRESSION	The cytokine oncostatin M (OM) activates human low density lipoprotein receptor (LDLR) gene transcription through a sterol-independent mechanism. Previous studies conducted in our laboratory have narrowed the OM-responsive element to promoter region -52 to +13, which contains the repeat 3 and two TATA-like sequences. We now identify LDLR promoter region -17 to -1 as a sterol-independent regulatory element (SIRE) that is critically involved in OM-, transcription factor CCAAT/enhancer-binding protein (C/EBP)-, and second messenger cAMP-mediated activation of LDLR transcription. The SIRE sequence overlaps the previously described TATA-like element and consists of an active C/EBP-binding site (-17 to -9) and a functional cAMP-responsive element (CRE) (-8 to -1), We demonstrate that (a) mutations within either the C/EBP or CRE site have no impact on basal or cholesterol-mediated repression of LDLR transcription, but they completely abolish OM-mediated activation of LDLR transcription; (b) replacing the repeat 3 sequence that contains the Sp1-binding site with a yeast transcription factor GAL4-binding site in the LDLR promoter construct does not affect OM inducibility, thereby demonstrating that OM induction is mediated through the SIRE sequence in conjunction with a strong activator bound to the repeat 3 sequence; (c) electrophoretic mobility shift and supershift assays confirm the specific binding of transcription factors C/EBP and cAMP-responsive element-binding protein to the SIRE; (d) cotransfection of a human C/EBP beta expression vector (pEF-NFIL6) with the LDLR promoter construct pLDLR234 increases LDLR promoter activity; and (e) OM and dibutyryl cAMP synergistically activate LDLR transcription through this regulatory element. This study identifies, for the first time, a cis-acting regulatory element in the LDLR promoter that is responsible for sterol-independent regulation of LDLR transcription.	VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA; Monsanto, St Louis, MO 63017 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Monsanto	Liu, JW (corresponding author), VA Palo Alto Hlth Care Syst, 3801 Miranda Ave, Palo Alto, CA 94304 USA.		Kraemer, Fredric/AAC-3633-2019	Kraemer, Fredric/0000-0003-2468-7807				Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; Botelho FM, 1998, J BIOL CHEM, V273, P5211, DOI 10.1074/jbc.273.9.5211; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GROVE RI, 1991, J BIOL CHEM, V266, P18194; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; LALLI E, 1994, J BIOL CHEM, V269, P17359; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; Li C, 1999, J BIOL CHEM, V274, P6747, DOI 10.1074/jbc.274.10.6747; Liu JW, 1997, J LIPID RES, V38, P2035; LIU JW, 1994, CELL GROWTH DIFFER, V5, P1333; Pak YK, 1996, J LIPID RES, V37, P985; RUDLING M, 1992, P NATL ACAD SCI USA, V89, P6983, DOI 10.1073/pnas.89.15.6983; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SMITH JR, 1990, J BIOL CHEM, V265, P2306; STOPECK AT, 1993, J BIOL CHEM, V268, P17489; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; TAKAGI T, 1988, CAN J PHYSL PHARM, V67, P968; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Wen XY, 1999, INT J ONCOL, V15, P173; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	26	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5214	5221		10.1074/jbc.275.7.5214	http://dx.doi.org/10.1074/jbc.275.7.5214			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671569	hybrid			2022-12-27	WOS:000085378200095
J	Ochiai, M; Ashida, M				Ochiai, M; Ashida, M			A pattern-recognition protein for beta-1,3-glucan - The binding domain and the cDNA cloning of beta-1,3-glucan recognition protein from the silkworm, Bombyx mori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRAYFISH PACIFASTACUS-LENIUSCULUS; MOLECULAR-CLONING; INNATE IMMUNITY; GLUCAN-BINDING; HUMORAL LECTIN; HEMOLYMPH; PURIFICATION; PROPHENOLOXIDASE; ACTIVATION; GENE	The beta-1,S-glucan recognition protein (beta GRP) has strong specific affinity for beta-1,3-glucan, a component of the fungal cell wall. Its interaction with beta-1,3-glucan initiates the activation of the prophenoloxidase cascade, which is an important defense system in invertebrates of many species. We cloned the cDNA of the beta GRP of the silkworm Bombyx mori. The beta GRP mRNA transcript was constitutively expressed in the hemocytes, fat body, and epithelial cells of the naive silkworm. At the same time, a bacterial or yeast challenge was indicated to intensify the transcription, Comparison of the deduced amino acid sequence with known sequences revealed that the beta GRP contained a region (Thr(264) to Pro(386)) displaying significant similarity to the catalytic regions of bacterial beta-1,3-glucanases and much higher similarity to the glucanase-like regions of Gram-negative bacteria-binding proteins found in the silkworm B, mori and the mosquito Anopheles gambiae, The region (Thr(264) to Pro(386)) Of the beta GRP, however, was demonstrated not to have appreciable affinity for beta-1,3-glucan. A recombinant peptide corresponding to an N-terminal region (Tyr(1) to Ala(102)) of the beta GRP bound strongly to beta-1,3-glucan. These results indicate that the binding domain of the beta GRP for beta-1,3-glucan is located in the N-terminal region. Glucanases and the current pattern-recognition proteins that contain a glucanase-like region seem to have a common origin in their molecular evolution.	Hokkaido Univ, Inst Low Temp Sci, Kita Ku, Sapporo, Hokkaido 0600819, Japan	Hokkaido University	Ochiai, M (corresponding author), Hokkaido Univ, Inst Low Temp Sci, Kita Ku, Sapporo, Hokkaido 0600819, Japan.	ochiai@orange.lowtem.hokudai.ac.jp	Ochiai, Masanori/A-4372-2012	Ochiai, Masanori/0000-0002-0022-347X				AMANAI K, 1990, COMP BIOCHEM PHYS B, V97, P471, DOI 10.1016/0305-0491(90)90146-K; ASHIDA M, 1981, INSECT BIOCHEM, V11, P57, DOI 10.1016/0020-1790(81)90041-X; Bachman ES, 1996, P NATL ACAD SCI USA, V93, P6808, DOI 10.1073/pnas.93.13.6808; BARRACCO MA, 1991, CELL TISSUE RES, V266, P491, DOI 10.1007/BF00318590; Beschin A, 1998, J BIOL CHEM, V273, P24948, DOI 10.1074/jbc.273.38.24948; BOHN H, 1984, J COMP PHYSIOL, V154, P457, DOI 10.1007/BF02515150; CHINO H, 1981, J LIPID RES, V22, P1042; COYNE KE, 1993, J BIOL CHEM, V268, P6689; DAKHOVA ON, 1993, BIOCHEM BIOPH RES CO, V194, P1359, DOI 10.1006/bbrc.1993.1974; Dimopoulos G, 1997, P NATL ACAD SCI USA, V94, P11508, DOI 10.1073/pnas.94.21.11508; DUVIC B, 1990, J BIOL CHEM, V265, P9327; HALL M, 1995, BIOCHEM BIOPH RES CO, V216, P939, DOI 10.1006/bbrc.1995.2711; HARADA T, 1968, ARCH BIOCHEM BIOPHYS, V124, P292, DOI 10.1016/0003-9861(68)90330-5; HULTMARK D, 1994, NATURE, V367, P116, DOI 10.1038/367116a0; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JOMORI T, 1991, J BIOL CHEM, V266, P13318; JUNCOSA M, 1994, J BIOL CHEM, V269, P14530; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Koizumi N, 1997, EUR J BIOCHEM, V248, P217, DOI 10.1111/j.1432-1033.1997.t01-1-00217.x; KOMANO H, 1985, DEV COMP IMMUNOL, V9, P31, DOI 10.1016/0145-305X(85)90057-6; KOTANI E, 1995, BBA-GENE STRUCT EXPR, V1260, P245, DOI 10.1016/0167-4781(94)00202-E; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee WJ, 1996, P NATL ACAD SCI USA, V93, P7888, DOI 10.1073/pnas.93.15.7888; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; MUTA T, 1995, J BIOL CHEM, V270, P892, DOI 10.1074/jbc.270.2.892; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; OCHIAI M, 1988, J BIOL CHEM, V263, P12056; OCHIAI M, 1992, CELL TISSUE RES, V268, P431, DOI 10.1007/BF00319149; PENDLAND JC, 1986, DEV COMP IMMUNOL, V10, P477, DOI 10.1016/0145-305X(86)90169-2; SCHIMMING S, 1992, EUR J BIOCHEM, V204, P13, DOI 10.1111/j.1432-1033.1992.tb16600.x; SEKI N, 1994, J BIOL CHEM, V269, P1370; SUN SC, 1990, SCIENCE, V250, P1729, DOI 10.1126/science.2270488; Wakshull E, 1999, IMMUNOPHARMACOLOGY, V41, P89, DOI 10.1016/S0162-3109(98)00059-9; WATANABE T, 1992, J BACTERIOL, V174, P186, DOI 10.1128/jb.174.1.186-190.1992; YAHATA N, 1990, GENE, V86, P113, DOI 10.1016/0378-1119(90)90122-8; YOSHIDA H, 1986, BIOCHEM BIOPH RES CO, V141, P1177, DOI 10.1016/S0006-291X(86)80168-1; YOSHIDA H, 1986, INSECT BIOCHEM, V16, P539, DOI 10.1016/0020-1790(86)90031-4; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854	41	174	189	0	16	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4995	5002		10.1074/jbc.275.7.4995	http://dx.doi.org/10.1074/jbc.275.7.4995			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671539	hybrid			2022-12-27	WOS:000085378200065
J	Wang, YX; Bjes, ES; Esser, AF				Wang, YX; Bjes, ES; Esser, AF			Molecular aspects of complement-mediated bacterial killing - Periplasmic conversion of C9 from a protoxin to a toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; MALTOSE-BINDING PROTEIN; MEMBRANE ATTACK COMPLEX; ESCHERICHIA-COLI; COMPONENT C9; FORMATION INVIVO; OUTER-MEMBRANE; SERUM; INDUCTION; CYTOPLASM	As part of the membrane attack complex complement protein C9 is responsible for direct killing of bacteria. Here we show that in the periplasmic space of an Escherichia coli cell C9 is converted from a protoxin to a toxin by periplasmic conditions missing in spheroplasts, This conversion is independent of the pathway by which C9 enters the periplasm. Both, C9 shocked into the periplasm and plasmid-expressed C9 targeted to the periplasm via a signal sequence are toxic. Toxicity re quires disulfide linked C9 because export into the periplasm of cells defective in disulfide bond synthesis (dsbA and dsbB mutants) is not toxic unless N-acetylcysteine is added externally to promote cystines, A N-terminal fragment, C9[1-144], is not toxic nor is cytoplasmically expressed C9, even in trxB mutants that are able to form disulfide bonds in the cytoplasm, Importantly, expression of full-length C9 in complement-resist ant cells has no effect on their viability. Expression and translocation into the periplasm may provide a novel model to identify molecular mechanisms of other bactericidal disulfide-linked proteins and to investigate the nature of bacterial complement resistance.	Univ Missouri, Sch Biol Sci, Div Cell Biol & Biophys, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Esser, AF (corresponding author), Univ Missouri, Sch Biol Sci, Div Cell Biol & Biophys, Kansas City, MO 64110 USA.	essera@umkc.edu			NIAID NIH HHS [AI19478] Funding Source: Medline; NIGMS NIH HHS [GM53748] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019478] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053748] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; Betton JM, 1996, J MOL BIOL, V262, P140, DOI 10.1006/jmbi.1996.0504; BHAKDI S, 1987, INFECT IMMUN, V55, P206, DOI 10.1128/IAI.55.1.206-210.1987; Carroll MC, 1998, ANNU REV IMMUNOL, V16, P545, DOI 10.1146/annurev.immunol.16.1.545; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; DANKERT JR, 1987, BIOCHEM J, V244, P393, DOI 10.1042/bj2440393; DANKERT JR, 1985, P NATL ACAD SCI USA, V82, P2128, DOI 10.1073/pnas.82.7.2128; DANKERT JR, 1986, BIOCHEMISTRY-US, V25, P1094, DOI 10.1021/bi00353a023; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; ESSER AF, 1988, METHOD ENZYMOL, V162, P551; ESSER AF, 1994, TOXICOLOGY, V87, P229, DOI 10.1016/0300-483X(94)90253-4; Gu X, 1996, J IMMUNOL METHODS, V189, P37, DOI 10.1016/0022-1759(95)00225-1; GUAN LT, 1980, INFECT IMMUN, V28, P387; JANDER G, 1994, EMBO J, V13, P5121, DOI 10.1002/j.1460-2075.1994.tb06841.x; JASKULA JC, 1994, J BACTERIOL, V176, P2326, DOI 10.1128/JB.176.8.2326-2338.1994; JOINER KA, 1988, ANNU REV MICROBIOL, V42, P201, DOI 10.1146/annurev.mi.42.100188.001221; KUBENS BS, 1988, ZBL BAKT-INT J MED M, V270, P52; LAINE RO, 1989, NATURE, V341, P63, DOI 10.1038/341063a0; LASSITER HA, 1994, PEDIATR RES, V35, P389, DOI 10.1203/00006450-199404000-00002; Lengweiler S, 1996, FEBS LETT, V380, P8, DOI 10.1016/0014-5793(95)01541-8; LEVENGOODFREYERMUTH SK, 1993, J BACTERIOL, V175, P222, DOI 10.1128/JB.175.1.222-228.1993; MACKAY SLD, 1990, J IMMUNOL, V145, P3367; MARTIN JL, 1993, J MOL BIOL, V230, P1097, DOI 10.1006/jmbi.1993.1226; MARVIN HJP, 1987, ANAL BIOCHEM, V164, P320, DOI 10.1016/0003-2697(87)90500-8; Rietsch A, 1998, ANNU REV GENET, V32, P163, DOI 10.1146/annurev.genet.32.1.163; Schneider EL, 1997, NAT BIOTECHNOL, V15, P581, DOI 10.1038/nbt0697-581; Stroud RM, 1998, CURR OPIN STRUC BIOL, V8, P525, DOI 10.1016/S0959-440X(98)80132-2; TAYLOR PW, 1995, VIRULENCE MECHANISMS OF BACTERIAL PATHOGENS, 2ND EDITION, P49; TAYLOR PW, 1983, INFECT IMMUN, V39, P122, DOI 10.1128/IAI.39.1.122-131.1983; THOM JR, 1988, J BACTERIOL, V170, P5654, DOI 10.1128/jb.170.12.5654-5661.1988; TOMLINSON S, 1990, BIOCHEMISTRY-US, V29, P1852, DOI 10.1021/bi00459a027; TOMLINSON S, 1993, CURR OPIN IMMUNOL, V5, P83, DOI 10.1016/0952-7915(93)90085-7; TOMLINSON S, 1995, J IMMUNOL, V155, P436; WRIGHT SD, 1981, J IMMUNOL, V127, P1146; WUNDERLICH M, 1993, J BIOL CHEM, V268, P24547	35	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4687	4692		10.1074/jbc.275.7.4687	http://dx.doi.org/10.1074/jbc.275.7.4687			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671498	hybrid			2022-12-27	WOS:000085378200024
J	Taylor, GA; Hudson, E; Resau, JH; Vande Woude, GF				Taylor, GA; Hudson, E; Resau, JH; Vande Woude, GF			Regulation of P311 expression by Met-hepatocyte growth factor/scatter factor and the ubiquitin/proteasome system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMORIGENICITY; PROTOONCOGENE; CELLS; PROTEASOME; METASTASIS; RNA	P311 is a mouse cDNA originally identified for its high expression in late-stage embryonic brain and adult cer ebellum, hippocampus, and olfactory bulb. The protein product of P311, however, had not been identified previously, and its function remains unknown. We report here that P311 expression is regulated at multiple levels by pathways that control cellular transformation. P311 mRNA expression was decreased sharply in both neural and smooth muscle cells when the cells were transformed by coexpression of the oncogenic tyrosine kinase receptor Met and its ligand hepatocyte growth factor/scatter factor. The P311 mRNA was found to encode an 8-kDa polypeptide that was subject to rapid degradation by the lactacystin-sensitive ubiquitin/proteasome system and an unidentified metalloprotease, resulting in a protein half-life of about 5 min. These data suggest that P311 expression is dramatically decreased by several pathways that regulate cellular growth.	Adv Biosci Labs, Basic Res Program, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Vande Woude, GF (corresponding author), Van Andel Res Inst, 201 Monroe Ave NW,Suite 400, Grand Rapids, MI 49503 USA.				NCI NIH HHS [N01-CO-46000] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO046000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; Dick LR, 1997, J BIOL CHEM, V272, P182; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Koochekpour S, 1997, CANCER RES, V57, P5391; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Laterra J, 1997, LAB INVEST, V76, P565; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RONNETT GV, 1994, NEUROSCIENCE, V63, P1081, DOI 10.1016/0306-4522(94)90574-6; SAITOH K, 1994, J PATHOL, V174, P191, DOI 10.1002/path.1711740308; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; STUDLER JM, 1993, EUR J NEUROSCI, V5, P614, DOI 10.1111/j.1460-9568.1993.tb00527.x; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; Taylor GA, 1996, J BIOL CHEM, V271, P20399, DOI 10.1074/jbc.271.34.20399; Taylor GA, 1998, ONCOGENE, V17, P1179, DOI 10.1038/sj.onc.1202004; TSO J, 1986, NUCLEIC ACIDS RES, V13, P2485; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5	23	30	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4215	4219		10.1074/jbc.275.6.4215	http://dx.doi.org/10.1074/jbc.275.6.4215			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660586	hybrid			2022-12-27	WOS:000085288800070
J	Wang, F; Chen, LF; Arcucci, O; Harvey, EV; Bowers, B; Xu, YH; Hammer, JA; Sellers, JR				Wang, F; Chen, LF; Arcucci, O; Harvey, EV; Bowers, B; Xu, YH; Hammer, JA; Sellers, JR			Effect of ADP and ionic strength on the kinetic and motile properties of recombinant mouse myosin V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOSOME DISTRIBUTION; UNCONVENTIONAL MYOSIN; SMOOTH-MUSCLE; MOTOR PROTEIN; LIGHT-CHAIN; GENE; MELANOCYTES; DOMAIN; ACTIN; TRANSPORT	Mouse myosin V is a two-headed unconventional myosin with an extended neck that binds six calmodulins. Double-headed (heavy meromyosin-like) and single-headed (subfragment 1-like) fragments of mouse myosin V were expressed in Sf9 cells, and intact myosin V was purified from mouse brain. The actin-activated MgATPase of the tissue-purified myosin V, and its expressed fragments had a high V-max and a low K-ATPase. Calcium regulated the MgATPase of intact myosin V but not of the fragments, Both the MgATPase activity and the in vitro motility were remarkably insensitive to ionic strength. Myosin V and its fragments translocated actin at very:low myosin surface densities. ADP markedly inhibited the actin-activated MgATPase activity and the in vitro motility, ADP dissociated from myosin V subfragment 1 at a rate of about 11.5 s(-1) under conditions where the V-max was 3.3 s(-1), indicating that, although not totally rate-limiting, ADP dissociation was close to the Fate-limiting step. The high affinity for actin and the slow rate of ADP release helps the myosin head to re main attached to actin for a large fraction of each ATPase cycle and allows actin filaments to be moved by only a few myosin V molecules in vitro.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Core Microscopy Facil, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Sellers, JR (corresponding author), NHLBI, Mol Cardiol Lab, NIH, 10 Ctr Dr,Bldg 10,Rm 8N202, Bethesda, MD 20892 USA.	jsellers@helix.nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL004229, ZIAHL004229] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benashski SE, 1997, J BIOL CHEM, V272, P20929, DOI 10.1074/jbc.272.33.20929; Bonafe N, 1998, J MUSCLE RES CELL M, V19, P129, DOI 10.1023/A:1005356511634; Cheney RE, 1998, METHOD ENZYMOL, V298, P3, DOI 10.1016/S0076-6879(98)98003-X; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; Coluccio LR, 1999, J BIOL CHEM, V274, P21575, DOI 10.1074/jbc.274.31.21575; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; ENGLE LJ, 1994, GENOMICS, V19, P407, DOI 10.1006/geno.1994.1088; ESPINDOLA FS, 1996, MOL BIOL CELL, V7, P372; HAARER BK, 1994, J CELL SCI, V107, P1055; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; LASH JA, 1990, NUCLEIC ACIDS RES, V18, P7176, DOI 10.1093/nar/18.23.7176; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Nascimento AAC, 1996, J BIOL CHEM, V271, P17561, DOI 10.1074/jbc.271.29.17561; Pastural E, 1997, NAT GENET, V16, P289, DOI 10.1038/ng0797-289; Pato MD, 1996, J BIOL CHEM, V271, P2689, DOI 10.1074/jbc.271.5.2689; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; Prekeris R, 1997, J CELL BIOL, V137, P1589, DOI 10.1083/jcb.137.7.1589; Provance DW, 1996, P NATL ACAD SCI USA, V93, P14554, DOI 10.1073/pnas.93.25.14554; RITCHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619, DOI 10.1073/pnas.90.18.8619; Sellers J. R., 1999, MYOSINS; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; UBER A, 1980, J ULTRASTRUCT RES, V71, P95; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; Wei Q., 1996, Molecular Biology of the Cell, V7, p226A; Wei Q, 1997, J MUSCLE RES CELL M, V18, P517, DOI 10.1023/A:1018659117569; Wu X, 1998, J CELL BIOL, V143, P241, DOI 10.1083/jcb.143.1.241; Wu XF, 1997, J CELL SCI, V110, P847; Zhao LP, 1996, P NATL ACAD SCI USA, V93, P10826, DOI 10.1073/pnas.93.20.10826	34	116	118	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4329	4335		10.1074/jbc.275.6.4329	http://dx.doi.org/10.1074/jbc.275.6.4329			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660602	hybrid			2022-12-27	WOS:000085288800086
J	Elias, MD; Tanaka, M; Izu, H; Matsushita, K; Adachi, O; Yamada, M				Elias, MD; Tanaka, M; Izu, H; Matsushita, K; Adachi, O; Yamada, M			Functions of amino acid residues in the active site of Escherichia coli pyrroloquinoline quinone-containing quinoprotein glucose dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRROLO-QUINOLINE QUINONE; METHANOL DEHYDROGENASE; ACINETOBACTER-CALCOACETICUS; METHYLOBACTERIUM-EXTORQUENS; UBIQUINONE OXIDOREDUCTASE; GLUCONOBACTER-SUBOXYDANS; ELECTRON-TRANSPORT; PQQ; COMPLEX; SEQUENCE	Several mutants of quinoprotein glucose dehydrogenase (GDH) in Escherichia coli, located around its cofactor pyrroloquinoline quinone (PQQ), were constructed by site-specific mutagenesis and characterized by enzymatic and kinetic analyses, Of these, critical mutants were further characterized after purification or by different amino acid substitutions. H262A mutant showed reduced affinities both for glucose and PQQ without significant effect on glucose oxidase activity, indicating that His-262 occurs very close to PQQ and glucose, but is not the electron acceptor from PQQH(2). W404A and W404F showed pronounced reductions of affinity for PQQ, and the latter rather than the former had equivalent glucose oxidase activity to the wild type, suggesting that Trp-404 may be a support for PQQ and important for the positioning of PQQ D466N, D466E, and K493A showed very low glucose oxidase activities without influence on the affinity for PQQ, Judging from the enzyme activities of D466E and K493A, as well as their absorption spectra of PQQ during glucose oxidation, we conclude that Asp-466 initiates glucose oxidation reaction by abstraction of a proton from glucose and Lys-493 is involved in electron transfer from PQQH(2).	Yamaguchi Univ, Fac Agr, Dept Biol Chem, Yamaguchi 7538515, Japan	Yamaguchi University	Yamada, M (corresponding author), Yamaguchi Univ, Fac Agr, Dept Biol Chem, 1677-1 Yoshida, Yamaguchi 7538515, Japan.	yamada@agr.yamaguchi-u.ac.jp		Yamada, Mamoru/0000-0003-4354-7324				AMEYAMA M, 1985, AGR BIOL CHEM TOKYO, V49, P1227, DOI 10.1080/00021369.1985.10866884; AMEYAMA M, 1981, FEBS LETT, V130, P179, DOI 10.1016/0014-5793(81)81114-3; Anthony C., 1993, P221; Anthony C, 1996, BIOCHEM J, V320, P697, DOI 10.1042/bj3200697; ANTHONY C, 1994, BIOCHEM J, V304, P665, DOI 10.1042/bj3040665; ANTHONY C, 1998, COMPREHENSIVE BIOL C, P155; BLAKE CCF, 1994, NAT STRUCT BIOL, V1, P102, DOI 10.1038/nsb0294-102; Braun M, 1998, BIOCHEMISTRY-US, V37, P1861, DOI 10.1021/bi971176p; Cozier GE, 1999, BIOCHEM J, V340, P639, DOI 10.1042/0264-6021:3400639; Cozier GE, 1995, BIOCHEM J, V312, P679, DOI 10.1042/bj3120679; DUINE JA, 1991, EUR J BIOCHEM, V200, P271, DOI 10.1111/j.1432-1033.1991.tb16183.x; DUINE JA, 1987, ADV ENZYMOL RAMB, V59, P169; DUINE JA, 1983, ANAL BIOCHEM, V133, P239, DOI 10.1016/0003-2697(83)90249-X; DUINE JA, 1979, FEBS LETT, V108, P443, DOI 10.1016/0014-5793(79)80584-0; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; FRANK J, 1989, EUR J BIOCHEM, V184, P187, DOI 10.1111/j.1432-1033.1989.tb15006.x; GHOSH M, 1995, STRUCTURE, V3, P177, DOI 10.1016/S0969-2126(01)00148-4; Goodwin PM, 1998, ADV MICROB PHYSIOL, V40, P1, DOI 10.1016/S0065-2911(08)60129-0; HOMMES RWJ, 1984, FEMS MICROBIOL LETT, V24, P329, DOI 10.1016/0378-1097(84)90274-X; IMANAGA Y, 1989, PQQ AND QUINOPROTEINS, P87; Itoh S, 1997, J AM CHEM SOC, V119, P439, DOI 10.1021/ja963366d; MACHLIN SM, 1988, J BACTERIOL, V170, P4739, DOI 10.1128/jb.170.10.4739-4747.1988; Maniatis T., 1982, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Matsushita K, 1996, J BIOL CHEM, V271, P4850; MATSUSHITA K, 1989, J BIOCHEM, V105, P633, DOI 10.1093/oxfordjournals.jbchem.a122716; MATSUSHITA K, 1987, J BACTERIOL, V169, P205, DOI 10.1128/jb.169.1.205-209.1987; MATSUSHITA K, 1995, BIOSCI BIOTECH BIOCH, V59, P1548, DOI 10.1271/bbb.59.1548; Matsushita K, 1997, MICROBIOL-UK, V143, P3149, DOI 10.1099/00221287-143-10-3149; Nakamura K, 1996, J BIOL CHEM, V271, P521, DOI 10.1074/jbc.271.1.521; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sode K, 1997, BIOTECHNOL LETT, V19, P1073, DOI 10.1023/A:1018428224215; VANSCHIE BJ, 1985, J BACTERIOL, V163, P493, DOI 10.1128/JB.163.2.493-499.1985; XIA ZX, 1992, J BIOL CHEM, V267, P22289; Xia ZX, 1996, J MOL BIOL, V259, P480, DOI 10.1006/jmbi.1996.0334; Yamada M, 1998, J BIOL CHEM, V273, P22021, DOI 10.1074/jbc.273.34.22021; YAMADA M, 1993, J BIOL CHEM, V268, P12812	37	23	28	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7321	7326		10.1074/jbc.275.10.7321	http://dx.doi.org/10.1074/jbc.275.10.7321			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702303	hybrid			2022-12-27	WOS:000085809600083
J	Henstra, SA; Duurkens, RH; Robillard, GT				Henstra, SA; Duurkens, RH; Robillard, GT			Multiple phosphorylation events regulate the activity of the mannitol transcriptional regulator MtlR of the Bacillus stearothermophilus phosphoenolpyruvate-dependent mannitol phosphotransferase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSION; BETA-GLUCOSIDE UTILIZATION; SUBTILIS LEVANASE OPERON; ESCHERICHIA-COLI; ANTITERMINATOR PROTEIN; BACTERIA; EXPRESSION; INDUCTION; TRANSPORT; COMPONENTS	D-Mannitol is taken up by Bacillus stearothermophilus and phosphorylated via a phosphoenolpyruvate-dependent phosphotransferase system (PTS), Transcription of the genes involved in mannitol uptake in this bacterium is regulated by the transcriptional regulator MtlR, a DNA-binding protein whose affinity for DNA is controlled by phosphorylation by the PTS proteins HPr and IICBmtl, The mutational and biochemical studies presented in this report reveal that two domains of MtlR, PTS regulation domain (PRD)-I and PRD-II, are phosphorylated by HPr, whereas a third IIA-like domain is phosphorylated by IICBmtl, An involvement of PRD-I and the IIA-like domain in a decrease in affinity of MtlR for DNA and of PRD-II in an increase in affinity is demonstrated by DNA footprint experiments using MtlR mutants. Since both PRD-I and PRD-II are phosphorylated by HPr, PRD-I needs to be dephosphorylated by IICBmtl and mannitol to obtain maximal affinity for DNA. This implies that a phosphoryl group can be transferred from HPr to IICBmtl via MtlR. Indeed, this transfer could be demonstrated by the phosphoenolpyruvate-dependent formation of [H-3]mannitol phosphate in the absence of IIA(mtl). Phosphoryl transfer experiments using MtlR mutants revealed that PRD-I and PRD-II are dephosphorylated via the IIA-like domain. Complementation experiments using two mutants with no or low phosphoryl transfer activity showed that phosphoryl transfer between MtlR molecules is possible, indicating that MtlR-MtlR interactions take place. Phosphorylation of the same site by HPr and dephosphorylation by IICBmtl have not been described before; they could also play a role in other PRD-containing proteins.	Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands	University of Groningen	Robillard, GT (corresponding author), Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; ARNAUD M, 1992, J BACTERIOL, V174, P3161, DOI 10.1128/jb.174.10.3161-3170.1992; Arnaud M, 1996, J BIOL CHEM, V271, P18966, DOI 10.1074/jbc.271.31.18966; Bachem S, 1998, J BACTERIOL, V180, P5319, DOI 10.1128/JB.180.20.5319-5326.1998; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen Q, 1997, J BIOL CHEM, V272, P17263, DOI 10.1074/jbc.272.28.17263; CRUTZ AM, 1990, J BACTERIOL, V172, P1043, DOI 10.1128/jb.172.2.1043-1050.1990; GRISAFI PL, 1989, J BACTERIOL, V171, P2719, DOI 10.1128/jb.171.5.2719-2727.1989; Henstra SA, 1996, J BACTERIOL, V178, P5586, DOI 10.1128/jb.178.19.5586-5591.1996; Henstra SA, 1999, J BIOL CHEM, V274, P4754, DOI 10.1074/jbc.274.8.4754; HUECK CJ, 1995, MOL MICROBIOL, V15, P395, DOI 10.1111/j.1365-2958.1995.tb02252.x; KRUGER S, 1995, J BACTERIOL, V177, P5590; Kruger S, 1996, J BACTERIOL, V178, P2637; LECOQ D, 1995, J BACTERIOL, V177, P1527, DOI 10.1128/jb.177.6.1527-1535.1995; Lindner C, 1999, MOL MICROBIOL, V31, P995, DOI 10.1046/j.1365-2958.1999.01262.x; LOLKEMA JS, 1992, NEW COMPR BIOCH, V21, P135; MAO QC, 1995, J BIOL CHEM, V270, P18295, DOI 10.1074/jbc.270.31.18295; Martin-Verstraete I, 1998, MOL MICROBIOL, V28, P293, DOI 10.1046/j.1365-2958.1998.00781.x; MARTINVERSTRAETE I, 1995, J BACTERIOL, V177, P6919, DOI 10.1128/jb.177.23.6919-6927.1995; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Reizer J, 1998, MOL MICROBIOL, V27, P1157, DOI 10.1046/j.1365-2958.1998.00747.x; ROBILLARD GT, 1987, BIOCHEMISTRY-US, V26, P5796, DOI 10.1021/bi00392a032; ROBILLARD GT, 1996, TRANSPORT PROCESSES, P549; ROOSSIEN FF, 1983, BIOCHIM BIOPHYS ACTA, V760, P185, DOI 10.1016/0304-4165(83)90141-1; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNETZ K, 1990, P NATL ACAD SCI USA, V87, P5074, DOI 10.1073/pnas.87.13.5074; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STULKE J, 1995, J BACTERIOL, V177, P6928; Stulke J, 1998, MOL MICROBIOL, V28, P865, DOI 10.1046/j.1365-2958.1998.00839.x; Tortosa P, 1997, J BIOL CHEM, V272, P17230, DOI 10.1074/jbc.272.27.17230; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	34	41	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7037	7044		10.1074/jbc.275.10.7037	http://dx.doi.org/10.1074/jbc.275.10.7037			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702268	hybrid, Green Published			2022-12-27	WOS:000085809600048
J	Perl, A; Colombo, E; Samoilova, E; Butler, MC; Banki, K				Perl, A; Colombo, E; Samoilova, E; Butler, MC; Banki, K			Human transaldolase-associated repetitive elements are transcribed by RNA polymerase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-I; MESSENGER-RNA; TRANSPOSABLE ELEMENT; MOLECULAR EVOLUTION; SURFACE ANTIGEN; FUNCTIONAL GENE; ALPHA-AMANITIN; ALU SEQUENCES; EXPRESSION; CLONING	Repetitive elements flanked by exons 2 and 3 of the human transaldolase gene, thus termed transaldolase-associated repetitive elements, TARE, were identified in human DNA, Nonpolyadenylated TARE transcripts were detected by Northern blot analysis and cloned by reverse transcriptase-mediated polymerase chain reaction from human T lymphocytes, A dominant 1085-nucleotide long transcript, TARE-6, contained two adjacent Alu elements, a right monomer and a complete dimer, oriented opposite to the direction of transcription of the transaldolase gene. Reverse transcriptase-polymerase chain reaction and in vitro transcription analyses showed that transcription of TARE-6 proceeded in the orientation of the RNA pol III promoter of the Alu dimer and opposite to the orientation of the TAL-H gene. TAREs lacking RNA polymerase III promoter showed no transcriptional activity. In vitro transcription of TARE-6 was resistant to 1 mu g/ml alpha-amanitin but sensitive to 100 mu g/ml alpha-amanitin and tagetitoxin, suggesting involvement of RNA polymerase III. TAREs in both the transaldolase and HSAG-1 genomic loci were surrounded by TA target site duplications. Homologies between transaldolase and HSAG-1 break off internally at splice donor and acceptor sites. The results suggest RNA polymerase III-mediated transcription of TARE may be a source of repetitive elements, contributing to distinct genes and thus shaping the human genome.	SUNY Hlth Sci Ctr, Coll Med, Dept Med, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Coll Med, Dept Microbiol & Immunol, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Coll Med, Dept Pathol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Perl, A (corresponding author), SUNY Hlth Sci Ctr, Coll Med, Dept Med, 750 E Adams St, Syracuse, NY 13210 USA.			Perl, Andras/0000-0002-5017-1348	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049221] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 49221] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARWAL RK, 1993, NUCLEIC ACIDS RES, V21, P5283, DOI 10.1093/nar/21.22.5283; Amutan M, 1996, CURR GENET, V29, P468; Arca B, 1997, GENETICS, V145, P267; Banki K, 1998, J BIOL CHEM, V273, P11944, DOI 10.1074/jbc.273.19.11944; BANKI K, 1994, J BIOL CHEM, V269, P2847; Banki K, 1997, GENOMICS, V45, P233, DOI 10.1006/geno.1997.4932; Banki K, 1996, FEBS LETT, V378, P161, DOI 10.1016/0014-5793(95)01446-2; Banki K, 1996, J BIOL CHEM, V271, P32994, DOI 10.1074/jbc.271.51.32994; BANKI K, 1994, J EXP MED, V180, P1649, DOI 10.1084/jem.180.5.1649; Banki K, 1999, J IMMUNOL, V162, P1466; BAQUER NZ, 1977, DEV MED CHILD NEUROL, V19, P81; Batzer MA, 1996, J MOL EVOL, V42, P3, DOI 10.1007/BF00163204; CAVALIERSMITH T, 1985, NATURE, V315, P283, DOI 10.1038/315283b0; CHAMBERLAIN JW, 1986, NUCLEIC ACIDS RES, V14, P3409, DOI 10.1093/nar/14.8.3409; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOAK TG, 1994, P NATL ACAD SCI USA, V91, P942, DOI 10.1073/pnas.91.3.942; FANNING TG, 1987, BIOCHIM BIOPHYS ACTA, V910, P203, DOI 10.1016/0167-4781(87)90112-6; GALAS DJ, 1981, P NATL ACAD SCI-BIOL, V78, P4858, DOI 10.1073/pnas.78.8.4858; GOLDING GB, 1994, P NATL ACAD SCI USA, V91, P7506, DOI 10.1073/pnas.91.16.7506; Hastings ML, 1997, NUCLEIC ACIDS RES, V25, P4296, DOI 10.1093/nar/25.21.4296; HEINRICH PC, 1976, CANCER RES, V36, P3189; HILDEBRANDT M, 1992, CELL, V69, P197, DOI 10.1016/0092-8674(92)90130-5; HURST LD, 1994, NATURE, V371, P381, DOI 10.1038/371381a0; HYNES RO, 1989, FIBRONECTIN; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; Li AW, 1997, MOL CELL ENDOCRINOL, V133, P177, DOI 10.1016/S0303-7207(97)00148-2; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; LONG MY, 1993, SCIENCE, V260, P91, DOI 10.1126/science.7682012; MAKALOWSKI W, 1994, TRENDS GENET, V10, P188, DOI 10.1016/0168-9525(94)90254-2; MARTIGNETTI JA, 1993, P NATL ACAD SCI USA, V90, P11563, DOI 10.1073/pnas.90.24.11563; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; Migheli Q, 1999, GENETICS, V151, P1005; MURPHY MH, 1983, NUCLEIC ACIDS RES, V11, P7695, DOI 10.1093/nar/11.22.7695; NOVELLO F, 1968, BIOCHEM J, V107, P775, DOI 10.1042/bj1070775; PAULSON KE, 1987, NUCLEIC ACIDS RES, V15, P5199, DOI 10.1093/nar/15.13.5199; PAULSON KE, 1986, NUCLEIC ACIDS RES, V14, P6145, DOI 10.1093/nar/14.15.6145; PERL A, 1989, NUCLEIC ACIDS RES, V17, P6841, DOI 10.1093/nar/17.17.6841; PIRAS G, 1994, J VIROL, V68, P6170, DOI 10.1128/JVI.68.10.6170-6179.1994; PRICE GB, 1985, IMMUNOL LETT, V9, P9, DOI 10.1016/0165-2478(85)90086-0; Rezsohazy R, 1997, NUCLEIC ACIDS RES, V25, P4048, DOI 10.1093/nar/25.20.4048; ROGER AJ, 1993, NATURE, V364, P289, DOI 10.1038/364289a0; Romans P, 1998, INSECT MOL BIOL, V7, P1, DOI 10.1046/j.1365-2583.1998.71046.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHAAFF I, 1990, EUR J BIOCHEM, V188, P597, DOI 10.1111/j.1432-1033.1990.tb15440.x; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHEN MR, 1991, J MOL EVOL, V33, P311; SOARES MB, 1985, MOL CELL BIOL, V5, P2090, DOI 10.1128/MCB.5.8.2090; SRIVASTAVA BIS, 1992, CANCER RES, V52, P4391; STANNERS CP, 1981, CELL, V27, P211, DOI 10.1016/0092-8674(81)90375-5; STEINBERG TH, 1990, J BIOL CHEM, V265, P499; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; TEMIN HM, 1985, MOL BIOL EVOL, V2, P455; ULLU E, 1985, NATURE, V318, P371, DOI 10.1038/318371a0; ULLU E, 1984, NATURE, V312, P171, DOI 10.1038/312171a0; WATSON JB, 1987, MOL CELL BIOL, V7, P3324, DOI 10.1128/MCB.7.9.3324; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; YURA T, 1992, NUCLEIC ACIDS RES, V20, P3305, DOI 10.1093/nar/20.13.3305; Zhang LN, 1998, NUCLEIC ACIDS RES, V26, P3687, DOI 10.1093/nar/26.16.3687; ZIEVE G, 1977, BIOCHEMISTRY-US, V16, P4520, DOI 10.1021/bi00639a029	62	10	11	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7261	7272		10.1074/jbc.275.10.7261	http://dx.doi.org/10.1074/jbc.275.10.7261			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702296	hybrid			2022-12-27	WOS:000085809600076
J	Zhu, XY; Scharf, E; Assoian, RK				Zhu, XY; Scharf, E; Assoian, RK			Induction of anchorage-independent growth by transforming growth factor-beta linked to anchorage-independent expression of cyclin D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; TGF-BETA; RETINOBLASTOMA PROTEIN; KINASE-ACTIVITY; PROGRESSION; ADHESION; ARREST; TRANSCRIPTION; REPRESSION; E-CDK2	Transforming growth factor-beta (TGF-beta) was originally identified, characterized, and named on the basis of its ability to induce anchorage-independent growth (phenotypic transformation). This effect has received little attention in recent years, probably because the induction of anchorage-independent growth by TGF-beta has been observed only in a few cell lines, of which NRK fibroblasts are among the best studied. We have previously reported that normal rat kidney cells have lost their normal adhesion requirement for expression of cyclin D1, and we now show that this loss is causal for the induction of anchorage-independent growth by TGF-beta. First, we show that TGF-beta fails to induce anchorage-independent growth in NIH-3T3 cells and human fibroblasts that have retained their adhesion requirement for expression of cyclin D1. Second, we show that TGF-beta complements rather than affects cyclin D-cdk4/6 kinase activity in NRK cells. Third, we show that forced expression of cyclin D1 in suspended 3T3 cells renders them susceptible to transformation by TGF-beta. These results may explain why the induction of anchorage-independent growth by TGF-beta is a rare event and yet also describe a molecular scenario in which the mesenchymal response to TGF-beta could indeed involve the acquisition of an anchorage-independent phenotype.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Assoian, RK (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 167 Johnson Pavill,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	rka@pharm.med.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA072639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048224] Funding Source: NIH RePORTER; NCI NIH HHS [CA72639] Funding Source: Medline; NIGMS NIH HHS [GM48224] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HAN EKH, 1993, J CELL BIOL, V122, P461, DOI 10.1083/jcb.122.2.461; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Iavarone A, 1997, NATURE, V387, P417; Kramer A, 1996, J BIOL CHEM, V271, P6579; Kramer A, 1997, CANCER RES, V57, P5117; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASSAGUE J, 1985, J BIOL CHEM, V260, P4551; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Philips A, 1999, ONCOGENE, V18, P1819, DOI 10.1038/sj.onc.1202530; Resnitzky D, 1997, MOL CELL BIOL, V17, P5640, DOI 10.1128/MCB.17.9.5640; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBERTS AB, 1983, FED PROC, V42, P2621; Schulze A, 1996, MOL CELL BIOL, V16, P4632; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZHU XY, 1999, CRC METH SIG TRANS, P129; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1	27	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6703	6706		10.1074/jbc.275.10.6703	http://dx.doi.org/10.1074/jbc.275.10.6703			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702223	hybrid			2022-12-27	WOS:000085809600003
J	Jung, SK; Kauri, LM; Qian, WJ; Kennedy, RT				Jung, SK; Kauri, LM; Qian, WJ; Kennedy, RT			Correlated oscillations in glucose consumption, oxygen consumption, and intracellular free Ca2+ in single islets of Langerhans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; INSULIN-SECRETION; CYTOPLASMIC CA2+; HEXOSE METABOLISM; ATP/ADP RATIO; CALCIUM; DEHYDROGENASE; MITOCHONDRIA; GLYCOLYSIS; ACTIVATION	Micron-sized sensors were used to monitor glucose and oxygen levels in the extracellular space of single islets of Langerhans in real-time. At 10 mM glucose, oscillations in intraislet glucose concentration were readily detected. Changes in glucose level correspond to changes in glucose consumption by glycolysis balanced by mass transport into the islet. Oscillations had a period of 3.1 +/- 0.2 min and amplitude of 0.8 +/- 0.1 mM glucose (n = 21). Superimposed on these oscillations were faster fluctuations in glucose level during the periods of low glucose consumption. Oxygen level oscillations that were out of phase with the glucose oscillations were also detected. Oscillations in both oxygen and glucose consumption were strongly dependent upon extracellular Ca2+ and sensitive to nifedipine. Simultaneous measurements of glucose with intracellular Ca2+ ([Ca2+](i)) revealed that decreases in [Ca2+](i) preceded increases in glucose consumption by 7.4 +/- 2.1 a during an oscillation (n = 9). Conversely, increases in [Ca2+](i) preceded increases in oxygen consumption by 1.5 +/- 0.2 s (n = 4). These results suggest that during oscillations, bursts of glycolysis begin after Ca2+ has stopped entering the cell. Glycolysis stimulates further Ca2+ entry; which in turn stimulates increases in respiration. The data during oscillation are in contrast to the time course of events during initial exposure to glucose. Under these conditions, a burst of oxygen consumption precedes the initial rise in [Ca2+](i), A model to explain these results is described.	Univ Florida, Dept Chem, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Kennedy, RT (corresponding author), Univ Florida, Dept Chem, Gainesville, FL 32611 USA.		Qian, Wei-Jun/C-6167-2011; QIAN, Wei-Jun/AAC-1907-2021; Kennedy, Robert/G-9095-2016	QIAN, Wei-Jun/0000-0002-5393-2827; Kennedy, Robert/0000-0003-2447-7471; Kauri, Lisa/0000-0003-3047-5720	NIDDK NIH HHS [R01-DK46960] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046960] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aspinwall CA, 1999, J BIOL CHEM, V274, P6360, DOI 10.1074/jbc.274.10.6360; BERSTEN P, 1993, DIABETES, V42, P670; Bertram R, 1998, BIOPHYS J, V74, P1722, DOI 10.1016/S0006-3495(98)77883-X; CHOU HF, 1990, DIABETES, V39, P112, DOI 10.2337/diabetes.39.1.112; Civelek VN, 1996, BIOCHEM J, V315, P1015, DOI 10.1042/bj3151015; COORE HG, 1963, NATURE, V197, P1264, DOI 10.1038/1971264a0; Cunningham BA, 1996, AM J PHYSIOL-ENDOC M, V271, pE702, DOI 10.1152/ajpendo.1996.271.4.E702; DENTON RM, 1985, AM J PHYSIOL, V249, pE543, DOI 10.1152/ajpendo.1985.249.6.E543; Detimary P, 1998, BIOCHEM J, V333, P269, DOI 10.1042/bj3330269; DUKES ID, 1994, J BIOL CHEM, V269, P10979; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; GILON P, 1993, J BIOL CHEM, V268, P22265; GILON P, 1992, J BIOL CHEM, V267, P20713; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hazelwood R.L., 1989, ENDOCRINE PANCREAS; HELLMAN B, 1992, BIOCHIM BIOPHYS ACTA, V1113, P295, DOI 10.1016/0304-4157(92)90003-S; Jung SK, 1999, ANAL CHEM, V71, P3642, DOI 10.1021/ac990271w; Jung SK, 1996, ANAL CHEM, V68, P591, DOI 10.1021/ac950424p; Jung SK, 1999, BIOCHEM BIOPH RES CO, V259, P331, DOI 10.1006/bbrc.1999.0784; KAMIN RA, 1980, ANAL CHEM, V52, P1198, DOI 10.1021/ac50058a010; Kennedy HJ, 1999, J BIOL CHEM, V274, P13281, DOI 10.1074/jbc.274.19.13281; LARSSON O, 1996, P NATL ACAD SCI USA, V93, P6161; LEECH CA, 1994, ENDOCRINOLOGY, V135, P365, DOI 10.1210/en.135.1.365; LONGO EA, 1991, J BIOL CHEM, V266, P9314; MALAISSE WJ, 1991, MOL CELL BIOCHEM, V107, P95; MARTIN F, 1995, J MOL ENDOCRINOL, V15, P177, DOI 10.1677/jme.0.0150177; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; MCCORMACK JG, 1990, BIOCHEM J, V267, P527, DOI 10.1042/bj2670527; MCCORMACK JG, 1980, BIOCHEM J, V190, P95, DOI 10.1042/bj1900095; MIESKES G, 1987, EUR J BIOCHEM, V167, P383, DOI 10.1111/j.1432-1033.1987.tb13349.x; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Nilsson T, 1996, BIOCHEM J, V314, P91, DOI 10.1042/bj3140091; ORAHILLY S, 1988, NEW ENGL J MED, V318, P1225, DOI 10.1056/NEJM198805123181902; PANTANO P, 1995, ELECTROANAL, V7, P405, DOI 10.1002/elan.1140070502; POLONSKY KS, 1988, NEW ENGL J MED, V318, P1231, DOI 10.1056/NEJM198805123181903; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; Schonekess BO, 1995, CAN J PHYSIOL PHARM, V73, P1632, DOI 10.1139/y95-725; SENER A, 1990, BIOCHIM BIOPHYS ACTA, V1019, P42, DOI 10.1016/0005-2728(90)90122-K; Sweet IR, 1996, AM J PHYSIOL-ENDOC M, V271, pE606, DOI 10.1152/ajpendo.1996.271.3.E606; SWOBODA BEP, 1965, J BIOL CHEM, V240, P2209; TORNHEIM K, 1991, J BIOL CHEM, V266, P15675; Tornheim K, 1997, DIABETES, V46, P1375, DOI 10.2337/diabetes.46.9.1375; VALDEOLMILLOS M, 1993, DIABETES, V42, P1210, DOI 10.2337/diabetes.42.8.1210; WARNOCK GL, 1994, PANCREATIC ISLET TRA, V1, P81; YANEY GC, 1995, DIABETES, V44, P1285, DOI 10.2337/diabetes.44.11.1285; ZHANG YN, 1993, ANAL CHIM ACTA, V281, P513, DOI 10.1016/0003-2670(93)85009-9	49	101	102	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6642	6650		10.1074/jbc.275.9.6642	http://dx.doi.org/10.1074/jbc.275.9.6642			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692473	hybrid			2022-12-27	WOS:000085654400085
J	Screen, SE; St Leger, RJ				Screen, SE; St Leger, RJ			Cloning, expression, and substrate specificity of a fungal chymotrypsin - Evidence for lateral gene transfer from an actinomycete bacterium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METARHIZIUM-ANISOPLIAE; STREPTOMYCES-GRISEUS; ENTOMOPATHOGENIC FUNGUS; PROTEASE; SEQUENCE; TRYPSIN; IDENTIFICATION; CONSERVATION; ENZYME	Unlike trypsins, chymotrypsins have not until now been found in fungi. Expressed sequence tag analysis of the deuteromycete Metarhizium anisopliae identified two trypsins (family S1) and a novel chymotrypsin (CHY1), CHY1 resembles actinomycete (bacterial) chymotrypsins (family S2) rather than other eukaryote enzymes (family S1) in being synthesized as a precursor species (374 amino acids, pI/MW: 5.07/88,279) containing a large N-terminal fragment (186 amino acids). Chy1 was expressed in Pichia pastoris yielding an enzyme with a chymotrypsin specificity for branched aliphatic and aromatic C-terminal amino acids, This is predictable as key catalytic residues determining the specificity of Streptomyces griseus chymotrypsins are conserved with CHY1, Mature (secreted) CHY1 (pI/MW: 8.29/18,499) shows closest overall amino acid identity to S. griseus protease C (55%) and clustered with other secreted bacterial S2 chymotrypsins that diverged widely from animal and endocellular bacterial enzymes in phylogenetic trees of the chymotrypsin superfamily. Conversely, actinomycete chymotrypsins are much more closely related to fungal proteases than to other eubacterial sequences. Complete genomes of yeast, gram eubacteria, archaebacteria, and mitochondria do not contain paralogous genes. Expressed sequence tag data bases from other fungi also lack chymotrypsin homologs, In light of this patchy distribution, we conclude that chy1 probably arose by lateral gene transfer from an actinomycete bacterium.	Univ Maryland, Dept Entomol, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	St Leger, RJ (corresponding author), Univ Maryland, Dept Entomol, 4112 Plant Sci Bldg, College Pk, MD 20742 USA.	rl106@umailsrv0.umd.edu	St. Leger, Raymond/N-3219-2013					BARRETT AJ, 1995, ARCH BIOCHEM BIOPHYS, V318, P247, DOI 10.1006/abbi.1995.1227; BERBEE ML, 1993, CAN J BOT, V71, P1114, DOI 10.1139/b93-131; Doolittle WE, 1998, TRENDS GENET, V14, P307; FELSENSTEIN J, 1995, PHYLIP PHYLOGENY INF; Gray MW, 1998, NUCLEIC ACIDS RES, V26, P865, DOI 10.1093/nar/26.4.865; Gurr S. J., 1987, SPECIAL PUBLICATIONS, P93; HARTLEY BS, 1979, PROC R SOC SER B-BIO, V205, P443, DOI 10.1098/rspb.1979.0078; Itzhaki H, 1998, J BIOL CHEM, V273, P7094, DOI 10.1074/jbc.273.12.7094; Joshi L, 1997, GENE, V197, P1, DOI 10.1016/S0378-1119(97)00132-7; Joshi L, 1999, J BIOL CHEM, V274, P9803, DOI 10.1074/jbc.274.14.9803; Lake JA, 1999, SCIENCE, V283, P2027, DOI 10.1126/science.283.5410.2027; Lang BF, 1997, NATURE, V387, P493, DOI 10.1038/387493a0; Lechevalier M. P., 1988, Actinomycetes in biotechnology., P327; Lesk AM, 1996, J MOL BIOL, V258, P501, DOI 10.1006/jmbi.1996.0264; MacCabe AP, 1996, MOL GEN GENET, V250, P367, DOI 10.1007/s004380050087; MILLER JR, 1989, MOL MICROBIOL, V3, P689, DOI 10.1111/j.1365-2958.1989.tb00217.x; MONOD M, 1995, CAN J BOT, V73, pS1081, DOI 10.1139/b95-361; Nicholas KB., 1997, GENEDOC TOOL EDITING; PENALVA MA, 1990, P R SOC BIOL LOND, V241, P161; READ RJ, 1988, J MOL BIOL, V200, P523, DOI 10.1016/0022-2836(88)90541-4; RYPNIEWSKI WR, 1993, PROTEIN ENG, V6, P341, DOI 10.1093/protein/6.4.341; RYPNIEWSKI WR, 1994, PROTEIN ENG, V7, P57, DOI 10.1093/protein/7.1.57; SAITOU N, 1989, MOL BIOL EVOL, V6, P514; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schenk S, 1999, J MOL EVOL, V48, P178, DOI 10.1007/PL00006456; Screen S, 1997, CURR GENET, V31, P511, DOI 10.1007/s002940050238; Screen S, 1998, GENE, V221, P17, DOI 10.1016/S0378-1119(98)00430-2; Sicheritz-Ponten T, 1998, BBA-BIOENERGETICS, V1365, P545, DOI 10.1016/S0005-2728(98)00099-1; SIDHU SS, 1995, J BIOL CHEM, V270, P7594, DOI 10.1074/jbc.270.13.7594; SIDHU SS, 1993, BIOCHEM CELL BIOL, V71, P454, DOI 10.1139/o93-067; STLEGER RJ, 1992, EUR J BIOCHEM, V204, P991, DOI 10.1111/j.1432-1033.1992.tb16721.x; STLEGER RJ, 1987, ARCH BIOCHEM BIOPHYS, V253, P221, DOI 10.1016/0003-9861(87)90655-2; STLEGER RJ, 1995, CAN J BOT, V73, pS1119, DOI 10.1139/b95-367; TAJIMA F, 1984, MOL BIOL EVOL, V1, P269; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANDEPEER Y, 1994, COMPUT APPL BIOSCI, V10, P569; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	37	49	59	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6689	6694		10.1074/jbc.275.9.6689	http://dx.doi.org/10.1074/jbc.275.9.6689			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692479	hybrid			2022-12-27	WOS:000085654400091
J	Vazquez-Prado, J; Medina, LD; Romero-Avila, MT; Gonzalez-Espinosa, C; Garcia-Sainz, JA				Vazquez-Prado, J; Medina, LD; Romero-Avila, MT; Gonzalez-Espinosa, C; Garcia-Sainz, JA			Norepinephrine- and phorbol ester-induced phosphorylation of alpha(1a)-adrenergic receptors - functional aspects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; INOSITOL PHOSPHOLIPID-METABOLISM; PROTEIN-KINASE-C; ALPHA(1B)-ADRENERGIC RECEPTOR; ALPHA-1-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; BETA(2)-ADRENERGIC RECEPTOR; MESSENGER-RNA; DESENSITIZATION; EXPRESSION	Maximal adrenergic responses in Rat-1 fibroblasts expressing alpha(1a)-adrenergic receptors are not blocked by activation of protein kinase C, In contrast, activation of protein kinase C induces the phosphorylation of cu,,adrenoreceptors and blocks their actions, The effect of norepinephrine and phorbol esters on alpha(1a)-adrenoreceptor phosphorylation and coupling to G proteins were studied. Both stimuli lead to dose-dependent receptor phosphorylation, Interestingly, protein kinase C activation affected to a much lesser extent the actions of alpha(1a)-adrenergic receptors than those of the cu,, subtype (norepinephrine elicited increases in calcium in whole cells and [S-35]GTP gamma S binding to membranes). Basal phosphorylation of alpha(1a)-adrenergic receptors was much less than that observed with the alpha(1b) subtype. The carboxyl terminus seems to be the main domain for receptor phosphorylation. Therefore, chimeric receptors, where the carboxyl-terminal tails of alpha(1a) and alpha(1b) adrenergic receptors were exchanged, were constructed and expressed. alpha(1a)-Adrenoreceptors wearing the carboxyl tail of the alpha(1b) subtype had a high basal phosphorylation and displayed a strong phosphorylation in response to norepinephrine and phorbol esters, Our results demonstrate that stimulation of alpha(1a)-adrenergic receptor, or activation of protein kinase C, leads to alpha(1a)-adrenergic receptor phosphorylation, alpha(1a)-Adrenoreceptors are affected to a much lesser extent than alpha(1b)-adrenoreceptors by protein kinase C activation.	Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biol Celular, Mexico City 04510, DF, Mexico; Univ Autonoma Metropolitana Iztapalapa, Dept Reprod Biol, Div Ciencias Biol & Salud, Mexico City 09340, DF, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Autonoma Metropolitana - Mexico	Garcia-Sainz, JA (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biol Celular, Apartado Postal 70-248, Mexico City 04510, DF, Mexico.		VAZQUEZ-PRADO, JOSE/C-1630-2017; Gonzalez-Espinosa, Claudia/C-4417-2019; GARCIA-SAINZ, JESUS ADOLFO/A-5389-2008	VAZQUEZ-PRADO, JOSE/0000-0001-5797-6643; Gonzalez-Espinosa, Claudia/0000-0001-7332-3829; GARCIA-SAINZ, JESUS ADOLFO/0000-0002-5235-0657; ROMERO, MA. TERESA/0000-0003-4505-5083				Bunemann M, 1999, ANNU REV PHYSIOL, V61, P169, DOI 10.1146/annurev.physiol.61.1.169; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; Diviani D, 1997, J BIOL CHEM, V272, P28712, DOI 10.1074/jbc.272.45.28712; Diviani D, 1996, J BIOL CHEM, V271, P5049; Garcia-Sainz JA, 1998, EUR J PHARMACOL, V342, P311, DOI 10.1016/S0014-2999(97)01465-9; GARCIASAINZ JA, 1992, VACCINE, V10, P341, DOI 10.1016/0264-410X(92)90375-T; GONZALEZ AL, 1995, TRENDS GENET, V11, P216, DOI 10.1016/S0168-9525(00)89051-4; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; HIEBLE JP, 1995, PHARMACOL REV, V47, P267; Hieble JP, 1996, PHARMACOL RES, V33, P145, DOI 10.1006/phrs.1996.0022; Hrometz SL, 1999, J PHARMACOL EXP THER, V290, P452; Hu ZW, 1996, J BIOL CHEM, V271, P8977, DOI 10.1074/jbc.271.15.8977; Hu ZW, 1999, MOL ENDOCRINOL, V13, P3, DOI 10.1210/me.13.1.3; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUROSE H, 1994, J BIOL CHEM, V269, P10093; LAMM MLG, 1994, MOL ENDOCRINOL, V8, P1537, DOI 10.1210/me.8.11.1537; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LEEBLUNDBERG LMF, 1987, J BIOL CHEM, V262, P3098; LEEBLUNDBERG LMF, 1985, P NATL ACAD SCI USA, V82, P5651, DOI 10.1073/pnas.82.17.5651; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; LEPOR H, 1993, PROSTATE, V22, P301, DOI 10.1002/pros.2990220404; Liggett S B, 1998, Adv Pharmacol, V42, P438; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; Medina LD, 1998, FEBS LETT, V422, P141, DOI 10.1016/S0014-5793(97)01615-3; OKAZAKI M, 1994, J CLIN INVEST, V94, P210, DOI 10.1172/JCI117309; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PRICE DT, 1993, J UROLOGY, V150, P546, DOI 10.1016/S0022-5347(17)35544-1; Rokosh DG, 1996, J BIOL CHEM, V271, P5839, DOI 10.1074/jbc.271.10.5839; Schwinn D A, 1998, Adv Pharmacol, V42, P390; SCHWINN DA, 1990, J BIOL CHEM, V265, P8183; SEKURA RD, 1983, J BIOL CHEM, V258, P14646; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; Theroux TL, 1996, MOL PHARMACOL, V50, P1376; VazquezPrado J, 1997, J BIOL CHEM, V272, P27330, DOI 10.1074/jbc.272.43.27330; VazquezPrado J, 1996, MOL PHARMACOL, V50, P17; Villalobos-Molina R, 1999, BRIT J PHARMACOL, V126, P1534, DOI 10.1038/sj.bjp.0702468; WIELAND T, 1994, METHOD ENZYMOL, V237, P3; WU DQ, 1992, J BIOL CHEM, V267, P25798	43	52	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6553	6559		10.1074/jbc.275.9.6553	http://dx.doi.org/10.1074/jbc.275.9.6553			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692461	hybrid			2022-12-27	WOS:000085654400073
J	Huber, A; Neuhuber, WL; Klugbauer, N; Ruth, P; Allescher, HD				Huber, A; Neuhuber, WL; Klugbauer, N; Ruth, P; Allescher, HD			Cysteine-rich protein 2, a novel substrate for cGMP kinase I in enteric neurons and intestinal smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIM-DOMAIN PROTEIN; NITRIC-OXIDE SYNTHASE; ZINC-FINGER MOTIF; CYCLIC-GMP; FOCAL ADHESION; INHIBITORY NEUROTRANSMISSION; DEFICIENT MICE; CELLS; PHOSPHORYLATION; FAMILY	Nitric oxide/cGMP/cGMP kinase I (cGKI) signaling causes relaxation of intestinal smooth muscle, In the gastrointestinal tract substrates of cGKI have not been identified yet. In the present study a protein interacting with cGKI beta has been isolated from a rat intestinal cDNA library using the yeast two-hybrid system. The protein was identified as cysteine-rich protein 2 (CRP2), recently cloned from rat brain (Okano, I., Yamamoto, T., Kaji, A., Kimura, T., Mizuno, K., and Nakamura, T. (1993) FEBS Lett. 333, 51-55). Recombinant CRP2 is specifically phosphorylated by cGKs but not by cAMP kinase in vitro. Co-transfection of CRP2 and cGKI beta into COS cells confirmed the phosphorylation of CRP2 in vivo. Cyclic GMP kinase I phosphorylated CRP2 at Ser-104, because the mutation to Ala completely prevented the in vivo phosphorylation, Immunohistochemical analysis using confocal laser scan microscopy showed a co-localization of CRP2 and cGKI in the inner part of the circular muscle layer, in the muscularis mucosae, and in specific neurons of the myenteric and submucosal plexus. The co-localization together with the specific phosphorylation of CRP2 by cGKI in vitro and in vivo suggests that CRP2 is a novel substrate of cGKI in neurons and smooth muscle of the small intestine.	Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany; Tech Univ Munich, Med Klin & Poliklin 2, D-81675 Munich, Germany; Univ Erlangen Nurnberg, Inst Anat, D-91054 Erlangen, Germany	Technical University of Munich; Technical University of Munich; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Erlangen Nuremberg	Ruth, P (corresponding author), Tech Univ Munich, Inst Pharmakol & Toxikol, Biedersteinerstr 29, D-80802 Munich, Germany.							Alioua A, 1998, J BIOL CHEM, V273, P32950, DOI 10.1074/jbc.273.49.32950; Allescher HD, 1996, AM J PHYSIOL-GASTR L, V271, pG568, DOI 10.1152/ajpgi.1996.271.4.G568; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Beall AC, 1997, J BIOL CHEM, V272, P11283; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BULT H, 1990, NATURE, V345, P346, DOI 10.1038/345346a0; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; GABELLA G, 1974, CELL TISSUE RES, V153, P63, DOI 10.1007/BF00225446; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HOFKER MH, 1990, GENOMICS, V6, P33, DOI 10.1016/0888-7543(90)90445-Z; HORSTRUP K, 1994, EUR J BIOCHEM, V225, P21, DOI 10.1111/j.1432-1033.1994.00021.x; Huber A, 1998, AM J PHYSIOL-GASTR L, V275, pG629, DOI 10.1152/ajpgi.1998.275.4.G629; ITOH Y, 1978, J PHARMACOL EXP THER, V207, P1022; Jain MK, 1996, J BIOL CHEM, V271, P10194, DOI 10.1074/jbc.271.17.10194; JESSEN KR, 1983, J NEUROSCI, V3, P2206; JIN JG, 1993, AM J PHYSIOL, V264, pG470, DOI 10.1152/ajpgi.1993.264.3.G470; KANADA A, 1992, EUR J PHARMACOL, V216, P287, DOI 10.1016/0014-2999(92)90372-B; Karim MA, 1996, GENOMICS, V31, P167, DOI 10.1006/geno.1996.0028; KEILBACH A, 1992, EUR J BIOCHEM, V208, P467, DOI 10.1111/j.1432-1033.1992.tb17209.x; Klemm K, 1998, ANN SURG, V227, P126, DOI 10.1097/00000658-199801000-00018; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; Lefebvre RA, 1998, BRIT J PHARMACOL, V124, P1439, DOI 10.1038/sj.bjp.0701992; Lincoln T M, 1995, Adv Pharmacol, V34, P305; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; Louis HA, 1997, J BIOL CHEM, V272, P27484, DOI 10.1074/jbc.272.43.27484; MADARA JL, 1987, PHYSL GASTROINTESTIN, V2, P1209; Markert T, 1996, BASIC RES CARDIOL, V91, P337; Mashimo H, 1996, J CLIN INVEST, V98, P8, DOI 10.1172/JCI118781; MCLAUGHLIN CR, 1994, NUCLEIC ACIDS RES, V22, P5477, DOI 10.1093/nar/22.24.5477; MIURA Y, 1992, FEBS LETT, V297, P171, DOI 10.1016/0014-5793(92)80353-I; Moore DD, 1995, GLOB MOB SURV; MurphyUllrich JE, 1996, J CELL SCI, V109, P2499; MURTHY KS, 1995, AM J PHYSIOL-CELL PH, V268, pC171, DOI 10.1152/ajpcell.1995.268.1.C171; OKANO I, 1993, FEBS LETT, V333, P51, DOI 10.1016/0014-5793(93)80373-3; Pfeifer A, 1999, Rev Physiol Biochem Pharmacol, V135, P105, DOI 10.1007/BFb0033671; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Pomies P, 1997, J CELL BIOL, V139, P157, DOI 10.1083/jcb.139.1.157; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; Ruth P, 1997, J BIOL CHEM, V272, P10522; SANDERS KM, 1992, AM J PHYSIOL, V262, P379; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Smolenski A, 1998, N-S ARCH PHARMACOL, V358, P134, DOI 10.1007/PL00005234; STARK ME, 1992, GASTROENTEROLOGY, V103, P1928, DOI 10.1016/0016-5085(92)91454-C; Tsui SKW, 1996, BIOCHEM MOL BIOL INT, V39, P747; WANG XK, 1992, J BIOL CHEM, V267, P9176; WARD SM, 1992, BRIT J PHARMACOL, V107, P1075, DOI 10.1111/j.1476-5381.1992.tb13409.x; WEISKIRCHEN R, 1993, ONCOGENE, V8, P2317; Zhou XB, 1996, J BIOL CHEM, V271, P19760, DOI 10.1074/jbc.271.33.19760	55	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5504	5511		10.1074/jbc.275.8.5504	http://dx.doi.org/10.1074/jbc.275.8.5504			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681529	hybrid			2022-12-27	WOS:000085474500036
J	Kiyono, M; Kaziro, Y; Satoh, T				Kiyono, M; Kaziro, Y; Satoh, T			Induction of Rac-guanine nucleotide exchange activity of Ras-GRF1/CDC25(Mm) following phosphorylation by the nonreceptor tyrosine kinase Src	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PROTEIN-COUPLED RECEPTORS; GROWTH-FACTOR RECEPTOR; SACCHAROMYCES-CEREVISIAE; PHOSPHOINOSITIDE 3-KINASE-GAMMA; DEPENDENT ACTIVATION; MEDIATES ACTIVATION; SIGNALING PATHWAY; RHO-GTPASES; P115 RHOGEF	Ras-GRF1/CDC25(Mm) has been implicated as a Ras-guanine nucleotide exchange factor (GEF) expressed in brain. Ras-GEF activity of Ras-GRF1 is augmented in response to Ca2+ influx and G protein beta gamma subunit (G beta gamma) stimulation. Ras-GRF1 also acts as a GEF toward Rac, but not Rho and Cdc42, when activated by G beta gamma-mediated signals, Tyrosine phosphorylation of Ras-GRF1 is critical for the induction of Rac-GEF activity as evidenced by inhibition by tyrosine kinase inhibitors. Herein, we show that the nonreceptor tyrosine kinase Src phosphorylates Ras-GRF1, thereby inducing Rac-GEF activity. Ras-GRF1 transiently expressed with v-Src was tyrosine-phosphorylated and showed significant GEF activity toward Rac, but not Rho and Cdc42, which was comparable with that induced by G beta gamma. In contrast, Ras-GEF activity remained unchanged. The recombinant c-Src protein phosphorylated affinity-purified glutathione S-transferase tagged Ras-GRF1 in vitro and thereby elicited Rac-GEF activity. Taken together, tyrosine phosphorylation by Src is sufficient for the induction of Rac-GEF activity of Ras-GRF1, which may imply the involvement of Src downstream of G beta gamma to regulate Ras-GRF1.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Satoh, T (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.	tkysato@bio.titech.ac.jp	Satoh, Takaya/K-2628-2014					Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Coso OA, 1996, J BIOL CHEM, V271, P3963; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; Fan WT, 1998, CURR BIOL, V8, P935, DOI 10.1016/S0960-9822(07)00376-4; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; ITO A, 1995, FEBS LETT, V368, P183, DOI 10.1016/0014-5793(95)00643-N; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P2505, DOI 10.1074/jbc.273.5.2505; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; Mattingly RR, 1999, CELL SIGNAL, V11, P603, DOI 10.1016/S0898-6568(99)00034-0; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; Nern A, 1998, NATURE, V391, P195, DOI 10.1038/34458; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Nishida K, 1999, FEBS LETT, V459, P186, DOI 10.1016/S0014-5793(99)01244-2; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Powers S, 1992, Semin Cancer Biol, V3, P209; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; SATOH T, 1988, BIOCHIM BIOPHYS ACTA, V949, P97, DOI 10.1016/0167-4781(88)90059-0; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; Satoh T, 1996, FEBS LETT, V386, P230, DOI 10.1016/0014-5793(96)00449-8; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SHOU CC, 1995, ONCOGENE, V10, P1887; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246	66	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5441	5446		10.1074/jbc.275.8.5441	http://dx.doi.org/10.1074/jbc.275.8.5441			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681520	hybrid			2022-12-27	WOS:000085474500027
J	Muramatsu, M; Katada, J; Hayashi, I; Majima, M				Muramatsu, M; Katada, J; Hayashi, I; Majima, M			Chymase as a proangiogenic factor - A possible involvement of chymase-angiotensin-dependent pathway in the hamster sponge angiogenesis model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; MAST-CELL CHYMASE; II-GENERATING ENZYMES; THERAPEUTIC IMPLICATIONS; RAT; HEART; CONVERSION; PROLIFERATION; PURIFICATION; LOCALIZATION	We investigated the profound involvement of chymase, an alternative angiotensin II-generating enzyme, in angiogenesis using a hamster sponge implant model. In vivo transfection of human pro-chymase cDNA or a direct injection of purified chymase into the sponges implanted resulted in marked increment of hemoglobin contents in the sponge granuloma tissues, demonstrating that chymase has an ability to elicit angiogenesis and is a potent angiogenic factor. Daily injection of basic fibroblast growth factor into the sponges implanted also induced angiogenesis, which was suppressed by the treatment with chymostatin, an inhibitor of chymase, or TCV-116, an antagonist of angiotensin II (Ang II) type 1 receptor. Expression of chymase mRNA and production of Ang II in the granuloma tissues were enhanced by the stimulation with basic fibroblast growth factor. Chymase activity in the sponge granulomas increased in parallel with the rise in hemoglobin contents, and mast cells observed in the granuloma tissues were positively stained with anti-chymase antibody, Exogenous administration not only of Ang II but of angiotensin I (Ang I) directly into the sponges could enhance angiogenesis. Chymostatin inhibited the angiogenesis induced by Ang I but not Ang II, suggesting the presence of a chymase-like Ang II-generating activity in the sponge granulomas. Our results may suggest a potential ability of chymase to promote angiogenesis through the local chymase-dependent and angiotensin-converting enzyme-dependent Ang II generating system in pathophysiological angiogenesis.	Kitasato Univ, Sch Med, Dept Pharmacol, Sagamihara, Kanagawa 2288555, Japan; Nippon Steel Corp Ltd, Adv Mat & Technol Res Labs, Life Sci Res Ctr, Kawasaki, Kanagawa 2110035, Japan	Kitasato University; Nippon Steel & Sumitomo Metal Corporation	Muramatsu, M (corresponding author), Pharmacia & Upjohn Inc, Res & Dev, Res Dept, Shinjuku Ku, 3-20-2 Nishi Shinjuku, Tokyo 1631448, Japan.		Majima, Masataka/ABH-3063-2021	Katada, Jun/0000-0003-3588-3686				ACETO JF, 1990, AM J PHYSIOL, V258, pH806, DOI 10.1152/ajpheart.1990.258.3.H806; BELL L, 1990, AM J PATHOL, V137, P7; CAUGHEY GH, 1988, BIOCHIM BIOPHYS ACTA, V952, P142, DOI 10.1016/0167-4838(88)90109-4; Chua CC, 1998, BBA-MOL CELL RES, V1401, P187, DOI 10.1016/S0167-4889(97)00129-8; CLINTON M, 1988, INT J MICROCIRC, V7, P315; COLVILLENASH PR, 1992, ANN RHEUM DIS, V51, P919, DOI 10.1136/ard.51.7.919; EISENBERG M, 1984, BIOCHEM BIOPH RES CO, V125, P279, DOI 10.1016/S0006-291X(84)80365-4; FERNANDEZ LA, 1985, J LAB CLIN MED, V105, P141; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; GIBBONS GH, 1992, J CLIN INVEST, V90, P456, DOI 10.1172/JCI115881; GOTO F, 1993, LAB INVEST, V69, P508; GRUBER BL, 1994, J IMMUNOL, V152, P5860; GRUBER BL, 1995, BLOOD, V86, P2488; GUBER BL, 1990, CLIN RES, V38, pA578; Hu DE, 1996, BRIT J PHARMACOL, V117, P545, DOI 10.1111/j.1476-5381.1996.tb15225.x; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; Ito K, 1995, Hypertens Res, V18, P69, DOI 10.1291/hypres.18.69; JOHNSON LA, 1988, BIOCHIM BIOPHYS ACTA, V953, P269, DOI 10.1016/0167-4838(88)90035-0; KOHARA K, 1993, HYPERTENSION, V21, P975, DOI 10.1161/01.HYP.21.6.975; LAGUNOFF D, 1963, ANN NY ACAD SCI, V103, P185, DOI 10.1111/j.1749-6632.1963.tb53698.x; LENOBLE FAC, 1991, EUR J PHARMACOL, V195, P305, DOI 10.1016/0014-2999(91)90552-2; LYALL F, 1988, J HYPERTENS, V6, pS438, DOI 10.1097/00004872-198812040-00138; Majima M, 1997, JPN J PHARMACOL, V75, P105, DOI 10.1254/jjp.75.105; Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137; MIZUTANI H, 1991, J EXP MED, V174, P821, DOI 10.1084/jem.174.4.821; NORRBY K, 1986, VIRCHOWS ARCH B, V52, P195, DOI 10.1007/BF02889963; OKAMURA T, 1990, J CARDIOVASC PHARM, V15, P353, DOI 10.1097/00005344-199003000-00002; OKUNISHI H, 1987, BIOCHEM BIOPH RES CO, V149, P1186, DOI 10.1016/0006-291X(87)90533-X; Okunishi H, 1984, J Hypertens, V2, P277; OKUNISHI H, 1993, JPN J PHARMACOL, V62, P207, DOI 10.1254/jjp.62.207; Otani A, 1998, CIRC RES, V82, P619, DOI 10.1161/01.RES.82.5.619; PAQUET JL, 1990, J HYPERTENS, V8, P565, DOI 10.1097/00004872-199006000-00010; PEACOCK DJ, 1992, J EXP MED, V175, P1135, DOI 10.1084/jem.175.4.1135; Pearse A.G.E., 1985, HISTOCHEMISTRY, V2; PLUNKETT ML, 1990, LAB INVEST, V62, P510; QU ZH, 1995, AM J PATHOL, V147, P564; REILLY CF, 1982, J BIOL CHEM, V257, P8619; ROBERTSON NE, 1991, CANCER RES, V51, P1339; SAARINEN J, 1994, J BIOL CHEM, V269, P18134; SAYAMA S, 1987, J BIOL CHEM, V262, P6808; SORBO J, 1994, INT J EXP PATHOL, V75, P43; SORBO J, 1992, AGENTS ACTIONS, V32, pC387; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; Takai S, 1996, LIFE SCI, V58, P591, DOI 10.1016/0024-3205(95)02328-3; TAYLOR S, 1982, NATURE, V297, P307, DOI 10.1038/297307a0; URATA H, 1991, J BIOL CHEM, V266, P17173; URATA H, 1993, J CLIN INVEST, V91, P1269, DOI 10.1172/JCI116325; WISE G N, 1956, Trans Am Ophthalmol Soc, V54, P729; ZAUBERMAN H, 1969, EXP EYE RES, V8, P77, DOI 10.1016/S0014-4835(69)80083-7	50	100	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5545	5552		10.1074/jbc.275.8.5545	http://dx.doi.org/10.1074/jbc.275.8.5545			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681534	hybrid			2022-12-27	WOS:000085474500041
J	Pink, JJ; Planchon, SM; Tagliarino, C; Varnes, ME; Siegel, D; Boothman, DA				Pink, JJ; Planchon, SM; Tagliarino, C; Varnes, ME; Siegel, D; Boothman, DA			NAD(P)H : quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCTASE DT-DIAPHORASE; BREAST-CANCER CELLS; MITOMYCIN-C; DNA-DAMAGE; HYDROGEN-PEROXIDE; HUMAN LUNG; RAT-LIVER; MENADIONE 2-METHYL-1,4-NAPHTHOQUINONE; POLY(ADP-RIBOSE) POLYMERASE; BIOREDUCTIVE ACTIVATION	beta-Lapachone activates a novel apoptotic response in a number of cell lines. We demonstrate that the enzyme NAD(P)H:quinone oxidoreductase (NQO1) substantially enhances the toxicity of beta-lapachone. NQO1 expression directly correlated with sensitivity to a 4-h pulse of beta-lapachone in a panel of breast cancer cell lines, and the NQO1 inhibitor, dicoumarol, significantly protected NQO1-expressing cells from all aspects of beta-lapachone toxicity. Stable transfection of the NQO1-deficient cell line, MDA-MB-468, with an NQO1 expression plasmid increased apoptotic responses and lethality after beta-lapachone exposure. Dicoumarol blocked both the apoptotic responses and lethality. Biochemical studies suggest that reduction of beta-lapachone by NQO1 leads to a futile cycling between the quinone and hydroquinone forms, with a concomitant loss of reduced NAD(P)H. In addition, the activation of a cysteine protease, which has characteristics consistent with the neutral calcium-dependent protease, calpain, is observed after beta-lapachone treatment. This is the first definitive elucidation of an intracellular target for beta-lapachone in tumor cells. NQO1 could be exploited for gene therapy, radiotherapy, and/or chemopreventive interventions, since the enzyme is elevated in a number of tumor types (i.e. breast and lung) and during neoplastic transformation.	Case Western Reserve Univ, Dept Radiat Oncol, Lab Mol Stress Responses, Ireland Comprehens Canc Ctr, Cleveland, OH 44106 USA; Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Denver, CO 80262 USA	Case Western Reserve University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Boothman, DA (corresponding author), Case Western Reserve Univ, Dept Radiat Oncol, Lab Mol Stress Responses, Ireland Comprehens Canc Ctr, Cleveland, OH 44106 USA.		Boothman, David/Q-7776-2019; Planchon, Sarah/A-5731-2009		NCI NIH HHS [CA51210, R01 CA092250] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051210, R01CA092250] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKMAN SA, 1987, J PHARMACOL EXP THER, V240, P486; BEALL HD, 1994, CANCER RES, V54, P3196; BEALL HD, 1995, MOL PHARMACOL, V48, P499; BELINSKY M, 1993, CANCER METAST REV, V12, P103, DOI 10.1007/BF00689804; BELLOMO G, 1982, J BIOL CHEM, V257, P1558; BOORSTEIN RJ, 1983, BIOCHEM BIOPH RES CO, V117, P30, DOI 10.1016/0006-291X(83)91536-X; BOORSTEIN RJ, 1984, BIOCHEM BIOPH RES CO, V118, P828, DOI 10.1016/0006-291X(84)91469-4; BOOTHMAN DA, 1989, P NATL ACAD SCI USA, V86, P4963, DOI 10.1073/pnas.86.13.4963; BOOTHMAN DA, 1989, CANCER RES, V49, P605; BOOTHMAN DA, 1987, CANCER RES, V47, P5361; BOOTHMAN DA, 1992, INT J RADIAT ONCOL, V24, P939, DOI 10.1016/0360-3016(92)90478-Z; BOOTHMAN DA, 1993, P NATL ACAD SCI USA, V90, P7200, DOI 10.1073/pnas.90.15.7200; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; CADENAS E, 1995, BIOCHEM PHARMACOL, V49, P127, DOI 10.1016/S0006-2952(94)00333-5; Chau YP, 1998, FREE RADICAL BIO MED, V24, P660, DOI 10.1016/S0891-5849(97)00337-7; CHEN S, 1995, MOL PHARMACOL, V47, P934; Cross JV, 1999, J BIOL CHEM, V274, P31150, DOI 10.1074/jbc.274.44.31150; DOCAMPO R, 1979, BIOCHEM PHARMACOL, V28, P723, DOI 10.1016/0006-2952(79)90348-4; DOCAMPO R, 1978, ARCH BIOCHEM BIOPHYS, V186, P292, DOI 10.1016/0003-9861(78)90438-1; DUTHIE SJ, 1989, BRIT J CANCER, V60, P566, DOI 10.1038/bjc.1989.314; FARBER E, 1984, CAN J BIOCHEM CELL B, V62, P486, DOI 10.1139/o84-066; Fitzsimmons SA, 1996, J NATL CANCER I, V88, P259, DOI 10.1093/jnci/88.5.259; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Frydman B, 1997, CANCER RES, V57, P620; Gustafson DL, 1996, MOL PHARMACOL, V50, P728; HESS R, 1994, TOXICOL LETT, V72, P43, DOI 10.1016/0378-4274(94)90008-6; HOLLANDER PM, 1975, ARCH BIOCHEM BIOPHYS, V169, P560, DOI 10.1016/0003-9861(75)90200-3; HOSODA S, 1974, J BIOL CHEM, V249, P6416; IYANAGI T, 1990, FREE RADICAL RES COM, V8, P259, DOI 10.3109/10715769009053359; JAISWAL AK, 1994, J BIOL CHEM, V269, P14502; JAISWAL AK, 1988, J BIOL CHEM, V263, P13572; JOSEPH P, 1994, ONCOL RES, V6, P525; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KEYES SR, 1984, CANCER RES, V44, P5638; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LI CJ, 1993, J BIOL CHEM, V268, P22463; MALKINSON AM, 1992, CANCER RES, V52, P4752; Manna SK, 1999, BIOCHEM PHARMACOL, V57, P763, DOI 10.1016/S0006-2952(98)00354-2; Marin A, 1997, BRIT J CANCER, V76, P923, DOI 10.1038/bjc.1997.485; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Pink JJ, 1996, BRIT J CANCER, V74, P1227, DOI 10.1038/bjc.1996.521; PLANCHON SM, 1995, CANCER RES, V55, P3706; Portela MPM, 1996, BIOCHEM PHARMACOL, V51, P275, DOI 10.1016/0006-2952(95)02168-X; Portela MPM, 1996, BIOCHEM PHARMACOL, V52, P1875; PRAKASH AS, 1993, BIOCHEMISTRY-US, V32, P5518, DOI 10.1021/bi00072a005; PREUSCH PC, 1991, FREE RADICAL BIO MED, V11, P77, DOI 10.1016/0891-5849(91)90191-5; Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382; Rauth AM, 1997, ONCOL RES, V9, P339; RILEY RJ, 1992, BIOCHEM PHARMACOL, V43, P1657, DOI 10.1016/0006-2952(92)90694-E; ROBERTSON N, 1994, EUR J CANCER, V30A, P1013, DOI 10.1016/0959-8049(94)90134-1; ROSS D, 1985, CHEM-BIOL INTERACT, V55, P177, DOI 10.1016/S0009-2797(85)80126-5; ROSS D, 1993, CANCER METAST REV, V12, P83, DOI 10.1007/BF00689803; ROSS D, 1994, ONCOL RES, V6, P493; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUERCH AR, 1978, EUR J BIOCHEM, V84, P197, DOI 10.1111/j.1432-1033.1978.tb12157.x; SIEGEL D, 1992, BIOCHEMISTRY-US, V31, P7879, DOI 10.1021/bi00149a019; Siegel D, 1998, CLIN CANCER RES, V4, P2065; Siegel D, 1999, PHARMACOGENETICS, V9, P113, DOI 10.1097/00008571-199902000-00015; SIEGEL D, 1990, CANCER RES, V50, P7483; Squier MKT, 1999, J CELL PHYSIOL, V178, P311, DOI 10.1002/(SICI)1097-4652(199903)178:3<311::AID-JCP5>3.3.CO;2-K; Squier MKT, 1997, J IMMUNOL, V158, P3690; Strobel H W, 1978, Methods Enzymol, V52, P89; THOR H, 1982, J BIOL CHEM, V257, P2419; Vanni A, 1998, MUTAT RES-FUND MOL M, V401, P55, DOI 10.1016/S0027-5107(97)00273-X; WEFERS H, 1983, ARCH BIOCHEM BIOPHYS, V224, P568, DOI 10.1016/0003-9861(83)90244-8; WILLIAMS JB, 1984, ARCH BIOCHEM BIOPHYS, V232, P408, DOI 10.1016/0003-9861(84)90556-3; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Wuerzberger SM, 1998, CANCER RES, V58, P1876; Zhao QJ, 1997, P NATL ACAD SCI USA, V94, P1669, DOI 10.1073/pnas.94.5.1669	70	316	329	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5416	5424		10.1074/jbc.275.8.5416	http://dx.doi.org/10.1074/jbc.275.8.5416			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681517	hybrid			2022-12-27	WOS:000085474500024
J	Suzuki, N; Ishizaki, J; Yokota, Y; Higashino, K; Ono, T; Ikeda, M; Fujii, N; Kawamoto, K; Hanasaki, K				Suzuki, N; Ishizaki, J; Yokota, Y; Higashino, K; Ono, T; Ikeda, M; Fujii, N; Kawamoto, K; Hanasaki, K			Structures, enzymatic properties, and expression of novel human and mouse secretory phospholipase A(2)s	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-MOLECULAR-WEIGHT; ACUTE LUNG INJURY; II PHOSPHOLIPASE-A2; BINDING-SITE; PANCREATIC PHOSPHOLIPASE-A2; RECOMBINANT EXPRESSION; RHEUMATOID-ARTHRITIS; GENE; RAT; CLONING	Mammalian secretory phospholipase A(2)s (sPLA(2)s) form a family of structurally related enzymes that are involved in a variety of physiological and pathological processes via the release of arachidonic acid from membrane phospholipids or the binding to specific membrane receptors. Here, we report the cloning and characterization of a novel sPLA(2) that is the sixth isoform of the sPLA(2) family found in humans. The novel human mature sPLA(2) consists of 123 amino acids (M-r = 14,000) and is most similar to group IIA sPLA(2) (sPLA(2)-IIA) with respect to the number and positions of cysteine residues as well as overall identity (51%), Therefore, this novel sPLA(2) should be categorized into group II and called group IIE (sPLA(2)-IIE) following the recently identified group IID sPLA(2) (sPLA(2)-IID). The enzymatic properties of recombinant human sPLA(2)-IIE were almost identical to those of sPLA(2)-IIA and IID in terms of Ca2+ requirement, optimal pH, substrate specificity, as well as high susceptibility to the sPLA(2) inhibitor indoxam. Along with the biochemical properties of proteins, genetic and evolutional similarities were also observed among these three types of group II sPLA(2)s as to the chromosomal location of the human gene (1p36) and the exon/intron organization. The expression of sPLA(2)-IIE transcripts in humans was restricted to the brain, heart, lung, and placenta in contrast to broad expression profiles for sPLA(2)-IIA and -IID. In sPLA(2)-IIA-deficient mice, the expression of sPLA(2)-IIE was markedly enhanced in the lung and small intestine upon endotoxin challenge, which contrasted with the reduced expression of sPLA(2)-IID mRNA In situ hybridization analysis revealed elevation of sPLA(2)-IIE mRNA at alveolar macrophage-like cells in the lung of endotoxin-treated mice. These findings suggest a distinct functional role of novel sPLA(2)-IIE in the progression of inflammatory processes.	Shionogi & Co Ltd, Shionogi Res Labs, Fukushima Ku, Osaka 5530002, Japan	Shionogi & Company Limited	Hanasaki, K (corresponding author), Shionogi & Co Ltd, Shionogi Res Labs, Fukushima Ku, Sagisu 5-12-4, Osaka 5530002, Japan.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arbibe L, 1997, J IMMUNOL, V159, P391; Arbibe L, 1998, J CLIN INVEST, V102, P1152, DOI 10.1172/JCI3236; ARITA H, 1991, J BIOL CHEM, V266, P19139; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; BRACKERTZ D, 1977, ARTHRITIS RHEUM, V20, P841, DOI 10.1002/art.1780200314; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; Copic A, 1999, J BIOL CHEM, V274, P26315, DOI 10.1074/jbc.274.37.26315; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P118, DOI 10.1016/0005-2744(68)90249-0; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Draheim SE, 1996, J MED CHEM, V39, P5159, DOI 10.1021/jm960487f; Fenard D, 1999, J CLIN INVEST, V104, P611, DOI 10.1172/JCI6915; Foreman-Wykert AK, 1999, J CLIN INVEST, V103, P715, DOI 10.1172/JCI5468; Furue S, 1997, GUT, V41, P826, DOI 10.1136/gut.41.6.826; Grass DS, 1996, J CLIN INVEST, V97, P2233, DOI 10.1172/JCI118664; GREEN JA, 1991, INFLAMMATION, V15, P355, DOI 10.1007/BF00917352; GRONROOS JM, 1992, DIGESTION, V52, P232, DOI 10.1159/000200958; Hagishita S, 1996, J MED CHEM, V39, P3636, DOI 10.1021/jm960395q; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; Hanasaki K, 1997, J BIOL CHEM, V272, P32792, DOI 10.1074/jbc.272.52.32792; Hanasaki K, 1999, ARCH BIOCHEM BIOPHYS, V372, P215, DOI 10.1006/abbi.1999.1511; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; HIGASHINO K, 1994, EUR J BIOCHEM, V225, P375, DOI 10.1111/j.1432-1033.1994.00375.x; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; KISHINO J, 1994, J BIOL CHEM, V269, P5092; Kitadokoro K, 1998, J BIOCHEM, V123, P619; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; Lan HY, 1996, AM J PATHOL, V149, P1119; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; NAKANO T, 1990, FEBS LETT, V273, P23, DOI 10.1016/0014-5793(90)81042-M; OHARA O, 1995, PROG LIPID RES, V34, P117, DOI 10.1016/0163-7827(94)00009-B; PRUZANSKI W, 1988, J RHEUMATOL, V15, P1351; RIGGINS GJ, 1995, CANCER RES, V55, P5184; Sawada H, 1999, EUR J BIOCHEM, V263, P826, DOI 10.1046/j.1432-1327.1999.00565.x; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; Sharp PA, 1997, CELL, V91, P875, DOI 10.1016/S0092-8674(00)80479-1; Spirio LN, 1996, CANCER RES, V56, P955; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; TOHKIN M, 1993, J BIOL CHEM, V268, P2865; TOJO H, 1993, J LIPID RES, V34, P837; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; VADAS P, 1986, LAB INVEST, V55, P391; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 1999, J BIOL CHEM, V274, P19152, DOI 10.1074/jbc.274.27.19152; VIAL D, 1995, J BIOL CHEM, V270, P17327, DOI 10.1074/jbc.270.29.17327; WOOLEY PH, 1985, J IMMUNOL, V135, P2443; YOKOTA Y, 1999, BIOCHIM BIOPHYS ACTA, V18, P213; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423	59	145	150	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5785	5793		10.1074/jbc.275.8.5785	http://dx.doi.org/10.1074/jbc.275.8.5785			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681567	hybrid			2022-12-27	WOS:000085474500074
J	Chang, MY; Potter-Perigo, S; Tsoi, C; Chait, A; Wight, TN				Chang, MY; Potter-Perigo, S; Tsoi, C; Chait, A; Wight, TN			Oxidized low density lipoproteins regulate synthesis of monkey aortic smooth muscle cell proteoglycans that have enhanced native low density lipoprotein binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CORONARY-ARTERIES; EXTRACELLULAR-MATRIX; CHONDROITIN SULFATE; ENDOTHELIAL-CELLS; GROWTH-FACTOR; ATHEROSCLEROTIC PLAQUES; MOLECULAR-CLONING; I BIGLYCAN; DECORIN; EXPRESSION	Oxidized low density lipoproteins (Ox-LDL) affect several biological processes involved in atherogenesis, However, it is not known whether Ox-LDL can regulate proteoglycan expression and thus affect arterial wall lipoprotein retention. This study evaluated whether Ox-LDL, as compared with native LDL, regulates proteoglycan expression by monkey arterial smooth muscle cells in vitro and whether proteoglycans synthesized in the presence of Ox LDL exhibit altered lipoprotein binding properties. Ox-LDL stimulated glycosaminoglycan synthesis, as measured by (SO4)-S-35 incorporation, by 30-50% over that of native LDL, The effect was maximal after 72 h of exposure to 5 mu g/ml of Ox-LDL, The molecular sizes of versican, biglycan, and decorin increased in response to Ox-LDL, as indicated by size exclusion chromatography and SDS-polyacrylamide gel electrophoresis. These effects could be mimicked by the lipid extract of Ox-LDL, These size increases were largely due to chain elongation and not to alterations in the ratio of (SO4)-S-35 to [H-3]glucosamine incorporation. Affinity chromatography indicated that Ox-LDL stimulated the synthesis of proteoglycans with high affinity for native LDL, Ox-LDL also specifically stimulated mRNA expression for biglycan (but not versican or decorin), which was correlated with increased expression of secreted biglycan, Thus, Ox-LDL may influence lipoprotein retention by regulating synthesis of biglycan and also by altering glycosaminoglycan synthesis of vascular proteoglycans so as to enhance lipoprotein binding properties.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Wight, TN (corresponding author), Univ Washington, Dept Pathol, Box 357470, Seattle, WA 98195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035816] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18645] Funding Source: Medline; NIDDK NIH HHS [DK02456, DK35816] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARES MPS, 1995, ARTERIOSCL THROM VAS, V15, P1584, DOI 10.1161/01.ATV.15.10.1584; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BIHARIVARGA M, 1988, ARTERIOSCLEROSIS, V8, P851, DOI 10.1161/01.ATV.8.6.851; Buege J A, 1978, Methods Enzymol, V52, P302; CAMEJO G, 1993, J BIOL CHEM, V268, P14131; Camejo German, 1993, Current Opinion in Lipidology, V4, P385, DOI 10.1097/00041433-199310000-00007; CARDOSO LEM, 1994, ARTERIOSCLER THROMB, V14, P115, DOI 10.1161/01.ATV.14.1.115; CHAIT A, 1982, METABOLISM, V31, P721, DOI 10.1016/0026-0495(82)90204-9; Chait Alan, 1994, Current Opinion in Lipidology, V5, P365, DOI 10.1097/00041433-199410000-00008; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG BH, 1980, J LIPID RES, V21, P284; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DALFERES ER, 1987, EXP MOL PATHOL, V47, P363, DOI 10.1016/0014-4800(87)90019-0; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; Ding GH, 1997, KIDNEY INT, V51, P147, DOI 10.1038/ki.1997.18; DODGE GR, 1991, GENOMICS, V10, P673, DOI 10.1016/0888-7543(91)90451-J; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; Evanko SP, 1998, AM J PATHOL, V152, P533; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; FOLCH J, 1957, J BIOL CHEM, V226, P497; Francis GA, 1996, BIOCHEMISTRY-US, V35, P15188, DOI 10.1021/bi9618169; FROSTEGARD J, 1990, P NATL ACAD SCI USA, V87, P904, DOI 10.1073/pnas.87.3.904; Frostegard J, 1997, ARTERIOSCL THROM VAS, V17, P963, DOI 10.1161/01.ATV.17.5.963; GALIS ZS, 1993, AM J PATHOL, V142, P1432; Gutierrez P, 1997, CARDIOVASC PATHOL, V6, P271, DOI 10.1016/S1054-8807(97)00001-X; Hascall V.C., 1981, CELL BIOL EXTRACELLU, P39; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HOLLMANN J, 1986, EXP CELL RES, V167, P484, DOI 10.1016/0014-4827(86)90188-6; HOOVER GA, 1988, ARTERIOSCLEROSIS, V8, P525, DOI 10.1161/01.ATV.8.5.525; JARVELAINEN HT, 1991, J BIOL CHEM, V266, P23274; JIMI S, 1994, ATHEROSCLEROSIS, V107, P109, DOI 10.1016/0021-9150(94)90146-5; JIMI S, 1995, ATHEROSCLEROSIS, V116, P15, DOI 10.1016/0021-9150(95)05515-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALDEN LT, 1991, J BIOL CHEM, V266, P13901; MOURAO PAS, 1981, BIOCHIM BIOPHYS ACTA, V674, P178, DOI 10.1016/0304-4165(81)90376-7; O'Brien KD, 1998, CIRCULATION, V98, P519, DOI 10.1161/01.CIR.98.6.519; PARHAMI F, 1993, J CLIN INVEST, V92, P471, DOI 10.1172/JCI116590; PIETILA K, 1992, ATHEROSCLEROSSIS, V42, P67; PILLAI S, 1980, BIOCHEM INT, V1, P55; PODET EJ, 1991, ARTERIOSCLER THROMB, V11, P116, DOI 10.1161/01.ATV.11.1.116; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; RIESSEN R, 1994, AM J PATHOL, V144, P962; Roh DD, 1998, AM J NEPHROL, V18, P344, DOI 10.1159/000013363; SANTRA M, 1994, J BIOL CHEM, V269, P579; SCHONHERR E, 1993, ARTERIOSCLER THROMB, V13, P1026, DOI 10.1161/01.ATV.13.7.1026; SCHONHERR E, 1991, J BIOL CHEM, V266, P17640; SRINIVASAN SR, 1986, ATHEROSCLEROSIS, V62, P201, DOI 10.1016/0021-9150(86)90094-8; Ungefroren H, 1996, J BIOL CHEM, V271, P15787, DOI 10.1074/jbc.271.26.15787; Vijayagopal P, 1996, ATHEROSCLEROSIS, V127, P195, DOI 10.1016/S0021-9150(96)05954-0; WAGNER WD, 1989, ATHEROSCLEROSIS, V75, P49, DOI 10.1016/0021-9150(89)90206-2; WAGNER WD, 1986, ARTERIOSCLEROSIS, V6, P407, DOI 10.1161/01.ATV.6.4.407; WASTESON A, 1973, BIOCHEM J, V136, P1069, DOI 10.1042/bj1361069; WIGHT TN, 1996, EXTRACELLULAR MATRIX, V1, P175; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; Witztum J L, 1994, J Atheroscler Thromb, V1, P71; WOSU L, 1984, CAN J BIOCHEM CELL B, V62, P984, DOI 10.1139/o84-126; YAO LY, 1994, MATRIX BIOL, V14, P213, DOI 10.1016/0945-053X(94)90185-6	59	76	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4766	4773		10.1074/jbc.275.7.4766	http://dx.doi.org/10.1074/jbc.275.7.4766			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671509	hybrid			2022-12-27	WOS:000085378200035
J	Draganescu, A; Hodawadekar, SC; Gee, KR; Brenner, C				Draganescu, A; Hodawadekar, SC; Gee, KR; Brenner, C			Fhit-nucleotide specificity probed with novel fluorescent and fluorogenic substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE TRIAD PROTEIN; TUMOR-SUPPRESSOR; CELL; 5',5'''-P-1,P-3-TRIPHOSPHATE; HYDROLASE; COMPLEXES; CANCER; FORM; ACID	Fhit, a member of the histidine triad superfamily of nucleotide-binding proteins, binds and cleaves diadenosine polyphosphates and functions as a tumor suppressor in human epithelial cancers. Function of Fhit in tumor suppression does not require diadenosine polyphosphate cleavage but correlates with the ability to form substrate complexes. As diadenosine polyphosphates are at lower cellular concentrations than mononucleotides, we sought to quantify interactions between Fhit and competitive inhibitors with the use of diadenosine polyphosphate analogs containing fluorophores in place of one nucleoside. Appp-S-(7-diethylamino-4-methyl-3-(4-succinimidylphenyl)) coumarin (ApppAMC), Appp-S-(4-4-difluoFo-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacine-3-yl) methylaminoacetyl (ApppBODIPY), and GpppBODIPY, synthesized in high yield, are effective Fhit substrates, producing AMP or GIMP plus fluorophore diphosphates. GpppBODIPY cleavage is accompanied by a 5.4-fold increase in fluorescence because BODIPY fluorescence is quenched by stacking with guanine. Titration of unlabeled diadenosine polyphosphates, inorganic pyrophosphate, mononucleotides, and inorganic phosphate into fluorescent assays provided values of K-m and K-I as competitive inhibitors. The data indicate that Fhit discriminates between good substrates via k(cat) and against cellular competitors in equilibrium binding terms. Surprisingly, pyrophosphate competes better than purine mononucleotides.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Mol Probes Inc, Eugene, OR 97402 USA	Jefferson University	Brenner, C (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,Rom 826, Philadelphia, PA 19107 USA.	brenner@dada.jci.tju.edu	Brenner, Charles/D-6339-2014	Brenner, Charles/0000-0002-4955-3226	NATIONAL CANCER INSTITUTE [R01CA075954] Funding Source: NIH RePORTER; NCI NIH HHS [CA75954, R01 CA075954-03, R01 CA075954] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abend A, 1999, BIOCHEMISTRY-US, V38, P3668, DOI 10.1021/bi981895j; Asensio AC, 1999, BBA-PROTEIN STRUCT M, V1432, P396, DOI 10.1016/S0167-4838(99)00102-8; BARNES LD, 1985, ANAL BIOCHEM, V144, P296, DOI 10.1016/0003-2697(85)90120-4; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; BARSHOP BA, 1991, ANAL BIOCHEM, V197, P266, DOI 10.1016/0003-2697(91)90387-9; Blackburn GM, 1998, NUCLEOS NUCLEOT, V17, P301, DOI 10.1080/07328319808005178; Brenner C, 1999, PHOSPHORUS SULFUR, V144, P745; Brenner C, 1999, J CELL PHYSIOL, V181, P179, DOI 10.1002/(SICI)1097-4652(199911)181:2<179::AID-JCP1>3.0.CO;2-8; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; Brenner C, 1997, PROTEIN ENG, V10, P1461, DOI 10.1093/protein/10.12.1461; Chaudhuri AR, 1999, J BIOL CHEM, V274, P24378, DOI 10.1074/jbc.274.34.24378; Dhar G, 1999, J BIOL CHEM, V274, P14568, DOI 10.1074/jbc.274.21.14568; Geeganage S, 1998, BIOCHEMISTRY-US, V37, P14500, DOI 10.1021/bi9815546; HEUBNER K, 1999, ADV ONCOL, V15, P3; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Jencks W. P., 1987, CATALYSIS CHEM ENZYM; Ji L, 1999, ANAL BIOCHEM, V271, P114, DOI 10.1006/abio.1999.4131; Ji L, 1999, CANCER RES, V59, P3333; KAROLIN J, 1994, J AM CHEM SOC, V116, P7801, DOI 10.1021/ja00096a042; KHALFAN H, 1986, HISTOCHEM J, V18, P497, DOI 10.1007/BF01675617; KORNBERG A, 1992, DNA REPLICATION, P54; Lima CD, 1997, STRUCTURE, V5, P763, DOI 10.1016/S0969-2126(97)00231-1; Liu XH, 1999, ANGEW CHEM INT EDIT, V38, P1244, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1244::AID-ANIE1244>3.0.CO;2-0; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Pace HC, 1998, P NATL ACAD SCI USA, V95, P5484, DOI 10.1073/pnas.95.10.5484; Pekarsky Y, 1998, P NATL ACAD SCI USA, V95, P8744, DOI 10.1073/pnas.95.15.8744; Ripoll C, 1996, DIABETES, V45, P1431, DOI 10.2337/diabetes.45.10.1431; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sozzi G, 1998, CANCER RES, V58, P5032; THOMPSON CB, 1984, J IMMUNOL, V133, P2333; Vartanian A, 1997, FEBS LETT, V415, P160, DOI 10.1016/S0014-5793(97)01086-7; Vartanian A, 1996, FEBS LETT, V381, P32, DOI 10.1016/0014-5793(96)00073-7	33	62	67	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4555	4560		10.1074/jbc.275.7.4555	http://dx.doi.org/10.1074/jbc.275.7.4555			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671479	hybrid, Green Accepted			2022-12-27	WOS:000085378200005
J	Quiram, PA; McIntosh, JM; Sine, SM				Quiram, PA; McIntosh, JM; Sine, SM			Pairwise interactions between neuronal alpha(7) acetylcholine receptors and alpha-conotoxin PnIB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR DISSECTION; SUBUNIT INTERFACES; IDENTIFICATION; SELECTIVITY; DETERMINANTS; RESIDUES; IMI	This work uses alpha-conotoxin PnIB to probe the agonist binding site of neuronal alpha(7) acetylcholine receptors, We mutated the 13 non-cysteine residues in CTx PnIB, expressed alpha(7)/5-hydroxytryptamine-3 homomeric receptors in 293 HEK cells, and measured binding of each mutant toxin to the expressed receptors by competition against the initial rate of I-125-alpha-bungarotoxin binding. The results reveal that residues Ser-4, Leu-5, Pro-6, Pro-7, Ala-9, and Leu-10 endow CTx PnIB with affinity for alpha(7)/5-hydroxytryptamine-3 receptors; side chains of these residues cluster in a localized region within the three-dimensional structure of CTx PnIB, We next mutated key residues in the seven loops of alpha(7) that converge at subunit interfaces to form the agonist binding site, The results reveal predominant contributions by residues Trp-149 and Tyr-93 in alpha(7) and smaller contributions by Ser-34, Arg-186, Tyr-188, and Tyr-195, To identify pairwise interactions that stabilize the receptor-conotoxin complex, we measured binding of receptor and toxin mutations and analyzed the results by double mutant cycles, The results reveal a single dominant interaction between Leu-10 of CTx PnIB and Trp-149 of alpha(7) that anchors the toxin to the binding site. We also find weaker interactions between Pro-6 of CTx PnIB and Trp-149 and between both Pro-g and Pro-7 and Tyr-93 of alpha(7). The overall results demonstrate that a localized hydrophobic region in CTx PnIB interacts with conserved aromatic residues on one of the two faces of the alpha(7) binding site.	Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Receptor Biol Lab, Rochester, MN 55905 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA	Mayo Clinic; Utah System of Higher Education; University of Utah	Sine, SM (corresponding author), Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Receptor Biol Lab, Rochester, MN 55905 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH053631, R01MH053631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031744, R37NS031744] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48677] Funding Source: Medline; NIMH NIH HHS [MH53631] Funding Source: Medline; NINDS NIH HHS [NS31744] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; ANDRUE D, 1994, METHODS MOL BIOL PEP, V35, P139; Groebe DR, 1997, BIOCHEMISTRY-US, V36, P6469, DOI 10.1021/bi970195w; HOROVITZ A, 1990, J MOL BIOL, V214, P613, DOI 10.1016/0022-2836(90)90275-Q; HU SH, 1997, BIOCHEMISTRY-US, V36, P11325; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; PRINCE RJ, 1997, NICOTINIC ACETYLCHOL, P31; Quiram PA, 1998, J BIOL CHEM, V273, P11001, DOI 10.1074/jbc.273.18.11001; Quiram PA, 1999, J BIOL CHEM, V274, P19517, DOI 10.1074/jbc.274.28.19517; Quiram PA, 1998, J BIOL CHEM, V273, P11007, DOI 10.1074/jbc.273.18.11007; SINE S, 1979, J BIOL CHEM, V254, P3315; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; Tsigelny I, 1997, BIOPHYS J, V73, P52, DOI 10.1016/S0006-3495(97)78047-0	14	63	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4889	4896		10.1074/jbc.275.7.4889	http://dx.doi.org/10.1074/jbc.275.7.4889			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671525	hybrid			2022-12-27	WOS:000085378200051
J	Blaxall, BC; Pellett, AC; Wu, SC; Pende, A; Port, JD				Blaxall, BC; Pellett, AC; Wu, SC; Pende, A; Port, JD			Purification and characterization of beta-adrenergic receptor mRNA-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; AU-RICH ELEMENT; AGONIST-INDUCED DESTABILIZATION; SMOOTH-MUSCLE CELLS; C-6 GLIOMA-CELLS; DOWN-REGULATION; GROWTH-FACTOR; MEDIATED DESTABILIZATION; GENE-TRANSCRIPTION; ELAV PROTEIN	beta-Adrenergic receptors (beta-ARs), like other G-protein-coupled receptors, can undergo post-transciptional regulation at the level of mRNA stability. In particular, the human beta(1)- and beta(2)-ARs and the hamster beta(2)-AR mRNA undergo beta-agonist-mediated destabilization. By UV cross-linking, we have previously described an similar to M-r 36,000 mRNA-binding protein, beta ARB, that binds to A/C+U-rich nucleotide regions within 3'-untranslated regions. Further, we have demonstrated previously that beta ARB is immunologically distinct from AUF1/heterogeneous nuclear ribonucleoprotein (hnRNP) D, another mRNA-binding protein associated with destabilization of A+U-rich mRNAs (Pende, A., Tremmel, K. D., De-Maria, C. T., Blaxall, B. C., Minobe, W., Sherman, J. A., Bisognano, J., Bristow, M. R., Brewer, G., and Port, J. D. (1996) J. Biol. Chem. 271, 8493-8501). In this report, we describe the peptide composition of beta ARB. Mass spectrometric analysis of an similar to M-r 36,000 band isolated from ribosomal salt wash proteins revealed the presence of two mRNA-binding proteins, hnRNP Al, and the elav-like protein, HuR, both of which are known to bind to A+U-rich nucleotide regions. By immunoprecipitation, HuR appears to be the biologically dominant RNA binding component of beta ARB. Although hnRNP Al and HuR can both be immunoprecipitated from ribosomal salt wash proteins, the composition of beta ARB (HuR alone versus HuR and hnRNP Al) appears to be dependent on the mRNA probe used. The exact role of HuR and hnRNP Al in the regulation of beta-AR mRNA stability remains to be determined.	Univ Colorado, Hlth Sci Ctr, Dept Med, Div Cardiol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Port, JD (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Cardiol, 4200 E 9th Ave,B139, Denver, CO 80262 USA.	david.port@uchsc.edu	Blaxall, Burns/ABD-8289-2021	Port, Jonathan D./0000-0001-7048-3544	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL051239, R01HL051239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007635] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL051239, HL51239] Funding Source: Medline; NIGMS NIH HHS [GM07635] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; ANANT S, 1997, NUCL ACIDS S SER, V36, P115; Antic D, 1999, GENE DEV, V13, P449, DOI 10.1101/gad.13.4.449; Atasoy U, 1998, J CELL SCI, V111, P3145; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; Belasco J.G., 2012, CONTROL MESSENGER RN; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1990, METHOD ENZYMOL, V181, P202; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Buzby JS, 1996, BLOOD, V88, P2889, DOI 10.1182/blood.V88.8.2889.bloodjournal8882889; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Dangel V, 1996, BIOCHEM J, V317, P925, DOI 10.1042/bj3170925; Danner S, 1997, EUR J PHARMACOL, V331, P73, DOI 10.1016/S0014-2999(97)01022-4; Danner S, 1998, J BIOL CHEM, V273, P3223, DOI 10.1074/jbc.273.6.3223; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DeMaria CT, 1997, J BIOL CHEM, V272, P27635, DOI 10.1074/jbc.272.44.27635; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Dempsey LA, 1998, GENOMICS, V49, P378, DOI 10.1006/geno.1998.5237; Dempsey LA, 1998, J BIOL CHEM, V273, P29224, DOI 10.1074/jbc.273.44.29224; Dempsey LA, 1999, J BIOL CHEM, V274, P1066, DOI 10.1074/jbc.274.2.1066; DEVEDJIAN JC, 1991, J BIOL CHEM, V266, P14359; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; FERRY RC, 1994, J BIOL CHEM, V269, P31850; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Gao FB, 1996, J CELL SCI, V109, P579; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; Hamilton BJN, 1997, J BIOL CHEM, V272, P28732, DOI 10.1074/jbc.272.45.28732; HOSODA K, 1995, MOL PHARMACOL, V48, P206; HOUGH C, 1994, J NEUROCHEM, V62, P421; HUANG LY, 1993, J BIOL CHEM, V268, P25769; IZZO NJ, 1994, J BIOL CHEM, V269, P1705; IZZO NJ, 1990, P NATL ACAD SCI USA, V87, P6268, DOI 10.1073/pnas.87.16.6268; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; Kiledjian M, 1997, MOL CELL BIOL, V17, P4870, DOI 10.1128/MCB.17.8.4870; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lazou A, 1998, BIOCHEM J, V332, P459, DOI 10.1042/bj3320459; Lee NH, 1998, J BIOL CHEM, V273, P22317, DOI 10.1074/jbc.273.35.22317; LEE NH, 1994, J BIOL CHEM, V269, P4291; LEFKOWITZ RJ, 1993, END SOC 75 ANN M PRO, P204; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MAK JCW, 1995, J CLIN INVEST, V96, P99, DOI 10.1172/JCI118084; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Mitchusson KD, 1998, BIOCHEM BIOPH RES CO, V252, P357, DOI 10.1006/bbrc.1998.9598; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Nabors LB, 1998, J NEUROIMMUNOL, V92, P152, DOI 10.1016/S0165-5728(98)00196-9; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; Peng SSY, 1996, MOL CELL BIOL, V16, P1490; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; PLANCK SR, 1988, NUCLEIC ACIDS RES, V16, P11663, DOI 10.1093/nar/16.24.11663; PORT JD, 1992, J BIOL CHEM, V267, P24103; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SAKAUE M, 1991, J BIOL CHEM, V266, P5743; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; THOLANIKUNNEL BG, 1995, J BIOL CHEM, V270, P12787, DOI 10.1074/jbc.270.21.12787; Tholanikunnel BG, 1997, J BIOL CHEM, V272, P11471; Tittelbach V, 1998, BIOCHEM PHARMACOL, V56, P967, DOI 10.1016/S0006-2952(98)00231-7; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Williams NG, 1998, J BIOL CHEM, V273, P24624, DOI 10.1074/jbc.273.38.24624; Wilson GM, 1999, J BIOL CHEM, V274, P33374, DOI 10.1074/jbc.274.47.33374; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; WRESCHNER DH, 1988, EUR J BIOCHEM, V172, P333, DOI 10.1111/j.1432-1033.1988.tb13891.x; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zhong HY, 1999, J NEUROCHEM, V72, P2388, DOI 10.1046/j.1471-4159.1999.0722388.x; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	76	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4290	4297		10.1074/jbc.275.6.4290	http://dx.doi.org/10.1074/jbc.275.6.4290			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660597	hybrid			2022-12-27	WOS:000085288800081
J	Rowan, BG; Weigel, NL; O'Malley, BW				Rowan, BG; Weigel, NL; O'Malley, BW			Phosphorylation of steroid receptor coactivator-1 - Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROGESTERONE-RECEPTOR; NUCLEAR-RECEPTOR; TRANSCRIPTIONAL ACTIVITY; HISTONE ACETYLTRANSFERASE; ESTROGEN-RECEPTOR; DNA-BINDING; IN-VITRO; HORMONE; CBP; SEQUENCE	Steroid receptor coactivator-1 (SRC-1) is a member of a coactivator family that enhance the activation of the steroid/nuclear receptor superfamily of ligand-stimulated transcription factors. To study the regulation of SRC-1 by signaling pathways in the cell, the major phosphorylation sites of SRC-1 were identified in COS-1 cells using a combination of in vivo labeling with [P-32]H3PO4, modified manual Edman degradation, phosphoamino acid analysis, endoproteinase digestion, and mutagenesis of the SRC-1 phosphorylation sites. Seven phosphorylation sites were identified in SRC-1: serine 372, serine 395, serine 517, serine 569, serine 1033, threonine 1179, and serine 1185, All the sites contained consensus sequences for the serine/threonine-proline-directed family of protein kinases, and two sites (serine 395 and threonine 1179) contained a perfect consensus sequence for the mitogen-activated protein kinase family (Erk-1 and Erk-2), Furthermore, Erk-2 phosphorylated threonine 1179 and serine 1185 (and to a lesser extent, serine 395) in vitro, suggesting the importance of this pathway for SRC-1 regulation. Treatment of cells expressing SRC-1 with epidermal growth factor enhanced the ligand-dependent, progesterone receptor-mediated activation of a target reporter gene. These results identify phosphorylation as a regulatory modification of SRC-1 and provide a basis upon which to identify signaling pathways that regulate SRC-1 function and, consequently, modify steroid/nuclear receptor action.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Weigel, NL (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.							AIT SA, 1998, NATURE, V396, P184; Allgood VE, 1997, BIOCHEMISTRY-US, V36, P224, DOI 10.1021/bi961125c; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; AUSTEN BM, 1976, BIOCHEM BIOPH RES CO, V72, P411, DOI 10.1016/S0006-291X(76)80058-7; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; DENNER LA, 1989, ENDOCRINOLOGY, V125, P3051, DOI 10.1210/endo-125-6-3051; Fraser RA, 1998, J BIOL CHEM, V273, P16199, DOI 10.1074/jbc.273.26.16199; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; McKenna NJ, 1998, P NATL ACAD SCI USA, V95, P11697, DOI 10.1073/pnas.95.20.11697; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; Weiss RE, 1999, EMBO J, V18, P1900, DOI 10.1093/emboj/18.7.1900; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Zanger K, 1999, MOL ENDOCRINOL, V13, P268, DOI 10.1210/me.13.2.268; ZHANG YX, 1994, J BIOL CHEM, V269, P31034	41	223	226	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4475	4483		10.1074/jbc.275.6.4475	http://dx.doi.org/10.1074/jbc.275.6.4475			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660621	hybrid			2022-12-27	WOS:000085288800105
J	Winkler, GS; Araujo, SJ; Fiedler, U; Vermeulen, W; Coin, F; Egly, JM; Hoeijmakers, JHJ; Wood, RD; Timmers, HTM; Weeda, G				Winkler, GS; Araujo, SJ; Fiedler, U; Vermeulen, W; Coin, F; Egly, JM; Hoeijmakers, JHJ; Wood, RD; Timmers, HTM; Weeda, G			TFIIH with inactive XPD helicase functions in transcription initiation but is defective in DNA repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; NUCLEOTIDE EXCISION-REPAIR; XERODERMA-PIGMENTOSUM; SACCHAROMYCES-CEREVISIAE; MOLECULAR ANALYSIS; OPEN COMPLEX; FACTOR BTF2; GENE; MUTATIONS; PROTEIN	TFIIH is a multisubunit protein complex involved in RNA polymerase II transcription and nucleotide excision repair, which removes a wide variety of DNA lesions including UV-induced photoproducts. Mutations in the DNA-dependent ATPase/helicase subunits of TFIIH, XPB and XPD, are associated with three inherited syndromes as follows: xeroderma pigmentosum with or without Cockayne syndrome and trichothiodystrophy. By using epitope-tagged XPD we purified mammalian TFIIH carrying a wild type or an active-site mutant XPD subunit. Contrary to XPB, XPD helicase activity was dispensable for in vitro transcription, catalytic formation of trinucleotide transcripts, and promoter opening. Moreover, in contrast to XPB, microinjection of mutant XPD cDNA did not interfere with in vivo transcription. These data show directly that XPD activity is not required for transcription. However, during DNA repair, neither 5' nor 3' incisions in defined positions around a DNA adduct were detected in the presence of TFIIH containing inactive XPD, although substantial damage-dependent DNA synthesis was induced by the presence of mutant XPD both in cells and cell extracts. The aberrant damage-dependent DNA synthesis caused by the mutant XPD does not lead to effective repair, consistent with the discrepancy between repair synthesis and survival in cells from a number of XP-D patients.	Erasmus Univ, Ctr Med Genet, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands; Univ Utrecht, Physiol Chem Lab, NL-3508 TA Utrecht, Netherlands; Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Erasmus University Rotterdam; Utrecht University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Hoeijmakers, JHJ (corresponding author), Erasmus Univ, Ctr Med Genet, Dept Cell Biol & Genet, POB 1788, NL-3000 DR Rotterdam, Netherlands.	Hoeijmakers@gen.fgg.eur.nl	Araújo, Sofia J/J-5681-2014; Vermeulen, Wim/W-8708-2019; Coin, Frédéric/F-5925-2013; Wood, Richard D/M-6319-2018; Hoeijmakers, Jan/AAX-6972-2021	Araújo, Sofia J/0000-0002-4749-8913; Vermeulen, Wim/0000-0003-3616-734X; Coin, Frédéric/0000-0002-5620-8519; Wood, Richard D/0000-0002-9495-6892; Winkler, Sebastiaan/0000-0002-0476-162X				Coin F, 1998, NAT GENET, V20, P184, DOI 10.1038/2491; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; Constantinou A, 1999, J BIOL CHEM, V274, P5637, DOI 10.1074/jbc.274.9.5637; de Boer J, 1998, MOL CELL, V1, P981, DOI 10.1016/S1097-2765(00)80098-2; de Boer J, 1998, CANCER RES, V58, P89; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; Dvir A, 1996, J BIOL CHEM, V271, P7245, DOI 10.1074/jbc.271.13.7245; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FLORES O, 1992, J BIOL CHEM, V267, P2786; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GERARD M, 1991, J BIOL CHEM, V266, P20940; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HOLSTEGE FCP, 1996, THESIS UTRECHT U UTR; JOHNSON RT, 1985, J CELL SCI, V76, P115; JOHNSON RT, 1992, MUTAT RES, V273, P97, DOI 10.1016/0921-8777(92)90072-B; Kadkhodayan S, 1997, MUTAT RES-DNA REPAIR, V385, P47, DOI 10.1016/S0921-8777(97)00030-X; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; Marinoni JC, 1997, EMBO J, V16, P1093, DOI 10.1093/emboj/16.5.1093; Marinoni JC, 1997, METHODS, V12, P235, DOI 10.1006/meth.1997.0476; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PATERSON MC, 1987, J CELL SCI, P161; QIU HF, 1993, GENE DEV, V7, P2161, DOI 10.1101/gad.7.11.2161; ROY R, 1994, J BIOL CHEM, V269, P9826; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SHIVJI MKK, 1998, DNA REPAIR PROTOCOLS; Sijbers AM, 1996, NUCLEIC ACIDS RES, V24, P3370, DOI 10.1093/nar/24.17.3370; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Sung P, 1996, J BIOL CHEM, V271, P10821, DOI 10.1074/jbc.271.18.10821; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TANTIN D, 1994, J BIOL CHEM, V269, P17397; Taylor EM, 1997, P NATL ACAD SCI USA, V94, P8658, DOI 10.1073/pnas.94.16.8658; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; VERMEULEN W, 1994, AM J HUM GENET, V54, P191; VERMEULEN W, 1994, COLD SPRING HARB SYM, V59, P317, DOI 10.1101/SQB.1994.059.01.036; WEBER CA, 1994, MUTAT RES LETT, V324, P147, DOI 10.1016/0165-7992(94)90012-4; Winkler GS, 1998, J BIOL CHEM, V273, P1092, DOI 10.1074/jbc.273.2.1092; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6	55	136	138	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4258	4266		10.1074/jbc.275.6.4258	http://dx.doi.org/10.1074/jbc.275.6.4258			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660593	hybrid			2022-12-27	WOS:000085288800077
J	Lavrukhin, OV; Fortune, JM; Wood, TG; Burbank, DE; Van Etten, JL; Osheroff, N; Lloyd, RS				Lavrukhin, OV; Fortune, JM; Wood, TG; Burbank, DE; Van Etten, JL; Osheroff, N; Lloyd, RS			Topoisomerase II from Chlorella virus PBCV-1 - Characterization of the smallest known type II topoisomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE; DROSOPHILA-MELANOGASTER; PURIFICATION; ENZYME; YEAST; EXPRESSION; MECHANISM; GENE	Type II topoisomerases, a family of enzymes that govern topological DNA interconversions, are essential to many cellular processes in eukaryotic organisms. Because no data are available about the functions of these enzymes in the replication of viruses that infect eukaryotic hosts, this led us to express and characterize the first topoisomerase II encoded by one of such viruses. Paramecium bursaria chlorella virus 1 (PBCV-1) infects certain chlorella-like green algae and encodes a 120-kDa protein with a similarity to type II topoisomerases. This protein was expressed in Saccharomyces cerevisiae and was highly active in relaxation of both negatively and positively supercoiled plasmid DNA, catenation of plasmid DNA, and decatenation of kinetoplast DNA networks. Its optimal activity was determined, and the omission of Mg2+ or its replacement with other divalent cations abolished DNA relaxation, All activities of the recombinant enzyme were ATP dependent. Increasing salt concentrations shifted DNA relaxation from a normally processive mechanism to a distributive mode. Thus, even though the PBCV-1 enzyme is considerably smaller than other eukaryotic topoisomerase II enzymes (whose molecular masses are typically 160-180 kDa), it displays all the catalytic properties expected for a type II topoisomerase.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Univ Nebraska, Dept Plant Pathol, Lincoln, NE 68588 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Vanderbilt University; University of Nebraska System; University of Nebraska Lincoln	Lloyd, RS (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.		Wood, Thomas/GWZ-2481-2022; Wood, Thomas/B-6172-2012	Wood, Thomas/0000-0001-8962-8571; Lloyd, R. Stephen/0000-0001-7273-372X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES005355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944, R01GM032441] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05355] Funding Source: Medline; NIGMS NIH HHS [GM33944, GM32441] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTIN CA, 1995, J BIOL CHEM, V270, P15739, DOI 10.1074/jbc.270.26.15739; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Champoux JJ, 1998, PROG NUCLEIC ACID RE, V60, P111, DOI 10.1016/S0079-6603(08)60891-0; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; ENGLUND PT, 1978, CELL, V14, P157, DOI 10.1016/0092-8674(78)90310-0; Fortune JM, 2000, PROG NUCLEIC ACID RE, V64, P221, DOI 10.1016/S0079-6603(00)64006-0; GARCIABEATO R, 1992, VIROLOGY, V188, P938, DOI 10.1016/0042-6822(92)90558-7; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GOTO T, 1984, J BIOL CHEM, V259, P422; Goulaouic H, 1999, NUCLEIC ACIDS RES, V27, P2443, DOI 10.1093/nar/27.12.2443; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; HALLIGAN BD, 1985, J BIOL CHEM, V260, P2475; Ho CK, 1997, J VIROL, V71, P1931, DOI 10.1128/JVI.71.3.1931-1937.1997; JAVAHERIAN K, 1982, NUCLEIC ACIDS RES, V10, P6945, DOI 10.1093/nar/10.21.6945; KINGSMAN SM, 1990, METHOD ENZYMOL, V185, P329; Li Y, 1997, VIROLOGY, V237, P360, DOI 10.1006/viro.1997.8805; McCullough AK, 1998, J BIOL CHEM, V273, P13136, DOI 10.1074/jbc.273.21.13136; MILLER KG, 1981, J BIOL CHEM, V256, P9334; Muller K, 1999, VIRUS GENES, V18, P243, DOI 10.1023/A:1008072319875; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; Osheroff N, 1998, BBA-GENE STRUCT EXPR, V1400, P1, DOI 10.1016/S0167-4781(98)00123-7; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; ROHOZINSKI J, 1989, VIROLOGY, V168, P363, DOI 10.1016/0042-6822(89)90277-8; Sambrook J., 2002, MOL CLONING LAB MANU; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; Shuman S, 1998, BBA-GENE STRUCT EXPR, V1400, P321, DOI 10.1016/S0167-4781(98)00144-4; Van Etten JL, 1999, ANNU REV MICROBIOL, V53, P447, DOI 10.1146/annurev.micro.53.1.447; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WASSERMAN RA, 1993, CANCER RES, V53, P3591	32	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6915	6921		10.1074/jbc.275.10.6915	http://dx.doi.org/10.1074/jbc.275.10.6915			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702252	hybrid			2022-12-27	WOS:000085809600032
J	McCabe, TJ; Fulton, D; Roman, LJ; Sessa, WC				McCabe, TJ; Fulton, D; Roman, LJ; Sessa, WC			Enhanced electron flux and reduced calmodulin dissociation may explain "calcium-independent" eNOS activation by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; GROWTH-FACTOR; ISOFORMS; IDENTIFICATION; PARTICULATE; RELEASE	Bovine endothelial nitric oxide synthase (eNOS) is phosphorylated directly by the protein kinase Akt at serine 1179. Mutation of this residue to the negatively charged aspartate (S1179D eNOS) increases nitric oxide (NO) production constitutively, in the absence of agonist challenge. Here, me examine the potential mechanism of how aspartate at 1179 increases eNOS activity using purified proteins. Examination of NO production and cytochrome c reduction resulted in no substantial changes in the K-m/EC50 for L-arginine, calmodulin, and calcium, whereas there was a a-fold increase in the rate of NO production for S1179D and a 2-4 fold increase in reductase activity (based on cytochrome c reduction). The observed increase in activity for both assays of NOS function indicates that a faster rate of electron flux through the reductase domain is likely the rate-limiting step in NO formation from eNOS, In addition, S1179D eNOS did show an increased resistance to inactivation by EGTA compared with mild type eNOS. These results suggest that a negative charge imposed at serine 1179, either by phosphorylation or by replacement with aspartate, increases eNOS catalytic activity by increasing electron flux at the reductase domain and by reducing calmodulin dissociation from activated eNOS when calcium levels are low.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Mol Cardiobiol Program, New Haven, CT 06536 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	Yale University; Yale University; University of Texas System; University of Texas Health San Antonio	Sessa, WC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06536 USA.	william.sessa@yale.edu	Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938	NHLBI NIH HHS [HL64793, HL57665, HL61371] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064793, R01HL061371, R37HL061371, R01HL057665] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CaulinGlaser T, 1997, CIRC RES, V81, P885; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; KELM M, 1988, BIOCHEM BIOPH RES CO, V154, P236, DOI 10.1016/0006-291X(88)90675-4; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; Martasek P, 1999, METHOD ENZYMOL, V301, P70; Masters B, 1967, METHOD ENZYMOL, V10, P565; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Miller RT, 1999, BIOCHEM BIOPH RES CO, V265, P184, DOI 10.1006/bbrc.1999.1643; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; PEACH MJ, 1985, HYPERTENSION, V7, pI94, DOI 10.1161/01.HYP.7.3_Pt_2.I94; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; TSUKAHARA H, 1994, KIDNEY INT, V45, P598, DOI 10.1038/ki.1994.78; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871	32	319	331	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6123	6128		10.1074/jbc.275.9.6123	http://dx.doi.org/10.1074/jbc.275.9.6123			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692402	hybrid			2022-12-27	WOS:000085654400014
J	Wu, LW; Mayo, LD; Dunbar, JD; Kessler, KM; Ozes, ON; Warren, RS; Donner, DB				Wu, LW; Mayo, LD; Dunbar, JD; Kessler, KM; Ozes, ON; Warren, RS; Donner, DB			VRAP is an adaptor protein that binds KDR, a receptor for vascular endothelial cell growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTAL EXPRESSION; TYROSINE KINASE; ANGIOGENESIS; IDENTIFICATION; SITES; FLT-1; FLK-1; VASCULOGENESIS; TISSUES; DOMAIN	A protein that binds the intracellular domain of KDR (KDR-IC), a receptor for vascular endothelial cell growth factor (VEGF), was identified by two-hybrid screening. Two-hybrid mapping showed that the VEGF receptor-associated protein (VRAP) interacted with tyrosine 951 in the kinase insert domain of HDR, Northern blot analysis identified multiple VRAP transcripts in peripheral leukocytes, spleen, thymus, heart, lung, and human umbilical vein endothelial cells (HUVEC). The predominant VRAP mRNA encodes a 389-amino acid protein that contains an SH2 domain and a C-terminal proline-rich motif. In HUVEC, VEGF promotes association of VRAP with KDR, Phospholipase C gamma and phosphatidylinositol S-kinase, effector proteins that are downstream of KDR and important to VEGF-induced endothelial cell survival and proliferative responses, associate constitutively with VRAP. These observations identify VRAP as an adaptor that recruits cytoplasmic signaling proteins to KDR, which plays an important role in normal and pathological angiogenesis.	Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; University of California System; University of California San Francisco	Donner, DB (corresponding author), Indiana Univ, Sch Med, Walther Oncol Ctr, 1044 W Walnut St, Indianapolis, IN 46202 USA.		Wu, Li-Wha/AAH-7768-2021	Wu, Li-Wha/0000-0001-7010-6220	NCI NIH HHS [CA 84018, CA 67891, CA 73023] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073023, R55CA067891, R01CA067891] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BREIER G, 1992, DEVELOPMENT, V114, P521; Choi K, 1998, DEVELOPMENT, V125, P725; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V240, P635, DOI 10.1006/bbrc.1997.7719; DEVRIES C, 1992, SCIENCE, V255, P939; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KIM J, 1993, NATURE, V262, P841; MATHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MONACCI WT, 1993, AM J PHYSIOL, V264, pC995, DOI 10.1152/ajpcell.1993.264.4.C995; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Sawano A, 1997, BIOCHEM BIOPH RES CO, V238, P487, DOI 10.1006/bbrc.1997.7327; SCHWEIKI D, 1993, J CLIN INVEST, V91, P2235; SHIBUYA M, 1990, ONCOGENE, V5, P519; Spurkland A, 1998, J BIOL CHEM, V273, P4539, DOI 10.1074/jbc.273.8.4539; Strawn LM, 1996, CANCER RES, V56, P3540; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096	30	88	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6059	6062		10.1074/jbc.275.9.6059	http://dx.doi.org/10.1074/jbc.275.9.6059			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692392	hybrid			2022-12-27	WOS:000085654400004
J	Adderley, SR; Fitzgerald, DJ				Adderley, SR; Fitzgerald, DJ			Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO INHIBITORS; PLATELET-AGGREGATION; IIIA RECEPTOR; IIB-IIIA; CELLS; FIBRINOGEN; INVIVO; POTENT; SEQUENCE; PEPTIDE	The platelet integrin glycoprotein (GP) IIb/IIIa, which mediates platelet aggregation, has been the target for novel antiplatelet agents, the GPIIb/IIIa antagonists. Several GPIIb/IIIa antagonists have been developed based on the peptide RGDS present in adhesion proteins, including the principle ligand fibrinogen. The apoptosis enzyme, procaspase-3, contains an RGD-recognition sequence and is activated by RGDS. We examined the effects of RGDS and several GPIIb/IIIa antagonists on cell death and procaspase-3 activation in rat neonatal cardiomyocytes, These antagonists do not recognize rat integrins, yet RGDS, orbofiban, and xemilofiban induced dose-dependent apoptosis and procaspase-3 activation in cardiomyocytes over 72 h, particularly under hypoxic conditions. Scrambled peptide, the monoclonal antibody 7E3 or integrelin (a peptide containing a KGD sequence), had little or no effect. Immunoprecipitation of procaspase-3 followed by treatment with the compounds showed that procaspase-3 was activated directly by RGDS, orbofiban, xemilofiban, and by monoclonal 7E3 antibody, the latter demonstrating that compounds must enter cells to induce apoptosis through caspase activation. Integrelin had no effect. Binding studies with H-3-SC52012B, a GPIIb/IIIa antagonist analogue of orbofiban, showed no specific binding to cardiomyocytes, but the radioligand accumulated intracellularly over 72 h. H-3-SC52012B also bound directly to human recombinant caspase-3 (K-d, 59 +/- 2 nm), and this was prevented by orbofiban, xemilofiban, and the monoclonal 7E3 antibody but not by integrelin. Finally confocal microscopy showed that RGDS co-localized with caspase-3 inside the cell. These data show that RGDS and its mimetics induce cardiomyocyte apoptosis by direct activation of procaspase-3.	Royal Coll Surgeons Ireland, Ctr Cardiovasc Sci, Dublin 2, Ireland	Royal College of Surgeons - Ireland; Trinity College Dublin	Fitzgerald, DJ (corresponding author), Royal Coll Surgeons Ireland, Ctr Cardiovasc Sci, 123 St Stephens Green, Dublin 2, Ireland.	dfitzgerald@rcsi.ie						Araya R, 1998, FEBS LETT, V439, P168, DOI 10.1016/S0014-5793(98)01363-5; BOUKERCHE H, 1989, BLOOD, V74, P909; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; COLLER BS, 1989, CIRCULATION, V80, P1766, DOI 10.1161/01.CIR.80.6.1766; COX D, 1994, MED RES REV, V14, P195, DOI 10.1002/med.2610140203; Cox D, 1999, THROMB HAEMOSTASIS, P727; DU XP, 1995, NATURE, V376, P37; FERGUSON TA, 1991, P NATL ACAD SCI USA, V88, P8072, DOI 10.1073/pnas.88.18.8072; FUSTER V, 1987, PROG CARDIOVASC DIS, V29, P325, DOI 10.1016/0033-0620(87)90001-6; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Kamat SG, 1997, J CARDIOVASC PHARM, V29, P156, DOI 10.1097/00005344-199702000-00002; Liu QD, 1997, BBA-PROTEIN STRUCT M, V1343, P316, DOI 10.1016/S0167-4838(97)00130-1; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PLOW EF, 1987, BIOCHEM PHARMACOL, V36, P4035, DOI 10.1016/0006-2952(87)90558-2; Quinn M, 1999, CIRCULATION, V99, P2231, DOI 10.1161/01.CIR.99.17.2231; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHEHERBINA A, 1999, BLOOD, V93, P4222; SIMPSON P, 1982, CIRC RES, V50, P101, DOI 10.1161/01.RES.50.1.101; Storgard CM, 1999, J CLIN INVEST, V103, P47, DOI 10.1172/JCI3756; Wang L, 1998, CIRC RES, V83, P516, DOI 10.1161/01.RES.83.5.516; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; ZABLOCKI JA, 1993, J MED CHEM, V36, P1811, DOI 10.1021/jm00065a003; ZABLOCKI JA, 1995, J MED CHEM, V38, P2378, DOI 10.1021/jm00013a014	30	82	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5760	5766		10.1074/jbc.275.8.5760	http://dx.doi.org/10.1074/jbc.275.8.5760			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681563	hybrid			2022-12-27	WOS:000085474500070
J	Feaver, WJ; Huang, WY; Gileadi, O; Myers, L; Gustafsson, CM; Kornberg, RD; Friedberg, EC				Feaver, WJ; Huang, WY; Gileadi, O; Myers, L; Gustafsson, CM; Kornberg, RD; Friedberg, EC			Subunit interactions in yeast transcription/repair factor TFIIH - Requirement for Tfb3 subunit in nucleotide excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II TRANSCRIPTION; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; ACTIVATING KINASE; CTD KINASE; FACTOR-B; MULTIPROTEIN COMPLEX; IN-VITRO; PROTEIN; GENES	ih yeast strain harboring a temperature-sensitive allele of TFB3 (tfb3(ts)), the 38-kDa subunit of the RNA polymerase II transcription/nucleotide excision repair factor TFIIH, was found to be sensitive to ultraviolet (UV) radiation and defective for nucleotide excision repair in vitro, Interestingly, tfb3(ts) failed to grow on medium containing caffeine. A comprehensive pairwise two-hybrid analysis between yeast TFIIH subunits identified novel interactions between Rad3 and Tfb8, Tfb4 and Ssl1, as well as Ssl2 and Tfb2. These interactions have facilitated a more complete model of the structure of TFIIH and the nucleotide excision repairosome.	Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75235 USA; Weizmann Inst Sci, Dept Mol Genet & Virol, IL-76100 Rehovot, Israel; Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Weizmann Institute of Science; Stanford University	Friedberg, EC (corresponding author), Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Gileadi, Opher/F-1105-2013; Huang, Wenya/G-9115-2011	Gileadi, Opher/0000-0001-6886-898X; Gustafsson, Claes/0000-0003-3531-8468	NCI NIH HHS [CA12420] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; Archambault J, 1996, GENETICS, V142, P737; BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; BARDWELL AJ, 1993, MOL MICROBIOL, V8, P1177, DOI 10.1111/j.1365-2958.1993.tb01662.x; BARDWELL L, 1994, P NATL ACAD SCI USA, V91, P3926, DOI 10.1073/pnas.91.9.3926; BARDWELL L, 1992, MOL CELL BIOL, V12, P3041, DOI 10.1128/MCB.12.7.3041; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Faye G, 1997, MOL GEN GENET, V255, P460, DOI 10.1007/s004380050518; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; Feaver WJ, 1997, J BIOL CHEM, V272, P19319, DOI 10.1074/jbc.272.31.19319; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; Feaver WJ, 1999, J BIOL CHEM, V274, P29564, DOI 10.1074/jbc.274.41.29564; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; Guzder SN, 1996, J BIOL CHEM, V271, P8903, DOI 10.1074/jbc.271.15.8903; Guzder SN, 1997, J BIOL CHEM, V272, P21665, DOI 10.1074/jbc.272.35.21665; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; Habraken Y, 1996, P NATL ACAD SCI USA, V93, P10718, DOI 10.1073/pnas.93.20.10718; MATSUI P, 1995, NUCLEIC ACIDS RES, V23, P767, DOI 10.1093/nar/23.5.767; Reed SH, 1998, J BIOL CHEM, V273, P29481, DOI 10.1074/jbc.273.45.29481; Rodriguez K, 1998, J BIOL CHEM, V273, P34180, DOI 10.1074/jbc.273.51.34180; Rowley R, 1999, GENETICS, V152, P61; SIEDE W, 1985, RADIAT ENVIRON BIOPH, V24, P1, DOI 10.1007/BF01212648; SIKORSKI RS, 1989, GENETICS, V122, P19; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; VALAY JG, 1993, J MOL BIOL, V234, P307, DOI 10.1006/jmbi.1993.1587; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WANG ZG, 1995, MOL CELL BIOL, V15, P2288; Wang ZG, 1997, MOL CELL BIOL, V17, P635, DOI 10.1128/MCB.17.2.635; Wang ZG, 1996, MUTAT RES-DNA REPAIR, V364, P33, DOI 10.1016/0921-8777(96)00019-5; Wang Zhigang, 1995, Methods (Orlando), V7, P177, DOI 10.1006/meth.1995.1023	36	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5941	5946		10.1074/jbc.275.8.5941	http://dx.doi.org/10.1074/jbc.275.8.5941			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681587	hybrid			2022-12-27	WOS:000085474500094
J	Manjula, BN; Malavalli, A; Smith, PK; Chan, NL; Arnone, A; Friedman, JM; Acharya, AS				Manjula, BN; Malavalli, A; Smith, PK; Chan, NL; Arnone, A; Friedman, JM; Acharya, AS			Cys-93-beta beta-succinimidophenyl polyethylene glycol 2000 hemoglobin A - Intramolecular cross-bridging of hemoglobin outside the central cavity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-BINDING-PROPERTIES; BLOOD SUBSTITUTE; ESCHERICHIA-COLI; T-STATE; AFFINITY	Bis(maleidophenyl)-PEG2000 (Bis-Mal-PEG2000), a new bifunctional protein cross-linker targeted to sulfhydryl groups, introduces intra-tetrameric cross-links into oxy-HbA in nearly quantitative yields. Structural as well as crystallographic analyses of the cross-linked species, Bis-Mal-PEG2000 HbA, identified Cys-93(beta) as the site of intramolecular cross-linking. The cross-bridging had only a limited influence on the O-2 affinity and cooperativity of HbA in 50 mM BisTris acetate, pH 7.4. However, the Bohr effect was reduced by similar to 60%. Bis-Mal-PEG2000 HbA retained sensitivity to the presence of allosteric effecters 2,3-diphosphoglycerate, IHP, and chloride, albeit to a lesser degree compared with HbA, Crystallographic analysis revealed the overall structure of deoxy-Bis-Mal-PEG2000 HbA to be similar to deoxy-HbA but for the loss of the salt bridge between Asp-94(beta) and His-146(beta), The large influence of the cross-bridging on the alkaline Bohr effect of HbA is consistent with the loss of this salt bridge. Unlike the "central cavity cross-bridges" described previously, the cross-link introduced by Bis-Mal-PEG2000 into HbA is an "outside the central cavity cross-bridge." In view of its oxy-conformational specificity and limited influence on O-2 affinity, this new cross-linking strategy holds promise for the stabilization of new designer low O-2 affinity Rbs generated by recombinant DNA technology for applications as Hb based therapeutics.	Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; BioAffin Syst, Roscoe, IL 61073 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Iowa	Manjula, BN (corresponding author), Albert Einstein Coll Med, Dept Physiol & Biophys, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			CHAN, NEI-LI/0000-0003-0139-6513	NHLBI NIH HHS [HL-58247, HL-38655, HL-51084] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL051084, P60HL038655, R01HL058247] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHARYA AS, 1983, J BIOL CHEM, V258, P2296; AMPULSKI RS, 1969, ANAL BIOCHEM, V32, P163, DOI 10.1016/0003-2697(69)90118-3; ANDERSON L, 1973, J MOL BIOL, V79, P495, DOI 10.1016/0022-2836(73)90401-4; ANNUNZIATO ME, 1993, BIOCONJUGATE CHEM, V4, P212, DOI 10.1021/bc00021a005; BENESCH RE, 1994, METHOD ENZYMOL, V231, P267; Bettati S, 1997, J BIOL CHEM, V272, P33077, DOI 10.1074/jbc.272.52.33077; BRUNGER AT, 1992, XPLOR VERSION 3 1; Bucci E, 1996, J LAB CLIN MED, V128, P146, DOI 10.1016/S0022-2143(96)90006-2; BUCCI E, 1994, ARTIF CELL BLOOD SUB, V22, P84; BUNN HF, 1993, AM J HEMATOL, V42, P112, DOI 10.1002/ajh.2830420122; CHATTERJEE R, 1986, J BIOL CHEM, V261, P9929; Gottfried DS, 1997, J BIOL CHEM, V272, P1571, DOI 10.1074/jbc.272.3.1571; HAUROWITZ FZ, 1938, PHYSIOL CHEM PHYS M, V254, P268; Hendrick JP, 1995, FASEB J, V9, P1559, DOI 10.1096/fasebj.9.15.8529835; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES RT, 1993, BIOCHEMISTRY-US, V32, P215, DOI 10.1021/bi00052a028; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KAVANAUGH JS, 1992, BIOCHEMISTRY-US, V31, P4111, DOI 10.1021/bi00131a030; Kavanaugh JS, 1998, BIOCHEMISTRY-US, V37, P4358, DOI 10.1021/bi9708702; KAVANAUGH JS, 1997, AM CRYST ASS ANN M S, V24, P93; LUISI BF, 1986, NATURE, V320, P555, DOI 10.1038/320555a0; MACLEOD RM, 1970, J BIOL CHEM, V245, P4875; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; ODONNELL JK, 1994, J BIOL CHEM, V269, P27692; RAO MJ, 1994, ARTIF CELL BLOOD SUB, V22, P695, DOI 10.3109/10731199409117900; Riggs A., 1981, Methods in Enzymology, V76, P5; SNYDER SR, 1987, P NATL ACAD SCI USA, V84, P7280, DOI 10.1073/pnas.84.20.7280; Vandegriff K D, 1992, Biotechnol Genet Eng Rev, V10, P403; WALDER RY, 1994, METHOD ENZYMOL, V231, P274; Winslow Robert M., 1996, P60	30	33	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5527	5534		10.1074/jbc.275.8.5527	http://dx.doi.org/10.1074/jbc.275.8.5527			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681532	hybrid			2022-12-27	WOS:000085474500039
J	Seon, AA; Pierre, TN; Redeker, V; Lacombe, C; Delfour, A; Nicolas, P; Amiche, M				Seon, AA; Pierre, TN; Redeker, V; Lacombe, C; Delfour, A; Nicolas, P; Amiche, M			Isolation, structure, synthesis, and activity of a new member of the calcitonin gene-related peptide family from frog skin and molecular cloning of its precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; SPINAL-CORD; CGRP GENE; PHARMACOLOGICAL CHARACTERIZATION; PREDICTED STRUCTURE; OPIOID-PEPTIDES; VAS-DEFERENS; IDENTIFICATION; AMYLIN; BRAIN	Calcitonin gene-related peptide has been extracted from the skin exudate of a single living specimen of the frog Phyllomedusa bicolor and purified to homogeneity by a two-step protocol. A total volume of 250 mu l of exudate yielded 380 mu g of purified peptide. Mass spectrometric analysis and gas phase sequencing of the purified peptide as well as chemical synthesis and cDNA analysis were consistent with the structure SCDTSTCATQRLADFLSRSGGIGSPDFVPTDVSANSF amide and the presence of a disulfide bridge linking Cys(2) and Cys(7), The skin peptide, named skin calcitonin gene-related peptide, differs significantly from all other members of the calcitonin gene-related peptide family of peptides at nine positions but binds with high affinity to calcitonin gene-related peptide receptors in the rat brain and acts as an agonist in the rat vas deferens bioassay with potencies equal to those of human CGRP, Reverse transcriptase-polymerase chain reaction coupled with cDNA cloning and sequencing demonstrated that skin calcitonin gene-related peptide isolated in the skin is identical to that present in the frog's central and enteric nervous systems. These data, which indicate for the first time the existence of calcitonin gene-related peptide in the frog skin, add further support to the brain-skin-gut triangle hypothesis as a useful tool in the identification and/or isolation of mammalian peptides that are present in the brain and other tissues in only minute quantities.	Univ Paris 06, CNRS, UMR 7592, Inst Jacques Monod,Lab Bioactivat Peptides, F-75251 Paris 05, France; Ecole Super Phys & Chim Ind Ville Paris, Neurobiol Lab, CNRS, UMR 7637, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	Amiche, M (corresponding author), Univ Paris 06, CNRS, UMR 7592, Inst Jacques Monod,Lab Bioactivat Peptides, 2 Pl Jussieu, F-75251 Paris 05, France.	amiche@ijm.jussieu.fr	Nicolas, Pierre/C-7908-2009; Redeker, Virginie/L-8929-2018; AMICHE, Mohamed/R-3684-2018	Redeker, Virginie/0000-0003-2694-8388; LACOMBE, Claire/0000-0001-9428-8145				AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; AMARA SG, 1985, SCIENCE, V229, P1094, DOI 10.1126/science.2994212; AMICHE M, 1994, J BIOL CHEM, V269, P17847; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLYEAR K, 1991, J MOL ENDOCRINOL, V6, P147, DOI 10.1677/jme.0.0060147; CONLON JM, 1993, PEPTIDES, V14, P581; COOPER GJS, 1994, ENDOCR REV, V15, P163, DOI 10.1210/er.15.2.163; EDBROOKE MR, 1985, EMBO J, V4, P715, DOI 10.1002/j.1460-2075.1985.tb03688.x; ERSPAMER V, 1981, PEPTIDES, V2, P7, DOI 10.1016/0196-9781(81)90003-6; ERSPAMER V, 1992, INT J DEV NEUROSCI, V10, P3, DOI 10.1016/0736-5748(92)90003-I; EYSSELEIN VE, 1991, PEPTIDES, V12, P289, DOI 10.1016/0196-9781(91)90014-G; FEUERSTEIN G, 1995, CAN J PHYSIOL PHARM, V73, P1070, DOI 10.1139/y95-152; Frobert Y, 1999, PEPTIDES, V20, P275, DOI 10.1016/S0196-9781(98)00172-7; Hall JM, 1998, TRENDS PHARMACOL SCI, V19, P303, DOI 10.1016/S0165-6147(98)01234-6; Hara M, 1996, J EXP MED, V184, P1385, DOI 10.1084/jem.184.4.1385; Jansz H, 1996, P NATL ACAD SCI USA, V93, P12344, DOI 10.1073/pnas.93.22.12344; JANSZ HS, 1992, ANN NY ACAD SCI, V657, P63, DOI 10.1111/j.1749-6632.1992.tb22757.x; KIMURA S, 1987, NEUROPEPTIDES, V9, P75, DOI 10.1016/0143-4179(87)90034-5; LAZARUS LH, 1993, PROG NEUROBIOL, V41, P473, DOI 10.1016/0301-0082(93)90027-P; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MINVIELLE S, 1986, FEBS LETT, V203, P7, DOI 10.1016/0014-5793(86)81425-9; MIYATA A, 1992, BIOCHEM BIOPH RES CO, V187, P1474, DOI 10.1016/0006-291X(92)90468-Z; MORRIS HR, 1984, NATURE, V308, P746, DOI 10.1038/308746a0; Niizeki H, 1997, J IMMUNOL, V159, P5183; PETERMANN JB, 1987, J BIOL CHEM, V262, P542; Poyner D, 1995, TRENDS PHARMACOL SCI, V16, P424, DOI 10.1016/S0165-6147(00)89093-8; RENDA T, 1989, ARCH HISTOL CYTOL, V52, P317, DOI 10.1679/aohc.52.Suppl_317; RINK TJ, 1993, TRENDS PHARMACOL SCI, V14, P113, DOI 10.1016/0165-6147(93)90081-T; Rist B, 1998, J MED CHEM, V41, P117, DOI 10.1021/jm970533r; SAGAN S, 1989, J BIOL CHEM, V264, P17100; SAGAN S, 1991, BRIT J PHARMACOL, V104, P428, DOI 10.1111/j.1476-5381.1991.tb12446.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shahbazi F, 1998, AM J PHYSIOL-REG I, V275, pR19, DOI 10.1152/ajpregu.1998.275.1.R19; STEENBERGH PH, 1985, FEBS LETT, V183, P408, DOI 10.1016/0014-5793(85)80820-6; VanRossum D, 1997, NEUROSCI BIOBEHAV R, V21, P649, DOI 10.1016/S0149-7634(96)00023-1; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WIMALAWANSA SJ, 1990, BIOCHEM BIOPH RES CO, V167, P993, DOI 10.1016/0006-291X(90)90621-S; Wimalawansa SJ, 1997, CRIT REV NEUROBIOL, V11, P167, DOI 10.1615/CritRevNeurobiol.v11.i2-3.40; Wisskirchen FM, 1998, BRIT J PHARMACOL, V123, P1673, DOI 10.1038/sj.bjp.0701783	41	22	32	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5934	5940		10.1074/jbc.275.8.5934	http://dx.doi.org/10.1074/jbc.275.8.5934			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681586	hybrid			2022-12-27	WOS:000085474500093
J	Subramanian, A; Miller, DM				Subramanian, A; Miller, DM			Structural analysis of alpha-enolase - Mapping the functional domains involved in down-regulation of the c-myc protooncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER-BINDING PROTEIN; MESSENGER-RNA; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; BURKITT-LYMPHOMA; TRANSGENIC MICE; POU DOMAIN; CELLS; GENE	Myc-binding protein-1 (MBP-1) is a 37-kDa protein with sequence homology to the 3' portion of the alpha-enolase gene. alpha-Enolase is a 48-kDa protein, which plays a critical role in the glycolytic pathway. MBP-1 binds to the c-myc P2 promoter and down-regulates c-myc expression. We have investigated the role of alpha-enolase in regulation of the c-myc protooncogene, RNase protection assay shows that alpha-enolase is transcribed into a single RNA species in HeLa cells. A start codon, 400 base pairs downstream of the alpha-enolase ATG, corresponds to the MBP-1 ATG, suggesting that MBP-1 is an alternative translation initiation product of the alpha-enolase RNA. Domain mapping was performed using constructs containing truncations of the alpha-enolase gene, In vitro binding to the c-myc gene was abolished after deletion of the N-terminal portion of alpha-enolase. In order to determine the relationship between DNA binding activity and transcription inhibition, we performed co-transfection assays in HeLa cells, These studies confirmed that an N-terminal deletion of alpha-enolase is unable to downregulate c-myc promoter activity. Our data suggest that Lu-enolase plays an important role in regulation of c-myc promoter activity in the form of an alternative translation product MBP-1, which is distinct from its role as a glycolytic enzyme.	Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Biochem, Birmingham, AL 35294 USA; Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40206 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Louisville	Miller, DM (corresponding author), 529 S Jackson St, Louisville, KY 40206 USA.	donaldmi@ulh.org						AARONSON RM, 1995, J BIOL CHEM, V270, P27752, DOI 10.1074/jbc.270.46.27752; BATTEY J, 1983, EMBO J, V2, P2375; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; CALLIGARIS R, 1995, P NATL ACAD SCI USA, V92, P11598, DOI 10.1073/pnas.92.25.11598; CHAUDHARY D, 1995, BIOCHEMISTRY-US, V34, P3438, DOI 10.1021/bi00010a036; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COOPER JA, 1983, NATURE, V302, P218, DOI 10.1038/302218a0; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; Ghosh AK, 1999, MOL CELL BIOL, V19, P2880; GIALLONGO A, 1986, P NATL ACAD SCI USA, V83, P6741, DOI 10.1073/pnas.83.18.6741; GIALLONGO A, 1990, EUR J BIOCHEM, V190, P567, DOI 10.1111/j.1432-1033.1990.tb15611.x; GRAVEN KK, 1993, J CELL PHYSIOL, V157, P544, DOI 10.1002/jcp.1041570314; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HEDGES SB, 1994, P NATL ACAD SCI USA, V91, P2621, DOI 10.1073/pnas.91.7.2621; KAGHAD M, 1990, NUCLEIC ACIDS RES, V18, P3638, DOI 10.1093/nar/18.12.3638; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Pancholi V, 1998, J BIOL CHEM, V273, P14503, DOI 10.1074/jbc.273.23.14503; RAY R, 1991, MOL CELL BIOL, V11, P2154, DOI 10.1128/MCB.11.4.2154; RAY RB, 1995, CANCER RES, V55, P3747; Ray RB, 1997, J CELL BIOCHEM, V64, P565, DOI 10.1002/(SICI)1097-4644(19970315)64:4<565::AID-JCB4>3.0.CO;2-P; Riu E, 1996, P NATL ACAD SCI USA, V93, P2198, DOI 10.1073/pnas.93.5.2198; SAKIMURA K, 1985, NUCLEIC ACIDS RES, V13, P4365, DOI 10.1093/nar/13.12.4365; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHREIBER E, 1993, NUCLEIC ACIDS RES, V21, P253, DOI 10.1093/nar/21.2.253; SEGIL N, 1988, BIOCHEM J, V251, P31, DOI 10.1042/bj2510031; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPENCER CA, 1991, ADV CANCER RES, V56, P1; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VALERA A, 1995, FASEB J, V9, P1067, DOI 10.1096/fasebj.9.11.7649406; WISTOW GJ, 1988, J CELL BIOL, V107, P2729, DOI 10.1083/jcb.107.6.2729; Wold F., 1971, ENZYMES, P499	41	221	251	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5958	5965		10.1074/jbc.275.8.5958	http://dx.doi.org/10.1074/jbc.275.8.5958			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681589	Green Submitted, hybrid			2022-12-27	WOS:000085474500096
J	Zhao, RX; Zhao, ZZJ				Zhao, RX; Zhao, ZZJ			Dissecting the interaction of SHP-2 with PZR, an immunoglobulin family protein containing immunoreceptor tyrosine-based inhibitory motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM SH2 DOMAINS; PHOSPHATASE SHP-2; SIGNAL-TRANSDUCTION; CELL-ADHESION; PECAM-1 CD31; MAP KINASE; RECEPTORS; ASSOCIATION; ACTIVATION; SH-PTP2	Tyrosine phosphorylation of membrane proteins plays a crucial role in cell signaling by recruiting Src homology 2 (SH2) domain-containing signaling molecules, Recently, we have isolated a transmembrane protein designated PZR that specifically binds tyrosine phosphatase SHP-2, which has two SH2 domains (Zhao, Z, J., and Zhao, R, (1998) J, Biol. Chem, 273, 29367-29372). PZR belongs to the immunoglobulin superfamily, Its intracellular segment contains four putative sites of tyrosine phosphorylation, By site-specific mutagenesis, we found that the tyrosine 241 and 263 embedded in the consensus immunoreceptor tyrosine-based inhibitory motifs VIYAQL and VVYADI, respectively, accounted for the entire tyrosine phosphorylation of PZR, The interaction between PZR and SHP-2 requires involvement of both tyrosyl residues of the former and both SH2 domains of the latter, since its was disrupted by mutating a single tyrosyl residue or an SH2 domain, Overexpression of catalytically inactive but not active forms of SHP-2 bearing intact SH2 domains in cells caused hyperphosphorylation of PZR, In vitro, tyrosine-phosphorylated PZR was efficiently dephosphorylated by the full-length form of SHP-2 but not by its SH2 domain-truncated form. Together, the data indicate that PZR serves not only as a specific anchor protein of SHP-2 on the plasma membrane but also as a physiological substrate of the enzyme, The coexisting binding and dephosphorylation of PZR by SHP-2 may function to terminate signal transduction initiated by PZR and SHP-2 and to set a threshold for the signal transduction to be initiated.	Vanderbilt Univ, Ingram Canc Ctr, Dept Med, Div Hematol Oncol, Nashville, TN 37232 USA	Vanderbilt University	Zhao, ZZJ (corresponding author), 547 MRB 2,2220 Pierce Ave, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [R01CA075218, P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057393] Funding Source: NIH RePORTER; NCI NIH HHS [CA-68485, CA75218] Funding Source: Medline; NHLBI NIH HHS [HL-57393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Blery M, 1998, P NATL ACAD SCI USA, V95, P2446, DOI 10.1073/pnas.95.5.2446; Cao MY, 1998, J BIOL CHEM, V273, P15765, DOI 10.1074/jbc.273.25.15765; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Isakov N, 1997, IMMUNOL RES, V16, P85, DOI 10.1007/BF02786325; Jackson DE, 1997, J BIOL CHEM, V272, P24868, DOI 10.1074/jbc.272.40.24868; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kuroiwa A, 1998, J BIOL CHEM, V273, P1070, DOI 10.1074/jbc.273.2.1070; Maeda A, 1998, J EXP MED, V187, P1355, DOI 10.1084/jem.187.8.1355; Meyaard L, 1997, IMMUNITY, V7, P283, DOI 10.1016/S1074-7613(00)80530-0; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Olcese L, 1996, J IMMUNOL, V156, P4531; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Sagawa K, 1997, J BIOL CHEM, V272, P31086, DOI 10.1074/jbc.272.49.31086; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; Stein-Gerlach M, 1998, INT J BIOCHEM CELL B, V30, P559, DOI 10.1016/S1357-2725(98)00002-8; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; TANAKA A, 1987, MOL CELL BIOL, V7, P1878; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Vely F, 1997, EUR J IMMUNOL, V27, P1994, DOI 10.1002/eji.1830270825; Vely F, 1997, J IMMUNOL, V159, P2075; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhao RX, 1999, BIOCHEM J, V338, P35, DOI 10.1042/0264-6021:3380035; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; Zhao ZZ, 1996, J BIOL CHEM, V271, P22251, DOI 10.1074/jbc.271.36.22251	48	46	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5453	5459		10.1074/jbc.275.8.5453	http://dx.doi.org/10.1074/jbc.275.8.5453			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681522	hybrid			2022-12-27	WOS:000085474500029
J	Azuma, Y; Kaji, K; Katogi, R; Takeshita, S; Kudo, A				Azuma, Y; Kaji, K; Katogi, R; Takeshita, S; Kudo, A			Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; OSTEOBLAST-LIKE CELLS; IN-VITRO; RHEUMATOID-ARTHRITIS; FACTOR RECEPTORS; SYNOVIAL-FLUIDS; FACTOR-BETA; ROS 17/2.8; TNF-ALPHA; INTERLEUKIN-1	Osteoclast progenitors differentiate into mature osteoclasts in the presence of receptor activator of NF-KB (RANK) ligand on stromal or osteoblastic cells and monocyte macrophage colony-stimulating factor (M-CSF), The soluble RANK ligand induces the same differentiation in vitro without stromal cells, Tumor necrosis factor-alpha (TNF-alpha), a potent cytokine involved in the regulation of osteoclast activity, promotes bone resorption via a primary effect on osteoblasts; however, it remains unclear whether TNF-alpha can also directly induce the differentiation of osteoclast progenitors into mature osteoclasts, This study revealed that TNF-alpha directly induced the formation of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells (MNCs), which produced resorption pits on bone in vitro in the presence of M-CSF, The bone resorption activity of TNF-alpha-induced MNCs was lower than that of soluble RANK ligand-induced MNCs; however, interleukin-lp stimulated this activity of TNF cu-induced MNCs without an increase in the number of MNCs, In this case, interleukin-lp did not induce TRAP-positive MNC formation. The osteoclast progenitors expressed TNF receptors, p55 and p75; and the induction of TRAP-positive MNCs by TNF-alpha was inhibited completely by an anti-p55 antibody and partially by an anti-p75 antibody. Our findings presented here are the first to indicate that TNF-alpha is a crucial differentiation factor for osteoclasts. Our results suggest that TNF-alpha and M-CSF play an important role in local osteolysis in chronic inflammatory diseases.	Tokyo Inst Technol, Dept Life Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Teijin Ltd, Teijin Inst Biomed Res, Hino, Tokyo 1918512, Japan	Tokyo Institute of Technology; Teijin Limited	Kudo, A (corresponding author), Tokyo Inst Technol, Dept Life Sci, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.	akudo@bio.titech.ac.jp	Kudo, Akira/C-7340-2015	Kudo, Akira/0000-0001-6289-3391				AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; Boyce BF, 1999, LAB INVEST, V79, P83; BURGER EH, 1982, J EXP MED, V156, P1604, DOI 10.1084/jem.156.6.1604; CHAUDHARY LR, 1992, ENDOCRINOLOGY, V130, P2528, DOI 10.1210/en.130.5.2528; DAVIES JE, 1993, CELL MATER, V3, P245; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; ELFORD PR, 1987, CALCIFIED TISSUE INT, V41, P151, DOI 10.1007/BF02563795; FAHLMAN C, 1994, BLOOD, V84, P1528; FELIX R, 1989, CALCIFIED TISSUE INT, V44, P356, DOI 10.1007/BF02556317; FELIX R, 1994, J CELL BIOCHEM, V55, P340, DOI 10.1002/jcb.240550311; Goodman SB, 1998, J BONE JOINT SURG BR, V80B, P531, DOI 10.1302/0301-620X.80B3.8158; HEEHAN KCF, 1995, J EXP MED, V181, P607; HOFSTETTER W, 1992, P NATL ACAD SCI USA, V89, P9637, DOI 10.1073/pnas.89.20.9637; ISHIMI Y, 1990, J IMMUNOL, V145, P3297; Jimi E, 1999, EXP CELL RES, V247, P84, DOI 10.1006/excr.1998.4320; JIMI E, 1995, ENDOCRINOLOGY, V136, P808, DOI 10.1210/en.136.2.808; Jimi E, 1996, ENDOCRINOLOGY, V137, P2187; KAHLE P, 1992, ANN RHEUM DIS, V51, P731, DOI 10.1136/ard.51.6.731; KAHN AJ, 1991, BONE, V2, P119; KANEHISA J, 1990, BONE, V11, P287, DOI 10.1016/8756-3282(90)90082-A; Kanik KS, 1998, J RHEUMATOL, V25, P16; KITAMURA K, 1993, BONE, V14, P829, DOI 10.1016/8756-3282(93)90311-W; KITAZAWA R, 1994, J CLIN INVEST, V94, P2397, DOI 10.1172/JCI117606; KODAMA H, 1991, J EXP MED, V173, P1291, DOI 10.1084/jem.173.5.1291; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; KUNO H, 1994, ENDOCRINOLOGY, V134, P2524, DOI 10.1210/en.134.6.2524; LERNER UH, 1993, J BONE MINER RES, V8, P147; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Matsuzaki K, 1998, BIOCHEM BIOPH RES CO, V246, P199, DOI 10.1006/bbrc.1998.8586; Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002-9440(10)65266-2; MILLS BG, 1991, BONE, V2, P175; Mundy G R, 1992, Immunol Ser, V56, P483; Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371-2380.1996; Nakamura I, 1996, J BONE MINER RES, V11, P1873; NANES MS, 1989, ENDOCRINOLOGY, V124, P339, DOI 10.1210/endo-124-1-339; NANES MS, 1991, ENDOCRINOLOGY, V128, P2577, DOI 10.1210/endo-128-5-2577; NEIDEL J, 1995, INFLAMM RES, V44, P217, DOI 10.1007/BF01782262; Ogata Y, 1999, J IMMUNOL, V162, P2754; OLD LJ, 1990, TUMOR NECROSIS FACTOR : STRUCTURE, MECHANISM OF ACTION, ROLE IN DISEASE AND THERAPY, P1; PANAGAKOS FS, 1994, INFLAMMATION, V18, P243, DOI 10.1007/BF01534267; PASSERI G, 1994, BONE MINER, V24, P109, DOI 10.1016/S0169-6009(08)80149-3; PFEILSCHIFTER J, 1989, J BONE MINER RES, V4, P113, DOI 10.1002/jbmr.5650040116; SAXNE T, 1988, ARTHRITIS RHEUM, V31, P1041, DOI 10.1002/art.1780310816; SCHEVEN BAA, 1986, NATURE, V321, P79, DOI 10.1038/321079a0; SMITH JB, 1990, RHEUMATOL INT, V10, P131, DOI 10.1007/BF02274828; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252; TAMURA T, 1993, J BONE MINER RES, V8, P953; TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179; THOMSON BM, 1987, J IMMUNOL, V138, P775; THOMSON BM, 1986, J EXP MED, V164, P104, DOI 10.1084/jem.164.1.104; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VANDERPLUIJM G, 1991, ENDOCRINOLOGY, V129, P1596; WESOLOWSKI G, 1995, EXP CELL RES, V219, P679, DOI 10.1006/excr.1995.1279; Xu JW, 1996, CLIN EXP RHEUMATOL, V14, P643; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	58	571	594	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4858	4864		10.1074/jbc.275.7.4858	http://dx.doi.org/10.1074/jbc.275.7.4858			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671521	hybrid			2022-12-27	WOS:000085378200047
J	Harvey, J; McKay, NG; Walker, KS; Van der Kaay, J; Downes, CP; Ashford, MLJ				Harvey, J; McKay, NG; Walker, KS; Van der Kaay, J; Downes, CP; Ashford, MLJ			Essential role of phosphoinositide 3-kinase in leptin-induced K-ATP channel activation in the rat CRI-G1 insulinoma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE POTASSIUM CHANNELS; PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3; IN-VIVO; SIGNAL-TRANSDUCTION; C2C12 MYOTUBES; HUMAN ISLETS; INHIBITION; WORTMANNIN; SECRETION	The mechanism by which leptin increases ATP-sensitive K+ (K-ATP) channel activity was investigated using the insulin-secreting cell line, CRI-G1. Wortmannin and LY 294002, inhibitors of phosphoinositide S-kinase (PI3-kinase), prevented activation of K-ATP channels by leptin, The inositol phospholipids phosphatidylinositol bisphosphate and phosphatidylinositol trisphosphate (PtdIns(3,4,5)P-3) mimicked the effect of leptin by increasing K-ATP channel activity in whole-cell and inside-out current recordings. LY 294002 prevented phosphatidylinositol bisphosphate, but not PtdIns(3,4,5)P-3, from increasing Ii,,, channel activity, consistent with the latter lipid acting as a membrane-associated messenger linking leptin receptor activation and Ii,,, channels. Signaling cascades, activated downstream from PI 3-kinase, utilizing PtdIns(3,4,5)P-3 as a second messenger and commonly associated with insulin and cytokine action (MAPK, p70 ribosomal protein-S6 kinase, stress-activated protein kinase 2, p38 MAPK, and protein kinase B), do not appear to be involved in leptin-mediated activation of Ii,,, channels in this cell line. Although PtdIns(3,4,5)P-3 appears a plausible and attractive candidate for the messenger that couples K-ATP channels to leptin receptor activation, direct measurement of PtdIns(3,4,5)P-3 demonstrated that insulin, but not leptin, increased global cellular levels of PtdIns(3,4,5)P-3. Possible mechanisms to explain the involvement of PI S-kinases in K-ATP channel regulation are discussed.	Univ Aberdeen, Aberdeen Ctr Energy Regulat & Obes, Inst Med Sci, Dept Biomed Sci, Aberdeen AB25 2ZD, Scotland; Univ Dundee, Inst Med Sci, Dept Biochem, Dundee DD1 5EH, Scotland	University of Aberdeen; University of Dundee	Ashford, MLJ (corresponding author), Univ Aberdeen, Aberdeen Ctr Energy Regulat & Obes, Inst Med Sci, Dept Biomed Sci, Aberdeen AB25 2ZD, Scotland.			Harvey, Jenni/0000-0002-9858-001X; Ashford, Michael/0000-0002-0861-7676				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Auwerx J, 1998, LANCET, V351, P737, DOI 10.1016/S0140-6736(97)06348-4; Banfic H, 1998, J BIOL CHEM, V273, P13, DOI 10.1074/jbc.273.1.13; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Berti L, 1997, DIABETOLOGIA, V40, P606, DOI 10.1007/s001250050722; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; CARRINGTON CA, 1986, J ENDOCRINOL, V109, P193, DOI 10.1677/joe.0.1090193; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Desbois-Mouthon C, 1998, BIOCHEM BIOPH RES CO, V243, P765, DOI 10.1006/bbrc.1998.8181; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Emilsson V, 1997, DIABETES, V46, P313, DOI 10.2337/diabetes.46.2.313; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; Fehmann HC, 1997, ACTA DIABETOL, V34, P249, DOI 10.1007/s005920050083; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Harvey J, 1998, J PHYSIOL-LONDON, V511, P695, DOI 10.1111/j.1469-7793.1998.695bg.x; Harvey J, 1997, J PHYSIOL-LONDON, V504, P527, DOI 10.1111/j.1469-7793.1997.527bd.x; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Kellerer M, 1997, DIABETOLOGIA, V40, P1358, DOI 10.1007/s001250050832; KHAN CR, 1994, DIABETES, V43, P1066; Kieffer TJ, 1997, DIABETES, V46, P1087, DOI 10.2337/diabetes.46.6.1087; Kulkarni RN, 1997, J CLIN INVEST, V100, P2729, DOI 10.1172/JCI119818; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Leclercq-Meyer V, 1998, MOL CELL ENDOCRINOL, V141, P111, DOI 10.1016/S0303-7207(98)00087-2; LEE K, 1995, J PHYSIOL-LONDON, V488, P319, DOI 10.1113/jphysiol.1995.sp020969; Lee K, 1999, J PHYSIOL-LONDON, V515, P439, DOI 10.1111/j.1469-7793.1999.439ac.x; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; POWIS G, 1994, CANCER RES, V54, P2419; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Seufert J, 1999, J CLIN ENDOCR METAB, V84, P670, DOI 10.1210/jc.84.2.670; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Spanswick D, 1997, NATURE, V390, P521, DOI 10.1038/37379; Srivastava AK, 1998, TRENDS PHARMACOL SCI, V19, P205, DOI 10.1016/S0165-6147(98)01208-5; Takahashi Y, 1997, J BIOL CHEM, V272, P12897, DOI 10.1074/jbc.272.20.12897; Tanabe K, 1997, BIOCHEM BIOPH RES CO, V241, P765, DOI 10.1006/bbrc.1997.7894; van der Kaay J, 1998, Methods Mol Biol, V105, P109; vanderKaay J, 1997, J BIOL CHEM, V272, P5477, DOI 10.1074/jbc.272.9.5477; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Yamashita T, 1998, BIOCHEM BIOPH RES CO, V246, P752, DOI 10.1006/bbrc.1998.8689	53	111	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4660	4669		10.1074/jbc.275.7.4660	http://dx.doi.org/10.1074/jbc.275.7.4660			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671495	hybrid			2022-12-27	WOS:000085378200021
J	Shimizu, H; Obayashi, E; Gomi, Y; Arakawa, H; Park, SY; Nakamura, H; Adachi, S; Shoun, H; Shiro, Y				Shimizu, H; Obayashi, E; Gomi, Y; Arakawa, H; Park, SY; Nakamura, H; Adachi, S; Shoun, H; Shiro, Y			Proton delivery in NO reduction by fungal nitric-oxide reductase - Cryogenic crystallography, spectroscopy, and kinetics of ferric-NO complexes of wild-type and mutant enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; CRYSTAL-STRUCTURE; RESONANCE RAMAN; FUSARIUM-OXYSPORUM; MOLECULAR STEREOCHEMISTRY; AMINO-ACID; ANGSTROM RESOLUTION; OXYGEN ACTIVATION; CARBON-MONOXIDE; LIGAND-BINDING	Fungal nitric-oxide reductase (NOR) is a heme enzyme that catalyzes the reduction of NO to N2O through its ferric-NO complex, the first intermediate of the catalysis. Crystal structures of the ferric-NO forms of wild type (WT) fungal NOR, and of the Ser(286) --> Val and Ser(286) --> Thr mutant enzymes were determined to 1.7-Angstrom resolution at cryogenic temperature (100 K). This shows a slightly tilted and bent NO binding to the heme iron, in sharp contrast to the highly bent NO coordination found in ferrous hemoproteins, In the WT structure, a specific hydrogen-bonding network that connects the active site to the solvent was identified, H2O(Wat(74))-Ser(286)-H2O- (Wat(33))-Asp(393)-solvent. Wat(74) is located 3.10 Angstrom from the iron-bound NO. Replacement of Ser(286) With Val or Thr scarcely alters the NO coordination structure but expels the water molecules, Wat(74) from the active site. The Asp(393) mutation does not influence the position of Wat74 but disrupts the hydrogen-bonding network at Wat(33), as evidenced by enzymatic, kinetic, and spectroscopic (resonance Raman and IR) results. The structural changes observed upon the Ser(286) or the Asp(393) mutation are consistent with the dramatic loss of the enzymatic activity for the NO reduction of fungal NOR. We have conclusively identified the water molecule, Wat(74), adjacent to the iron-bound NO as a proton donor to the Fe-NO moiety. In addition, we find the hydrogen-bonding network, H2O(Wat(74))-Ser-(286)-H2O(Wat(33))-Asp(393), as a proton delivery pathway in the NO reduction reaction by fungal NOR.	RIKEN, Harima Inst SPring 8, Sayo, Hyogo 6795148, Japan; Gakushuin Univ, Fac Sci, Toshima Ku, Tokyo 1700031, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan; Chuo Univ, Dept Appl Chem, Bunkyo Ku, Tokyo 1128551, Japan	RIKEN; Gakushuin University; University of Tsukuba; Chuo University	Shiro, Y (corresponding author), RIKEN, Harima Inst SPring 8, Sayo, Hyogo 6795148, Japan.	yshiro@mailman.riken.go.jp	Shimizu, Hideaki/C-4142-2017; Shiro, Yoshitsugu Y/J-3757-2014	Shimizu, Hideaki/0000-0003-0174-5947; Shiro, Yoshitsugu Y/0000-0003-0695-8327; Adachi, Shin-ichi/0000-0002-3676-1165				Andersen JF, 1998, STRUCTURE, V6, P1315, DOI 10.1016/S0969-2126(98)00131-2; BENKO B, 1983, P NATL ACAD SCI USA, V80, P7042, DOI 10.1073/pnas.80.22.7042; Brucker EA, 1998, PROTEINS, V30, P352, DOI 10.1002/(SICI)1097-0134(19980301)30:4<352::AID-PROT2>3.0.CO;2-L; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CHAMPION PM, 1982, J AM CHEM SOC, V104, P5469, DOI 10.1021/ja00384a037; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; CuppVickery JR, 1996, NAT STRUCT BIOL, V3, P632, DOI 10.1038/nsb0796-632; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; DEATHERAGE JF, 1979, J MOL BIOL, V134, P401, DOI 10.1016/0022-2836(79)90360-7; EDWARDS SL, 1988, BIOCHEMISTRY-US, V27, P8074, DOI 10.1021/bi00421a016; EDWARDS SL, 1990, J BIOL CHEM, V265, P2588; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; GERBER NC, 1994, J BIOL CHEM, V269, P4260; GOTOH O, 1992, J BIOL CHEM, V267, P83; Harutyunyan EH, 1996, J MOL BIOL, V264, P152, DOI 10.1006/jmbi.1996.0630; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; HU SZ, 1991, J AM CHEM SOC, V113, P2843, DOI 10.1021/ja00008a007; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; KIMATA Y, 1995, BIOCHEM BIOPH RES CO, V208, P96, DOI 10.1006/bbrc.1995.1310; KIZAWA H, 1991, J BIOL CHEM, V266, P10632; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; LIPSCOMB LA, 1993, INORG CHEM, V32, P281, DOI 10.1021/ic00055a009; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; MAXWELL JC, 1976, BIOCHEMISTRY-US, V15, P388, DOI 10.1021/bi00647a023; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mueller Ernest J., 1995, P83; NAKAHARA K, 1993, J BIOL CHEM, V268, P8350; Obayashi E, 1997, J AM CHEM SOC, V119, P7807, DOI 10.1021/ja9637816; Obayashi E, 1998, J AM CHEM SOC, V120, P12964, DOI 10.1021/ja9813764; Okamoto N, 1998, BIOCHEMISTRY-US, V37, P8839, DOI 10.1021/bi980469v; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Park SY, 1997, NAT STRUCT BIOL, V4, P827, DOI 10.1038/nsb1097-827; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; Peterson Julian A., 1995, P151; Poulos Thomas L., 1995, P125; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; RAAG R, 1989, BIOCHEMISTRY-US, V28, P7586, DOI 10.1021/bi00445a013; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rich AM, 1998, J AM CHEM SOC, V120, P10827, DOI 10.1021/ja980253g; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SCHEIDT WR, 1984, J AM CHEM SOC, V106, P3191, DOI 10.1021/ja00323a022; SCHEIDT WR, 1976, J AM CHEM SOC, V98, P1913, DOI 10.1021/ja00423a044; SCHEIDT WR, 1977, J AM CHEM SOC, V99, P7315, DOI 10.1021/ja00464a035; SCHEIDT WR, 1975, J AM CHEM SOC, V97, P17, DOI 10.1021/ja00834a005; SHIRO Y, 1994, BIOCHEMISTRY-US, V33, P8673, DOI 10.1021/bi00195a007; SHIRO Y, 1995, J BIOL CHEM, V270, P1617, DOI 10.1074/jbc.270.4.1617; SHOUN H, 1983, J BIOCHEM, V94, P1219, DOI 10.1093/oxfordjournals.jbchem.a134467; Singh UP, 1998, BBA-PROTEIN STRUCT M, V1384, P103, DOI 10.1016/S0167-4838(98)00006-5; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; UNO T, 1985, J BIOL CHEM, V260, P2023; Vidakovic M, 1998, BIOCHEMISTRY-US, V37, P9211, DOI 10.1021/bi980189f; Wang J., 1996, METHODS NITRIC OXIDE, P427; Weichsel A, 1998, NAT STRUCT BIOL, V5, P304, DOI 10.1038/nsb0498-304; WELLS AV, 1992, BIOCHEMISTRY-US, V31, P4384, DOI 10.1021/bi00133a002	60	94	97	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4816	4826		10.1074/jbc.275.7.4816	http://dx.doi.org/10.1074/jbc.275.7.4816			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671516	hybrid			2022-12-27	WOS:000085378200042
J	Cipollo, JF; Trimble, RB				Cipollo, JF; Trimble, RB			The accumulation of Man(6)GlcNAc(2)-PP-dolichol in the Saccharomyces cerevisiae Delta alg9 mutant reveals a regulatory role for the Alg3p alpha 1,3-man middle-arm addition in downstream oligosaccharide-lipid and glycoprotein glycan processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST EXTERNAL INVERTASE; N-LINKED GLYCOSYLATION; ENDOPLASMIC-RETICULUM; PROTEIN GLYCOSYLATION; H-1-NMR SPECTROSCOPY; IN-VIVO; BIOSYNTHESIS; GLUCOSE; GLUCOSYLATION; DEFICIENT	N-Glycans in nearly all eukaryotes are derived by transfer of a precursor Glc(3)Man(9)GlcNAc(2) from dolichol (Dol) to consensus Asn residues in nascent proteins in the endoplasmic reticulum, The Saccharomyces cerevisiae alg (asparagine-linked glycosylation) mutants fail tb synthesize oligosaccharide-lipid properly, and the alg9 mutant, accumulates Man(6)GlcNAc(2)-PP-Dol. Highfield H-1 NMR and methylation analyses of Man(6)GlcNAc(2) released with peptide-N-glycosidase F from invertase secreted by Delta alg9 yeast showed its structure to be Man alpha 1,2Man alpha 1,2Man alpha 1,3(Man alpha 1,3Man alpha 1,6)-Man beta 1, 4GlcNAc beta 1,4GlcNAc alpha/beta, confirming the addition of the alpha 1,3-linked Man to Man(5)GlcNAc(2)-PP-Dol prior to the addition of the final upper-arm al,g-linked Man. This Man(6)GlcNAc(2), is the endoglycosidase H-sensitive product of the Alg3p step. The Delta alg9 Hex7-10GlcNAc(2) elongation intermediates were released from invertase and similarly analyzed. When compared with alg3 sec18 and wild-type core mannans, Delta alg9 N-glycans reveal a regulatory role for the Alg3p-dependent alpha 1,3-linked Man in subsequent oligosaccharide-lipid and glycoprotein glycan maturation. The presence of this Man appears to provide structural information potentiating the downstream action of the endoplasmic reticulum glucosyltransferases Alg6p, Alg8p and Alg10p, glucosidases Gls1p and Gls2p, and the Golgi Och1p outerchain alpha 1,6-Man branch-initiating mannosyltransferase.	New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Trimble, RB (corresponding author), New York State Dept Hlth, Wadsworth Ctr, C-547, POB 509, Albany, NY 12201 USA.				NIGMS NIH HHS [GM 23900] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023900] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aebi M, 1996, GLYCOBIOLOGY, V6, P439, DOI 10.1093/glycob/6.4.439; BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BEARDEN JC, 1978, BIOCHIM BIOPHYS ACTA, V533, P525, DOI 10.1016/0005-2795(78)90398-7; Burda P, 1998, GLYCOBIOLOGY, V8, P455, DOI 10.1093/glycob/8.5.455; Burda P, 1998, J CLIN INVEST, V102, P647, DOI 10.1172/JCI2266; BYRD JC, 1982, J BIOL CHEM, V257, P4657; CHU FK, 1978, J BIOL CHEM, V253, P8691; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; GRAHAM TR, 1992, YEAST S, V8, P458; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; Imbach T, 1999, P NATL ACAD SCI USA, V96, P6982, DOI 10.1073/pnas.96.12.6982; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jakob CA, 1998, GLYCOBIOLOGY, V8, P155, DOI 10.1093/glycob/8.2.155; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; JARS MU, 1995, J BIOL CHEM, V270, P24810, DOI 10.1074/jbc.270.42.24810; JENSEN JW, 1982, J BIOL CHEM, V257, P9025; Korner C, 1998, P NATL ACAD SCI USA, V95, P13200, DOI 10.1073/pnas.95.22.13200; Nakayama K, 1997, FEBS LETT, V412, P547, DOI 10.1016/S0014-5793(97)00634-0; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Reiss G, 1996, GLYCOBIOLOGY, V6, P493, DOI 10.1093/glycob/6.5.493; Reiss G, 1997, EMBO J, V16, P1164, DOI 10.1093/emboj/16.6.1164; ROMERO PA, 1997, GLYCOBIOLOGY, V7, P1045; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; SNIDER MD, 1981, METHOD CELL BIOL, V23, P89, DOI 10.1016/S0091-679X(08)61493-4; STANLEY P, 1988, J BIOL CHEM, V263, P11374; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; TANNER W, 1995, GLYCOPROTEINS, P475; Tarentino A L, 1978, Methods Enzymol, V50, P574; TARENTINO AL, 1987, METHOD ENZYMOL, V138, P770; TRIMBLE RB, 1991, J BIOL CHEM, V266, P22807; TRIMBLE RB, 1986, J BIOL CHEM, V261, P9815; TRIMBLE RB, 1980, J BIOL CHEM, V255, P1892; TRIMBLE RB, 1992, GLYCOBIOLOGY, V2, P57, DOI 10.1093/glycob/2.1.57; TRIMBLE RB, 1993, TRENDS GLYCOSCI GLYC, V1, P1; TRUMBLY RJ, 1985, J BIOL CHEM, V260, P5683; TSAI PK, 1984, P NATL ACAD SCI-BIOL, V81, P6340, DOI 10.1073/pnas.81.20.6340; VEROSTEK MF, 1993, J BIOL CHEM, V268, P12104; VEROSTEK MF, 1993, J BIOL CHEM, V268, P12095; VEROSTEK MF, 1991, J BIOL CHEM, V266, P5547; WAECHTER CJ, 1973, J BIOL CHEM, V248, P7570; ZIEGLER F D, 1991, Glycobiology, V1, P605, DOI 10.1093/glycob/1.6.605	44	22	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4267	4277		10.1074/jbc.275.6.4267	http://dx.doi.org/10.1074/jbc.275.6.4267			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660594	hybrid			2022-12-27	WOS:000085288800078
J	Roy, R; Biswas, T; Lee, JC; Mitra, S				Roy, R; Biswas, T; Lee, JC; Mitra, S			Mutation of a unique aspartate residue abolishes the catalytic activity but not substrate binding of the mouse N-methylpurine-DNA glycosylase (MPG)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; ESCHERICHIA-COLI; FPG PROTEIN; DIRECT IDENTIFICATION; CRYSTAL-STRUCTURE; ENDONUCLEASE-III; PURIFICATION; MECHANISM; CLONING; SPECIFICITY	N-Methylpurine-DNA glycosylase (MPG) initiates base excision repair in DNA by removing a variety of alkylated purine adducts, Although Asp was identified as the active site residue in various DNA glycosylases based on the crystal structure, Glu-125 in human MPG: (Glu-145 in mouse MPG) was recently proposed to be the catalytic residue. Mutational analysis for all Asp residues in a truncated, fully active MPG protein showed that only Asp-152 (Asp-132 in the human protein), which is located near the active site, is essential for catalytic activity. However, the substrate binding was not affected in the inactive Glu-152, Asn-152, and Ala-152 mutants. Furthermore, mutation of Asp-152 did not significantly affect the intrinsic tryptophan fluorescence of the enzyme and the far UV CD spectra, although a small change in the near UV CD spectra of the mutants suggests localized conformational change in the aromatic residues. We propose that in addition to Glu-145 in mouse MPG, which functions as the activator of a water molecule for nucleophilic attack, Asp-152 plays an essential role either by donating a proton to the substrate base and, thus, facilitating its release or by stabilizing the steric configuration of the active site pocket.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Roy, R (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6136C Med Res Bldg, Galveston, TX 77555 USA.		Lee, James C/A-7849-2009		NATIONAL CANCER INSTITUTE [R01CA053791] Funding Source: NIH RePORTER; NCI NIH HHS [CA53791] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bruner SD, 1998, CURR BIOL, V8, P393, DOI 10.1016/S0960-9822(98)70158-7; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P15710; DODSON ML, 1994, J BIOL CHEM, V269, P32709; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P59; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Krokan HE, 1997, BIOCHEM J, V325, P1; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; LARSON K, 1985, MUTAT RES, V233, P211; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; Leblanc B, 1994, Methods Mol Biol, V30, P1; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; MCCARTHY TV, 1984, EMBO J, V3, P545, DOI 10.1002/j.1460-2075.1984.tb01844.x; Mitra S, 1997, MOL CELLS, V7, P305; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; PAIN R, 1996, CURRENT PROTOCOLS PR, V2; Rabow LE, 1997, BIOCHEMISTRY-US, V36, P5084, DOI 10.1021/bi963005a; ROY R, 1994, BIOCHEMISTRY-US, V33, P15131, DOI 10.1021/bi00254a024; Roy R, 1998, BIOCHEMISTRY-US, V37, P580, DOI 10.1021/bi972313l; SAMSON L, 1991, P NATL ACAD SCI USA, V88, P9127, DOI 10.1073/pnas.88.20.9127; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; Sidorkina OM, 1998, NUCLEIC ACIDS RES, V26, P5351, DOI 10.1093/nar/26.23.5351; Singer B, 1997, CHEM RES TOXICOL, V10, P713, DOI 10.1021/tx970011e; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Verdine GL, 1997, CHEM BIOL, V4, P329, DOI 10.1016/S1074-5521(97)90123-X; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	30	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4278	4282		10.1074/jbc.275.6.4278	http://dx.doi.org/10.1074/jbc.275.6.4278			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660595	hybrid			2022-12-27	WOS:000085288800079
J	Svergun, DI; Malfois, M; Koch, MHJ; Wigneshweraraj, SR; Buck, M				Svergun, DI; Malfois, M; Koch, MHJ; Wigneshweraraj, SR; Buck, M			Low resolution structure of the sigma 54 transcription factor revealed by x-ray solution scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-ANGLE-SCATTERING; DIRECT SHAPE DETERMINATION; COLI RNA-POLYMERASE; SYNCHROTRON RADIATION; SIGMA(N) SIGMA(54); PROMOTER DNA; DOMAINS; BIOPOLYMERS; BINDING	The sigma 54 RNA polymerase holoenzyme functions in enhancer-dependent transcription. The structural organization of the sigma 54 subunit of bacterial RNA polymerase in solution is analyzed by synchrotron x-ray scattering. Scattering patterns are collected from the full-length protein and from a large fragment able to bind the core RNA polymerase, and their low resolution shapes are restored using two ab initio shape determination techniques. The sigma 54 subunit is a highly elongated particle, and the core binding fragment can be unambiguously positioned inside the full-length protein. The boomerang-like shape of the core binding fragment is similar to that of the atomic model of a fragment of the Escherichia coli sigma 70 protein, indicating that, although the sigma 54 and sigma 70 factors are unrelated by primary sequence, they may share some structural similarity. Potential DNA binding surfaces of sigma 54 are also predicted by comparison with the sigma 54 core binding fragment.	DESY, European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany; Russian Acad Sci, Inst Cristallog, Moscow 117333, Russia; Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 2BB, England	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS; Imperial College London	Svergun, DI (corresponding author), DESY, European Mol Biol Lab, Hamburg Outstn, Notkestr 85, D-22603 Hamburg, Germany.		Malfois, Marc/L-2974-2014	Malfois, Marc/0000-0001-5231-1896; Svergun, Dmitri/0000-0003-0830-5696				BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; BOULIN CJ, 1988, NUCL INSTRUM METH A, V269, P312, DOI 10.1016/0168-9002(88)90895-9; BUCK M, 1992, NATURE, V358, P422, DOI 10.1038/358422a0; CANNON W, 1995, J MOL BIOL, V248, P781, DOI 10.1006/jmbi.1995.0260; CANNON W, 1994, MOL MICROBIOL, V11, P227, DOI 10.1111/j.1365-2958.1994.tb00303.x; Cannon WV, 1997, P NATL ACAD SCI USA, V94, P5006, DOI 10.1073/pnas.94.10.5006; Casaz P, 1997, P NATL ACAD SCI USA, V94, P12145, DOI 10.1073/pnas.94.22.12145; Feigin L. A., 1987, STRUCTURE ANAL SMALL, P839; GABRIEL A, 1982, NUCL INSTRUM METHODS, V201, P223, DOI 10.1016/0167-5087(82)90031-X; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; Kozin MB, 1997, J APPL CRYSTALLOGR, V30, P811, DOI 10.1107/S0021889897001830; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; MERRICK MJ, 1993, MOL MICROBIOL, V10, P903, DOI 10.1111/j.1365-2958.1993.tb00961.x; Missailidis S, 1997, MOL MICROBIOL, V24, P653, DOI 10.1046/j.1365-2958.1997.3691738.x; Mooney RA, 1999, CELL, V98, P687, DOI 10.1016/S0092-8674(00)81483-X; MOORE PB, 1980, J APPL CRYSTALLOGR, V13, P168, DOI 10.1107/S002188988001179X; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Shannon C. E., 1949, MATH THEORY COMMUNIC; STUHRMANN HB, 1970, Z PHYS CHEM NEUE FOL, V72, P177, DOI 10.1524/zpch.1970.72.4_6.177; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 1997, J APPL CRYSTALLOGR, V30, P798, DOI 10.1107/S0021889897001714; SVERGUN DI, 1991, ACTA CRYSTALLOGR A, V47, P736, DOI 10.1107/S0108767391006414; Svergun DI, 1996, ACTA CRYSTALLOGR A, V52, P419, DOI 10.1107/S0108767396000177; SVERGUN DI, 1993, J APPL CRYSTALLOGR, V26, P258, DOI 10.1107/S0021889892011828; WANG JT, 1995, SCIENCE, V270, P992, DOI 10.1126/science.270.5238.992; WONG CN, 1994, J MOL BIOL, V236, P81, DOI 10.1006/jmbi.1994.1120	32	30	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4210	4214		10.1074/jbc.275.6.4210	http://dx.doi.org/10.1074/jbc.275.6.4210			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660585	hybrid			2022-12-27	WOS:000085288800069
J	Xu, AD; Narayanan, N				Xu, AD; Narayanan, N			Reversible inhibition of the calcium-pumping ATPase in native cardiac sarcoplasmic reticulum by a calmodulin-binding protein - Evidence for calmodulin-dependent regulation of the V-max of calcium transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RYANODINE RECEPTOR; SKELETAL-MUSCLE; CA-ATPASE; VENTRICULAR MYOCYTES; RELEASE CHANNEL; HEART-MUSCLE; KINASE-II; PHOSPHORYLATION; PHOSPHOLAMBAN; MECHANISM	Calmodulin (CaM) and Ca2+/CaM-dependent protein kinase II (CaM kinase) are tightly associated with cardiac sarcoplasmic reticulum (SR) and are implicated in the regulation of transmembrane Ca2+ cycling. In order to assess the importance of membrane-associated CaM in modulating the Ca2+ pump (Ca2+-ATPase) function of BR, the present study investigated the effects of a synthetic, high affinity CaM-binding peptide (CaM BP; amino acid sequence, LKWKKLLKLLKKLLKLG) on the ATP-energized Ca2+ uptake, Ca2+-stimulated ATP hydrolysis, and CaM kinase-mediated protein phosphorylation in rabbit cardiac SR vesicles. The results revealed a strong concentration-dependent inhibitory action of CaM: BP on Ca2+ uptake and Ca2+-ATPase activities of SR (50% inhibition at similar to 2-3 mu M CaM BP), The inhibition, which followed the association of CaM BP with its SR target(s), was of rapid onset (manifested within 30 s) and was accompanied by a decrease in V-max of Ca2+ uptake, unaltered K-0.5 for Ca2+ activation of Ca2+ transport, and a 10-fold decrease in the apparent affinity of the Ca2+ ATPase for its substrate, ATP, Thus, the mechanism of inhibition involved alterations at the catalytic site but not the Ca2+-binding sites of the Ca2+-ATPase. Endogenous CaM kinase-mediated phosphorylation of Ca2+ ATPase, phospholamban, and ryanodine receptor-Ca2+ release channel was also strongly inhibited by CaM BP, The inhibitory action of CaM BP on SR Ca2+ pump function and protein phosphorylation was fully reversed by exogenous CaM (1-3 mu M). A peptide inhibitor of CaM kinase markedly attenuated the ability of CaM to reverse CAM BP-mediated inhibition of Ca2+ transport. These findings suggest a critical role for membrane-bound CaM in controlling the velocity of Ca2+ pumping in native cardiac SR. Consistent with its ability to inhibit SR Ca2+ pump function, CaM BP (1-2.5 mu M) caused marked depression of contractility and diastolic dysfunction in isolated perfused, spontaneously beating rabbit heart preparations. Full or partial recovery of contractile function occurred gradually following withdrawal of CaM BP from the perfusate, presumably due to slow dissociation of CaM BP from its target sites promoted by endogenous cytosolic CaM.	Univ Western Ontario, Dept Physiol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Narayanan, N (corresponding author), Univ Western Ontario, Dept Physiol, Med Sci Bldg, London, ON N6A 5C1, Canada.	nnarayan@physiology.uwo.ca						Alkayed NJ, 1996, FASEB J, V10, P1734; Allen BG, 1996, MOL CELL BIOCHEM, V155, P91; BAKER KJ, 1995, BIOCHEMISTRY-US, V34, P3596, DOI 10.1021/bi00011a014; BERS DM, 1991, EXCITATION CONTRACTI; BRUAN AP, 1995, ANNU REV PHYSIOL, V57, P417; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; COLYER J, 1993, CARDIOVASC RES, V27, P1766, DOI 10.1093/cvr/27.10.1766; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; DEGRADO WF, 1985, J CELL BIOCHEM, V29, P83, DOI 10.1002/jcb.240290204; DEMEIS L, 1981, SARCOPLASMIC RETICUL; duBell WH, 1996, J PHYSIOL-LONDON, V493, P793, DOI 10.1113/jphysiol.1996.sp021423; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FEHER JJ, 1990, CALCIUM HEART, P199; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; HAIN J, 1995, J BIOL CHEM, V270, P2074, DOI 10.1074/jbc.270.5.2074; HAWKINS C, 1994, J BIOL CHEM, V269, P31198; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; Jones DL, 1998, AM J PHYSIOL-HEART C, V274, pH98, DOI 10.1152/ajpheart.1998.274.1.H98; Kadambi VJ, 1997, BIOCHEM BIOPH RES CO, V239, P1, DOI 10.1006/bbrc.1997.7340; Li L, 1997, J PHYSIOL-LONDON, V501, P17, DOI 10.1111/j.1469-7793.1997.017bo.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTTON LJ, 1991, HEART CARDIOVASCULAR, P1203; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MAHANEY JE, 1991, BIOCHEMISTRY-US, V30, P7171, DOI 10.1021/bi00243a019; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; NARAYANAN N, 1981, BIOCHIM BIOPHYS ACTA, V678, P442, DOI 10.1016/0304-4165(81)90126-4; NARAYANAN N, 1991, BIOCHIM BIOPHYS ACTA, V1070, P83, DOI 10.1016/0005-2736(91)90149-3; Netticadan T, 1996, ARCH BIOCHEM BIOPHYS, V333, P368, DOI 10.1006/abbi.1996.0403; Odermatt A, 1996, J BIOL CHEM, V271, P14206, DOI 10.1074/jbc.271.24.14206; Osada M, 1998, AM J PHYSIOL-HEART C, V274, pH2025, DOI 10.1152/ajpheart.1998.274.6.H2025; Reddy LG, 1996, J BIOL CHEM, V271, P14964, DOI 10.1074/jbc.271.25.14964; Reddy LG, 1999, BIOPHYS J, V76, P3058, DOI 10.1016/S0006-3495(99)77458-8; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; Shorina EA, 1997, BIOCHEMISTRY-US, V36, P13455, DOI 10.1021/bi9709349; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Snajdrova L, 1998, J BIOL CHEM, V273, P28032, DOI 10.1074/jbc.273.43.28032; Solaro RJ, 1998, CIRC RES, V83, P471, DOI 10.1161/01.RES.83.5.471; TADA M, 1982, ANNU REV PHYSIOL, V44, P401, DOI 10.1146/annurev.ph.44.030182.002153; TAKASAGO T, 1991, J BIOCHEM-TOKYO, V109, P163, DOI 10.1093/oxfordjournals.jbchem.a123339; TOYOFUKU T, 1994, J BIOL CHEM, V269, P26492; TUANA BS, 1984, J BIOL CHEM, V259, P6979; VOSS JC, 1995, BIOCHEMISTRY-US, V34, P930, DOI 10.1021/bi00003a027; Waxham MN, 1998, J BIOL CHEM, V273, P17579, DOI 10.1074/jbc.273.28.17579; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; Xu A, 1998, AM J PHYSIOL-HEART C, V275, pH2087, DOI 10.1152/ajpheart.1998.275.6.H2087; Xu A, 1997, J MOL CELL CARDIOL, V29, P405, DOI 10.1006/jmcc.1996.0284; XU A, 1993, J BIOL CHEM, V268, P8394; Xu AD, 1999, BIOCHEM BIOPH RES CO, V258, P66, DOI 10.1006/bbrc.1999.0579	50	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4407	4416		10.1074/jbc.275.6.4407	http://dx.doi.org/10.1074/jbc.275.6.4407			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660612	hybrid			2022-12-27	WOS:000085288800096
J	Morel, N; Massoulie, J				Morel, N; Massoulie, J			Comparative expression of homologous proteins - A novel mode of transcriptional regulation by the coding sequence folding compatibility of chimeras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-GLOBIN GENE; HUMAN ACETYLCHOLINESTERASE; TERMINAL DOMAIN; CELL-LINES; FORMS; CONSTRUCTION; MYOGENESIS; SUBUNITS; PROMOTER; CLONING	Recombinant acetylcholinesterases (AChE) are produced at systematically different levels, depending on the enzyme species. To identify the cause of this difference, we designed expression vectors that differed only by the central region of the coding sequence, encoding Torpedo, rat, and Bungarus AChEs and two reciprocal rat/Bungarus and Bungarus/rat chimeras. We found that folding is a Limiting factor in the case of Torpedo AChE and the chimeras, for which only a limited fraction of the synthesized polypeptides becomes active and is secreted. In contrast, the fact that rat AChE is less well produced than Bungarus AChE reflects the levels of their respective mRNAs, which seem to be controlled by their transcription rates. A similar difference was observed in the coding and noncoding orientations; it seems to depend on multiple cis-elements. Using CAT constructs, we found that a DNA fragment from the Bungarus AChE gene stimulates expression of the reporter protein, whereas a homologous fragment from the rat AChE gene had no influence. This stimulating effect appears different from that of classical enhancers, although its mechanism remains unknown. In any case, the present results demonstrate that the coding region contributes to control the level of gene expression.	Ecole Normale Super, Neurobiol Cellulaire & Mol Lab, CNRS, UMR 8544, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Massoulie, J (corresponding author), Ecole Normale Super, Neurobiol Cellulaire & Mol Lab, CNRS, UMR 8544, 46 Rue Ulm, F-75005 Paris, France.	jean.massoulie@biologie.ens.fr	Morel, Nathalie/O-9012-2016					Bon S, 1997, J BIOL CHEM, V272, P3007, DOI 10.1074/jbc.272.5.3007; Bucht C, 1996, BBA-PROTEIN STRUCT M, V1292, P223, DOI 10.1016/0167-4838(95)00205-7; Chan RYY, 1999, P NATL ACAD SCI USA, V96, P4627, DOI 10.1073/pnas.96.8.4627; Cousin X, 1996, J BIOL CHEM, V271, P15099, DOI 10.1074/jbc.271.25.15099; COUSSEN F, 1995, EUR J CELL BIOL, V67, P254; DUVAL N, 1992, J CELL BIOL, V118, P641, DOI 10.1083/jcb.118.3.641; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FARNHAM PJ, 1990, MOL CELL BIOL, V10, P1390, DOI 10.1128/MCB.10.4.1390; Frobert Y, 1997, BBA-PROTEIN STRUCT M, V1339, P253, DOI 10.1016/S0167-4838(97)00009-5; FUENTES ME, 1993, NEURON, V10, P679, DOI 10.1016/0896-6273(93)90169-R; GIBNEY G, 1990, J BIOL CHEM, V265, P12576; Greenberg ME, 1993, CONTROL MESSENGER RN, P199, DOI 10.1016/B978-0-08-091652-1.50013-X; Incardona JP, 1996, MOL BIOL CELL, V7, P595, DOI 10.1091/mbc.7.4.595; JAMESPEDERSON M, 1995, J BIOL CHEM, V270, P3965, DOI 10.1074/jbc.270.8.3965; KRONMAN C, 1992, GENE, V121, P295, DOI 10.1016/0378-1119(92)90134-B; Luo ZD, 1998, J BIOL CHEM, V273, P28486, DOI 10.1074/jbc.273.43.28486; MARSH D, 1984, J NEUROCHEM, V43, P204, DOI 10.1111/j.1471-4159.1984.tb06698.x; Massoulie J, 1998, STRUCTURE AND FUNCTION OF CHOLINESTERASES AND RELATED PROTEINS, P3; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; Morel N, 1997, BIOCHEM J, V328, P121, DOI 10.1042/bj3280121; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; ROTUNDO RL, 1988, J BIOL CHEM, V263, P19398; SOREQ H, 1990, P NATL ACAD SCI USA, V87, P9688, DOI 10.1073/pnas.87.24.9688; YOST SE, 1993, MOL CELL BIOL, V13, P5439, DOI 10.1128/MCB.13.9.5439; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	25	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7304	7312		10.1074/jbc.275.10.7304	http://dx.doi.org/10.1074/jbc.275.10.7304			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702301	hybrid			2022-12-27	WOS:000085809600081
J	Spetea, C; Keren, N; Hundal, T; Doan, JM; Ohad, I; Andersson, B				Spetea, C; Keren, N; Hundal, T; Doan, JM; Ohad, I; Andersson, B			GTP enhances the degradation of the photosystem II D1 protein irrespective of its conformational heterogeneity at the Q(B) site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED D1-PROTEIN DEGRADATION; CHLOROPLAST MEMBRANES; THYLAKOID MEMBRANE; HIGHER-PLANTS; LOW-LIGHT; QB SITE; INHIBITOR; PHOTOINACTIVATION; PHOTOINHIBITION; IDENTIFICATION	The light exposure history and/or binding of different herbicides at the Q(B) site may induce heterogeneity of photosystem II acceptor side conformation that affects D1 protein degradation under photoinhibitory conditions. GTP was recently found to stimulate the D1 protein degradation of photoinactivated photosystem II (Spetea, C., Hundal, T., Lohmann, F., and Andersson, B. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 6547-6552). Here we report that GTP enhances the cleavage of the D1 protein D-E loop following exposure of thylakoid membranes to either high light, low light, or repetitive single turnover flashes but not to trypsin, GTP does not stimulate D1 protein degradation in the presence of herbicides known to affect the accessibility of the cleavage site to proteolysis, However, GTP stimulates degradation that can be induced even in darkness in some photosystem II conformers following binding of the PNO8 herbicide (Nakajima, Y., Yoshida, S., Inoue, Y., Yoneyama, K., and Ono, T. (1995) Biochim. Biophys. Acta 1230, 38-44), Both the PNO8- and the light-induced primary cleavage of the D1 protein occur in the grana membrane domains. The subsequent migration of photosytem II containing the D1 protein fragments to the stroma domains for secondary proteolysis is light-activated. We conclude that the GTP effect is not confined to a specific photoinactivation pathway nor to the conformational state of the photosytem II acceptor side. Consequently, GTP does not interact with the site of D1 protein cleavage but rather enhances the activity of the endogenous proteolytic system.	Hebrew Univ Jerusalem, Dept Biol Chem, IL-91904 Jerusalem, Israel; Stockholm Univ, Arrhenius Labs Nat Sci, Dept Biochem, SE-10691 Stockholm, Sweden; Linkoping Univ, Div Cell Biol, SE-58185 Linkoping, Sweden; Univ Paris 06, Dept Cell Biol, F-75005 Paris, France	Hebrew University of Jerusalem; Stockholm University; Linkoping University; UDICE-French Research Universities; Sorbonne Universite	Ohad, I (corresponding author), Hebrew Univ Jerusalem, Dept Biol Chem, IL-91904 Jerusalem, Israel.	ohad@vms.huji.ac.il	Andersson, Bertil/C-9328-2009; Wiklund, Cornelia Spetea/S-3635-2019	Keren, Nir/0000-0002-7356-8831				ADIR N, 1990, J BIOL CHEM, V265, P12563; Andersson B, 1997, PHYSIOL PLANTARUM, V100, P780, DOI 10.1034/j.1399-3054.1997.1000405.x; ANDERSSON B, 1976, BIOCHIM BIOPHYS ACTA, V423, P122, DOI 10.1016/0005-2728(76)90106-7; ARO EM, 1990, BIOCHIM BIOPHYS ACTA, V1019, P269, DOI 10.1016/0005-2728(90)90204-H; GONG H, 1991, J BIOL CHEM, V266, P21293; GREENBERG BM, 1987, EMBO J, V6, P2865, DOI 10.1002/j.1460-2075.1987.tb02588.x; HUNDAL T, 1990, BIOCHIM BIOPHYS ACTA, V1017, P235, DOI 10.1016/0005-2728(90)90190-F; JANSEN MAK, 1993, J BIOL CHEM, V268, P21246; Keren N, 1997, P NATL ACAD SCI USA, V94, P1579, DOI 10.1073/pnas.94.4.1579; KEREN N, 1995, J BIOL CHEM, V270, P806, DOI 10.1074/jbc.270.2.806; KEREN N, 1995, PHOTOSYNTHESIS LIGHT, V4, P299; KIRILOVSKY D, 1994, BIOCHEMISTRY-US, V33, P3087, DOI 10.1021/bi00176a043; Krieger-Liszkay A, 1998, BIOCHEMISTRY-US, V37, P17339, DOI 10.1021/bi9822628; KYLE DJ, 1983, ARCH BIOCHEM BIOPHYS, V222, P527, DOI 10.1016/0003-9861(83)90551-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lindahl M, 1996, J BIOL CHEM, V271, P29329, DOI 10.1074/jbc.271.46.29329; MARDER JB, 1984, J BIOL CHEM, V259, P3900; NAKAJIMA Y, 1995, BBA-BIOENERGETICS, V1230, P38, DOI 10.1016/0005-2728(95)00030-M; Nakajima Y, 1996, J BIOL CHEM, V271, P17383, DOI 10.1074/jbc.271.29.17383; OETTMEIER W, 1992, PHOTOSYSTEMS STRUCTU, P349; OHAD I, 1985, EMBO J, V4, P1655, DOI 10.1002/j.1460-2075.1985.tb03833.x; PRASIL O, 1992, PHOTOSYSTEMS STRUCTU, P295, DOI DOI 10.1016/B978-0-444-89440-3.50017-5; REGITZ G, 1976, J BIOL CHEM, V251, P247; RENGER G, 1976, BIOCHIM BIOPHYS ACTA, V440, P287, DOI 10.1016/0005-2728(76)90063-3; RIVAS JD, 1993, BIOCHEMISTRY-US, V32, P6944, DOI 10.1021/bi00078a019; SALTER AH, 1992, BIOCHEMISTRY-US, V31, P3990, DOI 10.1021/bi00131a014; Spetea C, 1999, P NATL ACAD SCI USA, V96, P6547, DOI 10.1073/pnas.96.11.6547; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREBST A, 1986, PHOTOSYNTH RES, V10, P381, DOI 10.1007/BF00118304; TREBST A, 1988, PHOTOSYNTH RES, V18, P163, DOI 10.1007/BF00042983; VANWIJK KJ, 1995, J BIOL CHEM, V270, P25685, DOI 10.1074/jbc.270.43.25685; VASS I, 1992, P NATL ACAD SCI USA, V89, P1408, DOI 10.1073/pnas.89.4.1408; VIRGIN I, 1990, FEBS LETT, V269, P45, DOI 10.1016/0014-5793(90)81115-5; ZER H, 1995, EUR J BIOCHEM, V231, P448, DOI 10.1111/j.1432-1033.1995.tb20718.x	34	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7205	7211		10.1074/jbc.275.10.7205	http://dx.doi.org/10.1074/jbc.275.10.7205			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702290	hybrid			2022-12-27	WOS:000085809600070
J	Majidi, M; Gutkind, JS; Lichy, JH				Majidi, M; Gutkind, JS; Lichy, JH			Deletion of the COOH terminus converts the ST5 p70 protein from an inhibitor of RAS signaling to an activator with transforming activity in NIH-3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; HUMAN CHROMOSOME-11; FACTOR RECEPTOR; SH3 DOMAINS; IDENTIFICATION; KINASE; BINDING; GENE; MAP	Expression of the human protein ST5-p70 correlates with reduced tumorigenic phenotype in mammalian cells, reverts their transformed phenotype, and restores their contact-dependent growth, Furthermore, expression of p70 in COS-7 cells suppresses activation of mitogen activated protein kinase MAPK/ERK2 by the largest ST5 product, p126, in response to epidermal growth factor stimulation. Here we show that deletions of the COOH-terminal region of p70 transform NIH3T3 cells and induce their anchorage-independent growth. Analysis of signaling leading to MAPK/ERK2 stimulation revealed that in COS-7 cells, expression of either p70-Delta C1 or p70-Delta C2 markedly enhanced ERK2 activity in a growth factor-independent manner. Whereas wild-type p70 slightly inhibited ERK2 activation by RAS and MEK2, co-expression or p70-Delta C1 or p70-Delta C2 with either protein stimulated ERK2 cooperatively. This activity was completely blocked by the dominant negative mutants RAS17N: or MEKAA suggesting that p70 functions upstream of RAS. Unlike wild-type p70, expression of p70-Delta C1 or p70-Delta C2 mutant did not interfere with the ability of ST5-p126 to stimulate ERK2. Taken together, the data suggest that the COOH-terminal tail, residues 489-609, contains some of the critical determinants for the function of p70, Loss of this region converts the protein from an inhibitor to a constitutive activator of the RAS-ERK2 pathway.	Armed Forces Inst Pathol, Dept Cellular Pathol, Washington, DC 20306 USA; NIDCR, NIH, Bethesda, MD 20892 USA	United States Department of Defense; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Majidi, M (corresponding author), Armed Forces Inst Pathol, Dept Cellular Pathol, Washington, DC 20306 USA.		Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 	NATIONAL CANCER INSTITUTE [R01CA064114] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA64114] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; CAPRIOGLIO DR, 1993, J BIOL CHEM, V268, P14310; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; CLUCK V, 1993, P NATL ACAD SCI USA, V90, P7039; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; COX AD, 1994, J BIOL CHEM, V269, P19203; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; Hubbs AE, 1999, ONCOGENE, V18, P2519, DOI 10.1038/sj.onc.1202554; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Iwasaki K, 1997, NEURON, V18, P613, DOI 10.1016/S0896-6273(00)80302-5; JAMES GL, 1994, J BIOL CHEM, V269, P27705; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; LAWRENCE A, 1996, J BIOL CHEM, V271, P11076; LICHY JH, 1992, CELL GROWTH DIFFER, V3, P541; Majidi M, 1998, J BIOL CHEM, V273, P16608, DOI 10.1074/jbc.273.26.16608; MCGUIRE TF, 1995, BIOCHEM BIOPH RES CO, V214, P295, DOI 10.1006/bbrc.1995.2287; MODI WS, 1991, CYTOGENET CELL GENET, V58, P1968; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICHARD CW, 1993, AM J HUM GENET, V52, P915; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	28	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6560	6565		10.1074/jbc.275.9.6560	http://dx.doi.org/10.1074/jbc.275.9.6560			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692462	hybrid			2022-12-27	WOS:000085654400074
J	Mitsuhashi, S; Mizushima, T; Yamashita, E; Yamamoto, M; Kumasaka, T; Moriyama, H; Ueki, T; Miyachi, S; Tsukihara, T				Mitsuhashi, S; Mizushima, T; Yamashita, E; Yamamoto, M; Kumasaka, T; Moriyama, H; Ueki, T; Miyachi, S; Tsukihara, T			X-ray structure of beta-carbonic anhydrase from the red alga, Porphyridium purpureum, reveals a novel catalytic site for CO2 hydration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; DIFFRACTION; EVOLUTION; PROTEIN	The carbonic anhydrases (CAs) fall into three evolutionarily distinct families designated alpha-, beta-, and gamma-CAs based on their primacy structure. beta-CAs are present in higher plants, algae, and prokaryotes, and are involved in inorganic carbon utilization, Here, we describe the novel x-ray structure of beta-CA from the red alga, Porphyridium purpureum, at 2.2-Angstrom resolution using intrinsic zinc multiwavelength anomalous diffraction phasing. The CA monomer is composed of two internally repeating structures, being folded as a pair of fundamentally equivalent motifs of an alpha/beta domain and three projecting alpha-helices. The motif is obviously distinct from that of either alpha- or gamma-CAs. This homodimeric CA appears like a tetramer with a pseudo 222 symmetry. The active site zinc is coordinated by a Cys-Asp-His-Cys tetrad that is strictly conserved among the beta-CAs, No water molecule is found in a zinc-liganding radius, indicating that the zinc-hydroxide mechanism in alpha-CAs, and possibly in gamma-CAs, is not directly applicable to the case in beta-CAs. Zinc coordination environments of the CAs provide an interesting example of the convergent evolution of distinct catalytic sites required for the same CO2 hydration reaction.	Kamaishi Labs, Marine Biotechnol Inst, Kamaishi, Iwate 0260001, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; RIKEN, Harima Inst, Sayo, Hyogo 6795143, Japan; Japan Synchrotron Radiat Res Inst, Sayo, Hyogo 6795198, Japan	Osaka University; RIKEN; Japan Synchrotron Radiation Research Institute	Mitsuhashi, S (corresponding author), Kamaishi Labs, Marine Biotechnol Inst, Kamaishi, Iwate 0260001, Japan.		Kumasaka, Takashi/D-7428-2018; Yamamoto, Masaki/B-7844-2015; Yamashita, Eiki/V-6758-2019	Kumasaka, Takashi/0000-0001-9289-1557; Yamamoto, Masaki/0000-0002-1311-1768; Yamashita, Eiki/0000-0002-4278-0039				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; AIZAWA K, 1986, FEMS MICROBIOL LETT, V39, P215, DOI 10.1016/0378-1097(86)90447-7; BADGER MR, 1994, ANNU REV PLANT PHYS, V45, P369, DOI 10.1146/annurev.pp.45.060194.002101; BRACEY MH, 1994, BIOCHEMISTRY-US, V33, P13126, DOI 10.1021/bi00248a023; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; COLEMAN JE, 1967, J BIOL CHEM, V242, P5212; Fortelle E., 1997, METHOD ENZYMOL, P472; HAKANSSON K, 1992, J MOL BIOL, V227, P1192, DOI 10.1016/0022-2836(92)90531-N; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HewettEmmett D, 1996, MOL PHYLOGENET EVOL, V5, P50, DOI 10.1006/mpev.1996.0006; JOHANSSON IM, 1993, EUR J BIOCHEM, V218, P439, DOI 10.1111/j.1432-1033.1993.tb18394.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kisker C, 1996, EMBO J, V15, P2323, DOI 10.1002/j.1460-2075.1996.tb00588.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LILJAS A, 1972, NATURE-NEW BIOL, V235, P131, DOI 10.1038/newbio235131a0; Mitsuhashi S, 1996, J BIOL CHEM, V271, P28703, DOI 10.1074/jbc.271.45.28703; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PROVART NJ, 1993, PLANT MOL BIOL, V22, P937, DOI 10.1007/BF00028967; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; ROWLETT RS, 1994, BIOCHEMISTRY-US, V33, P13967, DOI 10.1021/bi00251a003; STEINER H, 1975, EUR J BIOCHEM, V59, P253, DOI 10.1111/j.1432-1033.1975.tb02449.x; TASHIAN RE, 1989, BIOESSAYS, V10, P186, DOI 10.1002/bies.950100603; YAGAWA Y, 1987, PLANT CELL PHYSIOL, V28, P1253; Yamamoto M, 1998, J SYNCHROTRON RADIAT, V5, P222, DOI 10.1107/S0909049597014738	24	124	134	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5521	5526		10.1074/jbc.275.8.5521	http://dx.doi.org/10.1074/jbc.275.8.5521			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681531	hybrid			2022-12-27	WOS:000085474500038
J	Perry, ME; Mendrysa, SM; Saucedo, LJ; Tannous, P; Holubar, M				Perry, ME; Mendrysa, SM; Saucedo, LJ; Tannous, P; Holubar, M			p76(MDM2) inhibits the ability of p90(MDM2) to destabilize p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TUMOR-SUPPRESSOR; DNA-DAMAGE; ONCOPROTEIN MDM2; PROTEIN; GENE; DEGRADATION; EXPRESSION; RADIATION; ONCOGENE	The mdm2 oncogene encodes p90(MDM2), which binds to and inactivates the p53 tumor suppressor protein. p90(MDM2) inhibits p53 by blocking the transcriptional activation domain of p53 as well as by stimulating its degradation. Recently, we showed that another product of the wild-type mdm2 gene, p76(MDM2), lacks the first 49 amino acids of p90(MDM2) and cannot bind p53. Here, we report that, like p90(MDM2), p76(MDM2) is, expressed in both the nuclear and cytoplasmic compartments. Overexpression of p76(MDM2) antagonizes the ability of p90(MDM2) to stimulate the degradation of p53 and leads to an increase in the levels and activity of p53. Seven murine tissues express an alternatively spliced mdm2 mRNA that can encode p76(MDM2) but not p90(MDM2), as web as the normally spliced mdm2 mRNA that encodes both MDM2 proteins. All seven tissues express both MDM2 proteins. p90(MDM2) is much more abundant than p76(MDM2) in the testis, brain, heart, and kidney. However, in those tissues known to undergo p53-mediated apoptosis in response to gamma-irradiation, the thymus, spleen, and intestine, the levels of the MDM2 proteins are roughly equivalent, Our results indicate that the ratio of the two MDM2 proteins may regulate the response of tissues to DNA damage.	Univ Wisconsin, Mcardle Lab Canc Res 207A, Dept Oncol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Perry, ME (corresponding author), Univ Wisconsin, Mcardle Lab Canc Res 207A, Dept Oncol, 1400 Univ Ave, Madison, WI 53706 USA.			Tannous, Paul/0000-0001-7972-9651	NATIONAL CANCER INSTITUTE [P30CA007175, P30CA014520] Funding Source: NIH RePORTER; NCI NIH HHS [CA-70718, CA-14520-26, CA-07175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEOCALUNA R, 1995, NATURE, V0378; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Landers JE, 1997, CANCER RES, V57, P3562; LEACH FS, 1993, CANCER RES, V53, P2231; MacCallum DE, 1996, ONCOGENE, V13, P2575; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MENDRYSA SM, 2000, IN PRESS MOL CELL BI; MERRITT AJ, 1994, CANCER RES, V54, P614; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Saucedo LJ, 1999, J BIOL CHEM, V274, P8161, DOI 10.1074/jbc.274.12.8161; Saucedo LJ, 1998, CELL GROWTH DIFFER, V9, P119; Seavey SE, 1999, J VIROL, V73, P7590, DOI 10.1128/JVI.73.9.7590-7598.1999; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SIEGEL J, 1995, ONCOGENE, V11, P1363; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	49	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5733	5738		10.1074/jbc.275.8.5733	http://dx.doi.org/10.1074/jbc.275.8.5733			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681559	hybrid			2022-12-27	WOS:000085474500066
J	Tagliabue, E; Castiglioni, F; Ghirelli, C; Modugno, M; Asnaghi, L; Somenzi, G; Melani, C; Menard, S				Tagliabue, E; Castiglioni, F; Ghirelli, C; Modugno, M; Asnaghi, L; Somenzi, G; Melani, C; Menard, S			Nerve growth factor cooperates with p185(HER2) in activating growth of human breast carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; KINASE-ACTIVITY; NEU ONCOGENE; RECEPTOR; LINE; CANCER; EXPRESSION; INHIBITION; PROTEIN	Nerve growth factor (NGF) is known to exert a mitogenic effect on human breast cancer cells through proto-TrkA activation. Reverse transcriptase-PCR analysis of proto-TrkA expression in human breast carcinoma specimens and cell lines revealed trkA transcript in 12 of 14 human breast carcinoma specimens and in all of four cell lines tested, while cytofluorimetric and Western blot analysis indicated proto-TrkA expression in three of the four cell lines, NGF stimulated growth in only two of the three positive cell Lines. Inhibition of NGF-induced MAPK activation by an antibody directed against the extracellular domain of TrkA but not by an inhibitor of TrkA phosphorylation demonstrated the requirement of NGF binding but not of proto-TrkA kinase activity for MAPK activation, suggesting the recruitment of another kinase for transmission of the mitogenic signaling. Indeed, NGF induced tyrosine phosphorylation and stimulated kinase activity of p185(HER2), a kinase receptor of the HER family. A TrkA phosphorylation inhibitor did not affect this activation. Moreover, the two receptors were coprecipitated by antibodies directed against proto-TrkA and p185(HER2). Down-modulation of p185(HER2) expression in a breast carcinoma Line transfected with a construct containing an anti-p185(HER2) antibody sequence and expressing proto-TrkA impaired NGF-induced MAPK activation and proliferation. Together these data show that in cells expressing low levels of TrkA such as breast carcinoma cells, NGF must recruit other overexpressed receptors such as p185(HER2) in order to generate a biological signal that can induce breast cancer cell growth.	Ist Nazl Tumori, Dept Expt Oncol, Mol Targeting Unit, I-20133 Milan, Italy; Ist Nazl Tumori, Dept Expt Oncol, Immunotherapy & Gene Therapy Unit, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Menard, S (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Mol Targeting Unit, Via Venezian 1, I-20133 Milan, Italy.		Melani, Cecilia/C-2756-2017; Tagliabue, Elda/B-9377-2017	Melani, Cecilia/0000-0003-2734-739X; Tagliabue, Elda/0000-0001-9877-2903				Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BAUER J, 1992, J CELL PHYSIOL, V153, P437, DOI 10.1002/jcp.1041530302; BERG MM, 1992, J BIOL CHEM, V267, P13; BOLD RJ, 1995, J NEUROCHEM, V64, P2622; Bonini S, 1996, P NATL ACAD SCI USA, V93, P10955, DOI 10.1073/pnas.93.20.10955; CENTIS F, 1992, HYBRIDOMA, V11, P267, DOI 10.1089/hyb.1992.11.267; COLOMBO MP, 1992, J IMMUNOL, V149, P113; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Descamps S, 1998, J BIOL CHEM, V273, P16659, DOI 10.1074/jbc.273.27.16659; DJAKIEW D, 1991, CANCER RES, V51, P3304; EHRHARD PB, 1994, J IMMUNOL, V152, P2705; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; GORETZKI PE, 1987, SURGERY, V102, P1035; GRECO A, 1993, CELL GROWTH DIFFER, V4, P539; HASHIMOTO S, 1988, J CELL BIOL, V107, P1531, DOI 10.1083/jcb.107.4.1531; JANES PW, 1994, ONCOGENE, V9, P3601; JARDINES L, 1993, PATHOBIOLOGY, V61, P268, DOI 10.1159/000163805; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; McGregor LM, 1999, P NATL ACAD SCI USA, V96, P4540, DOI 10.1073/pnas.96.8.4540; OELMANN E, 1995, CANCER RES, V55, P2212; PELLEGRINI R, 1991, CANCER IMMUNOL IMMUN, V34, P37, DOI 10.1007/BF01741322; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; REVOLTELLA RP, 1980, J CELL PHYSIOL, V104, P27, DOI 10.1002/jcp.1041040105; RILKE F, 1991, INT J CANCER, V49, P44, DOI 10.1002/ijc.2910490109; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tagliabue E, 1996, BRIT J CANCER, V74, P1427, DOI 10.1038/bjc.1996.560; Tagliabue E, 1999, INT J BIOL MARKER, V14, P68, DOI 10.1177/172460089901400203; TAGLIABUE E, 1991, INT J CANCER, V47, P933, DOI 10.1002/ijc.2910470625	34	59	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5388	5394		10.1074/jbc.275.8.5388	http://dx.doi.org/10.1074/jbc.275.8.5388			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681513	hybrid			2022-12-27	WOS:000085474500020
J	Tomiuk, S; Zumbansen, M; Stoffel, W				Tomiuk, S; Zumbansen, M; Stoffel, W			Characterization and subcellular localization of murine and human magnesium-dependent neutral sphingomyelinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID SPHINGOMYELINASE; CELL-DIFFERENTIATION; SIGNAL-TRANSDUCTION; DISTINCT POOL; RAT-BRAIN; CERAMIDE; APOPTOSIS; PURIFICATION; GLUTATHIONE; STRESS	Sphingomyelinases (SMases) catalyze the hydrolysis of sphingomyelin, an essential lipid constituent of the plasma membrane, lysosomal membranes, endoplasmic reticulum, and the Golgi membrane stacks of mammalian cells. In this study, we report the biochemical and functional characterization and subcellular localization of magnesium-dependent nSMasel from overexpressing human embryronic kidney (HER293) cells. Site-directed mutagenesis of conserved residues probably involved in the enzymatic sphingomyelin cleavage as well as the removal of one or both putative transmembrane domains lead to the complete loss of enzymatic activity of human nSMasel expressed in HEK293 cells. Polyclonal antibodies raised against recombinant mammalian Masel immunoprecipitated and inactivated the enzyme in membrane extracts of overexpressing HEK293 cells and different murine tissues. Cell fractionation combined with immunoprecipitation studies localized the nSMasel protein predominantly in the microsomal fraction, The enzyme colocalized with marker proteins of the endoplasmic reticulum and the Golgi apparatus in immunocytochemistry. Anti-nSMasel antibodies did not affect the nSMase activity in the plasma membrane fraction and membrane extracts from murine brain. Our study leads to the conclusion that nSMasel is one of at least two mammalian neutral sphingomyelinases with different subcellular localization, tissue specificity, and enzymatic properties.	Univ Cologne, Inst Biochem, Fak Med, Lab Mol Neurowissensch, D-50931 Cologne, Germany	University of Cologne	Stoffel, W (corresponding author), Univ Cologne, Inst Biochem, Fak Med, Lab Mol Neurowissensch, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.							Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; Boesen-de Cock JGR, 1998, J BIOL CHEM, V273, P7560, DOI 10.1074/jbc.273.13.7560; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUAN RD, 1995, BBA-LIPID LIPID MET, V1259, P49, DOI 10.1016/0005-2760(95)00137-2; Fleischer S, 1974, Methods Enzymol, V31, P6; GATT S, 1976, BIOCHEM BIOPH RES CO, V68, P235, DOI 10.1016/0006-291X(76)90034-6; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HELLER M, 1966, BIOCHEM J, V9, P763; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; HOSTETLER KY, 1979, J LIPID RES, V20, P456; KANFER JN, 1966, J BIOL CHEM, V241, P1081; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; Liu B, 1998, J BIOL CHEM, V273, P34472, DOI 10.1074/jbc.273.51.34472; Liu B, 1997, SEMIN CELL DEV BIOL, V8, P311, DOI 10.1006/scdb.1997.0153; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; NILSSON A, 1969, BIOCHIM BIOPHYS ACTA, V176, P339, DOI 10.1016/0005-2760(69)90192-1; Nyberg L, 1996, BBA-LIPID LIPID MET, V1300, P42, DOI 10.1016/0005-2760(95)00245-6; OEFNER C, 1986, J MOL BIOL, V192, P605, DOI 10.1016/0022-2836(86)90280-9; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; Oorni K, 1998, J BIOL CHEM, V273, P29127, DOI 10.1074/jbc.273.44.29127; RAO BG, 1976, J LIPID RES, V17, P506; SPENCE MW, 1978, J NEUROCHEM, V30, P917, DOI 10.1111/j.1471-4159.1978.tb10804.x; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; SWANSON MA, 1955, METHOD ENZYMOL, V2, P541, DOI 10.1016/S0076-6879(55)02247-7; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P8414; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Veiga MP, 1999, BIOPHYS J, V76, P342, DOI 10.1016/S0006-3495(99)77201-2; Watts JD, 1999, CELL DEATH DIFFER, V6, P105, DOI 10.1038/sj.cdd.4400472; Watts JD, 1997, P NATL ACAD SCI USA, V94, P7292, DOI 10.1073/pnas.94.14.7292; WIDNELL CC, 1968, P NATL ACAD SCI USA, V61, P1050, DOI 10.1073/pnas.61.3.1050; Zhang P, 1997, J BIOL CHEM, V272, P9609; Zumbansen M, 1997, J BIOL CHEM, V272, P10904	37	91	91	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5710	5717		10.1074/jbc.275.8.5710	http://dx.doi.org/10.1074/jbc.275.8.5710			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681556	hybrid			2022-12-27	WOS:000085474500063
J	Ballou, LM; Cross, ME; Huang, S; McReynolds, EM; Zhang, BX; Lin, RZ				Ballou, LM; Cross, ME; Huang, S; McReynolds, EM; Zhang, BX; Lin, RZ			Differential regulation of the phosphatidylinositol 3-kinase/Akt and p70 S6 kinase pathways by the alpha(1A)-adrenergic receptor in rat-1 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; B C-AKT; PHOSPHOINOSITIDE 3-KINASE; INSULIN STIMULATION; GROWTH-FACTOR; IN-VIVO; ACTIVATION; PHOSPHORYLATION; P70(S6K); INHIBITION	Phosphatidylinositol (PI) 3-kinase and its downstream effector Akt are thought to be signaling intermediates that link cell surface receptors to p70 S6 kinase. We examined the effect of a G(q)-coupled receptor on PI 3-kinase/Akt signaling and p70 S6 kinase activation using Rat-1 fibroblasts stably expressing the human su,adrenergic receptor. Treatment of the cells with phenylephrine, a specific alpha(1)-adrenergic receptor agonist, activated p70 S6 kinase but did not activate PI 3-kinase or any of the three known isoforms of Akt. Furthermore, phenylephrine blocked the insulin-like growth factor-I (IGF-I)-induced activation of PI 3-kinase and the phosphorylation and activation of Akt-1. The effect of phenylephrine was not confined to signaling pathways that include insulin receptor substrate-1, as the alpha(1)-adrenergic receptor agonist also inhibited the platelet-derived growth factor-induced activation of PI 3-kinase and Akt-1. Although increasing the intracellular Ca2+ concentration with the ionophore A23187 inhibited the activation of Akt-1 by IGF-I, Ca2+ does not appear to play a role in the phenylephrine-mediated inhibition of the PI 3-kinase/Akt pathway. The differential ability of phenylephrine and IGF-I to activate Akt-1 resulted in a differential ability to protect cells from UV-induced apoptosis. These results demonstrate that activation of p70 S6 kinase by the alpha(1A)-adrenergic receptor in Rat-1 fibroblasts occurs in the absence of PI 3-kinase/Akt signaling. Furthermore, this receptor negatively regulates the PI 3-kinase/Akt pathway, resulting in enhanced cell death following apoptotic insult.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA; Audie L Murphy Mem Vet Hosp, Res Serv, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Lin, RZ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, Mail Code 7764,7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Lin, Richard/J-1754-2014	Lin, Richard/0000-0002-3473-7276				Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Amaldi F, 1997, Prog Mol Subcell Biol, V18, P1; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Boluyt MO, 1997, CIRC RES, V81, P176, DOI 10.1161/01.RES.81.2.176; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARTER AN, 1993, NEUROPROTOCOLS, V3, P107; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chen J, 1999, J PHARMACOL EXP THER, V289, P1376; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Coffer PJ, 1998, BIOCHEM J, V335, P1; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUERR RL, 1995, J CLIN INVEST, V95, P619, DOI 10.1172/JCI117706; Dufner A, 1999, MOL CELL BIOL, V19, P4525; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Graves LM, 1997, J BIOL CHEM, V272, P1920, DOI 10.1074/jbc.272.3.1920; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1996, TRANSLATIONAL CONTRO, P389; Kenny BA, 1996, BRIT J PHARMACOL, V118, P871, DOI 10.1111/j.1476-5381.1996.tb15480.x; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MEYUHAS O, 1998, TRANSLATIONAL CONTRO, P363; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; PETRITSCH C, 1995, EUR J BIOCHEM, V230, P431, DOI 10.1111/j.1432-1033.1995.0431h.x; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; Rybkin II, 2000, J BIOL CHEM, V275, P5460, DOI 10.1074/jbc.275.8.5460; SCHWINN DA, 1995, J PHARMACOL EXP THER, V272, P134; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Takasuga S, 1999, J BIOL CHEM, V274, P19545, DOI 10.1074/jbc.274.28.19545; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; Zhang BX, 1996, CIRC RES, V79, P94, DOI 10.1161/01.RES.79.1.94	55	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4803	4809		10.1074/jbc.275.7.4803	http://dx.doi.org/10.1074/jbc.275.7.4803			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671514	hybrid			2022-12-27	WOS:000085378200040
J	Rasko, DA; Wang, G; Palcic, MM; Taylor, DE				Rasko, DA; Wang, G; Palcic, MM; Taylor, DE			Cloning and characterization of the alpha(1,3/4) fucosyltransferase of Helicobacter pylori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENGINEERED TRUNCATED FORM; BLOOD-GROUP ANTIGENS; LEWIS FUT3 GENE; MONOCLONAL-ANTIBODIES; POLYACRYLAMIDE GELS; POINT MUTATIONS; GROUP SYSTEM; FUC-TIII; EXPRESSION; LIPOPOLYSACCHARIDE	The gastric pathogen Helicobacter pylori can express the histo blood group antigens, which are on the surface of many human cells. Most H. pylori strains express the type II carbohydrates, Lewis X and Y, whereas a small population express the type I carbohydrates, Lewis A and B. The expression of Lewis A and Lewis X, as in the case of H. pylori strain UA948, requires the addition of fucose in alpha 1,4 and alpha 1,3 linkages to type I or type II carbohydrate backbones, respectively. This work describes the cloning and characterization of a single H. pylori fucosyltransferase (FucT) enzyme, which has the ability to transfer fucose to both of the aforementioned linkages in a manner similar to the human fucosyltransferase V (Fuc-TV). Two homologous copies of the fucT gene have been identified in each of the genomes sequenced. The characteristic adenosine and cytosine tracts in the amino terminus and repeated regions in the carboxyl terminus are present in the DNA encoding the two UA948fucT genes, but these genes also contain differences when compared with previously identified H. pylori fucTs. The UA948fucTa gene encodes an approximately 52-kDa protein containing 475 amino acids, whereas UA948fucTb does not encode a full-length FucT protein. In vitro, UA948FucTa appears to add fucose with a greater than B-fold preference for type II chains but still retains significant activity using type I accepters. The addition of the fucose to the type II carbohydrate accepters, by UA948FucTa, does not appear to be affected by fucosylation at other sites on the carbohydrate acceptor, but the rate of fucose transfer is affected by terminal fucosylation of type I accepters. Through mutational analysis we demonstrate that only FucTa is active in this H. pylori isolate and that inactivation of this enzyme eliminates expression of all Lewis antigens.	Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Chem, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta	Taylor, DE (corresponding author), Univ Alberta, Dept Med Microbiol & Immunol, 1-28 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	diane.taylor@ualberta.ca		David, Rasko/0000-0002-7337-7154				Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Amano K, 1997, CLIN DIAGN LAB IMMUN, V4, P540, DOI 10.1128/CDLI.4.5.540-544.1997; Appelmelk BJ, 1998, INFECT IMMUN, V66, P70, DOI 10.1128/IAI.66.1.70-76.1998; Appelmelk BJ, 1996, INFECT IMMUN, V64, P2031, DOI 10.1128/IAI.64.6.2031-2040.1996; Aspinall GO, 1996, BIOCHEMISTRY-US, V35, P2489, DOI 10.1021/bi951852s; Breton C, 1998, GLYCOBIOLOGY, V8, P87, DOI 10.1093/glycob/8.1.87; BRETON C, 1996, GLYCOBIOLOGY, V8, pR7; CHAN NWC, 1995, GLYCOBIOLOGY, V5, P683, DOI 10.1093/glycob/5.7.683; Claeys D, 1998, GASTROENTEROLOGY, V115, P340, DOI 10.1016/S0016-5085(98)70200-8; Costa J, 1997, J BIOL CHEM, V272, P11613; Costache M, 1997, J BIOL CHEM, V272, P29721, DOI 10.1074/jbc.272.47.29721; Costache M, 1997, TRANSFUS CLIN BIOL, V4, P367, DOI 10.1016/S1246-7820(97)80042-0; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; Dupuy F, 1999, J BIOL CHEM, V274, P12257, DOI 10.1074/jbc.274.18.12257; Elmgren A, 1996, VOX SANG, V70, P97, DOI 10.1111/j.1423-0410.1996.tb01300.x; Elmgren A, 1997, J BIOL CHEM, V272, P21994, DOI 10.1074/jbc.272.35.21994; Gallet PF, 1998, GLYCOBIOLOGY, V8, P919, DOI 10.1093/glycob/8.9.919; GE Z, 1992, HELICOBACTER PYLORI; Ge ZM, 1997, J BIOL CHEM, V272, P21357, DOI 10.1074/jbc.272.34.21357; Hardy E, 1997, ANAL BIOCHEM, V244, P28, DOI 10.1006/abio.1996.9719; HENRY S, 1995, VOX SANG, V69, P166, DOI 10.1111/j.1423-0410.1995.tb02591.x; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; Martin SL, 1997, J BIOL CHEM, V272, P21349, DOI 10.1074/jbc.272.34.21349; MOLLICONE R, 1994, J BIOL CHEM, V269, P20987; Monteiro MA, 1998, J BIOL CHEM, V273, P11533, DOI 10.1074/jbc.273.19.11533; Negrini R, 1996, GASTROENTEROLOGY, V111, P655, DOI 10.1053/gast.1996.v111.pm8780570; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V196, P624, DOI 10.1006/bbrc.1993.2295; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; Pang H, 1998, GLYCOCONJUGATE J, V15, P961, DOI 10.1023/A:1006981724233; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SimoonsSmit IM, 1996, J CLIN MICROBIOL, V34, P2196, DOI 10.1128/JCM.34.9.2196-2200.1996; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAYLOR DE, 1987, AM J CLIN PATHOL, V87, P49, DOI 10.1093/ajcp/87.1.49; Taylor DE, 1998, GASTROENTEROLOGY, V115, P1113, DOI 10.1016/S0016-5085(98)70082-4; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang G, 1999, MOL MICROBIOL, V31, P1265, DOI 10.1046/j.1365-2958.1999.01268.x; WANG Y, 1990, GENE, V94, P23, DOI 10.1016/0378-1119(90)90463-2; WESTON BW, 1992, J BIOL CHEM, V267, P4152; Wirth HP, 1996, INFECT IMMUN, V64, P4598, DOI 10.1128/IAI.64.11.4598-4605.1996; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818	42	65	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4988	4994		10.1074/jbc.275.7.4988	http://dx.doi.org/10.1074/jbc.275.7.4988			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671538	hybrid			2022-12-27	WOS:000085378200064
J	Goldstein, BJ; Bittner-Kowalczyk, A; White, MF; Harbeck, M				Goldstein, BJ; Bittner-Kowalczyk, A; White, MF; Harbeck, M			Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B - Possible facilitation by the formation of a ternary complex with the GRB2 adaptor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAIN; HEMATOPOIETIC-CELLS; XENOPUS OOCYTES; INTACT-CELLS; ASSOCIATION; BINDING; INTERACTS; SIGNAL; ALPHA; IRS-1	Regulation of the steady-state tyrosine phosphorylation of the insulin receptor and its postreceptor substrates are essential determinants of insulin signal transduction. However, little is known regarding the molecular interactions that influence the balance of these processes, especially the phosphorylation state of postinsulin receptor substrates, such as insulin receptor substrate-1 (IRS-1). The specific activity of four candidate protein-tyrosine phosphatases (protein-tyrosine phosphatase 1B (PTP1B), SH2 domain-containing PT-Pase-2 (SHP-2), leukocyte common antigen-related (LAR), and leukocyte antigen-related phosphatase) (LRP) toward IRS-1 dephosphorylation was studied using recombinant proteins in vitro, PTP1B exhibited the highest specific activity (percentage dephosphorylated per mu g per min), and the enzyme activities varied over a range of 5.5 x 10(3). When evaluated as a ratio of activity versus IRS-1 to that versus p-nitrophenyl phosphate, PTP1B remained significantly more active by 3.1-293-fold, respectively. Overlay blots with recombinant Src homology 2 domains of IRS-1 adaptor proteins showed that the loss of IRS-1 binding of Crk, GRB2, SHP-2, and the p85 subunit of phosphatidylinositol 3'-kinase paralleled the rate of overall IRS-1 dephosphorylation, Further studies revealed that the adaptor protein GRB2 strongly promoted the formation of a stable protein complex between tyrosine-phosphorylated IRS-1 and catalytically inactive PTP1B, increasing their co-immunoprecipitation from an equimolar solution by 13.5 +/- 3.3-fold (n = 7; p < 0.01), Inclusion of GRB2 in a reaction mixture of IRS-1 and active PTP1B also increased the overall rate of IRS-1 tyrosine dephosphorylation by 2.7-3.9-fold (p < 0.01), These results provide new insight into novel molecular interactions involving PTP1B and GRB2 that may influence the steady-state capacity of IRS-1 to function as a phosphotyrosine scaffold and possibly affect the balance of postreceptor insulin signaling.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Dorrance H Hamilton Res Labs, Div Endocrinol Diabet & Metab Dis, Philadelphia, PA 19107 USA	Jefferson University	Goldstein, BJ (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Dorrance H Hamilton Res Labs, Div Endocrinol Diabet & Metab Dis, 349 Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.	Barry.Goldstein@mail.tju.edu			NIDDK NIH HHS [R01-DK43396] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043396] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad F, 1997, J BIOL CHEM, V272, P448; AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; Bandyopadhyay D, 1997, J BIOL CHEM, V272, P1639, DOI 10.1074/jbc.272.3.1639; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Charest A, 1997, ONCOGENE, V14, P1643, DOI 10.1038/sj.onc.1201008; Chen H, 1997, J BIOL CHEM, V272, P8026, DOI 10.1074/jbc.272.12.8026; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Evans J L, 1999, Expert Opin Investig Drugs, V8, P139, DOI 10.1517/13543784.8.2.139; Goldstein BJ, 1998, VITAM HORM, V54, P67, DOI 10.1016/S0083-6729(08)60922-X; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HASHIMOTO N, 1992, BIOCHEM J, V284, P569, DOI 10.1042/bj2840569; HASHIMOTO N, 1992, J BIOL CHEM, V267, P13811; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; KAMPS MP, 1991, METHOD ENZYMOL, V201, P101; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; KonKozlowski M, 1996, J BIOL CHEM, V271, P3856; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; Seely BL, 1996, DIABETES, V45, P1379, DOI 10.2337/diabetes.45.10.1379; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wong L, 1996, J BIOL CHEM, V271, P20981, DOI 10.1074/jbc.271.35.20981	38	330	358	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4283	4289		10.1074/jbc.275.6.4283	http://dx.doi.org/10.1074/jbc.275.6.4283			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660596	hybrid			2022-12-27	WOS:000085288800080
J	Hindenes, JO; Nerdal, W; Guo, W; Di, L; Small, DM; Holmsen, H				Hindenes, JO; Nerdal, W; Guo, W; Di, L; Small, DM; Holmsen, H			Physical properties of the transmembrane signal molecule, sn-1-stearoyl 2-arachidonoylglycerol - Acyl chain segregation and its biochemical implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; DIACYLGLYCEROL KINASE; PHOSPHOLIPASE-C; ARACHIDONOYL-DIACYLGLYCEROL; MODEL DIACYLGLYCEROLS; INDUCED TRANSLOCATION; CRYSTAL-STRUCTURE; MEMBRANE-FUSION; CONFORMATION; PHOSPHATIDYLCHOLINE	sn-1,2-Diacylglycerol (DAG), a key intermediate in lipid metabolism activates protein kinase C and is a fusogen. Phosphoinositides, the main sources of DAG in cell signaling, contain mostly stearoyl and arachidonoyl in the sn-1 and -2 positions, respectively. The polymorphic behavior of sn-1-stearoyl-2-arachidonoylglycerol (SAG) was studied by differential scanning calorimetry, x-ray powder diffraction, and solid state magic angle spinning (MAS) C-13 NMR, Three alpha phases were found in the dry state. X-ray diffraction indicated that the acyl chains packed in a hexagonal array in the alpha phase, and the two sub-alpha phases packed with pseudo-hexagonal symmetry. In the narrow angle range strong diffractions of similar to 31 and similar to 62 Angstrom were present. High power proton-decoupled MAS C-13 NMR of isotropic SAG gave 16 distinct resonances of the 20 arachidonoyl carbons and 5 distinct resonances of the 18 stearoyl carbons. Upon cooling, all resonances of stearoyl weakened and vanished in the sub-alpha, phase, whereas arachidonoyl carbons from 8/6 to 20 gave distinct resonances in the frozen phases. Remarkably, the omega-carbon of the two acyl chains had different chemical shifts in alpha, sub-alpha(1), and sub-alpha(2) phases. Large differences in spin lattice relaxation of the stearoyl and arachidonoyl methene and methyl groups were demonstrated by contact time (cross-polarization) MAS C-13 NMR experiments in the solid phases alpha, sub-alpha(1), and sub-alpha(2). This shows that stearoyl and arachidonoyl in SAG have different environments in the solid states (alpha, sub-alpha(1), and sub-alpha(2) phases) and may segregate during cooling. The NMR and long spacing x-ray diffraction results suggest that SAG does not pack in a conventional double layer with the two acyls in a hairpin fashion. Our findings thus provide a physicochemical basis for DAG hexagonal phase domain separation within membrane bilayers.	Univ Bergen, Dept Chem, N-5007 Bergen, Norway; Boston Univ, Sch Med, Dept Biophys, Boston, MA 02118 USA; Univ Bergen, Dept Biochem & Mol Biol, Bergen, Norway	University of Bergen; Boston University; University of Bergen	Nerdal, W (corresponding author), Univ Bergen, Dept Chem, Allegaten 41, N-5007 Bergen, Norway.	willy.nerdal@kj.uib.no		Small, Donald/0000-0002-3072-243X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL026335] Funding Source: NIH RePORTER; NHLBI NIH HHS [TG5T32HL-07291, 5 PO1HL26335] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPLEGATE KR, 1991, J LIPID RES, V32, P1645; APPLEGATE KR, 1991, J LIPID RES, V32, P1635; APPLEGATE KR, 1986, J LIPID RES, V27, P658; BALSINDE J, 1991, J BIOL CHEM, V266, P15638; Basanez G, 1996, BIOCHEMISTRY-US, V35, P15183, DOI 10.1021/bi9616561; Basanez G, 1996, BIOPHYS J, V70, P2299, DOI 10.1016/S0006-3495(96)79795-3; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P9378, DOI 10.1073/pnas.83.24.9378; BRUZIK KS, 1990, BIOCHIM BIOPHYS ACTA, V1023, P143, DOI 10.1016/0005-2736(90)90020-O; COORSSEN JR, 1990, BIOCHEM CELL BIOL, V68, P65, DOI 10.1139/o90-008; DALLING DK, 1981, J AM CHEM SOC, V103, P4817, DOI 10.1021/ja00406a025; Di L, 1995, BIOCHEMISTRY-US, V34, P16672, DOI 10.1021/bi00051a015; DI L, 1993, J LIPID RES, V34, P1611; Dibble ARG, 1996, BIOPHYS J, V71, P1877, DOI 10.1016/S0006-3495(96)79387-6; DORSET DL, 1988, CHEM PHYS LIPIDS, V48, P19, DOI 10.1016/0009-3084(88)90130-2; Epand RM, 1996, CHEM PHYS LIPIDS, V81, P101, DOI 10.1016/0009-3084(96)02575-3; FRANKS A, 1958, BRIT J APPL PHYS, V9, P349, DOI 10.1088/0508-3443/9/9/302; FUKAMI MH, 1995, EUR J BIOCHEM, V228, P579, DOI 10.1111/j.1432-1033.1995.tb20297.x; FYFE CA, 1983, SOLID STATE NMR CHEM, P180; GOLDBERG EM, 1995, BIOPHYS J, V69, P965, DOI 10.1016/S0006-3495(95)79970-2; GOLDBERG EM, 1994, BIOPHYS J, V66, P382, DOI 10.1016/S0006-3495(94)80788-X; GOTO M, 1995, J LIPID RES, V36, P2185; GUNSTONE FD, 1995, ANNU REP NMR SPECTRO, V31, P219; HA KS, 1993, J BIOL CHEM, V268, P10534; HAMILTON JA, 1991, J BIOL CHEM, V266, P1177; HARTMANN SR, 1962, PHYS REV, V128, P2042, DOI 10.1103/PhysRev.128.2042; Hinderliter AK, 1997, BIOCHEMISTRY-US, V36, P6141, DOI 10.1021/bi962715d; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; HOMAYOUN P, 1993, BIOCHEM BIOPH RES CO, V195, P144, DOI 10.1006/bbrc.1993.2022; Jimenez-Monreal AM, 1998, BBA-BIOMEMBRANES, V1373, P209, DOI 10.1016/S0005-2736(98)00106-0; KODALI DR, 1990, BIOCHEMISTRY-US, V29, P10771, DOI 10.1021/bi00500a008; KODALI DR, 1990, CHEM PHYS LIPIDS, V52, P163, DOI 10.1016/0009-3084(90)90111-4; KODALI DR, 1992, CHEM PHYS LIPIDS, V61, P169, DOI 10.1016/0009-3084(92)90009-E; KOLESNICK RN, 1990, J BIOL CHEM, V265, P10900; KRAMER RM, 1987, BIOCHEM J, V248, P779, DOI 10.1042/bj2480779; LEE MW, 1994, BIOCHEM J, V298, P213, DOI 10.1042/bj2980213; LEMAITRE RN, 1990, BIOCHEM J, V266, P291, DOI 10.1042/bj2660291; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; LUK AS, 1993, BIOCHEMISTRY-US, V32, P6965, DOI 10.1021/bi00078a022; MACDONALD ML, 1988, J BIOL CHEM, V263, P1584; MARKLEY KS, 1960, FATTY ACIDS, P162; MARONEY AC, 1989, J BIOL CHEM, V264, P2537; MAUCO G, 1984, BIOCHEM J, V224, P933, DOI 10.1042/bj2240933; MIZUNOKAMIYA M, 1995, J BIOCHEM-TOKYO, V118, P693, DOI 10.1093/oxfordjournals.jbchem.a124967; PASCHER I, 1981, J MOL BIOL, V153, P791, DOI 10.1016/0022-2836(81)90419-8; PUNNONEN K, 1992, J INVEST DERMATOL, V99, P221, DOI 10.1111/1523-1747.ep12650445; RETHWISCH DG, 1993, ANAL CHIM ACTA, V283, P1033, DOI 10.1016/0003-2670(93)80264-L; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; ROLDAN ERS, 1994, INT J BIOCHEM, V26, P951, DOI 10.1016/0020-711X(94)90089-2; Ruiz-Arguello MB, 1998, J BIOL CHEM, V273, P22977, DOI 10.1074/jbc.273.36.22977; Saito S, 1997, J BIOL CHEM, V272, P9503; SANCHEZMIGALLON MP, 1995, BIOPHYS J, V68, P558, DOI 10.1016/S0006-3495(95)80217-1; SANCHEZMIGALLON MP, 1994, ARCH BIOCHEM BIOPHYS, V314, P205, DOI 10.1006/abbi.1994.1431; SIMPSON CMF, 1991, J BIOL CHEM, V266, P15902; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; SOULAGES JL, 1995, P NATL ACAD SCI USA, V92, P5650, DOI 10.1073/pnas.92.12.5650; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Vance D. E., 1996, BIOCH LIPIDS LIPOPRO; Vigh L, 1998, TRENDS BIOCHEM SCI, V23, P369, DOI 10.1016/S0968-0004(98)01279-1; WALSH JP, 1994, J BIOL CHEM, V269, P21155	59	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6857	6867		10.1074/jbc.275.10.6857	http://dx.doi.org/10.1074/jbc.275.10.6857			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702245	hybrid			2022-12-27	WOS:000085809600025
J	Kelman, Z; Hurwitz, J				Kelman, Z; Hurwitz, J			A unique organization of the protein subunits of the DNA polymerase clamp loader in the archaeon Methanobacterium thermoautotrophicum Delta H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION-FACTOR-C; CELL NUCLEAR ANTIGEN; COMPLETE GENOME SEQUENCE; SACCHAROMYCES-CEREVISIAE; ATPASE ACTIVITY; ACCESSORY PROTEINS; EUKARYOTIC CELLS; ESCHERICHIA-COLI; SLIDING CLAMPS; III HOLOENZYME	Replication factor C (RFC, also called activator 1), in conjunction with proliferating cell nuclear antigen (PCNA), is responsible for processive DNA synthesis catalyzed by the eukaryotic replicative DNA polymerases delta and epsilon, Here we report the isolation and characterization of homologues of RFC and PCNA from the archaeon, Methanobacterium thermoautotrophicum Delta H. Zn contrast to the five subunit RFC complex isolated from eukaryotic cells, the mthRFC contains only two subunits, The two genes encoding the RFC subunits called, mthRFC1 and mthRFC3, were cloned, and the proteins (54.4 and 36.8 kDa, respectively) were overexpressed in Escherichia coli and purified individually and as a complex. The gene encoding PCNA was also cloned, and the protein was purified after overexpression in E, coli, Based on sizing column elution and subunit composition, the mthRFC complex appears to be a hexamer consisting of two mthRFC1 protomers and four mthRFC3 protomers, Although mthRFC differs in organization from its eukaryotic counterpart, it was shown to be functionally similar to eukaryotic RFC in: (i) catalyzing DNA-dependent ATP hydrolysis; (ii) binding preferentially to DNA primer ends; (iii) loading mthPCNA onto singly nicked circular DNA; and (iv) supporting mth-PolB-catalyzed PCNA-dependent DNA chain elongation. The importance and roles of RFC and PCNA in M. thermoautotrophicum Delta H replication are discussed.	Mem Sloan Kettering Canc Ctr, Dept Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Kelman, Z (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Mol Biol, Box 97,1275 York Ave, New York, NY 10021 USA.				NIGMS NIH HHS [GM 38559] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernander R, 1998, MOL MICROBIOL, V29, P955, DOI 10.1046/j.1365-2958.1998.00956.x; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cai JS, 1997, J BIOL CHEM, V272, P18974, DOI 10.1074/jbc.272.30.18974; Cai JS, 1996, P NATL ACAD SCI USA, V93, P12896, DOI 10.1073/pnas.93.23.12896; Chedin F, 1998, TRENDS BIOCHEM SCI, V23, P273, DOI 10.1016/S0968-0004(98)01243-2; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; De Felice M, 1999, J MOL BIOL, V291, P47, DOI 10.1006/jmbi.1999.2939; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Edgell DR, 1997, CELL, V89, P995, DOI 10.1016/S0092-8674(00)80285-8; Ellison V, 1998, J BIOL CHEM, V273, P5979, DOI 10.1074/jbc.273.10.5979; Gibbs E, 1997, J BIOL CHEM, V272, P2373; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HUANG CC, 1981, J BIOL CHEM, V256, P4087; Ishino Y, 1998, J BACTERIOL, V180, P2232, DOI 10.1128/JB.180.8.2232-2236.1998; JARVIS TC, 1989, J BIOL CHEM, V264, P12717; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P9515, DOI 10.1073/pnas.96.17.9515; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; KELMAN Z, 1995, GENE, V166, P177, DOI 10.1016/0378-1119(95)00556-7; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; Kelman Z, 1999, J BIOL CHEM, V274, P28751, DOI 10.1074/jbc.274.40.28751; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Koonin EV, 1997, MOL MICROBIOL, V25, P619, DOI 10.1046/j.1365-2958.1997.4821861.x; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LEE SH, 1991, J BIOL CHEM, V266, P594; ONRUST R, 1991, J BIOL CHEM, V266, P21681; Podust VN, 1998, J BIOL CHEM, V273, P12935, DOI 10.1074/jbc.273.21.12935; Podust VN, 1998, J BIOL CHEM, V273, P31992, DOI 10.1074/jbc.273.48.31992; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Uemori T, 1997, GENES CELLS, V2, P499, DOI 10.1046/j.1365-2443.1997.1380336.x; Uhlmann F, 1997, J BIOL CHEM, V272, P10058; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; YODER BL, 1991, J BIOL CHEM, V266, P22689; ZEIKUS JG, 1972, J BACTERIOL, V109, P707, DOI 10.1128/JB.109.2.707-713.1972	47	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7327	7336		10.1074/jbc.275.10.7327	http://dx.doi.org/10.1074/jbc.275.10.7327			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702304	hybrid			2022-12-27	WOS:000085809600084
J	Levin, JR; Blake, JJ; Ganunis, RA; Tullius, TD				Levin, JR; Blake, JJ; Ganunis, RA; Tullius, TD			The roles of specific template nucleosides in the formation of stable transcription complexes by Escherichia coli RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPSTREAM A-TRACTS; LAC UV5 PROMOTER; TERNARY COMPLEXES; NONTEMPLATE STRAND; ELONGATION COMPLEX; ALPHA-SUBUNIT; DNA-BINDING; IN-VIVO; INITIATION; RECOGNITION	We have examined the effects of removing individual template nucleosides on promoter escape by Escherichia coli RNA polymerase in vitro. The ability of DNA templates containing random single nucleoside gaps generated by hydroxyl radical treatment to support the production of stable ternary transcription complexes was analyzed. On two templates containing different promoter and initial transcribed regions, we found that removal of nucleosides on the template strand in the region from -13 to at least +8 relative to the transcription start site interfered with ternary complex formation. The downstream border of this region varied for the two templates, suggesting an effect of the specific nucleotide sequence on the stability of intermediates in the promoter escape process. On the nontemplate strand, removal of nucleosides in the vicinity of the -10 consensus promoter element interfered with escape, whereas removal of nucleosides in the vicinity of the transcription start site actually enhanced the yield of ternary complexes. On one template, removal of nucleosides in an A-tract containing region upstream of the promoter caused a significant decrease in promoter escape, consistent with previous suggestions that contacts between this region and the RNA polymerase play a role in promoter binding and/or initiation.	Goucher Coll, Dept Biol Sci, Baltimore, MD 21204 USA; Goucher Coll, Dept Chem, Baltimore, MD 21204 USA; Johns Hopkins Univ, Dept Chem, Baltimore, MD 21218 USA; Boston Univ, Dept Chem, Boston, MA 02215 USA	Johns Hopkins University; Boston University	Levin, JR (corresponding author), Goucher Coll, Dept Biol Sci, 1021 Dulaney Valley Rd, Baltimore, MD 21204 USA.	jlevin@goucher.edu	Tullius, Thomas D./A-9685-2008	Tullius, Thomas D./0000-0003-4425-796X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041930] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM041930, GM41930, R01 GM041930-10] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aiyar SE, 1998, P NATL ACAD SCI USA, V95, P14652, DOI 10.1073/pnas.95.25.14652; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; Balasubramanian B, 1998, P NATL ACAD SCI USA, V95, P9738, DOI 10.1073/pnas.95.17.9738; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; CRAIG ML, 1995, BIOCHEMISTRY-US, V34, P15624, DOI 10.1021/bi00048a004; DEUSCHLE U, 1986, EMBO J, V5, P2987, DOI 10.1002/j.1460-2075.1986.tb04596.x; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; ELLINGER T, 1994, J MOL BIOL, V239, P466, DOI 10.1006/jmbi.1994.1389; ELLINGER T, 1994, J MOL BIOL, V239, P455, DOI 10.1006/jmbi.1994.1388; Estrem ST, 1999, GENE DEV, V13, P2134, DOI 10.1101/gad.13.16.2134; FENG GH, 1994, J BIOL CHEM, V269, P22282; GRALLA JD, 1980, BIOCHEMISTRY-US, V19, P5864, DOI 10.1021/bi00566a031; HAYES JJ, 1989, BIOCHEMISTRY-US, V28, P9521, DOI 10.1021/bi00450a041; HSU LM, 1995, P NATL ACAD SCI USA, V92, P11588, DOI 10.1073/pnas.92.25.11588; KAMMERER W, 1986, EMBO J, V5, P2995, DOI 10.1002/j.1460-2075.1986.tb04597.x; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; Liu J, 1996, BIOCHEMISTRY-US, V35, P14999, DOI 10.1021/bi961455x; METZGER W, 1993, J MOL BIOL, V232, P35, DOI 10.1006/jmbi.1993.1368; NICKERSON CA, 1995, J BACTERIOL, V177, P5756, DOI 10.1128/jb.177.20.5756-5761.1995; Nudler E, 1999, J MOL BIOL, V288, P1, DOI 10.1006/jmbi.1999.2641; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; Ring BZ, 1996, CELL, V86, P485, DOI 10.1016/S0092-8674(00)80121-X; Rivetti C, 1999, EMBO J, V18, P4464, DOI 10.1093/emboj/18.16.4464; Roberts CW, 1996, CELL, V86, P495; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; Sambrook J., 2002, MOL CLONING LAB MANU; Shadle SE, 1997, NUCLEIC ACIDS RES, V25, P850, DOI 10.1093/nar/25.4.850; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; STUDIER FW, 1981, J MOL BIOL, V153, P503, DOI 10.1016/0022-2836(81)90405-8; TELESNITSKY APW, 1989, J MOL BIOL, V205, P315, DOI 10.1016/0022-2836(89)90343-4; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Wang DG, 1997, J BIOL CHEM, V272, P5989, DOI 10.1074/jbc.272.9.5989; WEREL W, 1991, EMBO J, V10, P2589, DOI 10.1002/j.1460-2075.1991.tb07800.x; ZHOU W, 1994, BIOCHEMISTRY-US, V33, P14926, DOI 10.1021/bi00253a032	39	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6885	6893		10.1074/jbc.275.10.6885	http://dx.doi.org/10.1074/jbc.275.10.6885			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702248	hybrid			2022-12-27	WOS:000085809600028
J	Raffai, R; Weisgraber, KH; MacKenzie, R; Rupp, B; Rassart, E; Hirama, T; Innerarity, TL; Milne, R				Raffai, R; Weisgraber, KH; MacKenzie, R; Rupp, B; Rassart, E; Hirama, T; Innerarity, TL; Milne, R			Binding of an antibody mimetic of the human low density lipoprotein receptor to apolipoprotein E is governed through electrostatic forces - Studies using site-directed mutagenesis and molecular modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODULATION; PROTEINS	Monoclonal antibody 2E8 is specific for an epitope that coincides with the binding site of the low density lipoprotein receptor (LDLR) on human apoE, Its reactivity with apoE variants resembles that of the LDLR: it binds well with apoE3 and poorly with apoE2, The heavy chain complementarity-determining region (CDRH) 2 of 2E8 shows homology to the ligand-binding domain of the LDLR, To define better the structural basis of the 2E8/apoE interaction and particularly the role of electrostatic interactions, we generated and characterized a panel of 2E8 variants, Replacement of acidic residues in the 2E8 CDRHs showed that Asp(52), Glu(53), and Asp(56) are essential for high-affinity binding. Although Asp(31) (CDRH1), Glu(58) (CDRH2), and Asp(97) (CDRH3) did not appear to be critical, the Asp(97) --> Ala variant acquired reactivity with apoE2. A Thr(57) --> Glu substitution increased affinity for both apoE3 and apoE2, The affinities of wild-type 2E8 and variants for apoE varied inversely with ionic strength, suggesting that electrostatic forces contribute to both antigen binding and isoform specificity. We propose a model of the 2E8 apoE immune complex that is based on the 2E8 and apoE crystal structures and that is consistent with the apoE-binding properties of mild-type 2E8 and its variants. Given the similarity between the LDLR and 2E8 in terms of specificity, the LDLR/ligand interaction may also have an important electrostatic component.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Ottawa Civic Hosp, Ottawa, ON K1Y 4W7, Canada; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif Lawrence Livermore Natl Lab, Livermore, CA 94550 USA; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Univ Quebec, Dept Sci Biol, Montreal, PQ H3C 3P8, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa Heart Institute; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; National Research Council Canada; University of Quebec; University of Quebec Montreal	Milne, R (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, 40 Ruskin St, Ottawa, ON K1Y 4W7, Canada.			Rupp, Bernhard/0000-0002-3300-6965	NHLBI NIH HHS [HL 41633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bieri S, 1998, BIOCHEMISTRY-US, V37, P10994, DOI 10.1021/bi980452c; Boren J, 1998, J CLIN INVEST, V101, P1084, DOI 10.1172/JCI1847; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; Clackson T, 1998, J MOL BIOL, V277, P1111, DOI 10.1006/jmbi.1998.1669; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; DJAVADIOHANIANC.L, 1991, IMMUNOCHEMISTRY SOLI, P201; Dong LM, 1996, NAT STRUCT BIOL, V3, P718, DOI 10.1038/nsb0896-718; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; INNERARITY TL, 1984, J BIOL CHEM, V259, P7261; KABAT EA, 1991, SEQUENCES PROTEIN IM; LALAZAR A, 1988, J BIOL CHEM, V263, P3542; MAHLEY RW, 1995, METABOLIC MOL BASES, P1953; NOVOTNY J, 1992, PROG BIOPHYS MOL BIO, V58, P203, DOI 10.1016/0079-6107(92)90006-R; RAFFAI R, 1995, J LIPID RES, V36, P1905; Raffai R, 1999, PROTEIN EXPRES PURIF, V16, P84, DOI 10.1006/prep.1999.1031; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; Schreiber G, 1996, NAT STRUCT BIOL, V3, P427, DOI 10.1038/nsb0596-427; Trakhanov S, 1999, ACTA CRYSTALLOGR D, V55, P122, DOI 10.1107/S090744499800938X; WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; [No title captured]	23	14	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7109	7116		10.1074/jbc.275.10.7109	http://dx.doi.org/10.1074/jbc.275.10.7109			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702278	hybrid			2022-12-27	WOS:000085809600058
J	Tomizawa, M; Kumaro, A; Perrot, V; Nakae, J; Accili, D; Rechler, MM				Tomizawa, M; Kumaro, A; Perrot, V; Nakae, J; Accili, D; Rechler, MM			Insulin inhibits the activation of transcription by a C-terminal fragment of the forkhead transcription factor FKHR - A mechanism for insulin inhibition of insulin-like growth factor-binding protein-1 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOMA-CELLS; PAX3-FKHR FUSION PROTEIN; CAENORHABDITIS-ELEGANS; GENE-EXPRESSION; ALVEOLAR RHABDOMYOSARCOMA; RESPONSE SEQUENCE; KINASE-B; PROMOTER ACTIVITY; MAMMALIAN-CELLS; MESSENGER-RNA	The forkhead rhabdomyosarcoma transcription factor (FKHR) is a promising candidate to be the transcription factor that binds to the insulin response element of the insulin-like growth factor-binding protein-1 (IGFBP-1) promoter and mediates insulin inhibition of IGFBP-1 promoter activity. Cotransfection of mouse FKHR increased IGFBP-1 promoter activity 2-3-fold in H4IIE rat hepatoma cells; insulin inhibited FKHR-stimulated promoter activity similar to 70%. A C-terminal fragment of mouse FKHR (residues 208-652) that contains the transcription activation domain fused to a Gal4 DNA binding domain potently stimulated Gal4 promoter activity. Insulin inhibited FKHR fragment-stimulated promoter activity by similar to 70%. Inhibition was abolished by coincubation with the phosphatidylinositol-3 kinase inhibitor, LY294002. The FKHR 208-652 fragment contains two consensus sites for phosphorylation by protein kinase B (PKB)/Akt, Ser-253 and Ser-316. Neither site is required for insulin inhibition of promoter activity stimulated by the FKHR fragment, and overexpression of Akt does not inhibit FKHR fragment-stimulated Gal4 promoter activity. These results suggest that insulin- and phosphatidylinositol-3 kinase-dependent phosphorylation of another site in the fragment by a kinase different from PKB/Akt inhibits transcription activation by the fragment. Phosphorylation of this site also may be involved in insulin inhibition of transcription activation by full-length FKHR, but only after phosphorylation of Ser-253 by PKB/Akt.	NIDDK, Growth & Dev Sect, Clin Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NICHD, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Rechler, MM (corresponding author), NIDDK, Growth & Dev Sect, Clin Endocrinol Branch, NIH, Bldg 10 Rm 8D12, Bethesda, MD 20892 USA.		Nakae, Jun/Q-6141-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK055006] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Allander SV, 1997, ENDOCRINOLOGY, V138, P4291, DOI 10.1210/en.138.10.4291; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Band CJ, 1997, J BIOL CHEM, V272, P138; BENNICELLI JL, 1995, ONCOGENE, V11, P119; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; BROWN AL, 1986, J BIOL CHEM, V261, P3144; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GOSWAMI R, 1994, ENDOCRINOLOGY, V134, P736, DOI 10.1210/en.134.2.736; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; Lee PDK, 1997, P SOC EXP BIOL MED, V216, P319; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; LEWITT MS, 1991, ENDOCRINOLOGY, V129, P2254, DOI 10.1210/endo-129-4-2254; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; MASSAGUE J, 1982, J BIOL CHEM, V257, P3958; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Murphy LJ, 1998, J MOL ENDOCRINOL, V21, P97, DOI 10.1677/jme.0.0210097; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; OOI GT, 1992, MOL ENDOCRINOL, V6, P2219, DOI 10.1210/me.6.12.2219; OOI GT, 1993, J BIOL CHEM, V268, P16664; ORLOWSKI CC, 1991, MOL ENDOCRINOL, V5, P1180, DOI 10.1210/mend-5-8-1180; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; RAJKUMAR K, 1995, ENDOCRINOLOGY, V136, P4029, DOI 10.1210/en.136.9.4029; Rechler MM, 1998, TRENDS ENDOCRIN MET, V9, P176, DOI 10.1016/S1043-2760(98)00047-2; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; ROBERTSON DG, 1994, BIOCHEM BIOPH RES CO, V200, P226, DOI 10.1006/bbrc.1994.1438; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sadowski I, 1998, ANAL BIOCHEM, V256, P245, DOI 10.1006/abio.1997.2518; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; SUBLETT JE, 1995, ONCOGENE, V11, P545; Suh DS, 1996, MOL ENDOCRINOL, V10, P1227, DOI 10.1210/me.10.10.1227; SUH DS, 1994, MOL ENDOCRINOL, V8, P794, DOI 10.1210/me.8.6.794; SUWANICHKUL A, 1993, J BIOL CHEM, V268, P9730; SUWANICHKUL A, 1994, J BIOL CHEM, V269, P30835; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tissenbaum HA, 1998, GENETICS, V148, P703; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X	62	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7289	7295		10.1074/jbc.275.10.7289	http://dx.doi.org/10.1074/jbc.275.10.7289			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702299	hybrid			2022-12-27	WOS:000085809600079
J	Wang, L; Slayden, RA; Barry, CE; Liu, J				Wang, L; Slayden, RA; Barry, CE; Liu, J			Cell wall structure of a mutant of Mycobacterium smegmatis defective in the biosynthesis of mycolic acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; TUBERCULOSIS; ARABINOGALACTAN; IDENTIFICATION; COMPONENTS; RESISTANCE; FRAGMENTS; ENVELOPE; FLUIDITY; CHELONAE	A mutant strain of Mycobacterium smegmatis defective in the biosynthesis of mycolic acids was recently isolated (Liu, J., and Nikaido, H. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 4011-4016), This mutant failed to synthesize full-length mycolic acids and accumulated a series of long chain beta-hydroxymeromycolates. In this work, we provide a detailed characterization of the localization of meromycolates and of the cell wall structure of the mutant. Thin layer chromatography showed that the insoluble cell wall matrix remaining after extraction with chloroform/methanol and SDS still contained a large portion of the total meromycolates. Matrix-assisted laser desorption/ionization and electrospray ionization mass spectroscopy analysis of fragments arising from Smith degradation of the insoluble cell wall matrix revealed that the meromycolates were covalently attached to arabinogalactan at the 5-OH positions of the terminal arabinofuranosyl residues. The arabinogalactan appeared to be normal in the mutant strain, as analyzed by NMR, Analysis of organic phase lipids showed that the mutant cell wall contained some of the extractable lipids but lacked glycopeptidolipids and lipooligosaccharides. Differential scanning calorimetry of the mutant cell wall failed to show the large cooperative thermal transitions typical of intact mycobacterial cell walls. Transmission electron microscopy showed that the mutant cell wall had an abnormal ultrastructure (without the electron-transparent zone associated with the asymmetric mycolate lipid layer). Taken together, these results demonstrate the importance of mycolic acids for the structural and functional integrity of the mycobacterial cell mall. The lack of highly organized lipid domains in the mutant cell wall explains the drug-sensitive and temperature-sensitive phenotypes of the mutant.	Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; NIAID, TB Res Sect, Host Def Lab, NIH, Rockville, MD 20852 USA	University of Toronto; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Liu, J (corresponding author), Univ Toronto, Dept Med Genet & Microbiol, 4382 Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	jun.liu@utoronto.ca	Barry, III, Clifton/H-3839-2012; Slayden, Richard/AAV-2582-2021; Liu, Jun/AAC-9209-2019; Barry, Clifton E/ABE-7992-2020; Slayden, Richard/O-8626-2016	Barry, III, Clifton/0000-0002-2927-270X; Slayden, Richard/0000-0001-6857-7277; Liu, Jun/0000-0002-0522-6733; Barry, Clifton E/0000-0002-2927-270X; Slayden, Richard/0000-0001-6857-7277	Intramural NIH HHS [Z01 AI000783-11] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000783, Z01AI000693] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARROW WW, 1982, J BACTERIOL, V150, P381, DOI 10.1128/JB.150.1.381-384.1982; Barry CE, 1996, TRENDS MICROBIOL, V4, P275, DOI 10.1016/0966-842X(96)10031-7; Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3; Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420; BESRA GS, 1995, BIOCHEMISTRY-US, V34, P4257, DOI 10.1021/bi00013a015; Besra GS, 1998, METH MOL B, V101, P91, DOI 10.1385/0-89603-471-2:91; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; DAFFE M, 1990, J BIOL CHEM, V265, P6734; DAFFE M, 1991, BIOCHEMISTRY-US, V30, P378, DOI 10.1021/bi00216a011; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; DITTMER JC, 1964, J LIPID RES, V5, P126; Dobson G., 1985, CHEM METHODS BACTERI, P237; GEORGE KM, 1995, J BIOL CHEM, V270, P27292, DOI 10.1074/jbc.270.45.27292; JACIN H, 1965, J CHROMATOGR, V18, P170, DOI 10.1016/S0021-9673(01)80341-1; Jackson M, 1999, MOL MICROBIOL, V31, P1573, DOI 10.1046/j.1365-2958.1999.01310.x; JARLIER V, 1994, FEMS MICROBIOL LETT, V123, P11, DOI 10.1111/j.1574-6968.1994.tb07194.x; JARLIER V, 1990, J BACTERIOL, V172, P1418, DOI 10.1128/jb.172.3.1418-1423.1990; Liu J, 1999, P NATL ACAD SCI USA, V96, P4011, DOI 10.1073/pnas.96.7.4011; Liu J, 1996, J BIOL CHEM, V271, P29545, DOI 10.1074/jbc.271.47.29545; LIU J, 1995, P NATL ACAD SCI USA, V92, P11254, DOI 10.1073/pnas.92.24.11254; Liu J, 1999, MYCOBACTERIA MOL BIO, P220; Marques MAM, 1998, INFECT IMMUN, V66, P2625, DOI 10.1128/IAI.66.6.2625-2631.1998; MCNEIL M, 1990, J BIOL CHEM, V265, P18200; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; Mdluli K, 1998, MOL MICROBIOL, V27, P1223, DOI 10.1046/j.1365-2958.1998.00774.x; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; Minnikin D. E., 1980, MICROBIOLOGICAL CLAS, P189; NIKAIDO H, 1993, MOL MICROBIOL, V8, P1025, DOI 10.1111/j.1365-2958.1993.tb01647.x; OrtaloMagne A, 1996, J BACTERIOL, V178, P456, DOI 10.1128/jb.178.2.456-461.1996; PAUL TR, 1992, J BACTERIOL, V174, P6508, DOI 10.1128/JB.174.20.6508-6517.1992; Shafran SD, 1996, NEW ENGL J MED, V335, P377, DOI 10.1056/NEJM199608083350602; Word Health Organization, 1997, ANT DRUG RES WORLD; Yuan Y, 1998, MOL MICROBIOL, V29, P1449, DOI 10.1046/j.1365-2958.1998.01026.x; Yuan Y, 1998, J BIOL CHEM, V273, P21282, DOI 10.1074/jbc.273.33.21282	34	48	51	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7224	7229		10.1074/jbc.275.10.7224	http://dx.doi.org/10.1074/jbc.275.10.7224			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702292	hybrid			2022-12-27	WOS:000085809600072
J	Klumpp, K; Doan, L; Roberts, NA; Handa, B				Klumpp, K; Doan, L; Roberts, NA; Handa, B			RNA and DNA hydrolysis are catalyzed by the influenza virus endonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; VIRAL COMPLEMENTARY RNA; ESCHERICHIA-COLI; ACTIVE-SITE; MESSENGER-RNA; POLYMERASE-I; AMINO-ACID; RESTRICTION ENDONUCLEASE; TRANSCRIPTION INVITRO; EXONUCLEASE ACTIVITY	The influenza virus polymerase complex contains a metal ion-dependent endonuclease activity, which generates short capped RNA primer molecules from capped RNA precursors. Previous studies have provided evidence for a two-metal ion mechanism of RNA cleavage, and the data are consistent with a direct interaction of a divalent metal ion with the catalytic water molecule. To refine the model of this active site, we have generated a series of DNA, RNA, and DNA RNA chimeric molecules to study the role of the 2'-hydroxy groups on nucleic acid substrates of the endonuclease, We could observe specific cleavage of nucleic acid substrates devoid of any 2'-hydroxy groups if they contained a cap structure (m7GpppG) at the 5'-end. The capped DNA endonuclease products were functional as primers for transcription initiation by the influenza virus polymerase, The apparent cleavage rates were about 5 times lower with capped DNA substrates as compared with capped RNA substrates. Cleavage rates with DNA substrates could be increased to RNA levels by substituting the deoxyribosyl moieties immediately 5' and 3' of the cleavage site with ribosyl moieties. Similarly, cleavage rates of RNA substrates could be lowered to DNA levels by exchanging the same two ribosyl groups with deoxyribosyl groups at the cleavage site. These results demonstrate that the 2'-hydroy groups are not essential for binding and cleavage of nucleic acids by the influenza virus endonuclease, but small differences of the nucleic acid conformation in the endonuclease active site can influence the overall rate of hydrolysis, The observed relative cleavage rates with DNA and RNA substrates argue against a direct interaction of a catalytic metal ion with a 2'-hydroxy group in the endonuclease active site.	Roche Discovery Welwyn, Welwyn Garden City AL7 3AY, Herts, England	Roche Holding	Klumpp, K (corresponding author), Roche Discovery Welwyn, 40 Broadwater Rd, Welwyn Garden City AL7 3AY, Herts, England.							BEATON AR, 1981, NUCLEIC ACIDS RES, V9, P4423, DOI 10.1093/nar/9.17.4423; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BISWAS SK, 1994, J VIROL, V68, P1819, DOI 10.1128/JVI.68.3.1819-1826.1994; BLAAS D, 1982, NUCLEIC ACIDS RES, V10, P4803; Blok V, 1996, J GEN VIROL, V77, P1025, DOI 10.1099/0022-1317-77-5-1025; BOULOY M, 1979, J VIROL, V32, P895, DOI 10.1128/JVI.32.3.895-904.1979; BRAAM J, 1983, CELL, V34, P609; Brautigam CA, 1998, J MOL BIOL, V277, P363, DOI 10.1006/jmbi.1997.1586; BROWNLEE GG, 1995, NUCLEIC ACIDS RES, V23, P2641, DOI 10.1093/nar/23.14.2641; CATON AJ, 1980, NUCLEIC ACIDS RES, V8, P2591, DOI 10.1093/nar/8.12.2591; Chen Y, 1997, BIOCHEMISTRY-US, V36, P2425; CIANCI C, 1995, J VIROL, V69, P3995, DOI 10.1128/JVI.69.7.3995-3999.1995; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DHAR R, 1980, CELL, V21, P495, DOI 10.1016/0092-8674(80)90486-9; Dismukes GC, 1996, CHEM REV, V96, P2909, DOI 10.1021/cr950053c; Doan L, 1999, BIOCHEMISTRY-US, V38, P5612, DOI 10.1021/bi9828932; ESTEBAN JA, 1994, J BIOL CHEM, V269, P31946; FODOR E, 1994, J VIROL, V68, P4092, DOI 10.1128/JVI.68.6.4092-4096.1994; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; Gonzalez S, 1999, J VIROL, V73, P631; HAGEN M, 1995, J GEN VIROL, V76, P603, DOI 10.1099/0022-1317-76-3-603; HAGEN M, 1994, J VIROL, V68, P1509, DOI 10.1128/JVI.68.3.1509-1515.1994; HONDA A, 1990, J BIOCHEM-TOKYO, V107, P624, DOI 10.1093/oxfordjournals.jbchem.a123097; HSU MT, 1987, P NATL ACAD SCI USA, V84, P8140, DOI 10.1073/pnas.84.22.8140; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; Jones SJ, 1996, J MOL BIOL, V264, P1154, DOI 10.1006/jmbi.1996.0703; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KATAYANAGI K, 1993, J BIOL CHEM, V268, P22092; KAWAKAMI K, 1983, NUCLEIC ACIDS RES, V11, P3637, DOI 10.1093/nar/11.11.3637; Klumpp K, 1998, J GEN VIROL, V79, P1033, DOI 10.1099/0022-1317-79-5-1033; Klumpp K, 1997, EMBO J, V16, P1248, DOI 10.1093/emboj/16.6.1248; KRUG RM, 1979, CELL, V18, P329, DOI 10.1016/0092-8674(79)90052-7; LAMB RA, 1983, ANNU REV BIOCHEM, V52, P467, DOI 10.1146/annurev.bi.52.070183.002343; LAMB RA, 1996, VIROLOGY, V1, P1353; Li ML, 1998, EMBO J, V17, P5844, DOI 10.1093/emboj/17.19.5844; Olsen DB, 1996, J BIOL CHEM, V271, P7435, DOI 10.1074/jbc.271.13.7435; PLOTCH SJ, 1981, CELL, V23, P847, DOI 10.1016/0092-8674(81)90449-9; PLOTCH SJ, 1979, P NATL ACAD SCI USA, V76, P1618, DOI 10.1073/pnas.76.4.1618; REINES D, 1994, TRANSCRIPTION MECHAN, P263; Sattar AKMA, 1996, BIOCHEMISTRY-US, V35, P16621, DOI 10.1021/bi961552q; SELENT U, 1992, BIOCHEMISTRY-US, V31, P4808, DOI 10.1021/bi00135a010; Shen BH, 1997, NUCLEIC ACIDS RES, V25, P3332, DOI 10.1093/nar/25.16.3332; SHI LC, 1995, VIROLOGY, V208, P38, DOI 10.1006/viro.1995.1127; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; THIELKING V, 1991, BIOCHEMISTRY-US, V30, P6416, DOI 10.1021/bi00240a011; Thomas MJ, 1998, CELL, V93, P627, DOI 10.1016/S0092-8674(00)81191-5; TISDALE M, 1995, ANTIMICROB AGENTS CH, V39, P2454, DOI 10.1128/AAC.39.11.2454; TOMASSINI J, 1994, ANTIMICROB AGENTS CH, V38, P2827, DOI 10.1128/AAC.38.12.2827; ULMANEN I, 1981, P NATL ACAD SCI-BIOL, V78, P7355, DOI 10.1073/pnas.78.12.7355; Wang J, 1996, BIOCHEMISTRY-US, V35, P8110, DOI 10.1021/bi960178r; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V; Wilcox DE, 1996, CHEM REV, V96, P2435, DOI 10.1021/cr950043b	54	13	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6181	6188		10.1074/jbc.275.9.6181	http://dx.doi.org/10.1074/jbc.275.9.6181			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692410	hybrid			2022-12-27	WOS:000085654400022
J	Rodriguez-Vilarino, S; Arribas, J; Arizti, P; Castano, JG				Rodriguez-Vilarino, S; Arribas, J; Arizti, P; Castano, JG			Proteolytic processing and assembly of the C5 subunit into the proteasome complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							20S PROTEASOME; MULTICATALYTIC PROTEINASE; RAT-LIVER; PRECURSOR COMPLEXES; BETA-SUBUNITS; COMPONENT C5; MATURATION; IDENTIFICATION; BIOGENESIS; CLONING	Assembly of mammalian 20 S proteasomes from individual subunits is beginning to be investigated. Proteasomes are made of four heptameric rings in the configuration alpha 7 beta 7 beta 7 alpha 7. By using anti-proteasome and anti-subunit-specific antibodies, we characterized the processing and assembly of the beta subunit C5. The C5 precursor (25 kDa) remains as a free non-assembled polypeptide in the cell. The conversion of the C5 precursor to mature C5 (23 kDa) occurs concomitantly with its incorporation into 15 S proteasome intermediate and 20 S mature proteasome complexes. This processing is dependent on proteasome activity and takes place in the cytosol. These results are not fully compatible with the hypothesis that postulates that assembly of proteasomes takes place via a "half-proteasome" intermediate that contains one full alpha-ring and one full beta-ring of unprocessed beta subunit precursors.	Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Castano, JG (corresponding author), Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain.	joseg.castano@uam.es	Arribas, Joaquin/M-4482-2014	Arribas, Joaquin/0000-0002-0504-0664; G. Castano, Jose/0000-0002-6579-8442				Arendt CS, 1999, EMBO J, V18, P3575, DOI 10.1093/emboj/18.13.3575; ARRIBAS J, 1990, J BIOL CHEM, V265, P13969; ARRIBAS J, 1994, J BIOL CHEM, V269, P12858; ARRIBAS J, 1991, J EXP MED, V173, P423, DOI 10.1084/jem.173.2.423; Castano JG, 1996, BIOCHEMISTRY-US, V35, P3782, DOI 10.1021/bi952540s; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; CHEN P, 1995, EMBO J, V14, P2620, DOI 10.1002/j.1460-2075.1995.tb07260.x; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; CUERVO AM, 1995, EUR J BIOCHEM, V227, P792, DOI 10.1111/j.1432-1033.1995.tb20203.x; DEMENA IR, 1993, BIOCHEM J, V296, P93, DOI 10.1042/bj2960093; FRENTZEL S, 1994, J MOL BIOL, V236, P975, DOI 10.1016/0022-2836(94)90003-5; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; HENDIL KB, 1988, BIOCHEM INT, V17, P471; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; LEE DH, 1992, BIOCHEM BIOPH RES CO, V182, P452, DOI 10.1016/0006-291X(92)91753-D; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Mengual E, 1996, J NEUROSCI, V16, P6331; Nandi D, 1996, J IMMUNOL, V156, P2361; Nandi D, 1997, EMBO J, V16, P5363, DOI 10.1093/emboj/16.17.5363; Ramos PC, 1998, CELL, V92, P489, DOI 10.1016/S0092-8674(00)80942-3; SAVILLE KJ, 1993, P NATL ACAD SCI USA, V90, P8842, DOI 10.1073/pnas.90.19.8842; SAVIOZ A, 1995, DNA SEQUENCE, V5, P307, DOI 10.3109/10425179509030985; Schmidt M, 1997, FASEB J, V11, P1235, DOI 10.1096/fasebj.11.14.9409542; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; Schmidtke G, 1997, J MOL BIOL, V268, P95, DOI 10.1006/jmbi.1997.0947; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; TAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1089, P95, DOI 10.1016/0167-4781(91)90090-9; TAMURA T, 1990, FEBS LETT, V264, P91, DOI 10.1016/0014-5793(90)80773-C; TAMURA T, 1995, CURR BIOL, V5, P766, DOI 10.1016/S0960-9822(95)00153-9; TANAKA K, 1989, BIOCHEM BIOPH RES CO, V159, P1309, DOI 10.1016/0006-291X(89)92253-5; Thomson S, 1996, BIOCHEM J, V315, P733, DOI 10.1042/bj3150733; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765	34	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6592	6599		10.1074/jbc.275.9.6592	http://dx.doi.org/10.1074/jbc.275.9.6592			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692467	hybrid			2022-12-27	WOS:000085654400079
J	Aslani, A; Simonsson, S; Elias, P				Aslani, A; Simonsson, S; Elias, P			A novel conformation of the Herpes simplex virus origin of DNA replication recognized by the origin binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 ORIGIN; UNWINDING ELEMENT; ORIS; SEQUENCE; HELICASE; ICP8; UL9	The Herpes simplex virus type I origin binding protein (OBP) is a sequence-specific DNA-binding protein and a dimeric DNA helicase encoded by the UL9 gene. It is required for the activation of the viral origin of DNA replication oriS. Here we demonstrate that the linear double-stranded form of oriS can be converted by heat treatment to a stable novel conformation referred to as oriS*. Studies using S1 nuclease suggest that oriS* consists of a central hairpin with an AT-rich sequence in the loop. Single-stranded oligonucleotides corresponding to the upper strand of oriS can adopt the same structure. OBP forms a stable complex with oriS*. We have identified structural features of oriS* recognized by OBP. The central oriS palindrome as well as sequences at the 5' side of the oriS palindrome were required for complex formation. Importantly, we found that mutations that have been shown to reduce oriS-dependent DNA replication also reduce the formation of the OBP-oriS*: complex. We suggest that oriS*: serves as an intermediate in the initiation of DNA replication providing the initiator protein with structural information for a selective and efficient assembly of the viral replication machinery.	Univ Gothenburg, Dept Biochem Med, SE-40530 Gothenburg, Sweden	University of Gothenburg	Elias, P (corresponding author), Univ Gothenburg, Dept Biochem Med, Box 440, SE-40530 Gothenburg, Sweden.		Simonsson, Stina/R-2699-2016	Simonsson, Stina/0000-0001-9020-3714				BOEHMER PE, 1994, J BIOL CHEM, V269, P29329; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; ELIAS P, 1986, P NATL ACAD SCI USA, V83, P6322, DOI 10.1073/pnas.83.17.6322; ELIAS P, 1992, J BIOL CHEM, V267, P17424; ELIAS P, 1990, J BIOL CHEM, V265, P17167; ELIAS P, 1988, P NATL ACAD SCI USA, V85, P2959, DOI 10.1073/pnas.85.9.2959; FIERER DS, 1992, J VIROL, V66, P3986, DOI 10.1128/JVI.66.7.3986-3995.1992; GUSTAFSSON CM, 1994, P NATL ACAD SCI USA, V91, P4629, DOI 10.1073/pnas.91.11.4629; Hammarsten O, 1997, NUCLEIC ACIDS RES, V25, P1753, DOI 10.1093/nar/25.9.1753; HERNANDEZ TR, 1991, J VIROL, V65, P1649, DOI 10.1128/JVI.65.3.1649-1652.1991; HUANG RY, 1993, EMBO J, V12, P4521, DOI 10.1002/j.1460-2075.1993.tb06141.x; Jin RZ, 1997, EMBO J, V16, P4456, DOI 10.1093/emboj/16.14.4456; Kornberg A., 1992, DNA REPLICATION; KOWALSKI D, 1989, EMBO J, V8, P4335, DOI 10.1002/j.1460-2075.1989.tb08620.x; Learn BA, 1997, P NATL ACAD SCI USA, V94, P1154, DOI 10.1073/pnas.94.4.1154; Lee SSK, 1999, J BIOL CHEM, V274, P18613, DOI 10.1074/jbc.274.26.18613; LOCKSHON D, 1988, MOL CELL BIOL, V8, P4018, DOI 10.1128/MCB.8.10.4018; Makhov AM, 1996, EMBO J, V15, P1742, DOI 10.1002/j.1460-2075.1996.tb00520.x; MARTIN DW, 1991, J VIROL, V65, P4359, DOI 10.1128/JVI.65.8.4359-4369.1991; Moore DD, 1995, GLOB MOB SURV; Nguyen-Huynh AT, 1998, J VIROL, V72, P3635, DOI 10.1128/JVI.72.5.3635-3645.1998; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; Roizman B, 1996, FIELDS VIROLOGY, P2231; Sambrook J., 2002, MOL CLONING LAB MANU; Simonsson S, 1998, J BIOL CHEM, V273, P24633, DOI 10.1074/jbc.273.38.24633; WONG SW, 1991, J VIROL, V65, P2601, DOI 10.1128/JVI.65.5.2601-2611.1991; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988	29	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5880	5887		10.1074/jbc.275.8.5880	http://dx.doi.org/10.1074/jbc.275.8.5880			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681580	hybrid			2022-12-27	WOS:000085474500087
J	Rybkin, II; Cross, ME; McReynolds, EM; Lin, RZ; Ballou, LM				Rybkin, II; Cross, ME; McReynolds, EM; Lin, RZ; Ballou, LM			alpha(1A) adrenergic receptor induces eukaryotic initiation factor 4E-binding protein 1 phosphorylation via a Ca2+-dependent pathway independent of phosphatidylinositol 3-kinase/Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; MESSENGER-RNA TRANSLATION; MAMMALIAN TARGET; SIGNALING PATHWAY; PHAS-I; INSULIN STIMULATION; FACTOR 4E; RAPAMYCIN; ACTIVATION; INHIBITION	Phosphorylation of the translation repressor eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) is thought to be partly responsible for increased protein synthesis induced by growth factors. This study investigated the effect of a G(q)-coupled receptor on protein synthesis and the phosphorylation state and function of 4E-BP1 in Rat-1 fibroblasts expressing the human alpha(1A) adrenergic receptor. Treatment of cells with phenylephrine (PE), a specific alpha(1) adrenergic receptor agonist, increased protein synthesis and induced the phosphorylation of 4E-BP1 and its release from translation initiation factor 4E. Although the PE-induced phosphorylation of 4E-BP1 was blocked by the phosphatidylinositol 3-kinase inhibitor LY294002, neither phosphatidylinositol a-kinase nor Akt, its downstream effector, is activated in cells treated with PE (Ballou, L. Rf,, Cross, M. E,, Huang, S., McReynolds, E, M., Zhang, B, L, and Lin, R. Z,, J. Biol. Chem. 275, 4803-4809). The effect of PE on 4E-BP1 phosphorylation was also abolished in cells depleted of intracellular Ca2+ and in cells pretreated with calmodulin antagonists. By contrast, phosphorylation of 4E-BP1 still occurred in cells in which the Ca2+ and diacylglycerol-dependent isoforms of protein kinase C were down-regulated by prolonged exposure to a phorbol ester. We conclude that activation of the alpha(1A) adrenergic receptor in Rat-1 fibroblasts leads to phosphorylation of 4E-BP1 via a pathway that is Ca2+- and calmodulin-dependent. Phosphatidylinositol 3-kinase, Akt, and phorbol ester-sensitive protein kinase C isoforms do not appear to be required in this signaling pathway.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Ballou, LM (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, Mail Code 7764,7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Lin, Richard/J-1754-2014	Lin, Richard/0000-0002-3473-7276; Rybkin, Igor/0000-0002-8434-1093				Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; Amaldi F, 1997, Prog Mol Subcell Biol, V18, P1; Ballou LM, 2000, J BIOL CHEM, V275, P4803, DOI 10.1074/jbc.275.7.4803; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Boluyt MO, 1997, CIRC RES, V81, P176, DOI 10.1161/01.RES.81.2.176; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chen J, 1999, J PHARMACOL EXP THER, V289, P1376; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; Diggle TA, 1996, BIOCHEM J, V316, P447, DOI 10.1042/bj3160447; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Fadden P, 1997, J BIOL CHEM, V272, P10240; Fleurent M, 1997, J BIOL CHEM, V272, P4006, DOI 10.1074/jbc.272.7.4006; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Graves LM, 1997, J BIOL CHEM, V272, P1920, DOI 10.1074/jbc.272.3.1920; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Heesom KJ, 1999, FEBS LETT, V457, P489, DOI 10.1016/S0014-5793(99)01094-7; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1996, TRANSLATIONAL CONTRO, P389; Kenny BA, 1996, BRIT J PHARMACOL, V118, P871, DOI 10.1111/j.1476-5381.1996.tb15480.x; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; KowalskiChauvel A, 1996, J BIOL CHEM, V271, P26356, DOI 10.1074/jbc.271.42.26356; KUMAR RV, 1991, EUR J BIOCHEM, V195, P313, DOI 10.1111/j.1432-1033.1991.tb15708.x; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Morley SJ, 1997, J BIOL CHEM, V272, P17887, DOI 10.1074/jbc.272.28.17887; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PALFREY HC, 1995, ADV SEC MESS PHOSPH, V30, P191; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PETRITSCH C, 1995, EUR J BIOCHEM, V230, P431, DOI 10.1111/j.1432-1033.1995.0431h.x; Polakiewicz RD, 1998, J BIOL CHEM, V273, P23534, DOI 10.1074/jbc.273.36.23534; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Proud CG, 1997, BIOCHEM J, V328, P329; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pyronnet S, 1998, ONCOGENE, V16, P2219, DOI 10.1038/sj.onc.1201748; Rao GN, 1999, J BIOL CHEM, V274, P12925, DOI 10.1074/jbc.274.18.12925; Rokosh DG, 1996, J BIOL CHEM, V271, P5839, DOI 10.1074/jbc.271.10.5839; Schluter KD, 1999, FASEB J, V13, pS17; SCHWINN DA, 1995, J PHARMACOL EXP THER, V272, P134; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Takahashi T, 1999, AM J PHYSIOL-HEART C, V276, pH1927, DOI 10.1152/ajpheart.1999.276.6.H1927; Takata M, 1999, J BIOL CHEM, V274, P20611, DOI 10.1074/jbc.274.29.20611; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744	59	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5460	5465		10.1074/jbc.275.8.5460	http://dx.doi.org/10.1074/jbc.275.8.5460			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681523	hybrid			2022-12-27	WOS:000085474500030
J	Yeliseev, AA; Kaplan, S				Yeliseev, AA; Kaplan, S			TspO of Rhodobacter sphaeroides - A structural and functional model for the mammalian peripheral benzodiazepine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT; IDENTIFICATION; PURIFICATION; CONSTRUCTION; MITOCHONDRIA; EXPRESSION; PORPHYRINS; OXIDASE; MUTANT; HEME	The function and specific structural aspects of the tryptophan-rich Sensory protein (TspO) of Rhodobacter sphaeroides 2.4.1 were studied using site-directed mutagenesis involving some 17 different amino acids. The choice of these amino acids changes was dictated from an analysis of the TspO family of proteins derived from the data bases, These studies demonstrated the importance of several highly conserved tryptophan residues in the sensory transduction pathway involving TspO through the proposed binding of an intermediate(s) in the tetrapyrrole biosynthesis pathway. These studies also revealed that the substitution of one or several of the amino acid residues dramatically affected, either directly or indirectly, the levels of TspO in the membranes of R, sphaeroides. Mounting evidence is presented suggesting that TspO normally forms a dimer within the bacterial outer membrane, and the dimer form of TspO may be the active form for TspO function. Because our earlier studies provided us with a functional framework within which to view these amino acid substitutions, we are able to suggest a preliminary model for TspO structure-function. Not only do these studies tell us more about TspO, but they also shed light on the TspO homologue, the drug-binding component of the mitochondrial peripheral benzodiazepine receptor. Mounting evidence draws numerous parallelism between these proteins and supports the significance of using TspO as a model for the structure and function of the mitochondrial protein.	Univ Texas, Hlth Sci Ctr, Dept Microbiol & Mol Genet, Sch Med, Houston, TX 77225 USA	University of Texas System; University of Texas Health Science Center Houston	Kaplan, S (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Microbiol & Mol Genet, Sch Med, POB 20708, Houston, TX 77225 USA.		Yeliseev, Alexei A/B-3143-2009		NIGMS NIH HHS [GM15590, GM5548] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; Dailey TA, 1997, METHOD ENZYMOL, V281, P340; DAVIS J, 1988, J BACTERIOL, V170, P320, DOI 10.1128/jb.170.1.320-329.1988; Diekert K, 1999, P NATL ACAD SCI USA, V96, P11752, DOI 10.1073/pnas.96.21.11752; ERASO JM, 1994, J BACTERIOL, V176, P32, DOI 10.1128/JB.176.1.32-43.1994; FARGES R, 1993, FEBS LETT, V335, P305, DOI 10.1016/0014-5793(93)80407-L; FARGES R, 1994, MOL PHARMACOL, V46, P1160; Goldman BS, 1998, P NATL ACAD SCI USA, V95, P5003, DOI 10.1073/pnas.95.9.5003; Isenman L, 1995, BBA-REV BIOMEMBRANES, V1241, P341, DOI 10.1016/0304-4157(95)00009-7; Joseph-Liauzun E, 1998, J BIOL CHEM, V273, P2146, DOI 10.1074/jbc.273.4.2146; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; Krueger KE, 1995, BBA-REV BIOMEMBRANES, V1241, P453, DOI 10.1016/0304-4157(95)00016-X; LACKS S, 1977, J MOL BIOL, V114, P153, DOI 10.1016/0022-2836(77)90289-3; Li H, 1998, ENDOCRINOLOGY, V139, P4991, DOI 10.1210/en.139.12.4991; Maniatis T., 1982, MOL CLONING LAB MANU; MARTIN JP, 1987, J BACTERIOL, V169, P2516, DOI 10.1128/jb.169.6.2516-2522.1987; MOORE MD, 1989, J BACTERIOL, V171, P4385, DOI 10.1128/JB.171.8.4385-4394.1989; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Rebeiz N, 1996, ARCH BIOCHEM BIOPHYS, V333, P475, DOI 10.1006/abbi.1996.0417; Simon R., 1983, BIOTECHNOLOGY, V1, P37; TAKETANI S, 1995, J BIOCHEM-TOKYO, V117, P875, DOI 10.1093/oxfordjournals.jbchem.a124790; VARGA AR, 1993, J BIOL CHEM, V268, P19842; VERMA A, 1987, P NATL ACAD SCI USA, V84, P2256, DOI 10.1073/pnas.84.8.2256; Yeliseev AA, 1997, P NATL ACAD SCI USA, V94, P5101, DOI 10.1073/pnas.94.10.5101; YELISEEV AA, 1995, J BIOL CHEM, V270, P21167, DOI 10.1074/jbc.270.36.21167; Yeliseev AA, 1999, J BIOL CHEM, V274, P21234, DOI 10.1074/jbc.274.30.21234; Yoshinaga T, 1997, METHOD ENZYMOL, V281, P355	28	76	82	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5657	5667		10.1074/jbc.275.8.5657	http://dx.doi.org/10.1074/jbc.275.8.5657			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681549	hybrid			2022-12-27	WOS:000085474500056
J	Cabibbo, A; Pagani, M; Fabbri, M; Rocchi, M; Farmery, MR; Bulleid, NJ; Sitia, R				Cabibbo, A; Pagani, M; Fabbri, M; Rocchi, M; Farmery, MR; Bulleid, NJ; Sitia, R			ERO1-L, a human protein that favors disulfide bond formation in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOMERASE; RETENTION; PATHWAY; CELLS; ER	Oxidizing conditions must be maintained in the endoplasmic reticulum (ER) to allow the formation of disulfide bonds in secretory proteins. Here we report the cloning and characterization of a mammalian gene (ERO1-L) that shares extensive homology with the Saccharomyces cerevisiae ERO1 gene, required in yeast for oxidative protein folding. When expressed in mammalian cells, the product of the human ERO1-L gene co localizes with ER markers and displays Endo-H-sensitive glycans, In isolated microsomes, ERO1-L behaves as a type II integral membrane protein. ERO1-L is able to complement several phenotypic traits of the yeast thermosensitive mutant ero1-1, including temperature and dithiothreitol sensitivity, and intrachain disulfide bond formation in carboxypeptidase Y, ERO1-L is no longer functional when either one of the highly conserved Cys-394 or Cys-397 is mutated. These results strongly suggest that ERO1-L is involved in oxidative ER protein folding in mammalian cells.	San Raffaele Sci Inst, Dept Biol & Technol Res, I-20132 Milan, Italy; Univ Bari, Ist Genet, I-70126 Bari, Italy; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Universita degli Studi di Bari Aldo Moro; University of Manchester	Cabibbo, A (corresponding author), San Raffaele Sci Inst, Dept Biol & Technol Res, Via Olgettina 58, I-20132 Milan, Italy.		Rocchi, Mariano/B-8451-2011; Sitia, Roberto/AAB-5005-2019; Pagani, Massimiliano/B-6354-2013; fabbri, marco/B-3258-2009	Sitia, Roberto/0000-0001-7086-4152; fabbri, marco/0000-0002-7056-4691; Pagani, Massimiliano/0000-0002-7017-9304; Bulleid, Neil/0000-0002-9839-5279	Telethon [E.0672] Funding Source: Medline	Telethon(Fondazione Telethon)		[Anonymous], 1991, Methods Enzymol, V194, P1; ATLSCHUL SF, 1990, J MOL BIOL, V215, P103; AUSTEN BM, 1984, BIOCHEM J, V224, P317, DOI 10.1042/bj2240317; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; BULLEID NJ, 1990, EMBO J, V9, P3527, DOI 10.1002/j.1460-2075.1990.tb07561.x; CHIEVERS PT, 1996, EMBO J, V15, P2659; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; Huppa JB, 1998, CELL, V92, P145, DOI 10.1016/S0092-8674(00)80907-1; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JAMSA E, 1994, YEAST, V10, P355, DOI 10.1002/yea.320100308; Jonda S, 1999, EMBO J, V18, P3271, DOI 10.1093/emboj/18.12.3271; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KAWASAKI H, 1995, PROTEIN PROFILE, V2, P297; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OTSU M, 1994, J BIOL CHEM, V269, P6874; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Reddy P, 1996, EMBO J, V15, P2077, DOI 10.1002/j.1460-2075.1996.tb00561.x; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; ROTH RA, 1987, BIOCHEMISTRY-US, V26, P4179, DOI 10.1021/bi00388a001; Sambrook J., 2002, MOL CLONING LAB MANU; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; Tortorella D, 1998, J CELL BIOL, V142, P365, DOI 10.1083/jcb.142.2.365; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; ZORNIG M, 1995, CYTOGENET CELL GENET, V71, P37, DOI 10.1159/000134057	39	242	251	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4827	4833		10.1074/jbc.275.7.4827	http://dx.doi.org/10.1074/jbc.275.7.4827			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671517	hybrid			2022-12-27	WOS:000085378200043
J	Chung, DH; Ohashi, K; Watanabe, M; Miyasaka, N; Hirosawa, S				Chung, DH; Ohashi, K; Watanabe, M; Miyasaka, N; Hirosawa, S			Mannose trimming targets mutant alpha(2)-plasmin inhibitor for degradation by the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; ALPHA-2-PLASMIN INHIBITOR; ENDOPLASMIC-RETICULUM; CONGENITAL DEFICIENCY; ALPHA2-PLASMIN INHIBITOR; ANTIGEN PRESENTATION; FIBRINOLYTIC STATES; QUALITY-CONTROL; PROTEIN; CALNEXIN	We have previously characterized the molecular and cellular mechanisms of alpha(2)-plasmin inhibitor (alpha(2)PI) deficiency. The mutant alpha(2)PI-Nara and alpha(2)PI-Okinawa proteins were found to be retained and degraded in cells stably expressing these mutant forms of alpha(2)PI. Degradation of the two mutant alpha(2)PI proteins, mediated by proteasomes, occurred after a lag time of 1.5 h during which glucose trimming took place. The mutant alpha(2)PI proteins were not ubiquitinated. Inhibition of mannosidase activity blocked the degradation of the mutant alpha(2)PI proteins without resulting in any changes in their binding to calnexin. Inhibition of glucose removal completely blocked the interaction between the alpha(2)PI proteins and the molecular chaperone calnexin, Under these conditions, mannose residues were removed from the oligosaccharides even when glucose residues were not processed. With mannose removal, the glucose-untrimmed mutant forms of alpha(2)PI, which failed to bind to calnexin, were degraded by proteasomes. The initiation of mannose trimming was a prerequisite for their degradation. Our findings show that modification of oligosaccharides of the mutant forms of alpha(2)PI determines their recognition by the degradation apparatus and that mannose trimming is important for targeting the mutant alpha(2)PI proteins for the degradation pathway.	Tokyo Med & Dent Univ, Dept Internal Med 1, Bunkyo Ku, Tokyo 1138519, Japan; Oita Med Sch, Dept Biochem, Hazama, Oita 8896692, Japan	Tokyo Medical & Dental University (TMDU); Oita University	Hirosawa, S (corresponding author), Tokyo Med & Dent Univ, Dept Internal Med 1, Bunkyo Ku, Yushima 1-5-45, Tokyo 1138519, Japan.							AOKI N, 1979, PROG CARDIOVASC DIS, V21, P267, DOI 10.1016/0033-0620(79)90014-8; AOKI N, 1980, BLOOD, V55, P483; AOKI N, 1977, J CLIN INVEST, V60, P361, DOI 10.1172/JCI108784; AOKI N, 1979, J CLIN INVEST, V63, P877, DOI 10.1172/JCI109387; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; Bonifacino JS, 1996, NATURE, V384, P405, DOI 10.1038/384405a0; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P528; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; HIROSAWA S, 1988, P NATL ACAD SCI USA, V85, P6836, DOI 10.1073/pnas.85.18.6836; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; Maki CG, 1996, CANCER RES, V56, P2649; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MIURA O, 1989, J CLIN INVEST, V83, P1598, DOI 10.1172/JCI114057; MIURA O, 1989, BIOCHEMISTRY-US, V28, P4934, DOI 10.1021/bi00438a003; MIURA O, 1989, J BIOL CHEM, V264, P18213; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; MOROI M, 1976, J BIOL CHEM, V251, P5956; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PAN YT, 1983, BIOCHEMISTRY-US, V22, P3975, DOI 10.1021/bi00285a038; Petrescu AJ, 1997, EMBO J, V16, P4302, DOI 10.1093/emboj/16.14.4302; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; RIZZOLO LJ, 1988, J BIOL CHEM, V263, P9520; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; SU K, 1993, J BIOL CHEM, V268, P14301; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WILLIAMS DB, 1995, CURR OPIN IMMUNOL, V7, P77, DOI 10.1016/0952-7915(95)80032-8; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800	42	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4981	4987		10.1074/jbc.275.7.4981	http://dx.doi.org/10.1074/jbc.275.7.4981			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671537	hybrid			2022-12-27	WOS:000085378200063
J	Miyata, S; Koshikawa, N; Yasumitsu, H; Miyazaki, K				Miyata, S; Koshikawa, N; Yasumitsu, H; Miyazaki, K			Trypsin stimulates integrin alpha(5)beta(1)-dependent adhesion to fibronectin and proliferation of human gastric carcinoma cells through activation of proteinase-activated receptor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; THROMBIN RECEPTOR; MOLECULAR-CLONING; MATRIX METALLOPROTEINASES; TYROSINE PHOSPHORYLATION; ENZYMATIC-PROPERTIES; SERINE PROTEINASES; TUMOR-CELLS; EXPRESSION; IDENTIFICATION	Trypsin is widely expressed in various non-pancreatic tissues at low levels and overexpressed in some types of human cancers. In the present study, we found that trypsin stimulates integrin-dependent adhesion and growth of MKN-1 human gastric carcinoma cells. MKN-1 cells expressed both proteinase-activated receptor-1 (PAR-1) and PAR-2, which are activated by thrombin and trypsin, respectively. Both trypsin and the PAR-S ligand SLIGKV promoted integrin alpha(5)beta(1)-mediated adhesion of MKN-1 cells to fibronectin, and less effectively integrin alpha(v)beta(3)-mediated cell adhesion to vitronectin, but not that to type IV collagen or laminin-l at all. Thrombin and the PAR-1 ligand SFLLRN promoted the cell adhesion to vitronectin more strongly than trypsin or the PAR-2 ligand, but not the cell adhesion to fibronectin at all. The cell adhesion-stimulating effect of the PAR-S ligand was significantly reduced by the pre-treatment of cells with trypsin, indicating that the effect of trypsin is mediated by PAR-S activation. The trypsin-stimulated cell adhesion to vitronectin, but not to fibronectin, was effectively inhibited by the Gi protein blocker pertussis toxin, and both cell adhesions were completely inhibited by the Src kinase inhibitor herbimycin A. Furthermore, trypsin and the PAR-2 ligand stimulated growth of MKN-1 cells more strongly than thrombin or the PAR-1 ligand. These results show that trypsin regulates cellular adhesion and proliferation by inducing PAR-BIG protein signalings, and that the integrin alpha(5)beta(1)- and integrin alpha(v)beta(3)-dependent cell adhesions are regulated by different PAR/G protein signalings.Trypsin is widely expressed in various non-pancreatic tissues at low levels and overexpressed in some types of human cancers. In the present study, we found that trypsin stimulates integrin-dependent adhesion and growth of MKN-1 human gastric carcinoma cells. MKN-1 cells expressed both proteinase-activated receptor-1 (PAR-1) and PAR-2, which are activated by thrombin and trypsin, respectively. Both trypsin and the PAR-S ligand SLIGKV promoted integrin alpha(5)beta(1)-mediated adhesion of MXN-1 cells to fibronectin, and less effectively integrin alpha(v)beta(3)-mediated cell adhesion to vitronectin, but not that to type IV collagen or laminin-1 at all. Thrombin and the PAR-1 ligand SFLLRN promoted the cell adhesion to vitronectin more strongly than trypsin or the PAR-2 ligand, but not the cell adhesion to fibronectin at all. The cell adhesion-stimulating effect of the PAR-S ligand was significantly reduced by the pre-treatment of cells with trypsin, indicating that the effect of trypsin is mediated by PAR-S activation. The trypsin-stimulated cell adhesion to vitronectin, but not to fibronectin, was effectively inhibited by the Gi protein blocker pertussis toxin, and both cell adhesions were completely inhibited by the Src kinase inhibitor herbimycin A. Furthermore, trypsin and the PAR-2 ligand stimulated growth of MKN-1 cells more strongly than thrombin or the PAR-1 ligand. These results show that trypsin regulates cellular adhesion and proliferation by inducing PAR-BIG protein signalings, and that the integrin alpha(5)beta(1)- and integrin alpha(v)beta(3)-dependent cell adhesions are regulated by different PAR/G protein signalings.	Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan	Yokohama City University; Yokohama City University	Miyazaki, K (corresponding author), Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, 641-12 Maioka, Yokohama, Kanagawa 2440813, Japan.	miyazaki@yokohama-cu.ac.jp	Koshikawa, Naohiko/S-7306-2017	Koshikawa, Naohiko/0000-0002-4539-888X				BAFFY G, 1994, J BIOL CHEM, V269, P8483; Belham CL, 1996, BIOCHEM J, V320, P939, DOI 10.1042/bj3200939; BLUMBERG PM, 1975, CELL, V6, P137, DOI 10.1016/0092-8674(75)90004-5; Bohm SK, 1996, BIOCHEM J, V314, P1009; Brass LF, 1997, THROMB HAEMOSTASIS, V78, P581; CHEN YH, 1994, J BIOL CHEM, V269, P27372; Chiang HS, 1996, BRIT J CANCER, V73, P902, DOI 10.1038/bjc.1996.161; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; COUGHLIN SR, 1994, P NATL ACAD SCI USA, V91, P9200, DOI 10.1073/pnas.91.20.9200; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Fox MT, 1997, FEBS LETT, V417, P267, DOI 10.1016/S0014-5793(97)01298-2; FUJIL K, 1995, EXP CELL RES, V220, P201, DOI 10.1006/excr.1995.1307; HIRAHARA F, 1995, INT J CANCER, V63, P176, DOI 10.1002/ijc.2910630205; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Kato Y, 1998, EUR J CANCER, V34, P1117, DOI 10.1016/S0959-8049(98)00077-X; Kawano N, 1997, HUM PATHOL, V28, P613, DOI 10.1016/S0046-8177(97)90085-X; KLEPFISH A, 1993, INT J CANCER, V53, P978; KOIVUNEN E, 1989, J BIOL CHEM, V264, P14095; Kong WY, 1997, P NATL ACAD SCI USA, V94, P8884, DOI 10.1073/pnas.94.16.8884; KOSHIKAWA N, 1992, CANCER RES, V52, P5046; Koshikawa N, 1997, FEBS LETT, V409, P442, DOI 10.1016/S0014-5793(97)00565-6; Koshikawa N, 1998, AM J PATHOL, V153, P937, DOI 10.1016/S0002-9440(10)65635-0; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Mirza H, 1996, J CLIN INVEST, V97, P1705, DOI 10.1172/JCI118597; Miyata S, 1998, CLIN EXP METASTAS, V16, P613, DOI 10.1023/A:1006576313979; Miyata S, 1999, J BIOCHEM, V125, P1067, DOI 10.1093/oxfordjournals.jbchem.a022388; Mizushima H, 1997, CELL GROWTH DIFFER, V8, P979; NIERODZIK MLR, 1992, CANCER RES, V52, P3267; Nierodzik MLR, 1996, BRIT J HAEMATOL, V92, P452, DOI 10.1046/j.1365-2141.1996.d01-1494.x; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; OKADA Y, 1992, J BIOL CHEM, V267, P21712; SANTULLI RJ, 1995, P NATL ACAD SCI USA, V92, P9151, DOI 10.1073/pnas.92.20.9151; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SEFTON BM, 1970, NATURE, V227, P843, DOI 10.1038/227843a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Sorsa T, 1997, J BIOL CHEM, V272, P21067, DOI 10.1074/jbc.272.34.21067; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	45	106	115	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4592	4598		10.1074/jbc.275.7.4592	http://dx.doi.org/10.1074/jbc.275.7.4592			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671485	hybrid			2022-12-27	WOS:000085378200011
J	Montgomery, HJ; Romanov, V; Guillemette, JG				Montgomery, HJ; Romanov, V; Guillemette, JG			Removal of a putative inhibitory element reduces the calcium-dependent calmodulin activation of neuronal nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVOCYTOCHROME P-450 BM3; REDUCTASE DOMAIN; BINDING DOMAINS; IDENTIFICATION; EXPRESSION; MECHANISM; SUBUNIT; ABSENCE; HEME; FMN	Neuronal nitric-oxide synthase (NOS) and endothelial NOS are constitutive NOS isoforms that are activated by binding calmodulin in response to elevated intracellular calcium. In contrast, the inducible NOS isoform binds calmodulin at low basal levels of calcium in resting cells. Primary sequence comparisons show that each constitutive NOS isozyme contains a polypeptide segment within its reductase domain, which is absent in the inducible NOS enzyme. To study a possible link between the presence of these additional polypeptide segments in constitutive NOS enzymes and their calcium-dependent calmodulin activation, three deletion mutants were created. The putative inhibitory insert was removed from the FMN binding regions of the neuronal NOS holoenzyme and from two truncated neuronal NOS reductase enzymes in which the calmodulin binding region was either included or deleted. All three mutant enzymes showed reduced incorporation of FMN and required reconstitution with exogenous FMN for activity. The combined removal of both the calmodulin binding domain and the putative inhibitory insert did not result in a calmodulin-independent neuronal NOS reductase. Thus, although the putative inhibitory element has an effect on the calcium-dependent calmodulin activation of neuronal NOS, it does not have the properties of the typical autoinhibitory domain found in calmodulin-activated enzymes.	Univ Waterloo, Dept Chem, Waterloo, ON N2L 3G1, Canada; Univ Waterloo, Guelph Waterloo Ctr Grad Work Chem & Biochem, Waterloo, ON N2L 3G1, Canada	University of Waterloo; University of Guelph; University of Waterloo; Guelph-Waterloo Centre for Graduate Work in Chemistry & Biochemistry	Guillemette, JG (corresponding author), Univ Waterloo, Dept Chem, Waterloo, ON N2L 3G1, Canada.	jguillem@sciborg.uwaterloo.ca						ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; Daff SN, 1997, BIOCHEMISTRY-US, V36, P13816, DOI 10.1021/bi971085s; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HEVEL JM, 1994, METHOD ENZYMOL, V233, P250; JAMES P, 1989, J BIOL CHEM, V264, P8289; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; KLIEN ML, 1993, J BIOL CHEM, V268, P7553; Lee SJ, 1998, J BIOL CHEM, V273, P27430, DOI 10.1074/jbc.273.42.27430; Lett CM, 1999, BBA-PROTEIN STRUCT M, V1432, P40, DOI 10.1016/S0167-4838(99)00071-0; Martasek P, 1998, J BIOL CHEM, V273, P34799, DOI 10.1074/jbc.273.52.34799; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; MASTERS BSS, 1965, J BIOL CHEM, V240, P4081; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; Munro AW, 1996, BBA-PROTEIN STRUCT M, V1296, P127, DOI 10.1016/0167-4838(96)00061-1; Narayanasami R, 1997, NITRIC OXIDE-BIOL CH, V1, P39, DOI 10.1006/niox.1996.0103; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Newton DC, 1998, ARCH BIOCHEM BIOPHYS, V359, P249, DOI 10.1006/abbi.1998.0917; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Rafferty S, 1996, BIOCHEM BIOPH RES CO, V220, P1002, DOI 10.1006/bbrc.1996.0522; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Ruan J, 1996, J BIOL CHEM, V271, P22679, DOI 10.1074/jbc.271.37.22679; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Shen AL, 1999, J BIOL CHEM, V274, P5391, DOI 10.1074/jbc.274.9.5391; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STRASBURG GM, 1988, J BIOL CHEM, V263, P542; Stuehr D.J., 1996, METHODS NITRIC OXIDE, P177; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635	40	64	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5052	5058		10.1074/jbc.275.7.5052	http://dx.doi.org/10.1074/jbc.275.7.5052			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671547	hybrid			2022-12-27	WOS:000085378200073
J	Wu, GH; Cruz-Ramos, H; Hill, S; Green, J; Sawers, G; Poole, RK				Wu, GH; Cruz-Ramos, H; Hill, S; Green, J; Sawers, G; Poole, RK			Regulation of cytochrome bd expression in the obligate aerobe Azotobacter vinelandii by CydR (Fnr) - Sensitivity to oxygen, reactive oxygen species, and nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOLOGICAL NITROGEN-FIXATION; IRON-SULFUR CLUSTERS; ESCHERICHIA-COLI; RESPIRATORY PROTECTION; TERMINAL OXIDASES; DNA-BINDING; GENE; TRANSCRIPTION; PROTEIN; PROMOTERS	Azotobacter vinelandii is an obligately aerobic bacterium in which aerotolerant nitrogen fixation requires cytochrome bd, Regulation of cytochrome bd expression is achieved by CydR (an Fnr homologue), which represses transcription of the oxidase genes cydAB. cydAB mRNA was mapped by primer extension; the transcriptional start site was determined, and putative -10 and -35 regions were deduced. Two "CydR boxes," one at the +1 site and one upstream of the -35 region, were identified. Transcriptionally inactive, purified CydR was converted, by adding NifS, cysteine, and Fe2+, into an active form possessing acid-labile sulfide and spectra suggesting a [4Fe-4S](2+) cluster. Reconstituted CydR specifically bound both CydR boxes cooperatively, with higher affinity for the nearer consensus +1 site. Low concentrations of O-2 or NO ([O-2]/[CydR] or [NO]/[CydR] = 0.1-0.6) elicited loss of the 420 nm absorbance attributed to the [4Fe-4S](2+) cluster, formation of a 315 nm species, and loss of ability to retard DNA migration. Retardation by reconstituted CydR was enhanced by superoxide dismutase and/or catalase, suggesting a role for reactive oxygen species in CydR inactivation. The role of CydR in regulating cydAB expression in the supposedly anoxic cytoplasm of A, vinelandii and similarities to cydAB regulation by Fnr in Escherichia coli are discussed.	Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; John Innes Ctr Plant Sci Res, Nitrogen Fixat Lab, Norwich NR4 7UH, Norfolk, England	University of Sheffield; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Poole, RK (corresponding author), Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Firth Ct,Western Bank, Sheffield S10 2TN, S Yorkshire, England.	r.poole@sheffield.ac.uk	Wu, Guanghui/A-3757-2016	Wu, Guanghui/0000-0002-9374-3190				AIBA H, 1981, J BIOL CHEM, V256, P1905; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Bertsova YV, 1998, BBA-BIOENERGETICS, V1363, P125, DOI 10.1016/S0005-2728(97)00094-7; BUTLER AR, 1988, ADV INORG CHEM, V32, P335, DOI 10.1016/S0898-8838(08)60235-4; CASTRO L, 1994, J BIOL CHEM, V269, P29409; Cotter PA, 1997, MOL MICROBIOL, V25, P605, DOI 10.1046/j.1365-2958.1997.5031860.x; COTTER PA, 1992, FEMS MICROBIOL LETT, V91, P31; Dmello R, 1997, MICROBIOL-UK, V143, P231, DOI 10.1099/00221287-143-1-231; DMELLO R, 1994, FEMS MICROBIOL LETT, V121, P115, DOI 10.1111/j.1574-6968.1994.tb07084.x; Dmello R, 1996, MICROBIOL-UK, V142, P755, DOI 10.1099/00221287-142-4-755; DMELLO R, 1994, MICROBIOL-UK, V140, P1395, DOI 10.1099/00221287-140-6-1395; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; Drapier JC, 1996, BIOESSAYS, V18, P549, DOI 10.1002/bies.950180706; FLINT DH, 1993, J BIOL CHEM, V268, P22369; Gennis R. B., 1996, ESCHERICHIA COLI SAL, P217; Green J, 1996, BIOCHEM J, V316, P887, DOI 10.1042/bj3160887; Green J, 1997, MOL MICROBIOL, V24, P593, DOI 10.1046/j.1365-2958.1997.3801737.x; GREEN J, 1991, P R SOC LOND B, V1310, P137; Guest John R., 1996, P317; HADDOCK BA, 1977, BACTERIOL REV, V41, P47, DOI 10.1128/MMBR.41.1.47-99.1977; HIDALGO E, 1995, J BIOL CHEM, V270, P20908, DOI 10.1074/jbc.270.36.20908; Hill S, 1999, FEMS MICROBIOL LETT, V175, P185, DOI 10.1111/j.1574-6968.1999.tb13618.x; HILL S, 1992, BIOL NITROGEN FIXATI, P86; Houston M, 1998, ARCH BIOCHEM BIOPHYS, V355, P1, DOI 10.1006/abbi.1998.0675; IUCHI S, 1990, J BACTERIOL, V172, P6020, DOI 10.1128/jb.172.10.6020-6025.1990; Jordan PA, 1997, FEBS LETT, V416, P349, DOI 10.1016/S0014-5793(97)01219-2; JUNEMANN S, 1995, J BIOL CHEM, V270, P16213, DOI 10.1074/jbc.270.27.16213; KELLY MJS, 1990, J BACTERIOL, V172, P6010, DOI 10.1128/jb.172.10.6010-6019.1990; KELLY MJS, 1991, THESIS U LONDON; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; Kiley PJ, 1998, FEMS MICROBIOL REV, V22, P341, DOI 10.1111/j.1574-6976.1998.tb00375.x; KIM J, 1994, BIOCHEMISTRY-US, V33, P389, DOI 10.1021/bi00168a001; KOLONAY JF, 1994, J BACTERIOL, V176, P4177, DOI 10.1128/JB.176.13.4177-4181.1994; Lynch AS, 1996, J BACTERIOL, V178, P6238, DOI 10.1128/JB.178.21.6238-6249.1996; MOSHIRI F, 1991, J BACTERIOL, V173, P6230, DOI 10.1128/jb.173.19.6230-6241.1991; MOSHIRI F, 1991, J BIOL CHEM, V266, P23169; Poole RK, 1996, J BACTERIOL, V178, P5487, DOI 10.1128/jb.178.18.5487-5492.1996; POOLE RK, 1983, BIOCHIM BIOPHYS ACTA, V726, P205, DOI 10.1016/0304-4173(83)90006-X; Poole RK, 1997, BIOSCIENCE REP, V17, P303, DOI 10.1023/A:1027336712748; Poole RK., 1988, BACTERIAL ENERGY TRA, P231; RHODES D, 1989, PROTEIN FUNCTION, P186; ROBSON RL, 1980, ANNU REV MICROBIOL, V34, P183, DOI 10.1146/annurev.mi.34.100180.001151; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sawers G, 1999, CURR OPIN MICROBIOL, V2, P181, DOI 10.1016/S1369-5274(99)80032-0; SPIRO S, 1991, TRENDS BIOCHEM SCI, V16, P310, DOI 10.1016/0968-0004(91)90125-F; THONYMEYER L, 1994, MOL MICROBIOL, V14, P705, DOI 10.1111/j.1365-2958.1994.tb01308.x; Tseng CP, 1996, J BACTERIOL, V178, P1094, DOI 10.1128/jb.178.4.1094-1098.1996; Wu GH, 1997, MICROBIOL-SGM, V143, P2197, DOI 10.1099/00221287-143-7-2197; YAGUE E, 1994, MOL MICROBIOL, V12, P41, DOI 10.1111/j.1365-2958.1994.tb00993.x; YANG T, 1986, BIOCHIM BIOPHYS ACTA, V848, P342, DOI 10.1016/0005-2728(86)90209-4	51	50	50	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4679	4686		10.1074/jbc.275.7.4679	http://dx.doi.org/10.1074/jbc.275.7.4679			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671497	hybrid			2022-12-27	WOS:000085378200023
J	Johnson, RE; Washington, MT; Prakash, S; Prakash, L				Johnson, RE; Washington, MT; Prakash, S; Prakash, L			Fidelity of human DNA polymerase eta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DINB; REPLICATION FIDELITY; REPAIR; DIMER; BYPASS; HOMOLOG; GENE	Xeroderma pigmentosum (XP) patients are highly sensitive to sunlight, and they suffer from a high incidence of skin cancers. The variant form of XP results from mutations in the hRAD30A gene, which encodes the DNA polymerase in humans, hPol eta. Of the eukaryotic DNA polymerases,only human Pol eta and its yeast counterpart have the ability to replicate DNA containing a cis-syn thymine-thymine (T-T) dimer. Here we measure the fidelity of hPol eta on all four nondamaged template bases and at each thymine residue of a cis-syn T-T dimer. Opposite all four nondamaged template bases, hPol eta mis-incorporates nucleotides with a frequency of similar to 10(-2) 10(-3), and importantly, hPol(eta) synthesizes DNA opposite the T-T dimer with the same accuracy and efficiency as opposite the nondamaged DNA. The low fidelity of hPol eta may derive from a flexible active site that renders the enzyme more tolerant of geometric distortions in DNA and enables it to synthesize DNA past a T-T dimer.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Prakash, L (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-104 Med Res Bldg,11th & Mech St, Galveston, TX 77555 USA.		Prakash, Satya/C-6420-2013	Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261; Washington, Todd/0000-0001-8680-2992	NIEHS NIH HHS [P30-ES06676] Funding Source: Medline; NIGMS NIH HHS [GM19261] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019261] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; CIARROCCHI G, 1982, J MOL BIOL, V155, P177, DOI 10.1016/0022-2836(82)90445-4; CLEAVER JE, 1980, CARCINOGENESIS, V1, P647, DOI 10.1093/carcin/1.8.647; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; Creighton S, 1995, METHOD ENZYMOL, V262, P232; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Goodman MF, 1997, P NATL ACAD SCI USA, V94, P10493, DOI 10.1073/pnas.94.20.10493; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 1999, J BIOL CHEM, V274, P15975, DOI 10.1074/jbc.274.23.15975; KEMMINK J, 1987, NUCLEIC ACIDS RES, V15, P4645, DOI 10.1093/nar/15.11.4645; KIM JK, 1995, PHOTOCHEM PHOTOBIOL, V62, P44, DOI 10.1111/j.1751-1097.1995.tb05236.x; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McDonald JP, 1997, GENETICS, V147, P1557; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; Reuven NB, 1999, J BIOL CHEM, V274, P31763, DOI 10.1074/jbc.274.45.31763; Roush AA, 1998, MOL GEN GENET, V257, P686; STRAUSS BS, 1991, BIOESSAYS, V13, P79, DOI 10.1002/bies.950130206; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; WANG CI, 1991, P NATL ACAD SCI USA, V88, P9072, DOI 10.1073/pnas.88.20.9072	23	353	359	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7447	7450		10.1074/jbc.275.11.7447	http://dx.doi.org/10.1074/jbc.275.11.7447			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713043	hybrid			2022-12-27	WOS:000085913300003
J	Gothie, E; Richard, DE; Berra, E; Pages, G; Pouyssegur, J				Gothie, E; Richard, DE; Berra, E; Pages, G; Pouyssegur, J			Identification of alternative spliced variants of human hypoxia-inducible factor-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; CLOSE SEQUENCE SIMILARITY; ARYL-HYDROCARBON RECEPTOR; ENDOTHELIAL GROWTH-FACTOR; FACTOR 1-ALPHA; MOLECULAR CHARACTERIZATION; TRANSCRIPTION FACTOR; CDNA CLONING; ARNT; GENE	Mammalian cells are able to sense oxygen and regulate a number of genes in response to hypoxia. The transcription factor Hypoxia Inducible Factor-1 (HIF-1) was identified as an important key component of the hypoxia signaling pathway. HIF-1 is a heterodimer composed of two members of the basic helix-loop-helix transcription factor superfamily containing a PAS (PER-ARNT-SIM) domain: HIF-1 alpha and HIF-1 beta/ARNT, During the cloning by reverse transcriptase-polymerase chain reaction of the human HIF-1 alpha subunit, we isolated two cDNA clones which corresponded to alternative splicing of the HIF-1 alpha gene. Polymerase chain reaction analysis and sequencing revealed that both clones possessed three additional base pairs between exons 1 and 2, Also, one of them lacked 127 base pairs corresponding to exon 14, We demonstrate that the mRNA of this truncated form is expressed in several human cells Lines and human skin but apparently not in rodents. When transfected in HEK 293 cells, the corresponding 736 amino acid protein (HIF-1 alpha(736)) is regulated by hypoxia in a similar manner as the full-length HIF-1 alpha (HIF-1 alpha(FL)). In luciferase transfection assays, both recombinant proteins HIF-1 alpha(736) and HIF-1 alpha(FL) dimerize with HIF-1 beta/ ARNT and activate the VEGF promoter upon hypoxia, However, the shorter HIF-1 alpha isoform is 3-fold less active than HIF-1 alpha(FL), a result consistent with the lack of the C-terminal transactivation domain. As expected, this small isoform can compete with the endogenous and transfected full-length HIF-1 alpha. Altogether, these results suggest that the HIF-1 alpha(736) isoform modulates gene expression upon hypoxia.	Ctr Antoine Lacassagne, Inst Signaling Dev Biol & Canc Res, CNRS, UMR 6543, F-06189 Nice, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Gothie, E (corresponding author), Ctr Antoine Lacassagne, Inst Signaling Dev Biol & Canc Res, CNRS, UMR 6543, 33 Ave Valombrose, F-06189 Nice, France.		Pages, Gilles/N-7135-2017; Berra, Edurne/F-9692-2011; Richard, Darren E./K-6760-2019	Berra, Edurne/0000-0002-3820-5744; Richard, Darren/0000-0003-2690-0480				Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; DRUTEL G, 1998, THESIS U PARIS 6; ELLIS L, 1986, COLD SPRING HARB SYM, V2, P773; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hirose K, 1996, MOL CELL BIOL, V16, P1706; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; Iyer NV, 1998, GENOMICS, V52, P159, DOI 10.1006/geno.1998.5416; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Li H, 1996, J BIOL CHEM, V271, P21262, DOI 10.1074/jbc.271.35.21262; Luo G, 1997, GENE EXPRESSION, V6, P287; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Pollenz RS, 1996, J BIOL CHEM, V271, P30886, DOI 10.1074/jbc.271.48.30886; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Takahata S, 1998, BIOCHEM BIOPH RES CO, V248, P789, DOI 10.1006/bbrc.1998.9012; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1997, EUR J BIOCHEM, V246, P155, DOI 10.1111/j.1432-1033.1997.t01-1-00155.x; Wenger RH, 1996, BIOCHEM BIOPH RES CO, V223, P54, DOI 10.1006/bbrc.1996.0845	30	88	90	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6922	6927		10.1074/jbc.275.10.6922	http://dx.doi.org/10.1074/jbc.275.10.6922			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702253	hybrid			2022-12-27	WOS:000085809600033
J	Lapinski, PE; Miller, GG; Tampe, R; Raghavan, M				Lapinski, PE; Miller, GG; Tampe, R; Raghavan, M			Pairing of the nucleotide binding domains of the transporter associated with antigen processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; HUMAN P-GLYCOPROTEIN; PEPTIDE-BINDING; MULTIDRUG-RESISTANCE; ABC TRANSPORTER; ENDOPLASMIC-RETICULUM; ENCODED TRANSPORTER; ATPASE ACTIVITY; TAP; SITE	The transporter associated with antigen processing (TAP) comprises two structurally related subunits, TAP1 and TAPS, that form stable complexes in endoplasmic reticulum (ER) membranes. TAP complexes function in the translocation of peptides from the cytosol into the ER lumen for presentation by major histocompatibility complex class I molecules. Each TAP subunit contains an N-terminal membrane-spanning region with multiple membrane-spanning segments, and a C-terminal, cytosolic nucleotide binding region. To study the nature of the interactions occurring on the cytosolic face of TAP1/TAP2 complexes, we investigated quaternary associations mediated by two C-terminal fragments of human TAP1 (Tlc, residues 452-748 and T1ctr, residues 472-748) and two C-terminal fragments of human TAPS (T2c, residues 399-686 and T2ctr, residues 433-686), Each of these constructs contains the core nucleotide binding region as well as a long or short N-terminal extension. We show stable complex formation between T1c and T2c but not between T1ctr and T2ctr, The mechanistic implications of Obese results are discussed. We also show that each of the constructs except T1ctr interacts with wild type TAP1 and TAP2, indicating possibilities for homodimerization of TAP1 and TAP2, or of oligomerization of TAP1/TAP2 heterodimers on membranes.	Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Univ Marburg, Sch Med, Inst Biochem, D-35033 Marburg, Germany	University of Michigan System; University of Michigan; Philipps University Marburg	Raghavan, M (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, 5641 Med Sci Bldg 2, Ann Arbor, MI 48109 USA.		Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044115] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI044115, R01 AI44115-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; Chen HL, 1996, NAT GENET, V13, P210, DOI 10.1038/ng0696-210; Dey S, 1998, METHOD ENZYMOL, V292, P318; Elliott T, 1997, ADV IMMUNOL, V65, P47, DOI 10.1016/S0065-2776(08)60741-5; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; Momburg F, 1998, ADV IMMUNOL, V68, P191, DOI 10.1016/S0065-2776(08)60560-X; MULLER KM, 1994, J BIOL CHEM, V269, P14032; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Nijenhuis M, 1996, J IMMUNOL, V157, P5467; NIJENHUIS M, 1996, J IMMUNOL, V156, P2184; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; PARHAM P, 1979, J IMMUNOL, V123, P342; PEDERSEN PL, 1995, J BIOENERG BIOMEMBR, V27, P3, DOI 10.1007/BF02110324; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; TAMPE R, 1997, UNUSUAL SECRETORY PA; Uebel S, 1997, P NATL ACAD SCI USA, V94, P8976, DOI 10.1073/pnas.94.17.8976; UEBEL S, 1995, J BIOL CHEM, V270, P18512, DOI 10.1074/jbc.270.31.18512; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; WANG K, 1994, FEBS LETT, V350, P337, DOI 10.1016/0014-5793(94)00806-X; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R	30	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6831	6840		10.1074/jbc.275.10.6831	http://dx.doi.org/10.1074/jbc.275.10.6831			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702242	hybrid			2022-12-27	WOS:000085809600022
J	Poussu, A; Lohi, O; Lehto, VP				Poussu, A; Lohi, O; Lehto, VP			Vear, a novel Gel-associated protein with VHS and gamma-adaptin "ear" domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREFELDIN-A; COAT PROTEINS; SH3 DOMAIN; CLATHRIN; MEMBRANE; MOLECULE; CLONING; CELLS; IDENTIFICATION; RECRUITMENT	The molecular basis of the selectivity and the details of the vesicle formation in endocytic and secretory pathways are still poorly known and most probably involve as yet unidentified components. Here we describe the cloning, expression, and tissue and cell distribution of a novel protein of 67 kDa (called Vear) that bears homology to several endocytosis-associated proteins in that it has a VHS domain in its N terminus. It is also similar to gamma-adaptin, the heavy subunit of AP-1, in having in its C terminus a typical "ear" domain. In immunofluorescence microscopy, Vear was seen in the Golgi complex as judged by a typical distribution pattern, a distinct colocalization with the Golgi marker gamma-adaptin, and a sensitivity to treatment of cells with brefeldin A. In cell fractionation, Vear partitioned with the post-nuclear membrane fraction. In transfection experiments, hemagglutinin-tagged full-length Vear and truncated Vear lacking the VHS domain assembled on and caused compaction of the Golgi complex. Golgi association without compaction was seen with the ear domain of Vear, whereas the VHS domain alone showed a diffuse membrane- and vesicle-associated distribution. The Golgi association and the bipartite structure along with the differential targeting of its domains suggest that Vear is involved in heterotypic vesicle/suborganelle interactions associated with the Golgi complex. Tissue-specific function of Vear is suggested by its high level of expression in kidney, muscle, and heart.	Univ Oulu, Dept Pathol, FIN-90410 Oulu, Finland	University of Oulu	Lehto, VP (corresponding author), Univ Oulu, Dept Pathol, POB 5000,Kajaanintie 52 D, FIN-90410 Oulu, Finland.		Lohi, Olli/AAW-6157-2021	Lohi, Olli/0000-0001-9195-0797				AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Bean AJ, 1997, NATURE, V385, P826, DOI 10.1038/385826a0; Brodsky FM, 1997, TRENDS CELL BIOL, V7, P175, DOI 10.1016/S0962-8924(97)01038-6; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; Clague MJ, 1999, CURR BIOL, V9, pR258, DOI 10.1016/S0960-9822(99)80158-4; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Lewin DA, 1998, BBA-MOL CELL RES, V1401, P129, DOI 10.1016/S0167-4889(97)00130-4; Lewin DA, 1998, FEBS LETT, V435, P263, DOI 10.1016/S0014-5793(98)01083-7; Lohi O, 1998, FEBS LETT, V440, P255, DOI 10.1016/S0014-5793(98)01401-X; Lohi O, 1998, J BIOL CHEM, V273, P21408, DOI 10.1074/jbc.273.33.21408; Mallet WG, 1996, J CELL SCI, V109, P3059; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Merilainen J, 1997, J BIOL CHEM, V272, P23278, DOI 10.1074/jbc.272.37.23278; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; MUURO S, 1999, CURR BIOL, V9, P377; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; Ponting CP, 1999, NUCLEIC ACIDS RES, V27, P229, DOI 10.1093/nar/27.1.229; ROBINSON MS, 1993, J CELL BIOL, V123, P67, DOI 10.1083/jcb.123.1.67; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J., 1989, MOL CLONING, pA1; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Seaman MNJ, 1996, J BIOL CHEM, V271, P25446, DOI 10.1074/jbc.271.41.25446; Takatsu H, 1998, J BIOL CHEM, V273, P24693, DOI 10.1074/jbc.273.38.24693; Takeshita T, 1996, BIOCHEM BIOPH RES CO, V225, P1035, DOI 10.1006/bbrc.1996.1290; TANG BL, 1995, EUR J CELL BIOL, V68, P199; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Traub LM, 1997, TRENDS CELL BIOL, V7, P43, DOI 10.1016/S0962-8924(96)20042-X; Warren G, 1998, CURR OPIN CELL BIOL, V10, P493, DOI 10.1016/S0955-0674(98)80064-1; Waters MG, 1999, CURR OPIN CELL BIOL, V11, P453, DOI 10.1016/S0955-0674(99)80065-9	39	89	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7176	7183		10.1074/jbc.275.10.7176	http://dx.doi.org/10.1074/jbc.275.10.7176			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702286	hybrid			2022-12-27	WOS:000085809600066
J	Redeker, V; Lachkar, S; Siavoshian, S; Charbaut, E; Rossier, J; Sobel, A; Curmi, PA				Redeker, V; Lachkar, S; Siavoshian, S; Charbaut, E; Rossier, J; Sobel, A; Curmi, PA			Probing the native structure of stathmin and its interaction domains with tubulin - Combined use of limited proteolysis, size exclusion chromatography, and mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-DESTABILIZING ACTIVITY; SECONDARY STRUCTURE PREDICTION; SITE-DIRECTED MUTAGENESIS; CELL REGULATIONS; PROTEIN-KINASE; IN-VITRO; PHOSPHORYLATION; PHOSPHOPROTEIN; GROWTH; ONCOPROTEIN-18	Stathmin is a cytosoluble phosphoprotein proposed to be a regulatory relay integrating diverse intracellular signaling pathway. Its interaction with tubulin modulates microtubule dynamics by destabilization of assembled microtubules or inhibition of their polymerization from free tubulin. The aim of this study was to probe the native structure of stathmin and to delineate its minimal region able to interact with tubulin. Limited proteolysis of stathmin revealed four structured domains within the native protein, corresponding to amino acid sequences 22-81 (I), 95-113 (II), 113-128 (III), and 128-149 (IV), which allows us to propose stathmin folding hypotheses. Furthermore, stathmin proteolytic fragments were mixed to interact with tubulin, and those that retained affinity for tubulin were isolated by size exclusion chromatography and identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The results indicate that, to interact with tubulin, a stathmin fragment must span a minimal core region from residues 42 to 126, which interestingly corresponds to the predicted alpha-helical "interaction region" of stathmin, In addition, an interacting stathmin fragment must include a short N- or C-terminal extension. The functional significance of these interaction constrains is further validated by tubulin polymerization inhibition assays with fragments designed on the basis of the tubulin binding results, The present results will help to optimize further stathmin structural studies and to develop molecular tools to target its interaction with tubulin.	Inst Fer Moulin, INSERM, U440, F-75005 Paris, France; Ecole Super Phys & Chim Ind Ville Paris, CNRS, UMR 7637, F-75005 Paris, France; CNRS, UPR 9063, LEBS, F-91198 Gif Sur Yvette, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Curmi, PA (corresponding author), Inst Fer Moulin, INSERM, U440, 17 Rue Fer Moulin, F-75005 Paris, France.	curmi@ifm.inserm.fr	CURMI, Patrick/G-4036-2013; Redeker, Virginie/L-8929-2018	Redeker, Virginie/0000-0003-2694-8388; CURMI, Patrick A./0000-0001-5045-8501				Antonsson B, 1998, J BIOL CHEM, V273, P8439, DOI 10.1074/jbc.273.14.8439; Antz C, 1999, NAT STRUCT BIOL, V6, P146; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BERETTA L, 1989, ENDOCRINOLOGY, V125, P1358, DOI 10.1210/endo-125-3-1358; BERETTA L, 1988, ENDOCRINOLOGY, V122, P40, DOI 10.1210/endo-122-1-40; CHNEIWEISS H, 1992, J NEUROCHEM, V58, P282, DOI 10.1111/j.1471-4159.1992.tb09308.x; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COHEN SL, 1995, PROTEIN SCI, V4, P1088, DOI 10.1002/pro.5560040607; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; CURMI PA, 1994, BIOCHEM J, V300, P331, DOI 10.1042/bj3000331; DiPaolo G, 1997, FEBS LETT, V416, P149, DOI 10.1016/S0014-5793(97)01188-5; DOYE V, 1990, J BIOL CHEM, V265, P11650; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; FRUTON JS, 1975, PROTEASES BIOL CONTR, P33; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Gavet O, 1998, J CELL SCI, V111, P3333; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; Gradin HM, 1998, J CELL BIOL, V140, P131, DOI 10.1083/jcb.140.1.131; Gradin HM, 1997, MOL CELL BIOL, V17, P3459, DOI 10.1128/MCB.17.6.3459; HAILAT N, 1990, ONCOGENE, V5, P1615; Horwitz SB, 1997, J BIOL CHEM, V272, P8129, DOI 10.1074/jbc.272.13.8129; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; HUBBARD SJ, 1994, PROTEIN SCI, V3, P757; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; KOPPEL J, 1990, J BIOL CHEM, V265, P3703; Kriwacki RW, 1997, J CHROMATOGR A, V777, P23, DOI 10.1016/S0021-9673(97)00527-X; KRIWACKI RW, 1998, J BIOMOL TECH, V9, P5; Larsson N, 1999, J CELL BIOL, V146, P1289, DOI 10.1083/jcb.146.6.1289; LEIGHTON IA, 1993, MOL CELL BIOCHEM, V128, P151, DOI 10.1007/BF01076766; Levin JM, 1997, PROTEIN ENG, V10, P771, DOI 10.1093/protein/10.7.771; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Manceau V, 1999, ELECTROPHORESIS, V20, P409, DOI 10.1002/(SICI)1522-2683(19990201)20:2<409::AID-ELPS409>3.3.CO;2-E; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; Maucuer A, 1997, J BIOL CHEM, V272, P23151, DOI 10.1074/jbc.272.37.23151; MAUCUER A, 1990, FEBS LETT, V264, P275, DOI 10.1016/0014-5793(90)80266-L; MELHEM RF, 1991, J BIOL CHEM, V266, P17747; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MORRICE NA, 1998, PROTEIN STRUCTURE PR, P117; Ozon S, 1997, EUR J BIOCHEM, V248, P794, DOI 10.1111/j.1432-1033.1997.t01-2-00794.x; Riederer BM, 1997, P NATL ACAD SCI USA, V94, P741, DOI 10.1073/pnas.94.2.741; Sambrok J., 1989, MOL CLONING LAB MANU; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHUBART UK, 1987, J BIOL CHEM, V262, P11871; SOBEL A, 1983, J BIOL CHEM, V258, P312; SOBEL A, 1989, J BIOL CHEM, V264, P3765; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D	48	36	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6841	6849		10.1074/jbc.275.10.6841	http://dx.doi.org/10.1074/jbc.275.10.6841			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702243	hybrid			2022-12-27	WOS:000085809600023
J	Samokyszyn, VM; Gall, WE; Zawada, G; Freyaldenhoven, MA; Chen, GP; Mackenzie, PI; Tephly, TR; Radominska-Pandya, A				Samokyszyn, VM; Gall, WE; Zawada, G; Freyaldenhoven, MA; Chen, GP; Mackenzie, PI; Tephly, TR; Radominska-Pandya, A			4-Hydroxyretinoic acid, a novel substrate for human liver microsomal UDP-glucuronosyltransferase(s) and recombinant UGT2B7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-H SYNTHASE; TRANS-RETINOIC ACID; HUMAN UDP-GLUCURONOSYLTRANSFERASE; 5,6-EPOXYRETINOIC ACID; 13-CIS-RETINOIC ACID; X-RECEPTOR; CHOLESTATIC AGENTS; (E)-RETINOIC ACID; CDNA CLONING; IDENTIFICATION	It is suggested that formation of more polar metabolites of all-trans-retinoic acid (atRA) via oxidative pathways limits its biological activity. In this report, we investigated the biotransformation of oxidized products of atRA via glucuronidation. For this purpose, we synthesized 4-hydroxy-RA (4-OH-RA) in radioactive and nonradioactive form, 4-hydroxy-retinyl acetate (4-OH-RAc), and 5,6-epoxy-RA, all of which are major products of atRA oxidation. Glucuronidation of these retinoids by human liver microsomes and human recombinant UDP-glucuronosyltransferases (UGTs) was characterized and compared with the glucuronidation of atRA. The human liver microsomes glucuronidated 4-OH-RA and 4-OH-RAc with 6- and 3-fold higher activity than atRA, respectively. Analysis of the glucuronidation products showed that the hydroxyl-linked glucuronides of 4-OH-RA and 4-OH-RAc were the major products, as opposed to the formation of the carboxyl-linked glucuronide with atRA, 4-oxo-RA, and 5,6-epoxy-RA. We have also determined that human recombinant UGT2B7 can glucuronidate atRA, 4-OH-RA, and 4-OH-RAc with activities similar to those found in human liver microsomes. We therefore postulate that this human isoenzyme, which is expressed in human liver, kidney, and intestine, plays a key role in the biological fate of atRA. We also propose that atRA induces its own oxidative metabolism via a cytochrome P450 (CYP26) and is further biotransformed into glucuronides via UGT-mediated pathways.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA; Univ Iowa, Dept Pharmacol, Iowa City, IA 52242 USA; Flinders Univ S Australia, Sch Med, Dept Clin Pharmacol, Bedford Pk, SA 5046, Australia	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Iowa; Flinders University South Australia	Radominska-Pandya, A (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, 4301 W Markham,Slot 516, Little Rock, AR 72205 USA.			Mackenzie, Peter/0000-0002-0697-6878	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051971, R01DK045123, R01DK049715] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51971, DK49715, DK45123] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBOTT FV, 1988, LIFE SCI, V43, P1685, DOI 10.1016/0024-3205(88)90479-1; Abu-Abed SS, 1998, J BIOL CHEM, V273, P2409, DOI 10.1074/jbc.273.4.2409; BATTAGLIA E, 1994, ARCH BIOCHEM BIOPHYS, V309, P266, DOI 10.1006/abbi.1994.1112; BLANER WS, 1994, RETINOIDS BIOL CHEM, V2, P229; BOCK KW, 1992, TRENDS PHARMACOL SCI, V13, P223, DOI 10.1016/0165-6147(92)90068-H; Braakhuis BJM, 1997, BRIT J CANCER, V76, P189, DOI 10.1038/bjc.1997.361; CARTER CA, 1996, ANTICANCER RES, V16, P1996; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN F, 1993, BIOCHEMISTRY-US, V32, P10648, DOI 10.1021/bi00091a015; Coffman BL, 1997, DRUG METAB DISPOS, V25, P1; Coffman BL, 1998, DRUG METAB DISPOS, V26, P73; Freyaldenhoven MA, 1998, CHEM RES TOXICOL, V11, P102, DOI 10.1021/tx970044u; Freyaldenhoven MA, 1996, CHEM RES TOXICOL, V9, P677, DOI 10.1021/tx960027p; Fujii H, 1997, EMBO J, V16, P4163, DOI 10.1093/emboj/16.14.4163; Gall WE, 1999, J STEROID BIOCHEM, V70, P101, DOI 10.1016/S0960-0760(99)00088-6; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; JANICKBUCKNER D, 1991, FASEB J, V5, P320, DOI 10.1096/fasebj.5.3.2001792; JOHN KV, 1967, BIOCHEM J, V103, P539, DOI 10.1042/bj1030539; KENSLER TW, 1981, CANCER RES, V41, P216; KRAFT JC, 1994, P NATL ACAD SCI USA, V91, P3067, DOI 10.1073/pnas.91.8.3067; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Mangelsdorf David J., 1994, P319; MCCORMICK AM, 1982, J BIOL CHEM, V257, P1730; MCCORMICK AM, 1978, BIOCHEMISTRY-US, V17, P4085, DOI 10.1021/bi00612a033; MCCORMICK AM, 1980, BIOCHEM J, V186, P4085; Mojarrabi B, 1996, BIOCHEM BIOPH RES CO, V225, P785, DOI 10.1006/bbrc.1996.1251; MUINDI JRF, 1992, CANCER RES, V52, P2138; OELBERG DG, 1984, J CLIN INVEST, V73, P1507, DOI 10.1172/JCI111356; PIJNAPPEL WWM, 1993, NATURE, V366, P340, DOI 10.1038/366340a0; RADOMINSKAPYREK A, 1986, J LIPID RES, V27, P89; Ray WJ, 1997, J BIOL CHEM, V272, P18702, DOI 10.1074/jbc.272.30.18702; RITTER JK, 1990, J BIOL CHEM, V265, P7900; ROBERTS AB, 1979, J BIOL CHEM, V254, P6296; SAMOKYSZYN VM, 1984, BIOCHEM BIOPH RES CO, V124, P430, DOI 10.1016/0006-291X(84)91571-7; Samokyszyn VM, 1997, CHEM RES TOXICOL, V10, P795, DOI 10.1021/tx970045m; SAMOKYSZYN VM, 1995, CHEM RES TOXICOL, V8, P807, DOI 10.1021/tx00047a022; SAMOKYSZYN VM, 1987, J BIOL CHEM, V262, P14119; SIETSEMA WK, 1982, J BIOL CHEM, V257, P4265; vanderLeede BM, 1997, J BIOL CHEM, V272, P17921, DOI 10.1074/jbc.272.29.17921; VERMA AK, 1980, CANCER RES, V40, P2367; VOGEL AI, 1972, TXB PRACTICAL ORGANI, P810; VORE M, 1985, TRENDS PHARMACOL SCI, V6, P256, DOI 10.1016/0165-6147(85)90118-X; VORE M, 1983, LIFE SCI, V32, P2989, DOI 10.1016/0024-3205(83)90650-1; WERTZ PW, 1979, NATURE, V277, P227, DOI 10.1038/277227a0; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; White JA, 1996, J BIOL CHEM, V271, P29922, DOI 10.1074/jbc.271.47.29922; ZILE MH, 1982, J BIOL CHEM, V257, P3537; ZILE MH, 1980, P NATL ACAD SCI-BIOL, V77, P3230, DOI 10.1073/pnas.77.6.3230	49	98	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6908	6914		10.1074/jbc.275.10.6908	http://dx.doi.org/10.1074/jbc.275.10.6908			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702251	hybrid			2022-12-27	WOS:000085809600031
J	Schense, JC; Hubbell, JA				Schense, JC; Hubbell, JA			Three-dimensional migration of neurites is mediated by adhesion site density and affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-MIGRATION; RGD; INTEGRINS; FIBRONECTIN; PEPTIDE; GROWTH; REGENERATION; OUTGROWTH; PROTEASES; FIBRIN	Three dimensional neurite outgrowth rates within fibrin matrices that contained variable amounts of RGD peptides were shown to depend on adhesion site density and affinity. Bi-domain peptides with a factor XIIIa substrate in one domain and a RGD sequence in the other domain were covalently incorporated into fibrin gels during coagulation through the action of the transglutaminase factor XIIIa, and the RGD-dependent effect on neurite outgrow-th was quantified, employing chick dorsal root ganglia cultured two- and three-dimensionally within the modified fibrin. Two separate bi-domain peptides were synthesized, one with a lower binding affinity linear RGD domain and another with a higher binding affinity cyclic RGD domain. Both peptides were crosslinked into fibrin gels at concentrations up to 8.2 mol of peptide/mol of fibrinogen, and their effect on neurite outgrowth was measured. Both two- and three-dimensional neurite outgrowth demonstrated a bi-phasic dependence on RGD concentration for both the linear and cyclic peptide, with intermediate adhesion site densities yielding maximal neurite extension and higher densities inhibiting outgrowth. The adhesion site density that yielded maximal outgrowth depended strongly on adhesion site affinity in both two and three dimensions, with lower densities of the higher affinity ligand being required (0.8-1.7 mol/mol for the linear peptide versus 0.2 mol/mol for the cyclic peptide yielding maximum neurite outgrowth rates in three-dimensional cultures).	Swiss Fed Inst Technol, Dept Mat, CH-8044 Zurich, Switzerland; Swiss Fed Inst Technol, Inst Biomed Engn, CH-8044 Zurich, Switzerland; Univ Zurich, CH-8044 Zurich, Switzerland; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; California Institute of Technology	Hubbell, JA (corresponding author), ETH Zurich, Inst Biomed Engn, Moussonstr 18, CH-8044 Zurich, Switzerland.		Hubbell, Jeffrey A/A-9266-2008	Hubbell, Jeffrey A/0000-0003-0276-5456				Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; Benelli R, 1998, AIDS, V12, P261, DOI 10.1097/00002030-199803000-00003; BISBY MA, 1992, MOL NEUROBIOL, V6, P107, DOI 10.1007/BF02780547; BIXBY JL, 1991, ANNU REV CELL BIOL, V7, P117, DOI 10.1146/annurev.cellbio.7.1.117; Condic ML, 1997, NATURE, V389, P852, DOI 10.1038/39878; DELLENBACK RJ, 1970, P SOC EXP BIOL MED, V134, P353; DICKINSON CD, 1994, J MOL BIOL, V236, P1079, DOI 10.1016/0022-2836(94)90013-2; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; DIMILLA PA, 1991, BIOPHYS J, V60, P15, DOI 10.1016/S0006-3495(91)82027-6; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Fu SY, 1997, MOL NEUROBIOL, V14, P67, DOI 10.1007/BF02740621; Herbert CB, 1996, J COMP NEUROL, V365, P380, DOI 10.1002/(SICI)1096-9861(19960212)365:3<380::AID-CNE4>3.0.CO;2-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ICHINOSE A, 1983, FEBS LETT, V153, P369, DOI 10.1016/0014-5793(83)80645-0; Jessell T, 1991, PRINCIPLES NEURAL SC, P908; Jois SDS, 1996, J BIOMOL STRUCT DYN, V14, P1; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; LANDER AD, 1989, TRENDS NEUROSCI, V12, P189, DOI 10.1016/0166-2236(89)90070-2; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LuckenbillEdds L, 1997, BRAIN RES REV, V23, P1, DOI 10.1016/S0165-0173(96)00013-6; MASSIA SP, 1991, J CELL BIOL, V114, P1089, DOI 10.1083/jcb.114.5.1089; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PITTMAN RN, 1989, DEV NEUROSCI-BASEL, V11, P361, DOI 10.1159/000111912; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Schense JC, 1999, BIOCONJUGATE CHEM, V10, P75, DOI 10.1021/bc9800769; SCHMIDT CE, 1995, J NEUROSCI, V15, P3400; SHEA TB, 1992, FEBS LETT, V307, P190, DOI 10.1016/0014-5793(92)80765-9; VARON S, 1972, METHODS TECHNIQUES N, P203; Yamada KM, 1997, MATRIX BIOL, V16, P137, DOI 10.1016/S0945-053X(97)90001-9; YAMADA KM, 1991, J BIOL CHEM, V266, P12809	32	132	133	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6813	6818		10.1074/jbc.275.10.6813	http://dx.doi.org/10.1074/jbc.275.10.6813			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702239	Green Submitted, hybrid, Green Accepted			2022-12-27	WOS:000085809600019
J	Bonnafous, P; Stegmann, T				Bonnafous, P; Stegmann, T			Membrane perturbation and fusion pore formation in influenza hemagglutinin-mediated membrane fusion - A new model for fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL ENVELOPE PROTEIN; PH-DEPENDENT FUSION; CELL-CELL FUSION; VIRUS HEMAGGLUTININ; KINETICS; HEMIFUSION; LIPOSOMES; ASYMMETRY; BILAYERS; MELITTIN	Low pH-induced fusion mediated by the hemagglutinin (HA) of influenza virus involves conformational changes in the protein that lead to the insertion of a "fusion peptide" domain of this protein into the target membrane and is thought to perturb the membrane, triggering fusion, By using whole virus, purified HA, or HA ectodomains, we found that shortly after insertion, pores of less than 26 Angstrom in diameter were formed in liposomal membranes. As measured by a novel assay, these pores stay open, or continue to close and open, for minutes to hours and persist after pH neutralization. With virus and purified HA, larger pores, allowing the leakage of dextrans, were seen at times web after insertion. For virus, dextran leakage was simultaneous with lipid mixing and the formation of "fusion pores," allowing the transfer of dextrans from the liposomal to the viral interior or vice versa, Pores did not form in the viral membrane in the absence of a target membrane. Based on these data, we propose a new model for fusion, in which HA initially forms a proteinaceous pore in the target, but not in the viral membrane, before a lipidic hemifusion intermediate is formed.	Inst Pharmacol & Biol Struct, CNRS, UPR 9062, F-31077 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Stegmann, T (corresponding author), Inst Pharmacol & Biol Struct, CNRS, UPR 9062, 205 Route Narbonne, F-31077 Toulouse, France.	stegmann@ipbs.fr	Bonnafous, Pierre/M-7845-2014					BENTZ J, 1990, FEBS LETT, V276, P1, DOI 10.1016/0014-5793(90)80492-2; BENTZ J, 1992, BIOPHYS J, V63, P448, DOI 10.1016/S0006-3495(92)81622-3; BLUMENTHAL R, 1991, ANN NY ACAD SCI, V635, P285, DOI 10.1111/j.1749-6632.1991.tb36499.x; Blumenthal R, 1996, J CELL BIOL, V135, P63, DOI 10.1083/jcb.135.1.63; BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND CM, 1972, NATURE-NEW BIOL, V238, P145, DOI 10.1038/newbio238145a0; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Chernomordik LV, 1998, J CELL BIOL, V140, P1369, DOI 10.1083/jcb.140.6.1369; Chernomordik LV, 1999, MOL MEMBR BIOL, V16, P33; CHERNOMORDIK LV, 1985, BIOCHIM BIOPHYS ACTA, V812, P643, DOI 10.1016/0005-2736(85)90257-3; CHERNOMORDIK LV, 1995, CURR OPIN STRUC BIOL, V5, P541, DOI 10.1016/0959-440X(95)80041-7; CHERNOMORDIK LV, 1993, FEBS LETT, V318, P71, DOI 10.1016/0014-5793(93)81330-3; Danieli T, 1996, J CELL BIOL, V133, P559, DOI 10.1083/jcb.133.3.559; DOMS RW, 1986, J VIROL, V57, P603, DOI 10.1128/JVI.57.2.603-613.1986; DOMS RW, 1986, J VIROL, V60, P833, DOI 10.1128/JVI.60.3.833-839.1986; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gray C, 1998, PROTEIN SCI, V7, P2359, DOI 10.1002/pro.5560071113; GUNTHERAUSBORN S, 1995, J BIOL CHEM, V270, P29279; HARTER C, 1988, BIOCHEMISTRY-US, V27, P1856, DOI 10.1021/bi00406a010; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; HUGHSON FM, 1995, CURR BIOL, V5, P265, DOI 10.1016/S0960-9822(95)00057-1; Jiricek R, 1997, BBA-BIOMEMBRANES, V1330, P17, DOI 10.1016/S0005-2736(97)00134-X; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; Klotz KH, 1996, J BIOL CHEM, V271, P2383, DOI 10.1074/jbc.271.5.2383; LINDAU M, 1995, CURR OPIN CELL BIOL, V7, P509, DOI 10.1016/0955-0674(95)80007-7; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P12553, DOI 10.1021/bi00039a009; Matsuzaki K, 1997, BIOPHYS J, V73, P831, DOI 10.1016/S0006-3495(97)78115-3; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; NEBEL S, 1995, BIOCHEMISTRY-US, V34, P5705, DOI 10.1021/bi00017a001; NICHOLSON C, 1993, BIOPHYS J, V65, P2277, DOI 10.1016/S0006-3495(93)81324-9; Rex S, 1998, BIOCHEMISTRY-US, V37, P2336, DOI 10.1021/bi971009p; RUIGROK RWH, 1986, EMBO J, V5, P41, DOI 10.1002/j.1460-2075.1986.tb04175.x; SIEGEL DP, 1993, BIOPHYS J, V65, P2124, DOI 10.1016/S0006-3495(93)81256-6; SIEGEL DP, 1993, VIRAL FUSION MECHANI, P475; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; SPRUCE AE, 1991, P NATL ACAD SCI USA, V88, P3623, DOI 10.1073/pnas.88.9.3623; STEGMANN T, 1985, BIOCHEMISTRY-US, V24, P3107, DOI 10.1021/bi00334a006; STEGMANN T, 1995, BIOCHEMISTRY-US, V34, P1825, DOI 10.1021/bi00006a002; STEGMANN T, 1987, EMBO J, V6, P2651, DOI 10.1002/j.1460-2075.1987.tb02556.x; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; STEGMANN T, 1993, VIRAL FUSION MECHANI, P89; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; TATULIAN SA, 1995, EMBO J, V14, P5514, DOI 10.1002/j.1460-2075.1995.tb00238.x; Tong SG, 1996, BIOCHEMISTRY-US, V35, P4956, DOI 10.1021/bi9526903; TSE FW, 1993, J CELL BIOL, V121, P543, DOI 10.1083/jcb.121.3.543; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; ZIMMERBERG J, 1994, J CELL BIOL, V127, P1885, DOI 10.1083/jcb.127.6.1885	51	72	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6160	6166		10.1074/jbc.275.9.6160	http://dx.doi.org/10.1074/jbc.275.9.6160			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692407	hybrid			2022-12-27	WOS:000085654400019
J	Calera, MR; Vallega, G; Pilch, PF				Calera, MR; Vallega, G; Pilch, PF			Dynamics of protein-tyrosine phosphatases in rat adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR KINASE; SIGNAL-TRANSDUCTION; NEGATIVE REGULATOR; GLUCOSE-TRANSPORT; LAR; MICE; DEPHOSPHORYLATION; SUBSTRATE-1; PATHWAY; CELLS	Protein-tyrosine phosphatases (PTPases) play a key role in maintaining the steady-state tyrosine phosphorylation of the insulin receptor (Ht) and its substrate proteins such as insulin receptor substrate 1 (IRS-1), However, the PTPase(s) that inactivate IR and IRS-1 under physiological conditions remain unidentified. Here, we analyze the subcellular distribution in rat adipocytes of several PTPases thought to be involved in the counterregulation of insulin signaling. We found that the transmembrane enzymes, protein-tyrosine phosphatase (PTP)-alpha and leukocyte common antigen-related (ZAR), were detected predominantly in the plasma membrane and to a lesser extent in the heavy microsomes, a distribution similar to that of insulin receptor, PTP-1B and IRS-1 were present in light microsomes and cytosol, whereas SHPTP2/Syp was exclusively cytosolic. Insulin induced a redistribution of PTP-alpha from the plasma membrane to the heavy microsomes in a parallel fashion with the receptor. The distribution of PTP-1B in the light microsomes from resting adipocytes was similar to that of IRS-1 as determined by sucrose velocity gradient fractionation. Analysis of the catalytic activity of partially purified rat adipocyte PTP-alpha and LAR and recombinant PTP-1B showed that all three PTPases dephosphorylate IR When a mix of IR/IRS-1 was used as a substrate, PTP-1B was particularly effective in dephosphorylating IRS-1. Considering that IR and IRS-1 can be dephosphorylated in internal membrane compartments from rat adipocytes (Kublaoui, B., Lee, J., and Pilch, P.F. (1995) J, Biol. Chem. 270, 59-65) and that PTP-alpha. and PTP-1B are the respective PTPases in these fractions, we conclude that these PTPases are responsible for the counterregulation of insulin signaling there, whereas both LAR and PTP-alpha may act upon cell surface insulin receptors.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Pilch, PF (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.			Pilch, Paul/0000-0003-1997-0499	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036424, R01DK030425] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 30425, DK 36424] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad F, 1997, J BIOL CHEM, V272, P448; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Arnott CH, 1999, J BIOL CHEM, V274, P26105, DOI 10.1074/jbc.274.37.26105; BEVAN AP, 1995, J BIOL CHEM, V270, P10784, DOI 10.1074/jbc.270.18.10784; Byon JCH, 1998, MOL CELL BIOCHEM, V182, P101, DOI 10.1023/A:1006868409841; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Chen H, 1997, J BIOL CHEM, V272, P8026, DOI 10.1074/jbc.272.12.8026; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; DING W, 1994, BIOCHEM BIOPH RES CO, V202, P902, DOI 10.1006/bbrc.1994.2015; Drake PG, 1998, MOL CELL BIOCHEM, V182, P79, DOI 10.1023/A:1006808100755; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Goldstein BJ, 1998, MOL CELL BIOCHEM, V182, P91, DOI 10.1023/A:1006812218502; HASHIMOTO N, 1992, J BIOL CHEM, V267, P13811; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KLEIN HH, 1987, J BIOL CHEM, V262, P10557; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; KUHNE MR, 1995, BIOCHEM BIOPH RES CO, V211, P190, DOI 10.1006/bbrc.1995.1795; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; Kummer JL, 1998, BIOCHEM BIOPH RES CO, V246, P282, DOI 10.1006/bbrc.1998.8599; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; LEE JS, 1993, J BIOL CHEM, V268, P4092; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; Liu SCH, 1999, J BIOL CHEM, V274, P18093, DOI 10.1074/jbc.274.25.18093; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; Ren JM, 1998, DIABETES, V47, P493, DOI 10.2337/diabetes.47.3.493; RODBELL M, 1964, J BIOL CHEM, V239, P375; Seely BL, 1996, DIABETES, V45, P1379, DOI 10.2337/diabetes.45.10.1379; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Weng LP, 1998, CURR BIOL, V8, P247, DOI 10.1016/S0960-9822(98)70106-X; WHITE MF, 1994, J BIOL CHEM, V269, P1; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Zhang WR, 1996, MOL ENDOCRINOL, V10, P575, DOI 10.1210/me.10.5.575	46	79	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6308	6312		10.1074/jbc.275.9.6308	http://dx.doi.org/10.1074/jbc.275.9.6308			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692429	hybrid			2022-12-27	WOS:000085654400041
J	Yoshimura, H; Hisabori, T; Yanagisawa, S; Ohmori, M				Yoshimura, H; Hisabori, T; Yanagisawa, S; Ohmori, M			Identification and characterization of a novel cAMP receptor protein in the cyanobacterium Synechocystis sp PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE ACTIVATOR PROTEIN; ESCHERICHIA-COLI; CYCLIC-AMP; ANABAENA-CYLINDRICA; BINDING; COMPLEX; DNA; ENZYMES; SIGNAL; KINASE	Three open reading frames of Synechocystis sp. PCC 6803 encoding a domain homologous with the cAMP binding domain of bacterial cAMP receptor protein were analyzed. These three open reading frames, sll1371, sll1924, and slr0593, which were named sycrp1, sycrp2, and sypk, respectively, were expressed in Escherichia coli as His tagged or glutathione S-transferase fusion proteins and purified, and their biochemical properties were investigated. The results obtained for equilibrium dialysis measurements using these recombinant proteins suggest that SYCRP1 and SYPK show it binding affinity for cAMP while SYCRP2 does not. The dissociation constant of His-tagged SYCRP1 for cAMP is approximately 3 mu M. A cross-linking experiment using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide revealed that His-tagged SYCRP1 forms a homodimer, and the presence or absence of cAMP does not affect the formation of the homodimer. The amino acid sequence reveals that SYCRP1 has a domain similar to the DNA binding domain of bacterial cAMP receptor protein in the COOH-terminal region. Consistent with this, His-tagged SYCRP1 forms a complex with DNA that contains the consensus sequence for E. coli cAMP receptor protein in the presence of cAMP. These results strongly suggest that SYCRP1 is a novel cAMP receptor protein.	Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Tokyo 1538902, Japan; Tokyo Inst Technol, Resources Utilizat Res Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan	University of Tokyo; Tokyo Institute of Technology	Ohmori, M (corresponding author), Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Tokyo 1538902, Japan.	cohmori@mail.ecc.u-tokyo.ac.jp	Hisabori, Toru/E-5205-2014	Hisabori, Toru/0000-0003-2046-0277				BOTSFORD JL, 1981, MICROBIOL REV, V45, P620, DOI 10.1128/MMBR.45.4.620-642.1981; BOTSFORD JL, 1992, MICROBIOL REV, V56, P100, DOI 10.1128/MMBR.56.1.100-122.1992; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN AM, 1989, P NATL ACAD SCI USA, V86, P7387, DOI 10.1073/pnas.86.19.7387; CARRE IA, 1993, J CELL SCI, V104, P1163; CHEN PF, 1985, ARCH BIOCHEM BIOPHYS, V241, P425, DOI 10.1016/0003-9861(85)90566-1; HANAMURA A, 1991, NUCLEIC ACIDS RES, V19, P4413, DOI 10.1093/nar/19.16.4413; HEYDUK T, 1989, BIOCHEMISTRY-US, V28, P6914, DOI 10.1021/bi00443a021; HISABORI T, 1984, PLANT CELL PHYSIOL, V25, P483; HOOD EE, 1979, BIOCHIM BIOPHYS ACTA, V588, P193, DOI 10.1016/0304-4165(79)90202-2; Kaneko T, 1996, DNA Res, V3, P109; Kiriyama H, 1999, FEBS LETT, V450, P95, DOI 10.1016/S0014-5793(99)00472-X; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKMAN RS, 1965, J BIOL CHEM, V240, P1309; MORI K, 1985, J BIOL CHEM, V260, P4838; OHMORI K, 1992, PLANT CELL PHYSIOL, V33, P21; OHMORI M, 1989, PLANT CELL PHYSIOL, V30, P911, DOI 10.1093/oxfordjournals.pcp.a077824; OHMORI M, 1988, ARCH MICROBIOL, V150, P203, DOI 10.1007/BF00425163; PASTAN I, 1970, SCIENCE, V169, P339, DOI 10.1126/science.169.3943.339; QUARMBY LM, 1994, PLANT MOL BIOL, V26, P1271, DOI 10.1007/BF00016474; REN YL, 1990, NUCLEIC ACIDS RES, V18, P5127, DOI 10.1093/nar/18.17.5127; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; TAKAHASHI M, 1980, BIOCHEMISTRY-US, V19, P5124, DOI 10.1021/bi00563a029; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TAYLOR SS, 1988, FASEB J, V2, P2677, DOI 10.1096/fasebj.2.11.3294077; Terauchi K, 1999, PLANT CELL PHYSIOL, V40, P248, DOI 10.1093/oxfordjournals.pcp.a029534; ValentinHansen P, 1996, MOL MICROBIOL, V20, P461, DOI 10.1046/j.1365-2958.1996.5341056.x; VANEY MC, 1989, BIOCHEMISTRY-US, V28, P4568, DOI 10.1021/bi00437a010; WEBER IT, 1984, P NATL ACAD SCI-BIOL, V81, P3973, DOI 10.1073/pnas.81.13.3973; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9	32	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6241	6245		10.1074/jbc.275.9.6241	http://dx.doi.org/10.1074/jbc.275.9.6241			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692419	hybrid			2022-12-27	WOS:000085654400031
J	Abu-Soud, HM; Hazen, SL				Abu-Soud, HM; Hazen, SL			Nitric oxide modulates the catalytic activity of myeloperoxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHILS EMPLOY; RAY CRYSTAL-STRUCTURE; HYDROGEN-PEROXIDE; ANTIMICROBIAL ACTIVITY; CHLORINATING ACTIVITY; ANGSTROM RESOLUTION; HYPOCHLOROUS ACID; RELAXING FACTOR; HEME-PROTEINS; COMPOUND-I	Myeloperoxidase (MPO), an abundant protein in neutrophils, monocytes, and subpopulations of tissue macrophages, is believed to play a critical role in host defenses and inflammatory tissue injury. To perform these functions, an array of diffusible radicals and reactive oxidant species may be formed through oxidation reactions catalyzed at the heme center of the enzyme. Myeloperoxidase and inducible nitric-oxide synthase are both stored in and secreted from the primary granules of activated leukocytes, and nitric oxide (nitrogen monoxide; NO) reacts with the iron center of hemeproteins at near diffusion-controlled rates. We now demonstrate that NO modulates the catalytic activity of MPO through distinct mechanisms. NO binds to both ferric (Fe(III), the catalytically active species) and ferrous (Fe(II)) forms of MPO, generating stable low-spin six-coordinate complexes, MPO-Fe(III) NO and MPO-Fe(II) NO, respectively. These nitrosyl complexes were spectrally distinguishable by their Soret absorbance peak and visible spectra, Stopped-flow kinetic analyses indicated that NO binds reversibly to both Pe(III) and Fe(II) forms of MPO through simple one-step mechanisms. The association rate constant for NO binding to MPO-Fe(III) was comparable to that observed with other hemoproteins whose activities are thought to be modulated by NO in vivo. In stark contrast, the association rate constant for NO binding to the reduced form of MPO, MPO-Fe(II), was over an order of magnitude slower, Similarly, a a-fold decrease was observed in the NO dissociation rate constant of the reduced versus native form of MPO. The lower NO association and dissociation rates observed suggest a remarkable conformational change that alters the affinity and accessibility of NO to the distal heme pocket of the enzyme following heme reduction. Incubation of NO with the active species of MPO (Fe(III) form) influenced peroxidase catalytic activity by dual mechanisms. Low levels of NO enhanced peroxidase activity through an effect on the rate-limiting step in catalysis, reduction of Compound II to the ground-state Fe(III) form. In contrast, higher levels of NO inhibited MPO catalysis through formation of the nitrosyl complex MPO-Fe(III)-NO. NO interaction with MPO may thus serve as a novel mechanism for modulating peroxidase catalytic activity, influencing the regulation of local inflammatory and infectious events in vivo.	Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Ohio; Cleveland State University	Abu-Soud, HM (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, 9500 Euclid Ave,NC-10, Cleveland, OH 44195 USA.	abusouh@ccf.org; hazens@ccf.org	Hazen, Stanley L/ABD-5845-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061878, R01HL062526] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61878, HL62526] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; AGNER K, 1941, ACTA PHYSIOL SCAND S, V2, P8; Agner K., 1972, STRUCTURE FUNCTION O, P329; Aratani Y, 1999, INFECT IMMUN, V67, P1828; Arnold EV, 1996, METHOD ENZYMOL, V269, P41; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V784, P189, DOI 10.1016/0167-4838(84)90127-4; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V788, P1, DOI 10.1016/0167-4838(84)90290-5; CASTRO L, 1994, J BIOL CHEM, V269, P29409; Cooper CE, 1999, BBA-BIOENERGETICS, V1411, P290, DOI 10.1016/S0005-2728(99)00021-3; Davey CA, 1996, BIOCHEMISTRY-US, V35, P10967, DOI 10.1021/bi960577m; DUGAD LB, 1990, J BIOL CHEM, V265, P7173; EDWARDS SL, 1988, BIOCHEMISTRY-US, V27, P8074, DOI 10.1021/bi00421a016; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; Evans TJ, 1996, P NATL ACAD SCI USA, V93, P9553, DOI 10.1073/pnas.93.18.9553; Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473; Freeman B A, 1995, Adv Pharmacol, V34, P45; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Harutyunyan EH, 1996, J MOL BIOL, V264, P152, DOI 10.1006/jmbi.1996.0630; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1997, J BIOL CHEM, V272, P16990, DOI 10.1074/jbc.272.27.16990; Hazen SL, 1998, J BIOL CHEM, V273, P4997, DOI 10.1074/jbc.273.9.4997; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; HURSHMAN AR, 1995, BIOCHEMISTRY-US, V34, P5627, DOI 10.1021/bi00016a038; HURST JK, 1991, PEROXIDASES CHEM BIO, P37; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; Kettle AJ, 1997, BIOCHEM J, V321, P503, DOI 10.1042/bj3210503; KETTLE AJ, 1991, BIOCHEM PHARMACOL, V41, P1485, DOI 10.1016/0006-2952(91)90565-M; KETTLE AJ, 1988, BIOCHEM J, V252, P529, DOI 10.1042/bj2520529; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; KETTLE AJ, 1988, BIOCHIM BIOPHYS ACTA, V956, P58, DOI 10.1016/0167-4838(88)90297-X; KLEBANOFF SJ, 1984, METHOD ENZYMOL, V105, P399; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTION, P1; LEE HC, 1991, BIOCHIM BIOPHYS ACTA, V1076, P317, DOI 10.1016/0167-4838(91)90285-8; London SJ, 1997, CANCER RES, V57, P5001; Marquez LA, 1995, J BIOL CHEM, V270, P30434, DOI 10.1074/jbc.270.51.30434; MONCADA S, 1991, PHARMACOL REV, V43, P109; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; NAUSEEF WM, 1986, BLOOD, V67, P1504; Nauseef WM, 1998, J MOL MED-JMM, V76, P661, DOI 10.1007/s001090050265; Nauseef WM, 1996, J BIOL CHEM, V271, P9546, DOI 10.1074/jbc.271.16.9546; NEWTON N, 1965, BIOCHIM BIOPHYS ACTA, V96, P476, DOI 10.1016/0005-2787(65)90564-2; ODAJIMA T, 1970, BIOCHIM BIOPHYS ACTA, V206, P71, DOI 10.1016/0005-2744(70)90083-5; OKEEFFE DH, 1978, J BIOL CHEM, V253, P3509; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Radi R, 1996, CHEM RES TOXICOL, V9, P828, DOI 10.1021/tx950176s; Reynolds WF, 1999, EXP NEUROL, V155, P31, DOI 10.1006/exnr.1998.6977; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SHARMA VS, 1983, BIOCHEMISTRY-US, V22, P3897, DOI 10.1021/bi00285a026; SHARMA VS, 1987, BIOCHEMISTRY-US, V26, P3837, DOI 10.1021/bi00387a015; SHIRO Y, 1995, J BIOL CHEM, V270, P1617, DOI 10.1074/jbc.270.4.1617; TAYLOR KL, 1995, ARCH BIOCHEM BIOPHYS, V316, P635, DOI 10.1006/abbi.1995.1083; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; VANDERWALT BJ, 1994, BIOCHEM PHARMACOL, V47, P1039, DOI 10.1016/0006-2952(94)90415-4; VINCENT SR, 1994, PROG NEUROBIOL, V42, P129, DOI 10.1016/0301-0082(94)90023-X; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WEVER R, 1982, BIOCHIM BIOPHYS ACTA, V709, P212, DOI 10.1016/0167-4838(82)90463-0; WINK DA, 1993, ARCH BIOCHEM BIOPHYS, V300, P115, DOI 10.1006/abbi.1993.1016; Wu WJ, 1999, J BIOL CHEM, V274, P25933, DOI 10.1074/jbc.274.36.25933; YONETANI T, 1972, J BIOL CHEM, V247, P2447; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	67	154	160	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5425	5430		10.1074/jbc.275.8.5425	http://dx.doi.org/10.1074/jbc.275.8.5425			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681518	hybrid			2022-12-27	WOS:000085474500025
J	Crosson, SM; Roesler, WJ				Crosson, SM; Roesler, WJ			Hormonal regulation of the phosphoenolpyruvate carboxykinase gene - Role of specific CCAAT/enhancer-binding protein isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C/EBP-ALPHA GENE; THYROID-HORMONE; GTP GENE; RESPONSE ELEMENT; HEPATOMA-CELLS; RAT-LIVER; TRANSCRIPTION; PROMOTER; EXPRESSION; AUTOREGULATION	The CCAAT/enhancer-binding protein alpha (C/EBP) is a transcription factor that trans-activates a number of metabolically important genes. Previous work has demonstrated that C/EBP alpha and C/EBP beta have the potential to mediate the cAMP responsiveness of phosphoenolpyruvate carboxykinase (PEPCK) in liver cells. However, these studies used GAL4 fusion proteins and artificial promoter-reporter gene vectors in transfection experiments; as a result, these studies only indicated that both isoforms had the potential to mediate the hormonal response and not which isoform actually participated in vivo. To address this issue, Fee produced hepatoma cell lines that stably expressed either a dominant negative inhibitor or antisense RNA for these two main liver C/EBP isoforms, Inhibition of all C/EBP isoforms via expression of the dominant negative protein eliminated cAMP responsiveness, and reduced glucocorticoid responsiveness, of the endogenous PEPCK gene in hepatoma cells. Antisense directed against C/EBP alpha mRNA, which reduced C/EBP alpha protein levels by nearly 80%, also significantly reduced the cAMP responsiveness of the endogenous PEPCK promoter, whereas antisense directed against C/EBP beta was without effect. There was no major alteration in cAMP signaling in the C/EBP alpha antisense cells, as cAMP induction of the C/EBP beta gene was similar to that in wild-type H4IIE cells. These data suggest that the alpha-isoform of C/EBP is specifically utilized for mediating the cAMP responsiveness of the PEPCK gene.	Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan	Roesler, WJ (corresponding author), Univ Saskatchewan, Dept Biochem, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.							ALAM T, 1992, J BIOL CHEM, V267, P5021; ALLEYNE GAO, 1969, J CLIN INVEST, V48, P364, DOI 10.1172/JCI105993; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Crosson SM, 1997, DIABETOLOGIA, V40, P1117, DOI 10.1007/s001250050796; DAVIES GF, 1995, ARCH BIOCHEM BIOPHYS, V323, P477, DOI 10.1006/abbi.1995.0070; Davies GF, 1999, BBA-MOL CELL RES, V1451, P122, DOI 10.1016/S0167-4889(99)00080-4; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GIRALT M, 1991, J BIOL CHEM, V266, P21991; Hanson R W, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P203; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; KATZ RA, 1983, BIOCHIM BIOPHYS ACTA, V73, P9258; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; LEGRAVEREND C, 1993, NUCLEIC ACIDS RES, V21, P1735, DOI 10.1093/nar/21.8.1735; Liu S, 1999, J CLIN INVEST, V103, P207, DOI 10.1172/JCI4243; LOOSE DS, 1985, BIOCHEMISTRY-US, V24, P4509, DOI 10.1021/bi00338a004; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; Olive M, 1996, J BIOL CHEM, V271, P2040, DOI 10.1074/jbc.271.4.2040; Park EA, 1999, J BIOL CHEM, V274, P211, DOI 10.1074/jbc.274.1.211; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; Roesler WJ, 1998, J BIOL CHEM, V273, P14950, DOI 10.1074/jbc.273.24.14950; ROESLER WJ, 1994, J BIOL CHEM, V269, P14276; ROGNSTAD R, 1979, J BIOL CHEM, V254, P1875; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; SCHMIDT EDL, 1993, BIOCHIM BIOPHYS ACTA, V1172, P82, DOI 10.1016/0167-4781(93)90272-F; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; TILGHMAN S M, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1304, DOI 10.1073/pnas.71.4.1304; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880; Yeagley D, 1998, J BIOL CHEM, V273, P18743, DOI 10.1074/jbc.273.30.18743	36	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5804	5809		10.1074/jbc.275.8.5804	http://dx.doi.org/10.1074/jbc.275.8.5804			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681569	hybrid			2022-12-27	WOS:000085474500076
J	Nelson, LD; Musso, M; Van Dyke, MW				Nelson, LD; Musso, M; Van Dyke, MW			The yeast STM1 gene encodes a purine motif triple helical DNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUADRUPLEX NUCLEIC-ACIDS; SACCHAROMYCES-CEREVISIAE; GAGA FACTOR; HUMAN-CELLS; TRANSCRIPTIONAL REGULATION; QUARTET STRUCTURES; BUDDING YEAST; REPLICATION; DROSOPHILA; SEQUENCES	The formation of triple helical DNA has been evoked in several cellular processes including transcription, replication, and recombination. Using conventional and affinity chromatography, we purified from Saccharomyces cerevisiae whole-cell extract a 35-kDa protein that avidly and specifically bound a purine motif tripler (with a K-d of 61 pM) but not a pyrimidine motif triplex or duplex DNA. Peptide microsequencing identified this protein as the product of the STM1 gene. Confirmation that Stm1p is a purine motif tripler-binding protein was obtained by electrophoretic mobility shift assays using either bacterially expressed, recombinant Stm1p or whole-cell extracts from stm1 Delta yeast. Stm1p has previously been identified as G4p2, a G-quartet nucleic acid-binding protein. This suggests that some proteins actually recognize features shared by G4 DNA and purine motif triplexes, e.g. Hoogsteen hydrogen-bonded guanines. Genetically, the STM1 gene has been identified as a multicopy suppressor of mutations in several genes involved in mitosis (e.g. TOM1, MPT5, and POP2). A possible role for multiplex DNA and its binding proteins in mitosis is discussed.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Van Dyke, MW (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Van Dyke, Michael W./AAY-6751-2020	Van Dyke, Michael W./0000-0003-0306-4002				Agazie YM, 1996, BIOCHEM J, V316, P461, DOI 10.1042/bj3160461; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARAN N, 1991, P NATL ACAD SCI USA, V88, P507, DOI 10.1073/pnas.88.2.507; BEAL PA, 1992, NUCLEIC ACIDS RES, V20, P2773, DOI 10.1093/nar/20.11.2773; BEHE MJ, 1995, NUCLEIC ACIDS RES, V23, P689, DOI 10.1093/nar/23.4.689; Bhat KM, 1996, DEVELOPMENT, V122, P1113; BIANCHI A, 1990, J BIOL CHEM, V265, P21789; Boulikas T, 1996, J CELL BIOCHEM, V60, P297, DOI 10.1002/(SICI)1097-4644(19960301)60:3<297::AID-JCB2>3.0.CO;2-R; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; BURKHOLDER GD, 1988, CHROMOSOMA, V97, P185, DOI 10.1007/BF00292959; BURKHOLDER GD, 1991, CHROMOSOMA, V101, P11, DOI 10.1007/BF00360681; Chen S, 1997, MOL ENDOCRINOL, V11, P3, DOI 10.1210/me.11.1.3; Cheng AJ, 1997, GENE, V197, P253, DOI 10.1016/S0378-1119(97)00269-2; Cheng AJ, 1998, ANTISENSE NUCLEIC A, V8, P215, DOI 10.1089/oli.1.1998.8.215; CHENG AJ, 1993, NUCLEIC ACIDS RES, V21, P5630, DOI 10.1093/nar/21.24.5630; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; COTTRELLE P, 1985, J BIOL CHEM, V260, P3090; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DUNN B, 1990, CURRENT PROTOCOLS MO; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; Foreman PK, 1996, GENETICS, V144, P1387; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; FRANTZ JD, 1995, J BIOL CHEM, V270, P9413, DOI 10.1074/jbc.270.16.9413; FRANTZ JD, 1995, J BIOL CHEM, V270, P20692, DOI 10.1074/jbc.270.35.20692; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; Guieysse AL, 1997, J MOL BIOL, V267, P289, DOI 10.1006/jmbi.1997.0884; Hata H, 1998, GENETICS, V148, P571; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; Hodges PE, 1999, NUCLEIC ACIDS RES, V27, P69, DOI 10.1093/nar/27.1.69; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; Jimenez-Garcia E, 1998, J BIOL CHEM, V273, P24640, DOI 10.1074/jbc.273.38.24640; KIKUCHI Y, 1994, MOL GEN GENET, V245, P107, DOI 10.1007/BF00279756; KIYAMA R, 1991, P NATL ACAD SCI USA, V88, P10450, DOI 10.1073/pnas.88.23.10450; Koch C, 1999, NUCLEIC ACIDS RES, V27, P2126, DOI 10.1093/nar/27.10.2126; KOHWI Y, 1993, GENE DEV, V7, P1766, DOI 10.1101/gad.7.9.1766; KOHWI Y, 1991, GENE DEV, V5, P2547, DOI 10.1101/gad.5.12b.2547; Lavasani S, 1998, J AUTOIMMUN, V11, P363, DOI 10.1006/jaut.1998.0211; Liu HY, 1997, EMBO J, V16, P5289, DOI 10.1093/emboj/16.17.5289; LIU ZP, 1993, P NATL ACAD SCI USA, V90, P3157, DOI 10.1073/pnas.90.8.3157; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; MAIDAK BL, 1994, NUCLEIC ACIDS RES, V22, P3485, DOI 10.1093/nar/22.17.3485; Meluh PB, 1997, GENE DEV, V11, P3401, DOI 10.1101/gad.11.24.3401; Musso M, 1996, NUCLEIC ACIDS RES, V24, P4924, DOI 10.1093/nar/24.24.4924; MUSSO M, 1995, NUCLEIC ACIDS RES, V23, P2320, DOI 10.1093/nar/23.12.2320; Musso M, 1998, BIOCHEMISTRY-US, V37, P3086, DOI 10.1021/bi9717486; Platero JS, 1998, J CELL BIOL, V140, P1297; POTAMAN VN, 1995, BIOCHEMISTRY-US, V34, P14885, DOI 10.1021/bi00045a033; Potaman VN, 1998, BIOCHEMISTRY-US, V37, P12952, DOI 10.1021/bi972510k; ROONEY SM, 1995, P NATL ACAD SCI USA, V92, P2141, DOI 10.1073/pnas.92.6.2141; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; Saleh A, 1998, J MOL BIOL, V282, P933, DOI 10.1006/jmbi.1998.2036; SANCAR GB, 1995, NUCLEIC ACIDS RES, V23, P4320, DOI 10.1093/nar/23.21.4320; SAWADOGO M, 1991, NUCLEIC ACIDS RES, V19, P674, DOI 10.1093/nar/19.3.674; SEN D, 1992, METHOD ENZYMOL, V211, P191; Shi XM, 1996, MOL CELL BIOL, V16, P669; Simos G, 1996, EMBO J, V15, P5437, DOI 10.1002/j.1460-2075.1996.tb00927.x; Sinclair D, 1998, ANNU REV MICROBIOL, V52, P533, DOI 10.1146/annurev.micro.52.1.533; SINGLETON SF, 1992, BIOCHEMISTRY-US, V31, P10995, DOI 10.1021/bi00160a008; UTSUGI T, 1995, BBA-GENE STRUCT EXPR, V1263, P285, DOI 10.1016/0167-4781(95)00123-X; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; Wilkins RC, 1997, NUCLEIC ACIDS RES, V25, P3963, DOI 10.1093/nar/25.20.3963; WILLIAMSON JR, 1994, ANNU REV BIOPH BIOM, V23, P703, DOI 10.1146/annurev.bb.23.060194.003415; Zhu J, 1999, BIOINFORMATICS, V15, P607, DOI 10.1093/bioinformatics/15.7.607	69	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5573	5581		10.1074/jbc.275.8.5573	http://dx.doi.org/10.1074/jbc.275.8.5573			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681538	hybrid			2022-12-27	WOS:000085474500045
J	Philip, A; Roux, P; Coulon, V; Bellanger, JM; Vie, A; Vignais, ML; Blanchard, JM				Philip, A; Roux, P; Coulon, V; Bellanger, JM; Vie, A; Vignais, ML; Blanchard, JM			Differential effect of Rac and Cdc42 on p38 kinase activity and cell cycle progression of nonadherent primary mouse fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; MAP KINASE; ACTIN POLYMERIZATION; PROTEIN-KINASES; RHO-GTPASES; ACTIVATION; TRANSFORMATION; ADHESION; CYTOSKELETON; EXPRESSION	The Rho GTPases play an important role in transducing signals linking plasma membrane receptors to the organization of the cytoskeleton and also regulate gene transcription. Here, we show that expression of constitutively active Ras or Cdc42, but not RhoA, RhoG;, and Rad, is sufficient to cause anchorage-independent cell cycle progression of mouse embryonic fibroblasts, However, in anchorage free conditions, whereas activation of either Cdc42 or Ras results in cyclin A transcription and cell cycle progression, Cdc42 is not required for Ras-mediated cyclin A induction, and the two proteins act in a synergistic manner in this process. Surprisingly, the ability of Cdc42 to induce p38 MAPK activity-in suspended mouse embryonic fibroblast was impaired. Moreover, inhibition of p38 activity allowed Rad to induce: anchorage-independent cyclin A transcription, indicating that p38 MAPK has an inhibitory function on cell cycle progression of primary fibroblasts. Finally, a Rac mutant, which is unable to induce lamellipodia and focal complex formation, promoted cyclin A transcription in the presence of SB203580, suggesting that the organization of the cytoskeleton is not required for anchorage-independent proliferation. This demonstrates a novel function for Cdc42, distinct from that of Rad, in the control of cell proliferation.	CNRS, UMR 5535, Inst Mol Genet, F-34293 Montpellier 5, France; CNRS, UPR 1086, Ctr Rech Biochim Macromol, F-34293 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Philip, A (corresponding author), CNRS, UMR 5535, Inst Mol Genet, IFR 24, F-34293 Montpellier 5, France.		Vignais, Marie Luce/D-5144-2017; Bellanger, Jean-Michel/S-2103-2019; Bellanger, Jean-Michel/D-1579-2017; Coulon, Vincent/B-2437-2009; PHILIPS, Alexandre/AAB-6047-2020; Coulon, Vincent/AFF-7934-2022; Roux, Pierre/D-8833-2017	Vignais, Marie Luce/0000-0002-0183-5953; Bellanger, Jean-Michel/0000-0001-9289-2349; Coulon, Vincent/0000-0002-3168-8755; Coulon, Vincent/0000-0002-3168-8755; 				Allen WE, 1997, J CELL SCI, V110, P707; Aspenstrom P, 1999, EXP CELL RES, V246, P20, DOI 10.1006/excr.1998.4300; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Le Gall M, 1998, ONCOGENE, V17, P1271, DOI 10.1038/sj.onc.1202057; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; OHagan RC, 1996, ONCOGENE, V13, P1323; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Philips A, 1999, ONCOGENE, V18, P1819, DOI 10.1038/sj.onc.1202530; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Schulze A, 1996, MOL CELL BIOL, V16, P4632; SYMONS M, 1995, CURR OPIN BIOTECH, V6, P668, DOI 10.1016/0958-1669(95)80110-3; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	43	51	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5911	5917		10.1074/jbc.275.8.5911	http://dx.doi.org/10.1074/jbc.275.8.5911			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681583	hybrid, Green Published			2022-12-27	WOS:000085474500090
J	Sorensen, TLM; Dupont, Y; Vilsen, B; Andersen, JP				Sorensen, TLM; Dupont, Y; Vilsen, B; Andersen, JP			Fast kinetic analysis of conformational changes in mutants of the Ca2+-ATPase of sarcoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; FUNCTIONAL CONSEQUENCES; ADENOSINE-TRIPHOSPHATASE; CA2+ BINDING; TRANSIENT KINETICS; CALCIUM-BINDING; ATPASE; TRANSPORT; PHOSPHORYLATION; MECHANISM	Rapid quench experiments at 25 degrees C were carried out on selected mutants of the sarco(endo)plasmic reticulum Ca2+-ATPase to assess the kinetics of the conformational changes of the dephosphoenzyme associated with ATP binding/phosphoryl transfer and the binding and dissociation of Ca2+ at the cytoplasmically facing transport sites. The mutants Gly(233) --> Glu, Gly(233) --> Val, Pro(312) --> Ala, Leu(319) --> Arg, and Lys(684) --> Arg differed conspicuously with respect to the behavior of the dephosphoenzyme, although they were previously shown to display a common block of the transformation of the phosphoenzyme from an ADP-sensitive to an ADP-insensitive form. The maximum rate of the ATP binding/phosphoryl transfer reaction was reduced 3.6-fold in mutant Gly(233) --> Glu and more than 50-fold in mutant Lys(684) --> Arg, relative to wild type, In mutant Leu(319) --> Arg, the rate of the Ca2+-binding transition was reduced as much as 10-30-fold depending on the presence of ATP. In mutants Gly(233),Glu, Gly(233), Val and pro(312) --> Ala, the rate of the Ca2+-binding transition was increased at least 2-3-fold at acid pH but not significantly at neutral pH, suggesting a destabilization of the protonated form. The rate of Ca2+ dissociation peas reduced is-fold in mutant pro(312) --> Ala and 3.5-fold in Leu(319) --> Arg, and increased at least 4-fold in a mutant in which the putative Ca2+ liganding residue Glu(309) was replaced by aspartate. The data support a model in which pro(312) and Leu(319) are closely associated with the cation binding pocket, Gly(233) is part of a long-range signal transmission pathway between the ion-binding sites and the catalytic site, and Lys(684) is an essential catalytic residue that may function in the same way as its counterpart in the soluble hydrolases belonging to the haloacid dehalogenase superfamily.	Aarhus Univ, Dept Physiol, DK-8000 Aarhus C, Denmark; Ctr Etud Nucl Grenoble, Lab Biophys Mol & Cellulaire, F-38054 Grenoble, France	Aarhus University; CEA	Andersen, JP (corresponding author), Aarhus Univ, Dept Physiol, Ole Worms Alle 160, DK-8000 Aarhus C, Denmark.	jpa@fi.au.dk	Sørensen, Thomas Lykke-Møller/AAA-7052-2020	Sorensen, Thomas Lykke-Moller/0000-0003-3873-3499; Andersen, Jens Peter/0000-0003-0654-4300; Vilsen, Bente/0000-0002-4727-9382				Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; Andersen JP, 1998, TRENDS CARDIOVAS MED, V8, P41, DOI 10.1016/S1050-1738(97)00121-7; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; BERGER RL, 1968, REV SCI INSTRUM, V39, P493, DOI 10.1063/1.1683415; Chen HC, 1997, J PHYS IV, V7, P27, DOI 10.1051/jp4:1997307; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DUPONT Y, 1978, NATURE, V273, P396, DOI 10.1038/273396a0; FORGE V, 1993, J BIOL CHEM, V268, P10953; FORGE V, 1993, J BIOL CHEM, V268, P10961; FROEHLICH JP, 1975, J BIOL CHEM, V250, P2013; FUJIMORI T, 1992, J BIOL CHEM, V267, P18466; GUILLAIN F, 1981, J BIOL CHEM, V256, P6140; Gutfreund H, 1995, KINETICS LIFE SCI; IKEMOTO N, 1981, J BIOL CHEM, V256, P8593; INESI G, 1988, METHOD ENZYMOL, V157, P154; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; JORGENSEN PL, 1985, BIOCHIM BIOPHYS ACTA, V821, P319, DOI 10.1016/0005-2736(85)90102-6; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Mintz E, 1997, BBA-BIOENERGETICS, V1318, P52, DOI 10.1016/S0005-2728(96)00132-6; MINTZ E, 1995, J BIOL CHEM, V270, P27160, DOI 10.1074/jbc.270.45.27160; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; PICK U, 1982, J BIOL CHEM, V257, P6120; RAUCH B, 1978, FEBS LETT, V93, P65, DOI 10.1016/0014-5793(78)80806-0; Ridder IS, 1999, BIOCHEM J, V339, P223, DOI 10.1042/0264-6021:3390223; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; Sorensen T, 1997, J BIOL CHEM, V272, P30244, DOI 10.1074/jbc.272.48.30244; SUMIDA M, 1978, J BIOL CHEM, V253, P8772; TAKISAWA H, 1978, J BIOCHEM-TOKYO, V83, P1275, DOI 10.1093/oxfordjournals.jbchem.a132034; TANFORD C, 1987, P NATL ACAD SCI USA, V84, P7094, DOI 10.1073/pnas.84.20.7094; VILSEN B, 1991, J BIOL CHEM, V266, P16157; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1995, ACTA PHYSIOL SCAND, V154, P1; VILSEN B, 1991, J BIOL CHEM, V266, P18839; VILSEN B, 1989, J BIOL CHEM, V264, P21024	35	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5400	5408		10.1074/jbc.275.8.5400	http://dx.doi.org/10.1074/jbc.275.8.5400			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681515	hybrid			2022-12-27	WOS:000085474500022
J	Patel, H; Margossian, SS; Chantler, PD				Patel, H; Margossian, SS; Chantler, PD			Locking regulatory myosin in the off-state with trifluoperazine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESSENTIAL LIGHT-CHAIN; SMOOTH-MUSCLE MYOSIN; SCALLOP MYOSIN; CRYSTAL-STRUCTURE; PEPTIDE COMPLEX; ATPASE ACTIVITY; MOTOR DOMAIN; BINDING; CALMODULIN; FRAGMENTS	Scallop striated adductor muscle myosin is a regulatory myosin, its activity being controlled directly through calcium binding. Here, we show that millimolar concentrations of trifluoperazine were effective at removal of all regulatory light chains from scallop myosin or myofibrils, More important, 200 mu M trifluoperazine, a concentration 10-fold less than that required for light-chain removal, resulted in the reversible elimination of actin-activated and intrinsic ATPase activities. Unlike desensitization induced by metal ion chelation, which leads to an elevation of activity in the absence of calcium concurrent with regulatory light-chain removal, trifluoperazine caused a decline in actin-activated MgATPase activity both in the presence and absence of calcium. Procedures were equally effective with respect to scallop myosin, myofibrils, subfragment-1, or desensitized myofibrils, Increased cu-helicity could be induced in the isolated essential light chain through addition of 100-200 mu M trifluoperazine, We propose that micromolar concentrations of trifluoperazine disrupt regulation by binding to a single high-affinity site located in the C-terminal domain of the essential light chain, which locks scallop myosin in a conformation resembling the off-state. At millimolar trifluoperazine concentrations, additional binding sites on both light chains would be filled, leading to regulatory light-chain displacement.	Univ London Royal Vet Coll, Unit Mol & Cellular Biol, London NW1 0TU, England	University of London; University of London Royal Veterinary College	Chantler, PD (corresponding author), Univ London Royal Vet Coll, Unit Mol & Cellular Biol, Royal Coll St, London NW1 0TU, England.							ASHIBA G, 1985, BIOCHEMISTRY-US, V24, P6618, DOI 10.1021/bi00344a048; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANTLER PD, 1978, BIOCHEMISTRY-US, V17, P5440, DOI 10.1021/bi00618a018; CHANTLER PD, 1981, BIOCHEMISTRY-US, V20, P210, DOI 10.1021/bi00504a035; CHANTLER PD, 1980, J MOL BIOL, V138, P473, DOI 10.1016/S0022-2836(80)80013-1; CHANTLER PD, 1985, J MOL BIOL, V181, P557, DOI 10.1016/0022-2836(85)90428-0; CHANTLER PD, 1986, J MOL BIOL, V192, P87, DOI 10.1016/0022-2836(86)90466-3; COOK WJ, 1994, BIOCHEMISTRY-US, V33, P15259, DOI 10.1021/bi00255a006; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; FROMHERZ S, 1995, P NATL ACAD SCI USA, V92, P7652, DOI 10.1073/pnas.92.17.7652; GOODWIN EB, 1990, J MOL BIOL, V216, P85, DOI 10.1016/S0022-2836(05)80062-2; HOUDUSSE A, 1995, P NATL ACAD SCI USA, V92, P10644, DOI 10.1073/pnas.92.23.10644; Houdusse A, 1996, STRUCTURE, V4, P21, DOI 10.1016/S0969-2126(96)00006-8; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; Huang W, 1998, EUR J BIOCHEM, V257, P457, DOI 10.1046/j.1432-1327.1998.2570457.x; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JACKSON AP, 1988, BIOCHEM J, V251, P515, DOI 10.1042/bj2510515; JANES D, 1999, J MUSCLE RES CELL M, V20, P80; Kalabokis VN, 1997, BIOCHEMISTRY-US, V36, P15834, DOI 10.1021/bi971932r; Kalabokis VN, 1996, J BIOL CHEM, V271, P26779, DOI 10.1074/jbc.271.43.26779; Katoh T, 1996, J BIOL CHEM, V271, P9992, DOI 10.1074/jbc.271.17.9992; Katoh T, 1997, ANAL BIOCHEM, V253, P78, DOI 10.1006/abio.1997.2346; KENDRICKJONES J, 1976, J MOL BIOL, V104, P747, DOI 10.1016/0022-2836(76)90180-7; KERRICK WGL, 1981, J GEN PHYSIOL, V77, P177, DOI 10.1085/jgp.77.2.177; Kleerekoper Q, 1998, J BIOL CHEM, V273, P8153, DOI 10.1074/jbc.273.14.8153; Kurzawa-Goertz SE, 1998, BIOCHEMISTRY-US, V37, P7517, DOI 10.1021/bi972844+; LEVIN RM, 1976, MOL PHARMACOL, V12, P581; MARSTON S, 1974, NATURE, V252, P38, DOI 10.1038/252038a0; Matthew JD, 1998, J BIOL CHEM, V273, P31289, DOI 10.1074/jbc.273.47.31289; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; NABESHIMA Y, 1987, J BIOL CHEM, V262, P10608; PerreaultMicale CL, 1996, J MUSCLE RES CELL M, V17, P543, DOI 10.1007/BF00124354; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; PROZIALECK WC, 1982, J PHARMACOL EXP THER, V222, P509; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROUFOGALIS BD, 1983, CAN J BIOCHEM CELL B, V61, P927, DOI 10.1139/o83-118; Rovner AS, 1997, J MUSCLE RES CELL M, V18, P103, DOI 10.1023/A:1018689102122; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STAFFORD WF, 1979, BIOCHEMISTRY-US, V18, P5273, DOI 10.1021/bi00591a002; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; SZENTGYO.AG, 1973, J MOL BIOL, V74, P179, DOI 10.1016/0022-2836(73)90106-X; SZENTGYORGYI AG, 1994, MYOLOGY, V2, P506; TRYBUS KM, 1994, J CELL BIOL, V124, P963, DOI 10.1083/jcb.124.6.963; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; VANDONSELAAR M, 1994, NAT STRUCT BIOL, V1, P795, DOI 10.1038/nsb1194-795; WATTERSON DM, 1980, J BIOL CHEM, V255, P962; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; YANG ZH, 1995, J BIOL CHEM, V270, P24646, DOI 10.1074/jbc.270.42.24646	51	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4880	4888		10.1074/jbc.275.7.4880	http://dx.doi.org/10.1074/jbc.275.7.4880			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671524	hybrid			2022-12-27	WOS:000085378200050
J	Windle, HJ; Fox, A; Ni Eidhin, D; Kelleher, D				Windle, HJ; Fox, A; Ni Eidhin, D; Kelleher, D			The thioredoxin system of Helicobacter pylori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-DERIVED FACTOR; HEAT-SHOCK PROTEIN; GASTRIC MUCUS GEL; CAMPYLOBACTER-PYLORI; DISULFIDE BRIDGES; POSSIBLE INVOLVEMENT; POLYMERIC STRUCTURE; EFFECTOR FUNCTIONS; IMMUNOGLOBULIN-G; REDOX REGULATION	This paper describes the purification of thioredoxin reductase (TR) and the characterization, purification, and cloning of thioredoxin (Trx) from Helicobacter pylori, purification, amino acid sequence analysis, and molecular cloning of the gene encoding thioredoxin revealed that it is a 12-kDa protein which possesses the conserved redox active motif CGPC, The gene encoding Trx was amplified by polymerase chain reaction and inserted into a pET expression vector and used to transform Escherichia coli, Trx was overexpressed by induction with isopropyl-1-thio-beta-D-galactopyranoside as a decahistidine fusion protein and was recovered from the cytoplasm as a soluble and active protein. The redox activity of this protein was characterized using several mammalian proteins of different architecture but all containing disulfide bonds. H. pylori thioredoxin efficiently reduced insulin, human immunoglobulins (IgG/ IgA/sIgA), and soluble mucin. Subcellular fractionation analysis of H. pylori revealed that thioredoxin was associated largely with the cytoplasm and inner membrane fractions of the cell in addition to being recovered in the phosphate-buffered saline-soluble fraction of freshly harvested cells. H, pylori TR was purified to homogeneity by chromatography on DEAE-52, Cibacron blue 3GA, and 2',5'-ADP-agarose. Gel filtration revealed that the native TR had a molecular mass of 70 kDa which represented a homodimer composed of two 35-kDa subunits, as determined by SDS-polyacrylamide gel electrophoresis. H. pylori TR (NADPH-dependent) efficiently catalyzed the reduction of 5,5'-dithiobis(nitrobenzoic acid) in the presence of either native or recombinant H, pylori Trx. H. pylori Trx behaved also as a stress response element as broth grown bacteria secreted Trx in response to chemical, biological, and environmental stresses. These observations suggest that Trx may conceivably assist H, pylori in the process of colonization by inducing focal disruption of the oligomeric structure of mucin while rendering host antibody inactive through catalytic reduction.	St James Hosp, Trinity Ctr Hlth Sci, Dept Clin Med, Trinity Coll Dublin, Dublin 8, Ireland	Trinity College Dublin	Windle, HJ (corresponding author), St James Hosp, Trinity Ctr Hlth Sci, Dept Clin Med, Trinity Coll Dublin, Dublin 8, Ireland.	hjwindle@tcd.ie						ALLEN A, 1982, ADV EXP MED BIOL, V144, P115; ALLEN A, 1985, DIGEST DIS SCI, V30, pS55, DOI 10.1007/BF01309386; Allen A, 1997, J PHYSIOL PHARMACOL, V48, P297; Asante M, 1997, GASTROENTEROLOGY, V113, P449, DOI 10.1053/gast.1997.v113.pm9247463; Aslund F, 1999, CELL, V96, P751, DOI 10.1016/S0092-8674(00)80584-X; Berggren M, 1996, ANTICANCER RES, V16, P3459; Birkholz S, 1998, DIGESTION, V59, P638, DOI 10.1159/000007568; Blanchard TG, 1999, CELL IMMUNOL, V191, P74, DOI 10.1006/cimm.1998.1421; Bogstedt AK, 1996, CLIN EXP IMMUNOL, V105, P202, DOI 10.1046/j.1365-2249.1996.d01-745.x; BREKKE OH, 1993, NATURE, V363, P628, DOI 10.1038/363628a0; Cao P, 1998, INFECT IMMUN, V66, P2984, DOI 10.1128/IAI.66.6.2984-2986.1998; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P4061, DOI 10.1021/bi9628580; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328; Darwin P E, 1996, Helicobacter, V1, P20, DOI 10.1111/j.1523-5378.1996.tb00004.x; DEKKER J, 1991, BIOCHEM J, V277, P423, DOI 10.1042/bj2770423; DORAI H, 1992, MOL IMMUNOL, V29, P1487, DOI 10.1016/0161-5890(92)90222-J; DORRINGTON KJ, 1982, MOL IMMUNOL, V19, P1215, DOI 10.1016/0161-5890(82)90286-3; Dunn BE, 1997, INFECT IMMUN, V65, P1181, DOI 10.1128/IAI.65.4.1181-1188.1997; Ejima K, 1999, PLACENTA, V20, P561, DOI 10.1053/plac.1999.0415; FAHIM REF, 1983, BIOCHEM J, V209, P117, DOI 10.1042/bj2090117; Fiocca R, 1999, J PATHOL, V188, P220, DOI 10.1002/(SICI)1096-9896(199906)188:2<220::AID-PATH307>3.0.CO;2-C; FURUKE K, 1995, INT IMMUNOL, V7, P985, DOI 10.1093/intimm/7.6.985; Gallegos A, 1996, CANCER RES, V56, P5765; GLEASON FK, 1988, FEMS MICROBIOL LETT, V54, P271, DOI 10.1111/j.1574-6968.1988.tb02747.x; GUSLANDI M, 1995, GUT, V37, P296, DOI 10.1136/gut.37.2.296; HAEFFNERCAVAILLON N, 1979, J IMMUNOL, V123, P1914; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HAZELL SL, 1986, J INFECT DIS, V153, P658, DOI 10.1093/infdis/153.4.658; Higashikubo A, 1999, BIOL PHARM BULL, V22, P900; HOLGREM A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; IWATA S, 1994, J IMMUNOL, V152, P5633; JACK HM, 1993, J IMMUNOL, V150, P4928; Jiang WP, 1998, BIOCHEM J, V331, P193, DOI 10.1042/bj3310193; Keenan JI, 1997, GUT, V41, pA18; KLEIN M, 1981, P NATL ACAD SCI-BIOL, V78, P524, DOI 10.1073/pnas.78.1.524; KLOMP LWJ, 1995, BIOCHEM J, V308, P831, DOI 10.1042/bj3080831; KOSTRZYNSKA M, 1994, J BACTERIOL, V176, P5938, DOI 10.1128/jb.176.19.5938-5948.1994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee J, 1997, J BIOL CHEM, V272, P23042, DOI 10.1074/jbc.272.37.23042; LINDH E, 1975, J IMMUNOL, V114, P284; LOZANO RM, 1994, ARCH BIOCHEM BIOPHYS, V309, P356, DOI 10.1006/abbi.1994.1124; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; Magnusson CGM, 1997, MOL IMMUNOL, V34, P709, DOI 10.1016/S0161-5890(97)00092-8; MAI UEH, 1992, J EXP MED, V175, P517, DOI 10.1084/jem.175.2.517; MANTLE M, 1981, BIOCHEM J, V195, P277, DOI 10.1042/bj1950277; MARKESICH DC, 1995, GUT, V36, P327, DOI 10.1136/gut.36.3.327; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MOBLEY HLT, 1988, J CLIN MICROBIOL, V26, P831, DOI 10.1128/JCM.26.5.831-836.1988; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Ota H, 1998, VIRCHOWS ARCH, V433, P419, DOI 10.1007/s004280050269; PEARSON JP, 1981, BIOCHEM J, V197, P155, DOI 10.1042/bj1970155; Phadnis SH, 1996, INFECT IMMUN, V64, P905, DOI 10.1128/IAI.64.3.905-912.1996; Powis G, 1998, CHEM-BIOL INTERACT, V112, P23, DOI 10.1016/S0009-2797(97)00148-8; Reddy PG, 1999, BIOCHEM BIOPH RES CO, V265, P345, DOI 10.1006/bbrc.1999.1691; RINGLER NJ, 1987, BIOCHEMISTRY-US, V26, P5322, DOI 10.1021/bi00391a016; RUSSEL M, 1995, METHOD ENZYMOL, V252, P264; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SAROSIEK J, 1988, SCAND J GASTROENTERO, V23, P585, DOI 10.3109/00365528809093916; SAROSIEK J, 1989, AM J GASTROENTEROL, V84, P506; SCHAFFER F M, 1991, Immunodeficiency Reviews, V3, P15; Scharf C, 1998, J BACTERIOL, V180, P1869, DOI 10.1128/JB.180.7.1869-1877.1998; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; Shimizu T, 1996, Helicobacter, V1, P207, DOI 10.1111/j.1523-5378.1996.tb00041.x; SIDEBOTHAM RL, 1991, J CLIN PATHOL, V44, P52, DOI 10.1136/jcp.44.1.52; SIDEBOTHAM RL, 1990, LANCET, V335, P193, DOI 10.1016/0140-6736(90)90279-E; Slomiany B L, 1989, Symp Soc Exp Biol, V43, P179; Slomiany BL, 1998, GEN PHARMACOL-VASC S, V31, P227, DOI 10.1016/S0306-3623(97)00456-4; SLOMIANY BL, 1992, J CLIN GASTROENTEROL, V14, pS114, DOI 10.1097/00004836-199206001-00020; SLOMIANY BL, 1995, GUT, V37, P589, DOI 10.1136/gut.37.4.589-c; SMITH MA, 1995, J ANTIMICROB CHEMOTH, V35, P751, DOI 10.1093/jac/35.6.751; STANWORTH DR, 1970, IMMUNOCHEMISTRY, V7, P321, DOI 10.1016/0019-2791(70)90172-2; STRYER L, 1967, BIOCHEMISTRY-US, V6, P1016, DOI 10.1021/bi00856a009; TABAK LA, 1995, ANNU REV PHYSIOL, V57, P547, DOI 10.1146/annurev.ph.57.030195.002555; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TAKATSU K, 1975, J IMMUNOL, V114, P1838; Tanaka N, 1993, Nihon Rinsho, V51, P3163; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vanet A, 1998, INFECT IMMUN, V66, P1023, DOI 10.1128/IAI.66.3.1023-1027.1998; Watanabe T, 1997, J GASTROEN HEPATOL, V12, P660, DOI 10.1111/j.1440-1746.1997.tb00531.x; Windle HJP, 1997, INFECT IMMUN, V65, P3132, DOI 10.1128/IAI.65.8.3132-3137.1997; XIA HX, 1993, J CLIN PATHOL, V46, P750, DOI 10.1136/jcp.46.8.750	86	61	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5081	5089		10.1074/jbc.275.7.5081	http://dx.doi.org/10.1074/jbc.275.7.5081			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671551	hybrid, Green Published			2022-12-27	WOS:000085378200077
J	Yang, XY; Wang, LH; Chen, TS; Hodge, DR; Resau, JH; DaSilva, L; Farrar, WL				Yang, XY; Wang, LH; Chen, TS; Hodge, DR; Resau, JH; DaSilva, L; Farrar, WL			Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPAR gamma) agonists - PPAR gamma co-association with transcription factor NFAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; CELLS; IL-2; GENE	T lymphocyte activation is highlighted by the induction of interleukin-2 (IL-2) gene expression, which governs much of the early lymphocyte proliferation responses. Peroxisome proliferator-activated receptor-gamma (PPAR gamma) is a member of the nuclear receptor superfamily of ligand-activated transcription factors. PPAR gamma mRNA expression was found in human peripheral blood T lymphocytes, raising the possibility of PPAR gamma involvement in the regulation of T cell function. Here we show that PPAR gamma ligands, troglitazone and 15-deoxy-Delta(12,14) prostaglandin J(2), but not PPAR alpha agonist Wy14643, inhibited IL-2 production and phytohemagglutinin-inducible proliferation in human peripheral blood T-cells in a dose-dependent manner. This inhibitory effect on IL-2 was restricted to the PPAR gamma 2-expressing, not the PPAR gamma-lacking, subpopulation of transfected Jurkat cells. The activated PPAR gamma physically associates with transcriptional factor NFAT regulating the IL-2 promoter, blocking NFAT DNA binding and transcriptional activity. This interaction with T-cell-specific transcription factors indicates an important immunomodulatory role for PPAR gamma in T lymphocytes and could suggest a previously unrecognized clinical potential for PPAR gamma ligands as immunotherapeutic drugs to treat T-cell-mediated diseases by targeting IL-2 gene expression.	NCI, Frederick Canc Res & Dev Ctr, Intramural Res Support Program, SAIC Frederick,NIH, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Cytokine Mol Mechanisms Sect, Lab Mol Immunoregulat,NIH, Frederick, MD 21702 USA; NCI, ABL Basic Res Program, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Farrar, WL (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Intramural Res Support Program, SAIC Frederick,NIH, POB B,Bldg 560,Rm 31-76, Frederick, MD 21702 USA.		Chen, Taosheng/I-6351-2013	Chen, Taosheng/0000-0001-6420-3809	NCI NIH HHS [N01-CO-56000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010253] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brun RP, 1997, CURR OPIN LIPIDOL, V8, P212, DOI 10.1097/00041433-199708000-00004; Chen RH, 1999, AM J PHYSIOL-RENAL, V276, pF777, DOI 10.1152/ajprenal.1999.276.5.F777; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; EVANS GA, 1994, J BIOL CHEM, V269, P23407; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; Greene M. E., 1995, Gene Expression, V4, P281; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Wang LH, 1999, J IMMUNOL, V162, P3897	18	333	351	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4541	4544		10.1074/jbc.275.7.4541	http://dx.doi.org/10.1074/jbc.275.7.4541			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671476	hybrid			2022-12-27	WOS:000085378200002
J	Lasley, RD; Narayan, P; Uittenbogaard, A; Smart, EJ				Lasley, RD; Narayan, P; Uittenbogaard, A; Smart, EJ			Activated cardiac adenosine A(1) receptors translocate out of caveolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; RAT VENTRICULAR MYOCYTES; NITRIC-OXIDE SYNTHASE; ADENYLYL-CYCLASE; ANGIOTENSIN-II; G-PROTEINS; STIMULATION; DESENSITIZATION; CARDIOMYOCYTES; MYOCARDIUM	The cardiac affects of the purine nucleoside, adenosine, are well known. Adenosine increases coronary blood flow, exerts direct negative chronotropic and dromotropic effects, and exerts indirect anti-adrenergic effects. These effects of adenosine are mediated via the activation of specific G protein-coupled receptors, There is increasing evidence that caveolae play a role in the compartmentalization of receptors and second messengers in the vicinity of the plasma membrane. Several reports demonstrate that G protein-coupled receptors redistribute to caveolae in response to receptor occupation. In this study, we tested the hypothesis that adenosine A(1) receptors would translocate to caveolae in the presence of agonists, Surprisingly, in unstimulated rat cardiac ventricular myocytes, 67 +/- 5% of adenosine A(1) receptors were isolated with caveolae. However, incubation with the adenosine A(1) receptor agonist 2-chlorocyclopentyladenosine induced the rapid translocation of the A(1) receptors from caveolae into non-caveolae plasma membrane, an effect that was blocked by the adenosine A(1) receptor antagonist, 8-cyclopentyl-1,3-dipropylxanthine. An adenosine A(2a) receptor agonist did not alter the localization of A(1) receptors to caveolae, These data suggest that the translocation of A(1) receptors out of caveolae and away from compartmentalized signaling molecules may explain why activation of ventricular myocyte A(1) receptors are associated with few direct effects.	Univ Kentucky, Dept Physiol, Sch Med, Lexington, KY 40536 USA; Univ Kentucky, Dept Surg, Sch Med, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Smart, EJ (corresponding author), Univ Kentucky, Dept Physiol, Sch Med, 800 Rose St,MS 508 C, Lexington, KY 40536 USA.	ejsmart@pop.uky.edu						ABDELLATIF MM, 1991, CIRC RES, V69, P800, DOI 10.1161/01.RES.69.3.800; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BARRY WH, 1995, ADV EXP MED BIOL, V382, P31; BELARDINELLI L, 1995, FASEB J, V9, P359, DOI 10.1096/fasebj.9.5.7896004; Blaukat A, 1996, J BIOL CHEM, V271, P32366, DOI 10.1074/jbc.271.50.32366; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Ciruela F, 1995, J NEUROSCI RES, V42, P818, DOI 10.1002/jnr.490420610; CYR C, 1993, J CARDIOVASC PHARM, V22, pS11, DOI 10.1097/00005344-199322008-00005; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; ENGSTROEM L, 1961, BIOCHIM BIOPHYS ACTA, V52, P36, DOI 10.1016/0006-3002(61)90901-5; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Figler RA, 1996, MOL PHARMACOL, V50, P1587; GRAHAM J, 1993, METHODS MOL BIOL, V19; Haasemann M, 1998, J CELL SCI, V111, P917; Henry P, 1996, CIRC RES, V78, P161, DOI 10.1161/01.RES.78.1.161; HILALDANDAN R, 1994, MOL PHARMACOL, V45, P1183; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459; LASLEY RD, 1998, MOL B INT U, V1, P133; LEE HT, 1993, AM J PHYSIOL, V265, pH1916, DOI 10.1152/ajpheart.1993.265.6.H1916; LINDEN J, 1985, CIRC RES, V56, P728, DOI 10.1161/01.RES.56.5.728; LINDEN J, 1991, FASEB J, V5, P2668, DOI 10.1096/fasebj.5.12.1916091; MAISEL AS, 1985, SCIENCE, V230, P183, DOI 10.1126/science.2994229; MARTENS D, 1988, CIRC RES, V63, P613, DOI 10.1161/01.RES.63.3.613; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MINSHALL RD, 1995, CIRC RES, V76, P773, DOI 10.1161/01.RES.76.5.773; MUSSER B, 1993, EUR J PHARM-MOLEC PH, V246, P105, DOI 10.1016/0922-4106(93)90086-O; Narayan P, 1998, J MOL CELL CARDIOL, V30, P913, DOI 10.1006/jmcc.1998.0648; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; Rybin VO, 1999, CIRC RES, V84, P980, DOI 10.1161/01.RES.84.9.980; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Song KS, 1997, CELL MOL BIOL, V43, P293; Song YJ, 1996, AM J PHYSIOL-CELL PH, V271, pC1233; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; Toya Y, 1998, ENDOCRINOLOGY, V139, P2025, DOI 10.1210/en.139.4.2025; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525	39	107	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4417	4421		10.1074/jbc.275.6.4417	http://dx.doi.org/10.1074/jbc.275.6.4417			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660613	hybrid			2022-12-27	WOS:000085288800097
J	Romanowski, P; Marr, JJ; Madine, MA; Rowles, A; Blow, JJ; Gautier, J; Laskey, RA				Romanowski, P; Marr, JJ; Madine, MA; Rowles, A; Blow, JJ; Gautier, J; Laskey, RA			Interaction of Xenopus Cdc2 center dot cyclin A1 with the origin recognition complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; DNA-REPLICATION; CELL-CYCLE; S-PHASE; YEAST ORIGIN; FISSION YEAST; EGG EXTRACTS; PROTEIN; MITOSIS; INITIATION	The initiation of DNA replication in eukaryotes is regulated in a minimum of at least two ways. First, several proteins, including origin recognition complex (ORC), Cdc6 protein, and the minichromosome maintenance (MCM) protein complex, need to be assembled on chromatin before initiation. Second, cyclin-dependent kinases regulate DNA replication in both a positive and a negative way by inducing the initiation of DNA replication at G(1)/S transition and preventing further rounds of origin firing within the same cell cycle. Here we characterize a link between the two levels. Immunoprecipitation of Xenopus origin recognition complex with anti XOrc1 or anti-XOrc2 antibodies specifically co immunoprecipitates a histone H1 kinase activity. The kinase activity is sensitive to several inhibitors of cyelin-dependent kinases including 6-dimethylaminopurine (6-DMAP), olomoucine, and p21(Cip1). This kinase activity also copurifies with ORC over several fractionation steps and was identified as a complex of the Cdc2 catalytic subunit and cyclin Al. Neither Cdk2 nor cyclin E could be detected in ORC immunoprecipitations. Reciprocal immunoprecipitations with anti-Xenopus Cdc2 or anti-Xenopus cyclin Al antibodies specifically eo-precipitate XOrc1 and XOrc2. Our results indicate that Xenopus ORC and Cdc2.cyclin Al physically interact and demonstrate a physical link between an active cyclin-dependent kinase and proteins involved in the initiation of DNA replication.	Wellcome Canc Res Campaign Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; Columbia Univ, Dept Dermatol & Genet, New York, NY 10032 USA	University of Cambridge; Columbia University	Laskey, RA (corresponding author), Wellcome Canc Res Campaign Inst, Tennis Court Rd, Cambridge CB2 1QR, England.	ra119@mole.bio.cam.ac.uk	Blow, J. Julian/B-3977-2009; Gautier, jean/A-2774-2008	Blow, J. Julian/0000-0002-9524-5849; 				BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Chevalier S, 1996, J CELL SCI, V109, P1173; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Coverley D, 1998, EXP CELL RES, V238, P63, DOI 10.1006/excr.1997.3829; Coverley D, 1996, EXP CELL RES, V225, P294, DOI 10.1006/excr.1996.0179; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GABRIELLI BG, 1992, J BIOL CHEM, V267, P1969; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; Goodger NM, 1996, J PATHOL, V178, P422, DOI 10.1002/(SICI)1096-9896(199604)178:4<422::AID-PATH497>3.0.CO;2-2; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Grallert B, 1996, GENE DEV, V10, P2644, DOI 10.1101/gad.10.20.2644; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Hardy CFJ, 1996, MOL CELL BIOL, V16, P1832; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; HOWE JA, 1995, GENE DEV, V9, P1164, DOI 10.1101/gad.9.10.1164; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; KOBAYASHI H, 1994, J BIOL CHEM, V269, P29153; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; Romanowski P, 1996, TRENDS CELL BIOL, V6, P184, DOI 10.1016/0962-8924(96)10015-5; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Strausfeld UP, 1996, J CELL SCI, V109, P1555; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; Takahara K, 1996, GENOMICS, V31, P119, DOI 10.1006/geno.1996.0018; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMASHITA M, 1991, DEV GROWTH DIFFER, V33, P617	55	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4239	4243		10.1074/jbc.275.6.4239	http://dx.doi.org/10.1074/jbc.275.6.4239			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660590	hybrid			2022-12-27	WOS:000085288800074
J	Wang, A; Schneider-Broussard, R; Kumar, AP; MacLeod, MC; Johnson, DG				Wang, A; Schneider-Broussard, R; Kumar, AP; MacLeod, MC; Johnson, DG			Regulation of BRCA1 expression by the Rb-E2F pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; MESSENGER-RNA; DNA-SYNTHESIS; HUMAN BREAST; S-PHASE; APOPTOSIS; P53	Inheritance of a mutant allele of the breast cancer susceptibility gene BRCA1 confers increased risk of developing breast and ovarian cancers. Likewise, inheritance of a mutant allele of the retinoblastoma susceptibility gene (RBI) results in the development of retinoblastoma and/or osteosarcoma, and both alleles are often mutated or inactivated in sporadic forms of these and other cancers. We now demonstrate that the product of the RBI gene, Rb, regulates the expression of the murine Brca1 and human BRCA1 genes through its ability to modulate E2F transcriptional activity. The Brca1 gene is identified as an in vivo target of E2F1 in a transgenic mouse model. The Brca1 promoter contains E2F DNA-binding sites that mediate transcriptional activation by E2F1 and repression by Rb, Moreover, ectopic expression of cyclin D1 and Cdk4 can stimulate the Brca1 promoter in an E2F-dependent manner, and this is inhibited by coexpression of the p16(INK4a) cyclin-dependent kinase inhibitor. The human BRCA1 promoter also contains a conserved E2F site and is similarly regulated by E2F1 and Rb. This functional link between the BRCA1 and Rb tumor suppressors may provide insight into the mechanism by which BRCA1 inactivation contributes to cancer development.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Johnson, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, POB 389, Smithville, TX 78957 USA.			Johnson, David/0000-0002-6223-1790	NCI NIH HHS [CA16672, CA79648] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA079648] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Chambers JA, 1996, GENOMICS, V38, P305, DOI 10.1006/geno.1996.0633; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hunt KK, 1997, CANCER RES, V57, P4722; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1995, ONCOGENE, V11, P1685; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; Shao NS, 1996, ONCOGENE, V13, P1; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wang AJ, 1999, NUCLEIC ACIDS RES, V27, P4609, DOI 10.1093/nar/27.23.4609; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	49	97	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4532	4536		10.1074/jbc.275.6.4532	http://dx.doi.org/10.1074/jbc.275.6.4532			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660629	hybrid			2022-12-27	WOS:000085288800113
J	Bain, DL; Franden, MA; McManaman, JL; Takimoto, GS; Horwitz, KB				Bain, DL; Franden, MA; McManaman, JL; Takimoto, GS; Horwitz, KB			The N-terminal region of the human progesterone A-receptor - Structural analysis and the influence of the DNA binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RECEPTOR; PHOSPHORYLATION SITES; LIMITED PROTEOLYSIS; HORMONE RECEPTOR; ALPHA-HELIX; B-ISOFORM; PROTEIN; TRANSCRIPTION; FORM; COOPERATIVITY	The role of the N-terminal region in nuclear receptor function was addressed by a biochemical and biophysical analysis of the progesterone receptor A-isoform lacking only the hormone binding domain (NT-A), Sedimentation studies demonstrate that NT-A is quantitatively monomeric, with a highly asymmetric shape. Contrary to dogma, the N-terminal region is structured as demonstrated by limited proteolysis, However, N-terminal structure is strongly stabilized by the DNA binding domain, possibly explaining the lack, of structure seen in isolated activation domains, Upon DNA binding, NT-A undergoes N-terminal mediated assembly, suggestive of DNA-induced allostery, and consistent with changes in protease accessibility of sites outside the DNA binding domain. Microsequencing reveals that protease-accessible regions are limited to previously identified phosphorylation motifs and to functional domain boundaries.	Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Bain, DL (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, 4200 E 9th Ave,B-151, Denver, CO 80262 USA.			Horwitz, Kathryn/0000-0001-7402-6455	NCI NIH HHS [CA26869] Funding Source: Medline; NIDDK NIH HHS [DK48238] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026869, R37CA026869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048238] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beck CA, 1996, J BIOL CHEM, V271, P19546, DOI 10.1074/jbc.271.32.19546; BIRNBAUMER M, 1983, J BIOL CHEM, V258, P7331; CARLSTEDTDUKE J, 1987, P NATL ACAD SCI USA, V84, P4437, DOI 10.1073/pnas.84.13.4437; CHRISTENSEN K, 1991, MOL ENDOCRINOL, V5, P1755, DOI 10.1210/mend-5-11-1755; Cohn E. J., 1943, PROTEINS AMINO ACIDS; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; ERIKSSON P, 1990, J BIOL CHEM, V265, P3535; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HARD T, 1990, BIOCHEMISTRY-US, V29, P5358; Hovland AR, 1998, J BIOL CHEM, V273, P5455, DOI 10.1074/jbc.273.10.5455; Hubbard SJ, 1998, BBA-PROTEIN STRUCT M, V1382, P191, DOI 10.1016/S0167-4838(97)00175-1; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; Kumar R, 1999, STEROIDS, V64, P310, DOI 10.1016/S0039-128X(99)00014-8; Kumar R, 1999, J BIOL CHEM, V274, P24737, DOI 10.1074/jbc.274.35.24737; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Meinke G, 1999, NAT STRUCT BIOL, V6, P471; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MEYER ME, 1992, J BIOL CHEM, V267, P10882; PAYVAR F, 1983, STEROID HORMONE RECE, P267; PESSEN H, 1985, METHOD ENZYMOL, V117, P219; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; PRICE NC, 1989, PROTEOLYTIC ENZYMES, P163; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; SARTORIUS CA, 1994, MOL ENDOCRINOL, V8, P1347, DOI 10.1210/me.8.10.1347; SegardMaurel I, 1996, BIOCHEMISTRY-US, V35, P1634, DOI 10.1021/bi951369h; Sem DS, 1997, J BIOL CHEM, V272, P18038, DOI 10.1074/jbc.272.29.18038; SMITH DF, 1988, ENDOCRINOLOGY, V122, P2816, DOI 10.1210/endo-122-6-2816; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; TAKIMOTO GS, 1991, J STEROID BIOCHEM, V39, P687, DOI 10.1016/0960-0760(91)90368-F; Tetel MJ, 1997, MOL ENDOCRINOL, V11, P1114, DOI 10.1210/me.11.8.1114; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011; Wong I, 1995, METHOD ENZYMOL, V259, P95; WRANGE O, 1984, J BIOL CHEM, V259, P4534; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Zhang YX, 1997, MOL ENDOCRINOL, V11, P823, DOI 10.1210/me.11.6.823; ZHANG YX, 1995, MOL ENDOCRINOL, V9, P1029, DOI 10.1210/me.9.8.1029; [No title captured]	49	77	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7313	7320		10.1074/jbc.275.10.7313	http://dx.doi.org/10.1074/jbc.275.10.7313			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702302	hybrid			2022-12-27	WOS:000085809600082
J	Li, FZ; Flanary, PL; Altieri, DC; Dohlman, HG				Li, FZ; Flanary, PL; Altieri, DC; Dohlman, HG			Cell division regulation by BIR1, a member of the inhibitor of apoptosis family in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; C GENE; SURVIVIN; DEATH	The inhibitor of apoptosis (IAP) gene family comprises molecules that block the activity of pro-apoptotic caspase proteases, Paradoxically, yeasts contain IAP proteins but no caspases and no apoptotic program. To determine the function of these proteins in vivo, we disrupted the BIR1 gene, encoding the only known IAP in yeast Saccharomyces cerevisiae, Sporulation of heterozygous diploids yielded no viable mutant haploids, indicating that BIR1 is an essential gene. By flow cytometry, some heterozygous mutants were polyploid accumulating >4 N DNA content. These cells exhibited a 20-40% reduction in growth rate, which was rescued by plasmid-borne over-expression of BIR1 but not by its human counterpart, survivin, Deletion analysis revealed that the N-terminal domain of Bir1, containing the conserved baculovirus IAP repeat, was able to partially complement the cell growth defect caused by BIR1 deletion. Moreover, the full-length and truncated forms of Bir1 accelerated cell division in wild-type cells. Finally, BIR1 heterozygous mutants exhibited grossly altered cell morphology with mis-shapen or abnormally long buds connected to an unusually large mother cell. These findings identify a novel function of IAP proteins in the pleiotropic control of cell division, in addition to their role in the suppression of apoptosis.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pathol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA	Yale University; Yale University	Altieri, DC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pathol, 295 Congress Ave, New Haven, CT 06536 USA.		Li, Fengzhi/GXF-0115-2022	Dohlman, Henrik/0000-0003-2443-0729	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL054131, R01HL054131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059167, R01GM055316, R29GM055316] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54131] Funding Source: Medline; NIGMS NIH HHS [GM59167, R01 GM059167, R01 GM055316, GM55316] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Fraser A, 1998, TRENDS CELL BIOL, V8, P219, DOI 10.1016/S0962-8924(98)01275-6; Fraser AG, 1999, CURR BIOL, V9, P292, DOI 10.1016/S0960-9822(99)80137-7; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; Haining WN, 1999, P NATL ACAD SCI USA, V96, P4936, DOI 10.1073/pnas.96.9.4936; Hinds MG, 1999, NAT STRUCT BIOL, V6, P648; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; PAYNE WE, 1993, MOL CELL BIOL, V13, P4351, DOI 10.1128/MCB.13.7.4351; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; SIKORSKI RS, 1989, GENETICS, V122, P19; Song JP, 1996, J BIOL CHEM, V271, P20273, DOI 10.1074/jbc.271.34.20273; Uren AG, 1998, TRENDS BIOCHEM SCI, V23, P159, DOI 10.1016/S0968-0004(98)01198-0; Uren AG, 1999, P NATL ACAD SCI USA, V96, P10170, DOI 10.1073/pnas.96.18.10170; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300	23	66	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6707	6711		10.1074/jbc.275.10.6707	http://dx.doi.org/10.1074/jbc.275.10.6707			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702224	hybrid			2022-12-27	WOS:000085809600004
J	Okajima, T; Chen, HH; Ito, H; Kiso, M; Tai, T; Furukawa, K; Urano, T; Furukawa, K				Okajima, T; Chen, HH; Ito, H; Kiso, M; Tai, T; Furukawa, K; Urano, T; Furukawa, K			Molecular cloning and expression of mouse GD1 alpha/GT1a alpha/GQ1b alpha synthase (ST6GalNAc VI) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURON-SPECIFIC GANGLIOSIDE; GALNAC ALPHA-2,6-SIALYLTRANSFERASE; CELLS; GQ1B-ALPHA; GD1-ALPHA; GLYCOLIPIDS; ANTIBODIES; GT1A-ALPHA; ANTIGENS; MEMBRANE	A novel member of the mouse CMP-NeuAc:beta-N-acetyl-galactosaminide alpha 2,6-sialyltransferase (ST6GalNAc) subfamily, designated ST6GalNAc VI, was identified by BLAST analysis of expressed sequence tags. The sequence of the cDNA clone of ST6GalNAc VI encoded a type II membrane protein with 43 amino acids composing the cytoplasmic domain, 21 amino acids composing the transmembrane region, and 269 amino acids composing the catalytic domain. The predicted amino acid sequence showed homology to the previously cloned ST6GalNAc III, IV, and V, with common amino acid sequences in sialyl motif L and S among these four enzymes. A fusion protein with protein A and extracts from L cells transfected with ST6GalNAc VI in an expression vector showed enzyme activity of alpha 2,6-sialyltransferase for GM1b, GT1b, and GD1a but not toward glycoproteins. Thin layer chromatography-immunostaining revealed that the products were GD1 alpha, GQ1b alpha, and GT1a alpha. Northern blotting revealed that this gene was expressed in a wide range of mouse tissues such as colon, liver, heart, spleen, and brain. It is concluded that this enzyme is a novel sialyltransferase involved in the synthesis of alpha-series gangliosides in the nervous tissues and many other tissues.	Nagoya Univ, Sch Med, Dept Biochem 2, Nagoya, Aichi 4660065, Japan; Nagoya Univ, Sch Med, Dept Surg 2, Nagoya, Aichi 4660065, Japan; Gifu Univ, Fac Agr, Dept Appl Bioorgan Chem, Gifu 5011193, Japan; Tokyo Metropolitan Inst Med Sci, Dept Tumor Immunol, Bunkyo Ku, Tokyo 1138613, Japan	Nagoya University; Nagoya University; Gifu University; Tokyo Metropolitan Institute of Medical Science	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Nagoya, Aichi 4660065, Japan.	koichi@med.nagoya-u.ac.jp	Okajima, Tetsuya/I-7332-2014	Okajima, Tetsuya/0000-0002-3677-648X; Urano, Takeshi/0000-0003-3383-3554				ANDO S, 1992, J BIOCHEM, V111, P287, DOI 10.1093/oxfordjournals.jbchem.a123751; Collins BE, 1997, J BIOL CHEM, V272, P1248, DOI 10.1074/jbc.272.2.1248; Ecsedy JA, 1998, J LIPID RES, V39, P2218; FURUKAWA K, 1985, BIOCHEMISTRY-US, V24, P7820, DOI 10.1021/bi00347a047; FURUYA S, 1994, J BIOL CHEM, V269, P32418; GILLARD BK, 1991, EXP CELL RES, V192, P433, DOI 10.1016/0014-4827(91)90062-Y; HIRABAYASHI Y, 1992, J BIOL CHEM, V267, P12973; HIRABAYASHI Y, 1990, J BIOL CHEM, V265, P8144; IRIE F, 1994, FEBS LETT, V351, P291, DOI 10.1016/0014-5793(94)00883-3; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kurosawa N, 1996, J BIOL CHEM, V271, P15109, DOI 10.1074/jbc.271.25.15109; KUROSAWA N, 1994, J BIOL CHEM, V269, P1402; KUSUNOKI S, 1993, BRAIN RES, V623, P83, DOI 10.1016/0006-8993(93)90013-D; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee YC, 1999, J BIOL CHEM, V274, P11958, DOI 10.1074/jbc.274.17.11958; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; MOMOEDA M, 1995, BBA-LIPID LIPID MET, V1256, P151, DOI 10.1016/0005-2760(95)00013-3; MURAYAMA K, 1986, CANCER RES, V46, P1395; MUTHING J, 1989, BIOCHEMISTRY-US, V28, P2923; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NAKAISHI H, 1988, CANCER RES, V48, P1753; Okajima T, 1999, J BIOL CHEM, V274, P28841, DOI 10.1074/jbc.274.41.28841; Okajima T, 1999, J BIOL CHEM, V274, P11479, DOI 10.1074/jbc.274.17.11479; Okajima T, 1999, J BIOL CHEM, V274, P30557, DOI 10.1074/jbc.274.43.30557; Sjoberg ER, 1996, J BIOL CHEM, V271, P7450, DOI 10.1074/jbc.271.13.7450; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P455; Tagawa Y, 1997, J NEUROIMMUNOL, V75, P196, DOI 10.1016/S0165-5728(97)00005-2; TAKI T, 1994, ANAL BIOCHEM, V221, P312, DOI 10.1006/abio.1994.1418; TAKI T, 1986, J BIOL CHEM, V261, P3075; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; TSUJI S, 1996, GLYCOBIOLOGY, V6, P5; TSUJI T, 1986, CARBOHYD RES, V151, P391, DOI 10.1016/S0008-6215(00)90358-6; WEN DX, 1992, J BIOL CHEM, V267, P21011; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; WU GS, 1995, J NEUROSCI, V15, P3739; YAMASHIRO S, 1995, J BIOL CHEM, V270, P6149, DOI 10.1074/jbc.270.11.6149	38	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6717	6723		10.1074/jbc.275.10.6717	http://dx.doi.org/10.1074/jbc.275.10.6717			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702226	hybrid			2022-12-27	WOS:000085809600006
J	Trost, M; Kochs, G; Haller, O				Trost, M; Kochs, G; Haller, O			Characterization of a novel serine/threonine kinase associated with nuclear bodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-RELATED MODIFIER; SYNDROME CRITICAL REGION; HUMAN MXA PROTEIN; ANTIVIRAL ACTIVITY; HUMAN HOMOLOG; VIRUS TRANSCRIPTION; INFLUENZA-VIRUS; EXPRESSION; INTERFERON; RESISTANCE	A novel protein kinase, Mx-interacting protein kinase (PKM), has been identified in a yeast two-hybrid screen for interaction partners of human MxA, an interferon-induced GTPase with antiviral activity against several RNA viruses. A highly conserved protein kinase domain is present in the N-terminal moiety of PKM, whereas an Mx interaction domain overlaps with C-terminal PEST sequences. PKM has a molecular weight of about 127,000 and exhibits high sequence homology to members of a recently described family of homeodomain-interacting protein kinases, Recombinant PKM has serine/threonine kinase activity that is abolished by a single amino acid substitution in the ATP binding domain (K221W). PKM catalyzes autophosphorylation and phosphorylation of various cellular and viral proteins. PKM is expressed constitutively and colocalizes with the interferon-inducible Sp100 protein and murine Mx1 in discrete nuclear structures known as nuclear bodies.	Univ Freiburg, Inst Med Mikrobiol & Hyg, Abt Virol, D-79008 Freiburg, Germany	University of Freiburg	Haller, O (corresponding author), Univ Freiburg, Inst Med Mikrobiol & Hyg, Abt Virol, D-79008 Freiburg, Germany.	haller@ukl.uni-freiburg.de						AEBI M, 1989, MOL CELL BIOL, V9, P5062, DOI 10.1128/MCB.9.11.5062; ALBANESE M, 1972, ACTA VIROL, V16, P267; BARIK S, 1991, J VIROL, V65, P1719, DOI 10.1128/JVI.65.4.1719-1726.1991; Begley DA, 1997, GENE, V200, P35, DOI 10.1016/S0378-1119(97)00350-8; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chelbi-Alix MK, 1998, J VIROL, V72, P1043, DOI 10.1128/JVI.72.2.1043-1051.1998; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; DREIDING P, 1985, VIROLOGY, V140, P192, DOI 10.1016/0042-6822(85)90460-X; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Georgiev O, 1996, GENE, V168, P165, DOI 10.1016/0378-1119(95)00764-4; GULDNER HH, 1992, J IMMUNOL, V149, P4067; Haller O, 1998, REV SCI TECH OIE, V17, P220, DOI 10.20506/rst.17.1.1084; HORISBERGER MA, 1987, J INTERFERON RES, V7, P331, DOI 10.1089/jir.1987.7.331; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; KISTNER O, 1989, J GEN VIROL, V70, P2421, DOI 10.1099/0022-1317-70-9-2421; Kochs G, 1998, METHODS, V15, P255, DOI 10.1006/meth.1998.0629; Kochs G, 1999, J BIOL CHEM, V274, P4370, DOI 10.1074/jbc.274.7.4370; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Landis H, 1998, J VIROL, V72, P1516, DOI 10.1128/JVI.72.2.1516-1522.1998; LAVAU C, 1995, ONCOGENE, V11, P871; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; Maul GG, 1998, BIOESSAYS, V20, P660, DOI 10.1002/(SICI)1521-1878(199808)20:8<660::AID-BIES9>3.0.CO;2-M; Moilanen AM, 1998, MOL BIOL CELL, V9, P2527, DOI 10.1091/mbc.9.9.2527; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; PITOSSI F, 1993, J VIROL, V67, P6726, DOI 10.1128/JVI.67.11.6726-6732.1993; Ponten A, 1997, J VIROL, V71, P2591, DOI 10.1128/JVI.71.4.2591-2599.1997; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; SCHNEIDERSCHAULIES S, 1994, J VIROL, V68, P6910, DOI 10.1128/JVI.68.11.6910-6917.1994; Shindoh N, 1996, BIOCHEM BIOPH RES CO, V225, P92, DOI 10.1006/bbrc.1996.1135; Song WJ, 1996, GENOMICS, V38, P331, DOI 10.1006/geno.1996.0636; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; STAEHELI P, 1988, MOL CELL BIOL, V8, P4524, DOI 10.1128/MCB.8.10.4524; Staeheli Peter, 1993, Trends in Cell Biology, V3, P268, DOI 10.1016/0962-8924(93)90055-6; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; STRANDEN AM, 1993, VIROLOGY, V197, P642, DOI 10.1006/viro.1993.1639; Weber F, 1998, VIROLOGY, V250, P9, DOI 10.1006/viro.1998.9329; Weber F, 1996, J VIROL, V70, P8361, DOI 10.1128/JVI.70.12.8361-8367.1996; Yasugi T, 1996, NUCLEIC ACIDS RES, V24, P2005, DOI 10.1093/nar/24.11.2005	46	23	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7373	7377		10.1074/jbc.275.10.7373	http://dx.doi.org/10.1074/jbc.275.10.7373			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702310	hybrid			2022-12-27	WOS:000085809600090
J	Yan, B; Hu, DD; Knowles, SK; Smith, JW				Yan, B; Hu, DD; Knowles, SK; Smith, JW			Probing chemical and conformational differences in the resting and active conformers of platelet integrin alpha(IIb)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IIB-IIIA COMPLEX; MEMBRANE GLYCOPROTEIN-IIB; LIGAND-BINDING; CYTOPLASMIC DOMAIN; BETA(3) SUBUNIT; GPIIB-IIIA; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; AFFINITY MODULATION; SIGNAL-TRANSDUCTION	Integrin alpha(IIb)beta(3) is the fibrinogen receptor that mediates platelet adhesion and aggregation. The ligand binding function of alpha(IIb)beta(3) is "activated" on the platelet surface by physiologic stimuli. Two forms of alpha(IIb)beta(3) can be purified from platelet lysates, These forms are facsimiles of the resting (Activation State-1 or AS-1) and the active (Activation State-2 or AS-2) conformations of the integrin found on the platelet surface. Here, the differences between purified AS-1 and AS-2 were examined to gain insight into the mechanism of activation. Four major findings are put forth. 1) The association rate (k(1)) between fibrinogen and the integrin is a key difference between AS-1 and AS-2. 2) Although the divalent ion Mn2+ enhances the ligand binding function of AS-1, this ion is unable to convert AS-1 to AS-2, Therefore, its effect on integrin is unrelated to activation. 3) Peptide mass fingerprints indicate that the chemical structure of AS-1 and AS-2 are virtually identical, calling into question the idea that post-translational modifications are necessary for activation. 4) The two forms of alpha(IIb)beta(3) have significant conformational differences at three positions. These include the junction of the heavy and light chain of alpha(IIb), the divalent ion binding sites on alpha(IIb), and at a disulfide-bonded knot linking the amino terminus of beta(3) to the cysteine-rich domain. These observations indicate that integrin is activated by a series of specific conformational rearrangements in the ectodomain that increase the rate of ligand association.	Burnham Inst, Canc Res Ctr, Program Cell Adhes, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Smith, JW (corresponding author), Burnham Inst, Canc Res Ctr, Program Cell Adhes, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [CA30199, CA69306] Funding Source: Medline; NHLBI NIH HHS [HL58925] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069306, P30CA030199] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058925] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARBAS CF, 1993, P NATL ACAD SCI USA, V90, P10003, DOI 10.1073/pnas.90.21.10003; BEER JH, 1992, BLOOD, V79, P117; Blystone SD, 1996, J BIOL CHEM, V271, P31458, DOI 10.1074/jbc.271.49.31458; BRAY PF, 1990, J BIOL CHEM, V265, P9587; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CALVETE JJ, 1989, BIOCHEM J, V261, P551, DOI 10.1042/bj2610551; CHARO IF, 1986, P NATL ACAD SCI USA, V83, P8351, DOI 10.1073/pnas.83.21.8351; COTTRELL JS, 1994, PEPTIDE RES, V7, P115; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Delwel GO, 1996, J BIOL CHEM, V271, P7293, DOI 10.1074/jbc.271.13.7293; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; FITZGERALD LA, 1985, ANAL BIOCHEM, V151, P169, DOI 10.1016/0003-2697(85)90067-3; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Garcia AJ, 1998, J BIOL CHEM, V273, P34710, DOI 10.1074/jbc.273.52.34710; GIESBERTS AN, 1995, BIOCHEM J, V309, P613, DOI 10.1042/bj3090613; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; Hu DD, 1999, J BIOL CHEM, V274, P4633, DOI 10.1074/jbc.274.8.4633; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Indig FE, 1997, BIOCHEM J, V327, P291, DOI 10.1042/bj3270291; Inomata M, 1996, ARCH BIOCHEM BIOPHYS, V328, P129, DOI 10.1006/abbi.1996.0152; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; KOUNS WC, 1991, BLOOD, V78, P3215; KOUNS WC, 1992, J BIOL CHEM, V267, P18844; Kumar CS, 1997, J BIOL CHEM, V272, P16390, DOI 10.1074/jbc.272.26.16390; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; LOFTUS JC, 1988, J BIOL CHEM, V263, P11025; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; Martin-Bermudo MD, 1998, J CELL BIOL, V141, P1073, DOI 10.1083/jcb.141.4.1073; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Pappin D J, 1997, Methods Mol Biol, V64, P165; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; Si-Tahar M, 1997, J BIOL CHEM, V272, P11636; Smith JW, 1997, MATRIX BIOL, V16, P173, DOI 10.1016/S0945-053X(97)90005-6; SMITH JW, 1994, J BIOL CHEM, V269, P32788; SMITH JW, 1994, J BIOL CHEM, V269, P960; Tozer EC, 1996, BIOCHEM CELL BIOL, V74, P785, DOI 10.1139/o96-085; VANKUPPEVELT THMSM, 1989, P NATL ACAD SCI USA, V86, P5415; VANWILLIGEN G, 1991, BIOCHEM J, V273, P115, DOI 10.1042/bj2730115; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YAN B, 1992, CHIN BIOCH J, V8, P755; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	55	62	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7249	7260		10.1074/jbc.275.10.7249	http://dx.doi.org/10.1074/jbc.275.10.7249			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702295	hybrid			2022-12-27	WOS:000085809600075
J	Yin, XY; Jedrzejewski, PT; Jiang, JX				Yin, XY; Jedrzejewski, PT; Jiang, JX			Casein kinase II phosphorylates lens connexin 45.6 and is involved in its degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION PROTEIN; EMBRYONIC CHICK LENS; KAPPA-B-ALPHA; MOLECULAR-CLONING; POSTTRANSLATIONAL PHOSPHORYLATION; EXPRESSION; DIFFERENTIATION; COMMUNICATION; RESIDUES; PEPTIDES	Connexin (Cx) 45.6, an avian counterpart of rodent Cx50, is phosphorylated in vivo, but the sites and function of the phosphorylation have not been elucidated. Our peptide mapping experiments showed that the Ser(363) site in the carboxyl (COOH) terminus of Cx45.6 was phosphorylated and that this site is within casein kinase (CK) II consensus sequence, although showing some similarity to CKI sequence. The peptide containing Ser(363) could be phosphorylated in vitro by CKII, but not by CKI. Furthermore, CKII phosphorylated Cx45.6 in embryonic lens membrane and the fusion protein containing the COOH terminus of Cx45.6. Two-dimensional peptide mapping experiments showed that one of the Cx45.6 peptides phosphorylated in vivo migrated to the same spot as one of those phosphorylated by CKII in vitro. Furthermore, CKII activity could be detected in lens lysates. To assess the function of this phosphorylation event, exogenous wild type and mutant Cx45.6 (Ser363, Ala) were expressed in lens primary cultures by retroviral infection. The mutant Cx45.6 was shown to be more stable having a longer half-life compared with wild type Cx45.6. Together, the evidence suggests that CKII is likely a kinase responsible for the Ser(363) phosphorylation, leading to the destablization and degradation of Cx45.6. The connexin degradation induced by phosphorylation has a broad functional significance in the regulation of gap junctions in vivo.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Northeastern Univ, Barnett Inst, Boston, MA 02115 USA	University of Texas System; University of Texas Health San Antonio; Northeastern University	Jiang, JX (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	jiangj@uthscsa.edu		Jiang, Jean/0000-0002-2185-5716	NEI NIH HHS [EY-02430, EY-12085] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012085, R29EY012085, R01EY002430] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALCAZAR A, 1988, NEUROCHEM RES, V13, P829, DOI 10.1007/BF00970750; BASSNETT S, 1994, J CELL SCI, V107, P799; BENNETT MVL, 1978, NEUROSCI RES PROG B, V16, P377; Berthoud VM, 1999, EXP EYE RES, V68, P475, DOI 10.1006/exer.1998.0635; BERTHOUD VM, 1994, INVEST OPHTH VIS SCI, V35, P4109; Berthoud VM, 1997, EUR J BIOCHEM, V244, P89, DOI 10.1111/j.1432-1033.1997.00089.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Dahm R, 1999, EXP EYE RES, V69, P45, DOI 10.1006/exer.1999.0670; ELVIRA M, 1993, J BIOL CHEM, V268, P14294; FEKETE DM, 1993, MOL CELL BIOL, V13, P2604, DOI 10.1128/MCB.13.4.2604; Goodenough D.A., 1992, Seminars in Cell Biology, V3, P49; GRUIJTERS WTM, 1987, J CELL SCI, V88, P351; Harlow E., 1988, ANTIBODIES LAB MANUA; Hertlein B, 1998, J MEMBRANE BIOL, V162, P247, DOI 10.1007/s002329900362; Hossain MZ, 1998, J CELL PHYSIOL, V174, P66; Jedrzejewski PT, 1997, ANAL CHEM, V69, P294, DOI 10.1021/ac9606618; JIANG JX, 1993, INVEST OPHTH VIS SCI, V34, P3558; Jiang JX, 1998, EUR J BIOCHEM, V255, P37, DOI 10.1046/j.1432-1327.1998.2550037.x; Jiang JX, 1998, INVEST OPHTH VIS SCI, V39, P537; JIANG JX, 1994, MOL BIOL CELL, V5, P363, DOI 10.1091/mbc.5.3.363; JIANG JX, 1995, DEV BIOL, V168, P649, DOI 10.1006/dbio.1995.1109; Jiang JX, 1996, P NATL ACAD SCI USA, V93, P1287, DOI 10.1073/pnas.93.3.1287; KISTLER J, 1987, INVEST OPHTH VIS SCI, V28, P1687; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; LAIRD DW, 1990, J CELL SCI, V97, P109; Lin JS, 1997, EUR J CELL BIOL, V73, P141; Lin JS, 1998, EUR J CELL BIOL, V76, P246; Liu ZQ, 1997, INT J PATTERN RECOGN, V11, P3, DOI 10.1142/S0218001497000020; MARIN O, 1994, EUR J BIOCHEM, V223, P647, DOI 10.1111/j.1432-1033.1994.tb19037.x; MASTESIC DF, 1994, MOL CARCINOGEN, V10, P226; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MENKO AS, 1984, DEV BIOL, V103, P129, DOI 10.1016/0012-1606(84)90014-9; MOORBY CD, 1995, EXP CELL RES, V219, P657, DOI 10.1006/excr.1995.1276; MORENO AP, 1994, CIRC RES, V74, P1050, DOI 10.1161/01.RES.74.6.1050; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J MEMBRANE BIOL, V116, P163, DOI 10.1007/BF01868674; PIATIGORSKY J, 1973, DEV BIOL, V34, P334, DOI 10.1016/0012-1606(73)90362-X; PURANAM KL, 1993, EXP CELL RES, V206, P85, DOI 10.1006/excr.1993.1123; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUP DM, 1993, J BIOL CHEM, V268, P706; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Songyang Z, 1996, MOL CELL BIOL, V16, P6486	47	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6850	6856		10.1074/jbc.275.10.6850	http://dx.doi.org/10.1074/jbc.275.10.6850			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702244	hybrid			2022-12-27	WOS:000085809600024
J	Kim, S; Ponka, P				Kim, S; Ponka, P			Effects of interferon-gamma and lipopolysaccharide on macrophage iron metabolism are mediated by nitric oxide-induced degradation of iron regulatory protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; RECEPTOR MESSENGER-RNA; TRANSFERRIN RECEPTOR; OXIDATIVE STRESS; NITROGEN MONOXIDE; FERRITIN SYNTHESIS; S-NITROSOTHIOLS; ACONITASE; STABILITY; CELLS	Iron regulatory proteins (IRP-1 and IRP-2) control the synthesis of transferrin receptors (TER) and ferritin by binding to iron-responsive elements, which are located in the 3'-untranslated region and the 5'-untranslated region of their respective mRNAs. Cellular iron levels affect binding of IRPs to iron-responsive elements and consequently expression of TfR and ferritin. Moreover, NO., a redox species of nitric oxide that interacts primarily with iron, can activate IRP-1 RNA binding activity resulting in an increase in TfR mRNA levels. Recently we found that treatment of RAW 264.7 cells (a murine macrophage cell line) with NO+ (nitrosonium ion, which causes S-nitrosylation of thiol groups) resulted in a rapid decrease in RNA binding of IRP-2 followed by IRP-2 degradation, and these changes were associated with a decrease in TfR mRNA levels (Kim, S., and Ponka, P. (1999) J. Biol Chem. 274, 33035-33042). In this study, we demonstrated that stimulation of RAW 264.7 cells with lipopolysaccharide (LPS) and interferon-pr (IFN-gamma) increased IRP-1 binding activity, whereas WA binding of IRP-2 decreased and was followed by a degradation of this protein. Moreover, the decrease of IRP-2 binding/protein levels was associated with a decrease in TfR mRNA levels in LPS/IFN-gamma-treated cells, and these changes were prevented by inhibitors of inducible nitric oxide synthase. Furthermore, LPS/IFN-gamma-stimulated RAW 264.7 cells showed increased rates of ferritin synthesis. These results suggest that NO+-mediated degradation of IRP-2 plays a major role in iron metabolism during inflammation.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Physiol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Ponka, P (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.		Ponka, Prem/A-4123-2011	Ponka, Prem/0000-0001-5835-1477				ADAMS DO, 1984, ANNU REV IMMUNOL, V2, P283, DOI 10.1146/annurev.immunol.2.1.283; Akaike T, 1997, J BIOCHEM-TOKYO, V122, P459; BASILION JP, 1994, ARCH BIOCHEM BIOPHYS, V311, P517, DOI 10.1006/abbi.1994.1270; BEINERT H, 1993, FASEB J, V7, P1442, DOI 10.1096/fasebj.7.15.8262329; BOURGEADE MF, 1992, NUCLEIC ACIDS RES, V20, P2997, DOI 10.1093/nar/20.12.2997; Bouton C, 1998, J BIOL CHEM, V273, P9403, DOI 10.1074/jbc.273.16.9403; Buga GM, 1998, AM J PHYSIOL-REG I, V275, pR1256, DOI 10.1152/ajpregu.1998.275.4.R1256; BYRD TF, 1989, J CLIN INVEST, V83, P1457, DOI 10.1172/JCI114038; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; EISENSTEIN RS, 1993, J BIOL CHEM, V268, P27363; EMERYGOODMAN A, 1993, NUCLEIC ACIDS RES, V21, P1457, DOI 10.1093/nar/21.6.1457; GREEN SJ, 1994, IMMUNOL LETT, V43, P87, DOI 10.1016/0165-2478(94)00158-8; GUO B, 1994, J BIOL CHEM, V269, P24252; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; HAMILTON TA, 1984, CELL IMMUNOL, V89, P478, DOI 10.1016/0008-8749(84)90348-4; Hanson ES, 1999, J BIOL CHEM, V274, P5047, DOI 10.1074/jbc.274.8.5047; Hanson ES, 1998, J BIOL CHEM, V273, P7588, DOI 10.1074/jbc.273.13.7588; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; Juckett MB, 1996, FREE RADICAL BIO MED, V20, P63, DOI 10.1016/0891-5849(95)02024-1; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; Kim S, 1999, J BIOL CHEM, V274, P33035, DOI 10.1074/jbc.274.46.33035; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KONIJN AM, 1994, BAIL CL HAE, V7, P829, DOI 10.1016/S0950-3536(05)80127-1; KONIJN AM, 1977, BRIT J HAEMATOL, V37, P7, DOI 10.1111/j.1365-2141.1977.tb08806.x; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Lok CN, 1999, J BIOL CHEM, V274, P24147, DOI 10.1074/jbc.274.34.24147; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; Oberle S, 1997, NITRIC OXIDE-BIOL CH, V1, P308, DOI 10.1006/niox.1997.0132; Oberle S., 1998, Nitric Oxide, V2, P104; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; PHILPOTT CC, 1993, J BIOL CHEM, V268, P17655; PONKA P, 1979, BIOCHIM BIOPHYS ACTA, V586, P278, DOI 10.1016/0304-4165(79)90100-4; Ponka P., 1998, Nitric Oxide, V2, P104; Recalcati S, 1998, BLOOD, V91, P1059, DOI 10.1182/blood.V91.3.1059.1059_1059_1066; RICHARDSON DR, 1995, BLOOD, V86, P3211; RICHARDSON DR, 1995, BBA-MOL CELL RES, V1266, P250, DOI 10.1016/0167-4889(95)00022-K; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; RICHARDSON DR, 1996, METH NEUROSCI, V31, P329; ROUAULT TA, 1991, CELL, V64, P381; Schalinske KL, 1997, P NATL ACAD SCI USA, V94, P10681, DOI 10.1073/pnas.94.20.10681; Schalinske KL, 1996, J BIOL CHEM, V271, P7168, DOI 10.1074/jbc.271.12.7168; Simon DI, 1996, P NATL ACAD SCI USA, V93, P4736, DOI 10.1073/pnas.93.10.4736; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Tacchini L, 1999, J BIOL CHEM, V274, P24142, DOI 10.1074/jbc.274.34.24142; THEIL EC, 1993, BIOFACTORS, V4, P87; THEIL EC, 1994, BIOCHEM J, V304, P1; Toth I, 1999, J BIOL CHEM, V274, P4467, DOI 10.1074/jbc.274.7.4467; Vanin AF, 1997, NITRIC OXIDE-BIOL CH, V1, P191, DOI 10.1006/niox.1997.0122; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; Weiss G, 1997, J IMMUNOL, V158, P420; Williams DLH, 1996, METHOD ENZYMOL, V268, P299	61	120	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6220	6226		10.1074/jbc.275.9.6220	http://dx.doi.org/10.1074/jbc.275.9.6220			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692416	hybrid			2022-12-27	WOS:000085654400028
J	Lala, P; Ito, S; Lingwood, CA				Lala, P; Ito, S; Lingwood, CA			Retroviral transfection of Madin-Darby canine kidney cells with human MDR1 results in a major increase in globotriaosylceramide and 10(5)- to 10(6)-fold increased cell sensitivity to verocytotoxin - Role of P-glycoprotein in glycolipid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT CANCER-CELLS; GOLGI-APPARATUS; MULTIDRUG-RESISTANCE; RETROGRADE TRANSPORT; SHIGA TOXIN; MDCK CELLS; SODIUM-BUTYRATE; 2 STRAINS; B-SUBUNIT; VEROTOXIN	Retroviral infection of the Madin-Darby canine kidney (MDCK) renal cell line with human MDR1 cDNA, encoding the P-glycoprotein (P-gp) multidrug resistance efflux pump, induces a major accumulation of the glycosphingolipid (GSL), globotriaosylceramide (Gal alpha 1-4Gal beta 1-4glucosylceramide-Gb(3)), the receptor for the E. coli-derived verotoxin (VT), to effect a similar to million-fold increase in cell sensitivity to VT. The shorter chain fatty acid isoforms of Gb(3) (primarily C16 and C18) are elevated and VT is internalized to the endoplasmic reticulum/nuclear envelope as we have reported for other hypersensitive cell lines. P-gp (but not MRP) inhibitors, e.g. ketoconazole or cyclosporin A (CsA) prevented the increased Gb, and VT sensitivity, concomitant with increased vinblastine sensitivity Gb, synthase was not significantly elevated in MDR1-MDCK cells and was not affected by CsA. In MDR1-MDCK cells, synthesis of fluorescent N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-aminocaproyl (NBD)-lactosylceramide (LacCer) and NBD-Gb(3) via NBD-glucosylceramide (GlcCer) from exogenous NBD-CG-ceramide, was prevented by CsA. me therefore propose that P-gp can mediate GlcCer translocation across the bilayer, from the cytosolic face of the Golgi to the lumen, to provide increased substrate for the lumenal synthesis of LacCer and subsequently Gb(3). These results provide a molecular mechanism for the observed increased sensitivity of multidrug-resistant tumors to VT and emphasize the potential of verotoxin as an antineoplastic, Two strains (I and II) of MDCK cells, which differ in their glycolipid profile, have been described. The original MDR1-MDCK parental cell was not specified, but the MDR1-MDCK GSL phenotype and glycolipid synthase activities indicate MDCK-I cells. However, the partial drug resistance of MDCK-I cells precludes their being the parental cell. We speculate that the retroviral transfection per se, or the subsequent selection for drug resistance, selected a subpopulation of MDCK-I cells in the parental MDCK-H cell culture and that drug resistance in MDR1-MDCK cells is thus a result of both MDR1 expression and a second, previously unrecognized, component, likely the high level of GlcCer synthesis in these cells.	Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Pediat, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto	Lingwood, CA (corresponding author), Hosp Sick Children, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							Arab S, 1999, ONCOL RES, V11, P33; Arab S, 1998, J NEURO-ONCOL, V40, P137, DOI 10.1023/A:1006010019064; Arab S, 1998, J CELL PHYSIOL, V177, P646, DOI 10.1002/(SICI)1097-4652(199812)177:4<646::AID-JCP15>3.0.CO;2-B; Arab S, 1997, ONCOL RES, V9, P553; BALDINI N, 1995, EUR J CELL BIOL, V68, P226; BATES SE, 1992, BIOCHEMISTRY-US, V31, P6366, DOI 10.1021/bi00143a002; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; BOULANGER J, 1994, ANAL BIOCHEM, V217, P1, DOI 10.1006/abio.1994.1075; BOYD B, 1989, NEPHRON, V51, P207, DOI 10.1159/000185286; Cabot MC, 1998, FEBS LETT, V431, P185, DOI 10.1016/S0014-5793(98)00744-3; Ernest S, 1997, NEPHRON, V77, P284, DOI 10.1159/000190289; FARAKASHIMSLEY H, 1995, P NATL ACAD SCI USA, V92, P6996; Gollapudi S, 1997, CANCER CHEMOTH PHARM, V40, P150, DOI 10.1007/s002800050640; HANSSON GC, 1986, EMBO J, V5, P483, DOI 10.1002/j.1460-2075.1986.tb04237.x; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HORIO M, 1989, J BIOL CHEM, V264, P14880; HORIO M, 1990, BIOCHIM BIOPHYS ACTA, V1027, P116, DOI 10.1016/0005-2736(90)90074-X; HUNTER J, 1993, BIOCHIM BIOPHYS ACTA, V1179, P1, DOI 10.1016/0167-4889(93)90069-2; IUPAC-IUB Commission on Biochemical Nomenclature, 1977, LIPIDS, V12, P455; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; Jette L, 1996, AM J PHYSIOL-RENAL, V270, pF756, DOI 10.1152/ajprenal.1996.270.5.F756; KARMALI MA, 1989, CLIN MICROBIOL REV, V2, P15, DOI 10.1128/CMR.2.1.15-38.1989; KHINE AA, 1994, J CELL PHYSIOL, V161, P319, DOI 10.1002/jcp.1041610217; LANNERT H, 1994, FEBS LETT, V342, P91, DOI 10.1016/0014-5793(94)80591-1; Lannert H, 1998, J BIOL CHEM, V273, P2939, DOI 10.1074/jbc.273.5.2939; Lavie Y, 1998, J BIOL CHEM, V273, P32380, DOI 10.1074/jbc.273.49.32380; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; Lingwood CA, 1998, ACTA BIOCHIM POL, V45, P351, DOI 10.18388/abp.1998_4230; LINGWOOD CA, 1994, NEPHRON, V66, P21, DOI 10.1159/000187761; Lingwood CA, 1996, TRENDS MICROBIOL, V4, P147, DOI 10.1016/0966-842X(96)10017-2; LINGWOOD CA, 1998, SHIGA TOXIN VEROTOXI, P129; LIPSKY NG, 1983, P NATL ACAD SCI-BIOL, V80, P2608, DOI 10.1073/pnas.80.9.2608; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; Lucci A, 1998, ANTICANCER RES, V18, P475; Meivar-Levy I, 1999, J BIOL CHEM, V274, P4607, DOI 10.1074/jbc.274.8.4607; MOLINARI A, 1994, INT J CANCER, V59, P789, DOI 10.1002/ijc.2910590614; Molinari A, 1998, INT J CANCER, V75, P885, DOI 10.1002/(SICI)1097-0215(19980316)75:6<885::AID-IJC11>3.0.CO;2-2; MORROW CS, 1994, J BIOL CHEM, V269, P10739; MYHER JJ, 1989, LIPIDS, V24, P396, DOI 10.1007/BF02535147; NICHOLS GE, 1986, BIOCHIM BIOPHYS ACTA, V887, P1, DOI 10.1016/0167-4889(86)90115-1; OBRIG TG, 1993, J BIOL CHEM, V268, P15484; PAGANO RE, 1988, BIOCHEMISTRY-US, V27, P4439, DOI 10.1021/bi00412a034; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; PUDYMAITIS A, 1991, ARCH BIOCHEM BIOPHYS, V286, P448, DOI 10.1016/0003-9861(91)90064-P; Puri A, 1998, P NATL ACAD SCI USA, V95, P14435, DOI 10.1073/pnas.95.24.14435; Raggers RJ, 1999, J CELL SCI, V112, P415; RAMOTAR K, 1990, BIOCHEM J, V272, P805, DOI 10.1042/bj2720805; RICHARDSON JCW, 1981, BIOCHIM BIOPHYS ACTA, V673, P26, DOI 10.1016/0304-4165(81)90307-X; SANDVIG K, 1991, J CELL BIOL, V113, P553, DOI 10.1083/jcb.113.3.553; SANDVIG K, 1994, J CELL BIOL, V126, P53, DOI 10.1083/jcb.126.1.53; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; WILLINGHAM MC, 1987, J HISTOCHEM CYTOCHEM, V35, P1451, DOI 10.1177/35.12.2890686; YUI SCK, 1992, ANAL BIOCHEM, V202, P188; Zhang YC, 1998, PHARMACEUT RES, V15, P1520, DOI 10.1023/A:1011990730230	56	85	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6246	6251		10.1074/jbc.275.9.6246	http://dx.doi.org/10.1074/jbc.275.9.6246			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692420	hybrid			2022-12-27	WOS:000085654400032
J	Okamoto, Y; Ninomiya, H; Miwa, S; Masaki, T				Okamoto, Y; Ninomiya, H; Miwa, S; Masaki, T			Cholesterol oxidation switches the internalization pathway of endothelin receptor type A from caveolae to clathrin-coated pits in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SMOOTH-MUSCLE CELLS; CYTOPLASMIC TAIL; GOLGI-APPARATUS; BETA-ARRESTIN; PHOSPHORYLATION; DESENSITIZATION; SPECIFICITY; ENDOCYTOSIS; FIBROBLASTS	We investigated the mechanism of endothelin receptor type A (ETA) internalization in Chinese hamster ovary cells using two assays; flow cytometric quantification of cell surface myc-ETA and in, situ localization of Cy5-labeled ET-1, In both assays, agonist-dependent internalization of myc-ETA was inhibited by nystatin and filipin, both of which disrupt internalization via caveolae, whereas it was barely affected by chlorpromazine and hypertonic sucrose, both of which disrupt internalization via clathrin coated pits. In addition to myc-ETA, ET-1 caused intracellular translocation of caveolin-1 and this translocation was also blocked by nystatin but not by chlorpromazine, These results strongly argue that ETA is internalized via caveolae but not clathrin-coated pits. Treatment of the cells with cholesterol oxidase reduced cellular cholesterol and caused intracellular translocation of caveolin-1 but did not affect cell surface localization of myc-ETA. In cholesterol oxidase-treated cells, however, both chlorpromazine and hypertonic sucrose effectively blocked ET-1-induced myc-ETA internalization and nystatin was less effective than in untreated cells. Accordingly, expression of a dominant negative form of beta-arrestin blocked myc-ETA internalization in cholesterol oxidase-treated cells but not in untreated cells. These results suggest that, in Chinese hamster ovary cells, 1) agonist-occupied ETA can be internalized either via caveolae or clathrin-coated pits; 2) of the two, the former is the default pathway; and 3) the oxidative state of cell surface cholesterol is one of the factors involved in the pathway selection.	Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 606, Japan; Tottori Univ, Fac Med, Dept Neurobiol, Yonago, Tottori 683, Japan; Natl Cardiovasc Ctr, Res Inst, Suita, Osaka 565, Japan	Kyoto University; Tottori University; National Cerebral & Cardiovascular Center - Japan	Masaki, T (corresponding author), Natl Cardiovasc Ctr, Res Inst, 5-7-1 Fujishirodai, Osaka 5658565, Japan.	masaki@ri.ncvc.go.jp	OKAMOTO, Yasuo/J-8438-2015; Eckhardt, Erik/G-1567-2010; Miwa, Soichi/D-8468-2012					Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Barlic J, 1999, J BIOL CHEM, V274, P16287, DOI 10.1074/jbc.274.23.16287; Bohm SK, 1997, BIOCHEM J, V322, P1; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; DAUTRYVARSAT A, 1983, P NATL ACAD SCI USA, V80, P9681; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; FRA AM, 1994, J BIOL CHEM, V269, P30745; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; Graf GA, 1999, J BIOL CHEM, V274, P12043, DOI 10.1074/jbc.274.17.12043; Haasemann M, 1998, J CELL SCI, V111, P917; HASHIDO K, 1992, BIOCHEM BIOPH RES CO, V187, P1241, DOI 10.1016/0006-291X(92)90436-O; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HOSODA K, 1991, FEBS LETT, V287, P23, DOI 10.1016/0014-5793(91)80007-P; Ishii I, 1998, J BIOL CHEM, V273, P9878, DOI 10.1074/jbc.273.16.9878; Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459; Ito K, 1999, EUR J BIOCHEM, V260, P112, DOI 10.1046/j.1432-1327.1999.00125.x; Jin WZ, 1999, J NEUROSCI, V19, P3773; Kifor O, 1998, J BIOL CHEM, V273, P21708, DOI 10.1074/jbc.273.34.21708; Koike T, 1998, BBA-MOL BASIS DIS, V1406, P327, DOI 10.1016/S0925-4439(98)00019-2; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; LANGE Y, 1989, J BIOL CHEM, V264, P3786; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LIU K, 1991, MOL CELL BIOCHEM, V108, P39; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MASAKI T, 1993, ENDOCR REV, V14, P256, DOI 10.1210/er.14.3.256; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Okamoto Y, 1997, J BIOL CHEM, V272, P21589, DOI 10.1074/jbc.272.34.21589; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Pollegioni L, 1999, BIOTECHNOL APPL BIOC, V30, P27; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SOFER A, 1995, J BIOL CHEM, V270, P12117, DOI 10.1074/jbc.270.20.12117; TAKAGI Y, 1995, J BIOL CHEM, V270, P10072, DOI 10.1074/jbc.270.17.10072; TAKASUKA T, 1992, J BIOCHEM-TOKYO, V112, P396, DOI 10.1093/oxfordjournals.jbchem.a123911; Teixeira A, 1999, J NEUROCHEM, V72, P120, DOI 10.1046/j.1471-4159.1999.0720120.x; Thyberg J, 1997, LAB INVEST, V77, P93; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107	49	137	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6439	6446		10.1074/jbc.275.9.6439	http://dx.doi.org/10.1074/jbc.275.9.6439			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692447	hybrid			2022-12-27	WOS:000085654400059
J	Hipkin, RW; Wang, YN; Schonbrunn, A				Hipkin, RW; Wang, YN; Schonbrunn, A			Protein kinase C activation stimulates the phosphorylation and internalization of the sst2A somatostatin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; IMMUNOHISTOCHEMICAL LOCALIZATION; MEDIATED ENDOCYTOSIS; ADENYLATE-CYCLASE; PEPTIDE RECEPTOR; PHOSPHOLIPASE-C; PITUITARY-CELLS; COS-7 CELLS; BINDING; MODULATION	The sst2A receptor is expressed in the endocrine, gastrointestinal, and neuronal systems as well. as in many hormone-sensitive tumors, This receptor is rapidly internalized and phosphorylated in growth hormone-R2 pituitary cells following somatostatin binding (Hipkin, R. W., Friedman, J., Clark, R, B., Eppler, C. M., and Schonbrunn, A. (1997) J. Biol. Chem. 272, 13869-13876). The protein kinase C (PKC) activator, phorbol 12-myristate 13-acetate (PMA), also stimulates sst2A phosphorylation. Here we examine the mechanisms and consequences of PMA and agonist-induced sst2A phosphorylation. Like somatostatin, both PMA and bombesin increased sst2A receptor phosphorylation within 2 min. The PKC inhibitor GF109203X blocked PMA- and bombesin- stimulated sst2A phosphorylation, whereas stimulation by the somatostatin analog SMS 201-995 was unaffected. Agonist and PMA each stimulated phosphorylation in two receptor domains, the third intracellular loop and the C-terminal tail, Functionally, PMA dramatically increased the internalization of the sst2A receptor-ligand complex, This PMA stimulation was blocked by GF109203X, whereas basal internalization was unaffected. However, neither basal nor PMA-stimulated internalization was altered by pertussis toxin, whereas both were blocked by hypertonic sucrose. Therefore PKC activation and agonist binding stimulate sst2A phosphorylation by distinct mechanisms, and PKC potentiates internalization of the sst2A receptor via clathrin-coated pits. Thus, hormonal stimulation of PKC-coupled receptors may provide a mechanism for regulating the inhibitory actions of somatostatin in target tissue.	Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77225 USA	University of Texas System; University of Texas Health Science Center Houston	Schonbrunn, A (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, POB 20708, Houston, TX 77225 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK032234, R01DK032234] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32234] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKBAR M, 1994, FEBS LETT, V348, P192, DOI 10.1016/0014-5793(94)00603-2; Chen LC, 1997, J BIOL CHEM, V272, P18666, DOI 10.1074/jbc.272.30.18666; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; Delange R J, 1978, Methods Cell Biol, V18, P169; Dent P, 1997, CELL SIGNAL, V9, P539, DOI 10.1016/S0898-6568(97)00048-X; Dournaud P, 1996, J NEUROSCI, V16, P4468; FELLEY CP, 1994, AM J PHYSIOL, V266, pG789, DOI 10.1152/ajpgi.1994.266.5.G789; Garcia DE, 1998, J NEUROSCI, V18, P2834; GOLARD A, 1993, J NEUROPHYSIOL, V70, P1639, DOI 10.1152/jn.1993.70.4.1639; GORDELADZE JO, 1989, EUR J BIOCHEM, V183, P397, DOI 10.1111/j.1432-1033.1989.tb14941.x; Greene NM, 1997, J BIOL CHEM, V272, P10341; Gu YZ, 1997, MOL ENDOCRINOL, V11, P527, DOI 10.1210/me.11.5.527; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; Hofland LJ, 1999, J CLIN ENDOCR METAB, V84, P775, DOI 10.1210/jc.84.2.775; Hukovic N, 1996, ENDOCRINOLOGY, V137, P4046, DOI 10.1210/en.137.9.4046; Hunyady B, 1997, ENDOCRINOLOGY, V138, P2632; Hurley JB, 1998, VISION RES, V38, P1341, DOI 10.1016/S0042-6989(97)00459-8; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KER A, 1998, FRONT BIOSCI, V3, pD1134; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; LISCHWE MA, 1982, ANAL BIOCHEM, V127, P453, DOI 10.1016/0003-2697(82)90203-2; MARIN P, 1991, P NATL ACAD SCI USA, V88, P9016, DOI 10.1073/pnas.88.20.9016; MATOZAKI T, 1986, J BIOL CHEM, V261, P1414; MAYOR F, 1987, J BIOL CHEM, V262, P6468; Meyerhof W, 1998, Rev Physiol Biochem Pharmacol, V133, P55; Mezey E, 1998, ENDOCRINOLOGY, V139, P414, DOI 10.1210/en.139.1.414; Murthy KS, 1996, J BIOL CHEM, V271, P23458, DOI 10.1074/jbc.271.38.23458; Nouel D, 1997, ENDOCRINOLOGY, V138, P296, DOI 10.1210/en.138.1.296; OSBORNE R, 1982, CANCER RES, V42, P4375; Parmar RM, 1999, BIOCHEM BIOPH RES CO, V263, P276, DOI 10.1006/bbrc.1999.1376; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; REUBI JC, 1995, J RECEPT SIGNAL TR R, V15, P379, DOI 10.3109/10799899509045228; Reubi JC, 1999, J CLIN ENDOCR METAB, V84, P2942, DOI 10.1210/jc.84.8.2942; Reubi JC, 1998, J CLIN ENDOCR METAB, V83, P3746, DOI 10.1210/jc.83.10.3746; Reubi JC, 1998, AM J PATHOL, V153, P233, DOI 10.1016/S0002-9440(10)65564-2; Roosterman D, 1997, J NEUROENDOCRINOL, V9, P741, DOI 10.1046/j.1365-2826.1997.00632.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schonbrunn A, 1996, METABOLISM, V45, P8, DOI 10.1016/S0026-0495(96)90069-4; SCHONBRUNN A, 1980, J BIOL CHEM, V255, P190; Shapiro MS, 1996, J NEUROPHYSIOL, V76, P311, DOI 10.1152/jn.1996.76.1.311; SHEN KZ, 1993, J PHYSIOL-LONDON, V470, P619, DOI 10.1113/jphysiol.1993.sp019878; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Williams BY, 1996, MOL PHARMACOL, V50, P716; ZEGGARI M, 1985, BIOCHEM BIOPH RES CO, V128, P850, DOI 10.1016/0006-291X(85)90124-X	47	69	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5591	5599		10.1074/jbc.275.8.5591	http://dx.doi.org/10.1074/jbc.275.8.5591			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681540	hybrid			2022-12-27	WOS:000085474500047
J	Gueguen, V; Macherel, D; Jaquinod, M; Douce, R; Bourguignon, J				Gueguen, V; Macherel, D; Jaquinod, M; Douce, R; Bourguignon, J			Fatty acid and lipoic acid biosynthesis in higher plant mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-CARRIER PROTEIN; PEA LEAF MITOCHONDRIA; ESCHERICHIA-COLI; GLYCINE DECARBOXYLASE; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; ARABIDOPSIS-THALIANA; MALONYL-COENZYME; OCTANOIC-ACID; GENE-PRODUCT	Fatty acid and lipoic acid biosynthesis were investigated in plant mitochondria. Although the mitochondria lack acetyl-CoA carboxylase, our experiments reveal that they contain the enzymatic equipment necessary to transform malonate into the two main building units for fatty acid synthesis: malonyl- and acetyl-acyl carrier protein (ACP), We demonstrated, by a new method based on a complementary use of high performance liquid chromatography and mass spectrometry, that the soluble mitochondrial fatty-acid synthase produces mainly three predominant acyl-ACPs as follows: octanoyl(C8)-, hexadecanoyl(C16)-, and octadecanoyl (C18)-ACP. Octanoate production is of primary interest since it has been postulated long ago to be a precursor of lipoic acid. By using a recombinant H apoprotein mutant as a potential acceptor for newly synthesized lipoic acid, we were able to detect limited amounts of lipoylated H protein in the presence of malonate, several sulfur donors, and cofactors, Finally, we present a scheme outlining the new biochemical pathway of fatty acid and lipoic acid synthesis in plant mitochondria.	Univ Grenoble 1, CEA, CNRS, Dept Biol Mol & Struct,URA 576,Lab Physiol Cellul, F-38054 Grenoble 9, France; Inst Biol Struct, CNRS, CEA, Lab Spectrometrie Mass Prot, F-38027 Grenoble 1, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Bourguignon, J (corresponding author), Univ Grenoble 1, CEA, CNRS, Dept Biol Mol & Struct,URA 576,Lab Physiol Cellul, 17 Rue Martyrs, F-38054 Grenoble 9, France.	jacques.bourguignon@cea.fr	Macherel, David/B-2084-2012	Macherel, David/0000-0002-3352-2185; Bourguignon, jacques/0000-0001-7517-0600				ALBERTS AW, 1972, J BIOL CHEM, V247, P3190; BALDET P, 1993, ARCH BIOCHEM BIOPHYS, V303, P67, DOI 10.1006/abbi.1993.1256; Baldet P, 1997, FEBS LETT, V419, P206, DOI 10.1016/S0014-5793(97)01458-0; BOURGUIGNON J, 1988, BIOCHEM J, V255, P169, DOI 10.1042/bj2550169; Brody S, 1997, FEBS LETT, V408, P217, DOI 10.1016/S0014-5793(97)00428-6; BRODY S, 1988, EUR J BIOCHEM, V173, P353, DOI 10.1111/j.1432-1033.1988.tb14005.x; Bui BTS, 1998, FEBS LETT, V440, P226, DOI 10.1016/S0014-5793(98)01464-1; Busby RW, 1999, J AM CHEM SOC, V121, P4706, DOI 10.1021/ja990134g; Chen XJ, 1997, MOL GEN GENET, V255, P341, DOI 10.1007/s004380050505; Choudens Sandrine Ollagnier-de, 1999, FEBS Letters, V453, P25; DOUCE R, 1994, BIOCHEM SOC T, V22, P184, DOI 10.1042/bst0220184; DOUCE R, 1987, METHOD ENZYMOL, V148, P403; Douce R., 1985, MITOCHONDRIA HIGHER; FUJIWARA K, 1994, J BIOL CHEM, V269, P16605; Fujiwara K, 1999, EUR J BIOCHEM, V260, P761, DOI 10.1046/j.1432-1327.1999.00204.x; Fujiwara K, 1997, J BIOL CHEM, V272, P31974, DOI 10.1074/jbc.272.51.31974; GREEN DE, 1995, BIOCHEM J, V309, P853, DOI 10.1042/bj3090853; Gueguen V, 1999, J BIOL CHEM, V274, P26344, DOI 10.1074/jbc.274.37.26344; GUERRA DJ, 1986, ARCH BIOCHEM BIOPHYS, V245, P274; Harwood JL, 1996, BBA-LIPID LIPID MET, V1301, P7, DOI 10.1016/0005-2760(95)00242-1; HAYDEN MA, 1992, J BIOL CHEM, V267, P9512; HAYDEN MA, 1993, BIOCHEMISTRY-US, V32, P3778, DOI 10.1021/bi00065a033; HERBERT AA, 1968, J GEN MICROBIOL, V53, P363, DOI 10.1099/00221287-53-3-363; Jordan SW, 1997, J BIOL CHEM, V272, P17903, DOI 10.1074/jbc.272.29.17903; KIM YS, 1991, BIOCHEM J, V273, P511, DOI 10.1042/bj2730511; KIM YS, 1988, ANAL BIOCHEM, V170, P45, DOI 10.1016/0003-2697(88)90087-5; KIM YS, 1985, J BIOL CHEM, V260, P5098; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Macherel D, 1996, EUR J BIOCHEM, V236, P27, DOI 10.1111/j.1432-1033.1996.00027.x; MIKOLAJCZYK S, 1990, EUR J BIOCHEM, V187, P431, DOI 10.1111/j.1432-1033.1990.tb15322.x; MORRIS TW, 1995, J BACTERIOL, V177, P1; MORRIS TW, 1994, J BIOL CHEM, V269, P16091; OHLROGGE J, 1995, PLANT CELL, V7, P957, DOI 10.1105/tpc.7.7.957; OLIVER DJ, 1990, PLANT PHYSIOL, V94, P833, DOI 10.1104/pp.94.2.833; PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R; PARES S, 1994, P NATL ACAD SCI USA, V91, P4850, DOI 10.1073/pnas.91.11.4850; PARRY RJ, 1983, TETRAHEDRON, V39, P1215, DOI 10.1016/S0040-4020(01)91887-3; PARRY RJ, 1978, J AM CHEM SOC, V100, P5243, DOI 10.1021/ja00484a073; PARRY RJ, 1977, J AM CHEM SOC, V99, P6464, DOI 10.1021/ja00461a061; Rebeille F, 1997, EMBO J, V16, P947, DOI 10.1093/emboj/16.5.947; Reche P, 1999, EMBO J, V18, P2673, DOI 10.1093/emboj/18.10.2673; REED KE, 1993, J BACTERIOL, V175, P1325, DOI 10.1128/JB.175.5.1325-1336.1993; Reed LJ, 1998, PROTEIN SCI, V7, P220, DOI 10.1002/pro.5560070125; RILEY KM, 1991, NEUROCHEM RES, V16, P117, DOI 10.1007/BF00965698; Rock C O, 1981, Methods Enzymol, V71 Pt C, P341; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schneider R, 1997, FEBS LETT, V407, P249, DOI 10.1016/S0014-5793(97)00360-8; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHINTANI DK, 1994, PLANT PHYSIOL, V104, P1221, DOI 10.1104/pp.104.4.1221; STUMPF DK, 1981, PLANT PHYSIOL, V68, P989, DOI 10.1104/pp.68.5.989; SULO P, 1993, J BIOL CHEM, V268, P17634; VANDENBOOM TJ, 1991, J BACTERIOL, V173, P6411, DOI 10.1128/jb.173.20.6411-6420.1991; VISE AB, 1967, J GEN MICROBIOL, V48, P87, DOI 10.1099/00221287-48-1-87; VIVEKANANDA J, 1988, J BIOL CHEM, V263, P4782; Wada H, 1997, P NATL ACAD SCI USA, V94, P1591, DOI 10.1073/pnas.94.4.1591; WHITE RH, 1980, J AM CHEM SOC, V102, P6605, DOI 10.1021/ja00541a059; WHITE RH, 1980, BIOCHEMISTRY-US, V19, P15, DOI 10.1021/bi00542a003; Yasuno R, 1998, PLANT PHYSIOL, V118, P935, DOI 10.1104/pp.118.3.935	59	142	149	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5016	5025		10.1074/jbc.275.7.5016	http://dx.doi.org/10.1074/jbc.275.7.5016			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671542	hybrid			2022-12-27	WOS:000085378200068
J	Zent, R; Fenczik, CA; Calderwood, DA; Liu, SC; Dellos, M; Ginsberg, MH				Zent, R; Fenczik, CA; Calderwood, DA; Liu, SC; Dellos, M; Ginsberg, MH			Class- and splice variant-specific association of CD98 with integrin beta cytoplasmic domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSION REGULATORY PROTEIN-1; AMINO-ACID-TRANSPORT; GP160-MEDIATED CELL-FUSION; MONOCLONAL-ANTIBODIES; SIGNAL-TRANSDUCTION; IN-VITRO; MODULATION; ACTIVATION; EXPRESSION; MIGRATION	CD98 is a type II transmembrane protein involved in neutral and basic amino acid transport and in cell fusion events. CD98 was implicated in the function of integrin adhesion receptors by its capacity to reverse suppression of integrin activation by isolated integrin beta(1A) domains. Here we report that CD98 associates with integrin beta cytoplasmic domains with a unique integrin class and splice variant specificity. In particular, CD98 interacted with the ubiquitous beta(1A) but not the muscle-specific splice variant, beta(1D), or leukocyte-specific beta(7) cytoplasmic domains. The ability of CD98 to associate with integrin cytoplasmic domains correlated with its capacity to reverse suppression of integrin activation. The association of CD98 with integrin beta(1A) cytoplasmic domains may regulate the function and localization of these membrane proteins.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Ginsberg, MH (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ginsberg@scripps.edu	Calderwood, David A/AAC-6954-2019	Calderwood, David A/0000-0002-0791-4142	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027214, R37AR027214] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48728] Funding Source: Medline; NIAMS NIH HHS [AR27214] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALIG L, 1992, J MED CHEM, V35, P4393, DOI 10.1021/jm00101a017; Baker EK, 1997, P NATL ACAD SCI USA, V94, P1973, DOI 10.1073/pnas.94.5.1973; Belkin AM, 1997, J CELL BIOL, V139, P1583, DOI 10.1083/jcb.139.6.1583; Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; Chandrasekaran S, 1999, J BIOL CHEM, V274, P11408, DOI 10.1074/jbc.274.16.11408; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Diaz LA, 1998, J BIOL REG HOMEOS AG, V12, P25; Estevez R, 1998, FASEB J, V12, P1319, DOI 10.1096/fasebj.12.13.1319; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; HAYNES BF, 1981, J IMMUNOL, V126, P1409; Higuchi S, 1998, J BONE MINER RES, V13, P44, DOI 10.1359/jbmr.1998.13.1.44; HODIVALA KJ, 1994, J CELL BIOL, V124, P589, DOI 10.1083/jcb.124.4.589; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Huttenlocher A, 1996, J CELL BIOL, V134, P1551, DOI 10.1083/jcb.134.6.1551; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ITO M, 1994, J IMMUNOL, V153, P3256; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Mannion BA, 1998, J BIOL CHEM, V273, P33127, DOI 10.1074/jbc.273.50.33127; Martin-Bermudo MD, 1998, J CELL BIOL, V141, P1073, DOI 10.1083/jcb.141.4.1073; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; Ohgimoto S, 1996, J GEN VIROL, V77, P2747, DOI 10.1099/0022-1317-77-11-2747; OHGIMOTO S, 1995, J IMMUNOL, V155, P3585; OHTA H, 1994, EMBO J, V13, P2044, DOI 10.1002/j.1460-2075.1994.tb06479.x; Okamoto K, 1997, J GEN VIROL, V78, P775, DOI 10.1099/0022-1317-78-4-775; Okamoto K, 1997, J GEN VIROL, V78, P83, DOI 10.1099/0022-1317-78-1-83; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; Pfeiffer R, 1999, EMBO J, V18, P49, DOI 10.1093/emboj/18.1.49; RAHILLY MA, 1993, J PATHOL, V170, P297, DOI 10.1002/path.1711700313; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SIMON EE, 1994, AM J PHYSIOL-RENAL, V267, pF612, DOI 10.1152/ajprenal.1994.267.4.F612; Suga S, 1997, MED MICROBIOL IMMUN, V185, P237, DOI 10.1007/s004300050036; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; Torrents D, 1999, NAT GENET, V21, P293, DOI 10.1038/6809; Tsurudome M, 1999, J IMMUNOL, V162, P2462; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853	44	88	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5059	5064		10.1074/jbc.275.7.5059	http://dx.doi.org/10.1074/jbc.275.7.5059			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671548	hybrid			2022-12-27	WOS:000085378200074
J	Tetsuka, T; Uranishi, H; Imai, H; Ono, T; Sonta, S; Takahashi, N; Asamitsu, K; Okamoto, T				Tetsuka, T; Uranishi, H; Imai, H; Ono, T; Sonta, S; Takahashi, N; Asamitsu, K; Okamoto, T			Inhibition of nuclear factor-kappa B-mediated transcription by association with the amino-terminal enhancer of split, a Groucho-related protein lacking WD40 repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; RAT MESANGIAL CELLS; DROSOPHILA-ENHANCER; SACCHAROMYCES-CEREVISIAE; REPRESSION DOMAIN; BINDING PROTEIN; KINASE KINASE-1; GENE-PRODUCT; DNA-BINDING; ACTIVATION	The amino-terminal enhancer of split (AES) encodes a 197-amino acid protein that is homologous to the NH2-terminal domain of the Drosophila Groucho protein but lacks COOH-terminal WD40 repeats. Although the Drosophila Groucho protein and its mammalian homologs, transducin-like enhancer of split proteins, are known to act as non-DNA binding corepressors, the role of the AES protein remains unclarified. Using the yeast two-hybrid system, we have identified the protein-protein interaction between AES and the p65 (Re1A) subunit of the transcription factor nuclear factor kappa B (NF-kappa B), which activates various target genes involved in inflammation, apoptosis, and embryonic development. The interaction between AES and p65 was confirmed by in vitro glutathione S-transferase pull down assay and by in vivo co-immunoprecipitation study. In transient transfection assays, AES repressed p65-driven gene expression. AES also inhibited NF-kappa B-dependent gene expression induced by tumor necrosis factor alpha, interleukin-1 beta, and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1, which is an upstream kinase for NF-kappa B activation. These data indicate that AES acts as a corepressor for NF-kappa B and suggest that AES may play a pivotal role in the regulation of NF-kappa B target genes.	Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Aichi Human Serv Ctr, Dept Genet, Inst Dev Res, Kasugai, Aichi 4800392, Japan	Nagoya City University	Okamoto, T (corresponding author), Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.		Ono, Takao/C-6065-2017	Ono, Takao/0000-0002-0498-8293; Asamitsu, Kaori/0000-0001-5333-8011				Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; COOPER JP, 1994, GENE DEV, V8, P1400, DOI 10.1101/gad.8.12.1400; COUREY AJ, 1995, BBA-GENE STRUCT EXPR, V1261, P1, DOI 10.1016/0167-4781(94)00234-T; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Huang JD, 1995, GENE DEV, V9, P3177, DOI 10.1101/gad.9.24.3177; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; MALLO M, 1993, MECH DEVELOP, V42, P67, DOI 10.1016/0925-4773(93)90099-J; Mallo M, 1995, CELL MOL BIOL RES, V41, P435; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; MIYASAKA H, 1993, EUR J BIOCHEM, V216, P343, DOI 10.1111/j.1432-1033.1993.tb18151.x; MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; OKAMOTO T, 1989, AIDS RES HUM RETROV, V5, P131, DOI 10.1089/aid.1989.5.131; Palaparti A, 1997, J BIOL CHEM, V272, P26604, DOI 10.1074/jbc.272.42.26604; Parkhurst SM, 1998, TRENDS GENET, V14, P130, DOI 10.1016/S0168-9525(98)01407-3; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Pinto M, 1996, J BIOL CHEM, V271, P33026, DOI 10.1074/jbc.271.51.33026; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Sato T, 1998, AIDS RES HUM RETROV, V14, P293, DOI 10.1089/aid.1998.14.293; SCHMIDT CJ, 1993, J BIOL CHEM, V268, P25681; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Song WJ, 1996, MOL CELL BIOL, V16, P115; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; Tetsuka T, 1996, J CLIN INVEST, V97, P2051, DOI 10.1172/JCI118641; Tetsuka T, 1996, J BIOL CHEM, V271, P11689, DOI 10.1074/jbc.271.20.11689; Tolkunova EN, 1998, MOL CELL BIOL, V18, P2804, DOI 10.1128/MCB.18.5.2804; Valentine SA, 1998, MOL CELL BIOL, V18, P6584, DOI 10.1128/MCB.18.11.6584; WAHI M, 1995, GENETICS, V140, P79; Yang JP, 1999, J BIOL CHEM, V274, P15662, DOI 10.1074/jbc.274.22.15662; Yoshida S, 1999, J IMMUNOL, V163, P351; Yoza BK, 1996, J BIOL CHEM, V271, P18306, DOI 10.1074/jbc.271.31.18306; Zandi E, 1999, MOL CELL BIOL, V19, P4547	50	78	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4383	4390		10.1074/jbc.275.6.4383	http://dx.doi.org/10.1074/jbc.275.6.4383			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660609	hybrid			2022-12-27	WOS:000085288800093
J	Ghosh, AK; Majumder, M; Steele, R; Yaciuk, P; Chrivia, J; Ray, R; Ray, RB				Ghosh, AK; Majumder, M; Steele, R; Yaciuk, P; Chrivia, J; Ray, R; Ray, RB			Hepatitis C virus NS5A protein modulates transcription through a novel cellular transcription factor SRCAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; CARCINOMA; INHIBITOR; KINASE; P21; PHOSPHORYLATION; REGION; VITRO; CELLS	Hepatitis C virus NS5A protein transcriptionally modulates cellular genes and promotes cell growth. NS5A is likely to exert its activity in concert with cellular factor(s), Using a yeast two-hybrid screen, we have demonstrated that NS5A interacts with the C-terminal end of a newly identified cellular transcription factor, SRCAP, The authenticity of this interaction was verified by a mammalian two-hybrid assay, in vitro pull-down experiment, and an in vivo coimmunoprecipitation assay in human hepatoma (HepG2) cells. An in vitro transient transfection assay demonstrated that SRCAP can efficiently activate transcription when recruited by the Gal4 DNA-binding domain to the promoter. However, down-regulation of p21 promoter activity by NS5A was enhanced following ectopic expression of SRCAP, Together these results suggest that the interaction of NS5A and SRCAP may be one of the mechanisms by which NS5A exerts its effect on cell growth regulation contributing to hepatitis C virus-mediated pathogenesis.	St Louis Univ, Dept Pathol, St Louis, MO 63104 USA; St Louis Univ, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA; St Louis Univ, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; St Louis Univ, Div Infect Dis & Immunol, St Louis, MO 63104 USA	Saint Louis University; Saint Louis University; Saint Louis University; Saint Louis University	Ray, RB (corresponding author), St Louis Univ, Dept Pathol, 1402 S Grand Blvd,4th Fl, St Louis, MO 63104 USA.				NIAID NIH HHS [AI45144] Funding Source: Medline; NIDDK NIH HHS [DK56143] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI045144, R01AI045144] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK056143] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DiBisceglie AM, 1997, HEPATOLOGY, V26, pS34, DOI 10.1002/hep.510260706; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gale M, 1999, J VIROL, V73, P6506, DOI 10.1128/JVI.73.8.6506-6516.1999; Ghosh AK, 1999, J GEN VIROL, V80, P1179, DOI 10.1099/0022-1317-80-5-1179; Ghosh AK, 1999, GENE, V235, P85, DOI 10.1016/S0378-1119(99)00206-1; Ghosh AK, 1999, BIOCHEM BIOPH RES CO, V260, P405, DOI 10.1006/bbrc.1999.0921; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HARPER JW, 1993, CELL, V75, P805; Hirota M, 1999, VIROLOGY, V257, P130, DOI 10.1006/viro.1999.9658; Ide Y, 1997, GENE, V201, P151, DOI 10.1016/S0378-1119(97)00440-X; Johnston H, 1999, J BIOL CHEM, V274, P16370, DOI 10.1074/jbc.274.23.16370; KANEKO T, 1994, BIOCHEM BIOPH RES CO, V205, P320, DOI 10.1006/bbrc.1994.2667; Kato N, 1997, J VIROL, V71, P8856, DOI 10.1128/JVI.71.11.8856-8859.1997; McKnight SL, 1996, GENE DEV, V10, P367, DOI 10.1101/gad.10.4.367; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PURCELL RH, 1994, P NATL ACAD SCI USA, V91, P2401, DOI 10.1073/pnas.91.7.2401; RAY RB, 1995, CANCER RES, V55, P3747; Reed KE, 1999, J BIOL CHEM, V274, P28011, DOI 10.1074/jbc.274.39.28011; Reed KE, 1997, J VIROL, V71, P7187, DOI 10.1128/JVI.71.10.7187-7197.1997; ROBERTS SGE, 1995, NATURE, V375, P105, DOI 10.1038/375105a0; SHEIKH MS, 1995, ONCOGENE, V11, P1899; Tan SL, 1999, P NATL ACAD SCI USA, V96, P5533, DOI 10.1073/pnas.96.10.5533; Tanimoto A, 1997, BIOCHEM BIOPH RES CO, V236, P360, DOI 10.1006/bbrc.1997.6967; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; Tu H, 1999, VIROLOGY, V263, P30, DOI 10.1006/viro.1999.9893; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388	29	71	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7184	7188		10.1074/jbc.275.10.7184	http://dx.doi.org/10.1074/jbc.275.10.7184			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702287	hybrid			2022-12-27	WOS:000085809600067
J	Nihalani, D; Merritt, S; Holzman, LB				Nihalani, D; Merritt, S; Holzman, LB			Identification of structural and functional domains in mixed lineage kinase dual leucine zipper-bearing kinase required for complex formation and stress-activated protein kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; PATHWAY; CASCADE; YEAST; STE5; JNK; DIMERIZATION; MECHANISM; FAMILY	Accumulating evidence suggests that mitogen-activated protein kinase signaling pathways form modular signaling complexes. Because the mixed lineage kinase dual leucine zipper-bearing kinase (DLK) is a large modular protein, structure-function analysis was undertaken to examine the role of DLK domains in macromolecular complex formation. DLK mutants were used to demonstrate that a DLK leucine zipper-leucine zipper interaction is necessary for DLK dimerization and to show that DLK dimerization mediated by the leucine zipper domain is prerequisite for DLK activity and subsequent activation of stress-activated protein kinase (SAPK), Heterologous mixed lineage kinase family members can he co-immunoprecipitated. However, the DLK leucine zipper domain interacted specifically only with the DLK leucine zipper domain; in contrast, DLK NH2-terminal region was sufficient to co-immunoprecipitate leucine zipper kinase and DLK, DLK has been shown to associate with the putative scaffold protein JIP1, This association occurred through the DLK NH2-terminal region and occurred independently of DLK catalytic activity. Although the DLK NH2-terminal region associated directly with JIP-1, this region did not interact directly with either DLK or leucine zipper kinase. Therefore, DLK may interact with heterologous mixed lineage kinase proteins via intermediary proteins. The NH2-terminal region of overexpressed DLK was required for activation of SAPK, These results provide evidence that protein complex formation is required for signal transduction from DLK to SAPK.	Univ Michigan, Sch Med, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA; Dept Vet Affairs, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan	Holzman, LB (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, Div Nephrol, 1560 MSRB 2, Ann Arbor, MI 48109 USA.		nihalani, deepak/AAK-9453-2020	Holzman, Lawrence/0000-0002-8961-234X	NIDDK NIH HHS [DK52886] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052886] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; CHOI KY, 1994, CELL, V78, P499; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hirai S, 1996, ONCOGENE, V12, P641; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Mata M, 1996, J BIOL CHEM, V271, P16888, DOI 10.1074/jbc.271.28.16888; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; PRINTEN JA, 1994, GENETICS, V138, P609; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143	30	59	60	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7273	7279		10.1074/jbc.275.10.7273	http://dx.doi.org/10.1074/jbc.275.10.7273			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702297	hybrid			2022-12-27	WOS:000085809600077
J	Rusinol, AE; Yang, L; Thewke, D; Panini, SR; Kramer, MF; Sinensky, MS				Rusinol, AE; Yang, L; Thewke, D; Panini, SR; Kramer, MF; Sinensky, MS			Isolation of a somatic cell mutant resistant to the induction of apoptosis by oxidized low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC LESIONS; OXYSTEROL-INDUCED APOPTOSIS; HUMAN ENDOTHELIAL-CELLS; COENZYME-A REDUCTASE; SMOOTH-MUSCLE CELLS; HUMAN-MONOCYTES; CULTURED HUMAN; CHOLESTEROL-METABOLISM; PERMEABILITY CHANGES; CA2+ CHANNELS	Oxidized low density Lipoprotein (oxLDL) induces apoptosis in macrophages, smooth muscle cells, and endothelial cells. To elucidate the molecular mechanism of oxLDL-induced cytotoxicity and determine its tissue specificity, we have used Chinese hamster ovary (CHO)-K1 cells expressing human CD36 (CHO/CD36), Expression of CD36 rendered these cells susceptible to killing by oxLDL, This cytotoxicity was due to the induction of apoptosis, Therefore, CD36 expression is the only requirement for oxLDL-induced apoptosis. Oxysterols apparently mediate the cytotoxicity of oxLDL in macrophage foam cells and endothelial cells. 25-Hydroxycholesterol at concentrations higher than 1 mu g/ml, killed CHO-K1 cells, by apoptosis, in medium supplemented with serum as a source of cholesterol, These effects mere not seen in a 25-hydroxycholesterol-resistant CHO/CD36 mutant (OXR), which was otherwise capable of undergoing apoptosis in response to staurosporine. This mutant was also resistant to killing by oxLDL, suggesting that oxysterols are at least partially responsible for the toxic effects of oxLDL. Oxysterol-induced apoptosis did not involve regulation of sterol regulatory element-binding protein proteolysis or the cholesterol biosynthetic pathway. 25-Hydroxycholesterol stimulated calcium uptake by CHO-K1 cells within 2 min after addition. Treatment of CHO or THP-1 (macrophage) cells with the calcium channel blocker nifedipine prevented 25-hydroxycholesterol induction of apoptosis, OXR showed no enhanced calcium uptake in response to 25-hydroxycholesterol.	E Tennessee State Univ, Dept Biochem & Mol Biol, James H Quillen Coll Med, Johnson City, TN 37614 USA	East Tennessee State University	Sinensky, MS (corresponding author), E Tennessee State Univ, Dept Biochem & Mol Biol, James H Quillen Coll Med, Box 70581, Johnson City, TN 37614 USA.							ACTON SL, 1994, J BIOL CHEM, V269, P21003; ARAKI S, 1990, BIOCHEM BIOPH RES CO, V168, P1194, DOI 10.1016/0006-291X(90)91155-L; Ares MPS, 1997, J LIPID RES, V38, P2049; Auge N, 1996, J BIOL CHEM, V271, P19251, DOI 10.1074/jbc.271.32.19251; Aupeix K, 1996, BIOCHEM J, V314, P1027, DOI 10.1042/bj3141027; AUPEIX K, 1995, IMMUNOBIOLOGY, V194, P415, DOI 10.1016/S0171-2985(11)80108-7; AyalaTorres S, 1997, EXP CELL RES, V235, P35, DOI 10.1006/excr.1997.3630; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Bjorkerud B, 1996, ARTERIOSCL THROM VAS, V16, P416, DOI 10.1161/01.ATV.16.3.416; Bjorkerud S, 1996, AM J PATHOL, V149, P367; BOISSONNEAULT GA, 1985, J CELL PHYSIOL, V125, P471, DOI 10.1002/jcp.1041250316; Brown AJ, 1997, J LIPID RES, V38, P1730; Calvo D, 1998, J LIPID RES, V39, P777; Chang TY, 1997, CURR OPIN LIPIDOL, V8, P65, DOI 10.1097/00041433-199704000-00003; CHISOLM GM, 1994, P NATL ACAD SCI USA, V91, P11452, DOI 10.1073/pnas.91.24.11452; CHRIST M, 1993, IMMUNOLOGY, V78, P455; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DEBONO DP, 1995, ATHEROSCLEROSIS, V114, P235, DOI 10.1016/0021-9150(94)05488-5; Dimmeler S, 1997, CIRCULATION, V95, P1760; Draczynska-Lusiak B, 1998, NEUROREPORT, V9, P527, DOI 10.1097/00001756-199802160-00028; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; EHRENWALD E, 1994, J CLIN INVEST, V93, P1493, DOI 10.1172/JCI117127; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; EscargueilBlanc I, 1997, ARTERIOSCL THROM VAS, V17, P331, DOI 10.1161/01.ATV.17.2.331; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; Harada K, 1997, FEBS LETT, V411, P63, DOI 10.1016/S0014-5793(97)00662-5; Harada-Shiba M, 1998, J BIOL CHEM, V273, P9681, DOI 10.1074/jbc.273.16.9681; HAVEL RI, 1955, J CLIN INVEST, V39, P1345; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HIRAMATSU K, 1987, ARTERIOSCLEROSIS, V7, P55, DOI 10.1161/01.ATV.7.1.55; JIANG S, 1994, EXP CELL RES, V21, P284; JUNTTIBERGGREN L, 1993, SCIENCE, V261, P86, DOI 10.1126/science.7686306; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; LAMB DJ, 1995, FEBS LETT, V374, P12, DOI 10.1016/0014-5793(95)01068-P; LEONARD S, 1988, BIOCHIM BIOPHYS ACTA, V947, P101, DOI 10.1016/0304-4157(88)90021-4; Lizard G, 1999, ARTERIOSCL THROM VAS, V19, P1190, DOI 10.1161/01.ATV.19.5.1190; Messmer UK, 1996, J BIOL CHEM, V271, P20192, DOI 10.1074/jbc.271.33.20192; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; MOREL DW, 1983, J LIPID RES, V24, P1070; Murugesan G, 1996, J CLIN INVEST, V97, P2736, DOI 10.1172/JCI118728; NAKANO T, 1994, P NATL ACAD SCI USA, V91, P1069, DOI 10.1073/pnas.91.3.1069; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Papassotiropoulos A, 1996, NEUROSCI LETT, V209, P33, DOI 10.1016/0304-3940(96)12595-7; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P3000, DOI 10.1073/pnas.82.9.3000; PEFFLEY D, 1988, SOMAT CELL MOLEC GEN, V14, P527, DOI 10.1007/BF01535308; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SEVANIAN A, 1995, J LIPID RES, V36, P1971; SINENSKY M, 1979, J BIOL CHEM, V254, P4482; SINENSKY M, 1980, P NATL ACAD SCI-BIOL, V77, P6621, DOI 10.1073/pnas.77.11.6621; SINENSKY M, 1979, FEBS LETT, V106, P129, DOI 10.1016/0014-5793(79)80709-7; SKRYMA R, 1994, FEBS LETT, V349, P289, DOI 10.1016/0014-5793(94)00690-3; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; Sugawa M, 1997, BRAIN RES, V761, P165, DOI 10.1016/S0006-8993(97)00468-X; Thewke DP, 1998, J BIOL CHEM, V273, P21402, DOI 10.1074/jbc.273.33.21402; YAROM M, 1985, J BIOL CHEM, V260, P6286; YLAHERTTUALA S, 1995, J CLIN INVEST, V95, P2692, DOI 10.1172/JCI117971; YUI S, 1993, ARTERIOSCLER THROMB, V13, P331, DOI 10.1161/01.ATV.13.3.331	63	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7296	7303		10.1074/jbc.275.10.7296	http://dx.doi.org/10.1074/jbc.275.10.7296			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702300	Green Published, hybrid			2022-12-27	WOS:000085809600080
J	Aoki, M; Schetter, C; Himly, M; Batista, O; Chang, HW; Vogt, PK				Aoki, M; Schetter, C; Himly, M; Batista, O; Chang, HW; Vogt, PK			The catalytic subunit of phosphoinositide 3-kinase: Requirements for oncogenicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; VIRUS GAG PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; REGULATORY SUBUNIT; C-AKT; TRANSFORMATION; ACTIVATION; SARCOMA; CARCINOMAS; SUFFICIENT	The retroviral oncogene p3k (v-p3k) of avian sarcoma virus 16 (ASV16) codes for the catalytic subunit of phosphoinositide (PI) 3-kinase, p110 alpha. The v-P3k protein is oncogenic in vivo and in vitro; its cellular counterpart, c-P3k, lacks oncogenicity, Fusion of viral Gag sequences to the amino terminus of c-P3k activates the transforming potential, Activation can also be achieved by the addition of a myristylation signal to the amino terminus or of a farnesylation signal to the carboxyl terminus of c-P3k, A mutated myristylation signal was equally effective; it also caused a strong increase in the kinase activity of P3k, Mutations that inactivate lipid kinase activity abolish oncogenicity, The transforming activity of P3k is correlated with the ability to induce activating phosphorylation in Akt. Point mutations and amino-terminal deletions recorded in v-P3k were shown to be irrelevant to the activation of oncogenic potential, Interactions of P3k with the regulatory subunit of PI 3-kinase, p85, or with Pas are not required for transformation, These results support the conclusion that the oncogenicity of P3k depends on constitutive lipid kinase activity. Akt is an important and probably essential downstream component of the oncogenic signal from P3k.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, BCC239, La Jolla, CA 92037 USA.		Vogt, Peter K./R-7547-2019; Aoki, Masahiro/A-5149-2016; Himly, Martin/D-1568-2015	Vogt, Peter K./0000-0002-4519-7500; Aoki, Masahiro/0000-0003-4316-9490; Himly, Martin/0000-0001-5416-085X	NATIONAL CANCER INSTITUTE [R35CA042564, R01CA078230] Funding Source: NIH RePORTER; NCI NIH HHS [CA 78230, CA 42564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Carpenter CL, 1996, BBA-REV CANCER, V1288, pM11, DOI 10.1016/0304-419X(96)00018-2; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Coffer PJ, 1998, BIOCHEM J, V335, P1; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; PEPINSKY RB, 1984, J VIROL, V52, P145, DOI 10.1128/JVI.52.1.145-153.1984; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SCHULTZ AM, 1983, J VIROL, V46, P355, DOI 10.1128/JVI.46.2.355-361.1983; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Verderame MF, 1996, J VIROL, V70, P2664, DOI 10.1128/JVI.70.4.2664-2668.1996; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WILLS JW, 1989, J VIROL, V63, P4331, DOI 10.1128/JVI.63.10.4331-4343.1989; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; WYSS A, 1990, J VIROL, V64, P5163, DOI 10.1128/JVI.64.10.5163-5166.1990; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Zvelebil MJ, 1996, PHILOS T R SOC B, V351, P217, DOI 10.1098/rstb.1996.0019	46	74	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6267	6275		10.1074/jbc.275.9.6267	http://dx.doi.org/10.1074/jbc.275.9.6267			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692423	hybrid			2022-12-27	WOS:000085654400035
J	Saitoh, H; Hinchey, J				Saitoh, H; Hinchey, J			Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; NUCLEAR-PORE COMPLEX; LAEVIS EGG EXTRACTS; COVALENT MODIFICATION; SENTRIN FAMILY; HEAT-SHOCK; RANGAP1; RAN; HOMOLOG; PML	Post-translational modification marked by the covalent attachment of the ubiquitin-like protein SUMO-1/ SMT3C has been implicated in a wide variety of cellular processes. Recently, two cDNAs encoding proteins related to SUMO-1 have been identified in human and mouse. The functions and regulation of these proteins, known as SUMO-2/SMT3A and SUMO-3/SMT3B, remain largely uncharacterized. We describe herein quantitative and qualitative distinctions between SUMO-1 and SUMO-2/3 in vertebrate cells, Much of this was accomplished through the application of an antibody that recognizes SUMO-2 and -3, but not SUMO-1. This antibody detected multiple SUMO-2/3-modified proteins and revealed that, together, SUMO-8 and -3 constitute a greater percentage of total cellular protein modification than does SUMO-1, Intriguingly, we found that there FT as a large pool of free, non-conjugated SUMO-2/3 and that the conjugation of SUMO-2/3 to high molecular mass proteins was induced when the cells were subjected to protein-damaging stimuli such as acute temperature fluctuation. In addition, we demonstrated that SUMO-2/3 conjugated poorly, if at all, to a major SUMO-1 substrate, the Ran GTPase-activating protein RanGAP1. Together, these results support the concept, of important distinctions between the SUMO-2/3 and SUMO-1 conjugation pathways and suggest a role for SUMO-2/3 in the cellular responses to environmental stress.	Picower Inst Med Res, Manhasset, NY 11030 USA	Northwell Health	Saitoh, H (corresponding author), Picower Inst Med Res, 350 Community Dr, Manhasset, NY 11030 USA.	hisaitoh@picower.edu						BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; CARLSON N, 1987, J CELL BIOL, V104, P547, DOI 10.1083/jcb.104.3.547; Chen A, 1998, BIOCHEM MOL BIOL INT, V46, P1161; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Hodges M, 1998, CURR BIOL, V8, pR749, DOI 10.1016/S0960-9822(07)00477-0; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jiang WD, 1996, MOL GEN GENET, V251, P153; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Johnson PR, 1997, TRENDS CELL BIOL, V7, P408, DOI 10.1016/S0962-8924(97)01132-X; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1998, J BIOL CHEM, V273, P11349, DOI 10.1074/jbc.273.18.11349; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lapenta V, 1997, GENOMICS, V40, P362, DOI 10.1006/geno.1996.4556; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lee GW, 1998, J BIOL CHEM, V273, P6503, DOI 10.1074/jbc.273.11.6503; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; PARAG HA, 1987, EMBO J, V6, P55, DOI 10.1002/j.1460-2075.1987.tb04718.x; SAITOH H, 1995, J BIOL CHEM, V270, P10658, DOI 10.1074/jbc.270.18.10658; Saitoh H, 1996, MOL BIOL CELL, V7, P1319, DOI 10.1091/mbc.7.9.1319; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Suzuki T, 1999, J BIOL CHEM, V274, P31131, DOI 10.1074/jbc.274.44.31131; Tsytsykova AV, 1998, MOL IMMUNOL, V35, P1057, DOI 10.1016/S0161-5890(98)00094-7; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113	36	668	704	2	40	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6252	6258		10.1074/jbc.275.9.6252	http://dx.doi.org/10.1074/jbc.275.9.6252			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692421	hybrid			2022-12-27	WOS:000085654400033
J	Saraceni-Richards, CA; Levy, SB				Saraceni-Richards, CA; Levy, SB			Evidence for interactions between helices 5 and 8 and a role for the interdomain loop in tetracycline resistance mediated by hybrid Tet proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MEMBRANE TOPOLOGY; SUBSTRATE-BINDING; TRANSPOSON TN10; SEQUENCE MOTIF; ANTIPORTER; DETERMINANTS; SUPERFAMILY; PBR322; EFFLUX	An interdomain hybrid Tet protein consisting of a class C alpha domain and a class B beta domain (Tet(C/B)) lacks detectable efflux ability and provides only minimal levels of resistance to tetracycline (Tc) (3 mu g/ml) compared with intact class B (256 mu g/ml) and class C (64 mu g/ml). Twenty-one independently isolated mutants of the Tet(C/B) protein with increased Tc resistance were generated by random chemical mutagenesis. Nine mutants with a Glu substitution for Gly-152 in helix 5 of the class C alpha domain produced a resistance of 48 mu g/ml, whereas another 9 with an Asp replacement of Gly-247 in helix 8 of the class B beta domain mediated resistance at 32 mu g/ml, The third type of mutation, found in 8 mutants expressing 24 mu g/ml resistance, was a S202F replacement in the putative interdomain cytoplasmic loop of Tet(C/B). The latter underscores a previously unappreciated function of the interdomain cytoplasmic loop. All three types of Tet(C/B) mutant proteins were expressed in amounts comparable with that of the original protein and demonstrated restored energy-dependent efflux of tetracycline, Site-directed mutational analysis demonstrated that a Gly-247 to Asn mutation could also facilitate Tc resistance by the Tet(C/B) hybrid, and a negatively charged side chain at position 152 was required for Tet(C/B) activity. These mutations appear to promote the necessary functional interactions between the interclass domains that do not occur in the Tet(C/B) hybrid protein and suggest a direct association between helix 5 and helix 8 in the function of Tet efflux proteins.	Tufts Univ, Sch Med, Ctr Adaptat Genet & Drug Resistance, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	Tufts University; Tufts University	Levy, SB (corresponding author), Tufts Univ, Sch Med, Ctr Adaptat Genet & Drug Resistance, 136 Harrison Ave, Boston, MA 02111 USA.				NIGMS NIH HHS [GM55430] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055430] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLARD JD, 1992, J BIOL CHEM, V267, P17809; CURIALE MS, 1982, J BACTERIOL, V151, P209, DOI 10.1128/JB.151.1.209-215.1982; CURIALE MS, 1984, J BACTERIOL, V157, P211, DOI 10.1128/JB.157.1.211-217.1984; ECKERT B, 1989, J BIOL CHEM, V264, P11663; GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; GRIFFITH JK, 1988, J BACTERIOL, V170, P598, DOI 10.1128/jb.170.2.598-604.1988; Jewell JE, 1999, J BACTERIOL, V181, P1689, DOI 10.1128/JB.181.5.1689-1693.1999; Kawabe T, 1999, FEBS LETT, V457, P169, DOI 10.1016/S0014-5793(99)01032-7; Kimura T, 1996, FEBS LETT, V388, P50, DOI 10.1016/0014-5793(96)00514-5; Kimura T, 1997, J BIOL CHEM, V272, P580; Kimura T, 1998, J BIOL CHEM, V273, P5243, DOI 10.1074/jbc.273.9.5243; Kimura-Someya T, 1998, J BIOL CHEM, V273, P32806, DOI 10.1074/jbc.273.49.32806; Klyachko KA, 1997, J BACTERIOL, V179, P2189, DOI 10.1128/jb.179.7.2189-2193.1997; Levy SB, 1999, ANTIMICROB AGENTS CH, V43, P1523, DOI 10.1128/AAC.43.6.1523; Maniatis T., 1992, MOL CLONING LAB MANU; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; MCMURRY LM, 1995, J BIOL CHEM, V270, P22752, DOI 10.1074/jbc.270.39.22752; MCNICHOLAS P, 1992, J BACTERIOL, V174, P7926, DOI 10.1128/JB.174.24.7926-7933.1992; MILLER KW, 1993, ANAL BIOCHEM, V215, P118, DOI 10.1006/abio.1993.1563; NGUYEN TT, 1983, GENE, V25, P83, DOI 10.1016/0378-1119(83)90170-1; Okusu H, 1996, J BACTERIOL, V178, P306, DOI 10.1128/JB.178.1.306-308.1996; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; RUBIN RA, 1991, J BACTERIOL, V173, P4503, DOI 10.1128/JB.173.14.4503-4509.1991; RUBIN RA, 1990, J BACTERIOL, V172, P2303, DOI 10.1128/jb.172.5.2303-2312.1990; Sahin-Toth M, 1999, BIOCHEMISTRY-US, V38, P813, DOI 10.1021/bi982200h; SaraceniRichards CA, 1997, J BACTERIOL, V179, P1135, DOI 10.1128/jb.179.4.1135-1142.1997; TUCKMAN M, 1998, 38 ANN M INT C ANT A; Varela MF, 1995, MOL MEMBR BIOL, V12, P313, DOI 10.3109/09687689509072433; WATERS SH, 1983, NUCLEIC ACIDS RES, V11, P6089, DOI 10.1093/nar/11.17.6089; YAMAGUCHI A, 1991, FEBS LETT, V282, P415, DOI 10.1016/0014-5793(91)80527-A; YAMAGUCHI A, 1991, J BIOL CHEM, V266, P6045; YAMAGUCHI A, 1993, BIOCHEMISTRY-US, V32, P5698, DOI 10.1021/bi00072a027; YAMAGUCHI A, 1990, FEBS LETT, V265, P17, DOI 10.1016/0014-5793(90)80872-G; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P19155	35	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6101	6106		10.1074/jbc.275.9.6101	http://dx.doi.org/10.1074/jbc.275.9.6101			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692399	hybrid			2022-12-27	WOS:000085654400011
J	Tujebajeva, RM; Harney, JW; Berry, MJ				Tujebajeva, RM; Harney, JW; Berry, MJ			Selenoprotein P expression, purification, and immunochemical characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN READING FRAME; HG-SE COMPLEX; MESSENGER-RNA; SELENOCYSTEINE INSERTION; LIPID-PEROXIDATION; ALZHEIMERS-DISEASE; LIVER NECROSIS; RAT; SELENIUM; CELLS	Most selenoproteins contain a single selenocysteine residue per polypeptide chain, encoded by an in-frame UGA codon, Selenoprotein P is unique in that its mRNA encodes 10-12 selenocysteine residues, depending on species. In addition to the high number of selenocysteines, the protein is cysteine- and histidine-rich. The function of selenoprotein P has remained elusive, in part due to the inability to express the recombinant protein. This has been attributed to presumed inefficient translation through the selenocysteine/stop codons, Herein, we report for the first time the expression of recombinant rat selenoprotein P in a transiently transfected human epithelial kidney cell line, as well as the endogenously expressed protein from HepG2 and Chinese hamster ovary cells. The majority of the expressed protein migrates with the predicted 57-kDa size of full-length glycosylated selenoprotein P. Based on the histidine-rich nature of selenoprotein P, we have purified the recombinant and endogenously expressed proteins using nickel-agarose affinity chromatography, We show that the recombinant rat and endogenous human proteins react in Western blotting and immunoprecipitation assays with commercial anti-histidine antibodies. The ability to express, purify, and immunochemically detect the recombinant protein provides a foundation for investigating the functions and efficiency of expression of this intriguing protein.	Brigham & Womens Hosp, Dept Med, Div Thyroid, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Berry, MJ (corresponding author), Brigham & Womens Hosp, Dept Med, Div Thyroid, 77 Ave Louis Pasteur, Boston, MA 02115 USA.				NIDDK NIH HHS [DK52963] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052963] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*AIAG INC, 1998, QLAEXPRESS DET ASS H; AKESSON B, 1994, BBA-PROTEIN STRUCT M, V1204, P243, DOI 10.1016/0167-4838(94)90014-0; Atkins J.F., 1999, RNA WORLD NATURE MOD, P637; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BERRY MJ, 1991, J BIOL CHEM, V266, P14155; BERRY MJ, 1994, NUCLEIC ACIDS RES, V22, P3753, DOI 10.1093/nar/22.18.3753; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; BURK RF, 1994, J NUTR, V124, P1891, DOI 10.1093/jn/124.10.1891; BURK RF, 1980, J CLIN INVEST, V65, P1024, DOI 10.1172/JCI109754; Burk RF, 1997, HISTOCHEM CELL BIOL, V108, P11, DOI 10.1007/s004180050141; BURK RF, 1995, HEPATOLOGY, V21, P561; CHOI IS, 1994, BIOCHEMISTRY-US, V33, P601, DOI 10.1021/bi00168a027; Cornett CR, 1998, NEUROTOXICOLOGY, V19, P339; Cuajungco MP, 1997, NEUROBIOL DIS, V4, P137, DOI 10.1006/nbdi.1997.0163; Deibel MA, 1996, J NEUROL SCI, V143, P137, DOI 10.1016/S0022-510X(96)00203-1; Dreher I, 1997, J BIOL CHEM, V272, P29364, DOI 10.1074/jbc.272.46.29364; Dreher I, 1997, J TRACE ELEM MED BIO, V11, P83, DOI 10.1016/S0946-672X(97)80031-4; Fujii M, 1997, GENE, V199, P211, DOI 10.1016/S0378-1119(97)00369-7; Fujii Motoko, 1997, Kobe Journal of Medical Sciences, V43, P13; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HILL KE, 1993, P NATL ACAD SCI USA, V90, P537, DOI 10.1073/pnas.90.2.537; HILL KE, 1991, J BIOL CHEM, V266, P10050; Himeno S, 1996, J BIOL CHEM, V271, P15769, DOI 10.1074/jbc.271.26.15769; Kim IY, 1997, P NATL ACAD SCI USA, V94, P418, DOI 10.1073/pnas.94.2.418; KOELMAN JH, 1973, NATURE, V245, P385; Kollmus H, 1996, NUCLEIC ACIDS RES, V24, P1195, DOI 10.1093/nar/24.7.1195; KOSTA L, 1975, NATURE, V254, P238, DOI 10.1038/254238a0; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; Mostert V, 1998, ARCH BIOCHEM BIOPHYS, V357, P326, DOI 10.1006/abbi.1998.0809; SAIJOH K, 1995, MOL BRAIN RES, V30, P301, DOI 10.1016/0169-328X(94)00007-2; Saito Y, 1999, J BIOL CHEM, V274, P2866, DOI 10.1074/jbc.274.5.2866; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; Sasakura C, 1998, J INORG BIOCHEM, V71, P159, DOI 10.1016/S0162-0134(98)10048-X; Steinert P, 1998, BIOL CHEM, V379, P683, DOI 10.1515/bchm.1998.379.6.683; Steinsapir J, 1998, J CLIN INVEST, V102, P1895, DOI 10.1172/JCI4672; Suppmann S, 1999, EMBO J, V18, P2284, DOI 10.1093/emboj/18.8.2284; Suzuki KT, 1998, BBA-PROTEIN STRUCT M, V1429, P102, DOI 10.1016/S0167-4838(98)00221-0; WHITE MW, 1987, EUR J BIOCHEM, V170, P87, DOI 10.1111/j.1432-1033.1987.tb13670.x; Yan J, 1998, J NEUROSCI, V18, P8682; Yoneda S, 1997, TOXICOL APPL PHARM, V143, P274, DOI 10.1006/taap.1996.8095; Yoneda S, 1997, BIOCHEM BIOPH RES CO, V231, P7, DOI 10.1006/bbrc.1996.6036	41	45	51	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6288	6294		10.1074/jbc.275.9.6288	http://dx.doi.org/10.1074/jbc.275.9.6288			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692426	hybrid			2022-12-27	WOS:000085654400038
J	Gaither, LA; Eide, DJ				Gaither, LA; Eide, DJ			Functional expression of the human hZIP2 zinc transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE ENCODES; IRON; PROTEIN; FAMILY; NRAMP2; YEAST; CELLS; RAT	Zinc is an essential nutrient for humans, yet we know little about how this metal ion is taken up by mammalian cells. In this report, we describe the characterization of hZip2, a human zinc transporter identified by its similarity to zinc transporters recently characterized in fungi and plants. hZip2 is a member of the ZIP family of eukaryotic metal ion transporters that includes two other human genes, hZIP1 and hZIP3, and genes in mice and rats. To test whether hZip2 is a zinc transporter, we examined Zn-65 uptake activity in transfected K562 erythroleukemia cells expressing hZip2 from the CMV promoter. hZip2-expressing cells accumulated more zinc than control cells because of an increased initial zinc uptake rate. This activity was time-, temperature-, and concentration-dependent and saturable with an apparent K-m of 3 mu M. hZip2 zinc uptake activity was inhibited by several other transition metals, suggesting that this protein may transport other substrates as R-ell. hZip2 activity was not energy-dependent, nor did it require K+ or Na+ gradients. Zinc uptake by hZip2 was stimulated by HCO3- treatment, suggesting a Zn2+-HCO3- cotransport mechanism. Finally, hZip2 was exclusively localized in the plasma membrane. These results indicate that hZip2 is a zinc transporter, and its identification provides one of the first molecular tools to study zinc uptake in mammalian cells.	Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Eide, DJ (corresponding author), Univ Missouri, Dept Nutr Sci, 217 Gwynn Hall, Columbia, MO 65211 USA.				NIGMS NIH HHS [GM56285] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056285] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ATHERTON DJ, 1979, CLIN SCI, V56, P505, DOI 10.1042/cs0560505; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Cleland W W, 1979, Methods Enzymol, V63, P103; Costello LC, 1999, J BIOL CHEM, V274, P17499, DOI 10.1074/jbc.274.25.17499; Cuajungco MP, 1997, NEUROBIOL DIS, V4, P137, DOI 10.1006/nbdi.1997.0163; DILLAHA CJ, 1953, JAMA-J AM MED ASSOC, V152, P509, DOI 10.1001/jama.1953.03690060025009; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; Eng BH, 1998, J MEMBRANE BIOL, V166, P1, DOI 10.1007/s002329900442; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Grotz N, 1998, P NATL ACAD SCI USA, V95, P7220, DOI 10.1073/pnas.95.12.7220; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HO NS, 1989, GENE, V77, P51; Korshunova YO, 1999, PLANT MOL BIOL, V40, P37, DOI 10.1023/A:1026438615520; Reyes JG, 1996, AM J PHYSIOL-CELL PH, V270, pC401, DOI 10.1152/ajpcell.1996.270.2.C401; Sambrook J., 2002, MOL CLONING LAB MANU; Savigni DL, 1998, J PHYSIOL-LONDON, V508, P837, DOI 10.1111/j.1469-7793.1998.837bp.x; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; SUHY DA, 1995, MET IONS BIOL SYST, P557; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TORRUBIA JOA, 1989, J CELL PHYSIOL, V138, P316, DOI 10.1002/jcp.1041380214; VASQUEZ F, 1995, BIOL TRACE ELEM RES, V50, P109; WALSH CT, 1994, ENVIRON HEALTH PERSP, V102, P5, DOI 10.2307/3431820; Yamaguchi S, 1995, Kokubyo Gakkai Zasshi, V62, P78; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	28	246	264	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5560	5564		10.1074/jbc.275.8.5560	http://dx.doi.org/10.1074/jbc.275.8.5560			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681536	hybrid			2022-12-27	WOS:000085474500043
J	Liaw, PCY; Neuenschwander, PF; Smirnov, MD; Esmon, CT				Liaw, PCY; Neuenschwander, PF; Smirnov, MD; Esmon, CT			Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE BLOOD-VESSELS; FACTOR-X; BINDING; THROMBOMODULIN; THROMBIN; DOMAIN; SITE; IDENTIFICATION; FLUORESCENCE; PROTHROMBIN	The endothelial cell protein C receptor (EPCR) functions as an important regulator of the protein C anticoagulant pathway by binding protein C and enhancing activation by the thrombin-thrombomodulin complex. EPCR binds to both protein C and activated protein C (APC) with high affinity. A soluble form of EPCR (sEPCR) circulates in plasma and inhibits APC anticoagulant activity. In this study, we investigate the mechanisms by which sEPCR modulates APC function. Soluble EPCR inhibited the inactivation of factor Va by APC only in the presence of phospholipid vesicles. By using flow cytometric analysis in the presence of 3 mM CaCl2 and 0.6 mM MgCl2, sEPCR inhibited the binding of protein C and APC to phospholipid vesicles (K-i = 40 +/- 7 and 38 +/- 4 nM, respectively), Without MgCl2 the K-i values increased approximately 4-fold. Double label flow cytometric analysis using fluorescein-APC and Texas Red-sEPCR indicated that the APC sEPCR complex does not interact with phospholipid vesicles. By using surface plasmon resonance, we found that sEPCR also inhibited binding of protein C to phospholipid in a dose dependent fashion (K-i = 32 nM). To explore the possibility that sEPCR evokes structural changes in APC, fluorescence spectroscopy studies were performed to monitor sEPCR/Fl-APC interactions. sEPCR binds saturably to Fl-APC (K-d = 27 +/- 13 nM) with a maximum decrease in Fl-APC fluorescence of 10.8 +/- 0.6%. sEPCR also stimulated the amidolytic activity of APC toward synthetic substrates. We conclude that sEPCR binding to APC blocks phospholipid interaction and alters the active site of APC.	Oklahoma Med Res Fdn, Howard Hughes Med Inst, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Esmon, CT (corresponding author), Oklahoma Med Res Fdn, Howard Hughes Med Inst, 825 NE 13th St, Oklahoma City, OK 73104 USA.	Charles-Esmon@omrf.ouhsc.edu			NHLBI NIH HHS [P01 HL54804] Funding Source: Medline; PHS HHS [P50 54502] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; CASTELLINO FJ, 1995, TRENDS CARDIOVAS MED, V5, P55, DOI 10.1016/1050-1738(94)00031-X; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; ESMON CT, 1992, ARTERIOSCLER THROMB, V12, P135, DOI 10.1161/01.ATV.12.2.135; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; Fredenburgh JC, 1997, J BIOL CHEM, V272, P25493, DOI 10.1074/jbc.272.41.25493; Fukudome K, 1998, J EXP MED, V187, P1029, DOI 10.1084/jem.187.7.1029; Fukudome K, 1996, J BIOL CHEM, V271, P17491, DOI 10.1074/jbc.271.29.17491; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GODING JW, 1976, J IMMUNOL METHODS, V13, P215, DOI 10.1016/0022-1759(76)90068-5; GU JM, 2000, IN PRESS BLOOD; Kurosawa S, 1997, J CLIN INVEST, V100, P411, DOI 10.1172/JCI119548; Kurosawa S, 1998, BLOOD, V91, P725, DOI 10.1182/blood.V91.2.725; Laszik Z, 1997, CIRCULATION, V96, P3633; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4172, DOI 10.1021/bi00638a006; Nishioka J, 1996, THROMB HAEMOSTASIS, V75, P275; OWEN WG, 1981, J BIOL CHEM, V256, P5532; PERSSON E, 1995, EUR J BIOCHEM, V234, P293, DOI 10.1111/j.1432-1033.1995.293_c.x; PRIGENTDACHARY J, 1986, EUR J BIOCHEM, V155, P133, DOI 10.1111/j.1432-1033.1986.tb09468.x; Regan LM, 1997, J BIOL CHEM, V272, P26279, DOI 10.1074/jbc.272.42.26279; Regan LM, 1996, J BIOL CHEM, V271, P17499, DOI 10.1074/jbc.271.29.17499; Shen L, 1999, THROMB HAEMOSTASIS, V82, P1078, DOI 10.1055/s-0037-1614332; Smirnov MD, 1998, J BIOL CHEM, V273, P9031, DOI 10.1074/jbc.273.15.9031; Smith OP, 1999, BRIT J HAEMATOL, V104, P202, DOI 10.1046/j.1365-2141.1999.01186.x; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; SUGO T, 1984, J BIOL CHEM, V259, P5705; TAYLOR F, 1991, BLOOD, V78, P357, DOI 10.1182/blood.V78.2.357.357; TAYLOR FB, 2000, IN PRESS BLOOD; Xu J, 1999, J BIOL CHEM, V274, P6704, DOI 10.1074/jbc.274.10.6704; YE J, 1992, J BIOL CHEM, V267, P11023; Yegneswaran S, 1997, J BIOL CHEM, V272, P25013, DOI 10.1074/jbc.272.40.25013	33	141	150	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5447	5452		10.1074/jbc.275.8.5447	http://dx.doi.org/10.1074/jbc.275.8.5447			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681521	hybrid			2022-12-27	WOS:000085474500028
J	Liu, Y; de Montellano, PRO				Liu, Y; de Montellano, PRO			Reaction intermediates and single turnover rate constants for the oxidation of heme by human heme oxygenase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE; RESONANCE RAMAN; CATALYTIC SITE; REDUCTASE; HYPERBILIRUBINEMIA; LIGAND; ALPHA; HISTIDINE-25; CONVERSION; EXPRESSION	Heme oxygenase converts heme to biliverdin, iron, and CO in a reaction with two established intermediates, alpha-meso-hydroxyheme and verdoheme. Transient kinetic studies show that the conversion of Fe3+-heme to Fe3+-verdoheme is biphasic. Electron transfer to the heme (0.11 s(-1) at 4 degrees C and 0.49 s(-1) at 25 degrees C) followed by rapid O-2 binding yields the ferrous dioxy complex. Transfer of an electron (0.056 s(-1) at 4 degrees C and 0.21 s(-1) at 25 degrees C) to this complex triggers the formation of alpha-meso-hydroxyheme and its subsequent O-2-dependent fragmentation to Fe3+-verdoheme. The conversion of Fe3+ verdoheme to Fe3+-biliverdin is also biphasic. Thus, reduction of Fe3+ to Fe2+-verdoheme (0.15 s(-1) at 4 degrees C and 0.55 s(-1) at 25 degrees C) followed by O-2 binding and an electron transfer produces Fe3+-biliverdin (0.025 s(-1) at 4 degrees C and 0.10 s(-1) at 25 degrees C). The conversion of Fe3+-biliverdin to free biliverdin is triphasic. Reduction of Fe3+-biliverdin (0.035 s(-1) at 4 degrees C and 0.15 s(-1) at 25 degrees C), followed by rapid release of Fe2+ (0.19 s(-1) at 4 degrees C and 0.39 s(-1) at 25 degrees C), yields the biliverdin-enzyme complex from which biliverdin slowly dissociates (0.007 s(-1) at 4 degrees C and 0.03 s(-1) at 25 degrees C). The rate of Fe2+ release agrees with the rate of Fe3+-biliverdin reduction. Fe2+ release clearly precedes biliverdin dissociation. In the absence of biliverdin reductase, biliverdin release is the rate-limiting step, but in its presence biliverdin release is accelerated and the overall rate of heme degradation is limited by the conversion of Fe2+-verdoheme to the Fe3+-biliverdin.	Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.				NIDDK NIH HHS [DK30297] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030297] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Burnett AL, 1998, NAT MED, V4, P84, DOI 10.1038/nm0198-084; De Montellano PRO, 1998, ACCOUNTS CHEM RES, V31, P543; Dierks EA, 1998, BIOCHEMISTRY-US, V37, P1839, DOI 10.1021/bi972458s; Dolphin, 1979, PORPHYRINS, VVI, P257; DRUMMOND GS, 1981, P NATL ACAD SCI-BIOL, V78, P6466, DOI 10.1073/pnas.78.10.6466; ITOMAKI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P253, DOI 10.1006/abbi.1995.1160; KAPPAS A, 1988, PEDIATRICS, V81, P485; Liu Y, 1997, J BIOL CHEM, V272, P6909, DOI 10.1074/jbc.272.11.6909; MAINES MD, 1992, BIOCHIM BIOPHYS ACTA, V1131, P166, DOI 10.1016/0167-4781(92)90072-8; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MAINES MD, 1986, J BIOL CHEM, V261, P411; MAINES MD, 1992, HEME OXYGENASE CLIN, P109; MAINES MD, 1992, HEME OXYGENASE CLIN, P203; MASTERS BSS, 1980, PHARMACOL THERAPEUT, V9, P227; Matera KM, 1996, J BIOL CHEM, V271, P6618, DOI 10.1074/jbc.271.12.6618; MCCOUBREY WK, 1993, ARCH BIOCHEM BIOPHYS, V302, P402, DOI 10.1006/abbi.1993.1231; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; Migita CT, 1998, J BIOL CHEM, V273, P945, DOI 10.1074/jbc.273.2.945; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; Sambrook J., 2002, MOL CLONING LAB MANU; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; SUN J, 1993, BIOCHEMISTRY-US, V32, P14151, DOI 10.1021/bi00214a012; SUN J, 1994, BIOCHEMISTRY-US, V33, P13734, DOI 10.1021/bi00250a026; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VERMILION JL, 1981, J BIOL CHEM, V256, P266; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WILKS A, 1995, BIOCHEMISTRY-US, V34, P4421, DOI 10.1021/bi00013a034; WILKS A, 1995, J AM CHEM SOC, V117, P2925, DOI 10.1021/ja00115a027; WILKS A, 1994, J BIOL CHEM, V269, P29553; WILKS A, 1993, J BIOL CHEM, V268, P22357; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; YOSHIDA T, 1981, J BIOCHEM-TOKYO, V90, P125, DOI 10.1093/oxfordjournals.jbchem.a133441; YOSHIDA T, 1978, J BIOL CHEM, V253, P4230; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x; YOSHINAGA T, 1990, BIOCHEM J, V270, P659, DOI 10.1042/bj2700659; Zakhary R, 1997, P NATL ACAD SCI USA, V94, P14848, DOI 10.1073/pnas.94.26.14848; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	42	130	135	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5297	5307		10.1074/jbc.275.8.5297	http://dx.doi.org/10.1074/jbc.275.8.5297			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681502	hybrid			2022-12-27	WOS:000085474500009
J	Mitchell, DC; Litman, BJ				Mitchell, DC; Litman, BJ			Effect of ethanol and osmotic stress on receptor conformation - Reduced water activity amplifies the effect of ethanol on metarhodopsin II formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ETHYLENE GLYCOL); BOVINE RHODOPSIN; CHOLESTEROL; MECHANISM; MEMBRANES; ORDER; PHOSPHOLIPIDS; UNSATURATION; EQUILIBRIUM; ANESTHESIA	The combined effects of ethanol and osmolytes on both the extent of formation of metarhodopsin II (MII), which binds and activates transducin, and on acyl chain packing were examined in rod outer segment disc membranes. The ethanol-induced increase in MII formation was amplified by the addition of neutral osmolytes. This enhancement was linear with osmolality, At 360 millios-molal, the osmolality of human plasma, 50 mM ethanol was 2.7 times more potent than at 0 osmolality, demonstrating the importance of water activity in in vitro experiments dealing with ethanol potency. Ethanol disordered acyl chain packing, and increasing osmolality enhanced this acyl chain disordering. Prior osmotic stress data showed a release of 35 +/- 2 water molecules upon MII formation. Ethanol increases this number to 49 water molecules, suggesting that ethanol replaces 15 additional water molecules upon MII formation. Amplification of ethanol effects on MII formation and acyl chain packing by osmolytes suggests that ethanol increases the equilibrium concentration of MII both by disordering acyl chain packing and by disrupting rhodopsin-water hydrogen bonds, demonstrating a direct effect of ethanol on rhodopsin. At physiologically relevant levels of osmolality and ethanol, about 90% of ethanol's effect is due to disordered acyl chain packing.	NIAAA, Sect Fluorescence Studies, Lab Membrane Biophys & Biochem, NIH, Rockville, MD 20853 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Litman, BJ (corresponding author), Pk Bldg,Room 158,12420 Parklawn Dr, Rockville, MD 20852 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000080, ZIAAA000080, Z01AA000072, Z01AA000105] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		[Anonymous], BIOMEMBR A&B; ARAKAWA T, 1985, BIOCHEMISTRY-US, V24, P6756, DOI 10.1021/bi00345a005; BARRY JA, 1994, BIOCHEMISTRY-US, V33, P8082, DOI 10.1021/bi00192a013; CHIOU JS, 1990, SCIENCE, V248, P583, DOI 10.1126/science.2159183; CHIOU JS, 1992, BIOCHIM BIOPHYS ACTA, V1110, P225, DOI 10.1016/0005-2736(92)90363-Q; Deitrich RA, 1996, ALCOHOL CLIN EXP RES, V20, P1, DOI 10.1111/j.1530-0277.1996.tb01033.x; EYRING H, 1973, ANESTHESIOLOGY, V38, P415, DOI 10.1097/00000542-197305000-00001; FRANKS F, 1982, BIOPHYSICS WATER; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KIBELBEK J, 1991, BIOCHEMISTRY-US, V30, P6761, DOI 10.1021/bi00241a019; Klemm WR, 1998, ALCOHOL, V15, P249, DOI 10.1016/S0741-8329(97)00130-4; LEHTONEN JYA, 1994, BIOPHYS J, V66, P1981, DOI 10.1016/S0006-3495(94)80991-9; LITMAN BJ, 1996, LIPIDS S, V31, P193; MAEDA A, 1993, BIOCHEMISTRY-US, V32, P12033, DOI 10.1021/bi00096a013; MATHEWS RG, 1963, J GEN PHYSIOL, V47, P215; MILLER KW, 1985, INT REV NEUROBIOL, V270, P1; Mitchell DC, 1998, BIOPHYS J, V74, P879, DOI 10.1016/S0006-3495(98)74011-1; Mitchell DC, 1996, J BIOL CHEM, V271, P19033, DOI 10.1074/jbc.271.32.19033; MITCHELL DC, 1992, BIOCHEMISTRY-US, V31, P662, DOI 10.1021/bi00118a005; MITCHELL DC, 1994, BIOCHEMISTRY-US, V33, P12752, DOI 10.1021/bi00209a004; Mitchell DC, 1999, BIOCHEMISTRY-US, V38, P7617, DOI 10.1021/bi990634m; MITCHELL DC, 1990, BIOCHEMISTRY-US, V29, P9143, DOI 10.1021/bi00491a007; Parsegian VA, 1995, METHOD ENZYMOL, V259, P43; RAND RP, 1993, BIOCHEMISTRY-US, V32, P5925, DOI 10.1021/bi00074a001; Rath P, 1998, BIOCHEM J, V329, P713, DOI 10.1042/bj3290713; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; SLATER SJ, 1993, BIOCHEMISTRY-US, V32, P3714, DOI 10.1021/bi00065a025; SMITH HG, 1982, METHOD ENZYMOL, V81, P57; STRAUME M, 1990, BIOCHEMISTRY-US, V29, P9135, DOI 10.1021/bi00491a006; STRAUME M, 1987, BIOCHEMISTRY-US, V26, P5113, DOI 10.1021/bi00390a033; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; Yeagle PL, 1997, BIOCHEMISTRY-US, V36, P9649, DOI 10.1021/bi970908a	33	37	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5355	5360		10.1074/jbc.275.8.5355	http://dx.doi.org/10.1074/jbc.275.8.5355			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681509	hybrid			2022-12-27	WOS:000085474500016
J	Sanchez, LB; Galperin, MY; Muller, M				Sanchez, LB; Galperin, MY; Muller, M			Acetyl-CoA synthetase from the amitochondriate eukaryote Giardia lamblia belongs to the newly recognized superfamily of acyl-CoA synthetases (nucleoside diphosphate-forming)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PYROCOCCUS-FURIOSUS; ACETATE FORMATION; TRICHOMONAS-VAGINALIS; SUCCINATE THIOKINASE; PYRUVATE METABOLISM; ATP SYNTHESIS; COENZYME-A; PURIFICATION; EXPRESSION	The gene coding for the acetyl-CoA. synthetase (ADP-forming) from the amitochondriate eukaryote Giardia lamblia has been expressed in Escherichia coli. The recombinant enzyme exhibited the same substrate specificity as the native enzyme, utilizing acetyl-CoA and adenine nucleotides as preferred substrates and less efficiently, propionyl- and succinyl-CoA. N- and C-terminal parts of the G. lamblia acetyl-CoA sythetase sequence were found to be homologous to the alpha- and beta-subunits, respectively, of succinyl-CoA synthetase, Sequence analysis of homologous enzymes from various bacteria archaea, and the eukaryote, Plasmodium fad ciparum, identified conserved features in their organization, which allowed us to delineate a new superfamily of acyl-CoA synthetases (nucleoside diphosphate-forming) and its signature motifs, The representatives of this new superfamily of thiokinases vary in their domain arrangement, some consisting of separate alpha- and beta-subunits and others comprising fusion proteins in alpha-beta or beta-alpha orientation. The presence of homologs of acetyl synthetase (ADP-forming) in such human pathogens as G. lamblia, Yersinia pestis, Bordetella pertussis, Pseudomonas aeruginosa, Vibrio cholerae, Salmonella typhi, Porphyromonas gingivalis, and the malaria agent P. falciparum suggests that they might be used as potential drug targets.	Rockefeller Univ, New York, NY 10021 USA; Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA	Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Sanchez, LB (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	sanchel@rockvax.rockefeller.edu	Galperin, Michael Y./B-5859-2013	Galperin, Michael Y./0000-0002-2265-5572	NIAID NIH HHS [AI11942] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI011942] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [Z01LM000073] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Adachi J., 1996, COMPUT SCI MONOGR, V28, P1; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; BAILEY DL, 1993, PROTEIN SCI, V2, P1255, DOI 10.1002/pro.5560020808; Binieda A, 1999, BIOCHEM J, V340, P793, DOI 10.1042/0264-6021:3400793; Bower S, 1996, J BACTERIOL, V178, P4122, DOI 10.1128/jb.178.14.4122-4130.1996; BRIDGER WA, 1987, BIOCHEM SOC SYMP, P103; BUCK D, 1985, BIOCHEMISTRY-US, V24, P6245, DOI 10.1021/bi00343a031; CHISTOSERDOVA LV, 1994, J BACTERIOL, V176, P7398, DOI 10.1128/JB.176.23.7398-7404.1994; ELSHOURBAGY NA, 1992, EUR J BIOCHEM, V204, P491, DOI 10.1111/j.1432-1033.1992.tb16659.x; Fraser ME, 1999, J MOL BIOL, V285, P1633, DOI 10.1006/jmbi.1998.2324; Galperin MY, 1997, PROTEIN SCI, V6, P2639; Galperin MY, 1998, GENOME RES, V8, P779, DOI 10.1101/gr.8.8.779; Glasemacher J, 1997, EUR J BIOCHEM, V244, P561, DOI 10.1111/j.1432-1033.1997.00561.x; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; HILDEBRAND JG, 1969, J BIOL CHEM, V244, P2606; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; JENKINS TM, 1991, BIOCHEM BIOPH RES CO, V179, P892, DOI 10.1016/0006-291X(91)91902-O; Johnson JD, 1998, J BIOL CHEM, V273, P27580, DOI 10.1074/jbc.273.42.27580; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; KISHINO H, 1990, J MOL EVOL, V31, P151, DOI 10.1007/BF02109483; KUMARI S, 1995, J BACTERIOL, V177, P2878, DOI 10.1128/jb.177.10.2878-2886.1995; Mai XH, 1996, J BACTERIOL, V178, P5897, DOI 10.1128/jb.178.20.5897-5903.1996; MAJUMDAR R, 1991, BIOCHIM BIOPHYS ACTA, V1076, P86, DOI 10.1016/0167-4838(91)90223-M; MATSUYAMA A, 1994, BBA-GENE STRUCT EXPR, V1219, P559, DOI 10.1016/0167-4781(94)90089-2; MICHEL TA, 1990, FEMS MICROBIOL LETT, V68, P189; Muller M, 1998, SYST ASSOC SPEC VOL, V56, P109; NISHIMURA JS, 1986, ADV ENZYMOL RAMB, V58, P141; NISHIYAMA M, 1991, MOL GEN GENET, V226, P1, DOI 10.1007/BF00273580; Oliynyk M, 1996, CHEM BIOL, V3, P833, DOI 10.1016/S1074-5521(96)90069-1; PLOUX O, 1992, BIOCHEM J, V287, P685, DOI 10.1042/bj2870685; REEVES RE, 1977, J BIOL CHEM, V252, P726; Reizer J, 1997, CURR OPIN STRUC BIOL, V7, P407, DOI 10.1016/S0959-440X(97)80059-0; SAIER MH, 1990, RES MICROBIOL, V141, P1033, DOI 10.1016/0923-2508(90)90077-4; Sanchez LB, 1996, FEBS LETT, V378, P240, DOI 10.1016/0014-5793(95)01463-2; Sanchez LB, 1999, GENE, V233, P225, DOI 10.1016/S0378-1119(99)00134-1; SCHAFER T, 1991, ARCH MICROBIOL, V155, P366; STEINBUCHEL A, 1986, MOL BIOCHEM PARASIT, V20, P57, DOI 10.1016/0166-6851(86)90142-8; Tang L, 1998, GENE, V216, P255, DOI 10.1016/S0378-1119(98)00338-2; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Valenzuela JG, 1998, J BIOL CHEM, V273, P30583, DOI 10.1074/jbc.273.46.30583; Van Hellemond JJ, 1998, P NATL ACAD SCI USA, V95, P3036, DOI 10.1073/pnas.95.6.3036; WEITZMAN PDJ, 1978, FEBS LETT, V88, P255, DOI 10.1016/0014-5793(78)80187-2; WOLODKO WT, 1994, J BIOL CHEM, V269, P10883	44	90	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5794	5803		10.1074/jbc.275.8.5794	http://dx.doi.org/10.1074/jbc.275.8.5794			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681568	hybrid			2022-12-27	WOS:000085474500075
J	Saville, B; Wormke, M; Wang, F; Nguyen, T; Enmark, E; Kuiper, G; Gustafsson, JA; Safe, S				Saville, B; Wormke, M; Wang, F; Nguyen, T; Enmark, E; Kuiper, G; Gustafsson, JA; Safe, S			Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-MESSENGER-RNA; BREAST-CANCER CELLS; ER-BETA; CHROMOSOMAL LOCALIZATION; INDEPENDENT ACTIVATION; MOLECULAR MECHANISMS; RESPONSIVE ELEMENT; C-FOS; ALPHA; EXPRESSION	17 beta-Estradiol (E2) induces expression of several genes via estrogen receptor (ER)-Sp1 protein interactions with GC-rich promoter elements in which Sp1 but not ER binds DNA. This study reports the ligand- and cell context-dependent ERalpha/Sp1 and ERbeta/Sp1 action using an E2-responsive construct (pSp1) containing a GC-rich promoter. Both ERalpha and ERbeta proteins physically interact with Sp1 (coimmunoprecipitation) and preferentially bind to the C-terminal region of this protein in pull-down assays. E2- and antiestrogen-dependent transcriptional activation of ERalpha/Sp1 was observed in MCF-7, MDA-MB-231, and LnCaP cells, but not in HeLa cells. E2 did not affect or significantly decrease ERbeta/Sp1 action, and antiestrogens had minimal effects in the same 4 cell lines. Exchange of activation function-1 (AF-1) domains of ER subtypes gave chimeric ERalpha/beta (AF-2(alpha)/AF-2 beta) and ERbeta/alpha (AF-1 beta/AF-S alpha) proteins that resembled wild-type ER (alpha or beta) in terms of physical association with Sp1 protein. Transcriptional activation studies with chimeric ERBbeta/alpha and ERalpha/beta showed that only ERalpha/beta can activate transcription from an Sp1 element, not ERbeta/alpha. This indicates that the AF-1 domain from ERalpha is responsible for activation at an Sp1 element, independent of ER subtype context. In order to further characterize this observation, deletion constructs in the AF-1 domain of both ERalpha and ERalpha/beta were made, and transactivation studies indicated that the region between amino acids 79 and 117 of this domain is important for activation at an Sp1 element.	Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; Karolinska Inst, Novum, Ctr Biotechnol & Human Nutr, S-14186 Huddinge, Sweden	Texas A&M University System; Texas A&M University College Station; Karolinska Institutet	Safe, S (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA.	ssafe@cvm.tamu.edu			NATIONAL CANCER INSTITUTE [R01CA076636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106] Funding Source: NIH RePORTER; NCI NIH HHS [CA76636] Funding Source: Medline; NIEHS NIH HHS [ES09106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arts J, 1997, ENDOCRINOLOGY, V138, P5067, DOI 10.1210/en.138.11.5067; Barkhem T, 1998, MOL PHARMACOL, V54, P105, DOI 10.1124/mol.54.1.105; Brandenberger AW, 1997, J CLIN ENDOCR METAB, V82, P3509, DOI 10.1210/jc.82.10.3509; Byers M, 1997, MOL ENDOCRINOL, V11, P172, DOI 10.1210/me.11.2.172; CampbellThompson ML, 1997, BIOCHEM BIOPH RES CO, V240, P478, DOI 10.1006/bbrc.1997.7683; Clark J. H., 1992, TXB ENDOCRINOLOGY, P35; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Dotzlaw H, 1997, J CLIN ENDOCR METAB, V82, P2371, DOI 10.1210/jc.82.7.2371; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; DUBIK D, 1992, ONCOGENE, V7, P1587; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; Hess RA, 1997, NATURE, V390, P509, DOI 10.1038/37352; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HYDER SM, 1995, MOL CELL ENDOCRINOL, V112, P35, DOI 10.1016/0303-7207(95)03581-Q; Iafrati MD, 1997, NAT MED, V3, P545, DOI 10.1038/nm0597-545; JORDAN VC, 1994, BREAST CANCER RES TR, V31, P41, DOI 10.1007/BF00689675; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KORACH KS, 1994, PRINCIPLES PHARM BAS, P809; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Moore JT, 1998, BIOCHEM BIOPH RES CO, V247, P75, DOI 10.1006/bbrc.1998.8738; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Onoe Y, 1997, ENDOCRINOLOGY, V138, P4509, DOI 10.1210/en.138.10.4509; Pace P, 1997, J BIOL CHEM, V272, P25832, DOI 10.1074/jbc.272.41.25832; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; PHILIPS A, 1993, J BIOL CHEM, V268, P14103; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Qin CH, 1999, ENDOCRINOLOGY, V140, P2501, DOI 10.1210/en.140.6.2501; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SAVOURET JF, 1991, EMBO J, V10, P1875, DOI 10.1002/j.1460-2075.1991.tb07713.x; Shughrue PJ, 1997, P NATL ACAD SCI USA, V94, P11008, DOI 10.1073/pnas.94.20.11008; Shughrue PJ, 1996, STEROIDS, V61, P678, DOI 10.1016/S0039-128X(96)00222-X; Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882; Tremblay A, 1998, ENDOCRINOLOGY, V139, P111, DOI 10.1210/en.139.1.111; Tremblay GB, 1998, CANCER RES, V58, P877; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Uht RM, 1997, ENDOCRINOLOGY, V138, P2900, DOI 10.1210/en.138.7.2900; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; Wang F, 1998, NUCLEIC ACIDS RES, V26, P3044, DOI 10.1093/nar/26.12.3044; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; Watanabe T, 1997, BIOCHEM BIOPH RES CO, V236, P140, DOI 10.1006/bbrc.1997.6915; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Xie W, 1999, ENDOCRINOLOGY, V140, P219, DOI 10.1210/en.140.1.219; ZACHAREWSKI TR, 1994, CANCER RES, V54, P2707; Zou AH, 1999, MOL ENDOCRINOL, V13, P418, DOI 10.1210/me.13.3.418; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	60	340	352	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5379	5387		10.1074/jbc.275.8.5379	http://dx.doi.org/10.1074/jbc.275.8.5379			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681512	hybrid			2022-12-27	WOS:000085474500019
J	Xu, P; LaVallee, P; Hoidal, JR				Xu, P; LaVallee, P; Hoidal, JR			Repressed expression of the human xanthine oxidoreductase gene - E-box and TATA-like elements restrict ground state transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIA-REPERFUSION INJURY; HUMAN ENDOTHELIAL CELLS; RENAL EPITHELIAL-CELLS; TFII-I; OXIDASE ACTIVITY; URIC-ACID; DEHYDROGENASE GENE; BINDING-PROTEINS; LESS PROMOTER; DNA-BINDING	Studies were initiated to address the basis for the low xanthine oxidoreductase (XOR) activity in humans relative to nonprimate mammalian species. The expression of the XOR in humans is strikingly lower than in mice, and both transcription rates and core promoter activity of the gene are repressed. Analysis of human XOR promoter activity in hepatocytes and vascular endothelial cells showed that the region from -258 to -1 contains both repressor and activator binding regions regulating core promoter activity. The region between -138 and -1 is necessary and sufficient for initiating, and the region between -258 and -228 is critical for restricting core promoter activity. Within the latter region, site-directed mutations identified a consensus sequence "acacaggtgtgg" (-242 to -230) that contains an E-box that binds a repressor. In addition, the TATA-like element is also required to restrict promoter activity and TFIID binds to this site. The results demonstrate that both an E-box and TATA-like element are required to restrict gene activity. A model is proposed to account for human XOR regulation.	Univ Utah, Hlth Sci Ctr, Dept Internal Med, Div Resp Crit Care & Occupat Med, Salt Lake City, UT 84132 USA; Vet Affairs Med Ctr, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Hoidal, JR (corresponding author), Univ Utah, Hlth Sci Ctr, Div Pulm, Wintrobe Bldg,Rm 743A,50 N Med Dr, Salt Lake City, UT 84132 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040665] Funding Source: NIH RePORTER; NHLBI NIH HHS [5RO1HL40665] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABADEH S, 1992, BIOCHIM BIOPHYS ACTA, V1117, P25, DOI 10.1016/0304-4165(92)90157-P; AKAIKE T, 1990, J CLIN INVEST, V85, P739, DOI 10.1172/JCI114499; AMAYA Y, 1990, J BIOL CHEM, V265, P14170; AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; ATHAR M, 1989, J CLIN INVEST, V83, P1137, DOI 10.1172/JCI113993; BECKER BF, 1989, PFLUG ARCH EUR J PHY, V415, P127, DOI 10.1007/BF00370582; CAZZANIGA G, 1994, GENOMICS, V23, P390, DOI 10.1006/geno.1994.1515; CHOW CW, 1995, NUCLEIC ACIDS RES, V23, P3132, DOI 10.1093/nar/23.16.3132; CHOW CW, 1994, NUCLEIC ACIDS RES, V22, P1846, DOI 10.1093/nar/22.10.1846; Clark MP, 1998, NUCLEIC ACIDS RES, V26, P1801, DOI 10.1093/nar/26.7.1801; Clark MP, 1998, NUCLEIC ACIDS RES, V26, P2813, DOI 10.1093/nar/26.11.2813; DARNELL JE, 1982, NATURE, V297, P365, DOI 10.1038/297365a0; DAVIES KJA, 1986, BIOCHEM J, V235, P747, DOI 10.1042/bj2350747; DIAMOND JR, 1986, KIDNEY INT, V29, P478, DOI 10.1038/ki.1986.24; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; DUPONT GP, 1992, J CLIN INVEST, V89, P197, DOI 10.1172/JCI115563; FALCIANI F, 1992, BIOCHEM J, V285, P1001, DOI 10.1042/bj2851001; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; GRANGER DN, 1988, AM J PHYSIOL, V255, pH1269, DOI 10.1152/ajpheart.1988.255.6.H1269; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; Harrison R, 1997, BIOCHEM SOC T, V25, P786, DOI 10.1042/bst0250786; HASSOUN PM, 1994, AM J PHYSIOL, V266, pL163, DOI 10.1152/ajplung.1994.266.2.L163; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HOWELL RR, 1960, J BIOL CHEM, V235, P3544; IKEDA K, 1995, EUR J BIOCHEM, V233, P73, DOI 10.1111/j.1432-1033.1995.073_1.x; Ikeda K, 1998, MOL CELL BIOL, V18, P10, DOI 10.1128/MCB.18.1.10; INOSTROZA JA, 1992, CELL, V70, P477; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAFFE EA, 1973, J CLIN INVEST, V52, P2757, DOI 10.1172/JCI107471; KAWAMURA T, 1991, KIDNEY INT, V40, P291, DOI 10.1038/ki.1991.213; KELLOGG EW, 1977, J BIOL CHEM, V252, P6721; LEWIS BA, 1995, J BIOL CHEM, V270, P28139; LINAS SL, 1990, AM J PHYSIOL, V258, pF711, DOI 10.1152/ajprenal.1990.258.3.F711; Manley JL, 1996, PHILOS T ROY SOC B, V351, P517, DOI 10.1098/rstb.1996.0050; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERSCHER S, 1994, BIOTECHNIQUES, V16, P1024; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; MUXFELDT M, 1987, BASIC RES CARDIOL, V82, P486, DOI 10.1007/BF01907096; PALLER MS, 1991, KIDNEY INT, V40, P1041, DOI 10.1038/ki.1991.312; PEDEN DB, 1990, P NATL ACAD SCI USA, V87, P7638, DOI 10.1073/pnas.87.19.7638; PFEFFER KD, 1994, J IMMUNOL, V153, P1789; RODELL TC, 1987, J APPL PHYSIOL, V63, P2159, DOI 10.1152/jappl.1987.63.5.2159; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; SAIKI RK, 1988, SCIENCE, V239, P481; Sanders SA, 1997, EUR J BIOCHEM, V245, P541, DOI 10.1111/j.1432-1033.1997.00541.x; Slot O, 1994, Ugeskr Laeger, V156, P2396; WAJNER M, 1989, BIOCHIM BIOPHYS ACTA, V991, P79, DOI 10.1016/0304-4165(89)90031-7; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P365, DOI 10.1016/0003-9861(76)90088-6; XU P, 1994, GENOMICS, V23, P289, DOI 10.1006/geno.1994.1498; Xu P, 1996, GENOMICS, V34, P173, DOI 10.1006/geno.1996.0262; XU P, 1994, BIOCHEM BIOPH RES CO, V199, P998, DOI 10.1006/bbrc.1994.1328; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	58	42	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5918	5926		10.1074/jbc.275.8.5918	http://dx.doi.org/10.1074/jbc.275.8.5918			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681584	hybrid			2022-12-27	WOS:000085474500091
J	Zhu, CX; Tse-Dinh, YC				Zhu, CX; Tse-Dinh, YC			The acidic triad conserved in type IA DNA topoisomerases is required for binding of Mg(II) and subsequent conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TERMINAL FRAGMENT; DOMAIN; MECHANISM; AFFINITY; PROTEINS	The acidic residues Asp-111, Asp-113, and Glu-115 of Escherichia coli DNA topoisomerase I are located near the active site Tyr-319 and are conserved in type IA topoisomerase sequences with counterparts in type IIA DNA topoisomerases. Their exact functional roles in catalysis have not been clearly defined. Mutant enzymes with two or more of these residues converted to alanines were found to have >90% loss of activity in the relaxation assay with 6 mM Mg(II) present. Mg(II) concentrations (15-20 mM) inhibitory for the wild type enzyme are needed by these double mutants for maximal relaxation activity. The triple mutant D111A/D113A/E115A had no detectable relaxation activity. Mg(II) binding to wild type enzyme resulted in an altered conformation detectable by Glu-C proteolytic digestion. This conformational change was not observed for the triple mutant or for the double mutant D111A/D113A. Direct measurement of Mg(II) bound showed the loss of 1-2 Mg(II) ions for each enzyme molecule due to the mutations. These results demonstrate a functional role for these acidic residues in the binding of Mg(II) to induce the conformational change required for the relaxation of supercoiled DNA by the enzyme.	New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA	New York Medical College	Tse-Dinh, YC (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Basic Sci Bldg,Rm 128, Valhalla, NY 10595 USA.	yuk-ching_tse-dinh@nymc.edu			NIGMS NIH HHS [GM54226] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054226] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahumada A, 1998, BIOCHEM BIOPH RES CO, V251, P509, DOI 10.1006/bbrc.1998.9500; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4205, DOI 10.1093/nar/26.18.4205; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERANSTEED RK, 1989, PROTEINS, V6, P249, DOI 10.1002/prot.340060307; Berger JM, 1998, P NATL ACAD SCI USA, V95, P7876, DOI 10.1073/pnas.95.14.7876; BHATTACHARYYA T, 1991, EUR J BIOCHEM, V200, P739, DOI 10.1111/j.1432-1033.1991.tb16239.x; Chen SJ, 1998, J BIOL CHEM, V273, P6050, DOI 10.1074/jbc.273.11.6050; DOMANICO PL, 1991, J INORG BIOCHEM, V42, P87, DOI 10.1016/0162-0134(91)80035-G; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; LIMA CD, 1993, J MOL BIOL, V232, P1213, DOI 10.1006/jmbi.1993.1474; Liu QY, 1999, P NATL ACAD SCI USA, V96, P881, DOI 10.1073/pnas.96.3.881; PRUSS GJ, 1986, J BACTERIOL, V168, P276, DOI 10.1128/jb.168.1.276-282.1986; Suerbaum S, 1998, GENE, V210, P151, DOI 10.1016/S0378-1119(98)00065-1; Tse-Dinh YC, 1998, BBA-GENE STRUCT EXPR, V1400, P19, DOI 10.1016/S0167-4781(98)00125-0; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Zhu CX, 1999, METH MOL B, V94, P145; Zhu CX, 1997, J BIOL CHEM, V272, P16206, DOI 10.1074/jbc.272.26.16206; ZHU CX, 1995, BIOCHEM MOL BIOL INT, V35, P375; Zhu CX, 1998, J BIOL CHEM, V273, P8783, DOI 10.1074/jbc.273.15.8783	23	58	60	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5318	5322		10.1074/jbc.275.8.5318	http://dx.doi.org/10.1074/jbc.275.8.5318			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681504	hybrid			2022-12-27	WOS:000085474500011
J	Anderson, LB; Ouellette, AJA; Barry, BA				Anderson, LB; Ouellette, AJA; Barry, BA			Probing the structure of photosystem II with amines and phenylhydrazine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; SITE-DIRECTED MUTANTS; ACTIVE-SITE; CHLORIDE REQUIREMENT; CRYSTAL-STRUCTURE; ELECTRON-DONOR; OXIDASE; MANGANESE; TYROSINE; MECHANISM	Photosynthetic oxygen evolution is catalyzed at the manganese-containing active site of photosystem II (PSII). Amines are analogs of substrate water and inhibitors of oxygen evolution. Recently, the covalent incorporation of C-14 from [C-14]methylamine and benzylamine into PSII subunits has been demonstrated (Ouellette, A. J. A., Anderson, L. B., and Barry, B. A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 2204-2209). To obtain more information concerning these labeling reactions. t-[C-14]butylamine and phenylhydrazine were employed as probes. Neither compound can be oxidized by a transamination or addition/elimination mechanism, but both can react with activated carbonyl groups, produced as a result of posttranslational modification of amino acid residues, to give amine-derived adducts. C-14 incorporation into the PSII subunits D2/D1 and CP47 was obtained upon treatment of PSII with either t-[C-14]butylamine or [C-14]phenylhydrazine. For t-butyl-amine and methylamine, the amount of labeling increased when PSII was treated with denaturing agents. Labeling of CP47, D2, and D1 with methylamine and phenylhydrazine approached a one-to-one stoichiometry, assuming that D2 and D1 each have one binding site. Evidence was obtained suggesting that reductive stabilization and/or access are modulated by PSII light reactions. These results support the proposal that PSII subunits D2, D1, and CP47 contain quinocofactors and that access to these sites is sterically limited.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Gortner Lab 140, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities	Barry, BA (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, Gortner Lab 140, St Paul, MN 55108 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043273] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43273] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRY BA, 1995, METHOD ENZYMOL, V258, P303; BARRY BA, 1987, P NATL ACAD SCI USA, V84, P7099, DOI 10.1073/pnas.84.20.7099; BARRY BA, 1994, MOL BIOL CYANOBACTER, V1, P215; BECKER HD, 1974, CHEM QUINONOID COMPO, V1, P335; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BOERNER RJ, 1993, J BIOL CHEM, V268, P1817; BOERNER RJ, 1993, J BIOL CHEM, V268, P17151; BOERNER RJ, 1994, J BIOL CHEM, V269, P134; Bollag DM, 1991, PROTEIN METHODS; BRITT RD, 1996, OXYGENIC PHOTOSYNTHE, V4, P137; BUSER CA, 1990, BIOCHEMISTRY-US, V29, P8977, DOI 10.1021/bi00490a014; COREY EJ, 1969, J AM CHEM SOC, V91, P1429, DOI 10.1021/ja01034a027; DEVITRY C, 1991, J BIOL CHEM, V266, P16614; ECKERT TS, 1983, J AM CHEM SOC, V105, P4431, DOI 10.1021/ja00351a049; FRANKEL LK, 1989, FEBS LETT, V257, P279, DOI 10.1016/0014-5793(89)81552-2; GERKEN S, 1988, FEBS LETT, V237, P69, DOI 10.1016/0014-5793(88)80174-1; GHANOTAKIS DF, 1984, FEBS LETT, V167, P127, DOI 10.1016/0014-5793(84)80846-7; GHANOTAKIS DF, 1984, BIOCHIM BIOPHYS ACTA, V765, P388, DOI 10.1016/0005-2728(84)90180-4; HARTMANN C, 1987, J BIOL CHEM, V262, P962; JANES SM, 1991, BIOCHEMISTRY-US, V30, P4599, DOI 10.1021/bi00232a034; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; KLEIN RFX, 1988, J ORG CHEM, V53, P5994, DOI 10.1021/jo00261a002; Klinman JP, 1996, J BIOL CHEM, V271, P27189, DOI 10.1074/jbc.271.44.27189; KNOWLES PF, 1984, COPPER PROTEINS COPP, V2, P104; Li RB, 1998, STRUCTURE, V6, P293, DOI 10.1016/S0969-2126(98)00033-1; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; Ma CL, 1996, BIOPHYS J, V71, P1961, DOI 10.1016/S0006-3495(96)79394-3; Means G E, 1977, Methods Enzymol, V47, P469; MILLER AF, 1991, BIOCHIM BIOPHYS ACTA, V1056, P1, DOI 10.1016/S0005-2728(05)80067-2; MIYAO M, 1983, BIOCHIM BIOPHYS ACTA, V725, P87, DOI 10.1016/0005-2728(83)90227-X; MURE M, 1995, J AM CHEM SOC, V117, P8698, DOI 10.1021/ja00139a002; MURE M, 1995, METHOD ENZYMOL, V258, P39; MURE M, 1993, J AM CHEM SOC, V115, P7117, DOI 10.1021/ja00069a008; MURE M, 1995, J AM CHEM SOC, V117, P8707, DOI 10.1021/ja00139a003; NOREN GH, 1992, BIOCHEMISTRY-US, V31, P3335, DOI 10.1021/bi00128a005; OHSHIRO Y, 1991, BIOORG CHEM, V19, P169, DOI 10.1016/0045-2068(91)90033-L; OKAYAMA S, 1976, BIOCHIM BIOPHYS ACTA, V440, P331, DOI 10.1016/0005-2728(76)90067-0; Ouellette AJA, 1998, P NATL ACAD SCI USA, V95, P2204, DOI 10.1073/pnas.95.5.2204; PARSONS MR, 1995, STRUCTURE, V3, P1171, DOI 10.1016/S0969-2126(01)00253-2; Patzlaff JS, 1996, BIOCHEMISTRY-US, V35, P7802, DOI 10.1021/bi960056z; PICCIONI R, 1982, METHODS CHLOROPLAST, P985; Rhee KH, 1997, NATURE, V389, P522, DOI 10.1038/39103; RODRIGUEZ EJ, 1989, J AM CHEM SOC, V111, P7947, DOI 10.1021/ja00202a041; SANDUSKY PO, 1983, FEBS LETT, V162, P339, DOI 10.1016/0014-5793(83)80784-4; SANDUSKY PO, 1984, BIOCHIM BIOPHYS ACTA, V766, P603, DOI 10.1016/0005-2728(84)90121-X; SANDUSKY PO, 1986, BIOCHIM BIOPHYS ACTA, V849, P85, DOI 10.1016/0005-2728(86)90099-X; TAMURA N, 1986, BIOCHIM BIOPHYS ACTA, V850, P369, DOI 10.1016/0005-2728(86)90193-3; VIGNEVICH V, 1993, J MOL BIOL, V229, P243, DOI 10.1006/jmbi.1993.1022; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078	49	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4920	4927		10.1074/jbc.275.7.4920	http://dx.doi.org/10.1074/jbc.275.7.4920			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671529	hybrid			2022-12-27	WOS:000085378200055
J	Boerth, NJ; Judd, BA; Koretzky, GA				Boerth, NJ; Judd, BA; Koretzky, GA			Functional association between SLAP-130 and SLP-76 in Jurkat T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; INTERLEUKIN-2 PRODUCTION; ACTIVATION; PHOSPHORYLATION; SUBSTRATE; STIMULATION; ZAP-70	T cell antigen receptor (TCR) engagement results in protein-tyrosine kinase activation which initiates signaling cascades leading to induction of the interleukin-2 gene. Previous studies identified two substrates of the TCR-induced protein-tyrosine kinases, SH2 domain-containing leukocyte specific protein of 76 kDa (SLP-76) and SLP-76-associated phosphoprotein of 130 kDa (SLAP-130). While SLP-76 appears to couple the TCR. with downstream signals, SLAP-130 may play a negative regulatory role in T cell activation. In this study, we demonstrate that consistent with its ability to abrogate the SLP-76 augmentation of TCR-induced activation of the NFAT/AP1 region of the interleukin-2 promoter, overexpression of SLAP-130 also interferes with the rescue of signaling in SLP-76-deficient Jurkat cells in cotransfection experiments. The effect of SLAP-130 on SLP-76 function is specific for regulating TCR-induced ERK activation, but not phospholipase C gamma 1 phosphorylation, By generating both deletion and point mutants of SLAP-130, we identified tyrosine 559 as critical for the interaction between SLP-76 and SLAP-130. We show that mutation of this residue in context of full-length SLAP-130 diminishes the ability of SLAP-130 to abrogate SLP-76 function, These data suggest that the SLAP-130/SLP-76 association is important for the negative regulatory role that SLAP-130 appears to play in T cell signaling.	Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Interdisciplinary Grad Program Immunol & Mol Biol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Koretzky, GA (corresponding author), Abramson Canc Ctr, Dept Pathol, 421 Curie Blvd,428 BRB 2-3, Philadelphia, PA 19104 USA.		Koretzky, Gary/AAU-5381-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053256] Funding Source: NIH RePORTER; NIGMS NIH HHS [1 RO1 GM 53256] Funding Source: Medline; PHS HHS [2T32A107260-11] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHU KT, 1994, J BIOL CHEM, V269, P24095; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; daSilva AJ, 1997, J IMMUNOL, V158, P2007; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; Fang N, 1999, J BIOL CHEM, V274, P16206, DOI 10.1074/jbc.274.23.16206; Fang N, 1996, J IMMUNOL, V157, P3769; IMBODEN JB, 1985, J IMMUNOL, V134, P663; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; IZQUIERDO M, 1994, J EXP MED, V180, P401, DOI 10.1084/jem.180.1.401; IZQUIERDO M, 1994, EUR J IMMUNOL, V24, P2462, DOI 10.1002/eji.1830241031; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; Liu J, 1998, P NATL ACAD SCI USA, V95, P8779, DOI 10.1073/pnas.95.15.8779; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Marie-Cardine A, 1998, FEBS LETT, V435, P55, DOI 10.1016/S0014-5793(98)01040-0; Marie-Cardine A, 1998, J BIOL CHEM, V273, P25789, DOI 10.1074/jbc.273.40.25789; MarieCardine A, 1997, J BIOL CHEM, V272, P16077, DOI 10.1074/jbc.272.26.16077; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J IMMUNOL, V159, P1639; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Raab M, 1999, J BIOL CHEM, V274, P21170, DOI 10.1074/jbc.274.30.21170; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RUDD CE, 1991, ADV EXP MED BIOL, V292, P85; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; WARD SG, 1992, EUR J IMMUNOL, V22, P45, DOI 10.1002/eji.1830220108; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WU J, 1995, MOL CELL BIOL, V15, P4337; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	54	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5143	5152		10.1074/jbc.275.7.5143	http://dx.doi.org/10.1074/jbc.275.7.5143			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671560	hybrid			2022-12-27	WOS:000085378200086
J	Hesselberth, JR; Miller, D; Robertus, J; Ellington, AD				Hesselberth, JR; Miller, D; Robertus, J; Ellington, AD			In vitro selection of RNA molecules that inhibit the activity of ricin A-chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-GLYCOSIDASE ACTIVITY; RIBOSOMAL-RNA; IN-VITRO; BIOLOGICAL WARFARE; RECEPTOR-BINDING; GROWTH-FACTOR; STEM-LOOP; APTAMERS; MECHANISM; LIGANDS	The cytotoxin ricin disables translation by depurinating a conserved site in eukaryotic rRNA. In vitro selection has been used to generate RNA ligands (aptamers) specific for the catalytic ricin A-chain (RTA), The anti-RTA aptamers bear no resemblance to the normal RTA substrate, the sarcin-ricin loop (SRL), and were not depurinated by RTA. An initial 80-nucleotide RNA ligand was minimized to a 31-nucleotide aptamer that contained all sequences and structures necessary for interacting with RTA. This minimal RNA formed high affinity complexes with RTA (K-d = 7.3 nM) which could compete directly with the SRL for binding to RTA. The aptamer inhibited RTA depurination of the SRL and could partially protect translation from RTA inhibition. The IC50 of the aptamer for RTA in an in vitro translation assay is 100 nM, roughly 3 orders of magnitude lower than a small molecule inhibitor of ricin, pteroic acid, and 2 orders of magnitude lower than the best known RNA inhibitor. The novel anti-RTA aptamers may find application as diagnostic reagents for a potential biological warfare agent and hold promise as scaffolds for the development of strong ricin inhibitors.	Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Ellington, AD (corresponding author), Univ Texas, Dept Chem & Biochem, 2500 Speedway A4800,MBB 3-424, Austin, TX 78712 USA.			Hesselberth, Jay/0000-0002-6299-179X				Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; Bell SD, 1998, J BIOL CHEM, V273, P14309, DOI 10.1074/jbc.273.23.14309; Blind M, 1999, P NATL ACAD SCI USA, V96, P3606, DOI 10.1073/pnas.96.7.3606; Chen XY, 1996, J AM CHEM SOC, V118, P3067, DOI 10.1021/ja9600385; Chen XY, 1998, BIOCHEMISTRY-US, V37, P11605, DOI 10.1021/bi980990p; Christopher GW, 1997, JAMA-J AM MED ASSOC, V278, P412, DOI 10.1001/jama.278.5.412; Conrad RC, 1996, METHOD ENZYMOL, V267, P336; Conrad RC, 1995, MOL DIVERS, V1, P69, DOI 10.1007/BF01715810; Coombs GS, 1999, J BIOL CHEM, V274, P24074, DOI 10.1074/jbc.274.34.24074; Correll CC, 1998, P NATL ACAD SCI USA, V95, P13436, DOI 10.1073/pnas.95.23.13436; Day PJ, 1996, BIOCHEMISTRY-US, V35, P11098, DOI 10.1021/bi960880n; Eitzen E, 1998, MED MANAGEMENT BIOL, V3rd; ENDO Y, 1988, J BIOL CHEM, V263, P8735; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ENDO Y, 1991, J MOL BIOL, V221, P193, DOI 10.1016/0022-2836(91)90814-M; Famulok M, 1999, CURR OPIN STRUC BIOL, V9, P324, DOI 10.1016/S0959-440X(99)80043-8; Famulok M, 1998, CURR OPIN CHEM BIOL, V2, P320, DOI 10.1016/S1367-5931(98)80004-5; GIVER L, 1993, NUCLEIC ACIDS RES, V21, P5509, DOI 10.1093/nar/21.23.5509; GIVER L, 1993, GENE, V137, P19, DOI 10.1016/0378-1119(93)90246-Y; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Good PD, 1997, GENE THER, V4, P45, DOI 10.1038/sj.gt.3300354; GREEN R, 1990, NATURE, V347, P406, DOI 10.1038/347406a0; Hirao I, 1998, MOL DIVERS, V4, P75, DOI 10.1023/A:1026401917416; JELLINEK D, 1994, BIOCHEMISTRY-US, V33, P10450, DOI 10.1021/bi00200a028; JELLINEK D, 1993, P NATL ACAD SCI USA, V90, P11227, DOI 10.1073/pnas.90.23.11227; Jhaveri S, 1998, BIOORG MED CHEM LETT, V8, P2285, DOI 10.1016/S0960-894X(98)00414-4; JHAVERI SD, 1997, ANN REP COMB CHEM MO, V1, P169; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MLSNA D, 1993, PROTEIN SCI, V2, P429; Munishkin A, 1997, P NATL ACAD SCI USA, V94, P12280, DOI 10.1073/pnas.94.23.12280; Osborne SE, 1997, CURR OPIN CHEM BIOL, V1, P5, DOI 10.1016/S1367-5931(97)80102-0; READY MP, 1991, PROTEINS, V10, P270, DOI 10.1002/prot.340100311; Rezaie AR, 1998, BIOCHEMISTRY-US, V37, P13138, DOI 10.1021/bi9808518; Robertus JD, 1996, TOXICON, V34, P1325, DOI 10.1016/S0041-0101(96)00103-1; Symensma TL, 1999, J VIROL, V73, P4341, DOI 10.1128/JVI.73.5.4341-4349.1999; Symensma TL, 1996, J VIROL, V70, P179, DOI 10.1128/JVI.70.1.179-187.1996; SZEWCZAK AA, 1993, P NATL ACAD SCI USA, V90, P9581, DOI 10.1073/pnas.90.20.9581; TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988; vandeLocht A, 1997, EMBO J, V16, P2977, DOI 10.1093/emboj/16.11.2977; WEEKS KM, 1995, BIOCHEMISTRY-US, V34, P7728, DOI 10.1021/bi00023a020; Wiener SL, 1996, MIL MED, V161, P251, DOI 10.1093/milmed/161.5.251; Yan XJ, 1997, J MOL BIOL, V266, P1043, DOI 10.1006/jmbi.1996.0865; Zilinskas RA, 1997, JAMA-J AM MED ASSOC, V278, P418, DOI 10.1001/jama.278.5.418	44	82	94	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4937	4942		10.1074/jbc.275.7.4937	http://dx.doi.org/10.1074/jbc.275.7.4937			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671531	hybrid			2022-12-27	WOS:000085378200057
J	Ibberson, M; Uldry, M; Thorens, B				Ibberson, M; Uldry, M; Thorens, B			GLUTX1, a novel mammalian glucose transporter expressed in the central nervous system and insulin-sensitive tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; HYPERGLYCEMIA; FIBROBLASTS; SEQUENCE; NEURONS; SIGNAL; FAMILY; CELLS; SITE	Based on homology with GLUT1-5, we have isolated a cDNA for a novel glucose transporter, GLUTX1. This cDNA encodes a protein of 478 amino acids that shows between 29 and 32% identity with rat GLUT1-5 and 32-36% identity with plant and bacterial hexose transporters. Unlike GLUT1-5, GLUTX1 has a short extracellular loop between transmembrane domain (TM) 1 and TM2 and a long extracellular loop between TM9 and TM10 that contains the only N-glycosylation site. When expressed in Xenopus oocytes, GLUTX1 showed strong transport activity only after suppression of a dileucine internalization motif present in the amino-terminal region. Transport activity was inhibited by cytochalasin B and partly competed by D-fructose and D-galactose. The Michaelis-Menten constant for glucose was approximately 2 mM, When translated in reticulocytes lysates, GLUTX1 migrates as a 35-kDa protein that becomes glycosylated in the presence of microsomal membranes, Western blot analysis of GLUTX1 transiently expressed in HEK293T cells revealed a diffuse band with a molecular mass of 37-50 kDa that could be converted to a similar to 35-kDa polypeptide following enzymatic deglycosylation. Immunofluorescence microscopy detection of GLUTX1 transfected into HEK293T cells showed an intracellular staining. Mutation of the dileucine internalization motif induced expression of GLUTX1 at the cell surface, GLUTX1 mRNA was detected in testis, hypothalamus, cerebellum, brainstem, hippocampus, and adrenal gland, We hypothesize that, in a similar fashion to GLUT4 in vivo cell surface expression of GLUTX1 may be inducible by a hormonal or other stimulus.	Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland		Thorens, B (corresponding author), Inst Pharmacol & Toxicol, 27 Rue Bugnon, CH-1005 Lausanne, Switzerland.			Ibberson, Mark/0000-0003-3152-5670				BURANT CF, 1992, J BIOL CHEM, V267, P14523; Chiou TJ, 1996, PLANT PHYSIOL, V110, P511, DOI 10.1104/pp.110.2.511; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; GILBOE DP, 1972, ANAL BIOCHEM, V47, P20, DOI 10.1016/0003-2697(72)90274-6; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; Guillam MT, 1997, NAT GENET, V17, P327, DOI 10.1038/ng1197-327; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HEDIGER MA, 1994, PHYSIOL REV, V74, P993, DOI 10.1152/physrev.1994.74.4.993; INUKAI K, 1994, BIOCHEM J, V302, P355, DOI 10.1042/bj3020355; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; OOMURA Y, 1974, NATURE, V247, P284, DOI 10.1038/247284a0; ORSINI JC, 1990, BRAIN RES BULL, V25, P49, DOI 10.1016/0361-9230(90)90251-T; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; RUSSELL RRB, 1992, J BIOL CHEM, V267, P4631; SARAVOLAC EG, 1997, FACILITATIVE GLUCOSE, P39; Seatter MJ, 1998, BIOCHEMISTRY-US, V37, P1322, DOI 10.1021/bi972322u; SMITH TF, 1985, NUCLEIC ACIDS RES, V13, P645, DOI 10.1093/nar/13.2.645; Stenbit AE, 1996, J CLIN INVEST, V98, P629, DOI 10.1172/JCI118833; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Thorens B, 1996, AM J PHYSIOL-GASTR L, V270, pG541, DOI 10.1152/ajpgi.1996.270.4.G541; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; WIDMANN C, 1995, BIOCHEM J, V310, P203, DOI 10.1042/bj3100203; YETTEFTI K, 1995, J AUTONOM NERV SYST, V51, P191, DOI 10.1016/0165-1838(94)00130-C; Younes M, 1997, ANTICANCER RES, V17, P2747	32	192	204	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4607	4612		10.1074/jbc.275.7.4607	http://dx.doi.org/10.1074/jbc.275.7.4607			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671487	hybrid			2022-12-27	WOS:000085378200013
J	Lyon, M; Rushton, G; Askari, JA; Humphries, MJ; Gallagher, JT				Lyon, M; Rushton, G; Askari, JA; Humphries, MJ; Gallagher, JT			Elucidation of the structural features of heparan sulfate important for interaction with the Hep-2 domain of fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; HUMAN-PLASMA FIBRONECTIN; FACTOR SCATTER FACTOR; BINDING DOMAIN; INTEGRIN ALPHA-4-BETA-1; DIMETHYL-SULFOXIDE; CELL-ADHESION; MAMMARY CELLS; IDENTIFICATION; AFFINITY	The interaction of fibronectin with cell surface heparan sulfate proteoglycans is important biologically in inducing reorganization of the cytoskeleton and the assembly of focal adhesions. The major heparan sulfate-binding site in fibronectin, which is also implicated in these morphological events, is the COOH-terminal Hep-2 domain. We describe the first extensive study of the structural determinants required for the interaction between heparan sulfate/heparin and Hep-a. It is clear that, in heparan sulfate, there is a very prominent role for N-sulfate groups, as opposed to a relatively small apparent contribution from carboxyl groups. Furthermore, a minimal octasaccharide binding sequence appeared to contain at least two 2-O-sulfated iduronate residues, but no 6-O-sulfate groups. However, affinity was enhanced by the presence of 6-O-sulfates, and the interaction with Hep-a also increased progressively with oligosaccharide size up to a maximum length of a tetradecasaccharide, This overall specificity is compatible with recent information on the structure of Hep-a (Sharma, A., Askari, J, A, Humphries, M, J,, Jones, E, Y,, and Stuart, D, I. (1999) EMBO J. 18, 1468-1479) in which two separate, positively charged clusters, involving up to fl basic amino acid residues (mostly arginines with their preferential ability to co-ordinate sulfate groups), could form a single extended binding site.	Univ Manchester, Dept Med Oncol, Christie Hosp NHS Trust, Canc Res Campaign, Manchester M20 4BX, Lancs, England; Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	Christie NHS Foundation Trust; Christie Hospital; University of Manchester; University of Manchester	Lyon, M (corresponding author), Univ Manchester, Dept Med Oncol, Christie Hosp NHS Trust, Canc Res Campaign, Manchester M20 4BX, Lancs, England.			Lyon, Malcolm/0000-0001-9575-6879; Humphries, Martin/0000-0002-4331-6967				ATKINS EDT, 1976, HEPARIN CHEM CLIN US, P21; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; BENECKY MJ, 1988, BIOCHEMISTRY-US, V27, P7565, DOI 10.1021/bi00419a058; BENTLEY KL, 1985, J BIOL CHEM, V260, P7250; Bloom L, 1999, MOL BIOL CELL, V10, P1521, DOI 10.1091/mbc.10.5.1521; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; COUCHMAN JR, 1988, J CELL PHYSIOL, V136, P226, DOI 10.1002/jcp.1041360204; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; EVINGTON JRN, 1985, BIOCHEM SOC T, V13, P243, DOI 10.1042/bst0130243; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FROMM JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P279, DOI 10.1006/abbi.1995.9963; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; INGHAM KC, 1993, BIOCHEMISTRY-US, V32, P12548, DOI 10.1021/bi00097a035; INGHAM KC, 1990, BIOCHEM J, V272, P605, DOI 10.1042/bj2720605; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P451, DOI 10.1093/glycob/4.4.451; JAIKARIA NS, 1991, BIOCHEMISTRY-US, V30, P1538, DOI 10.1021/bi00220a014; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; KELLER KL, 1980, BIOCHEMISTRY-US, V19, P2529, DOI 10.1021/bi00552a035; LLOYD AG, 1971, BIOCHEM PHARMACOL, V20, P637, DOI 10.1016/0006-2952(71)90150-X; LYON M, 1994, J BIOL CHEM, V269, P11216; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; MAKAREM R, 1994, J BIOL CHEM, V269, P4005; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; OGAMO A, 1985, BIOCHIM BIOPHYS ACTA, V841, P30; Rahmoune H, 1998, BIOCHEMISTRY-US, V37, P6003, DOI 10.1021/bi972468t; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; STAMATOGLOU SC, 1983, J CELL BIOL, V96, P1820, DOI 10.1083/jcb.96.6.1820; TAYLOR RL, 1972, BIOCHEMISTRY-US, V11, P1383, DOI 10.1021/bi00758a009; Walker A, 1996, BIOCHEM J, V317, P871, DOI 10.1042/bj3170871; WINTERBOURNE DJ, 1981, J BIOL CHEM, V256, P4310; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; Woods A, 1998, MATRIX BIOL, V17, P477, DOI 10.1016/S0945-053X(98)90095-6; YAMADA KM, 1980, J BIOL CHEM, V255, P6055; YONEDA J, 1995, EXP CELL RES, V217, P169, DOI 10.1006/excr.1995.1076	45	74	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4599	4606		10.1074/jbc.275.7.4599	http://dx.doi.org/10.1074/jbc.275.7.4599			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671486	hybrid			2022-12-27	WOS:000085378200012
J	Kasahara, T; Kasahara, M				Kasahara, T; Kasahara, M			Three aromatic amino acid residues critical for galactose transport in yeast Gal2 transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT1 GLUCOSE-TRANSPORTER; PUTATIVE TRANSMEMBRANE SEGMENT-10; SACCHAROMYCES-CEREVISIAE; SUGAR TRANSPORTERS; SUBSTRATE RECOGNITION; COMPLETE GENOME; TRYPTOPHAN-388; FORSKOLIN; BINDING; FAMILY	Tyr(446) in putative transmembrane segment 10 (TM10) of the yeast galactose transporter Ga12 has previously been identified as essential for galactose recognition. In the present study, alignment of the amino acid sequences of 63 sugar transporters or related proteins revealed 14 aromatic sites, including Tyr(446) Of Ga12, that are conserved in >75% of these proteins. The importance of the remaining 13 conserved aromatic amino acids was examined individually by random mutagenesis using degenerate primers. Galactose transport-positive clones were identified by plate selection and subjected to DNA sequencing. For those transport-positive clones corresponding to Tyr(352) and phe(504) mutants, all the amino acid substitutions comprised aromatic residues. The importance of the aromatic residues at these sites was further investigated by replacing them individually with each of the other 19 amino acids and measuring the galactose transport activity of the resulting mutants. Among both Tyr(352) and Phe(504) mutants, the other aromatic amino acids support-ed galactose transport; no other amino acids conferred high affinity transport activity. Thus, at least three aromatic sites are critical for galactose transport: one at the extracellular boundary of putative TM7 (Tyr(352)), One in the middle of putative TM10 (Tyr(446)), and one in the middle of putative TM12 (Phe(504)).	Teikyo Univ, Biophys Lab, Sch Med, Hachioji, Tokyo 1920395, Japan	Teikyo University	Kasahara, M (corresponding author), Teikyo Univ, Biophys Lab, Sch Med, Hachioji, Tokyo 1920395, Japan.							BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BELL GI, 1993, J BIOL CHEM, V268, P19161; BISSON LF, 1993, CRIT REV BIOCHEM MOL, V28, P259, DOI 10.3109/10409239309078437; Boles E, 1997, FEMS MICROBIOL REV, V21, P85, DOI 10.1016/S0168-6445(97)00052-1; Doege H, 1998, BIOCHEM J, V329, P289, DOI 10.1042/bj3290289; Dutzler R, 1996, STRUCTURE, V4, P127, DOI 10.1016/S0969-2126(96)00016-0; Forst D, 1998, NAT STRUCT BIOL, V5, P37, DOI 10.1038/nsb0198-37; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; Gracy J, 1998, BIOINFORMATICS, V14, P164, DOI 10.1093/bioinformatics/14.2.164; INUKAI K, 1994, BIOCHEM J, V302, P355, DOI 10.1042/bj3020355; Kasahara M, 1998, J BIOL CHEM, V273, P29106, DOI 10.1074/jbc.273.44.29106; Kasahara M, 1996, FEBS LETT, V389, P174, DOI 10.1016/0014-5793(96)00567-4; Kasahara M, 1997, J BIOL CHEM, V272, P16721, DOI 10.1074/jbc.272.27.16721; Kasahara T, 1996, BIOCHEM J, V315, P177, DOI 10.1042/bj3150177; Kasahara T, 1998, J BIOL CHEM, V273, P29113, DOI 10.1074/jbc.273.44.29113; KATAGIRI H, 1993, BIOCHEM J, V291, P861, DOI 10.1042/bj2910861; Kruckeberg AL, 1999, BIOCHEM J, V339, P299, DOI 10.1042/0264-6021:3390299; Kruckeberg AL, 1996, ARCH MICROBIOL, V166, P283, DOI 10.1007/s002030050385; Liang H, 1998, MOL CELL BIOL, V18, P926, DOI 10.1128/MCB.18.2.926; MORI H, 1994, J BIOL CHEM, V269, P11578; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; NISHIZAWA K, 1995, J BIOL CHEM, V270, P2423, DOI 10.1074/jbc.270.6.2423; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Olsowski A, 1998, BIOCHEMISTRY-US, V37, P10738, DOI 10.1021/bi980440r; Paulsen IT, 1998, FEBS LETT, V430, P116, DOI 10.1016/S0014-5793(98)00629-2; QUIOCHO FA, 1993, BIOCHEM SOC T, V21, P442, DOI 10.1042/bst0210442; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHURMANN A, 1993, BIOCHEM J, V290, P497, DOI 10.1042/bj2900497; Seatter MJ, 1998, BIOCHEMISTRY-US, V37, P1322, DOI 10.1021/bi972322u; SHERMAN F, 1986, LAB COURSE MANUAL ME, P164; Walmsley AR, 1998, TRENDS BIOCHEM SCI, V23, P476, DOI 10.1016/S0968-0004(98)01326-7; WANDEL S, 1994, FEBS LETT, V348, P114, DOI 10.1016/0014-5793(94)00558-3; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301	35	18	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4422	4428		10.1074/jbc.275.6.4422	http://dx.doi.org/10.1074/jbc.275.6.4422			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660614	hybrid			2022-12-27	WOS:000085288800098
J	Yasukawa, T; Suzuki, T; Suzuki, T; Ueda, T; Ohta, S; Watanabe, K				Yasukawa, T; Suzuki, T; Suzuki, T; Ueda, T; Ohta, S; Watanabe, K			Modification defect at anticodon wobble nucleotide of mitochondrial tRNAs(Leu)(UUR) with pathogenic mutations of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNALEU(UUR) GENE; CELLS LACKING MTDNA; TRANSFER-RNA; MYCOPLASMA-CAPRICOLUM; PROTEIN-SYNTHESIS; POINT MUTATION; TRANSCRIPTION TERMINATION; MYOCLONIC EPILEPSY; CODON RECOGNITION; DIABETES-MELLITUS	The mitochondrial tRNA(Leu)(UUR) (R = A or Gr) gene possesses several hot spots for pathogenic mutations. A point:mutation at nucleotide position 3243 or 3271 is associated with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes and maternally inherited diabetes with deafness. Detailed studies on two tRNAs(Leu)(UUR) with the 3243 or 3271 mutation revealed some common characteristics in cybrid cells: (i) a decreased life span, resulting in a 70% decrease in the amounts of the tRNAs in the steady state, (ii) a slight decrease in the ratios of aminoacyl-tRNAs(Leu)(UUR) versus uncharged tRNAs(Leu)(UUR), and (iii) accurate aminoacylation with leucine without any misacylation. As a marked result, both of the mutant tRNA molecules were deficient in a modification of uridine that occurs in the normal tRNA(Leu)(UUR) at the first position of the anticodon, The lack of this modification may lead to the mistranslation of leucine into non-cognate phenylalanine codons by mutant tRNAsLeU(UUR), according to the mitochondrial wobble rule, and/or a decrease in the rate of mitochondrial protein synthesis. This finding could explain why two different mutations (3243 and 3271) manifest indistinguishable clinical features.	Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; Nippon Med Sch, Inst Gerontol, Dept Biochem & Cell Biol, Nakahara Ku, Kawasaki, Kanagawa 2110063, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Bunkyo Ku, Tokyo 1138656, Japan	University of Tokyo; Nippon Medical School; University of Tokyo	Ohta, S (corresponding author), Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.		Suzuki, Tsutomu/J-1776-2015; Ueda, Takuya/K-5217-2014; Yasukawa, Takehiro/AAP-1335-2020	Suzuki, Tsutomu/0000-0002-9731-1731; Ueda, Takuya/0000-0002-7760-8271; Yasukawa, Takehiro/0000-0001-9531-8780				ANDACHI Y, 1989, J MOL BIOL, V209, P37, DOI 10.1016/0022-2836(89)90168-X; ANDACHI Y, 1987, P NATL ACAD SCI USA, V84, P7398, DOI 10.1073/pnas.84.21.7398; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BANKS JF, 1994, ANAL CHEM, V66, P406, DOI 10.1021/ac00075a015; BARRELL BG, 1980, P NATL ACAD SCI-BIOL, V77, P3164, DOI 10.1073/pnas.77.6.3164; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; DONISKELLER H, 1980, NUCLEIC ACIDS RES, V8, P3133, DOI 10.1093/nar/8.14.3133; Dunbar DR, 1996, HUM MOL GENET, V5, P123, DOI 10.1093/hmg/5.1.123; ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47; Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189; GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HAYASHI J, 1990, BIOCHEM BIOPH RES CO, V167, P216, DOI 10.1016/0006-291X(90)91753-F; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1993, BIOCHEM BIOPH RES CO, V197, P1049, DOI 10.1006/bbrc.1993.2584; HECKMAN JE, 1980, P NATL ACAD SCI-BIOL, V77, P3159, DOI 10.1073/pnas.77.6.3159; Helm M, 1999, NUCLEIC ACIDS RES, V27, P756, DOI 10.1093/nar/27.3.756; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; INAGAKI Y, 1995, J MOL BIOL, V251, P486, DOI 10.1006/jmbi.1995.0450; KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403; KEITH G, 1995, BIOCHIMIE, V77, P142, DOI 10.1016/0300-9084(96)88118-1; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5; KOBAYASHI Y, 1991, AM J HUM GENET, V49, P590; KUCHINO Y, 1987, METHOD ENZYMOL, V155, P379; MANFREDI G, 1995, NEUROMUSCULAR DISORD, V5, P391, DOI 10.1016/0960-8966(94)00079-O; Matsuyama S, 1998, J BIOL CHEM, V273, P3363, DOI 10.1074/jbc.273.6.3363; MICHEAL WM, 1996, FEBS LETT, V433, P93; SAMUELSSON T, 1983, J BIOL CHEM, V258, P3178; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SILVESTRI G, 1992, AM J HUM GENET, V51, P1213; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Suzuki T, 1997, EMBO J, V16, P1122, DOI 10.1093/emboj/16.5.1122; Suzuki T, 1996, FEBS LETT, V381, P195, DOI 10.1016/0014-5793(96)00107-X; SUZUKI T, 1999, J MASS SPECTROM SOC, V47, P168; Suzuki Y, 1996, DIABETES CARE, V19, P1304, DOI 10.2337/diacare.19.11.1304; Tomita K, 1998, BBA-GENE STRUCT EXPR, V1399, P78, DOI 10.1016/S0167-4781(98)00099-2; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; WAKITA K, 1994, NUCLEIC ACIDS RES, V22, P347, DOI 10.1093/nar/22.3.347; Watanabe Kimitsuna, 1995, P225	44	209	216	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4251	4257		10.1074/jbc.275.6.4251	http://dx.doi.org/10.1074/jbc.275.6.4251			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660592	hybrid			2022-12-27	WOS:000085288800076
J	Benbernou, N; Muegge, K; Durum, SK				Benbernou, N; Muegge, K; Durum, SK			Interleukin (IL)-7 induces rapid activation of Pyk2, which is bound to Janus kinase 1 and IL-7R alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; FOCAL ADHESION KINASE; RECEPTOR-GAMMA-CHAIN; N-TERMINAL KINASE; DEFECTIVE LYMPHOID DEVELOPMENT; MICE LACKING JAK3; DEFICIENT MICE; SIGNALING PATHWAY; COUPLED RECEPTORS; IL-7 RECEPTOR	Interleukin-7 (IL-7) receptor signaling begins with activation of the Janus tyrosine kinases Jak1 and Jak3, which are associated with the receptor complex. To identify potential targets of these kinases, we examined Pyk2 (a member of the focal adhesion kinase family) using an IL-7-dependent murine thymocyte line, D1. We demonstrate that stimulation of D1 (or normal pro-T) cells by IL-7 rapidly increased tyrosine phosphorylation and enzymatic activity of Pyk2, with kinetics slightly lagging that of Jak1 and Jak3 phosphorylation. Conversely, IL-7 withdrawal resulted in a marked decrease of Pyk2 phosphorylation. Pyk2 was found to be physically associated with Jak1 prior to IL-7 stimulation and to increase its association with lL-7R alpha chain following IL-7 stimulation. Pyk2 appeared to be involved in cell survival, because antisense Pyk2 accelerated the cell death process. Activation of Pyk2 via the muscarinic and nicotinic receptors using carbachol or via intracellular Ca2+ rise using ionomycin/phorbol myristate acetate promoted survival in the absence of IL-7. These data support a role for Pyk2 in coupling Jak signaling to the trophic response.	NCI, Intramural Res Support Program, SAIC Frederick, Frederick Canc Res & Dev Ctr,NIH, Frederick, MD 21702 USA; NCI, Mol Immunoregulat Lab, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Durum, SK (corresponding author), NCI, Mol Immunoregulat Lab, NIH, Bldg 560,Rm 31-71, Frederick, MD 21702 USA.	durums@mail.ncifcrf.gov		durum, scott/0000-0003-1307-9582	NCI NIH HHS [N01-CO-56000] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; Andreev J, 1999, MOL CELL BIOL, V19, P2338; APPLEBY MW, 1995, J EXP MED, V182, P811, DOI 10.1084/jem.182.3.811; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; Candotti F, 1998, SPRINGER SEMIN IMMUN, V19, P401, DOI 10.1007/BF00792599; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; Cazaubon S, 1997, J NEUROSCI, V17, P6203; Corcoran AE, 1998, NATURE, V391, P904, DOI 10.1038/36122; DADI H, 1994, BLOOD, V84, P1579; Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; Durum SK, 1998, J EXP MED, V188, P2233, DOI 10.1084/jem.188.12.2233; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; FOXWELL BMJ, 1995, EUR J IMMUNOL, V25, P3041, DOI 10.1002/eji.1830251109; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0; Girault JA, 1998, MOL MED, V4, P751, DOI 10.1007/BF03401769; Gomez J, 1998, CRIT REV IMMUNOL, V18, P185, DOI 10.1615/CritRevImmunol.v18.i3.20; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; Guo XYD, 1998, BLOOD, V92, p253A; Higuchi M, 1996, EUR J IMMUNOL, V26, P1322, DOI 10.1002/eji.1830260622; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Hofmeister R, 1999, CYTOKINE GROWTH F R, V10, P41, DOI 10.1016/S1359-6101(98)00025-2; ILIC D, 1975, NATURE, V377, P539; Kim K, 1998, J IMMUNOL, V160, P5735; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lev S, 1999, MOL CELL BIOL, V19, P2278; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li XO, 1997, J BIOL CHEM, V272, P14996, DOI 10.1074/jbc.272.23.14996; Liu ZY, 1997, J CLIN INVEST, V99, P1798, DOI 10.1172/JCI119344; MALABARBA MG, 1995, J BIOL CHEM, V270, P9630, DOI 10.1074/jbc.270.16.9630; Maraskovsky E, 1997, CELL, V89, P1011, DOI 10.1016/S0092-8674(00)80289-5; Miyazaki T, 1998, GENE DEV, V12, P770, DOI 10.1101/gad.12.6.770; Nelms K, 1998, ADV EXP MED BIOL, V452, P37; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; Ohba T, 1998, BIOCHEM J, V330, P1249, DOI 10.1042/bj3301249; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Park SY, 1995, IMMUNITY, V3, P771, DOI 10.1016/1074-7613(95)90066-7; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Reif K, 1998, IMMUNITY, V8, P395, DOI 10.1016/S1074-7613(00)80545-2; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SECKINGER P, 1994, J IMMUNOL, V153, P97; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; VENKITARAMAN AR, 1992, P NATL ACAD SCI USA, V89, P12083, DOI 10.1073/pnas.89.24.12083; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Yasue T, 1997, P NATL ACAD SCI USA, V94, P10307, DOI 10.1073/pnas.94.19.10307; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; ZENG YX, 1994, FEBS LETT, V353, P289, DOI 10.1016/0014-5793(94)01065-X; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	64	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7060	7065		10.1074/jbc.275.10.7060	http://dx.doi.org/10.1074/jbc.275.10.7060			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702271	hybrid			2022-12-27	WOS:000085809600051
J	Nishi, T; Forgac, M				Nishi, T; Forgac, M			Molecular cloning and expression of three isoforms of the 100-kDa a subunit of the mouse vacuolar proton-translocating ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; 116-KDA POLYPEPTIDE; STRUCTURAL-CHANGES; CDNA SEQUENCE; GENE ENCODES; V-ATPASES; PUMP; VPH1P; (H+)-ATPASE; SYNTHASES	We have identified cDNAs encoding three isoforms (a1, a2, and a3) of the 100-kDa a subunit of the mouse vacuolar proton-translocating ATPase (V-ATPase), The predicted protein sequences of the three isoforms are 838, 856, and 834 amino acids, respectively, and they display approximately 50% identity between isoforms, Northern blot analysis demonstrated that all three isoforms are expressed in most tissues examined. However, the al isoform is expressed most heavily in brain and heart, a2 in liver and kidney, and a3 in liver, lung, heart, brain, spleen, and kidney. We also identified multiple alternatively spliced variants for each isoform, Reverse transcriptase-mediated polymerase chain reaction revealed that one splicing variant of the al isoform (a1-I) was expressed only in brain, whereas two other variants (a1-II and a1-III) were expressed in tissues other than brain. These alternatively spliced forms differ in the presence or absence of 6-7 amino acid residues near the amino and carboxyl termini of the proteins encoded. The a3 isoform is also encoded by three alternatively spliced variants, two of which are predicted to encode a protein that is truncated near the border of the amino- and carboxyl-terminal domains of the a subunit and therefore lacks the integral transmembrane-spanning helices thought to participate in proton translocation, Expression of each isoform (with the exception of a1-I) was detectable at all developmental stages investigated, with a1-I absent only in day 7 embryos. The results obtained suggest that isoforms of the 100-kDa a subunit may contribute to tissue-specific functions of the V-ATPase.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM034478, R37 GM034478, GM34478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; Capaldi RA, 1996, J BIOENERG BIOMEMBR, V28, P397, DOI 10.1007/BF02113980; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; Fillingame RH, 1997, J EXP BIOL, V200, P217; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Futai M, 1996, J BIOENERG BIOMEMBR, V28, P409, DOI 10.1007/BF02113982; GLUCK SL, 1992, J BIOENERG BIOMEMBR, V24, P351, DOI 10.1007/BF00762528; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; Kane PM, 1999, J BIOENERG BIOMEMBR, V31, P49, DOI 10.1023/A:1005444513542; KANE PM, 1995, J BIOL CHEM, V270, P17025; KIBAK H, 1992, J BIOENERG BIOMEMBR, V24, P415, DOI 10.1007/BF00762534; LEE CK, 1990, MOL IMMUNOL, V27, P1137; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Li YP, 1996, BIOCHEM BIOPH RES CO, V218, P813, DOI 10.1006/bbrc.1996.0145; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Margolles-Clark E, 1999, J BIOENERG BIOMEMBR, V31, P29, DOI 10.1023/A:1005440412633; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; Pedersen PL, 1996, J BIOENERG BIOMEMBR, V28, P389, DOI 10.1007/BF02113979; PENG SB, 1994, J BIOL CHEM, V269, P17262; Peng SB, 1999, J BIOL CHEM, V274, P2549, DOI 10.1074/jbc.274.4.2549; PERIN MS, 1991, J BIOL CHEM, V266, P3877; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	36	114	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6824	6830		10.1074/jbc.275.10.6824	http://dx.doi.org/10.1074/jbc.275.10.6824			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702241	hybrid			2022-12-27	WOS:000085809600021
J	Aso, T; Yamazaki, K; Amimoto, K; Kuroiwa, A; Higashi, H; Matsuda, Y; Kitajima, S; Hatakeyama, M				Aso, T; Yamazaki, K; Amimoto, K; Kuroiwa, A; Higashi, H; Matsuda, Y; Kitajima, S; Hatakeyama, M			Identification and characterization of Elongin A2, a new member of the Elongin family of transcription elongation factors, specifically expressed in the testis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TUMOR-SUPPRESSOR PROTEIN; TATA-BINDING PROTEIN; COLLAGEN GENE COL2A1; FACTOR-SIII; INSITU HYBRIDIZATION; SUBUNIT; COMPLEX; DOMAINS	The Elongin complex stimulates the rate of transcription elongation by RNA polymerase II by suppressing the transient pausing of the polymerase at many sites along the DNA template. Elongin is composed of a transcriptionally active A subunit and two small regulatory B and C subunits, the latter of which bind stably to each other to form a binary complex that interacts with Elongin A and strongly induces its transcriptional activity. To further understand the roles of Elongin in transcriptional regulation, Re attempted to identify Elongin-related proteins. sere, we report on the cloning, expression, and characterization of human Elongin A2, a novel transcription elongation factor that exhibited 47% identity and 61% similarity to Elongin A. Biochemical studies have shown that Elongin A2 stimulates the rate of transcription elongation by RNA polymerase II and is capable of forming a stable complex with Elongin BC, However, in contrast to Elongin A, its transcriptional activity is not activated by Elongin BC. Northern blot analysis revealed that Elongin A2 mRNA was specifically expressed in the testis, suggesting that Elongin A2 may regulate the transcription of testis-specific genes.	Japanese Fdn Canc Res, Inst Canc, Dept Viral Oncol, Toshima Ku, Tokyo 1708455, Japan; Tokyo Med & Dent Univ, Inst Med Res, Dept Biochem Genet, Tokyo 1138510, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Lab Anim Genet, Nagoya, Aichi 4648601, Japan; Hokkaido Univ, Grad Sch Environm Earth Sci, Div Biosci, Lab Cytogenet, Sapporo, Hokkaido 0600810, Japan; Hokkaido Univ, Fac Sci, Chromosome Res Unit, Sapporo, Hokkaido 0600810, Japan	Japanese Foundation for Cancer Research; Tokyo Medical & Dental University (TMDU); Nagoya University; Hokkaido University; Hokkaido University	Aso, T (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Viral Oncol, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.		Higashi, Hideaki/F-6872-2012	Kuroiwa, Asato/0000-0002-3942-3372				Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; Aso T, 1996, GENE, V168, P277, DOI 10.1016/0378-1119(95)00750-4; Blau J, 1996, MOL CELL BIOL, V16, P2044; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; CIPRESPALACIN G, 1994, P NATL ACAD SCI USA, V91, P8087, DOI 10.1073/pnas.91.17.8087; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CROWLEY TE, 1993, NATURE, V361, P557, DOI 10.1038/361557a0; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; Hansen SK, 1997, CELL, V91, P71, DOI 10.1016/S0092-8674(01)80010-6; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KISHIDA T, 1995, CANCER RES, V55, P4544; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; NAKANISHI T, 1995, J BIOL CHEM, V270, P8991, DOI 10.1074/jbc.270.15.8991; Pan GH, 1997, J BIOL CHEM, V272, P24563, DOI 10.1074/jbc.272.39.24563; REINES D, 1992, J BIOL CHEM, V267, P3795; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SCHMIDT EE, 1995, DEVELOPMENT, V121, P2373; TAKAHASHI E, 1989, JPN J HUM GENET, V34, P307, DOI 10.1007/BF01929213; TAKAHASHI E, 1990, HUM GENET, V86, P14; Upadhyaya AB, 1999, J BIOL CHEM, V274, P18040, DOI 10.1074/jbc.274.25.18040; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	29	26	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6546	6552		10.1074/jbc.275.9.6546	http://dx.doi.org/10.1074/jbc.275.9.6546			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692460	hybrid			2022-12-27	WOS:000085654400072
J	Bijnens, AP; Gils, A; Knockaert, I; Stassen, JM; Declerck, PJ				Bijnens, AP; Gils, A; Knockaert, I; Stassen, JM; Declerck, PJ			Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; COMPLEX-FORMATION; TISSUE-TYPE; ENDOTHELIAL-CELLS; INTERACTION SITES; STRUCTURAL BASIS; SUBSTRATE; PURIFICATION; EXPRESSION; FORM	The serpin plasminogen activator inhibitor type 1 (PAI-1) is an important protein in the regulation of fibrinolysis and inhibits its target proteinases through formation of a covalent complex. In the present study, we have identified the epitope of two PAI-1 neutralizing monoclonal antibodies (MA-33H1F7 and MA-55F4C12). Based upon differential cross-reactivity data of these monoclonals with PAI-1 from different species and on a sequence alignment between these PAI-1s, combined with the three-dimensional structure, we predicted that the residues Glu(128)-Val(129)-Glu(130)-Arg(131) and Lys(154) (at the hinge region between alpha-helix F and the main part of the PAI-1-molecule) might form the major site of interaction. Therefore a variety of alanine mutants were generated and evaluated for their affinity toward both monoclonal antibodies. The affinity constants of MA-55F4C12 and MA-33HIF7 for PAI-1 were 2.1 +/- 1.6 x 10(9) M-1 and 5.4 +/- 1.7 x 10(9) M-1, respectively, but decreased between 13- and 270-fold upon mutation of Lys(154) to Ala(154) or Glu(128)-Val(129)-Glu(130)-Arg(131) to Ala-Ala-Ala-Ala. The combined mutations (PAI-1-EVER/K), however, resulted in an absence of binding to either of the antibodies. Both antibodies bound to PAI-1-wt/t-PA complexes with a similar affinity as to PAI-1-wt (K-A = 4-5 x 10(9) M-1). The epitope localization reveals the molecular basis for the neutralizing properties of both monoclonal antibodies. In addition, it provides new insights into the validity of various models that have been proposed for the serpin/proteinase complex, excluding full insertion of the reactive-site loop.	Catholic Univ Louvain, Fac Pharmaceut Sci, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium; Boehringer Ingelheim KG, Cardiovasc Pharmacol, D-88397 Biberach, Germany	Universite Catholique Louvain; Boehringer Ingelheim	Declerck, PJ (corresponding author), Catholic Univ Louvain, Fac Pharmaceut Sci, Lab Pharmaceut Biol & Phytopharmacol, Evenstr 4, B-3000 Louvain, Belgium.		Declerck, Paul J/A-2330-2017	Declerck, Paul J/0000-0003-1259-9105				AERTGEERTS K, 1994, J STRUCT BIOL, V113, P239, DOI 10.1006/jsbi.1994.1058; Aertgeerts K, 1997, J STRUCT BIOL, V118, P236, DOI 10.1006/jsbi.1997.3860; ANDREASEN PA, 1986, FEBS LETT, V209, P213, DOI 10.1016/0014-5793(86)81113-9; ASAKURA S, 1990, J BIOL CHEM, V265, P5135; AUDENAERT AM, 1994, J BIOL CHEM, V269, P19559; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; Bijnens AP, 1997, THROMB HAEMOSTASIS, V77, P350; Bjorquist P, 1997, BBA-PROTEIN STRUCT M, V1341, P87, DOI 10.1016/S0167-4838(97)00065-4; Carrell RW, 1996, BIOL CHEM H-S, V377, P1; Collen D, 1996, CIRCULATION, V94, P197, DOI 10.1161/01.CIR.94.2.197; Debrock S, 1997, BBA-PROTEIN STRUCT M, V1337, P257, DOI 10.1016/S0167-4838(96)00173-2; DEBROCK S, 1995, FEBS LETT, V376, P243, DOI 10.1016/0014-5793(95)01289-0; Debrock S, 1998, THROMB HAEMOSTASIS, V79, P597; DECLERCK PJ, 1992, J BIOL CHEM, V267, P11693; Gils A, 1998, THROMB HAEMOSTASIS, V80, P531; Gils A, 1996, BIOCHEMISTRY-US, V35, P7474, DOI 10.1021/bi960079d; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HOFMANN KJ, 1992, FIBRINOLYSIS, V6, P263, DOI 10.1016/0268-9499(92)90080-2; Jonsson U., 1992, ADV BIOSENSOR, P291; KEIJER J, 1991, BLOOD, V78, P401; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUITHOF EKO, 1984, BLOOD, V64, P907; Lawrence DA, 1997, NAT STRUCT BIOL, V4, P339, DOI 10.1038/nsb0597-339; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MUNCH M, 1993, BIOCHIM BIOPHYS ACTA, V1202, P29, DOI 10.1016/0167-4838(93)90059-Z; Ngo TH, 1998, THROMB HAEMOSTASIS, V79, P808, DOI 10.1055/s-0037-1615069; Ngo TH, 1997, FIBRINOLYSIS PROTEOL, V11, P37, DOI 10.1016/S0268-9499(97)80007-0; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; PERRIE AM, 1993, FIBRINOLYSIS, V7, P257, DOI 10.1016/0268-9499(93)90134-H; Picard V, 1999, J BIOL CHEM, V274, P4586, DOI 10.1074/jbc.274.8.4586; SANCHO E, 1994, EUR J BIOCHEM, V224, P125, DOI 10.1111/j.1432-1033.1994.tb20003.x; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Stratikos E, 1998, J BIOL CHEM, V273, P15582, DOI 10.1074/jbc.273.25.15582; Sui GC, 1998, BIOCHEM J, V331, P409, DOI 10.1042/bj3310409; URANO T, 1992, EUR J BIOCHEM, V209, P985, DOI 10.1111/j.1432-1033.1992.tb17372.x; vanZonneveld AJ, 1995, GENE, V167, P49, DOI 10.1016/0378-1119(95)00614-1; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303	42	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6375	6380		10.1074/jbc.275.9.6375	http://dx.doi.org/10.1074/jbc.275.9.6375			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692438	hybrid			2022-12-27	WOS:000085654400050
J	LaPres, JJ; Glover, E; Dunham, EE; Bunger, MK; Bradfield, CA				LaPres, JJ; Glover, E; Dunham, EE; Bunger, MK; Bradfield, CA			ARA9 modifies agonist signaling through an increase in cytosolic aryl hydrocarbon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; AH RECEPTOR; LIGAND-BINDING; STEROID-HORMONES; DIOXIN RECEPTOR; EXPRESSION; CONTAINS; DOMAINS; MOUSE; TRANSACTIVATION	The aryl hydrocarbon receptor (AHR) is a ligand activated transcription factor that mediates the effects of agonists like 2,3,7,8-tetrachlorodibenzo-p-dioxin. In the current model for AHR signaling, the unliganded receptor is found in the cytosol as part of a complex with a dimer of the 90-kDa heat shock protein and an immunophilin-like molecule, ARA9. In yeast, expression of ARA9 results in an increase in the maximal agonist response and a leftward shift in the AHR dose-response curve. To better understand the mechanism by which ARA9 modifies AHR signal transduction, we performed a series of coexpression experiments in yeast and mammalian cells. Our results demonstrate that ARA9's influence on AHR signaling is not due to inhibition of a membrane pump or modification of the receptor's transactivation properties. Using receptor photoaffinity labeling experiments, we were able to show that ARA9 enhances AHR signal transduction by increasing the available AHR binding sites within the cytosolic compartment of the cell. Our evidence suggests that ARA9's effects are related to its role as a cellular chaperone; i.e. we observed that expression of ARA9 increases the fraction of AHR in the cytosol and also stabilized the receptor under heat stress.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bradfield, CA (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.				NCI NIH HHS [T32 CA09135] Funding Source: Medline; NIEHS NIH HHS [ES07015, ES05703] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES005703, R29ES005703, T32ES007015, R01ES005703] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bartel P. L., 1993, CELLULAR INTERACTION, P153; BRADFIELD CA, 1991, MOL PHARMACOL, V39, P13; BRADFIELD CA, 1988, MOL PHARMACOL, V34, P229; CARVER LA, 1994, J BIOL CHEM, V269, P30109; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; JAIN S, 1994, J BIOL CHEM, V269, P31518; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; Kralli A, 1996, J BIOL CHEM, V271, P17152, DOI 10.1074/jbc.271.29.17152; KRALLI A, 1995, P NATL ACAD SCI USA, V92, P4701, DOI 10.1073/pnas.92.10.4701; Kuzhandaivelu N, 1996, NUCLEIC ACIDS RES, V24, P4741, DOI 10.1093/nar/24.23.4741; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Ma Q, 1997, J BIOL CHEM, V272, P8878; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; NICKERSON M, 1956, NATURE, V178, P697, DOI 10.1038/178697b0; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POLAND A, 1989, MOL PHARMACOL, V36, P113; POLAND A, 1986, J BIOL CHEM, V261, P6352; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; SMITH RH, 1994, VIROLOGY, V202, P760, DOI 10.1006/viro.1994.1398; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; Whitlock JP, 1997, DRUG METAB REV, V29, P1107, DOI 10.3109/03602539709002245	30	92	93	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6153	6159		10.1074/jbc.275.9.6153	http://dx.doi.org/10.1074/jbc.275.9.6153			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692406	hybrid			2022-12-27	WOS:000085654400018
J	Sheng, HM; Shao, JY; Dixon, DA; Williams, CS; Prescott, SM; DuBois, RN; Beauchamp, RD				Sheng, HM; Shao, JY; Dixon, DA; Williams, CS; Prescott, SM; DuBois, RN; Beauchamp, RD			Transforming growth factor-beta 1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN COLON-CANCER; SYNTHASE-2 GENE-EXPRESSION; MESSENGER-RNA DEGRADATION; TGF-BETA RECEPTOR; N-TERMINAL KINASE; TRANSCRIPTIONAL REGULATION; POSTTRANSCRIPTIONAL REGULATION; INDUCTION; TGF-BETA-1; PROTEIN	Oncogenic ras induces the expression of cycloogygenase-2 (COX-2) in a variety of cells. Here we investigated the role of transforming growth factor-beta (TGF-beta) in the Res-mediated induction of COX-2 in intestinal epithelial cells (RIE-1). RIE-1 cells were transfected with an inducible Ha.Ras(Val12) cDNA and are referred as RIE-iRas cells. the addition of 5 mM isopropyl-1-thio-beta-D-galactopyranoside (IPTG) induced the expression of Ha-Ras-(val12) closely followed by an increase in the expression of COX-2. Neutralizing anti-TGF-beta antibody partially blocked the Ras-induced increase In COX-2. Combined treatment with IPTG and TGF-beta 1 resulted in a 20-50-fold increase in the levels of COX-2 mRNA The t(1/2) of COX-2 mRNA was increased from 13 to 24 min by Ha-Res induction alone. The addition of TGF-beta 1 further stabilized the COX-2 mRNA (t(1/2) > 50 min). Stable transfection of a luciferase reporter construct containing the COX-2 3'-untranslated region (3'-UTR) revealed that TGF-beta 1 treatment and Ras induction each stabilized the COX-2 3'-UTR. Combined treatment with IPTG and TGF-beta 1 synergistically increased the luciferase activity. Furthermore, a conserved AU-rich region located in the proximal COX-2 3'-UTR is required for maximal stabilization of COX-2 3'-UTR by Res or TGF-beta 1 and is necessary for the synergistic stabilization of COX-2 3'-UTR by oncogenic Res and TGF-beta 1.	Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Dept Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Dept Cell Biol, Nashville, TN 37232 USA; Univ Utah, Huntsman Canc Inst, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Sheng, HM (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN 37232 USA.		DuBois, Raymond N./AAX-8869-2020; Williams, christopher S/A-1186-2009	Beauchamp, Robert Daniel/0000-0002-8446-4114	NCI NIH HHS [CA-69457] Funding Source: Medline; NIDDK NIH HHS [DK-47297, DK-52334] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047297, R01DK047297, R01DK052334] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARTEAGA CL, 1993, CELL GROWTH DIFFER, V4, P193; AVERY A, 1993, BRIT J CANCER, V68, P137, DOI 10.1038/bjc.1993.301; BARNARD JA, 1993, GASTROENTEROLOGY, V105, P67, DOI 10.1016/0016-5085(93)90011-Z; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BOS JL, 1989, CANCER RES, V49, P4682; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DERYNCK R, 1987, CANCER RES, V47, P707; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FILMUS J, 1992, ONCOGENE, V7, P521; FRIEDMAN E, 1995, CANCER EPIDEM BIOMAR, V4, P549; GEISER AG, 1991, MOL CELL BIOL, V11, P84, DOI 10.1128/MCB.11.1.84; GILBERT RS, 1994, J CELL PHYSIOL, V159, P67, DOI 10.1002/jcp.1041590110; GILBERT RS, 1994, CELL MOL BIOL RES, V40, P653; HAFEZ MM, 1992, CELL GROWTH DIFFER, V3, P753; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Jacoby RF, 1996, CANCER RES, V56, P710; KARGMAN SL, 1995, CANCER RES, V55, P2556; KO TC, 1993, SURGERY, V114, P147; KO TC, 1995, ONCOGENE, V10, P177; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; KUROKOWA M, 1987, BIOCHEM BIOPH RES CO, V142, P775, DOI 10.1016/0006-291X(87)91481-1; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Li JL, 1996, ENDOCRINOLOGY, V137, P2522, DOI 10.1210/en.137.6.2522; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mestre JR, 1997, CANCER RES, V57, P2890; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pilbeam C, 1997, ENDOCRINOLOGY, V138, P4672, DOI 10.1210/en.138.11.4672; RAO CV, 1995, CANCER RES, V55, P1464; Reddy BS, 1996, CANCER RES, V56, P4566; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; Robson H, 1996, BRIT J CANCER, V74, P753, DOI 10.1038/bjc.1996.432; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SANO H, 1995, CANCER RES, V55, P3785; SCHROY P, 1990, CANCER RES, V50, P261; Shao JY, 1999, CARCINOGENESIS, V20, P185, DOI 10.1093/carcin/20.2.185; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 1998, J BIOL CHEM, V273, P22120, DOI 10.1074/jbc.273.34.22120; Sheng HM, 1997, CELL GROWTH DIFFER, V8, P463; Sheng HM, 1999, ONCOGENE, V18, P855, DOI 10.1038/sj.onc.1202397; SIEWEKE MH, 1990, SCIENCE, V248, P1656, DOI 10.1126/science.2163544; SIEWEKE MH, 1994, CRIT REV ONCOGENESIS, V5, P297, DOI 10.1615/CritRevOncog.v5.i2-3.90; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; THUN MJ, 1993, CANCER RES, V53, P1322; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Williams CS, 1996, AM J PHYSIOL-GASTR L, V270, pG393; Winesett MP, 1996, CARCINOGENESIS, V17, P989, DOI 10.1093/carcin/17.5.989; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Zhang F, 1998, J BIOL CHEM, V273, P2424, DOI 10.1074/jbc.273.4.2424; ZHANG XY, 1994, CANCER RES, V54, P6122	66	182	190	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6628	6635		10.1074/jbc.275.9.6628	http://dx.doi.org/10.1074/jbc.275.9.6628			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692471	hybrid			2022-12-27	WOS:000085654400083
J	Huber, D; Balda, MS; Matter, K				Huber, D; Balda, MS; Matter, K			Occludin modulates transepithelial migration of neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-EPITHELIAL MIGRATION; TIGHT JUNCTION; MEMBRANE-PROTEIN; CELL-ADHESION; ZO-1; PERMEABILITY; BARRIER; ARCHITECTURE; INVOLVEMENT; COMPONENT	Neutrophils cross epithelial sheets to reach inflamed mucosal surfaces by migrating along the paracellular route, To avoid breakdown of the epithelial barrier, this process requires coordinated opening and closing of tight junctions, the most apical intercellular junctions in epithelia. To determine the function of epithelial tight junction proteins in this process, we analyzed neutrophil migration across monolayers formed by stably transfected epithelial cells expressing wild-type and mutant occludin, a membrane protein of tight junctions with four transmembrane domains and both termini in the cytosol, We found that expression of mutants with a modified N-terminal cytoplasmic domain up-regulated migration, whereas deletion of the C-terminal cytoplasmic domain did not have an effect, The N-terminal cytosolic domain was also found to be important for the linear arrangement of occludin within tight junctions but not for the permeability barrier. Moreover, expression of mutant occludin bearing a mutation in one of the two extracellular domains inhibited neutrophil migration. The effects of transfected occludin mutants on neutrophil migration did not correlate with their effects on selective paracellular permeability and transepithelial electrical resistance. Hence, specific domains and functional properties of occludin modulate transepithelial migration of neutrophils.	Univ Geneva, Dept Biol Cellulaire, CH-1211 Geneva 4, Switzerland	University of Geneva	Matter, K (corresponding author), Univ Geneva, Dept Biol Cellulaire, 30 Quai Ernest-Ansermet, CH-1211 Geneva 4, Switzerland.		Matter, Karl/C-4880-2008	Matter, Karl/0000-0001-8026-7220; /0000-0002-8427-6746				ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; Balda MS, 1998, J CELL SCI, V111, P541; BALDA MS, 1999, IN PRESS J CELL BIOC; Bamforth SD, 1999, J CELL SCI, V112, P1879; CEREIJIDO M, 1991, TIGHT JUNCTIONS, P1; Chen YH, 1997, J CELL BIOL, V138, P891, DOI 10.1083/jcb.138.4.891; CRAMER EB, 1980, P NATL ACAD SCI-BIOL, V77, P4069, DOI 10.1073/pnas.77.7.4069; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; Dewald B, 1986, Methods Enzymol, V132, P267; Dunon D, 1996, CURR OPIN CELL BIOL, V8, P714, DOI 10.1016/S0955-0674(96)80114-1; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Huber D, 1999, INVAS METAST, V18, P70; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; Lapierre LA, 1999, J CELL SCI, V112, P3723; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; Marti J, 1998, IEE P-OPTOELECTRON, V145, P117, DOI 10.1049/ip-opt:19981767; Matter K, 1999, INT REV CYTOL, V186, P117; McCarthy KM, 1996, J CELL SCI, V109, P2287; MILKS LC, 1983, J CELL BIOL, V96, P1241, DOI 10.1083/jcb.96.5.1241; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Ohsugi M, 1997, DEV BIOL, V185, P261, DOI 10.1006/dbio.1997.8560; Parkos CA, 1997, BIOESSAYS, V19, P865, DOI 10.1002/bies.950191006; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Tsukita S, 1999, CURR OPIN CELL BIOL, V11, P628, DOI 10.1016/S0955-0674(99)00016-2; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399	34	88	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5773	5778		10.1074/jbc.275.8.5773	http://dx.doi.org/10.1074/jbc.275.8.5773			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681565	hybrid			2022-12-27	WOS:000085474500072
J	Hayashi, T; Faustman, D				Hayashi, T; Faustman, D			Essential role of human leukocyte antigen-encoded proteasome subunits in NF-kappa B activation and prevention of tumor necrosis factor-alpha-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DNA-BINDING SUBUNIT; MULTICATALYTIC PROTEINASE COMPLEX; SITE-SPECIFIC PHOSPHORYLATION; 20S PROTEASOME; MICE LACKING; CELL-DEATH; C-REL; SIGNAL TRANSDUCTION; TARGETED DISRUPTION; IMMUNE-RESPONSES	The multisubunit proteasome complex is the principal mediator of nonlysosomal protein degradation. The proteasome subunit varies minimally between cells with the exception of LMP2, LMP7, and LMP10 subunits in rodent and human cells. LMP2 and LMP7 subunits are encoded by the human lymphocyte antigen region, and they optimize proteolytic mediated antigen presentation. The proteasome is also important for the function of transcription factor nuclear factor-kappa B (NF-kappa B). It is required for NF-kappa B subunits p50 and p52 generation and catalyzes degradation of phosphorylated I kappa B alpha. These proteasome-mediated reactions have now been shown to be defective in T2 cells, a human lymphocyte cell line that lacks both LMP2 and LMP7. Although T2 cells contain normal expression of p100 and p105, the abundance of p50 and p52 was greatly reduced. Tumor necrosis factor-alpha (TNF-alpha) induced normal phosphorylation of I kappa B alpha but failed to induce degradation of phosphorylated I kappa B alpha. Both DNA binding assays and luciferase assays revealed that TNF-alpha-induced NF-kappa B activation is defective in T2 cells. Unlike parental cells, T2 cells were susceptible to TNF-alpha-induced apoptosis. These data indicate human leukocyte antigen-linked proteasome subunits are essential for NF-kappa B activation and protection of cells from TNF-alpha-induced apoptosis.	Massachusetts Gen Hosp E, Immunobiol Lab, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University	Faustman, D (corresponding author), Massachusetts Gen Hosp E, Immunobiol Lab, Bldg 149,13th St, Charlestown, MA 02129 USA.	denise.faustman@cbrc2.mgh.harvard.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011151] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE11151] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; AKIYAMA KY, 1994, SCIENCE, V265, P1231, DOI 10.1126/science.8066462; Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALDWIN AS, 1996, ANNU REV IMMUNOL, V12, P141; Bauer VW, 1996, GENE, V181, P63, DOI 10.1016/S0378-1119(96)00463-5; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BELICH MP, 1994, CURR BIOL, V4, P769, DOI 10.1016/S0960-9822(00)00174-3; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; CHEN ISY, 1983, J VIROL, V45, P104, DOI 10.1128/JVI.45.1.104-113.1983; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Coux O, 1998, J BIOL CHEM, V273, P8820, DOI 10.1074/jbc.273.15.8820; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; Cui HL, 1997, P NATL ACAD SCI USA, V94, P7515, DOI 10.1073/pnas.94.14.7515; DAWSON BA, 1991, J CELL BIOCHEM, V46, P166, DOI 10.1002/jcb.240460210; DeMartino GN, 1996, J BIOL CHEM, V271, P3112, DOI 10.1074/jbc.271.6.3112; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; Foo SY, 1999, TRENDS GENET, V15, P229; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; FRUH K, 1994, EMBO J, V13, P3236, DOI 10.1002/j.1460-2075.1994.tb06625.x; Fu YN, 1998, ANN NY ACAD SCI, V842, P138, DOI 10.1111/j.1749-6632.1998.tb09642.x; GACZYNSKA M, 1994, P NATL ACAD SCI USA, V91, P9213, DOI 10.1073/pnas.91.20.9213; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; Griffin TA, 1998, J EXP MED, V187, P97, DOI 10.1084/jem.187.1.97; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; JAMIESON C, 1991, J IMMUNOL, V147, P416; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kageshita T, 1999, AM J PATHOL, V154, P745, DOI 10.1016/S0002-9440(10)65321-7; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KISHI F, 1993, GENE, V133, P243; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; May MJ, 1999, SCIENCE, V284, P271, DOI 10.1126/science.284.5412.271; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MOLITOR JA, 1991, NEW BIOL, V3, P987; Nandi D, 1996, EXP CLIN IMMUNOGENET, V13, P20; Nandi D, 1997, EMBO J, V16, P5363, DOI 10.1093/emboj/16.17.5363; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NEUBERG M, 1989, NATURE, V341, P243, DOI 10.1038/341243a0; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; Pahl HL, 1996, CURR OPIN CELL BIOL, V8, P340, DOI 10.1016/S0955-0674(96)80007-X; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; Schmidt M, 1997, FASEB J, V11, P1235, DOI 10.1096/fasebj.11.14.9409542; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; Sears C, 1998, J BIOL CHEM, V273, P1409, DOI 10.1074/jbc.273.3.1409; Seeger M, 1996, J MOL BIOL, V263, P423, DOI 10.1006/jmbi.1996.0586; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Snapper CM, 1996, J IMMUNOL, V156, P183; Stohwasser R, 1996, FEBS LETT, V383, P109, DOI 10.1016/0014-5793(96)00110-X; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WILHELMSEN KC, 1984, J VIROL, V49, P521, DOI 10.1128/JVI.49.2.521-529.1984; WRIGHT KL, 1995, J EXP MED, V181, P1459, DOI 10.1084/jem.181.4.1459; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yang G, 1997, J IMMUNOL, V159, P3068; Zandi E, 1999, MOL CELL BIOL, V19, P4547; ZHOU P, 1993, P NATL ACAD SCI USA, V90, P2681, DOI 10.1073/pnas.90.7.2681; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765	103	64	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5238	5247		10.1074/jbc.275.7.5238	http://dx.doi.org/10.1074/jbc.275.7.5238			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671572	hybrid			2022-12-27	WOS:000085378200098
J	Kaznacheyeva, E; Zubov, A; Nikolaev, A; Alexeenko, V; Bezprozvanny, I; Mozhayeva, GN				Kaznacheyeva, E; Zubov, A; Nikolaev, A; Alexeenko, V; Bezprozvanny, I; Mozhayeva, GN			Plasma membrane calcium channels in human carcinoma A431 cells are functionally coupled to inositol 1,4,5-trisphosphate receptor-phosphatidylinositol 4,5-bisphosphate complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELEASE; ENTRY; INFLUX; TRANSDUCTION; DEPLETION; MECHANISM; INSP(3); SIGNAL	In most nonexcitable cells, calcium (Ca2+) release from inositol 1,4,5-trisphosphate (InsP(3))-sensitive intracellular Ca2+ stores is coupled to Ca2+ influx (calcium release-activated channels (I-CRAC)) pathway. Despite intense investigation, the molecular identity of I-CRAC and the mechanism of its activation remain poorly understood, InsP(3)-dependent miniature calcium channels (I-min) display functional properties characteristic for I-CRAC. Here we used patch clamp recordings of I-min channels in human carcinoma A431 cells to demonstrate that I-min activity was greatly enchanced in the presence of anti-phosphatidylinositol 4,5-bisphosphate antibody (PIP(2)Ab) and diminished in the presence of PIP2. Anti-PIP2 antibody induced a greater than B-fold increase in I-min,sensitivity for InsP(3) activation and an almost 4-fold change in I-min maximal open probability. The addition of exogenous PIP2 vesicles to the cytosolic surface of inside-out patches inhibited I-min activity. These results lead us to propose an existence of a Ca2+ influx pathway in nonexcitable cells activated via direct conformational coupling with a selected population of InsP(3) receptors, located just underneath the plasma membrane and coupled to PIP2. The described pathway provides for a highly compartmentalized Ca2+ influx and intracellular Ca2+ store refilling mechanism.	Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mozhayeva, GN (corresponding author), Russian Acad Sci, Inst Cytol, 4 Tikhoretsky Ave, St Petersburg 194064, Russia.		Kaznacheyeva, Elena V/I-7260-2017	Kaznacheyeva, Elena V/0000-0003-1273-1188	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038082] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38082] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; FUKAMI K, 1988, P NATL ACAD SCI USA, V85, P9057, DOI 10.1073/pnas.85.23.9057; Gregory RB, 1999, BIOCHEM J, V341, P401, DOI 10.1042/0264-6021:3410401; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huser J, 1999, J PHYSIOL-LONDON, V514, P101, DOI 10.1111/j.1469-7793.1999.101af.x; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Kerschbaum HH, 1999, SCIENCE, V283, P836, DOI 10.1126/science.283.5403.836; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kiselyov KI, 1999, PFLUG ARCH EUR J PHY, V437, P305, DOI 10.1007/s004240050784; Kiselyov KI, 1997, FEBS LETT, V407, P309, DOI 10.1016/S0014-5793(97)00366-9; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; Lupu VD, 1998, J BIOL CHEM, V273, P14067, DOI 10.1074/jbc.273.23.14067; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MOZHAYEVA GN, 1990, FEBS LETT, V277, P233, DOI 10.1016/0014-5793(90)80853-B; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; Petersen CCH, 1996, PFLUG ARCH EUR J PHY, V432, P286, DOI 10.1007/s004240050135; Putney JW, 1999, BIOESSAYS, V21, P38; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RUKNUDIN A, 1991, J CELL BIOL, V112, P125, DOI 10.1083/jcb.112.1.125; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; VACA L, 1995, AM J PHYSIOL-CELL PH, V269, pC733, DOI 10.1152/ajpcell.1995.269.3.C733; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Zubov AI, 1999, J BIOL CHEM, V274, P25983, DOI 10.1074/jbc.274.37.25983	28	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4561	4564		10.1074/jbc.275.7.4561	http://dx.doi.org/10.1074/jbc.275.7.4561			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671480	hybrid			2022-12-27	WOS:000085378200006
J	Moon, IJ; Choi, K; Choi, YK; Kim, JE; Lee, Y; Schreiber, AD; Park, JG				Moon, IJ; Choi, K; Choi, YK; Kim, JE; Lee, Y; Schreiber, AD; Park, JG			Potent growth inhibition of leukemic cells by novel ribbon-type antisense oligonucleotides to c-myb1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; C-MYB; GENE INHIBITION; MESSENGER-RNA; IN-VIVO; OLIGODEOXYNUCLEOTIDES; DIFFERENTIATION; EXPRESSION; PHOSPHOROTHIOATE; PROLIFERATION	We studied the effects of antisense oligonucleotides (AS oligos) with a novel structure. The AS oligos were covalently closed to avoid exonuclease activities by enzymatic ligation of two identical molecules. The AS oligos of a ribbon type (RiAS oligos) consist of two loops containing multiple antisense sequences and a stem connecting the two loops. Three antisense sequences targeting different binding sites were placed in a loop that was designed to form a minimal secondary structure by itself. RiAS oligos were found to be stable because they largely preserved their structural integrity after 24 h incubation in the presence of either exonuclease III or serums. When a human promyelocytic cell line, HL-60, was treated with RiAS oligos to c-myb, c-myb expression was effectively ablated, Cell growth was inhibited by >90% determined by both the 3-[4,5-dimethythiazol-2-yl]-2,5-diphenyltetrazolium bromide assay and [H-3]thymidine incorporation. Further, when the leukemic cell line K562 was treated with c-myb RiAS oligos, colony formation on soft agarose was reduced by 92 +/- 2%. These results suggest that RiAS oligos may be employed for developing molecular antisense drugs as well as for the functional study of a gene.	Keimyung Univ, Dongsan Med Ctr, Lab Gene Therapy Res, Inst Med Sci, Taegu 700712, South Korea; Korea Res Inst Biosci & Biotechnol, Mol Cell Biol Res Div, Taejon 305606, South Korea; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	Keimyung University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); University of Pennsylvania	Park, JG (corresponding author), Keimyung Univ, Dongsan Med Ctr, Lab Gene Therapy Res, Inst Med Sci, 194 Dong San Dong, Taegu 700712, South Korea.							AKHTAR S, 1991, LIFE SCI, V49, P1793, DOI 10.1016/0024-3205(91)90480-Y; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; CAPACCIOLI S, 1993, BIOCHEM BIOPH RES CO, V197, P818, DOI 10.1006/bbrc.1993.2552; DOLNICK BJ, 1991, CANCER INVEST, V9, P185, DOI 10.3109/07357909109044229; FERRARI S, 1990, CELL GROWTH DIFFER, V1, P543; Flanagan WM, 1997, MOL CELL BIOCHEM, V172, P213, DOI 10.1023/A:1006852613083; FURDON PJ, 1989, NUCLEIC ACIDS RES, V17, P9193, DOI 10.1093/nar/17.22.9193; GEWIRTZ AM, 1993, LEUKEMIA LYMPHOMA, V11, P131, DOI 10.3109/10428199309047876; Gryaznov S, 1996, NUCLEIC ACIDS RES, V24, P1508, DOI 10.1093/nar/24.8.1508; HIJIYA N, 1994, P NATL ACAD SCI USA, V91, P4499, DOI 10.1073/pnas.91.10.4499; KAMANO H, 1990, LEUKEMIA RES, V14, P831, DOI 10.1016/0145-2126(90)90171-5; KASTAN MB, 1989, BLOOD, V74, P1517; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; Matsuda M, 1996, MOL BIOL CELL, V7, P1095, DOI 10.1091/mbc.7.7.1095; MELANI C, 1991, CANCER RES, V51, P2897; Melotti P, 1996, BLOOD, V87, P2221, DOI 10.1182/blood.V87.6.2221.bloodjournal8762221; NESTEROVA M, 1995, NAT MED, V1, P528, DOI 10.1038/nm0695-528; OFFENSPERGER WB, 1993, EMBO J, V12, P1257, DOI 10.1002/j.1460-2075.1993.tb05767.x; RATAJCZAK MZ, 1992, BLOOD, V79, P1956; Roush W, 1997, SCIENCE, V276, P1192, DOI 10.1126/science.276.5316.1192; RUBIN E, 1995, NUCLEIC ACIDS RES, V23, P3547, DOI 10.1093/nar/23.17.3547; Thaler DS, 1996, P NATL ACAD SCI USA, V93, P1352, DOI 10.1073/pnas.93.3.1352; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; TOMITA N, 1995, HYPERTENSION, V26, P131, DOI 10.1161/01.HYP.26.1.131; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; Williams SA, 1996, LEUKEMIA, V10, P1980; YOUNG SL, 1991, P NATL ACAD SCI USA, V88, P10023, DOI 10.1073/pnas.88.22.10023	29	18	25	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4647	4653		10.1074/jbc.275.7.4647	http://dx.doi.org/10.1074/jbc.275.7.4647			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671493	hybrid, Green Published			2022-12-27	WOS:000085378200019
J	Subtil, A; Lampson, MA; Keller, SR; McGraw, TE				Subtil, A; Lampson, MA; Keller, SR; McGraw, TE			Characterization of the insulin-regulated endocytic recycling mechanism in 3T3-L1 adipocytes using a novel reporter molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4 GLUCOSE-TRANSPORTER; RAT ADIPOSE-CELLS; TRANS-GOLGI NETWORK; HAMSTER OVARY CELLS; GTP-GAMMA-S; PLASMA-MEMBRANE; CYTOPLASMIC DOMAIN; SUBCELLULAR TRAFFICKING; INTERNALIZATION MOTIF; RECEPTOR EXTERNALIZATION	The endocytic trafficking of the GLUT4 glucose trans porter and the insulin-regulated aminopeptidase (IRAP) are regulated by insulin. We have used a chimera between the intracellular domain of IRAP and the extracellular and transmembrane domains of the transferrin receptor (vpTR) to characterize IRAP-like trafficking in 3T3-L1 adipocytes, Our data demonstrate that the cytoplasmic domain of IRAP is sufficient to target vpTR to the insulin-regulated, slow recycling pathway in adipocytes and that the dynamic retention of vpTR is dependent on a di-leucine motif. Our kinetic analysis demonstrates that vpTR recycles as a single kinetic pool and that vpTR is very efficiently sorted from endosomes to the insulin-regulated recycling pathway. An implication of these findings is that the key step in the dynamic retention of vpTR occurs within the early endosomal system. We have previously shown that vpTR is trafficked by an insulin-regulated pathway in Chinese hamster ovary cells (Johnson, A. O,, Subtil, A., Petrush, R., Kobylarz, K., Keller, S,, and Me Graw, T. E. (1998) J. Biol, Chem, 273, 17968-17977), The behavior of vpTR in Chinese hamster ovary cells is similar to its behavior in 3T3-L1 adipocytes, The main difference is that insulin has a larger effect on the trafficking of vpTR in the adipocytes, We concluded that the insulin-regulated slow recycling endocytic mechanism is expressed in many different cell types and therefore is not a unique characteristic of cells that express GLUT4.	Cornell Univ, Weill Grad Sch Med Sci, Dept Biochem, New York, NY 10021 USA; Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA	Cornell University; Dartmouth College	McGraw, TE (corresponding author), Cornell Univ, Weill Grad Sch Med Sci, Dept Biochem, 1300 York Ave, New York, NY 10021 USA.	temcgraw@mail.med.cornell.edu	Subtil, Agathe/C-7464-2017	Subtil, Agathe/0000-0002-7481-4846	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025336, R56DK025336, R55DK025336, R56DK052852, R01DK052852] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25336, DK52852] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDINI G, 1991, J BIOL CHEM, V266, P4037; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CALDERHEAD DM, 1988, J BIOL CHEM, V263, P12171; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1995, ANNU REV NUTR, V15, P441, DOI 10.1146/annurev.nu.15.070195.002301; DAVIS RJ, 1987, J BIOL CHEM, V262, P16041; Egert S, 1997, CARDIOVASC RES, V35, P283, DOI 10.1016/S0008-6363(97)00133-8; El-Jack AK, 1999, MOL BIOL CELL, V10, P1581, DOI 10.1091/mbc.10.5.1581; Elmendorf JS, 1998, J BIOL CHEM, V273, P13289, DOI 10.1074/jbc.273.21.13289; EVANS JL, 1995, CELL SIGNAL, V7, P365, DOI 10.1016/0898-6568(95)00007-C; FROST SC, 1985, J BIOL CHEM, V260, P2646; GARIPPA RJ, 1994, J CELL BIOL, V124, P705, DOI 10.1083/jcb.124.5.705; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; Ghosh RN, 1998, J CELL BIOL, V142, P923, DOI 10.1083/jcb.142.4.923; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; HANPETER D, 1995, MOL MEMBR BIOL, V12, P263, DOI 10.3109/09687689509072426; Hansen PA, 1998, J BIOL CHEM, V273, P18173, DOI 10.1074/jbc.273.29.18173; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; Hausdorff SF, 1999, J BIOL CHEM, V274, P24677, DOI 10.1074/jbc.274.35.24677; HERMAN GA, 1994, P NATL ACAD SCI USA, V91, P12750, DOI 10.1073/pnas.91.26.12750; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Johnson AO, 1998, J BIOL CHEM, V273, P17968, DOI 10.1074/jbc.273.28.17968; JOHNSON LS, 1994, J CELL PHYSIOL, V158, P29, DOI 10.1002/jcp.1041580105; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; Kandror KV, 1998, BIOCHEM J, V331, P829, DOI 10.1042/bj3310829; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; Lee W, 1997, J BIOL CHEM, V272, P21427, DOI 10.1074/jbc.272.34.21427; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; Malide D, 1997, J HISTOCHEM CYTOCHEM, V45, P1083, DOI 10.1177/002215549704500806; Mallet WG, 1999, J CELL BIOL, V146, P345, DOI 10.1083/jcb.146.2.345; MARSH BJ, 1995, J CELL BIOL, V130, P1081, DOI 10.1083/jcb.130.5.1081; MARTIN S, 1994, BIOCHEM J, V300, P743, DOI 10.1042/bj3000743; Martin S, 1997, J CELL SCI, V110, P2281; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MARTYS JL, 1995, J BIOL CHEM, V270, P25976, DOI 10.1074/jbc.270.43.25976; MASTICK CC, 1994, J BIOL CHEM, V269, P6089; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Ross SA, 1998, BIOCHEM J, V330, P1003; Ross SA, 1997, BIOCHEM BIOPH RES CO, V239, P247, DOI 10.1006/bbrc.1997.7459; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SATOH S, 1993, J BIOL CHEM, V268, P17820; SHIMIZU Y, 1994, BIOCHEM BIOPH RES CO, V202, P660, DOI 10.1006/bbrc.1994.1981; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Subtil A, 1997, J CELL BIOL, V136, P583, DOI 10.1083/jcb.136.3.583; Sumitani S, 1997, ENDOCRINOLOGY, V138, P1029, DOI 10.1210/en.138.3.1029; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TANNER LI, 1989, J CELL BIOL, V108, P1537, DOI 10.1083/jcb.108.4.1537; TANNER LI, 1987, J BIOL CHEM, V262, P8975; VANNUCCI SJ, 1992, BIOCHEM J, V288, P325, DOI 10.1042/bj2880325; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Waters SB, 1997, J BIOL CHEM, V272, P23323, DOI 10.1074/jbc.272.37.23323; WILEY HS, 1982, J BIOL CHEM, V257, P4222; YANG J, 1993, J BIOL CHEM, V268, P4600; YEH JI, 1995, BIOCHEMISTRY-US, V34, P15523, DOI 10.1021/bi00047a018; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	69	75	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4787	4795		10.1074/jbc.275.7.4787	http://dx.doi.org/10.1074/jbc.275.7.4787			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671512	hybrid			2022-12-27	WOS:000085378200038
J	Yoneyama, H; Maseda, H; Kamiguchi, H; Nakae, T				Yoneyama, H; Maseda, H; Kamiguchi, H; Nakae, T			Function of the membrane fusion protein, MexA, of the MexA, B-OprM efflux pump in Pseudomonas aeruginosa without an anchoring membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; OUTER-MEMBRANE; MOLECULAR-CLONING; DRUG-RESISTANCE; TRANSPORT; EXTRUSION; TOPOLOGY	Resistance of Pseudomonas aeruginosa to multiple species of antibiotics is largely attributable to expression of the MexA, B-OprM efflux pump. The MexA protein is thought to be located at the inner membrane and has been assumed to link the xenobiotics-exporting subunit, MexB, and the outer membrane channel protein, OprM, To verify this assumption, we analyzed membrane anchoring and localization of the MexA protein. n-[9,10-H-3]Palmitic acid incorporation experiments revealed that MexA was radiolabeled with palmitic acid, suggesting that the MexA anchors the inner membrane via the fatty acid moiety, To evaluate the role of lipid modification and inner membrane anchoring, we substituted cysteine 24 with phenylalanine or tyrosine and tested whether or not these mutant MexAs function properly. When the mutant mexAs were expressed in the strain lacking chromosomal mexA in the presence of n-[9,10-H-3]palmitic acid, we found undetectable radiolabeling at the MexA band, These transformants restored antibiotic resistance to the level of the wild-type strain, indicating that lipid modification is not essential for MexA function. These mutant strains contained both processed and unprocessed forms of the MexA proteins. Cellular fractionation experiments revealed that an unprocessed form of MexA anchored the inner membrane probably via an uncleaved signal sequence, whereas the processed form was undetectable in the membrane fraction. To assure that the lipid-free MexA polypeptide could be unbound to the membrane, we analyzed the two-dimensional membrane topology by the gene fusion technique. A total of 78 mexA-blaM fusions covering the entire MexA polypeptide were constructed, and all fusion sites were shown to be located at the periplasm, To answer the question of whether or not membrane anchoring is essential for the MexA function, we replaced the signal sequence of the MexA protein with that of the azurin protein, which contains a cleavable signal sequence but no lipid modification site. The signal sequence of the azurin-MexA hybrid protein was properly processed and bore the mature MexA which was fully recovered in the soluble fraction. The transformant, which expressed azurin-MexA hybrid protein restored the antibiotic resistance to a level indistinguishable from that of the wild-type strain. We concluded from these results that the MexA protein is fully functional as expressed in the periplasmic space without anchoring the inner membrane. This finding questioned the assumption that the membrane fusion proteins connect the inner and outer membranes.	Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Shimokasuya 2591193, Japan	Tokai University	Yoneyama, H (corresponding author), Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Shimokasuya 2591193, Japan.	yoneyama@is.icc.u-tokai.ac.jp						BOWLER LD, 1989, MOL MICROBIOL, V3, P1277, DOI 10.1111/j.1365-2958.1989.tb00278.x; BRYAN LE, 1979, PSEUDOMONAS AERUGINO, P219; DINH T, 1994, J BACTERIOL, V176, P3825, DOI 10.1128/JB.176.13.3825-3831.1994; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; Guan L, 1999, J BIOL CHEM, V274, P10517, DOI 10.1074/jbc.274.15.10517; Kohler T, 1997, MOL MICROBIOL, V23, P345, DOI 10.1046/j.1365-2958.1997.2281594.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XZ, 1998, J BACTERIOL, V180, P2987, DOI 10.1128/JB.180.11.2987-2991.1998; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA D, 1993, J BACTERIOL, V175, P6299, DOI 10.1128/JB.175.19.6299-6313.1993; Ma Dzwokai, 1994, Trends in Microbiology, V2, P489, DOI 10.1016/0966-842X(94)90654-8; MASUDA N, 1995, ANTIMICROB AGENTS CH, V39, P645, DOI 10.1128/AAC.39.3.645; MIZUNO T, 1978, J BIOCHEM, V84, P179, DOI 10.1093/oxfordjournals.jbchem.a132106; MORSHED SRM, 1995, BIOCHEM BIOPH RES CO, V210, P356, DOI 10.1006/bbrc.1995.1669; NAKAE T, 1995, MICROBIOL IMMUNOL, V39, P221, DOI 10.1111/j.1348-0421.1995.tb02193.x; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; POOLE K, 1993, J BACTERIOL, V175, P7363, DOI 10.1128/JB.175.22.7363-7372.1993; POOLE K, 1993, MOL MICROBIOL, V10, P529, DOI 10.1111/j.1365-2958.1993.tb00925.x; Poole K, 1996, MOL MICROBIOL, V21, P713, DOI 10.1046/j.1365-2958.1996.281397.x; Rensing C, 1997, J BACTERIOL, V179, P6871, DOI 10.1128/jb.179.22.6871-6879.1997; SAIER MH, 1994, MOL MICROBIOL, V11, P841, DOI 10.1111/j.1365-2958.1994.tb00362.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SILVER S, 1992, MICROBIOL REV, V56, P195, DOI 10.1128/MMBR.56.1.195-228.1992; SKVIRSKY RC, 1995, J BACTERIOL, V177, P6153, DOI 10.1128/jb.177.21.6153-6159.1995; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Yoneyama H, 1997, BIOCHEM BIOPH RES CO, V233, P611, DOI 10.1006/bbrc.1997.6506; Yoneyama H, 1998, BIOCHEM BIOPH RES CO, V244, P898, DOI 10.1006/bbrc.1998.8351; Yoneyama H, 1996, MICROBIOL-UK, V142, P2137, DOI 10.1099/13500872-142-8-2137; Zgurskaya HI, 1999, J MOL BIOL, V285, P409, DOI 10.1006/jmbi.1998.2313; ZHANG YB, 1990, GENE, V96, P51, DOI 10.1016/0378-1119(90)90340-W	31	57	59	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4628	4634		10.1074/jbc.275.7.4628	http://dx.doi.org/10.1074/jbc.275.7.4628			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671490	hybrid			2022-12-27	WOS:000085378200016
J	Yuasa, K; Omori, K; Yanaka, N				Yuasa, K; Omori, K; Yanaka, N			Binding and phosphorylation of a novel male germ cell-specific cGMP-dependent protein kinase-anchoring protein by cGMP-dependent protein kinase I alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT RII; MOLECULAR CHARACTERIZATION; MAMMALIAN SPERM; GOLGI MEMBRANE; SMOOTH-MUSCLE; MESSENGER-RNA; RAT; CLONING; IDENTIFICATION; EXPRESSION	cGMP-dependent protein kinase (cGK) is a major cellular receptor of cGMP and plays important roles in cGMP-dependent signal transduction pathways. To isolate the components of the cGMP/cGK signaling pathway such as substrates and regulatory proteins of cCK, we employed the yeast two-hybrid system using cGK-I alpha as a bait and isolated a novel male germ cell-specific 42-kDa protein, GKAP42 (42-kDa cGMP-dependent protein kinase anchoring protein). Although the N-terminal region (amino acids 1-66) of cGK-I alpha is sufficient for the association with GKAP42, GKAP42 could not interact with cGK-I beta, cGK-II, or cAMP-dependent protein kinase, GKAP42 mRNA is specifically expressed in testis, where it is restricted to the spermatocytes and early round spermatids. Endogenous cGK-I is co immunoprecipitated with anti-GKAP42 ia antibody from mouse testis tissue, suggesting that cGK-I physiologically interacts with GKAP42. Immunocytochemical observations revealed that GKAP42 is localized to the Golgi complex and that cGK-I alpha is co-localized to the Golgi complex when coexpressed with GKAP42. Although both cGK-I alpha and -I beta, but not cAMP-dependent protein kinase, phosphorylated GKAP42 in vitro, GKAP42 was a good substrate only for cGK-I alpha in intact cells, suggesting that the association with kinase protein is required for the phosphorylation in vivo. Finally, we demonstrated that the kinase-deficient mutant of cGK-I alpha stably associates with GKAP42 and that binding of cGMP to cGK-I alpha facilitates their release from GKAP42. These findings suggest that GKAP42 functions as an anchoring protein for cGK-I alpha and that cGK-I alpha may participate in germ cell develop ment through phosphorylation of Golgi-associated proteins such as GKAP42.	Tanabe Seiyaku Co Ltd, Discovery Res Lab, Yodogawa Ku, Osaka 5328505, Japan; Tanabe Seiyaku Co Ltd, Discovery Res Lab, Toda, Saitama 3358505, Japan	Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation	Yanaka, N (corresponding author), Tanabe Seiyaku Co Ltd, Discovery Res Lab, Yodogawa Ku, 16-89 Kashima 3 Chome, Osaka 5328505, Japan.	n-yanaka@tanabe.co.jp	Yanaka, Noriyuki/P-9096-2016					BIENDY JA, 1996, NATURE, V380, P162; BUTT E, 1994, J BIOL CHEM, V269, P14509; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; Chu DM, 1997, J BIOL CHEM, V272, P31922, DOI 10.1074/jbc.272.50.31922; COLBRAN JL, 1992, J BIOL CHEM, V267, P9589; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Fritzler MJ, 1995, J BIOL CHEM, V270, P31262, DOI 10.1074/jbc.270.52.31262; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Funaki T, 1996, CELL STRUCT FUNCT, V21, P63, DOI 10.1247/csf.21.63; Gautier-Courteille C, 1998, ENDOCRINOLOGY, V139, P2588, DOI 10.1210/en.139.5.2588; GEAHLEN RL, 1980, J BIOL CHEM, V255, P1164; GLASS DB, 1983, J BIOL CHEM, V258, P4797; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; Hall KU, 1999, J BIOL CHEM, V274, P3485, DOI 10.1074/jbc.274.6.3485; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; HUGGINS JP, 1989, BIOCHEM J, V260, P829, DOI 10.1042/bj2600829; IMAIZUMI K, 1994, MOL BRAIN RES, V26, P189, DOI 10.1016/0169-328X(94)90090-6; Johnson LR, 1997, DEV BIOL, V192, P340, DOI 10.1006/dbio.1997.8767; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Matsukuma S, 1999, MAMM GENOME, V10, P1, DOI 10.1007/s003359900932; Misumi Y, 1997, J BIOL CHEM, V272, P23851, DOI 10.1074/jbc.272.38.23851; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; OYEN O, 1989, FEBS LETT, V246, P57, DOI 10.1016/0014-5793(89)80253-4; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Rotem R, 1998, AM J PHYSIOL-ENDOC M, V274, pE218, DOI 10.1152/ajpendo.1998.274.2.E218; Salanova M, 1999, ENDOCRINOLOGY, V140, P2297, DOI 10.1210/en.140.5.2297; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; SPRUILL WA, 1981, ENDOCRINOLOGY, V109, P2239, DOI 10.1210/endo-109-6-2239; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; TEGGE W, 1995, BIOCHEMISTRY-US, V34, P10569, DOI 10.1021/bi00033a032; THORNETJOMSLAND G, 1988, ANAT REC, V221, P591, DOI 10.1002/ar.1092210205; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; Vijayaraghavan S, 1999, MOL ENDOCRINOL, V13, P705, DOI 10.1210/me.13.5.705; Vijayaraghavan S, 1997, J BIOL CHEM, V272, P4747, DOI 10.1074/jbc.272.8.4747; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0; Yuasa K, 1999, J BIOL CHEM, V274, P37429, DOI 10.1074/jbc.274.52.37429; Zhao JK, 1997, J BIOL CHEM, V272, P31929, DOI 10.1074/jbc.272.50.31929	53	57	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4897	4905		10.1074/jbc.275.7.4897	http://dx.doi.org/10.1074/jbc.275.7.4897			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671526	hybrid			2022-12-27	WOS:000085378200052
J	Smith, C; Estavillo, D; Emsley, J; Bankston, LA; Liddington, RC; Cruz, MA				Smith, C; Estavillo, D; Emsley, J; Bankston, LA; Liddington, RC; Cruz, MA			Mapping the collagen-binding site in the I domain of the glycoprotein Ia/IIa (integrin alpha(2)beta(1))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ADHESION; ALPHA-2-BETA-1 VLA-2; CRYSTAL-STRUCTURE; LAMININ RECEPTOR; FLOW CONDITIONS; IDENTIFICATION; CELLS; CD49B/CD29; GPIA/IIA; PROTEINS	The I domain present within the alpha 2 chain of the integrin alpha(2)beta(1) (GPIa/IIa) contains the principal collagen-binding site. Based on the crystal structure of the alpha 2-I domain, a hypothetical model was proposed in which collagen binds to a groove on the upper surface of the I domain (Emsley, J,, King, S. L,, Bergelson, J, M,, and Liddington, R, C, (1997) J, Biol, Chem, 272, 28512-28517), We have introduced point mutations into 13 residues on the upper surface of the domain. Recombinant mutant proteins were assayed for binding to monoclonal antibodies 6F1 and 12F1, to collagen under static conditions, and for the ability to retain adhesive activity under flow conditions. The mutations to residues surrounding the metal ion-dependent adhesion site that caused the greatest loss of collagen binding under both static and flow conditions are N154S in the beta A-alpha 1 turn, N190D in the PB-PC turn, D219R in the alpha 3-alpha 4 turn, and E256V and H258V in the beta D-alpha 5 turn. Mutation in one of the residues that coordinate the metal binding, S155A, completely lost the adhesive activity under flow but bound normally under static conditions, whereas the mutation Y285F had the converse effect. We conclude that the upper surface of the domain, including the metal ion-dependent adhesion site motif, defines the collagen recognition site.	Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Leicester	Cruz, MA (corresponding author), Brigham & Womens Hosp, Dept Med, Div Hematol, 221 Longwood Ave,LMRC-605, Boston, MA 02115 USA.		emsley, jonas/A-8509-2016	emsley, jonas/0000-0002-8949-8030	NHLBI NIH HHS [R01 HL54876] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054876] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAHOU WF, 1994, BLOOD, V84, P3734, DOI 10.1182/blood.V84.11.3734.bloodjournal84113734; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; COLLER BS, 1989, BLOOD, V74, P182; DEMBO M, 1988, PROC R SOC SER B-BIO, V234, P55, DOI 10.1098/rspb.1988.0038; Depraetere H, 1997, THROMB HAEMOSTASIS, V77, P981; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Estavillo D, 1999, J BIOL CHEM, V274, P35921, DOI 10.1074/jbc.274.50.35921; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; PISCHEL KD, 1987, J IMMUNOL, V138, P226; SAELMAN EUM, 1994, BLOOD, V83, P1244; SAELMAN EUM, 1993, BLOOD, V82, P3029; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Verkleij MW, 1998, BLOOD, V91, P3808; ZIJENAH LS, 1990, BIOCHEM J, V268, P481, DOI 10.1042/bj2680481	23	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4205	4209		10.1074/jbc.275.6.4205	http://dx.doi.org/10.1074/jbc.275.6.4205			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660584	hybrid			2022-12-27	WOS:000085288800068
J	Shehin, SE; Stephenson, RO; Greenlee, WF				Shehin, SE; Stephenson, RO; Greenlee, WF			Transcriptional regulation of the human CYP1B1 gene - Evidence for involvement of an aryl hydrocarbon receptor response element in constitutive expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AH-RECEPTOR; CYTOCHROME-P450 1B1; DNA; BINDING; DIOXIN; IDENTIFICATION; INDUCTION; SEQUENCE; CELLS; ARNT	The cytochrome P450 1B1 gene (CYP1B1) is expressed constitutively and is inducible by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the human breast adenocarcinoma cell line MCF-7 but not in the human hepatoma cell line HepG2, Genomic DNA isolated from both cell lines was digested with the methylation-sensitive restriction enzyme isoschizomers MspI and HpaII, and subjected to Southern analysis with a probe for the CYP1B1 promoter/enhancer region. Although differences were observed in methylation patterns for the CYP1B1 gene from MCF-7 and HepG2 cells, treatment with the demethylating agent 5-azacytidine (10 mu M for 6 days) did not activate CYP1B1 mRNA expression in HepG2 cells. Furthermore, treatment with the histone deacetylase inhibitor trichostatin A (100 nM for 24 h) did not activate CYP1B1 mRNA expression in HepG2 cells. Comparative analysis of the constitutive expression of luciferase/1B1 reporter constructs containing a series of deletions in the 5' enhancer region indicated that in MCF-7 cells the region from -987 to -732 (relative to the transcription start site) was necessary for maximal levels of activity. Mutation of the aryl hydrocarbon receptor response elements (dioxin response elements) in this region showed that the dioxin response elements located at -833 is essential for constitutive gene expression in MCF-7 cells. In HepG2 cells, reporter gene activity was at least equal or greater than the activity observed in MCF-7 cells, which is in marked contrast to the expression of the native CYYP1B1 gene. Taken together these findings indicate that the observed cell-specific differences in CYP1B1 constitutive expression are not mediated by DNA promoter/enhancer methylation, but are likely due to either 1) inaccessibility of the 5'-enhancer region in HepG2 cells to transcriptional activators due to a higher order chromatin structure that does not involve histone acetylation, or 2) the action of a repressor protein at cis-elements located outside of the -2296 to +25 region examined with the CYP1B1 reporter constructs. Furthermore, at least one of the dioxin response elements in the enhancer region is required for constitutive expression of CYP1B1.	Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Toxicol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Greenlee, WF (corresponding author), Chem Ind Inst Toxicol, 6 Davis Dr, Res Triangle Pk, NC 27709 USA.							BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; Buters JTM, 1999, P NATL ACAD SCI USA, V96, P1977, DOI 10.1073/pnas.96.5.1977; Chen JD, 1998, CRIT REV EUKAR GENE, V8, P169, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.40; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CREUSOT F, 1982, J BIOL CHEM, V257, P2041; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DENOME RM, 1988, MOL CELL BIOL, V8, P4829, DOI 10.1128/MCB.8.11.4829; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; Eltom SE, 1999, MOL PHARMACOL, V55, P594; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; Hayes CL, 1996, P NATL ACAD SCI USA, V93, P9776, DOI 10.1073/pnas.93.18.9776; Heidel SM, 1998, MOL PHARMACOL, V54, P1000, DOI 10.1124/mol.54.6.1000; Kress S, 1997, CANCER RES, V57, P1264; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; Mannervik M, 1999, SCIENCE, V284, P606, DOI 10.1126/science.284.5414.606; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORGAN JE, 1992, P NATL ACAD SCI USA, V89, P11622, DOI 10.1073/pnas.89.23.11622; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; ROUET P, 1992, BIOTECHNIQUES, V13, P700; Sambrook J., 2002, MOL CLONING LAB MANU; Shimada T, 1996, CANCER RES, V56, P2979; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Spink DC, 1997, J STEROID BIOCHEM, V62, P223, DOI 10.1016/S0960-0760(97)00024-1; Stoilov I, 1997, HUM MOL GENET, V6, P641, DOI 10.1093/hmg/6.4.641; STRAUSS WM, 1993, CURRENT PROTOCOLS MO; SUTTER TR, 1994, J BIOL CHEM, V269, P13092; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Tang WM, 1996, J BIOL CHEM, V271, P28324, DOI 10.1074/jbc.271.45.28324; Wenger RH, 1997, BIOL CHEM, V378, P609; Wo YYP, 1997, J BIOL CHEM, V272, P26702, DOI 10.1074/jbc.272.42.26702; Wolffe AP, 1996, CURR BIOL, V6, P234, DOI 10.1016/S0960-9822(02)00465-7; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; YAO EF, 1992, BIOCHEMISTRY-US, V31, P5060, DOI 10.1021/bi00136a019; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhang LY, 1998, J BIOL CHEM, V273, P5174, DOI 10.1074/jbc.273.9.5174	41	65	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6770	6776		10.1074/jbc.275.10.6770	http://dx.doi.org/10.1074/jbc.275.10.6770			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702233	hybrid			2022-12-27	WOS:000085809600013
J	Li, LG; Popko, JL; Umezawa, T; Chiang, VL				Li, LG; Popko, JL; Umezawa, T; Chiang, VL			5-Hydroxyconiferyl aldehyde modulates enzymatic methylation for syringyl monolignol formation, a new view of monolignol biosynthesis in angiosperms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; 4-COUMARATE-COA LIGASE GENES; CELL-SUSPENSION CULTURES; O-METHYLTRANSFERASE; LIGNIN BIOSYNTHESIS; CAFFEOYL-COA; ASPEN; COENZYME; EXPRESSION; WOOD	S-Adenosyl-L-methionine-dependent caffeate O-methyltransferase (COMT, EC 2.1.1.6) has traditionally been thought to catalyze the methylation of caffeate and 5-hydroxyferulate for the biosynthesis of syringyl monolignol, a lignin constituent of angiosperm wood that enables efficient lignin degradation for cellulose production. However, recent recognition that coniferyl aldehyde prevents 5-hydroxyferulate biosynthesis in lignifying tissue, and that the hydroxylated form of coniferyl aldehyde, 5-hydroxyconiferyl aldehyde, is an alternative COMT substrate, demands a re-evaluation of the role of COMT during monolignol biosynthesis, Based on recombinant aspen (Populus tremuloides) COMT enzyme kinetics coupled with mass spectrometry analysis, this study establishes for the first time that COMT is in fact a 5-hydroxyconiferyl aldehyde O-methyltransferase (AldOMT), and that 5-hydroxyconiferyl aldehyde is both the preferred AldOMT substrate and an inhibitor of caffeate and 5-hydroxyferulate methylation, as measured by K-m and K-i values. 5-Hydroxyconiferyl aldehyde also inhibited the caffeate and 5-hydroxyferulate methylation activities of xylem proteins from various angiosperm tree species, The evidence that syringyl monolignol biosynthesis is independent of caffeate and 5-hydroxyferulate methylation supports our previous discovery that coniferyl aldehyde prevents ferulate B-hydroxylation and at the same time ensures a coniferyl aldehyde 5-hydroxylase (CAld5H)-mediated biosynthesis of 5-hydroxyconiferyl aldehyde. Together, our results provide conclusive evidence for the presence of a CAld5H/AldOMT-catalyzed coniferyl aldehyde 5-hydroxylation/methylation pathway that directs syringyl monolignol biosynthesis in angiosperms.	Michigan Technol Univ, Sch Forestry & Wood Prod, Plant Biotechnol Res Ctr, Houghton, MI 49931 USA	Michigan Technological University	Chiang, VL (corresponding author), Michigan Technol Univ, Sch Forestry & Wood Prod, Plant Biotechnol Res Ctr, Houghton, MI 49931 USA.	vchiang@mtu.edu	Li, Laigeng/AAA-2067-2020	Li, Laigeng/0000-0001-6924-4431				BANERJEE SK, 1962, CAN J CHEM, V40, P2175, DOI 10.1139/v62-334; BOUDET AM, 1995, NEW PHYTOL, V129, P203, DOI 10.1111/j.1469-8137.1995.tb04292.x; BROWN SA, 1955, CAN J BIOCHEM PHYS, V33, P948; BROWN SA, 1956, CAN J BIOCHEM PHYS, V34, P769, DOI 10.1139/y56-081; BUGOS RC, 1991, PLANT MOL BIOL, V17, P1203, DOI 10.1007/BF00028736; BUGOS RC, 1992, PHYTOCHEMISTRY, V31, P1495, DOI 10.1016/0031-9422(92)83093-E; BYERRUM RU, 1954, J BIOL CHEM, V210, P633; CHANG H, 1973, TAPPI, V56, P132; Chen F, 1999, PLANTA, V207, P597, DOI 10.1007/s004250050523; CHIANG VL, 1990, HOLZFORSCHUNG, V44, P309, DOI 10.1515/hfsg.1990.44.4.309; DURST N, 1995, PLANT CYTOCHROMES P4, P171; FREUDENBERG K, 1965, SCIENCE, V148, P595, DOI 10.1126/science.148.3670.595; Fukushima K, 1997, ISWPC - 9TH INTERNATIONAL SYMPOSIUM ON WOOD AND PULPING CHEMISTRY - POSTER PRESENTATIONS, P281; GRAND C, 1984, FEBS LETT, V169, P7, DOI 10.1016/0014-5793(84)80278-1; Grisebach H., 1981, The biochemistry of plants. A comprehensive treatise. Volume 7. Secondary plant products., P457; GROSS GG, 1975, BIOCHEM PHYSIOL PFL, V168, P41; HIGUCHI T, 1963, CAN J BIOCHEM PHYS, V41, P613; HIGUCHI T, 1963, CAN J BIOCHEM PHYS, V41, P621; HIGUCHI T, 1967, AGR BIOL CHEM TOKYO, V31, P1459, DOI 10.1080/00021369.1967.10858983; HIGUCHI T, 1963, CAN J BIOCHEM PHYS, V41, P65; Higuchi T, 1997, BIOCH MOL BIOL WOOD, P131; Higuchi T., 1985, BIOSYNTHESIS BIODEGR; Hu WJ, 1999, NAT BIOTECHNOL, V17, P808, DOI 10.1038/11758; Hu WJ, 1998, P NATL ACAD SCI USA, V95, P5407, DOI 10.1073/pnas.95.9.5407; Joshi CP, 1998, PLANT MOL BIOL, V37, P663, DOI 10.1023/A:1006035210889; KAMSTEEG J, 1981, Z PFLANZENPHYSIOL, V102, P435, DOI 10.1016/S0044-328X(81)80178-X; KNEUSEL RE, 1989, ARCH BIOCHEM BIOPHYS, V269, P455, DOI 10.1016/0003-9861(89)90129-X; KOJIMA M, 1989, J BIOCHEM-TOKYO, V105, P265, DOI 10.1093/oxfordjournals.jbchem.a122651; KUHNL T, 1989, PLANT SCI, V60, P21, DOI 10.1016/0168-9452(89)90039-3; KURODA H, 1981, PHYTOCHEMISTRY, V20, P2635, DOI 10.1016/0031-9422(81)85258-2; KURODA H, 1975, PHYTOCHEMISTRY, V14, P1759, DOI 10.1016/0031-9422(75)85289-7; KUTSUKI H, 1982, PHYTOCHEMISTRY, V21, P267, DOI 10.1016/S0031-9422(00)95248-8; Lee D, 1996, PLANT PHYSIOL, V112, P193, DOI 10.1104/pp.112.1.193; Li LG, 1997, P NATL ACAD SCI USA, V94, P5461, DOI 10.1073/pnas.94.10.5461; Li LG, 1999, PLANT MOL BIOL, V40, P555, DOI 10.1023/A:1006244325250; LOZOYA E, 1988, EUR J BIOCHEM, V176, P661, DOI 10.1111/j.1432-1033.1988.tb14328.x; MATERN U, 1995, CAN J BOT, V73, pS511, DOI 10.1139/b95-290; Meng HB, 1996, ARCH BIOCHEM BIOPHYS, V330, P329, DOI 10.1006/abbi.1996.0260; MOCK HP, 1993, PHYTOCHEMISTRY, V32, P575, DOI 10.1016/S0031-9422(00)95139-2; Osakabe K, 1999, P NATL ACAD SCI USA, V96, P8955, DOI 10.1073/pnas.96.16.8955; PAKUSCH AE, 1989, ARCH BIOCHEM BIOPHYS, V271, P488, DOI 10.1016/0003-9861(89)90299-3; POTTS J R M, 1974, Journal of Biological Chemistry, V249, P5019; Sarkanen KV., 1971, LIGNINS OCCURRENCE F; Sarkarnen K., 1971, LIGNINS OCCURRENCE F, P639; Shimada M., 1973, Mokuzai Gakkaishi (Journal of the Japan Wood Research Society), V19, P13; SHIMADA M, 1972, PHYTOCHEMISTRY, V11, P2247, DOI 10.1016/S0031-9422(00)88384-3; STOCKIGT J, 1975, Z NATURFORSCH C, V30, P352; STRUBE RE, 1963, ORG SYNTH, V4, P417; TAN KS, 1992, J PLANT PHYSIOL, V140, P460, DOI 10.1016/S0176-1617(11)80825-4; TANAKA M, 1991, ARCH BIOCHEM BIOPHYS, V284, P151, DOI 10.1016/0003-9861(91)90277-P; TROTTER PC, 1990, TAPPI J, V73, P198; Tsai CJ, 1998, PLANT PHYSIOL, V117, P101, DOI 10.1104/pp.117.1.101; URBAN P, 1994, EUR J BIOCHEM, V222, P843, DOI 10.1111/j.1432-1033.1994.tb18931.x; VAUGHAN PFT, 1975, PHYTOCHEMISTRY, V14, P2383, DOI 10.1016/0031-9422(75)80349-9; Wang ZX, 1997, ARCH BIOCHEM BIOPHYS, V347, P249, DOI 10.1006/abbi.1997.0337; Whetten RW, 1998, ANNU REV PLANT PHYS, V49, P585, DOI 10.1146/annurev.arplant.49.1.585; YE ZH, 1995, PLANT PHYSIOL, V108, P459, DOI 10.1104/pp.108.2.459; YE ZH, 1994, PLANT CELL, V6, P1427, DOI 10.1105/tpc.6.10.1427; Zhang XH, 1997, PLANT PHYSIOL, V113, P65, DOI 10.1104/pp.113.1.65; Zhong RQ, 1998, PLANT CELL, V10, P2033, DOI 10.1105/tpc.10.12.2033	60	199	212	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6537	6545		10.1074/jbc.275.9.6537	http://dx.doi.org/10.1074/jbc.275.9.6537			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692459	hybrid, Green Published			2022-12-27	WOS:000085654400071
J	Garay-Arroyo, A; Colmenero-Flores, JM; Garciarrubio, A; Covarrubias, AA				Garay-Arroyo, A; Colmenero-Flores, JM; Garciarrubio, A; Covarrubias, AA			Highly hydrophilic proteins in prokaryotes and eukaryotes are common during conditions of water deficit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME MODULATION FACTOR; SACCHAROMYCES-CEREVISIAE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; NEUROSPORA-CRASSA; OSMOTIC-STRESS; GENE; EXPRESSION; YEAST; DEHYDRATION	The late embryogenesis abundant (LEA) proteins are plant proteins that are synthesized at the onset of desiccation in maturing seeds and in vegetative organs exposed to water deficit. Here, we show that most LEA proteins are comprised in a more widespread group, which we call "hydrophilins," The defining characteristics of hydrophilins are high glycine content (>6%) and a high hydrophilicity index (>1.0). By data base searching, we show that this criterion selectively differentiates most known LEA proteins as well as additional proteins from different taxons. We found that within the genomes of Escherichia coli and Saccharomyces cerevisiae, only 5 and 12 proteins, respectively, meet our criterion. Despite their deceivingly loose definition, hydrophilins usually represent <0.2% of the proteins of a genome. Additionally, we demonstrate that the criterion that defines hydrophilins seems to be an excellent predictor of responsiveness to hyperosmosis since most of the genes encoding these proteins in E. coli and S. cerevisiae are induced by osmotic stress. Evidence for the participation of one of the E. coli hydrophilins in the adaptive response to hyperosmotic conditions is presented. Apparently, hydrophilins represent analogous adaptations to a common problem in such diverse taxons as prokaryotes and eukaryotes.	Univ Nacl Autonoma Mexico, Dept Plant Mol Biol, Inst Biotechnol, Cuernavaca 62250, Morelos, Mexico; Univ Nacl Autonoma Mexico, Dept Biostruct & Reconocimiento Mol, Inst Biotechnol, Cuernavaca 62250, Morelos, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	Covarrubias, AA (corresponding author), Univ Nacl Autonoma Mexico, Dept Plant Mol Biol, Inst Biotechnol, Apdo Postal 510-3, Cuernavaca 62250, Morelos, Mexico.		Colmenero-Flores, Jose Manuel/AAE-4969-2020; Colmenero-Flores, José Manuel/K-7160-2014; Garay, Adriana/AIE-6806-2022; Arroyo, Adriana/D-8934-2019	Colmenero-Flores, Jose Manuel/0000-0001-9475-1187; Colmenero-Flores, José Manuel/0000-0001-9475-1187; Garay, Adriana/0000-0003-1575-6284; Arroyo, Adriana/0000-0003-1575-6284				ALTMAN S, 1981, CELL, V26, P299, DOI 10.1016/0092-8674(81)90198-7; AMEGADZIE BY, 1990, YEAST, V6, P429, DOI 10.1002/yea.320060508; ARONSON AI, 1989, MOL MICROBIOL, V3, P437, DOI 10.1111/j.1365-2958.1989.tb00189.x; BAKER J, 1988, PLANT MOL BIOL, V11, P277, DOI 10.1007/BF00027385; Bray EA, 1997, TRENDS PLANT SCI, V2, P48, DOI 10.1016/S1360-1385(97)82562-9; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLOSE TJ, 1993, PLANT PHYSIOL, V101, P773, DOI 10.1104/pp.101.3.773; Close TJ, 1997, PHYSIOL PLANTARUM, V100, P291, DOI 10.1034/j.1399-3054.1997.1000210.x; Close TJ, 1996, PHYSIOL PLANTARUM, V97, P795, DOI 10.1111/j.1399-3054.1996.tb00546.x; COLLART M, 1995, CURRENT PROTOCOL S23, V2; ColmeneroFlores JM, 1997, PLANT MOL BIOL, V35, P393, DOI 10.1023/A:1005802505731; DANYLUK J, 1994, FEBS LETT, V344, P20, DOI 10.1016/0014-5793(94)00353-X; DURE L, 1993, PLANT J, V3, P363, DOI 10.1046/j.1365-313X.1993.t01-18-00999.x; Dure L., 1993, PLANT RESPONSES CELL, V10, P91; DUVICK JP, 1992, J BIOL CHEM, V267, P18814; GALAU GA, 1993, PLANT PHYSIOL, V101, P695, DOI 10.1104/pp.101.2.695; Garay-Arroyo A, 1999, YEAST, V15, P879, DOI 10.1002/(SICI)1097-0061(199907)15:10A<879::AID-YEA428>3.3.CO;2-H; GASSENSCHMIDT U, 1995, BBA-GEN SUBJECTS, V1243, P477, DOI 10.1016/0304-4165(94)00176-X; GAXIOLA R, 1992, EMBO J, V11, P3157, DOI 10.1002/j.1460-2075.1992.tb05392.x; Ingram J, 1996, ANNU REV PLANT PHYS, V47, P377, DOI 10.1146/annurev.arplant.47.1.377; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LABERGE S, 1993, PLANT PHYSIOL, V101, P1411, DOI 10.1104/pp.101.4.1411; Lisse T, 1996, BIOL CHEM, V377, P555, DOI 10.1515/bchm3.1996.377.9.555; MCCUBBIN WD, 1985, CAN J BIOCHEM CELL B, V63, P803, DOI 10.1139/o85-102; MIRALLES VJ, 1995, MOL MICROBIOL, V17, P653, DOI 10.1111/j.1365-2958.1995.mmi_17040653.x; Mtwisha L, 1998, PLANT MOL BIOL, V37, P513, DOI 10.1023/A:1005904219201; REMACHA M, 1995, MOL CELL BIOL, V15, P4754; ROBERTS AN, 1988, MOL CELL BIOL, V8, P2411, DOI 10.1128/MCB.8.6.2411; SPRINGER ML, 1992, GENE DEV, V6, P1052, DOI 10.1101/gad.6.6.1052; STEPHENS MA, 1984, J MOL BIOL, V176, P333, DOI 10.1016/0022-2836(84)90493-5; VARELA JCS, 1992, MOL MICROBIOL, V6, P2183, DOI 10.1111/j.1365-2958.1992.tb01392.x; VOLKER U, 1994, MICROBIOL-UK, V140, P741, DOI 10.1099/00221287-140-4-741; WADA A, 1995, BIOCHEM BIOPH RES CO, V214, P410, DOI 10.1006/bbrc.1995.2302; WEI CL, 1995, J BIOL CHEM, V270, P22788, DOI 10.1074/jbc.270.39.22788; WHITE BT, 1993, DEV BIOL, V160, P254, DOI 10.1006/dbio.1993.1303; YAMAGISHI M, 1993, EMBO J, V12, P625, DOI 10.1002/j.1460-2075.1993.tb05695.x; YOSHIDA Y, 1990, EUR J BIOCHEM, V192, P49, DOI 10.1111/j.1432-1033.1990.tb19193.x	37	318	370	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5668	5674		10.1074/jbc.275.8.5668	http://dx.doi.org/10.1074/jbc.275.8.5668			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681550	hybrid, Green Published			2022-12-27	WOS:000085474500057
J	Lawrence, DA; Olson, ST; Muhammad, S; Day, DE; Kvassman, JO; Ginsburg, D; Shore, JD				Lawrence, DA; Olson, ST; Muhammad, S; Day, DE; Kvassman, JO; Ginsburg, D; Shore, JD			Partitioning of serpin-proteinase reactions between stable inhibition and substrate cleavage is regulated by the rate of serpin reactive center loop insertion into beta-sheet A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; HUMAN ANTITHROMBIN-III; CONFORMATIONAL-CHANGES; CRYSTAL-STRUCTURE; PROTEASE COMPLEXES; SERINE PROTEINASE; SUICIDE SUBSTRATE; ESCHERICHIA-COLI; HINGE REGION; BOND LOOP	The serpin family of serine proteinase inhibitors is a mechanistically unique class of naturally occurring proteinase inhibitors that trap target enzymes as stable covalent acyl-enzyme complexes. This mechanism appears to require both cleavage of the serpin reactive center loop (RCL) by the proteinase and a significant conformational change in the serpin structure involving rapid insertion of the RCL into the center of an existing beta-sheet, serpin beta-sheet A. The present study demonstrates that partitioning between inhibitor and substrate modes of reaction can be altered by varying either the rates of RCL insertion or deacylation using a library of serpin RCL mutants substituted in the critical P-14 hinge residue and three different proteinases. We fur ther correlate the changes in partitioning with the actual rates of RCL insertion for several of the variants upon reaction with the different proteinases as determined by fluorescence spectroscopy of specific RCL-labeled inhibitor mutants. These data demonstrate that the serpin mechanism follows a branched pathway, and that the formation of a stable inhibited complex is dependent upon both the rate of the RCL conformational change and the rate of enzyme deacylation.	Amer Red Cross, Holland Lab, Dept Biochem, Rockville, MD 20855 USA; Univ Illinois, Dept Mol Biol & Oral Dis, Chicago, IL 60612 USA; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Henry Ford Hlth Syst, Detroit, MI 48202 USA	American Red Cross; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Henry Ford Health System; Henry Ford Hospital	Lawrence, DA (corresponding author), Amer Red Cross, Holland Lab, Dept Biochem, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	lawrenced@usa.redcross.org		Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055374, R01HL055747, R01HL049184] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55747, HL55374, HL49184] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BJORK I, 1992, J BIOL CHEM, V267, P1976; BJORK I, 1992, J BIOL CHEM, V267, P19047; BODE W, 1994, FIBRINOLYSIS, V8, P161, DOI 10.1016/0268-9499(94)90714-5; BRUCH M, 1988, J BIOL CHEM, V263, P16626; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Carrell RW, 1992, CURR OPIN STRUC BIOL, V2, P438; Chuang YJ, 1999, J BIOL CHEM, V274, P28142, DOI 10.1074/jbc.274.40.28142; COHEN AB, 1977, P NATL ACAD SCI USA, V74, P4311, DOI 10.1073/pnas.74.10.4311; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; DAVIS AE, 1992, NAT GENET, V1, P354, DOI 10.1038/ng0892-354; DECLERCK PJ, 1992, J BIOL CHEM, V267, P11693; DOOLITTLE RF, 1983, SCIENCE, V222, P417, DOI 10.1126/science.6604942; Egelund R, 1998, BIOCHEMISTRY-US, V37, P6375, DOI 10.1021/bi973043+; FA M, 1995, BIOCHEMISTRY-US, V34, P13833, DOI 10.1021/bi00042a015; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P3634, DOI 10.1021/bi00410a017; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; Gils A, 1997, J BIOL CHEM, V272, P12662, DOI 10.1074/jbc.272.19.12662; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; KEIJER J, 1991, BLOOD, V78, P1254; Kjoller L, 1996, EUR J BIOCHEM, V241, P38, DOI 10.1111/j.1432-1033.1996.0038t.x; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; Kvassman JO, 1998, BIOCHEMISTRY-US, V37, P15491, DOI 10.1021/bi9814787; KVASSMAN JO, 1995, J BIOL CHEM, V270, P27942, DOI 10.1074/jbc.270.46.27942; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1994, BIOCHEMISTRY-US, V33, P3643, DOI 10.1021/bi00178a022; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; Lukacs CM, 1996, NAT STRUCT BIOL, V3, P888, DOI 10.1038/nsb1096-888; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; NILSSON T, 1982, FEBS LETT, V142, P111, DOI 10.1016/0014-5793(82)80230-5; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OLSON ST, 1991, J BIOL CHEM, V266, P6342; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHECHTER NM, 1993, J BIOL CHEM, V268, P23626; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; Sharp AM, 1999, STRUCTURE, V7, P111, DOI 10.1016/S0969-2126(99)80018-5; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Skinner R, 1998, J MOL BIOL, V283, P9, DOI 10.1006/jmbi.1998.2083; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; vanMeijer M, 1997, BLOOD, V90, P1874, DOI 10.1182/blood.V90.5.1874; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; Xue YF, 1998, STRUCT FOLD DES, V6, P627, DOI 10.1016/S0969-2126(98)00064-1	58	99	104	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5839	5844		10.1074/jbc.275.8.5839	http://dx.doi.org/10.1074/jbc.275.8.5839			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681574	hybrid			2022-12-27	WOS:000085474500081
J	Chapman, NR; Perkins, ND				Chapman, NR; Perkins, ND			Inhibition of the RelA(p65) NF-kappa B subunit by Egr-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR EGR-1; NECROSIS-FACTOR-ALPHA; DNA-BINDING SITE; GENE-EXPRESSION; INDUCED APOPTOSIS; NUCLEAR FACTOR; INTEGRATOR P300; RESPONSE FACTOR; CHAIN PROMOTER; MICE LACKING	Induction of transcription from the human immunodeficiency virus 1 long terminal repeat by the RelA (p65) NF-kappa B subunit has been shown to be dependent upon an interaction with the zinc finger DNA-binding domain of Sp1. It was unknown, however, whether NF-kappa B could also interact with other zinc finger-containing transcription factors. In this study we demonstrate that the early growth response transcription factor Egr-1, whose DNA-binding domain shares a high degree of homology with that of Sp1, can also interact with RelA in vitro and regulate NF-kappa B transcriptional activity in vivo. Similar to the interaction with Sp1, the Rel homology domain of RelA interacts with the zinc finger domain of Egr-1, Surprisingly, and in contrast to Sp1, Egr-1 specifically represses RelA transcriptional activity through its zinc finger domain. Moreover, the interaction between RelA and the Egr-1 zinc fingers is mutually exclusive with DNA binding suggesting a model in which Egr-1 directly sequesters NF-kappa B from its target promoters. Because Egr-1 is induced by many of the same stimuli that activate NF-kappa B, this novel transcriptional regulatory mechanism has many implications for the involvement of both factors in cellular processes such as apoptosis and the response to stress and infection.	Univ Dundee, Dept Biochem, Div Gene Express & Regulat, Dundee DD1 5EH, Scotland	University of Dundee	Perkins, ND (corresponding author), Univ Dundee, Dept Biochem, Div Gene Express & Regulat, MSI WTB Complex,Dow St, Dundee DD1 5EH, Scotland.		Chapman, Neil/C-9888-2011	Chapman, Neil/0000-0002-4853-2909				ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; Ahmed MM, 1997, J BIOL CHEM, V272, P33056, DOI 10.1074/jbc.272.52.33056; Attar RM, 1997, SEMIN CANCER BIOL, V8, P93, DOI 10.1006/scbi.1997.0060; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Catania MV, 1999, NEUROSCIENCE, V91, P1529, DOI 10.1016/S0306-4522(98)00544-2; CHENG T, 1994, J BIOL CHEM, V269, P30848; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; Cogswell PC, 1997, J EXP MED, V185, P491, DOI 10.1084/jem.185.3.491; de Belle I, 1999, ONCOGENE, V18, P3633, DOI 10.1038/sj.onc.1202696; Decker EL, 1998, J BIOL CHEM, V273, P26923, DOI 10.1074/jbc.273.41.26923; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dinkel A, 1997, J IMMUNOL, V159, P2678; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; EBERT SN, 1995, J BIOL CHEM, V270, P17299, DOI 10.1074/jbc.270.29.17299; Fitzgerald KA, 1999, J IMMUNOL, V162, P4920; Franzoso G, 1996, EMBO J, V15, P3403, DOI 10.1002/j.1460-2075.1996.tb00706.x; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Hartikka J, 1996, HUM GENE THER, V7, P1205, DOI 10.1089/hum.1996.7.10-1205; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Huang RP, 1998, CELL DEATH DIFFER, V5, P96, DOI 10.1038/sj.cdd.4400322; Huang RP, 1999, J CELL BIOCHEM, V73, P227, DOI 10.1002/(SICI)1097-4644(19990501)73:2<227::AID-JCB9>3.0.CO;2-B; Huang RP, 1997, J CELL BIOCHEM, V66, P489, DOI 10.1002/(SICI)1097-4644(19970915)66:4<489::AID-JCB8>3.0.CO;2-H; HUANG RP, 1995, CANCER RES, V55, P5054; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1998, J MOL MED-JMM, V76, P613, DOI 10.1007/s001090050258; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Lin JX, 1997, MOL CELL BIOL, V17, P3714, DOI 10.1128/MCB.17.7.3714; Liu CT, 1996, CRIT REV ONCOGENESIS, V7, P101, DOI 10.1615/CritRevOncog.v7.i1-2.70; Liu CT, 1998, CANCER GENE THER, V5, P3; Maltzman JS, 1996, MOL CELL BIOL, V16, P2283; MCCOY C, 1995, MOL CELL BIOL, V15, P6100; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Muthukkumar S, 1997, J BIOL CHEM, V272, P27987, DOI 10.1074/jbc.272.44.27987; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Ravi R, 1998, CANCER RES, V58, P4531; SHINGU T, 1994, J BIOL CHEM, V269, P32551; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Silverman ES, 1998, BIOCHEM J, V336, P183, DOI 10.1042/bj3360183; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Svaren J, 1996, MOL CELL BIOL, V16, P3545; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Swirnoff AH, 1998, MOL CELL BIOL, V18, P512, DOI 10.1128/MCB.18.1.512; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Thottassery JV, 1999, J BIOL CHEM, V274, P3199, DOI 10.1074/jbc.274.5.3199; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang D, 1997, ONCOGENE, V14, P2291, DOI 10.1038/sj.onc.1201069; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wu BY, 1997, J VIROL, V71, P3161, DOI 10.1128/JVI.71.4.3161-3167.1997; Yan SF, 1998, P NATL ACAD SCI USA, V95, P8298, DOI 10.1073/pnas.95.14.8298; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4	73	98	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4719	4725		10.1074/jbc.275.7.4719	http://dx.doi.org/10.1074/jbc.275.7.4719			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671503	hybrid			2022-12-27	WOS:000085378200029
J	Hansen, GH; Niels-Christiansen, LL; Thorsen, E; Immerdal, L; Danielsen, EM				Hansen, GH; Niels-Christiansen, LL; Thorsen, E; Immerdal, L; Danielsen, EM			Cholesterol depletion of enterocytes - Effect on the Golgi complex and apical membrane trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; INTESTINAL MICROVILLAR PROTEINS; PIG SMALL-INTESTINE; INFLUENZA-VIRUS HEMAGGLUTININ; BRUSH-BORDER ENZYMES; INTRACELLULAR-TRANSPORT; EPITHELIAL-CELLS; MDCK CELLS; AMINOPEPTIDASE-N; SUCRASE-ISOMALTASE	Intestinal brush border enzymes, including aminopeptidase N and sucrase-isomaltase, are associated with "rafts" (membrane microdomains rich in cholesterol and sphingoglycolipids). To assess the functional role of rafts in the present work, we studied the effect of cholesterol depletion on apical membrane trafficking in enterocytes. Cultured mucosal explants of pig small intestine were treated for 2 h with the cholesterol sequestering agent methyl-beta-cyclodextrin and lovastatin, an inhibitor of hydroxymethylglutaryl-coenzyme A reductase. The treatment reduced the cholesterol content >50%. Morphologically, the Golgis complex/trans-Golgi network was partially transformed into numerous 100-200 nm vesicles. By immunogold electron microscopy, aminopeptidase N was localized in these Golgi-derived vesicles as well as at the basolateral cell surface, indicating a partial missorting. Biochemically, the rates of the Golgi-associated complex glycosylation and association with rafts of newly synthesized aminopeptidase N were reduced, and less of the enzyme had reached the brush border membrane after 2 h of labeling. In contrast, the basolateral Na+/K+-ATPase was neither missorted nor raft-associated. Our results implicate the Golgi complex/trans-Golgi network in raft formation and suggest a close relationship between this event and apical membrane trafficking.	Univ Copenhagen, Panum Inst, Dept Med Biochem & Genet, Biochem Lab C, DK-2200 Copenhagen N, Denmark	University of Copenhagen	Danielsen, EM (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Biochem & Genet, Biochem Lab C, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.							Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; Apodaca G, 1996, EMBO J, V15, P1471, DOI 10.1002/j.1460-2075.1996.tb00491.x; Booth A G, 1974, Biochem J, V142, P575; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHRISTIANSEN K, 1981, BIOCHIM BIOPHYS ACTA, V647, P188, DOI 10.1016/0005-2736(81)90245-5; Danielsen EM, 1997, MOL BIOL CELL, V8, P2241, DOI 10.1091/mbc.8.11.2241; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; DANIELSEN EM, 1995, J CELL BIOL, V131, P939, DOI 10.1083/jcb.131.4.939; DANIELSEN EM, 1995, GASTROENTEROLOGY, V109, P1039, DOI 10.1016/0016-5085(95)90561-8; DANIELSEN EM, 1982, BIOCHEM J, V204, P639, DOI 10.1042/bj2040639; DANIELSEN EM, 1982, BIOCHEM J, V202, P647, DOI 10.1042/bj2020647; DANIELSEN EM, 1989, EUR J CELL BIOL, V49, P123; Farquhar MG, 1998, TRENDS CELL BIOL, V8, P2, DOI 10.1016/S0962-8924(97)01187-2; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; GAMBLE W, 1978, J LIPID RES, V19, P1068; GARCIA M, 1993, J CELL SCI, V104, P1281; Hailstones D, 1998, J LIPID RES, V39, P369; Hannan LA, 1996, J CELL BIOL, V133, P1265, DOI 10.1083/jcb.133.6.1265; Hansen GH, 1999, GASTROENTEROLOGY, V116, P610, DOI 10.1016/S0016-5085(99)70183-6; HANSEN GH, 1987, EUR J CELL BIOL, V43, P253; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; LAEMLLI VK, 1970, NATURE, V227, P68; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Leung SM, 1998, J BIOL CHEM, V273, P17732, DOI 10.1074/jbc.273.28.17732; Mazzarello P, 1998, NATURE, V392, P543, DOI 10.1038/33266; Mirre C, 1996, AM J PHYSIOL-CELL PH, V271, pC887, DOI 10.1152/ajpcell.1996.271.3.C887; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Presley JF, 1998, MOL BIOL CELL, V9, P1617, DOI 10.1091/mbc.9.7.1617; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SJOSTROM H, 1978, EUR J BIOCHEM, V88, P503, DOI 10.1111/j.1432-1033.1978.tb12476.x; SJOSTROM H, 1980, J BIOL CHEM, V255, P1332; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Wang H, 1996, J NUTR, V126, P1455, DOI 10.1093/jn/126.5.1455; Weimbs T, 1997, TRENDS CELL BIOL, V7, P393, DOI 10.1016/S0962-8924(97)01130-6; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247	51	134	139	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5136	5142		10.1074/jbc.275.7.5136	http://dx.doi.org/10.1074/jbc.275.7.5136			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671559	hybrid			2022-12-27	WOS:000085378200085
J	Schneider, C; Brash, AR				Schneider, C; Brash, AR			Stereospecificity of hydrogen abstraction in the conversion of arachidonic acid to 15R-HETE by aspirin-treated cyclooxygenase-2 - Implications for the alignment of substrate in the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CRYSTAL-STRUCTURE; PROSTAGLANDIN; SYNTHASE; ACETYLATION; INHIBITION	The initial and rate-limiting step in prostaglandin biosynthesis is stereoselective removal of the pro-S hydrogen from the 13-carbon of arachidonic acid. This is followed by oxygenation at C-11, formation of the five-membered ring, and a second oxygenation at C-15 to yield the endoperoxide product, prostaglandin G(2). Aspirin treatment of cyclooxygenase-2 is known to acetylate an active site serine, block prostaglandin biosynthesis, and give 15R-hydroxyeicosatetraenoic acid (15R-HETE) as the only product. 15R-HETE and prostaglandins have opposite stereoconfigurations of the 15-hydroxyl. To understand the changes that lead to 15R-HETE synthesis in aspirin-treated COX-2, we employed pro-R- and pro-S-labeled [13-H-3]arachidonic acids to investigate the selectivity of the initial hydrogen abstraction. Remarkably, aspirin-treated COX-2 formed 15R-HETE with removal of the pro-S hydrogen at C-13 (3-9% retention of pro-S tritium label), the same stereoselectivity as in the formation of prostaglandins by native cyclooxygenase, To account for this result and the change in oxygenase specificity, we suggest that the bulky serine acetyl group forces a realignment of the omega end of the arachidonic acid carbon chain. This can rationalize abstraction of the C-13 pro-S hydrogen, the blocking of prostaglandin synthesis, and the formation of 15R-HETE as the sole enzymatic product.	Vanderbilt Univ, Sch Med, Dept Pharmacol, Div Clin Pharmacol, Nashville, TN 37232 USA	Vanderbilt University	Brash, AR (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, Div Clin Pharmacol, 23rd Ave Pierce, Nashville, TN 37232 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053638] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-53638] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boeglin WE, 1998, P NATL ACAD SCI USA, V95, P6744, DOI 10.1073/pnas.95.12.6744; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; HAMBERG M, 1967, J BIOL CHEM, V242, P5344; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; Jisaka M, 2000, J BIOL CHEM, V275, P1287, DOI 10.1074/jbc.275.2.1287; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; LOLL PJ, 1995, NAT STRUCT BIOL, V2, P637, DOI 10.1038/nsb0895-637; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MANCINI JA, 1994, FEBS LETT, V342, P33, DOI 10.1016/0014-5793(94)80579-2; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; POWELL WS, 1982, METHOD ENZYMOL, V86, P530; Rieke CJ, 1999, J BIOL CHEM, V274, P17109, DOI 10.1074/jbc.274.24.17109; Rowlinson SW, 1999, J BIOL CHEM, V274, P23305, DOI 10.1074/jbc.274.33.23305; Schwarz K, 1998, BIOCHEMISTRY-US, V37, P15327, DOI 10.1021/bi9816204; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157	18	67	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4743	4746		10.1074/jbc.275.7.4743	http://dx.doi.org/10.1074/jbc.275.7.4743			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671506	hybrid			2022-12-27	WOS:000085378200032
J	Dey, R; Moraes, CT				Dey, R; Moraes, CT			Lack of oxidative phosphorylation and low mitochondrial membrane potential decrease susceptibility to apoptosis and do not modulate the protective effect of Bcl-x(L) in osteosarcoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-MEDIATED APOPTOSIS; CYTOCHROME-C RELEASE; PERMEABILITY-TRANSITION; NUCLEAR APOPTOSIS; BCL-X; BAX; DEATH; ACTIVATION; DNA; INHIBITORS	We explored the role of low mitochondrial membrane potential (Delta Psi m) and the lack of oxidative phosphorylation in apoptosis by assessing the susceptibility of osteosarcoma cell lines with and without mitochondrial DNA to staurosporine-induced death. Our cells without mitochondrial DNA had low Delta Psi m and no functional oxidative phosphorylation. Contrary to our expectation, these cells were more resistant to staurosporine-induced death than were the parental cells. This reduced susceptibility was associated with decreased activation of caspase 3 but not with the mitochondrial permeability transition pore or cytochrome c release from the mitochondria. Apoptosis in both cell lines was associated with an increase in Delta Psi m. Bcl-x(L) could protect both cell types against caspase 3 activation and apoptosis by a mechanism that does not appear to be mediated by mitochondrial function or modulation of Delta Psi m. Nevertheless, we found that Bcl-x(L) expression can stimulate cell respiration in cells with mitochondrial DNA. Our results showed that the lack of functional oxidative phosphorylation and/or low mitochondrial membrane potential are associated with an antiapoptotic effect, possibly contributing to the development of some types of cancer. It also reinforces a model in which Bcl-x(L) can exert an antiapoptotic effect by stimulating oxidative phosphorylation and/or inhibiting caspase activation.	Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA	University of Miami; University of Miami	Moraes, CT (corresponding author), Univ Miami, Sch Med, Dept Neurol, 1501 NW 9th Ave, Miami, FL 33136 USA.		Moraes, Carlos/AAT-3818-2021					Adachi S, 1998, J BIOL CHEM, V273, P19892, DOI 10.1074/jbc.273.31.19892; Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Barrientos A, 1998, J BIOL CHEM, V273, P14210, DOI 10.1074/jbc.273.23.14210; Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Brustugun OT, 1998, CELL DEATH DIFFER, V5, P660, DOI 10.1038/sj.cdd.4400399; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; Decaudin D, 1997, CANCER RES, V57, P62; Eguchi Y, 1997, CANCER RES, V57, P1835; Eguchi Y, 1999, CANCER RES, V59, P2174; Fall CP, 1999, BBA-BIOENERGETICS, V1410, P77, DOI 10.1016/S0005-2728(98)00177-7; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hao HL, 1999, HUM MOL GENET, V8, P1117, DOI 10.1093/hmg/8.6.1117; HOCKENBERY DM, 1995, BIOESSAYS, V17, P631, DOI 10.1002/bies.950170709; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; IMBERTI R, 1992, RES COMMUN CHEM PATH, V78, P27; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kitagawa H, 1999, FEBS LETT, V443, P181, DOI 10.1016/S0014-5793(98)01709-8; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1999, CANCER RES, V59, P1693; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 1998, CELL DEATH DIFFER, V5, P547, DOI 10.1038/sj.cdd.4400387; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchetti P, 1996, CANCER RES, V56, P2033; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marusich MF, 1997, BBA-MOL BASIS DIS, V1362, P145, DOI 10.1016/S0925-4439(97)00061-6; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Newmeyer DD, 1998, NEURON, V21, P653, DOI 10.1016/S0896-6273(00)80580-2; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PEIFENG L, 1999, EMBO J, V18, P6027; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; Vander Heiden MG, 1999, MOL CELL, V3, P159; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; WILSON GN, 1978, P NATL ACAD SCI USA, V75, P5367, DOI 10.1073/pnas.75.11.5367; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	70	172	177	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7087	7094		10.1074/jbc.275.10.7087	http://dx.doi.org/10.1074/jbc.275.10.7087			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702275	hybrid			2022-12-27	WOS:000085809600055
J	Liu, XW; Katagiri, Y; Jiang, H; Gong, LJ; Guo, LY; Shibutani, M; Johnson, AC; Guroff, G				Liu, XW; Katagiri, Y; Jiang, H; Gong, LJ; Guo, LY; Shibutani, M; Johnson, AC; Guroff, G			Cloning and characterization of the promoter region of the rat epidermal growth factor receptor gene and its transcriptional regulation by nerve growth factor in BC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 CELLS; PHEOCHROMOCYTOMA CELLS; DOWN-REGULATION; RETINOIC ACID; SEQUENCE; EXPRESSION; ELEMENT; IDENTIFICATION; BINDING; ABSENCE	Our previous studies have shown that treatment of PC12 cells with nerve growth factor (NGF) causes a profound down-regulation of the epidermal growth factor receptor (EGFR) mRNA and protein. Further, the NGF-induced down-regulation of the EGFR is under transcriptional control. To elucidate the molecular mechanism of this down-regulation we have cloned a 2.7-kilobase sequence from the promoter region of the rat EG;FR from a rat P1 library. Six transcriptional start sites were identified by 5'-rapid amplification of cDNA ends and primer extension. Sequence analysis showed a 62% overall homology with the human EGFR promoter region. To investigate its transcription, 1.1 kilobases of the 5'-flanking sequence were fused to a luciferase reporter gene. This sequence exhibited functional promoter activity in transient transfection experiments with PC12, C6, and CV-1 cells. Treatment of PC12 cells with NGF inhibited promoter activity. By transfection of promoter deletion constructs, a silencer element was found between nucleotides -260 and -181, and TCC repeat sequences appeared to be at least partially responsible for the down-regulation of the EGFR by NGF. Supportive evidence for the relevance of this sequence was obtained from gel mobility shift assays and by transfection of TCC mutation constructs. Our results demonstrate that TCC repeat sequences are required for the down-regulation of rat EGFR by NGF in PC12 cells and may lead to the identification of the NGF-responsive transcription factors.	NCI, Mol Biol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; NICHD, Growth Factors Sect, NIH, Bethesda, MD 20892 USA; NICHD, Dev & Mol Immun Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Johnson, AC (corresponding author), NCI, Mol Biol Lab, Div Basic Sci, NIH, Bldg 37,Rm 2D18, Bethesda, MD 20892 USA.	aj2e@ih.gov	Shibutani, Makoto/C-2510-2013; Shibutani, Makoto/AGK-2801-2022	Shibutani, Makoto/0000-0003-3417-9697	NATIONAL CANCER INSTITUTE [Z01BC008000] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAKI E, 1987, J BIOL CHEM, V262, P16186; BOORSTEIN WR, 1989, METHOD ENZYMOL, V180, P347; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHANDLER CE, 1983, J CELL PHYSIOL, V114, P321, DOI 10.1002/jcp.1041140311; FROMM M, 1982, Journal of Molecular and Applied Genetics, V1, P457; GILL GN, 1987, MOL CELL ENDOCRINOL, V51, P169, DOI 10.1016/0303-7207(87)90027-X; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HALEY J, 1987, ONCOGENE RES, V1, P375; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HOU XY, 1994, CELL GROWTH DIFFER, V5, P801; Hudson L G, 1991, Genet Eng (N Y), V13, P137; HUDSON LG, 1990, P NATL ACAD SCI USA, V87, P7536, DOI 10.1073/pnas.87.19.7536; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; Katagiri Y, 1997, J BIOL CHEM, V272, P31278, DOI 10.1074/jbc.272.50.31278; KING CR, 1985, NUCLEIC ACIDS RES, V13, P8477, DOI 10.1093/nar/13.23.8477; LAZAROVICI P, 1987, J CELL BIOL, V104, P1611, DOI 10.1083/jcb.104.6.1611; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MCKEON C, 1984, J BIOL CHEM, V259, P6636; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; Saleh M, 1996, CANCER RES, V56, P393; Shibutani M, 1998, J BIOL CHEM, V273, P6878, DOI 10.1074/jbc.273.12.6878; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TOGARI A, 1985, J NEUROSCI, V5, P307; UEDA K, 1987, J BIOL CHEM, V262, P17432; XU YH, 1984, P NATL ACAD SCI-BIOL, V81, P7308, DOI 10.1073/pnas.81.23.7308; ZHENG ZS, 1992, CELL GROWTH DIFFER, V3, P225	34	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7280	7288		10.1074/jbc.275.10.7280	http://dx.doi.org/10.1074/jbc.275.10.7280			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702298	hybrid			2022-12-27	WOS:000085809600078
J	Morishima, Y; Kanelakis, KC; Silverstein, AM; Dittmar, KD; Estrada, L; Pratt, WB				Morishima, Y; Kanelakis, KC; Silverstein, AM; Dittmar, KD; Estrada, L; Pratt, WB			The Hsp organizer protein Hop enhances the rate of but is not essential for glucocorticoid receptor folding by the multiprotein Hsp90-based chaperone system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; HORMONE-BINDING DOMAIN; PROGESTERONE-RECEPTOR; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL HETEROCOMPLEX; COMPLEX; RECONSTITUTION; CONFORMATION; P23; TRANSFORMATION	A system consisting of five purified proteins: Hsp90, Hsp70, Hop, Hsp40, and p23, acts as a machinery for assembly of glucocorticoid receptor (GR).Hsp90 heterocomplexes. Hop binds independently to Hsp90 and to Hsp70 to form a Hsp90.Hop.Hsp70.Hsp40 complex that is sufficient to convert the GR to its steroid binding form, and this four-protein complex will form stable GR.Hsp90 heterocomplexes if p23 is added to the system (Dittmar, K, D,, Banach, M., Galigniana, M. D., and Pratt, W. B. (1998) J. Biol. Chem. 273, 7358-7366). Hop has been considered essential for the formation of receptor.Hsp90 heterocomplexes and GR folding. Here we use Hsp90 and Hsp70 purified free of all traces of Hop and Hsp40 to show that Hop is not required for GR Hsp40 heterocomplex assembly and activation of steroid binding activity. Rather, Hop enhances the rate of the process. We also show that Hsp40 is not essential for GR folding by the five-protein system but enhances a process that occurs less effectively when it is not present. By carrying out assembly in the presence of radiolabeled steroid to bind to the GR as soon as it is converted to the steroid binding state, we show that the folding change is brought about by only two essential components, Hsp90 and Hsp70, and that Hop, Hsp40, and p23 act as nonessential co-chaperones.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Pratt, WB (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 MSRB III, Ann Arbor, MI 48109 USA.			Estrada, Lourdes/0000-0002-3645-4456	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31573] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bohen SP, 1998, MOL CELL BIOL, V18, P3330, DOI 10.1128/MCB.18.6.3330; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; CZAR MJ, 1994, J BIOL CHEM, V269, P11155; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HONORE B, 1992, J BIOL CHEM, V267, P8485; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; Modarress KJ, 1997, J BIOL CHEM, V272, P23986, DOI 10.1074/jbc.272.38.23986; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; Prapapanich V, 1998, MOL CELL BIOL, V18, P944, DOI 10.1128/MCB.18.2.944; Pratt WB, 1998, TRENDS ENDOCRIN MET, V9, P244, DOI 10.1016/S1043-2760(98)00059-9; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; PRATT WB, 1993, STEROID HORMONE ACTI, P64; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Srinivasan G, 1997, J STEROID BIOCHEM, V60, P1, DOI 10.1016/S0960-0760(96)00182-3; Stancato LF, 1996, BIOCHEMISTRY-US, V35, P554, DOI 10.1021/bi9511649; Stancato LF, 1996, J BIOL CHEM, V271, P8831, DOI 10.1074/jbc.271.15.8831; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Toft DO, 1998, TRENDS ENDOCRIN MET, V9, P238, DOI 10.1016/S1043-2760(98)00060-5; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xu M, 1998, J BIOL CHEM, V273, P13918, DOI 10.1074/jbc.273.22.13918	43	86	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6894	6900		10.1074/jbc.275.10.6894	http://dx.doi.org/10.1074/jbc.275.10.6894			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702249	hybrid			2022-12-27	WOS:000085809600029
J	Ulery, PG; Beers, J; Mikhailenko, I; Tanzi, RE; Rebeck, GW; Hyman, BT; Strickland, DK				Ulery, PG; Beers, J; Mikhailenko, I; Tanzi, RE; Rebeck, GW; Hyman, BT; Strickland, DK			Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP) - Evidence that LRP contributes to the pathogenesis of Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; GENE; ASSOCIATION; COMPLEXES; BINDING; LIGANDS; CELLS; DEGRADATION; INHIBITOR	beta-Amyloid peptide (A beta), which plays a central role in the pathogenesis of Alzheimer's disease, is derived from the transmembrane beta-amyloid precursor protein (APP) by proteolytic processing. Although mechanisms associated with A beta generation are not fully understood, it is known that A beta can be generated within endosomal compartments upon internalization of APP from the cell surface. The low density lipoprotein receptor-related protein (LRP) was previously shown to mediate the endocytosis of APP isoforms containing the Kunitz proteinase inhibitor domain (Kounnas, M. Z., Moir, R, D,, Rebeck, G. W., Bush, A. I., Argraves, W, S., Tanzi, R. E., Hyman, B, T., and Strickland, D. K. (1995) Cell 82, 331-340; Knauer, M, F., Orlando, R.A., and Glabe, C.G. (1996) Brain Res. 740, 6-14), The objective of the current study was to test the hypothesis that LRP-mediated internalization of cell surface APP can modulate APP processing and thereby affect A beta generation. Here, we show that long term culturing of cells in the presence of the LRP-antagonist RAP leads to increased cell surface levels of APP and a significant reduction in A beta synthesis. Further, restoring LRP function in LRP-deficient cells results in a substantial increase in A beta production. These findings demonstrate that LRP contributes to A beta generation and suggest novel pharmacological approaches to reduce A beta levels based on selective LRP blockade.	Amer Red Cross, Jerome H Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA; Massachusetts Gen Hosp, Dept Neurol, Alzheimers Res Unit, Boston, MA 02129 USA; George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20037 USA; George Washington Univ, Med Ctr, Inst Biomed Sci, Washington, DC 20037 USA	American Red Cross; Harvard University; Massachusetts General Hospital; George Washington University; George Washington University	Strickland, DK (corresponding author), Amer Red Cross, Jerome H Holland Lab, Dept Vasc Biol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.		Tanzi, Rudolph/AAE-9622-2019; Rebeck, George William/J-2192-2012	Tanzi, Rudolph/0000-0002-7032-1454; Rebeck, George William/0000-0001-6276-248X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050784, P01HL054710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012406, R37AG012406] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54710, HL50784] Funding Source: Medline; NIA NIH HHS [AG12406] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Hamik A, 1999, J BIOL CHEM, V274, P4962, DOI 10.1074/jbc.274.8.4962; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1991, J BIOL CHEM, V266, P21232; Ho LB, 1996, J BIOL CHEM, V271, P30929, DOI 10.1074/jbc.271.48.30929; Hollenbach E, 1998, NEUROLOGY, V50, P1905, DOI 10.1212/WNL.50.6.1905; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; Kang DE, 1997, NEUROLOGY, V49, P56, DOI 10.1212/WNL.49.1.56; Knauer MF, 1996, BRAIN RES, V740, P6, DOI 10.1016/S0006-8993(96)00711-1; Koo EH, 1996, J CELL SCI, V109, P991; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KUENTZEL SL, 1993, BIOCHEM J, V295, P367, DOI 10.1042/bj2950367; LADU MJ, 1994, J BIOL CHEM, V269, P23403; Lambert JC, 1998, LANCET, V351, P1787, DOI 10.1016/S0140-6736(05)78749-3; LOPES MBS, 1994, FEBS LETT, V338, P301, DOI 10.1016/0014-5793(94)80288-2; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; Moir RD, 1998, J BIOL CHEM, V273, P5013, DOI 10.1074/jbc.273.9.5013; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; Narita M, 1997, J NEUROCHEM, V69, P1904; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; REBECK GW, 1993, NEURON, V11, P575; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; SCHMAIER AH, 1993, J CLIN INVEST, V92, P2540, DOI 10.1172/JCI116863; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; VANNOSTRAND WE, 1991, P NATL ACAD SCI USA, V88, P10302, DOI 10.1073/pnas.88.22.10302; WavrantDeVrieze F, 1997, NEUROSCI LETT, V227, P68, DOI 10.1016/S0304-3940(97)00304-2; Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, J CELL SCI, V107, P719	44	222	229	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7410	7415		10.1074/jbc.275.10.7410	http://dx.doi.org/10.1074/jbc.275.10.7410			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702315	hybrid			2022-12-27	WOS:000085809600095
J	Valledor, AF; Comalada, M; Xaus, J; Celada, A				Valledor, AF; Comalada, M; Xaus, J; Celada, A			The differential time-course of extracellular-regulated kinase activity correlates with the macrophage response toward proliferation or activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CSF-1 SIGNAL-TRANSDUCTION; EPIDERMAL GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE; INDEPENDENT PATHWAYS; PRIMARY CULTURES; RAT HEPATOCYTES; GENE-EXPRESSION; DNA-SYNTHESIS; TNF-ALPHA	Bone marrow-derived macrophages proliferate in response to specific growth factors, including macrophage colony-stimulating factor (M-CSF), When stimulated with activating factors, such as lipopolysaccharide (LPS), macrophages stop proliferating and produce proinflammatory cytokines, Although triggering opposed responses, both M-CSF and LPS induce the activation of extracellular-regulated kinases (ERKs) 1 and 2. However, the time-course of ERK activation is different; maximal activation by M-CSF and LPS occurred after 5 and 15 min of stimulation, respectively. Granulocyte/macrophage colony-stimulating factor, interleukin 3, and TPA, all of which induced macrophage proliferation, also induced ERK activity, which was maximal at 5 min poststimulation, The use of PD98059, which specifically blocks ERK 1 and 2 activation, demonstrated that ERK activity was necessary for macrophage proliferation in response to these factors. The treatment with phosphatidylcholine-specific phospholipase C (PC-PLC) inhibited macrophage proliferation, induced the expression of cytokines, and triggered a pattern of ERK activation equivalent to that induced by LPS, Moreover, PD98059 inhibited the expression of cytokines induced by LPS or PC-PLC, thus suggesting that ERK activity is also required for macrophage activation by these two agents. Activation of the JNK pathway did not discriminate between proliferative and activating stimuli. In conclusion, our results allow to correlate the differences in the time-course of ERK activity with the macrophase response toward proliferation or activation.	Univ Barcelona, Fac Biol, Dept Fisiol Biol Macrofag, E-08028 Barcelona, Spain; Univ Barcelona, Fundacio August Pi & Sunyer, Dept Fisiol Biol Macrofag, E-08028 Barcelona, Spain	University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Celada, A (corresponding author), Univ Barcelona, Fac Biol, Dept Fisiol Biol Macrofag, Campus Bellvitge,Av Diagonal 645, E-08028 Barcelona, Spain.		Valledor, Annabel/H-5653-2015; Celada, Antonio/I-1714-2016	Valledor, Annabel/0000-0003-4232-2633; 				ADAMS DO, 1984, ANNU REV IMMUNOL, V2, P283, DOI 10.1146/annurev.immunol.2.1.283; Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CELADA A, 1992, J IMMUNOL, V148, P1102; CELADA A, 1989, EUR J IMMUNOL, V19, P1103, DOI 10.1002/eji.1830190621; CELADA A, 1984, J EXP MED, V160, P55, DOI 10.1084/jem.160.1.55; Celada A, 1996, J EXP MED, V184, P61, DOI 10.1084/jem.184.1.61; CELADA A, 1994, IMMUNOL TODAY, V15, P100, DOI 10.1016/0167-5699(94)90150-3; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; Foey AD, 1998, J IMMUNOL, V160, P920; Hamilton JA, 1997, J LEUKOCYTE BIOL, V62, P145, DOI 10.1002/jlb.62.2.145; Hamilton JA, 1997, IMMUNOL TODAY, V18, P313, DOI 10.1016/S0167-5699(97)01084-0; Hara T, 1996, STEM CELLS, V14, P605, DOI 10.1002/stem.140605; Hoffmeyer A, 1999, J BIOL CHEM, V274, P4319, DOI 10.1074/jbc.274.7.4319; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Ishizuka T, 1997, P NATL ACAD SCI USA, V94, P6358, DOI 10.1073/pnas.94.12.6358; Jaworowski A, 1996, BIOCHEM J, V320, P1011, DOI 10.1042/bj3201011; Krause A, 1998, J BIOL CHEM, V273, P23681, DOI 10.1074/jbc.273.37.23681; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Miyajima Atsushi, 1997, Leukemia (Basingstoke), V11, P418; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; Neuberger MS, 1997, CELL, V90, P971, DOI 10.1016/S0092-8674(00)80362-1; REIMANN T, 1994, J IMMUNOL, V153, P5740; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sarbassov DD, 1997, MOL ENDOCRINOL, V11, P2038, DOI 10.1210/me.11.13.2038; Scherle PA, 1998, J IMMUNOL, V161, P5681; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V; Tombes RM, 1998, BIOCHEM J, V330, P1451; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tschaikowsky K, 1998, J PHARMACOL EXP THER, V285, P800; VAIRO G, 1991, IMMUNOL TODAY, V12, P362, DOI 10.1016/0167-5699(91)90067-4; Valledor AF, 1999, J IMMUNOL, V163, P2452; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; Xaus J, 1999, IMMUNITY, V11, P103, DOI 10.1016/S1074-7613(00)80085-0	44	111	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7403	7409		10.1074/jbc.275.10.7403	http://dx.doi.org/10.1074/jbc.275.10.7403			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702314	hybrid			2022-12-27	WOS:000085809600094
J	Venkatakrishnan, G; Salgia, R; Groopman, JE				Venkatakrishnan, G; Salgia, R; Groopman, JE			Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; SMOOTH-MUSCLE CELLS; MALIGNANT MELANOMA-CELLS; FOCAL TYROSINE KINASE; BETA-GAMMA-SUBUNITS; COUPLED RECEPTORS; ANGIOTENSIN-II; PHOSPHOLIPASE-C; MEDIATED ACTIVATION; HUMAN NEUTROPHILS	Ovarian cancer typically disseminates widely in the abdomen, a characteristic that limits curative therapy. The mechanisms that promote ovarian cancer cell migration are incompletely understood. We studied model SK-OV-3 ovarian cancer cells and observed robust expression of the gamma chemokine receptors CXCR-1 and CXCR-2. Interleukin-8 (IL-8) treatment caused shape changes in the cells, with membrane ruffling and formation/retraction of thin actin-like projections, as detected by time-lapse microscopy. Stimulation of the CXCR-1/2 receptors by human interleukin 8 (IL-8) rapidly activated the p44/42 mitogen-activated protein (extracellular signal-regulated kinase (Erk1/2)) kinase pathway. Treatment of SK-OV-3 cells with the inhibitors genestein and herbimycin A indicated that tyrosine kinases were involved in the IL-8 activation of Erk1 and Erk2. Of note, IL-8 induced transient phosphorylation of the epidermal growth factor (EGF) receptor and its association with the adaptor molecules Shc and Grb2. This transactivation of the EGF receptor was dependent on intracellular Ca2+ mobilization. Furthermore AG1478, a specific inhibitor of the EGF receptor kinase, blocked Erk1 and Erk2 activation. c-Src kinase was not involved in the LL-g-mediated phosphorylation of the EGF receptor, but was critical for Shc phosphorylation and downstream Erk1/2 kinase activation. These results suggest important "cross-talk" between chemokine and growth factor pathways that may link signals of cell migration and proliferation in ovarian cancer.	Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA; Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Med, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Groopman, JE (corresponding author), Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, 3rd Floor,4 Blackfan Circ, Boston, MA 02115 USA.				NCI NIH HHS [CA77846] Funding Source: Medline; NHLBI NIH HHS [HL55187, HL43510] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K12CA077846] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055187] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bar-Eli M, 1999, PATHOBIOLOGY, V67, P12, DOI 10.1159/000028045; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Corps AN, 1997, INT J CANCER, V73, P151, DOI 10.1002/(SICI)1097-0215(19970926)73:1<151::AID-IJC23>3.0.CO;2-I; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DETMERS PA, 1991, J IMMUNOL, V147, P4211; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Dutt P, 1998, J IMMUNOL, V161, P3652; Eguchi S, 1999, HYPERTENSION, V33, P201, DOI 10.1161/01.HYP.33.1.201; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; EHRENGRUBER MU, 1995, FEBS LETT, V359, P229, DOI 10.1016/0014-5793(95)00048-E; Ellerbroek SM, 1998, INT J CANCER, V78, P331, DOI 10.1002/(SICI)1097-0215(19981029)78:3<331::AID-IJC13>3.0.CO;2-9; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Gelderloos JA, 1998, J BIOL CHEM, V273, P5908, DOI 10.1074/jbc.273.10.5908; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; JONES SA, 1995, FEBS LETT, V364, P211, DOI 10.1016/0014-5793(95)00397-R; Jones SA, 1997, J BIOL CHEM, V272, P16166, DOI 10.1074/jbc.272.26.16166; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; LEE CH, 1992, J BIOL CHEM, V267, P16044; LHEUREUX GP, 1995, BLOOD, V85, P522, DOI 10.1182/blood.V85.2.522.bloodjournal852522; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; LOETSCHER P, 1994, FEBS LETT, V341, P187, DOI 10.1016/0014-5793(94)80454-0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; Mellado M, 1998, J IMMUNOL, V161, P805; Miyamoto M, 1998, CANCER IMMUNOL IMMUN, V47, P47, DOI 10.1007/s002620050503; Murphy PM, 1997, SEMIN HEMATOL, V34, P311; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; Rainger GE, 1998, BLOOD, V92, P4819, DOI 10.1182/blood.V92.12.4819.424k16_4819_4827; Richardson RM, 1998, J BIOL CHEM, V273, P10690, DOI 10.1074/jbc.273.17.10690; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Salgia R, 1999, BLOOD, V94, P4233; SCHADENDORF D, 1993, J IMMUNOL, V151, P2667; Singh RK, 1998, CANCER RES, V58, P1532; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; WANG JM, 1990, BIOCHEM BIOPH RES CO, V169, P165, DOI 10.1016/0006-291X(90)91449-3; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; WATANABE T, 1995, J BIOL CHEM, V270, P8984, DOI 10.1074/jbc.270.15.8984; Westermann AM, 1997, CANCER TREAT REV, V23, P113, DOI 10.1016/S0305-7372(97)90024-4; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; Youngs SJ, 1997, INT J CANCER, V71, P257, DOI 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	66	180	186	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6868	6875		10.1074/jbc.275.10.6868	http://dx.doi.org/10.1074/jbc.275.10.6868			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702246	hybrid			2022-12-27	WOS:000085809600026
J	Brenner, R; Jegla, TJ; Wickenden, A; Liu, Y; Aldrich, RW				Brenner, R; Jegla, TJ; Wickenden, A; Liu, Y; Aldrich, RW			Cloning and functional characterization of novel large conductance calcium-activated potassium channel beta subunits, hKCNMB3 and hKCNMB4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CHANNEL; SMOOTH-MUSCLE; TRANSMITTER RELEASE; OVERLAP EXTENSION; SPLICE VARIANTS; MODULATION; IDENTIFICATION; CHARYBDOTOXIN; CELLS; MSLO	We present the cloning and characterization of two novel calcium-activated potassium channel beta subunits, hKCNMB3 and hKCNMB4, that are enriched in the testis and brain, respectively. We compare and contrast the steady state and kinetic properties of these beta subunits with the previously cloned mouse beta 1 (mKCNMB1) and the human beta 2 subunit (hKCNMB2). Once inactivation is removed, we find that hKCNMB2 has properties similar to mHCNMB1, hKCNMB2 slows Hslo1 channel gating and shifts the current-voltage relationship to more negative potentials. hKCNMB3 and hKCNMB4 have distinct effects on slo currents not observed with mKCNMB1 and hKCNMB2. Although we found that hHCNMB3 does interact with Hslo channels, its effects on Hslo1 channel properties were slight, increasing Hslo1 activation rates, In contrast, hKCNMB4 slows Hslo1 gating kinetics, and modulates the apparent calcium sensitivity of Hslo1. We found that the different effects of the beta subunits on some Hslo1 channel properties are calcium-dependent. mKCNMB1 and hKCNMB2 slow activation at 1 mu M but not at 10 mu M free calcium concentrations. hKCNMB4 decreases Hslo1 channel openings at low calcium concentrations but increases channel openings at high calcium concentrations. These results suggest that beta subunits in diverse tissue types fine-tune slo channel properties to the needs of a particular cell.	Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA; Icagen, Durham, NC 27703 USA	Howard Hughes Medical Institute; Stanford University	Aldrich, RW (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA.	raldrich@leland.stanford.edu		Brenner, Robert/0000-0002-1036-8031; Jegla, Timothy/0000-0001-8616-2390	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH048108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023294] Funding Source: NIH RePORTER; NIMH NIH HHS [MH48108] Funding Source: Medline; NINDS NIH HHS [NS23294] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ANWER K, 1993, AM J PHYSIOL, V265, pC976, DOI 10.1152/ajpcell.1993.265.4.C976; Catterall WA, 1999, ANN NY ACAD SCI, V868, P144, DOI 10.1111/j.1749-6632.1999.tb11284.x; Cox DH, 1997, J GEN PHYSIOL, V109, P633, DOI 10.1085/jgp.109.5.633; Cui J, 1997, J GEN PHYSIOL, V109, P647, DOI 10.1085/jgp.109.5.647; DiChiara TJ, 1997, J NEUROSCI, V17, P4942; Dworetzky SI, 1996, J NEUROSCI, V16, P4543; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; Hanner M, 1998, J BIOL CHEM, V273, P16289, DOI 10.1074/jbc.273.26.16289; Hanner M, 1997, P NATL ACAD SCI USA, V94, P2853, DOI 10.1073/pnas.94.7.2853; HARRIS DC, 1995, QUANTITATIVE CHEM AN, P49; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Jiang Z, 1999, GENOMICS, V55, P57, DOI 10.1006/geno.1998.5627; Joiner WJ, 1998, NAT NEUROSCI, V1, P462, DOI 10.1038/2176; Jones EMC, 1998, P ROY SOC B-BIOL SCI, V265, P685, DOI 10.1098/rspb.1998.0348; KNAUS HG, 1994, J BIOL CHEM, V269, P3921; KNAUS HG, 1994, J BIOL CHEM, V269, P23336; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Latorre R., 1994, HDB MEMBRANE CHANNEL, P79; Marrion NV, 1998, NATURE, V395, P900, DOI 10.1038/27674; MCMANUS OB, 1991, J PHYSIOL-LONDON, V443, P739, DOI 10.1113/jphysiol.1991.sp018861; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; Meera P, 1997, P NATL ACAD SCI USA, V94, P14066, DOI 10.1073/pnas.94.25.14066; Navaratnam DS, 1997, NEURON, V19, P1077, DOI 10.1016/S0896-6273(00)80398-0; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Nimigean CM, 1999, J GEN PHYSIOL, V113, P425, DOI 10.1085/jgp.113.3.425; Oberst C, 1997, ONCOGENE, V14, P1109, DOI 10.1038/sj.onc.1200930; Poolos NP, 1999, J NEUROSCI, V19, P5205; Prakriya M, 1999, J NEUROPHYSIOL, V81, P2267, DOI 10.1152/jn.1999.81.5.2267; Ramanathan K, 1999, SCIENCE, V283, P215, DOI 10.1126/science.283.5399.215; REINHART PH, 1995, J NEUROSCI, V15, P4572; Riazi MA, 1999, GENOMICS, V62, P90, DOI 10.1006/geno.1999.5975; ROBITAILLE R, 1993, NEURON, V11, P645, DOI 10.1016/0896-6273(93)90076-4; ROBITAILLE R, 1992, J NEUROSCI, V12, P297; Sah P, 1996, TRENDS NEUROSCI, V19, P150, DOI 10.1016/S0166-2236(96)80026-9; Saito M, 1997, J BIOL CHEM, V272, P11710, DOI 10.1074/jbc.272.18.11710; Sansom SC, 1997, J BIOL CHEM, V272, P9902; Stockand JD, 1998, PHYSIOL REV, V78, P723, DOI 10.1152/physrev.1998.78.3.723; Tanaka Y, 1997, J PHYSIOL-LONDON, V502, P545, DOI 10.1111/j.1469-7793.1997.545bj.x; TORO L, 1991, J BIOENERG BIOMEMBR, V23, P561, DOI 10.1007/BF00785811; TsengCrank J, 1996, P NATL ACAD SCI USA, V93, P9200, DOI 10.1073/pnas.93.17.9200; Vogalis F, 1996, AM J PHYSIOL-GASTR L, V271, pG629, DOI 10.1152/ajpgi.1996.271.4.G629; Wallner M, 1999, P NATL ACAD SCI USA, V96, P4137, DOI 10.1073/pnas.96.7.4137; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185; Wanner SG, 1999, BIOCHEMISTRY-US, V38, P5392, DOI 10.1021/bi983040c; Warbington L, 1996, INVERTEBR NEUROSCI, V2, P51, DOI 10.1007/BF02336660; Warrens AN, 1997, GENE, V186, P29, DOI 10.1016/S0378-1119(96)00674-9; Xia XM, 1999, J NEUROSCI, V19, P5255, DOI 10.1523/jneurosci.19-13-05255.1999; Xie JY, 1998, SCIENCE, V280, P443, DOI 10.1126/science.280.5362.443	51	397	412	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6453	6461		10.1074/jbc.275.9.6453	http://dx.doi.org/10.1074/jbc.275.9.6453			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692449	hybrid			2022-12-27	WOS:000085654400061
J	Cobb, BA; Petrash, JM				Cobb, BA; Petrash, JM			Characterization of alpha-crystallin-plasma membrane binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-LIKE ACTIVITY; EYE LENS TRANSPARENCY; A-CRYSTALLIN; BOVINE LENS; INTERMOLECULAR EXCHANGE; MOLECULAR-WEIGHT; SUBUNIT EXCHANGE; LIGHT-SCATTERING; B-CRYSTALLIN; PROTEINS	alpha-Crystallin, a large lenticular protein complex made up of two related subunits (alpha A- and alpha B-crystallin), is known to associate increasingly with fiber cell plasma membranes with age and/or the onset of cataract, To understand better the binding mechanism, we developed a sensitive membrane binding assay using lens plasma membranes and recombinant human alpha A- and alpha B-crystallins conjugated to a small fluorescent tag (Alexa350(R)). Both alpha A and alpha B homopolymer complexes, as well as a reconstituted 3:1 heteromeric complex, bind to lens membranes in a specific, saturable, and partially irreversible manner that is sensitive to both time and temperature. The amount of alpha-crystallin that binds to the membrane increases under acidic pH conditions and upon removal of exposed intrinsic membrane protein domains but is not affected at high ionic strength, suggesting that alpha-crystallin binds to the fiber cell plasma membranes mainly through hydrophobic interactions. The binding capacity and affinity for the reconstituted 3:1 heteromeric complex were measured to be 3.45 +/- 0.11 ng/mu g of membrane and 4.57 +/- 0.50 x 10(-4) mu g(-1) of membrane, respectively, The present membrane binding data support the hypothesis that the physical properties of a mixed alpha-crystallin complex may hold particular relevance for the function of alpha-crystallin within the lens.	Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Petrash, JM (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid Ave,Box 8096, St Louis, MO 63110 USA.				NEI NIH HHS [EY06901, EY02687, EY50673, P30 EY002687, F31 EY006901, F31 EY006901-03] Funding Source: Medline; NIDDK NIH HHS [P60 DK020579, P30 DK020579] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY002687, F31EY006901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020579, P60DK020579] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; Babizhayev MA, 1996, OPHTHALMIC RES, V28, P365, DOI 10.1159/000267931; BESSEMS GJH, 1986, EXP EYE RES, V43, P1019, DOI 10.1016/0014-4835(86)90079-5; BESSEMS GJH, 1983, EXP EYE RES, V37, P627, DOI 10.1016/0014-4835(83)90137-9; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BINDELS JG, 1983, MECH AGEING DEV, V21, P1, DOI 10.1016/0047-6374(83)90011-8; BLOEMENDAL H, 1981, MOL CELLULAR BIOL EY, P221; Borchman D, 1996, EXP EYE RES, V63, P407, DOI 10.1006/exer.1996.0130; BOURS J, 1987, OPHTHALMIC RES, V19, P235, DOI 10.1159/000265500; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; Boyle DL, 1996, CURR EYE RES, V15, P577, DOI 10.3109/02713689609000769; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; BRADY JP, 1998, INVEST OPHTH VIS SCI, V39, pB257; CARVER JA, 1992, FEBS LETT, V311, P143, DOI 10.1016/0014-5793(92)81386-Z; CARVER JA, 1994, BBA-PROTEIN STRUCT M, V1204, P195, DOI 10.1016/0167-4838(94)90009-4; CARVER JA, 1993, BIOCHIM BIOPHYS ACTA, V1164, P22, DOI 10.1016/0167-4838(93)90107-3; CENEDELLA RJ, 1992, CURR EYE RES, V11, P801, DOI 10.3109/02713689209000753; COLOSIMO A, 1976, J MOL BIOL, V100, P47, DOI 10.1016/S0022-2836(76)80033-2; Das BK, 1997, CURR EYE RES, V16, P303, DOI 10.1076/ceyr.16.4.303.10691; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; Derham BK, 1997, BBA-GEN SUBJECTS, V1336, P187, DOI 10.1016/S0304-4165(97)00029-9; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; FITZGERALD PG, 1991, CURR EYE RES, V10, P417, DOI 10.3109/02713689109001750; FLESCHNER CR, 1992, CURR EYE RES, V11, P739, DOI 10.3109/02713689209000748; GOPALAKRISHNAN S, 1992, INVEST OPHTH VIS SCI, V33, P2936; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; IFEANYI F, 1990, CURR EYE RES, V9, P259, DOI 10.3109/02713689009044521; IFEANYI F, 1991, EXP EYE RES, V52, P535, DOI 10.1016/0014-4835(91)90054-I; KEELING P, 1983, J MEMBRANE BIOL, V74, P217, DOI 10.1007/BF02332125; Lee JS, 1997, J PROTEIN CHEM, V16, P283, DOI 10.1023/A:1026305025816; Liang P, 1997, J CELL SCI, V110, P1431; MIESBAUER LR, 1994, J BIOL CHEM, V269, P12494; MULDERS JWM, 1985, EUR J BIOCHEM, V152, P721, DOI 10.1111/j.1432-1033.1985.tb09253.x; Panchuk-Voloshina N, 1999, J HISTOCHEM CYTOCHEM, V47, P1179, DOI 10.1177/002215549904700910; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; RUSSELL P, 1981, EXP EYE RES, V32, P511, DOI 10.1016/S0014-4835(81)80030-9; Sun TX, 1998, FEBS LETT, V430, P401, DOI 10.1016/S0014-5793(98)00707-8; TAKEMOTO L, 1992, CURR EYE RES, V11, P651, DOI 10.3109/02713689209000738; Tang DX, 1998, EXP EYE RES, V66, P559, DOI 10.1006/exer.1997.0467; Tang DX, 1999, OPHTHALMIC RES, V31, P452, DOI 10.1159/000055571; VANDENOETELAAR PJM, 1990, BIOCHEMISTRY-US, V29, P3488, DOI 10.1021/bi00466a010; VERETOUT F, 1989, J MOL BIOL, V205, P713, DOI 10.1016/0022-2836(89)90316-1; XIA JZ, 1994, BIOPHYS J, V66, P861, DOI 10.1016/S0006-3495(94)80862-8; Xia JZ, 1996, BIOPHYS J, V71, P2815, DOI 10.1016/S0006-3495(96)79477-8	47	91	93	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6664	6672		10.1074/jbc.275.9.6664	http://dx.doi.org/10.1074/jbc.275.9.6664			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692476	hybrid, Green Accepted			2022-12-27	WOS:000085654400088
J	Jiang, LH; Gawler, DJ; Hodson, N; Milligan, CJ; Pearson, HA; Porter, V; Wray, D				Jiang, LH; Gawler, DJ; Hodson, N; Milligan, CJ; Pearson, HA; Porter, V; Wray, D			Regulation of cloned cardiac L-type calcium channels by cGMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; CHICK HEART-CELLS; CA2+ CHANNEL; BETA-SUBUNIT; CYCLIC-GMP; XENOPUS-OOCYTES; SKELETAL-MUSCLE; NITRIC-OXIDE; FUNCTIONAL EXPRESSION; VENTRICULAR MYOCYTES	We have studied the effect of 8-bromo-cyclic GMP (8-Br-cGMP) on cloned cardiac L-type calcium channel currents to determine the site and mechanism of action underlying the functional effect. Rabbit cardiac alpha(1C) subunit, in the presence or absence of beta(1) subunit (rabbit skeletal muscle) or beta(2) subunit (rat cardiac/brain), was expressed in Xenopus oocytes, and two-electrode voltage-clamp recordings were made 2 or 3 days later. Application of 8-Br-cGMP caused decreases in calcium channel currents in cells expressing the alpha(1C) subunit, whether or not a beta subunit was co-expressed. No inhibition of currents by 8-Br-cGMP was observed in the presence of the protein kinase G inhibitor KT5823. Substitutions of serine residues by alanine were made at residues Ser(533) and Ser(1371) on the alpha(1C) subunit. As for wild type, the mutant S1371A exhibited inhibition of calcium channel currents by 8-Br-cGMP, whereas no effect of 8-Br-cGMP was observed for mutant S533A. Inhibition of calcium currents by 8-Br-cGMP was also observed in the additional presence of the alpha(2)delta subunit for wild type channels but not for the mutant S533A These results indicate that cGMP causes inhibition of L-type calcium channel currents by phosphorylation of the alpha(1C) subunit at position Ser(533) via the action of protein kinase G.	Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Wray, D (corresponding author), Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England.	d.wray@leeds.ac.uk	Jiang, Lin-Hua/D-2030-2010; Jiang, Lin-Hua/AAU-1078-2020	Jiang, Lin-Hua/0000-0001-6398-0411; Jiang, Lin-Hua/0000-0001-6398-0411; Hodson, Nigel/0000-0002-7486-1976				Alioua A, 1998, J BIOL CHEM, V273, P32950, DOI 10.1074/jbc.273.49.32950; BRICKLEY K, 1995, FEBS LETT, V364, P129, DOI 10.1016/0014-5793(95)00371-F; Campbell DL, 1996, J GEN PHYSIOL, V108, P277, DOI 10.1085/jgp.108.4.277; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P491; CHIK CL, 1995, J NEUROSCI, V15, P3104; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; DEWAARD, 1996, FEBS LETT, V380, P272; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; Dolphin AC, 1998, J PHYSIOL-LONDON, V506, P3, DOI 10.1111/j.1469-7793.1998.003bx.x; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FOURNIER F, 1993, FEBS LETT, V317, P118, DOI 10.1016/0014-5793(93)81504-S; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; GRIDER JR, 1993, AM J PHYSIOL, V264, pG334, DOI 10.1152/ajpgi.1993.264.2.G334; Gurnett CA, 1997, J BIOL CHEM, V272, P18508, DOI 10.1074/jbc.272.29.18508; HADDAD GE, 1995, MOL CELL BIOCHEM, V148, P89, DOI 10.1007/BF00929507; HARTZELL HC, 1986, NATURE, V323, P273, DOI 10.1038/323273a0; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HELL JW, 1993, J BIOL CHEM, V268, P19451; HILLE B, 1992, IONIC CHANNELS EXCIT, P83; Hosey MM, 1996, TRENDS CARDIOVAS MED, V6, P265, DOI 10.1016/S1050-1738(96)00109-0; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; JAHN H, 1988, EUR J BIOCHEM, V178, P535, DOI 10.1111/j.1432-1033.1988.tb14480.x; Johnson BD, 1997, J NEUROSCI, V17, P1243; Kamp TJ, 1996, J PHYSIOL-LONDON, V492, P89, DOI 10.1113/jphysiol.1996.sp021291; KOKATE TG, 1993, AM J PHYSIOL, V265, pC47, DOI 10.1152/ajpcell.1993.265.1.C47; LACERDA AE, 1994, BIOPHYS J, V66, P1833, DOI 10.1016/S0006-3495(94)80977-4; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; LEVI RC, 1989, PFLUG ARCH EUR J PHY, V413, P685, DOI 10.1007/BF00581823; McDonald LJ, 1996, P SOC EXP BIOL MED, V211, P1; MERY PF, 1993, J BIOL CHEM, V268, P26286; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Perets T, 1996, FEBS LETT, V384, P189, DOI 10.1016/0014-5793(96)00303-1; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHULZ R, 1994, TRENDS PHARMACOL SCI, V15, P255, DOI 10.1016/0165-6147(94)90321-2; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SINGERLAHAT D, 1992, FEBS LETT, V306, P113, DOI 10.1016/0014-5793(92)80980-U; SPERELAKIS N, 1994, MOL CELL BIOCHEM, V140, P103, DOI 10.1007/BF00926749; TOHSE N, 1991, CIRC RES, V69, P325, DOI 10.1161/01.RES.69.2.325; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; WAHLER GM, 1995, AM J PHYSIOL-CELL PH, V268, pC45, DOI 10.1152/ajpcell.1995.268.1.C45; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WILSON GG, 1994, PFLUG ARCH EUR J PHY, V428, P186, DOI 10.1007/BF00374857; XIONG ZL, 1995, J MOL CELL CARDIOL, V27, P75, DOI 10.1016/S0022-2828(08)80009-0; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8; YATANI A, 1994, CIRC RES, V75, P315, DOI 10.1161/01.RES.75.2.315; Yusaf SP, 1996, PFLUG ARCH EUR J PHY, V433, P91, DOI 10.1007/s004240050253; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0	57	87	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6135	6143		10.1074/jbc.275.9.6135	http://dx.doi.org/10.1074/jbc.275.9.6135			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692404	hybrid			2022-12-27	WOS:000085654400016
J	Mihara, H; Kurihara, T; Watanabe, T; Yoshimura, T; Esaki, N				Mihara, H; Kurihara, T; Watanabe, T; Yoshimura, T; Esaki, N			cDNA cloning, purification, and characterization of mouse liver selenocysteine lyase - Candidate for selenium delivery protein in selenoprotein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIFS-LIKE PROTEIN; ESCHERICHIA-COLI; AMINO-ACID; RAT-LIVER; IDENTIFICATION; SEQUENCE; ENZYME; SELENOPHOSPHATE; BIOSYNTHESIS; MECHANISM	Selenocysteine lyase (SCL) (EC 4.4.1.16) is a pyridoxal 5'-phosphate-dependent enzyme that specifically catalyzes the decomposition of L-selenocysteine to L-alanine and elemental selenium. The enzyme was proposed to function as a selenium delivery protein to selenophosphate synthetase in selenoprotein biosynthesis (Lacourciere, G. M., and Stadtman, T. C. (1998) J. Biol. Chem. 273, 30921-30926). We purified SCL from pig liver and determined its partial amino acid sequences. Mouse cDNA clones encoding peptides resembling pig SCL were found in the expressed sequence tag data base, and their sequences were used as probes to isolate full-length mouse liver cDNA. The cDNA for mouse SCL (mSCL) was determined to be 2,172 base pairs in length, containing an open reading frame encoding a polypeptide chain of 432 amino acid residues (M-r 47,201). We also determined the sequence of the N-terminal region of putative human SCL. These enzymes were shown to be distantly related in primary structure to NifS, which catalyzes the desulfurization of L-cysteine to provide sulfur for iron-sulfur clusters. The recombinant mSCL overproduced in Escherichia coli was a homodimer with the subunit M-r of 47,000. The enzyme was pyridoxal phosphate dependent and highly specific to L-selenocysteine (the k(cat)/K-m value for L-selenocysteine was about 4,200 times higher than that for L-cysteine). Reverse transcriptase-polymerase chain reaction and Western blot analyses revealed that mSCL is cytosolic and predominantly exists in the liver, kidney, and testis, where mouse selenophosphate synthetase is also abundant, supporting the view that mSCL functions in cooperation with selenophosphate synthetase in selenoprotein synthesis. This is the first report of the primary structure of mammalian SCL.	Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan	Kyoto University	Esaki, N (corresponding author), Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan.		Mihara, Hisaaki/F-2172-2010	Mihara, Hisaaki/0000-0002-5153-4403				BLOBEL G, 1966, P NATL ACAD SCI USA, V55, P1283, DOI 10.1073/pnas.55.5.1283; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOCAT P, 1987, METHOD ENZYMOL, V143, P493; COMBS GF, 1984, ANNU REV NUTR, V4, P257, DOI 10.1146/annurev.nu.04.070184.001353; ESAKI N, 1981, BIOCHEMISTRY-US, V20, P4492, DOI 10.1021/bi00518a039; ESAKI N, 1985, ARCH BIOCHEM BIOPHYS, V238, P418, DOI 10.1016/0003-9861(85)90182-1; ESAKI N, 1982, J BIOL CHEM, V257, P4386; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6324; FORSTROM JW, 1978, BIOCHEMISTRY-US, V17, P2639, DOI 10.1021/bi00606a028; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Guimaraes MJ, 1996, P NATL ACAD SCI USA, V93, P15086, DOI 10.1073/pnas.93.26.15086; GYULA K, 1999, EMBO J, V18, P3981; Lacourciere GM, 1998, J BIOL CHEM, V273, P30921, DOI 10.1074/jbc.273.47.30921; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Land T, 1998, MOL CELL, V2, P807, DOI 10.1016/S1097-2765(00)80295-6; LEINWEBER FJ, 1987, METHOD ENZYMOL, V143, P15; Mihara H, 1997, J BIOL CHEM, V272, P22417, DOI 10.1074/jbc.272.36.22417; Mihara H, 1999, J BIOL CHEM, V274, P14768, DOI 10.1074/jbc.274.21.14768; Nakai Y, 1998, FEBS LETT, V433, P143, DOI 10.1016/S0014-5793(98)00897-7; Patzer SI, 1999, J BACTERIOL, V181, P3307, DOI 10.1128/JB.181.10.3307-3309.1999; STADTMAN TC, 1979, P 3 INT S ORG SEL TE, P115; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; TANAKA H, 1987, METHOD ENZYMOL, V143, P240; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VERES Z, 1994, J BIOL CHEM, V269, P10597; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; ZINONI F, 1986, P NATL ACAD SCI USA, V83, P4650, DOI 10.1073/pnas.83.13.4650	30	71	80	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6195	6200		10.1074/jbc.275.9.6195	http://dx.doi.org/10.1074/jbc.275.9.6195			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692412	hybrid			2022-12-27	WOS:000085654400024
J	Nakamura, N; Yamamoto, A; Wada, Y; Futai, M				Nakamura, N; Yamamoto, A; Wada, Y; Futai, M			Syntaxin 7 mediates endocytic trafficking to late endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; CATHEPSIN-D; PROTEIN-TRANSPORT; MEMBRANE-FUSION; BINDING; VACUOLE; HOMOLOG; PATHWAY; GOLGI; IDENTIFICATION	The lysosome functions are ensured by accurate membrane trafficking in the cell. We found that mouse syntaxin 7 could complement yeast vam3 and pep12 mutants defective in docking/fusion to vacuolar and prevacuolar membranes, respectively. Immunohistochemical studies showed that syntaxin 7 is localized to late endosomes, but not to early endosomes. Induced expression of mutant syntaxin 7 blocked endocytic transport from early to late endosomes but did not block the transport of cathepsin D and lamp-2 from the trans-Golgi network to lysosomes. Thus, syntaxin 7 mediates the endocytic trafficking from early endosomes to late endosomes and lysosomes. These results also suggest that the biosynthetic pathway utilizes a different machinery from that of the endocytic pathway in the docking/fusion to late endosomes.	Osaka Univ, Inst Sci & Ind Res, Div Biol Sci, Osaka 5670047, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Osaka 5670047, Japan; Kansai Med Univ, Dept Physiol, Osaka 5708506, Japan	Osaka University; Japan Science & Technology Agency (JST); Kansai Medical University	Futai, M (corresponding author), Osaka Univ, Inst Sci & Ind Res, Div Biol Sci, Osaka 5670047, Japan.							Andrejewski N, 1999, J BIOL CHEM, V274, P12692, DOI 10.1074/jbc.274.18.12692; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; BASSHAM DC, 1995, P NATL ACAD SCI USA, V92, P7262, DOI 10.1073/pnas.92.16.7262; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Burd CG, 1997, MOL BIOL CELL, V8, P1089, DOI 10.1091/mbc.8.6.1089; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Clague MJ, 1999, CURR BIOL, V9, pR258, DOI 10.1016/S0960-9822(99)80158-4; Cowles CR, 1997, EMBO J, V16, P2769, DOI 10.1093/emboj/16.10.2769; Daro E, 1997, J CELL BIOL, V139, P1747, DOI 10.1083/jcb.139.7.1747; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; DELBRUCK R, 1994, EUR J CELL BIOL, V64, P7; DIMENT S, 1988, J BIOL CHEM, V263, P6901; Futai M, 1998, J BIOCHEM-TOKYO, V124, P259, DOI 10.1093/oxfordjournals.jbchem.a022105; GRANGER BL, 1990, J BIOL CHEM, V265, P12036; Gu F, 1999, FEBS LETT, V452, P61, DOI 10.1016/S0014-5793(99)00561-X; Gu F, 1997, J CELL BIOL, V139, P1183, DOI 10.1083/jcb.139.5.1183; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Jahn R, 1998, NATURE, V393, P14, DOI 10.1038/29871; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Le Borgne R, 1998, CURR OPIN CELL BIOL, V10, P499; Lewin DA, 1998, BBA-MOL CELL RES, V1401, P129, DOI 10.1016/S0167-4889(97)00130-4; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Nakamura N, 1997, J BIOL CHEM, V272, P11344; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; RICHO GR, 1994, J BIOL CHEM, V269, P14806; RIJNBOUTT S, 1992, J BIOL CHEM, V267, P15665; Sato MH, 1997, J BIOL CHEM, V272, P24530, DOI 10.1074/jbc.272.39.24530; Stefan CJ, 1999, J BIOL CHEM, V274, P1835, DOI 10.1074/jbc.274.3.1835; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; Traub LM, 1997, CURR OPIN CELL BIOL, V9, P527, DOI 10.1016/S0955-0674(97)80029-4; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WADA Y, 1992, J BIOL CHEM, V267, P18665; Wada Y, 1997, J CELL SCI, V110, P1299; Wang H, 1997, GENE, V199, P39, DOI 10.1016/S0378-1119(97)00343-0; WHITNEY JA, 1995, CELL, V83, P703; Wong SH, 1998, J BIOL CHEM, V273, P375, DOI 10.1074/jbc.273.1.375	44	89	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6523	6529		10.1074/jbc.275.9.6523	http://dx.doi.org/10.1074/jbc.275.9.6523			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692457	hybrid			2022-12-27	WOS:000085654400069
J	Ryle, MJ; Seefeldt, LC				Ryle, MJ; Seefeldt, LC			Hydrolysis of nucleoside triphosphates other than ATP by nitrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII NITROGENASE; IRON PROTEIN; FE-PROTEIN; MOFE-PROTEIN; ADENOSINE 5'-TRIPHOSPHATE; MGATP; COMPLEX; STATE; AZOFERREDOXIN; TRANSDUCTION	The hydrolysis of ATP to ADP and P-i is an integral part of all substrate reduction reactions catalyzed by nitrogenase. In this work, evidence is presented that nitrogenases isolated from Azotobacter vinelandii and Clostridium pasteurianum can hydrolyze MgGTP, MgITP, and MgUTP to their respective nucleoside diphosphates at rates comparable to those measured for MgATP hydrolysis. The reactions were dependent on the presence of both the iron (Fe) protein and the molybdenum-iron (MoFe) protein. The oxidation state of nitrogenase was found to greatly influence the nucleotide hydrolysis rates. MgATP hydrolysis rates were 20 times higher under dithionite reducing conditions (similar to 4000 nmol of MgADP formed per min/mg of Fe protein) as compared with indigo disulfonate oxidizing conditions (200 nmol of MgADP formed per min/mg of Fe protein). In contrast, MgGTP, MgITP, and MgUTP hydrolysis rates were significantly higher under oxidizing conditions (1400-2000 nmol of MgNDP formed per min/mg of Fe protein) as compared with reducing conditions (80-230 nmol of MgNDP formed per min/mg of Fe protein). The K-m values for MgATP, MgGTP, MgUTP, and MgITP hydrolysis were found to be similar (330-540 mu M) for both the reduced and oxidized states of nitrogenase, Incubation of Fe and MoFe proteins with each of the MgNTP molecules and AlF4- resulted in the formation of non-dissociating protein-protein complexes, presumably with trapped AlF4-. MgNDP. The implications of these results in understanding how nucleotide hydrolysis is coupled to substrate reduction in nitrogenase are discussed.	Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA	Utah System of Higher Education; Utah State University	Seefeldt, LC (corresponding author), Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA.	seefeldt@cc.usu.edu		Seefeldt, Lance/0000-0002-6457-9504				Burgess B. K., 1985, MOLYBDENUM ENZYMES, P161; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURNS RC, 1969, BIOCHIM BIOPHYS ACTA, V171, P253, DOI 10.1016/0005-2744(69)90158-2; CHRISTIANSEN J, 1995, J AM CHEM SOC, V117, P10017, DOI 10.1021/ja00145a012; CHROMY V, 1974, CLIN CHEM, V20, P1362; DEITS TL, 1990, J BIOL CHEM, V265, P3859; Duyvis MG, 1996, FEBS LETT, V380, P233, DOI 10.1016/0014-5793(96)00019-1; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; Hathaway G M, 1979, Methods Enzymol, V60, P495; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; LANZILOTTA WN, 1995, BIOCHEMISTRY-US, V34, P10713, DOI 10.1021/bi00034a003; Lanzilotta WN, 1996, BIOCHEMISTRY-US, V35, P7188, DOI 10.1021/bi9603985; LARSEN C, 1995, ARCH BIOCHEM BIOPHYS, V323, P215, DOI 10.1006/abbi.1995.9972; LJONES T, 1978, BIOCHEMISTRY-US, V17, P1866, DOI 10.1021/bi00603a010; Lowe D. J., 1995, Nitrogen fixation: fundamentals and applications. Proceedings of the 10th International Congress on Nitrogen Fixation, St. Petersburg, Russia, May 28-June 3 1995., P103; Miller RW, 1997, BIOCHEM J, V322, P737, DOI 10.1042/bj3220737; MILLER RW, 1993, BIOCHEM J, V291, P709, DOI 10.1042/bj2910709; Mortenson L. E., 1981, Current perspectives in nitrogen fixation., P75; MORTENSON LE, 1993, ADV ENZYMOL RAMB, V67, P299; MORTENSON LE, 1964, P NATL ACAD SCI USA, V52, P272, DOI 10.1073/pnas.52.2.272; Renner KA, 1996, BIOCHEMISTRY-US, V35, P5353, DOI 10.1021/bi960441o; Ryle MJ, 1996, BIOCHEMISTRY-US, V35, P4766, DOI 10.1021/bi960026w; Ryle MJ, 1996, BIOCHEMISTRY-US, V35, P9424, DOI 10.1021/bi9608572; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; Seefeldt LC, 1997, ACCOUNTS CHEM RES, V30, P260, DOI 10.1021/ar960260e; SEEFELDT LC, 1994, ANAL BIOCHEM, V221, P379, DOI 10.1006/abio.1994.1429; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; SEEFELDT LC, 1993, PROTEIN SCI, V2, P93; TSO MYW, 1972, BIOCHIM BIOPHYS ACTA, V267, P600, DOI 10.1016/0005-2728(72)90193-4; WALKER GA, 1974, BIOCHEMISTRY-US, V13, P2382, DOI 10.1021/bi00708a023; WATT GD, 1994, J INORG BIOCHEM, V53, P281, DOI 10.1016/0162-0134(94)85115-8; WATT GD, 1975, BIOCHEMISTRY-US, V14, P4266, DOI 10.1021/bi00690a019; WEAST RC, 1988, CRC HDB CHEM PHYSICS; WOLLE D, 1992, J BIOL CHEM, V267, P3667; YATES MG, 1991, BIOL NITROGEN FIXATI, P685; Yousafzai FK, 1999, BIOCHEM J, V339, P511, DOI 10.1042/0264-6021:3390511; ZUMFT WG, 1973, BIOCHIM BIOPHYS ACTA, V292, P413, DOI 10.1016/0005-2728(73)90047-9	37	19	19	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6214	6219		10.1074/jbc.275.9.6214	http://dx.doi.org/10.1074/jbc.275.9.6214			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692415	hybrid			2022-12-27	WOS:000085654400027
J	Graves, PR; Yu, LJ; Schwarz, JK; Gales, J; Sausville, EA; O'Connor, PM; Piwnica-Worms, H				Graves, PR; Yu, LJ; Schwarz, JK; Gales, J; Sausville, EA; O'Connor, PM; Piwnica-Worms, H			The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; TYROSINE KINASE; DNA-DAMAGE; NUCLEAR EXPORT; FISSION YEAST; G(2) ARREST; HUMAN WEE1; PHOSPHORYLATES CDC2; CHECKPOINT PATHWAY; DEPENDENT KINASES	A checkpoint operating in the G(2) phase of the cell cycle prevents entry into mitosis in the presence of DNA damage, UCN-01, a protein kinase inhibitor currently undergoing clinical trials for cancer treatment, abrogates G(2) checkpoint function and sensitizes p53-defective cancer cells to DNA damaging agents. In most species, the G(2) checkpoint prevents the Cdc25 phosphatase from removing inhibitory phosphate groups from the mitosis-promoting kinase Cdc2. This is accomplished by maintaining Cdc25 in a phosphorylated form that binds 14-3-3 proteins. The checkpoint kinases, Chk1 and Cds1, are proposed to regulate the interactions between human Cdc25C and 14-3-3 proteins by phosphorylating Cdc25C on serine 216. 14-3-3 proteins, in turn, function to keep Cdc25C out of the nucleus. Here we report that UCN-01 caused loss of both serine 216 phosphorylation and 14-3-3 binding to Cdc25C in DNA-damaged cells. In addition, UCN-01 potently inhibited the ability of Chk1 to phosphorylate Cdc25C in vitro. In contrast, Cds1 was refractory to inhibition by UCN-01 in vitro, and Cds1 was still phosphorylated in irradiated cells treated with UCN-01. Thus, neither Cds1 nor kinases upstream of Cds1, such as ataxia telangiectasia-mutated, are targets of UCN-01 action in vivo. Taken together our results identify the Chk1 kinase and the Cdc25C pathway as potential targets of G(2) checkpoint abrogation by UCN-01.	Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; NCI, Dev Therapeut Program, Div Canc Treatment & Diagnosis, NIH, Bethesda, MD 20892 USA	Howard Hughes Medical Institute; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Piwnica-Worms, H (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol & Physiol, Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.		Piwnica-Worms, Helen/C-5214-2012					ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Atherton-Fessler S, 1993, Semin Cell Biol, V4, P433, DOI 10.1006/scel.1993.1051; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FAN SJ, 1995, CANCER RES, V55, P1649; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HONDA R, 1992, BIOCHEM BIOPH RES CO, V186, P1333, DOI 10.1016/S0006-291X(05)81552-9; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LI JK, 1995, MOL BIOL CELL, V6, P1111, DOI 10.1091/mbc.6.9.1111; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Liu F, 1999, MOL CELL BIOL, V19, P5113; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; OConnor PM, 1997, CANCER SURV, V29, P151; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Shao RG, 1997, CANCER RES, V57, P4029; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Yang J, 1999, TRENDS CELL BIOL, V9, P207, DOI 10.1016/S0962-8924(99)01577-9; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yu LJ, 1998, J BIOL CHEM, V273, P33455, DOI 10.1074/jbc.273.50.33455; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zeng Y, 1999, MOL CELL BIOL, V19, P7410	65	496	514	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5600	5605		10.1074/jbc.275.8.5600	http://dx.doi.org/10.1074/jbc.275.8.5600			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681541	hybrid			2022-12-27	WOS:000085474500048
J	Ishiguro, K; Kadomatsu, K; Kojima, T; Muramatsu, H; Tsuzuki, S; Nakamura, E; Kusugami, K; Saito, H; Muramatsu, T				Ishiguro, K; Kadomatsu, K; Kojima, T; Muramatsu, H; Tsuzuki, S; Nakamura, E; Kusugami, K; Saito, H; Muramatsu, T			Syndecan-4 deficiency impairs focal adhesion formation only under restricted conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; MOLECULAR-CLONING; FIBRONECTIN; EXPRESSION; CELLS; GENE; ORGANIZATION; DOMAIN	Two domains of fibronectin deliver two different but cooperative signals required for focal adhesion formation. The signal from the cell-binding domain is mediated by integrins, whereas the signal from the heparin-binding domain is recognized by heparan sulfate proteoglycans, of which syndecan-4 has been hypothesized to be involved in focal adhesion formation. We generated mice deficient in syndecan-4 to study its role directly. Even in fibroblasts from syndecan-4-deficient mice, focal adhesions were formed, and actin fibers terminated normally at focal adhesions when they were cultured on coverslips coated with fibronectin or with a mixture of its cell-binding and heparin-binding fragments. However, when the cells were cultured on the cell-binding fragment and the heparin-binding fragment was added to the medium, focal adhesion formation was impaired in the syndecan-4 null fibroblasts as compared with that in wild-type cells. Therefore, syndecan-4 is essential for promoting focal adhesion formation only when the signal of the heparin-binding domain of fibronectin is delivered as a soluble form, most probably from the apical surface, When the signal is delivered as a substratum-bound form, other molecule(s) also participate(s) in the signal reception.	Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Internal Med 1, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Hlth Sci, Dept Med Technol, Higashi Ku, Nagoya, Aichi 4618673, Japan	Nagoya University; Nagoya University; Nagoya University	Muramatsu, T (corresponding author), Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		Kojima, Tetsuhito/I-6271-2014; Kadomatsu, Kenji/G-8083-2012	Kojima, Tetsuhito/0000-0002-1905-1065; Ishiguro, Kazuhiro/0000-0003-1776-2805; Tsuzuki, Shinobu/0000-0002-3209-3550				BACIU PC, 1995, MOL BIOL CELL, V6, P1503, DOI 10.1091/mbc.6.11.1503; BROWN GM, 1991, ANN OCCUP HYG, V35, P389, DOI 10.1093/annhyg/35.4.389; CAREY DJ, 1994, EXP CELL RES, V214, P12, DOI 10.1006/excr.1994.1228; CizmeciSmith G, 1997, ARTERIOSCL THROM VAS, V17, P172, DOI 10.1161/01.ATV.17.1.172; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; GRINNELL F, 1994, J INVEST DERMATOL, V103, P155, DOI 10.1111/1523-1747.ep12392625; Igakura T, 1998, DEV BIOL, V194, P152, DOI 10.1006/dbio.1997.8819; Ishiguro K, 1999, HISTOCHEM CELL BIOL, V112, P25, DOI 10.1007/s004180050388; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; Li JA, 1997, CIRC RES, V81, P785; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; Tsuzuki S, 1997, J BIOCHEM-TOKYO, V122, P17; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1988, COLLAGEN REL RES, V8, P155; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; Yamada KM, 1989, CURR OPIN CELL BIOL, V1, P956, DOI 10.1016/0955-0674(89)90065-3	22	114	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5249	5252		10.1074/jbc.275.8.5249	http://dx.doi.org/10.1074/jbc.275.8.5249			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681494	hybrid			2022-12-27	WOS:000085474500001
J	Kubo, Y; Konishi, S; Kawabe, T; Nada, S; Yamaguchi, A				Kubo, Y; Konishi, S; Kawabe, T; Nada, S; Yamaguchi, A			Proximity of periplasmic loops in the metal-tetracycline/H+ antiporter of Escherichia coli observed on site-directed chemical cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTANTS; LIGAND-INDUCED CHANGES; LACTOSE PERMEASE; SUPPRESSOR MUTATION; RESISTANCE PROTEIN; ACTIVE EFFLUX; MUTAGENESIS; TRANSPORT	Our precious study on second-site suppressor mutations of the Tn10-encoded metal-tetracycline/H+ anti-porter suggested that Leu(30) and Ala(354), located in periplasmic loop 1-2 and 11-12, respectively, are conformationally linked to each other (Kawabe, T., and Yamaguchi, A. (1999) FEES Lett. 457, 169-173), To determine the spatial proximity of these two residues, crosslinking gel-shift assays of the L30C/A354C double mutant were performed after the mutant had been oxidized with Cu2+/o-phenanthroline. The results indicated that Leu(30) and Ala(354) are close to each other but that Gly(62), which is located in cytoplasmic loop 2-3, and Ala(354) are distant from each other, as a negative control. Then, a single Cys residue was introduced into each of the six periplasmic loop regions (P1-P6), and eleven double mutants were constructed. Of these eleven double Cys mutants, the L30C/A354C and L30C/T235C mutants showed a mobility shift on oxidation, indicating that P1 is spatially close to P4 as well as P6, In contrast, the other nine mutants, L30C/S92C, L30C/S156C, L30C/S296C, S92C/S296C, S92C/T235C, S92C/A354C, S156C/T235C, S156C/S296C, and S156C/A354C, showed no mobility shift under oxidized conditions on intramolecular cross-linking. The S92C and S296C mutants showed dimerization on intermolecular cross-linking, indicating that P2 and P5 are located at the periphery of the helix bundle.	Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, Ibaraki, Osaka 5670047, Japan; Osaka Univ, Fac Pharmaceut Sci, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Ibaraki, Osaka 5670047, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Yamaguchi, A (corresponding author), Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, 8-1 Mihogaoka, Ibaraki, Osaka 5670047, Japan.		Kubo, Yoshiyuki/Q-6069-2019	Kubo, Yoshiyuki/0000-0002-7905-5666				GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; Kaback HR, 1997, CURR OPIN STRUC BIOL, V7, P537, DOI 10.1016/S0959-440X(97)80119-4; Kawabe T, 1999, FEBS LETT, V457, P169, DOI 10.1016/S0014-5793(99)01032-7; Kimura T, 1997, J BIOL CHEM, V272, P580; KIMURA T, 1995, FEBS LETT, V362, P47, DOI 10.1016/0014-5793(95)00205-N; Kimura T, 1997, BIOCHEMISTRY-US, V36, P6941, DOI 10.1021/bi9631879; Kimura T, 1998, J BIOL CHEM, V273, P5243, DOI 10.1074/jbc.273.9.5243; Kimura T, 1996, BIOCHEMISTRY-US, V35, P15896, DOI 10.1021/bi961568g; Kimura-Someya T, 1998, J BIOL CHEM, V273, P32806, DOI 10.1074/jbc.273.49.32806; Konishi S, 1999, FEBS LETT, V461, P315, DOI 10.1016/S0014-5793(99)01490-8; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEVY SB, 1992, ANTIMICROB AGENTS CH, V36, P695, DOI 10.1128/AAC.36.4.695; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; SOMEYA Y, 1995, BIOCHEMISTRY-US, V34, P7, DOI 10.1021/bi00001a002; Sun JZ, 1998, BIOCHEMISTRY-US, V37, P8020, DOI 10.1021/bi973192s; Sun JZ, 1997, BIOCHEMISTRY-US, V36, P11959, DOI 10.1021/bi971172k; Wang QD, 1999, BIOCHEMISTRY-US, V38, P3120, DOI 10.1021/bi982507g; Wu JH, 1998, BIOCHEMISTRY-US, V37, P15785, DOI 10.1021/bi981501o; Wu JH, 1999, BIOCHEMISTRY-US, V38, P2320, DOI 10.1021/bi982288z; Wu JH, 1999, BIOCHEMISTRY-US, V38, P1715, DOI 10.1021/bi982342b; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YAMAGUCHI A, 1990, FEBS LETT, V265, P17, DOI 10.1016/0014-5793(90)80872-G; YAMAGUCHI A, 1993, FEBS LETT, V324, P131, DOI 10.1016/0014-5793(93)81378-D; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P7490; YOSHIDA H, 1990, J BACTERIOL, V172, P6942, DOI 10.1128/jb.172.12.6942-6949.1990	27	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5270	5274		10.1074/jbc.275.8.5270	http://dx.doi.org/10.1074/jbc.275.8.5270			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681498	hybrid			2022-12-27	WOS:000085474500005
J	Matsumura, I; Tanaka, H; Kawasaki, A; Okajima, J; Daino, H; Hashimoto, K; Wakao, H; Nakajima, K; Kato, T; Miyazaki, H; Kanakura, Y				Matsumura, I; Tanaka, H; Kawasaki, A; Okajima, J; Daino, H; Hashimoto, K; Wakao, H; Nakajima, K; Kato, T; Miyazaki, H; Kanakura, Y			Increased D-type cyclin expression together with decreased cdc2 activity confers megakaryocytic differentiation of a human thrombopoietin-dependent hematopoietic cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAY; RECOMBINANT HUMAN THROMBOPOIETIN; MYELOBLASTIC-LEUKEMIA CELLS; MPL LIGAND; IN-VITRO; POLYPLOID MEGAKARYOCYTES; SHC PHOSPHORYLATION; CYTOPLASMIC DOMAIN; ACTIVATION; ERYTHROPOIETIN	At the late phase of megakaryocytopoiesis, megakaryocytes undergo endomitosis, which is characterized by DNA replication without cell division. Although a number of cell. cycle regulatory molecules have been identified, the precise roles of these molecules in megakaryocytic endomitosis are largely unknown. In a human interleukin-3-dependent cell line transfected with the thrombopoietin (TPO) receptor c-mpl (F-36P-mpl), either treatment with TPO or the overexpression of activated ras (Ha-Ras(G12V)) induced megakaryocytic maturation with polyploid formation, We found that TPO stimulation or Ha-Ras(G12V) expression led to up-regulation of cyclin D1, cyclin D2, and cyclin D3 expression. In addition, expression levels of cyclin A and cyclin B were reduced during the total course of both TPO- and Ha-Ras(G12V)-induced megakaryocytic differentiation, thereby leading to decreased cdc2 kinase activity. Neither the induced expression of cyclin DI, cyclin D2, or cyclin D3 nor the expression of a dominant negative form of cdc2 alone could induce megakaryocytic differentiation of F-36P-mpl cells. In contrast, overexpression of dominant negative cdc2 together with cyclin D1, cyclin D2, or cyclin D3 facilitated megakaryocytic differentiation in the absence of TPO. These results suggest that both D-type cyclin expression and decreased cdc2 kinase activity may participate in megakaryocytic differentiation.	Osaka Univ, Sch Med, Dept Hematol Oncol, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan; Helix Res Inst, Chiba 2920812, Japan; Osaka City Univ, Sch Med, Dept Immunol, Abeno Ku, Osaka 5458585, Japan; Kirin Brewery Co Ltd, Pharmaceut Res Lab, Takasaki, Gumma 3701202, Japan	Osaka University; Osaka University; Osaka Metropolitan University; Kirin Brewery Company Limited	Matsumura, I (corresponding author), Osaka Univ, Sch Med, Dept Hematol Oncol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Kato, Takashi/AFO-2557-2022; WAKAO, Hiroshi/A-4242-2012	Kato, Takashi/0000-0003-0384-7971; 				Adachi M, 1997, BLOOD, V90, P126; Alexander WS, 1996, EMBO J, V15, P6531, DOI 10.1002/j.1460-2075.1996.tb01044.x; Brodsky W Y, 1977, Int Rev Cytol, V50, P275; BROUDY VC, 1995, BLOOD, V85, P1719, DOI 10.1182/blood.V85.7.1719.bloodjournal8571719; CHIBA S, 1991, BLOOD, V78, P2261; deSauvage FJ, 1996, J EXP MED, V183, P651, DOI 10.1084/jem.183.2.651; FARESE AM, 1995, BLOOD, V86, P54, DOI 10.1182/blood.V86.1.54.bloodjournal86154; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Garcia P, 1996, ONCOGENE, V13, P695; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; GURNEY AL, 1994, SCIENCE, V265, P1445, DOI 10.1126/science.8073287; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KAUSHANSKY K, 1995, P NATL ACAD SCI USA, V92, P3234, DOI 10.1073/pnas.92.8.3234; Kikuchi J, 1997, BLOOD, V89, P3980, DOI 10.1182/blood.V89.11.3980; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; LIE M, 1996, GENE DEV, V10, P142; Matsumura I, 1998, MOL CELL BIOL, V18, P4282, DOI 10.1128/MCB.18.7.4282; Matsumura I, 1996, BLOOD, V88, P3074, DOI 10.1182/blood.V88.8.3074.bloodjournal8883074; MATSUMURA I, 1995, BLOOD, V86, P703, DOI 10.1182/blood.V86.2.703.bloodjournal862703; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Melemed AS, 1997, BLOOD, V90, P3462, DOI 10.1182/blood.V90.9.3462; Morse L, 1997, IMMUNITY, V6, P47, DOI 10.1016/S1074-7613(00)80241-1; Nagata Y, 1997, J CELL BIOL, V139, P449, DOI 10.1083/jcb.139.2.449; PIDARD D, 1983, J BIOL CHEM, V258, P2582; Porteu F, 1996, MOL CELL BIOL, V16, P2473; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; VARMUZA S, 1988, DEVELOPMENT, V102, P127; Vitrat N, 1998, BLOOD, V91, P3711; WANG ZY, 1995, BLOOD, V86, P3783, DOI 10.1182/blood.V86.10.3783.bloodjournal86103783; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; ZEIGLER FC, 1994, BLOOD, V84, P4045, DOI 10.1182/blood.V84.12.4045.bloodjournal84124045; Zhang Y, 1998, J BIOL CHEM, V273, P1387, DOI 10.1074/jbc.273.3.1387; Zhang Y, 1996, J BIOL CHEM, V271, P4266; Zimmet JM, 1997, MOL CELL BIOL, V17, P7248, DOI 10.1128/MCB.17.12.7248	43	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5553	5559		10.1074/jbc.275.8.5553	http://dx.doi.org/10.1074/jbc.275.8.5553			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681535	hybrid			2022-12-27	WOS:000085474500042
J	Pentikainen, MO; Oorni, K; Kovanen, PT				Pentikainen, MO; Oorni, K; Kovanen, PT			Lipoprotein lipase (LPL) strongly links native and oxidized low density lipoprotein particles to decorin-coated collagen - Roles for both dimeric and monomeric forms of LPL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY ATHEROSCLEROTIC PLAQUES; SMOOTH-MUSCLE CELLS; DIET-INDUCED ATHEROSCLEROSIS; AMERICAN-HEART-ASSOCIATION; PLASMA-LIPOPROTEINS; APOLIPOPROTEIN-E; HEPARAN-SULFATE; PREMATURE ATHEROSCLEROSIS; VASCULAR-LESIONS; ARTERIAL-WALL	Low density lipoprotein (LDL) and oxidized LDL are associated with collagen in the arterial intima, where the collagen is coated by the small proteoglycan decorin. When incubated in physiological ionic conditions, decorin-coated collagen bound only small amounts of native and oxidized LDL, the interaction being weak. When decorin-coated collagen was first allowed to bind lipoprotein lipase (LPL), binding of native and oxidized LDL increased dramatically (23- and 7-fold, respectively). This increase depended on strong interactions between LPL that was bound to the glycosaminoglycan chains of the collagen-bound decorin and native and oxidized LDL (kDa 12 and 5.9 nM respectively). To distinguish between binding to monomeric (inactive) and dimeric (catalytically active) forms of LPL, affinity chromatography on heparin columns was conducted, which showed that native LDL bound to the monomeric LPL, whereas oxidized LDL, irrespective of the type of modification (Cu2+, 2,2'-azobis(2-amidinopropane)hydrochloride, hypochlorite, or soybean 15-lipoxygenase), bound preferably to dimeric LPL, However, catalytic activity of LPL was not required for binding to oxidized LDL. Finally, immunohistochemistry of atherosclerotic lesions of human coronary arteries revealed specific areas in which LDL, LPL, decorin, and collagen type I were present. The results suggest that LPL can retain LDL in atherosclerotic lesions along decorin-coated collagen fibers.	Wihuri Res Inst, SF-00140 Helsinki, Finland	Wihuri Research Institute	Pentikainen, MO (corresponding author), Wihuri Res Inst, Kalliolinnantie 4, SF-00140 Helsinki, Finland.		Oorni, Katariina/G-2484-2011	Oorni, Katariina/0000-0002-9525-0250				Auerbach BJ, 1996, J BIOL CHEM, V271, P1329, DOI 10.1074/jbc.271.3.1329; Babaev VR, 1999, J CLIN INVEST, V103, P1697, DOI 10.1172/JCI6117; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Benlian P, 1996, NEW ENGL J MED, V335, P848, DOI 10.1056/NEJM199609193351203; Bergo M, 1996, BIOCHEM J, V313, P893, DOI 10.1042/bj3130893; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; Boren J, 1998, CIRCULATION, V98, P314; Boren J, 1998, J CLIN INVEST, V101, P2658, DOI 10.1172/JCI2265; BROWN MS, 1981, SCIENCE, V212, P628, DOI 10.1126/science.6261329; CAMEJO G, 1982, ADV LIPID RES, V19, P1; Carrero P, 1996, BBA-LIPID LIPID MET, V1299, P198, DOI 10.1016/0005-2760(95)00209-X; DICORLETO PE, 1975, P SOC EXP BIOL MED, V148, P1101, DOI 10.3181/00379727-148-38696; GOLDBERG IJ, 1986, J CLIN INVEST, V78, P1523, DOI 10.1172/JCI112744; Goldberg IJ, 1996, J LIPID RES, V37, P693; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hendriks WL, 1996, BIOCHEM J, V314, P563, DOI 10.1042/bj3140563; Holvoet P, 1998, ARTERIOSCL THROM VAS, V18, P415, DOI 10.1161/01.ATV.18.3.415; JONASSON L, 1987, J LIPID RES, V28, P437; Jukema JW, 1996, CIRCULATION, V94, P1913, DOI 10.1161/01.CIR.94.8.1913; KHOO JC, 1981, J BIOL CHEM, V256, P7105; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lookene A, 1997, BIOCHEMISTRY-US, V36, P5267, DOI 10.1021/bi962699k; Lookene A, 1996, BIOCHEMISTRY-US, V35, P12155, DOI 10.1021/bi960008e; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lucas M, 1997, J BIOL CHEM, V272, P13000, DOI 10.1074/jbc.272.20.13000; Makoveichuk E, 1998, BIOCHEM BIOPH RES CO, V252, P703, DOI 10.1006/bbrc.1998.9596; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; NIEVELSTEINPOST P, 1994, ARTERIOSCLER THROMB, V14, P1151, DOI 10.1161/01.ATV.14.7.1151; O'Brien KD, 1998, CIRCULATION, V98, P519, DOI 10.1161/01.CIR.98.6.519; OBRIEN KD, 1992, J CLIN INVEST, V89, P1544, DOI 10.1172/JCI115747; OBRIEN KD, 1994, AM J PATHOL, V144, P538; Olivecrona G, 1997, METHOD ENZYMOL, V286, P102; Oorni K, 1997, J BIOL CHEM, V272, P21303, DOI 10.1074/jbc.272.34.21303; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; Pentikainen MO, 1997, J BIOL CHEM, V272, P7633, DOI 10.1074/jbc.272.12.7633; PIHA M, 1995, BIOCHEMISTRY-US, V34, P10120, DOI 10.1021/bi00032a004; POSNER I, 1983, ARCH BIOCHEM BIOPHYS, V226, P306, DOI 10.1016/0003-9861(83)90297-7; REYMER PWA, 1995, NAT GENET, V10, P28, DOI 10.1038/ng0595-28; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SAXENA U, 1989, J BIOL CHEM, V264, P4349; SAXENA U, 1993, BIOCHEM BIOPH RES CO, V194, P769, DOI 10.1006/bbrc.1993.1888; SAXENA U, 1993, J BIOL CHEM, V268, P14812; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; Schissel SL, 1996, J CLIN INVEST, V98, P1455, DOI 10.1172/JCI118934; Semenkovich CF, 1998, J LIPID RES, V39, P1141; Shimada M, 1996, P NATL ACAD SCI USA, V93, P7242, DOI 10.1073/pnas.93.14.7242; SIVARAM P, 1994, J BIOL CHEM, V269, P9409; STARY HC, 1995, CIRCULATION, V92, P1355, DOI 10.1161/01.CIR.92.5.1355; STARY HC, 1994, ARTERIOSCLER THROMB, V14, P840, DOI 10.1161/01.ATV.14.5.840; Tabas I, 1999, ANNU REV NUTR, V19, P123, DOI 10.1146/annurev.nutr.19.1.123; Tozer EC, 1997, CIRC RES, V80, P208, DOI 10.1161/01.RES.80.2.208; VANCE JE, 1982, ARTERIOSCLEROSIS, V2, P390, DOI 10.1161/01.ATV.2.5.390; VILELLA E, 1993, J LIPID RES, V34, P1555; VOLKER W, 1986, J HISTOCHEM CYTOCHEM, V34, P1293, DOI 10.1177/34.10.2427568; Yagyu H, 1999, J LIPID RES, V40, P1677; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P10143, DOI 10.1073/pnas.88.22.10143; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; Zambon A, 1996, J LIPID RES, V37, P2394	61	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5694	5701		10.1074/jbc.275.8.5694	http://dx.doi.org/10.1074/jbc.275.8.5694			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681554	hybrid			2022-12-27	WOS:000085474500061
J	Schoepp, B; Breton, J; Parot, P; Vermeglio, A				Schoepp, B; Breton, J; Parot, P; Vermeglio, A			Relative orientation of the hemes of the cytochrome bc(1) complexes from Rhodobacter sphaeroides, Rhodospirillum rubrum, and beef heart mitochondria - A linear dichroism study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL-PROTEIN COMPLEXES; HIGHER-PLANTS; BC1 COMPLEX; TETRAHEME CYTOCHROME; THYLAKOID MEMBRANE; ELECTRON-TRANSFER; C OXIDOREDUCTASE; REDOX PROPERTIES; REACTION CENTERS; BACTERIA	The orientation of the chromophores in the cytochrome bc(1) of Rhodospirillum rubrum, Rhodobacter sphaeroides, and beef heart mitochondria is reported, The combination of redox-resolved absorption spectrophotometry and linear dichroism experiments at low temperature allows the determination of the orientation of the three hemes with respect to the membrane plane. The orientations of the b(H)-and b(L)-hemes of the R. sphaeroides and beef heart mitochondrial complexes are similar to those determined by crystallographic studies of the mitochondrial cytochrome bc(1). On the other hand the orientations of the b-hemes of the R. rubrum complex lead to the conclusion that the b(H)-heme is more perpendicular to the membrane plane than the b(L)-heme. This could be explained by a specific organization of the b-hemes due to subunit composition of the complex or, alternatively, to a different spatial position of the heme transitions with respect to the porphyrin macrocycle compared with the other complexes. Moreover, our results demonstrate a different orientation of the heme c(1) of the three studied complexes in comparison to crystallographic studies. This difference may arise from the above hypothesis on the transitions of the heme or from flexibility of this subunit in function of its redox state.	Inst Biol Struct & Microbiol, CNRS UPR 9036, Lab Bioenerget & Ingn Prot, F-13402 Marseille 20, France; CEA, Dept Biol Cellulaire & Mol, Sect Bioenerget, F-91191 Gif Sur Yvette, France; CEA, DSV, DEVM, Lab Bioenerget Cellulaire, F-13108 St Paul Les Durance, France	UDICE-French Research Universities; Aix-Marseille Universite; CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA	Schoepp, B (corresponding author), Inst Biol Struct & Microbiol, CNRS UPR 9036, Lab Bioenerget & Ingn Prot, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	schoepp@ibsm.cnrs-mrs.fr	Schoepp-Cothenet, Barbara/AAH-8911-2021; PAROT, Pierre/B-3959-2012; Parot, Pierre/Q-4444-2019; PAROT, Pierre/C-1742-2017	Schoepp-Cothenet, Barbara/0000-0002-6820-4478; 				Adar F., 1978, PORPHYRINS, P167; ANDREWS KM, 1990, BIOCHEMISTRY-US, V29, P2645, DOI 10.1021/bi00463a004; ARUTJUNJAN AM, 1978, FEBS LETT, V95, P40, DOI 10.1016/0014-5793(78)80047-7; BERRY EA, 1991, J BIOL CHEM, V266, P9064; BRETON J, 1977, THESIS U PARIS 11 OR; Brugna M, 1998, J BACTERIOL, V180, P3719, DOI 10.1128/JB.180.14.3719-3723.1998; Brugna M, 1999, J BIOL CHEM, V274, P16766, DOI 10.1074/jbc.274.24.16766; BRUGNA M, 2000, IN PRESS P NATL ACAD; CLAYTON RK, 1960, BIOCHIM BIOPHYS ACTA, V37, P503, DOI 10.1016/0006-3002(60)90507-2; CRAMER WA, 1994, CURR OPIN STRUC BIOL, V4, P536, DOI 10.1016/S0959-440X(94)90216-X; Crofts AR, 1998, CURR OPIN STRUC BIOL, V8, P501, DOI 10.1016/S0959-440X(98)80129-2; CROWDER MS, 1982, FEBS LETT, V144, P204, DOI 10.1016/0014-5793(82)80638-8; EATON WA, 1967, J CHEM PHYS, V46, P2533, DOI 10.1063/1.1841081; ERECINSKA M, 1978, BIOCHIM BIOPHYS ACTA, V501, P63, DOI 10.1016/0005-2728(78)90095-6; GABELLINI N, 1983, FEBS LETT, V153, P146, DOI 10.1016/0014-5793(83)80136-7; GARCIA D, 1994, BIOCHIMIE, V76, P666, DOI 10.1016/0300-9084(94)90143-0; Gouterman M., 1978, PORPHYRINS, P1, DOI DOI 10.1016/B978-0-12-220103-5.50008-8; GUNER S, 1991, BIOCHIM BIOPHYS ACTA, V1058, P269, DOI 10.1016/S0005-2728(05)80247-6; HAWORTH P, 1982, BIOCHIM BIOPHYS ACTA, V682, P152, DOI 10.1016/0005-2728(82)90129-3; HOFRICHTER J, 1976, ANNU REV BIOPHYS BIO, V5, P511, DOI 10.1146/annurev.bb.05.060176.002455; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Kallas T, 1994, MOL BIOL CYANOBACTER, V1, P259, DOI DOI 10.1007/978-94-011-0227-8_9; KRIAUCIUNAS A, 1989, BIOCHIM BIOPHYS ACTA, V976, P70, DOI 10.1016/S0005-2728(89)80190-2; Le Moigne C, 1999, BIOCHEMISTRY-US, V38, P1066, DOI 10.1021/bi9805487; LEMESLEMEUNIER D, 1993, J BIOL CHEM, V268, P15626; Menin L, 1997, BIOCHEMISTRY-US, V36, P12175, DOI 10.1021/bi971162j; NELSON BD, 1974, BIOCHIM BIOPHYS ACTA, V357, P358, DOI 10.1016/0005-2728(74)90025-5; PALMER G, 1994, BIOCHEMISTRY-US, V33, P176, DOI 10.1021/bi00167a023; RIEDEL A, 1991, J BIOL CHEM, V266, P17838; Schoepp B, 2000, J BIOL CHEM, V275, P5275, DOI 10.1074/jbc.275.8.5275; TAPIE P, 1982, BIOCHIM BIOPHYS ACTA, V682, P339, DOI 10.1016/0005-2728(82)90047-0; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; VERMEGLIO A, 1989, FEBS LETT, V243, P259, DOI 10.1016/0014-5793(89)80140-1; YU L, 1991, BIOCHEMISTRY-US, V30, P4934, DOI 10.1021/bi00234a014; Yurkov V, 1998, PHOTOSYNTH RES, V57, P129, DOI 10.1023/A:1006087403692; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	36	6	15	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5284	5290		10.1074/jbc.275.8.5284	http://dx.doi.org/10.1074/jbc.275.8.5284			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681500	hybrid			2022-12-27	WOS:000085474500007
J	Kimura, Y; Takaoka, M; Tanaka, S; Sassa, H; Tanaka, K; Polevoda, B; Sherman, F; Hirano, H				Kimura, Y; Takaoka, M; Tanaka, S; Sassa, H; Tanaka, K; Polevoda, B; Sherman, F; Hirano, H			N-alpha-acetylation and proteolytic activity of the yeast 20 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-DEGRADATION; EUKARYOTIC CELLS; SITE FORMATION; RAT-LIVER; ACETYLTRANSFERASE; PURIFICATION; IDENTIFICATION; ACIDOPHILUM; COMPLETION	N-alpha-Acetylation, catalyzed co-translationally with N-alpha-acetyltransferase (NAT), is the most common modifications of eukaryotic proteins. In yeast, there are at least three NATs: NAT1, MAK3, and NAT3, The 20 S proteasome subunits were purified from the normal strain and each of the deletion mutants, nat1, mak3, and nat3. The electrophoretic mobility of these subunits was compared by two-dimensional gel electrophoresis. Shifts toward the alkaline side of the gel and unblocking of the N terminus of certain of the subunits in one or another of the mutants indicated that the alpha 1, alpha 2, alpha 3, alpha 4, alpha 7, and beta 3 subunits were acetylated with NAT1, the alpha 5 and alpha 6 subunits were acetylated with MAK3, and the beta 4 subunit was acetylated with NAT3. Furthermore, the Ac-Met-Phe-Leu and Ac-Met-Phe-Arg termini of the alpha 5 and alpha 6 subunits, respectively, extended the known types of MAK3 substrates, Thus, nine subunits were N (alpha)-acetylated, whereas the remaining five were processed, resulting in the loss of the N-terminal region. The 20 S proteasomes derived from either the natl mutant or the normal strain were similar in respect to chymotrypsinlike, trypsin-like, and peptidylglutamyl peptide hydrolyzing activities in vitro, suggesting that N-alpha-acetylation does not play a major functional role in these activities. However, the chymotrypsin-like activity in the absence of sodium dodecyl sulfate was slightly higher in the natl mutant than in the normal strain.	Yokohama City Univ, Kihara Inst Biol Res, Grad Sch Integrated Sci, Yokohama, Kanagawa 2440813, Japan; Kamakura Womens Coll, Kamakura, Kanagawa 2478511, Japan; Tokyo Metropolitan Inst Med Sci, Tokyo 1138613, Japan; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	Yokohama City University; Kamakura Women's University; Tokyo Metropolitan Institute of Medical Science; University of Rochester	Hirano, H (corresponding author), Yokohama City Univ, Kihara Inst Biol Res, Grad Sch Integrated Sci, Maioka 641-12, Yokohama, Kanagawa 2440813, Japan.		Polevoda, Bogdan/A-4880-2008; Sassa, Hidenori/Q-7561-2018		NIGMS NIH HHS [R01 GM12702] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM012702] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHSTETTER T, 1984, J BIOL CHEM, V259, P3344; Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; Arendt CS, 1999, EMBO J, V18, P3575, DOI 10.1093/emboj/18.13.3575; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JL, 1979, J BIOL CHEM, V254, P1447; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HIRANO H, 1982, PHYTOCHEMISTRY, V21, P1513, DOI 10.1016/0031-9422(82)85008-5; HIRANO H, 1990, ELECTROPHORESIS, V11, P573, DOI 10.1002/elps.1150110708; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOUGH R, 1987, J BIOL CHEM, V262, P8303; Jager S, 1999, J MOL BIOL, V291, P997, DOI 10.1006/jmbi.1999.2995; LEE FJS, 1989, J BACTERIOL, V171, P5795, DOI 10.1128/jb.171.11.5795-5802.1989; LEE FJS, 1989, FEBS LETT, V256, P139, DOI 10.1016/0014-5793(89)81734-X; LEE FJS, 1988, J BIOL CHEM, V263, P14948; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1998, UBIQUITIN BIOL CELL, P127; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; MOLEVODA B, 1999, EMBO J, V18, P6155; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; Ramos PC, 1998, CELL, V92, P489, DOI 10.1016/S0092-8674(00)80942-3; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; SHERMAN F, 1993, METHODS IN PROTEIN SEQUENCE ANALYSIS, P173; Smith MW, 1997, PLANT PHYSIOL, V113, P281, DOI 10.1104/pp.113.1.281; TANAKA K, 1988, J BIOL CHEM, V263, P16209; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TERCERO JC, 1992, J BIOL CHEM, V267, P20277; TERCERO JC, 1993, J BACTERIOL, V175, P3192, DOI 10.1128/JB.175.10.3192-3194.1993; TOKUNAGA F, 1990, FEBS LETT, V263, P373, DOI 10.1016/0014-5793(90)81417-M	35	93	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4635	4639		10.1074/jbc.275.7.4635	http://dx.doi.org/10.1074/jbc.275.7.4635			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671491	hybrid			2022-12-27	WOS:000085378200017
J	Lickert, H; Bauer, A; Kemler, R; Stappert, J				Lickert, H; Bauer, A; Kemler, R; Stappert, J			Casein kinase II phosphorylation of E-cadherin increases E-cadherin/beta-catenin interaction and strengthens cell-cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; ALPHA-CATENIN; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; COMPLEX; BINDING; PLAKOGLOBIN; UVOMORULIN; PROTEINS; APC	beta-Catenin, a member of the Armadillo repeat protein family, binds directly to the cytoplasmic domain of E-cadherin, linking it via alpha-catenin to the actin cytoskeleton. A 30-amino acid region within the cytoplasmic domain of E-cadherin, conserved among all classical cadherins, has been shown to be essential for beta-catenin binding. This region harbors several putative casein kinase II (CKII) and glycogen synthase kinase-3 beta (GSK-3 beta) phosphorylation sites and is highly phosphorylated, Here we report that in vitro this region is indeed phosphorylated by CKII and GSK-3 beta, which results in an increased binding of beta-catenin to E-cadherin, Additionally, in mouse NIH3T3 fibroblasts expression of E-cadherin with mutations in putative CKII sites resulted in reduced cell-cell contacts. Thus, phosphorylation of the E-cadherin cytoplasmic domain by CKII and GSK-3 beta appears to modulate the affinity between beta-catenin and E-cadherin, ultimately modifying the strength of cell-cell adhesion.	Max Planck Inst Immunbiol, Dept Mol Embryol, D-79108 Freiburg, Germany	Max Planck Society	Stappert, J (corresponding author), Max Planck Inst Immunbiol, Dept Mol Embryol, Stubeweg 51, D-79108 Freiburg, Germany.		Lickert, Heiko/K-9045-2013					Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ABERLE H, 1994, J CELL SCI, V107, P3655; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BUTZ S, 1994, FEBS LETT, V355, P195, DOI 10.1016/0014-5793(94)01205-9; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huber O, 1997, J CELL SCI, V110, P1759; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; Obama H, 1997, J BIOL CHEM, V272, P11017; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sefton M, 1996, MOL REPROD DEV, V44, P77, DOI 10.1002/(SICI)1098-2795(199605)44:1&lt;77::AID-MRD9&gt;3.0.CO;2-Q; Serres M, 1997, EXP CELL RES, V231, P163, DOI 10.1006/excr.1996.3443; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; STAPPERT J, 1999, ADV MOL CEL, V28, P27; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492	33	158	161	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5090	5095		10.1074/jbc.275.7.5090	http://dx.doi.org/10.1074/jbc.275.7.5090			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671552	hybrid			2022-12-27	WOS:000085378200078
J	Lin, F; Blake, DL; Callebaut, I; Skerjanc, IS; Holmer, L; McBurney, MW; Paulin-Levasseur, M; Worman, HJ				Lin, F; Blake, DL; Callebaut, I; Skerjanc, IS; Holmer, L; McBurney, MW; Paulin-Levasseur, M; Worman, HJ			MAN1, an inner nuclear membrane protein that shares the LEM domain with lamina-associated polypeptide 2 and emerin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DREIFUSS MUSCULAR-DYSTROPHY; PRIMARY BILIARY-CIRRHOSIS; B-RECEPTOR; INTEGRAL PROTEIN; ENVELOPE PROTEIN; CDNA CLONING; DNA-BINDING; IDENTIFICATION; CHROMATIN; GENE	The "MAN antigens" are polypeptides recognized by autoantibodies from a patient with a collagen vascular disease and localized to the nuclear envelope. We now show that one of the human MAN antigens termed MAN1 is a 82.3-kDa protein with an amino-terminal domain followed by two hydrophobic segments and a carboxyl-terminal tail. The MAN1 gene contains seven protein-coding exons and is assigned to human chromosome 12q14, Its mRNA is approximately 5.5 kilobases and is detected in several different cell types that were examined. Cell extraction experiments show that MAN1 is an integral membrane protein, When expressed in transfected cells, MAN1 is exclusively targeted to the nuclear envelope, consistent with an inner nuclear membrane localization. Protein sequence analysis reveals that MAN1 shares a conserved globular domain of approximately 40 amino acids, which we term the LEM module, with inner nuclear membrane proteins lamina-associated polypeptide 2 and emerin. The LEM module is also present in two proteins of Caenorhabditis elegans. These results show that MAN1 is an integral protein of the inner nuclear membrane that shares the LEM module with other proteins of this subcellular localization.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Anat & Cell Biol, New York, NY 10032 USA; Univ Ottawa, Dept Biol, Ottawa, ON K1N 6N5, Canada; Univ Paris 06, LMCP, CNRS, UMR 7590, F-75252 Paris 05, France; Univ Paris 07, LMCP, CNRS, UMR 7590, F-75252 Paris 05, France; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; Univ Ottawa, Dept Med, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Ottawa Reg Canc Ctr, Ottawa, ON K1N 6N5, Canada	Columbia University; Columbia University; University of Ottawa; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Western University (University of Western Ontario); University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Worman, HJ (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St,10th Floor,Rm 508, New York, NY 10032 USA.		Skerjanc, Ilona/AAN-3318-2020; Holmer, Lars/N-7736-2019	Holmer, Lars/0000-0003-3629-0049	NCI NIH HHS [5 P30 CA13696, R01-CA66974] Funding Source: Medline; NCRR NIH HHS [1S10 RR10506] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066974, P30CA013696] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR010506] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AsheryPadan R, 1997, J BIOL CHEM, V272, P2493; Berger R, 1996, GENOME RES, V6, P361, DOI 10.1101/gr.6.5.361; BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; Collas P, 1996, J CELL BIOL, V135, P1715, DOI 10.1083/jcb.135.6.1715; Courvalin JC, 1997, SEMIN LIVER DIS, V17, P79, DOI 10.1055/s-2007-1007185; COURVALIN JC, 1990, J EXP MED, V172, P961, DOI 10.1084/jem.172.3.961; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Dechat T, 1998, EMBO J, V17, P4887, DOI 10.1093/emboj/17.16.4887; Duan Y, 1998, SCIENCE, V282, P740, DOI 10.1126/science.282.5389.740; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; EMERY AEH, 1989, J MED GENET, V26, P637, DOI 10.1136/jmg.26.10.637; Furukawa K, 1997, BIOCHEM BIOPH RES CO, V238, P240, DOI 10.1006/bbrc.1997.7235; Furukawa K, 1999, J CELL SCI, V112, P2485; FURUKAWA K, 1995, EMBO J, V14, P1626, DOI 10.1002/j.1460-2075.1995.tb07151.x; Furukawa K, 1998, J BIOL CHEM, V273, P4213, DOI 10.1074/jbc.273.7.4213; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HAREL A, 1989, J CELL SCI, V94, P463; HARRIS CA, 1995, GENOMICS, V28, P198, DOI 10.1006/geno.1995.1131; HARRIS CA, 1994, P NATL ACAD SCI USA, V91, P6283, DOI 10.1073/pnas.91.14.6283; Holmer L, 1998, GENOMICS, V54, P469, DOI 10.1006/geno.1998.5615; Kawahire S, 1997, J BIOCHEM-TOKYO, V121, P881, DOI 10.1093/oxfordjournals.jbchem.a021669; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lang C, 1999, J CELL SCI, V112, P749; Manilal S, 1996, HUM MOL GENET, V5, P801, DOI 10.1093/hmg/5.6.801; MARTIN L, 1995, J BIOL CHEM, V270, P8822, DOI 10.1074/jbc.270.15.8822; McKnight CJ, 1997, NAT STRUCT BIOL, V4, P180, DOI 10.1038/nsb0397-180; Nagano A, 1996, NAT GENET, V12, P254, DOI 10.1038/ng0396-254; Ostlund C, 1999, J CELL SCI, V112, P1709; PADAN R, 1990, J BIOL CHEM, V265, P7808; PaulinLevasseur M, 1996, CHROMOSOMA, V104, P367, DOI 10.1007/s004120050128; RACKWITZ HR, 1984, GENE, V30, P195, DOI 10.1016/0378-1119(84)90120-3; Rolls MM, 1999, J CELL BIOL, V146, P29, DOI 10.1083/jcb.146.1.29; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SAKAI RK, 1988, SCIENCE, V239, P487; Sambrook J., 2002, MOL CLONING LAB MANU; SCHULER E, 1994, J BIOL CHEM, V269, P11312; SENIOR A, 1988, J CELL BIOL, V107, P2029, DOI 10.1083/jcb.107.6.2029; Skerjanc IS, 1996, J BIOL CHEM, V271, P3555, DOI 10.1074/jbc.271.7.3555; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; SOULLAM B, 1993, J CELL BIOL, V120, P1093, DOI 10.1083/jcb.120.5.1093; SOULLAM B, 1995, J CELL BIOL, V130, P15, DOI 10.1083/jcb.130.1.15; Wilhelmsen KC, 1996, ANN NEUROL, V39, P507, DOI 10.1002/ana.410390413; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; WORMAN HJ, 1991, HEPATOLOGY, V14, P1269, DOI 10.1016/0270-9139(91)90159-S; WORMAN HJ, 1990, J CELL BIOL, V111, P1534; Ye Q, 1996, J BIOL CHEM, V271, P14653, DOI 10.1074/jbc.271.25.14653; YE Q, 1994, J BIOL CHEM, V269, P11306; Ye QA, 1997, J BIOL CHEM, V272, P14983, DOI 10.1074/jbc.272.23.14983	55	266	277	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4840	4847		10.1074/jbc.275.7.4840	http://dx.doi.org/10.1074/jbc.275.7.4840			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671519	hybrid			2022-12-27	WOS:000085378200045
J	Prasad, R; Dianov, GL; Bohr, VA; Wilson, SH				Prasad, R; Dianov, GL; Bohr, VA; Wilson, SH			FEN1 stimulation of DNA polymerase beta mediates an excision step in mammalian long patch base excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAP ENDONUCLEASE-1; PURIFIED PROTEINS; SUBSTRATE-BINDING; PHOSPHATE LYASE; SITE REPAIR; RECONSTITUTION; PATHWAY; 3'-EXO/ENDONUCLEASE; REQUIREMENT; MECHANISM	In mammalian cells, single-base lesions, such as uracil and abasic sites, appear to be repaired by at least two base excision repair (BER) subpathways: "single-nucleotide BER" requiring DNA synthesis of just one nucleotide and "long patch BER" requiring multi-nucleotide DNA synthesis. In single-nucleotide BER, DNA polymerase beta (beta-pol) accounts for both gap filling DNA synthesis and removal of the 5'-deoxyribose phosphate (dRP) of the abasic site, whereas the involvement of various DNA polymerases in long patch BER is less well understood. Recently, we found that beta-pol plays a role in mammalian cell extract-mediated long patch BER, in that formation of a key excision product, 5'-dRP-trinucleotide (5'-dRP-N-3), is dependent upon beta-pol (Dianov, G. L., Prasad, R., Wilson, S. H., and Bohr, V.A. (1999) J, Biol, Chem. 274, 13741-13743). The structure-specific endonuclease flap endonuclease 1 (FEN1) has also been suggested to be involved in long patch BER excision, Here, we demonstrate by immunodepletion experiments that 5'-dRP-N-3 excision in long patch BER of uracil-DNA in a human lymphoid cell extract is, indeed, dependent upon FEN1, Next, we reconstituted the excision step of long patch BER using purified human proteins and an oligonucleotide substrate with 5'-dRP at the margin of a one-nucleotide gap. Formation of the excision product 5'-dRP-N-3 was dependent upon both strand displacement DNA synthesis by beta-pol and FEN1 excision, FEN1 stimulated strand displacement DNA synthesis of beta-pol, FEN1 acting either alone, or without DNA synthesis by beta-pol, produced a two-nucleotide excision product, 5'-dRP-N-1, but not 5'-dRP-N-3. These results demonstrate that human FEN1 and beta-pol can cooperate in long patch BER excision and specify the predominant excision product seen with a cell extract.	NIEHS, NIH, Struct Biol Lab, Res Triangle Pk, NC 27709 USA; NIA, NIH, Mol Genet Lab, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Wilson, SH (corresponding author), NIEHS, NIH, Struct Biol Lab, 111 TW Alexander Dr,Bldg 101,Rm B246, Res Triangle Pk, NC 27709 USA.		Wilson, Samuel H/E-6644-2019; Bohr, Vilhelm/AAP-5931-2020	Wilson, Samuel H/0000-0002-1702-5293; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050158, Z01ES050158] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Beard WA, 1995, METHOD ENZYMOL, V262, P98; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; Forsina G., 1996, J BIOL CHEM, V271, P9573; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; HORTON JK, 2000, IN PRESS J BIOL CHEM, V275; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; MANELY JL, 1980, P NATL ACAD SCI USA, V77, P3855; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MOSBAUGH DW, 1994, PROG NUCLEIC ACID RE, V48, P315, DOI 10.1016/S0079-6603(08)60859-4; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Nicholl ID, 1997, BIOCHEMISTRY-US, V36, P7557, DOI 10.1021/bi962950w; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; PRICE A, 1992, FEBS LETT, V300, P101, DOI 10.1016/0014-5793(92)80173-E; REIN DC, 1990, EUKARYOTIC NUCLEUS M, V1, P95; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; Wilson SH, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P693; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0	40	181	189	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4460	4466		10.1074/jbc.275.6.4460	http://dx.doi.org/10.1074/jbc.275.6.4460			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660619	hybrid			2022-12-27	WOS:000085288800103
J	Furukawa, K; Mizushima, N; Noda, T; Ohsumi, Y				Furukawa, K; Mizushima, N; Noda, T; Ohsumi, Y			A protein conjugation system in yeast with homology to biosynthetic enzyme reaction of prokaryotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-ACTIVATING ENZYME; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; KINASE-C; GENE; MOLYBDOPTERIN; SMT3P	Protein conjugation, such as ubiquitination, is the process by which the C-terminal glycine of a small modifier protein is covalently attached to target protein(s) through sequential reactions with an activating enzyme and conjugating enzymes. Here we report on a novel protein conjugation system in yeast. A newly identified ubiquitin related modifier, Urm1 is a 99-amino acid protein terminated with glycine-glycine. Urm1 is conjugated to target proteins, which requires the C-terminal glycine of Urm1. At the first step of this reaction, Urm1 forms a thioester with a novel E1-like protein, Uba4. Delta urm1 and Delta uba4 cells showed a temperature-sensitive growth phenotype. Urm1 and Uba4 show similarity to prokaryotic proteins essential for molybdopterin and thiamin biosynthesis, although the Urm1 system is not involved in these pathways. This is the fifth conjugation system in yeast, following ubiquitin, Smt3, Rub1, and Apg12, but it is unique in respect to relation to prokaryotic enzyme systems. This fact may provide an important clue regarding evolution of protein conjugation systems in eukaryotic cells.	Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; Japan Sci & Technol Corp, PRESTO, Okazaki, Aichi 444, Japan; Suntory Inst Med Res & Dev, Gunma 3700503, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Japan Science & Technology Agency (JST)	Ohsumi, Y (corresponding author), Natl Inst Basic Biol, Dept Cell Biol, 38 Nishigonaka, Okazaki, Aichi 4448585, Japan.		Mizushima, Noboru/C-3635-2009; Ohsumi, Yoshinori/C-6449-2009; Noda, Takeshi/B-7240-2008	Mizushima, Noboru/0000-0002-6258-6444; Ohsumi, Yoshinori/0000-0003-2384-2166; Noda, Takeshi/0000-0003-3581-7961				Appleyard MVCL, 1998, J BIOL CHEM, V273, P14869, DOI 10.1074/jbc.273.24.14869; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hohmann S, 1998, BBA-PROTEIN STRUCT M, V1385, P201, DOI 10.1016/S0167-4838(98)00069-7; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; James P, 1996, GENETICS, V144, P1425; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PRAEKELT UM, 1994, YEAST, V10, P481, DOI 10.1002/yea.320100407; Rajagopalan KV, 1997, BIOCHEM SOC T, V25, P757, DOI 10.1042/bst0250757; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; Sloan J, 1999, NUCLEIC ACIDS RES, V27, P854, DOI 10.1093/nar/27.3.854; Takahashi Y, 1999, BIOCHEM BIOPH RES CO, V259, P582, DOI 10.1006/bbrc.1999.0821; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Taylor SV, 1998, J BIOL CHEM, V273, P16555, DOI 10.1074/jbc.273.26.16555; Unkles SE, 1999, J BIOL CHEM, V274, P19286, DOI 10.1074/jbc.274.27.19286; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5	28	127	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7462	7465		10.1074/jbc.275.11.7462	http://dx.doi.org/10.1074/jbc.275.11.7462			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713047	hybrid			2022-12-27	WOS:000085913300007
J	Resnick, EM; Schreihofer, DA; Periasamy, A; Shupnik, MA				Resnick, EM; Schreihofer, DA; Periasamy, A; Shupnik, MA			Truncated estrogen receptor product-1 suppresses estrogen receptor transactivation by dimerization with estrogen receptors alpha and beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; NUCLEAR HORMONE-RECEPTOR; MESSENGER-RNA ISOFORMS; RAT PITUITARY; TRANSCRIPTIONAL ACTIVITY; PROGESTERONE RECEPTORS; THYROID-HORMONE; DNA-BINDING; ACTIVATION; COACTIVATOR	The estrogen receptor (ER) is a ligand-activated transcription factor that acts as a homodimer. Truncated estrogen receptor product-1 (TERP-1) is a pituitary-specific, estrogen-induced, isoform of rat ER alpha that is transcribed from a unique start site and contains only the C-terminal region of the full-length receptor. TERP-1 does not affect transcription directly but suppresses ligand-activated ER alpha and ER beta activity. Because TERP-1 contains a dimerization domain and part of the coactivator binding pocket, we hypothesized that it modulates ER function by direct interactions with full-length ER or the steroid receptor coactivator, SRC-1. Localization studies demonstrate that TERP-1 is present in the cytoplasm and nucleus of transfected cells and colocalizes with nuclear ER. Protein binding studies show that TERP-1 forms heterodimers with both ER alpha and ER beta and inhibits ER alpha binding to its cognate DNA response element. TERP-1 also binds SRC-1, and increasing levels of SRC-1 decrease the TERP-1-ER alpha interactions, in agreement with the rescue of TERP-1-suppressed ER alpha transcriptional activity by SRC-I. Mutational analysis of TERP-1 and ER alpha in the activation helix and the AF-2 dimerization helix indicates that TERP-1 acts predominantly through dimerization with ER alpha. Therefore, TERP-1 suppression of ER transcription occurs primarily by formation of inactive heterodimers and secondarily by competition for coactivators.	Univ Virginia, Dept Internal Med, Charlottesville, VA 22903 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22903 USA; Univ Virginia, Dept Biol, Charlottesville, VA 22903 USA	University of Virginia; University of Virginia; University of Virginia	Shupnik, MA (corresponding author), Univ Virginia, Dept Internal Med, Charlottesville, VA 22903 USA.	mas3x@virginia.edu	Periasamy, Ammasi/B-1279-2010		NICHD NIH HHS [U54 HD28934, R01 HD25719/DK57082] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD028934] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025719] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chen DS, 1999, MOL CELL BIOL, V19, P1002; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; Eng FCS, 1998, J BIOL CHEM, V273, P28371, DOI 10.1074/jbc.273.43.28371; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Friend KE, 1997, MOL CELL ENDOCRINOL, V131, P147, DOI 10.1016/S0303-7207(97)00098-1; FRIEND KE, 1995, P NATL ACAD SCI USA, V92, P4367, DOI 10.1073/pnas.92.10.4367; FUQUA SAW, 1991, CANCER RES, V51, P105; FURLOW JD, 1990, ENDOCRINOLOGY, V127, P1028, DOI 10.1210/endo-127-3-1028; Hanstein B, 1999, MOL ENDOCRINOL, V13, P129, DOI 10.1210/me.13.1.129; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HOTCHKISS J, 1994, PHYSL REPRODUCTION, V2, P711; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; Jeyakumar M, 1997, MOL ENDOCRINOL, V11, P755, DOI 10.1210/me.11.6.755; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; MacGregor JI, 1998, PHARMACOL REV, V50, P151; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; Mitchner NA, 1998, ENDOCRINOLOGY, V139, P3976, DOI 10.1210/en.139.9.3976; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Norris JD, 1998, J BIOL CHEM, V273, P6679, DOI 10.1074/jbc.273.12.6679; Oate SA, 1995, SCIENCE, V270, P1354, DOI DOI 10.1126/SCIENCE.270.5240.1354.PUBMED:7481822; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; SALOMONSSON M, 1994, J STEROID BIOCHEM, V48, P447, DOI 10.1016/0960-0760(94)90192-9; Schaufele F, 1999, MOL ENDOCRINOL, V13, P935, DOI 10.1210/me.13.6.935; Schodin DJ, 1995, J BIOL CHEM, V270, P31163, DOI 10.1074/jbc.270.52.31163; Schreihofer DA, 1999, MOL ENDOCRINOL, V13, P320, DOI 10.1210/me.13.2.320; Seel WG, 1998, MOL ENDOCRINOL, V12, P1551, DOI 10.1210/mend.12.10.0184; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Seol W, 1997, MOL CELL BIOL, V17, P7126, DOI 10.1128/MCB.17.12.7126; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SHUPNIK MA, 1991, J BIOL CHEM, V266, P17084; Shupnik MA, 1998, J CLIN ENDOCR METAB, V83, P3965, DOI 10.1210/jc.83.11.3965; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WANG YL, 1991, MOL ENDOCRINOL, V5, P1707, DOI 10.1210/mend-5-11-1707; WEIGEL NL, 1992, MOL ENDOCRINOL, V6, P1585, DOI 10.1210/me.6.10.1585; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899	58	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7158	7166		10.1074/jbc.275.10.7158	http://dx.doi.org/10.1074/jbc.275.10.7158			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702284	hybrid			2022-12-27	WOS:000085809600064
J	Skapek, SX; Jansen, D; Wei, TF; McDermott, T; Huang, WP; Olson, EN; Lee, EYHP				Skapek, SX; Jansen, D; Wei, TF; McDermott, T; Huang, WP; Olson, EN; Lee, EYHP			Cloning and characterization of a novel Kruppel-associated box family transcriptional repressor that interacts with the retinoblastoma gene product, RB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEINS; CELL-CYCLE PROGRESSION; SKELETAL-MUSCLE CELLS; LARGE T-ANTIGEN; S-PHASE ENTRY; BINDING PROTEIN; SUSCEPTIBILITY GENE; HISTONE DEACETYLASE; GROWTH SUPPRESSION; POINT MUTATIONS	The retinoblastoma gene product, RB, seems to function as a key tumor suppressor by repressing the expression of genes activated by members of the E2F family of transcription factors. In order to accomplish this, RB has been proposed to interact with a transcriptional repressor. However, no genuine transcriptional repressors have been identified by virtue of interaction with RB. By using the yeast two-hybrid system, we have identified a novel member of a known family of transcriptional repressors that contain zinc fingers of the Kruppel type and a portable transcriptional repressor motif known as the Kruppel-associated box (KRAB). The mouse and human forms of the novel RB-associated KRAB protein (RBaK) are widely expressed. The amino acid motif that links the KRAB domain and zinc fingers appears to be required for interaction with RB in vitro. Human RBaK ectopically expressed in fibroblasts is an 80-kDa protein that is localized to the nucleus. The expression of either RB or RBaK in 10T1/2 fibroblasts represses the activation of an E2F-dependent promoter and decreases DNA synthesis to a similar degree. However, a mutant form of RBaK that cannot interact with RB in vitro is unable to prevent DNA synthesis. We present a model in which RB physically interacts with the novel transcriptional repressor RBaK to repress E2F-dependent genes and prevent DNA synthesis.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Wilford Hall USAF Med Ctr, Dept Pediat, San Antonio, TX 78236 USA; Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75235 USA	University of Texas System; University of Texas Health San Antonio; United States Department of Defense; United States Air Force; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lee, EYHP (corresponding author), Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78345 USA.	Leee@uthscsa.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD001105] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA049649, R37CA049649, R29CA049649] Funding Source: NIH RePORTER; NCI NIH HHS [CA49649] Funding Source: Medline; NICHD NIH HHS [K08-HD01105] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADNANE J, 1995, ONCOGENE, V10, P381; [Anonymous], 1982, MOL CLONING LAB MANU; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; Bellefroid EJ, 1998, BBA-GENE STRUCT EXPR, V1398, P321, DOI 10.1016/S0167-4781(98)00057-8; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BELLEFROID EJ, 1995, P NATL ACAD SCI USA, V92, P10757, DOI 10.1073/pnas.92.23.10757; BRADY JP, 1994, GENE, V149, P299, DOI 10.1016/0378-1119(94)90165-1; BRAY P, 1991, P NATL ACAD SCI USA, V88, P9563, DOI 10.1073/pnas.88.21.9563; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FRIEDMAN JR, 1999, GENE DEV, V10, P2067; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Grondin B, 1996, J BIOL CHEM, V271, P15458, DOI 10.1074/jbc.271.26.15458; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LANE D, 1988, ANTIBODIES LAB MANUA, P55; LANGE R, 1995, DNA CELL BIOL, V14, P971, DOI 10.1089/dna.1995.14.971; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lin SCJ, 1996, SEMIN CANCER BIOL, V7, P279, DOI 10.1006/scbi.1996.0036; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Mazarakis N, 1996, GENOMICS, V33, P247, DOI 10.1006/geno.1996.0189; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Odeberg J, 1998, GENOMICS, V50, P213, DOI 10.1006/geno.1998.5309; PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908; Perez M, 1996, FEBS LETT, V387, P117, DOI 10.1016/0014-5793(96)00474-7; POTT U, 1995, J NEUROCHEM, V65, P1955; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; Shih HH, 1998, MOL CELL BIOL, V18, P4732, DOI 10.1128/MCB.18.8.4732; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; Skapek SX, 1997, PROG RETIN EYE RES, V16, P591, DOI 10.1016/S1350-9462(96)00033-X; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; THIESEN H-J, 1990, New Biologist, V2, P363; THIESEN HJ, 1993, ANN NY ACAD SCI, V684, P243, DOI 10.1111/j.1749-6632.1993.tb32298.x; VISSING H, 1995, FEBS LETT, V369, P153, DOI 10.1016/0014-5793(95)00728-R; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WICK MJ, 1995, GENE, V152, P227, DOI 10.1016/0378-1119(94)00676-J; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	88	33	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7212	7223		10.1074/jbc.275.10.7212	http://dx.doi.org/10.1074/jbc.275.10.7212			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702291	hybrid			2022-12-27	WOS:000085809600071
J	Van Linden, AA; Cottin, V; Leu, C; Riches, DWH				Van Linden, AA; Cottin, V; Leu, C; Riches, DWH			Phosphorylation of the membrane proximal region of tumor necrosis factor receptor CD120a (p55) at ERK consensus sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; KAPPA-B ACTIVATION; TNF RECEPTOR; MOUSE MACROPHAGES; CYTOPLASMIC DOMAIN; SIGNAL-TRANSDUCTION; SUBSTRATE RECOGNITION; CELL-DEATH; IDENTIFICATION; ALPHA	The interaction of tumor necrosis factor-alpha with its receptor CD120a (p55) initiates downstream signaling cascades that include the activation of the mitogen-activated protein kinase (MAPH), p42(mapk/erk2), The membrane proximal region of CD120a (p55) is Ser-, Thr-, and Pro-rich and contains four mitogen-activated protein kinase consensus phosphorylation sites. In recent work, we showed that CD120a (p55) itself is a target of phosphorylation by p42(mapk/erk2), and after phosphorylation, the receptor is redistributed from the cell surface and Golgi complex to intracellular tubular structures associated with elements of the endoplasmic reticulum, The goal of this study was to define the specific amino acid residues that are phosphorylated, Deletional mutagenesis of the cytoplasmic domain of CD120a (p55) indicated that two sites located between residues 207-254 and 250-300 were phosphorylated predominantly on Thr and Ser residues, respectively. Site-directed mutagenesis of Ser and Thr residues contained within the extracellular signal-regulated kinase (ERK) consensus sequences indicated that the preferred residues were Thr-236 and Ser-270, Primary phosphorylation at these sites appeared to enable subsequent phosphorylation at Ser-240 and Ser-244, although the level of phosphorylation of these latter two sites was less than the preferred sites. Through the use of specific ligation of CD120a (p55) alone and mice deficient in CD120a (p55), CD120b (p75), or both receptors, CD120a (p55) was shown to be necessary and sufficient for the induction of kinase activity. These findings thus suggest that the phosphorylation of Thr-236 and Ser-270 within the membrane proximal region of CD120a (p55) are the preferred sites of phosphorylation by p4(2mapk/erk2) and may set in motion phosphorylation at other sites.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Cell Biol Program, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Riches, DWH (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Cell Biol Program, Neustadt Room D405,1400 Jackson St, Denver, CO 80206 USA.				NHLBI NIH HHS [HL56556, HL55549] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056556, R01HL055549] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEYAERT R, 1995, J BIOL CHEM, V270, P23293, DOI 10.1074/jbc.270.40.23293; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; Chan ED, 1997, P NATL ACAD SCI USA, V94, P13169, DOI 10.1073/pnas.94.24.13169; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; Darnay BG, 1997, FEBS LETT, V410, P361, DOI 10.1016/S0014-5793(97)00652-2; DARNAY BG, 1994, J BIOL CHEM, V269, P20299; DARNAY BG, 1995, J BIOL CHEM, V270, P14867, DOI 10.1074/jbc.270.25.14867; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Kalb A, 1996, J BIOL CHEM, V271, P28097, DOI 10.1074/jbc.271.45.28097; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kennedy NJ, 1998, J IMMUNOL, V160, P4881; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Pinckard JK, 1997, J BIOL CHEM, V272, P10784; Riches DWH, 1998, J BIOL CHEM, V273, P22800, DOI 10.1074/jbc.273.35.22800; RICHES DWH, 1991, J BIOL CHEM, V266, P24785; Riches DWH, 1996, MOL CELLULAR BIOL WO, P95; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; Weiss T, 1997, J IMMUNOL, V158, P2398; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; Winston BW, 1997, J IMMUNOL, V159, P4491; WINSTON BW, 1995, J IMMUNOL, V155, P1525; WINSTON BW, 1995, J BIOL CHEM, V270, P27391, DOI 10.1074/jbc.270.46.27391; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; Wu MY, 1997, J BIOL CHEM, V272, P17154, DOI 10.1074/jbc.272.27.17154; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhang LR, 1997, J BIOL CHEM, V272, P14762, DOI 10.1074/jbc.272.23.14762; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	45	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6996	7003		10.1074/jbc.275.10.6996	http://dx.doi.org/10.1074/jbc.275.10.6996			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702263	hybrid			2022-12-27	WOS:000085809600043
J	Wehland, M; Bernhard, F				Wehland, M; Bernhard, F			The RcsAB box - Characterization of a new operator essential for the regulation of exopolysaccharide biosynthesis in enteric bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; CAPSULAR POLYSACCHARIDE SYNTHESIS; BORDETELLA-PERTUSSIS; ERWINIA-AMYLOVORA; NUCLEOTIDE-SEQUENCE; COLANIC ACID; VI-ANTIGEN; POSITIVE REGULATOR; SALMONELLA-TYPHI; RNA-POLYMERASE	The interaction of the two transcriptional regulators RcsA and RcsB with a specific operator is a common mechanism in the activation of capsule biosynthesis in enteric bacteria. We describe RcsAB binding sites in the wza promoter of the operon for colanic acid biosynthesis in Escherichia coli K-12, in the galF promoter of the operon for K2 antigen biosynthesis in Klebsiella pneumoniae, and in the tviA (vipR) promoter of the operon for Vi antigen biosynthesis in Salmonella typhi. We further show the interaction of RcsAB with the rcsA promoters of various species, indicating that rcsA autoregulation also depends on the presence of both proteins. The compilation of all identified RcsAB binding sites revealed the conserved core sequence TaAGaatatTCctA, which we propose to be termed RcsAB box. The RcsAB box is also part of Bordetella pertussis BvgA binding sites and may represent a more distributed recognition motif within the LuxR superfamily of transcriptional regulators. The RcsAB box is essential for the induction of Rcs-regulated promoters. Site-specific mutations of conserved nucleotides in the RcsAB boxes of the E. coli wza and rcsA promoters resulted in an exopolysaccharide-negative phenotype and in the reduction of reporter gene expression.	Free Univ Berlin, Inst Kristallog, D-14195 Berlin, Germany	Free University of Berlin	Bernhard, F (corresponding author), Free Univ Berlin, Inst Kristallog, Takustr 6, D-14195 Berlin, Germany.	fbern@chemie.fu-berlin.de		Bernhard, Frank/0000-0002-4860-1783; Wehland, Markus/0000-0002-8160-859X				ALLEN P, 1987, J GEN MICROBIOL, V133, P331; ARAKAWA Y, 1995, J BACTERIOL, V177, P1788, DOI 10.1128/jb.177.7.1788-1796.1995; Bailey TL, 1998, BIOINFORMATICS, V14, P48, DOI 10.1093/bioinformatics/14.1.48; BAKER EE, 1959, J IMMUNOL, V83, P680; Bereswill S, 1997, J BACTERIOL, V179, P1354, DOI 10.1128/jb.179.4.1354-1361.1997; BERNHARD F, 1990, MOL PLANT MICROBE IN, V3, P429, DOI 10.1094/MPMI-3-429; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOUCHER PE, 1994, J MOL BIOL, V241, P363, DOI 10.1006/jmbi.1994.1513; Boucher PE, 1997, J BACTERIOL, V179, P1755, DOI 10.1128/jb.179.5.1755-1763.1997; BRILL JA, 1988, J BACTERIOL, V170, P2599, DOI 10.1128/jb.170.6.2599-2611.1988; BUGERT P, 1995, MOL MICROBIOL, V15, P917, DOI 10.1111/j.1365-2958.1995.tb02361.x; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CHATTERJEE A, 1990, MOL PLANT MICROBE IN, V3, P144, DOI 10.1094/MPMI-3-144; COLEMAN M, 1990, J GEN MICROBIOL, V136, P1799, DOI 10.1099/00221287-136-9-1799; DEVINE JH, 1989, P NATL ACAD SCI USA, V86, P5688, DOI 10.1073/pnas.86.15.5688; Dierksen KP, 1996, J BACTERIOL, V178, P5053, DOI 10.1128/jb.178.16.5053-5056.1996; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Ebel W, 1999, J BACTERIOL, V181, P577, DOI 10.1128/JB.181.2.577-584.1999; Felix A, 1934, LANCET, V2, P186; GEIDER K, 1985, GENE, V33, P341, DOI 10.1016/0378-1119(85)90242-2; GOTTESMAN S, 1985, J BACTERIOL, V162, P1111, DOI 10.1128/JB.162.3.1111-1119.1985; GOTTESMAN S, 1991, MOL MICROBIOL, V5, P1599, DOI 10.1111/j.1365-2958.1991.tb01906.x; Hashimoto Y, 1996, J BACTERIOL, V178, P1430, DOI 10.1128/jb.178.5.1430-1436.1996; HASHIMOTO Y, 1993, J BACTERIOL, V175, P4456, DOI 10.1128/JB.175.14.4456-4465.1993; HENIKOFF SJC, 1990, METHOD ENZYMOL, V183, P111; HOUNG HSH, 1992, J BACTERIOL, V174, P5910, DOI 10.1128/jb.174.18.5910-5915.1992; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; JAYARATNE P, 1993, J BACTERIOL, V175, P5384, DOI 10.1128/JB.175.17.5384-5394.1993; Kelm O, 1997, MOL GEN GENET, V256, P72, DOI 10.1007/s004380050547; LEIGH JA, 1992, ANNU REV MICROBIOL, V46, P307, DOI 10.1146/annurev.mi.46.100192.001515; MCCALLUM KL, 1991, INFECT IMMUN, V59, P494, DOI 10.1128/IAI.59.2.494-502.1991; Miller J.H., 1972, EXPT MOL GENETICS; POETTER K, 1991, MOL GEN GENET, V229, P155, DOI 10.1007/BF00264225; ROY CR, 1991, J BACTERIOL, V173, P2385, DOI 10.1128/JB.173.7.2385-2392.1991; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCARLATO V, 1990, P NATL ACAD SCI USA, V87, P6753, DOI 10.1073/pnas.87.17.6753; Sledjeski DD, 1996, J BACTERIOL, V178, P1204, DOI 10.1128/jb.178.4.1204-1206.1996; STEVENS AM, 1994, P NATL ACAD SCI USA, V91, P12619, DOI 10.1073/pnas.91.26.12619; Stevenson G, 1996, J BACTERIOL, V178, P4885, DOI 10.1128/jb.178.16.4885-4893.1996; STIBITZ S, 1994, J BACTERIOL, V176, P5615, DOI 10.1128/JB.176.18.5615-5621.1994; STOUT V, 1991, J BACTERIOL, V173, P1738, DOI 10.1128/jb.173.5.1738-1747.1991; STOUT V, 1990, J BACTERIOL, V172, P659, DOI 10.1128/jb.172.2.659-669.1990; Stout V, 1996, J BACTERIOL, V178, P4273, DOI 10.1128/jb.178.14.4273-4280.1996; TORRESCABASSA AS, 1987, J BACTERIOL, V169, P981, DOI 10.1128/jb.169.3.981-989.1987; Virlogeux I, 1996, J BACTERIOL, V178, P1691, DOI 10.1128/jb.178.6.1691-1698.1996; Wehland M, 1999, J BIOL CHEM, V274, P3300, DOI 10.1074/jbc.274.6.3300; Zu T, 1996, MOL MICROBIOL, V21, P557, DOI 10.1111/j.1365-2958.1996.tb02564.x	47	125	131	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7013	7020		10.1074/jbc.275.10.7013	http://dx.doi.org/10.1074/jbc.275.10.7013			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702265	hybrid			2022-12-27	WOS:000085809600045
J	Sakakibara, A; Hattori, S				Sakakibara, A; Hattori, S			Chat, a Cas/HEF1-associated adaptor protein that integrates multiple signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SUBSTRATE-RELATED PROTEIN; MEDIATED CELL-ADHESION; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; C-SRC; DOCKING PROTEIN; CAS-L; P130(CAS); CRK	Cas ((C) under bar rk-(a) under bar ssociated (s) under bar ubstrate) and HEF1 ((h) under bar uman (e) under bar nhancer of (f) under bar ilamentation) are related adaptor proteins that function in integrin-mediated cell adhesion and antigen receptor signaling pathways. We report here a molecular cloning of Chat ((C) under bar as/(H) under bar SEF1-(a) under bar ssociated signal transducer) that associates with Cas and HEF1, Chat is a 78-kDa signaling molecule with an N-terminal SH2 domain and is expressed in a wide range of tissues. In hematopoietic cells, a 115-kDa isoform of Chat (Chat-IF) was specifically expressed. Chat is associated with Cas in brain, and Chat-II is associated with HEF1 in splenocytes, Deletion analyses revealed that Chat and Cas are associated with each other by their C-terminal domains. Treatment of PC12 cells with epidermal growth factor or nerve growth factor increased the phosphorylation level of Chat. This increase was suppressed by an inhibitor of mitogen-activated protein (MAP) kinase kinase, PD98059, suggesting the phosphorylation of Chat by MAP kinase, In Chat overexpressed COS? cells, the activity of c-Jun N-terminal kinase was up-regulated. After the epidermal growth factor stimulation, Chat and Cas were colocalized with actin filaments at ruffling membranes. These findings suggest that Chat transduces signals of tyrosine kinases and MAP kinase to Cas signaling pathway.	Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Div Biochem & Cellular Biol, Tokyo 1878502, Japan	National Center for Neurology & Psychiatry - Japan	Hattori, S (corresponding author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Div Biochem & Cellular Biol, 4-1-1 Ogawahigashi, Tokyo 1878502, Japan.	hattori@ncnp.go.jp						Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ishino M, 1995, ONCOGENE, V11, P2331; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Law SF, 1996, MOL CELL BIOL, V16, P3327; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; Lu YM, 1999, J BIOL CHEM, V274, P10047, DOI 10.1074/jbc.274.15.10047; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ohashi Y, 1998, J BIOL CHEM, V273, P6446, DOI 10.1074/jbc.273.11.6446; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; SONGYANG Z, 1992, CELL, V72, P767; Takahashi H, 1998, DEV GROWTH DIFFER, V40, P431; van Agthoven T, 1998, EMBO J, V17, P2799, DOI 10.1093/emboj/17.10.2799; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Woodard AS, 1998, J CELL SCI, V111, P469	45	51	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6404	6410		10.1074/jbc.275.9.6404	http://dx.doi.org/10.1074/jbc.275.9.6404			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692442	hybrid			2022-12-27	WOS:000085654400054
J	Shirakawa, H; Landsman, D; Postnikov, YV; Bustin, M				Shirakawa, H; Landsman, D; Postnikov, YV; Bustin, M			NBP-45, a novel nucleosomal binding protein with a tissue-specific and developmentally regulated expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL-PROTEINS; CHROMATIN; TRANSCRIPTION; DOMAIN; HMG-17; ACTIVATION; DNA; ENHANCEMENT; REGION; CORES	Here we characterize a novel murine nuclear protein, which we named NBP-45, that is related to the ubiquitous nuclear proteins HMG-14/-17, binds specifically to nucleosome core particles, and can function as a transcriptional activator. NBP-45 mRNA is expressed at low levels and in variable amounts in all mouse tissues tested but is especially abundant in RNA extracted from 7-day-old mouse embryos, suggesting that it functions in early embryonic development, NBP-45 is composed of 406 amino acids and is encoded by a single size transcript. The region spanning the N-terminal 85 amino acids contains three segments that are highly homologous to functionally important domains in the HMG-14/-17 protein family: the nuclear localization signal, the nucleosome binding domain, and the chromatin unfolding domain. The protein region spanning the C-terminal 321 amino acids has a 42% content of negatively charged residues. The first 23 amino acids contain a region necessary for nuclear entry of the protein, the region spanning residues 12-40 is the main nucleosomal binding domain of the protein, and the negatively charged, C-terminal domain is necessary for transcription activation. The functional domains of NBP-45 are indicative of a nuclear protein that binds to nucleosomes, thereby creating a chromatin region of high local negative charge. Our studies establish the nucleosomal binding domain as a protein motif that is present in other than just the ubiquitous HMG-14/-17 proteins. We suggest that the nucleosomal binding domain motif is a protein module that facilitates binding to nucleosomes in chromatin.	NCI, Prot Sect, Div Basic Sci, NIH, Bethesda, MD 20892 USA; NIH, Computat Biol Branch, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Bustin, M (corresponding author), NCI, Prot Sect, Div Basic Sci, NIH, Bldg 37,Rm 3D-12, Bethesda, MD 20892 USA.	bustin@helix.nih.gov	Landsman, David/C-5923-2009; Landsman, David/GZK-5496-2022; Bustin, Michael/G-6155-2015; Shirakawa, Hitoshi/D-1406-2009	Landsman, David/0000-0002-9819-6675; SHIRAKAWA, HITOSHI/0000-0002-4828-5274; Bustin, Michael/0000-0002-5147-7242	NATIONAL LIBRARY OF MEDICINE [Z01LM000071, ZIALM000071] Funding Source: NIH RePORTER	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ABERCROMBIE BD, 1978, EUR J BIOCHEM, V84, P173, DOI 10.1111/j.1432-1033.1978.tb12154.x; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; BIANCHI ME, 1995, DNA PROTEIN STRUCTUR, P177; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; COOK GR, 1989, J BIOL CHEM, V264, P1799; CRIPPA MP, 1992, J MOL BIOL, V228, P442, DOI 10.1016/0022-2836(92)90833-6; Davie JR, 1998, CURR OPIN GENET DEV, V8, P173, DOI 10.1016/S0959-437X(98)80138-X; Ding HF, 1997, MOL CELL BIOL, V17, P5843, DOI 10.1128/MCB.17.10.5843; Hock R, 1998, EMBO J, V17, P6992, DOI 10.1093/emboj/17.23.6992; Hock R, 1998, J CELL BIOL, V143, P1427, DOI 10.1083/jcb.143.6.1427; Johns EW, 1982, HMG CHROMOSOMAL PROT; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; KORNBERG RD, 1989, METHOD ENZYMOL, V170, P3; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Korschen HG, 1999, NATURE, V400, P761, DOI 10.1038/23468; KORSCHEN HG, 1995, NEURON, V15, P627, DOI 10.1016/0896-6273(95)90151-5; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; POSTNIKOV YV, 1995, J MOL BIOL, V252, P423, DOI 10.1006/jmbi.1995.0508; POSTNIKOV YV, 1994, NUCLEIC ACIDS RES, V22, P4520, DOI 10.1093/nar/22.21.4520; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; Saperas N, 1999, ARCH BIOCHEM BIOPHYS, V361, P135, DOI 10.1006/abbi.1998.0965; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRIESCHMANN L, 1995, MOL CELL BIOL, V15, P6663; TRIESCHMANN L, 1995, EMBO J, V14, P1478, DOI 10.1002/j.1460-2075.1995.tb07134.x; Vestner B, 1998, J BIOL CHEM, V273, P9409, DOI 10.1074/jbc.273.16.9409; Weigmann N, 1997, DNA CELL BIOL, V16, P1207, DOI 10.1089/dna.1997.16.1207; Wolffe A., 1995, CHROMATIN STRUCTURE; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171	37	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6368	6374		10.1074/jbc.275.9.6368	http://dx.doi.org/10.1074/jbc.275.9.6368			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692437	hybrid			2022-12-27	WOS:000085654400049
J	Sevigny, J; Robson, SC; Waelkens, E; Csizmadia, E; Smith, RN; Lemmens, R				Sevigny, J; Robson, SC; Waelkens, E; Csizmadia, E; Smith, RN; Lemmens, R			Identification and characterization of a novel hepatic canalicular ATP diphosphohydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; EPIDERMAL GROWTH-FACTOR; CELL-ADHESION MOLECULE; LIVER ECTO-ATPASE; NUCLEOSIDE TRANSPORTER; PLASMA-MEMBRANE; LI-7A CELLS; NUCLEOTIDES; EXPRESSION; ADENOSINE	We have identified and characterized a novel ATP diphosphohydrolase (ATPDase) with features of E-type ATPases from porcine liver. Immunoblotting with a specific monoclonal antibody to this ectoenzyme revealed high expression in liver with lesser amounts in kidney and duodenum. This ATPDase was localized by immunohistochemistry to the bile canalicular domain of hepatocytes and to the luminal side of the renal ductular epithelium, In contrast, ATPDase/cd39 was detected in vascular endothelium and smooth muscle in these organs, We purified the putative ATPDase from liver by immunoaffinity techniques and obtained a heavily glycosylated protein with a molecular mass estimated at 75 kDa. This enzyme hydrolyzed all tri- and diphospho-nucleosides but not AMP or diadenosine polyphosphates, There was an absolute requirement for divalent cations (Ca2+ > Mg2+). Biochemical activity was unaffected by sodium azide or other inhibitors of ATPases, Kinetic parameters derived from purified preparations of hepatic ATPDase indicated V-max of 8.5 units/mg of protein with apparent K-m of 100 mu M for both ATP or ADP as substrates. NH2-terminal amino acid sequencing revealed near 50% identity with rat liver lysosomal (Ca2+-Mg2+)-ATPase. The different biochemical properties and localization of the hepatic ATPDase suggest pathophysiological functions that are distinct from the vascular ATPDase/cd39.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA; Katholieke Univ Leuven, Dept Biochem, B-3000 Louvain, Belgium; Massachusetts Gen Hosp, Immunopathol Unit, Dept Pathol, Boston, MA 02114 USA; Limburgs Univ Ctr, Dept MBW, B-3590 Diepenbeek, Belgium	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; KU Leuven; Harvard University; Massachusetts General Hospital; Hasselt University	Sevigny, J (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, 99 Brookline Ave,R 359, Boston, MA 02215 USA.		Sevigny, Jean/E-8039-2012; Sévigny, Jean/AGH-9323-2022; Robson, Simon C./AAA-8537-2021	Sevigny, Jean/0000-0003-2922-1600; Sévigny, Jean/0000-0003-2922-1600; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057307] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL57307] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson CM, 1997, TRENDS PHARMACOL SCI, V18, P387, DOI 10.1016/S0165-6147(97)01106-1; Bach FH, 1997, NAT MED, V3, P944, DOI 10.1038/nm0997-944; BARTLES JR, 1985, J BIOL CHEM, V260, P2792; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; Beaudoin A.R, 1996, BIOMEMBRANES, V5, P369; Chadwick BP, 1998, GENOMICS, V50, P357, DOI 10.1006/geno.1998.5317; Chadwick BP, 1997, MAMM GENOME, V8, P668, DOI 10.1007/s003359900534; Chari RS, 1996, AM J PHYSIOL-GASTR L, V270, pG246; CHE MX, 1992, J BIOL CHEM, V267, P9684; Che MX, 1997, FASEB J, V11, P101, DOI 10.1096/fasebj.11.2.9039951; COLMAN RF, 1983, ANNU REV BIOCHEM, V52, P67, DOI 10.1146/annurev.bi.52.070183.000435; COTE YP, 1992, BIOCHIM BIOPHYS ACTA, V1160, P246, DOI 10.1016/0167-4838(92)90084-Q; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; Esch JSA, 1999, BIOCHEMISTRY-US, V38, P2248, DOI 10.1021/bi982426k; EZAKI J, 1992, J BIOCHEM, V112, P33, DOI 10.1093/oxfordjournals.jbchem.a123861; FOX IH, 1978, ANNU REV BIOCHEM, V47, P655, DOI 10.1146/annurev.bi.47.070178.003255; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GAO JP, 1993, ARCH BIOCHEM BIOPHYS, V303, P90, DOI 10.1006/abbi.1993.1259; Gao L, 1998, J BIOL CHEM, V273, P15358, DOI 10.1074/jbc.273.25.15358; Goding JW, 1998, IMMUNOL REV, V161, P11, DOI 10.1111/j.1600-065X.1998.tb01568.x; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Kegel B, 1997, NEUROPHARMACOLOGY, V36, P1189, DOI 10.1016/S0028-3908(97)00115-9; KEPPENS S, 1993, GEN PHARMACOL, V24, P283, DOI 10.1016/0306-3623(93)90304-G; KEPPENS S, 1989, FEBS LETT, V248, P137, DOI 10.1016/0014-5793(89)80448-X; Keppler D, 1997, FASEB J, V11, P15, DOI 10.1096/fasebj.11.1.9034161; KNOWLES AF, 1988, ARCH BIOCHEM BIOPHYS, V263, P264, DOI 10.1016/0003-9861(88)90635-2; KNOWLES AF, 1995, BIOCHEM BIOPH RES CO, V207, P529, DOI 10.1006/bbrc.1995.1220; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAJTHA LG, 1958, NATURE, V182, P191, DOI 10.1038/182191a0; LALIBERTE JF, 1982, J BIOL CHEM, V257, P3869; LEBEL D, 1978, ANAL BIOCHEM, V85, P86, DOI 10.1016/0003-2697(78)90277-4; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; LIN SH, 1989, J BIOL CHEM, V264, P14408; LUTHJE J, 1989, KLIN WOCHENSCHR, V67, P317, DOI 10.1007/BF01741386; Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294; Mulero JJ, 1999, J BIOL CHEM, V274, P20064, DOI 10.1074/jbc.274.29.20064; MURRAY AW, 1971, ANNU REV BIOCHEM, V40, P811, DOI 10.1146/annurev.bi.40.070171.004115; Nagy AK, 1997, MOL CHEM NEUROPATHOL, V31, P135, DOI 10.1007/BF02815238; NOVIKOFF AB, 1960, AM J MED, V29, P102, DOI 10.1016/0002-9343(60)90011-5; PLESNER L, 1995, INT REV CYTOL, V158, P141; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; Scott LJ, 1997, HEPATOLOGY, V25, P995, DOI 10.1002/hep.510250434; Sevigny J, 1997, BBA-GEN SUBJECTS, V1334, P73, DOI 10.1016/S0304-4165(96)00079-7; SEVIGNY J, 1994, M S-MED SCI, V10, P836, DOI 10.4267/10608/2718; Sevigny J, 1998, AM J PHYSIOL-GASTR L, V275, pG473, DOI 10.1152/ajpgi.1998.275.3.G473; SEVIGNY J, 2000, ECTO ATPASES RELATED, P79; SEVIGNY J, 1997, THESIS SHERBROOKE U; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Smith TM, 1998, BBA-PROTEIN STRUCT M, V1386, P65, DOI 10.1016/S0167-4838(98)00063-6; Strobel RS, 1996, J BIOL CHEM, V271, P16323, DOI 10.1074/jbc.271.27.16323; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang TF, 1998, J BIOL CHEM, V273, P11392, DOI 10.1074/jbc.273.18.11392; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; Wiley JS, 1997, NAT MED, V3, P25, DOI 10.1038/nm0197-25; Zimmermann H, 1998, NEUROCHEM INT, V32, P421, DOI 10.1016/S0197-0186(97)00126-5; Zimmermann H, 1996, DRUG DEVELOP RES, V39, P337, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<337::AID-DDR15>3.0.CO;2-Z; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345; Zimmermann H., 2000, ECTO ATPASES RELATED, P1; Zoeteweij JP, 1996, HEPATOLOGY, V23, P858, DOI 10.1002/hep.510230429	61	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5640	5647		10.1074/jbc.275.8.5640	http://dx.doi.org/10.1074/jbc.275.8.5640			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681547	hybrid			2022-12-27	WOS:000085474500054
J	Tatsumi, Y; Tsurimoto, T; Shirahige, K; Yoshikawa, H; Obuse, C				Tatsumi, Y; Tsurimoto, T; Shirahige, K; Yoshikawa, H; Obuse, C			Association of human origin recognition complex 1 with chromatin DNA and nuclease-resistant nuclear structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST ORIGIN; REPLICATION ORIGINS; BUDDING YEAST; FISSION YEAST; MCM PROTEINS; HUMAN-CELLS; S-PHASE; IN-VIVO; XENOPUS; HOMOLOG	An origin recognition complex (ORC) consisting of six polypeptides has been identified as a DNA replication origin-binding factor in Saccharomyces cerevisiae, Homologues of ORC subunits have been discovered among eukaryotes, and we have prepared monoclonal antibodies against a human homologue of ORC1 (hORC1) to study its localization in human cells. It was thus found to associate with nuclei throughout the cell cycle and to be resistant to nonionic detergent treatment, in contrast to MCM proteins, which are other replication factors, the association of which with nuclei is clearly dependent on the phase of the cell cycle, A characteristic feature of hORC1 is dissociation by NaCl in a narrow concentration range around 0.25 hi, suggesting interaction with some specific partner(s) in nuclei. Nuclease treatment experiments and UV cross-linking experiments further indicated interaction with both nuclease-resistant nuclear structures and chromatin DNA. Although its DNA binding was unaffected, some variation in the cell cycle was apparent, the association with nuclear structures being less stable in the M phase. Interestingly, the less stable association occurred concomitantly with hyperphosphorylation of hORC1, suggesting that this hyperphosphorylation may be involved in M phase changes.	Nara Inst Sci & Technol, Nara 6300101, Japan	Nara Institute of Science & Technology	Obuse, C (corresponding author), Nara Inst Sci & Technol, 8916-5 Takayama, Nara 6300101, Japan.		Obuse, Chikashi/F-5273-2011	Tsurimoto, Toshiki/0000-0001-7597-2216; Tatsumi, Yasutoshi/0000-0003-2646-7410				Aladjem MI, 1998, SCIENCE, V281, P1005, DOI 10.1126/science.281.5379.1005; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Asano M, 1999, EMBO J, V18, P2435, DOI 10.1093/emboj/18.9.2435; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Carpenter PB, 1998, J BIOL CHEM, V273, P24891, DOI 10.1074/jbc.273.38.24891; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Carr A, 1999, EMBO J, V18, P1598, DOI 10.1093/emboj/18.6.1598; Chesnokov I, 1999, GENE DEV, V13, P1289, DOI 10.1101/gad.13.10.1289; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Frankel S, 1997, J CELL SCI, V110, P1999; Fujita M, 1998, GENES CELLS, V3, P737, DOI 10.1046/j.1365-2443.1998.00226.x; Fujita M, 1999, J BIOL CHEM, V274, P25927, DOI 10.1074/jbc.274.36.25927; Fujita M, 1997, J BIOL CHEM, V272, P10928; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Ishiai M, 1997, GENOMICS, V46, P294, DOI 10.1006/geno.1997.5003; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Kalejta RF, 1998, MOL CELL, V2, P797, DOI 10.1016/S1097-2765(00)80294-4; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; Landis G, 1997, P NATL ACAD SCI USA, V94, P3888, DOI 10.1073/pnas.94.8.3888; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MASUKATA H, 1993, MOL BIOL CELL, V4, P1121, DOI 10.1091/mbc.4.11.1121; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; Obuse C, 1996, MOL BIOL CELL, V7, P43, DOI 10.1091/mbc.7.1.43; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Perkins G, 1998, MOL CELL, V2, P23, DOI 10.1016/S1097-2765(00)80110-0; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Pinto S, 1999, NEURON, V23, P45, DOI 10.1016/S0896-6273(00)80752-7; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Quintana DG, 1998, J BIOL CHEM, V273, P27137, DOI 10.1074/jbc.273.42.27137; QUINTANA DG, 1999, FRONT BIOSCI, V4, P805, DOI DOI 10.2741/QUINTANA; Ritzi M, 1998, J BIOL CHEM, V273, P24543, DOI 10.1074/jbc.273.38.24543; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; Takahara K, 1996, GENOMICS, V31, P119, DOI 10.1006/geno.1996.0018; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Triolo T, 1996, NATURE, V381, P251, DOI 10.1038/381251a0; Tugal T, 1998, J BIOL CHEM, V273, P32421, DOI 10.1074/jbc.273.49.32421; Wolf DA, 1996, J BIOL CHEM, V271, P32503, DOI 10.1074/jbc.271.51.32503; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; Ye Q, 1996, J BIOL CHEM, V271, P14653, DOI 10.1074/jbc.271.25.14653	48	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5904	5910		10.1074/jbc.275.8.5904	http://dx.doi.org/10.1074/jbc.275.8.5904			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681582	hybrid			2022-12-27	WOS:000085474500089
J	Koo, SH; Towle, HC				Koo, SH; Towle, HC			Glucose regulation of mouse S-14 gene expression in hepatocytes - Involvement of a novel transcription factor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE GENE; ELEMENT-BINDING PROTEIN; CARBOHYDRATE RESPONSE ELEMENT; UPSTREAM STIMULATORY FACTOR; THYROID-HORMONE; S14 GENE; FUNCTIONAL SYNERGISM; LIPOGENIC ENZYMES; STEROL REGULATION; SPOT-14 PROTEIN	Transcription of genes encoding enzymes required for lipogenesis is induced in hepatocytes in response to elevated glucose metabolism. We have previously mapped the carbohydrate-response elements (ChoREs) of the rat liver-type pyruvate kinase (L-PK) and S-14 genes and found them to share significant sequence similarity. However, progress in unraveling this signaling pathway has been hampered due to the difficulty in identifying the key factor(s) that bind to these ChoREs. To gain further insight into the nature of the carbohydrate-responsive transcription factor, the glucose regulatory sequences from the mouse S-14 gene were examined in primary hepatocytes. Three elements were found to be essential for supporting the glucose response: a thyroid hormone-response element between -1522 and -1494, an accessory factor site between -1421 and -1392, and the ChoRE between -1450 and -1425, Of these, only the accessory factor site was conserved between the rat and mouse S-14 genes. Investigation of the ChoRE sequence indicated that two half E box motifs are critical for the response to glucose. Electrophoretic mobility shift assays revealed a complex formed between the mouse S-14 ChoRE and liver nuclear proteins. This complex was also formed by ChoREs from the rat S-14 and L-PK genes but not by mutants of these sites that are inactive in supporting the glucose response. These results suggest the presence of a novel transcription factor complex that mediates the glucose-regulated transcription of S-14 and L-PK genes.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Towle, HC (corresponding author), 6-155 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.		Koo, Seung-Hoi/E-2763-2015	Koo, Seung-Hoi/0000-0001-8769-2879	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026919] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK26919] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown SB, 1997, J BIOL CHEM, V272, P2163, DOI 10.1074/jbc.272.4.2163; Clarke SD, 1996, J NUTR, V126, pS1105, DOI 10.1093/jn/126.suppl_4.1105S; DOIRON B, 1994, J BIOL CHEM, V269, P10213; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Foufelle F, 1996, BIOCHEM SOC T, V24, P372, DOI 10.1042/bst0240372; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; Grillasca JP, 1997, FEBS LETT, V401, P38, DOI 10.1016/S0014-5793(96)01433-0; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; Hasegawa J, 1999, J BIOL CHEM, V274, P1100, DOI 10.1074/jbc.274.2.1100; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JUMP DB, 1990, J BIOL CHEM, V265, P3474; JUMP DB, 1985, ENDOCRINOLOGY, V117, P2259, DOI 10.1210/endo-117-6-2259; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; KINLAW WB, 1995, J BIOL CHEM, V270, P16615, DOI 10.1074/jbc.270.28.16615; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; LIAW C, 1983, BIOCHEMISTRY-US, V22, P213, DOI 10.1021/bi00270a031; LIU HC, 1994, MOL ENDOCRINOL, V8, P1021, DOI 10.1210/me.8.8.1021; LIU ZR, 1993, J BIOL CHEM, V268, P12787; LIU ZR, 1995, BIOCHEM J, V308, P105, DOI 10.1042/bj3080105; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARIASH CN, 1986, J BIOL CHEM, V261, P9583; MARIASH CN, 1984, BIOCHEM BIOPH RES CO, V123, P1122; MARIASH CN, 1980, J CLIN INVEST, V65, P1126, DOI 10.1172/JCI109766; Moriizumi S, 1998, GENE EXPRESSION, V7, P103; NARAYAN P, 1984, P NATL ACAD SCI-BIOL, V81, P4687, DOI 10.1073/pnas.81.15.4687; Osborne TF, 1998, METHODS, V16, P42, DOI 10.1006/meth.1998.0643; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SEELIG S, 1981, P NATL ACAD SCI-BIOL, V78, P4733, DOI 10.1073/pnas.78.8.4733; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; SHIH HM, 1995, BIOTECHNIQUES, V18, P813; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SHIH HM, 1992, J BIOL CHEM, V267, P13222; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; Yamada K, 1999, BIOCHEM BIOPH RES CO, V257, P44, DOI 10.1006/bbrc.1999.0410	52	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5200	5207		10.1074/jbc.275.7.5200	http://dx.doi.org/10.1074/jbc.275.7.5200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671567	hybrid			2022-12-27	WOS:000085378200093
J	Lando, D; Pongratz, I; Poellingers, L; Whitelaw, ML				Lando, D; Pongratz, I; Poellingers, L; Whitelaw, ML			A redox mechanism controls differential DNA binding activities of hypoxia-inducible factor (HIF) 1 alpha and the HIF-like factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; DISULFIDE BOND FORMATION; PAS DOMAIN PROTEIN-1; TRANSCRIPTION FACTOR; DIOXIN RECEPTOR; ALPHA-SUBUNIT; ACTIVATION; REF-1; CELLS; THIOREDOXIN	Hypoxia-inducible factor 1 alpha (HIF-1 alpha) and the HIF-like factor (HLF) are two highly related basic Helix-Loop-Helix/Per-Arnt-Sim (bHLH/PAS) homology transcription factors that undergo dramatically increased function at low oxygen levels. Despite strong similarities in their activation mechanisms (e.g, they both undergo rapid hypoxia-induced protein stabilization, bind identical target DNA sequences, and induce synthetic reporter genes to similar degrees), they are both essential for embryo survival via distinct functions during vascularization (HIF-1 alpha) or catecholamine production (HLF). It is currently unknown how such specificity of action is achieved. We report here that DNA binding by HLF, but not by HIF-1 alpha, is dependent upon reducing redox conditions. In vitro DNA binding and mammalian two-hybrid assays showed that a unique cysteine in the DNA-binding basic region of HLF is a target for the reducing activity of redox factor Ref-1. Although the N-terminal DNA-binding domain of HIF-1 alpha can function in the absence of Ref-1, we found that the C-terminal region containing the transactivation domain requires Ref-1 for fall activity. Our data reveal that the hypoxia-inducible factors are subject to complex redox control mechanisms that can target discrete regions of the proteins and are the first to establish a discriminating control mechanism for differential regulation of RIF-la and HLF activity.	Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia; Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	University of Adelaide; Karolinska Institutet	Whitelaw, ML (corresponding author), Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia.	murray.whitelaw@adelaide.edu.au	Lando, David/A-2546-2010; Lando, David/AAH-3052-2019	Lando, David/0000-0001-5783-8769				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Asai T, 1997, BIOCHEM BIOPH RES CO, V236, P71, DOI 10.1006/bbrc.1997.6906; Aslund F, 1999, CELL, V96, P751, DOI 10.1016/S0092-8674(00)80584-X; Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; BENEZRA R, 1994, CELL, V79, P1057, DOI 10.1016/0092-8674(94)90036-1; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BRESNICK EH, 1988, BIOCHEMISTRY-US, V27, P2866, DOI 10.1021/bi00408a030; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Hayashi S, 1997, NUCLEIC ACIDS RES, V25, P4035, DOI 10.1093/nar/25.20.4035; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; Hunter T, 1998, CELL, V92, P141, DOI 10.1016/S0092-8674(00)80906-X; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kappel A, 1999, BLOOD, V93, P4284, DOI 10.1182/blood.V93.12.4284.412k25_4284_4292; Liu YX, 1998, J BIOL CHEM, V273, P15257, DOI 10.1074/jbc.273.24.15257; Makino Y, 1999, J BIOL CHEM, V274, P3182, DOI 10.1074/jbc.274.5.3182; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Nakshatri H, 1996, J BIOL CHEM, V271, P28784, DOI 10.1074/jbc.271.46.28784; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Okamoto K, 1999, J BIOL CHEM, V274, P10363, DOI 10.1074/jbc.274.15.10363; OKUNO H, 1993, ONCOGENE, V8, P695; Pongratz I, 1998, MOL CELL BIOL, V18, P4079, DOI 10.1128/MCB.18.7.4079; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1998, J LAB CLIN MED, V131, P207, DOI 10.1016/S0022-2143(98)90091-9; SIMONS SS, 1995, METHOD ENZYMOL, V251, P406; SNYDER GH, 1981, BIOCHEMISTRY-US, V20, P6509, DOI 10.1021/bi00526a001; Sogawa K, 1998, P NATL ACAD SCI USA, V95, P7368, DOI 10.1073/pnas.95.13.7368; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; Tell G, 1998, BIOCHEM BIOPH RES CO, V252, P178, DOI 10.1006/bbrc.1998.9548; Tell G, 1998, J BIOL CHEM, V273, P25062, DOI 10.1074/jbc.273.39.25062; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	60	145	155	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4618	4627		10.1074/jbc.275.7.4618	http://dx.doi.org/10.1074/jbc.275.7.4618			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671489	hybrid			2022-12-27	WOS:000085378200015
J	McManus, DC; Scott, BR; Frank, PG; Franklin, V; Schultz, JR; Marcel, YL				McManus, DC; Scott, BR; Frank, PG; Franklin, V; Schultz, JR; Marcel, YL			Distinct central amphipathic alpha-helices in apolipoprotein A-I contribute to the in vivo maturation of high density lipoprotein by either activating lecithin-cholesterol acyltransferase or binding lipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; APOA-I; PLASMA APOLIPOPROTEINS; PHOSPHOLIPID-BINDING; KNOCKOUT MICE; HEART-DISEASE; CONFORMATION; ALTERS; HDL; ATHEROSCLEROSIS	Recombinant adenoviruses with cDNAs for human apolipoprotein A-I (wild type (wt) apoA-I) and three mutants, referred to as Delta 4-5A-I, Delta 5-6A-I, and Delta 6-7A-I, that have deletions removing regions coding for amino acids 100-143, 122-165, and 144-186, respectively, were created to study structure/function relationships of apoA-I in vivo, All mutants were expressed at lower concentrations than wt apoA-I in plasma of fasting apoA-I-deficient mice. The Delta 5-6A-I mutant was found primarily in the lipid-poor high density lipoprotein (HDL) pool and at lower concentrations than Delta 4-5A-I and Delta 6-7A-I that formed more buoyant HDL2/3 particles. At an elevated adenovirus dose and earlier blood sampling from fed mice, both Delta 5-6A-I and Delta 6-7A-I increased HDL-free cholesterol and phospholipid but not cholesteryl ester, In contrast, wt apoA-I and Delta 4-5A-I produced significant increases in HDL cholesteryl ester, Further analysis showed that Delta 6-7A-I and native apoA-I could bind similar amounts of phospholipid and cholesterol that were reduced slightly for Delta 5-6A-I and greatly for Delta 4-5A-I. We conclude from these findings that amino acids (aa) 100-143, specifically helix 4 (aa 100-121), contributes to the maturation of HDL through a role in lipid binding and that the downstream sequence (aa 144-186) centered around helix 6 (aa 144-165) is responsible for the activation of lecithin-cholesterol acyltransferase.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Dept Pathol & Lab Med, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Dept Biochem Microbiol & Immunol, Ottawa, ON K1Y 4W7, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute	Marcel, YL (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, 40 Ruskin St, Ottawa, ON K1Y 4W7, Canada.		Frank, Philippe G/A-3463-2011	Frank, Philippe G/0000-0003-4857-5279; Scott, Brian/0000-0002-7012-4696				ANANTHARAMAIAH GM, 1990, ARTERIOSCLEROSIS, V10, P95, DOI 10.1161/01.ATV.10.1.95; BANKA CL, 1991, J BIOL CHEM, V266, P23886; Bergeron J, 1997, BBA-LIPID LIPID MET, V1344, P139, DOI 10.1016/S0005-2760(96)00136-1; BERGERON J, 1995, J BIOL CHEM, V270, P27429, DOI 10.1074/jbc.270.46.27429; BREWER HB, 1978, BIOCHEM BIOPH RES CO, V80, P623, DOI 10.1016/0006-291X(78)91614-5; BROUILLETTE CG, 1995, BBA-LIPID LIPID MET, V1256, P103, DOI 10.1016/0005-2760(95)00018-8; CALABRESI L, 1993, BIOCHEMISTRY-US, V32, P6477, DOI 10.1021/bi00076a023; CALABRESI L, 1992, BIOCHIM BIOPHYS ACTA, V1124, P195, DOI 10.1016/0005-2760(92)90098-G; Davidson WS, 1996, P NATL ACAD SCI USA, V93, P13605, DOI 10.1073/pnas.93.24.13605; Dhoest A, 1997, J BIOL CHEM, V272, P15967, DOI 10.1074/jbc.272.25.15967; DOBIASOVA M, 1991, ARTERIOSCLER THROMB, V11, P64, DOI 10.1161/01.ATV.11.1.64; Durbin DM, 1997, J BIOL CHEM, V272, P31333, DOI 10.1074/jbc.272.50.31333; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; Frank PG, 1998, BIOCHEMISTRY-US, V37, P13902, DOI 10.1021/bi981205b; Frank PG, 1997, BIOCHEMISTRY-US, V36, P1798, DOI 10.1021/bi962118r; HOLVOET P, 1995, BIOCHEMISTRY-US, V34, P13334, DOI 10.1021/bi00041a009; Holvoet P, 1998, J CLIN INVEST, V102, P379, DOI 10.1172/JCI3038; Laccotripe M, 1997, J BIOL CHEM, V272, P17511, DOI 10.1074/jbc.272.28.17511; Lindholm EM, 1998, BIOCHEMISTRY-US, V37, P4863, DOI 10.1021/bi972888i; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MENG QH, 1993, J BIOL CHEM, V268, P16966; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; MILLER NE, 1977, LANCET, V1, P965, DOI 10.1016/S0140-6736(77)92274-7; MINNICH A, 1992, J BIOL CHEM, V267, P16553; Mishra VK, 1998, BIOCHEMISTRY-US, V37, P10313, DOI 10.1021/bi980042o; Mishra VK, 1996, BIOCHEMISTRY-US, V35, P11210, DOI 10.1021/bi960760f; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; PARKS JS, 1995, J LIPID RES, V36, P349; Plump AS, 1997, J LIPID RES, V38, P1033; Rigotti A, 1997, CURR OPIN LIPIDOL, V8, P181, DOI 10.1097/00041433-199706000-00009; Rogers DP, 1997, BIOCHEMISTRY-US, V36, P288, DOI 10.1021/bi961876e; SCHMIDT HHJ, 1995, J BIOL CHEM, V270, P5469, DOI 10.1074/jbc.270.10.5469; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; Sorci-Thomas MG, 1998, J BIOL CHEM, V273, P11776, DOI 10.1074/jbc.273.19.11776; SORCITHOMAS M, 1993, J BIOL CHEM, V268, P21403; SorciThomas MG, 1997, J BIOL CHEM, V272, P7278, DOI 10.1074/jbc.272.11.7278; SOUTAR AK, 1975, BIOCHEMISTRY-US, V14, P3057, DOI 10.1021/bi00685a003; Uboldi P, 1996, J LIPID RES, V37, P2557	39	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5043	5051		10.1074/jbc.275.7.5043	http://dx.doi.org/10.1074/jbc.275.7.5043			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671546	hybrid			2022-12-27	WOS:000085378200072
J	Sherman, DL; Brophy, PJ				Sherman, DL; Brophy, PJ			A tripartite nuclear localization signal in the PDZ-domain protein L-periaxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELINATING SCHWANN-CELLS; BASIC-PROTEIN; GENE; PSD-95/SAP90; EXPRESSION; SEQUENCES; TRANSPORT; COMPLEX; SYNGAP; KINASE	The murine Periaxin gene encodes two PDZ-domain proteins in myelin-forming Schwann cells of the vertebrate peripheral nervous system (Dytrych, L., Sherman, D. L., Gillespie, C. S., and Brophy, P. J. (1998) J. Biol. Chem, 273, 5794-5800), Here we show that L-periaxin is targeted to the nucleus of embryonic Schwann cells. Subsequently, the protein redistributes to the plasma membrane processes of the myelinating Schwann cell where it is believed to function in a signaling complex. In contrast, L-periaxin remains in the nucleus when expressed ectopically in oligodendrocytes, the myelin-forming glia of the central nervous system. The nuclear localization signal (NLS) is basic and tripartite and comprises three signals that act synergistically, Nuclear targeting of L-periaxin is energy-dependent and is inhibited by cell-cell contact. These data show that L-periaxin is a member of a growing family of proteins that can shuttle between the nucleus and cortical signaling/adherence complexes.	Univ Edinburgh, Dept Preclin Vet Sci, Edinburgh EH9 1QH, Midlothian, Scotland	University of Edinburgh	Brophy, PJ (corresponding author), Univ Edinburgh, Dept Preclin Vet Sci, Summerhall, Edinburgh EH9 1QH, Midlothian, Scotland.							ALI SA, 1995, BIOTECHNIQUES, V18, P746; BERRYMAN MA, 1992, J HISTOCHEM CYTOCHEM, V40, P845, DOI 10.1177/40.6.1350287; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; Dytrych L, 1998, J BIOL CHEM, V273, P5794, DOI 10.1074/jbc.273.10.5794; FISCHERFANTUZZI L, 1988, MOL CELL BIOL, V8, P5495, DOI 10.1128/MCB.8.12.5495; GILLESPIE CS, 1994, NEURON, V12, P497, DOI 10.1016/0896-6273(94)90208-9; Gottardi CJ, 1996, P NATL ACAD SCI USA, V93, P10779, DOI 10.1073/pnas.93.20.10779; GOW A, 1992, J CELL BIOL, V119, P605, DOI 10.1083/jcb.119.3.605; Gumbiner BM, 1998, CURR OPIN GENET DEV, V8, P430, DOI 10.1016/S0959-437X(98)80114-7; HOGAN B, 1994, MANIPULATING MOUSE E, P226; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Mirsky R, 1996, CURR OPIN NEUROBIOL, V6, P89, DOI 10.1016/S0959-4388(96)80013-4; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; Pedraza L, 1997, J NEUROSCI RES, V50, P258, DOI 10.1002/(SICI)1097-4547(19971015)50:2<258::AID-JNR14>3.0.CO;2-4; Scherer SS, 1995, DEVELOPMENT, V121, P4265; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SHIEH MW, 1993, PLANT PHYSIOL, V101, P353, DOI 10.1104/pp.101.2.353; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; Yang N, 1999, BIOCHEM J, V338, P793, DOI 10.1042/0264-6021:3380793	29	56	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4537	4540		10.1074/jbc.275.7.4537	http://dx.doi.org/10.1074/jbc.275.7.4537			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671475	hybrid			2022-12-27	WOS:000085378200001
J	Slack, JL; Schooley, K; Bonnert, TP; Mitcham, JL; Qwarnstrom, EE; Sims, JE; Dower, SK				Slack, JL; Schooley, K; Bonnert, TP; Mitcham, JL; Qwarnstrom, EE; Sims, JE; Dower, SK			Identification of two major sites in the type I interleukin-1 receptor cytoplasmic region responsible for coupling to pro-inflammatory signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; IL-1 RECEPTOR; DROSOPHILA TOLL; MOLECULAR-CLONING; T-CELLS; KINASE; GENE; PROTEIN; MYD88; ACTIVATION	Type I interleukin-1 receptor is the prototype for a family of proteins, which play a central role in early responses to injury and infection, The similarity of function across the family is reflected in similarity in signaling: all members tested couple to activation of NF kappa B and stress kinases. The coupling to these pathways is mediated by a 200-residue intracellular domain (the Toll/interleukin-l receptor domain), in which sequence conservation is primarily confined to three short motifs (boxes 1, 2, and 3) located at amino acid residue positions 10 (box 1), 60 (box 2), and 170 (box 3). We have analyzed the contribution of these motifs to function by alanine scanning mutagenesis of the human interleukin-1 receptor type I. Mutant receptors were tested for expression, ligand binding, activation of receptor-associated kinase(s), NF kappa B, stress kinases, and transcription. Mutations in all three motifs led to low cell surface expression. Mutants in box 3 were, however, wild type for signaling, whereas mutants in boxes 1 and 2 were defective. We conclude that the conserved motifs box 1 and box 2 mediate the coupling of molecules in the family to inflammation signaling pathways.	Univ Sheffield, Royal Hallamshire Hosp, Div Mol & Genet Med, Funct Genomics Grp, Sheffield S10 2JF, S Yorkshire, England; Immunex Res & Dev Corp, Seattle, WA 98101 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	University of Sheffield; University of Washington; University of Washington Seattle	Dower, SK (corresponding author), Univ Sheffield, Royal Hallamshire Hosp, Div Mol & Genet Med, Funct Genomics Grp, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.			Qwarnstrom, Eva/0000-0003-4417-8663; Sims, John/0000-0002-5667-9185; dower, steve/0000-0002-4675-4225				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; BIRD TA, 1991, J BIOL CHEM, V266, P22661; Born TL, 1998, J BIOL CHEM, V273, P29445, DOI 10.1074/jbc.273.45.29445; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; Dinarello CA, 1996, CURR TOP MICROBIOL, V216, P133; DOWER SK, 1986, NATURE, V324, P266, DOI 10.1038/324266a0; DOWER SK, 1985, MOL IMMUNOL, V22, P937, DOI 10.1016/0161-5890(85)90080-X; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; HEGUY A, 1992, J BIOL CHEM, V267, P2605; KUNO K, 1993, J BIOL CHEM, V268, P13510; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LEUNG KY, 1994, J BIOL CHEM, V269, P1579; Levashina EA, 1998, J MOL BIOL, V278, P515, DOI 10.1006/jmbi.1998.1705; LORD KA, 1990, ONCOGENE, V5, P1095; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MARTIN M, 1994, EUR J IMMUNOL, V24, P1566, DOI 10.1002/eji.1830240717; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; MITCHAM JL, 1995, CYTOKINE, V7, P595; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Parnet P, 1996, J BIOL CHEM, V271, P3967; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; QWARNSTROM EE, 1988, J BIOL CHEM, V263, P8261; QWARNSTROM EE, 1991, P NATL ACAD SCI USA, V88, P1232, DOI 10.1073/pnas.88.4.1232; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; ROSETTO M, 1995, BIOCHEM BIOPH RES CO, V209, P111, DOI 10.1006/bbrc.1995.1477; SIMS JE, 1994, EUR CYTOKINE NETW, V5, P539; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; URDAL DL, 1988, J BIOL CHEM, V263, P2870; Valles S, 1999, J BIOL CHEM, V274, P20103, DOI 10.1074/jbc.274.29.20103; Volpe F, 1997, FEBS LETT, V419, P41, DOI 10.1016/S0014-5793(97)01426-9; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Zhu P, 1998, BIOCHEM J, V330, P975, DOI 10.1042/bj3300975	49	236	255	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4670	4678		10.1074/jbc.275.7.4670	http://dx.doi.org/10.1074/jbc.275.7.4670			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671496	hybrid			2022-12-27	WOS:000085378200022
J	Kassam, A; Winrow, CJ; Fernandez-Rachubinski, F; Capone, JP; Rachubinski, RA				Kassam, A; Winrow, CJ; Fernandez-Rachubinski, F; Capone, JP; Rachubinski, RA			The peroxisome proliferator response element of the gene encoding the peroxisomal beta-oxidation enzyme enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase is a target for constitutive androstane receptor beta/9-cis-retinoic acid receptor-mediated transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HYDRATASE-DEHYDROGENASE; NUCLEAR FACTOR-IV; ACTIVATED RECEPTOR; RETINOIC ACID; THYROID-HORMONE; FATTY-ACIDS; NGFI-B; ORPHAN; SUPERFAMILY; ALPHA	The genes encoding the first two enzymes of the peroxisomal beta-oxidation pathway, acyl-CoA oxidase (AOx) and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase (HD), contain upstream cis-acting regulatory regions termed peroxisome proliferator response elements (PPRE), Transcription of these genes is mediated through the binding of peroxisome proliferator-activated receptor or (PPAR alpha), which binds to a PPRE as a heterodimer with the 9-cis-retinoic acid receptor (RXR alpha). Here we demonstrate that the HD-PPRE is also a target for the constitutive androstane receptor beta (CAR beta) In vitro binding analysis showed that CAR beta bound the HD-PPRE, but not the AOx-PPRE, as a heterodimer with RXR alpha, Binding of CAR beta/RXR alpha to the HD-PPRE occurred via determinants that overlap partially with those required for PPAR alpha/RXR alpha binding. In vivo, CAR beta/RXR alpha activated transcription from an HD-PPRE luciferase reporter construct, Interestingly, CAR beta was shown to also modulate PPAR alpha/RXR alpha-mediated transactivation in a response element-specific manner. In the presence of the peroxisome proliferator, Wy-14,643, CAR beta had no effect on PPAR alpha/RXR alpha-mediated transactivation from the HD-PPRE but antagonized transactivation from the AOx-PPRE in both the presence and the absence of proliferator, Our results illustrate that transcription of the AOx and HD genes is differentially regulated by CAR beta and that the HD gene is a specific target for regulation by CAR beta, Overall, this study proposes a novel role for CAR beta in the regulation of peroxisomal beta-oxidation.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	University of Alberta; University of Alberta; McMaster University	Rachubinski, RA (corresponding author), Univ Alberta, Dept Cell Biol, Med Sci Bldg 5-14, Edmonton, AB T6G 2H7, Canada.		Winrow, Christopher/K-1864-2014	Winrow, Christopher/0000-0001-8248-4157				BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; CARTER ME, 1993, J BIOL CHEM, V268, P13805; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; CHU RY, 1995, J BIOL CHEM, V270, P29636; DAVIS IJ, 1991, MOL ENDOCRINOL, V5, P854, DOI 10.1210/mend-5-6-854; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Dowell P, 1999, J BIOL CHEM, V274, P15901, DOI 10.1074/jbc.274.22.15901; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; Feltkamp D, 1999, J BIOL CHEM, V274, P10421, DOI 10.1074/jbc.274.15.10421; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Hunter J, 1996, MOL CELL ENDOCRINOL, V116, P213, DOI 10.1016/0303-7207(95)03717-9; Kassam A, 1999, J BIOL CHEM, V274, P22895, DOI 10.1074/jbc.274.32.22895; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Lambe KG, 1996, EUR J BIOCHEM, V239, P1, DOI 10.1111/j.1432-1033.1996.0001u.x; LYNCH JP, 1993, MOL ENDOCRINOL, V7, P776, DOI 10.1210/me.7.6.776; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; PAULSEN RE, 1992, J BIOL CHEM, V267, P16491; Picard D, 1998, NATURE, V395, P543, DOI 10.1038/26850; Rachubinski RA, 1999, J BIOL CHEM, V274, P18278, DOI 10.1074/jbc.274.26.18278; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Winrow Christopher J., 1994, Gene Expression, V4, P53; Winrow CJ, 1998, J BIOL CHEM, V273, P31442, DOI 10.1074/jbc.273.47.31442; ZHANG BW, 1993, J BIOL CHEM, V268, P12939; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	41	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4345	4350		10.1074/jbc.275.6.4345	http://dx.doi.org/10.1074/jbc.275.6.4345			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660604	hybrid			2022-12-27	WOS:000085288800088
J	Martens, JR; Navarro-Polanco, R; Coppock, EA; Nishiyama, A; Parshley, L; Grobaski, TD; Tamkun, MM				Martens, JR; Navarro-Polanco, R; Coppock, EA; Nishiyama, A; Parshley, L; Grobaski, TD; Tamkun, MM			Differential targeting of shaker-like potassium channels to lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNEL; PLASMA-MEMBRANE; HIPPOCAMPAL-NEURONS; CAVEOLAE; PROTEINS; EXPRESSION; IDENTIFICATION; MICRODOMAINS; PURIFICATION; COMPLEXES	Ion channel targeting within neuronal and muscle membranes is an important determinant of electrical excitability, Recent evidence suggests that there exists within the membrane specialized microdomains commonly referred to as lipid rafts. These domains are enriched in cholesterol and sphingolipids and concentrate a number of signal transduction proteins such as nitric-oxide synthase, ligand-gated receptors, and multiple protein kinases, Here, we demonstrate that the voltage-gated K+ channel Kv2.1, but not Kv4.2, targets to lipid rafts in both heterologous expression sg systems and rat brain. The Kv2.1 association with lipid rafts does not appear to involve caveolin. Depletion of cellular cholesterol alters the buoyancy of the Kv2.1 associated rafts and shifts the midpoint of Kv2.1 inactivation by nearly 40 mV without affecting peak current density or channel activation. The differential targeting of K+ channels to lipid rafts represents a novel mechanism both for the subcellular sorting of K+ channels to regions of the membrane rich in signaling complexes and for modulating channel properties via alterations in lipid content.	Colorado State Univ, Dept Physiol, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Biochem, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Mol Biol, Ft Collins, CO 80523 USA	Colorado State University; Colorado State University; Colorado State University	Tamkun, MM (corresponding author), Colorado State Univ, Dept Physiol, Ft Collins, CO 80523 USA.	tamkunmm@lamar.colostate.edu	Navarro-Polanco, Ricardo/AAQ-6152-2021		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD008496] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049330] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-49330] Funding Source: Medline; NICHD NIH HHS [1F32HD08496-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Arnold DB, 1999, NEURON, V23, P149, DOI 10.1016/S0896-6273(00)80761-8; Colman DR, 1999, NEURON, V23, P649, DOI 10.1016/S0896-6273(01)80024-6; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; Fiset C, 1997, J PHYSIOL-LONDON, V500, P51, DOI 10.1113/jphysiol.1997.sp021998; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Hulme JT, 1999, CIRC RES, V85, P489, DOI 10.1161/01.RES.85.6.489; Ikezu T, 1998, BRAIN RES, V804, P177, DOI 10.1016/S0006-8993(98)00498-3; Isshiki M, 1998, P NATL ACAD SCI USA, V95, P5009, DOI 10.1073/pnas.95.9.5009; Jonas EA, 1996, CURR OPIN NEUROBIOL, V6, P318, DOI 10.1016/S0959-4388(96)80114-0; JORGENSEN AO, 1989, J CELL BIOL, V109, P135, DOI 10.1083/jcb.109.1.135; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Klemic KG, 1998, BIOPHYS J, V74, P1779, DOI 10.1016/S0006-3495(98)77888-9; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; MALETICSAVATIC M, 1995, J NEUROSCI, V15, P3840; Masserini M, 1999, J NEUROCHEM, V73, P1, DOI 10.1046/j.1471-4159.1999.0730001.x; MAYS DJ, 1995, J CLIN INVEST, V96, P282, DOI 10.1172/JCI118032; Nakahira K, 1996, J BIOL CHEM, V271, P7084, DOI 10.1074/jbc.271.12.7084; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Perez AS, 1998, NEUROSCI LETT, V258, P121, DOI 10.1016/S0304-3940(98)00846-5; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scannevin RH, 1996, J CELL BIOL, V135, P1619, DOI 10.1083/jcb.135.6.1619; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sobko A, 1998, EMBO J, V17, P4723, DOI 10.1093/emboj/17.16.4723; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; TRIMMER JS, 1991, P NATL ACAD SCI USA, V88, P10764, DOI 10.1073/pnas.88.23.10764; Volonte D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554	35	215	219	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7443	7446		10.1074/jbc.275.11.7443	http://dx.doi.org/10.1074/jbc.275.11.7443			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713042	hybrid			2022-12-27	WOS:000085913300002
J	Waggoner, DJ; Drisaldi, B; Bartnikas, TB; Casareno, RLB; Prohaska, JR; Gitlin, JD; Harris, DA				Waggoner, DJ; Drisaldi, B; Bartnikas, TB; Casareno, RLB; Prohaska, JR; Gitlin, JD; Harris, DA			Brain copper content and cuproenzyme activity do not vary with prion protein expression level	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; MICE; LOCALIZATION; CHAPERONE; REGION; CELLS; PRP	Prion diseases are neurodegenerative disorders that result from conformational transformation of a normal cell surface glycoprotein, PrPC, into a pathogenic isoform, PrPSc. Although the normal physiological function of PrPC has remained enigmatic, the recent observation that the protein binds copper ions with micromolar affinity suggests a possible role in brain copper metabolism, In this study, we have used mice that express 0, 1, and 10 times the normal level of PrP to assess the effect of PrP expression level on the amount of brain copper and on the properties of two brain cuproenzymes, Using mass spectrometry, we find that the amount of ionic copper in subcellular fractions from brain is similar in all three lines of mice. In addition, the enzymatic activities of Cu-Zn superoxide dismutase and cytochrome c oxidase in brain extracts are similar in these groups of animals, as is the incorporation of Cu-64 into Cu-Zn superoxide dismutase both in cultured cerebellar neurons and in vivo, Our results differ from those of another set of published studies, and they require a re-evaluation of the role of PrPC in copper metabolism.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA; Univ Minnesota, Dept Biochem & Mol Biol, Duluth, MN 55812 USA	Washington University (WUSTL); Washington University (WUSTL); University of Minnesota System; University of Minnesota Duluth	Harris, DA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.			Harris, David/0000-0002-6985-5790	NIA NIH HHS [AG12925] Funding Source: Medline; NICHD NIH HHS [T32 HD07507] Funding Source: Medline; NIDDK NIH HHS [DK44464] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044464, R37DK044464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012925] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; Brown DR, 1998, BIOCHEM J, V334, P423, DOI 10.1042/bj3340423; Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; Crapo J D, 1978, Methods Enzymol, V53, P382; Culotta VC, 1999, ADV EXP MED BIOL, V448, P247; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DEROBERTIS E, 1962, J NEUROCHEM, V9, P23; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; Harris DA, 1999, CLIN MICROBIOL REV, V12, P429, DOI 10.1128/CMR.12.3.429; Herms J, 1999, J NEUROSCI, V19, P8866, DOI 10.1523/JNEUROSCI.19-20-08866.1999; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Linder M, 1991, BIOCH COPPER; Lippard SJ, 1999, SCIENCE, V284, P748, DOI 10.1126/science.284.5415.748; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Miura T, 1999, BIOCHEMISTRY-US, V38, P11560, DOI 10.1021/bi9909389; Miura T, 1996, FEBS LETT, V396, P248, DOI 10.1016/0014-5793(96)01104-0; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; PROHASKA JR, 1991, J NUTR, V121, P355, DOI 10.1093/jn/121.3.355; PRUSINER SB, 1999, PRION BIOL DIS; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Sayre LM, 1999, CURR OPIN CHEM BIOL, V3, P220, DOI 10.1016/S1367-5931(99)80035-0; SMITH RM, 1983, NEUROBIOLOGY TRACE E, V1, P1; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Waggoner DJ, 1999, NEUROBIOL DIS, V6, P221, DOI 10.1006/nbdi.1999.0250; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030	34	158	162	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7455	7458		10.1074/jbc.275.11.7455	http://dx.doi.org/10.1074/jbc.275.11.7455			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713045	hybrid			2022-12-27	WOS:000085913300005
J	Atamna, H; Paler-Martinez, A; Ames, BN				Atamna, H; Paler-Martinez, A; Ames, BN			N-t-butyl hydroxylamine, a hydrolysis product of alpha-phenyl-N-t-butyl nitrone, is more potent in delaying senescence in human lung fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROXIDE SPIN LABELS; OXIDATIVE DAMAGE; NITRIC-OXIDE; MITOCHONDRIAL-FUNCTION; RADICAL PRODUCTION; TERT-BUTYLNITRONE; BRAIN PROTEINS; LIFE-SPAN; OLD RATS; SUPEROXIDE	alpha-Phenyl-N-t-butyl nitrone (PBN), a spin trap, scavenges hydroxyl radicals, protects tissues from oxidative injury, and delays senescence of both normal human lung fibroblasts (IMR90) and senescence-accelerated mice. N-t-butyl hydroxylamine and benzaldehyde are the breakdown products of PEN. N-t-Butyl hydroxylamine delays senescence of IMR90 cells at concentrations as low as 10 mu M compared with 200 mu M PEN to produce a similar effect, suggesting that N-t-butyl hydroxylamine is the active form of PEN. N-Benzyl hydroxylamine and N-methyl hydroxylamine compounds unrelated to PEN were also effective in delaying senescence, suggesting the active functional group is the N-hydroxylamine. All the N-hydroxylamines tested significantly decreased the endogenous production of oxidants, as measured by the oxidation of 2',7'-dichlorodihydrofluorescin and the increase in the GSH/GSSG ratio. The acceleration of senescence induced by hydrogen peroxide is reversed by the N-hydroxylamines. DNA damage, as determined by the level of apurinic/apyrimidinic sites, also decreased significantly following treatment with N-hydroxylamines. The N-hydroxylamines appear to be effective through mitochondria; they delay age-dependent changes in mitochondria as measured by accumulation of rhodamine-123, they prevent reduction of cytochrome C-FeIII by superoxide radical, and they reverse an age dependent decay of mitochondrial aconitase, suggesting they react with the superoxide radical.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Ames, BN (corresponding author), CHORI, Div Biochem & Mol Biol, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.				NATIONAL CANCER INSTITUTE [R35CA039910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017140] Funding Source: NIH RePORTER; NCI NIH HHS [CA39910] Funding Source: Medline; NIA NIH HHS [AG17140] Funding Source: Medline; NIEHS NIH HHS [ES01896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBANO E, 1986, BIOCHEM PHARMACOL, V35, P3955, DOI 10.1016/0006-2952(86)90010-9; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BELKIN S, 1987, ARCH BIOCHEM BIOPHYS, V256, P232, DOI 10.1016/0003-9861(87)90441-3; BRITIGAN BE, 1990, J BIOL CHEM, V265, P17533; Butterfield DA, 1997, P NATL ACAD SCI USA, V94, P674, DOI 10.1073/pnas.94.2.674; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; CHAMULITRAT W, 1995, FREE RADICAL RES, V23, P1, DOI 10.3109/10715769509064014; CHAMULITRAT W, 1993, J BIOL CHEM, V268, P11520; CHEN K, 1989, BIOCHEMISTRY-US, V28, P2496, DOI 10.1021/bi00432a022; CHEN K, 1988, BIOCHIM BIOPHYS ACTA, V970, P270, DOI 10.1016/0167-4889(88)90126-7; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; Dikalov SI, 1999, J BIOL CHEM, V274, P9392, DOI 10.1074/jbc.274.14.9392; EDAMATSU R, 1995, BIOCHEM BIOPH RES CO, V211, P847, DOI 10.1006/bbrc.1995.1889; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; Gee P, 1998, MUTAT RES-GEN TOX EN, V412, P115, DOI 10.1016/S1383-5718(97)00172-1; Gold LS, 1997, HDB CARCINOGENIC POT, P1; GUARRIER.V, 1973, EUR J BIOCHEM, V34, P455, DOI 10.1111/j.1432-1033.1973.tb02779.x; Hagen TM, 1998, ANN NY ACAD SCI, V854, P214, DOI 10.1111/j.1749-6632.1998.tb09904.x; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; Hagen TM, 1998, P NATL ACAD SCI USA, V95, P9562, DOI 10.1073/pnas.95.16.9562; HARMAN D, 1961, J GERONTOL, V16, P247, DOI 10.1093/geronj/16.3.247; Hensley K, 1998, J NEUROCHEM, V71, P2549; Kashiwakura I, 1997, RES COMMUN MOL PATH, V98, P67; KRISHNA MC, 1992, P NATL ACAD SCI USA, V89, P5537, DOI 10.1073/pnas.89.12.5537; Krishna MC, 1996, J BIOL CHEM, V271, P26018, DOI 10.1074/jbc.271.42.26018; KUBO K, 1992, BIOCHEMISTRY-US, V31, P3703, DOI 10.1021/bi00129a020; Lakritz J, 1996, J PHARMACOL EXP THER, V278, P1408; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Nakashima M, 1999, FREE RADICAL BIO MED, V26, P722, DOI 10.1016/S0891-5849(98)00257-3; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; Parman T, 1999, NAT MED, V5, P582, DOI 10.1038/8466; Rota C, 1999, J BIOL CHEM, V274, P28161, DOI 10.1074/jbc.274.40.28161; Saito K, 1998, BIOL PHARM BULL, V21, P401; Saito K, 1998, BIOSCI BIOTECH BIOCH, V62, P792, DOI 10.1271/bbb.62.792; SAMUNI A, 1988, J BIOL CHEM, V263, P17921; SAMUNI A, 1990, FREE RADICAL RES COM, V9, P241, DOI 10.3109/10715769009145682; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; SEN S, 1993, FREE RADICAL RES COM, V19, P255, DOI 10.3109/10715769309056513; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SWARTZ HM, 1990, FREE RADICAL RES COM, V9, P399, DOI 10.3109/10715769009145700; Twomey P, 1997, FREE RADICAL BIO MED, V22, P909, DOI 10.1016/S0891-5849(96)00477-7; Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168; YUE TL, 1992, BRAIN RES, V574, P193, DOI 10.1016/0006-8993(92)90816-R; Zhang RL, 1999, FREE RADICAL BIO MED, V26, P1245, DOI 10.1016/S0891-5849(98)00328-1; Zhang RL, 1998, FREE RADICAL BIO MED, V24, P332, DOI 10.1016/S0891-5849(97)00267-0	47	120	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6741	6748		10.1074/jbc.275.10.6741	http://dx.doi.org/10.1074/jbc.275.10.6741			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702229	hybrid			2022-12-27	WOS:000085809600009
J	Gormley, NA; Bath, AJ; Halford, SE				Gormley, NA; Bath, AJ; Halford, SE			Reactions of BglI and other type II restriction endonucleases with discontinuous recognition sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA RECOGNITION; ECORV ENDONUCLEASE; BINDING-PROPERTIES; CRYSTAL-STRUCTURE; METAL-IONS; SEQUENCES; CLEAVAGE; AFFINITY; COMPLEXES; MUTANTS	Type II restriction enzymes generally recognize continuous sequences of 4-8 consecutive base pairs on DNA, but some recognize discontinuous sites where the specified sequence is interrupted by a defined length of nonspecific DNA. To date, a mechanism has been established for only one type II endonuclease with a discontinuous site, SfiI at GGCCNNNNNGGCC (where N is any base). In contrast to orthodox. enzymes such as EcoRV, dimeric proteins that act at a single site, SfiI is a tetramer that interacts with two sites before cleaving DNA. BglI has a similar recognition sequence (GCCNNNNNGGC) to SfiI but a crystal structure like EcoRV. BglI and several other endonucleases with discontinuous sites were examined to see if they need two sites for their DNA cleavage reactions. The enzymes included some with sites containing lengthy segments of nonspecific DNA, such as XcmI (CCANNNNNNNNNTGG). In all cases, they acted at individual sites. Elongated recognition sites do not necessitate unusual reaction mechanisms. Other experiments on BglI showed that it bound to and cleaved DNA in the same manner as EcoRV, thus further delineating a distinct group of restriction enzymes with similar structures and a common reaction mechanism.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Halford, SE (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.							AGGARWAL AK, 1995, CURR OPIN STRUC BIOL, V5, P11, DOI 10.1016/0959-440X(95)80004-K; Baldwin GS, 1999, J MOL BIOL, V288, P87, DOI 10.1006/jmbi.1999.2672; Bickle TA, 1993, NUCLEASES, P89; Bilcock DT, 1999, J BIOL CHEM, V274, P36379, DOI 10.1074/jbc.274.51.36379; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cao WG, 1999, BIOCHEMISTRY-US, V38, P8080, DOI 10.1021/bi9903796; Deibert M, 1999, EMBO J, V18, P5805, DOI 10.1093/emboj/18.21.5805; Dorner LF, 1999, J MOL BIOL, V285, P1515, DOI 10.1006/jmbi.1998.2408; Embleton ML, 1999, J MOL BIOL, V289, P785, DOI 10.1006/jmbi.1999.2822; Engler LE, 1997, J MOL BIOL, V269, P82, DOI 10.1006/jmbi.1997.1027; Erskine SG, 1997, BIOCHEMISTRY-US, V36, P7567, DOI 10.1021/bi970155s; Erskine SG, 1998, J MOL BIOL, V275, P759, DOI 10.1006/jmbi.1997.1517; GABBARA S, 1992, J BIOL CHEM, V267, P18623; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; KADDURAHDAOUK R, 1985, J BIOL CHEM, V260, P5345; KONG H, 1994, J BIOL CHEM, V269, P683; Kong HM, 1998, BIOL CHEM, V379, P605; KOSTREWA D, 1995, BIOCHEMISTRY-US, V34, P683, DOI 10.1021/bi00002a036; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; LAGUNAVICIUS A, 1997, BIOCHEMISTRY-US, V37, P11903; LEE YH, 1979, J BIOL CHEM, V254, P6838; LESSER DR, 1993, P NATL ACAD SCI USA, V90, P7548, DOI 10.1073/pnas.90.16.7548; Martin AM, 1999, BIOCHEMISTRY-US, V38, P8430, DOI 10.1021/bi9905359; Nastri HG, 1997, J BIOL CHEM, V272, P25761, DOI 10.1074/jbc.272.41.25761; Newman M, 1998, EMBO J, V17, P5466, DOI 10.1093/emboj/17.18.5466; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; NOBBS TJ, 1995, J MOL BIOL, V252, P399, DOI 10.1006/jmbi.1995.0506; Nobbs TJ, 1998, J MOL BIOL, V281, P419, DOI 10.1006/jmbi.1998.1966; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; QIANG BQ, 1984, NUCLEIC ACIDS RES, V12, P4507, DOI 10.1093/nar/12.11.4507; Reuter M, 1998, J BIOL CHEM, V273, P8294, DOI 10.1074/jbc.273.14.8294; Roberts R, 1993, NUCLEASES, P35; Roberts RJ, 1999, NUCLEIC ACIDS RES, V27, P312, DOI 10.1093/nar/27.1.312; Sambrook J., 2002, MOL CLONING LAB MANU; SHINOMIYA T, 1980, NUCLEIC ACIDS RES, V8, P43, DOI 10.1093/nar/8.1.43; Siksnys V, 1999, J MOL BIOL, V291, P1105, DOI 10.1006/jmbi.1999.2977; Stanford NP, 1999, J MOL BIOL, V288, P105, DOI 10.1006/jmbi.1999.2673; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; Szczelkun MD, 1996, EMBO J, V15, P6335, DOI 10.1002/j.1460-2075.1996.tb01023.x; Szczelkun MD, 1996, EMBO J, V15, P1460, DOI 10.1002/j.1460-2075.1996.tb00488.x; TAYLOR JD, 1989, BIOCHEMISTRY-US, V28, P6198, DOI 10.1021/bi00441a011; TAYLOR JD, 1991, BIOCHEMISTRY-US, V30, P8743, DOI 10.1021/bi00100a005; TERRY BJ, 1985, J BIOL CHEM, V260, P3130; Thomas MP, 1999, NUCLEIC ACIDS RES, V27, P3438, DOI 10.1093/nar/27.17.3438; Travers AA, 1991, CURR OPIN STRUC BIOL, V1, P114, DOI 10.1016/0959-440X(91)90019-P; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6082, DOI 10.1021/bi00141a018; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P1113, DOI 10.1021/bi00004a002; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P697, DOI 10.1021/bi00002a037; WENTZELL LM, 1995, J MOL BIOL, V248, P581, DOI 10.1006/jmbi.1995.0244; Wentzell LM, 1998, J MOL BIOL, V281, P433, DOI 10.1006/jmbi.1998.1967; WILSON GG, 1991, ANNU REV GENET, V25, P585, DOI 10.1146/annurev.ge.25.120191.003101; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; Wright DJ, 1999, J BIOL CHEM, V274, P31896, DOI 10.1074/jbc.274.45.31896; YANG CC, 1992, BIOCHEMISTRY-US, V31, P9657, DOI 10.1021/bi00155a019; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZEBALA JA, 1992, J BIOL CHEM, V267, P8106; ZEBALA JA, 1992, J BIOL CHEM, V267, P8097	59	31	31	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6928	6936		10.1074/jbc.275.10.6928	http://dx.doi.org/10.1074/jbc.275.10.6928			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702254	hybrid			2022-12-27	WOS:000085809600034
J	Arata, Y; Fujita, M; Ohtani, K; Kijima, S; Kato, JY				Arata, Y; Fujita, M; Ohtani, K; Kijima, S; Kato, JY			Cdk2-dependent and -independent pathways in E2F-mediated S phase induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; DEPENDENT KINASE-ACTIVITY; TRANSCRIPTION FACTOR E2F1; DNA-POLYMERASE-ALPHA; CELL-CYCLE; MAMMALIAN-CELLS; REPLICATION ORIGINS; PROTEIN-KINASE; CDC2 KINASE; EXPRESSION	The transcription factor E2F plays an important role in G(1) to S phase transition in the higher eukaryotic cell cycle. Although a number of E2F-inducible genes have been identified, the biochemical cascades from E2F to the S phase entry remain to be investigated. In this study, we generated stably transfected mouse NIH3T3 cells that express exogenous human E2F-1 under the control of a heavy metal-inducible metallothionein promoter and analyzed the molecular mechanism of the E2F-1-mediated initiation of chromosomal DNA replication. Ectopic E2F-1 expression in cells arrested in G(0)/G(1) by serum deprivation enabled them to progress through G(1) and to enter S phase. During the G(1) progression, mouse cyclin E, but little of cyclin D1, was induced to express, which subsequently activated Cdk2. Experiments using the Cdk inhibitory proteins p27, p18, and p19 proved that the activity of Cdk2, but not of Cdk4, was required for S phase entry mediated by E2F-1. Minichromosome maintenance proteins (MCM) 4 and 7, the components of the DNA-replication initiation complex (RC), were constitutively expressed during the cell cycle, although the MCM genes are well known E2F-1-inducible genes. However, tight association of these two proteins with chromatin depended upon ectopic E2F-1 expression. In contrast, the Cdc45 protein, another RC component, which turned out to be a transcriptional target of E2Fs, was induced to express and subsequently bound to chromatin in response to E2F-1. Experiments utilizing a chemical Cdk-specific inhibitor, butyrolactone I, revealed that Cdk2 activity was required only for chromatin binding of the Cdc45 proteins, and not for the expression of Cdc45 or chromatin binding of MCM4 and -7, These results indicate that at least two separate pathways function downstream of E2F to initiate S phase; one depends upon the activity of Cdk2 and the other does not.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Aichi Canc Ctr, Res Inst, Labs Viral Oncol, Nagoya, Aichi 464, Japan; Tokyo Med & Dent Univ, Grad Sch Dent, Human Gene Sci Ctr, Tokyo 1138510, Japan	Nara Institute of Science & Technology; Aichi Cancer Center; Tokyo Medical & Dental University (TMDU)	Kato, JY (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Nara 6300101, Japan.	jkata@bs.aist-nara.ac.jp	Arata, Yukinobu/AAE-3467-2019	Fujita, Masatoshi/0000-0001-6617-2452				Akamatsu E, 1998, J BIOL CHEM, V273, P16494, DOI 10.1074/jbc.273.26.16494; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Cook DM, 1996, ONCOGENE, V13, P1789; Dalton S, 1997, MOL CELL BIOL, V17, P5867, DOI 10.1128/MCB.17.10.5867; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fujita M, 1996, J BIOL CHEM, V271, P4349; Fujita M, 1998, J BIOL CHEM, V273, P17095, DOI 10.1074/jbc.273.27.17095; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KITAGAWA M, 1993, ONCOGENE, V8, P2425; Kurokawa K, 1999, ONCOGENE, V18, P2718, DOI 10.1038/sj.onc.1202628; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; Ohtani K, 1999, ONCOGENE, V18, P2299, DOI 10.1038/sj.onc.1202544; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; SARDET C, 1997, PROGR GENE EXPRESSIO, V2, P1; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Tada S, 1999, CURR BIOL, V9, P211, DOI 10.1016/S0960-9822(99)80092-X; Tada S, 1998, BIOL CHEM, V379, P941; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tsuruga H, 1997, GENES CELLS, V2, P381, DOI 10.1046/j.1365-2443.1997.1290327.x; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593; Zou L, 1997, MOL CELL BIOL, V17, P553, DOI 10.1128/MCB.17.2.553	46	71	77	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6337	6345		10.1074/jbc.275.9.6337	http://dx.doi.org/10.1074/jbc.275.9.6337			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692433	hybrid			2022-12-27	WOS:000085654400045
J	Furuya, T; Kashuba, C; Docampo, R; Moreno, SNJ				Furuya, T; Kashuba, C; Docampo, R; Moreno, SNJ			A novel phosphatidylinositol-phospholipase C of Trypanosoma cruzi that is lipid modified and activated during trypomastigote to amastigote differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; YEAST SACCHAROMYCES-CEREVISIAE; PROTEIN KINASE-C; PLASMA-MEMBRANE; DICTYOSTELIUM-DISCOIDEUM; ALPHA(D)-GLOBIN FRAGMENT; CALCIUM HOMEOSTASIS; INOSITOL PHOSPHATES; H+-ATPASE; GENE	The phosphoinositide (PI)-specific phospholipase C gene (TcPI-PLC) of the protozoan parasite Trypanosoma cruzi was cloned, sequenced, expressed in Escherichia coli, and the protein product (TcPI-PLC) was shown to have enzymatic characteristics similar to those of mammalian delta-type PI-PLCs, The TcPI-PLC gene is expressed at high levels in the epimastigote and amastigote stages of the parasite, and its expression is induced during the differentiation of trypomastigotes into amastigotes, where TcPI-PLC associates with the plasma membrane and increases its catalytic activity. In contrast to other PI-PLCs described so far, the deduced amino acid sequence of TcPI-PLC revealed some unique features such as an N-myristoylation consensus sequence at its aminoterminal end, lack of an apparent pleckstrin homology domain and a highly charged linker region between the catalytic X and Y domains, TcPI-PLC is lipid modified in vivo, as demonstrated by metabolic labeling with [H-3]myristate and [H-3]palmitate and fatty acid analysis of the immunoprecipitated protein, and may constitute the first example of a new group of PI-PLCs.	Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign	Moreno, SNJ (corresponding author), Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, 2001 S Lincoln Ave, Urbana, IL 61802 USA.	s-moreno@uiuc.edu	Furuya, Tetsuya/J-5916-2013	Furuya, Tetsuya/0000-0003-3979-7072				AERTS RJ, 1985, CELL, V43, P653, DOI 10.1016/0092-8674(85)90237-5; Armah DA, 1999, J BIOL CHEM, V274, P5931, DOI 10.1074/jbc.274.9.5931; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BIZZOZERO OA, 1995, METHOD ENZYMOL, V250, P361; BONE GJ, 1956, NATURE, V178, P308, DOI 10.1038/178308a0; BOOMINAR A, 1994, BIOCHEM J, V297, P181; Boutin JA, 1997, CELL SIGNAL, V9, P15, DOI 10.1016/S0898-6568(96)00100-3; Brazill DT, 1998, J BIOL CHEM, V273, P8161, DOI 10.1074/jbc.273.14.8161; BUSA WB, 1984, AM J PHYSIOL, V246, pR409, DOI 10.1152/ajpregu.1984.246.4.R409; Coccetti P, 1998, BBA-MOL CELL RES, V1405, P147, DOI 10.1016/S0167-4889(98)00099-8; Coukell MB, 1997, MICROBIOL-UK, V143, P3877, DOI 10.1099/00221287-143-12-3877; DEDOMENECH EEM, 1992, FEMS MICROBIOL LETT, V95, P267, DOI 10.1111/j.1574-6968.1992.tb05377.x; DOCAMPO R, 1991, BIOCHEM J, V275, P407, DOI 10.1042/bj2750407; DOCAMPO R, 1993, MOL BIOCHEM PARASIT, V59, P305, DOI 10.1016/0166-6851(93)90228-P; DRAYER AL, 1992, J BIOL CHEM, V267, P18387; DUMPHY JT, 1998, BIOCHIM BIOPHYS ACTA, V1436, P245; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; FRAIDENRAICH D, 1993, P NATL ACAD SCI USA, V90, P10140, DOI 10.1073/pnas.90.21.10140; Furger A, 1997, MOL CELL BIOL, V17, P4372, DOI 10.1128/MCB.17.8.4372; Garrido MN, 1996, CELL MOL BIOL, V42, P859; Godsel LM, 1999, EMBO J, V18, P2057, DOI 10.1093/emboj/18.8.2057; GOMEZ ML, 1989, MOL BIOCHEM PARASIT, V36, P101, DOI 10.1016/0166-6851(89)90182-5; Grellier P, 1999, MOL BIOCHEM PARASIT, V98, P239, DOI 10.1016/S0166-6851(98)00172-8; Irvine R, 1996, NATURE, V380, P581, DOI 10.1038/380581a0; KYLE J, 1982, J MOL BIOL, V157, P105; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MGS, 1997, ANNU REV MICROBIOL, V51, P463, DOI 10.1146/annurev.micro.51.1.463; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lopez-Estrano C, 1998, MOL CELL BIOL, V18, P4620, DOI 10.1128/MCB.18.8.4620; Lu HG, 1998, MOL CELL BIOL, V18, P2309, DOI 10.1128/MCB.18.4.2309; MORENO SNJ, 1994, J EXP MED, V180, P1535, DOI 10.1084/jem.180.4.1535; MORENO SNJ, 1992, MOL BIOCHEM PARASIT, V52, P251, DOI 10.1016/0166-6851(92)90057-Q; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Nozaki T, 1999, MOL BIOCHEM PARASIT, V102, P283, DOI 10.1016/S0166-6851(99)00108-5; OLIVEIRA MM, 1993, MOL CELL BIOCHEM, V124, P91, DOI 10.1007/BF00929200; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; PAYNE WE, 1993, MOL CELL BIOL, V13, P4351, DOI 10.1128/MCB.13.7.4351; Quijada L, 1997, J BIOL CHEM, V272, P4493, DOI 10.1074/jbc.272.7.4493; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Rolin S, 1998, MOL BIOCHEM PARASIT, V93, P251, DOI 10.1016/S0166-6851(98)00046-2; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMATZ DM, 1982, PARASITOLOGY, V85, P115, DOI 10.1017/S0031182000054202; SKEIKY YAW, 1992, J EXP MED, V176, P201, DOI 10.1084/jem.176.1.201; TOMLINSON S, 1995, PARASITOLOGY, V110, P547, DOI 10.1017/S0031182000065264; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; Van Der Heyden N, 2000, MOL BIOCHEM PARASIT, V105, P237, DOI 10.1016/S0166-6851(99)00184-X; Verdun RE, 1998, INFECT IMMUN, V66, P5393, DOI 10.1128/IAI.66.11.5393-5398.1998; WONG S, 1992, MOL BIOCHEM PARASIT, V55, P187, DOI 10.1016/0166-6851(92)90139-B; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417; YOKOO T, 1993, P NATL ACAD SCI USA, V90, P1804, DOI 10.1073/pnas.90.5.1804	55	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6428	6438		10.1074/jbc.275.9.6428	http://dx.doi.org/10.1074/jbc.275.9.6428			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692446	hybrid			2022-12-27	WOS:000085654400058
J	Jayaraman, T; Marks, AR				Jayaraman, T; Marks, AR			Calcineurin is downstream of the inositol 1,4,5-trisphosphate receptor in the apoptotic and cell growth pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATASE CALCINEURIN; SIGNAL-TRANSDUCTION; NF-AT; DEATH; FAMILY; ACTIVATION; SURVIVAL; PROTEINS; PHOSPHORYLATION; HYBRIDOMAS	The inositol 1,4,5-trisphosphate receptor (IP3R) is a calcium (Ca2+) release channel found on the endoplasmic reticulum of virtually all types of cells. Human T lymphocytes (Jurkat) that are made deficient in IP3R do not generate Ca2+ signals in response to T cell receptor stimulation, fail to translocate the nuclear factor for activated T cells to the nucleus, and are remarkably resistant to induction of apoptosis with CD95 (Fas), dexamethasone, gamma irradiation, and T cell receptor stimulation using anti-CD3 antibody. Expression of constitutively active calcineurin A in IP3R-deficient T cells restored nuclear factor for activated T cells translocation to the nucleus and dephosphorylation of Bad and rendered the cells sensitive to apoptotic inducers, Induction of apoptosis required both active calcineurin A (Delta CnA) and activation-dependent colocalization of CnA with its substrate. Thus, the Ca2+-dependent phosphatase calcineurin (CnA) is downstream of the IP3R in both the cell growth and apoptotic signaling pathways.	Columbia Univ, Coll Phys & Surg, Dept Med, Mol Cardiol Program, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Pharmacol, Mol Cardiol Program, New York, NY 10032 USA	Columbia University; Columbia University	Marks, AR (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, Mol Cardiol Program, P&S 9-401,630 W 168th St, New York, NY 10032 USA.				NHLBI NIH HHS [HL61503, HL56180] Funding Source: Medline; NIAID NIH HHS [AI39794] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056180, R01HL061503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI039794, R01AI039794] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; BERARD NB, 1994, EUR J IMMUNOL, V24, P325; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; FRUMAN DA, 1992, EUR J IMMUNOL, V22, P2513, DOI 10.1002/eji.1830221008; HARNICK DJ, 1995, J BIOL CHEM, V270, P2833, DOI 10.1074/jbc.270.6.2833; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; JAYARAMAN T, 1995, P NATL ACAD SCI USA, V92, P6007, DOI 10.1073/pnas.92.13.6007; KELEKER A, 1997, MOL CELL BIOL, V12, P7040; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; MARKS AR, 1996, AM J PHYSIOL, V41, pH597; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; Miskin JE, 1998, SCIENCE, V281, P562, DOI 10.1126/science.281.5376.562; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Oukka M, 1998, IMMUNITY, V9, P295, DOI 10.1016/S1074-7613(00)80612-3; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PREMACK BA, 1992, AM J PHYSIOL, V263, pC1119, DOI 10.1152/ajpcell.1992.263.6.C1119; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	30	74	78	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6417	6420		10.1074/jbc.275.9.6417	http://dx.doi.org/10.1074/jbc.275.9.6417			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692444	hybrid			2022-12-27	WOS:000085654400056
J	Quinn, JM; Barraco, P; Eriksson, M; Merchant, S				Quinn, JM; Barraco, P; Eriksson, M; Merchant, S			Coordinate copper- and oxygen-responsive Cyc6 and Cpx1 expression in Chlamydomonas is mediated by the same element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASTIDIC CYTOCHROME-C; DOMAIN-DNA COMPLEX; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; NUCLEAR TRANSFORMATION; METALLOTHIONEIN GENE; COMPLEMENTARY-DNA; CANDIDA-GLABRATA; REINHARDTII; YEAST	Chlamydomonas reinhardtii activates the transcription of the Cyc6 and the Cpx1 genes (encoding cytochrome c(6) and coprogen oxidase) in response to copper deficiency. Mutational analysis of promoter regions of the Cyc6 and Cpx1 genes revealed a four nucleotide sequence, GTAC, which was absolutely essential for copper responsiveness. The Cyc6 promoter contains two copper response elements, each with a functionally important GTAC sequence, whereas the Cpx1 promoter contains only one. This may contribute to the stronger and more tightly regulated expression of the Cyc6 gene. Mutation or deletion of sequences flanking the GTACs implicates additional nucleotides contributing to copper-responsive expression, but none are absolutely essential. Metal ion selectivity of Cpx1 expression is identical to that described previously for Cyc6 and is restricted to the copper deficiency-induced Cpx1 transcript, The Cyc6 and Cpx1 genes are also induced by oxygen deficiency. Reporter gene constructs indicate that the induction occurs at the level of transcription and requires the same GTAC sequence that is critical for copper responsiveness. We suggest that components of the copper-responsive signal transduction pathway are used for some of the changes in gene expression in hypoxic cells.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Merchant, S (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, POB 951569, Los Angeles, CA 90095 USA.	merchant@chem.ucla.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM042143, R01GM042143, R37GM042143] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42143] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; Borghouts C, 1998, MOL GEN GENET, V260, P492, DOI 10.1007/s004380050922; BOYLE JS, 1995, TRENDS GENET, V11, P8, DOI 10.1016/S0168-9525(00)88977-5; CASASFINET JR, 1992, BIOCHEMISTRY-US, V31, P6617, DOI 10.1021/bi00143a036; DAVIES JP, 1992, NUCLEIC ACIDS RES, V20, P2959, DOI 10.1093/nar/20.12.2959; DAVIES JP, 1994, MOL CELL BIOL, V14, P5165, DOI 10.1128/MCB.14.8.5165; DEBUCHY R, 1989, EMBO J, V8, P2803, DOI 10.1002/j.1460-2075.1989.tb08426.x; DEHOSTOS EL, 1989, MOL GEN GENET, V218, P229, DOI 10.1007/BF00331273; DROPPA M, 1984, P NATL ACAD SCI-BIOL, V81, P2369, DOI 10.1073/pnas.81.8.2369; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; GOLDSCHMIDTCLERMONT M, 1986, J MOL BIOL, V191, P421, DOI 10.1016/0022-2836(86)90137-3; Hewitt E. J., 1983, Metals and micronutrients: uptake and utilization by plants, P277; HILL KL, 1991, J BIOL CHEM, V266, P15060; Hill KL, 1996, PLANT PHYSIOL, V112, P697, DOI 10.1104/pp.112.2.697; HILL KL, 1995, EMBO J, V14, P857, DOI 10.1002/j.1460-2075.1995.tb07067.x; HILL KL, 1992, PLANT PHYSIOL, V100, P319, DOI 10.1104/pp.100.1.319; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOWE G, 1992, PLANT PHYSIOL, V98, P127, DOI 10.1104/pp.98.1.127; Jensen LT, 1998, EMBO J, V17, P5400, DOI 10.1093/emboj/17.18.5400; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; KINDLE KL, 1990, P NATL ACAD SCI USA, V87, P1228, DOI 10.1073/pnas.87.3.1228; KINDLE KL, 1998, MOL BIOL CHLOROPLAST, V7, P41; Knight SAB, 1997, CH MICROBIOL SER, P316; Koch KA, 1997, CHEM BIOL, V4, P549, DOI 10.1016/S1074-5521(97)90241-6; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; LI HH, 1995, J BIOL CHEM, V270, P23504, DOI 10.1074/jbc.270.40.23504; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; MEHRA RK, 1989, J BIOL CHEM, V264, P19747; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; Merchant S, 1997, CH MICROBIOL SER, P450; MERCHANT S, 1991, EMBO J, V10, P1383, DOI 10.1002/j.1460-2075.1991.tb07658.x; MERCHANT S, 1990, J BIOL CHEM, V265, P12372; MERCHANT S, 1987, J BIOL CHEM, V262, P9062; MERCHANT S, 1986, J BIOL CHEM, V261, P5850; MERCHANT S, 1998, MOL BIOL CHLAMYDOMON, V7, P597; OSTERBERG R, 1974, NATURE, V249, P382, DOI 10.1038/249382a0; Patikoglou G, 1997, ANNU REV BIOPH BIOM, V26, P289, DOI 10.1146/annurev.biophys.26.1.289; Pena MMO, 1998, MOL CELL BIOL, V18, P2514, DOI 10.1128/MCB.18.5.2514; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; Quinn JM, 1998, METHOD ENZYMOL, V297, P263; Quinn JM, 1999, J BIOL CHEM, V274, P14444, DOI 10.1074/jbc.274.20.14444; QUINN JM, 1995, PLANT CELL, V7, P623, DOI 10.1105/tpc.7.5.623; SANDMANN G, 1986, ARCH MICROBIOL, V145, P76, DOI 10.1007/BF00413030; SANDMANN G, 1983, ARCH MICROBIOL, V134, P23, DOI 10.1007/BF00429401; SOMMER AL, 1939, PLANT PHYSL BETHESDA, V14, P339; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; THORVALDSEN JL, 1994, BIOCHEMISTRY-US, V33, P9566, DOI 10.1021/bi00198a024; WELCH J, 1989, EMBO J, V8, P255, DOI 10.1002/j.1460-2075.1989.tb03371.x; Winge DR, 1998, PROG NUCLEIC ACID RE, V58, P165; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x; ZHOU PB, 1993, BIOFACTORS, V4, P105	54	90	103	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6080	6089		10.1074/jbc.275.9.6080	http://dx.doi.org/10.1074/jbc.275.9.6080			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692397	hybrid			2022-12-27	WOS:000085654400009
J	Wadleigh, DJ; Reddy, ST; Kopp, E; Ghosh, S; Herschman, HR				Wadleigh, DJ; Reddy, ST; Kopp, E; Ghosh, S; Herschman, HR			Transcriptional activation of the cyclooxygenase-2 gene in endotoxin-treated RAW 264.7 macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGEN-INDUCIBLE CYCLOOXYGENASE; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; N-TERMINAL KINASE; FACTOR KAPPA-B; RESPONSE ELEMENT; NUCLEAR FACTOR; PROTEIN-KINASE; PHORBOL ESTER; EXPRESSION; CELLS	Cyclooxygenase-2 (COX-2), the enzyme primarily responsible for induced prostaglandin synthesis, is an immediate early gene induced by endotoxin in macrophages, We investigated the cis-acting elements of the COX-2 5'-flanking sequence, the transcription factors and signaling pathways responsible for transcriptional activation of the COX-2 gene in endotoxin-treated murine RAW 264.7 macrophages, Luciferase reporter constructs with alterations in presumptive cis-acting transcriptional regulatory elements demonstrate that the cyclic AMP-response element and two nuclear factor interleukin-6 (CCAAT/enhancer-binding protein (C/EBP)) sites of the COX-2 promoter are required for optimal endotoxin-dependent induction. In contrast, the E-box and NF-kappa B sites are not required for endotoxin-dependent induction. Inhibition of endotoxin-induced NF-kappa B activation by expression of an inhibitor-kappa B a mutant does not block endotoxin-dependent COX-2 reporter activity, Overexpression of c-Jun, C/EBP beta, and C/EBP delta enhances induction of the COX-2 reporter, while overexpression of cyclic AMP-response element-binding protein or "dominant negative" C/EBP beta represses COX-2 induction. In addition, endotoxin rapidly and transiently elicits c-Jun phosphorylation in RAW 264.7 macrophages. Cotransfection of the COX-2 reporter with dominant negative expression vectors shows that endotoxin-induced COX-2 gene expression requires signaling through a Ras-independent pathway involving the adapter protein ECSIT and the signaling kinases MEKK1 and JNK. In contrast, endotoxin-induced COX-2 reporter activity is not blocked by overexpression of dominant-negative forms of Raf-1, ERK1, or ERR2.	Univ Calif Los Angeles, Mol Biol Inst 341, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Yale University; Howard Hughes Medical Institute; Yale University	Herschman, HR (corresponding author), Univ Calif Los Angeles, Mol Biol Inst 341, 650 Charles E Young Dr E, Los Angeles, CA 90095 USA.				NIAID NIH HHS [AI34567, AI33443] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI033443, R01AI033443, U01AI034567, U19AI034567] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abate A, 1998, PROSTAG OTH LIPID M, V56, P277, DOI 10.1016/S0090-6980(98)00061-6; Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; CHANMUGAM P, 1995, J BIOL CHEM, V270, P5418, DOI 10.1074/jbc.270.10.5418; Chen G, 1999, LIFE SCI, V64, P1231, DOI 10.1016/S0024-3205(99)00055-7; Chen G, 1998, BIOCHEM PHARMACOL, V55, P1621, DOI 10.1016/S0006-2952(98)00021-5; Chinery R, 1999, CANCER RES, V59, P2739; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; Diaz-Cazorla M, 1999, J AM SOC NEPHROL, V10, P943; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FLETCHER JR, 1993, ARCH SURG-CHICAGO, V128, P1192; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; Ingalls RR, 1999, INFECT DIS CLIN N AM, V13, P341, DOI 10.1016/S0891-5520(05)70078-7; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; Kage K, 1999, BIOCHEM BIOPH RES CO, V254, P259, DOI 10.1006/bbrc.1998.9875; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Kopp E, 1999, GENE DEV, V13, P2059, DOI 10.1101/gad.13.16.2059; LEE SH, 1992, J BIOL CHEM, V267, P25934; Li S, 1999, BRAIN RES, V825, P86, DOI 10.1016/S0006-8993(99)01225-1; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; Reddy ST, 2000, J BIOL CHEM, V275, P3107, DOI 10.1074/jbc.275.5.3107; REDDY ST, 1994, J BIOL CHEM, V269, P15473; RODRIGUEZ M, 1996, ONCOGENE, V12, P24425; ROTH GJ, 1994, BLOOD, V83, P885; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; Suh N, 1998, CANCER RES, V58, P717; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; von Knethen A, 1999, J IMMUNOL, V163, P2858; Wadleigh DJ, 1999, BIOCHEM BIOPH RES CO, V264, P865, DOI 10.1006/bbrc.1999.1606; Wang Z, 1999, PROSTAG LEUKOTR ESS, V60, P243, DOI 10.1054/plef.1999.0031; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; Williams JA, 1997, J BIOL CHEM, V272, P25693, DOI 10.1074/jbc.272.41.25693; WILLIAMS TJ, 1973, NATURE, V246, P215, DOI 10.1038/246215a0; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yamamoto S, 1998, INT J TISSUE REACT, V20, P17	45	307	311	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6259	6266		10.1074/jbc.275.9.6259	http://dx.doi.org/10.1074/jbc.275.9.6259			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692422	hybrid			2022-12-27	WOS:000085654400034
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			The packing of the transmembrane segments of human multidrug resistance P-glycoprotein is revealed by disulfide cross-linking analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ATPASE ACTIVITY; DRUG-BINDING SITE; FUNCTIONAL CONSEQUENCES; SUBSTRATE-SPECIFICITY; LABELING SITES; DOMAIN; LOCALIZATION; TRANSPORT; MUTATIONS; RESIDUES	Residues from several transmembrane (TM) segments of P-glycoprotein (P-gp) likely form the drug-binding site(s), To determine the organization of the TM segments, pairs of cysteine residues were introduced into the predicted TM segments of a Cys-less P-gp, and the mutant protein was subjected to oxidative cross-linking. In SDS gels, the cross-linked product migrated with a slower mobility than the native protein. The cross-linked products were not detected in the presence of dithiothreitol, Cross-linking was observed in 12 of 125 mutants, The pattern of cross-linking suggested that TM6 is close to TMs 10, 11, and 12, while TM12 is close to TMs 4, 5, and 6, In some mutants the presence of drug substrate colchicine, verapamil, cyclosporin A, or vinblastine either enhanced or inhibited cross-linking. Cross-linking was inhibited in the presence of ATP plus vanadate, These results suggest that the TM segments critical for drug binding must be close to each other and exhibit different conformational changes in response to binding of drug substrate or vanadate trapping of nucleotide, Based on these results, we propose a model for the arrangement of the TM segments.	Univ Toronto, Dept Med, MRC, Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, MRC, Grp Membrane Biol, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA80900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Chen G, 1997, J BIOL CHEM, V272, P5974, DOI 10.1074/jbc.272.9.5974; Demmer A, 1997, J BIOL CHEM, V272, P20913, DOI 10.1074/jbc.272.33.20913; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; Hafkemeyer P, 1998, BIOCHEMISTRY-US, V37, P16400, DOI 10.1021/bi980871+; Hanna M, 1996, BIOCHEMISTRY-US, V35, P3625, DOI 10.1021/bi951333p; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; KAJIJI S, 1993, BIOCHEMISTRY-US, V32, P4185, DOI 10.1021/bi00067a005; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; Liu RH, 1997, BIOCHEMISTRY-US, V36, P2836, DOI 10.1021/bi9627119; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LOO TW, 1993, J BIOL CHEM, V268, P19965; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; Rice WJ, 1997, J BIOL CHEM, V272, P31412, DOI 10.1074/jbc.272.50.31412; Schinkel AH, 1997, SEMIN CANCER BIOL, V8, P161, DOI 10.1006/scbi.1997.0068; Shoshani T, 1998, MOL PHARMACOL, V54, P623; THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383	36	101	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5253	5256		10.1074/jbc.275.8.5253	http://dx.doi.org/10.1074/jbc.275.8.5253			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681495	hybrid			2022-12-27	WOS:000085474500002
J	Lu, ZL; Hulme, EC				Lu, ZL; Hulme, EC			A network of conserved intramolecular contacts defines the off-state of the transmembrane switch mechanism in a seven-transmembrane receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(1B)-ADRENERGIC RECEPTOR; LIGAND-BINDING; ALPHA-HELICES; RHODOPSIN; MUTAGENESIS; ACTIVATION; MUTATIONS; ASPARTATE; RESIDUE; DOMAIN	Activation of the rhodopsin-like 7-transmembrane (7-TM) receptors requires switching interhelical constraints that stabilize the inactive state to a new set of contacts in the activated state, which binds the cognate G-protein. The free energy to drive this is provided by agonist binding, which has higher affinity to the active than to the inactive conformation. We have sought specific interhelical constraint contacts, using the M-1, muscarinic acetylcholine receptor as a model. Histidine substitutions of particular groups of amino acids, in transmembrane domains 3, 6, and 7, created high-affinity Zn2+ binding sites, demonstrating the close proximity of their side chains in the inactive state. Alanine point substitutions have shown the effect of weakening the individual intramolecular contacts. In each case, the acetylcholine affinity was increased, implying promotion of the activated state. These amino acids are highly conserved throughout the 7-TM receptor superfamily We propose that they form an important part of a network Of conserved interhelical contacts that defines the off-state of a general transmembrane switch mechanism.	Natl Inst Med Res, MRC, Div Phys Biochem, London NW7 1AA, England	MRC National Institute for Medical Research	Lu, ZL (corresponding author), Natl Inst Med Res, MRC, Div Phys Biochem, The Ridgeway,Mill Hill, London NW7 1AA, England.			Lu, Zhiliang/0000-0002-3442-1415				Audoly L, 1997, MOL PHARMACOL, V51, P61, DOI 10.1124/mol.51.1.61; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; Biebermann H, 1998, FASEB J, V12, P1461, DOI 10.1096/fasebj.12.14.1461; Bohm SK, 1997, J BIOL CHEM, V272, P2363; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; Gabilondo AM, 1996, EUR J PHARMACOL, V307, P243, DOI 10.1016/0014-2999(96)00247-6; HIGAKI JN, 1992, TRENDS BIOCHEM SCI, V17, P100, DOI 10.1016/0968-0004(92)90245-5; Hulme EC, 1998, J PHYSIOLOGY-PARIS, V92, P269, DOI 10.1016/S0928-4257(98)80031-4; JONES PG, 1995, EUR J PHARM-MOLEC PH, V288, P251, DOI 10.1016/0922-4106(95)90036-5; Lu ZL, 1999, J BIOL CHEM, V274, P7309, DOI 10.1074/jbc.274.11.7309; Lu ZL, 1997, MOL PHARMACOL, V51, P234, DOI 10.1124/mol.51.2.234; PAGE KM, 1995, EUR J PHARM-MOLEC PH, V289, P429, DOI 10.1016/0922-4106(95)90151-5; Porter JE, 1996, J BIOL CHEM, V271, P28318, DOI 10.1074/jbc.271.45.28318; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; Shyu JF, 1996, J BIOL CHEM, V271, P31127, DOI 10.1074/jbc.271.49.31127; Spalding TA, 1998, J BIOL CHEM, V273, P21563, DOI 10.1074/jbc.273.34.21563; SUH SS, 1991, PROTEIN ENG, V4, P301, DOI 10.1093/protein/4.3.301; Thirstrup K, 1996, J BIOL CHEM, V271, P7875, DOI 10.1074/jbc.271.14.7875; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; Vichi P, 1999, J BIOL CHEM, V274, P10331, DOI 10.1074/jbc.274.15.10331; Wang JF, 1997, MOL PHARMACOL, V52, P306, DOI 10.1124/mol.52.2.306	23	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5682	5686		10.1074/jbc.275.8.5682	http://dx.doi.org/10.1074/jbc.275.8.5682			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681552	hybrid			2022-12-27	WOS:000085474500059
J	Osaka, H; Malany, S; Molles, BE; Sine, SM; Taylor, P				Osaka, H; Malany, S; Molles, BE; Sine, SM; Taylor, P			Pairwise electrostatic interactions between alpha-neurotoxins and gamma, delta, and epsilon subunits of the nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; DOUBLE MUTANT CYCLES; MOLECULAR DISSECTION; CHOLINERGIC RECEPTOR; TORPEDO-CALIFORNICA; CRYSTAL-STRUCTURE; LIGAND-BINDING; RESIDUES; IDENTIFICATION; SELECTIVITY	alpha-Neurotoxins bind with high affinity to alpha-gamma and alpha-delta subunit interfaces of the nicotinic acetylcholine receptor. Since this high affinity complex likely involves a van der Waals surface area of similar to 1200 Angstrom(2) and 25-35 residues on the receptor surface, analysis of side chains should delineate major interactions and the orientation of bound alpha-neurotoxin, Three distinct regions on the gamma subunit, defined by Trp(55), Leu(119), Asp(174), and Glu(176), contribute to alpha-toxin affinity. Of six charge reversal mutations on the three loops of Naja mossambica mossambica alpha-toxin, Lys(27) --> Glu, Arg(33) --> Glu, and Arg(36) --> Glu in loop II reduce binding energy substantially, while mutations in loops I and III hare little effect. Paired residues were analyzed by thermodynamic mutant cycles to delineate electrostatic linkages between the six alpha-toxin charge reversal mutations and three key residues on the gamma subunit. Large coupling energies were found between Arg(33) at the tip of loop II and gamma Leu(119) (-5.7 kcal/mol) and between Lys(27) and gamma Glu(176) (-5.9 kcal/mol). gamma Trp(55) couples strongly to both Arg(33) and Lys(27), whereas gamma Asp(174) couples minimally to charged alpha-toxin residues. Arg(36), despite strong energetic contributions, does not partner with any gamma subunit residues, perhaps indicating its proximity to the alpha subunit. By analyzing cationic, neutral and anionic residues in the mutant cycles, interactions at gamma 176 and gamma 119 can be distinguished from those at gamma 55.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Receptor Biol Lab, Rochester, MN 55905 USA	University of California System; University of California San Diego; Mayo Clinic	Osaka, H (corresponding author), Natl Inst Neurosci, Natl Ctr Neurol & Psychiat, Dept Degenerat Neurol Dis, Tokyo 1878502, Japan.				NIGMS NIH HHS [GM T32-07752, GM 18360] Funding Source: Medline; NINDS NIH HHS [NS 31744] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018360, R37GM018360, T32GM007752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031744, R37NS031744] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; Ackermann EJ, 1997, BIOCHEMISTRY-US, V36, P12836, DOI 10.1021/bi971513u; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; CHANG C. C., 1963, ARCH INTERNATL PHARMACODYN THER, V144, P241; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; CHANGEUX JP, 1970, P NATL ACAD SCI USA, V67, P1241, DOI 10.1073/pnas.67.3.1241; Chiara DC, 1998, FEBS LETT, V423, P223, DOI 10.1016/S0014-5793(98)00093-3; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Clackson T, 1998, J MOL BIOL, V277, P1111, DOI 10.1006/jmbi.1998.1669; CZAJKOWSKI C, 1995, J BIOL CHEM, V270, P3160, DOI 10.1074/jbc.270.7.3160; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; ENDO T, 1987, PHARMACOL THERAPEUT, V34, P403, DOI 10.1016/0163-7258(87)90002-7; Faiman GA, 1996, PROTEIN ENG, V9, P315, DOI 10.1093/protein/9.3.315; GERSHONI JM, 1983, P NATL ACAD SCI-BIOL, V80, P4973, DOI 10.1073/pnas.80.16.4973; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; Hucho F, 1996, EUR J BIOCHEM, V239, P539, DOI 10.1111/j.1432-1033.1996.0539u.x; JANIN J, 1990, J BIOL CHEM, V265, P16027; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KREIENKAMP HJ, 1994, J BIOL CHEM, V269, P8108; Le Novere N, 1999, BIOPHYS J, V76, P2329, DOI 10.1016/S0006-3495(99)77390-X; MACHOLD J, 1995, EUR J BIOCHEM, V234, P427, DOI 10.1111/j.1432-1033.1995.427_b.x; Martin M, 1996, J BIOL CHEM, V271, P13497, DOI 10.1074/jbc.271.23.13497; Martin MD, 1997, BIOCHEMISTRY-US, V36, P10742, DOI 10.1021/bi970896t; NEUBIG RR, 1979, BIOCHEMISTRY-US, V18, P5464, DOI 10.1021/bi00591a032; Osaka H, 1999, J BIOL CHEM, V274, P9581, DOI 10.1074/jbc.274.14.9581; Osaka H, 1998, J BIOL CHEM, V273, P12758, DOI 10.1074/jbc.273.21.12758; OSWALD RE, 1982, FEBS LETT, V139, P225, DOI 10.1016/0014-5793(82)80857-0; Prince RJ, 1996, J BIOL CHEM, V271, P25770, DOI 10.1074/jbc.271.42.25770; Quiram PA, 1998, J BIOL CHEM, V273, P11001, DOI 10.1074/jbc.273.18.11001; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; SINE S, 1979, J BIOL CHEM, V254, P3315; Sine SM, 1997, J BIOL CHEM, V272, P23521, DOI 10.1074/jbc.272.38.23521; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1981, J BIOL CHEM, V256, P6692; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; Sugiyama N, 1998, MOL PHARMACOL, V53, P787, DOI 10.1124/mol.53.4.787; Sugiyama N, 1996, J BIOL CHEM, V271, P26575, DOI 10.1074/jbc.271.43.26575; Taylor P, 1998, J PHYSIOL-PARIS, V92, P79, DOI 10.1016/S0928-4257(98)80142-3; Tsigelny I, 1997, BIOPHYS J, V73, P52, DOI 10.1016/S0006-3495(97)78047-0; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; Vijayakumar M, 1998, J MOL BIOL, V278, P1015, DOI 10.1006/jmbi.1998.1747	45	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5478	5484		10.1074/jbc.275.8.5478	http://dx.doi.org/10.1074/jbc.275.8.5478			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681526	hybrid			2022-12-27	WOS:000085474500033
J	Hirao, I; Madin, K; Endo, Y; Yokoyama, S; Ellington, AD				Hirao, I; Madin, K; Endo, Y; Yokoyama, S; Ellington, AD			RNA aptamers that bind to and inhibit the ribosome-inactivating protein, pepocin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICIN-A-CHAIN; N-GLYCOSIDASE ACTIVITY; SUBCELLULAR-LOCALIZATION; IDENTITY ELEMENTS; ESCHERICHIA-COLI; LOOP; RECOGNITION; RESOLUTION; MECHANISM; PURIFICATION	Pepocin, isolated from Cucurbita pepo, is a ribosome-inactivating protein (RIP). RIPs site-specifically recognize and depurinate an adenosine at position 4324 in rat 28 S rRNA, rendering the ribosome incapable of interacting with essential elongation factors. Aptamers that target pepocin were isolated from a degenerate RNA pool by in vitro selection. A conserved hairpin motif, quite different from the sequence of the toxin-substrate domain in rat 28 S rRNA, was identified in the aptamer sequences. The aptamers selectively bind to pepocin with dissociation constants between 20 and 30 nM and inhibit the N-glycosidase activity of pepocin on rat liver 28 S rRNA, Competitive binding experiments using aptamer variants suggest that the conserved hairpin region in the anti-pepocin aptamer binds near the catalytic site on pepocin and prevents the interaction of pepocin and 28 S rRNA. Anti-RIP aptamers have potential use in diagnostic systems for the detection of pepocin or could be used as therapy to prevent the action of pepocin in mammalian cells.	Univ Texas, Dept Biochem, Austin, TX 78712 USA; RIKEN, JST, ERATO, Yokoyama CytoLog Project, Wako, Saitama 3510198, Japan; Ehime Univ, Dept Appl Chem, Matsuyama, Ehime 790, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan	University of Texas System; University of Texas Austin; Japan Science & Technology Agency (JST); RIKEN; Ehime University; University of Tokyo	Ellington, AD (corresponding author), Univ Texas, Dept Biochem, ICMB A4800,26th & Speedway, Austin, TX 78712 USA.	andy.ellington@mail.utexas.edu	Yokoyama, Shigeyuki/N-6911-2015; Hirao, Ichiro/G-3041-2012	Yokoyama, Shigeyuki/0000-0003-3133-7338; 				BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; BARTEL DP, 1995, RNA PROTEIN INTERACT, P248; Baskerville S, 1998, COLD SPRING HARBOR M, P203; Bell SD, 1998, J BIOL CHEM, V273, P14309, DOI 10.1074/jbc.273.23.14309; CONRAD RC, 1995, NUCL ACID PROTEIN IN, P285; Convery MA, 1998, NAT STRUCT BIOL, V5, P133, DOI 10.1038/nsb0298-133; ENDO Y, 1988, J BIOL CHEM, V263, P8735; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ENDO Y, 1991, J MOL BIOL, V221, P193, DOI 10.1016/0022-2836(91)90814-M; ENDO Y, 1988, BIOCHIM BIOPHYS ACTA, V954, P224, DOI 10.1016/0167-4838(88)90075-1; GLUCK A, 1992, J MOL BIOL, V226, P411, DOI 10.1016/0022-2836(92)90956-K; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; HIRAO I, 1999, IN PRESS MOL DIVERSI; Hornung V, 1998, BIOCHEMISTRY-US, V37, P7260, DOI 10.1021/bi972969e; INWARD CD, 1995, J INFECTION, V30, P213, DOI 10.1016/S0163-4453(95)90693-2; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; MILFORD DV, 1990, ARCH DIS CHILD, V65, P716, DOI 10.1136/adc.65.7.716; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; Orita M, 1996, NUCLEIC ACIDS RES, V24, P611, DOI 10.1093/nar/24.4.611; ORITA M, 1993, NUCLEIC ACIDS RES, V21, P5670, DOI 10.1093/nar/21.24.5670; Rowsell S, 1998, NAT STRUCT BIOL, V5, P970, DOI 10.1038/2946; SZEWCZAK AA, 1995, J MOL BIOL, V247, P81, DOI 10.1006/jmbi.1994.0124; SZEWCZAK AA, 1993, P NATL ACAD SCI USA, V90, P9581, DOI 10.1073/pnas.90.20.9581; WEEKS KM, 1995, BIOCHEMISTRY-US, V34, P7728, DOI 10.1021/bi00023a020; WOOL IG, 1992, TRENDS BIOCHEM SCI, V17, P266, DOI 10.1016/0968-0004(92)90407-Z; Yoshinari S, 1996, EUR J BIOCHEM, V242, P585, DOI 10.1111/j.1432-1033.1996.0585r.x; Yoshinari S, 1997, BIOSCI BIOTECH BIOCH, V61, P324, DOI 10.1271/bbb.61.324	27	25	39	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4943	4948		10.1074/jbc.275.7.4943	http://dx.doi.org/10.1074/jbc.275.7.4943			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671532	hybrid			2022-12-27	WOS:000085378200058
J	Zhao, YW; Mazzone, T				Zhao, YW; Mazzone, T			Transport and processing of endogenously synthesized ApoE on the macrophage cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E GENE-EXPRESSION; BONE-MARROW TRANSPLANTATION; HUMAN APOLIPOPROTEIN-E; E-DEFICIENT MICE; HEPG2 CELLS; ATHEROSCLEROSIS; SECRETION; DEGRADATION; PATHWAY	We have previously established the presence of a pool of apoE sequestered on the macrophage cell surface by demonstrating its displacement from a cell monolayer at 4 degrees C. In this series of experiments, we use a cell surface biotinylation protocol to directly quantitate apoE on the macrophage cell surface and evaluate its transport to and from this cell surface pool. In human monocyte-derived macrophages labeled to equilibrium and in a mouse macrophage cell line transfected to constitutively express human apoE3, approximately 8% of total cellular apoE was present on the surface, but only a portion of this surface pool served as a direct precursor to secreted apoE. The half-life of apoE on the macrophage cell surface was calculated to be approximately 12 min. On SDS-polyacrylamide gel electrophoresis, the apoE isolated from the surface fraction of cells labeled to equilibrium migrated in an isoform pattern distinct from that observed from the intracellular fraction, with the surface fraction migrating predominantly in a higher molecular weight isoform, Pulse labeling experiments demonstrated that newly synthesized apoE reached the cell surface by 10 min but was predominantly in a low molecular weight isoform. There was also a lag between appearance of apoE on the cell surface and its appearance in the medium. Biotinylated apoE, which accumulated in the medium, even from pulse labeled cells, was predominantly in the high molecular weight isoform. Additional experiments demonstrated that low molecular weight apoE present on the cell surface was modified to higher molecular weight apoE by the addition of sialic acid residues prior to secretion and that this conversion was inhibited by brefeldin A. These results demonstrate an unexpected complexity in the transport and cellular processing of macrophage cell surface apoE, Factors that modulate the size and turnover of the cell surface pool of apoE in the macrophage remain to be identified and investigated.	Rush Med Coll, Dept Med, Chicago, IL 60612 USA; Rush Med Coll, Dept Biochem, Chicago, IL 60612 USA	Rush University; Rush University	Mazzone, T (corresponding author), Rush Med Coll, Dept Med, 1653 W Congress Pkwy, Chicago, IL 60612 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039653] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 57489, HL 39653] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASHEERUDDIN K, 1992, J BIOL CHEM, V267, P1219; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; BOISVERT WA, 1995, J CLIN INVEST, V96, P1118, DOI 10.1172/JCI118098; Duan HW, 1997, J BIOL CHEM, V272, P31156, DOI 10.1074/jbc.272.49.31156; DUAN HW, 1995, J CLIN INVEST, V96, P915, DOI 10.1172/JCI118139; Fazio S, 1999, J BIOL CHEM, V274, P8247, DOI 10.1074/jbc.274.12.8247; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; Glick BS, 1998, CELL, V95, P883, DOI 10.1016/S0092-8674(00)81713-4; LILLYSTAUDERMAN M, 1993, J LIPID RES, V34, P190; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Lucas M, 1996, J BIOL CHEM, V271, P13454, DOI 10.1074/jbc.271.23.13454; MAZZONE T, 1992, J BIOL CHEM, V267, P1081; Mazzone T, 1996, CURR OPIN LIPIDOL, V7, P303, DOI 10.1097/00041433-199610000-00008; MAZZONE T, 1989, J LIPID RES, V30, P1055; MAZZONE T, 1986, BIOCHIM BIOPHYS ACTA, V875, P396; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; ROSA P, 1992, J BIOL CHEM, V267, P12227; Schmitt M, 1999, J LIPID RES, V40, P39; VOLZ B, 1995, J CELL BIOL, V130, P537, DOI 10.1083/jcb.130.3.537; WILLIAMS DL, 1995, J LIPID RES, V36, P745; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; ZANNI EE, 1989, J BIOL CHEM, V264, P9137; ZANNIS VI, 1986, J BIOL CHEM, V261, P3415; ZANNIS VI, 1984, J BIOL CHEM, V259, P5495; Zhao YW, 1999, J LIPID RES, V40, P1029	25	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4759	4765		10.1074/jbc.275.7.4759	http://dx.doi.org/10.1074/jbc.275.7.4759			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671508	hybrid			2022-12-27	WOS:000085378200034
J	Vanhanen, S; West, M; Kroon, JTM; Lindner, N; Casey, J; Cheng, Q; Elborough, KM; Slabas, AR				Vanhanen, S; West, M; Kroon, JTM; Lindner, N; Casey, J; Cheng, Q; Elborough, KM; Slabas, AR			A consensus sequence for long-chain fatty-acid alcohol oxidases from Candida identifies a family of genes involved in lipid omega-oxidation in yeast with homologues in plants and bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; TROPICALIS; PROTEIN; DNA; CDNA; ACYLTRANSFERASE; CYTOCHROMES; ENCODES; MALTOSA	The yeast Candida cloacae is capable of growing on alkanes and fatty acids as sole carbon sources. Transfer of cultures from a glucose medium to one containing oleic acid induced seven proteins of M-r 102,000, 73,000, 61,000, 54,000, and 46,000 and two in the region of M-r 45,000 and repressed a protein of M-x 64,000, The induction of the M-r 73,000 protein reached a 7-fold maximum 24 h after induction. The protein was confirmed by its enzyme: activity to be a long-chain fatty-acid alcohol oxidase (LC-FAO) and purified to homogeneity from microsomes by a rapid procedure involving hydrophobic chromatography, An internal peptide of 30 amino acids was sequenced. A 1100-base pair cDNA fragment containing the LC-FAO peptide coding sequence was used to isolate a single exon genomic clone containing the full-length coding sequence of an LC-FAO (fao1), The fool gene product was expressed in Escherichia coli and was translated as a functional long-chain alcohol oxidase, which was present in the membrane fraction. In addition, full-length coding sequences for a Candida tropicalis LC-FAO (faoT) and a second C. cloacae LC-FAO (fao2) were isolated. The DNA sequences obtained had open reading frames of 2094 (fao1), 2091 (fao2), and 2112 (faoT) base pairs. The derived amino acid sequences of fao2 and faoT showed 89.4 and 76.2% similarities to fool, The fao1 gene is much more highly induced on alkane than is fao2, Although this study describes the first known DNA sequences encoding LC-FAOs from any source, there are unassigned Arabidopsis sequences and an unassigned Mycobacterium sequence in the Gen-Bank(TM) Data Bank that show strong homology to the described LC-FAO sequences. The conservation of sequence between yeast, plants, and bacteria suggests that an as yet undescribed family of long-chain fatty-acid oxidases exists in both eukaryotes and prokaryotes.	Univ Durham, Dept Biol Sci, Lipid Mol Biol Grp, Durham DH1 3LE, England; Uniqema Int, NL-2800 AA Gouda, Netherlands; Unilever Res, Colworth House, Sharnbrook MK44 1LQ, Beds, England	Durham University; Unilever	Slabas, AR (corresponding author), Univ Durham, Dept Biol Sci, Lipid Mol Biol Grp, South Rd, Durham DH1 3LE, England.	A.R.Slabas@Durham.ac.uk	Cheng, Qi/C-9922-2018; Kroon, Johan Theodorus Maria/S-8415-2019	Cheng, Qi/0000-0003-1269-6386; Kroon, Johan Theodorus Maria/0000-0003-2086-6074				AKABORI S, 1972, Patent No. 5502; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN AP, 1994, PLANT MOL BIOL, V26, P211, DOI 10.1007/BF00039533; BROWN AP, 1995, PLANT MOL BIOL, V29, P267, DOI 10.1007/BF00043651; CASEY J, 1990, J GEN MICROBIOL, V136, P1197, DOI 10.1099/00221287-136-7-1197; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; DICKINSON FM, 1992, BIOCHEM J, V282, P325, DOI 10.1042/bj2820325; ELBOROUGH KM, 1994, PLANT MOL BIOL, V24, P21, DOI 10.1007/BF00040571; GEISSLER J, 1981, FEBS LETT, V126, P152, DOI 10.1016/0014-5793(81)80229-3; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; HALL TC, 1978, P NATL ACAD SCI USA, V75, P3196, DOI 10.1073/pnas.75.7.3196; IKUTA S, 1977, J BIOCHEM-TOKYO, V82, P1741, DOI 10.1093/oxfordjournals.jbchem.a131872; ILCHENKO AP, 1984, MIKROBIOLOGIYA, V50, P903; KATO N, 1976, EUR J BIOCHEM, V64, P341, DOI 10.1111/j.1432-1033.1976.tb10307.x; KEMP GD, 1988, APPL MICROBIOL BIOT, V29, P370, DOI 10.1007/BF00265821; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MATHEWS FS, 1985, PROG BIOPHYS MOL BIO, V45, P1, DOI 10.1016/0079-6107(85)90004-5; MAUERSBERGER S, 1992, APPL MICROBIOL BIOT, V37, P66; MOREAU RA, 1979, ARCH BIOCHEM BIOPHYS, V194, P422, DOI 10.1016/0003-9861(79)90636-2; Nishida Y, 1996, Audiol Neurootol, V1, P31; Ohkuma M, 1998, J BIOL CHEM, V273, P3948, DOI 10.1074/jbc.273.7.3948; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; PICATAGGIO S, 1992, BIO-TECHNOL, V10, P894, DOI 10.1038/nbt0892-894; PICATAGGIO S, 1991, Patent No. 9106660; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; SAHM H, 1982, METHOD ENZYMOL, V89, P424; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGLARD D, 1992, YEAST, V8, P1065, DOI 10.1002/yea.320081209; SAVITHA J, 1991, FEMS MICROBIOL LETT, V80, P221, DOI 10.1111/j.1574-6968.1991.tb04665.x; Schou C, 1998, BIOCHEM J, V330, P565, DOI 10.1042/bj3300565; TYKARSKA E, 1990, J PROTEIN CHEM, V9, P83, DOI 10.1007/BF01024988; VRELINK A, 1991, J MOL BIOL, V219, P533; WERNER W, 1970, FRESEN Z ANAL CHEM, V252, P224; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	35	33	43	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4445	4452		10.1074/jbc.275.6.4445	http://dx.doi.org/10.1074/jbc.275.6.4445			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660617	hybrid			2022-12-27	WOS:000085288800101
J	Wang, TL; Dowal, L; El-Maghrabi, MR; Rebecchi, M; Scarlata, S				Wang, TL; Dowal, L; El-Maghrabi, MR; Rebecchi, M; Scarlata, S			The pleckstrin homology domain of phospholipase C-beta(2) links the binding of G beta gamma to activation of the catalytic core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE BINDING; ADRENERGIC-RECEPTOR KINASE; G(BETA-GAMMA) SUBUNITS; MEMBRANE-BINDING; HIGH-AFFINITY; C ISOZYMES; G-PROTEINS; SUBSTRATE; C-DELTA-1; EFFECTOR	Pleckstrin homology (PR) domains are membrane tethering devices found in many signal transducing proteins. These domains also couple to the beta gamma subunits of GTP binding proteins (G proteins), but whether this association transmits allosteric information to the catalytic core is unclear. To address this question, we constructed protein chimeras in which the PH domain of phospholipase C-beta(2) (PLC-beta(2)), which is regulated by G beta gamma, replaces the PH domain of PLC-delta(1) which binds to, but is not regulated by, G beta gamma. We found that attachment of the PH domain of PLC-beta(2) onto PLC-delta(1) not only causes the membrane-binding properties of PLC-delta(1) to become similar to those of PLC-beta(2), but also results in a G beta gamma-regulated enzyme. Thus, PH domains are more than simple tethering devices and mediate regulatory signals to the host protein.	SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Anesthesiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Scarlata, S (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053132] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53132] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bromann PA, 1997, J BIOL CHEM, V272, P16240, DOI 10.1074/jbc.272.26.16240; Chuang TT, 1997, EUR J BIOCHEM, V245, P533, DOI 10.1111/j.1432-1033.1997.00533.x; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lomasney JW, 1996, J BIOL CHEM, V271, P25316, DOI 10.1074/jbc.271.41.25316; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Runnels LW, 1996, BIOCHEMISTRY-US, V35, P16824, DOI 10.1021/bi961606w; Runnels LW, 1999, BIOCHEMISTRY-US, V38, P1488, DOI 10.1021/bi9821519; Runnels LW, 1998, BIOCHEMISTRY-US, V37, P15563, DOI 10.1021/bi9811258; Tall E, 1997, BIOCHEMISTRY-US, V36, P7239, DOI 10.1021/bi9702288; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; Wang TL, 1999, BIOCHEMISTRY-US, V38, P1517, DOI 10.1021/bi982008f; Williams RL, 1996, STRUCTURE, V4, P1387, DOI 10.1016/S0969-2126(96)00146-3	23	71	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7466	7469		10.1074/jbc.275.11.7466	http://dx.doi.org/10.1074/jbc.275.11.7466			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713048	hybrid			2022-12-27	WOS:000085913300008
J	Kesarwani, M; Azam, M; Natarajan, K; Mehta, A; Datta, A				Kesarwani, M; Azam, M; Natarajan, K; Mehta, A; Datta, A			Oxalate decarboxylase from Collybia velutipes - Molecular cloning and its overexpression to confer resistance to fungal infection in transgenic tobacco and tomato	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCLEROTINIA-SCLEROTIORUM; OXALIC-ACID; AGROBACTERIUM-TUMEFACIENS; CALCIUM-OXALATE; PLANTS; GENE; EXPRESSION; OXIDASE; PATHOGENESIS; CHITINASES	Oxalic acid is present as nutritional stress in many crop plants like Amaranth and Lathyrus, Oxalic acid has also been found to be involved in the attacking mechanism of several phytopathogenic fungi. A full-length cDNA for oxalate decarboxylase, an oxalate-catabolizing enzyme, was isolated by using 5'-rapid amplification of cDNA ends-polymerase chain reaction of a partial cDNA as cloned earlier from our laboratory (Mehta, A, and Datta, A. (1991) J. Biol. Chem, 266, 23548-23553). By screening a genomic library from Collybia velutipes with this cDNA as a probe, a genomic clone has been isolated. Sequence analyses and comparison of the genomic sequence with the cDNA sequence revealed that the cDNA is interrupted with 17 small introns, The cDNA has been successfully expressed in cytosol and vacuole of transgenic tobacco and tomato plants, The transgenic plants show normal phenotype, and the transferred trait is stably inherited to the next generation. The recombinant enzyme is partially glycosylated and shows oxalate decarboxylase activity in vitro as well as in vivo. Transgenic tobacco and tomato plants expressing oxalate decarboxylase show remarkable resistance to phytopathogenic fungus Sclerotinia sclerotiorum that utilizes oxalic acid during infestation. The result presented in the paper represents a novel approach to develop transgenic plants resistant to fungal infection.	Jawaharlal Nehru Univ, Natl Ctr Plant Genome Res, New Delhi 110067, India; Jawaharlal Nehru Univ, Sch Life Sci, Mol Biol Lab, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Institute of Plant Genome Research (NIPGR); Jawaharlal Nehru University, New Delhi; Jawaharlal Nehru University, New Delhi	Datta, A (corresponding author), Jawaharlal Nehru Univ, Natl Ctr Plant Genome Res, Jawaharlal Nehru Univ Campus, New Delhi 110067, India.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANGENON G, 1994, PLANT MOL BIOL MANUA, pC1; BATEMAN DF, 1965, PHYTOPATHOLOGY, V55, P204; BOLAND GJ, 1994, CAN J PLANT PATHOL, V16, P93, DOI 10.1080/07060669409500766; CONN K L, 1990, Canadian Plant Disease Survey, V70, P66; DICKMAN MB, 1992, PHYSIOL MOL PLANT P, V41, P255, DOI 10.1016/0885-5765(92)90025-Q; FERRAR PH, 1993, PHYSIOL MOL PLANT P, V43, P415, DOI 10.1006/pmpp.1993.1069; GODOY G, 1990, PHYSIOL MOL PLANT P, V37, P179, DOI 10.1016/0885-5765(90)90010-U; GOLD MH, 1993, MICROBIOL REV, V57, P605, DOI 10.1128/MMBR.57.3.605-622.1993; Grison R, 1996, NAT BIOTECHNOL, V14, P643, DOI 10.1038/nbt0596-643; HERMANN H, 1992, GENE, V119, P137, DOI 10.1016/0378-1119(92)90079-5; HOBBS SLA, 1990, PLANT MOL BIOL, V15, P851, DOI 10.1007/BF00039425; HOLLOWAY WD, 1989, J AGR FOOD CHEM, V37, P337, DOI 10.1021/jf00086a014; JACH G, 1995, PLANT J, V8, P97, DOI 10.1046/j.1365-313X.1995.08010097.x; JONGEDIJK E, 1995, EUPHYTICA, V85, P173, DOI 10.1007/BF00023946; JONSSON L, 1994, BBA-PROTEIN STRUCT M, V1207, P255, DOI 10.1016/0167-4838(94)00083-2; KRITZMAN G, 1977, EXP MYCOL, V1, P280, DOI 10.1016/S0147-5975(77)80003-0; LANE BG, 1993, J BIOL CHEM, V268, P12239; LUMSDEN RD, 1979, PHYTOPATHOLOGY, V69, P890, DOI 10.1094/Phyto-69-890; MALATHI K, 1970, PHYTOCHEMISTRY, V9, P1603, DOI 10.1016/S0031-9422(00)85283-8; MARGO P, 1984, FEMS MICROBIOL LETT, V24, P9; MAYER AM, 1979, PHYTOCHEMISTRY, V18, P193, DOI 10.1016/0031-9422(79)80057-6; MEHTA A, 1991, J BIOL CHEM, V266, P23548; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NAGEL R, 1990, FEMS MICROBIOL LETT, V67, P325, DOI [10.1016/0378-1097(90)90017-K, 10.1111/j.1574-6968.1990.tb04041.x]; NEUHAUS JM, 1991, P NATL ACAD SCI USA, V88, P10362, DOI 10.1073/pnas.88.22.10362; Palmer JD, 1991, CURR OPIN GENET DEV, V1, P470, DOI 10.1016/S0959-437X(05)80194-7; RAVEN JA, 1976, NEW PHYTOL, V76, P415, DOI 10.1111/j.1469-8137.1976.tb01477.x; REGINATO AJ, 1989, SEMIN ARTHRITIS RHEU, V18, P198, DOI 10.1016/0049-0172(89)90062-0; Rogers SO, 1994, PLANT MOL BIOL MANUA, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPENCER PS, 1986, LANCET, V2, P1066, DOI 10.1016/S0140-6736(86)90468-X; SPERRY JS, 1988, PLANT PHYSIOL, V88, P581, DOI 10.1104/pp.88.3.581; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANHAUTE E, 1983, EMBO J, V2, P411, DOI 10.1002/j.1460-2075.1983.tb01438.x; WILLIAMS AW, 1990, SEMIN NEPHROL, V10, P2; WILLIAMS HE, 1989, J UROLOGY, V141, P742, DOI 10.1016/S0022-5347(17)40999-2; WU GS, 1995, PLANT CELL, V7, P1357, DOI 10.1105/tpc.7.9.1357	39	96	110	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7230	7238		10.1074/jbc.275.10.7230	http://dx.doi.org/10.1074/jbc.275.10.7230			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702293	hybrid			2022-12-27	WOS:000085809600073
J	Nemeth-Cahalan, KL; Hall, JE				Nemeth-Cahalan, KL; Hall, JE			pH and calcium regulate the water permeability of aquaporin 0	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR INTRINSIC PROTEIN; XENOPUS OOCYTES; MIP FAMILY; FROG LENS; MEMBRANE-PROTEIN; CHANNEL PROTEINS; MOUSE; TRANSPORT; CELL; EXPRESSION	Aquaporins increase the water permeability in many cell types across many species. We investigated the effects of external pH and Ca2+ on water permeability of Xenopus oocytes injected with aquaporin cRNA by measuring the rate of swelling in hypotonic solutions. Lowering pH to 6.5 increased the water permeability of aquaporin (AQP0) 3.4 +/- 0.4-fold. Diethylpyrocarbonate pretreatment increased water permeability 4.2 +/- 0.5-fold and abolished pH sensitivity, suggesting that the pH regulation is mediated by an external histidine. Lowering Ca2+ increased mater permeability 4.1 +/- 0.1-fold. The effects of Ca2+ and pH each required the presence of histidine 40, indicating a critical role of this amino acid in facilitating the modulation of water permeability. Clamping intracellular Ca2+ at high or low values abolished sensitivity to external Ca2+, suggesting that Ca2+ acts at an internal site. Three different calmodulin inhibitors each increased AQP0 water permeability, suggesting that Ca2+ may act through calmodulin. None of the above altered the water permeability induced by AQP1 or AQP4. Because the greatest change in AQP0 water permeability is in the normal pH range found in the lens (7.2-6.5), this paper provides evidence for regulation of an aquaporin by pH under physiological conditions.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine	Hall, JE (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.	jhall@uci.edu	Hall, James E/K-6306-2012		NEI NIH HHS [EY5661] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bell J.E., 1988, PROTEINS ENZYMES; Bevington P. R., 1969, DATA REDUCTION ERROR, P56; Cahalan K, 1998, J GEN PHYSIOL, V112, p27A; Cahalan KL, 1999, BIOPHYS J, V76, pA183; Chandy G, 1997, J MEMBRANE BIOL, V159, P29, DOI 10.1007/s002329900266; COSTELLO MJ, 1989, INVEST OPHTH VIS SCI, V30, P975; DUNCAN G, 1984, HUMAN CATARACT FORMA, P132; DUNIA I, 1987, J CELL BIOL, V105, P1679, DOI 10.1083/jcb.105.4.1679; ECHEVARRIA M, 1993, AM J PHYSIOL, V265, pC1349, DOI 10.1152/ajpcell.1993.265.5.C1349; GIRSCH SJ, 1991, CURR EYE RES, V10, P839, DOI 10.3109/02713689109013880; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; Ishida N, 1997, BIOCHEM BIOPH RES CO, V238, P891, DOI 10.1006/bbrc.1997.7396; JUNG JS, 1994, J BIOL CHEM, V269, P14648; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; KUSHMERICK C, 1995, EXP EYE RES, V61, P351, DOI 10.1016/S0014-4835(05)80129-0; LOUIS CF, 1990, EXP EYE RES, V50, P495, DOI 10.1016/0014-4835(90)90038-V; Mathias RT, 1997, PHYSIOL REV, V77, P21, DOI 10.1152/physrev.1997.77.1.21; Mene P, 1996, J AM SOC NEPHROL, V7, P983; Misaka T, 1996, FEBS LETT, V381, P208, DOI 10.1016/0014-5793(96)00092-0; MUGGLETONHARRIS AL, 1987, DEVELOPMENT, V99, P473; Mulders SM, 1998, PFLUG ARCH EUR J PHY, V436, P599, DOI 10.1007/s004240050677; MULDERS SM, 1995, J BIOL CHEM, V270, P9010, DOI 10.1074/jbc.270.15.9010; Noh SJ, 1998, J CELL PHYSIOL, V176, P412, DOI 10.1002/(SICI)1097-4652(199808)176:2<412::AID-JCP20>3.0.CO;2-3; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120; PASQUALE LR, 1990, BIOPHYS J, V58, P939, DOI 10.1016/S0006-3495(90)82438-3; Paterson CA, 1997, CURR EYE RES, V16, P333, DOI 10.1076/ceyr.16.4.333.10689; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; Sasaki S, 1998, ANNU REV PHYSIOL, V60, P199, DOI 10.1146/annurev.physiol.60.1.199; SHIELS A, 1993, CURR EYE RES, V12, P913, DOI 10.3109/02713689309020398; Shiels A, 1996, NAT GENET, V12, P212, DOI 10.1038/ng0296-212; SHIONO S, 1993, BIOCHEM BIOPH RES CO, V193, P667, DOI 10.1006/bbrc.1993.1676; TAKEHANA M, 1990, EXP EYE RES, V50, P671, DOI 10.1016/0014-4835(90)90112-8; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Yang BX, 1997, J BIOL CHEM, V272, P16140, DOI 10.1074/jbc.272.26.16140; ZAMPIGHI GA, 1989, J CELL BIOL, V108, P2255, DOI 10.1083/jcb.108.6.2255; Zeuthen T, 1999, J BIOL CHEM, V274, P21631, DOI 10.1074/jbc.274.31.21631	41	193	195	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6777	6782		10.1074/jbc.275.10.6777	http://dx.doi.org/10.1074/jbc.275.10.6777			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702234	hybrid			2022-12-27	WOS:000085809600014
J	Bates, DM; Popescu, CV; Khoroshilova, N; Vogt, K; Beinert, H; Munck, E; Kiley, PJ				Bates, DM; Popescu, CV; Khoroshilova, N; Vogt, K; Beinert, H; Munck, E; Kiley, PJ			Substitution of leucine 28 with histidine in the Escherichia coli transcription factor FNR results in increased stability of the [4Fe-4S](2+) cluster to oxygen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEINS; ANGSTROM RESOLUTION; GENE-REGULATION; DNA-BINDING; IN-VITRO; MUTANTS; EXPRESSION; REPRESSOR; SYSTEM; 4FE-4S	To understand the role of the [4Fe-4S](2+) cluster in controlling the activity of the Escherichia coli transcription factor FNR (fumarate nitrate reduction) during changes in O-2 availability, we have characterized a mutant FNR protein containing a substitution of Leu-28 with His (FNR-L28H) which, unlike its wild type (WT) counterpart, is functional under aerobic growth conditions. The His-28 substitution appears to stabilize the [4Fe-4S](2+) cluster of FNR-L28H in the presence of O-2 because air-exposed FNR-L28H did not undergo the rapid [4Fe-4S](2+) to [2Fe-2S](2+) cluster conversion or concomitant loss in site-specific DNA binding and dimerization, which are characteristic of WT-FNR under these conditions. This increased cluster stability was not a result of His-28 replacing the WT-FNR cluster ligands because substitution of any of these four Cys residues (cysteine 20, 23, 29, or 122) with Ser resulted in [4Fe-4S](2+) cluster-deficient preparations of FNR-L28H. The Mossbauer spectra of FNR-L28H indicated that the coordination environment of the [4Fe-4S](2+) cluster did not differ from that of WT-FNR. Whole cell Mossbauer spectroscopy showed that aerobically grown cells overexpressing FNR-L28H had levels of the FNR species containing the [4Fe-4S](2+) cluster similar to those of cells grown under anaerobic conditions. Thus, the increase in cluster stability is sufficient to allow accumulation of the [4Fe-4S](2+) cluster form of FNR-L28H under aerobic conditions and provides a reasonable explanation for why this mutant protein is functional under aerobic growth conditions. From these results, we present a model to explain how WT-FNR is normally inactivated under aerobic growth conditions.	Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA; Carnegie Mellon Univ, Dept Chem, Pittsburgh, PA 15123 USA; Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Grad Sch, Inst Enzyme Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; Carnegie Mellon University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Kiley, PJ (corresponding author), Univ Wisconsin, Sch Med, Dept Biomol Chem, 1300 Univ Ave, Madison, WI 53706 USA.	pjkiley@facstaff.wisc.edu		Kiley, Patricia/0000-0002-8771-1782; Popescu, Codrina/0000-0003-2369-3383	NIGMS NIH HHS [GM-45844, GM-22701] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045844, R01GM022701] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATES DM, 1995, J BACTERIOL, V177, P3972, DOI 10.1128/jb.177.14.3972-3978.1995; Beinert H, 1999, CURR OPIN CHEM BIOL, V3, P152, DOI 10.1016/S1367-5931(99)80027-1; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Dibar-Ure M. C., 1971, MOSSBAUER EFFECT MET, V7, P245; Dixon R, 1998, ARCH MICROBIOL, V169, P371, DOI 10.1007/s002030050585; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; Flint DH, 1996, CHEM REV, V96, P2315, DOI 10.1021/cr950041r; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; Green J, 1996, BIOCHEM J, V316, P887, DOI 10.1042/bj3160887; GREEN J, 1991, P ROY SOC B-BIOL SCI, V244, P137, DOI 10.1098/rspb.1991.0062; GUNSALUS RP, 1994, RES MICROBIOL, V145, P437, DOI 10.1016/0923-2508(94)90092-2; HUYNH BH, 1979, BIOCHIM BIOPHYS ACTA, V576, P192, DOI 10.1016/0005-2795(79)90497-5; IBERS JA, 1980, SCIENCE, V209, P223, DOI 10.1126/science.7384796; Johnson MK, 1998, CURR OPIN CHEM BIOL, V2, P173, DOI 10.1016/S1367-5931(98)80058-6; Jordan PA, 1997, FEBS LETT, V416, P349, DOI 10.1016/S0014-5793(97)01219-2; KENNEDY MC, 1984, J BIOL CHEM, V259, P4463; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; Kiley PJ, 1998, FEMS MICROBIOL REV, V22, P341, DOI 10.1111/j.1574-6976.1998.tb00375.x; KILEY PJ, 1991, J BACTERIOL, V173, P16, DOI 10.1128/jb.173.1.16-22.1991; KUNKEL TA, 1989, CURRENT PROTOCOLS MO; LAMBDEN PR, 1976, J GEN MICROBIOL, V97, P145, DOI 10.1099/00221287-97-2-145; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; LAZAZZERA BA, 1993, GENE DEV, V7, P1993, DOI 10.1101/gad.7.10.1993; LYNCH AS, 1996, ESCHERICHIA COLI SAL, V1, P1526; Melville SB, 1996, P NATL ACAD SCI USA, V93, P1226, DOI 10.1073/pnas.93.3.1226; MELVILLE SB, 1990, J BIOL CHEM, V265, P18733; Miller J. H., 1972, EXPT MOL GENETICS, P431; Mulholland SE, 1999, BIOCHEMISTRY-US, V38, P10442, DOI 10.1021/bi9908742; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; Popescu CV, 1998, P NATL ACAD SCI USA, V95, P13431, DOI 10.1073/pnas.95.23.13431; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; SHARROCKS AD, 1990, FEBS LETT, V270, P119, DOI 10.1016/0014-5793(90)81248-M; Soriano A, 1996, BIOCHEMISTRY-US, V35, P12479, DOI 10.1021/bi960974x; SPIRO S, 1994, ANTON LEEUW INT J G, V66, P23, DOI 10.1007/BF00871630; Stout CD, 1998, J MOL BIOL, V278, P629, DOI 10.1006/jmbi.1998.1732; UNDEN G, 1995, ARCH MICROBIOL, V164, P81; VanSpanning RJM, 1997, MOL MICROBIOL, V23, P893, DOI 10.1046/j.1365-2958.1997.2801638.x; ZIEGELHOFFER EC, 1995, J MOL BIOL, V245, P351, DOI 10.1006/jmbi.1994.0029	39	69	70	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6234	6240		10.1074/jbc.275.9.6234	http://dx.doi.org/10.1074/jbc.275.9.6234			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692418	hybrid			2022-12-27	WOS:000085654400030
J	de Vet, ECJM; Hilkes, YHA; Fraaije, MW; van den Bosch, H				de Vet, ECJM; Hilkes, YHA; Fraaije, MW; van den Bosch, H			Alkyl-dihydroxyacetonephosphate synthase - Presence and role of flavin adenine dinucleotide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VANILLYL-ALCOHOL OXIDASE; GLYCEROLIPID BIOSYNTHESIS; PEROXISOMAL DISORDERS; NUCLEOTIDE-SEQUENCE; PHOSPHATE SYNTHASE; LIPID-SYNTHESIS; MECHANISM; DEFICIENCY; BINDING; IDENTIFICATION	Alkyl-dihydroxyacetonephosphate synthase is a peroxisomal enzyme involved in ether lipid synthesis, It catalyzes the exchange of the acyl chain in acyl-dihydroxy acetonephosphate for a long chain fatty alcohol, yielding the first ether linked intermediate, i.e. alkyl-dihydroxyacetonephosphate, in the pathway of ether lipid biosynthesis. Although this reaction is not a net redox reaction, the amino acid sequence of the enzyme suggested the presence of a flavin adenine dinucleotide (FAD)-binding domain. In this study we show that alkyl-dihydroxy acetonephosphate synthase contains an essential FAD molecule as cofactor, which is evidenced by fluorescence properties, UV-visible absorption spectra and the observation that the enzyme activity is dependent on the presence of this cofactor in a coupled in vitro transcription/translation assay. Furthermore, we could demonstrate that the FAD cofactor directly participates in catalysis. Upon incubation of the enzyme with the substrate palmitoyl-dihydroxy acetonephosphate, the flavin moiety is reduced, indicating that in this initial step the substrate is oxidized. Stopped flow experiments show that the reduction of the flavin moiety is a monophasic process yielding a oxygen stable, reduced enzyme species. Upon addition of hexadecanol to the reduced enzyme species, the flavin moiety is efficiently reoxidized. A hypothetical reaction mechanism is proposed that is consistent with the data in this paper and with previous studies.	Univ Utrecht, Biomembrane Inst, Ctr Biomembranes & Lipid Enzymol, NL-3584 CH Utrecht, Netherlands; Univ Pavia, Dept Genet & Microbiol, I-27100 Pavia, Italy	Utrecht University; University of Pavia	van den Bosch, H (corresponding author), Univ Utrecht, Biomembrane Inst, Ctr Biomembranes & Lipid Enzymol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.		Fraaije, Marco/E-8421-2014	Fraaije, Marco/0000-0001-6346-5014				Biermann J, 1999, EUR J BIOCHEM, V261, P492, DOI 10.1046/j.1432-1327.1999.00295.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN AJ, 1983, J BIOL CHEM, V258, P4184; BROWN AJ, 1982, J BIOL CHEM, V257, P8835; DALZIEL K, 1962, BIOCHEM J, V84, P244, DOI 10.1042/bj0840244; DAVIS PA, 1981, ARCH BIOCHEM BIOPHYS, V211, P20, DOI 10.1016/0003-9861(81)90424-0; DAVIS PA, 1979, J BIOL CHEM, V254, P4760; de Vet ECJM, 1998, J BIOL CHEM, V273, P10296, DOI 10.1074/jbc.273.17.10296; de Vet ECJM, 1998, BIOCHEM BIOPH RES CO, V252, P629, DOI 10.1006/bbrc.1998.9670; de Vet ECJM, 1998, BIOCHEM BIOPH RES CO, V242, P277, DOI 10.1006/bbrc.1997.7950; de Vet ECJM, 1999, BBA-MOL CELL BIOL L, V1436, P299, DOI 10.1016/S0005-2760(98)00118-0; DEJONG E, 1992, EUR J BIOCHEM, V208, P651; DeVet ECJM, 1997, EUR J BIOCHEM, V247, P511; deVet ECJM, 1997, BBA-LIPID LIPID MET, V1346, P25, DOI 10.1016/S0005-2760(97)00014-3; deVet ECJM, 1997, J BIOL CHEM, V272, P798, DOI 10.1074/jbc.272.2.798; Fraaije MW, 1998, EUR J BIOCHEM, V253, P712, DOI 10.1046/j.1432-1327.1998.2530712.x; Fraaije MW, 1998, TRENDS BIOCHEM SCI, V23, P206, DOI 10.1016/S0968-0004(98)01210-9; FRIEDBERG SJ, 1980, J BIOL CHEM, V255, P1074; FRIEDBERG SJ, 1987, BIOCHEM BIOPH RES CO, V145, P1177, DOI 10.1016/0006-291X(87)91561-0; FRIEDBERG SJ, 1971, BIOCHEMISTRY-US, V14, P570; GHISLA S, 1980, J BIOL CHEM, V255, P5688; Hajra AK, 1995, PROG LIPID RES, V34, P343, DOI 10.1016/0163-7827(95)00013-5; HAJRA AK, 1982, ANN NY ACAD SCI, V386, P170, DOI 10.1111/j.1749-6632.1982.tb21415.x; HAJRA AK, 1970, BIOCHEM BIOPH RES CO, V39, P1037, DOI 10.1016/0006-291X(70)90663-7; KELLERMANN OK, 1982, METHOD ENZYMOL, V90, P459; KUICHI K, 1982, BIOCHEMISTRY-US, V21, P5076; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Macheroux P, 1996, J BIOL CHEM, V271, P25850, DOI 10.1074/jbc.271.42.25850; Mattevi A, 1997, STRUCTURE, V5, P907, DOI 10.1016/S0969-2126(97)00245-1; Muh U, 1996, BIOCHEMISTRY-US, V35, P11710, DOI 10.1021/bi9601363; PORTER DJT, 1977, J BIOL CHEM, V252, P4464; SCHRAKAMP G, 1985, J LIPID RES, V26, P867; SNYDER F, 1970, J BIOL CHEM, V245, P5853; Thai TP, 1997, FEBS LETT, V420, P205, DOI 10.1016/S0014-5793(97)01495-6; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; WANDERS RJA, 1995, J NEUROPATH EXP NEUR, V54, P726, DOI 10.1097/00005072-199509000-00016; WELLS MA, 1971, BIOCHIM BIOPHYS ACTA, V248, P80, DOI 10.1016/0005-2760(71)90077-4; ZOMER AWM, 1993, BIOCHIM BIOPHYS ACTA, V1170, P189, DOI 10.1016/0005-2760(93)90070-P	38	27	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6276	6283		10.1074/jbc.275.9.6276	http://dx.doi.org/10.1074/jbc.275.9.6276			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692424	Green Published, hybrid			2022-12-27	WOS:000085654400036
J	Drake, MT; Downs, MA; Traub, LM				Drake, MT; Downs, MA; Traub, LM			Epsin binds to clathrin by associating directly with the clathrin-terminal domain - Evidence for cooperative binding through two discrete sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; TYROSINE KINASE SUBSTRATE; ASSEMBLY PROTEIN AP-3; EH-DOMAIN; ARRESTIN/CLATHRIN INTERACTION; NERVE-TERMINALS; COATED VESICLES; ADAPTER COMPLEX; EPS15; IDENTIFICATION	Epsin is a recently identified protein that appears to play an important role in clathrin-mediated endocytosis. The central region of epsin 1, the so-called DPW domain, binds to the heterotetrameric AP-2 adaptor complex by associating directly with the globular appendage of the alpha subunit. We have found that this central portion of epsin 1 also associates with clathrin. The interaction with clathrin is direct and not mediated by epsin-bound AP-2. Alanine scanning mutagenesis shows that clathrin binding depends on the sequence (LMD)-L-257-LADV located within the epsin 1 DPW domain. This sequence, related to the known clathrin-binding sequences in the adaptor beta subunits, amphiphysin, and beta-arrestin, facilitates the association of epsin 1 with the terminal domain of the clathrin heavy chain, Unexpectedly, inhibiting the binding of AP-2 to the GST-epsin DPW fusion protein by progressively deleting DPW triplets but leaving the LMDLADV sequence intact, diminishes the association of clathrin in parallel with AP-2. Because the beta subunit of the AP-2 complex also contains a clathrin-binding site, optimal association with soluble clathrin appears to depend on the presence of at least two distinct clathrin-binding sites, and we show that a second clathrin-binding sequence (LVDLD)-L-480, located within the carboxyl-terminal segment of epsin 1, also interacts with clathrin directly. The LMDLADV and LVDLD sequences act cooperatively in clathrin recruitment assays, suggesting that they bind to different sites on the clathrin-terminal domain. The evolutionary conservation of similar clathrin-binding sequences in several metazoan epsin-like molecules suggests that the ability to establish multiple protein-protein contacts within a developing clathrin-coated bud is an important aspect of epsin function.	Washington Univ, Sch Med, Dept Internal Med, Div Hematol, St Louis, MO 63110 USA	Washington University (WUSTL)	Traub, LM (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Hematol, Box 8125,660 S Euclid Ave, St Louis, MO 63110 USA.			Traub, Linton/0000-0002-1303-0298	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053249] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53249] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Achiriloaie M, 1999, MOL CELL BIOL, V19, P1410; AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; Arneson LS, 1999, J BIOL CHEM, V274, P17794, DOI 10.1074/jbc.274.25.17794; Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; Carbone R, 1997, CANCER RES, V57, P5498; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Coda L, 1998, J BIOL CHEM, V273, P3003, DOI 10.1074/jbc.273.5.3003; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Dreyling MH, 1996, P NATL ACAD SCI USA, V93, P4804, DOI 10.1073/pnas.93.10.4804; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; Hussain NK, 1999, J BIOL CHEM, V274, P15671, DOI 10.1074/jbc.274.22.15671; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; Kay BK, 1999, PROTEIN SCI, V8, P435; Kelly RB, 1999, NAT CELL BIOL, V1, pE8, DOI 10.1038/8957; Kibbey RG, 1998, J CELL BIOL, V142, P59, DOI 10.1083/jcb.142.1.59; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Lee A, 1999, CURR BIOL, V9, P261, DOI 10.1016/S0960-9822(99)80115-8; Li Y, 1998, J BIOL CHEM, V273, P16265, DOI 10.1074/jbc.273.26.16265; McPherson PS, 1998, BIOCHEM BIOPH RES CO, V244, P701, DOI 10.1006/bbrc.1998.8331; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; MURPHY JE, 1992, J BIOL CHEM, V267, P10850; MURPHY JE, 1991, J BIOL CHEM, V266, P4401; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; PAGE LJ, 1995, J CELL BIOL, V131, P619, DOI 10.1083/jcb.131.3.619; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; SAITO Y, 1992, J BIOCHEM-TOKYO, V112, P448, DOI 10.1093/oxfordjournals.jbchem.a123920; Salcini AE, 1999, INT J BIOCHEM CELL B, V31, P805, DOI 10.1016/S1357-2725(99)00042-4; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Tebar F, 1999, MOL BIOL CELL, V10, P2687, DOI 10.1091/mbc.10.8.2687; ter Haar E, 1998, CELL, V95, P563, DOI 10.1016/S0092-8674(00)81623-2; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401; YE WL, 1995, J BIOL CHEM, V270, P10933, DOI 10.1074/jbc.270.18.10933	55	117	120	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6479	6489		10.1074/jbc.275.9.6479	http://dx.doi.org/10.1074/jbc.275.9.6479			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692452	hybrid, Green Submitted			2022-12-27	WOS:000085654400064
J	Gonias, SL; Carmichael, A; Mettenburg, JM; Roadcap, DW; Irvin, WP; Webb, DJ				Gonias, SL; Carmichael, A; Mettenburg, JM; Roadcap, DW; Irvin, WP; Webb, DJ			Identical or overlapping sequences in the primary structure of human alpha(2)-microglobulin are responsible for the binding of nerve growth factor-beta, platelet-derived growth factor-BB, and transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APPARENT EQUILIBRIUM CONDITIONS; PROTEINASE COMPLEX-FORMATION; RECEPTOR-RELATED PROTEIN; NITRIC-OXIDE SYNTHESIS; NECROSIS-FACTOR-ALPHA; HUMAN ALPHA-2-MACROGLOBULIN; HUMAN ALPHA(2)-MACROGLOBULIN; ALZHEIMERS-DISEASE; BAIT REGION; MOUSE ALPHA(2)-MACROGLOBULIN	alpha(2)-Macroglobulin (alpha(2)M) functions as a proteinase inhibitor and as a carrier of diverse growth factors. In this study, we localized binding sites for platelet-derived growth factor-RE (PDGF-BB) and nerve growth factor-beta (NGF-beta) to a linear sequence in the 180-kDa human alpha(2)M subunit which includes amino acids 591-774. A glutathione S-transferase fusion protein containing amino acids 591-774 (FP3) bound PDGF-BB and NGF-beta in ligand blotting assays whereas five other fusion proteins, which collectively include amino acids 99-590 and 775-1451 did not. The K-D values for PDGF-BB and NGF-beta binding to immobilized FP3 were 300 +/- 40 and 180 +/- 30 nM, respectively; these values were comparable with those determined using methylamine-modified alpha(2)M, suggesting that higher-order alpha(2)M structure is not necessary for PDGF-BB and NGF-beta binding. PDGF-BB and NGF-beta blocked the binding of transforming growth factor-beta 1 (TGF-beta 1) to FP3, Furthermore, murinoglobulin, which is the only known member of the alpha-macroglobulin family that does not bind TGF-beta, also failed to bind PDGF-BB and NGF-beta. These results support the hypothesis that either a single linear sequence in human alpha(2)M or overlapping sequences are responsible for the binding of TGF-beta, PDGF-BB, and NGF-beta, even though there is minimal sequence identity between these three growth factors. FP3 blocked the binding of PDGF-BB to a purified chimeric protein, in which the extracellular domain of the PDGF beta receptor was fused to the IgG(1) Fc domain, and to PDGF receptors on NIH 3T3 cells. Thus, FP3 may inhibit the activity of PDGF-BB.	Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Gynecol Oncol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Gonias, SL (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pathol, Box 214, Charlottesville, VA 22908 USA.				NATIONAL CANCER INSTITUTE [R01CA053462] Funding Source: NIH RePORTER; NCI NIH HHS [CA-53462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN GR, 1995, J BIOL CHEM, V270, P25133, DOI 10.1074/jbc.270.42.25133; BARAMOVA EN, 1990, BIOCHEMISTRY-US, V29, P1069, DOI 10.1021/bi00456a032; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; Birkenmeier G, 1998, EUR J ENDOCRINOL, V139, P224, DOI 10.1530/eje.0.1390224; BJORK I, 1982, BIOCHEM J, V207, P347; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; Boisset N, 1996, J BIOL CHEM, V271, P25762, DOI 10.1074/jbc.271.42.25762; BONNER JC, 1995, J BIOL CHEM, V270, P16236, DOI 10.1074/jbc.270.27.16236; CROOKSTON KP, 1994, J BIOL CHEM, V269, P1533; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DESTROOPER B, 1992, FEBS LETT, V308, P50, DOI 10.1016/0014-5793(92)81048-Q; Fabrizi C, 1999, EXP NEUROL, V155, P252, DOI 10.1006/exnr.1998.6978; GETTINS P, 1990, BIOCHEMISTRY-US, V25, P5011; GONIAS SL, 1982, BIOCHIM BIOPHYS ACTA, V705, P306, DOI 10.1016/0167-4838(82)90252-7; Gunnarsson M, 1998, ARCH BIOCHEM BIOPHYS, V359, P192, DOI 10.1006/abbi.1998.0902; HALL SW, 1992, BIOCHEM J, V281, P569, DOI 10.1042/bj2810569; Howard GC, 1996, J BIOL CHEM, V271, P14105, DOI 10.1074/jbc.271.24.14105; Hughes SR, 1998, P NATL ACAD SCI USA, V95, P3275, DOI 10.1073/pnas.95.6.3275; HUSSAINI IM, 1990, BIOCHEM J, V270, P291, DOI 10.1042/bj2700291; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; Krimbou L, 1998, J LIPID RES, V39, P2373; LAMARRE J, 1991, LAB INVEST, V65, P3; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; Liao A, 1998, HUM MOL GENET, V7, P1953, DOI 10.1093/hmg/7.12.1953; LYSIAK JJ, 1995, J BIOL CHEM, V270, P21919, DOI 10.1074/jbc.270.37.21919; MATTHIJS G, 1991, NUCLEIC ACIDS RES, V19, P5102, DOI 10.1093/nar/19.18.5102; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Nielsen KL, 1996, J BIOL CHEM, V271, P12909, DOI 10.1074/jbc.271.22.12909; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; OVERBERGH L, 1994, GENOMICS, V22, P530, DOI 10.1006/geno.1994.1426; Pericak-Vance MA, 1998, NEUROBIOL AGING, V19, pS39, DOI 10.1016/S0197-4580(98)00037-2; Qazi U, 1998, J BIOL CHEM, V273, P8987, DOI 10.1074/jbc.273.15.8987; QUIGLEY JP, 1983, J BIOL CHEM, V258, P7903; Rogaeva EA, 1999, NAT GENET, V22, P19, DOI 10.1038/8729; RUDASINGHAM V, 1999, NAT GENET, V22, P17; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; SALVESEN GS, 1981, BIOCHEM J, V195, P453, DOI 10.1042/bj1950453; SOKER S, 1993, J BIOL CHEM, V268, P7685; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SOTTRUPJENSEN L, 1986, FEBS LETT, V205, P20, DOI 10.1016/0014-5793(86)80857-2; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; SWENSON RP, 1980, J BIOL CHEM, V255, P8087; UMANS L, 1995, J BIOL CHEM, V270, P19778, DOI 10.1074/jbc.270.34.19778; VANGOOL D, 1993, NEUROBIOL AGING, V14, P233, DOI 10.1016/0197-4580(93)90006-W; VANLEUVEN F, 1981, J BIOL CHEM, V256, P9016; Weaver AM, 1995, J BIOL CHEM, V270, P30741, DOI 10.1074/jbc.270.51.30741; WEBB DJ, 1992, ARCH BIOCHEM BIOPHYS, V292, P487, DOI 10.1016/0003-9861(92)90020-W; WEBB DJ, 1995, BIOCHEM J, V312, P579, DOI 10.1042/bj3120579; Webb DJ, 1998, LAB INVEST, V78, P939; Webb DJ, 1998, J BIOL CHEM, V273, P13339, DOI 10.1074/jbc.273.21.13339; Webb DJ, 1996, J BIOL CHEM, V271, P24982, DOI 10.1074/jbc.271.40.24982; WOLF BB, 1994, BIOCHEMISTRY-US, V33, P11270, DOI 10.1021/bi00203a024; WOLLENBERG GK, 1991, AM J PATHOL, V138, P265; Wu SM, 1998, J IMMUNOL, V161, P4356	56	47	48	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5826	5831		10.1074/jbc.275.8.5826	http://dx.doi.org/10.1074/jbc.275.8.5826			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681572	hybrid			2022-12-27	WOS:000085474500079
J	Kapatos, G; Stegenga, SL; Hirayama, K				Kapatos, G; Stegenga, SL; Hirayama, K			Identification and characterization of basal and cyclic AMP response elements in the promoter of the rat GTP cyclohydrolase I gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPERIOR CERVICAL-GANGLIA; MESSENGER-RNA EXPRESSION; CCAAT-BINDING PROTEINS; TRANSCRIPTION FACTOR; TETRAHYDROBIOPTERIN BIOSYNTHESIS; NF-Y; ACTIVATION DOMAIN; HYDROXYLASE GENE; DOPAMINE NEURONS; C/EBP-BETA	5812 base pairs of rat GTP cyclohydrolase I (GTPCH) 5'-flanking region were cloned and sequenced, and the transcription start site was determined for the gene in rat liver. Progressive deletion analysis using transient transfection assays of luciferase reporter constructs defined the core promoter as a highly conserved 142-base pair GC rich sequence upstream from the cap site. DNase I footprint analysis of this region revealed (5' -> 3') a Sp1/GC box, a noncanonical cAMP-response element (CRE), a CCAAT-box, and an E-box. Transcription from the core promoter in PC12 but not C6 or Rata cells was enhanced by incubation with 8-bromo-cyclic AMP. Mutagenesis showed that both the CRE and CCAAT-box independently contribute to basal and cAMP-dependent activity. The combined CRE and CCAAT-box cassette was also found to enhance basal transcription and confer cAMP sensitivity on a heterologous minimal promoter. The addition of the Sp1/GC box sequence to this minimal promoter construct inhibited basal transcription without affecting the cAMP response. EMSA showed that nuclear proteins from PC12 but not C6 or Rata cells bind the CRE as a complex containing activating transcription factor (ATF)-4 and CCAAT enhancer binding protein beta, while both PC12 and C6 cell nuclear extracts were recruited by the CCAAT-box as a complex containing nuclear factor Y, Overexpression of ATF-4 in PC12 cells was found to transactivate the GTPCH promoter response to cAMP. These studies suggest that the elements required for cell type-specific cAMP-dependent enhancement of gene transcription are located along the GTPCH core promoter and include the CRE and adjacent CCAAT-box and the proteins ATF-4, CCAAT enhancer-binding protein beta, and nuclear factor Y.	Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Cellular & Clin Neurobiol Program, Detroit, MI 48201 USA	Wayne State University	Kapatos, G (corresponding author), Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Cellular & Clin Neurobiol Program, 2309 Scott Hall,540 E Canfield, Detroit, MI 48201 USA.	gkapato@med.wayne.edu			NINDS NIH HHS [NS26081] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026081] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alonso CR, 1996, J BIOL CHEM, V271, P22271, DOI 10.1074/jbc.271.36.22271; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Ausubel FM, 1988, MOL REPROD DEV; Baler R, 1997, J BIOL CHEM, V272, P6979, DOI 10.1074/jbc.272.11.6979; Bevilacqua MA, 1997, J BIOL CHEM, V272, P20736, DOI 10.1074/jbc.272.33.20736; BOULARAND S, 1995, J BIOL CHEM, V270, P3757, DOI 10.1074/jbc.270.8.3757; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; Dassesse D, 1997, BRAIN RES, V777, P187, DOI 10.1016/S0006-8993(97)01111-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DSa C, 1996, MOL BRAIN RES, V41, P105, DOI 10.1016/0169-328X(96)00073-3; Eggers A, 1998, J BIOL CHEM, V273, P18499, DOI 10.1074/jbc.273.29.18499; Faniello MC, 1999, J BIOL CHEM, V274, P7623, DOI 10.1074/jbc.274.12.7623; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HATAKEYAMA K, 1991, J BIOL CHEM, V266, P765; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hirayama K, 1998, J NEUROCHEM, V70, P164; HIRAYAMA K, 1995, NEUROCHEM INT, V27, P157, DOI 10.1016/0197-0186(95)00008-V; HIRAYAMA K, 1993, J NEUROCHEM, V61, P1006, DOI 10.1111/j.1471-4159.1993.tb03614.x; ICHINOSE H, 1995, J BIOL CHEM, V270, P10062, DOI 10.1074/jbc.270.17.10062; ICHINOSE H, 1994, NAT GENET, V8, P236, DOI 10.1038/ng1194-236; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KAUFMAN S, 1974, CIBA F S, V22, P85; KWON NS, 1989, J BIOL CHEM, V264, P20496; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Lentz SI, 1996, NEUROCHEM INT, V28, P569, DOI 10.1016/0197-0186(95)00124-7; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LI XY, 1992, J BIOL CHEM, V267, P8984; Liang GS, 1997, J BIOL CHEM, V272, P24088, DOI 10.1074/jbc.272.38.24088; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Maxam A M, 1980, Methods Enzymol, V65, P499; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Nagatsu I, 1995, J NEURAL TRANSM-GEN, V102, P175, DOI 10.1007/BF01281153; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; ORKIN SH, 1983, NUCLEIC ACIDS RES, V11, P4727, DOI 10.1093/nar/11.14.4727; Osawa H, 1996, J BIOL CHEM, V271, P17296, DOI 10.1074/jbc.271.29.17296; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; RONCHI AE, 1995, J BIOL CHEM, V270, P21934, DOI 10.1074/jbc.270.37.21934; Shimoji M, 1999, J NEUROCHEM, V72, P757, DOI 10.1046/j.1471-4159.1999.0720757.x; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; Stegenga SL, 1996, J NEUROCHEM, V66, P2541; Supp DM, 1996, DEV BIOL, V176, P284, DOI 10.1006/dbio.1996.0134; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; WERNER ER, 1990, J BIOL CHEM, V265, P3189; Witter K, 1996, GENE, V171, P285, DOI 10.1016/0378-1119(95)00886-1; ZHU M, 1994, J BIOL CHEM, V269, P11825	56	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5947	5957		10.1074/jbc.275.8.5947	http://dx.doi.org/10.1074/jbc.275.8.5947			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681588	hybrid			2022-12-27	WOS:000085474500095
J	Rampazzo, C; Johansson, M; Gallinaro, L; Ferraro, P; Hellman, U; Karlsson, A; Reichard, P; Bianchi, V				Rampazzo, C; Johansson, M; Gallinaro, L; Ferraro, P; Hellman, U; Karlsson, A; Reichard, P; Bianchi, V			Mammalian 5 '(3 ')-deoxyribonucleotidase, cDNA cloning, and overexpression of the enzyme in Escherichia coli and mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE CYCLES; HUMAN-PLACENTA; 5'-NUCLEOTIDASE; DEOXYRIBONUCLEOTIDE; IDENTIFICATION; NUCLEOTIDASE; DEFICIENCY; EXPRESSION; ANCHOR; CD73	5'(3')-Deoxyribonucleotidase is a ubiquitous enzyme in mammalian cells whose physiological function is not known. It was earlier purified to homogeneity from human placenta. We determined the amino acid sequences of several internal peptides and with their aid found an expressed sequence tag clone with the complete cDNA for a murine enzyme of 23.9 kDa, The DNA was cloned into appropriate plasmids and introduced into Escherichia coli and ecdyson-inducible 293 and V79 cells. The recombinant enzyme was purified to homogeneity from transformed E. coli and was found to be identical with the native enzyme. After induction with ponasterone, the transfected mammalian cells showed a gradual increase of enzyme activity. A human expressed sequence tag clone contained a large part of the cDNA of the human enzyme but lacked the 5'-end corresponding to 51 amino acids of the murine enzyme. Several polymerase chain reaction-based approaches to find this sequence met with no success. A mouse/human hybrid cDNA that had substituted the missing human 5'-end with the corresponding mouse sequence coded for a fully active enzyme.	Univ Padua, Dept Biol, I-35131 Padua, Italy; Karolinska Inst, Med Nobel Inst, Dept Biochem 1, SE-17177 Stockholm, Sweden; Huddinge Univ Hosp, Div Clin Virol F68, SE-14186 Huddinge, Sweden; Uppsala Univ, Ludwig Inst Canc Res, SE-75142 Uppsala, Sweden	University of Padua; Karolinska Institutet; Karolinska Institutet; Ludwig Institute for Cancer Research; Uppsala University	Bianchi, V (corresponding author), Univ Padua, Dept Biol, I-35131 Padua, Italy.	vbianchi@civ.bio.unipd.it	Karlsson, Anna/E-7945-2018	Karlsson, Anna/0000-0001-6843-6685				Amici A, 1997, FEBS LETT, V419, P263, DOI 10.1016/S0014-5793(97)01464-6; BIANCHI V, 1986, P NATL ACAD SCI USA, V83, P986, DOI 10.1073/pnas.83.4.986; BIANCHI V, 1987, MOL CELL BIOL, V7, P4218, DOI 10.1128/MCB.7.12.4218; BIANCHI V, 1994, J BIOL CHEM, V269, P16677; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FRITZSON P, 1971, BIOCHIM BIOPHYS ACTA, V235, P128, DOI 10.1016/0005-2744(71)90040-4; FRITZSON P, 1973, EUR J BIOCHEM, V38, P408, DOI 10.1111/j.1432-1033.1973.tb03074.x; Fritzson P, 1977, Adv Enzyme Regul, V16, P43, DOI 10.1016/0065-2571(78)90066-3; Gazziola C, 1999, EXP CELL RES, V253, P474, DOI 10.1006/excr.1999.4681; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; Hellman U, 1997, SPRING LAB MAN, P97; HIRONO A, 1987, BRIT J HAEMATOL, V65, P35, DOI 10.1111/j.1365-2141.1987.tb06132.x; HOGLUND L, 1990, J BIOL CHEM, V265, P6589; HOGLUND L, 1988, CANCER RES, V48, P3681; ITOH R, 1993, COMP BIOCHEM PHYS B, V105, P13, DOI 10.1016/0305-0491(93)90163-Y; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; MAGNUSSON G, 1971, EUR J BIOCHEM, V20, P225, DOI 10.1111/j.1432-1033.1971.tb01384.x; MISUMI Y, 1990, EUR J BIOCHEM, V191, P563, DOI 10.1111/j.1432-1033.1990.tb19158.x; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; OKA J, 1994, BIOCHEM BIOPH RES CO, V205, P917, DOI 10.1006/bbrc.1994.2752; PAGLIA DE, 1984, P NATL ACAD SCI-BIOL, V81, P588, DOI 10.1073/pnas.81.2.588; PIEC G, 1991, BIOCHEM J, V273, P409, DOI 10.1042/bj2730409; Rampazzo C, 1999, EUR J BIOCHEM, V261, P689, DOI 10.1046/j.1432-1327.1999.00320.x; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; Resta R, 1998, IMMUNOL REV, V161, P95, DOI 10.1111/j.1600-065X.1998.tb01574.x; RESTA R, 1994, J IMMUNOL, V153, P1046; Sambrook J., 2002, MOL CLONING LAB MANU; SPYCHALA J, 1988, J BIOL CHEM, V263, P18759; TJERNSHAUGEN H, 1976, BIOCHEM J, V154, P77, DOI 10.1042/bj1540077; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	30	55	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5409	5415		10.1074/jbc.275.8.5409	http://dx.doi.org/10.1074/jbc.275.8.5409			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681516	hybrid			2022-12-27	WOS:000085474500023
J	Schecter, AD; Calderon, TM; Berman, AB; McManus, CM; Fallon, JT; Rossikhina, M; Zhao, WX; Christ, G; Berman, JW; Taubman, MB				Schecter, AD; Calderon, TM; Berman, AB; McManus, CM; Fallon, JT; Rossikhina, M; Zhao, WX; Christ, G; Berman, JW; Taubman, MB			Human vascular smooth muscle cells possess functional CCR5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; C-C CHEMOKINE; SIMIAN IMMUNODEFICIENCY VIRUS; TISSUE FACTOR EXPRESSION; MOLECULAR-CLONING; GROWTH-FACTOR; ENVELOPE GLYCOPROTEIN; CORONARY SYNDROMES; ENDOTHELIAL-CELLS; MESSENGER-RNA	CC chemokine receptors are important modulators of inflammation. Although CC chemokine receptors have been found predominantly on leukocytes, recent studies have suggested that vascular smooth muscle cells respond to CC chemokines. We now report that human smooth muscle cells express CCR5, a co-receptor for human immunodeficiency virus. CCR5 mRNA was detectable by RNA blot hybridization in human aortic and coronary artery smooth muscle cells. The cDNA generated by reverse transcription-polymerase chain reaction from aortic smooth muscle cells had 100% identity throughout the entire coding region with the CCR5 cloned from THP-1 cells. By immunohistochemistry, CCR5 and the CCR5 ligand, macrophage inflammatory protein-1 beta (MIP-1 beta), were detected in smooth muscle cells and macrophages of the atherosclerotic plaque. In smooth muscle cell culture, MIP-1 beta induced a significant increase in intracellular calcium concentrations, which was blocked by an antibody to CCR5. In addition, MIP-1 beta caused a calcium-dependent increase in tissue factor activity. Tissue factor is the initiator of coagulation and is thought to play a key role in arterial thrombosis. These data suggest that human arterial smooth muscle cells express functional CCR5 receptors and MIP-1 beta is an agonist for these cells.	Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA; Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Urol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Taubman, MB (corresponding author), Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, Box 1269,1 Gustave L Levy Pl, New York, NY 10029 USA.	mark.taubman@mssm.edu		Fallon, John/0000-0002-7677-4868	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054469, P01HL029019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052974] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 54469, HL29019] Funding Source: Medline; NIMH NIH HHS [MH52974] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALEXANDER RW, 1985, HYPERTENSION, V7, P447, DOI 10.1161/01.HYP.7.3.447; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ANNEX BH, 1995, CIRCULATION, V91, P619, DOI 10.1161/01.CIR.91.3.619; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BERK BC, 1985, J CLIN INVEST, V75, P1083, DOI 10.1172/JCI111772; BERK BC, 1986, SCIENCE, V232, P87, DOI 10.1126/science.3485309; BERK BC, 1991, BIOCHEM J, V274, P799, DOI 10.1042/bj2740799; BROCK TA, 1985, HYPERTENSION, V7, pI105, DOI 10.1161/01.HYP.7.3_Pt_2.I105; CARSON SD, 1987, BLOOD, V70, P490; CHALIFOUX LV, 1992, LAB INVEST, V67, P338; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CHRIST GJ, 1992, AM J PHYSIOL, V263, pC373, DOI 10.1152/ajpcell.1992.263.2.C373; Cockwell P, 1998, KIDNEY INT, V54, P827, DOI 10.1046/j.1523-1755.1998.00053.x; Edinger AL, 1997, P NATL ACAD SCI USA, V94, P14742, DOI 10.1073/pnas.94.26.14742; ENSOLI B, 1991, HEMATOL ONCOL CLIN N, V5, P281, DOI 10.1016/S0889-8588(18)30441-6; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GOLDMAN WF, 1990, CELL CALCIUM, V11, P221, DOI 10.1016/0143-4160(90)90073-4; Hayes IM, 1998, ARTERIOSCL THROM VAS, V18, P397, DOI 10.1161/01.ATV.18.3.397; Horuk R, 1996, J LEUKOCYTE BIOL, V59, P29, DOI 10.1002/jlb.59.1.29; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; KOCH AE, 1995, CLIN IMMUNOL IMMUNOP, V77, P307, DOI 10.1006/clin.1995.1157; LUKACS NW, 1994, AM J PATHOL, V144, P711; Luo Y, 1996, J IMMUNOL, V157, P2143; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Marmur JD, 1996, CIRCULATION, V94, P1226, DOI 10.1161/01.CIR.94.6.1226; MENE P, 1987, AM J PHYSIOL, V253, pF458, DOI 10.1152/ajprenal.1987.253.3.F458; MOORE EDW, 1990, CELL CALCIUM, V11, P157, DOI 10.1016/0143-4160(90)90068-6; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; Moreno PR, 1996, CIRCULATION, V94, P3090, DOI 10.1161/01.CIR.94.12.3090; MORGAN KG, 1985, PFLUG ARCH EUR J PHY, V405, P77, DOI 10.1007/BF00591101; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NEMERSON Y, 1995, THROMB HAEMOSTASIS, V74, P180; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Raport CJ, 1996, J LEUKOCYTE BIOL, V59, P18, DOI 10.1002/jlb.59.1.18; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROLLINS BJ, 1990, AM J PATHOL, V136, P1229; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Rottman JB, 1997, AM J PATHOL, V151, P1341; Rucker J, 1998, AIDS RES HUM RETROV, V14, pS241; Schecter AD, 1997, J CLIN INVEST, V100, P2276, DOI 10.1172/JCI119765; Schecter AD, 1997, J BIOL CHEM, V272, P28568, DOI 10.1074/jbc.272.45.28568; SCHUTTEN M, 1995, SCAND J IMMUNOL, V41, P18, DOI 10.1111/j.1365-3083.1995.tb03528.x; Staerman F, 1997, INT J IMPOT RES, V9, P1, DOI 10.1038/sj.ijir.3900265; Sullivan N, 1998, J VIROL, V72, P6332, DOI 10.1128/JVI.72.8.6332-6338.1998; TAUBMAN MB, 1993, J CLIN INVEST, V91, P547, DOI 10.1172/JCI116234; Taubman MB, 1997, THROMB HAEMOSTASIS, V78, P200; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; Tinkle BT, 1997, J VIROL, V71, P4809, DOI 10.1128/JVI.71.6.4809-4814.1997; Toschi V, 1997, CIRCULATION, V95, P594, DOI 10.1161/01.CIR.95.3.594; VALENTE AJ, 1988, J CELL PHYSIOL, V136, P479, DOI 10.1002/jcp.1041360312; Wilcox J N, 1994, J Atheroscler Thromb, V1 Suppl 1, pS10; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; Youn BS, 1997, BLOOD, V89, P4448, DOI 10.1182/blood.V89.12.4448; ZHAO WX, 1995, J UROLOGY, V154, P1571, DOI 10.1016/S0022-5347(01)66931-3	59	117	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5466	5471		10.1074/jbc.275.8.5466	http://dx.doi.org/10.1074/jbc.275.8.5466			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681524	hybrid			2022-12-27	WOS:000085474500031
J	Schoepp, B; Chabaud, E; Breyton, C; Vermeglio, A; Popot, JL				Schoepp, B; Chabaud, E; Breyton, C; Vermeglio, A; Popot, JL			On the spatial organization of hemes and chlorophyll in cytochrome b(6) f - A linear and circular dichroism study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION-CENTER; PIGMENT-PROTEIN COMPLEXES; ELECTRON-TRANSFER CHAIN; AMINO-ACID INSERTIONS; RHODOBACTER-SPHAEROIDES; RHODOPSEUDOMONAS-SPHAEROIDES; THYLAKOID MEMBRANE; BF COMPLEX; CRYSTAL-STRUCTURE; RIESKE PROTEIN	The organization of chromophores in the cytochrome b(6)f from Chlamydomonas reinhardtii has been studied spectroscopically. Linear dichroism (LD) measurements, performed on the complex co-reconstituted into vesicles with photosynthetic reaction centers as an internal standard, allow the determination of the orientations of the chromophore with respect to the membrane plane. The orientations of the b(H)- and b(L)-hemes are comparable to those determined crystallographically on the cytochrome bc(1). The excitonic CD signal, resulting from the interaction between b-hemes, is similar to that reported for the cytochrome bc(1). LD and CD data are consistent with the differences between the b(6)f and bc(1) leaving the orientation of the b-hemes unaffected. By contrast, the LD data yield a different orientation for the heme f as compared either to the heme c(1) in the crystallographic structures or to the heme fas studied by electron paramagnetic resonance. This difference could either result from incorrect assumptions regarding the orientations of the electronic transitions of the f-heme or may point to the possibility of a redox-dependent movement of cytochrome f. The chlorophyll a was observed in a well defined orientation, further corroborating a specific binding site for it in the b(6)f complex.	CNRS, Lab Bioenerget & Ingn Prot, F-13402 Marseille 20, France; CNRS UPR 9052, Lab Physicochim Mol Membranes Biol, F-75005 Paris, France; Univ Paris 07, Inst Biol Physicochim, F-75005 Paris, France; CEA, DSV, DEVM, Lab Bioenerget Cellulaire, F-13108 St Paul Les Durance, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; CEA	Schoepp, B (corresponding author), CNRS, Lab Bioenerget & Ingn Prot, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.		Schoepp-Cothenet, Barbara/AAH-8911-2021	Schoepp-Cothenet, Barbara/0000-0002-6820-4478				Adar F., 1978, PORPHYRINS, P167; ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P6162, DOI 10.1073/pnas.84.17.6162; ANDREWS KM, 1990, BIOCHEMISTRY-US, V29, P2645, DOI 10.1021/bi00463a004; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bald D., 1992, RES PHOTOSYNTHESIS, VI, P629; BERGSTROM J, 1982, BIOCHIM BIOPHYS ACTA, V682, P452, DOI 10.1016/0005-2728(82)90060-3; Breton J, 1982, PHOTOSYNTHESIS, P153; BRETON J, 1977, THESIS U PARIS 11 OR; BRETON J, 1984, ADV PHOTOSYNTHETIC R, P11; Breyton C, 1997, J BIOL CHEM, V272, P21892, DOI 10.1074/jbc.272.35.21892; Bron P, 1999, J MOL BIOL, V287, P117, DOI 10.1006/jmbi.1999.2604; Brugna M, 1998, J BACTERIOL, V180, P3719, DOI 10.1128/JB.180.14.3719-3723.1998; Brugna M, 1999, J BIOL CHEM, V274, P16766, DOI 10.1074/jbc.274.24.16766; BRUGNA M, 2000, IN PRESS P NATL ACAD; Carrell CJ, 1997, STRUCTURE, V5, P1613, DOI 10.1016/S0969-2126(97)00309-2; Cramer WA, 1996, ANNU REV PLANT PHYS, V47, P477, DOI 10.1146/annurev.arplant.47.1.477; CRAMER WA, 1994, CURR OPIN STRUC BIOL, V4, P536, DOI 10.1016/S0959-440X(94)90216-X; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; CROWDER MS, 1982, FEBS LETT, V144, P204, DOI 10.1016/0014-5793(82)80638-8; Degli Esposti M, 1989, Eur J Biochem, V182, P27, DOI 10.1111/j.1432-1033.1989.tb14796.x; DEISENHOFER J, 1995, J MOL BIOL, V246, P429, DOI 10.1006/jmbi.1994.0097; Duneau JP, 1997, J BIOMOL STRUCT DYN, V15, P555, DOI 10.1080/07391102.1997.10508966; DUTTON PL, 1971, BIOCHIM BIOPHYS ACTA, V226, P63, DOI 10.1016/0005-2728(71)90178-2; EATON WA, 1967, J CHEM PHYS, V46, P2533, DOI 10.1063/1.1841081; ERECINSKA M, 1978, BIOCHIM BIOPHYS ACTA, V501, P63, DOI 10.1016/0005-2728(78)90095-6; ESPOSTI MD, 1987, BIOCHIM BIOPHYS ACTA, V892, P245, DOI 10.1016/0005-2728(87)90228-3; Gouterman M., 1978, PORPHYRINS, P1, DOI 10.1016/B978-0-12-220103-5.50008-8; HAWORTH P, 1982, BIOCHIM BIOPHYS ACTA, V682, P152, DOI 10.1016/0005-2728(82)90129-3; HEINZ DW, 1994, J MOL BIOL, V236, P869, DOI 10.1006/jmbi.1994.1195; HEINZ DW, 1993, NATURE, V361, P561, DOI 10.1038/361561a0; HOFRICHTER J, 1976, ANNU REV BIOPHYS BIO, V5, P511, DOI 10.1146/annurev.bb.05.060176.002455; HOPE AB, 1993, BIOCHIM BIOPHYS ACTA, V1143, P1, DOI 10.1016/0005-2728(93)90210-7; HURT EC, 1983, FEBS LETT, V153, P413, DOI 10.1016/0014-5793(83)80655-3; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JOLIOT P, 1988, BIOCHIM BIOPHYS ACTA, V933, P319, DOI 10.1016/0005-2728(88)90039-4; Joliot P, 1998, BIOCHEMISTRY-US, V37, P10404, DOI 10.1021/bi980546m; Kallas T, 1994, MOL BIOL CYANOBACTER, V1, P259, DOI DOI 10.1007/978-94-011-0227-8_9; KLOLMA FJ, 2000, IN PRESS BIOPHYS J, V78; Kuras R, 1998, BIOCHEMISTRY-US, V37, P16280, DOI 10.1021/bi9813476; LEMOIGNE C, 1998, THESIS U PARIS 11 OR; MAILER C, 1972, CAN J BIOCHEM CELL B, V50, P1048, DOI 10.1139/o72-145; Martinez SE, 1996, PROTEIN SCI, V5, P1081; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; Metzger SU, 1997, BBA-BIOENERGETICS, V1319, P233, DOI 10.1016/S0005-2728(96)00164-8; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Mosser G, 1997, J BIOL CHEM, V272, P20263, DOI 10.1074/jbc.272.32.20263; PALMER G, 1994, BIOCHEMISTRY-US, V33, P176, DOI 10.1021/bi00167a023; Peterman EJG, 1998, BIOPHYS J, V75, P389, DOI 10.1016/S0006-3495(98)77523-X; PETKE JD, 1979, PHOTOCHEM PHOTOBIOL, V30, P203, DOI 10.1111/j.1751-1097.1979.tb07138.x; Pierre Y, 1997, J BIOL CHEM, V272, P21901, DOI 10.1074/jbc.272.35.21901; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; POPOT JL, 2000, IN PRESS ANN REV BIO; RAFFERTY CN, 1979, BIOCHIM BIOPHYS ACTA, V546, P189, DOI 10.1016/0005-2728(79)90039-2; RICH PR, 1987, BIOCHIM BIOPHYS ACTA, V892, P138, DOI 10.1016/0005-2728(87)90256-8; RICH PR, 1986, J BIOENERG BIOMEMBR, V18, P145, DOI 10.1007/BF00743461; RICH PR, 1992, BIOCHEM SOC T, V20, pR241; RIEDEL A, 1991, J BIOL CHEM, V266, P17838; Schoepp B, 1999, FEBS LETT, V450, P245, DOI 10.1016/S0014-5793(99)00511-6; Schoepp B, 2000, J BIOL CHEM, V275, P5284, DOI 10.1074/jbc.275.8.5284; Stowell MHB, 1997, SCIENCE, V276, P812, DOI 10.1126/science.276.5313.812; TAPIE P, 1982, BIOCHIM BIOPHYS ACTA, V682, P339, DOI 10.1016/0005-2728(82)90047-0; TIEDE DM, 1987, BIOCHEMISTRY-US, V26, P397, DOI 10.1021/bi00376a010; VERMEGLIO A, 1989, FEBS LETT, V243, P259, DOI 10.1016/0014-5793(89)80140-1; VERMEGLIO A, 1980, BIOCHIM BIOPHYS ACTA, V593, P299, DOI 10.1016/0005-2728(80)90067-5; VERMEGLIO A, 1977, BIOCHIM BIOPHYS ACTA, V459, P516, DOI 10.1016/0005-2728(77)90050-0; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Zhang HM, 1999, J BIOL CHEM, V274, P1581, DOI 10.1074/jbc.274.3.1581; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	68	24	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5275	5283		10.1074/jbc.275.8.5275	http://dx.doi.org/10.1074/jbc.275.8.5275			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681499	hybrid			2022-12-27	WOS:000085474500006
J	Shoji, H; Tsuchida, K; Kishi, H; Yamakawa, N; Matsuzaki, T; Liu, ZH; Nakamura, T; Sugino, H				Shoji, H; Tsuchida, K; Kishi, H; Yamakawa, N; Matsuzaki, T; Liu, ZH; Nakamura, T; Sugino, H			Identification and characterization of a PDZ protein that interacts with activin type II receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-DIFFERENTIATION FACTOR; DOMAIN-CONTAINING PROTEINS; SERINE THREONINE KINASE; TGF-BETA RECEPTOR; EXPRESSION CLONING; MESSENGER-RNA; ACTIVATION; CELLS; PURIFICATION; FOLLISTATIN	We have identified a mouse PDZ protein that interacts with the activin type IIA receptor (ActRIIA), which we named activin receptor-interacting protein 1 (ARIP1), By using yeast two-hybrid screening, we isolated a cDNA clone of ARIP1 from a mouse brain cDNA library, We detected two forms of ARIP1 ARIP1-long and ARIP1-short, which may be produced by alternative splicing. ARIP1-long had one guanylate kinase domain in the NH2-terminal region, followed by two WW domains and five PDZ domains (PDZ1-5). ARIP1-short had a deletion in the NH2-terminal region and lacked the guanylate kinase domain. Both forms interacted with ActRIIA through PDZ5. The COOH-terminal residues of ActRIIA (ESSL) agree with a PDZ-binding consensus motif, and ARIP1 recognized the consensus sequence. ARIP1 interacts specifically with ActRIIA among the receptors for the transforming growth factor beta family. Interestingly, ARIP1 also interacted with Smad3, which is an activin/ transforming growth factor beta intracellular signaling molecule. The mRNA of ARIP1 was more abundant in the brain than in other tissues. Overexpression of ARIP1 controls activin-induced and Smad3-induced transcription in activin-responsive cell lines, These findings suggest that ARIP1 has a significant role in assembling activin signaling molecules at specific subcellular sites and in regulating signal transduction in neuronal cells.	Univ Tokushima, Inst Enzyme Res, Tokushima 7708503, Japan	Tokushima University	Sugino, H (corresponding author), Univ Tokushima, Inst Enzyme Res, 3-18-15 Kuramot, Tokushima 7708503, Japan.		Kishi, Hiroko/AAR-9148-2021; Tsuchida, Kunihiro/A-4501-2012	Kishi, Hiroko/0000-0003-2896-7355; Tsuchida, Kunihiro/0000-0002-3983-5756				ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; Attisano L, 1996, MOL CELL BIOL, V16, P1066; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Ethier JF, 1997, ENDOCRINOLOGY, V138, P2425, DOI 10.1210/en.138.6.2425; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; FANN MJ, 1994, P NATL ACAD SCI USA, V91, P43, DOI 10.1073/pnas.91.1.43; Hashimoto O, 1997, J BIOL CHEM, V272, P13835, DOI 10.1074/jbc.272.21.13835; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Inokuchi K, 1996, FEBS LETT, V382, P48, DOI 10.1016/0014-5793(96)00135-4; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; Link BA, 1998, DEV BIOL, V199, P226, DOI 10.1006/dbio.1998.8918; LIU F, 1995, MOL CELL BIOL, V15, P3479; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; Nishi N, 1996, PROSTATE, V28, P139; Ono S, 1998, EUR J NEUROSCI, V10, P2143, DOI 10.1046/j.1460-9568.1998.00225.x; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; Sagara Y, 1998, J NEUROSCI, V18, P6662; Sambrook J., 2002, MOL CLONING LAB MANU; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; Shieh BH, 1997, P NATL ACAD SCI USA, V94, P12682, DOI 10.1073/pnas.94.23.12682; Shoji H, 1998, BIOCHEM BIOPH RES CO, V246, P320, DOI 10.1006/bbrc.1998.8613; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tretter YP, 1996, NEUROREPORT, V7, P1819, DOI 10.1097/00001756-199607290-00026; TSUCHIDA K, 1995, ENDOCRINOLOGY, V136, P5493, DOI 10.1210/en.136.12.5493; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; Willis SA, 1996, MOL ENDOCRINOL, V10, P367, DOI 10.1210/me.10.4.367; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677	40	86	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5485	5492		10.1074/jbc.275.8.5485	http://dx.doi.org/10.1074/jbc.275.8.5485			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681527	hybrid			2022-12-27	WOS:000085474500034
J	Balsinde, J; Balboa, MA; Yedgar, S; Dennis, EA				Balsinde, J; Balboa, MA; Yedgar, S; Dennis, EA			Group V phospholipase A(2)-mediated oleic acid mobilization in lipopolysaccharide-stimulated P388D(1) macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN D-2 GENERATION; ARACHIDONIC-ACID; MAST-CELLS; ENDOPEROXIDE SYNTHASE-2; DELAYED PHASE; A(2) ENZYMES; RELEASE; ACTIVATION; CYCLOOXYGENASE-2; INVOLVEMENT	P388D(1) macrophages prelabeled with [H-3]arachidonic acid (AA) respond to bacterial lipopolysaccharide (LPS) by mobilizing AA in a process that takes several hours and is mediated by the concerted actions of the group IV cytosolic phospholipase A(2) and the group V secretory phospholipase A(2) (sPLA(2)). Here we show that when the LPS-activated cells are prelabeled with [H-3]oleic acid (OA), they also mobilize and release OA to the extracellular medium. The time and concentration dependence of the LPS effect on OA release fully resemble those of the AA release. Experiments in which both AA and OA release are measured simultaneously indicate that AA is released 3 times more efficiently than OA, Importantly, LPS-stimulated OA release is strongly inhibited by the selective sPLA(2) inhibitors 3-(3-acetamide-1-benzyl-2-ethylindolyl-5-oxy)propane sulfonic acid and carboxymethylcellulose-linked phosphatidylethanolamine. The addition of exogenous recombinant sPLA(2) to the cells also triggers OA release. These data implicate a functionally active sPLA(2) as being essential for the cells to release OA upon stimulation with LPS, OA release is also inhibited by methyl arachidonyl fluorophosphonate but not by bromoenol lactone, indicating that the group IV cytosolic phospholipase A(2) is also involved in the process, Together, these data reveal that OA release occurs during stimulation of the P388D(1) macrophages by LPS and that the regulatory features of the OA release are strikingly similar to those previously found for the AA release.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	University of California System; University of California San Diego; Hebrew University of Jerusalem	Balsinde, J (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.		Balsinde, Jesús/C-7833-2018; Balboa, María A./V-9493-2018; Dennis, Edward A./M-5554-2019	Balsinde, Jesús/0000-0002-4157-6714; Balboa, María A./0000-0002-2130-5298; Dennis, Edward A./0000-0003-3738-3140	NICHD NIH HHS [HD26171] Funding Source: Medline; NIGMS NIH HHS [GM2051] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Balsinde J, 1999, J BIOL CHEM, V274, P25967, DOI 10.1074/jbc.274.37.25967; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; Dan P, 1998, BIOCHEMISTRY-US, V37, P6199, DOI 10.1021/bi972066l; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Fonteh AN, 1998, BBA-LIPID LIPID MET, V1393, P253, DOI 10.1016/S0005-2760(98)00079-4; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; Ito Y, 1998, J NEUROCHEM, V71, P2278; Kambe T, 1999, FEBS LETT, V453, P81, DOI 10.1016/S0014-5793(99)00702-4; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; MARSHALL LA, 1995, J PHARMACOL EXP THER, V274, P1254; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; MURAKAMI M, 1995, J IMMUNOL, V155, P4445; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; Sawada H, 1999, EUR J BIOCHEM, V263, P826, DOI 10.1046/j.1432-1327.1999.00565.x; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Tada K, 1998, J IMMUNOL, V161, P5008; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; XING MZ, 1995, J CELL PHYSIOL, V165, P566, DOI 10.1002/jcp.1041650315	33	57	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4783	4786		10.1074/jbc.275.7.4783	http://dx.doi.org/10.1074/jbc.275.7.4783			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671511	hybrid			2022-12-27	WOS:000085378200037
J	Javid-Majd, F; Mullins, LS; Raushel, FM; Stapleton, MA				Javid-Majd, F; Mullins, LS; Raushel, FM; Stapleton, MA			The differentially conserved residues of carbamoyl-phosphate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBONIC-PHOSPHORIC ANHYDRIDE; SITE-DIRECTED MUTAGENESIS; ATP-BINDING-SITES; ESCHERICHIA-COLI; KINETIC MECHANISM; LARGE SUBUNIT; ACTIVE-SITE; DOMAINS; DISSOCIATION; INHIBITION	Carbamoyl-phosphate synthetase (CPS) from Escherichia coli is a heterodimeric protein. The larger of the two subunits (M-r similar to 118,000) contains a pair of homologous domains of approximately 400 residues each that are similar to 40% identical in amino acid sequence. The carboxy phosphate (residues 1-400) and carbamoyl phosphate domains (residues 553-933) also contain similar to 79 differentially conserved residues. These are residues that are conserved throughout the bacterial evolution of CPS in one of these homologous domains but not the other. The role of these differentially conserved residues in the structural and catalytic properties of CPS was addressed by swapping segments of these residues from one domain to the other. Nine of these chimeric mutant enzymes were constructed, expressed, purified, and characterized. A majority of the mutants were unable to synthesize any carbamoyl phosphate and the rest were severely crippled. True tandem repeat chimeric proteins were constructed by the complete substitution of one homologous domain sequence for the other. Neither of the two possible chimeric proteins was structurally stable. These results have been interpreted to demonstrate that the two homologous domains in the large subunit of CPS are functionally and structurally nonequivalent. This nonequivalence is a direct result of the specific functions each of these domains must perform during the overall synthesis of carbamoyl phosphate in the wild type enzyme and the specific structural alterations imposed by the differentially conserved residues.	Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Raushel, FM (corresponding author), Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA.		Raushel, Frank/B-7125-2015	Raushel, Frank/0000-0002-5918-3089	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK030343, R01DK030343] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 30343] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON PM, 1970, BIOCHEMISTRY-US, V9, P171, DOI 10.1021/bi00803a022; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3164, DOI 10.1021/bi00874a013; BOETTCHER BR, 1980, J BIOL CHEM, V255, P7129; BRAXTON BL, 1992, BIOCHEMISTRY-US, V31, P2309, DOI 10.1021/bi00123a015; Braxton BL, 1996, BIOCHEMISTRY-US, V35, P11918, DOI 10.1021/bi961305m; FOLEY R, 1971, BIOCHEMISTRY-US, V10, P4562, DOI 10.1021/bi00800a034; Guy HI, 1997, J BIOL CHEM, V272, P19913, DOI 10.1074/jbc.272.32.19913; Guy HI, 1998, J BIOL CHEM, V273, P14172, DOI 10.1074/jbc.273.23.14172; Guy HI, 1997, J BIOL CHEM, V272, P29255, DOI 10.1074/jbc.272.46.29255; Guy HI, 1996, J BIOL CHEM, V271, P13762, DOI 10.1074/jbc.271.23.13762; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holden HM, 1998, CURR OPIN STRUC BIOL, V8, P679, DOI 10.1016/S0959-440X(98)80086-9; JavidMajd F, 1996, BIOCHEMISTRY-US, V35, P14362, DOI 10.1021/bi961184q; MAREYA SM, 1995, BIOORGAN MED CHEM, V3, P525, DOI 10.1016/0968-0896(95)00042-F; MAREYA SM, 1994, BIOCHEMISTRY-US, V33, P2945, DOI 10.1021/bi00176a026; MATTHEWS SL, 1972, BIOCHEMISTRY-US, V11, P1176, DOI 10.1021/bi00757a010; MILES BW, 1993, BIOCHEMISTRY-US, V32, P232, DOI 10.1021/bi00052a030; MULLINS LS, 1991, J BIOL CHEM, V266, P8236; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; PIETTE J, 1984, P NATL ACAD SCI-BIOL, V81, P4134, DOI 10.1073/pnas.81.13.4134; POST LE, 1990, J BIOL CHEM, V265, P7742; POWERS SG, 1976, P NATL ACAD SCI USA, V73, P3020, DOI 10.1073/pnas.73.9.3020; POWERS SG, 1977, J BIOL CHEM, V252, P3558; POWERS SG, 1978, J BIOL CHEM, V253, P1258; RAUSHEL FM, 1979, BIOCHEMISTRY-US, V18, P3424, DOI 10.1021/bi00582a033; Raushel FM, 1998, CURR OPIN CHEM BIOL, V2, P624, DOI 10.1016/S1367-5931(98)80094-X; RAUSHEL FM, 1980, BIOCHEMISTRY-US, V19, P3170, DOI 10.1021/bi00555a009; RAUSHEL FM, 1978, BIOCHEMISTRY-US, V17, P5587, DOI 10.1021/bi00619a001; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; Sahay N, 1998, J BIOL CHEM, V273, P31195, DOI 10.1074/jbc.273.47.31195; SNODGRASS PJ, 1969, J LAB CLIN MED, V73, P940; Stapleton MA, 1996, BIOCHEMISTRY-US, V35, P14352, DOI 10.1021/bi961183y; Thoden JB, 1999, ACTA CRYSTALLOGR D, V55, P8, DOI 10.1107/S0907444998006234; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; WIMMER MJ, 1979, J BIOL CHEM, V254, P1854	36	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5073	5080		10.1074/jbc.275.7.5073	http://dx.doi.org/10.1074/jbc.275.7.5073			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671550	hybrid			2022-12-27	WOS:000085378200076
J	Lindstrom, WM; Flynn, J; Reich, NO				Lindstrom, WM; Flynn, J; Reich, NO			Reconciling structure and function in HhaI DNA cytosine-C-5 methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; S-ADENOSYLMETHIONINE; CRYSTAL-STRUCTURE; DEPENDENT METHYLTRANSFERASES; CATALYTIC MECHANISM; KINETIC MECHANISM; SEQUENCE MOTIFS; STEADY-STATE; TARGET BASE; BINDING	Pre-steady state partitioning analysis of the HhaI DNA methyltransferase directly demonstrates the catalytic competence of the enzyme DNA complex and the lack of catalytic competence of the enzyme-S-adenosyl-L-methionine (AdoMet) complex. The enzyme.AdoMet complex does form, albeit with a 50-fold decrease in affinity compared with the ternary enzyme.AdoMet.DNA complex. These findings reconcile the distinct binding orientations previously observed within the binary enzyme.AdoMet and ternary enzyme.S-adenosyl-L-homocysteine.DNA crystal structures. The affinity of the enzyme for DNA is increased 900-fold in the presence of its cofactor, and the preference for hemimethylated DNA is increased to 12-fold over unmethylated DNA We suggest that this preference is partially due to the energetic cost of retaining a cavity in place of the B-methyl moiety in the ternary complex with the unmethylated DNA, as revealed by the corresponding crystal structures. The hemi- and unmethylated substrates alter the fates and lifetimes of discrete enzyme substrate intermediates during the catalytic cycle. Hemimethylated substrates partition toward product formation versus dissociation significantly more than unmethylated substrates. The mammalian DNA cytosine-C-5 methyltransferase Dnmt1 shows an even more pronounced partitioning toward product formation.	Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Program Biochem & Mol Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Reich, NO (corresponding author), Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA.	reich@chem.ucsb.edu			NIGMS NIH HHS [GM 463333] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams GM, 1997, BIOCHEMISTRY-US, V36, P8284, DOI 10.1021/bi961885n; Allan BW, 1998, J BIOL CHEM, V273, P2368, DOI 10.1074/jbc.273.4.2368; ALLAN BW, 1966, BIOCHEMISTRY-US, V35, P14757; Bhattacharya SK, 1999, J BIOL CHEM, V274, P14743, DOI 10.1074/jbc.274.21.14743; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; Cleland W W, 1979, Methods Enzymol, V63, P103; CLELAND WW, 1975, BIOCHEMISTRY-US, V14, P3220, DOI 10.1021/bi00685a029; DUBEY AK, 1992, NUCLEIC ACIDS RES, V20, P3167, DOI 10.1093/nar/20.12.3167; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; Fasman G. D., 1975, HDB BIOCH MOL BIOL; Fersht A., 1985, ENZYME STRUCTURE MEC; Flynn J, 1996, BIOCHEMISTRY-US, V35, P7308, DOI 10.1021/bi9600512; Flynn J, 1998, BIOCHEMISTRY-US, V37, P15162, DOI 10.1021/bi9810609; Gong WM, 1997, NUCLEIC ACIDS RES, V25, P2702, DOI 10.1093/nar/25.14.2702; GREENE PJ, 1978, NUCLEIC ACIDS RES, V5, P2373, DOI 10.1093/nar/5.7.2373; Holz B, 1998, NUCLEIC ACIDS RES, V26, P1076, DOI 10.1093/nar/26.4.1076; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; Jeltsch A, 1998, J MOL BIOL, V275, P747, DOI 10.1006/jmbi.1997.1492; JOST JP, 1993, DNA METHYLATION MOL; Klimasauskas S, 1998, EMBO J, V17, P317, DOI 10.1093/emboj/17.1.317; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; Kumar S, 1997, NUCLEIC ACIDS RES, V25, P2773, DOI 10.1093/nar/25.14.2773; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; Laskowski RA, 1995, J MOL GRAPHICS, V13, P328; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; McCullough AK, 1997, J BIOL CHEM, V272, P27210, DOI 10.1074/jbc.272.43.27210; MI S, 1993, NUCLEIC ACIDS RES, V21, P2459, DOI 10.1093/nar/21.10.2459; MOE JG, 1992, BIOCHEMISTRY-US, V31, P8421, DOI 10.1021/bi00151a005; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NORTHROP DB, 1982, METHOD ENZYMOL, V87, P607; O'Gara M, 1998, NAT STRUCT BIOL, V5, P872, DOI 10.1038/2312; O'Gara M, 1999, J MOL BIOL, V287, P201, DOI 10.1006/jmbi.1999.2608; OGara M, 1996, J MOL BIOL, V263, P597, DOI 10.1006/jmbi.1996.0601; OGara M, 1996, J MOL BIOL, V261, P634, DOI 10.1006/jmbi.1996.0489; Pues H, 1999, BIOCHEMISTRY-US, V38, P1426, DOI 10.1021/bi9818016; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2940, DOI 10.1021/bi00225a030; REICH NO, 1993, J BIOL CHEM, V268, P9191; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2933, DOI 10.1021/bi00225a029; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7440, DOI 10.1021/bi00484a013; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; Rose I A, 1980, Methods Enzymol, V64, P47; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; Segel I. H., 1975, ENZYME KINETICS, P320; Sheikhnejad G, 1999, J MOL BIOL, V285, P2021, DOI 10.1006/jmbi.1998.2426; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; SMITH DW, 1992, NUCLEIC ACIDS RES, V20, P6091, DOI 10.1093/nar/20.22.6091; Stivers JT, 1998, NUCLEIC ACIDS RES, V26, P3837, DOI 10.1093/nar/26.16.3837; VIDGREN J, 1994, NATURE, V368, P354, DOI 10.1038/368354a0; WU JC, 1987, J BIOL CHEM, V262, P4778; ZAPPIA V, 1980, J CHROMATOGR, V189, P399, DOI 10.1016/S0021-9673(00)80319-2; Zingg JM, 1998, BIOCHEM J, V332, P223, DOI 10.1042/bj3320223; Zinoviev VV, 1998, BIOL CHEM, V379, P481, DOI 10.1515/bchm.1998.379.4-5.481	58	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4912	4919		10.1074/jbc.275.7.4912	http://dx.doi.org/10.1074/jbc.275.7.4912			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671528	hybrid			2022-12-27	WOS:000085378200054
J	Persechini, A; Yano, K; Stemmer, PM				Persechini, A; Yano, K; Stemmer, PM			Ca2+ binding and energy coupling in the calmodulin-myosin light chain kinase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SKELETAL-MUSCLE; QUANTITATIVE-ANALYSIS; NEUTRON-SCATTERING; ENZYME ACTIVATION; STRUCTURAL BASIS; CALCIUM-BINDING; MECHANISM; KINETICS; DOMAINS	We have previously shown that 3 Ca2+ ions are released cooperatively and 1 independently from the complex:between (Ca2+)(4)-calmodulin and skeletal muscle myosin light chain kinase or a peptide containing its core calmodulin-binding sequence. We now have found that three Ca2+-binding sites also function cooperatively in equilibrium Ca-2+ binding to these complexes, Replacement of sites I and II in calmodulin by a copy of sites III and IV abolishes these cooperative effects. Energy coupling-dependent increases in Ca2+-binding affinity in the mutant and native calmodulin complexes with enzyme are considerably less than in the peptide complexes, although the complexes have similar affinities. Ca2+ binding to three sites in the native calmodulin-enzyme complex is enhanced; the affinity of the remaining site is slightly reduced. In the mutant enzyme complex Ca2+ binding to one pair of sites is enhanced; the other pair is unaffected. In this complex reversal of enzyme activation occurs when Ca2+ dissociates from the pair of sites with enhanced affinity; more rapid dissociation from the other pair has no effect, although both pairs participate in activation. Ca2+-independent interactions with calmodulin clearly play a major role in the enzyme complex, and appear to weaken Ca2+ dependent interactions with the core calmodulin-binding sequence.	Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; Dept Pediat, Omaha, NE 68198 USA	University of Rochester	Persechini, A (corresponding author), Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA.			Stemmer, Paul/0000-0003-3315-9846	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044322] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44322] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; BAYLEY P, 1984, BIOCHEM BIOPH RES CO, V120, P185, DOI 10.1016/0006-291X(84)91431-1; BLUMENTHAL DK, 1987, METHOD ENZYMOL, V139, P115; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; COX JA, 1981, J BIOL CHEM, V256, P3218; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; FITZSIMONS DP, 1992, J BIOL CHEM, V267, P23903; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Johnson JD, 1996, J BIOL CHEM, V271, P761, DOI 10.1074/jbc.271.2.761; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; Krueger JK, 1998, BIOCHEMISTRY-US, V37, P13997, DOI 10.1021/bi981311d; Krueger JK, 1997, BIOCHEMISTRY-US, V36, P6017, DOI 10.1021/bi9702703; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MAMARBACHI A, 1987, CELL CALCIUM, V8, P473, DOI 10.1016/0143-4160(87)90030-3; MCCARTHY JJ, 1994, ANAL BIOCHEM, V221, P250, DOI 10.1006/abio.1994.1409; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; OLWIN BB, 1985, BIOCHEMISTRY-US, V24, P8081, DOI 10.1021/bi00348a037; OLWIN BB, 1984, J BIOL CHEM, V259, P949; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; Persechini A, 1996, J BIOL CHEM, V271, P62, DOI 10.1074/jbc.271.1.62; PERSECHINI A, 1994, J BIOL CHEM, V269, P16148; Persechini A, 1996, J BIOL CHEM, V271, P19279, DOI 10.1074/jbc.271.32.19279; Persechini A, 1996, BIOCHEMISTRY-US, V35, P224, DOI 10.1021/bi952383x; Persechini A, 1996, J BIOL CHEM, V271, P32217, DOI 10.1074/jbc.271.50.32217; SHENOLIKAR S, 1979, EUR J BIOCHEM, V100, P329, DOI 10.1111/j.1432-1033.1979.tb04175.x; Shoshan-Barmatz V, 1998, INT REV CYTOL, V183, P185, DOI 10.1016/S0074-7696(08)60145-X; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758	34	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4199	4204		10.1074/jbc.275.6.4199	http://dx.doi.org/10.1074/jbc.275.6.4199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660583	hybrid			2022-12-27	WOS:000085288800067
J	Sun, XG; Wu, F; Datta, R; Kharbanda, S; Kufe, D				Sun, XG; Wu, F; Datta, R; Kharbanda, S; Kufe, D			Interaction between protein kinase C delta and the c-Abl tyrosine kinase in the cellular response to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOLYTIC ACTIVATION; SIGNAL-TRANSDUCTION; CELLS; GROWTH; PHOSPHORYLATION; EXPRESSION; APOPTOSIS	Protein kinase C (PKC) isoforms are phosphorylated on tyrosine in the response of cells to oxidative stress. The present studies demonstrate that treatment of cells with hydrogen peroxide (H2O2) induces binding of the PKC delta isoform and the c-Abl protein-tyrosine kinase. The results show that c-Abl phosphorylates PKC delta in the H2O2 response. We also show that PKC delta phosphorylates and activates c-Abl in vitro. In cells, induction of c-Abl activity by H2O2 is attenuated by the PKC delta inhibitor, rottlerin, and by overexpression of the regulatory domain of PKC delta. These findings support a functional interaction between PKC delta and c-Abl in the cellular response to oxidative stress.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.				NCI NIH HHS [CA42802] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042802] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; GSCHWENDT M, 1994, FEBS LETT, V347, P773; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KONISHI H, 1997, P NATL ACAD SCI USA, V94, P11223; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LI WQ, 1994, J BIOL CHEM, V269, P2349; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; ONO Y, 1988, J BIOL CHEM, V263, P6927; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	28	179	185	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7470	7473		10.1074/jbc.275.11.7470	http://dx.doi.org/10.1074/jbc.275.11.7470			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713049	hybrid			2022-12-27	WOS:000085913300009
J	Wang, ZY; Melmed, S				Wang, ZY; Melmed, S			Pituitary tumor transforming gene (PTTG) transforming and transactivation activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC INHIBITOR; C-JUN	Pituitary tumor transforming gene (PTTG) is a newly identified transforming gene, the functional mechanism of which is little understood. Computational analysis reveals a C terminus rich in Glu and Pro, a known characteristic of transcriptional activation domains. We report here that murine PTTG indeed possesses transactivation ability, which correlates highly with its transforming properties. Pro(139), Ser(159) pro(157) pro(158) -Ser(159)-Pro(160) (PPXP motif), and Leu(120)-Asp(121)-phe(122)- Asp(123)-Leu(124) Were found to be important for transarctivation. Mutation to Ala at a key Pro(139) residue not only disrupted the transactivation function but also resulted in the loss of transforming ability in NIH3T3 cells. A murine PTTG cDNA that encodes a variant C-terminal tail (Gly-Lys-Gly-Val-Arg-Ser-Asn-Gly-Cys-Lys-Asp-Leu- Val-Thr) was cloned. This novel PTTG is devoid of transactivation and transforming ability; deletion of its variant C-terminal tail restores both transactivation and transforming ability. These results show a high correlation between the transforming and transactivation functions of PTTG and also indicate that the novel PTTG variant may function as an endogenous competitor to wild-type PTTG.	Univ Calif Los Angeles, Cedars Sinai Res Inst, Sch Med, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Melmed, S (corresponding author), Cedars Sinai Med Ctr, 8700 Beverly Blvd, Los Angeles, CA 90048 USA.				NCI NIH HHS [CA75979] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075979] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; Heaney AP, 1999, NAT MED, V5, P1317, DOI 10.1038/15275; HESKETH R, 1995, ONCOGENE TUMOR SUPPR, P16; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Prezant TR, 1999, J CLIN ENDOCR METAB, V84, P1149, DOI 10.1210/jc.84.3.1149; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J., 2002, MOL CLONING LAB MANU; Wang ZY, 2000, ENDOCRINOLOGY, V141, P763, DOI 10.1210/en.141.2.763; Wang ZY, 1997, J BIOL CHEM, V272, P27957, DOI 10.1074/jbc.272.44.27957; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	14	47	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7459	7461		10.1074/jbc.275.11.7459	http://dx.doi.org/10.1074/jbc.275.11.7459			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713046	hybrid			2022-12-27	WOS:000085913300006
J	Peterson, RT; Beal, PA; Comb, MJ; Schreiber, SL				Peterson, RT; Beal, PA; Comb, MJ; Schreiber, SL			FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; MAMMALIAN TARGET; CATALYTIC SUBUNIT; SIGNALING PATHWAY; RAPAMYCIN; PHOSPHORYLATION; ACTIVATION; 4E-BP1; INITIATION; INHIBITION	The FKBP12-rapamycin associated protein (FRAP, also RAFT, mTOR) belongs to a family of phosphatidylinositol kinase-related kinases, These kinases mediate cellular responses to stresses such as DNA damage and nutrient deprivation in a variety of eukaryotes from yeast to humans. FRAP regulates G(1) cell cycle progression and translation initiation in part by controlling the phosphorylation states of a number of translational and cell cycle regulators. Although FRAP is known to be phosphorylated in vivo and to phosphorylate several proteins (including itself) in vitro, FRAP's phosphorylation sites and substrate specificity are unknown. We report here the identification of a FRAP autophosphorylation site. This site, Ser-2481, is located in a hydrophobic region near the conserved carboxyl-terminal FRAP tail. We demonstrate that the COOH-terminal tail is required for FRAP kinase activity and for signaling to the translational regulator p70(s6k) (ribosomal subunit S6 kinase), Phosphorylation of wild-type but not kinase-inactive FRAP occurs at Ser-2481 in vivo, suggesting that Ser-2481 phosphorylation is a marker of FRAP autokinase activity in cells. FRAP autophosphorylation is blocked completely by wortmannin treatment but not by rapamycin treatment, amino acid deprivation, or serum withdrawal, treatments that lead to acute dephosphorylation of eIF4E-binding protein (4E-BP1) and p70(s6k). Ser-2481 phosphorylation increases slightly upon c-Akt/ PHB activation and dramatically upon calyculin A treatment of T-cells, These results suggest that FRAP-responsive dephosphorylation of 4E-BP1 and p70(s6k) occurs through a mechanism other than inhibition of intrinsic FRAP kinase activity.	Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA; New England Biolabs Inc, Beverly, MA 01915 USA	Harvard University; Harvard University; Harvard University; Howard Hughes Medical Institute	Schreiber, SL (corresponding author), Harvard Univ, Dept Chem & Chem Biol, 12 Oxford St, Cambridge, MA 02138 USA.	sls@slsiris.harvard.edu		Peterson, Randall/0000-0003-0727-3469	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038627, R37GM038627] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-38627] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; Concannon P, 1997, HUM MUTAT, V10, P100, DOI 10.1002/(SICI)1098-1004(1997)10:2<100::AID-HUMU2>3.0.CO;2-O; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; HANSEN BS, 1972, J BIOL CHEM, V247, P3854; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Kuruvilla FG, 1999, CHEM BIOL, V6, pR129, DOI 10.1016/S1074-5521(99)80070-2; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Peterson RT, 1998, CURR BIOL, V8, pR248, DOI 10.1016/S0960-9822(98)70152-6; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Smith RIL., 1993, ECOSYSTEMS WORLD A, P51; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	41	264	281	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7416	7423		10.1074/jbc.275.10.7416	http://dx.doi.org/10.1074/jbc.275.10.7416			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702316	Green Published, hybrid			2022-12-27	WOS:000085809600096
J	Kim, MH; Lu, M; Kelly, M; Hersh, LB				Kim, MH; Lu, M; Kelly, M; Hersh, LB			Mutational analysis of basic residues in the rat vesicular acetylcholine transporter - Identification of a transmembrane ion pair and evidence that histidine is not involved in proton translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRACYCLINE H+ ANTIPORTER; ESCHERICHIA-COLI; LACTOSE PERMEASE; LAC PERMEASE; MONOAMINE TRANSPORTER; SYNAPTIC VESICLES; CHARGED RESIDUES; SALT BRIDGES; MUTAGENESIS; MEMBRANE	The function of positively charged residues and the interaction of positively and negatively charged residues of the rat vesicular acetylcholine transporter (rVAChT) were studied. Changing Lys-131 in transmembrane domain helix 2 (TM2) to Ala or Leu eliminated transport activity, with no effect on vesamicol binding. However, replacement by His or Arg retained transport activity, suggesting a positive charge in this position is critical. Mutation of His-444 in TM12 or His-413 in the cytoplasmic loop between TM10 and TM11 was without effect on ACh transport, but vesamicol binding was reduced with His-413 mutants. Changing His-338 in TM8 to Ala or Lys did not effect ACh transport, however replacement with Cys or Arg abolished activity. Mutation of both of the transmembrane histidines or all three of the luminal loop histidines showed no change in acetylcholine transport. The mutant H338A/D398N between oppositely charged residues in transmembrane domains showed no vesamicol binding, however the charge reversal mutant H338DID398H restored binding, This suggests that His-338 forms an ion pair with Asp-398. The charge neutralizing mutant K131A/D425N or the charge exchanged mutant K131D/D425K did not restore ACh transport. Taken together these results provide new insights into the tertiary structure in VAChT.	Univ Kentucky, Albert B Chandler Med Ctr, Dept Biochem, Lexington, KY 40536 USA	University of Kentucky	Hersh, LB (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Dept Biochem, 800 Rose St, Lexington, KY 40536 USA.				NATIONAL INSTITUTE ON AGING [R15AG005983] Funding Source: NIH RePORTER; NIA NIH HHS [AG05983] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAHR BA, 1992, BIOCHEMISTRY-US, V31, P5752, DOI 10.1021/bi00140a010; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P12644, DOI 10.1021/bi00210a012; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; Fei YJ, 1997, BIOCHEMISTRY-US, V36, P452, DOI 10.1021/bi962058p; GINTY DD, 1991, J BIOL CHEM, V266, P15325; HONIG BH, 1984, P NATL ACAD SCI-BIOL, V81, P5412, DOI 10.1073/pnas.81.17.5412; HORI R, 1989, J BIOL CHEM, V264, P12232; Kim MH, 1999, J BIOL CHEM, V274, P673, DOI 10.1074/jbc.274.2.673; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; LEE JA, 1989, BIOCHEMISTRY-US, V28, P2540, DOI 10.1021/bi00432a029; LEE JI, 1992, J BIOL CHEM, V267, P20758; Merickel A, 1997, J BIOL CHEM, V272, P5403, DOI 10.1074/jbc.272.9.5403; Muller M, 1996, J BIOL CHEM, V271, P1877; Nguyen ML, 1996, PROG BRAIN RES, V109, P97; Nguyen ML, 1998, BIOCHEMISTRY-US, V37, P13400, DOI 10.1021/bi9802263; PADAN E, 1985, P NATL ACAD SCI USA, V82, P6765, DOI 10.1073/pnas.82.20.6765; PARSONS SM, 1993, INT REV NEUROBIOL, V35, P279, DOI 10.1016/S0074-7742(08)60572-3; PUTTNER IB, 1988, P NATL ACAD SCI USA, V85, P1467, DOI 10.1073/pnas.85.5.1467; Ramos CHI, 1999, BIOCHEMISTRY-US, V38, P9783, DOI 10.1021/bi9828627; ROGHANI A, 1994, P NATL ACAD SCI USA, V91, P10620, DOI 10.1073/pnas.91.22.10620; SAHINTOTH M, 1993, BIOCHEMISTRY-US, V32, P10027, DOI 10.1021/bi00089a019; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; SAID HM, 1993, BIOCHEM J, V290, P237, DOI 10.1042/bj2900237; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIRVAN A, 1994, FEBS LETT, V356, P145, DOI 10.1016/0014-5793(94)01252-0; SUCHI R, 1992, BIOCHEMISTRY-US, V31, P12500, DOI 10.1021/bi00164a029; Varoqui H, 1998, J BIOL CHEM, V273, P9094, DOI 10.1074/jbc.273.15.9094; Yamaguchi A, 1996, BIOCHEMISTRY-US, V35, P4359, DOI 10.1021/bi952116r; YAMAGUCHI A, 1991, J BIOL CHEM, V266, P6045; ZHANG YM, 1994, J BIOL CHEM, V269, P19573	31	18	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6175	6180		10.1074/jbc.275.9.6175	http://dx.doi.org/10.1074/jbc.275.9.6175			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692409	hybrid			2022-12-27	WOS:000085654400021
J	Kuhnel, F; Zender, L; Paul, Y; Tietze, MK; Trautwein, C; Manns, M; Kubicka, S				Kuhnel, F; Zender, L; Paul, Y; Tietze, MK; Trautwein, C; Manns, M; Kubicka, S			NF kappa B mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; VIRAL GENE-EXPRESSION; HEPATOCYTES IN-VIVO; INDUCED CELL-DEATH; RECOMBINANT ADENOVIRUS; LIVER-REGENERATION; CONCANAVALIN-A; THERAPY; MICE; VECTORS	NF kappa B is an essential survival factor in several physiological conditions such as embryonal liver development and liver regeneration. However, NF kappa B is also a main mediator of the cellular response to a variety of extracellular stress stimuli, and it has been shown that some viral-induced host cell apoptosis appears to be dependent on NF kappa B activation, The activation of NF kappa B upon viral infection may be a rapid way of initiating an innate immune response against the viral particles, We have assessed the role of NFkB during the early phase of adenoviral hepatitis in a nude mouse model using an adenoviral vector expressing a mutant form of I kappa B alpha. Administration of a LacZ-expressing adenoviral vector induces NFkB DNA and correlates with the up-regulation of Fas (CD95) mRNA, but not Fast (CD95L) mRNA, during the early phase of adenoviral hepatitis. The rapid increase in NF kappa B DNA binding after adenoviral infection of the liver could be very effectively inhibited by I kappa B alpha. Compared with the LacZ control virus, the I kappa B alpha-expressing adenoviral vector inhibits the increase of Fas (CD95) mRNA expression, in particular in the very early phase of the hepatitis. Reporter gene experiments in hepatoma cell Lines with a Fas promoter-luciferase construct indicated that the repression of Fas (CD95) mRNA by I kappa B alpha was transcriptionally mediated. The functional relevance of the NF kappa B-dependent increase in Fas (CD95) transcription was assessed by caspase 3 assays and terminal dUTP nick-end labeling tests. Compared with the control, I kappa B alpha adenoviral infection resulted in reduced caspase 3 activity during the early phase of viral hepatitis and in a prevention of Liver cell apoptosis 24 h after adenoviral administration. Therefore our study demonstrates a new pro-apoptotic function of NF kappa B in Fas (CD95)-mediated apoptosis of hepatocytes. Interestingly, NF kappa B mediates liver cell apoptosis upon viral infection even in a phase where tumor necrosis factor-alpha is already induced, as shown by the time curves of tumor necrosis factor-alpha serum levels, Therefore, the pro- or anti-apoptotic role of NF kappa B appears to be more determined by the nature of the death stimulus than by the origin of the tissue.	Med Hsch Hannover, Dept Gastroenterol & Hepatol, D-30625 Hannover, Germany	Hannover Medical School	Kubicka, S (corresponding author), Med Hsch Hannover, Dept Gastroenterol & Hepatol, Carl Neubergstr 1, D-30625 Hannover, Germany.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ANTWERP DJV, 1996, SCIENCE, V274, P787; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CASANO FJ, 1994, GENOMICS, V20, P474, DOI 10.1006/geno.1994.1203; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chirmule N, 1999, HUM GENE THER, V10, P259, DOI 10.1089/10430349950019048; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Gao GP, 1996, J VIROL, V70, P8934, DOI 10.1128/JVI.70.12.8934-8943.1996; Gil J, 1999, MOL CELL BIOL, V19, P4653; GINSBERG HS, 1989, P NATL ACAD SCI USA, V86, P3823, DOI 10.1073/pnas.86.10.3823; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Jaeschke H, 1998, J IMMUNOL, V160, P3480; JAFFE HA, 1992, NAT GENET, V1, P372, DOI 10.1038/ng0892-372; Kafri T, 1998, P NATL ACAD SCI USA, V95, P11377, DOI 10.1073/pnas.95.19.11377; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; KAY MA, 1995, NAT GENET, V11, P191, DOI 10.1038/ng1095-191; Kimura K, 1997, BBA-GENE STRUCT EXPR, V1352, P238, DOI 10.1016/S0167-4781(97)00060-2; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; Kubicka S, 1999, J BIOL CHEM, V274, P32137, DOI 10.1074/jbc.274.45.32137; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Kuprash DV, 1999, J IMMUNOL, V162, P4045; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LEIST M, 1995, J IMMUNOL, V154, P1307; LI QT, 1993, HUM GENE THER, V4, P403, DOI 10.1089/hum.1993.4.4-403; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LIEBER A, 1995, P NATL ACAD SCI USA, V92, P6210, DOI 10.1073/pnas.92.13.6210; Lieber A, 1996, J VIROL, V70, P8944, DOI 10.1128/JVI.70.12.8944-8960.1996; Lieber A, 1998, J VIROL, V72, P9267, DOI 10.1128/JVI.72.11.9267-9277.1998; Lieber A, 1997, J VIROL, V71, P8798, DOI 10.1128/JVI.71.11.8798-8807.1997; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Marianneau P, 1997, J VIROL, V71, P3244, DOI 10.1128/JVI.71.4.3244-3249.1997; Matsui K, 1998, J IMMUNOL, V161, P3469; MORSY MA, 1993, J CLIN INVEST, V92, P1580, DOI 10.1172/JCI116739; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Schiedner G, 1998, NAT GENET, V18, P180, DOI 10.1038/ng0298-180; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Strand S, 1998, NAT MED, V4, P588, DOI 10.1038/nm0598-588; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Swantek JL, 1999, J BIOL CHEM, V274, P11667, DOI 10.1074/jbc.274.17.11667; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TIEGS G, 1992, J CLIN INVEST, V90, P196, DOI 10.1172/JCI115836; Trautwein C, 1998, GASTROENTEROLOGY, V114, P1035, DOI 10.1016/S0016-5085(98)70324-5; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WU HY, 1994, J BIOL CHEM, V269, P20067; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362; YANG YP, 1995, P NATL ACAD SCI USA, V92, P7257, DOI 10.1073/pnas.92.16.7257; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; You LR, 1999, J VIROL, V73, P1672, DOI 10.1128/JVI.73.2.1672-1681.1999	70	136	139	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6421	6427		10.1074/jbc.275.9.6421	http://dx.doi.org/10.1074/jbc.275.9.6421			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692445	hybrid			2022-12-27	WOS:000085654400057
J	Muller-Hartmann, H; Deissler, H; Naumann, F; Schmitz, B; Schroer, J; Doerfler, W				Muller-Hartmann, H; Deissler, H; Naumann, F; Schmitz, B; Schroer, J; Doerfler, W			The human 20-kDa 5 '-(CGG)(n)-3 '-binding protein is targeted to the nucleus and affects the activity of the FMR1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRAGILE-X-SYNDROME; REPEAT EXPANSIONS; TRIPLET REPEATS; RIBOSOMAL DNA; HUMAN GENOME; GENE; CGG; SEQUENCES; LOCATION; DISEASE	Previous reports have described the human DNA CGG repeat-binding protein (CGGBP1 or p20), which binds specifically to nonmethylated, but not to methylated, 5'-(CGG)(n)-3' repeats in the promoter of the fragile X mental retardation I (FMRI) gene. The results of transfection experiments into human HeLa cells using a p20-green fluorescent protein fusion construct indicate that the p20 protein is targeted to the nucleus, By deletion analyses, a nuclear localization signal has been found between amino acids 80 and 84. Deletions between amino acids 69 and 71 and between 95 and 167 interfere with 5'-(CGG)(n)-3' binding. The results of electrophoretic mobility shift assays using DNA with 5'-(CGG)(n)-3' repeats of different lengths render it likely that oligomers of the p20 protein bind to the repeat. In cotransfection experiments, the activity of the FMR1 promoter is reduced by the presence of p20, Upon transfection of the p20 cDNA construct into HeLa cells, transcription of the endogenous FMRI gene is decreased, The green fluorescent protein-p20 fusion protein associates preferentially with the telomeres of the short arms of human chromosomes 13, 14, 15, 21, and 22, Their telomeres carry the genes for the 28 S rRNA, which contain 5'-(CGG)(n)-3' repeats. The translated region of the p20 gene from three healthy, five fragile X syndrome, and five premutation-carrying individuals has been sequenced, but mutations have not been detected.	Univ Cologne, Inst Genet, D-50931 Cologne, Germany	University of Cologne	Doerfler, W (corresponding author), Univ Cologne, Inst Genet, Weyertal 121, D-50931 Cologne, Germany.			Deissler, Heidrun/0000-0003-0086-7811				Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; BABLANIAN R, 1965, VIROLOGY, V26, P100, DOI 10.1016/0042-6822(65)90030-9; BEHNKRAPPA A, 1994, HUM MUTAT, V3, P19, DOI 10.1002/humu.1380030104; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; Chiurazzi P, 1998, HUM MOL GENET, V7, P109, DOI 10.1093/hmg/7.1.109; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; Deissler H, 1997, J BIOL CHEM, V272, P16761, DOI 10.1074/jbc.272.27.16761; Deissler H, 1996, J BIOL CHEM, V271, P4327; DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; EVANS HJ, 1974, CHROMOSOMA, V48, P405, DOI 10.1007/BF00290996; GONZALEZ IL, 1995, GENOMICS, V27, P320, DOI 10.1006/geno.1995.1049; HENDERSON AS, 1972, P NATL ACAD SCI USA, V69, P3394, DOI 10.1073/pnas.69.11.3394; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HilgerEversheim K, 1997, CANCER RES, V57, P3001; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; Mandel JL, 1992, CURR OPIN GENET DEV, V2, P422, DOI 10.1016/S0959-437X(05)80153-4; MUIZNIEKS I, 1994, FEBS LETT, V344, P251, DOI 10.1016/0014-5793(94)00394-7; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; SIEBERT PD, 1993, BIOTECHNIQUES, V14, P244; SMEETS HJM, 1995, HUM MOL GENET, V4, P2103, DOI 10.1093/hmg/4.11.2103; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Warren S T, 1993, Curr Opin Neurobiol, V3, P752, DOI 10.1016/0959-4388(93)90149-S; Warren ST, 1996, SCIENCE, V271, P1374, DOI 10.1126/science.271.5254.1374; WARREN ST, 1994, JAMA-J AM MED ASSOC, V271, P536, DOI 10.1001/jama.271.7.536; Wells RD, 1998, J BIOL CHEM, V273, P19532, DOI 10.1074/jbc.273.31.19532; WILLIAMS M, 1992, NUCLEIC ACIDS RES, V20, P4935, DOI 10.1093/nar/20.18.4935	29	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6447	6452		10.1074/jbc.275.9.6447	http://dx.doi.org/10.1074/jbc.275.9.6447			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692448	hybrid			2022-12-27	WOS:000085654400060
J	Corbeil, D; Roper, K; Hellwig, A; Tavian, M; Miraglia, S; Watt, SM; Simmons, PJ; Peault, B; Buck, DW; Huttner, WB				Corbeil, D; Roper, K; Hellwig, A; Tavian, M; Miraglia, S; Watt, SM; Simmons, PJ; Peault, B; Buck, DW; Huttner, WB			The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE KIDNEY PROMININ; SURFACE POLARITY; DISTINCT MEMBER; PROTEIN FAMILY; HUMAN HOMOLOG; CACO-2; DIFFERENTIATION; LINES; HT-29; CD34	The human AC133 antigen and mouse prominin are structurally related plasma membrane proteins. However, their tissue distribution is distinct, with the AC133 antigen being found on hematopoietic stem and progenitor cells and prominin on various epithelial cells. To determine whether the human AC133 antigen and mouse prominin are orthologues or distinct members of a protein family, we examined the human epithelial cell line Caco-2 for the possible expression of the AC133 antigen. By both immunofluorescence and immunoprecipitation, the AC133 antigen was found to be expressed on the surface of Caco-2 cells. interestingly, immunore-activity for the AC133 antigen, but not its mRNA level, was down-regulated upon differentiation of Caco-2 cells. The AC133 antigen was specifically located at the apical rather than basolateral plasma membrane. An apical localization of the AC133 antigen was also observed in various human embryonic epithelia including the neural tube, gut, and kidney. Electron microscopy revealed that, within the apical plasma membrane of Caco-2 cells, the AC133 antigen was confined to microvilli and absent from the planar, intermicrovillar regions. This specific subcellular localization did not depend on an epithelial phenotype, because the AC133 antigen on hematopoietic stem cells, as well as that ectopically expressed in fibroblasts, was selectively found in plasma membrane protrusions. Hence, the human AC133 antigen shows the features characteristic of mouse prominin in epithelial and transfected non-epithelial cells, ie. a selective association with apical microvilli and plasma membrane protrusions, respectively, Conversely; flow cytometry of murine CD34(+) bone marrow progenitors revealed the cell surface expression of prominin, Taken together, the data strongly suggest that the AC133 antigen is the human orthologue of prominin.	Univ Heidelberg, Dept Neurobiol, D-69120 Heidelberg, Germany; Max Planck Inst Mol Biol & Genet, D-01307 Dresden, Germany; CNRS, Unite Propre Rech 9064, Nogent Sur Marne, France; INSERM U506, Villejuif, France; AmCell Corp, Sunnyvale, CA 94089 USA; John Radcliffe Hosp, Inst Mol Med, Med Res Council Mol Haematol, Oxford OX3 9DS, England; Hanson Ctr Canc Res, Adelaide, SA 5000, Australia	Ruprecht Karls University Heidelberg; Max Planck Society; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Oxford	Huttner, WB (corresponding author), Univ Heidelberg, Dept Neurobiol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany.		Corbeil, Denis/A-6519-2010; Tavian, Manuela/E-4210-2018; Watt, Suzanne/AAV-4908-2021; Huttner, Wieland B./P-4080-2018; Corbeil, Denis/AFL-1008-2022; Corbeil, Denis/L-2340-2019; Tavian, Manuela/S-3201-2019	Tavian, Manuela/0000-0003-4746-3240; Corbeil, Denis/0000-0003-1181-3659; Tavian, Manuela/0000-0003-4746-3240; Roper, Katja/0000-0002-3361-766X				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Corbeil D, 1999, J CELL SCI, V112, P1023; Corbeil D, 1998, BLOOD, V91, P2625, DOI 10.1182/blood.V91.7.2625.2625_2625_2626; de Wynter EA, 1998, STEM CELLS, V16, P387, DOI 10.1002/stem.160387; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; HARRIS DS, 1992, P NATL ACAD SCI USA, V89, P7556, DOI 10.1073/pnas.89.16.7556; HOWELL S, 1992, BIOCHEM J, V284, P595, DOI 10.1042/bj2840595; Krause DS, 1996, BLOOD, V87, P1; KRAUSE DS, 1994, BLOOD, V84, P691; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LIN GS, 1995, EUR J IMMUNOL, V25, P1508, DOI 10.1002/eji.1830250606; Maw MA, 2000, HUM MOL GENET, V9, P27, DOI 10.1093/hmg/9.1.27; Miraglia S, 1997, BLOOD, V90, P5013, DOI 10.1182/blood.V90.12.5013.5013_5013_5021; Miraglia S, 1998, BLOOD, V91, P4390, DOI 10.1182/blood.V91.11.4390; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; NISHIO H, 1997, 6 INT WKSH C KOB JAP, P974; OGIERDENIS E, 1988, J BIOL CHEM, V263, P6031; PINTO M, 1983, BIOL CELL, V47, P323; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROUSSET M, 1986, BIOCHIMIE, V68, P1035, DOI 10.1016/S0300-9084(86)80177-8; SIMONS K, 1992, COLD SPRING HARB SYM, V57, P611, DOI 10.1101/SQB.1992.057.01.067; VACHON PH, 1992, GASTROENTEROLOGY, V103, P414, DOI 10.1016/0016-5085(92)90829-N; Weigmann A, 1997, P NATL ACAD SCI USA, V94, P12425, DOI 10.1073/pnas.94.23.12425; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012	26	352	366	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5512	5520		10.1074/jbc.275.8.5512	http://dx.doi.org/10.1074/jbc.275.8.5512			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681530	hybrid			2022-12-27	WOS:000085474500037
J	Linderoth, NA; Popowicz, A; Sastry, S				Linderoth, NA; Popowicz, A; Sastry, S			Identification of the peptide-binding site in the heat shock chaperone/tumor rejection antigen gp96 (Grp94)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOTOXIC T-LYMPHOCYTES; STRESS-INDUCED PROTEINS; ENDOPLASMIC-RETICULUM; IN-VIVO; IMMUNITY; CANCER; GENERATION; TAP; IMMUNOTHERAPY; IMMUNIZATION	Heat shock protein (HSP)-peptide complexes from tumor cells elicit specific protective immunity when injected into inbred mice bearing the same specific type of tumor. The HSP-mediated specific immunogenicity also occurs with virus-infected cells. The immune response is solely due to endogenous peptides noncovalently bound to HSP. A vesicular stomatitis virus capsid-derived pep tide ligand bearing a photoreactive azido group was specifically bound by and cross-linked to murine HSP glycoprotein (gp) 96. The peptide-binding site was mapped by specific proteolysis of the cross-links followed by analysis of the cross-linked peptides using a judicious combination of SDS-gel electrophoresis, mass spectrometry, and amino acid sequencing. The minimal peptide-binding site was mapped to amino acid residues 624-630 in a highly conserved region of gp96. A model of the peptide binding pocket of gp96 was constructed based on the known crystallographic structure of major histocompatibility complex class I molecule bound to a similar peptide. The gp96-peptide model predicts that the peptide ligand is held in a groove formed by alpha-helices and lies on a surface consisting of antiparallel beta-sheets. Interestingly, in this model, the peptide binding pocket abuts the dimerization domain of gp96, which may have implications for the extraordinary stability of peptide-gp96 complexes, and for the faithful relay of peptides to major histocompatibility complex class I molecule for antigen presentation.	Rockefeller Univ, Genet Mol Lab, New York, NY 10021 USA; Rockefeller Univ, Comp Serv, New York, NY 10021 USA	Rockefeller University; Rockefeller University	Sastry, S (corresponding author), Rockefeller Univ, Genet Mol Lab, Box 174,1230 York Ave, New York, NY 10021 USA.	sastrys@rockvax.rockefeller.edu						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arnold D, 1997, J EXP MED, V186, P461, DOI 10.1084/jem.186.3.461; Arnold-Schild D, 1999, J IMMUNOL, V162, P3757; Basu S, 1999, J EXP MED, V189, P797, DOI 10.1084/jem.189.5.797; BLACHERE NE, 1993, J IMMUNOTHER, V14, P352, DOI 10.1097/00002371-199311000-00016; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chandawarkar RY, 1999, J EXP MED, V189, P1437, DOI 10.1084/jem.189.9.1437; Ciupitu AMT, 1998, J EXP MED, V187, P685, DOI 10.1084/jem.187.5.685; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Gharahdaghi F, 1996, ANAL BIOCHEM, V233, P94, DOI 10.1006/abio.1996.0012; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Heikema A, 1997, IMMUNOL LETT, V57, P69, DOI 10.1016/S0165-2478(97)00048-5; HERMANSON G, 1996, BIOCONJUGATE TECHNIQ, P261; Ishii T, 1999, J IMMUNOL, V162, P1303; Janetzki S, 1998, J IMMUNOTHER, V21, P269, DOI 10.1097/00002371-199807000-00004; Lammert E, 1997, EUR J IMMUNOL, V27, P923, DOI 10.1002/eji.1830270418; Landon, 1977, Methods Enzymol, V47, P145; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; Nicchitta CV, 1998, CURR OPIN IMMUNOL, V10, P103, DOI 10.1016/S0952-7915(98)80039-3; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Przepiorka D, 1998, MOL MED TODAY, V4, P478, DOI 10.1016/S1357-4310(98)01345-8; Roman E, 1996, IMMUNOLOGY, V88, P487, DOI 10.1046/j.1365-2567.1996.d01-697.x; Sastry S, 1999, J BIOL CHEM, V274, P12023, DOI 10.1074/jbc.274.17.12023; Soti C, 1998, Pathol Oncol Res, V4, P316; Spee P, 1997, EUR J IMMUNOL, V27, P2441, DOI 10.1002/eji.1830270944; Srivastava P K, 1991, Semin Immunol, V3, P57; Srivastava PK, 1998, IMMUNITY, V8, P657, DOI 10.1016/S1074-7613(00)80570-1; SRIVASTAVA PK, 1991, CURR TOP MICROBIOL, V167, P109; SRIVASTAVA PK, 1987, P NATL ACAD SCI USA, V84, P3807, DOI 10.1073/pnas.84.11.3807; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Tamura Y, 1997, SCIENCE, V278, P117, DOI 10.1126/science.278.5335.117; UDONO H, 1994, P NATL ACAD SCI USA, V91, P3077, DOI 10.1073/pnas.91.8.3077; UDONO H, 1994, J IMMUNOL, V152, P5398; UDONO H, 1993, J EXP MED, V178, P1391, DOI 10.1084/jem.178.4.1391; Wearsch PA, 1996, PROTEIN EXPRES PURIF, V7, P114, DOI 10.1006/prep.1996.0015; Wearsch PA, 1996, BIOCHEMISTRY-US, V35, P16760, DOI 10.1021/bi962068q; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152; WOLF H, 1988, COMPUT APPL BIOSCI, V4, P187; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	43	62	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5472	5477		10.1074/jbc.275.8.5472	http://dx.doi.org/10.1074/jbc.275.8.5472			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681525	hybrid			2022-12-27	WOS:000085474500032
J	Xu, J; Qu, DF; Esmon, NL; Esmon, CT				Xu, J; Qu, DF; Esmon, NL; Esmon, CT			Metalloproteolytic release of endothelial cell protein C receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIN ADHESION MOLECULE; LARGE BLOOD-VESSELS; ACTIVATION; THROMBOMODULIN; MECHANISM; THROMBIN; PLASMA; IDENTIFICATION; CLONING; COAGULATION	Previous studies observed that there is about 100 ng/ml soluble endothelial cell protein C receptor (EPCR) in human plasma and that the levels increase in inflammatory diseases. In this study we examine the potential mechanisms involved in release of EPCR from cells. We find that EPCR is released from the surface of endothelium and transfected 293 cells by a metalloprotease in a constitutive fashion. The mass of soluble EPCR is 4 kDa less than intact EPCR. Release is blocked by either the hydroxamic acid based inhibitor, KD-IX-73-4 or by 1,10-phenanthroline, but not by matrix metalloprotease inhibitors. Release is stimulated by phorbol 12-myristate 13-acetate, thrombin, interleukin-1 beta, and hydrogen peroxide. Stimulation with these agents reduces EPCR expression levels sufficiently to decrease the rate of protein C activation to a limited extent. The influence of phorbol 12-myristate 13-acetate on both EPCR release and inhibition of protein C activation are enhanced by microtubule disruption with nocodazole, EPCR release is augmented by transfection of EPCR expressing 293 cells with caveolin, suggesting that release is caveolae dependent. These studies indicate that metalloproteolytic release of EPCR is a highly regulated process that is sensitive to both coagulation factors and inflammatory mediators.	Oklahoma Med Res Fdn, Howard Hughes Med Inst, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Esmon, CT (corresponding author), Oklahoma Med Res Fdn, Howard Hughes Med Inst, 825 NE 13th St, Oklahoma City, OK 73104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007207, P01HL054804] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07207, P01 HL54804] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANGALORE N, 1994, THROMB HAEMOSTASIS, V72, P465; BAZIL V, 1994, J IMMUNOL, V152, P1314; BERNARD GR, 1998, CRIT CARE MED, V27, pS4; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1989, J BIOL CHEM, V264, P4743; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Fukudome K, 1998, J EXP MED, V187, P1029, DOI 10.1084/jem.187.7.1029; Fukudome K, 1996, J BIOL CHEM, V271, P17491, DOI 10.1074/jbc.271.29.17491; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; GLASER CB, 1992, J CLIN INVEST, V90, P2565, DOI 10.1172/JCI116151; GU JM, 2000, IN PRESS BLOOD; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Kurosawa S, 1997, J CLIN INVEST, V100, P411, DOI 10.1172/JCI119548; Kurosawa S, 1998, BLOOD, V91, P725, DOI 10.1182/blood.V91.2.725; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Laszik Z, 1997, CIRCULATION, V96, P3633; LASZIK ZG, 2000, 89 ANN M US CAN AC P; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P19341; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Malek AM, 1996, J CELL SCI, V109, P713; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Regan LM, 1996, J BIOL CHEM, V271, P17499, DOI 10.1074/jbc.271.29.17499; Smith OP, 1997, LANCET, V350, P1590, DOI 10.1016/S0140-6736(97)06356-3; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; STEARNSKUROSAWA DJ, 1999, THROMB HAEMOSTASIS S; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; TAKANO S, 1990, BLOOD, V76, P2024; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Xu J, 1999, J BIOL CHEM, V274, P6704, DOI 10.1074/jbc.274.10.6704	34	173	180	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					6038	6044		10.1074/jbc.275.8.6038	http://dx.doi.org/10.1074/jbc.275.8.6038			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681599	hybrid			2022-12-27	WOS:000085474500106
J	Verhoeven, EEA; van Kesteren, M; Moolenaar, GF; Visse, R; Goosen, N				Verhoeven, EEA; van Kesteren, M; Moolenaar, GF; Visse, R; Goosen, N			Catalytic sites for 3 ' and 5 ' incision of Escherichia coli nucleotide excision repair are both located in UvrC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL REGION; (A)BC EXCINUCLEASE; ACTIVE-SITE; DNA; PROTEIN; BINDING; COMPLEX; ENDONUCLEASE; 3'-INCISION	Nucleotide excision repair in Escherichia coli is a multistep process in which DNA damage is removed by incision of the DNA on both sides of the damage, followed by removal of the oligonucleotide containing the lesion. The two incision reactions take place in a complex of damaged DNA with UvrB and UvrC. It has been shown (Lin, J.-J., and Sancar, A, (1992) J. Biol, Chem. 267, 17688-17692) that the catalytic site for incision on the 5' side of the damage is located in the UvrC protein. Here we show that the catalytic site for incision on the 3' side is in this protein as well, because substitution R42A abolishes 3' incision, whereas formation of the UvrBC-DNA complex and the 5' incision reaction are unaffected. Ar-42 is part of a region that is homologous to the catalytic domain of the homing endonuclease I-TevI. We propose that the UvrC protein consists of two functional parts, with the N-terminal half for the 3' incision reaction and the C-terminal half containing all the determinants for the 5' incision reaction.	Leiden Univ, Gorlaeus Labs, Leiden Inst Chem, Genet Mol Lab, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Goosen, N (corresponding author), Leiden Univ, Gorlaeus Labs, Leiden Inst Chem, Genet Mol Lab, Einsteinweg 55,POB 9502, NL-2300 RA Leiden, Netherlands.	N.Goosen@chem.Leidenuniv.nl						Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; BROUWER J, 1988, NUCLEIC ACIDS RES, V16, P7703, DOI 10.1093/nar/16.15.7703; DERBYSHIRE V, 1997, J MOL BIOL, V247, P197; Gordienko I, 1998, EMBO J, V17, P626, DOI 10.1093/emboj/17.2.626; Kowalski JC, 1999, NUCLEIC ACIDS RES, V27, P2115, DOI 10.1093/nar/27.10.2115; LIN JJ, 1991, P NATL ACAD SCI USA, V88, P6824, DOI 10.1073/pnas.88.15.6824; LIN JJ, 1992, J BIOL CHEM, V267, P17693; LIN JJ, 1992, J BIOL CHEM, V267, P17688; Moolenaar GF, 1998, J BIOL CHEM, V273, P34896, DOI 10.1074/jbc.273.52.34896; Moolenaar GF, 1998, NUCLEIC ACIDS RES, V26, P462, DOI 10.1093/nar/26.2.462; Moolenaar GF, 1997, MUTAT RES-DNA REPAIR, V385, P195, DOI 10.1016/S0921-8777(97)00042-6; Moolenaar GF, 1995, J BIOL CHEM, V270, P30508, DOI 10.1074/jbc.270.51.30508; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VISSE R, 1992, J BIOL CHEM, V267, P6736; VISSE R, 1991, J BIOL CHEM, V266, P7609; Zou Y, 1999, EMBO J, V18, P4889, DOI 10.1093/emboj/18.17.4889; ZWETSLOOT JCM, 1986, MUTAT RES, V166, P89, DOI 10.1016/0167-8817(86)90044-1	20	97	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5120	5123		10.1074/jbc.275.7.5120	http://dx.doi.org/10.1074/jbc.275.7.5120			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671556	hybrid, Green Published			2022-12-27	WOS:000085378200082
J	Close, BE; Tao, K; Colley, KT				Close, BE; Tao, K; Colley, KT			Polysialyltransferase-1 autopolysialylation is not requisite for polysialylation of neural cell adhesion molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY-REGULATED MEMBER; GOLGI VESICLE MEMBRANES; POLYSIALIC ACID UNITS; MUTANT DEFICIENT; LUNG-CARCINOMA; SIGNAL ANCHOR; WILMS TUMOR; N-CAM; STX; GLYCOPROTEINS	Polysialyltransferase-1 (PST; ST8Sia TV) is one of the alpha 2,8-polysialyltransferases responsible for the polysialylation of the neural cell adhesion molecule (NCAM), The presence of polysialic acid on NCAM has been shown, to modulate cell-cell and cell-matrix interactions. We previously reported that the PST enzyme itself is modified by alpha 2,8-linked polysialic acid chains in vivo. To understand the role of autopolysialylation in PST enzymatic activity, we employed a mutagenesis approach. We found that PST is modified by five Asn-linked oligosaccharides and that the vast majority of the polysialic acid is found on the oligosaccharide modifying Asn-74. In addition, the presence of the oligosaccharide on Asn 119 appeared to be required for folding of PST into an active enzyme. Co-expression of the PST Asn mutants with NCAM demonstrated that autopolysialylation is not required for PST polysialyltransferase activity. Notably, catalytically active, non-autopolysialylated PST does not polysialylate any endogenous COS-1 cell proteins, highlighting the protein specificity of polysialylation. Immunoblot analyses of NCAM polysialylation by polysialylated and non-autopolysialylated PST suggests that the NCAM is polysialylated to a higher degree by autopolysialylated PST. We conclude that autopolysialylation of PST is not required for, but does enhance, NCAM polysialylation.	Univ Illinois, Coll Med, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Colley, KT (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Biol, 1819 W Polk St,MC 536, Chicago, IL 60612 USA.	karenc@uic.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048134, R01GM048134] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48134] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; Close BE, 1998, J BIOL CHEM, V273, P34586, DOI 10.1074/jbc.273.51.34586; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EDELMAN GM, 1985, ANNU REV BIOCHEM, V54, P135, DOI 10.1146/annurev.bi.54.070185.001031; FINNE J, 1983, BIOCHEM BIOPH RES CO, V112, P482, DOI 10.1016/0006-291X(83)91490-0; FINNE J, 1987, J IMMUNOL, V138, P4402; GLICK MC, 1991, PROG CLIN BIOL RES, V366, P267; Horstkorte R, 1999, EXP CELL RES, V246, P122, DOI 10.1006/excr.1998.4255; KIBBELAAR RE, 1989, J PATHOL, V159, P23, DOI 10.1002/path.1711590108; KITAZUME S, 1994, J BIOL CHEM, V269, P22712; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; Kudo M, 1998, GLYCOBIOLOGY, V8, P771, DOI 10.1093/glycob/8.8.771; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; Martersteck CM, 1996, GLYCOBIOLOGY, V6, P289, DOI 10.1093/glycob/6.3.289; MICHALIDES R, 1994, INT J CANCER, P34; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; Muhlenhoff M, 1998, CURR OPIN STRUC BIOL, V8, P558, DOI 10.1016/S0959-440X(98)80144-9; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; ROBBINS JB, 1974, NEW ENGL J MED, V290, P1216, DOI 10.1056/NEJM197405302902202; ROTH J, 1992, SCIENCE, V256, P673, DOI 10.1126/science.1585182; ROTH J, 1988, AM J PATHOL, V133, P596; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; ROTH J, 1987, P NATL ACAD SCI USA, V84, P1969, DOI 10.1073/pnas.84.7.1969; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; RUTISHAUSER U, 1985, J CELL BIOL, V101, P1842, DOI 10.1083/jcb.101.5.1842; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SADOUL R, 1983, NATURE, V304, P347, DOI 10.1038/304347a0; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; Storms SD, 1998, J BIOL CHEM, V273, P27124, DOI 10.1074/jbc.273.42.27124; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; TROY FA, 1995, BIOL SIALIC ACIDS, P94; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; YOSHIDA Y, 1995, J BIOCHEM-TOKYO, V118, P658, DOI 10.1093/oxfordjournals.jbchem.a124960; ZUBER C, 1992, J BIOL CHEM, V267, P9965	45	42	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4484	4491		10.1074/jbc.275.6.4484	http://dx.doi.org/10.1074/jbc.275.6.4484			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660622	hybrid			2022-12-27	WOS:000085288800106
J	Salvatore, CA; Tilley, SL; Latour, AM; Fletcher, DS; Koller, BH; Jacobson, MA				Salvatore, CA; Tilley, SL; Latour, AM; Fletcher, DS; Koller, BH; Jacobson, MA			Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MAST-CELLS; MOLECULAR-CLONING; PHARMACOLOGICAL CHARACTERIZATION; MEDIATOR RELEASE; A(2B) RECEPTORS; TNF-ALPHA; IN-VITRO; RAT; EXPRESSION; AGONISTS	The A(3) adenosine receptor (A3AR) is one of four receptor subtypes for adenosine and is expressed in a broad spectrum of tissues. In order to study the function of A3AR, a mouse line carrying a mutant A(3) allele was generated. Mice homozygous for targeted disruption of the A3AR gene, A3AR(-/-) are fertile and visually and histologically indistinguishable from wild type mice. The lack of a functional receptor in the A3AR-/- mice was confirmed by molecular and pharmacological analyses. The absence of A3AR protein expression in the A3AR(-/-) mice was demonstrated by lack of N-6-(4-amino-3-[I-125]iodobenzyl)adenosine binding to bone marrow-derived mast cell membranes that were found to express high levels of A3AR in wild type mice. In A3AR(-/-) mice, the density of A(1) and A(2A) adenosine receptor subtypes was the same as in A3AR(+/+) mice as determined by radioligand binding to brain membranes. Additionally, A(2B), receptor transcript expression was not affected by ablation of the A3AR gene. A3AR(-/-) mice have basal heart rates and arterial blood pressures indistinguishable from A3AR(+/+) mice. Functionally, in contrast to wild type mice, adenosine and the A3AR-specific agonist, 2-chloro-N-6-(3-iodobenzyl)-adenosine-5'-N-methyl-carboxamide (S-Cl-IB-MECA), elicit no potentiation of antigen-dependent degranulation of bone marrow-derived mast cells from A3AR(-/-) mice as measured by hexosaminidase release. Also, the ability of 2Cl-IB-MECA to inhibit lipopolysaccharide-induced tumor necrosis factor-alpha production in vivo was decreased in A3AR(-/-) mice in comparison to A3AR(+/+) mice. The A(2A) adenosine receptor agonist, 2-p-(2-carboxyethyl)phenylamino)-5'-N-ethylcarboxamidoadenosine, produced inhibition of lipopolysaccharide-stimulated tumor necrosis factor-alpha production in both A3AR(-/-) and A3AR(+/+) mice. These results show that the inhibition in vivo can be mediated by multiple subtypes, specifically the A(3) and A(2A) adenosine receptors, and A3AR activation plays an important role in both pro- and anti-inflammatory responses.	Merck Res Labs, Dept Pharmacol, W Point, PA 19486 USA; Merck & Co Inc, Merck Sharp & Dohme Res Labs, Dept Anim Pharmacol, Rahway, NJ 07065 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	Merck & Company; Merck & Company; University of North Carolina; University of North Carolina Chapel Hill	Jacobson, MA (corresponding author), Merck Res Labs, Dept Pharmacol, WP26-265, W Point, PA 19486 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058554] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-58554] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG S, 1995, CARDIOVASC RES, V29, P647, DOI 10.1016/0008-6363(96)88635-4; Auchampach JA, 1997, MOL PHARMACOL, V52, P846, DOI 10.1124/mol.52.5.846; BELLARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73; Bowlin TL, 1997, CELL MOL BIOL, V43, P345; BRUNS RF, 1986, MOL PHARMACOL, V29, P331; CUSHLEY MJ, 1984, AM REV RESPIR DIS, V129, P380; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; DOYLE MP, 1994, AM J PHYSIOL, V266, pH2042, DOI 10.1152/ajpheart.1994.266.5.H2042; Feoktistov I, 1998, BIOCHEM PHARMACOL, V55, P627, DOI 10.1016/S0006-2952(97)00512-1; FEOKTISTOV I, 1995, J CLIN INVEST, V96, P1979, DOI 10.1172/JCI118245; FOZARD JR, 1993, BRIT J PHARMACOL, V109, P3, DOI 10.1111/j.1476-5381.1993.tb13522.x; HANNON JP, 1995, BRIT J PHARMACOL, V115, P945, DOI 10.1111/j.1476-5381.1995.tb15902.x; Hasko G, 1996, J IMMUNOL, V157, P4634; Hill RJ, 1997, J PHARMACOL EXP THER, V280, P122; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JACOBSON KA, 1993, FEBS LETT, V336, P57, DOI 10.1016/0014-5793(93)81608-3; JACOBSON KA, 1992, J MED CHEM, V35, P407, DOI 10.1021/jm00081a001; LEVRAUX V, 1993, LIFE SCI, V52, P1917, DOI 10.1016/0024-3205(93)90632-D; Liang BT, 1998, P NATL ACAD SCI USA, V95, P6995, DOI 10.1073/pnas.95.12.6995; LINDEN J, 1985, CIRC RES, V56, P279, DOI 10.1161/01.RES.56.2.279; Linden J, 1999, MOL PHARMACOL, V56, P705; LINDEN J, 1994, TRENDS PHARMACOL SCI, V15, P298, DOI 10.1016/0165-6147(94)90011-6; LINDEN J, 1993, MOL PHARMACOL, V44, P524; MARQUARDT DL, 1988, BIOCHEM PHARMACOL, V37, P4019, DOI 10.1016/0006-2952(88)90088-3; MARQUARDT DL, 1994, J IMMUNOL, V152, P4508; MARQUARDT DL, 1978, J IMMUNOL, V120, P871; MEYERHOF W, 1991, FEBS LETT, V284, P155, DOI 10.1016/0014-5793(91)80674-R; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; PEACHELL PT, 1988, AM REV RESPIR DIS, V138, P1143, DOI 10.1164/ajrccm/138.5.1143; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; RAMKUMAR V, 1993, J BIOL CHEM, V268, P16887; RAMKUMAR V, 1995, J IMMUNOL, V154, P5436; ROTTEM M, 1992, BLOOD, V79, P972; SAJJADI FG, 1993, BIOCHIM BIOPHYS ACTA, V1179, P105, DOI 10.1016/0167-4889(93)90077-3; Sajjadi FG, 1996, J IMMUNOL, V156, P3435; SALVATORE CA, 1993, P NATL ACAD SCI USA, V90, P10365, DOI 10.1073/pnas.90.21.10365; SAMBROOK J, 1989, MOL CLONING LABORATO, V7, P43; SCHWARTZ LB, 1979, J IMMUNOL, V123, P1445; Sullivan GW, 1998, DRUG DEVELOP RES, V45, P103, DOI 10.1002/(SICI)1098-2299(199811/12)45:3/4<103::AID-DDR4>3.0.CO;2-W; TERAI T, 1995, EUR J PHARMACOL, V279, P217, DOI 10.1016/0014-2999(95)00165-H; VanSchaick EA, 1996, EUR J PHARMACOL, V308, P311, DOI 10.1016/0014-2999(96)00373-1; VONLUBITZ DKJE, 1994, EUR J PHARMACOL, V263, P59, DOI 10.1016/0014-2999(94)90523-1; Walker BAM, 1997, AM J RESP CELL MOL, V16, P531, DOI 10.1165/ajrcmb.16.5.9160835; Yao Y, 1997, BIOCHEM BIOPH RES CO, V232, P317, DOI 10.1006/bbrc.1997.6290; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	46	258	270	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4429	4434		10.1074/jbc.275.6.4429	http://dx.doi.org/10.1074/jbc.275.6.4429			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660615	hybrid			2022-12-27	WOS:000085288800099
J	Erdahl, WL; Chapman, CJ; Taylor, RW; Pfeiffer, DR				Erdahl, WL; Chapman, CJ; Taylor, RW; Pfeiffer, DR			Ionomycin, a carboxylic acid ionophore, transports Pb2+ with high selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREEZE-THAW EXTRUSION; CATION-TRANSPORT; LEAD-EXPOSURE; FREE CALCIUM; A23187; 4-BRA23187; CELLS; VESICLES; CA2+; SPECIFICITY	Studies utilizing phospholipid vesicle loaded with chelator/indicators for polyvalent cations show that ionomycin transports divalent cations with the selectivity sequence Pb2+ > Cd2+ > Zn2+ > Mn2+ > Ca2+ > Cu2+ > Co2+ > Ni2+ > Sr2+. The selectivity of this ionophore for Pb2+ is in contrast to that observed for A23178 and 4-BrA23187, which transport Pb2+ at efficiencies that are intermediate between those of other cations, When the selectivity difference of ionomycin for Pb2+ versus Ca2+ was calculated from relative rates of transport, with either cation present individually and all other conditions held constant, a value of similar to 450 was obtained. This rose to similar to 3200 when both cations were present and transported simultaneously. 1 mu M Pb2+ inhibited the transport of 1 mM Ca2+ by similar to 50%, whereas the rate of Pb2+ transport approached a maximum at a concentration of 10 mu M Pb2+ when 1 mM Ca2+ was also present. Plots of log rate versus log ionomycin or log Pb2+ concentration indicated that the transporting species is of 1:1 stoichiometry, ionophore to Pb2+, but that complexes containing an additional Pb2+ may occur. The species transporting Pb2+ may include H.IPb.OH, wherein ionomycin is ionized once and the presence of OH- maintains charge neutrality. Ionomycin retained a high efficiency for Pb2+ transport in A20 B lymphoma cells loaded with Indo-1. Both Pb2+ entry and efflux were observed. Ionomycin should be considered primarily as an ionophore for Pb2+, rather than Ca2+, of possible value for the investigation and treatment of Pb2+ intoxication.	Ohio State Univ, Dept Med Biochem, Columbus, OH 43210 USA; Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA	Ohio State University; University of Oklahoma System; University of Oklahoma - Norman	Pfeiffer, DR (corresponding author), Ohio State Univ, Dept Med Biochem, 1645 Neil Ave,310A Hamilton Hall, Columbus, OH 43210 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049181] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49181] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARSLAN P, 1985, J BIOL CHEM, V260, P2719; Baes C.F., 1976, HYDROLYSIS CATIONS, DOI 10.1002/bbpc.19770810252; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BEELER TJ, 1979, J BIOL CHEM, V254, P6229; Besunder JB, 1997, J PEDIATR-US, V130, P966, DOI 10.1016/S0022-3476(97)70285-3; CHAPMAN CJ, 1991, CHEM PHYS LIPIDS, V60, P201, DOI 10.1016/0009-3084(91)90042-A; CHAPMAN CJ, 1990, CHEM PHYS LIPIDS, V55, P73, DOI 10.1016/0009-3084(90)90068-3; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; Davies C.W., 1962, ION ASS; DIEGEL ML, 1994, J BIOL CHEM, V269, P11409; DIVIRGILIO F, 1988, BIOCHEM J, V256, P959, DOI 10.1042/bj2560959; DOMINGO JL, 1995, REPROD TOXICOL, V9, P105, DOI 10.1016/0890-6238(94)00060-3; Erdahl WL, 1996, BIOCHEMISTRY-US, V35, P13817, DOI 10.1021/bi961391q; Erdahl WL, 1995, BIOPHYS J, V69, P2350, DOI 10.1016/S0006-3495(95)80104-9; ERDAHL WL, 1994, BIOPHYS J, V66, P1678, DOI 10.1016/S0006-3495(94)80959-2; FRY DW, 1978, ANAL BIOCHEM, V90, P809, DOI 10.1016/0003-2697(78)90172-0; GOYER RA, 1995, ENV HLTH PERSPECT, V123, P1; Gutgesell M E, 1996, Va Med Q, V123, P190; HINKLE PM, 1992, J BIOL CHEM, V267, P25553; Jones MM, 1997, PHARMACOL TOXICOL, V80, P182, DOI 10.1111/j.1600-0773.1997.tb00393.x; KAUFFMAN RF, 1980, J BIOL CHEM, V255, P2735; Kerper LE, 1997, TOXICOL APPL PHARM, V146, P127, DOI 10.1006/taap.1997.8234; Kerper LE, 1997, J BIOL CHEM, V272, P8346, DOI 10.1074/jbc.272.13.8346; Kristal-Boneh E, 1998, AM J EPIDEMIOL, V147, P458, DOI 10.1093/oxfordjournals.aje.a009471; Lanphear BP, 1998, ENVIRON RES, V76, P120, DOI 10.1006/enrs.1997.3801; LEE BK, 1995, OCCUP ENVIRON MED, V52, P13, DOI 10.1136/oem.52.1.13; Legare ME, 1998, TOXICOL SCI, V46, P90; Lifshitz M, 1997, ANN MED, V29, P83, DOI 10.3109/07853899708998747; LIU CM, 1978, J BIOL CHEM, V253, P5892; Marriott I, 1996, J BIOL CHEM, V271, P26732, DOI 10.1074/jbc.271.43.26732; Martell A. E., 1977, CRITICAL STABILITY C, V3; Mielke HW, 1998, ENVIRON HEALTH PERSP, V106, P217, DOI 10.2307/3433922; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; QUINN MR, 1995, NEUROSCI LETT, V196, P65, DOI 10.1016/0304-3940(95)11845-N; REED PW, 1982, POLYETHER ANTIBIOTIC; Schanne FAX, 1997, BBA-MOL BASIS DIS, V1360, P247, DOI 10.1016/S0925-4439(97)00006-9; Sensi SL, 1997, J NEUROSCI, V17, P9554; SPRINGER ME, 1988, INORG CHEM, V27, P165, DOI 10.1021/ic00274a033; STILES MK, 1991, J BIOL CHEM, V266, P8336; SYLVA RN, 1980, J CHEM SOC DALTON, P1577, DOI 10.1039/dt9800001577; Thomas TP, 1997, ARCH BIOCHEM BIOPHYS, V342, P351, DOI 10.1006/abbi.1997.0121; TOEPLITZ BK, 1979, J AM CHEM SOC, V101, P3344, DOI 10.1021/ja00506a035; VOGEL AI, 1961, QUANTITATIVE INORGAN, P415; Wang E, 1998, BIOPHYS J, V75, P1244, DOI 10.1016/S0006-3495(98)74044-5; YUCHI A, 1993, B CHEM SOC JPN, V66, P3377, DOI 10.1246/bcsj.66.3377	46	27	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7071	7079		10.1074/jbc.275.10.7071	http://dx.doi.org/10.1074/jbc.275.10.7071			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702273	hybrid			2022-12-27	WOS:000085809600053
J	Garton, SD; Temple, CA; Dhawan, IK; Barber, MJ; Rajagopalan, KV; Johnson, MK				Garton, SD; Temple, CA; Dhawan, IK; Barber, MJ; Rajagopalan, KV; Johnson, MK			Resonance Raman characterization of biotin sulfoxide reductase - Comparing oxomolybdenum enzymes in the Me2SO reductase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY-ABSORPTION SPECTROSCOPY; NORMAL-COORDINATE ANALYSIS; CRYSTAL-STRUCTURE; RHODOBACTER-SPHAEROIDES; DMSO REDUCTASE; ANGSTROM RESOLUTION; CATALYTIC MECHANISM; SP DENITRIFICANS; SULFITE OXIDASE; ACTIVE-SITE	Resonance Raman spectroscopy has been used to define active site structures for oxidized Mo(VI) and reduced Mo(IV) forms of recombinant Rhodobacter sphaeroides biotin sulfoxide reductase expressed in Escherichia coli. On the basis of O-18/O-16 labeling studies involving water and the alternative substrate dimethyl sulfoxide and the close correspondence to the resonance Raman spectra previously reported for dimethyl sulfoxide reductase (Garton, S. D., Hilton, J., Oku, H., Crouse, B. R., Rajagopalan, K. V., and Johnson, M. K. (1997) J. Am. Chem. Soc. 119, 12906-12916), vibrational modes associated with a terminal oxo ligand and the two molybdopterin dithiolene ligands have been assigned. The results indicate that the enzyme cycles between mono-oxo-Mo(VI) and des-oxo-Mo(VI) forms with both molybdopterin dithiolene ligands remaining coordinated in both redox states. Direct evidence for an oxygen atom transfer mechanism is provided by O-18/O-16 labeling studies, which show that the terminal oxo group at the molybdenum center is exchangeable with water during redox cycling and originates from the substrate in substrate-oxidized samples. Biotin sulfoxide reductase is not reduced by biotin or the nonphysiological products, dimethyl sulfide and trimethylamine, However, product-induced changes in the Mo=O stretching frequency provide direct evidence for a product-associated mono-oxo-Mo(VI) catalytic intermediate. The results indicate that biotin sulfoxide reductase is thermodynamically tuned to catalyze the reductase reaction, and a detailed catalytic mechanism is proposed.	Univ Georgia, Dept Chem, Athens, GA 30602 USA; Univ Georgia, Ctr Metalloenzyme Studies, Athens, GA 30602 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Duke University; State University System of Florida; University of South Florida	Johnson, MK (corresponding author), Univ Georgia, Dept Chem, Athens, GA 30602 USA.				NIGMS NIH HHS [GM 32696, GM 00091] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032696] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams B, 1999, BIOCHEMISTRY-US, V38, P8501, DOI 10.1021/bi9902034; BASTIAN NR, 1991, J BIOL CHEM, V266, P45; Baugh PE, 1997, J BIOL INORG CHEM, V2, P634, DOI 10.1007/s007750050178; Boyington JC, 1997, SCIENCE, V275, P1305, DOI 10.1126/science.275.5304.1305; CLARK RJH, 1978, J CHEM SOC DALTON, P1714, DOI 10.1039/dt9780001714; COLLIN RJ, 1973, J MOL STRUCT, V19, P531; Czjzek M, 1998, J MOL BIOL, V284, P435, DOI 10.1006/jmbi.1998.2156; Dias JM, 1999, STRUCTURE, V7, P65, DOI 10.1016/S0969-2126(99)80010-0; DROZDZEWSKI PM, 1988, APPL SPECTROSC, V42, P1575, DOI 10.1366/0003702884429841; FABIAN H, 1993, VIB SPECTROSC, V4, P125, DOI 10.1016/0924-2031(93)87032-O; Garton SD, 1997, J AM CHEM SOC, V119, P12906, DOI 10.1021/ja972109l; Garton SD, 1997, J AM CHEM SOC, V119, P2590, DOI 10.1021/ja963931c; GARTON SD, 1999, THESIS U GEORGIA ATH; George GN, 1996, J AM CHEM SOC, V118, P1113, DOI 10.1021/ja953317l; George GN, 1999, J AM CHEM SOC, V121, P1256, DOI 10.1021/ja982843k; GRUBER S, 1990, J AM CHEM SOC, V112, P8179, DOI 10.1021/ja00178a059; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; Johnson MK, 1997, J BIOL INORG CHEM, V2, P797, DOI 10.1007/s007750050198; KILPATRICK L, 1995, BIOCHEMISTRY-US, V34, P3032, DOI 10.1021/bi00009a034; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; McAlpine AS, 1997, J BIOL INORG CHEM, V2, P690, DOI 10.1007/s007750050185; McAlpine AS, 1998, J MOL BIOL, V275, P613, DOI 10.1006/jmbi.1997.1513; PIERSON DE, 1990, J BACTERIOL, V172, P2194, DOI 10.1128/jb.172.4.2194-2198.1990; POLLOCK VV, 1995, ARCH BIOCHEM BIOPHYS, V318, P322, DOI 10.1006/abbi.1995.1236; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; SCHINDELIN H, 1996, SCIENCE, V272, P1616; SCHLAPFER CW, 1975, INORG CHEM, V14, P1338, DOI 10.1021/ic50148a028; Schneider F, 1996, J MOL BIOL, V263, P53, DOI 10.1006/jmbi.1996.0555; TEMPLE CA, 2000, IN PRESS BIOCHEMISTR, V39; WILLIS LJ, 1987, SPECTROCHIM ACTA A, V43, P51, DOI 10.1016/0584-8539(87)80198-8	31	37	37	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6798	6805		10.1074/jbc.275.10.6798	http://dx.doi.org/10.1074/jbc.275.10.6798			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702237	hybrid			2022-12-27	WOS:000085809600017
J	Kanzaki, M; Watson, RT; Artemyev, NO; Pessin, JE				Kanzaki, M; Watson, RT; Artemyev, NO; Pessin, JE			The trimeric GTP-binding protein (Gq/G11) alpha subunit is required for insulin-stimulated GLUT4 translocation in 3T3L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; KINASE-B-ALPHA; 3T3-L1 ADIPOCYTES; PLASMA-MEMBRANE; SKELETAL-MUSCLE; PHOSPHOLIPASE-C; RAT ADIPOCYTES; DNA-SYNTHESIS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE)	To investigate the potential role of trimeric GTP-binding proteins regulating GLUT4 translocation in adipocytes, wild type and constitutively active G(q) (G(q)/Q209L), G(i) (G(i)/Q205L), and G(s) (G(s)/Q227L) alpha subunit mutants were expressed in 3T3L1 adipocytes, Although expression of neither the wild type nor G(i)/Q205L and G(s)/Q227L alpha subunit mutants had any effect on the basal or insulin-stimulated translocation of a co-expressed GLUT4-enhanced green fluorescent protein (EGFP) fusion protein, expression of G(q)/Q209L resulted in GLUT4-EGFP translocation in the absence of insulin. In contrast, microinjection of an inhibitory G(q)/G(11) alpha subunit-specific antibody but not a G(i) or G(s) alpha subunit antibody prevented insulin-stimulated endogenous GLUT4 translocation, Consistent with a required role for GTP-bound G(q)/G(11), expression of the regulators of G protein signaling (RGS4 and RGS16) also attenuated insulin-stimulated GLUT4-EGFP translocation. To assess the relationship between G(q)/G(11) function with the phosphatidylinositol 3-kinase dependent pathway, expression of a dominant-interfering p85 regulatory subunit, as well as wortmannin treatment inhibited insulin-stimulated but not G(q)/Q209L-stimulated GLUT4-EGFP translocation, Furthermore, G(q)/Q209L did not induce the in vivo accumulation of phosphatidylinositol-3,4,5-trisphosphate (PIP3), whereas expression of the RGS proteins did not prevent the insulin-stimulated accumulation of PIP3. Together, these data demonstrate that insulin stimulation of GLUT4 translocation requires at least two independent signal transduction pathways, one mediated through the phosphatidylinositol 3-kinase and another through the trimeric GTP-binding proteins G(q) and/or G(11).	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Pessin, JE (corresponding author), Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA.		Kanzaki, Makoto/H-6680-2017	Kanzaki, Makoto/0000-0002-6884-2955; Artemyev, Nikolai/0000-0002-5266-6854	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033823, R01DK033823] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK29525, DK48781, DK33823] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Al-Hasani H, 1998, J BIOL CHEM, V273, P17504, DOI 10.1074/jbc.273.28.17504; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Androsch R, 1996, THERMOCHIM ACTA, V271, P1, DOI 10.1016/0040-6031(95)02594-4; BALDINI G, 1991, J BIOL CHEM, V266, P4037; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Chen D, 1999, MOL CELL BIOL, V19, P4684; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; DRAZNIN B, 1987, J BIOL CHEM, V262, P14385; ELMENDORF JS, 1995, BIOCHEM BIOPH RES CO, V208, P1147, DOI 10.1006/bbrc.1995.1453; Elmendorf JS, 1998, J BIOL CHEM, V273, P13289, DOI 10.1074/jbc.273.21.13289; Fischer Y, 1996, AM J PHYSIOL-CELL PH, V270, pC1211, DOI 10.1152/ajpcell.1996.270.4.C1211; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Han XX, 1998, AM J PHYSIOL-ENDOC M, V274, pE700, DOI 10.1152/ajpendo.1998.274.4.E700; Haruta T, 1998, ENDOCRINOLOGY, V139, P358, DOI 10.1210/en.139.1.358; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Imamura T, 1999, MOL CELL BIOL, V19, P6765; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; JHON DY, 1993, J BIOL CHEM, V268, P6654; KANAI F, 1993, J BIOL CHEM, V268, P14523; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; Kishi K, 1996, J BIOL CHEM, V271, P26561, DOI 10.1074/jbc.271.43.26561; Kishi K, 1998, DIABETES, V47, P550, DOI 10.2337/diabetes.47.4.550; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; KLIP A, 1987, J BIOL CHEM, V262, P9141; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; LAM K, 1994, J BIOL CHEM, V269, P20648; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEE AD, 1995, FEBS LETT, V361, P51, DOI 10.1016/0014-5793(95)00147-2; LEE CW, 1994, J BIOL CHEM, V269, P25335; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; MEINKOTH JL, 1992, J BIOL CHEM, V267, P13239; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; OBERMAIERKUSSER B, 1988, BIOCHEM J, V256, P515, DOI 10.1042/bj2560515; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Olson AL, 1996, ANNU REV NUTR, V16, P235, DOI 10.1146/annurev.nu.16.070196.001315; Omata W, 1997, BIOCHEM BIOPH RES CO, V241, P401, DOI 10.1006/bbrc.1997.7810; OMATSUKANBE M, 1992, FEBS LETT, V314, P246, DOI 10.1016/0014-5793(92)81481-Z; OmatsuKanbe M, 1996, BIOCHEM J, V315, P25, DOI 10.1042/bj3150025; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; RATTIGAN S, 1991, BIOCHIM BIOPHYS ACTA, V1094, P217, DOI 10.1016/0167-4889(91)90012-M; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; SHIBATA H, 1995, J BIOL CHEM, V270, P11489, DOI 10.1074/jbc.270.19.11489; Shimizu Y, 1996, BIOCHEM J, V314, P485, DOI 10.1042/bj3140485; SMITH U, 1984, J BIOL CHEM, V259, P8758; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SMREKA AV, 1993, J BIOL CHEM, V268, P9667; Standaert ML, 1999, J BIOL CHEM, V274, P14074, DOI 10.1074/jbc.274.20.14074; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; Tanishita T, 1997, J BIOCHEM, V122, P90; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; Williams CJ, 1998, DEV BIOL, V198, P116, DOI 10.1006/dbio.1998.8892; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107	82	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7167	7175		10.1074/jbc.275.10.7167	http://dx.doi.org/10.1074/jbc.275.10.7167			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702285	hybrid			2022-12-27	WOS:000085809600065
J	Zhou, YF; Bowie, JU				Zhou, YF; Bowie, JU			Building a thermostable membrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI DIACYLGLYCEROL KINASE; ESCHERICHIA-COLI; HELIX; SOLUBILIZATION; MUTAGENESIS	The poor stability of membrane proteins in detergent solution is one of the main technical barriers to their structural and functional characterization. Here we describe a solution to this problem for diacylglycerol kinase (DGK), an integral membrane protein from Escherichia coli. Twelve enhanced stability mutants of DGK were obtained using a simple screen. Four of the mutations were combined to create a quadruple mutant that had improved stability in a wide range of detergents. In n-octylglucoside, the wild-type DGK had a thermal inactivation half-life of 6 min at 55 degrees C, while the quadruple mutant displayed a half-life of 35 min at 80 degrees C. In addition, the quadruple mutant had improved thermodynamic stability. Our approach should be applicable to other membrane proteins that can be conveniently assayed.	Univ Calif Los Angeles, US DOE, Lab Struct Biol & Mol Med, Dept Chem & Biochem, Los Angeles, CA 90095 USA	United States Department of Energy (DOE); University of California System; University of California Los Angeles	Bowie, JU (corresponding author), Univ Calif Los Angeles, US DOE, Lab Struct Biol & Mol Med, Dept Chem & Biochem, 405 Hilgard Ave, Los Angeles, CA 90095 USA.	bowie@ewald.mbi.ucal.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047485, R01GM059164, R29GM047485] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47485-08, GM59164-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Badola P, 1997, J BIOL CHEM, V272, P24176, DOI 10.1074/jbc.272.39.24176; Booth PJ, 1997, BIOCHEMISTRY-US, V36, P197, DOI 10.1021/bi962200m; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Chen GQ, 1997, PROTEIN ENG, V10, P1061, DOI 10.1093/protein/10.9.1061; CHUANG HYK, 1972, ARCH BIOCHEM BIOPHYS, V152, P502, DOI 10.1016/0003-9861(72)90245-7; Giver L, 1998, P NATL ACAD SCI USA, V95, P12809, DOI 10.1073/pnas.95.22.12809; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; HJELMELAND LM, 1984, METHOD ENZYMOL, V104, P305; Lau FW, 1999, J MOL BIOL, V290, P559, DOI 10.1006/jmbi.1999.2905; Lau FW, 1997, BIOCHEMISTRY-US, V36, P5884, DOI 10.1021/bi963095j; LeCoutre J, 1997, P NATL ACAD SCI USA, V94, P10167, DOI 10.1073/pnas.94.19.10167; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LOOMIS CR, 1985, J BIOL CHEM, V260, P4091; MILLER KJ, 1992, MOL PLANT MICROBE IN, V5, P363, DOI 10.1094/MPMI-5-363; Pace C N, 1986, Methods Enzymol, V131, P266; Sanders CR, 1996, BIOCHEMISTRY-US, V35, P8610, DOI 10.1021/bi9604892; SMITH RL, 1994, J BACTERIOL, V176, P5459, DOI 10.1128/JB.176.17.5459-5465.1994; TOMAZIC SJ, 1988, J BIOL CHEM, V263, P3092; Vinogradova O, 1997, BIOPHYS J, V72, P2688, DOI 10.1016/S0006-3495(97)78912-4; Zhou YF, 1997, NAT STRUCT BIOL, V4, P986, DOI 10.1038/nsb1297-986	20	133	146	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6975	6979		10.1074/jbc.275.10.6975	http://dx.doi.org/10.1074/jbc.275.10.6975			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702260	hybrid			2022-12-27	WOS:000085809600040
J	Barnea, E; Bergman, Y				Barnea, E; Bergman, Y			Synergy of SF1 and RAR in activation of Oct-3/4 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROIDOGENIC FACTOR-I; RETINOIC ACID RECEPTORS; EMBRYONAL CARCINOMA-CELLS; LONG TERMINAL REPEAT; NUCLEAR HORMONE-RECEPTOR; MOLONEY LEUKEMIA-VIRUS; LTR BINDING-PROTEIN; TRANSCRIPTION FACTOR; GENE-EXPRESSION; POU-DOMAIN	The Oct-3/4 transcription factor is expressed in the earliest stages of embryogenesis, and is thus likely to play an important role in regulation of initial decisions in development For the first time, We have shown that SF1 and Oct-3/4 are co-expressed in embryonal carcinoma (EC) P19 cells, and their expression is down-regulated with very similar kinetics following retinoic acid (RA) induced differentiation of these cells, suggesting a functional relationship between the two. Previously, Re have shown that the Oct-3/4 promoter harbors an RA-responsive element, RAREoct, which functions in EC cells as a binding site for positive regulators of transcription, such as RAR and RXR. In this study we have identified in the Oct-3/4 promoter two novel SF1-binding sites: SF1(a) and SF1(b). The proximal site, SF1(a), is located within the RAREoct, and the distal site, SF1(b), is located between nucleotide -193 and -209 of the Oct-3/4 promoter. Both sites contribute to activation of Oct-3/4 promoter in EC cells, with SF1(a) playing a more crucial role. SF1, and its isoforms ELP2 and ELP3 bind to both SF1 sites and activate the Oct-3/4 promoter. This activation depends on the presence of SF1 DNA-binding domain. Thus, Oct-3/4 is the first EC-specific gene reported that is regulated by SF1. Interestingly, SF1 and RAR form a novel complex on the RAREoct sequence that synergistically activate the Oct-3/4 promoter. Both RARE and SF1 cis regulatory elements, as well as the SF1 DNA-binding domain, are needed for this synergism, SF1 and Oct-3/4 transcription factors play a role in the same developmental regulatory cascade.	Hebrew Univ Jerusalem, Hadassah Med Sch, Hubert H Humphrey Ctr Expt Med & Canc Res, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Bergman, Y (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Hubert H Humphrey Ctr Expt Med & Canc Res, POB 12272, IL-91120 Jerusalem, Israel.	yberg@md2.huji.ac.il						Akmal KM, 1997, BIOL REPROD, V56, P549, DOI 10.1095/biolreprod56.2.549; BENSHUSHAN E, 1995, MOL CELL BIOL, V15, P1034; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; Carlone DL, 1997, MOL ENDOCRINOL, V11, P292, DOI 10.1210/me.11.3.292; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; Crawford PA, 1997, MOL CELL BIOL, V17, P3997, DOI 10.1128/MCB.17.7.3997; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; DOLLE P, 1990, DEVELOPMENT, V110, P1133; Dorn C, 1999, J BIOL CHEM, V274, P13870, DOI 10.1074/jbc.274.20.13870; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GOLDSTEIN B, 1990, J CELL PHYSIOL, V143, P205, DOI 10.1002/jcp.1041430202; Halvorson LM, 1999, MOL ENDOCRINOL, V13, P106, DOI 10.1210/me.13.1.106; HAMANN L, 1994, MOL CELL BIOL, V14, P5786, DOI 10.1128/MCB.14.9.5786; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; Imhof A, 1998, CURR BIOL, V8, pR422, DOI 10.1016/S0960-9822(98)70268-4; Ito M, 1998, MOL ENDOCRINOL, V12, P290, DOI 10.1210/me.12.2.290; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KOTOMURA N, 1994, J BIOCHEM-TOKYO, V116, P1309, DOI 10.1093/oxfordjournals.jbchem.a124680; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; LeDrean Y, 1996, MOL ENDOCRINOL, V10, P217, DOI 10.1210/me.10.3.217; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LENARDO MJ, 1989, SCIENCE, V243, P544, DOI 10.1126/science.2536195; LEONE TC, 1995, J BIOL CHEM, V270, P16308, DOI 10.1074/jbc.270.27.16308; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; Liu Z, 1997, MOL ENDOCRINOL, V11, P127, DOI 10.1210/me.11.2.127; LUO XR, 1995, ENDOCR RES, V21, P517, DOI 10.3109/07435809509030469; Mangelsdorf David J., 1994, P319; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MEIER P, 1995, DEV BIOL, V169, P1, DOI 10.1006/dbio.1995.1121; MENDELSOHN C, 1992, DEV BIOL, V152, P50, DOI 10.1016/0012-1606(92)90155-A; Minucci S, 1996, EMBO J, V15, P888, DOI 10.1002/j.1460-2075.1996.tb00423.x; Monte D, 1998, J BIOL CHEM, V273, P4585, DOI 10.1074/jbc.273.8.4585; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; NINOMIYA Y, 1995, J BIOCHEM-TOKYO, V118, P380, DOI 10.1093/oxfordjournals.jbchem.a124918; OHNO CK, 1994, MOL CELL BIOL, V14, P3166, DOI 10.1128/MCB.14.5.3166; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; OKAZAWA H, 1991, EMBO J, V10, P2997, DOI 10.1002/j.1460-2075.1991.tb07850.x; PALMIERI SL, 1994, DEV BIOL, V166, P259, DOI 10.1006/dbio.1994.1312; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Pesce M, 1998, MECH DEVELOP, V71, P89, DOI 10.1016/S0925-4773(98)00002-1; PIKARSKY E, 1994, MOL CELL BIOL, V14, P1026, DOI 10.1128/MCB.14.2.1026; RICE DA, 1991, MOL ENDOCRINOL, V5, P1552, DOI 10.1210/mend-5-10-1552; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SCHOORLEMMER J, 1994, MOL CELL BIOL, V14, P1122, DOI 10.1128/MCB.14.2.1122; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; Sugawara T, 1996, BIOCHEMISTRY-US, V35, P9052, DOI 10.1021/bi960057r; SYLVESTER I, 1994, NUCLEIC ACIDS RES, V22, P901, DOI 10.1093/nar/22.6.901; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TAKAYAMA K, 1994, J BIOCHEM-TOKYO, V116, P193, DOI 10.1093/oxfordjournals.jbchem.a124493; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; Tremblay JJ, 1999, MOL CELL BIOL, V19, P2567; TSUKIYAMA T, 1989, MOL CELL BIOL, V9, P4670, DOI 10.1128/MCB.9.11.4670; TSUKIYAMA T, 1992, NUCLEIC ACIDS RES, V20, P1477, DOI 10.1093/nar/20.7.1477; TSUKIYAMA T, 1992, MOL CELL BIOL, V12, P1286, DOI 10.1128/MCB.12.3.1286; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; UEDA H, 1991, NUCLEIC ACIDS RES, V19, P3689, DOI 10.1093/nar/19.13.3689; UEDA H, 1990, GENE DEV, V4, P624, DOI 10.1101/gad.4.4.624; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; Wiebel FF, 1997, MOL CELL BIOL, V17, P3977, DOI 10.1128/MCB.17.7.3977; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; Woodson KG, 1997, MOL ENDOCRINOL, V11, P117, DOI 10.1210/me.11.2.117; YOUNG Y, 1996, DEVELOPMENT, V122, P881; Yu RN, 1998, MOL ENDOCRINOL, V12, P1010, DOI 10.1210/me.12.7.1010; Zeitoun K, 1999, MOL ENDOCRINOL, V13, P239, DOI 10.1210/me.13.2.239; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; Zhang PL, 1996, MOL ENDOCRINOL, V10, P147, DOI 10.1210/me.10.2.147; ZHANG PL, 1995, MOL ENDOCRINOL, V9, P1571, DOI 10.1210/me.9.11.1571	91	68	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6608	6619		10.1074/jbc.275.9.6608	http://dx.doi.org/10.1074/jbc.275.9.6608			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692469	hybrid			2022-12-27	WOS:000085654400081
J	Heydorn, A; Petersen, BO; Duus, JO; Bergmann, S; Suhr-Jessen, T; Nielsen, J				Heydorn, A; Petersen, BO; Duus, JO; Bergmann, S; Suhr-Jessen, T; Nielsen, J			Biosynthetic studies of the glycopeptide teicoplanin by H-1 and C-13 NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEICHOMYCETICUS-NOV-SP; ANTIBIOTICS; VANCOMYCIN	The biosynthesis of the glycopeptide antibiotic teicoplanin was studied by growing a teicoplanin producing strain of Actinoplanes teichomyceticus (ATCC 31121) on glucose containing either 34.0% [1-C-13]glucose or 9.7% [U-C-13]glucose. The fractional enrichment pattern of teicoplanin produced in the medium containing [1-C-13]glucose was obtained from a one-dimensional C-13 spectrum. The enrichment pattern showed characteristic peaks indicating that amino acids 3 and 7 are derived from acetate, whereas amino acids 1, 2, 4, 5, and 6 are derived from tyrosine, Multiplet structures in heteronuclear single quantum coherence spectra of teicoplanin produced in the medium containing [U-C-13]glucose showed characteristic coupling patterns supporting these results. Fractional enrichment patterns and multiplet structures of the three sugars in teicoplanin showed that about 50% of the sugars have the same labeling pattern as the glucose substrate whereas the rest have a labeling pattern showing that they are reassembled, probably from precursors in the primary metabolism.	Tech Univ Denmark, Dept Biotechnol, Ctr Proc Biotechnol, DK-2800 Lyngby, Denmark; Carlsberg Lab, Dept Chem, DK-2500 Copenhagen, Denmark; Alpharma, DK-2300 Copenhagen, Denmark	Technical University of Denmark	Nielsen, J (corresponding author), Tech Univ Denmark, Dept Biotechnol, Ctr Proc Biotechnol, Block 223, DK-2800 Lyngby, Denmark.	jn@ibt.dtu.dk	Duus, Jens Øllgaard/N-4279-2013; Nielsen, Jens/Q-1347-2017	Duus, Jens Øllgaard/0000-0003-3625-1250; Nielsen, Jens/0000-0002-9955-6003				BOCK K, 1982, ANNU REP NMR SPECTRO, V13, P1; BROGDEN RN, 1994, DRUGS, V47, P823, DOI 10.2165/00003495-199447050-00008; CHUNG SK, 1986, J ANTIBIOT, V39, P642, DOI 10.7164/antibiotics.39.642; Gasper MP, 1996, ANAL CHEM, V68, P2501, DOI 10.1021/ac960154q; HAMMOND SJ, 1982, J CHEM SOC CHEM COMM, P344, DOI 10.1039/c39820000344; HAMMOND SJ, 1983, J CHEM SOC CHEM COMM, P116, DOI 10.1039/c39830000116; HOSODA J, 1977, AGR BIOL CHEM TOKYO, V41, P2007, DOI 10.1080/00021369.1977.10862798; KRIVDIN LB, 1989, PROG NUCL MAG RES SP, V21, P293, DOI 10.1016/0079-6565(89)80007-X; LANCINI G, 1997, BIOTECHNOLOGY PRODUC, P371; MALABARBA A, 1986, J ANTIBIOT, V39, P1430, DOI 10.7164/antibiotics.39.1430; MCGAHREN WJ, 1980, J AM CHEM SOC, V102, P1671, DOI 10.1021/ja00525a036; PARENTI F, 1978, J ANTIBIOT, V31, P276, DOI 10.7164/antibiotics.31.276; Pelzer S, 1999, ANTIMICROB AGENTS CH, V43, P1565, DOI 10.1128/AAC.43.7.1565; REYNOLDS PE, 1989, EUR J CLIN MICROBIOL, V8, P943, DOI 10.1007/BF01967563; Schmidt K, 1999, METAB ENG, V1, P166, DOI 10.1006/mben.1999.0114; Solenberg PJ, 1997, CHEM BIOL, V4, P195, DOI 10.1016/S1074-5521(97)90288-X; SZYPERSKI T, 1995, EUR J BIOCHEM, V232, P433, DOI 10.1111/j.1432-1033.1995.433zz.x; van Wageningen AMA, 1998, CHEM BIOL, V5, P155, DOI 10.1016/S1074-5521(98)90060-6	18	7	8	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6201	6206		10.1074/jbc.275.9.6201	http://dx.doi.org/10.1074/jbc.275.9.6201			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692413	hybrid			2022-12-27	WOS:000085654400025
J	Pfeiffer, S; Schmidt, K; Mayer, B				Pfeiffer, S; Schmidt, K; Mayer, B			Dityrosine formation outcompetes tyrosine nitration at low steady-state concentrations of peroxynitrite - Implications for tyrosine modification by nitric oxide/superoxide in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED HUMAN-NEUTROPHILS; HYDROGEN PEROXIDE SYSTEM; REACTIVE NITROGEN; CARBON-DIOXIDE; NITROTYROSINE FORMATION; CATALYZED OXIDATION; PROTEIN OXIDATION; OXIDE; SUPEROXIDE; OXYGEN	Formation of peroxynitrite from NO and O-2(.) is considered an important trigger for cellular tyrosine nitration under pathophysiological conditions. However, this view has been questioned by a recent report indicating that NO and O-2(radical anion) generated simultaneously from (Z)-1-{N-[3-aminopropyl]-N-[4-(3-aminopropylammonio)butyl]-amino}diazen-1-ium-1,2-diolate] (SPER/NO) and hypoxanthine/xanthine oxidase, respectively, exhibit much lower nitrating efficiency than authentic peroxynitrite (Pfeiffer, S. and Mayer, B. (1998) J. Biol. Chem, 273, 27280-27285), The present study extends those earlier findings to several alternative NO/O-2(radical anion)-generating systems and provides evidence that the apparent lack of tyrosine nitration by NO/O-2(radical anion) is due to a pronounced decrease of nitration efficiency at low steady-state concentrations of authentic peroxynitrite. The decrease in the yields of 3-nitrotyrosine was accompanied by an increase in the recovery of dityrosine, showing that dimerization of tyrosine radicals outcompetes the nitration reaction at low peroxynitrite concentrations. The observed inverse dependence on peroxynitrite concentration of dityrosine formation and tyrosine nitration is predicted by a kinetic model assuming that radical formation by peroxynitrous acid homolysis results in the generation of tyrosyl radicals that either dimerize to yield dityrosine or combine with (NO2)-N-. radical to form 3-nitrotyrosine. The present results demonstrate that very high fluxes (>2 mu M/s) of NO/O-2(radical anion) are required to render peroxynitrite an efficient trigger of tyrosine nitration and that dityrosine is a major product of tyrosine modification caused by low steady-state concentrations of peroxynitrite.	Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, A-8010 Graz, Austria	University of Graz	Pfeiffer, S (corresponding author), Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, Univ Pl 2, A-8010 Graz, Austria.		Mayer, Bernd/B-9391-2008	Mayer, Bernd/0000-0002-2921-3494				AMADO R, 1984, METHOD ENZYMOL, V107, P377; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bray RC., 1975, ENZYMES, V12, P299, DOI DOI 10.1016/S1874-6047(08)60229-2; Brovkovych V, 1997, J PHYSIOL PHARMACOL, V48, P633; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; Coddington JW, 1999, J AM CHEM SOC, V121, P2438, DOI 10.1021/ja982887t; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; Estevez AG, 1998, PROG BRAIN RES, V118, P269; Ferdinandy P, 1999, AM J PHYSIOL-HEART C, V276, pH1861, DOI 10.1152/ajpheart.1999.276.6.H1861; FRIDOVICH L, 1985, CRC HDB METHODS OXYG, P51; Fu S, 1998, BIOCHEM J, V333, P519, DOI 10.1042/bj3330519; Fu SL, 1998, J BIOL CHEM, V273, P28603, DOI 10.1074/jbc.273.44.28603; Gow A, 1996, ARCH BIOCHEM BIOPHYS, V333, P42, DOI 10.1006/abbi.1996.0362; Gunther MR, 1997, J BIOL CHEM, V272, P17086, DOI 10.1074/jbc.272.27.17086; Halliwell B, 1997, FEBS LETT, V411, P157, DOI 10.1016/S0014-5793(97)00469-9; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; Hensley K, 1998, J NEUROSCI, V18, P8126; HUNTER EPL, 1989, FREE RADICAL BIO MED, V6, P581, DOI 10.1016/0891-5849(89)90064-6; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; ISCHIROPOULOS H, 1995, FEBS LETT, V364, P279, DOI 10.1016/0014-5793(95)00307-U; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; Jacob JS, 1996, J BIOL CHEM, V271, P19950, DOI 10.1074/jbc.271.33.19950; Kato Y, 1998, FEBS LETT, V439, P231, DOI 10.1016/S0014-5793(98)01372-6; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; Koppenol WH, 1998, FREE RADICAL BIO MED, V25, P385, DOI 10.1016/S0891-5849(98)00093-8; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; Lemercier JN, 1997, ARCH BIOCHEM BIOPHYS, V345, P160, DOI 10.1006/abbi.1997.0240; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; Lymar SV, 1998, INORG CHEM, V37, P294, DOI 10.1021/ic970946i; Mahler H.R., 1963, ENZYMES, V8, P285; MALINSKI T, 1993, J CEREBR BLOOD F MET, V13, P355, DOI 10.1038/jcbfm.1993.48; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; McBride AG, 1997, FEBS LETT, V417, P231, DOI 10.1016/S0014-5793(97)01284-2; McCormick ML, 1998, J BIOL CHEM, V273, P32030, DOI 10.1074/jbc.273.48.32030; Merenyi G, 1999, J PHYS CHEM A, V103, P5685, DOI 10.1021/jp984686h; Merenyi G, 1998, CHEM RES TOXICOL, V11, P243, DOI 10.1021/tx980026s; Merenyi G, 1998, CHEM RES TOXICOL, V11, P712, DOI 10.1021/tx980043h; MISRA HP, 1972, J BIOL CHEM, V247, P188; Nakao LS, 1999, CHEM RES TOXICOL, V12, P1010, DOI 10.1021/tx990055i; Pfeiffer S, 1997, J BIOL CHEM, V272, P3465, DOI 10.1074/jbc.272.6.3465; Pfeiffer S, 1997, FREE RADICAL BIO MED, V22, P787, DOI 10.1016/S0891-5849(96)00407-8; Pfeiffer S, 1998, J BIOL CHEM, V273, P27280, DOI 10.1074/jbc.273.42.27280; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; SCHMIDT K, 1997, NITRIC OXIDE PROTOCO, V100, P101; Shigenaga MK, 1997, P NATL ACAD SCI USA, V94, P3211, DOI 10.1073/pnas.94.7.3211; Skinner KA, 1997, ARCH BIOCHEM BIOPHYS, V342, P282, DOI 10.1006/abbi.1997.0114; TINGBEALL HP, 1993, BLOOD, V81, P2774; TSAI JHM, 1994, J AM CHEM SOC, V116, P4115, DOI 10.1021/ja00088a072; Uppu RM, 1997, CHEM RES TOXICOL, V10, P1331, DOI 10.1021/tx970056f; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; VANDERVLIET A, 1994, FEBS LETT, V339, P89, DOI 10.1016/0014-5793(94)80391-9; VasquezVivar J, 1996, BIOCHEM J, V314, P869, DOI 10.1042/bj3140869; Wang JP, 1998, BRIT J PHARMACOL, V125, P517, DOI 10.1038/sj.bjp.0702106; WONG K, 1985, INFLAMMATION, V9, P407, DOI 10.1007/BF00916340; Wu WJ, 1999, J BIOL CHEM, V274, P25933, DOI 10.1074/jbc.274.36.25933; Yasmin W, 1997, CARDIOVASC RES, V33, P422, DOI 10.1016/S0008-6363(96)00254-4; ZHANG ZG, 1995, J NEUROL SCI, V128, P22, DOI 10.1016/0022-510X(94)00216-B	64	141	146	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6346	6352		10.1074/jbc.275.9.6346	http://dx.doi.org/10.1074/jbc.275.9.6346			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692434	hybrid			2022-12-27	WOS:000085654400046
J	Pitt, JJ; Da Silva, E; Gorman, JJ				Pitt, JJ; Da Silva, E; Gorman, JJ			Determination of the disulfide bond arrangement of Newcastle disease virus hemagglutinin neuraminidase - Correlation with a beta-sheet propeller structural fold predicted for Paramyxoviridae attachment proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LASER-DESORPTION-IONIZATION; TIME-OF-FLIGHT; INFLUENZA-VIRUS; MASS-SPECTROMETRY; SENDAI VIRUS; 3-DIMENSIONAL STRUCTURE; ANTIPEPTIDE ANTIBODIES; NUCLEOTIDE-SEQUENCE; STRUCTURE ALIGNMENT; 2.2-A RESOLUTION	Disulfide bonds stabilize the structure and functions of the hemagglutinin neuraminidase attachment glycoprotein (HN) of Newcastle disease virus. Until this study, the disulfide linkages of this HN and structurally similar attachment proteins of other members of the paramyxoviridae family were undefined. To define these linkages, disulfide-linked peptides were produced by peptic digestion of purified HN ectodomains of the Queensland strain of Newcastle disease virus, isolated by reverse phase high performance liquid chromatography, and analyzed by mass spectrometry. Analysis of peptides containing a single disulfide bond revealed Cys(531)-Cys(542) and Cys(172)-Cys(196) linkages and that HN ectodomains dimerize via Cys(123), Another peptide, with a chain containing Cys(186) linked to a chain containing Cys(238), Cys(247), and Cys(251), was cleaved at Met(249) with cyanogen bromide. Subsequent tandem mass spectrometry established Cys(186)-Cys(247) and Cys(238)-Cys(251) linkages. A glycopeptide with a chain containing Cys(344) linked to a chain containing Cys(455), Cys(461), and Cys(465) was treated sequentially with peptide-N-glycosidase F and trypsin. Further treatment of this peptide by one round of manual Edman degradation or tandem mass spectrometry established Cys(344)-Cys(461) and Cys(455) Cys(465) linkages, These data, establishing the disulfide linkages of all thirteen cysteines of this protein, are consistent with published predictions that the paramyxoviridae HN forms a beta-propeller structural fold.	Biomol Res Inst, Parkville, Vic 3052, Australia		Gorman, JJ (corresponding author), Biomol Res Inst, 343 Royal Parade, Parkville, Vic 3052, Australia.							BAKER AT, 1987, PROTEINS, V2, P111, DOI 10.1002/prot.340020205; BEAN MF, 1992, ANAL BIOCHEM, V201, P216, DOI 10.1016/0003-2697(92)90331-Z; BERTHIAU.L, 1974, ARCH GES VIRUSFORSCH, V45, P39, DOI 10.1007/BF01240540; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; BLUMBERG B, 1985, CELL, V41, P269, DOI 10.1016/0092-8674(85)90080-7; BURMEISTER WP, 1992, EMBO J, V11, P49, DOI 10.1002/j.1460-2075.1992.tb05026.x; COLLINS PL, 1991, J VIROL, V65, P2362, DOI 10.1128/JVI.65.5.2362-2371.1991; COLMAN PM, 1983, NATURE, V303, P41, DOI 10.1038/303041a0; COLMAN PM, 1993, J VIROL, V67, P2972, DOI 10.1128/JVI.67.6.2972-2980.1993; COLMAN PM, 1989, INFLUENZA VIRUSES, P175; DENG RT, 1994, VIROLOGY, V204, P17, DOI 10.1006/viro.1994.1506; DENG RT, 1995, VIROLOGY, V209, P457, DOI 10.1006/viro.1995.1278; Emmerson P. T., 1994, ENCY VIROLOGY, P914; Epa VC, 1997, PROTEINS, V29, P264, DOI 10.1002/(SICI)1097-0134(199711)29:3<264::AID-PROT2>3.0.CO;2-B; GORMAN JJ, 1988, J BIOL CHEM, V263, P12522; Gorman JJ, 1996, RAPID COMMUN MASS SP, V10, P529, DOI 10.1002/(SICI)1097-0231(19960331)10:5<529::AID-RCM522>3.0.CO;2-9; Gorman JJ, 1997, PROTEIN SCI, V6, P1308, DOI 10.1002/pro.5560060619; HIEBERT SW, 1985, J VIROL, V54, P1; HODDER AN, 1994, AVIAN DIS, V38, P103, DOI 10.2307/1591843; HODDER AN, 1993, J GEN VIROL, V74, P1081, DOI 10.1099/0022-1317-74-6-1081; IORIO RM, 1992, J GEN VIROL, V73, P1167, DOI 10.1099/0022-1317-73-5-1167; JORGENSEN ED, 1987, VIROLOGY, V156, P12, DOI 10.1016/0042-6822(87)90431-4; KATTA V, 1995, P ASMS C MASS SPECTR, V43, P1277; KINGSBURY DW, 1978, INTERVIROLOGY, V10, P137, DOI 10.1159/000148979; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamb R.A., 1989, INFLUENZA VIRUSES, P1; Lamb Robert A., 1996, P577; Langedijk JPM, 1997, J VIROL, V71, P6155, DOI 10.1128/JVI.71.8.6155-6167.1997; LING R, 1989, J GEN VIROL, V70, P1441, DOI 10.1099/0022-1317-70-6-1441; MARKWELL MAK, 1991, PARAMYXOVIRUSES, P407; MCINNES LW, 1994, VIROLOGY, V200, P470; MCINNES LW, 1997, J VIROL, V71, P3083; MIRZA AM, 1993, J BIOL CHEM, V268, P21425; MIURA N, 1985, FEBS LETT, V188, P112, DOI 10.1016/0014-5793(85)80885-1; MORRISON T, 1991, J VIROL, V65, P813, DOI 10.1128/JVI.65.2.813-822.1991; MORRISON T, 1991, PARAMYXOVIRUSES, P347; MORRISON TG, 1988, VIRUS RES, V10, P113, DOI 10.1016/0168-1702(88)90010-X; NG DTW, 1989, J CELL BIOL, V109, P3273, DOI 10.1083/jcb.109.6.3273; RICHMAN AV, 1971, APPL MICROBIOL, V21, P1099, DOI 10.1128/AEM.21.6.1099-1100.1971; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; ROUSE JC, 1995, J AM SOC MASS SPECTR, V6, P822, DOI 10.1016/1044-0305(95)00325-8; SAKAGUCHI T, 1989, VIROLOGY, V169, P260, DOI 10.1016/0042-6822(89)90151-7; SHEEHAN JP, 1987, VIROLOGY, V161, P603, DOI 10.1016/0042-6822(87)90158-9; Smyth DG., 1967, METHOD ENZYMOL, V11, P214; SUCKAN D, 1996, P ASMS C MASS SPECTR, V44, P1339; SULLENDER WM, 1991, PARAMYXOVIRUSES, P383; THOMPSON SD, 1988, J VIROL, V62, P4653, DOI 10.1128/JVI.62.12.4653-4660.1988; TULIP WR, 1991, J MOL BIOL, V221, P487, DOI 10.1016/0022-2836(91)80069-7; VARGHESE JN, 1991, J MOL BIOL, V221, P473, DOI 10.1016/0022-2836(91)80068-6; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; Wharton SA, 1989, INFLUENZA VIRUSES, P153; YAZDANPARAST R, 1987, J BIOL CHEM, V262, P2507; YAZDANPARAST R, 1986, ANAL BIOCHEM, V153, P348, DOI 10.1016/0003-2697(86)90102-8	54	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6469	6478		10.1074/jbc.275.9.6469	http://dx.doi.org/10.1074/jbc.275.9.6469			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692451	hybrid			2022-12-27	WOS:000085654400063
J	Schang, LM; Hwang, GJH; Dynlacht, BD; Speicher, DW; Bantly, A; Schaffer, PA; Shilatifard, A; Ge, H; Shiekhattar, R				Schang, LM; Hwang, GJH; Dynlacht, BD; Speicher, DW; Bantly, A; Schaffer, PA; Shilatifard, A; Ge, H; Shiekhattar, R			Human PC4 is a substrate-specific inhibitor of RNA polymerase II phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK-ACTIVATING KINASE; C-TERMINAL DOMAIN; TRANSCRIPTION FACTOR TFIIH; CYCLIN-DEPENDENT KINASES; PROTEIN-KINASE; CATALYTIC SUBUNIT; COACTIVATOR PC4; DNA; REPAIR; SUPPRESSION	The activity of cyclin-dependent protein kinases (cdks) is physiologically regulated by phosphorylation, association with the specific cyclin subunits, and repression by specific cdh. inhibitors. All three physiological regulatory mechanisms are specific for one or more cdks, but none is known to be substrate specific. In contrast, synthetic cdk peptide inhibitors that specifically inhibit cdk phosphorylation of only some substrates, "aptamers," have been described, Here, we show that PC4, a naturally occurring transcriptional coactivator, competitively inhibits cdk-1, -2, and -7-mediated phosphorylation of the largest subunit of RNA polymerase I (RNAPII), but it does not inhibit phosphorylation of other substrates of the same kinases, Interestingly, the phosphorylated form of PC4 is devoid of kinase inhibitory activity. We also show that wild-type PC4 but not the kinase inhibitory-deficient mutant of PC4 represses transcription in vivo. Our results point to a novel role for PC4 as a specific inhibitor of RNAPII phosphorylation.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA; NICHD, Mol Embryol Lab, NIH, Bethesda, MD 20892 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02558 USA; St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA	The Wistar Institute; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Harvard University; Saint Louis University	Shiekhattar, R (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	shiekhattar@wistar.upenn.edu	Schang, Luis/F-9576-2012	Schang, Luis Maria/0000-0002-5789-8590				BALLARD DW, 1988, J BIOL CHEM, V263, P8450; Bochar DA, 1999, J BIOL CHEM, V274, P13162, DOI 10.1074/jbc.274.19.13162; Brandsen J, 1997, NAT STRUCT BIOL, V4, P900, DOI 10.1038/nsb1197-900; Cohen BA, 1998, P NATL ACAD SCI USA, V95, P14272, DOI 10.1073/pnas.95.24.14272; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; Fisher RP, 1997, CURR OPIN GENET DEV, V7, P32, DOI 10.1016/S0959-437X(97)80106-2; GE H, 1994, P NATL ACAD SCI USA, V91, P12691, DOI 10.1073/pnas.91.26.12691; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; Jordan R, 1999, J VIROL, V73, P8843, DOI 10.1128/JVI.73.10.8843-8847.1999; KAM A, 1994, SCIENCE, V264, P436; Kannan F, 1999, MOL CELL BIOL, V19, P899; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Malik S, 1998, P NATL ACAD SCI USA, V95, P2192, DOI 10.1073/pnas.95.5.2192; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Pan ZQ, 1996, J BIOL CHEM, V271, P22111, DOI 10.1074/jbc.271.36.22111; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Werten S, 1999, J BIOL CHEM, V274, P3693, DOI 10.1074/jbc.274.6.3693; Werten S, 1998, EMBO J, V17, P5103, DOI 10.1093/emboj/17.17.5103; Werten S, 1998, J MOL BIOL, V276, P367, DOI 10.1006/jmbi.1997.1534	38	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6071	6074		10.1074/jbc.275.9.6071	http://dx.doi.org/10.1074/jbc.275.9.6071			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692395	hybrid			2022-12-27	WOS:000085654400007
J	Lu-Kuo, JM; Fruman, DA; Joyal, DM; Cantley, LC; Katz, HR				Lu-Kuo, JM; Fruman, DA; Joyal, DM; Cantley, LC; Katz, HR			Impaired Kit- but not Fc epsilon RI-initiated mast cell activation in the absence of phosphoinositide 3-kinase p85 alpha gene products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY IGE RECEPTOR; BRUTONS TYROSINE KINASE; CYTOSOLIC PHOSPHOLIPASE A(2); PLECKSTRIN HOMOLOGY DOMAINS; ONCOGENE C-KIT; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE; GROWTH-FACTOR; HEMATOPOIETIC-CELLS; SIGNAL-TRANSDUCTION	The class I-A phosphoinositide 8-kinases (PI3Ks) consist of a 110-kDa catalytic domain and a regulatory subunit encoded by the p85 alpha, p85 beta, or p55 gamma genes. We have determined the effects of disrupting the p85 alpha gene on the responses of mast cells stimulated by the cross-linking of Kit and Fc epsilon RI, receptors that reflect innate and adaptive responses, respectively. The absence of p85 alpha gene products partially inhibited Kit ligand/stem cell factor-induced secretory granule exocytosis, proliferation, and phosphorylation of the serine/threonine kinase Akt. In contrast, p85 alpha gene products were not required for Fc epsilon RI-initiated exocytosis and phosphorylation of Akt. LY294002, which inhibits all classes of PI3Ks, strongly suppressed Kit- and Fc epsilon RI-induced responses in p85 alpha -/- mast cells, revealing the contribution of another PI3K family member(s). In contrast to B lymphocytes, mast cell proliferation was not dependent on Bruton's tyrosine kinase, a downstream effector of PI3K, revealing a distinct pathway of PI3K-dependent proliferation in mast cells. Our findings represent the first example of receptor-specific usage of different PI3K family members in a single cell type. In addition, because Kit- but not Fc epsilon RI-initiated signaling is associated with mast cell proliferation, the results provide evidence that distinct biologic functions signaled by these two receptors may reflect differential usage of PI3Ks.	Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Katz, HR (corresponding author), Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Smith Bldg,6th Floor,1 Jimmy Fund Way, Boston, MA 02115 USA.	hrkatz@mbcrr.harvard.edu	Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041144, U01AI031599, U19AI031599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36110] Funding Source: Medline; NIAID NIH HHS [AI41144, AI31599] Funding Source: Medline; NIGMS NIH HHS [R01 GM041890] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BARKER SA, 1995, MOL BIOL CELL, V6, P1145, DOI 10.1091/mbc.6.9.1145; BECK D, 1995, BLOOD, V86, P3132, DOI 10.1182/blood.V86.8.3132.bloodjournal8683132; BERNSTEIN A, 1990, CIBA F SYMP, V148, P158; BESMER P, 1997, COLONY STIMULATING F, P369; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BISCHOFF SC, 1992, J EXP MED, V175, P237, DOI 10.1084/jem.175.1.237; Brorson K, 1997, J IMMUNOL, V159, P135; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COLUMBO M, 1992, J IMMUNOL, V149, P599; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fruman DA, 1996, GENOMICS, V37, P113, DOI 10.1006/geno.1996.0527; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Galli SJ, 1997, INT ARCH ALLERGY IMM, V113, P14, DOI 10.1159/000237497; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; HAMANN K, 1995, BRIT J DERMATOL, V133, P203, DOI 10.1111/j.1365-2133.1995.tb02616.x; Hata D, 1998, J EXP MED, V187, P1235, DOI 10.1084/jem.187.8.1235; HEINRICH MC, 1993, BLOOD, V82, P771, DOI 10.1182/blood.V82.3.771.bloodjournal823771; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Huber M, 1998, EMBO J, V17, P7311, DOI 10.1093/emboj/17.24.7311; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; IRANI AMA, 1992, BLOOD, V80, P3009; Ishizuka T, 1999, J IMMUNOL, V162, P2087; Joseph M, 1997, EUR J IMMUNOL, V27, P2212, DOI 10.1002/eji.1830270914; Jouvin M H, 1995, Semin Immunol, V7, P29, DOI 10.1016/1044-5323(95)90005-5; Kinashi T, 1999, J IMMUNOL, V162, P2850; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; KITAMURA Y, 1978, BLOOD, V52, P447; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; Lu-Kuo JM, 1999, J BIOL CHEM, V274, P5791, DOI 10.1074/jbc.274.9.5791; Marquardt DL, 1996, J IMMUNOL, V156, P1942; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Maurer D, 1996, J IMMUNOL, V157, P607; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; MURAKAMI M, 1995, J EXP MED, V182, P197, DOI 10.1084/jem.182.1.197; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; Patella V, 1998, CIRCULATION, V97, P971; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RA C, 1989, J BIOL CHEM, V264, P15323; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Rodewald HR, 1996, SCIENCE, V271, P818, DOI 10.1126/science.271.5250.818; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SERVE H, 1994, J BIOL CHEM, V269, P6026; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; TURNER AM, 1992, BLOOD, V80, P374; VANHAESEBROECK B, 1997, TRENDS BIOCHEM SCI, V22, P17209; Vosseller K, 1997, MOL BIOL CELL, V8, P909, DOI 10.1091/mbc.8.5.909; Wang QH, 1999, MOL CELL BIOL, V19, P4008; WEISS RR, 1995, J INVEST DERMATOL, V104, P101, DOI 10.1111/1523-1747.ep12613587; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404; YANO H, 1995, BIOCHEM J, V312, P145, DOI 10.1042/bj3120145; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIEGLER I, 1993, J BIOL CHEM, V268, P12544	80	74	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					6022	6029		10.1074/jbc.275.8.6022	http://dx.doi.org/10.1074/jbc.275.8.6022			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681597	hybrid			2022-12-27	WOS:000085474500104
J	Seyfang, A; Landfear, SM				Seyfang, A; Landfear, SM			Four conserved cytoplasmic sequence motifs are important for transport function of the Leishmania inositol/H+ symporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-TETRACYCLINE/H+ ANTIPORTER; GLUCOSE TRANSPORTERS; LACTOSE PERMEASE; ESCHERICHIA-COLI; 2 HALVES; EXPRESSION; COTRANSPORTER; DONOVANI; CLONING; GENES	The protozoan Leishmania donovani has amyo-inositol/proton symporter (MIT) that is a member of a large sugar transporter superfamily. Active transport by MIT is driven by the proton electrochemical gradient across the parasite membrane, and MIT is a prototype for understanding the function of an active transporter in lower eukaryotes. MIT contains two duplicated 6- or 7-amino acid motifs within cytoplasmic loops, which are highly conserved among 50 members of the sugar transporter superfamily and are designated A(1), A(2) ((V)(D/E)(R/K)Phi GR(WK)), and B-1 (PESPR Phi L), B-2 (VPETKG). In particular, the three acidic residues within these motifs, Glu(187)(B-1), Asp(300)(A(2)), and Glu(429)(B-2) in MIT, are highly conserved with 96, 78, and 96% amino acid identity within the analyzed members of this transporter superfamily ranging from bacteria, archaea, and fungi to plants and the animal kingdom. We have used site-directed mutagenesis in combination with functional expression of transporter mutants in Xenopus oocytes and overexpression in Leishmania transfectants to investigate the significance of these three acidic residues in the B-1, A(2) and B-2 motifs, Alteration to the uncharged amides greatly reduced MIT transport function to 23% (E187Q), 1.4% (D300N), and 3% (E429Q) of wild-type activity, respectively, by affecting V-max but not substrate affinity, Conservative mutations that retained the charge revealed a less pronounced effect on inositol transport with 39% (E187D), 16% (D300E) and 20% (E429D) remaining transport activity. Immunofluorescence microscopy of oocyte cryosections confirmed that MIT mutants were expressed on the oocyte surface in similar quantity to MIT wild type. The proton uncouplers carbonylcyanide-4-(trifluoromethoxy) phenylhydrazone and dinitrophenol inhibited inositol transport by 50-70% in the wild type as web as in E187Q, D300N, and E429Q, despite their reduced transport activities, suggesting that transport in these mutants is still proton-coupled. Furthermore, temperature-dependent uptake studies showed an increased Arrhenius activation energy for the B-1-E187Q and the B-2-E429Q mutants, which supports the idea of an impaired transporter cycle in these mutants, We conclude that the conserved acidic residues Glu(187), Asp(300), and Glu(429) are critical for transport function of MIT.	Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Sch Med, Portland, OR 97201 USA	Oregon Health & Science University	Seyfang, A (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.	aseyfang@mail.mcg.edu	Seyfang, Andreas/H-2445-2012	Seyfang, Andreas/0000-0001-6231-9955	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025920] Funding Source: NIH RePORTER; NIAID NIH HHS [AI25920, AI01162] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; Barrett MP, 1998, MOL BIOCHEM PARASIT, V91, P195, DOI 10.1016/S0166-6851(97)00192-8; Burchmore RJS, 1998, J BIOL CHEM, V273, P29118, DOI 10.1074/jbc.273.44.29118; CHANG CS, 1986, P NATL ACAD SCI USA, V83, P100, DOI 10.1073/pnas.83.1.100; Danielson MA, 1997, J BIOL CHEM, V272, P32878, DOI 10.1074/jbc.272.52.32878; DEGORGOLAS M, 1994, NATURE, V372, P734, DOI 10.1038/372734b0; DREW ME, 1995, MOL CELL BIOL, V15, P5508; GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; Henderson PJF, 1991, CURR OPIN STRUC BIOL, V1, P590, DOI 10.1016/S0959-440X(05)80082-X; HUTCHISON CA, 1991, METHOD ENZYMOL, V202, P356; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; JESSENMARSHALL AE, 1995, J BIOL CHEM, V270, P16251, DOI 10.1074/jbc.270.27.16251; JessenMarshall AE, 1996, J BIOL CHEM, V271, P1400, DOI 10.1074/jbc.271.3.1400; KEITHLY JS, 1976, J PROTOZOOL, V23, P244, DOI 10.1111/j.1550-7408.1976.tb03763.x; Klamo EM, 1996, J BIOL CHEM, V271, P14937, DOI 10.1074/jbc.271.25.14937; KWON HM, 1992, J BIOL CHEM, V267, P6297; LAINSON R, 1978, NATURE, V273, P595, DOI 10.1038/273595a0; LANGFORD CK, 1995, BIOCHEMISTRY-US, V34, P11814, DOI 10.1021/bi00037a020; LANGFORD CK, 1994, J BIOL CHEM, V269, P17939; LANGFORD CK, 1992, MOL BIOCHEM PARASIT, V55, P51, DOI 10.1016/0166-6851(92)90126-5; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; Lostao MP, 1995, FEBS LETT, V377, P181, DOI 10.1016/0014-5793(95)01339-3; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Pazdernik NJ, 1997, J BIOL CHEM, V272, P26110, DOI 10.1074/jbc.272.42.26110; PIPER RC, 1995, J CELL BIOL, V128, P499, DOI 10.1083/jcb.128.4.499; Prasad PD, 1998, J BIOL CHEM, V273, P7501, DOI 10.1074/jbc.273.13.7501; REIZER J, 1994, BBA-REV BIOMEMBRANES, V1197, P133, DOI 10.1016/0304-4157(94)90003-5; RUSSELL DG, 1986, J IMMUNOL, V136, P2613; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schurmann A, 1997, BIOCHEMISTRY-US, V36, P12897, DOI 10.1021/bi971173c; Seyfang A, 1997, J BIOL CHEM, V272, P24210, DOI 10.1074/jbc.272.39.24210; SKELLY PJ, 1994, J BIOL CHEM, V269, P4247; SZKUTNICKA K, 1989, J BACTERIOL, V171, P4486, DOI 10.1128/JB.171.8.4486-4493.1989; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; Vasudevan G, 1998, P NATL ACAD SCI USA, V95, P9873, DOI 10.1073/pnas.95.17.9873; VIEIRA L, 1995, J BIOL CHEM, V270, P5299, DOI 10.1074/jbc.270.10.5299; YAMAGUCHI A, 1993, J BIOL CHEM, V268, P6496; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P19155; Zar JH, 1984, BIOSTAT ANAL, P150	43	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5687	5693		10.1074/jbc.275.8.5687	http://dx.doi.org/10.1074/jbc.275.8.5687			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681553	hybrid			2022-12-27	WOS:000085474500060
J	Heath, RJ; Li, J; Roland, GE; Rock, CO				Heath, RJ; Li, J; Roland, GE; Rock, CO			Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; ESCHERICHIA-COLI; MYCOBACTERIUM-TUBERCULOSIS; FABI; TARGET; ELONGATION; MECHANISM; INHA; GENE	Enoyl-acyl carrier protein reductase (FabI) plays a determinant role in completing cycles of elongation in type II fatty acid synthase systems and is an important target for antibacterial drugs. The FabI component of Staphylococcus aureus (saFabI) was identified, and its properties were compared with Escherichia coli FabI (ecFabI), ecFabI and saFabI had similar specific activities, and saFabI expression complemented the E, coli fabI (Ts) mutant, illustrating that the Gram-positive FabI was interchangeable with the Gram-negative FabI enzyme. However, ecFabI was specific for NADH, whereas saFabI exhibited specific and positive cooperative binding of NADPH, Triclosan and hexachlorophene inhibited both ecFabI and saFabI, The triclosan-resistant ecFabI(G93V) protein was also refractory to hexachlorophene inhibition, illustrating that both drugs bind at the FabI active site. Both the introduction of a plasmid expressing the safabI gene or a missense mutation in the chromosomal safabI gene led to triclosan resistance in S, aureus; however, these strains did not exhibit cross-resistance to hexachlorophene, The replacement of the ether linkage in triclosan by a carbon bridge in hexachlorophene prevented the formation of a stable FabI-NAD(P)(+)-drug ternary complex. Thus, the formation of this ternary complex is a key determinant of the antibacterial activity of FabI inhibitors.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Parke Davis Pharmaceut Res, Dept Infect Dis, Ann Arbor, MI 48105 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	St Jude Children's Research Hospital; Pfizer; University of Tennessee System; University of Tennessee Health Science Center	Rock, CO (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.			Heath, Richard/0000-0002-1795-1254	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034496, R37GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldock C, 1998, BIOCHEM PHARMACOL, V55, P1541; Baldock C, 1996, SCIENCE, V274, P2107, DOI 10.1126/science.274.5295.2107; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Bergler H, 1996, EUR J BIOCHEM, V242, P689, DOI 10.1111/j.1432-1033.1996.0689r.x; BERGLER H, 1994, J BIOL CHEM, V269, P5493; Bhargava HN, 1996, AM J INFECT CONTROL, V24, P209, DOI 10.1016/S0196-6553(96)90017-6; CORNER TR, 1971, J BACTERIOL, V108, P501, DOI 10.1128/JB.108.1.501-507.1971; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; GUMP WS, 1968, BIS PHENOLS, P257; Heath RJ, 1996, J BIOL CHEM, V271, P1833, DOI 10.1074/jbc.271.4.1833; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Heath RJ, 1998, J BIOL CHEM, V273, P30316, DOI 10.1074/jbc.273.46.30316; Heath RJ, 1999, J BIOL CHEM, V274, P11110, DOI 10.1074/jbc.274.16.11110; JONES CL, 1986, J BACTERIOL, V166, P29, DOI 10.1128/jb.166.1.29-33.1986; JOSWICK HL, 1971, J BACTERIOL, V108, P492, DOI 10.1128/JB.108.1.492-500.1971; JUNGERMA.E, 1968, J AM OIL CHEM SOC, V45, P345, DOI 10.1007/BF02667108; Levy CW, 1999, NATURE, V398, P383, DOI 10.1038/18803; McMurry LM, 1998, NATURE, V394, P531, DOI 10.1038/28970; McMurry LM, 1999, ANTIMICROB AGENTS CH, V43, P711, DOI 10.1128/AAC.43.3.711; MOLNAR NM, 1969, J SOC COSMET CHEM, V20, P103; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Novick R.P., 1990, MOL BIOL STAPHYLOCOC; PITCHER DG, 1989, LETT APPL MICROBIOL, V8, P151, DOI 10.1111/j.1472-765X.1989.tb00262.x; REGOS J, 1979, DERMATOLOGICA, V158, P72, DOI 10.1159/000250746; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; SILVERNALE JN, 1971, J BACTERIOL, V108, P482, DOI 10.1128/JB.108.1.482-491.1971; Stewart MJ, 1999, J MOL BIOL, V290, P859, DOI 10.1006/jmbi.1999.2907; VISCHER WA, 1974, ZBL BAKT-INT J MED M, V226, P376; WEEKS G, 1968, J BIOL CHEM, V243, P1180; WHITE DC, 1968, J BACTERIOL, V95, P2198, DOI 10.1128/JB.95.6.2198-2209.1968	31	196	207	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4654	4659		10.1074/jbc.275.7.4654	http://dx.doi.org/10.1074/jbc.275.7.4654			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671494	hybrid			2022-12-27	WOS:000085378200020
J	Luders, J; Demand, J; Hohfeld, J				Luders, J; Demand, J; Hohfeld, J			The ubiquitin-related BAG-1 provides a link between the molecular chaperones Hsc70/Hsp70 and the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOTIC PROTEIN BAG-1; HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; 20S PROTEASOME; PIM1 PROTEASE; CANCER-CELLS; DNA-REPAIR; RECEPTOR; HSC70; DEGRADATION	The BAG-1 protein modulates the chaperone activity of Hsc70 and Hsp70 in the mammalian cytosol and nucleus. Remarkably, BAG-1 possesses a ubiquitin-like domain at its amino terminus, suggesting a link to the ubiquitin/proteasome system. Here we show that BAG-1 is indeed associated with the 26 S proteasome in HeLa cells. Binding of the chaperone cofactor to the proteolytic complex is regulated by ATP hydrolysis and is not mediated by Hsc70 and Hsp70. The presented findings reveal a role of BAG-1 as a physical link between the Hsc70/Hsp70 chaperone system and the proteasome. In fact, targeting of BAG-1 to the proteasome promotes an association of the chaperones with the proteolytic complex in vitro and in vivo. A regulatory function of the chaperone cofactor at the interface between protein folding and protein degradation is thus indicated.	Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany	Max Planck Society	Hohfeld, J (corresponding author), Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany.		Lüders, Jens/H-2812-2015	Lüders, Jens/0000-0002-9018-7977				Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; Gebauer M, 1998, MOL CELL BIOL, V18, P6238, DOI 10.1128/MCB.18.11.6238; Gebauer M, 1997, FEBS LETT, V417, P109, DOI 10.1016/S0014-5793(97)01267-2; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Hohfeld J, 1998, BIOL CHEM, V379, P269; HOHFELD J, 1995, CELL, V83, P589; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Luders J, 1998, BIOL CHEM, V379, P1217, DOI 10.1515/bchm.1998.379.10.1217; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Savel'ev AS, 1998, J BIOL CHEM, V273, P20596, DOI 10.1074/jbc.273.32.20596; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Takayama S, 1998, CANCER RES, V58, P3116; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Tomoyasu T, 1998, MOL MICROBIOL, V30, P567, DOI 10.1046/j.1365-2958.1998.01090.x; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; [No title captured]	46	370	378	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4613	4617		10.1074/jbc.275.7.4613	http://dx.doi.org/10.1074/jbc.275.7.4613			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671488	hybrid			2022-12-27	WOS:000085378200014
J	Mohana-Borges, R; Pacheco, ABF; Sousa, FJR; Foguel, D; Almeida, DF; Silva, JL				Mohana-Borges, R; Pacheco, ABF; Sousa, FJR; Foguel, D; Almeida, DF; Silva, JL			LexA repressor forms stable dimers in solution - The role of specific DNA in tightening protein-protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HIGH-PRESSURE; BINDING DOMAIN; ARC REPRESSOR; DIMERIZATION; RECOGNITION; CLEAVAGE; DAMAGE; OLIGOMERIZATION; SPECTROSCOPY	Cooperativity in the interactions among proteins subunits and DNA is crucial for DNA recognition. LexA repressor was originally thought to bind DNA as a monomer, with cooperativity leading to tighter binding of the second monomer, The main support for this model was a high value of the dissociation constant for the LexA dimer (micromolar range). Here we show that the protein is a dimer at nanomolar concentrations under different conditions, The reversible dissociation of LexA dimer was investigated by the effects of hydrostatic pressure or urea, using fluorescence emission and polarization to monitor the dissociation process. The dissociation constant lies in the picomolar range (lower than 20 pM). LexA monomers associate with an unusual large volume change (340 ml/mol), indicating the burial of a large surface area upon dimerization, Whereas nonspecific DNA has no stabilizing effect, specific DNA induces tightening of the dimer and a 750-fold decrease in the K-d. In contrast to the previous model, a tight dimer rather than a monomer is the functional repressor. Accordingly, the LexA dimer only loses its ability to recognize a specific DNA sequence by RecA-induced autoproteolysis, Our work provides insights into the linkage between protein-protein interactions, DNA recognition, and DNA repair.	Univ Fed Rio de Janeiro, Ctr Nacl Ressonancia Magnet Nucl Macromol, ICB, Dept Bioquim Med,Programa Biol Estrutural, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Silva, JL (corresponding author), Univ Fed Rio de Janeiro, Ctr Nacl Ressonancia Magnet Nucl Macromol, ICB, Dept Bioquim Med,Programa Biol Estrutural, BR-21941590 Rio De Janeiro, Brazil.		SILVA, JERSON Lima/GRF-1442-2022; Pacheco, Ana Beatriz Furlanetto/J-2617-2013; Silva, Jerson/J-8984-2014; Borges, Ronaldo S Mohana/C-5575-2013	SILVA, JERSON Lima/0000-0001-9523-9441; Pacheco, Ana Beatriz Furlanetto/0000-0002-7899-9657; Silva, Jerson/0000-0001-9523-9441; Foguel, Debora/0000-0001-7312-7115				Beechem JM., 2002, TOPICS FLUORESCENCE, P241, DOI DOI 10.1007/0-306-47058-6_5; Bitinaite J, 1998, P NATL ACAD SCI USA, V95, P10570, DOI 10.1073/pnas.95.18.10570; BLANCHE PJ, 1981, BIOCHIM BIOPHYS ACTA, V665, P408, DOI 10.1016/0005-2760(81)90253-8; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Cho S, 1998, BIOCHEMISTRY-US, V37, P11301, DOI 10.1021/bi972916x; FOGH RH, 1994, EMBO J, V13, P3936, DOI 10.1002/j.1460-2075.1994.tb06709.x; FOGUEL D, 1994, P NATL ACAD SCI USA, V91, P8244, DOI 10.1073/pnas.91.17.8244; Foguel D, 1998, J BIOL CHEM, V273, P9050, DOI 10.1074/jbc.273.15.9050; Grillo AO, 1999, J MOL BIOL, V287, P539, DOI 10.1006/jmbi.1999.2625; Harrington W F, 1973, Methods Enzymol, V27, P306; HEREMANS K, 1982, ANNU REV BIOPHYS BIO, V11, P1, DOI 10.1146/annurev.bb.11.060182.000245; Holmbeck SMA, 1998, J MOL BIOL, V284, P533, DOI 10.1006/jmbi.1998.2207; JONAS J, 1994, ANNU REV BIOPH BIOM, V23, P287, DOI 10.1146/annurev.bb.23.060194.001443; JOSEPHS R, 1967, P NATL ACAD SCI USA, V58, P1587, DOI 10.1073/pnas.58.4.1587; KIM B, 1992, SCIENCE, V255, P203, DOI 10.1126/science.1553548; Kohler JJ, 1999, P NATL ACAD SCI USA, V96, P11735, DOI 10.1073/pnas.96.21.11735; Konola JT, 1998, J MOL BIOL, V276, P405, DOI 10.1006/jmbi.1997.1531; LEWIS LK, 1994, J MOL BIOL, V241, P507, DOI 10.1006/jmbi.1994.1528; LITTLE JW, 1985, P NATL ACAD SCI USA, V82, P2301, DOI 10.1073/pnas.82.8.2301; LITTLE JW, 1994, METHOD ENZYMOL, V244, P266; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; Luisi B., 1995, DNA PROTEIN STRUCTUR, P1; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; NEET KE, 1994, PROTEIN SCI, V3, P2167, DOI 10.1002/pro.5560031202; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Pace C N, 1986, Methods Enzymol, V131, P266; PALADINI AA, 1981, BIOCHEMISTRY-US, V20, P2587, DOI 10.1021/bi00512a034; Peat TS, 1996, NATURE, V380, P727, DOI 10.1038/380727a0; Rentzeperis D, 1999, NAT STRUCT BIOL, V6, P569; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; SCHNARR M, 1985, BIOCHEMISTRY-US, V24, P2812, DOI 10.1021/bi00332a032; Shaner SL, 1996, J MOL RECOGNIT, V9, P468, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<468::AID-JMR284>3.0.CO;2-W; Silva JL, 1996, CURR OPIN STRUC BIOL, V6, P166, DOI 10.1016/S0959-440X(96)80071-6; SILVA JL, 1993, ANNU REV PHYS CHEM, V44, P89, DOI 10.1146/annurev.pc.44.100193.000513; SILVA JL, 1992, J MOL BIOL, V223, P545, DOI 10.1016/0022-2836(92)90669-B; SILVA JL, 1993, PROTEIN SCI, V2, P945, DOI 10.1002/pro.5560020608; SMITH TL, 1995, J MOL BIOL, V249, P729, DOI 10.1006/jmbi.1995.0332; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VONHIPPEL PH, 1994, SCIENCE, V263, P769, DOI 10.1126/science.8303292; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WEBER G, 1983, Q REV BIOPHYS, V16, P89, DOI 10.1017/S0033583500004935; Weber G, 1992, PROTEIN INTERACTIONS; WU JQ, 1993, BIOCHEMISTRY-US, V32, P12531, DOI 10.1021/bi00097a033	45	72	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4708	4712		10.1074/jbc.275.7.4708	http://dx.doi.org/10.1074/jbc.275.7.4708			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671501	hybrid			2022-12-27	WOS:000085378200027
J	Salmon, AL; Johnsen, AH; Bienert, M; McMurray, G; Nandha, KA; Bloom, SR; Shaw, C				Salmon, AL; Johnsen, AH; Bienert, M; McMurray, G; Nandha, KA; Bloom, SR; Shaw, C			Isolation, structural characterization, and bioactivity of a novel neuromedin U analog from the defensive skin secretion of the Australasian tree frog, Litoria caerulea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SPINAL-CORD; ACTIVE PEPTIDES; PHARMACOLOGICAL ACTIVITY; SMALL-INTESTINE; GUINEA-PIG; RAT; U-8; PURIFICATION; CONSERVATION; EXPRESSION	We report the isolation of a novel bioactive peptide, neuromedin U-23 (NmU-23), from the defensive skin secretion of the Australasian tree frog, Litoria caerulea. The primary structure of the peptide was established by a combination of microsequencing, mass spectroscopy and site-directed antiserum immunoreactivity as SDEEVQVPGGVISNGYFLFRPRN-amide (M-r 2580.6), A synthetic replicate of frog NmU-23 displaced monoradioiodinated rat NmU-23 from uterine membranes in a dose-dependent fashion indistinguishable from nonisotopically labeled rat NmU-23. In a rat uterine smooth muscle strip preparation, synthetic frog NmU-23 produced dose-dependent contractions identical to porcine NmU-25, However, in a preparation of human urinary bladder muscle strip, the synthetic frog peptide was more potent than porcine NmU-25 in eliciting contraction and produced desensitization of the preparation to the latter peptide. This report demonstrates that the defensive skin secretion of a frog contains a novel peptide exhibiting a high degree of primary structural similarity to the endogenous vertebrate peptide, NmU, and that this frog skin analog displays biological activity in mammalian tissues.	Queens Univ Belfast, Dept Med, Nat Drug Discovery Lab, Med Clin, Belfast BT12 6BJ, Antrim, North Ireland; Rigshosp, Dept Clin Chem, DK-2100 Copenhagen, Denmark; Inst Mol Pharmacol, D-10315 Berlin, Germany; Dept Pharmacol, Oxford OX2 3QT, England; Royal Postgrad Med Sch, Dept Med, London W12 0NN, England	Queens University Belfast; Rigshospitalet; University of Copenhagen; Imperial College London	Salmon, AL (corresponding author), Queens Univ Belfast, Dept Med, Nat Drug Discovery Lab, Med Clin, Mulhouse Bldg,Grosvenor Rd, Belfast BT12 6BJ, Antrim, North Ireland.							ANASTASI A, 1965, COMP BIOCHEM PHYSIOL, V14, P43; ANASTASI A, 1968, ARCH BIOCHEM BIOPHYS, V125, P57, DOI 10.1016/0003-9861(68)90638-3; ANASTASI A, 1971, EXPERIENTIA, V27, P166, DOI 10.1007/BF02145873; AUSTIN C, 1995, J MOL ENDOCRINOL, V14, P157, DOI 10.1677/jme.0.0140157; BARTHALMUS GT, 1988, PHARMACOL BIOCHEM BE, V30, P957, DOI 10.1016/0091-3057(88)90126-8; BENITOORFILA MA, 1991, EUR J PHARMACOL, V193, P329, DOI 10.1016/0014-2999(91)90147-I; BERTOLINI A, 1986, NEUROPEPTIDES, V8, P25, DOI 10.1016/0143-4179(86)90061-2; BROWN DR, 1988, EUR J PHARMACOL, V155, P159, DOI 10.1016/0014-2999(88)90415-3; CONLON JM, 1988, J NEUROCHEM, V51, P988, DOI 10.1111/j.1471-4159.1988.tb01837.x; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DOMIN J, 1992, REGUL PEPTIDES, V41, P1, DOI 10.1016/0167-0115(92)90508-R; DOMIN J, 1989, J BIOL CHEM, V264, P20881; DOMIN J, 1986, BIOCHEM BIOPH RES CO, V140, P1127, DOI 10.1016/0006-291X(86)90752-7; DOMIN J, 1987, PEPTIDES, V8, P779, DOI 10.1016/0196-9781(87)90058-1; ERSPAMER V, 1984, COMP BIOCHEM PHYS C, V77, P99, DOI 10.1016/0742-8413(84)90137-3; ERSPAMER V, 1981, PEPTIDES, V2, P7, DOI 10.1016/0196-9781(81)90003-6; ERSPAMER V, 1985, PEPTIDES, V6, P7, DOI 10.1016/0196-9781(85)90343-2; ERSPAMER V, 1986, COMP BIOCHEM PHYS C, V85, P125, DOI 10.1016/0742-8413(86)90063-0; ESPARMER V, 1994, AMPHIBIAN BIOL INTEG, P231; GARDINER SM, 1990, AM J PHYSIOL, V258, pE32; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GUARINI S, 1988, NEUROPEPTIDES, V11, P69, DOI 10.1016/0143-4179(88)90012-1; KAGE R, 1991, REGUL PEPTIDES, V33, P191, DOI 10.1016/0167-0115(91)90213-Z; LAZARUS LH, 1993, PROG NEUROBIOL, V41, P473, DOI 10.1016/0301-0082(93)90027-P; LO G, 1992, MOL ENDOCRINOL, V6, P1538, DOI 10.1210/me.6.10.1538; MAGGI CA, 1990, BRIT J PHARMACOL, V99, P186, DOI 10.1111/j.1476-5381.1990.tb14675.x; Malendowicz LK, 1998, HORM METAB RES, V30, P374, DOI 10.1055/s-2007-978901; MALENDOWICZ LK, 1994, NEUROPEPTIDES, V26, P47, DOI 10.1016/0143-4179(94)90092-2; MALENDOWICZ LK, 1994, RES EXP MED, V194, P69, DOI 10.1007/BF02576368; MINAMINO N, 1988, BIOCHEM BIOPH RES CO, V156, P355, DOI 10.1016/S0006-291X(88)80848-9; MINAMINO N, 1985, PEPTIDES, V6, P245, DOI 10.1016/0196-9781(85)90381-X; MINAMINO N, 1985, BIOCHEM BIOPH RES CO, V130, P1078, DOI 10.1016/0006-291X(85)91726-7; MOR A, 1994, P NATL ACAD SCI USA, V91, P10295, DOI 10.1073/pnas.91.22.10295; MURPHY R, 1990, PEPTIDES, V11, P613, DOI 10.1016/0196-9781(90)90066-E; NANDHA KA, 1993, BIOMED RES-TOKYO, V14, P71; NANDHA KA, 1993, ENDOCRINOLOGY, V133, P482, DOI 10.1210/en.133.2.482; OHARTE F, 1991, PEPTIDES, V12, P11, DOI 10.1016/0196-9781(91)90159-M; OHARTE F, 1991, PEPTIDES, V12, P809, DOI 10.1016/0196-9781(91)90138-F; PIERIBONE VA, 1992, J NEUROSCI, V12, P3361; ROSEGHINI M, 1988, COMP BIOCHEM PHYS C, V91, P281, DOI 10.1016/0742-8413(88)90030-8; ROSEGHINI M, 1989, COMP BIOCHEM PHYS C, V94, P455, DOI 10.1016/0742-8413(89)90097-2; STONE DJM, 1992, J CHEM SOC CHEM COMM, P1224, DOI 10.1039/c39920001224; STONE DJM, 1993, J CHEM RES, V4, P138; SUMI S, 1987, LIFE SCI, V41, P1585, DOI 10.1016/0024-3205(87)90725-9; WAUGH RJ, 1993, J CHEM SOC PERK T, V5, P73; ZIELINSKI WJ, 1989, ANIM BEHAV, V38, P1083, DOI 10.1016/S0003-3472(89)80149-6	46	33	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4549	4554		10.1074/jbc.275.7.4549	http://dx.doi.org/10.1074/jbc.275.7.4549			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671478	hybrid			2022-12-27	WOS:000085378200004
J	Tuerk, EE; Schreiber, J; Wegner, M				Tuerk, EE; Schreiber, J; Wegner, M			Protein stability and domain topology determine the transcriptional activity of the mammalian glial cells missing homolog, GCMb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; JC VIRUS; DROSOPHILA; EXPRESSION; SWITCH; FATE; TST-1	The glial cells missing (GCM) family of transcription factors consists of Drosophila GCM and the mammalian proteins GCMa and GCMb. They are expressed in a highly restricted manner during development and are known or assumed to be important regulators of developmental fate decisions. As the biochemical properties of GCMb have not been studied so far, we have undertaken a detailed structure-function analysis of the mouse GCMb (mGCMb) protein. DNA-binding specificity was very similar to that of other GCM proteins. Nevertheless, mGCMb was only a weak transcriptional activator in a number of different tissue culture systems. Interestingly, this was not due to an intrinsic absence of transactivation potential. In effect, we were able to identify two separate transactivation domains within mGCMb, one carboxyl-terminally adjacent to the DNA-binding domain and the second within the extreme carboxyl terminus. Activity of both transactivation domains was, however, modulated by an inhibitory region unique to mGCMb and located between the two transactivation domains. Furthermore, pulse-chase experiments proved that the mGCMb protein has a half-life approximately four times shorter than mGCMa. Introduction of the above mentioned inhibitory domain of mGCMb into mGCMa shortened the half-life of mGCMa to a value typical of mGCMb with a concomitant reduction in transactivation potential, Given the strong correlation between protein stability and transactivation potential, functional differences between the two mammalian GCM homologs are likely due to differences in stability with a single inhibitory region in mGCMb being involved in the reduction of both.	Univ Hamburg, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Wegner, M (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol, Martinistr 52, D-20246 Hamburg, Germany.	wegner@plexus.uke.uni-hamburg.de	Schreiber, Jacob/GWC-3164-2022	Wegner, Michael/0000-0002-4586-3294				Akiyama Y, 1996, P NATL ACAD SCI USA, V93, P14912, DOI 10.1073/pnas.93.25.14912; Akiyama-Oda Y, 1998, DEV GENES EVOL, V208, P578, DOI 10.1007/s004270050217; Altshuller Y, 1996, FEBS LETT, V393, P201, DOI 10.1016/0014-5793(96)00890-3; Basyuk E, 1999, DEV DYNAM, V214, P303, DOI 10.1002/(SICI)1097-0177(199904)214:4<303::AID-AJA3>3.3.CO;2-2; Bernardoni R, 1998, DEVELOPMENT, V125, P3189; DISTELHORST CW, 1989, J BIOL CHEM, V264, P13080; Fuchs SY, 1999, MOL CELL BIOL, V19, P3289; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HOSOYA T, 1995, CELL, V82, P1025, DOI 10.1016/0092-8674(95)90281-3; JONES BW, 1995, CELL, V82, P1013, DOI 10.1016/0092-8674(95)90280-5; Kammerer M, 1999, CYTOGENET CELL GENET, V84, P43, DOI 10.1159/000015210; Kanemura Y, 1999, FEBS LETT, V442, P151, DOI 10.1016/S0014-5793(98)01650-0; Kim JS, 1998, P NATL ACAD SCI USA, V95, P12364, DOI 10.1073/pnas.95.21.12364; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P23033, DOI 10.1074/jbc.273.36.23033; Miller AA, 1998, EMBO J, V17, P6316, DOI 10.1093/emboj/17.21.6316; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; Reifegerste R, 1999, MECH DEVELOP, V82, P141, DOI 10.1016/S0925-4773(99)00027-1; RENNER K, 1994, P NATL ACAD SCI USA, V91, P6433, DOI 10.1073/pnas.91.14.6433; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Schreiber J, 1997, P NATL ACAD SCI USA, V94, P4739, DOI 10.1073/pnas.94.9.4739; Schreiber J, 1998, NUCLEIC ACIDS RES, V26, P2337, DOI 10.1093/nar/26.10.2337; Sock E, 1996, J BIOL CHEM, V271, P17512, DOI 10.1074/jbc.271.29.17512; UNTER PJ, 1999, DEVELOPMENT, V126, P1247; Vincent S, 1996, DEVELOPMENT, V122, P131; WEGNER M, 1993, P NATL ACAD SCI USA, V90, P4743, DOI 10.1073/pnas.90.10.4743	25	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4774	4782		10.1074/jbc.275.7.4774	http://dx.doi.org/10.1074/jbc.275.7.4774			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671510	hybrid			2022-12-27	WOS:000085378200036
J	Khan, KMF; Falcone, DJ				Khan, KMF; Falcone, DJ			Selective activation of MAPK(erk1/2) by laminin-1 peptide alpha 1 : Ser(2091)-Arg(2108) regulates macrophage degradative phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PROTEIN-KINASE; PLASMINOGEN-ACTIVATOR; UROKINASE EXPRESSION; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; INDUCTION; PROTEOGLYCAN; RELEASE; GROWTH	Components of the extracellular matrix contain cryptic domains, which are exposed by proteolysis and elicit biological responses distinct from intact molecules. The disparate cellular response to extracellular matrix fragments and parent intact molecules suggests differential recognition and signaling pathways. In experiments reported here, we demonstrate that urokinase and matrix metalloproteinase-9 expression by RAW264.7 macrophages is stimulated by a synthetic laminin peptide derived from the alpha 1-chain (SRARKQAASIKVAVSADR), whereas intact laminin-l has no effect on proteinase expression by macrophages. Incubation of macrophages with alpha 1:SRARKQAASIKVAVSADR stimulates tyrosine phosphorylation of several proteins including mitogen-activated protein kinase (MAPK)(erk1/2). In contrast, neither intact laminin-1 nor the alpha 1-chain peptide CDPGY-IGSR stimulated protein tyrosine phosphorylation in these cells. Inhibition of tyrosine kinases or protein kinase C blocked alpha 1-chain peptide-induced phosphorylation of MAPK(erk1/2) and the up-regulation of steady state levels of urokinase mRNA and matrix metalloproteinase-9 activity. A MAPK kinase inhibitor blocked alpha 1-chain-induced phosphorylation of MAPK(erk1/2) and the induction of proteinase expression. Intact laminin-1, which was unable to induce macrophage proteinase expression, failed to stimulate the phosphorylation of MAPK(erk1/2). These data demonstrate that incubation of macrophages with alpha 1:SRARKQAASIKVAVSADR, but not intact laminin-1, triggers protein kinase C-dependent activation of MAPK(erk1/2), leading to the up-regulation of proteinase expression.	Cornell Univ, Joan & Sanford I Weill Med Col, Dept Pathol, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Med Col, Dept Cell Biol, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Med Col, Dept Vasc Biol Ctr, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University	Falcone, DJ (corresponding author), Cornell Univ, Coll Med, Dept Pathol, Rm A678,1300 York Ave, New York, NY 10021 USA.	dfalcone@mail.med.cornell.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040819] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL07432, R01-HL40819] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aplin AE, 1998, PHARMACOL REV, V50, P197; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CORCORAN ML, 1995, J BIOL CHEM, V270, P10365, DOI 10.1074/jbc.270.18.10365; DEGEN SJF, 1987, BIOCHEMISTRY-US, V26, P8270, DOI 10.1021/bi00399a038; FALCONE DJ, 1993, J CELL PHYSIOL, V155, P595, DOI 10.1002/jcp.1041550317; FALCONE DJ, 1991, J BIOL CHEM, V266, P22726; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; HUNNINGHAKE GW, 1981, SCIENCE, V212, P925, DOI 10.1126/science.7233186; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Khan KMF, 1997, J BIOL CHEM, V272, P8270, DOI 10.1074/jbc.272.13.8270; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; LIN TH, 1994, J CELL BIOL, V126, P1585, DOI 10.1083/jcb.126.6.1585; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; ODEKON LE, 1991, IMMUNOLOGY, V74, P114; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SENIOR RM, 1980, J CLIN INVEST, V66, P859, DOI 10.1172/JCI109926; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; Shattil SJ, 1997, J CLIN INVEST, V100, P1, DOI 10.1172/JCI119500; SHAW LM, 1995, J BIOL CHEM, V270, P23648, DOI 10.1074/jbc.270.40.23648; TURPEENNIEMIHUJANEN T, 1986, J BIOL CHEM, V261, P1883; Wei JY, 1998, J BIOL CHEM, V273, P5903, DOI 10.1074/jbc.273.10.5903; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143	26	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4492	4498		10.1074/jbc.275.6.4492	http://dx.doi.org/10.1074/jbc.275.6.4492			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660623	hybrid			2022-12-27	WOS:000085288800107
J	Grigorieva, I; Grigoriev, VG; Rowney, RK; Hoover, RG				Grigorieva, I; Grigoriev, VG; Rowney, RK; Hoover, RG			Regulation of c-myc transcription by interleukin-2 (IL-2) Identification of a novel IL-2 response element interacting with STAT-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL STIMULATORY FACTOR; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; HUMAN-LYMPHOCYTES; TRANS-ACTIVATION; DNA-REPLICATION; GENE-EXPRESSION; LIGAND-BINDING; NK-CELLS; T-CELLS	Regulation of c-myc expression is known to occur at the level of transcription initiation. However, the participating promoter elements and their cognate binding proteins have not been fully characterized. c-myc transcription can be stimulated by a number of cytokines including interleukin-2 (IL-2). We have identified a novel IL-2-responsive element, located in the 5'-flanking region of the c-myc gene, between nucleotides -1406 and -1387 (relative to the P2 promoter). This element belongs to the family of interferon-gamma activation site-like responsive elements and has the core sequence TTC-CAATAA, We confirmed that IL-2-mediated signaling involves activation by phosphorylation of Jak2 tyrosine kinase and subsequently STATE. The transcription factor STATE binds the TTCCAATAA motif within this responsive element and, therefore, is probably involved in enhancing c-myc transcription upon IL-2 stimulation. Our results propose participation of Jak2 and STATE in IL-2-induced up-regulation of c-myc.	St Louis Univ, Dept Pathol, St Louis, MO 63104 USA	Saint Louis University	Grigorieva, I (corresponding author), St Louis Univ, Dept Pathol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	grigorii@slucare1.sluh.edu			NATIONAL CANCER INSTITUTE [P01CA055819, R01CA041165] Funding Source: NIH RePORTER; NCI NIH HHS [CA-41165, CA-55819] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALITALO K, 1984, MED BIOL, V62, P304; ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; ASTEAMEZAGA M, 1994, CELL IMMUNOL, V156, P480, DOI 10.1006/cimm.1994.1192; Azzoni L, 1996, J IMMUNOL, V157, P3235; AZZONI L, 1995, J IMMUNOL, V154, P491; BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; BACON CM, 1995, P NATL ACAD SCI USA, V92, P7307, DOI 10.1073/pnas.92.16.7307; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BROOME HE, 1987, MOL CELL BIOL, V7, P2988, DOI 10.1128/MCB.7.8.2988; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; Heim MH, 1996, EUR J CLIN INVEST, V26, P1, DOI 10.1046/j.1365-2362.1996.103248.x; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; Hoover R G, 1995, Curr Top Microbiol Immunol, V194, P257; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; KAWAHARA A, 1995, P NATL ACAD SCI USA, V92, P8724, DOI 10.1073/pnas.92.19.8724; Kerkhoff E, 1995, NUCLEIC ACIDS RES, V23, P4857, DOI 10.1093/nar/23.23.4857; KORNBLUTH J, 1988, J IMMUNOL, V141, P3234; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KUMAR S, 1989, NUCLEIC ACIDS RES, V17, P2819, DOI 10.1093/nar/17.7.2819; LANG JC, 1988, BRIT J CANCER, V58, P62; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Ling MM, 1997, ANAL BIOCHEM, V254, P157, DOI 10.1006/abio.1997.2428; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARZLUFF WF, 1984, TRANSCRIPTION TRANSL, P91; MAUTNER J, 1995, NUCLEIC ACIDS RES, V23, P72, DOI 10.1093/nar/23.1.72; Miller TL, 1996, J CELL BIOCHEM, V60, P560, DOI 10.1002/(SICI)1097-4644(19960315)60:4<560::AID-JCB12>3.0.CO;2-L; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Murphy LC, 1996, DNA CELL BIOL, V15, P543, DOI 10.1089/dna.1996.15.543; PETERSON CL, 1986, MOL CELL BIOL, V6, P4168, DOI 10.1128/MCB.6.12.4168; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; Rebollo A, 1996, ADV IMMUNOL, V63, P127, DOI 10.1016/S0065-2776(08)60856-1; REED JC, 1985, P NATL ACAD SCI USA, V82, P4221, DOI 10.1073/pnas.82.12.4221; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; VANWIJNEN AJ, 1992, BIOTECHNIQUES, V12, P400; Wang KS, 1999, J IMMUNOL, V162, P299; WeberNordt RM, 1996, BLOOD, V88, P809; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zou X, 1997, CURR TOP MICROBIOL, V224, P57	60	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7343	7350		10.1074/jbc.275.10.7343	http://dx.doi.org/10.1074/jbc.275.10.7343			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702306	hybrid			2022-12-27	WOS:000085809600086
J	Liu, YY; Han, TY; Giuliano, AE; Hansen, N; Cabot, MC				Liu, YY; Han, TY; Giuliano, AE; Hansen, N; Cabot, MC			Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST CANCER-CELLS; DAUNORUBICIN-INDUCED APOPTOSIS; MULTIDRUG-RESISTANCE; GLUTATHIONE; ACTIVATION; STRESS; DEATH; BCL-2; ACCUMULATION; TRANSFERASE	Previous work from our laboratory demonstrated that increased competence to glycosylate ceramide conferred adriamycin resistance in MCF-7 breast cancer cells (Liu, Y. Y., Han, T. Y., Giuliano, A. E., and M. C. Cabot. (1999) J. Biol. Chem. 274, 1140-1146), This was achieved by cellular transfection with glucosylceramide synthase (GCS), the enzyme that converts ceramide to glucosylceramide, With this, we hypothesized that a decrease in cellular ceramide glycosylation would result in heightened drug sensitivity and reverse adriamycin resistance, To down-regulate ceramide glycosylation potential, we transfected adriamycin-resistant breast cancer cells (MCF-7-AdrR) with GCS antisense (asGCS), using a pcDNA 3.1/his A vector and developed a new cell Line, MCF-7-AdrR/asGCS. Reverse transcription-polymerase chain reaction assay and Western blot analysis revealed marked decreases in both GCS mRNA and protein in MCF-7-AdrR/asGCS cells compared with the MCF-7-AdrR parental cells. MCF-7-AdrR/asGCS cells exhibited 30% less GCS activity by in vitro enzyme assay (19.7 +/- 1.1 versus 27.4 +/- 2.3 pmol GC/h/mu g protein, p < 0.001) and mere 28-fold more sensitive to adriamycin (EC50, 0.44 +/- 0.01 versus 12.4 +/- 0.7 mu M, p < 0.0001). GCS antisense transfected cells were also 2.4-fold more sensitive to C-6-ceramide compared with parental cells (EC50 = 4.0 +/- 0.03 versus 9.6 +/- 0.5 mu M, p < 0.0005). Under adriamycin stress, GCS antisense transfected cells compared with parental cells displayed time- and dose-dependent increases in endogenous ceramide and dramatically higher levels of apoptotic effector, caspase-3. Western blotting showed that adriamycin sensitivity, introduced by asGCS gene transfection, was independent of P-glycoprotein and Bcl-2 expression. In summary, this work shows that transfection of GCS antisense tempers the expression of native GCS and restores cell sensitivity to adriamycin. Therefore, limiting the potential to glycosylate ceramide, which is an apoptotic signal in chemotherapy and radiotherapy, provides a promising approach to combat drug resistance.	St Johns Hlth Ctr, John Wayne Canc Inst, Santa Monica, CA 90404 USA	John Wayne Cancer Institute	Cabot, MC (corresponding author), St Johns Hlth Ctr, John Wayne Canc Inst, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.			Liu, Yong-Yu/0000-0002-7968-0162	NCI NIH HHS [CA77632] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077632] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATIST G, 1986, J BIOL CHEM, V261, P5544; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Cai ZZ, 1997, J BIOL CHEM, V272, P6918, DOI 10.1074/jbc.272.11.6918; CHUMA SJ, 1997, CANCER RES, V57, P1270; COWAN KH, 1986, P NATL ACAD SCI USA, V83, P9328, DOI 10.1073/pnas.83.24.9328; FAIRCHILD CR, 1990, MOL PHARMACOL, V37, P801; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FRESHNEY RI, 1994, CULTURE ANIMALS CELL; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; HALDAR S, 1995, P NATL ACAD SCI USA, V93, P5325; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; INOKUCHI J, 1990, CANCER RES, V50, P6731; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Jarvis WD, 1998, MOL PHARMACOL, V54, P844, DOI 10.1124/mol.54.5.844; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lavie Y, 1997, J BIOL CHEM, V272, P1682, DOI 10.1074/jbc.272.3.1682; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Liu YY, 1999, EXP CELL RES, V252, P464, DOI 10.1006/excr.1999.4649; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; Lucci A, 1999, INT J ONCOL, V15, P541; Lucci A, 1998, ANTICANCER RES, V18, P475; LUCCI A, 1999, CANCER, V86, P299; MIMNAUGH EG, 1991, BIOCHEM PHARMACOL, V42, P391, DOI 10.1016/0006-2952(91)90727-M; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; Monney L, 1998, EUR J BIOCHEM, V251, P295, DOI 10.1046/j.1432-1327.1998.2510295.x; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SHUKLA GS, 1990, ARCH BIOCHEM BIOPHYS, V283, P372, DOI 10.1016/0003-9861(90)90657-K; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; Spinedi A, 1998, CELL DEATH DIFFER, V5, P785, DOI 10.1038/sj.cdd.4400428; Takeda Y, 1999, J BIOL CHEM, V274, P10654, DOI 10.1074/jbc.274.15.10654; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Thomas RL, 1999, J BIOL CHEM, V274, P30580, DOI 10.1074/jbc.274.43.30580; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Yamashita T, 1999, P NATL ACAD SCI USA, V96, P9142, DOI 10.1073/pnas.96.16.9142; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	43	108	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7138	7143		10.1074/jbc.275.10.7138	http://dx.doi.org/10.1074/jbc.275.10.7138			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702281	hybrid			2022-12-27	WOS:000085809600061
J	Tzianabos, AO; Finberg, RW; Wang, Y; Chan, M; Onderdonk, AB; Jennings, HJ; Kasper, DL				Tzianabos, AO; Finberg, RW; Wang, Y; Chan, M; Onderdonk, AB; Jennings, HJ; Kasper, DL			T cells activated by zwitterionic molecules prevent abscesses induced by pathogenic bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTOCOMPATIBILITY COMPLEX-MOLECULES; ANTIGEN-PRESENTING CELLS; MYELIN BASIC-PROTEIN; BACTEROIDES-FRAGILIS; CAPSULAR POLYSACCHARIDE; INTRAABDOMINAL ABSCESSES; STRUCTURAL ELUCIDATION; SYNTHETIC COPOLYMER-1; ANTIBODY-RESPONSE; MHC MOLECULES	Immunologic paradigms classify bacterial polysaccharides as T cell-independent antigens, However, these models fail to explain how zwitterionic polysaccharides (Zps) confer protection against intraabdominal abscess formation in a T cell-dependent manner. Here, we demonstrate that Zps elicit a potent CD4+ T cell response in vitro that requires available major histocompatibility complex class H molecules on antigen-presenting cells. Specific chemical modifications to Zps show that: 1) the activity is specific for carbohydrate structure, and 2) the proliferative response depends upon free amino and carboxyl groups on the repeating units of these polysaccharides, Peptides synthesized to mimic the zwitterionic charge motif associated with Zps also exhibited these biologic properties. Lysine-aspartic acid (KD) peptides with more than 15 repeating units stimulated CD4+ T cells in vitro and conferred protection against abscesses induced by bacteria such as Bacteroides fragilis and Staphylococcus aureus. Evidence for the biologic importance of T cell activation by these zwitterionic polymers was provided when human CD4+ T cells stimulated with these molecules in vitro and adoptively transferred to rats in vivo conferred protection against intraabdominal abscesses induced by viable bacterial challenge. These studies demonstrate that bacterial polysaccharides with a distinct charge motif activate T cells and that this activity confers immunity to a distinct pathologic response to bacterial infection.	Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Infect Dis, Boston, MA 02115 USA; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; National Research Council Canada	Tzianabos, AO (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.	atzianabos@channing.harvard.edu	Finberg, Robert W/E-3323-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034073, R21AI039576, R01AI039576] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 34073, AI 39576] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAUMANN H, 1992, BIOCHEMISTRY-US, V31, P4081, DOI 10.1021/bi00131a026; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; Brubaker JO, 1999, J IMMUNOL, V162, P2235; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; Corinti S, 1997, J EXP MED, V186, P899, DOI 10.1084/jem.186.6.899; Deehan MR, 1998, J IMMUNOL, V160, P2692; FINBERG RW, 1992, J IMMUNOL, V149, P2055; Fridkis-Hareli M, 1998, J IMMUNOL, V160, P4386; FRIDKISHARELI M, 1995, CELL IMMUNOL, V163, P229, DOI 10.1006/cimm.1995.1121; FridkisHareli M, 1997, INT IMMUNOL, V9, P925, DOI 10.1093/intimm/9.7.925; HARDING CV, 1993, J IMMUNOL, V151, P2419; HARDING CV, 1991, P NATL ACAD SCI USA, V88, P2740, DOI 10.1073/pnas.88.7.2740; HAREGEWOIN A, 1989, NATURE, V340, P309, DOI 10.1038/340309a0; Harnett MM, 1998, PARASITE IMMUNOL, V20, P551, DOI 10.1046/j.1365-3024.1998.00181.x; HAURUM JS, 1994, J EXP MED, V180, P739, DOI 10.1084/jem.180.2.739; ISHIOKA GY, 1992, J IMMUNOL, V148, P2446; KASPER DL, 1979, J INFECT DIS, V140, P724, DOI 10.1093/infdis/140.5.724; KASPER DL, 1977, J INFECT DIS, V136, P75, DOI 10.1093/infdis/136.1.75; LAL RB, 1990, AM J TROP MED HYG, V42, P56, DOI 10.4269/ajtmh.1990.42.56; LINDBERG B, 1980, CARBOHYD RES, V78, P111, DOI 10.1016/S0008-6215(00)83664-2; Lochnit G, 1998, J BIOL CHEM, V273, P466, DOI 10.1074/jbc.273.1.466; MARCH J, 1992, ADV ORG CHEM, P1202; MARKHAM RB, 1985, J IMMUNOL, V134, P4112; MICHAELSSON E, 1994, J EXP MED, V180, P745, DOI 10.1084/jem.180.2.745; MORITA CT, 1995, IMMUNITY, V3, P495, DOI 10.1016/1074-7613(95)90178-7; MULLER E, 1988, INFECT IMMUN, V56, P259, DOI 10.1128/IAI.56.1.259-266.1988; ONDERDONK AB, 1976, INFECT IMMUN, V13, P22, DOI 10.1128/IAI.13.1.22-26.1976; ONDERDONK AB, 1977, J INFECT DIS, V136, P82, DOI 10.1093/infdis/136.1.82; PANTOSTI A, 1991, INFECT IMMUN, V59, P2075, DOI 10.1128/IAI.59.6.2075-2082.1991; PAOLETTI LC, 1992, J CLIN INVEST, V89, P203, DOI 10.1172/JCI115564; POLK BF, 1977, ANN INTERN MED, V86, P569, DOI 10.7326/0003-4819-86-5-569; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; Reeves RE, 1941, J BIOL CHEM, V139, P511; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; TAYLOR CE, 1989, INFECT IMMUN, V57, P180, DOI 10.1128/IAI.57.1.180-185.1989; TZIANABOS AO, 1993, SCIENCE, V262, P416, DOI 10.1126/science.8211161; TZIANABOS AO, 1992, J BIOL CHEM, V267, P18230; TZIANABOS AO, 1994, INFECT IMMUN, V62, P3590, DOI 10.1128/IAI.62.8.3590-3593.1994; Tzianabos AO, 1995, J CLIN INVEST, V96, P2727, DOI 10.1172/JCI118340; TZIANABOS AO, 1994, INFECT IMMUN, V62, P4881, DOI 10.1128/IAI.62.11.4881-4886.1994; Tzianabos AO, 1999, J IMMUNOL, V163, P893; ZHENG B, 1992, SCIENCE, V256, P1560, DOI 10.1126/science.1598588; [No title captured]	43	89	104	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6733	6740		10.1074/jbc.275.10.6733	http://dx.doi.org/10.1074/jbc.275.10.6733			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702228	hybrid			2022-12-27	WOS:000085809600008
J	Jacob, R; Alfalah, M; Grunberg, J; Obendorf, M; Naim, HY				Jacob, R; Alfalah, M; Grunberg, J; Obendorf, M; Naim, HY			Structural determinants required for apical sorting of an intestinal brush-border membrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; INFLUENZA-VIRUS HEMAGGLUTININ; LACTASE-PHLORIZIN HYDROLASE; SUCRASE-ISOMALTASE COMPLEX; HUMAN AMINOPEPTIDASE-N; MDCK CELLS; EPITHELIAL-CELLS; INTRACELLULAR-TRANSPORT; CYTOPLASMIC DOMAIN	The distinct protein and lipid constituents of the apical and basolateral membranes in polarized cells are sorted by specific signals. O-Glycosylation of a highly polarized intestinal brush-border protein sucrase isomaltase is implicated in its apical sorting through interaction with sphingolipid-cholesterol microdomains, We characterized the structural determinants required for this mechanism by focusing on two major domains in pro-SI, the membrane anchor and the Ser/Thr-rich stalk domain. Deletion mutants lacking either domain, pro-SIDelta ST (stalk-free) and pro-SIDelta MA (membrane anchor-free), were constructed and expressed in polarized Madin-Darby canine kidney cells. In the absence of the membrane anchoring domain, pro-SIDelta MA does not associate with Lipid rafts and the mutant is randomly delivered to both membranes. Therefore, the O-glycosylated stalk region is not sufficient per se for the high fidelity of apical sorting of pro SI. Pro-SIDelta MA does not associate either with lipid rafts and its targeting behavior is similar to that of pro-SIDelta MA. Only wild type pro-SI containing both determinants, the stalk region and membrane anchor, associates with Lipid microdomains and is targeted correctly to the apical membrane, However, not all sequences in the stalk region are required for apical sorting. Only O-glycosylation of a stretch of 12 amino acids (Ala(37)-pro(48)) juxtapose the membrane anchor is required in conjunction with the membrane anchoring domain for correct targeting of pro-SI to the apical membrane, Other O-glycosylated domains within the stalk (Ala(49)-Pro(57)) are not sufficient for apical sorting. We conclude that the recognition signal for apical sorting of pro-SI comprises O-glycosylation of the Ala(37) Pro(48) stretch and requires the presence of the membrane anchoring domain.	Hannover Sch Vet Med, Dept Physiol Chem, D-30559 Hannover, Germany	University of Veterinary Medicine Hannover, Foundation	Naim, HY (corresponding author), Hannover Sch Vet Med, Dept Physiol Chem, Bunteweg 17, D-30559 Hannover, Germany.		Al Falah, Dr. Marwan/C-6281-2011; Jacob, Ralf/B-8163-2011					Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; GREEN F, 1987, GENE, V57, P101, DOI 10.1016/0378-1119(87)90181-8; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; Jacob R, 1999, J BIOL CHEM, V274, P8061, DOI 10.1074/jbc.274.12.8061; JACOB R, 1994, J BIOL CHEM, V269, P2712; JOKINEN M, 1985, J BIOL CHEM, V260, P1314; KITAGAWA Y, 1994, EXP CELL RES, V213, P449, DOI 10.1006/excr.1994.1222; KOZARSKY K, 1988, P NATL ACAD SCI USA, V85, P4335, DOI 10.1073/pnas.85.12.4335; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; MATLIN K, 1983, J CELL BIOL, V97, P627, DOI 10.1083/jcb.97.3.627; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; Mirre C, 1996, AM J PHYSIOL-CELL PH, V271, pC887, DOI 10.1152/ajpcell.1996.271.3.C887; Monlauzeur L, 1998, J BIOL CHEM, V273, P30263, DOI 10.1074/jbc.273.46.30263; Moolenaar CEC, 1997, J CELL SCI, V110, P557; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; NAIM HY, 1988, J BIOL CHEM, V263, P7242; Naim HY, 1999, J BIOL CHEM, V274, P17961, DOI 10.1074/jbc.274.25.17961; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1993, BIOCHEM J, V296, P607, DOI 10.1042/bj2960607; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; VOGEL LK, 1992, J BIOL CHEM, V267, P2794; VOGEL LK, 1992, FEBS LETT, V308, P14, DOI 10.1016/0014-5793(92)81039-O; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929	40	67	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6566	6572		10.1074/jbc.275.9.6566	http://dx.doi.org/10.1074/jbc.275.9.6566			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692463	hybrid			2022-12-27	WOS:000085654400075
J	Jarvis, SE; Magga, JM; Beedle, AM; Braun, JEA; Zamponi, GW				Jarvis, SE; Magga, JM; Beedle, AM; Braun, JEA; Zamponi, GW			G protein modulation of N-type calcium channels is facilitated by physical interactions between syntaxin 1A and G beta gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNELS; FUNCTIONAL EXPRESSION; KINASE-C; SUBCELLULAR-DISTRIBUTION; SYNAPTIC TRANSMISSION; SYMPATHETIC NEURONS; RECEPTOR INHIBITION; VOLTAGE DEPENDENCE; INTRACELLULAR LOOP; DOMAIN-II	The direct modulation of N-type calcium channels by G protein beta gamma subunits is considered a key factor in the regulation of neurotransmission. Some of the molecular determinants that govern the binding interaction of N-type channels and G beta gamma have recently been identified (see, Le., Zamponi, G. W., Bourinet, E., Nelson, D., Nargeot, J., and Snutch, T. P. (1997) Nature 385, 442-446); however, little is known about cellular mechanisms that modulate this interaction. Here we report that a protein of the presynaptic vesicle release complex, syntaxin 1A, mediates a crucial role in the tonic inhibition of N-type channels by G beta gamma. When syntaxin 1A was coexpressed with (N-type) alpha(1B) + alpha(2)-delta + beta(1b) channels in tsA-201 cells, the channels underwent a 18 mV negative shift in half-inactivation potential, as well as a pronounced tonic G protein inhibition as assessed by its reversal by strong membrane depolarizations. This tonic inhibition was dramatically attenuated following incubation with botulinum toxin C, indicating that syntaxin 1A expression was indeed responsible for the enhanced G; protein modulation. However, when G protein beta gamma subunits were concomitantly coexpressed, the toxin became ineffective in removing G protein inhibition, suggesting that syntaxin LA optimizes, rather than being required for G protein modulation of N-type channels. We also demonstrate that G beta gamma physically binds to syntaxin 1A, and that syntaxin 1A can simultaneously interact with G beta gamma and the synprint motif of the N-type channel II-III linker. Taken together, our experiments suggest a mechanism by which syntaxin IA mediates a colocalization of G protein beta gamma subunits and N-type calcium channels, thus resulting in more effective G protein coupling to, and regulation of, the channel. Thus, the interactions between syntaxin, G proteins, and N-type calcium channels are part of the structural specialization of the presynaptic terminal.	Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Physiol & Biophys, Neurosci Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Zamponi, GW (corresponding author), Univ Calgary, Dept Pharmacol & Therapeut, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.		Beedle, Aaron/AAI-7014-2020; Beedle, Aaron M/K-1902-2015	Beedle, Aaron M/0000-0002-1019-3235; Zamponi, Gerald W./0000-0002-0644-9066; Magga, Johanna/0000-0003-4688-9098				BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; Bech-Hansen NT, 1998, NAT GENET, V19, P264, DOI 10.1038/947; BEECH DJ, 1992, NEURON, V8, P97, DOI 10.1016/0896-6273(92)90111-P; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BOLAND LM, 1993, J NEUROSCI, V13, P515; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; CAMPBELL V, 1995, J PHYSIOL-LONDON, V485, P365, DOI 10.1113/jphysiol.1995.sp020735; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; DUNLAP K, 1981, J PHYSIOL-LONDON, V317, P519, DOI 10.1113/jphysiol.1981.sp013841; ELMSLIE KS, 1992, J PHYSIOL-LONDON, V456, P107, DOI 10.1113/jphysiol.1992.sp019329; Fisher SE, 1997, GENOMICS, V45, P340, DOI 10.1006/geno.1997.4941; FUJITA Y, 1993, NEURON, V10, P585, DOI 10.1016/0896-6273(93)90162-K; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hamid J, 1999, J BIOL CHEM, V274, P6195, DOI 10.1074/jbc.274.10.6195; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; IKEDA SR, 1989, J PHYSIOL-LONDON, V409, P221, DOI 10.1113/jphysiol.1989.sp017494; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Lee JH, 1999, J NEUROSCI, V19, P1912; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Page KM, 1997, J NEUROSCI, V17, P1330; Patil PG, 1996, BIOPHYS J, V71, P2509, DOI 10.1016/S0006-3495(96)79444-4; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; QUIN N, 1997, P NATL ACAD SCI USA, V94, P8866; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; Stanley EF, 1997, NATURE, V385, P340, DOI 10.1038/385340a0; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; STEA A, 1994, P NATL ACAD SCI USA, V91, P10567; Sutton KG, 1999, NATURE, V401, P800, DOI 10.1038/44586; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; SWARTZ KJ, 1993, NEURON, V11, P305, DOI 10.1016/0896-6273(93)90186-U; TOMLINSON WJ, 1993, NEUROPHARMACOLOGY, V32, P1117, DOI 10.1016/0028-3908(93)90006-O; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; Yokoyama CT, 1997, J NEUROSCI, V17, P6929; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zamponi GW, 1998, P NATL ACAD SCI USA, V95, P4035, DOI 10.1073/pnas.95.7.4035; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9	51	109	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6388	6394		10.1074/jbc.275.9.6388	http://dx.doi.org/10.1074/jbc.275.9.6388			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692440	hybrid			2022-12-27	WOS:000085654400052
J	Kataoka, H; Kume, N; Miyamoto, S; Minami, M; Murase, T; Sawamura, T; Masaki, T; Hashimoto, N; Kita, T				Kataoka, H; Kume, N; Miyamoto, S; Minami, M; Murase, T; Sawamura, T; Masaki, T; Hashimoto, N; Kita, T			Biosynthesis and post-translational processing of lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) - N-linked glycosylation affects cell-surface expression and ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; HUMAN THYROTROPIN RECEPTOR; INSULIN-RECEPTOR; SCAVENGER RECEPTOR; LDL RECEPTOR-1; ALPHA-SUBUNIT; BETA-SUBUNIT; E-SELECTIN; OLIGOSACCHARIDES; MACROPHAGES	LOX-1 (lectin-like oxidized low density lipoprotein receptor-1) is a type II membrane protein belonging to the C-type lectin family that can act as a cell-surface receptor for atherogenic oxidized low density lipoprotein (Ox-LDL) and may play crucial roles in atherogenesis. In this study, we show, by pulse-chase labeling and glycosidase digestion, that LOX-1 is synthesized as a 40-kDa precursor protein with N-linked high mannose carbohydrate chains (pre-LOX-1), which is subsequently further glycosylated and processed into the 48-kDa mature form within 40 min, Furthermore, when treated with an N-glycosylation inhibitor, tunicamycin, both tumor necrosis factor-alpha-activated bovine aortic endothelial cells and CHO-K1 cells stably expressing bovine LOX-1 (BLOX-1-CHO) exclusively produced a 32-kDa deglycosylated form of LOX-1, Cell enzyme-linked immunosorbent assay, flow cytometry, and immunofluorescence confocal microscopy demonstrated that the deglycosylated form of LOX-1 is not efficiently transported to the cell surface, but is retained in the endoplasmic reticulum or Golgi apparatus in tumor necrosis factor-alpha-activated bovine aortic endothelial cells, but not in BLOX-1-CHO cells. Radiolabeled Ox-LDL binding studies revealed that the deglycosylated form of LOX-1 expressed on the cell surface of BLOX-1-CHO cells has a reduced affinity for Ox-LDL binding, Taken together, N-linked glycosylation appears to play key roles in the cell-surface expression and ligand binding of LOX-1.	Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Neurosurg, Sakyo Ku, Kyoto 6068507, Japan; Natl Cardiovasc Ctr, Res Inst, Dept Biosci, Osaka 5658565, Japan	Kyoto University; Kyoto University; National Cerebral & Cardiovascular Center - Japan	Kume, N (corresponding author), Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.		Kataoka, Hiroharu/GPT-3596-2022; Sawamura, Tatsuya/E-7103-2010	Kataoka, Hiroharu/0000-0001-8507-7557				ASANO T, 1993, FEBS LETT, V324, P258, DOI 10.1016/0014-5793(93)80129-I; BASTIAN W, 1993, DIABETES, V42, P966, DOI 10.2337/diabetes.42.7.966; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOCHOLA J, 1993, J BIOL CHEM, V268, P2312; COLLIER E, 1993, BIOCHEMISTRY-US, V32, P7818, DOI 10.1021/bi00081a029; DING DXH, 1995, J BIOL CHEM, V270, P24580, DOI 10.1074/jbc.270.41.24580; ELBEIN AD, 1987, METHOD ENZYMOL, V138, P661; FEIGE JJ, 1988, J BIOL CHEM, V263, P14023; FONG LG, 1987, J LIPID RES, V28, P1466; GOLDBERGER A, 1994, J BIOL CHEM, V269, P17183; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Hart Gerald W., 1992, Current Opinion in Cell Biology, V4, P1017, DOI 10.1016/0955-0674(92)90134-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; JOHNSTON GI, 1989, J BIOL CHEM, V264, P1816; Kataoka H, 1999, CIRCULATION, V99, P3110, DOI 10.1161/01.CIR.99.24.3110; KATOH S, 1995, J EXP MED, V182, P419, DOI 10.1084/jem.182.2.419; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KUME N, 1991, BIOCHIM BIOPHYS ACTA, V1091, P63, DOI 10.1016/0167-4889(91)90223-K; Kume N, 1998, CIRC RES, V83, P322, DOI 10.1161/01.RES.83.3.322; LECONTE I, 1992, J BIOL CHEM, V267, P17415; LECONTE I, 1994, J BIOL CHEM, V269, P18062; MOLLER LB, 1993, J BIOL CHEM, V268, P11152; Moriwaki H, 1998, ARTERIOSCL THROM VAS, V18, P1541, DOI 10.1161/01.ATV.18.10.1541; Moriwaki H, 1998, FEBS LETT, V440, P29, DOI 10.1016/S0014-5793(98)01414-8; Murase T, 1998, CIRC RES, V83, P328, DOI 10.1161/01.RES.83.3.328; Nagayama Y, 1998, J BIOL CHEM, V273, P33423, DOI 10.1074/jbc.273.50.33423; Oka K, 1998, P NATL ACAD SCI USA, V95, P9535, DOI 10.1073/pnas.95.16.9535; PAHLSSON P, 1995, EUR J IMMUNOL, V25, P2452, DOI 10.1002/eji.1830250907; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUSSO D, 1991, MOL ENDOCRINOL, V5, P29, DOI 10.1210/mend-5-1-29; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; SEMMES OJ, 1992, INT J IMMUNOPHARMACO, V14, P583, DOI 10.1016/0192-0561(92)90119-6; SMEETS EF, 1993, EUR J IMMUNOL, V23, P147, DOI 10.1002/eji.1830230124; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; SZECOWKA J, 1990, ENDOCRINOLOGY, V126, P1834, DOI 10.1210/endo-126-4-1834; Thornhill WB, 1996, J BIOL CHEM, V271, P19093, DOI 10.1074/jbc.271.32.19093; TIFFT CJ, 1992, J BIOL CHEM, V267, P3268; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Wright A, 1998, J IMMUNOL, V160, P3393; Yoshida H, 1998, BIOCHEM J, V334, P9, DOI 10.1042/bj3340009	41	62	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6573	6579		10.1074/jbc.275.9.6573	http://dx.doi.org/10.1074/jbc.275.9.6573			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692464	hybrid			2022-12-27	WOS:000085654400076
J	Kruse, O; Hankamer, B; Konczak, C; Gerle, C; Morris, E; Radunz, A; Schmid, GH; Barber, J				Kruse, O; Hankamer, B; Konczak, C; Gerle, C; Morris, E; Radunz, A; Schmid, GH; Barber, J			Phosphatidylglycerol is involved in the dimerization of photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; CYANOBACTERIUM OSCILLATORIA-CHALYBEA; LIPID-PROTEIN INTERACTIONS; CYTOCHROME-C-OXIDASE; 3-DIMENSIONAL STRUCTURE; BIOCHEMICAL-CHARACTERIZATION; CHLAMYDOMONAS-REINHARDTII; ELECTRON CRYSTALLOGRAPHY; D1-CORE PEPTIDE; GREEN PLANTS	Photosystem II core dimers (450 kDa) and monomers (230 kDa) consisting of CP47, CP43, the D1 and D2 proteins, the extrinsic 33-kDa subunit, and the low molecular weight polypeptides PsbE, PsbF, PsbH, PsbI, PsbK, PsbL, PshTc, and PsbW were isolated by sucrose density gradient centrifugation. The photosystem II core dimers were treated with phospholipase A2 (PL-A2), which cuts phosphatidylglycerol (PG) and phosphatidylcholine molecules at the sn-2 position. The PL-A2-treated dimers dissociated into two core monomers and further, yielding a CP47-D1-D2 subcomplex and CP43. Thin layer chromatography showed that photosystem II dimers contained four times more PG than their monomeric counterparts but with similar levels of phosphatidylcholine. Consistent with this was the finding that, compared with monomers, the dimers contained a higher level of trans-hexadecanoic fatty acid (C16:1 Delta 3tr), which is specific to PG of the thylakoid membrane. Moreover, treatment of dimers with PL-A2 increased the free level of this fatty acid specific to PG compared with untreated dimers. Further evidence that PG is involved in stabilizing the dimeric state of photosystem II comes from reconstitution experiments. Using size exclusion chromatography, it was shown that PG containing C16:1 Delta 3tr, but not other lipid classes, induced significant dimerization of isolated photosystem II monomers. Moreover, this dimerization was observed by electron crystallography when monomers were reconstituted into thylakoid lipids containing PG. The unit cell parameters, p2 symmetry axis, and projection map of the reconstituted dimer was similar to that observed for two dimensional crystals of the native dimer.	Univ Bielefeld, Dept Biol, D-33615 Bielefeld, Germany; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England	University of Bielefeld; Imperial College London	Kruse, O (corresponding author), Univ Bielefeld, Dept Biol, D-33615 Bielefeld, Germany.	Olaf.Kruse@Biolgie.Uni-Bielefeld.de	Kruse, Olaf/O-1127-2015; Hankamer, Ben D/C-9688-2015	Hankamer, Ben D/0000-0001-9284-4929; Kruse, Olaf/0000-0001-9874-382X; Morris, Edward/0000-0003-3544-0041; Gerle, Christoph/0000-0002-7265-2804				ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; BARBATO R, 1992, J CELL BIOL, V119, P325, DOI 10.1083/jcb.119.2.325; BOEKEMA EJ, 1995, P NATL ACAD SCI USA, V92, P175, DOI 10.1073/pnas.92.1.175; CHAPMAN DJ, 1983, PLANTA, V157, P218, DOI 10.1007/BF00405185; DEBUCH H, 1968, H-S Z PHYSIOL CHEM, V349, P896, DOI 10.1515/bchm2.1968.349.2.896; DITTMER JC, 1964, J LIPID RES, V5, P126; El Maanni A, 1998, PLANT PHYSIOL BIOCH, V36, P609, DOI 10.1016/S0981-9428(98)80009-0; Fragata M, 1997, J MOL STRUCT, V405, P151, DOI 10.1016/S0022-2860(96)09600-7; FRAGATA M, 1994, TRENDS PHOTOCHEM PHO, V3, P201; GARNIER J, 1990, BIOCHIM BIOPHYS ACTA, V1020, P153, DOI 10.1016/0005-2728(90)90046-7; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; Hankamer B, 1997, ANNU REV PLANT PHYS, V48, P641, DOI 10.1146/annurev.arplant.48.1.641; Hankamer B, 1999, NAT STRUCT BIOL, V6, P560, DOI 10.1038/9341; Hankamer B, 1997, EUR J BIOCHEM, V243, P422, DOI 10.1111/j.1432-1033.1997.0422a.x; HARWOOD JL, 1984, LIPIDS PLANTS MICROB, P36; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; HOBE S, 1994, EMBO J, V13, P3423, DOI 10.1002/j.1460-2075.1994.tb06647.x; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; KRUSE O, 1995, Z NATURFORSCH C, V50, P380; KRUSE O, 1994, Z NATURFORSCH C, V49, P115; Kruse O, 1997, FEBS LETT, V408, P276, DOI 10.1016/S0014-5793(97)00439-0; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI G, 1989, BIOCHEMISTRY-US, V28, P7446, DOI 10.1021/bi00444a044; Lyon MK, 1998, BBA-BIOENERGETICS, V1364, P403, DOI 10.1016/S0005-2728(98)00064-4; Marr KM, 1996, J CELL BIOL, V132, P823, DOI 10.1083/jcb.132.5.823; MCCOURT P, 1985, PLANT PHYSIOL, V78, P853, DOI 10.1104/pp.78.4.853; MICHEL H, 1988, J BIOL CHEM, V263, P1123; Morris EP, 1997, STRUCTURE, V5, P837, DOI 10.1016/S0969-2126(97)00237-2; MOSKALENKO AA, 1992, FEBS LETT, V314, P271, DOI 10.1016/0014-5793(92)81487-7; Nilsson A, 1997, J BIOL CHEM, V272, P18350, DOI 10.1074/jbc.272.29.18350; NORBY JG, 1991, SOC GEN PHY, V46, P173; NUSSBERGER S, 1993, J MOL BIOL, V234, P347, DOI 10.1006/jmbi.1993.1591; OCONNOR HE, 1998, BIOCHIM BIOPHYS ACTA, V1365, P63; PETER GF, 1991, PLANT CELL PHYSIOL, V32, P1237; RADUNZ A, 1976, Z NATURFORSCH C, V31, P589; REILLY PL, 1995, J IMMUNOL, V155, P529; Rhee KH, 1997, NATURE, V389, P522, DOI 10.1038/39103; ROUGHAN PG, 1968, ANAL BIOCHEM, V22, P74, DOI 10.1016/0003-2697(68)90261-3; SANTINI C, 1994, EUR J BIOCHEM, V221, P307, DOI 10.1111/j.1432-1033.1994.tb18742.x; SCHALLER GE, 1995, J BIOL CHEM, V270, P12526, DOI 10.1074/jbc.270.21.12526; SCHMID GH, 1993, IMMUNOLOGIE ANWENDUN, P93; Schmid VHR, 1997, P NATL ACAD SCI USA, V94, P7667, DOI 10.1073/pnas.94.14.7667; SEIBERT M, 1987, J CELL BIOL, V105, P2257, DOI 10.1083/jcb.105.5.2257; Siegenthaler P. A., 1998, LIPIDS PHOTOSYNTHESI, V6; SIEGENTHALER PA, 1994, PLANT LIPID METABOLISM, P170; Summer EJ, 1997, PLANT PHYSIOL, V113, P1359, DOI 10.1104/pp.113.4.1359; TREMOLIERES A, 1994, EUR J BIOCHEM, V221, P721, DOI 10.1111/j.1432-1033.1994.tb18785.x; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7; Zheleva D, 1998, J BIOL CHEM, V273, P16122, DOI 10.1074/jbc.273.26.16122	54	143	156	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6509	6514		10.1074/jbc.275.9.6509	http://dx.doi.org/10.1074/jbc.275.9.6509			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692455	hybrid			2022-12-27	WOS:000085654400067
J	Zhu, DM; Tekle, E; Huang, CY; Chock, PB				Zhu, DM; Tekle, E; Huang, CY; Chock, PB			Inositol tetrakisphosphate as a frequency regulator in calcium oscillations in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; POSITIVE FEEDBACK; GENE-EXPRESSION; RAT HEPATOCYTES; 1,4,5-TRISPHOSPHATE; 1,3,4,5-TETRAKISPHOSPHATE; PHOSPHORYLATION; TRISPHOSPHATE; MECHANISM; RECEPTOR	Cellular signaling mediated by inositol (1,4,5)trisphosphate (Ins(1,4,5)P-3) results in oscillatory intracellular calcium (Ca2+) release. Because the amplitude of the Ca2+ spikes is relatively invariant, the extent of the agonist-mediated effects must reside in their ability to regulate the oscillating frequency. Using electroporation techniques, we show that Ins(1,4,5)P-3, Ins(1,3,4,5)P-4, and Ins(1,3,4,6)P-4 cause a rapid intracellular Ca2+ release in resting HeLa cells and a transient increase in the frequency of ongoing Ca2+ oscillations stimulated by histamine. Two poorly metabolizable analogs of Ins(1,4,5)P-3, Ins(2,4,5)P-3, and 2,3-dideoxy-Ins(1,4,5)P-3, gave a single Ca2+ spike and failed to alter the frequency of ongoing oscillations. Complete inhibition of Ins (1,4,5)P-3 3-kinase (IP3K) by either adriamycin or its specific antibody blocked Ca2+ oscillations. Partial inhibition of IP3K causes a significant reduction in frequency. Taken together, our results indicate that Ins(1,3,4,5)P-4 is the frequency regulator in vivo, and IP3K, which phosphorylates Ins(1,4,5)P-3 to Ins(1,3,4,5)P-4, plays a major regulatory role in intracellular Ca2+ oscillations.	NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Chock, PB (corresponding author), NHLBI, Biochem Lab, NIH, Bldg 3,Rm 204,3 Ctr Dr,MSC-0342, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000202, ZIAHL000202] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bennett DL, 1996, J BIOL CHEM, V271, P6356, DOI 10.1074/jbc.271.11.6356; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; Bootman MD, 1996, BIOCHEM J, V314, P347, DOI 10.1042/bj3140347; CUTHBERTSON KSR, 1991, CELL CALCIUM, V12, P97, DOI 10.1016/0143-4160(91)90012-4; DASILVA CP, 1994, J BIOL CHEM, V269, P12521; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; DOUGHNEY C, 1988, BIOCHEM J, V251, P927, DOI 10.1042/bj2510927; ELY JA, 1990, BIOCHEM J, V268, P333, DOI 10.1042/bj2680333; GAWLER DJ, 1990, BIOCHEM J, V272, P519, DOI 10.1042/bj2720519; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; HAROOTUNIAN AT, 1991, CELL CALCIUM, V12, P153, DOI 10.1016/0143-4160(91)90017-9; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; HUGHES PJ, 1989, J BIOL CHEM, V264, P19871; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; LI YX, 1995, AM J PHYSIOL-CELL PH, V269, pC1079, DOI 10.1152/ajpcell.1995.269.5.C1079; Lockyer PJ, 1999, BIOCHEM BIOPH RES CO, V255, P421, DOI 10.1006/bbrc.1999.0217; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; Murphy CT, 1996, MOL PHARMACOL, V50, P1223; PALMER S, 1989, CELL SIGNAL, V1, P147, DOI 10.1016/0898-6568(89)90004-1; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PUTNEY JW, 1994, TRENDS ENDOCRIN MET, V5, P256, DOI 10.1016/1043-2760(94)P3085-L; RYU SH, 1987, FASEB J, V1, P388, DOI 10.1096/fasebj.1.5.2824270; SHEARS SB, 1992, ADV 2 MESSENGER PHOS, P63; TEKLE E, 1991, P NATL ACAD SCI USA, V88, P4230, DOI 10.1073/pnas.88.10.4230; TEKLE E, 1994, P NATL ACAD SCI USA, V91, P11512, DOI 10.1073/pnas.91.24.11512; TSUNODA Y, 1997, NEW BIOL, V3, P3; WOODS NM, 1987, CELL CALCIUM, V8, P79, DOI 10.1016/0143-4160(87)90038-8; Zhu DM, 1996, BIOCHEMISTRY-US, V35, P7214, DOI 10.1021/bi952471h; ZWILLER J, 1988, BIOCHEM BIOPH RES CO, V155, P767, DOI 10.1016/S0006-291X(88)80561-8	34	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6063	6066		10.1074/jbc.275.9.6063	http://dx.doi.org/10.1074/jbc.275.9.6063			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692393	hybrid			2022-12-27	WOS:000085654400005
J	Biwa, T; Sakai, M; Matsumura, T; Kobori, S; Kaneko, K; Miyazaki, A; Hakamata, H; Horiuchi, S; Shichiri, M				Biwa, T; Sakai, M; Matsumura, T; Kobori, S; Kaneko, K; Miyazaki, A; Hakamata, H; Horiuchi, S; Shichiri, M			Sites of action of protein kinase C and phosphatidylinositol 3-kinase are distinct in oxidized low density lipoprotein-induced macrophage proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; RAT PERITONEAL-MACROPHAGES; SCAVENGER RECEPTOR; GM-CSF; T-CELLS; SIGNAL TRANSDUCTION; FACTOR PROMOTER; LIGAND ACTIVITY; CROSS-LINKING; GROWTH-FACTOR	Oxidized low density lipoprotein (Ox-LDL) can induce macrophage proliferation in vitro. To explore the mechanisms involved in this process, we reported that activation of protein kinase C (PKC) is involved in its signaling pathway (Matsumura, T., Sakai, M., Kobori, S., Biwa, T., Takemura, T., Matsuda, H., Hakamata, H., Horiuchi, S., and Shichiri, Ri. (1997) Arterioscler. Thromb. Vasc. Biol, 17, 3013-3020) and that expression of granulocyte/macrophage colony-stimulating factor (GM-CSF) and its subsequent release in the culture medium are important (Biwa, T., Hakamata, H., Sakai Ri., Miyazaki, A., Suzuki, H., Kodama, T., Shichiri, M., and Horiuchi, S. (1998) J. Biol. Chem. 273, 28305-28313). However, a recent study also demonstrated the involvement of phosphatidylinositol 3-kinase (PI3K) in this process. In the present study, we investigated the role of PKC and 13K in Ox-LDL induced macrophage proliferation. Ox-LDL- induced macrophage proliferation was inhibited by 90%: by a PK inhibitor, calphostin C, and 50% by a PI3K inhibitor, wortmannin. Ox-LDL-induced expression of GM-CSF and its subsequent release were inhibited by calphostin C but not by wortmannin, whereas recombinant GM-CSF-induced macrophage proliferation was inhibited by wortmannin by 50% but not by calphostin C. Ox-LDL activated PI3K at two time points (10 min and 4 h), and the activation at the second but not first point was significantly inhibited by calphostin C and anti-GM-CSF antibody. Our results suggest that PKC plays a role upstream in the signaling pathway to GM-CSF induction, whereas PI3K is involved, at least in part, downstream in the signaling pathway after GRP CSF induction.	Kumamoto Univ, Sch Med, Dept Metab Med, Kumamoto 8608556, Japan; Kumamoto Univ, Sch Med, Dept Biochem, Kumamoto 8608556, Japan	Kumamoto University; Kumamoto University	Horiuchi, S (corresponding author), Kumamoto Univ, Sch Med, Dept Metab Med, Honjo 1-1-1, Kumamoto 8608556, Japan.							AagaardTillery KM, 1996, J IMMUNOL, V156, P4543; Al-Shami A, 1999, J BIOL CHEM, V274, P5333, DOI 10.1074/jbc.274.9.5333; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BAGLEY CJ, 1995, J LEUKOCYTE BIOL, V57, P739, DOI 10.1002/jlb.57.5.739; Biwa T, 1998, J BIOL CHEM, V273, P28305, DOI 10.1074/jbc.273.43.28305; BRORSON KA, 1991, J IMMUNOL, V147, P3601; COLEMAN DL, 1989, J IMMUNOL, V145, P4134; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; HAKAMATA H, 1994, ARTERIOSCLER THROMB, V14, P1860, DOI 10.1161/01.ATV.14.11.1860; HAMILTON JA, 1981, J CELL PHYSIOL, V106, P445, DOI 10.1002/jcp.1041060314; Hamilton JA, 1999, ARTERIOSCL THROM VAS, V19, P98, DOI 10.1161/01.ATV.19.1.98; HerreraVelit P, 1996, J IMMUNOL, V156, P1157; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Hiraguri M, 1997, J ALLERGY CLIN IMMUN, V100, pS45; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Martens JS, 1999, J BIOL CHEM, V274, P10903, DOI 10.1074/jbc.274.16.10903; Martens JS, 1998, J BIOL CHEM, V273, P4915, DOI 10.1074/jbc.273.9.4915; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; Matsumura T, 1997, ARTERIOSCL THROM VAS, V17, P3013, DOI 10.1161/01.ATV.17.11.3013; Matsumura T, 1999, J BIOL CHEM, V274, P37665, DOI 10.1074/jbc.274.53.37665; McLeish KR, 1998, J LEUKOCYTE BIOL, V64, P537, DOI 10.1002/jlb.64.4.537; Miike S, 1999, J LEUKOCYTE BIOL, V65, P700, DOI 10.1002/jlb.65.5.700; MITAJIMA A, 1993, BLOOD, V82, P1960; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; MIYATAKE S, 1985, EMBO J, V4, P2561, DOI 10.1002/j.1460-2075.1985.tb03971.x; MIYAZAKI A, 1994, J BIOL CHEM, V269, P5264; MIYAZAKI A, 1991, BIOCHIM BIOPHYS ACTA, V1082, P143; Moore KJ, 1998, ARTERIOSCL THROM VAS, V18, P1647, DOI 10.1161/01.ATV.18.10.1647; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OKADA T, 1994, J BIOL CHEM, V269, P3563; RAPOPORT AP, 1992, BLOOD REV, V6, P43, DOI 10.1016/0268-960X(92)90007-D; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P680, DOI 10.1161/01.ATV.10.5.680; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sakai M, 1998, TRENDS CARDIOVAS MED, V8, P119, DOI 10.1016/S1050-1738(97)00139-4; Sakai M, 1999, ARTERIOSCL THROM VAS, V19, P1726, DOI 10.1161/01.ATV.19.7.1726; Sakai M, 1996, J BIOL CHEM, V271, P27346, DOI 10.1074/jbc.271.44.27346; SAKAI M, 1994, J BIOL CHEM, V269, P31430; SAKAI M, 1992, FEBS LETT, V314, P199, DOI 10.1016/0014-5793(92)80974-L; Sakai M, 1996, ARTERIOSCL THROM VAS, V16, P600, DOI 10.1161/01.ATV.16.4.600; Sato Y, 1996, ATHEROSCLEROSIS, V125, P15, DOI 10.1016/0021-9150(96)05829-7; SHACKELFORD RE, 1995, J BIOL CHEM, V270, P3475, DOI 10.1074/jbc.270.8.3475; SPAGNOLI LG, 1991, ATHEROSCLEROSIS, V88, P87, DOI 10.1016/0021-9150(91)90260-A; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SUGIMOTO K, 1990, INT IMMUNOL, V2, P787, DOI 10.1093/intimm/2.8.787; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YUI S, 1993, ARTERIOSCLER THROMB, V13, P331, DOI 10.1161/01.ATV.13.3.331	50	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5810	5816		10.1074/jbc.275.8.5810	http://dx.doi.org/10.1074/jbc.275.8.5810			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681570	hybrid			2022-12-27	WOS:000085474500077
J	Fukumoto, S; Mutoh, T; Hasegawa, T; Miyazaki, H; Okada, M; Goto, G; Furukawa, K; Urano, T; Furukawa, K				Fukumoto, S; Mutoh, T; Hasegawa, T; Miyazaki, H; Okada, M; Goto, G; Furukawa, K; Urano, T; Furukawa, K			GD3 synthase gene expression in PC12 cells results in the continuous activation of TrkA and ERK1/2 and enhanced proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; GANGLIOSIDE-MEDIATED MODULATION; NEURONAL DIFFERENTIATION; RAT-BRAIN; TYROSINE PHOSPHORYLATION; PHEOCHROMOCYTOMA CELLS; MONOCLONAL-ANTIBODIES; RECEPTOR FUNCTION; LEUKEMIA-CELLS; HUMAN-MELANOMA	A rat pheochromocytoma cell line (PC12) transfected with ganglioside GD3 synthase gene showed a marked change in the ganglioside profile and enhanced proliferation and no response of neurite extension to nerve growth factor (NGF) stimulation. In these transfectant cells, a continuous phosphorylation of TrkA and the activation of ERK1/2 without NGF treatment were observed. Proliferation inhibition experiments with kinase inhibitors such as herbimycin A, K-252a, and PD98059 revealed that the enhanced proliferation was actually due to the activation of the Ras/MEK/ERK pathway. A TrkA dimer was detected in the GD3 synthase transfectant cells regardless of NGF treatment by crosslinking and immunoblotting, The increased expression of GD1b and GT1b in these transfectant cells might induce the conformational change of TrkA to form a dimer and to be activated continuously, These results may indicate regulatory roles of gangliosides in cell proliferation under physiological and malignant processes.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Fukui Med Sch, Dept Internal Med 2, Fukui 9101193, Japan; Nagasaki Univ, Sch Dent, Dept Pediat Dent, Nagasaki 8528588, Japan; Nagasaki Univ, Sch Med, Dept Pediat, Nagasaki 8528588, Japan; Hokkaido Univ, Sch Dent, Dept Pediat Dent, Sapporo, Hokkaido 0608586, Japan	Nagoya University; University of Fukui; Nagasaki University; Nagasaki University; Hokkaido University	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.		Mutoh, Tatsuro/H-4317-2019	Mutoh, Tatsuro/0000-0001-7712-8481; Fukumoto, Satoshi/0000-0002-5046-6891; Urano, Takeshi/0000-0003-3383-3554				BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; CARUBIA JM, 1984, BIOCHEM BIOPH RES CO, V120, P500, DOI 10.1016/0006-291X(84)91282-8; DANIOTTI JL, 1991, J NEUROCHEM, V57, P2054, DOI 10.1111/j.1471-4159.1991.tb06421.x; EVELETH DD, 1992, J CELL BIOL, V117, P291, DOI 10.1083/jcb.117.2.291; Farooqui T, 1997, J NEUROCHEM, V68, P2348; FERRARI G, 1995, J BIOL CHEM, V270, P3074, DOI 10.1074/jbc.270.7.3074; FURUKAWA K, 1990, GANGLIOSIDES MELANOM, P15; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; HERSEY P, 1986, CANCER RES, V46, P6083; HOUGHTON AN, 1985, P NATL ACAD SCI USA, V82, P1242, DOI 10.1073/pnas.82.4.1242; Hynds DL, 1997, J NEUROSCI RES, V47, P617, DOI 10.1002/(SICI)1097-4547(19970315)47:6<617::AID-JNR7>3.0.CO;2-G; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; KAWAI K, 1994, JPN J PSYCHIAT NEUR, V48, P655; KOJIMA N, 1994, J BIOL CHEM, V269, P30451; Ledeen RW, 1998, ANN NY ACAD SCI, V845, P161, DOI 10.1111/j.1749-6632.1998.tb09669.x; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Liu H, 1997, GLYCOBIOLOGY, V7, P1067, DOI 10.1093/glycob/7.8.1067; Lloyd KO, 1998, GLYCOCONJUGATE J, V15, P627, DOI 10.1023/A:1006924128550; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MERRITT WD, 1987, CANCER RES, V47, P1724; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; Nakano J, 1996, J INVEST DERMATOL, V107, P543, DOI 10.1111/1523-1747.ep12582802; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; Okada M, 1996, CANCER RES, V56, P2844; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; ROSNER H, 1992, NEUROCHEM INT, V20, P339, DOI 10.1016/0197-0186(92)90048-V; SIDDIQUI B, 1984, CANCER RES, V44, P5262; STROM A, 1997, GENE DEV, V11, P3163; SUZUKI K, 1965, J NEUROCHEM, V12, P969, DOI 10.1111/j.1471-4159.1965.tb10256.x; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; THAMPOE IJ, 1989, CANCER RES, V49, P6258; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Watanabe Y, 1996, J BIOCHEM-TOKYO, V120, P1020; WEIS FMB, 1990, J BIOL CHEM, V265, P12059; WELTE K, 1987, J IMMUNOL, V139, P1763; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; Yamamoto A, 1996, J NEUROCHEM, V66, P26; YAMASHIRO S, 1995, J BIOL CHEM, V270, P6149, DOI 10.1074/jbc.270.11.6149; YU RK, 1988, J NEUROCHEM, V50, P1825, DOI 10.1111/j.1471-4159.1988.tb02484.x	45	95	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5832	5838		10.1074/jbc.275.8.5832	http://dx.doi.org/10.1074/jbc.275.8.5832			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681573	hybrid			2022-12-27	WOS:000085474500080
J	Loewen, CJR; Molday, RS				Loewen, CJR; Molday, RS			Disulfide-mediated oligomerization of peripherin/Rds and Rom-1 in photoreceptor disk membranes - Implications for photoreceptor outer segment morphogenesis and degeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT RETINITIS-PIGMENTOSA; RDS MUTANT MICE; RETINAL DEGENERATION; SLOW RDS; ROD PHOTORECEPTORS; MOLECULAR-CLONING; GENE; PROTEIN; MUTATIONS; LOCALIZATION	Peripherin/Rds is a tetraspanning membrane protein that has been implicated in photoreceptor outer segment morphogenesis and inherited retinal degenerative diseases. Together with the structurally related protein, Rom-1, it forms a complex along the rims of rod and cone disc membranes. We have compared the oligomeric structure of these proteins from nonreduced and dithiothreitol reduced membranes by velocity sedimentation, SDS-gel electrophoresis, immunoaffinity chromatography, and chemical cross-linking. Under reducing conditions peripherin/Rds and Rom-1 existed as homomeric and heteromeric core complexes devoid of intermolecular disulfide bonds. Under nonreducing conditions core complexes associated through intermolecular disulfide bonds to form oligomers. One intermediate-size oligomer contained monomers and disulfide-linked dimers of peripherin/Rds and Rom-1, while larger oligomers consisted only of disulfide-linked peripherin/Rds dimers when analyzed on nonreducing SDS gels. Consistent with this result, disc membranes contained twice as much peripherin/Rds as Rom-1. Peripherin/Rds individually expressed in COS-1 cells also formed disulfide-linked oligomers bridged through Cys-150 residues, whereas Rom-1 showed little tendency to form oligomers, These results indicate that peripherin/Rds and Rom-1 associate noncovalently to form multisubunit core complexes, Peripherin/Rds containing core complexes interact through specific intermolecular disulfide bonds to form oligomers which may play a crucial role in photoreceptor disc morphogenesis and retinal degenerative diseases.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Molday, RS (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.				NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER; NEI NIH HHS [EY 2422] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARIKAWA K, 1992, J CELL BIOL, V116, P659, DOI 10.1083/jcb.116.3.659; BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3; Boesze-Battaglia K, 1998, BIOCHEMISTRY-US, V37, P9477, DOI 10.1021/bi980173p; CLARKE G, 2000, IN PRESS NAT GENET; CONNELL G, 1991, P NATL ACAD SCI USA, V88, P723, DOI 10.1073/pnas.88.3.723; CONNELL GJ, 1990, BIOCHEMISTRY-US, V29, P4691, DOI 10.1021/bi00471a025; CORLESS JM, 1987, J COMP NEUROL, V257, P24, DOI 10.1002/cne.902570104; Dryja TP, 1997, INVEST OPHTH VIS SCI, V38, P1972; FARRAR GJ, 1991, NATURE, V354, P478, DOI 10.1038/354478a0; Goldberg AFX, 1998, BIOCHEMISTRY-US, V37, P680, DOI 10.1021/bi972036i; Goldberg AFX, 1996, BIOCHEMISTRY-US, V35, P6144, DOI 10.1021/bi960259n; GOLDBERG AFX, 1995, BIOCHEMISTRY-US, V34, P14213, DOI 10.1021/bi00043a028; Goldberg AFX, 1996, P NATL ACAD SCI USA, V93, P13726, DOI 10.1073/pnas.93.24.13726; HAWKINS RK, 1985, EXP EYE RES, V41, P701, DOI 10.1016/0014-4835(85)90179-4; KAIJAWRA K, 1991, NATURE, V354, P480; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; Kedzierski W, 1997, INVEST OPHTH VIS SCI, V38, P498; Kedzierski W, 1996, J CELL SCI, V109, P2551; Li ML, 1998, J VIROL, V72, P2160, DOI 10.1128/JVI.72.3.2160-2167.1998; Locker JK, 1999, J CELL BIOL, V144, P267, DOI 10.1083/jcb.144.2.267; Luczak JA, 1998, J BIOL CHEM, V273, P2073, DOI 10.1074/jbc.273.4.2073; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MOLDAY RS, 1994, PROG RETIN EYE RES, V13, P271, DOI 10.1016/1350-9462(94)90013-2; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589; Moritz OL, 1996, INVEST OPHTH VIS SCI, V37, P352; NICOLS BE, 1993, NAT GENET, V3, P202; ROOF DJ, 1982, J CELL BIOL, V95, P487, DOI 10.1083/jcb.95.2.487; SAGA M, 1993, HUM GENET, V92, P519, DOI 10.1007/BF00216463; SANYAL S, 1981, NEUROSCI LETT, V21, P23, DOI 10.1016/0304-3940(81)90051-3; Shapiro L, 1996, NEURON, V17, P435, DOI 10.1016/S0896-6273(00)80176-2; STEINBERG RH, 1980, J COMP NEUROL, V190, P501, DOI 10.1002/cne.901900307; TRAVIS GH, 1992, NEURON, V9, P113, DOI 10.1016/0896-6273(92)90226-4; TRAVIS GH, 1989, NATURE, V338, P70, DOI 10.1038/338070a0; TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G; USUKURA J, 1981, BIOMED RES-TOKYO, V2, P177, DOI 10.2220/biomedres.2.177; WELEBER RG, 1993, ARCH OPHTHALMOL-CHIC, V111, P1531, DOI 10.1001/archopht.1993.01090110097033; WELLS J, 1993, NAT GENET, V3, P213, DOI 10.1038/ng0393-213; WETZEL MG, 1994, INVEST OPHTH VIS SCI, V35, P1519	40	101	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5370	5378		10.1074/jbc.275.8.5370	http://dx.doi.org/10.1074/jbc.275.8.5370			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681511	hybrid			2022-12-27	WOS:000085474500018
J	McKean, AL; Ke, JS; Song, JP; Che, P; Achenbach, S; Nikolau, BJ; Wurtele, ES				McKean, AL; Ke, JS; Song, JP; Che, P; Achenbach, S; Nikolau, BJ; Wurtele, ES			Molecular characterization of the non-biotin-containing subunit of 3-methylcrotonyl-CoA carboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPIONYL-COA CARBOXYLASE; COENZYME-A CARBOXYLASE; ARABIDOPSIS-THALIANA; ACIDAMINOCOCCUS-FERMENTANS; MESSENGER-RNA; BOVINE KIDNEY; GENES; PURIFICATION; CLONING; ENZYMES	The biotin enzyme, 3-methylcrotonyl-CoA carboxylase (MCCase) (3-methylcrotonyl-CoA:carbon-dioxide ligase (ADP-forming), EC 6.4.1.4), catalyzes a pivotal reaction required for both leucine catabolism and isoprenoid metabolism. MCCase is a heteromeric enzyme composed of biotin-containing (MCC-A) and non-biotin-containing (MCC-B) subunits. Although the sequence of the MCC-A subunit was previously determined, the primary structure of the MCC-B subunit is unknown. Based upon sequences of biotin enzymes that use substrates structurally related to 3-methylcrotonyl-CoA, we isolated the MCC-B cDNA and gene of Arabidopsis. Antibodies directed against the bacterially produced recombinant protein encoded by the MCC-B cDNA react solely with the MCC-B subunit of the purified MCCase and inhibit MCCase activity. The primary structure of the MCC-B subunit shows the highest similarity to carboxyltransferase domains of biotin enzymes that use methyl-branched thiol esters as substrate or products. The single copy MCC-B gene of Arabidopsis is interrupted by nine introns. MCC-A and MCC-B mRNAs accumulate in all cell types and organs, with the highest accumulation occurring in rapidly growing and metabolically active tissues. In addition, these two mRNAs accumulate coordinately in an approximately equal molar ratio, and they each account for between 0.01 and 0.1 mol ac of cellular mRNA The sequence of the Arabidopsis MCC-B gene has enabled the identification of animal paralogous MCC-B cDNAs and genes, which may have an impact on the molecular understanding of the lethal inherited metabolic disorder methylcrotonylglyciuria.	Iowa State Univ, Dept Bot, Ames, IA 50011 USA; Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University; Iowa State University	Wurtele, ES (corresponding author), Iowa State Univ, Dept Bot, 441 Bessey Hall, Ames, IA 50011 USA.	mash@iastate.edu		Wurtele, Eve/0000-0003-1552-9495				ALBAN C, 1993, PLANT PHYSIOL, V102, P957, DOI 10.1104/pp.102.3.957; Anderson MD, 1998, PLANT PHYSIOL, V118, P1127, DOI 10.1104/pp.118.4.1127; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; Aubert S, 1996, FEBS LETT, V383, P175, DOI 10.1016/0014-5793(96)00244-X; Bott M, 1997, EUR J BIOCHEM, V250, P590, DOI 10.1111/j.1432-1033.1997.0590a.x; BOUTRY M, 1993, PLANT MITOCHONDRIA E, P321; BRADY PS, 1982, J BIOL CHEM, V257, P742; CANTWELL SG, 1978, J BACTERIOL, V135, P324, DOI 10.1128/JB.135.2.324-333.1978; CHEN Y, 1993, ARCH BIOCHEM BIOPHYS, V305, P103, DOI 10.1006/abbi.1993.1398; DEAN C, 1985, EMBO J, V4, P3055, DOI 10.1002/j.1460-2075.1985.tb04045.x; DIEZ TA, 1994, ARCH BIOCHEM BIOPHYS, V310, P64, DOI 10.1006/abbi.1994.1141; FALL RR, 1977, BIOCHEMISTRY-US, V16, P4000, DOI 10.1021/bi00637a010; GOODALL GJ, 1991, EMBO J, V10, P2635, DOI 10.1002/j.1460-2075.1991.tb07806.x; Guan XN, 1999, ARCH BIOCHEM BIOPHYS, V362, P12, DOI 10.1006/abbi.1998.1014; HECTOR ML, 1980, ARCH BIOCHEM BIOPHYS, V199, P28, DOI 10.1016/0003-9861(80)90252-0; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HUDER JB, 1993, J BIOL CHEM, V268, P24564; Jacob U, 1997, STRUCTURE, V5, P415, DOI 10.1016/S0969-2126(97)00198-6; Ke JS, 1997, PLANT PHYSIOL, V113, P357, DOI 10.1104/pp.113.2.357; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMHONWAH AM, 1994, GENOMICS, V19, P500, DOI 10.1006/geno.1994.1099; LAU EP, 1980, ARCH BIOCHEM BIOPHYS, V205, P352, DOI 10.1016/0003-9861(80)90117-4; LAU EP, 1979, P NATL ACAD SCI USA, V76, P214, DOI 10.1073/pnas.76.1.214; MACK M, 1994, EUR J BIOCHEM, V226, P41, DOI 10.1111/j.1432-1033.1994.tb20024.x; MOSS J, 1971, ADV ENZYMOL RAMB, V35, P321; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NES WD, 1985, PROC R SOC SER B-BIO, V225, P425, DOI 10.1098/rspb.1985.0071; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RODWELL VW, 1969, METABOLIC PATHWAYS A, V3, P191; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIELE U, 1975, EUR J BIOCHEM, V60, P259, DOI 10.1111/j.1432-1033.1975.tb20998.x; Scott KD, 1996, BIOTECHNIQUES, V20, P974; Simpson C. G., 1993, Plant molecular biology labfax., P183; SONG J, 1993, THESIS IOWA STATE U; SONG JP, 1994, P NATL ACAD SCI USA, V91, P5779, DOI 10.1073/pnas.91.13.5779; SWEETMAN L, 1989, METABOLIC BASIS INHE, P791; THORNTON CG, 1993, J BACTERIOL, V175, P5301, DOI 10.1128/JB.175.17.5301-5308.1993; VOYTAS DF, 1990, GENETICS, V126, P713; Wallace T. P., 1993, Plant molecular biology labfax., P287; WANG X, 1994, J BIOL CHEM, V269, P11760; WEAVER LM, 1995, PLANT PHYSIOL, V107, P1013, DOI 10.1104/pp.107.3.1013; WURTELE ES, 1992, PLANT PHYSIOL, V99, P1699, DOI 10.1104/pp.99.4.1699; WURTELE ES, 1990, ARCH BIOCHEM BIOPHYS, V278, P179, DOI 10.1016/0003-9861(90)90246-U; WURTELE ES, 2000, IN PRESS METHODS ENZ; YANAI Y, 1995, PLANT CELL PHYSIOL, V36, P779, DOI 10.1093/oxfordjournals.pcp.a078822	47	26	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5582	5590		10.1074/jbc.275.8.5582	http://dx.doi.org/10.1074/jbc.275.8.5582			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681539	hybrid			2022-12-27	WOS:000085474500046
J	Chua, BT; Guo, K; Li, P				Chua, BT; Guo, K; Li, P			Direct cleavage by the calcium-activated protease calpain can lead to inactivation of caspases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; THYMOCYTE APOPTOSIS; DATP	Caspases, a unique family of cysteine proteases involved in cytokine activation and in the execution of apoptosis can be sub-grouped according to the length of their prodomain. Long prodomain caspases such as caspase-8 and caspase-9 are believed to act mainly as upstream caspases to cleave downstream short prodomain caspases such as caspases-3 and -7. We report here the identification of caspases as direct substrates of calcium-activated proteases, calpains. Calpains cleave caspase-7 at sites distinct from those of the upstream caspases, generating proteolytically inactive fragments. Caspase-8 and caspase-9 can also be directly cleaved by calpains, Two calpain cleavage sites in caspase-9 have been identified by N-terminal sequencing of the cleaved products. Cleavage of caspase-9 by calpain generates truncated caspase-9 that is unable to activate caspase-3 in cell lysates, Furthermore, direct cleavage of caspase-9 by calpain blocks dATP and cytochrome-c induced caspase-3 activation. Therefore our results suggest that calpains may act as negative regulators of caspase processing and apoptosis by effectively inactivating upstream caspases.	Inst Mol & Cell Biol, Lab Apoptosis Regulat, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Li, P (corresponding author), Inst Mol & Cell Biol, Lab Apoptosis Regulat, 30 Med Dr, Singapore 117609, Singapore.							Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; ELCE JS, 1995, PROTEIN ENG, V8, P843, DOI 10.1093/protein/8.8.843; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; KRBBUTAT MHG, 1997, MOL CELL BIOL, V17, P460; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MAGHDIGUIAN S, 1999, NAT MED, V5, P503; McGinnis KM, 1999, J NEUROCHEM, V72, P1853, DOI 10.1046/j.1471-4159.1999.0721853.x; Porn-Ares MI, 1998, CELL DEATH DIFFER, V5, P1028, DOI 10.1038/sj.cdd.4400424; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Squier MKT, 1997, J IMMUNOL, V158, P3690; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tong JX, 1996, EXP NEUROL, V138, P45, DOI 10.1006/exnr.1996.0045; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; ZHIVOTOVSKY B, 1994, BIOCHEM BIOPH RES CO, V202, P120, DOI 10.1006/bbrc.1994.1901; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	18	245	256	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5131	5135		10.1074/jbc.275.7.5131	http://dx.doi.org/10.1074/jbc.275.7.5131			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671558	hybrid			2022-12-27	WOS:000085378200084
J	Reddy, GB; Das, KP; Petrash, JM; Surewicz, WK				Reddy, GB; Das, KP; Petrash, JM; Surewicz, WK			Temperature-dependent chaperone activity and structural properties of human alpha A- and alpha B-crystallins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; MOLECULAR CHAPERONE; SECONDARY STRUCTURE; INFRARED-SPECTROSCOPY; HYDROPHOBIC SURFACES; QUATERNARY STRUCTURE; SUBSTRATE; SPECTRA; INSIGHT; BINDS	The chaperone activity and biophysical properties of recombinant human alpha A- and alpha B-crystallins were studied by light scattering and spectroscopic methods. While the chaperone function of alpha A-crystallin markedly improves with an increase in temperature, the activity of alpha B homopolymer appears to change very little upon heating. Compared with alpha B-crystallin, the alpha A-homopolymer is markedly less active at low temperatures, but becomes a more active species at high temperatures. At physiologically relevant temperatures, the alpha B homopolymer appears to be modestly (two times or less) more potent chaperone than alpha A homopolymer, In contrast to very similar thermotropic changes in the secondary structure of both homopolymers, alpha A- and alpha B-crystallins markedly differ with respect to the temperature-dependent surface hydrophobicity profiles, Upon heating, alpha A-crystallin undergoes a conformational transition resulting in the exposure of additional hydrophobic sites, whereas no such transition occurs for alpha B-crystallin, The correlation between temperature-dependent changes in the chaperone activity and hydrophobicity properties of the individual homopolymers supports the view that the chaperone activity of a crystallin is dependent on the presence of surface-exposed hydrophobic patches. However, the present data also show that the surface hydrophobicity is not the sole determinant of the chaperone function of alpha-crystallin.	Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; Washington Univ, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA	Case Western Reserve University; Washington University (WUSTL)	Surewicz, WK (corresponding author), Case Western Reserve Univ, Dept Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.	wks3@pop.cwru.edu	Reddy, G Bhanuprakash/AAJ-3494-2020	Reddy, G Bhanuprakash/0000-0003-4787-3944; Das, Kali/0000-0001-7686-9077	NEI NIH HHS [EY11694] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011694] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; Das BK, 1997, BIOCHEM BIOPH RES CO, V236, P370, DOI 10.1006/bbrc.1997.6950; DAS KP, 1995, BIOCHEM J, V311, P367, DOI 10.1042/bj3110367; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; DERETIC D, 1994, J BIOL CHEM, V269, P16853; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; HOENDERS HJ, 1981, MOL CELLULAR BIOL EY, P279; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Muchowski PJ, 1998, P NATL ACAD SCI USA, V95, P1004, DOI 10.1073/pnas.95.3.1004; Rajaraman K, 1996, J BIOL CHEM, V271, P27595, DOI 10.1074/jbc.271.44.27595; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; RAMAN B, 1994, J BIOL CHEM, V269, P27264; Rao PV, 1995, BBA-GEN SUBJECTS, V1245, P439, DOI 10.1016/0304-4165(95)00125-5; SAX CM, 1994, ADV ENZYMOL, V69, P153; Sharma KK, 1998, J BIOL CHEM, V273, P8965, DOI 10.1074/jbc.273.15.8965; Smulders RHPH, 1997, FEBS LETT, V409, P101, DOI 10.1016/S0014-5793(97)00498-5; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; SUREWICZ WK, 1995, BIOCHEMISTRY-US, V34, P9655, DOI 10.1021/bi00030a001; WANG KY, 1994, J BIOL CHEM, V269, P13601	34	166	169	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4565	4570		10.1074/jbc.275.7.4565	http://dx.doi.org/10.1074/jbc.275.7.4565			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671481	hybrid			2022-12-27	WOS:000085378200007
J	Yan, ZP; Subbaramaiah, K; Camilli, T; Zhang, F; Tanabe, T; McCaffrey, TA; Dannenberg, AJ; Weksler, BB				Yan, ZP; Subbaramaiah, K; Camilli, T; Zhang, F; Tanabe, T; McCaffrey, TA; Dannenberg, AJ; Weksler, BB			Benzo[alpha]pyrene induces the transcription of cyclooxygenase-2 in vascular smooth muscle cells - Evidence for the involvement of extracellular signal-regulated kinase and NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE-2; HUMAN COLON-CANCER; EPITHELIAL-CELLS; GENE-EXPRESSION; CIGARETTE-SMOKING; BCL-2 EXPRESSION; NUCLEAR FACTOR; H SYNTHASE; BENZO<A>PYRENE; ACTIVATION	Polycyclic aromatic hydrocarbons, such as benzo[alpha]pyrene (B[alpha]P) present in tobacco smoke and tar, have been implicated in the development of atherosclerosis as well as cancer. Increased expression of cyclooxygenase-2 (COX-2) has been detected both in atherosclerotic lesions and in epithelial cancers. To determine whether polycyclic aromatic hydrocarbons might directly affect COX expression in vascular cells, we investigated the effects of B[alpha]P on COX-2 expression in human and rat arterial smooth muscle cells (SMC), Treatment with B[alpha]P increased levels of COX-2 protein and mRNA and enhanced prostaglandin synthesis. Nuclear runoff assays and transient transfections revealed increased COX-2 gene transcription after treatment with B[alpha]P. Experiments were done to define the signaling mechanism by which B[alpha]P induced COX-2, B[alpha]P caused a rapid increase in phosphorylation of extracellular signal-regulated kinase (ERK); pharmacologic inhibition of mitogen-activated protein kinase kinase blocked B[alpha]P-mediated induction of COX-2, Depletion of the intracellular antioxidant, glutathione, with buthionine sulfoximine significantly increased B[alpha]P-mediated induction of COX-2 while exposure to N-acetylcysteine, a precursor of glutathione, suppressed the induction of COX-2 by B[alpha]P. Several lines of evidence suggest that the induction of COX-2 by B[alpha]P is mediated, at least in part, by NF-kappa B, Treatment with B[alpha]P increased binding of NF-kappa B to DNA. Moreover, B[alpha]P-mediated stimulation of COX-2 promoter activity was blocked when a construct containing a mutagenized NF-kappa B site was used. Pharmacological inhibitors of NF-kappa B blocked the induction of COX-2 protein and the stimulation of COX-2 promoter activity by B[alpha]P, Taken together, these data are likely to be important for understanding the atherogenic effects of tobacco smoke.	Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, Dept Med, New York, NY 10021 USA; Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, Dept Cardiothorac Surg, New York, NY 10021 USA; Natl Cardiovasc Ctr, Res Inst, Dept Pharmacol, Suita, Osaka 5658565, Japan	Cornell University; NewYork-Presbyterian Hospital; Cornell University; NewYork-Presbyterian Hospital; National Cerebral & Cardiovascular Center - Japan	Weksler, BB (corresponding author), Cornell Univ, Weill Med Coll, Div Hematol Oncol, New York, NY 10021 USA.				NHLBI NIH HHS [HL55627, HL5699987] Funding Source: Medline; NIA NIH HHS [AG12712] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055627] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012712, R37AG012712] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; ALBERT RE, 1977, CANCER RES, V37, P2232; AUSUBEL FA, 1995, CURRENT PROTOCOLS MO, V2; Baker CSR, 1999, ARTERIOSCL THROM VAS, V19, P646, DOI 10.1161/01.ATV.19.3.646; Beasley D, 1999, AM J PHYSIOL-HEART C, V276, pH1369, DOI 10.1152/ajpheart.1999.276.4.H1369; BOND JA, 1980, TOXICOL APPL PHARM, V52, P323, DOI 10.1016/0041-008X(80)90119-2; BOND JA, 1979, LIFE SCI, V25, P425, DOI 10.1016/0024-3205(79)90574-5; BOOLBOL SK, 1996, CANCER RES, V56, P3785; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAGOSTINI F, 1995, CANCER EPIDEM BIOMAR, V4, P111; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; ELING TE, 1992, PHARMACOL THERAPEUT, V53, P261, DOI 10.1016/0163-7258(92)90012-O; ELING TE, 1986, J BIOL CHEM, V261, P5023; FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; GUTHRIE J, 1982, CANCER RES, V42, P1620; Hanrahan JP, 1996, AM J RESP CRIT CARE, V153, P861, DOI 10.1164/ajrccm.153.2.8564146; Hennekens CH, 1997, ANNU REV PUBL HEALTH, V18, P37, DOI 10.1146/annurev.publhealth.18.1.37; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HOUGH JL, 1993, ARTERIOSCLER THROMB, V13, P1721, DOI 10.1161/01.ATV.13.12.1721; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; IZZOTTI A, 1994, CANCER RES, V54, pS1994; Jacobs DR, 1999, ARCH INTERN MED, V159, P733, DOI 10.1001/archinte.159.7.733; JONES DA, 1993, J BIOL CHEM, V268, P9049; KANNEL WB, 1981, AM HEART J, V101, P319, DOI 10.1016/0002-8703(81)90197-6; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kelley DJ, 1997, CARCINOGENESIS, V18, P795, DOI 10.1093/carcin/18.4.795; LaPointe MC, 1999, HYPERTENSION, V33, P276, DOI 10.1161/01.HYP.33.1.276; Larrivee JF, 1998, J IMMUNOL, V160, P1419; Liu XH, 1998, CANCER RES, V58, P4245; MARNETT LJ, 1978, BIOCHEM BIOPH RES CO, V82, P210, DOI 10.1016/0006-291X(78)90597-1; MCCAFFREY TA, 1988, J EXP MED, V167, P163, DOI 10.1084/jem.167.1.163; McCaffrey TA, 1997, J CLIN INVEST, V100, P2182, DOI 10.1172/JCI119754; OU XL, 1992, TOXICOLOGY, V74, P243, DOI 10.1016/0300-483X(92)90143-3; Pratico D, 1996, J BIOL CHEM, V271, P8919, DOI 10.1074/jbc.271.15.8919; PRITCHARD KA, 1994, J BIOL CHEM, V269, P8504; Qu SX, 1996, CARCINOGENESIS, V17, P53, DOI 10.1093/carcin/17.1.53; Ramos KS, 1996, ARCH BIOCHEM BIOPHYS, V332, P213, DOI 10.1006/abbi.1996.0335; RAMOS KS, 1995, LIFE SCI, V57, P627, DOI 10.1016/0024-3205(95)00314-V; RIMARACHIN JA, 1994, ARTERIOSCLER THROMB, V14, P1021, DOI 10.1161/01.ATV.14.7.1021; Romero DL, 1997, TOXICOL APPL PHARM, V144, P62, DOI 10.1006/taap.1997.8113; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 1999, ONCOGENE, V18, P855, DOI 10.1038/sj.onc.1202397; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Spandidos DA, 1996, BIOCHEM BIOPH RES CO, V220, P137, DOI 10.1006/bbrc.1996.0370; Speir E, 1998, CIRC RES, V83, P210, DOI 10.1161/01.RES.83.2.210; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; Subbaramaiah K, 1996, CANCER RES, V56, P4424; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P5397, DOI 10.1073/pnas.91.12.5397; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Wong SCY, 1998, CIRCULATION, V98, P100, DOI 10.1161/01.CIR.98.2.100; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG SK, 1976, P NATL ACAD SCI USA, V73, P2594, DOI 10.1073/pnas.73.8.2594; Zhang F, 1998, J BIOL CHEM, V273, P2424, DOI 10.1074/jbc.273.4.2424; Zhang YJ, 1998, ATHEROSCLEROSIS, V140, P325, DOI 10.1016/S0021-9150(98)00136-1; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	61	101	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4949	4955		10.1074/jbc.275.7.4949	http://dx.doi.org/10.1074/jbc.275.7.4949			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671533	hybrid			2022-12-27	WOS:000085378200059
J	Kukol, A; Arkin, IT				Kukol, A; Arkin, IT			Structure of the Influenza C virus CM2 protein transmembrane domain obtained by site-specific infrared dichroism and global molecular dynamics searching	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B VIRUS; CONFORMATIONAL-CHANGES; SECONDARY STRUCTURE; RNA SEGMENT-6; ION CHANNELS; NB; BACTERIORHODOPSIN; SELECTIVITY; M-2	The 115-residue protein CM2 from Influenza C virus has been recently characterized as a tetrameric integral membrane glycoprotein. infrared spectroscopy and site-directed infrared dichroism were utilized here to determine its transmembrane structure. The transmembrane domain of CM2 is cy-helical, and the helices are tilted by beta = (14.6 +/- 3.0)degrees from the membrane normal. The rotational pitch angle about the helix axis omega for the 1-C-13-labeled residues Gly(59) and Leu(66) is omega = (218 +/- 17)degrees, where w is defined as zero for a residue pointing in the direction of the helix tilt. A detailed structure was obtained from a global molecular dynamics search utilizing the orientational data as an energy refinement term. The structure consists of a left-handed coiled-coil with a helix crossing angle of Omega = 16 degrees, The putative transmembrane pore is occluded by the residue Met(65). In addition hydrogen/deuterium exchange experiments show that the core is not accessible to water.	Univ Cambridge, Dept Biochem, Cambridge Ctr Mol Recognit, Cambridge CB2 1GA, England	University of Cambridge	Arkin, IT (corresponding author), Univ Cambridge, Dept Biochem, Cambridge Ctr Mol Recognit, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	sa232@cam.ac.uk	Arkin, Isaiah/GQA-4328-2022; Kukol, Andreas/AAR-4569-2020	Kukol, Andreas/0000-0002-8859-010X; Arkin, Isaiah/0000-0002-7659-1746				ADAMS PD, 1995, NAT STRUCT BIOL, V2, P154, DOI 10.1038/nsb0295-154; Arkin IT, 1997, J AM CHEM SOC, V119, P8973, DOI 10.1021/ja964253x; BRAIMAN MS, 1988, ANNU REV BIOPHYS BIO, V17, P541; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; Cladera J, 1996, BIOPHYS J, V70, P2882, DOI 10.1016/S0006-3495(96)79858-2; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DUFF KC, 1992, VIROLOGY, V190, P485, DOI 10.1016/0042-6822(92)91239-Q; HONGO S, 1994, J GEN VIROL, V75, P3503, DOI 10.1099/0022-1317-75-12-3503; Hongo S, 1997, J VIROL, V71, P2786, DOI 10.1128/JVI.71.4.2786-2792.1997; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; KAUPPINEN JK, 1981, APPL SPECTROSC, V35, P271, DOI 10.1366/0003702814732634; Kovacs FA, 1997, BIOPHYS J, V73, P2511, DOI 10.1016/S0006-3495(97)78279-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kukol A, 1999, BIOPHYS J, V77, P1594, DOI 10.1016/S0006-3495(99)77007-4; Kukol A, 1999, J MOL BIOL, V286, P951, DOI 10.1006/jmbi.1998.2512; Lamb RA, 1997, VIROLOGY, V229, P1, DOI 10.1006/viro.1997.8451; PAULING L, 1951, P NATL ACAD SCI USA, V37, P205, DOI 10.1073/pnas.37.4.205; Pekosz A, 1997, VIROLOGY, V237, P439, DOI 10.1006/viro.1997.8788; Pinto LH, 1997, P NATL ACAD SCI USA, V94, P11301, DOI 10.1073/pnas.94.21.11301; Sansom MSP, 1998, BIOESSAYS, V20, P992, DOI 10.1002/(SICI)1521-1878(199812)20:12<992::AID-BIES5>3.0.CO;2-7; Sansom MSP, 1998, CURR OPIN STRUC BIOL, V8, P237, DOI 10.1016/S0959-440X(98)80045-6; Sansom MSP, 1997, VIROLOGY, V233, P163, DOI 10.1006/viro.1997.8578; Sunstrom NA, 1996, J MEMBRANE BIOL, V150, P127, DOI 10.1007/s002329900037; TADESSE L, 1991, J AM CHEM SOC, V113, P7036, DOI 10.1021/ja00018a052; Tieleman DP, 1999, BIOPHYS J, V76, P1757, DOI 10.1016/S0006-3495(99)77337-6; Torres J, 1995, BIOCHEMISTRY-US, V34, P16320, DOI 10.1021/bi00050a012; TSUBOI M, 1962, J POLYM SCI, V59, P139, DOI 10.1002/pol.1962.1205916712	28	30	32	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4225	4229		10.1074/jbc.275.6.4225	http://dx.doi.org/10.1074/jbc.275.6.4225			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660588	hybrid			2022-12-27	WOS:000085288800072
J	McCready, TL; Islam, BF; Schmitz, FJ; Luu, HA; Dawson, JF; Holmes, CFB				McCready, TL; Islam, BF; Schmitz, FJ; Luu, HA; Dawson, JF; Holmes, CFB			Inhibition of protein phosphatase-1 by clavosines A and B - Novel members of the calyculin family of toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONGE DISCODERMIA-CALYX; BIOACTIVE MARINE METABOLITES; NATURAL PRODUCT INHIBITORS; RHAMNOSE-BINDING LECTINS; OKADAIC ACID; CATALYTIC SUBUNIT; STRUCTURAL BASIS; RECOGNITION; MODEL; PROTEIN-PHOSPHATASE-1	Site-directed mutagenesis was used to investigate the mechanism of interaction between the catalytic subunit of human protein phosphatase-l (PP-1c gamma) and members of the calyculin family of toxins. Clavosines A and B are related to calyculins but are glycosylated with a trimethoxy rhamnose group. We provide experimental evidence implicating Tyr-134 as an important residue in PP-1c gamma that mediates interactions with the calyculins. Mutation of Tyr-134 to Phe, to prevent hydrogen bond formation, resulted in a slight increase in sensitivity of PP-1c gamma to clavosines A and B and calyculin A. In contrast, a Y134A mutant was 10-fold less sensitive to inhibition by all three inhibitors. The greatest effect on inhibition was found by substituting an Asp for Tyr-134 in the phosphatase. Clavosine B inhibited PP-1c gamma Y134D with a 310-fold decrease in potency. Clavosine A and calyculin A were also markedly poorer inhibitors of this mutant. These results suggest that a hydrogen bond between Tyr-134 and the calyculins is unlikely to be essential for inhibitor binding to the phosphatase. The clavosines and calyculin A were tested for their ability to inhibit other mutants of PP-1c gamma (including Ile-133, Val-223, and Cys-291). Our mutagenesis studies provide an experimental basis for assessing models of calyculin binding found in the literature (Lindvall, M. K., Pihko, P. M., and Koskinen, A. M. (1997) J. Biol. Chem. 272, 23312-23316; Gupta, V., Ogawa, A. K., Du, X., Houk, K. N., and Armstrong, R. W. (1997) J. Med. Chem. 40, 3199-3206; Gauss, C. M., Sheppeck, I. J., Nairn, A. C., and Chamberlain, R. (1997) Bioorg. Med. Chem. 5, 1751-1773). A new model for clavosine and calyculin A binding to PP-lc is presented that is consistent with previous structure-function experiments and which accommodates key structural features of the clavosines, including the novel rhamnose moiety.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA	University of Alberta; University of Oklahoma System; University of Oklahoma - Norman	McCready, TL (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.		Dawson, John/HDM-6702-2022					Bagu JR, 1997, J BIOL CHEM, V272, P5087, DOI 10.1074/jbc.272.8.5087; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; BOYD MR, 1995, DRUG DEVELOP RES, V34, P91, DOI 10.1002/ddr.430340203; CHAM BE, 1990, CANCER LETT, V55, P221, DOI 10.1016/0304-3835(90)90122-E; Craig M, 1996, BIOCHEM CELL BIOL, V74, P569, DOI 10.1139/o96-061; DAWSON JF, 1998, THESIS U ALBERTA EDM; Dumdei EJ, 1997, J ORG CHEM, V62, P2636, DOI 10.1021/jo961745j; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Elgavish S, 1997, TRENDS BIOCHEM SCI, V22, P462, DOI 10.1016/S0968-0004(97)01146-8; Fu X, 1998, J ORG CHEM, V63, P7957, DOI 10.1021/jo981249q; GABIUS HJ, 1987, CANCER INVEST, V5, P39, DOI 10.3109/07357908709020305; Gauss CM, 1997, BIOORGAN MED CHEM, V5, P1751, DOI 10.1016/S0968-0896(97)00145-4; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Gupta V, 1997, J MED CHEM, V40, P3199, DOI 10.1021/jm960873x; HOLMES CFB, 1991, TOXICON, V29, P469, DOI 10.1016/0041-0101(91)90021-I; HOSONO M, 1993, BIOL PHARM BULL, V16, P239; Huang HB, 1997, P NATL ACAD SCI USA, V94, P3530, DOI 10.1073/pnas.94.8.3530; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KATO Y, 1988, DRUG EXP CLIN RES, V14, P723; KATO Y, 1986, J AM CHEM SOC, V108, P2780, DOI 10.1021/ja00270a061; KATO Y, 1988, J ORG CHEM, V53, P3930, DOI 10.1021/jo00252a009; Kennelly P.J., 1999, FRONT BIOSCI, V4, pD372, DOI [10.2741/kennelly, DOI 10.2741/KENNELLY]; Lindvall MK, 1997, J BIOL CHEM, V272, P23312, DOI 10.1074/jbc.272.37.23312; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MATSUNAGA S, 1991, TETRAHEDRON, V47, P2999, DOI 10.1016/S0040-4020(01)96031-4; Matsunaga S, 1997, J ORG CHEM, V62, P2640, DOI 10.1021/jo961746b; MATSUNAGA S, 1991, TETRAHEDRON LETT, V32, P5605, DOI 10.1016/0040-4039(91)80096-O; Matsunaga S, 1997, TETRAHEDRON LETT, V38, P3763, DOI 10.1016/S0040-4039(97)00748-X; NORMAN SA, 1994, MAMM GENOME, V5, P41, DOI 10.1007/BF00360567; OKADA A, 1991, AGR BIOL CHEM TOKYO, V55, P2765, DOI 10.1080/00021369.1991.10871036; QUINN RJ, 1993, BIOORG MED CHEM LETT, V3, P1029, DOI 10.1016/S0960-894X(00)80281-4; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; Steube KG, 1998, ANTICANCER RES, V18, P129; SUGANUMA M, 1990, CANCER RES, V50, P3521; Tateno H, 1998, J BIOL CHEM, V273, P19190, DOI 10.1074/jbc.273.30.19190; Volter KE, 1999, BIOORG MED CHEM LETT, V9, P717, DOI 10.1016/S0960-894X(99)00066-9; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Zhang LF, 1996, BIOCHEMISTRY-US, V35, P1606, DOI 10.1021/bi9521396	38	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4192	4198		10.1074/jbc.275.6.4192	http://dx.doi.org/10.1074/jbc.275.6.4192			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660582	hybrid			2022-12-27	WOS:000085288800066
J	Moore, TM; Garg, R; Johnson, C; Coptcoat, MJ; Ridley, AJ; Morris, JDH				Moore, TM; Garg, R; Johnson, C; Coptcoat, MJ; Ridley, AJ; Morris, JDH			PSK, a novel STE20-like kinase derived from prostatic carcinoma that activates the c-Jun N-terminal kinase mitogen-activated protein kinase pathway and regulates actin cytoskeletal organization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATINOCYTE GROWTH-FACTOR; GERMINAL CENTER KINASE; TYROSINE KINASE; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; ANDROGEN RECEPTOR; FOCAL ADHESIONS; STRESS-RESPONSE; CANCER CELLS; IN-VITRO	Degenerate polymerase chain reaction against conserved kinase catalytic subdomains identified 15 tyrosine and serine-threonine kinases expressed in surgically removed prostatic carcinoma tissues, including six receptor kinases (PDGFBR, IGF1-R, VEGFR2, MET, RYK, and EPH-A1), six non-receptor kinases (ABL, JAK1, JAK2, TYK2, PLK-1, and EMK), and three novel kinases, Several of these kinases are oncogenic, and may function in the development of prostate cancer. One of the novel kinases is a new member of the sterile 20 (STE20) family of serine-threonine kinases which we have called prostate-derived STE20-like kinase (PSK) and characterized functionally. PSK encodes an open reading frame of 3705 nucleotides and contains an N-terminal:kinase domain. Immunoprecipitated PSK phosphorylates myelin basic protein and transfected PSK stimulates MKK4 and MKK7 and activates the c-Jun N-terminal kinase mitogen-activated protein kinase pathway. Microinjection of PSK into cells results in localization of PSK to a vesicular compartment and causes a marked reduction in actin stress fibers, In contrast, C-terminally truncated PSK (1-349) did not localize to this compartment or induce a decrease in stress fibers demonstrating a requirement for the C terminus. Kinase-defective PSK (K57A) was unable to reduce stress fibers. PSK is the first member of the STE20 family lacking a Cdc42/Rac binding domain that has been shown to regulate both the c-Jun N-terminal kinase mitogen-activated protein kinase pathway and the actin cytoskeleton.	Kings Coll London, Sch Med & Dent, Rayne Inst, Acad Dept Surg,Mol Oncol Lab, London SE5 9NU, England; UCL Branch, Ludwig Inst Canc Res, London W1P 8BT, England; UCL, Dept Biochem & Mol Biol, London W1P 8BT, England	University of London; King's College London; Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London	Morris, JDH (corresponding author), Kings Coll London, Sch Med & Dent, Rayne Inst, Acad Dept Surg,Mol Oncol Lab, 123 Coldharbour Lane, London SE5 9NU, England.	jonathan.morris@kcl.ac.uk		Morris, Jonathan/0000-0002-3211-1798; Ridley, Anne/0000-0001-8186-5708				Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Chew TL, 1998, J MUSCLE RES CELL M, V19, P839, DOI 10.1023/A:1005417926585; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; CULIG Z, 1994, CANCER RES, V54, P5474; Dawson DM, 1998, J NATL CANCER I, V90, P519, DOI 10.1093/jnci/90.7.519; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Ferrer FA, 1997, J UROLOGY, V157, P2329, DOI 10.1016/S0022-5347(01)64775-X; Foltz IN, 1998, J BIOL CHEM, V273, P9344, DOI 10.1074/jbc.273.15.9344; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Gioeli D, 1999, CANCER RES, V59, P279; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hirai S, 1996, ONCOGENE, V12, P641; Hobisch A, 1998, CANCER RES, V58, P4640; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Leav I, 1998, HUM PATHOL, V29, P668, DOI 10.1016/S0046-8177(98)90274-X; Leung HY, 1997, ONCOGENE, V15, P1115, DOI 10.1038/sj.onc.1201256; Ligos JM, 1998, BIOCHEM BIOPH RES CO, V249, P380, DOI 10.1006/bbrc.1998.9163; Manes S, 1999, J BIOL CHEM, V274, P6935, DOI 10.1074/jbc.274.11.6935; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MARU Y, 1990, ONCOGENE, V5, P445; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; *NAT I CAN, 1997, CAN CANC STAT, P15; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Okamoto M, 1997, CANCER RES, V57, P141; Osada S, 1997, ONCOGENE, V14, P2047, DOI 10.1038/sj.onc.1201043; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Putz T, 1999, CANCER RES, V59, P227; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROEHRBORN CG, 1991, MECHANISMS OF PROGRESSION TO HORMONE-INDEPENDENT GROWTH OF BREAST AND PROSTATIC CANCER, P97; RUIZPEREZ VL, 1995, CURR GENET, V28, P309, DOI 10.1007/BF00326428; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Shi CS, 1999, BLOOD, V93, P1338, DOI 10.1182/blood.V93.4.1338.404k27_1338_1345; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tsuka H, 1998, INT J ONCOL, V13, P927; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; Van Eyk JE, 1998, J BIOL CHEM, V273, P23433, DOI 10.1074/jbc.273.36.23433; VLAHOS CJ, 1993, J CELL BIOCHEM, V52, P404, DOI 10.1002/jcb.240520405; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146	77	74	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4311	4322		10.1074/jbc.275.6.4311	http://dx.doi.org/10.1074/jbc.275.6.4311			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660600	hybrid			2022-12-27	WOS:000085288800084
J	Acharya, S; Foletta, VC; Lee, JW; Rayborn, ME; Rodriguez, IR; Young, WS; Hollyfield, JG				Acharya, S; Foletta, VC; Lee, JW; Rayborn, ME; Rodriguez, IR; Young, WS; Hollyfield, JG			SPACRCAN, a novel human interphotoreceptor matrix hyaluronan-binding proteoglycan synthesized by photoreceptors and pinealocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; MACULAR DEGENERATION; HUMAN RETINA; IMMUNOCYTOCHEMICAL LOCALIZATION; SEQUENCE-ANALYSIS; CALCIUM; GLAND; PROTEINS; GLYCOPROTEIN; EXPRESSION	The interphotoreceptor matrix is a unique extracellular complex occupying the interface between photoreceptors and the retinal pigment epithelium in the fundus of the eye. Because of the putative supportive role in photoreceptor maintenance, it is likely that constituent molecules play key roles in photoreceptor function and may be targets for inherited retinal disease. In this study we identify and characterize SPACRCAN, a novel chondroitin proteoglycan in this matrix. SPACRCAN was cloned from a human retinal cDNA library and the gene localized to chromosome 3q11.2. Analysis of SPACRCAN mRNA and protein revealed that SPACRCAN is expressed exclusively by photoreceptors and pinealocytes, SPACRCAN synthesized by photoreceptors is localized to the interphotoreceptor matrix where it surrounds both rods and cones, The functional protein contains 1160 amino acids with a large central mucin domain, three consensus sites for glycosaminoglycan attachment, two epidermal growth factor-like repeats, a putative hyaluronan-binding motif, and a potential transmembrane domain near the C-terminal, Lectin and Western blotting indicate an M-r around 400,000 before and 230,000 after chondroitinase ABC digestion. Removal of N- and O-linked oligosaccharides reduces the M-r to approximately 160,000, suggesting that approximately 60% of the mass of SPACRCAN is carbohydrate. Finally, we demonstrate that SPACRCAN binds hyaluronan and propose that associations between SPACRCAN and hyaluronan may be involved in organization of the insoluble interphotoreceptor matrix, particularly as SPACRCAN is the major proteoglycan present in this matrix.	Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA; NEI, NIH, Bethesda, MD 20892 USA; NIMH, NIH, Bethesda, MD 20892 USA	Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Hollyfield, JG (corresponding author), Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Young, W Scott Scott/A-9333-2009; Young, W Scott/N-3716-2019	Young, W Scott Scott/0000-0001-6614-5112; Young, W Scott/0000-0001-6614-5112	NATIONAL EYE INSTITUTE [R01EY002362] Funding Source: NIH RePORTER; NEI NIH HHS [EY 02362] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Acharya S, 1998, J BIOL CHEM, V273, P31599, DOI 10.1074/jbc.273.47.31599; Acharya S, 1998, GLYCOBIOLOGY, V8, P997, DOI 10.1093/glycob/8.10.997; ADLER AJ, 1982, EXP EYE RES, V34, P423, DOI 10.1016/0014-4835(82)90088-4; ADLER AJ, 1981, EXP EYE RES, V32, P755, DOI 10.1016/0014-4835(81)90025-7; ARENDT J, 1995, MELATONIN MAMMALIAN, P18; BERMAN ER, 1982, METHOD ENZYMOL, V81, P77; BERMAN ER, 1968, BIOCHEM J, V108, P75, DOI 10.1042/bj1080075; BERMAN ER, 1969, MODERN PROBLEMS OPHT, V8, P5; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Blackshaw S, 1997, J NEUROSCI, V17, P8074; BOURDON MA, 1985, P NATL ACAD SCI USA, V82, P1321, DOI 10.1073/pnas.82.5.1321; BRADLEY DJ, 1994, P NATL ACAD SCI USA, V91, P439, DOI 10.1073/pnas.91.2.439; BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5; CHAITIN MH, 1994, EXP EYE RES, V58, P359, DOI 10.1006/exer.1994.1026; COUCHMAN JR, 1984, NATURE, V307, P650, DOI 10.1038/307650a0; CRAFT CM, 1994, J BIOL CHEM, V269, P4613; EAKIN RM, 1973, 3 EYE; FEENEY L, 1973, DEV BIOL, V32, P101, DOI 10.1016/0012-1606(73)90223-6; FEENEY L, 1973, DEV BIOL, V32, P115, DOI 10.1016/0012-1606(73)90224-8; FONG SL, 1984, J NEUROCHEM, V42, P1667, DOI 10.1111/j.1471-4159.1984.tb12758.x; FONG SL, 1984, J BIOL CHEM, V259, P6534; GALVEZ JMG, 1977, EXP NEUROL, V56, P151, DOI 10.1016/0014-4886(77)90145-5; GOLD GH, 1986, P NATL ACAD SCI USA, V83, P1150, DOI 10.1073/pnas.83.4.1150; GOLD GH, 1980, P NATL ACAD SCI-BIOL, V77, P5557, DOI 10.1073/pnas.77.9.5557; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519; HAGEMAN GS, 1991, PROGR RETINAL RES, V10, P207; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HASCALL VC, 1994, METHOD ENZYMOL, V230, P390; Hollyfield JG, 1999, INVEST OPHTH VIS SCI, V40, P2767; Hollyfield JG, 1999, EXP EYE RES, V69, P311, DOI 10.1006/exer.1999.0707; Hollyfield JG, 1998, EXP EYE RES, V66, P241, DOI 10.1006/exer.1997.0422; HOLLYFIELD JG, 1990, EXP EYE RES, V50, P335, DOI 10.1016/0014-4835(90)90220-O; HOLLYFIELD JG, 1989, EXTRACELLULAR INTRAC, P1; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; HUMBERT W, 1995, CELL TISSUE RES, V279, P565, DOI 10.1007/BF00318168; JAPHA JL, 1976, ACTA ANAT, V94, P533, DOI 10.1159/000144585; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRSTIC R, 1976, CELL TISSUE RES, V174, P129, DOI 10.1007/BF00222155; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI YL, 1982, BIOCHEM BIOPH RES CO, V108, P1601; LAZARUS HS, 1992, INVEST OPHTH VIS SCI, V33, P364; LUKASZYK A, 1975, AM J ANAT, V143, P451, DOI 10.1002/aja.1001430404; MANN DM, 1990, J BIOL CHEM, V265, P5317; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; Max M, 1998, J BIOL CHEM, V273, P26820, DOI 10.1074/jbc.273.41.26820; NOVENBERG U, 1992, NEURON, V8, P849; Plaas AHK, 1997, J BIOL CHEM, V272, P20603, DOI 10.1074/jbc.272.33.20603; PLANTNER JJ, 1992, EXP EYE RES, V54, P113, DOI 10.1016/0014-4835(92)90075-4; PLANTNER JJ, 1992, CURR EYE RES, V11, P91, DOI 10.3109/02713689209069171; PORRELLO K, 1986, CURR EYE RES, V5, P981, DOI 10.3109/02713688608995180; RODRIGUES MM, 1986, INVEST OPHTH VIS SCI, V27, P844; ROHLICH P, 1970, EXP EYE RES, V10, P80, DOI 10.1016/S0014-4835(70)80013-6; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHOEN TJ, 1995, BIOCHEM BIOPH RES CO, V213, P181, DOI 10.1006/bbrc.1995.2114; SCOTT J E, 1973, Biochemical Society Transactions, V1, P787; SCOTT JE, 1983, J MICROSC-OXFORD, V129, P209, DOI 10.1111/j.1365-2818.1983.tb04175.x; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SHIBATA S, 1992, J BIOL CHEM, V267, P6548; Spiess AN, 1999, BIOTECHNIQUES, V26, P46, DOI 10.2144/99261bm06; Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722; Vigh B, 1998, BIOL CELL, V90, P653, DOI 10.1016/S0248-4900(99)80022-7; Wang X, 1996, MOL BRAIN RES, V41, P269, DOI 10.1016/0169-328X(96)00107-6; WATANABE E, 1995, J BIOL CHEM, V270, P26876, DOI 10.1074/jbc.270.45.26876; WOOD JG, 1984, J COMP NEUROL, V228, P299, DOI 10.1002/cne.902280214; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; YANG BH, 1993, J BIOL CHEM, V268, P8617; YAO XY, 1994, INVEST OPHTH VIS SCI, V35, P744; YAO XY, 1990, INVEST OPHTH VIS SCI, V31, P2051; Yasuda Y, 1998, NEUROSCI RES, V32, P313, DOI 10.1016/S0168-0102(98)00098-4	71	56	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6945	6955		10.1074/jbc.275.10.6945	http://dx.doi.org/10.1074/jbc.275.10.6945			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702256	hybrid, Green Submitted			2022-12-27	WOS:000085809600036
J	Kishimoto, K; Matsumoto, K; Ninomiya-Tsuji, J				Kishimoto, K; Matsumoto, K; Ninomiya-Tsuji, J			TAK1 mitogen-activated protein kinase kinase kinase is activated by autophosphorylation within its activation loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA SIGNAL-TRANSDUCTION; N-TERMINAL KINASE; INTERLEUKIN-1; DIMERIZATION; RECEPTOR; JNK; IDENTIFICATION; EXPRESSION; REGULATOR; PATHWAYS	TAK1, a member of the mitogen-activated kinase kinase kinase family, is activated in vivo by various cytokines, including interleukin-1 (IL-1), or when ectopically expressed together with the TAK1-binding protein TAB1, However, this molecular mechanism of activation is not yet understood. We show here that endogenous TAK1 is constitutively associated with TAB1 and phosphorylated following IL-1 stimulation. Furthermore, TAK1 is constitutively phosphorylated when ectopically overexpressed with TAB1. In both cases, dephosphorylation of TAK1 renders it inactive, but it can be reactivated by preincubation with ATP, A mutant of TAK1 that lacks kinase activity is not phosphorylated either following IL-1 treatment or when coexpressed with TAB1, indicating that TAK1 phosphorylation is due to autophosphorylation. Furthermore, mutation to alanine of a conserved serine residue (Ser-192) in the activation loop between kinase domains VII and VIII abolishes both phosphorylation and activation of TAK1. These results suggest that IL-1 and ectopic expression of TAB1 both activate TAK1 via autophosphorylation of Ser-192.	Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Japan Sci & Technol Corp, CREST, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University; Japan Science & Technology Agency (JST)	Matsumoto, K (corresponding author), Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Chikusa Ku, Nagoya, Aichi 4648602, Japan.	g44177@nucc.cc.nagoya-u.ac.jp		Ninomiya-Tsuji, Jun/0000-0002-5584-0176				Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; LUO KX, 1991, METHOD ENZYMOL, V201, P149; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Siow YL, 1997, J BIOL CHEM, V272, P7586, DOI 10.1074/jbc.272.12.7586; Stock J, 1996, CURR BIOL, V6, P825, DOI 10.1016/S0960-9822(02)00605-X; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	32	222	227	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7359	7364		10.1074/jbc.275.10.7359	http://dx.doi.org/10.1074/jbc.275.10.7359			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702308	hybrid			2022-12-27	WOS:000085809600088
J	Jayaraman, S; Haggie, P; Wachter, RM; Remington, SJ; Verkman, AS				Jayaraman, S; Haggie, P; Wachter, RM; Remington, SJ; Verkman, AS			Mechanism and cellular applications of a green fluorescent protein-based halide sensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVING CELLS; CHLORIDE; INDICATORS; PH; MITOCHONDRIAL; ORGANELLES; VISCOSITY; DIFFUSION; EMISSION; VARIANTS	We report the application of a targetable green fluorescent protein-based cellular halide indicator. Fluorescence titrations of the purified recombinant yellow fluorescent protein YFP-H148Q indicated a pK(a) of 7.14 in the absence of Cl-, which increased to 7.86 at 150 mM Cl-. At pH 7.5, YFP-H148Q fluorescence decreased maximally by similar to 2-fold with a K-D of 100 mM Cl-. YFP-H148Q had a fluorescence lifetime of 8.1 ns that was independent of pH and [Cl-]. Circular dichroism and absorption spectroscopy revealed distinct Cl--dependent spectral changes indicating Cl-/YFP binding. Stopped-flow kinetic analysis showed a biexponential time course of YFP-H148Q fluorescence (time constants <100 ms) in response to changes in pH or [Cl-], establishing a 1:1 YFP-H148Q/Cl- binding mechanism, Photobleaching analysis revealed a millisecond triplet state relaxation process that was insensitive to anions and aqueous-phase quenchers. The anion selectivity sequence for YFP-H148Q quenching (ClO4(-) similar to I- > SCN- > NO3- > Cl- > Br- > formate > acetate) indicated strong binding of weakly hydrated chaotropic ions, The biophysical data suggest that YFP-H148Q anion sensitivity involves ground state anion binding to a site close to the tri-amino acid chromophore. YFP-H148Q transfected mammalian cells were brightly fluorescent with cytoplasmic/nuclear staining. Ionophore calibrations indicated similar YFP-H148Q pH and anion sensitivities in cells and aqueous solutions. Cyclic AMP-regulated Cl- transport through plasma membrane cystic fibrosis transmembrane conductance regulator Cl- channels was assayed with excellent sensitivity from the time course of YFP-H148Q fluorescence in response to extracellular Cl-/I- exchange. The green fluorescent protein-based halide sensor described here should have numerous applications, such as anion channel cloning by screening of mammalian expression libraries and discovery of compounds that correct the cystic fibrosis phenotype by screening of combinatorial libraries.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Univ Oregon, Dept Phys, Eugene, OR 97403 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Oregon; University of Oregon	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower,Box 0521, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu			NHLBI NIH HHS [HL59198] Funding Source: Medline; NIDDK NIH HHS [DK43840, DK35124] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R37DK035124, R01DK043840] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIWERSI J, 1991, BIOCHEMISTRY-US, V30, P7879, DOI 10.1021/bi00246a001; BIWERSI J, 1994, ANAL BIOCHEM, V219, P139, DOI 10.1006/abio.1994.1242; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Dawson David C., 1999, Physiological Reviews, V79, pS47; De Giorgi F, 1999, METHOD CELL BIOL, V58, P75; DeGiorgi F, 1996, GENE, V173, P113, DOI 10.1016/0378-1119(95)00687-7; Elsliger MA, 1999, BIOCHEMISTRY-US, V38, P5296, DOI 10.1021/bi9902182; FUSHIMI K, 1991, J CELL BIOL, V112, P719, DOI 10.1083/jcb.112.4.719; HALM DR, 1992, J GEN PHYSIOL, V99, P339, DOI 10.1085/jgp.99.3.339; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HEIM R, 1996, CURR BIOL, V6, P1178; Jayaraman S, 1999, AM J PHYSIOL-CELL PH, V277, pC1008, DOI 10.1152/ajpcell.1999.277.5.C1008; Jayaraman S, 1999, AM J PHYSIOL-CELL PH, V276, pC747, DOI 10.1152/ajpcell.1999.276.3.C747; Kneen M, 1998, BIOPHYS J, V74, P1591, DOI 10.1016/S0006-3495(98)77870-1; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Mansoura MK, 1999, HUM GENE THER, V10, P861, DOI 10.1089/10430349950018274; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Partikian A, 1998, J CELL BIOL, V140, P821, DOI 10.1083/jcb.140.4.821; Periasamy N, 1996, PHOTOCHEM PHOTOBIOL, V63, P265, DOI 10.1111/j.1751-1097.1996.tb03023.x; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; Siegel MS, 1997, NEURON, V19, P735, DOI 10.1016/S0896-6273(00)80955-1; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; VERKMAN AS, 1990, AM J PHYSIOL, V259, pC375, DOI 10.1152/ajpcell.1990.259.3.C375; Wachter RM, 1999, CURR BIOL, V9, pR628, DOI 10.1016/S0960-9822(99)80408-4; Wachter RM, 1998, STRUCTURE, V6, P1267, DOI 10.1016/S0969-2126(98)00127-0	29	238	257	2	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6047	6050		10.1074/jbc.275.9.6047	http://dx.doi.org/10.1074/jbc.275.9.6047			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692389	hybrid			2022-12-27	WOS:000085654400001
J	Sachs, K; Maretzki, D; Meyer, CK; Hofmann, KP				Sachs, K; Maretzki, D; Meyer, CK; Hofmann, KP			Diffusible ligand all-trans-retinal activates opsin via a palmitoylation-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; G-PROTEIN; BOVINE RHODOPSIN; INTRINSIC FLUORESCENCE; SIGNALING STATE; ALPHA-SUBUNIT; BINDING; PHOTORECEPTOR; PURIFICATION; ACYLATION	In rhodopsin's function as it photoreceptor, 11-cis-retinal is covalently bound to Lys(296) via a protonated Schiff base. 11-cis/all-trans photoisomerization and relaxation through intermediates lead to the metarhodopsin II photoproduct, which couples to transducin (G(t)), Here we have analyzed a different signaling state that arises from noncovalent binding of all-trans retinal (atr) to the aporeceptor opsin and enhances the very low opsin activity by several orders of magnitude. Like with metarhodopsin II, coupling of G(t) to opsin-atr is sensitive to competition by synthetic peptides from the COOH termini of both G(t)alpha and G(t)gamma. However, atr does not compete with 11-cis-retinal incorporation into the Lys(296) binding site and formation of the light-sensitive pigment. Blue light illumination fails to photorevert opsin-atr to the ground state. Thus noncovalently bound atr has no access to the light-dependent binding site and reaction pathway. Moreover, in contrast to light-dependent signaling, removal of the palmitoyl anchors at Cys(322) and Cys(323) in the rhodopsin COOH terminus impairs the atr-stimulated activity. Repahmitoylation by autoacylation with palmitoyl-coenzyme A restores most of the original activity. We hypothesize that the palmitoyl moieties are part of a second binding pocket for the chromophore, mediating hydrophobic interactions that can activate a large part of the catalytic receptor/G-protein interface.	Humboldt Univ, Univ Klinikum Charite, Inst Med Phys & Biophys, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hofmann, KP (corresponding author), Humboldt Univ, Univ Klinikum Charite, Inst Med Phys & Biophys, D-10098 Berlin, Germany.	klaus_peter.hofmann@charite.de						ARNIS S, 1995, BIOCHEMISTRY-US, V34, P9333, DOI 10.1021/bi00029a008; ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; Buczylko J, 1996, J BIOL CHEM, V271, P20621, DOI 10.1074/jbc.271.34.20621; Cai KW, 1999, BIOCHEMISTRY-US, V38, P7925, DOI 10.1021/bi9900119; CHEN YS, 1978, MEMBRANE BIOCHEM, V1, P107, DOI 10.3109/09687687809064162; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; DAEMEN FJM, 1978, NATURE, V276, P847, DOI 10.1038/276847a0; ERNST OP, 1995, J BIOL CHEM, V270, P10580, DOI 10.1074/jbc.270.18.10580; GUY PM, 1990, BIOCHEMISTRY-US, V29, P6954, DOI 10.1021/bi00482a003; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HAMM HE, 1991, CELL MOL NEUROBIOL, V11, P563, DOI 10.1007/BF00741446; Han M, 1998, BIOCHEMISTRY-US, V37, P8253, DOI 10.1021/bi980147r; HAN M, 2000, IN PRESS METHODS ENZ, P315; Helmreich EJM, 1996, BBA-REV BIOMEMBRANES, V1286, P285, DOI 10.1016/S0304-4157(96)00013-5; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HOFMAN KP, 1999, IN PRESS P 224 S NOV, P158; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KHORANA HG, 1992, J BIOL CHEM, V267, P1; Kisselev OG, 1999, P NATL ACAD SCI USA, V96, P4898, DOI 10.1073/pnas.96.9.4898; Korschen HG, 1999, NATURE, V400, P761, DOI 10.1038/23468; KUHN H, 1982, METHOD ENZYMOL, V81, P556; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; Melia TJ, 1997, BIOPHYS J, V73, P3182, DOI 10.1016/S0006-3495(97)78344-9; MORRISON DF, 1991, J BIOL CHEM, V266, P20118; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PALCZEWSKI K, 1993, METH NEUROSCI, V15, P217; PAPAC DI, 1992, J BIOL CHEM, V267, P16889; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Sachs K, 2000, METHOD ENZYMOL, V315, P238; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; Seitz HR, 1999, BIOCHEMISTRY-US, V38, P7950, DOI 10.1021/bi990298+; Surya A, 1998, EXP EYE RES, V66, P599, DOI 10.1006/exer.1997.0453; SURYA A, 1995, J BIOL CHEM, V270, P5024, DOI 10.1074/jbc.270.10.5024; Veit M, 1998, BBA-LIPID LIPID MET, V1394, P90, DOI 10.1016/S0005-2760(98)00097-6; WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9	40	67	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6189	6194		10.1074/jbc.275.9.6189	http://dx.doi.org/10.1074/jbc.275.9.6189			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692411	hybrid			2022-12-27	WOS:000085654400023
J	Szabo, EZ; Numata, L; Shull, GE; Orlowski, J				Szabo, EZ; Numata, L; Shull, GE; Orlowski, J			Kinetic and pharmacological properties of human brain Na+/H+ exchanger isoform 5 stably expressed in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH REGULATION; RAT HIPPOCAMPAL-NEURONS; ATP DEPENDENCE; FUNCTIONAL-PROPERTIES; PROTON INHIBITION; NA/H EXCHANGER; CA2+ CURRENTS; H+ EXCHANGER; CA1 NEURONS; ANTIPORTER	The recently cloned Na+/H+ exchanger isoform 5 (NHE5) is expressed predominantly in brain, yet Little is known about its functional properties, To facilitate its characterization, a full-length cDNA encoding human NHE5 was stably transfected into NHE-deficient Chinese hamster ovary AP-1 cells. Pharmacological analyses revealed that H-i(+)-activated Na-22(+) influx mediated by NHE5 was inhibited by several classes of drugs (amiloride compounds, 3-methylsulfonyl-4-piperidinobenzoyl guanidine methanesulfonate, cimetidine, and harmaline) at half-maximal concentrations that were intermediate to those determined for the high affinity NHE1 and the low affinity NHE3 isoforms, but closer to the latter. Kinetic analyses showed that the extracellular Na+ dependence of NHE5 activity followed a simple hyperbolic relationship with an apparent affinity constant (K-Na) of 18.6 +/- 1.6 mM. By contrast to other NHE isoforms, NHE5 also exhibited a first-order dependence on the intracellular H+ concentration, achieving half-maximal activation at pH 6.43 +/- 0.08. Extracellular monovalent cations, such as H+ and Li+, but not K+, acted as effective competitive inhibitors of Na-22(+) influx by NHE5. In addition, the transport activity of NHE5 was highly dependent on cellular ATP levels. Overall, these functional features distinguish NHE5 from other family members and closely resemble those of an amiloride-resistant NHE isoform identified in hippocampal neurons.	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada; Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	McGill University; University System of Ohio; University of Cincinnati	Orlowski, J (corresponding author), McGill Univ, Dept Physiol, 3655 Drummond St,McIntyre Med Sci Bldg, Montreal, PQ H3G 1Y6, Canada.			Orlowski, John/0000-0001-7371-175X	NIDDK NIH HHS [DK50594] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050594, R01DK050594] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aharonovitz O, 1999, AM J PHYSIOL-CELL PH, V276, pC1303, DOI 10.1152/ajpcell.1999.276.6.C1303; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; Attaphitaya S, 1999, J BIOL CHEM, V274, P4383, DOI 10.1074/jbc.274.7.4383; Babinski K, 1999, J NEUROCHEM, V72, P51, DOI 10.1046/j.1471-4159.1999.0720051.x; Baird NR, 1999, J BIOL CHEM, V274, P4377, DOI 10.1074/jbc.274.7.4377; Baxter KA, 1996, J PHYSIOL-LONDON, V493, P457, DOI 10.1113/jphysiol.1996.sp021396; Bell SM, 1999, AM J PHYSIOL-CELL PH, V276, pC788, DOI 10.1152/ajpcell.1999.276.4.C788; BENOS DJ, 1994, J BIOL CHEM, V269, P13811; Bookstein C, 1996, AM J PHYSIOL-CELL PH, V271, pC1629, DOI 10.1152/ajpcell.1996.271.5.C1629; Boussouf A, 1997, GLIA, V19, P74, DOI 10.1002/(SICI)1098-1136(199701)19:1<74::AID-GLIA8>3.0.CO;2-A; BOYARSKY G, 1990, P NATL ACAD SCI USA, V87, P5921, DOI 10.1073/pnas.87.15.5921; BOYARSKY G, 1993, GLIA, V8, P241, DOI 10.1002/glia.440080404; Brookes N, 1997, GLIA, V21, P64; BURNS KD, 1991, AM J PHYSIOL, V261, pF607, DOI 10.1152/ajprenal.1991.261.4.F607; CASSEL D, 1986, J BIOL CHEM, V261, P5460; Chambrey R, 1997, AM J PHYSIOL-CELL PH, V272, pC90, DOI 10.1152/ajpcell.1997.272.1.C90; Chambrey R, 1997, AM J PHYSIOL-CELL PH, V273, pC1064, DOI 10.1152/ajpcell.1997.273.3.C1064; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Church J, 1998, J PHYSIOL-LONDON, V511, P119, DOI 10.1111/j.1469-7793.1998.119bi.x; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; COUNILLON L, 1993, P NATL ACAD SCI USA, V90, P4508, DOI 10.1073/pnas.90.10.4508; Cox GA, 1997, CELL, V91, P139, DOI 10.1016/S0092-8674(01)80016-7; Demaurex N, 1997, J GEN PHYSIOL, V109, P117, DOI 10.1085/jgp.109.2.117; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; GAILLARD S, 1990, J PHYSIOL-LONDON, V425, P71, DOI 10.1113/jphysiol.1990.sp018093; GOSS GG, 1994, J BIOL CHEM, V269, P8741; Ikeda T, 1997, J BIOCHEM-TOKYO, V121, P295; IVES HE, 1983, J BIOL CHEM, V258, P9710; JEAN T, 1985, J BIOL CHEM, V260, P9678; KAPUS A, 1994, J BIOL CHEM, V269, P23544; Kiss L, 1999, J NEUROPHYSIOL, V81, P1839, DOI 10.1152/jn.1999.81.4.1839; LAZDUNSKI M, 1985, J MOL CELL CARDIOL, V17, P1029, DOI 10.1016/S0022-2828(85)80119-X; Lenox RH, 1998, J CLIN PSYCHIAT, V59, P37; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; LITTLE PJ, 1988, J BIOL CHEM, V263, P16780; Ma E, 1997, NEUROSCIENCE, V79, P591, DOI 10.1016/S0306-4522(96)00674-4; Orlowski J, 1996, J BIOL CHEM, V271, P19922, DOI 10.1074/jbc.271.33.19922; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; OTSU K, 1992, J BIOL CHEM, V267, P8089; RALEYSUSMAN KM, 1993, BRAIN RES, V614, P308, DOI 10.1016/0006-8993(93)91049-X; RALEYSUSMAN KM, 1991, J BIOL CHEM, V266, P2739; Ritucci NA, 1998, AM J PHYSIOL-REG I, V275, pR1152, DOI 10.1152/ajpregu.1998.275.4.R1152; Rorig B, 1996, J PHYSIOL-LONDON, V490, P31; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; SCHOLZ W, 1995, CARDIOVASC RES, V29, P260, DOI 10.1016/S0008-6363(96)88579-8; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; SCHWIENING CJ, 1994, J PHYSIOL-LONDON, V475, P59, DOI 10.1113/jphysiol.1994.sp020049; SHRODE LD, 1994, GLIA, V12, P196, DOI 10.1002/glia.440120305; Takahashi KI, 1996, NEUROSCI RES, V24, P109, DOI 10.1016/0168-0102(95)00989-2; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TOLKOVSKY AM, 1987, NEUROSCIENCE, V22, P1093, DOI 10.1016/0306-4522(87)92984-8; Tombaugh GC, 1996, J PHYSIOL-LONDON, V493, P719, DOI 10.1113/jphysiol.1996.sp021417; Tombaugh GC, 1997, J NEUROPHYSIOL, V77, P639, DOI 10.1152/jn.1997.77.2.639; TRAYNELIS SF, 1990, NATURE, V345, P347, DOI 10.1038/345347a0; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; YU FH, 1993, J BIOL CHEM, V268, P25536; Zhai J, 1998, PFLUG ARCH EUR J PHY, V435, P539, DOI 10.1007/s004240050550	59	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6302	6307		10.1074/jbc.275.9.6302	http://dx.doi.org/10.1074/jbc.275.9.6302			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692428	hybrid			2022-12-27	WOS:000085654400040
J	Campbell, WA; Sah, DE; Medina, MM; Albina, JE; Coleman, WB; Thompson, NL				Campbell, WA; Sah, DE; Medina, MM; Albina, JE; Coleman, WB; Thompson, NL			TA1/LAT-1/CD98 light chain and system L activity, but not 4F2/CD98 heavy chain, respond to arginine availability in rat hepatic cells - Loss of response in tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-TRANSPORT; GAMMA-GLUTAMYL-TRANSPEPTIDASE; HAMSTER OVARY CELLS; GENE-EXPRESSION; MOLECULAR-CLONING; SURFACE-ANTIGEN; LIVER; PROTEIN; HEPATOCYTES; CD98	Tumor associated gene-1/L amino acid transporter-1 (TA1/LAT-1) was recently identified as a light chain of the CD98 amino acid transporter and cellular activation marker. Our previous studies with primary rat hepatocyte cultures demonstrated that TA1 RNA levels were responsive to media amino acid concentrations, suggesting adaptive regulation, High level TA1 expression associated with transformed cells also suggested a role in tumor progression. The present study examined the relationship of TA1/CD98 expression, adaptive response, and associated amino acid transport to neoplastic transformation using a panel of well characterized rat hepatic cell lines. We found 1) increased expression of TA1 in response to amino acid depletion, specific for arginine but not glutamine; 2) loss of TA1 response to arginine in gamma-glutamyl transpeptidase-positive transformed and tumorigenic cells; 3) no appreciable response of 4F2/CD98 heavy chain to arginine levels; and 4) correlation of system L amino acid transport activity in response to arginine with changes in TA1/LAT-1 mRNA but not total immunoreacting protein. Our results suggest this CD98 Light chain may act as an environmental sensor, responding to amino acid availability and that its regulation is complex. We hypothesize that altered TA1 expression is an early event in hepatocarcinogenesis giving neoplastic cells a growth or survival advantage, particularly under conditions of limited amino acid availability.	Brown Univ, Rhode Isl Hosp, Div Med Oncol, Sch Med, Providence, RI 02903 USA; Brown Univ, Rhode Isl Hosp, Dept Surg, Sch Med, Providence, RI 02903 USA; Grad Program Pathobiol, Providence, RI 02903 USA; Univ N Carolina, Dept Pathol, Chapel Hill, NC 27599 USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; University of North Carolina; University of North Carolina Chapel Hill	Thompson, NL (corresponding author), Brown Univ, Rhode Isl Hosp, Div Med Oncol, Sch Med, 593 Eddy St, Providence, RI 02903 USA.	Nancy_Thompson@brown.edu			NATIONAL CANCER INSTITUTE [R01CA073611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007272] Funding Source: NIH RePORTER; NCI NIH HHS [CA73611] Funding Source: Medline; NIEHS NIH HHS [T32ESO7272] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aulak KS, 1999, J BIOL CHEM, V274, P30424, DOI 10.1074/jbc.274.43.30424; BODE BP, 1995, HEPATOLOGY, V21, P511; Borsani G, 1999, NAT GENET, V21, P297, DOI 10.1038/6815; BRACY DS, 1986, J BIOL CHEM, V261, P1514; Broer S, 1997, BIOCHEM J, V324, P535, DOI 10.1042/bj3240535; CHEN ZP, 1992, J BIOL CHEM, V267, P6946; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Coleman WB, 1997, AM J PATHOL, V151, P353; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GAUGITSCH HW, 1992, J BIOL CHEM, V267, P11267; GAZZOLA GC, 1981, ANAL BIOCHEM, V115, P368, DOI 10.1016/0003-2697(81)90019-1; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; HANIGAN MH, 1993, BIOCHEMISTRY-US, V32, P6302, DOI 10.1021/bi00075a026; HANIGAN MH, 1995, CARCINOGENESIS, V16, P181, DOI 10.1093/carcin/16.2.181; Hara K, 1999, BIOCHEM BIOPH RES CO, V262, P720, DOI 10.1006/bbrc.1999.1051; HEMLER ME, 1982, J IMMUNOL, V129, P623; HIXSON DC, 1985, CANCER RES, V45, P3742; Hyatt SL, 1997, J BIOL CHEM, V272, P19951, DOI 10.1074/jbc.272.32.19951; INOUE Y, 1995, CANCER RES, V55, P3525; Jousse C, 1998, BIOCHEM J, V334, P147, DOI 10.1042/bj3340147; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; KILBERG MS, 1994, FASEB J, V8, P13, DOI 10.1096/fasebj.8.1.8299885; KILBERG MS, 1989, METHOD ENZYMOL, V173, P564; Mannion BA, 1998, J BIOL CHEM, V273, P33127, DOI 10.1074/jbc.273.50.33127; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; NOVAK DA, 1994, BIOCHEM J, V301, P671, DOI 10.1042/bj3010671; OHGIMOTO S, 1995, J IMMUNOL, V155, P3585; OZONO S, 1985, CANCER LETT, V29, P49, DOI 10.1016/0304-3835(85)90122-3; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Pitot HC, 1996, J CANCER RES CLIN, V122, P257, DOI 10.1007/BF01261401; POHJANPELTO P, 1990, MOL CELL BIOL, V10, P5814, DOI 10.1128/MCB.10.11.5814; Prasad PD, 1999, BIOCHEM BIOPH RES CO, V255, P283, DOI 10.1006/bbrc.1999.0206; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P6526, DOI 10.1073/pnas.84.18.6526; SANG JS, 1995, CANCER RES, V55, P1152; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; SHOTWELL MA, 1982, J BIOL CHEM, V257, P2974; Shultz VD, 1999, TOXICOL APPL PHARM, V154, P84, DOI 10.1006/taap.1998.8555; Shultz VD, 1997, PATHOBIOLOGY, V65, P14, DOI 10.1159/000164099; SOLT DB, 1985, J NATL CANCER I, V74, P437; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; Torrents D, 1999, NAT GENET, V21, P293, DOI 10.1038/6809; TSAO MS, 1985, AM J PATHOL, V118, P306; TSAO MS, 1984, EXP CELL RES, V154, P38, DOI 10.1016/0014-4827(84)90666-9; Tsurudome M, 1999, J IMMUNOL, V162, P2462; Warren AP, 1996, BLOOD, V87, P3676, DOI 10.1182/blood.V87.9.3676.bloodjournal8793676; WAXMAN DJ, 1990, BIOCHEM J, V271, P113, DOI 10.1042/bj2710113; WEISSBACH L, 1982, J BIOL CHEM, V257, P2006; Wolf DA, 1996, CANCER RES, V56, P5012	52	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5347	5354		10.1074/jbc.275.8.5347	http://dx.doi.org/10.1074/jbc.275.8.5347			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681508	hybrid			2022-12-27	WOS:000085474500015
J	Golser, R; Gorren, ACF; Leber, A; Andrew, P; Habisch, HJ; Werner, ER; Schmidt, K; Venema, RC; Mayer, B				Golser, R; Gorren, ACF; Leber, A; Andrew, P; Habisch, HJ; Werner, ER; Schmidt, K; Venema, RC; Mayer, B			Interaction of endothelial and neuronal nitric-oxide syntheses with the bradykinin B2 receptor - Binding of an inhibitory peptide to the oxygenase domain blocks uncoupled NADPH oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARGININE; SUPEROXIDE GENERATION; ELECTRON-TRANSFER; SYNTHASE ACTIVITY; SKELETAL-MUSCLE; SHEAR-STRESS; NO SYNTHASE; TETRAHYDROBIOPTERIN; CAVEOLIN; ACTIVATION	Endothelial nitric oxide synthase (type III) (eNOS) was reported to form an inhibitory complex with the bradykinin receptor B2 (B2R) from which the enzyme is released in an active form upon receptor activation (Ju, H., Venema, V. J., Marrero, M, B., and Venema, R. C. (1998) J. Biol, Chem. 273, 24025-24029). Using a synthetic peptide derived from the known inhibitory sequence of the B2R (residues 310-329) we studied the interaction of the receptor with purified eNOS and neuronal nitric-oxide synthase (type I) (nNOS). The peptide inhibited formation of L-citrulline by eNOS and nNOS with IC50 values of 10.6 +/- 0.4 mu M and 7.1 +/- 0.6 mu M, respectively, Inhibition was not due to an interference df the peptide with L-arginine or tetrahydrobiopterin binding. The NADPH oxidase activity of nNOS measured in the absence of L-arginine was inhibited by the peptide with an IC50 of 3.7 +/- 0.6 mu M but the cytochrome c reductase activity of the enzyme was much less susceptible to inhibition (IC50 >0.1 mM), Steady-state absorbance spectra of nNOS recorded during uncoupled NADPH oxidation showed that the heme remained oxidized in the presence of the synthetic peptide consisting of amino acids 310-329 of the B2R, whereas the reduced oxyferrous heme complex was accumulated in its absence. These data suggest that binding of the B2R 310-329 peptide blocks flavin to heme electron transfer. Co-immunoprecipitation of B2R and nNOS from human embryonic kidney cells stably transfected with human nNOS suggests that the B2R may functionally interact with nNOS in vivo, This interaction of nNOS with the B2R may recruit the enzyme to allow for the effective coupling of bradykinin signaling to the nitric oxide pathway.	Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, A-8010 Graz, Austria; Univ Innsbruck, Inst Med Chem & Biochem, A-6020 Innsbruck, Austria; Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA	University of Graz; University of Innsbruck; University System of Georgia; Augusta University	Mayer, B (corresponding author), Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, Univ Pl 2, A-8010 Graz, Austria.	mayer@kfunigraz.ac.at	Mayer, Bernd/B-9391-2008	Habisch, Hansjorg/0000-0001-5537-506X; Mayer, Bernd/0000-0002-2921-3494; Gorren, Antonius Cornelis Franciscus/0000-0003-3476-6162; Werner, Ernst R./0000-0003-1948-3391	NHLBI NIH HHS [HL62152, HL57201] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057201, R29HL057201, R01HL062152] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; Adak S, 1999, J BIOL CHEM, V274, P26907, DOI 10.1074/jbc.274.38.26907; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bommel HM, 1998, J BIOL CHEM, V273, P33142, DOI 10.1074/jbc.273.50.33142; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Busse R, 1998, J VASC RES, V35, P73, DOI 10.1159/000025568; Cosentino F, 1999, CARDIOVASC RES, V43, P274, DOI 10.1016/S0008-6363(99)00134-0; COSENTINO F, 1995, CIRCULATION, V91, P139, DOI 10.1161/01.CIR.91.1.139; CULCASI M, 1994, J BIOL CHEM, V269, P12589; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Eliasson MJL, 1999, J NEUROSCI, V19, P5910, DOI 10.1523/JNEUROSCI.19-14-05910.1999; Endres M, 1998, NEUROSCI LETT, V248, P41, DOI 10.1016/S0304-3940(98)00224-9; Estevez AG, 1998, J NEUROSCI, V18, P923; FELDMAN PL, 1993, J MED CHEM, V36, P491, DOI 10.1021/jm00056a009; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Firestein BL, 1999, J BIOL CHEM, V274, P10545, DOI 10.1074/jbc.274.15.10545; Fleming I, 1997, J VASC RES, V34, P165, DOI 10.1159/000159220; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Ghosh S, 1998, J BIOL CHEM, V273, P22267, DOI 10.1074/jbc.273.35.22267; GONZELEZZULUETA M, 1988, J NEUROSCI, V18, P2040; HARTENECK C, 1994, BIOCHEM J, V304, P683, DOI 10.1042/bj3040683; Hashida-Okumura A, 1999, J BIOL CHEM, V274, P11736, DOI 10.1074/jbc.274.17.11736; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; Holthusen H, 1997, PAIN, V69, P87, DOI 10.1016/S0304-3959(96)03262-9; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; Ju H, 1998, J BIOL CHEM, V273, P24025, DOI 10.1074/jbc.273.37.24025; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Katusic ZS, 1996, FREE RADICAL BIO MED, V20, P443, DOI 10.1016/0891-5849(96)02116-8; KLATT P, 1994, J BIOL CHEM, V269, P1674; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; KLATT P, 1992, J BIOL CHEM, V267, P11374; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; Kurz T, 1997, J MOL CELL CARDIOL, V29, P2561, DOI 10.1006/jmcc.1997.0492; List BM, 1997, BIOCHEM J, V323, P159, DOI 10.1042/bj3230159; Marrero MB, 1999, BIOCHEM J, V343, P335, DOI 10.1042/0264-6021:3430335; MAYER B, 1994, NEUROPHARMACOLOGY, V33, P1253, DOI 10.1016/0028-3908(94)90024-8; Mayer B, 1996, METHOD ENZYMOL, V268, P420; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; Mayer B, 1997, NITRIC OXIDE-BIOL CH, V1, P50, DOI 10.1006/niox.1996.0102; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Nakamura A, 1996, BRIT J PHARMACOL, V117, P407, DOI 10.1111/j.1476-5381.1996.tb15205.x; OLKEN NM, 1991, BIOCHEM BIOPH RES CO, V177, P828, DOI 10.1016/0006-291X(91)91864-9; POU S, 1992, J BIOL CHEM, V267, P24173; Pou S, 1999, J BIOL CHEM, V274, P9573, DOI 10.1074/jbc.274.14.9573; Prabhakar P, 1998, J BIOL CHEM, V273, P27383, DOI 10.1074/jbc.273.42.27383; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; PRITCHARD KA, 1995, CIRC RES, V77, P510, DOI 10.1161/01.RES.77.3.510; Riethmuller C, 1999, J BIOL CHEM, V274, P16047, DOI 10.1074/jbc.274.23.16047; Sase K, 1997, TRENDS CARDIOVAS MED, V7, P28, DOI 10.1016/S1050-1738(96)00121-1; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; SHENG H, 1995, LUNG, V173, P373; Stroes E, 1997, J CLIN INVEST, V99, P41, DOI 10.1172/JCI119131; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Teixeira CE, 1998, BRIT J UROL, V81, P432; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Venema VJ, 1996, BIOCHEM BIOPH RES CO, V226, P703, DOI 10.1006/bbrc.1996.1417; Venema VJ, 1997, J BIOL CHEM, V272, P28187, DOI 10.1074/jbc.272.45.28187; WERNER ER, 1994, BIOCHEM J, V304, P189, DOI 10.1042/bj3040189; Werner ER, 1996, BIOCHEM J, V320, P193, DOI 10.1042/bj3200193; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804	72	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5291	5296		10.1074/jbc.275.8.5291	http://dx.doi.org/10.1074/jbc.275.8.5291			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681501	hybrid			2022-12-27	WOS:000085474500008
J	Takeda, A; Perry, G; Abraham, NG; Dwyer, BE; Kutty, RK; Laitinen, JT; Petersen, RB; Smith, MA				Takeda, A; Perry, G; Abraham, NG; Dwyer, BE; Kutty, RK; Laitinen, JT; Petersen, RB; Smith, MA			Overexpression of heme oxygenase in neuronal cells, the possible interaction with tau	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIENT FOREBRAIN ISCHEMIA; RAT-BRAIN; ALZHEIMERS-DISEASE; MESSENGER-RNA; OXIDATIVE STRESS; CARBON-MONOXIDE; PC12 CELLS; PROTEIN; INDUCTION; EXPRESSION	Increased expression of heme oxygenase-1 (HO-1) is a common feature in a number of neurodegenerative diseases. Interestingly, the spatial distribution of HO-1 expression in diseased brain is essentially identical to that of pathological expression of tau. In this study, we explored the relationship between HO-1 and tau, using neuroblastoma cells stably transfected with sense and antisense HO-1 constructs as well as with the vector alone. In transfected cells overexpressing HO-1, the activity of heme oxygenase was increased, and conversely, the level of tau protein was dramatically decreased when compared with antisense HO-1 or CEP transfected cells. The suppression of tau protein expression was almost completely reversed by zinc-deuteroporphyrin, a specific inhibitor of heme oxygenase activity. The activated forms of ERKs (extracellular signal-regulated kinases) were also decreased in cells overexpressing HO-I although no changes in the expression of total ERB-1/2 proteins were observed. These data are in agreement with the finding that the expression of tau is regulated through signal cascades including the ERKs, whose activities are modulated by oxidative stresses. The expression of tan and HO-1 may be regulated by oxidative stresses in a coordinated manner and play a pivotal role in the cytoprotection of neuronal cells.	Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA; New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA; Vet Affairs Med Ctr, Res Serv, White River Junction, VT 05009 USA; NEI, NIH, Bethesda, MD 20892 USA; Univ Kuopio, Dept Physiol, FIN-70211 Kuopio, Finland	Case Western Reserve University; New York Medical College; US Department of Veterans Affairs; Veterans Health Administration (VHA); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); University of Eastern Finland	Smith, MA (corresponding author), Case Western Reserve Univ, Inst Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.		Smith, Mark A/A-9053-2009; Petersen, Robert/B-5075-2011; Perry, George/A-8611-2009	Petersen, Robert/0000-0002-3154-0072; Perry, George/0000-0002-6547-0172; Laitinen, Jarmo T/0000-0002-9490-3686	NIA NIH HHS [AG14249, AG09287] Funding Source: Medline; NINDS NIH HHS [NS38648] Funding Source: Medline; NATIONAL EYE INSTITUTE [Z01EY000308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038648] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009287, R01AG014249] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; ABRAHAM NG, 1988, INT J BIOCHEM, V20, P543, DOI 10.1016/0020-711X(88)90093-6; CASTELLANI R, 1995, BRAIN RES, V696, P268, DOI 10.1016/0006-8993(95)00535-X; Castellani R, 1996, BRAIN RES, V737, P195, DOI 10.1016/0006-8993(96)00729-9; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; Esclaire F, 1997, J NEUROSCI RES, V49, P309, DOI 10.1002/(SICI)1097-4547(19970801)49:3<309::AID-JNR6>3.0.CO;2-G; EWING JF, 1992, J NEUROCHEM, V58, P1140, DOI 10.1111/j.1471-4159.1992.tb09373.x; EWING JF, 1993, J NEUROCHEM, V60, P1512, DOI 10.1111/j.1471-4159.1993.tb03315.x; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; JOHNSON RA, 1995, HYPERTENSION, V25, P166, DOI 10.1161/01.HYP.25.2.166; Koistinaho J, 1996, EUR J NEUROSCI, V8, P2265, DOI 10.1111/j.1460-9568.1996.tb01190.x; KUTTY RK, 1995, P NATL ACAD SCI USA, V92, P1177, DOI 10.1073/pnas.92.4.1177; KUTTY RK, 1994, ANN NY ACAD SCI, V738, P427; LAITINEN JT, 1995, BRAIN RES, V694, P246, DOI 10.1016/0006-8993(95)00761-E; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Lesort M, 1997, MOL BRAIN RES, V45, P127, DOI 10.1016/S0169-328X(96)00284-7; MAINES MD, 1988, FASEB J, V2, P25557; MATTSON MP, 1995, NATURE, V373, P481, DOI 10.1038/373481a0; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; Nunomura A, 1999, J NEUROSCI, V19, P1959; Perry G, 1999, NEUROREPORT, V10, P2411, DOI 10.1097/00001756-199908020-00035; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; PREMKUMAR DRD, 1995, J NEUROCHEM, V65, P1399; Sadot E, 1998, J NEUROCHEM, V70, P428; Sayre LM, 1997, J NEUROCHEM, V68, P2092; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; Smith MA, 1997, J NEUROSCI, V17, P2653; Smith MA, 1996, NATURE, V382, P120, DOI 10.1038/382120b0; SMITH MA, 1994, AM J PATHOL, V145, P42; Song XO, 1998, NEUROTOXICOLOGY, V19, P73; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Takeda A, 1996, NEUROSCI LETT, V205, P169, DOI 10.1016/0304-3940(96)12405-8; TAKEDA A, 1994, BRAIN RES, V666, P120, DOI 10.1016/0006-8993(94)90292-5; TAKEDA A, 2000, IN PRESS J NEUROCHEM; TRAKSHEL GM, 1988, ARCH BIOCHEM BIOPHYS, V260, P732, DOI 10.1016/0003-9861(88)90503-6; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VILE GF, 1993, J BIOL CHEM, V268, P14678; Xie HQ, 1997, J NEUROCHEM, V69, P1020; Yu SM, 1997, CIRCULATION, V95, P1269; [No title captured]	41	155	165	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5395	5399		10.1074/jbc.275.8.5395	http://dx.doi.org/10.1074/jbc.275.8.5395			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681514	hybrid			2022-12-27	WOS:000085474500021
J	Cheng, YQ; Walton, JD				Cheng, YQ; Walton, JD			A eukaryotic alanine racemase gene involved in cyclic peptide biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNGUS COCHLIOBOLUS-CARBONUM; HOST-SPECIFIC TOXIN; DISEASE RESISTANCE GENE; OPEN READING FRAME; HC-TOXIN; HELMINTHOSPORIUM-CARBONUM; HISTONE DEACETYLASE; THREONINE ALDOLASE; SELECTIVE TOXINS; KEY ENZYME	The cyclic tetrapeptide HC-toxin is an essential virulence determinant for the plant pathogenic fungus Cochliobolus carbonum and an inhibitor of histone deacetylase. The major form of RC-toxin contains the D-isomers of Ala and Pro. The non-ribosomal peptide synthetase that synthesizes HC-toxin has only one epimerizing domain for conversion of L-Pro to D-Pro; the source of D-Ala has remained unknown. Here we present the cloning and characterization of a new gene involved in HC-toxin biosynthesis, TOXG. TOXG is present only in HC-toxin-producing (Tox2(+)) isolates of C. carbonum. TOXG is able to support D-Ala-independent growth of a strain of Escherichia coli defective in D-Ala synthesis. A C. carbonum strain with both of its copies of TOXG mutated grows normally in culture, and although it no lon ger makes the three forms of HC-toxin that contain D-Ala, it still makes a minor form of HC-toxin that contains Gly in place of D-Ala. The addition of D-Ala to the culture medium restores production of the D-Ala-containing forms of HC-toxin by the toxG mutant. The toxG mutant has only partially reduced virulence. It is concluded that TOXG encodes an alanine racemase whose function is to synthesize D-Ala for incorporation into HC-toxin.	Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48824 USA; Michigan State Univ, Dept Bot & Plant Pathol, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Walton, JD (corresponding author), Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48824 USA.			Cheng, Eric/0000-0001-9336-2593				Ahn JH, 1998, MOL GEN GENET, V260, P462, DOI 10.1007/s004380050917; Ahn JH, 1997, MOL PLANT MICROBE IN, V10, P207, DOI 10.1094/MPMI.1997.10.2.207; Ahn JH, 1996, PLANT CELL, V8, P887, DOI 10.1105/tpc.8.5.887; ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; BROSCH G, 1995, PLANT CELL, V7, P1941, DOI 10.1105/tpc.7.11.1941; Brown DW, 1996, P NATL ACAD SCI USA, V93, P1418, DOI 10.1073/pnas.93.4.1418; CARROLL AM, 1994, FUNGAL GENET NEWSLET, V41, P22, DOI DOI 10.4148/1941-4765.1367; Cheng YQ, 1999, MICROBIOL-UK, V145, P3539, DOI 10.1099/00221287-145-12-3539; DarkinRattray SJ, 1996, P NATL ACAD SCI USA, V93, P13143, DOI 10.1073/pnas.93.23.13143; DECRECYLAGARD V, 1995, CR ACAD SCI III-VIE, V318, P927; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAMMOCK LG, 1974, B ENVIRON CONTAM TOX, V12, P759, DOI 10.1007/BF01685927; HOFFMANN K, 1994, J BIOL CHEM, V269, P12710; Jansonius JN, 1998, CURR OPIN STRUC BIOL, V8, P759, DOI 10.1016/S0959-440X(98)80096-1; JOHAL GS, 1992, SCIENCE, V258, P985, DOI 10.1126/science.1359642; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; KIM SD, 1985, TETRAHEDRON LETT, V26, P969, DOI 10.1016/S0040-4039(00)98488-0; Kleinkauf H, 1996, EUR J BIOCHEM, V236, P335, DOI 10.1111/j.1432-1033.1996.00335.x; Kocher H.P., 1994, Int. Patent Appl., Patent No. [WO 9425606 A2, 9425606]; Liu JQ, 1997, J BACTERIOL, V179, P3555, DOI 10.1128/jb.179.11.3555-3560.1997; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; MEELEY RB, 1992, PLANT CELL, V4, P71, DOI 10.1105/tpc.4.1.71; MEELEY RB, 1991, PLANT PHYSIOL, V97, P1080, DOI 10.1104/pp.97.3.1080; Monschau N, 1997, FEMS MICROBIOL LETT, V150, P55, DOI 10.1016/S0378-1097(97)00096-7; PANACCIONE DG, 1992, P NATL ACAD SCI USA, V89, P6590, DOI 10.1073/pnas.89.14.6590; Ransom RF, 1997, PLANT PHYSIOL, V115, P1021, DOI 10.1104/pp.115.3.1021; RASMUSSEN JB, 1988, PLANT PHYSIOL, V86, P187, DOI 10.1104/pp.86.1.187; RASMUSSEN JB, 1987, THESIS MICHIGAN STAT; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEFFER RP, 1967, PHYTOPATHOLOGY, V57, P1288; SCOTTCRAIG JS, 1992, J BIOL CHEM, V267, P26044; STEIN T, 1995, BIOCHEMISTRY-US, V34, P4633, DOI 10.1021/bi00014a017; TANIS SP, 1986, HETEROCYCLES, V24, P3423; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Trapp SC, 1998, MOL GEN GENET, V257, P421, DOI 10.1007/s004380050666; Tudzynski B, 1998, FUNGAL GENET BIOL, V25, P157, DOI 10.1006/fgbi.1998.1095; VANHOOF A, 1991, PHYSIOL MOL PLANT P, V39, P259, DOI 10.1016/0885-5765(91)90034-F; Walton J. D., 1988, Molecular Plant-Microbe Interactions, V1, P128, DOI 10.1094/MPMI-1-128; WALTON JD, 1982, BIOCHEM BIOPH RES CO, V107, P785, DOI 10.1016/0006-291X(82)90592-7; Walton JD, 1996, PLANT CELL, V8, P1723, DOI 10.1105/tpc.8.10.1723; WALTON JD, 1987, P NATL ACAD SCI USA, V84, P8444, DOI 10.1073/pnas.84.23.8444; WEBER G, 1994, CURR GENET, V26, P120, DOI 10.1007/BF00313798; WIJSMAN HJW, 1972, GENET RES, V20, P269, DOI 10.1017/S001667230001380X; YU JJ, 1995, APPL ENVIRON MICROB, V61, P2365, DOI 10.1128/AEM.61.6.2365-2371.1995	45	58	65	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4906	4911		10.1074/jbc.275.7.4906	http://dx.doi.org/10.1074/jbc.275.7.4906			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671527	hybrid			2022-12-27	WOS:000085378200053
J	Grantham, J; Llorca, O; Valpuesta, JM; Willison, KR				Grantham, J; Llorca, O; Valpuesta, JM; Willison, KR			Partial occlusion of both cavities of the eukaryotic chaperonin with antibody has no effect upon the rates of beta-actin or alpha-tubulin folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CCT; POLYPEPTIDE; THERMOSOME; SUBUNITS; RELEASE; DOMAIN; GROEL	The eukaryotic chaperonin containing T-complex polypeptide 1 (CCT) is required in vivo for the production of native actin and tubulin. It is a 900-kDa oligomer formed from two back-to back rings, each containing eight different subunits surrounding a central cavity in which interactions with substrates are thought to occur, Here, we show that a monoclonal antibody recognizing the C terminus of the CCT alpha subunit can bind inside, and partially occlude, both cavities of apo-CCT, Rabbit reticulocyte lysate was programmed to synthesize beta-actin and alpha-tubulin in the presence and absence of anti-CCT alpha antibody. The binding of the antibody inside the cavity and its occupancy of a large part of it does not prevent the folding of beta-actin and alpha-tubulin by CCT, despite the fact that all the CCT in the in vitro translation reactions was continuously bound by two antibody molecules. Furthermore, no differences in the protease susceptibility of actin bound to CCT in the presence and absence of the monoclonal antibody were detected, indicating that the antibody molecules do not perturb the conformation of actin folding intermediates substantially. These data indicate that complete sequestration of substrate by CCT may not be required for productive folding, suggesting that there are differences in its folding mechanism compared with the Group I chaperonins.	Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England; CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Willison, KR (corresponding author), Inst Canc Res, Chester Beatty Labs, 237 Fulham Rd, London SW3 6JB, England.		Valpuesta, Jose M/AAA-6002-2019; Llorca, Oscar/P-2784-2019; Grantham, Julie/A-5002-2009; Valpuesta, José M/T-1977-2017; Llorca, Oscar/K-1144-2014	Llorca, Oscar/0000-0001-5705-0699; Valpuesta, José M/0000-0001-7468-8053; Llorca, Oscar/0000-0001-5705-0699				BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Farr GW, 1997, CELL, V89, P927, DOI 10.1016/S0092-8674(00)80278-0; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; KUBOTA H, 1997, GUIDEBOOK MOL CHAPER, P207; Liou AKF, 1998, BIOL CHEM, V379, P311, DOI 10.1515/bchm.1998.379.3.311; Liou AKF, 1997, EMBO J, V16, P4311, DOI 10.1093/emboj/16.14.4311; Llorca O, 1999, NAT STRUCT BIOL, V6, P639; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; Sakikawa C, 1999, J BIOL CHEM, V274, P21251, DOI 10.1074/jbc.274.30.21251; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; XU X, 1997, NATURE, V388, P741	16	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4587	4591		10.1074/jbc.275.7.4587	http://dx.doi.org/10.1074/jbc.275.7.4587			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671484	hybrid			2022-12-27	WOS:000085378200010
J	Murakumo, Y; Roth, T; Ishii, H; Rasio, D; Numata, S; Croce, CM; Fishel, R				Murakumo, Y; Roth, T; Ishii, H; Rasio, D; Numata, S; Croce, CM; Fishel, R			A human REV7 homolog that interacts with the polymerase zeta catalytic subunit hREV3 and the spindle assembly checkpoint protein hMAD2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOCRINE NEOPLASIA TYPE-2; DAMAGE-INDUCED MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; DNA-POLYMERASE; MITOTIC CHECKPOINT; ESCHERICHIA-COLI; FEEDBACK-CONTROL; BUDDING YEAST; REPAIR; GENE	Widespread alteration of the genomic DNA is a hallmark of tumors, and alteration of genes involved in DNA maintenance have been shown to contribute to the tumorigenic process. The DNA polymerase xi of Saccharomyces cerevisiae is required for error-prone repair following DNA damage and consists of a complex between three proteins, scRev1, scRev3, and scRev7, Here we describe a candidate human homolog of S. cerevisiae Rev7 (hREV7), which was identified in a yeast two-hybrid screen using the human homolog of S. cerevisiae Rev3 (hREV3), The hREV7 gene product displays 23% identity and 53% similarity with scREV7, as well as 23% identity and 54% similarity with the human mitotic checkpoint protein hMAD2. hREV7 is located on human chromosome 1p36 in a region of high loss of heterozygosity in human tumors, although no alterations of hREV3 or hREV7 were found in primary human tumors or human tumor cell lines. The interaction domain between hREV3 and hREV7 was determined and suggests that hREV7 probably functions with hREV3 in the human DNA polymerase xi complex. In addition, we have identified an interaction between hREV7 and hMAD2 but not hMAD1. While overexpression of hREV7 does not lead to cell cycle arrest, we entertain the possibility that it may act as an adapter between DNA repair and the spindle assembly checkpoint.	Thomas Jefferson Univ, Kimmel Canc Ctr BLSB933, Genet & Mol Biol Program, Kimmel Canc Inst,Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Fishel, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr BLSB933, Genet & Mol Biol Program, Kimmel Canc Inst,Dept Microbiol & Immunol, 233 S 10th St, Philadelphia, PA 19107 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	NATIONAL CANCER INSTITUTE [P01CA021124, R35CA039860, P01CA051083] Funding Source: NIH RePORTER; NCI NIH HHS [CA51083, CA21124, CA39860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allshire RC, 1997, CURR OPIN GENET DEV, V7, P264, DOI 10.1016/S0959-437X(97)80137-2; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P284, DOI 10.1016/S0968-0004(98)01257-2; Baynton K, 1998, MOL CELL BIOL, V18, P960, DOI 10.1128/MCB.18.2.960; BELLO MJ, 1994, INT J CANCER, V57, P172, DOI 10.1002/ijc.2910570207; BELLO MJ, 1994, GENE CHROMOSOME CANC, V9, P296, DOI 10.1002/gcc.2870090411; BOVERI T, 1914, FISCHER; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Farr KA, 1998, MOL CELL BIOL, V18, P2738, DOI 10.1128/MCB.18.5.2738; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Friedberg EC, 1999, CELL, V98, P413, DOI 10.1016/S0092-8674(00)81970-4; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Gorbsky GJ, 1997, BIOESSAYS, V19, P193, DOI 10.1002/bies.950190303; Guerrette S, 1998, MOL CELL BIOL, V18, P6616, DOI 10.1128/MCB.18.11.6616; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; Hardwick KG, 1999, GENETICS, V152, P509; Hardwick KG, 1998, TRENDS GENET, V14, P1, DOI 10.1016/S0168-9525(97)01340-1; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; Holbeck SL, 1997, GENETICS, V147, P1017; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Kironmai KM, 1998, MOL CELL BIOL, V18, P1424, DOI 10.1128/MCB.18.3.1424; Kuwamoto K, 1999, PHOTODERMATOL PHOTO, V15, P127, DOI 10.1111/j.1600-0781.1999.tb00072.x; LARIMER FW, 1989, J BACTERIOL, V171, P230, DOI 10.1128/jb.171.1.230-237.1989; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; LAWRENCE CW, 1984, MOL GEN GENET, V195, P487, DOI 10.1007/BF00341451; Lawrence CW, 1996, CANCER SURV, V28, P21; LI R, 1993, NATURE, V366, P82, DOI 10.1038/366082a0; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li XR, 1997, MOL CELL BIOL, V17, P2723, DOI 10.1128/MCB.17.5.2723; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LOEB LA, 1991, CANCER RES, V51, P3075; Maniatis T., 1982, MOL CLONING LAB MANU; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McDonald JP, 1997, GENETICS, V147, P1557; MOLEY JF, 1992, CANCER RES, V52, P770; Morelli C, 1998, CYTOGENET CELL GENET, V83, P18, DOI 10.1159/000015157; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; MULLIGAN LM, 1993, GENE CHROMOSOME CANC, V6, P166, DOI 10.1002/gcc.2870060307; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SIMON M, 1995, CANCER RES, V55, P4696; Tang MJ, 1998, P NATL ACAD SCI USA, V95, P9755, DOI 10.1073/pnas.95.17.9755; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; TORPEY LE, 1994, YEAST, V10, P1503, DOI 10.1002/yea.320101115; Walker GC, 1998, P NATL ACAD SCI USA, V95, P10348, DOI 10.1073/pnas.95.18.10348; Wang YC, 1997, MOL CELL BIOL, V17, P620, DOI 10.1128/MCB.17.2.620; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; WILSON TM, 1995, CANCER RES, V55, P5146; Xiao W, 1998, CARCINOGENESIS, V19, P945, DOI 10.1093/carcin/19.5.945	55	155	161	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4391	4397		10.1074/jbc.275.6.4391	http://dx.doi.org/10.1074/jbc.275.6.4391			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660610	hybrid			2022-12-27	WOS:000085288800094
J	Salerno, MS; Mordvinov, VA; Sanderson, CJ				Salerno, MS; Mordvinov, VA; Sanderson, CJ			Binding of octamer factors to a novel 3 '-positive regulatory element in the mouse interleukin-5 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELLS; EXPRESSION; PROMOTER; EOSINOPHILS; IL-5; DIFFERENTIATION; LYMPHOKINES; ANTIBODY; PATHWAYS; PROTEINS	The development of eosinophilia is regulated by interleukin (IL)-5, The biological specificity of eosinophilia suggests a tight and independent regulation of IL-5 expression. A number of regulatory regions in the 5'-end of the IL-5 gene have been described; many of them are involved in the regulation of other genes, and it is not clear how the specific expression of IL-5 is regulated. In this study, we report the finding of a novel 3'-regulatory element. Data base analysis of a a-kilobase fragment of the 3'-end of the mouse IL-5 gene revealed the presence of a 40-base pair-long repetitive sequence that consists of four direct repeats of ATGAATGA distributed in a symmetrical manner, This sequence, named mouse downstream regulatory element-1 (mDRE1), was shown to be protected in DNase I footprinting assays in vitro, Electrophoretic mobility shift assays using specific antibodies identified the transcription factors Oct-1 and Oct-2 as responsible for the formation of the specific complexes with mDRE1 and nuclear extracts from both EL4 and primary T-cells. Competition electrophoretic mobility shift assays with oligonucleotides containing different numbers of ATGAATGA repeats showed that Oct-1 and Oct-2 bind to different motifs in the mDRE1 sequence. Deletion of mDRE1 from a 9.5-kilobase IL-5 gene construct significantly decreased the expression of the luciferase reporter gene, suggesting that it plays a positive role in the expression of the IL-5 gene.	Curtin Univ Technol, Mol Immunol Grp, Sch Biomed Sci, Perth, WA 6000, Australia	Curtin University	Sanderson, CJ (corresponding author), Curtin Univ Technol, Mol Immunol Grp, Sch Biomed Sci, Level 5,MRF Bldg, Rear 50 Murray St, Perth, WA 6000, Australia.		Mordvinov, Viatcheslav A/S-8277-2017	Mordvinov, Viatcheslav A/0000-0002-6173-0774				Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Barata LT, 1998, J ALLERGY CLIN IMMUN, V101, P222, DOI 10.1016/S0091-6749(98)70387-2; Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; BUTTERWORTH AE, 1975, NATURE, V256, P727, DOI 10.1038/256727a0; BUTTERWORTH AE, 1984, ADV PARASIT, V23, P143, DOI 10.1016/S0065-308X(08)60287-0; CAMPBELL HD, 1988, EUR J BIOCHEM, V174, P345, DOI 10.1111/j.1432-1033.1988.tb14104.x; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; Csonga R, 1998, J IMMUNOL, V160, P273; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GRUARTGOUILLEUX V, 1995, EUR J IMMUNOL, V25, P1431, DOI 10.1002/eji.1830250544; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; KAMPS MP, 1990, MOL CELL BIOL, V10, P5464, DOI 10.1128/MCB.10.10.5464; Karlen S, 1996, BLOOD, V88, P211; KARLEN S, 1993, J VIROL, V67, P4296, DOI 10.1128/JVI.67.7.4296-4306.1993; Kubo M, 1997, EMBO J, V16, P4007, DOI 10.1093/emboj/16.13.4007; Kwon J, 1996, J BIOL CHEM, V271, P22383, DOI 10.1074/jbc.271.37.22383; LATHE R, 1987, GENE, V57, P193, DOI 10.1016/0378-1119(87)90122-3; LECAM A, 1995, EUR J BIOCHEM, V231, P620; Lederer JA, 1996, J EXP MED, V184, P397, DOI 10.1084/jem.184.2.397; LEE HJ, 1993, J IMMUNOL, V151, P6135; NAORA H, 1994, BLOOD, V83, P3620; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwenger GTF, 1998, LEUKEMIA LYMPHOMA, V28, P443, DOI 10.3109/10428199809058351; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; Thomas MA, 1999, BBA-GENE STRUCT EXPR, V1444, P61, DOI 10.1016/S0167-4781(98)00268-1; Thomas MA, 1999, EUR J BIOCHEM, V265, P300, DOI 10.1046/j.1432-1327.1999.00732.x; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; WARREN HS, 1995, J IMMUNOL, V154, P5144; YAMAGATA T, 1995, MOL CELL BIOL, V15, P3830	31	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4525	4531		10.1074/jbc.275.6.4525	http://dx.doi.org/10.1074/jbc.275.6.4525			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660628	hybrid			2022-12-27	WOS:000085288800112
J	Cha, JH; Brooke, JS; Ivey, KN; Eidels, L				Cha, JH; Brooke, JS; Ivey, KN; Eidels, L			Cell surface monkey CD9 antigen is a coreceptor that increases diphtheria toxin sensitivity and diphtheria toxin receptor affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR ACTIVITY; HEPARIN-BINDING; MEMBRANE-PROTEIN; OVERLAP EXTENSION; BACTERIAL TOXINS; EGF PRECURSOR; VERO CELLS; EXPRESSION; GENE; ASSOCIATION	Monkey (Mk) CD9 antigen has been shown previously to increase the diphtheria toxin (DT) sensitivity of cells when co-expressed with Mk proHB-EGF (DT receptor). We have elucidated here the mechanism whereby Mk CD9 influences Mk proHB-EGF and present evidence that Mk CD9 is a coreceptor for DT, We observed that Mk CD9 not only increased the DT sensitivity but also increased the DT receptor affinity of cells. Furthermore, the higher the Mk CD9/Mk proHB-EGF ratio, the higher the affinity. In contrast, mouse (Ms) CD9 did not increase the toxin sensitivity or receptor affinity of cells when co-expressed with Mk proHB-EGF. Using Mk/Ms chimeric CD9 molecules, we determined that the second extracellular domain of Mk CD9 is responsible for both increased sensitivity and receptor affinity. This domain of Mk CD9 also interacts with Mk proHB-EGF in a yeast two-hybrid system. Our findings thus suggest that Mk CD9 has a direct physical interaction with Mk proHB-EGF to form a DT receptor complex and that this contact may change the conformation of the receptor to increase DT binding affinity and consequently increase toxin sensitivity. We thus propose that Mk CD9 is a coreceptor for DT.	Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Eidels, L (corresponding author), Univ Texas, SW Med Ctr, Dept Microbiol, 6000 Harry Hines Blvd, Dallas, TX 75235 USA.			Cha, Jeong-Heon/0000-0002-9385-2653	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016805] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-16805] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMOND BD, 1994, J BIOL CHEM, V269, P26635; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Brooke JS, 1998, BIOCHEM BIOPH RES CO, V248, P297, DOI 10.1006/bbrc.1998.8953; BROWN JG, 1993, P NATL ACAD SCI USA, V90, P8184, DOI 10.1073/pnas.90.17.8184; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; Cha JH, 1999, BIOCHEM BIOPH RES CO, V254, P325, DOI 10.1006/bbrc.1998.9899; Cha JH, 1998, MOL MICROBIOL, V29, P1275, DOI 10.1046/j.1365-2958.1998.01015.x; CIEPLAK W, 1987, J BIOL CHEM, V262, P13246; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; DORLAND RB, 1979, J BIOL CHEM, V254, P1337; EIDELS L, 1982, INFECT IMMUN, V37, P1054, DOI 10.1128/IAI.37.3.1054-1058.1982; EIDELS L, 1983, MICROBIOL REV, V47, P596, DOI 10.1128/MMBR.47.4.596-620.1983; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; HOBMAN TC, 1990, VIROLOGY, V178, P122, DOI 10.1016/0042-6822(90)90385-5; HOOPER KP, 1995, BIOCHEM BIOPH RES CO, V206, P710, DOI 10.1006/bbrc.1995.1100; Hooper KP, 1996, BIOCHEM BIOPH RES CO, V220, P675, DOI 10.1006/bbrc.1996.0463; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; IWAMOTO R, 1991, J BIOL CHEM, V266, P20463; KAUFMAN RJ, 1982, MOL CELL BIOL, V2, P1304, DOI 10.1128/MCB.2.11.1304; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MIDDLEBROOK JL, 1978, J BIOL CHEM, V253, P7325; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; MIDDLEBROOK JL, 1977, CAN J MICROBIOL, V23, P183, DOI 10.1139/m77-026; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; PAPPENHEIMER AM, 1972, IMMUNOCHEMISTRY, V9, P891, DOI 10.1016/0019-2791(72)90163-2; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; PROIA RL, 1981, J BIOL CHEM, V256, P4991; RUBINSTEIN E, 1993, THROMB RES, V71, P377, DOI 10.1016/0049-3848(93)90162-H; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4	38	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6901	6907		10.1074/jbc.275.10.6901	http://dx.doi.org/10.1074/jbc.275.10.6901			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702250	Green Published, hybrid			2022-12-27	WOS:000085809600030
J	Bayliss, MT; Howat, S; Davidson, C; Dudhia, J				Bayliss, MT; Howat, S; Davidson, C; Dudhia, J			The organization of aggrecan in human articular cartilage - Evidence for age-related changes in the rate of aggregation of newly synthesized molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALURONATE-BINDING-PROPERTIES; PROTEOGLYCAN; AFFINITY; REGION	The effect of age on the incorporation of newly synthesized aggrecan into the extracellular matrix of human articular cartilage was investigated, This property was measured in a pulse-chase explant culture system by determining the distribution of radiolabeled molecules ([S-35]sulfate-labeled) between a nondissociating extract (phosphate-buffered saline), which extracts mainly nonaggregated macromolecules, and a dissociating extract (4 M GnHCl) containing mainly aggrecan that was complexed irt situ with hyaluronan. The rate of incorporation of aggrecan into aggregates was much slower in mature cartilage than in tissue obtained from younger individuals, Furthermore, autoradiography showed that in mature cartilage, newly synthesized aggrecan is not transported from the pericellular environment within the first 18 h of chase culture, whereas in immature cartilage, it moves into the intercellular space during the same period, i.e. aggrecan is processed in the extracellular space very differently in young and adult articular cartilage. Experiments were also performed to show that the interaction of link protein with newly synthesized aggrecan depends on the maturity of the G(1) domain of aggrecan. This investigation has shown that the extracellular aggregation of aggrecan in adult human articular cartilage involves a number of intermediate structures. These have not been identified in the very young cartilage obtained from laboratory animals or in porcine and bovine articular cartilage obtained from the abattoir.	Univ London Royal Vet Coll, London NW1 0TU, England; Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England	University of London; University of London Royal Veterinary College; University of Cambridge	Bayliss, MT (corresponding author), Univ London Royal Vet Coll, Royal Coll St, London NW1 0TU, England.			Dudhia, Jayesh/0000-0002-2503-697X				Bank RA, 1998, BIOCHEM J, V330, P345, DOI 10.1042/bj3300345; Bayliss MT, 1999, J BIOL CHEM, V274, P15892, DOI 10.1074/jbc.274.22.15892; BAYLISS MT, 1984, BIOSCIENCE REP, V4, P827, DOI 10.1007/BF01138164; BAYLISS MT, 1990, BIOCHEM SOC T, V18, P799, DOI 10.1042/bst0180799; BAYLISS MT, 1983, BIOCHEM J, V215, P705, DOI 10.1042/bj2150705; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BONNET F, 1985, BIOCHEM J, V228, P77, DOI 10.1042/bj2280077; BROCKLEHURST R, 1984, J BONE JOINT SURG AM, V66A, P95, DOI 10.2106/00004623-198466010-00013; Buschmann MD, 1996, J HISTOCHEM CYTOCHEM, V44, P423, DOI 10.1177/44.5.8627000; CARNEY SL, 1986, ANAL BIOCHEM, V156, P38, DOI 10.1016/0003-2697(86)90150-8; Dudhia J, 1996, BIOCHEM J, V313, P933, DOI 10.1042/bj3130933; GRAY ML, 1988, J ORTHOPAED RES, V6, P777, DOI 10.1002/jor.1100060602; HARDINGHAM TE, 1994, EUR J CLIN CHEM CLIN, V32, P249; HASCALL VC, 1970, J BIOL CHEM, V245, P4920; Maroudas A, 1998, ARCH BIOCHEM BIOPHYS, V350, P61, DOI 10.1006/abbi.1997.0492; MELCHING LI, 1985, J BIOL CHEM, V260, P6279; MELCHING LI, 1990, BIOCHIM BIOPHYS ACTA, V1035, P20, DOI 10.1016/0304-4165(90)90168-V; OEGEMA TR, 1980, NATURE, V288, P583, DOI 10.1038/288583a0; PLAAS AHK, 1984, BIOCHEM J, V220, P337, DOI 10.1042/bj2200337; PLAAS AHK, 1986, BIOCHEM J, V234, P221, DOI 10.1042/bj2340221; RYU J, 1984, ARTHRITIS RHEUM, V27, P49, DOI 10.1002/art.1780270109; SAH RLY, 1990, BIOCHEM J, V267, P803, DOI 10.1042/bj2670803; SANDY JD, 1989, ARCH BIOCHEM BIOPHYS, V271, P300, DOI 10.1016/0003-9861(89)90280-4; SANDY JD, 1989, BIOCHEM J, V258, P875, DOI 10.1042/bj2580875; VERZIJL N, 1998, 4J T AM ORTH RES SOC, P860	25	47	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6321	6327		10.1074/jbc.275.9.6321	http://dx.doi.org/10.1074/jbc.275.9.6321			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692431	hybrid			2022-12-27	WOS:000085654400043
J	Brown, KD; Lataxes, TA; Shangary, S; Mannino, JL; Giardina, JF; Chen, JD; Baskaran, R				Brown, KD; Lataxes, TA; Shangary, S; Mannino, JL; Giardina, JF; Chen, JD; Baskaran, R			Ionizing radiation exposure results in up-regulation of Ku70 via a p53/ataxia-telangiectasia-mutated protein-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; CELL-CYCLE CHECKPOINT; DOUBLE-STRAND BREAKS; ATAXIA-TELANGIECTASIA; V(D)J RECOMBINATION; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; NUCLEAR-PROTEIN; KINASE ACTIVITY; C-ABL	Genome damaging events, such as gamma-irradiation exposure, result in the induction of pathways that activate DNA repair mechanisms, halt cell cycle progression, and/or trigger apoptosis. We have investigated the effects of gamma-irradiation on cellular levels of the Ku autoantigens. Ku70 and Ku80 have been shown to form a heterodimeric complex that can bind tightly to free DNA ends and activate the protein kinase DNA-PKcs, We have found that irradiation results in an up-regulation of cellular levels of Ku70, but not Ku80, and that this enhanced level of Ku70 accumulates within the nucleus. Further, we uncovered that the postirradiation up-regulation of Ku70 utilizes a mechanism that is dependent on both p53 and damage response protein kinase ATM (ataxia-telangiectasia-mutated); however, the activation of DNA-PK does not require Ku70 up regulation. These findings suggest that Ku70 up-regulation provides the cell with a means of assuring either proper DNA repair or an appropriate response to DNA damage independent of DNA-PKcs activation.	Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Louisiana State Univ, Med Ctr, Dept Microbiol Immunol & Parasitol, New Orleans, LA 70112 USA; Louisiana State Univ, Med Ctr, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Louisiana State University System; Louisiana State University System; Louisiana State University System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Brown, KD (corresponding author), Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, 1901 Perdido St,MEB Rm 7101, New Orleans, LA 70112 USA.							Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Aoki Y, 1998, AM J PHYSIOL-LUNG C, V275, pL1164, DOI 10.1152/ajplung.1998.275.6.L1164; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Baskaran R, 1999, CELL GROWTH DIFFER, V10, P387; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Bliss TM, 1997, J BIOL CHEM, V272, P5765, DOI 10.1074/jbc.272.9.5765; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Brown KD, 1999, AM J HUM GENET, V64, P46, DOI 10.1086/302223; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Burma S, 1999, J BIOL CHEM, V274, P17139, DOI 10.1074/jbc.274.24.17139; Camara-Clayette V, 1999, NUCLEIC ACIDS RES, V27, P1656, DOI 10.1093/nar/27.7.1656; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; COX R, 1986, MOL BIOL MED, V3, P229; Dar ME, 1997, MUTAT RES-DNA REPAIR, V384, P169, DOI 10.1016/S0921-8777(97)00021-9; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; GENERSCH E, 1995, EMBO J, V14, P791, DOI 10.1002/j.1460-2075.1995.tb07057.x; Giffin W, 1999, MOL CELL BIOL, V19, P4065; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grandvaux N, 1999, J CELL SCI, V112, P503; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Kumaravel TS, 1998, INT J RADIAT BIOL, V74, P481, DOI 10.1080/095530098141357; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; LAVIN MF, 1995, TRENDS BIOCHEM SCI, V20, P382, DOI 10.1016/S0968-0004(00)89083-0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LITTLE JB, 1985, RADIAT RES, V101, P81, DOI 10.2307/3576305; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Milne GT, 1996, MOL CELL BIOL, V16, P4189; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Myung K, 1998, P NATL ACAD SCI USA, V95, P7664, DOI 10.1073/pnas.95.13.7664; Myung K, 1997, EMBO J, V16, P3172, DOI 10.1093/emboj/16.11.3172; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; PAINTER RB, 1981, MUTAT RES, V84, P183, DOI 10.1016/0027-5107(81)90061-0; Pang DL, 1997, CANCER RES, V57, P1412; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; REEVES WH, 1992, RHEUM DIS CLIN N AM, V18, P391; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; RUNGER TM, 1992, MUTAT RES, V293, P47, DOI 10.1016/0921-8777(92)90007-P; Smith Martin L., 1995, Current Opinion in Oncology, V7, P69; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	60	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6651	6656		10.1074/jbc.275.9.6651	http://dx.doi.org/10.1074/jbc.275.9.6651			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692474	hybrid			2022-12-27	WOS:000085654400086
J	Gerona, RRL; Larsen, EC; Kowalchyk, JA; Martin, TFJ				Gerona, RRL; Larsen, EC; Kowalchyk, JA; Martin, TFJ			The C terminus of SNAP25 is essential for Ca2+-dependent binding of synaptotagmin to SNARE complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT NEUROMUSCULAR-JUNCTION; SYNAPTIC VESICLE DOCKING; NEUROTRANSMITTER RELEASE; BOTULINUM TOXIN; MEMBRANE-FUSION; CLOSTRIDIAL NEUROTOXINS; REGULATED EXOCYTOSIS; TRANSMITTER RELEASE; TETANUS TOXIN; T-SNARE	The plasma membrane soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins syntaxin and synaptosome-associated protein of 25 kDa (SNAP25) and the vesicle SNARE protein vesicle-associated membrane protein (VAMP) are essential for a late Ca2+-dependent step in regulated exocytosis, but their precise roles and regulation by Ca2+ are poorly understood. Botulinum neurotoxin (BoNT) E, a protease that cleaves SNAP25 at Arg(180)-Ile(181), completely inhibits this late step in PC12 cell membranes, whereas BoNT A, which cleat es SNAP25 at Gln(197)-Arg(198), is only partially inhibitory. The difference in toxin effectiveness was found to result from a reversal of BoNT A but not BoNT E inhibition by elevated Ca2+ concentrations. BoNT A treatment essentially increased the Ca2+ concentration required to activate exocytosis, which suggested a role for the C terminus of SNAP25 in the Ca2+ regulation of exocytosis. Synaptotagmin, a proposed Ca2+ sensor for exocytosis, was found to bind SNAP25 in a Ca2+-stimulated manner Ca2+-dependent binding was abolished by BoNT E treatment, whereas BoNT A treatment increased the Ca2+ concentration required for binding, The C terminus of SNAP25 was also essential for Ca2+- dependent synaptotagmin binding to SNAP25.syntaxin and SNAP25.syntaxin.VAMP SNARE complexes. These results clarify classical observations on the Ca2+ reversal of BoNT A inhibition of neurosecretion, and they suggest that an essential role for the C terminus of SNAP25 in regulated exocytosis is to mediate Ca2+-dependent interactions between synaptotagmin and SNARE protein complexes.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Martin, TFJ (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.				NIDDK NIH HHS [DK25861, DK40428] Funding Source: Medline; NIGMS NIH HHS [GM07215] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040428, R37DK025861, R01DK025861] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; BINZ T, 1994, J BIOL CHEM, V269, P1617; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Calakos N, 1996, PHYSIOL REV, V76, P1; Capogna M, 1997, J NEUROSCI, V17, P7190; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Davis AF, 1999, NEURON, V24, P363, DOI 10.1016/S0896-6273(00)80850-8; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; DREYER F, 1981, NEUROSCI LETT, V26, P307, DOI 10.1016/0304-3940(81)90150-6; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Jahn R, 1998, NATURE, V393, P14, DOI 10.1038/29871; KAUFFMAN JA, 1985, TOXICOL APPL PHARM, V79, P211, DOI 10.1016/0041-008X(85)90342-4; Kee Y, 1996, J NEUROSCI, V16, P1975; Lawrence GW, 1997, BIOCHEMISTRY-US, V36, P3061, DOI 10.1021/bi9622478; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LI C, 1995, J BIOL CHEM, V270, P24898, DOI 10.1074/jbc.270.42.24898; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; LOMNETH R, 1991, J NEUROCHEM, V57, P1413, DOI 10.1111/j.1471-4159.1991.tb08308.x; LUNDH H, 1977, J NEUROL SCI, V32, P29, DOI 10.1016/0022-510X(77)90037-5; Martin TFJ, 1997, J BIOL CHEM, V272, P14447, DOI 10.1074/jbc.272.22.14447; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; MOLGO J, 1990, J PHYSIOLOGY PARIS, V84, P152; MOLGO J, 1989, ACTA PHYSIOL SCAND, V137, P497, DOI 10.1111/j.1748-1716.1989.tb08786.x; MONTECUCCO C, 1993, TRENDS BIOCHEM SCI, V18, P324, DOI 10.1016/0968-0004(93)90065-U; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; SADOUL K, 1995, J CELL BIOL, V128, P1019, DOI 10.1083/jcb.128.6.1019; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/jbc.270.18.10566; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; Schivell AE, 1996, J BIOL CHEM, V271, P27770, DOI 10.1074/jbc.271.44.27770; SELLIN LC, 1983, ACTA PHYSIOL SCAND, V119, P127, DOI 10.1111/j.1748-1716.1983.tb07317.x; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; SIMPSON LL, 1986, INFECT IMMUN, V52, P858, DOI 10.1128/IAI.52.3.858-862.1986; SIMPSON LL, 1978, J PHARMACOL EXP THER, V206, P661; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Vaidyanathan VV, 1999, J NEUROCHEM, V72, P327, DOI 10.1046/j.1471-4159.1999.0720327.x; Washbourne P, 1997, FEBS LETT, V418, P1, DOI 10.1016/S0014-5793(97)01328-8; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weis WI, 1998, NATURE, V395, P328, DOI 10.1038/26354; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642	62	188	197	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6328	6336		10.1074/jbc.275.9.6328	http://dx.doi.org/10.1074/jbc.275.9.6328			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692432	hybrid			2022-12-27	WOS:000085654400044
J	Poulin, B; Sekiya, F; Rhee, SG				Poulin, B; Sekiya, F; Rhee, SG			Differential roles of the Src homology 2 domains of phospholipase C-gamma l (PLC-gamma l) in platelet-derived growth factor-induced activation of PLC-gamma l in intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; SH2 DOMAINS; FACTOR RECEPTOR; ANTIGEN RECEPTOR; BINDING-SITE; C-GAMMA-1; ASSOCIATION; PHOSPHORYLATION; SPECIFICITY; STIMULATION	Upon stimulation of cells with platelet-derived growth factor (PDGF), phospholipase C-gamma 1 (PLC-gamma 1) binds to the tyrosine-phosphorylated PDGF receptor through one or both of its Src homology 2 (SH2) domains, is phosphorylated by the receptor kinase, and is thereby activated to hydrolyze phosphatidylinositol 4,5-bisphosphate, Association of PLC-gamma 1 with the insoluble subcellular fraction is also enhanced in PDGF-stimulated cells. The individual roles of the two SH2 domains of PLC-gamma 1 in mediating the interaction between the enzyme and the PDGF receptor have now been investigated by functionally disabling each domain. A critical Arg residue in each SH2 domain was mutated to Ala, Both wild-type and mutant PLC-gamma 1 proteins were transiently expressed in a PLC-gamma 1-deficient fibroblast cell line, and these transfected cells were stimulated with PDGF, The mutant protein in which the COOH-terminal SH2 domain was disabled bound to the PDGF receptor. Accordingly, it was phosphorylated by the receptor, catalyzed the production of inositol phosphates, and mobilized intracellular calcium to extents similar to (but slightly less than) those observed with the wild-type enzyme. In contrast, the mutant in which the NH2-terminal SH2 domain was impaired did not bind to the PDGF receptor and consequently was neither phosphorylated nor activated. These results suggest that the NH2-terminal SH2 domain, but not the COOH-terminal SH2 domain, of PLC-gamma 1 is required for PDGF-induced activation of PLC-gamma 1, Functional impairment of the SH2 domains did not affect the PDGF-induced redistribution of PLC-gamma 1, suggesting that recruitment of PLC-gamma 1 to the particulate fraction does not involve the SH2 domains.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Rhee, SG (corresponding author), NHLBI, Lab Cell Signaling, NIH, Bldg 3,Rm 122, Bethesda, MD 20892 USA.	sgrhee@nih.gov						ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; BALLA T, 1994, J BIOL CHEM, V269, P16101; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BROWN JP, 1985, NATURE, V313, P491, DOI 10.1038/313491a0; DASGUPTA JD, 1992, J EXP MED, V175, P285, DOI 10.1084/jem.175.1.285; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; HUANG PS, 1995, FEBS LETT, V358, P287, DOI 10.1016/0014-5793(94)01453-8; Ji QS, 1999, MOL CELL BIOL, V19, P4961; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM JW, 1990, J BIOL CHEM, V265, P3940; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; LAROSE L, 1995, J BIOL CHEM, V270, P3858, DOI 10.1074/jbc.270.8.3858; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; NAKANISHI O, 1993, J BIOL CHEM, V268, P10754; NEL AE, 1995, J BIOL CHEM, V270, P18428, DOI 10.1074/jbc.270.31.18428; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554; Smith MR, 1996, BIOCHEM BIOPH RES CO, V222, P186, DOI 10.1006/bbrc.1996.0719; Stoica B, 1998, J IMMUNOL, V160, P1059; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; YANG LJ, 1994, J BIOL CHEM, V269, P7156; Yu JH, 1998, J BIOL CHEM, V273, P30199, DOI 10.1074/jbc.273.46.30199; Zhang L, 1998, Methods Mol Biol, V105, P47; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6411	6416		10.1074/jbc.275.9.6411	http://dx.doi.org/10.1074/jbc.275.9.6411			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692443	hybrid			2022-12-27	WOS:000085654400055
J	Suen, TC; Goss, PE				Suen, TC; Goss, PE			Characterization of a repressor element and a juxtaposed tissue-restricted activator element located on the distal neu gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-RECEPTOR; HUMAN-BREAST-CANCER; HUMAN ERBB-2 GENE; NEGATIVE REGULATORY ELEMENTS; HUMAN MAMMARY-CARCINOMA; TRANSCRIPTIONAL REPRESSION; TYROSINE KINASE; MAMMALIAN-CELLS; OVARIAN-CANCER; EXPRESSION	The proto-oncogene neu (HER2 or c-erbB2) is overexpressed with or without gene amplification in 20-30% of breast cancers. In patients, neu amplification or overexpression in breast and ovarian cancer correlates with poor prognosis and tumor resistance to chemotherapy neu-induced transformation can be reversed by the suppression of neu gene transcription. To further understand how neu gene transcription is regulated and to identify a possible transcriptional repressor(s) of neu, we identified a negative regulatory element known previously to be located within a 1-kilobase (kb) DNA fragment of an unknown sequence, upstream of the proximal neu gene promoter. One of several DNA fragments subcloned from this region suppressed transcriptional activity: of the proximal lieu gene promoter. Sequencing of the I-kb fragment confirmed the location of the repressor element to be between an AluI and a RsaI sites, around 1.4 kb upstream to the translation start site. Various deletions were introduced into the AluI-RsaI fragment and subcloned into both the native neu promoter and a heterologous thymidine kinase promoter. Subsequent transfections and reporter gene assays in cell lines of various tissues of origin confirmed and narrowed the repressor activity to a 120-base pair NlaIV-MslI fragment located between -1385 and -1266. Importantly, specific protein binding activity to this element could be detected with nuclear extracts isolated from these cell Lines. In contrast, a 28-base pair MslI-RsaI fragment (-1265 to -1238), located immediately 3' of the putative repressor element, was found to form protein-DNA complexes with only nuclear extracts isolated fi om a colon carcinoma cell line. This specific protein binding activity correlated with a previously unknown transcriptional stimulatory activity only in this cell line.	Princess Margaret Hosp, Dept Med Oncol, Breast Grp, Toronto, ON M5G 2M9, Canada; Toronto Hosp, Oncol Res Labs, Breast Canc Prevent Program, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Goss, PE (corresponding author), Princess Margaret Hosp, Dept Med Oncol, Breast Grp, Rm 5-303,610 Univ Ave, Toronto, ON M5G 2M9, Canada.							Baasner S, 1996, ONCOGENE, V13, P901; BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen YY, 1997, J BIOL CHEM, V272, P14110, DOI 10.1074/jbc.272.22.14110; Chen YY, 1996, J BIOL CHEM, V271, P5183; CHEN YY, 1994, ONCOGENE, V9, P2269; COHEN JA, 1989, ONCOGENE, V4, P81; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Deng J, 1998, ONCOGENE, V17, P2167, DOI 10.1038/sj.onc.1202148; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERTL AP, 1993, GENE, V136, P361, DOI 10.1016/0378-1119(93)90496-P; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Grooteclaes M, 1999, CANCER RES, V59, P2527; GROOTECLAES M, 1994, CANCER RES, V54, P4193; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; HUNG MC, 1995, GENE, V159, P65, DOI 10.1016/0378-1119(94)00459-6; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MATIN A, 1994, ONCOGENE, V9, P1333; MATIN A, 1993, CELL GROWTH DIFFER, V4, P1051; Miller SJ, 1996, DNA CELL BIOL, V15, P749, DOI 10.1089/dna.1996.15.749; MILLER SJ, 1994, INT J ONCOL, V4, P599; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PRESS MF, 1990, ONCOGENE, V5, P953; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SUEN TC, 1991, MOL CELL BIOL, V11, P354, DOI 10.1128/MCB.11.1.354; Suen TC, 1999, J BIOL CHEM, V274, P31297, DOI 10.1074/jbc.274.44.31297; SUEN TC, 1990, MOL CELL BIOL, V10, P6305; TAL M, 1987, MOL CELL BIOL, V7, P2587; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; Ueno NT, 1997, ONCOGENE, V15, P953, DOI 10.1038/sj.onc.1201250; WHITE MRA, 1992, ONCOGENE, V7, P677; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAN DH, 1991, MOL CELL BIOL, V11, P1875, DOI 10.1128/MCB.11.4.1875; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; Yu DH, 1996, ONCOGENE, V13, P1359; Zhang D, 1998, MOL PSYCHIATR, V3, P112, DOI 10.1038/sj.mp.4000369; ZHAO XY, 1992, MOL CELL BIOL, V12, P2739, DOI 10.1128/MCB.12.6.2739	64	5	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6600	6607		10.1074/jbc.275.9.6600	http://dx.doi.org/10.1074/jbc.275.9.6600			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692468	hybrid			2022-12-27	WOS:000085654400080
J	Leo, C; Li, H; Chen, JD				Leo, C; Li, H; Chen, JD			Differential mechanisms of nuclear receptor regulation by receptor-associated coactivator 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; LIGAND-BINDING DOMAIN; HISTONE ACETYLTRANSFERASE; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL REPRESSION; CRYSTAL-STRUCTURE; CO-REPRESSOR; N-COR; COMPLEX; CBP	Steroid and nuclear receptor coactivators (NCoAs) have been implicated in the regulation of nuclear receptor function by enhancing ligand-dependent transcriptional activation of target gene expression. We have previously isolated receptor-associated coactivator 3 (RAC3), which belongs to the steroid receptor coactivator family. In this study, we investigated the differential mechanisms by which RAC3 interacts with and modulates the transcriptional activity of different nuclear receptors. We found that the vitamin D receptor (VDR) and estrogen receptor beta interact with different alpha-helical LXYLL motifs of RAC3. Peptides corresponding to these motifs have diverse affinities for the VDR and estrogen receptor beta, and mutation of specific motifs differentially impairs the ability of RAC3 to interact with these receptors in vitro. Consequently, these mutations inhibit the enhancement of transcriptional activation by these receptors in vivo. Furthermore, we found that the activation function-2 (AF-2) domain of the retinoid X receptor interferes with RAC3 binding to a DNA-bound VDR/retinoid X receptor (RXR) heterodimer, whereas the VDR AF-2 domain is required for this interaction. These results suggest a receptor-specific binding preference for the different LXYLL motifs of RAC3, which may provide flexibility for RAGS to differentially regulate the function of different nuclear receptors.	Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Toxicol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Chen, JD (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Toxicol, 55 Lake Ave N, Worcester, MA 01655 USA.				NIDDK NIH HHS [1RO1 DK52888-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052888] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Baudino TA, 1998, J BIOL CHEM, V273, P16434, DOI 10.1074/jbc.273.26.16434; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen JD, 1998, CRIT REV EUKAR GENE, V8, P169, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.40; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kraichely DM, 1999, J BIOL CHEM, V274, P14352, DOI 10.1074/jbc.274.20.14352; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; Li H, 1998, J BIOL CHEM, V273, P5948, DOI 10.1074/jbc.273.10.5948; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Ma H, 1999, MOL CELL BIOL, V19, P6164; Mak HY, 1999, MOL CELL BIOL, V19, P3895; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Takeyama KI, 1999, MOL CELL BIOL, V19, P1049; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	44	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5976	5982		10.1074/jbc.275.8.5976	http://dx.doi.org/10.1074/jbc.275.8.5976			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681591	hybrid			2022-12-27	WOS:000085474500098
J	Moreno, CS; Park, S; Nelson, K; Ashby, D; Hubalek, F; Lane, WS; Pallas, DC				Moreno, CS; Park, S; Nelson, K; Ashby, D; Hubalek, F; Lane, WS; Pallas, DC			WD40 repeat proteins striatin and S/G(2) nuclear autoantigen are members of a novel family of calmodulin-binding proteins that associate with protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNITS; CATALYTIC SUBUNIT; SMOOTH-MUSCLE; PHOSPHORYLATION; IDENTIFICATION; KINASE; CELLS; CHANNELS; TERMINUS; TYPE-2A	Protein phosphatase 2A (PP2A) is a multifunctional serine/threonine phosphatase that is critical to many cellular processes including development, neuronal signaling, cell cycle regulation, and viral transformation. PP2A has been implicated in Ca2+-dependent signaling pathways, but how PP2A is targeted to these pathways is not understood. We have identified two calmodulin (CaM)-binding proteins that form stable complexes with the PP2A A/C heterodimer and may represent a novel family of PP2A B-type subunits. These two proteins, striatin and S/G(2) nuclear autoantigen (SG2NA), are highly related WD40 repeat proteins of previously unknown function and distinct subcellular localizations. Striatin has been reported to associate with the post-synaptic densities of neurons, whereas SG2NA has been reported to be a nuclear protein expressed primarily during the S and G(2) phases of the cell cycle. We show that SG2NA, like striatin, binds to CaM in a Ca2+-dependent manner. in addition to CaM and PP2A, several unidentified proteins stably associate with the striatin-PP2A and SG2NA-PP2A complexes. Thus, one mechanism of targeting and organizing PP2A with components of Ca2+-dependent signaling pathways may be through the molecular scaffolding proteins striatin and SG2NA.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Dana Farber Canc Inst, Div Cellular & Mol Biol, Boston, MA 02115 USA; Harvard Univ, Microchem Facil, Cambridge, MA 02138 USA	Emory University; Harvard University; Dana-Farber Cancer Institute; Harvard University	Pallas, DC (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd, Atlanta, GA 30322 USA.		Moreno, Carlos S/B-3863-2009	Moreno, Carlos S/0000-0002-5582-0028; Hubalek, Frantisek/0000-0003-3983-7900	NCI NIH HHS [CA57327, R01 CA057327] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057327] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; Bartoli M, 1998, J BIOL CHEM, V273, P22248, DOI 10.1074/jbc.273.35.22248; Castets F, 1996, J CELL BIOL, V134, P1051, DOI 10.1083/jcb.134.4.1051; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FERRIGNO P, 1993, MOL BIOL CELL, V4, P669, DOI 10.1091/mbc.4.7.669; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; Groschner K, 1996, BIOCHEM J, V318, P513, DOI 10.1042/bj3180513; HOPKIN K, 1995, J NIH RES, V7, P27; LEE J, 1993, J BIOL CHEM, V268, P19192; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; MURO Y, 1995, BIOCHEM BIOPH RES CO, V207, P1029, DOI 10.1006/bbrc.1995.1288; Ogris E, 1999, J BIOL CHEM, V274, P14382, DOI 10.1074/jbc.274.20.14382; Ogris E, 1997, ONCOGENE, V15, P911, DOI 10.1038/sj.onc.1201259; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; SOLA MM, 1991, BIOCHIM BIOPHYS ACTA, V1094, P211, DOI 10.1016/0167-4889(91)90011-L; Tanabe O, 1996, FEBS LETT, V379, P107, DOI 10.1016/0014-5793(95)01500-0; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; Tian LJ, 1998, J BIOL CHEM, V273, P13531, DOI 10.1074/jbc.273.22.13531; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Zhou XB, 1996, J BIOL CHEM, V271, P19760, DOI 10.1074/jbc.271.33.19760; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023	29	157	160	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5257	5263		10.1074/jbc.275.8.5257	http://dx.doi.org/10.1074/jbc.275.8.5257			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681496	Green Accepted, hybrid			2022-12-27	WOS:000085474500003
J	Reshkin, SJ; Bellizzi, A; Albarani, V; Guerra, L; Tommasino, M; Paradiso, A; Casavola, V				Reshkin, SJ; Bellizzi, A; Albarani, V; Guerra, L; Tommasino, M; Paradiso, A; Casavola, V			Phosphoinositide 3-kinase is involved in the tumor-specific activation of human breast cancer cell Na+/H+ exchange, motility, and invasion induced by serum deprivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; NA-H EXCHANGE; INTRACELLULAR PH; PHOSPHATIDYLINOSITOL 3-KINASE; BLOOD-FLOW; HYPOXIA; MICROENVIRONMENT; CARCINOMA; LINES; INTEGRIN	Whereas the tumor acidic extracellular pH plays a crucial role in the invasive process, the mechanism(s) behind this acidification, especially in low nutrient conditions, are unclear. The regulation of the Na+/H+ exchanger (NHE) and invasion by serum deprivation were studied in a series of breast epithelial cell lines representing progression from non-tumor to highly metastatic cells. Whereas serum deprivation reduced lactate production in all three cells lines, it inhibited NHE activity in the non-tumor cells and stimulated it in the tumor cells with a larger stimulation in the metastatic cells. The stimulation of NHE in the tumor cell lines was the result of an increased affinity of the internal H+ regulatory site of the NHE without changes in sodium kinetics or expression, Serum deprivation conferred increased cell motility and invasive ability that were abrogated by specific inhibition of the NHE, Inhibition of phosphoinositide 3-kinase by overexpression of a dominant-negative mutant or wortmannin incubation inhibited NHE activity and invasion in serum replete conditions while potentiating the serum deprivation-dependent activation of the NHE and invasion. These results indicate that the up-regulation of the NHE by a phosphoinositide 3-kinase-dependent mechanism plays an essential role in increased tumor cell invasion induced by serum deprivation.	Univ Bari, Dept Gen & Environm Physiol, I-70126 Bari, Italy; Oncol Inst Bari, Expt Oncol Lab, I-70126 Bari, Italy; Deutsch Krebsforschungszentrum, Angew Tumorvirol, D-6900 Heidelberg, Germany	Universita degli Studi di Bari Aldo Moro; Helmholtz Association; German Cancer Research Center (DKFZ)	Reshkin, SJ (corresponding author), Univ Bari, Dept Gen & Environm Physiol, Via Amendola 165-A, I-70126 Bari, Italy.	reshkin@biologia.uniba.it	paradiso, angelo V/J-9457-2018; Reshkin, Stephan/AAI-6680-2020	Reshkin, Stephan/0000-0001-9757-5908; GUERRA, Lorenzo/0000-0003-3950-9405; CASAVOLA, Valeria/0000-0003-4471-4948				An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BOYER MJ, 1992, CANCER RES, V52, P4441; BRANDT RB, 1982, METHOD ENZYMOL, V89, P35; CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Cuvier C, 1997, CLIN EXP METASTAS, V15, P19; D'Amato G, 1998, CRIT REV ONCOGENESIS, V9, P275; Demaurex N, 1997, J GEN PHYSIOL, V109, P117, DOI 10.1085/jgp.109.2.117; FARBER E, 1990, BIOCHEM PHARMACOL, V39, P1837, DOI 10.1016/0006-2952(90)90599-G; FODSTAD O, 1994, J CELL BIOCHEM, V56, P23, DOI 10.1002/jcb.240560106; Gatenby RA, 1996, CANCER RES, V56, P5745; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Griffiths L, 1997, CANCER RES, V57, P570; GUPTA A, 1994, AM J PHYSIOL, V266, pC1083, DOI 10.1152/ajpcell.1994.266.4.C1083; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HOPKINS DM, 1992, J PATHOL, V166, P317, DOI 10.1002/path.1711660316; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kraus M, 1996, TUMOR BIOL, V17, P133, DOI 10.1159/000217977; KRAYERPAWLOWSKA D, 1991, J MEMBRANE BIOL, V120, P173, DOI 10.1007/BF01872400; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; MartinezZaguilan R, 1996, CLIN EXP METASTAS, V14, P176, DOI 10.1007/BF00121214; Mazure NM, 1996, CANCER RES, V56, P3436; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Montcourrier P, 1997, CLIN EXP METASTAS, V15, P382, DOI 10.1023/A:1018446104071; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; Parkins CS, 1997, BRIT J CANCER, V75, P319, DOI 10.1038/bjc.1997.53; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; PRICE JE, 1994, J CELL BIOCHEM, V56, P16, DOI 10.1002/jcb.240560105; Price JE, 1996, BREAST CANCER RES TR, V39, P93, DOI 10.1007/BF01806081; Radinsky R, 1995, CANCER METAST REV, V14, P323, DOI 10.1007/BF00690601; Reif K, 1997, CURR BIOL, V7, P285, DOI 10.1016/S0960-9822(06)00151-5; RESHKIN SJ, 1995, INT J ONCOL, V7, P371; Reynolds TY, 1996, CANCER RES, V56, P5754; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Scott PAE, 1998, INT J CANCER, V75, P706, DOI 10.1002/(SICI)1097-0215(19980302)75:5<706::AID-IJC8>3.0.CO;2-2; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; SICZKOWSKI M, 1994, AM J PHYSIOL, V267, pC745, DOI 10.1152/ajpcell.1994.267.3.C745; Singh RK, 1997, CLIN EXP METASTAS, V15, P140, DOI 10.1023/A:1018400826845; SOULE HD, 1990, CANCER RES, V50, P6075; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; STUBBS M, 1995, ADV ENZYME REGUL, V35, P101, DOI 10.1016/0065-2571(94)00016-V; Tedone T, 1997, FASEB J, V11, P785, DOI 10.1096/fasebj.11.10.9271363; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; Tominaga T, 1998, MOL BIOL CELL, V9, P2287, DOI 10.1091/mbc.9.8.2287; VAUPEL P, 1989, CANCER RES, V49, P6449; Vaupel PW, 1997, KLIN PADIATR, V209, P243, DOI 10.1055/s-2008-1043957; WATSON AJM, 1992, J BIOL CHEM, V267, P956; Webb SD, 1999, J THEOR BIOL, V196, P237, DOI 10.1006/jtbi.1998.0836; Yamagata M, 1998, BRIT J CANCER, V77, P1726, DOI 10.1038/bjc.1998.289	56	123	129	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5361	5369		10.1074/jbc.275.8.5361	http://dx.doi.org/10.1074/jbc.275.8.5361			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681510	hybrid			2022-12-27	WOS:000085474500017
J	Fukunaga, K; Noguchi, T; Takeda, H; Matozaki, T; Hayashi, Y; Itoh, H; Kasuga, M				Fukunaga, K; Noguchi, T; Takeda, H; Matozaki, T; Hayashi, Y; Itoh, H; Kasuga, M			Requirement for protein-tyrosine phosphatase SHP-2 in insulin-induced activation of c-Jun NH2-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; MITOGENIC SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; RECEPTOR SUBSTRATE-1; DEPENDENT ACTIVATION; COUPLED RECEPTORS; BINDING-PROTEINS; GENE-EXPRESSION; DOCKING PROTEIN; MUSCLE-CELLS	Mitogen-activated protein kinases, including extracellular signal-regulated kinases and c-Jun NH2-terminal kinases (JNKs), are activated by insulin. Although the mechanism by which the insulin receptor activates extracellular signal-regulated kinases is relatively well defined, the pathway that leads to JNK activation is poorly understood. Overexpression of a catalytically inactive mutant (SHP-2C/S) of the protein-tyrosine phosphatase SHP-2 in Rat-1 fibroblasts that also express human insulin receptors has now revealed that activation of JNKs by insulin and epidermal growth factor, but not that by anisomycin or sorbitol, requires SHP-2, A dominant negative mutant (RasN17) of Ha-Ras blocked insulin-induced JNK activation, whereas a dominant negative mutant (RacN17) of Rad or a specific inhibitor (LY294002) of phosphoinositide 3-kinase did not, indicating a role for Ras, but not for Rac or phosphoinositide 3-kinase, in this effect. SHP-2C/S markedly inhibited Ras activation in response to insulin without affecting insulin-induced tyrosine phosphorylation of cellular substrates or the dissociation of the Crk-p130(Cas) complex. In contrast, SHP-2C/S did not inhibit activation of JNKs induced by a constitutively active mutant (RasV12) of Ha-Ras, Furthermore, expression of myristoylated SOS, which functions as a potent activator of Ras, induced JNK activation even when SHP-2 was inactivated. These results suggest that SHP-2 contributes to JNK activation in response to insulin by positively regulating the Ras signaling pathway at the same level as, or upstream from, SOS.	Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Kobe, Hyogo 6500017, Japan; Kobe Univ, Sch Med, Dept Pathol 1, Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University; Kobe University	Noguchi, T (corresponding author), Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.							Adachi M, 1996, CELL, V85, P15; Allard JD, 1996, DEVELOPMENT, V122, P1137; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Desbois-Mouthon C, 1998, BIOCHEM BIOPH RES CO, V243, P765, DOI 10.1006/bbrc.1998.8181; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P2505, DOI 10.1074/jbc.273.5.2505; LopezIlasaca M, 1997, BIOCHEM BIOPH RES CO, V232, P273, DOI 10.1006/bbrc.1997.6289; MARCUSOHN J, 1995, CURR BIOL, V5, P1296, DOI 10.1016/S0960-9822(95)00256-9; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Miller BS, 1996, BIOCHEMISTRY-US, V35, P8769, DOI 10.1021/bi952651r; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; SAWADA T, 1995, BIOCHEM BIOPH RES CO, V214, P737, DOI 10.1006/bbrc.1995.2347; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shapiro PS, 1996, J BIOL CHEM, V271, P5750, DOI 10.1074/jbc.271.10.5750; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; SIMMONS JG, 1995, MOL ENDOCRINOL, V9, P1157, DOI 10.1210/me.9.9.1157; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Sorokin A, 1998, BIOCHEM J, V334, P595, DOI 10.1042/bj3340595; Standaert ML, 1999, ENDOCRINOLOGY, V140, P2145, DOI 10.1210/en.140.5.2145; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Takeda H, 1998, ONCOGENE, V16, P3019, DOI 10.1038/sj.onc.1201839; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664	51	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5208	5213		10.1074/jbc.275.7.5208	http://dx.doi.org/10.1074/jbc.275.7.5208			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671568	hybrid			2022-12-27	WOS:000085378200094
J	Selvamurugan, N; Pulumati, MR; Tyson, DR; Partridge, NC				Selvamurugan, N; Pulumati, MR; Tyson, DR; Partridge, NC			Parathyroid hormone regulation of the rat collagenase-3 promoter by protein kinase A-dependent transactivation of core binding factor alpha 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR CBFA1; MESSENGER-RNA EXPRESSION; OSTEOBLAST-LIKE CELLS; HYPERTROPHIC CHONDROCYTES; INTERSTITIAL COLLAGENASE; CLEIDOCRANIAL DYSPLASIA; BONE-DEVELOPMENT; GENE-EXPRESSION; RECEPTOR; PEPTIDE	Previously we showed that the activator protein-1 site and the runt domain binding site in the collagenase-3 promoter act cooperatively in response to parathyroid hormone (PTH) in the rat osteoblastic osteosarcoma cell line, UMR 106-01, Our results of the expression pattern of core binding factor alpha 1 (Cbfa1), which binds to the runt domain site, indicated that there is no change in the levels of Cbfa1 protein or RNA under either control conditions or after PTH treatment. The importance of posttranslational modification of Cbfa1 in the signaling pathway for PTH-induced collagenase-3 promoter activity was analyzed. PTH stimulation of collagenase-3 promoter activity was completely abrogated by protein kinase A (PKA) inhibition. To determine the role of PKA activity with respect to Cbfa1 activation (in addition to its known activity of phosphorylating cAMP-response element-binding protein to enhance c-fos promoter activity), we utilized the heterologous Gal4 transcription system. PTH stimulated the transactivation of activation domain-3 in Cbfa1 through the PKA site. In vitro phosphorylation studies indicated that the PKA site in the wild type activation domain-3 is a substrate for phosphorylation by PKA, Thus, we demonstrate that PTH induces a PKA-dependent transactivation of Cbfa1, and this transactivation is required for collagenase-3 promoter activity in UMR cells.	St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA	Saint Louis University	Partridge, NC (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, 1402 S Grand Blvd, St Louis, MO 63104 USA.		Selvamurugan, Nagarajan/P-7894-2016; Tyson, Darren/Z-2815-2019	Selvamurugan, Nagarajan/0000-0003-3713-1920; Tyson, Darren/0000-0002-3272-4308; Partridge, Nicola/0000-0002-5406-4814	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK047420, R01DK047420, R01DK048109] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48109, R01 DK047420, DK47420] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; AZARANI A, 1995, J BIOL CHEM, V270, P23166, DOI 10.1074/jbc.270.39.23166; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Chang DJ, 1998, J BIOL CHEM, V273, P4892, DOI 10.1074/jbc.273.9.4892; Daga A, 1996, GENE DEV, V10, P1194, DOI 10.1101/gad.10.10.1194; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Fluhmann B, 1998, MOL CELL ENDOCRINOL, V139, P89, DOI 10.1016/S0303-7207(98)00070-7; FOSANG AJ, 1993, BIOCHEM J, V295, P273, DOI 10.1042/bj2950273; FUJIMORI A, 1992, ENDOCRINOLOGY, V130, P29, DOI 10.1210/en.130.1.29; FUKAYAMA S, 1994, ENDOCRINOLOGY, V134, P1851, DOI 10.1210/en.134.4.1851; FUKUMOTO S, 1992, J CELL PHYSIOL, V152, P346, DOI 10.1002/jcp.1041520216; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; Gao YH, 1998, BIOCHEM BIOPH RES CO, V252, P697, DOI 10.1006/bbrc.1998.9643; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; Greenfield EM, 1996, J BIOL CHEM, V271, P10984, DOI 10.1074/jbc.271.18.10984; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Huang YF, 1998, BONE, V23, P327, DOI 10.1016/S8756-3282(98)00115-X; Jimenez MJG, 1999, MOL CELL BIOL, V19, P4431; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 1997, EUR J BIOCHEM, V248, P369, DOI 10.1111/j.1432-1033.1997.00369.x; KREAM BE, 1993, MOL ENDOCRINOL, V7, P399, DOI 10.1210/me.7.3.399; Lanske B, 1998, ENDOCRINOLOGY, V139, P5194, DOI 10.1210/en.139.12.5194; Li J, 1998, J BIOL CHEM, V273, P31009, DOI 10.1074/jbc.273.47.31009; MATTOT V, 1995, J CELL SCI, V108, P529; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo-124-1-301; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Onyia JE, 1997, J CELL BIOCHEM, V67, P265, DOI 10.1002/(SICI)1097-4644(19971101)67:2<265::AID-JCB12>3.0.CO;2-E; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pearman AT, 1996, J BIOL CHEM, V271, P25715, DOI 10.1074/jbc.271.41.25715; QUINN CO, 1990, J BIOL CHEM, V265, P22342; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; SCOTT DK, 1992, MOL ENDOCRINOL, V6, P2153, DOI 10.1210/me.6.12.2153; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; StahleBackdahl M, 1997, LAB INVEST, V76, P717; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Tetradis S, 1998, J BONE MINER RES, V13, P1846, DOI 10.1359/jbmr.1998.13.12.1846; Tetradis S, 1996, ENDOCRINOLOGY, V137, P5435, DOI 10.1210/en.137.12.5435; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Tyson DR, 1999, ENDOCRINOLOGY, V140, P1255, DOI 10.1210/en.140.3.1255; Winchester SK, 1999, J CELL PHYSIOL, V181, P479, DOI 10.1002/(SICI)1097-4652(199912)181:3<479::AID-JCP12>3.0.CO;2-D; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; Xiao ZS, 1998, GENE, V214, P187, DOI 10.1016/S0378-1119(98)00227-3; Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481	50	167	170	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5037	5042		10.1074/jbc.275.7.5037	http://dx.doi.org/10.1074/jbc.275.7.5037			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671545	hybrid			2022-12-27	WOS:000085378200071
J	Wang, BC; Zou, JX; Ek-Rylander, B; Ruoslahti, E				Wang, BC; Zou, JX; Ek-Rylander, B; Ruoslahti, E			R-Ras contains a proline-rich site that binds to SH3 domains and is required for integrin activation by R-Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; SRC HOMOLOGY-3 DOMAINS; CELL-ADHESION; EXTRACELLULAR-MATRIX; MOLECULAR-CLONING; ADAPTER PROTEINS; NCK; PHOSPHORYLATION; IDENTIFICATION; MODULATION	R-Ras contains a proline-rich motif that resembles SH3 domain-binding sites but that has escaped notice previously. We show here that this site in R-Ras is capable of binding SH3 domains and that the SH3 domain binding may be important for R-Ras function. A fusion protein containing the SH3 domains of the adaptor protein Nck interacted strongly with the R-Ras proline-rich sequence and with the intact protein. The binding was independent of whether R-Ras was in its GDP or GTP form. The Nck binding, which was mediated by the second of the three SH3 domains of Nck, was obliterated by mutations in the proline-rich sequence of R-Ras. The interaction of Nck with R-Ras could also be shown in yeast two-hybrid assays and by co-immunoprecipitation in human cells transfected with Nck and R-Ras, Previous results have shown that the expression of a constitutively active R-Ras mutant, R-Ras(38V), converts mouse 32D monocytic cells into highly adherent cells, Introducing the proline mutations into R-Ras(38V) sup pressed the effect of R-Ras on 32D cell adhesion while not affecting GTP binding. These results reveal an unexpected regulatory pathway that controls R-Ras through an SH3 domain interaction. This pathway appears to be important for the ability of R-Ras to control cell adhesion.	Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Ruoslahti, E (corresponding author), Burnham Inst, Ctr Canc Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA067224, P30CA030199] Funding Source: NIH RePORTER; NCI NIH HHS [CA30199, CA 67224] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bouvard D, 1998, J CELL SCI, V111, P657; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Choudhury GG, 1996, AM J PHYSIOL-RENAL, V270, pF295, DOI 10.1152/ajprenal.1996.270.2.F295; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; Holland SJ, 1998, CURR OPIN NEUROBIOL, V8, P117, DOI 10.1016/S0959-4388(98)80015-9; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOHANSSON MW, 1994, J CELL BIOL, V126, P1299, DOI 10.1083/jcb.126.5.1299; Kashiwagi H, 1997, J CELL BIOL, V137, P1433, DOI 10.1083/jcb.137.6.1433; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; Kitamura Y, 1997, BIOCHEM J, V322, P873, DOI 10.1042/bj3220873; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; Ramos JW, 1998, J BIOL CHEM, V273, P33897, DOI 10.1074/jbc.273.51.33897; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; Soans C, 1996, J CELL BIOL, V135, P781, DOI 10.1083/jcb.135.3.781; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG BC, 1995, J BIOL CHEM, V270, P23239, DOI 10.1074/jbc.270.40.23239; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; Winning RS, 1996, DEV BIOL, V179, P309, DOI 10.1006/dbio.1996.0262; Yauch RL, 1997, J EXP MED, V186, P1347, DOI 10.1084/jem.186.8.1347; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	49	43	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5222	5227		10.1074/jbc.275.7.5222	http://dx.doi.org/10.1074/jbc.275.7.5222			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671570	hybrid			2022-12-27	WOS:000085378200096
J	Xiao, GZ; Jiang, D; Thomas, P; Benson, MD; Guan, KL; Karsenty, G; Franceschi, RT				Xiao, GZ; Jiang, D; Thomas, P; Benson, MD; Guan, KL; Karsenty, G; Franceschi, RT			MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCORBIC-ACID; IN-VIVO; OSTEOCALCIN GENE; MC3T3-E1 CELLS; GROWTH-FACTOR; FACTOR-BETA; EXPRESSION; KINASE; DIFFERENTIATION; MATRIX	The bone-specific transcription factor, Cbfa1, regulates expression of the osteocalcin (OCN) gene and is essential for bone formation. However, little is known about the mechanisms regulating Cbfa1 activity. This work examines the role of the MAPK pathway in regulating Cbfa1-dependent transcription. Stimulation of MAPK by transfecting a constitutively active form of MEK1, MEK(SP), into MC3T3-E1 preosteoblast cells increased endogenous OCN mRNA, while a dominant negative mutant, MEK(DN), was inhibitory. MEK(SP) also stimulated activity of a 147-base pair minimal OCN promoter, and this stimulation required an intact copy of OSE2, the DNA binding site for Cbfa1. Effects of MEK(SP) were specific to Cbfa1-positive osteoblast-like cells. A purified His-tagged Cbfa1 fusion protein was directly, phosphorylated by activated recombinant MAPK in vitro, Furthermore, P-32 metabolic labeling studies demonstrated that MEK(SP) clearly enhanced phosphorylation of Cbfa1 in intact cells, while MEK(DN) decreased phosphorylation. The specific MEK1/MER2 inhibitor, PD98059, inhibited extracellular matrix-dependent up-regulation of the OCN promoter, indicating that the MAPK pathway and, presumably, Cbfa1 phosphorylation are also required for responsiveness of osteoblasts to extracellular matrix signals. This study is the first demonstration that Cbfa1 is controlled by MAPKs and suggests that this pathway has an important role in the control of osteoblast-specific gene expression.	Univ Michigan, Dept Periodont Prevent & Geriatr, Sch Dent, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Sch Med, Ann Arbor, MI 48109 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Baylor College of Medicine	Franceschi, RT (corresponding author), Univ Michigan, Dept Periodont Prevent & Geriatr, Sch Dent, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.	rennyf@umich.edu	Benson, M. Douglas/L-9125-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R56DE011723, R01DE012211] Funding Source: NIH RePORTER; NICHD NIH HHS [T32-HD007505] Funding Source: Medline; NIDCR NIH HHS [DE12211, DE 11723] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Franceschi RT, 1999, CRIT REV ORAL BIOL M, V10, P40, DOI 10.1177/10454411990100010201; FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235; FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843; Frendo JL, 1998, J BIOL CHEM, V273, P30509, DOI 10.1074/jbc.273.46.30509; GERSTENFELD LC, 1987, DEV BIOL, V122, P49, DOI 10.1016/0012-1606(87)90331-9; GHOSHCHOUDHURY N, 1998, BONE, V23; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; Jikko A, 1999, J BONE MINER RES, V14, P1075, DOI 10.1359/jbmr.1999.14.7.1075; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Mahmoodian F, 1996, ARCH BIOCHEM BIOPHYS, V336, P86, DOI 10.1006/abbi.1996.0535; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; RENKAWITZ R, 1979, MOL GEN GENET, V173, P1, DOI 10.1007/BF00267685; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Schmidt C, 1998, J BIOL CHEM, V273, P5081, DOI 10.1074/jbc.273.9.5081; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; Suzawa M, 1999, ENDOCRINOLOGY, V140, P2125, DOI 10.1210/en.140.5.2125; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOGARI A, 1995, JPN J PHARMACOL, V68, P255, DOI 10.1254/jjp.68.255; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wu XY, 1996, J BIOL CHEM, V271, P3265, DOI 10.1074/jbc.271.6.3265; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103	39	468	499	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4453	4459		10.1074/jbc.275.6.4453	http://dx.doi.org/10.1074/jbc.275.6.4453			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660618	hybrid			2022-12-27	WOS:000085288800102
J	Busse, D; Doughty, RS; Ramsey, TT; Russell, WE; Price, JO; Flanagan, WM; Shawver, LK; Arteaga, CL				Busse, D; Doughty, RS; Ramsey, TT; Russell, WE; Price, JO; Flanagan, WM; Shawver, LK; Arteaga, CL			Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE MACHINERY; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; RESTRICTION POINT; DNA-SYNTHESIS; MICE LACKING; ACTIVATION; PROTEIN; RAS; CANCER	We have used quinazoline inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase to study the link between EGFR signaling and G(1) to S traverse. Treatment of A431 and MDA-468 human tumor cells with 0.1-10 mu M AG-1478 inhibited basal and ligand-stimulated EGFR phosphorylation without a decrease in receptor content, EGF-binding sites, or binding affinity. Incubation of A431 cells with 0.1-1 mu M AG-1517 abrogated I-125-EGF internalization. Both AG-1478 and AG-1517 markedly inhibited A431 and MDA-468 colony formation in soft agarose at concentrations between 0.01 and 1 mu M. Daily injections of AG-1478 at 50 mg/kg delayed A431 tumor formation in athymic nude mice. A transient exposure of A431 cells to AG-1478 resulted in a dose-dependent up-regulation of the cyclin-dependent kinase inhibitor p27, down-regulation of cyclin D1 and of active MAPK, and hypophosphorylation of the retinoblastoma protein (Rb), These changes were temporally associated with recruitment of tumor cells in G(1) phase and a marked reduction of the proportion of cells in S phase. Upon removal of the kinase inhibitor, EGFR and Rb phosphorylation and the levels of cyclin D1 protein were quickly restored, but the cells did not reenter S phase until p27 protein levels were decreased. Phosphorothioate p27 oligonucleotides decreased p27 protein in A431 cells and abrogated the quinazoline-mediated G(1) arrest. Treatment of A431 cells with PD 098509, a synthetic inhibitor of MEK1, inhibited MAPK activity without inducing G(1) arrest or increasing the levels of p27, However, treatment with LY 294002, an inhibitor of phosphatidylinositol 3-kinase (PI3K), inhibited basal Akt activity, up-regulated p27, and recruited cells in G(1)., These data suggest that p27 is required for the growth arrest that follows interruption of the EGFR kinase in receptor-overexpressing cells. In addition, the G(1) arrest and up-regulation of p27 resulting from EGFR blockade are not due to the interruption of MAPK, but to the interruption of constitutively active PI3K function.	Vanderbilt Univ, Sch Med, Div Med Oncol, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37232 USA; Vanderbilt Canc Ctr, Nashville, TN 37232 USA; Sugen Inc, S San Francisco, CA 94080 USA; Gilead Sci Inc, Foster City, CA 94404 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Pfizer; Gilead Sciences	Arteaga, CL (corresponding author), Vanderbilt Univ, Sch Med, Div Med Oncol, Dept Med, 22nd Ave S,1956 TVC, Nashville, TN 37232 USA.		Russell, William/A-7307-2009		NCI NIH HHS [CA68485, R01 CA80195] Funding Source: Medline; NIDDK NIH HHS [R01 DK53804] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485, R01CA080195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053804] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Arteaga CL, 1997, J BIOL CHEM, V272, P23247, DOI 10.1074/jbc.272.37.23247; BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; Baselga J, 1997, J MAMMARY GLAND BIOL, V2, P165, DOI 10.1023/A:1026355831693; BenBassat H, 1997, CANCER RES, V57, P3741; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; CARPENTER CL, 1996, CURR OPIN CELL BIOL, V8, P154; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; Clurman BE, 1998, P NATL ACAD SCI USA, V95, P15158, DOI 10.1073/pnas.95.26.15158; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; Fan Z, 1997, CLIN CANCER RES, V3, P1943; FAN Z, 1993, CANCER RES, V53, P4667; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; FILMUS J, 1987, MOL CELL BIOL, V7, P251, DOI 10.1128/MCB.7.1.251; Flanagan WM, 1999, P NATL ACAD SCI USA, V96, P3513, DOI 10.1073/pnas.96.7.3513; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Han YC, 1996, CANCER RES, V56, P3859; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Katayose Y, 1997, CANCER RES, V57, P5441; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; KAWAMOTO T, 1984, J BIOL CHEM, V259, P7761; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; Mittnacht S, 1997, CURR BIOL, V7, P219, DOI 10.1016/S0960-9822(97)70094-0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Peng D, 1996, CANCER RES, V56, P3666; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG NP, 1993, ONCOGENE, V8, P279; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Wu XP, 1996, ONCOGENE, V12, P1397; Zvelebil MJ, 1996, PHILOS T R SOC B, V351, P217, DOI 10.1098/rstb.1996.0019	61	184	192	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6987	6995		10.1074/jbc.275.10.6987	http://dx.doi.org/10.1074/jbc.275.10.6987			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702262	hybrid			2022-12-27	WOS:000085809600042
J	de Heredia, ML; Izquierdo, JM; Cuezva, JM				de Heredia, ML; Izquierdo, JM; Cuezva, JM			A conserved mechanism for controlling the translation of beta-F1-ATPase mRNA between the fetal liver and cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYLASE MESSENGER-RNA; MITOCHONDRIAL F1-ATPASE COMPLEX; OXIDATIVE-PHOSPHORYLATION GENES; HYPOXIA-INDUCIBLE FACTOR-1; 3' UNTRANSLATED REGION; AMINO-ACID-SEQUENCE; RAT-LIVER; 3'-UNTRANSLATED REGION; BETA-SUBUNIT; ATP SYNTHASE	To characterize the mechanisms governing the biogenesis of mitochondria in cancer, we studied the mitochondrial phenotype and the mechanisms controlling the expression of the beta subunit of the mitochondrial H+-ATP synthase (beta-F1-ATPase) gene in the rat FAO and AS80D hepatomas, When compared with normal adult rat liver, the relative cellular content of the mitochondrial beta-F1-ATPase and glutamate dehydrogenase, as well as of mitochondrial DNA, was severely reduced in both cell lines. A paradoxical increase in the cellular abundance of beta-F1-ATPase mRNA was observed in cancer cells. Run-on transcription assays and the estimation of mRNA half-lives revealed that the increased abundance of beta-F1-ATPase mRNA results from the stabilization of the transcript in cancer. In vitro translation assays revealed a specific inhibition of the synthesis of the beta-precursor when translation reactions were carried out in the presence of extracts derived from cancer cells. The inhibitory effect was recapitulated using an RNA chimera that contained the 3'-untranslated region of beta-F1-ATPase mRNA. Hepatoma extracts also contained an increased activity of the developmentally regulated translation-inhibitory proteins that bind the 3'-untranslated region of beta-F1-ATPase mRNA The results indicate that the expression of this gene in hepatoma cells is controlled by the same mechanisms that regulate its expression in the Liver during fetal development.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Dept Mol Biol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Cuezva, JM (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Dept Mol Biol, E-28049 Madrid, Spain.		Cuezva, Jose M/F-8381-2011; Cuezva, Jose M/AAR-5392-2020; López de Heredia, Miguel/A-7727-2008	López de Heredia, Miguel/0000-0003-2826-9565; Cuezva Marcos, Jose Manuel/0000-0003-1118-248X				Amara FM, 1996, J BIOL CHEM, V271, P20126, DOI 10.1074/jbc.271.33.20126; ANNEX BH, 1990, MOL CELL BIOL, V10, P5671, DOI 10.1128/MCB.10.11.5671; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Chen JQ, 1996, CARCINOGENESIS, V17, P2783, DOI 10.1093/carcin/17.12.2783; Chen JQ, 1998, CARCINOGENESIS, V19, P2187, DOI 10.1093/carcin/19.12.2187; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRZANOWSKALIGHTOWLERS ZMA, 1994, J BIOL CHEM, V269, P27322; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; Cuezva JM, 1997, J BIOENERG BIOMEMBR, V29, P365, DOI 10.1023/A:1022450831360; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; CzyzykKrzeska MF, 1996, J BIOL CHEM, V271, P3293, DOI 10.1074/jbc.271.6.3293; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; CZYZYKRZESKA MF, 1994, J BIOL CHEM, V269, P9940; Decaudin D, 1998, INT J ONCOL, V12, P141; DECKER CJ, 1995, CURR OPIN CELL BIOL, V7, P386, DOI 10.1016/0955-0674(95)80094-8; DESCHATRETTE J, 1974, BIOCHIMIE, V56, P1603; Egea G, 1997, BIOCHEM J, V322, P557, DOI 10.1042/bj3220557; FaureVigny H, 1996, MOL CARCINOGEN, V16, P165, DOI 10.1002/(SICI)1098-2744(199607)16:3<165::AID-MC7>3.0.CO;2-G; GADALETA MN, 1990, EUR J BIOCHEM, V187, P501, DOI 10.1111/j.1432-1033.1990.tb15331.x; GARBOCZI DN, 1988, BIOCHEMISTRY-US, V27, P553, DOI 10.1021/bi00402a008; GLAICHENHAUS N, 1986, EMBO J, V5, P1261, DOI 10.1002/j.1460-2075.1986.tb04355.x; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; Heddi A, 1996, BBA-MOL BASIS DIS, V1316, P203, DOI 10.1016/0925-4439(96)00026-9; HENTZE MW, 1995, CURR OPIN CELL BIOL, V7, P393, DOI 10.1016/0955-0674(95)80095-6; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; IZQUIERDO JM, 1990, J BIOL CHEM, V265, P9090; IZQUIERDO JM, 1993, FEBS LETT, V323, P109, DOI 10.1016/0014-5793(93)81459-D; Izquierdo JM, 1997, MOL CELL BIOL, V17, P5255, DOI 10.1128/MCB.17.9.5255; IZQUIERDO JM, 1995, J BIOL CHEM, V270, P10342, DOI 10.1074/jbc.270.17.10342; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; KWON YK, 1993, MOL CELL BIOL, V13, P6547, DOI 10.1128/MCB.13.10.6547; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; LEE JH, 1990, J BIOL CHEM, V265, P4664; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; Lithgow T, 1997, TRENDS BIOCHEM SCI, V22, P110, DOI 10.1016/S0968-0004(97)01007-4; LO CH, 1968, CANCER RES, V28, P1; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; LUCIAKOVA K, 1992, EUR J BIOCHEM, V205, P1187, DOI 10.1111/j.1432-1033.1992.tb16889.x; LUIS AM, 1993, J BIOL CHEM, V268, P1868; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; MALTER JS, 1991, J BIOL CHEM, V266, P3167; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; NAKASHIMA RA, 1984, CANCER RES, V44, P5702; NAKASHIMA RA, 1988, CANCER RES, V48, P913; Ostronoff LK, 1995, BIOCHEM BIOPH RES CO, V217, P1094, DOI 10.1006/bbrc.1995.2881; Ostronoff LK, 1996, BIOCHEM J, V316, P183, DOI 10.1042/bj3160183; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Ricart J, 1997, BIOCHEM J, V324, P635, DOI 10.1042/bj3240635; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; SCARINO ML, 1987, EXP CELL RES, V170, P1, DOI 10.1016/0014-4827(87)90112-1; Schultz RA, 1998, J BIOL CHEM, V273, P3447, DOI 10.1074/jbc.273.6.3447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TORRONI A, 1990, J BIOL CHEM, V265, P20589; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VALCARCE C, 1988, J BIOL CHEM, V263, P7767; VAUPEL P, 1991, CANCER RES, V51, P3316; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WARREN HY, 1981, J BIOL CHEM, V256, P10224; WEINHOUSE S, 1983, ADV ENZYME REGUL, V21, P369, DOI 10.1016/0065-2571(83)90024-9; WEINHOUSE S, 1973, FED PROC, V32, P2162; Wiener CM, 1996, BIOCHEM BIOPH RES CO, V225, P485, DOI 10.1006/bbrc.1996.1199; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	69	52	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7430	7437		10.1074/jbc.275.10.7430	http://dx.doi.org/10.1074/jbc.275.10.7430			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702318	hybrid			2022-12-27	WOS:000085809600098
J	Nakano, Y; Suzuki, N; Yoshida, Y; Nezu, T; Yamashita, Y; Koga, T				Nakano, Y; Suzuki, N; Yoshida, Y; Nezu, T; Yamashita, Y; Koga, T			Thymidine diphosphate-6-deoxy-L-lyxo-4-hexulose reductase synthesizing dTDP-6-deoxy-L-talose from Actinobacillus actinomycetemcomitans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYSACCHARIDE ANTIGENS; SEROTYPE-B; IDENTIFICATION; GENE; LIPOPOLYSACCHARIDE; 6-DEOXY-L-TALAN; SPECIFICITY; SALMONELLAE; RHAMNOSE; SEQUENCE	The serotype c-specific polysaccharide antigen of Actinobacillus actinomycetemcomitans NCTC 9710 contains an unusual sugar, 6-deoxy-L-talose, which has been identified as a constituent of cell wall components in some bacteria. Two genes coding for thymidine diphosphate (dTDP)-6-deoxy-L-lyxo-4-hexulose reductases were identified in the gene cluster required for biosynthesis of serotype c-specific polysaccharide. Both dTDP-6-deoxy-L-lyxo-4-hexulose reductases were overproduced and purified from Escherichia coli transformed with the plasmids containing these genes. The sugar nucleotides converted by both reductases were purified by reversed-phase high performance liquid chromatography and identified by III nuclear magnetic resonance and gas-liquid chromatography. The results indicated that one of two reductases produced dTDP-6-deoxy-L-talose and the other produced dTDP-L-rhamnose (dTDP-6-deoxy-L-mannose). The amino acid sequence of the dTDP-6-deoxy-L-oxy-L-lyxo-4-hexulose reductase forming dTDP-6-deoxy-L-talose shared only weak homology with that forming dTDP-L-rhamnose, despite the fact that these two enzymes catalyze the reduction of the same substrate and the products are determined by the stereospecificity of the reductase activity. Neither the gene for dTDP-6-deoxy-L-talose biosynthesis nor its corresponding protein product has been found in other bacteria; this biosynthetic pathway is identified here for the first time.	Kyushu Univ, Fac Dent, Dept Prevent Dent, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Dept Prosthet Dent 1, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Nakano, Y (corresponding author), Kyushu Univ, Fac Dent, Dept Prevent Dent, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.		Nakano, Yoshio/J-3182-2013	Nakano, Yoshio/0000-0001-9848-3124				AMANO K, 1989, INFECT IMMUN, V57, P2942, DOI 10.1128/IAI.57.10.2942-2946.1989; CALIFANO JV, 1991, ORAL MICROBIOL IMMUN, V6, P228, DOI 10.1111/j.1399-302X.1991.tb00482.x; DEBRUYN A, 1976, CARBOHYD RES, V47, P158, DOI 10.1016/S0008-6215(00)83559-4; DeShazer D, 1998, MOL MICROBIOL, V30, P1081, DOI 10.1046/j.1365-2958.1998.01139.x; GAUGLER RW, 1973, J BIOL CHEM, V248, P6041; JANN B, 1995, CARBOHYD RES, V278, P155, DOI 10.1016/0008-6215(95)00243-6; LEONTEIN K, 1978, CARBOHYD RES, V62, P359, DOI 10.1016/S0008-6215(00)80882-4; MACPHERSON DF, 1994, MOL MICROBIOL, V11, P281, DOI 10.1111/j.1365-2958.1994.tb00308.x; MELO A, 1968, J BIOL CHEM, V243, P1475; Nakano Y, 1998, BBA-GENE STRUCT EXPR, V1442, P409, DOI 10.1016/S0167-4781(98)00174-2; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; Roberts IS, 1996, ANNU REV MICROBIOL, V50, P285, DOI 10.1146/annurev.micro.50.1.285; RUSSA R, 1995, ARCH MICROBIOL, V163, P345, DOI 10.1007/BF00404207; Sambrook J., 2002, MOL CLONING LAB MANU; SHIBUYA N, 1991, J BIOL CHEM, V266, P16318; TAKAHASHI T, 1991, INFECT IMMUN, V59, P18, DOI 10.1128/IAI.59.1.18-23.1991; Tonetti M, 1996, J BIOL CHEM, V271, P27274, DOI 10.1074/jbc.271.44.27274; VERMA N, 1989, J BACTERIOL, V171, P5694, DOI 10.1128/jb.171.10.5694-5701.1989; WYK P, 1989, J BACTERIOL, V171, P5687, DOI 10.1128/jb.171.10.5687-5693.1989; Yoshida Y, 1999, J BIOL CHEM, V274, P16933, DOI 10.1074/jbc.274.24.16933; Yoshida Y, 1998, INFECT IMMUN, V66, P107, DOI 10.1128/IAI.66.1.107-114.1998; Zahringer U, 1997, CARBOHYD RES, V300, P143, DOI 10.1016/S0008-6215(96)00304-7	22	37	41	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6806	6812		10.1074/jbc.275.10.6806	http://dx.doi.org/10.1074/jbc.275.10.6806			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702238	hybrid			2022-12-27	WOS:000085809600018
J	Wu, SJ; Tambyraja, R; Zhang, WT; Zahn, S; Grodillot, AP; Chaiken, I				Wu, SJ; Tambyraja, R; Zhang, WT; Zahn, S; Grodillot, AP; Chaiken, I			Epitope randomization redefines the functional role of glutamic acid 110 in interleukin-5 receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; HIGH-AFFINITY BINDING; ALPHA-CHAIN; GM-CSF; 3-DIMENSIONAL STRUCTURE; IL-5; MUTAGENESIS; PROTEINS; DOMAIN; IDENTIFICATION	Sequence randomization through functional phage display of single chain human interleukin (IL)-5 was used to investigate the limits of replaceability of the Glu(110) residues that form a part of the receptor-binding epitope. Mutational analysis revealed unexpected affinity for IL-5 receptor a chain with variants containing E110W or E110Y. Escherichia coli-expressed Glu(110) variants containing E110W in the otherwise sequence-intact N-terminal half, including a variant with an E110A replacement in the sequence-disabled C-terminal half, were shown by their CD spectra to be folded into secondary structures similar to that of single chain human IL-5 (scIL-5), Biosensor kinetics analysis revealed that (E110W/A5)scIL-5 and (E110W/A6)scIL-5 had receptor a chain binding affinities similar to that of (wt/A5)scIL-5. However, (E110W/A6)scIL-5 had a significantly reduced bioactivity in TF-1 cell proliferation compared with both (wt/A5)scIL-5 and (E110W/A5)scIL-5, and this activity reduction was disproportionately greater than the much smaller effect of Glu(110) mutation on receptor binding affinity. The marked and disproportionate decrease in TF-1 proliferation observed with (E110W/A6)scIL-5 suggests a role for Glu(110) in the biological activity mediated by the signal transducing receptor beta c subunit of the IL-5 receptor. This is also consistent with the lack of stimulation of JAK2 phosphorylation by the (E110W/ A6)scIL-5 mutant in recombinant 293T cells, as compared with the concentration-dependent stimulation seen for scIL-5. The results reveal the dispensability of charge in the Glu(110) locus of IL-5 for receptor a chain binding and, in contrast, its heretofore underappreciated importance for receptor activation.	Univ Penn, Sch Med, Dept Med, Stellar Chance Labs 909, Philadelphia, PA 19104 USA	University of Pennsylvania	Chaiken, I (corresponding author), Univ Penn, Sch Med, Dept Med, Stellar Chance Labs 909, 422 Curie Blvd, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055648] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI/GM40462-01] Funding Source: Medline; NIGMS NIH HHS [R01 GM55648-03] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; AMES RS, 1995, J IMMUNOL, V154, P6355; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1992, SCIENCE, V257, P410, DOI 10.1126/science.1631562; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; CHAIKEN IM, 1999, IL 5 MOL DRUG TARGET, P167; CLACKSON T, 1994, TRENDS BIOTECHNOL, V12, P173, DOI 10.1016/0167-7799(94)90079-5; CUNNINGHAM BC, 1994, EMBO J, V13, P2508, DOI 10.1002/j.1460-2075.1994.tb06540.x; DEVOS R, 1993, J BIOL CHEM, V268, P6581; DIEDERICHS K, 1991, SCIENCE, V258, P1358; EGAN RW, 1999, IL5 MOL DRUG TARGET, P321; GRABER P, 1995, J BIOL CHEM, V270, P15762, DOI 10.1074/jbc.270.26.15762; Howard M, 1994, GUIDEBOOK CYTOKINES; JOHANSON K, 1995, J BIOL CHEM, V270, P9459, DOI 10.1074/jbc.270.16.9459; Jones JT, 1998, J BIOL CHEM, V273, P11667, DOI 10.1074/jbc.273.19.11667; Karlen S, 1998, Int Rev Immunol, V16, P227, DOI 10.3109/08830189809042996; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li J, 1996, J BIOL CHEM, V271, P1817, DOI 10.1074/jbc.271.4.1817; Li J, 1997, P NATL ACAD SCI USA, V94, P6694, DOI 10.1073/pnas.94.13.6694; Li J, 1996, J BIOL CHEM, V271, P31729, DOI 10.1074/jbc.271.49.31729; LOPEZ AF, 1992, IMMUNOL TODAY, V13, P495, DOI 10.1016/0167-5699(92)90025-3; LOWMAN HB, 1991, BIOCHEMISTRY-US, V30, P10832, DOI 10.1021/bi00109a004; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; MITA S, 1989, P NATL ACAD SCI USA, V86, P2311, DOI 10.1073/pnas.86.7.2311; Monfardini C, 1998, J BIOL CHEM, V273, P7657, DOI 10.1074/jbc.273.13.7657; MORTON T, 1995, P NATL ACAD SCI USA, V92, P10879, DOI 10.1073/pnas.92.24.10879; Morton Thomas A., 1994, Journal of Molecular Recognition, V7, P47, DOI 10.1002/jmr.300070107; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; POWERS R, 1992, SCIENCE, V256, P1673, DOI 10.1126/science.256.5064.1673; REDFIELD C, 1991, BIOCHEMISTRY-US, V30, P11029, DOI 10.1021/bi00110a004; SANDERSON C, 1998, IL5 MOL DRUG TARGET; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194; Wu SJ, 1999, J BIOL CHEM, V274, P20479, DOI 10.1074/jbc.274.29.20479; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; ZHONG GM, 1994, BIOTECHNIQUES, V16, P838	38	11	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7351	7358		10.1074/jbc.275.10.7351	http://dx.doi.org/10.1074/jbc.275.10.7351			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702307	hybrid			2022-12-27	WOS:000085809600087
J	Ishida, W; Hamamoto, T; Kusanagi, K; Yagi, K; Kawabata, M; Takehara, K; Sampath, TK; Kato, M; Miyazono, K				Ishida, W; Hamamoto, T; Kusanagi, K; Yagi, K; Kawabata, M; Takehara, K; Sampath, TK; Kato, M; Miyazono, K			Smad6 is a Smad1/5-induced smad inhibitor - Characterization of bone morphogenetic protein-responsive element in the mouse Smad6 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; BETA; IDENTIFICATION; TRANSCRIPTION; ACTIVATORS; ANTAGONIST; INDUCTION; RECEPTORS; SEQUENCE	Smad6 is an inhibitory Smad that is induced by bone morphogenetic proteins (BMPs) and interferes with BMP signaling. We have isolated the mouse Smad6 promoter and identified the regions responsible for transcriptional activation by BMPs. The proximal BMP-responsive element (PBE) in the Smad6 promoter is important for the transcriptional activation by BMPs and contains a 28 base pair GC-rich sequence including four overlapping copies of the GCCGnCGC-like motif, which is a binding site for Drosophila Mad and Medea. We generated a luciferase reporter construct (3GC2-Lux) containing three repeats of the GC-rich sequence derived from the PBE. BMPs and BMP receptors induced transcriptional activation of 3GC2-Lux in various cell types, and this activation was enhanced by cotransfection of BMP-responsive Smads, i.e. Smad1 or Smad5, Moreover, direct DNA binding of BMP-responsive Smads and common-partner Smad4 to the GC-rich sequence of PBE was observed. These results indicate that the expression of Smad6 is regulated by the effects of BMP-activated Smad1/5 on the Smad6 promoter.	Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan; Japan Soc Promot Sci, Res Future Program, Toshima Ku, Tokyo 1708455, Japan; Kanazawa Univ, Sch Med, Dept Dermatol, Kanazawa, Ishikawa 9208640, Japan; Creat Biomol Inc, Hopkinton, MA 01748 USA	Japanese Foundation for Cancer Research; Japan Society for the Promotion of Science; Kanazawa University	Kato, M (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.							Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Beppu H, 1997, BIOCHEM BIOPH RES CO, V235, P499, DOI 10.1006/bbrc.1997.6816; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Gazzerro E, 1998, J CLIN INVEST, V102, P2106, DOI 10.1172/JCI3459; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Harada S, 1997, MOL ENDOCRINOL, V11, P1832, DOI 10.1210/me.11.12.1832; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KUSANAGAI K, 2000, IN PRESS MOL BIOL CE; Liu XJ, 1998, CANCER RES, V58, P4752; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Meno C, 1999, MOL CELL, V4, P287, DOI 10.1016/S1097-2765(00)80331-7; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1999, J CLIN INVEST, V104, P5, DOI 10.1172/JCI6094; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Shimizu A, 1998, GENES CELLS, V3, P125, DOI 10.1046/j.1365-2443.1998.00174.x; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Takase M, 1998, BIOCHEM BIOPH RES CO, V244, P26, DOI 10.1006/bbrc.1998.8200; Thisse C, 1999, DEVELOPMENT, V126, P229; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	40	222	241	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6075	6079		10.1074/jbc.275.9.6075	http://dx.doi.org/10.1074/jbc.275.9.6075			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692396	hybrid			2022-12-27	WOS:000085654400008
J	Beyermann, M; Rothemund, S; Heinrich, N; Fechner, K; Furkert, J; Dathe, M; Winter, R; Krause, E; Bienert, M				Beyermann, M; Rothemund, S; Heinrich, N; Fechner, K; Furkert, J; Dathe, M; Winter, R; Krause, E; Bienert, M			A role for a helical connector between two receptor binding sites of a long-chain peptide hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICOTROPIN-RELEASING-FACTOR; NUCLEAR-MAGNETIC-RESONANCE; GENE-RELATED PEPTIDE; PARATHYROID-HORMONE; HUMAN CALCITONIN; COMPETITIVE ANTAGONISTS; BIOLOGICAL-ACTIVITY; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; FACTOR ANALOGS	The conformational freedom of single-chain peptide hormones, such as the 41-amino acid hormone corticotropin releasing factor (CRF), is a major obstacle to the determination of their biologically relevant conformation, and thus hampers insights into the mechanism of ligand-receptor interaction, Since N- and C-terminal truncations of CRF lead to loss of biological activity, it has been thought that almost the entire peptide is essential for receptor activation. Here we show the existence of two segregated receptor binding sites at the N- and C termini of CRF, connection of which is essential for receptor binding and activation. Connection of the two binding sites by highly flexible E-aminocaproic acid residues resulted in CRF analogues that remained full, although weak agonists (EC50: 100-300 nM) independent of linker length. Connection of the two sites by an appropriate helical peptide led to a very potent analogue, which adopted, in contrast to CRF itself, a stable, monomer conformation in aqueous solution. Analogues in which the two sites were connected by helical linkers of different lengths were potent agonists; their significantly different biopotencies (EC50:0.6-50 nM), however, suggest the relative orientation between the two binding sites rather than the maintenance of a distinct distance between them to be essential for a high potency.	Forsch Inst Mol Pharmakol, D-10315 Berlin, Germany		Beyermann, M (corresponding author), Forsch Inst Mol Pharmakol, Alfred Kowalke Str 4, D-10315 Berlin, Germany.	beyermann@fmp-berlin.de						BARDEN JA, 1993, BIOCHEMISTRY-US, V32, P7126, DOI 10.1021/bi00079a008; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; Beyermann M, 1996, J MED CHEM, V39, P3324, DOI 10.1021/jm960116z; Blankenfeldt W, 1996, BIOCHEMISTRY-US, V35, P5955, DOI 10.1021/bi9601520; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN W, 1983, J MOL BIOL, V169, P921, DOI 10.1016/S0022-2836(83)80143-0; Brunger A. T, 1993, XPLOR MANUAL VERSION; Chalmers DT, 1996, TRENDS PHARMACOL SCI, V17, P166, DOI 10.1016/0165-6147(96)81594-X; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CLORE GM, 1986, J MOL BIOL, V191, P553, DOI 10.1016/0022-2836(86)90147-6; COY DH, 1985, J MED CHEM, V28, P181, DOI 10.1021/jm00380a006; COY DH, 1987, J MED CHEM, V30, P219, DOI 10.1021/jm00384a039; Dathe M, 1996, INT J PEPT PROT RES, V47, P383; DENEF C, 1989, METHOD ENZYMOL, V168, P47; ENGLANDER SW, 1987, BIOCHEMISTRY-US, V26, P5953, DOI 10.1021/bi00393a001; FEYEN JHM, 1992, BIOCHEM BIOPH RES CO, V187, P8, DOI 10.1016/S0006-291X(05)81450-0; GULYAS J, 1995, P NATL ACAD SCI USA, V92, P10575, DOI 10.1073/pnas.92.23.10575; Heinrich N, 1998, ENDOCRINOLOGY, V139, P651, DOI 10.1210/en.139.2.651; KORNREICH WD, 1992, J MED CHEM, V35, P1870, DOI 10.1021/jm00088a024; MATON PN, 1990, PEPTIDES, V11, P485, DOI 10.1016/0196-9781(90)90047-9; Motta A, 1998, PROTEINS, V32, P314, DOI 10.1002/(SICI)1097-0134(19980815)32:3<314::AID-PROT7>3.3.CO;2-J; Pellegrini M, 1997, J MED CHEM, V40, P3025, DOI 10.1021/jm970181o; Pellegrini M, 1998, J BIOL CHEM, V273, P10420, DOI 10.1074/jbc.273.17.10420; Perrin MH, 1998, ENDOCRINOLOGY, V139, P566, DOI 10.1210/en.139.2.566; RITTEL W, 1976, EXPERIENTIA, V32, P246, DOI 10.1007/BF01937791; Rivier J, 1998, J MED CHEM, V41, P2614, DOI 10.1021/jm980164e; RIVIER J, 1984, SCIENCE, V224, P889, DOI 10.1126/science.6326264; RIVIER J, 1993, J MED CHEM, V36, P2851, DOI 10.1021/jm00072a003; Rohde E, 1996, BIOCHEM PHARMACOL, V52, P829, DOI 10.1016/0006-2952(96)00300-0; ROMIER C, 1993, PROTEIN ENG, V6, P149, DOI 10.1093/protein/6.2.149; Rothemund S, 1997, J PEPT RES, V50, P184; Rothemund S, 1996, PEPTIDE RES, V9, P79; SCHOLTZ JM, 1993, BIOCHEMISTRY-US, V32, P9668, DOI 10.1021/bi00088a019; SEGRE GV, 1979, J BIOL CHEM, V254, P6980; SMITH DD, 1993, J MED CHEM, V36, P2536, DOI 10.1021/jm00069a012; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; UNSON CG, 1989, J BIOL CHEM, V264, P789; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0; Vickery BH, 1996, J BONE MINER RES, V11, P1943; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WUTHRICH K, 1984, J MOL BIOL, V180, P715, DOI 10.1016/0022-2836(84)90034-2	42	47	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5702	5709		10.1074/jbc.275.8.5702	http://dx.doi.org/10.1074/jbc.275.8.5702			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681555	hybrid			2022-12-27	WOS:000085474500062
J	Fujiki, Y; Sato, T; Ito, M; Watanabe, A				Fujiki, Y; Sato, T; Ito, M; Watanabe, A			Isolation and characterization of cDNA, clones for the E1 beta and E2 subunits of the branched-chain alpha-ketoacid dehydrogenase complex in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAIZE ROOT-TIPS; SENESCENCE-ASSOCIATED GENE; COENZYME-A CARBOXYLASE; HIGHER-PLANT CELLS; ZEA-MAYS L; ACID DEHYDROGENASE; DIHYDROLIPOAMIDE ACETYLTRANSFERASE; PEROXISOMAL DEGRADATION; ASPARAGINE SYNTHETASE; METABOLIC-REGULATION	Branched-chain alpha-ketoacid dehydrogenase (BCKDH) has been known in mammals to be a key enzyme of the catabolic pathway of branched-chain amino acids. We have isolated two cDNA clones encoding the E1 beta and E2 subunits of BCKDH, respectively, from Arabidopsis thaliana. Proteins encoded in these cDNA sequences had putative mitochondrial targeting sequences and conserved domains reported for their mammalian counterparts. Northern blot and immunoblot analyses showed that transcripts from the respective genes and E2 protein markedly accumulated in leaves kept in the dark. We found that the activity of BCKDH in the leaf extracts also increased when plants were placed in the dark. Addition of sucrose to detached leaves inhibited the accumulation of transcripts, whereas application of a photosynthesis inhibitor strongly induced the expression of these genes even under light illumination. These observations indicate that the cellular sugar level is likely responsible for the dark-induced expression of these genes. The transcript levels of these genes were also high in senescing leaves, in which photosynthetic activity is low and free amino acids from degraded protein are likely to serve as an alternative energy source.	Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Watanabe, A (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan.	watanabe@biol.s.u-tokyo.ac.jp	Fujiki, Yuki/F-1580-2011; Ito, Masaki/G-4252-2013	Fujiki, Yuki/0000-0002-4037-028X; Ito, Masaki/0000-0002-9635-9709				ALBAN C, 1993, PLANT PHYSIOL, V102, P957, DOI 10.1104/pp.102.3.957; Anderson MD, 1998, PLANT PHYSIOL, V118, P1127, DOI 10.1104/pp.118.4.1127; APREES T, 1990, PLANT PHYSL BIOCH MO, P106; Aubert S, 1996, FEBS LETT, V383, P175, DOI 10.1016/0014-5793(96)00244-X; AZUMI Y, 1991, PLANT PHYSIOL, V95, P577, DOI 10.1104/pp.95.2.577; BAYSDORFER C, 1988, PLANT PHYSIOL, V88, P1381, DOI 10.1104/pp.88.4.1381; BLOCK KP, 1988, METHOD ENZYMOL, V166, P201; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETHARTE MS, 1994, PLANT PHYSIOL, V105, P19, DOI 10.1104/pp.105.1.19; BROUQUISSE R, 1991, PLANT PHYSIOL, V96, P619, DOI 10.1104/pp.96.2.619; Chevalier C, 1996, PLANT J, V9, P1, DOI 10.1046/j.1365-313X.1996.09010001.x; CHUANG DT, 1995, METABOLIC MOL BASES, P1239; DAHL HHM, 1987, J BIOL CHEM, V262, P7398; DANNER DJ, 1989, J BIOL CHEM, V264, P7742; DAVIES DD, 1978, PLANT PHYSIOL, V61, P54, DOI 10.1104/pp.61.1.54; DIEUAIDE M, 1992, PLANT PHYSIOL, V99, P595, DOI 10.1104/pp.99.2.595; DUNFORD R, 1990, PHYTOCHEMISTRY, V29, P41, DOI 10.1016/0031-9422(90)89006-U; FUJIKI Y, 1997, PLANT PHYSIOL, V114, pS95; FUSSEY SPM, 1988, P NATL ACAD SCI USA, V85, P8654, DOI 10.1073/pnas.85.22.8654; GENIX P, 1990, PLANT PHYSIOL, V94, P717, DOI 10.1104/pp.94.2.717; GERBLING H, 1993, BOT ACTA, V106, P380, DOI 10.1111/j.1438-8677.1993.tb00764.x; GERBLING H, 1989, PLANT PHYSIOL, V91, P1387, DOI 10.1104/pp.91.4.1387; GOODWIN GW, 1988, METHOD ENZYMOL, V166, P189; GRIFFIN TA, 1988, J BIOL CHEM, V263, P14008; GUAN YH, 1995, J BIOL CHEM, V270, P5412, DOI 10.1074/jbc.270.10.5412; GUEST JR, 1987, FEMS MICROBIOL LETT, V44, P417, DOI 10.1111/j.1574-6968.1987.tb02324.x; HARPER AE, 1989, ANN NY ACAD SCI, V573, P267, DOI 10.1111/j.1749-6632.1989.tb15003.x; HENSEL LL, 1993, PLANT CELL, V5, P553, DOI 10.1105/tpc.5.5.553; HUMMEL KB, 1988, J BIOL CHEM, V263, P6165; JAMES F, 1993, PLANT PHYSIOL BIOCH, V31, P845; JOURNET EP, 1986, J BIOL CHEM, V261, P3193; KERR PS, 1985, PLANT PHYSIOL, V78, P576, DOI 10.1104/pp.78.3.576; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM HM, 1994, PLANT PHYSIOL, V106, P1347, DOI 10.1104/pp.106.4.1347; LAM HM, 1995, PLANT CELL, V7, P887, DOI 10.1105/tpc.7.7.887; LAU KS, 1988, BIOCHEMISTRY-US, V27, P1972, DOI 10.1021/bi00406a025; LEUTHY MH, 1994, BIOCHIM BIOPHYS ACTA, V1187, P95; LUETHY MH, 1998, PLANT PHYSIOL, V118, P329; MITA S, 1995, PLANT PHYSIOL, V107, P895, DOI 10.1104/pp.107.3.895; MITSUBUCHI H, 1991, J BIOL CHEM, V266, P14686; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; NOBUKUNI Y, 1990, BIOCHEMISTRY-US, V29, P1154, DOI 10.1021/bi00457a009; REED LJ, 1985, CURR TOP CELL REGUL, V27, P41; SAGLIO PH, 1980, PLANT PHYSIOL, V66, P516, DOI 10.1104/pp.66.3.516; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT GW, 1981, J CELL BIOL, V91, P468, DOI 10.1083/jcb.91.2.468; SHEEN J, 1990, PLANT CELL, V2, P1027, DOI 10.1105/tpc.2.10.1027; Shimada Y, 1998, PLANT CELL PHYSIOL, V39, P139, DOI 10.1093/oxfordjournals.pcp.a029350; Somerville C.R., 1982, METHODS CHLOROPLAST, P129; STITT M, 1985, PLANTA, V166, P354, DOI 10.1007/BF00401173; Truernit E, 1996, PLANT CELL, V8, P2169, DOI 10.1105/tpc.8.12.2169; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; YEAMAN SJ, 1989, BIOCHEM J, V257, P625, DOI 10.1042/bj2570625; YOSHIDA KT, 1994, PLANT CELL PHYSIOL, V35, P1003	55	39	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					6007	6013		10.1074/jbc.275.8.6007	http://dx.doi.org/10.1074/jbc.275.8.6007			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681595	hybrid			2022-12-27	WOS:000085474500102
J	Oh, CD; Chang, SH; Yoon, YM; Lee, SJ; Lee, YS; Kang, SS; Chun, JS				Oh, CD; Chang, SH; Yoon, YM; Lee, SJ; Lee, YS; Kang, SS; Chun, JS			Opposing role of mitogen-activated protein kinase subtypes, Erk-1/2 and p38, in the regulation of chondrogenesis of mesenchymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-CADHERIN; IN-VITRO; CARTILAGE DIFFERENTIATION; LIMB CHONDROGENESIS; CELL-ADHESION; MAP KINASE; EXPRESSION; BONE; PRECARTILAGE; CONDENSATION	The present studies were performed to determine subtype-specific roles of mitogen-activated protein kinase in chondrogenesis, Erk-1/2 activities, downstream of protein kinase C, decreased as chondrogenesis proceeded, whereas p38 activities, independent of protein kinase C, continuously increased during chondrogenesis. Inhibition of Erk-1/2 with PD98059 enhanced chondrogenesis up to 1.7-fold, whereas inhibition of p38 with SB203580 reduced it to about 30% of the control level. Inhibition of Erk-1/2 or p38 did not affect precartilage condensation. However, cartilage nodule formation was significantly blocked by the inhibition of p38, whereas Erk-1/2 inhibition did not affect it. Modulation of chondrogenesis by the inhibition of Erk-1/2 and p38 was accompanied by altered expression of adhesion molecules in an opposite way. Expression of N-cadherin was reduced as chondrogenesis proceeded. Inhibition of p38 caused sustained expression of N-cadherin, whereas Erk-1/2 inhibition accelerated the reduction of N-cadherin expression. Expression of integrin alpha 5 beta 1 and fibronectin were found to transiently increase during chondrogenesis. Inhibition of p38 caused continuous increase of expression of these molecules, whereas Erk-1/2 inhibition accelerated the decrease of expression of these molecules at a later period of chondrogenesis. Because temporal expression of these adhesion molecules regulates chondrogenesis, the above results indicate that Erk-1/2 and p38 conversely regulate chondrogenesis at post-precartilage condensation stages by modulating expression of adhesion molecules.	Kyungpook Natl Univ, Dept Biol, Pook Gu, Taegu 702701, South Korea; Korea Canc Ctr Hosp, Lab Radiat Effect, Nowon Gu, Seoul 139706, South Korea	Kyungpook National University; National Cancer Center - Korea (NCC)	Chun, JS (corresponding author), Kyungpook Natl Univ, Dept Biol, Pook Gu, Taegu 702701, South Korea.	jschun@kyungpook.ac.kr		Oh, Chundo/0000-0002-5419-8011				AHRENS PB, 1977, DEV BIOL, V60, P69, DOI 10.1016/0012-1606(77)90110-5; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AULTHOUSE AL, 1987, DEV BIOL, V120, P377, DOI 10.1016/0012-1606(87)90240-5; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Chang SH, 1998, J BIOL CHEM, V273, P19213, DOI 10.1074/jbc.273.30.19213; CHOI B, 1995, BIOCHEM BIOPH RES CO, V216, P1034, DOI 10.1006/bbrc.1995.2724; Chun JS, 1996, J BIOL CHEM, V271, P13008, DOI 10.1074/jbc.271.22.13008; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Duprez DM, 1996, DEV BIOL, V174, P448, DOI 10.1006/dbio.1996.0087; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; FRENZ DA, 1989, DEV BIOL, V136, P97, DOI 10.1016/0012-1606(89)90133-4; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Kim JY, 1999, BIOCHEM J, V337, P275, DOI 10.1042/0264-6021:3370275; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; MAINI PK, 1991, INT REV CYTOL, V129, P91; Maleski MP, 1996, EXP CELL RES, V225, P55, DOI 10.1006/excr.1996.0156; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; Nakamura K, 1999, EXP CELL RES, V250, P351, DOI 10.1006/excr.1999.4535; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; OBERLENDER SA, 1994, DEVELOPMENT, V120, P177; PACIFICI M, 1993, DEV DYNAM, V198, P123, DOI 10.1002/aja.1001980206; Quarto R, 1997, ENDOCRINOLOGY, V138, P4966, DOI 10.1210/en.138.11.4966; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; ROARK EF, 1994, DEV DYNAM, V200, P103, DOI 10.1002/aja.1002000203; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593; Solursh M, 1989, CURR OPIN CELL BIOL, V1, P989, DOI 10.1016/0955-0674(89)90070-7; Stott NS, 1999, J CELL PHYSIOL, V180, P314, DOI 10.1002/(SICI)1097-4652(199909)180:3<314::AID-JCP2>3.3.CO;2-P; Tavella S, 1997, J CELL SCI, V110, P2261; TAVELLA S, 1994, EXP CELL RES, V215, P354, DOI 10.1006/excr.1994.1352; TSONIS PA, 1994, EXP CELL RES, V213, P433, DOI 10.1006/excr.1994.1220; WIDELITZ RB, 1993, J CELL PHYSIOL, V156, P399, DOI 10.1002/jcp.1041560224	41	186	193	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5613	5619		10.1074/jbc.275.8.5613	http://dx.doi.org/10.1074/jbc.275.8.5613			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681543	hybrid			2022-12-27	WOS:000085474500050
J	Dan, S; Marton, I; Dekel, M; Bravdo, BA; He, SM; Withers, SG; Shoseyov, O				Dan, S; Marton, I; Dekel, M; Bravdo, BA; He, SM; Withers, SG; Shoseyov, O			Cloning, expression, characterization, and nucleophile identification of family 3, Aspergillus niger beta-glucosidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSIDE HYDROLYSIS; PURIFICATION; WENTII; BETA-GLUCOSIDASE-A3; MECHANISMS; CELLULOSE; YEAST	The beta-glucosidase from Aspergillus niger (CMI. CC 324262) was purified, and an N-terminal sequence and two internal sequences were determined. BglI genomic gene and the cDNA were cloned from a genomic library and by reverse transcriptase-polymerase chain reaction, respectively. The cDNA was successfully expressed in Saccharomyces cerevisiae and Pichia pastoris. Sequence analysis revealed that the gene encodes a 92-kDa enzyme that is a member of glycosidase family 3. H-1-NMR analysis of the reaction catalyzed by this enzyme confirmed that, in common with other family 3 glycosidases, this enzyme hydrolyzes with net retention of anomeric configuration. Accordingly, the enzyme was inactivated by a-deoxy-a-fluoro beta-glucosyl fluoride, with kinetic parameters of k(i) = 4.5 min(-1), K-I = 35.4 mM, through the trapping of a covalent glycosyl enzyme intermediate, The catalytic competence of this intermediate was demonstrated by the fact that incubation with linamarin resulted in reactivation, presumably via a transglycosylation mechanism. Peptic digestion of the 2-deoxy-2-fluoroglucosyl enzyme and subsequent analysis of high pressure liquid chromatography eluates by electrospray ionization triple quadrupole mass spectrometry in the neutral loss mode allowed the localization of a 2-deoxy-2-fluoroglucosyl-peptide. Sequence determination of this labeled peptide by tandem mass spectrometry in the daughter ion scan mode permitted the identification of Asp-261 as the catalytic nucleophile within the sequence VMSDW, Asp-261 is fully conserved within this family, consistent with its key role, and aligns with the aspartic acid residue previously identified in the Aspergillus wentii enzyme by labeling with conduritol B epoxide.	Hebrew Univ Jerusalem, Fac Agr, Kennedy Leigh Ctr Hort Res, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Fac Agr, Otto Warburg Ctr Agr Biotechnol, IL-76100 Rehovot, Israel; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada	Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of British Columbia	Shoseyov, O (corresponding author), Hebrew Univ Jerusalem, Fac Agr, Kennedy Leigh Ctr Hort Res, POB 12, IL-76100 Rehovot, Israel.	shoseyov@agri.huji.ac.il						BAUSE E, 1974, H-S Z PHYSIOL CHEM, V355, P438, DOI 10.1515/bchm2.1974.355.1.438; BEGUIN P, 1994, FEMS MICROBIOL REV, V13, P25, DOI 10.1016/0168-6445(94)90099-X; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; Davies G. J., 1998, INCOMPREHENSIVE BIOL, P119; DEKKER RFH, 1986, BIOTECHNOL BIOENG, V28, P1438, DOI 10.1002/bit.260280918; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; Hrmova M, 1996, J BIOL CHEM, V271, P5277, DOI 10.1074/jbc.271.9.5277; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KERNS G, 1986, ACTA BIOTECHNOL, V6, P355, DOI 10.1002/abio.370060408; KITPREECHAVANICH V, 1986, AGR BIOL CHEM TOKYO, V50, P1703, DOI 10.1080/00021369.1986.10867655; Le Traon-Masson MP, 1998, ENZYME MICROB TECH, V22, P374, DOI 10.1016/S0141-0229(97)00206-8; LEATHERBARROW RJ, 1994, GRA FIT VERSION 3 0; LEGLER G, 1980, J CHEM SOC PERK T 2, P1376, DOI 10.1039/p29800001376; LEGLER G, 1979, EUR J BIOCHEM, V101, P85, DOI 10.1111/j.1432-1033.1979.tb04219.x; LEGLER G, 1968, H-S Z PHYSIOL CHEM, V349, P767, DOI 10.1515/bchm2.1968.349.1.767; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; Ly HD, 1999, ANNU REV BIOCHEM, V68, P487, DOI 10.1146/annurev.biochem.68.1.487; Mackenzie LF, 1998, J AM CHEM SOC, V120, P5583, DOI 10.1021/ja980833d; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MCCLEARY BV, 1988, METHOD ENZYMOL, V160, P575; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; PENTTILA ME, 1984, MOL GEN GENET, V194, P494, DOI 10.1007/BF00425564; ROESER KR, 1981, BIOCHIM BIOPHYS ACTA, V657, P321, DOI 10.1016/0005-2744(81)90318-1; ROMBOUTS FM, 1978, PROCESS BIOCHEM, V13, P9; SHOSEYOV O, 1990, J AGR FOOD CHEM, V38, P1387, DOI 10.1021/jf00096a019; SHOSEYOV O, 1988, PHYTOCHEMISTRY, V27, P1973, DOI 10.1016/0031-9422(88)80080-3; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STERNBERG D, 1977, CAN J MICROBIOL, V23, P139, DOI 10.1139/m77-020; UNNO T, 1993, BIOSCI BIOTECH BIOCH, V57, P2172, DOI 10.1271/bbb.57.2172; Varghese JN, 1999, STRUCTURE, V7, P179, DOI 10.1016/S0969-2126(99)80024-0; WATANABE T, 1992, EUR J BIOCHEM, V209, P651, DOI 10.1111/j.1432-1033.1992.tb17332.x; WITHERS SG, 1995, PROTEIN SCI, V4, P361; Wong AW, 1998, J BIOL CHEM, V273, P34057, DOI 10.1074/jbc.273.51.34057; WOODWARD J, 1982, ENZYME MICROB TECH, V4, P73, DOI 10.1016/0141-0229(82)90084-9; YEOH HH, 1986, APPL MICROBIOL BIOT, V25, P25	35	118	137	1	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4973	4980		10.1074/jbc.275.7.4973	http://dx.doi.org/10.1074/jbc.275.7.4973			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671536	hybrid			2022-12-27	WOS:000085378200062
J	Graham, KC; Litchfield, DW				Graham, KC; Litchfield, DW			The regulatory beta subunit of protein kinase CK2 mediates formation of tetrameric CK2 complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-2; ALPHA-SUBUNIT; II-ALPHA; CELLULAR-REGULATION; RECEPTOR CHIMERAE; INTERACTION SITES; TRANSPHOSPHORYLATION; PHOSPHORYLATION; EXPRESSION; ACTIVATION	Protein kinase CK2 is a tetrameric enzyme composed of two catalytic (alpha and/or alpha') subunits and two regulatory (beta) subunits. Because CK2 beta is synthesized in excess of CK2 alpha, we hypothesized that formation of CK2 beta homodimers precedes the incorporation of the catalytic subunits of CK2 into complexes. To test this hypothesis, we cotransfected cells with two epitope-tagged variants of CK2 beta. The results of these cotransfection studies demonstrate that interactions between two CK2 beta subunits take place in the absence of CK2 alpha. Together with results from previous biosynthetic labeling studies, these results suggest that formation of CK2 beta homodimers occurs before incorporation of catalytic subunits of CK2 into CK2 complexes. We also cotransfected Cos-7 cells with a deletion fragment of CK2 beta (i.e. Myc-beta 1-166) together with full-length hemagglutinin (HA)-tagged CK2 beta and/or CK2 alpha', Although complexes between Myc-beta 1-166 and HA-beta were readily detected, we obtained no evidence of direct interactions between Myc-beta 1-166 and HA-CK2 alpha', These results suggest that residues within the N-terminal 166 amino acids of CK2 beta are sufficient for interactions between CK2 beta subunits, whereas the C-terminal domain of CK2 beta is required for complex formation with the catalytic subunits of CK2. Finally, we observed that expression of full-length HA-beta promotes phosphorylation of Myc-beta 1-166 by HA-CK2 alpha'.	Univ Western Ontario, Hlth Sci Ctr, Dept Biochem, London, ON N6A 5C1, Canada	London Health Sciences Centre; University of Manitoba; Children's Hospital Research Institute of Manitoba; Western University (University of Western Ontario)	Litchfield, DW (corresponding author), Univ Western Ontario, Hlth Sci Ctr, Dept Biochem, London, ON N6A 5C1, Canada.	litchfi@julian.uwo.c	Litchfield, David/E-4636-2015	Litchfield, David/0000-0002-2425-6620				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; APPEL K, 1995, ONCOGENE, V11, P1971; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; BOLDYREFF B, 1993, BIOCHEMISTRY-US, V32, P12672, DOI 10.1021/bi00210a016; Boldyreff B, 1996, FEBS LETT, V379, P153, DOI 10.1016/0014-5793(95)01497-7; BOSC DG, 1995, J BIOL CHEM, V270, P25872, DOI 10.1074/jbc.270.43.25872; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Canossa M, 1996, J BIOL CHEM, V271, P5812, DOI 10.1074/jbc.271.10.5812; Chantalat L, 1999, EMBO J, V18, P2930, DOI 10.1093/emboj/18.11.2930; Chen MZ, 1997, P NATL ACAD SCI USA, V94, P9136, DOI 10.1073/pnas.94.17.9136; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; CHENWU JLP, 1988, MOL CELL BIOL, V8, P4981, DOI 10.1128/MCB.8.11.4981; DAYAMAKIN M, 1994, CANCER RES, V54, P2262; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Faust RA, 1996, CANCER LETT, V101, P31, DOI 10.1016/0304-3835(96)04110-9; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; GIETZ RD, 1995, J BIOL CHEM, V270, P13017, DOI 10.1074/jbc.270.22.13017; Guerra B, 1998, FEBS LETT, V434, P115, DOI 10.1016/S0014-5793(98)00962-4; Hagemann C, 1997, FEBS LETT, V403, P200, DOI 10.1016/S0014-5793(97)00011-2; HARLOW E, 1988, ANTIBODIES LAB MANUA, P526; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; Krehan A, 1996, BIOCHEMISTRY-US, V35, P4966, DOI 10.1021/bi951989i; Krehan A, 1999, MOL CELL BIOCHEM, V191, P21, DOI 10.1023/A:1006861102599; KUSK M, 1995, J MOL BIOL, V253, P703, DOI 10.1006/jmbi.1995.0584; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; Leroy D, 1997, J BIOL CHEM, V272, P20820, DOI 10.1074/jbc.272.33.20820; Li DX, 1997, J BIOL CHEM, V272, P3773, DOI 10.1074/jbc.272.6.3773; LITCHFIELD DW, 1990, FEBS LETT, V261, P117, DOI 10.1016/0014-5793(90)80650-8; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; Litchfield DW, 1996, BIOCHEM CELL BIOL, V74, P541, DOI 10.1139/o96-458; LUSCHER B, 1994, EUR J BIOCHEM, V220, P521, DOI 10.1111/j.1432-1033.1994.tb18651.x; Marin O, 1997, BIOCHEMISTRY-US, V36, P7192, DOI 10.1021/bi962885q; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Penner CG, 1997, J CELL BIOCHEM, V64, P525; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Shore LJ, 1997, J BIOL CHEM, V272, P12536, DOI 10.1074/jbc.272.19.12536; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; TARTARE S, 1991, J BIOL CHEM, V266, P9900; TOMBIN H, 1979, P NATL ACAD SCI USA, V76, P4350; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YENICE S, 1994, PROSTATE, V24, P11, DOI 10.1002/pros.2990240105	54	74	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5003	5010		10.1074/jbc.275.7.5003	http://dx.doi.org/10.1074/jbc.275.7.5003			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671540	hybrid			2022-12-27	WOS:000085378200066
J	Uren, A; Reichsman, F; Anest, V; Taylor, WG; Muraiso, K; Bottaro, DP; Cumberledge, S; Rubin, JS				Uren, A; Reichsman, F; Anest, V; Taylor, WG; Muraiso, K; Bottaro, DP; Cumberledge, S; Rubin, JS			Secreted frizzled-related protein-1 binds directly to wingless and is a biphasic modulator of Wnt signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; SPEMANN ORGANIZER; XENOPUS EMBRYOS; DROSOPHILA; GENE; FAMILY; ANTAGONIST; RECEPTORS; APOPTOSIS; CANCER	Secreted Frizzled-related protein-1 (sFRP-1) contains a cysteine-rich domain homologous to the putative Wnt-binding site of Frizzleds. To facilitate the biochemical and biological analysis of sFRP-1, we developed a mammalian recombinant expression system that yields similar to 3 mg of purified protein/liter of conditioned medium. Using this recombinant protein, we demonstrated that sFRP-1 and Wg (wingless) interact in enzyme-linked immunosorbent and co-precipitation assays. Surprisingly, a derivative lacking the cysteine-rich domain retained the ability to bind Wg, Cross-linking experiments performed with radioiodinated sFRP-1 provided definitive evidence that sFRP-1 and Wg bind directly to each other. Besides detecting a cross-linked complex consistent in size with 1:1 stoichiometry of sFRP-1 and Wg, we also observed a larger complex whose size suggested the presence of a second sFRP-1 molecule. The formation of both complexes was markedly enhanced by an optimal concentration of exogenous heparin, emphasizing the potential importance of heparan-sulfate proteoglycan in Wnt binding and signaling. sFRP-1 exerted a biphasic effect on Wg activity in an armadillo stabilization assay, increasing armadillo level at low concentrations but reducing it at higher concentrations. These results provide new insights about the Wnt binding and biological activity of sFRPs.	NCI, Cellular & Mol Biol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01002 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Massachusetts System; University of Massachusetts Amherst	Rubin, JS (corresponding author), NCI, Cellular & Mol Biol Lab, Div Basic Sci, NIH, Bldg 37,Rm 1E24,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.		Bottaro, Donald P/AAF-3853-2020; Bottaro, Donald P/F-8550-2010	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334; Reichsman, Frieda/0000-0003-4522-350X	NATIONAL CANCER INSTITUTE [Z01BC010251, ZIABC010251] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abu-Jawdeh G, 1999, LAB INVEST, V79, P439; Ashe HL, 1999, NATURE, V398, P427, DOI 10.1038/18892; Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bhat KM, 1998, CELL, V95, P1027, DOI 10.1016/S0092-8674(00)81726-2; Binari RC, 1997, DEVELOPMENT, V124, P2623; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Chang JHT, 1999, HUM MOL GENET, V8, P575, DOI 10.1093/hmg/8.4.575; CUMBERLEDGE S, 1993, NATURE, V363, P549, DOI 10.1038/363549a0; Dale TC, 1998, BIOCHEM J, V329, P209; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Devereux TR, 1999, ONCOGENE, V18, P4726, DOI 10.1038/sj.onc.1202858; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; Hoang B, 1996, J BIOL CHEM, V271, P26131, DOI 10.1074/jbc.271.42.26131; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Kispert A, 1996, DEVELOPMENT, V122, P3627; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Lin KM, 1997, P NATL ACAD SCI USA, V94, P11196, DOI 10.1073/pnas.94.21.11196; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Mayr T, 1997, MECH DEVELOP, V63, P109, DOI 10.1016/S0925-4773(97)00035-X; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller HAJ, 1999, DEVELOPMENT, V126, P577; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Pennisi E, 1998, SCIENCE, V281, P1438, DOI 10.1126/science.281.5382.1438; Pfeffer PL, 1997, INT J DEV BIOL, V41, P449; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Salic AN, 1997, DEVELOPMENT, V124, P4739; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wang YS, 1996, J BIOL CHEM, V271, P4468; Wolf V, 1997, FEBS LETT, V417, P385, DOI 10.1016/S0014-5793(97)01324-0; Xu QH, 1998, DEVELOPMENT, V125, P4767; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Zhang J, 1998, DEVELOPMENT, V125, P3075; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4	57	312	341	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4374	4382		10.1074/jbc.275.6.4374	http://dx.doi.org/10.1074/jbc.275.6.4374			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660608	hybrid, Green Submitted			2022-12-27	WOS:000085288800092
J	Ajenjo, N; Aaronson, DS; Ceballos, E; Richard, C; Leon, J; Crespo, P				Ajenjo, N; Aaronson, DS; Ceballos, E; Richard, C; Leon, J; Crespo, P			Myeloid leukemia cell growth and differentiation are independent of mitogen-activated protein kinase ERK1/2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; NIH 3T3 CELLS; MAP KINASE; MEGAKARYOCYTIC DIFFERENTIATION; CONSTITUTIVE ACTIVATION; HEMATOPOIETIC-CELLS; K562 CELLS; PHILADELPHIA-CHROMOSOME; SUSTAINED ACTIVATION; SIGNALING PATHWAYS	The mitogen-activated protein kinase ERK1/2 pathway is essential in the control of cell proliferation and differentiation in most cellular systems. As such, it has been considered a potential target for antineoplastic therapy. For this purpose, we have examined the role of ERK activation in myeloid leukemia cell growth and differentiation. Using a representative set of myeloid leukemia cell lines, we show that cell proliferation was not accompanied by increases on ERK1/2 activation, and mitogenic stimulation did not enhance ERK activity. Moreover, abolition of ERK function by the inhibitor PD98059 or by a dominant inhibitory mutant ERK2 had no significant effects on proliferation. With the aid of various differentiation inducers, we found that within the same cell line, differentiation to a given lineage could occur with and without ERK1/2 activation, depending on the stimulus. Also, a differentiator could have the same effect in the presence or absence of ERK stimulation, depending on the cell line. ERK inhibition did not affect the differentiation elicited by stimuli whose effects were accompanied by ERK activation. Finally, constitutive ERK activity was also ineffective on proliferation and differentiation. Thus, our results indicate that ERK1/2 activation is not an essential requirement for leukemic cell growth and differentiation.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Cantabria, Dept Mol Biol, Unidad Biol Mol Canc, Santander 39011, Spain; Hosp Univ Marques de Valdecilla, Hematol Serv, Santander 39010, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Universidad de Cantabria; Hospital Universitario Marques de Valdecilla (HUMV)	Crespo, P (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		Leon, Javier/K-4615-2014; Crespo, Piero/M-3273-2014	Ajenjo Diez, Nuria/0000-0002-9435-6467; Crespo, Piero/0000-0003-2825-7783; Leon, Javier/0000-0001-5803-0112				ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; Barge RMY, 1998, LEUKEMIA, V12, P699, DOI 10.1038/sj.leu.2400991; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; BRUNET A, 1994, ONCOGENE, V9, P3379; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Crespo P, 1998, BIOCHEM BIOPH RES CO, V245, P554, DOI 10.1006/bbrc.1998.8480; CRESPO P, 1994, J BIOL CHEM, V269, P21103; DELGADO MD, 1995, ONCOGENE, V10, P1659; Descamps S, 1998, J BIOL CHEM, V273, P16659, DOI 10.1074/jbc.273.27.16659; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Englaro W, 1998, J BIOL CHEM, V273, P9966, DOI 10.1074/jbc.273.16.9966; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GRENDINER E, 1998, J BIOL CHEM, V273, P10436; Hara T, 1998, BIOCHEM BIOPH RES CO, V247, P542, DOI 10.1006/bbrc.1998.8816; Heimbrook DC, 1998, CURR OPIN CELL BIOL, V10, P284, DOI 10.1016/S0955-0674(98)80152-X; Herrera R, 1998, EXP CELL RES, V238, P407, DOI 10.1006/excr.1997.3847; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Ihle JN, 1996, ADV CANCER RES, V68, P23, DOI 10.1016/S0065-230X(08)60351-6; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; Kinoshita E, 1997, FEBS LETT, V407, P343, DOI 10.1016/S0014-5793(97)00373-6; KISHI K, 1985, LEUKEMIA RES, V9, P381, DOI 10.1016/0145-2126(85)90060-8; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUBBERT M, 1988, BLOOD REV, V2, P121, DOI 10.1016/0268-960X(88)90034-3; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Melemed AS, 1997, BLOOD, V90, P3462, DOI 10.1182/blood.V90.9.3462; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; OKA H, 1995, CANCER RES, V55, P4182; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PERRIMON N, 1994, CURR OPIN CELL BIOL, V6, P260, DOI 10.1016/0955-0674(94)90145-7; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROMERO P, 1989, ONCOGENE, V4, P93; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; ROWLEY PT, 1981, EXP HEMATOL, V9, P32; Schramek H, 1997, J BIOL CHEM, V272, P11426; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Sundaram M, 1996, BIOESSAYS, V18, P473, DOI 10.1002/bies.950180609; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Towatari M, 1997, LEUKEMIA, V11, P479, DOI 10.1038/sj.leu.2400617; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VALTIERI M, 1987, J IMMUNOL, V138, P4042; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; Visser M, 1996, LEUKEMIA, V10, P1395; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; [No title captured]	54	31	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7189	7197		10.1074/jbc.275.10.7189	http://dx.doi.org/10.1074/jbc.275.10.7189			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702288	hybrid			2022-12-27	WOS:000085809600068
J	Gu, C; Cooper, DMF				Gu, C; Cooper, DMF			Ca2+, Sr2+, and Ba2+ identify distinct regulatory sites on adenylyl cyclase (AC) types VI and VIII and consolidate the apposition of capacitative cation entry channels and Ca2+-sensitive ACs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING MOTIF; C6-2B GLIOMA-CELLS; CALMODULIN; DOMAIN; SELECTIVITY; INHIBITION; EXPRESSION; DIVERSITY; FEEDBACK; BRAIN	Ca2+-sensitive adenylyl cyclases may act as early integrators of the two major second messenger-signaling pathways mediated by Ca2+ and cBMP, Ca2+ stimulation of adenylyl cyclase type I (ACI) and adenylyl cyclase type VIII (ACVIII) is mediated by calmodulin and the site on these adenylyl cyclases that interacts with calmodulin has been defined. By contrast, the mechanism whereby Ca2+ inhibits adenylyl cyclase type V (ACV) and adenylyl cyclase type VI (ACVI) is unknown. In this study, Ca2+, Sr2+, and Ba2+ were compared to probe the involvement of E-F hand-like domains in both Ca2+ stimulation and inhibition of ACVIII and ACVI, respectively. HEK 293 cells transfected with ACVIII cDNA and C6-2B glioma cells (where the endogenous adenylyl cyclases is predominantly ACM) were used to compare the effects of these three cations in in vitro and in vivo measurements. The in vitro data identified two Ca2+ regulatory sites for both ACVIII and ACVI, Striking;ly different potency series for these cations at mediating high affinity stimulation and inhibition of ACVIII and ACVI, respectively, effectively rule out the possibility that calmodulin or proteins utilizing similar Ca2+-binding motifs mediate inhibition of ACVI. On the other hand, the low affinity inhibition that is common to both ACVIII and ACVI showed virtually identical potency profiles for the IIa cation series, indicating a common site of action. Remarkably, whereas Sr2+ was rather ineffective at regulating these was rather ineffective at regulating these cyclases (particularly ACVI) in vitro, adequate concentrations accumulated in the vicinity of these enzymes as a consequence of capacitative cation entry to partially regulate both of these activities in vivo. This latter finding consolidates earlier observations that Ca2+-sensitive adenylyl cyclases detect and respond to capacitative cation entry rather than global cytosolic cation concentrations.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Neurosci, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cooper, DMF (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Box C-236,4200 E 9th Ave, Denver, CO 80262 USA.		Gu, Chen/E-3163-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032483] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32483] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CECH SY, 1980, MOL CELL BIOCHEM, V33, P67; CERDAN S, 1984, J BIOL CHEM, V259, P323; CHAO SH, 1984, MOL PHARMACOL, V26, P75; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; Cooper Dermot M.F., 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P23; COOPER DMF, 1994, METHOD ENZYMOL, V238, P71; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; CROUCH TH, 1980, BIOCHEMISTRY-US, V19, P3692, DOI 10.1021/bi00557a009; DEBERNARDI MA, 1993, BIOCHEM J, V293, P325, DOI 10.1042/bj2930325; Drake SK, 1996, BIOCHEMISTRY-US, V35, P6697, DOI 10.1021/bi952430l; Fagan KA, 1998, J BIOL CHEM, V273, P9297, DOI 10.1074/jbc.273.15.9297; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; Fraichard A, 1996, BIOCHIMIE, V78, P259, DOI 10.1016/0300-9084(96)82189-4; Gu C, 1999, J BIOL CHEM, V274, P8012, DOI 10.1074/jbc.274.12.8012; Guillou JL, 1999, J BIOL CHEM, V274, P35539, DOI 10.1074/jbc.274.50.35539; KLEE CB, 1980, ANNU REV BIOCHEM, V49, P489, DOI 10.1146/annurev.bi.49.070180.002421; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LI C, 1995, J BIOL CHEM, V270, P24898, DOI 10.1074/jbc.270.42.24898; Louzao MC, 1996, J BIOL CHEM, V271, P14807, DOI 10.1074/jbc.271.25.14807; McConnell TS, 1997, BIOCHEMISTRY-US, V36, P8293, DOI 10.1021/bi9700678; Nakahashi Y, 1997, J BIOL CHEM, V272, P18093, DOI 10.1074/jbc.272.29.18093; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; Scholich K, 1997, P NATL ACAD SCI USA, V94, P2915, DOI 10.1073/pnas.94.7.2915; STEER ML, 1975, J BIOL CHEM, V250, P2080; STEINBRUECKNER BE, 1995, ZBL BAKT-INT J MED M, V282, P54, DOI 10.1016/S0934-8840(11)80797-8; STOIBER H, 1995, MOL IMMUNOL, V32, P371, DOI 10.1016/0161-5890(94)00156-U; Stout JG, 1998, BIOCHEMISTRY-US, V37, P14860, DOI 10.1021/bi9812930; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1991, J BIOL CHEM, V266, P8595; WU ZL, 1993, J BIOL CHEM, V268, P23766; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209	40	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6980	6986		10.1074/jbc.275.10.6980	http://dx.doi.org/10.1074/jbc.275.10.6980			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702261	hybrid			2022-12-27	WOS:000085809600041
J	Mao, CG; Xu, RJ; Bielawska, A; Obeid, LM				Mao, CG; Xu, RJ; Bielawska, A; Obeid, LM			Cloning of an alkaline ceramidase from Saccharomyces cerevisiae - An enzyme with reverse (CoA-independent) ceramide synthase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; HUMAN ACID CERAMIDASE; FARBER-DISEASE; SERINE PALMITOYLTRANSFERASE; MOLECULAR-CLONING; SPHINGOSINE-1-PHOSPHATE; PURIFICATION; BIOSYNTHESIS; YEAST; DNA	Ceramide is not only a core intermediate of sphingolipids but also an important modulator of many cellular events including apoptosis, cell cycle arrest, senescence, differentiation, and stress responses. Its turnover may be tightly regulated. However, little is known about the regulation of its metabolism because most enzymes responsible for its synthesis and breakdown have yet to be cloned. Here we report the cloning and characterization of the yeast gene YPC1 (YBR183w) by screening Saccharomyces cerevisiae genes whose overexpression bestows resistance to fumonisin B1. We demonstrate that the yeast gene YPC1 encodes an alkaline ceramidase activity responsible for the breakdown of dihydroceramide and phytoceramide but not unsaturated ceramide. YPC1 ceramidase activity was confirmed by in vitro studies using an Escherichia coli expression system. Importantly, YPC1p also has reverse activity, catalyzing synthesis of phytoceramide from palmitic acid and phytosphingosine. This ceramide synthase activity is CoA-independent and is resistant to fumonisin B1, thus explaining why YPC1 was cloned as a fumonisin B1-resistant gene.	Med Univ S Carolina, Ralph H Johnson Vet Adm Hosp, Div Gen Internal Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem, Charleston, SC 29425 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina; Medical University of South Carolina	Obeid, LM (corresponding author), Div Gen Internal Med, 114 Doughty St,Rm 602 STB,POB 250779, Charleston, SC 29425 USA.	obeidl@musc.edu	xu, rui/GRX-5734-2022	obeid, lina/0000-0002-0734-0847	NATIONAL INSTITUTE ON AGING [R01AG016583, R29AG012467, R55AG012467] Funding Source: NIH RePORTER; NIA NIH HHS [AG12467, AG16583] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Beeler T, 1998, J BIOL CHEM, V273, P30688, DOI 10.1074/jbc.273.46.30688; BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; Bielawska A, 2000, METHOD ENZYMOL, V311, P499; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Chatelut M, 1996, CLIN CHIM ACTA, V245, P61, DOI 10.1016/0009-8981(95)06173-8; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; El Bawab S, 1999, J BIOL CHEM, V274, P27948, DOI 10.1074/jbc.274.39.27948; GATT S, 1966, J BIOL CHEM, V241, P3724; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 1997, BIOCHEM SOC T, V25, P1171, DOI 10.1042/bst0251171; HASSLER DF, 1993, ADV LIPID RES, V26, P49; Hertervig E, 1997, CANCER, V79, P448, DOI 10.1002/(SICI)1097-0142(19970201)79:3<448::AID-CNCR4>3.0.CO;2-E; ITO M, 1995, J BIOL CHEM, V270, P24370, DOI 10.1074/jbc.270.41.24370; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Li CM, 1998, GENOMICS, V50, P267, DOI 10.1006/geno.1998.5334; MANDALA SM, 1995, J ANTIBIOT, V48, P349, DOI 10.7164/antibiotics.48.349; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; Mitsutake S, 1997, ANAL BIOCHEM, V247, P52, DOI 10.1006/abio.1997.2022; MOMOI T, 1982, BIOCHEM J, V205, P419, DOI 10.1042/bj2050419; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Okino N, 1998, J BIOL CHEM, V273, P14368, DOI 10.1074/jbc.273.23.14368; PINTO WJ, 1992, J BACTERIOL, V174, P2575, DOI 10.1128/jb.174.8.2575-2581.1992; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; Skrzypek MS, 1999, J BACTERIOL, V181, P1134, DOI 10.1128/JB.181.4.1134-1140.1999; SPENCE MW, 1986, BIOCHEM CELL BIOL, V64, P400, DOI 10.1139/o86-056; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; SUGITA M, 1972, SCIENCE, V178, P1100, DOI 10.1126/science.178.4065.1100; WU WI, 1995, J BIOL CHEM, V270, P13171, DOI 10.1074/jbc.270.22.13171; YADA Y, 1995, J BIOL CHEM, V270, P12677, DOI 10.1074/jbc.270.21.12677	40	139	151	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6876	6884		10.1074/jbc.275.10.6876	http://dx.doi.org/10.1074/jbc.275.10.6876			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702247	hybrid			2022-12-27	WOS:000085809600027
J	Chin, MT; Maemura, K; Fukumoto, S; Jain, MK; Layne, MD; Watanabe, M; Hsieh, CM; Lee, ME				Chin, MT; Maemura, K; Fukumoto, S; Jain, MK; Layne, MD; Watanabe, M; Hsieh, CM; Lee, ME			Cardiovascular basic helix loop helix factor 1, a novel transcriptional repressor expressed preferentially in the developing and adult cardiovascular system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART TUBE FORMATION; SMOOTH-MUSCLE CELLS; EMBRYOS LACKING; DNA-BINDING; VENTRAL MORPHOGENESIS; HAIRY; GENE; PROTEINS; MOUSE; DEFECTS	We have cloned a cardiovascular-restricted basic helix-loop-helix factor that interacts with arylhydrocarbon receptor nuclear translocator (ARNT) in a yeast two-hybrid screen. Cardiovascular helix-loop-helix factor 1 (CHF1) is distantly related to the hairy family of transcriptional repressors, We analyzed its expression pattern during mouse embryo development. At day 8.5, the expression of CHF1 is first detected in the primitive ventricle of the primordial heart tube and persists throughout gestation. In rat hearts, this expression is down-regulated after birth, concurrent with terminal differentiation of cardiomyocytes, In the developing vasculature, CHF1 first appears in the dorsal aorta at day 9.0, which precedes the reported expression of smooth muscle cell markers, and persists into adulthood. In an in vitro system of smooth muscle cell differentiation, CHF1 mRNA was barely detectable in undifferentiated cells but was induced highly in differentiated smooth muscle cells, To determine whether CHF1 might affect the function of ARNT, we performed transfection studies, Co-transfection of CHF1 inhibited ARNT/EPAS1-dependent transcription by 85% and this inhibition is dose-dependent. In electrophoretic mobility studies, CHF1 inhibited the binding of the ARNT/EPAS1 heterodimer to its target site. Our data suggest that CHF1 functions as a transcriptional repressor and may play an important role in cardiovascular development.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Cardiovasc Div,Program Dev Cardiovasc Bi, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Lee, ME (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Cardiovasc Div,Program Dev Cardiovasc Bi, 75 Francis St,Thorn 11, Boston, MA 02115 USA.			Layne, Matthew/0000-0003-0007-4870	NHLBI NIH HHS [HL 03747, HL 03745, HL 57664] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057664] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; DAWSON SR, 1995, MOL CELL BIOL, V15, P6923; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Firulli AB, 1998, NAT GENET, V18, P266, DOI 10.1038/ng0398-266; Fisher A, 1998, BIOESSAYS, V20, P298, DOI 10.1002/(SICI)1521-1878(199804)20:4&lt;298::AID-BIES6&gt;3.0.CO;2-M; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Fishman MC, 1997, CELL, V91, P153, DOI 10.1016/S0092-8674(00)80397-9; Fishman MC, 1997, DEVELOPMENT, V124, P2099; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Issack PS, 1998, CELL GROWTH DIFFER, V9, P837; Jain MK, 1998, CIRC RES, V83, P980, DOI 10.1161/01.RES.83.10.980; Jain MK, 1998, J BIOL CHEM, V273, P5993, DOI 10.1074/jbc.273.11.5993; Jain MK, 1996, J BIOL CHEM, V271, P10194, DOI 10.1074/jbc.271.17.10194; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; Kho CJ, 1997, J BIOL CHEM, V272, P13426, DOI 10.1074/jbc.272.20.13426; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Lu JR, 1999, P NATL ACAD SCI USA, V96, P552, DOI 10.1073/pnas.96.2.552; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; Maemura K, 1999, J BIOL CHEM, V274, P31565, DOI 10.1074/jbc.274.44.31565; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; OBRIEN TX, 1993, P NATL ACAD SCI USA, V90, P5157, DOI 10.1073/pnas.90.11.5157; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Schneider S, 1996, BIOTECHNIQUES, V20, P960; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; YOSHIZUMI M, 1995, J CLIN INVEST, V95, P2275, DOI 10.1172/JCI117918; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	45	133	138	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6381	6387		10.1074/jbc.275.9.6381	http://dx.doi.org/10.1074/jbc.275.9.6381			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692439	hybrid			2022-12-27	WOS:000085654400051
J	Isawa, H; Yuda, M; Yoneda, K; Chinzei, Y				Isawa, H; Yuda, M; Yoneda, K; Chinzei, Y			The insect salivary protein, prolixin-S, inhibits factor IXa generation and Xase complex formation in the blood coagulation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; PHOSPHOLIPID-BINDING SITE; RHODNIUS-PROLIXUS; FACTOR-XIA; BLOODSUCKING INSECT; MEMBRANE-BINDING; NITRIC-OXIDE; FACTOR-X; TISSUE FACTOR; CDNA CLONING	Prolixin-S is a salivary anticoagulant of the blood-sucking insect, Rhodnius prolixus, and known as an inhibitor of the intrinsic Xase. We report here its inhibitory mechanisms with additional important anticoagulation activities. me found prolixin-S specifically bound to factor IS/IXa in the presence of Ca2+ ions. Light scattering and surface plasmon resonance studies showed that prolixin-S interfered with fatter IX/IXa binding to the phospholipid membrane, indicating that prolixin-S inhibit Xase activity of factor IXa by interference with its Xase complex formation. Furthermore, reconstitution experiments showed that prolixin-S binding to factor IX strongly inhibited factor IX alpha generation by factor XIa, We also found that prolixin-S inhibited factor IXa generation by factor Ma-tissue factor complex and factor IX alpha generation by factor Xa, These results suggest that prolixin-S inhibits both intrinsic and extrinsic coagulations by sequential inhibition of all coagulation pathways in which factor IC participates. It was also suggested that prolixin-S may bind to factor IX/IXa by recognizing conformational change of the Gla domain induced by Ca2+ binding.	Mie Univ, Sch Med, Dept Med Zool, Tsu, Mie 5140001, Japan	Mie University	Yuda, M (corresponding author), Mie Univ, Sch Med, Dept Med Zool, 2-174 Edobashi, Tsu, Mie 5140001, Japan.							ASTERMARK J, 1992, J BIOL CHEM, V267, P3249; CHAMPAGNE DE, 1995, J BIOL CHEM, V270, P8691, DOI 10.1074/jbc.270.15.8691; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Freedman SJ, 1996, J BIOL CHEM, V271, P16227, DOI 10.1074/jbc.271.27.16227; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAILANI D, 1993, SEMIN THROMB HEMOST, V19, P396, DOI 10.1055/s-2007-993291; HELLMANN K, 1965, NATURE, V207, P265, DOI 10.1038/207265a0; JACOBS M, 1994, J BIOL CHEM, V269, P25494; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; LAW JH, 1992, ANNU REV BIOCHEM, V61, P87, DOI 10.1146/annurev.bi.61.070192.000511; LAWSON JH, 1991, J BIOL CHEM, V266, P11317; LIEBMAN HA, 1987, J BIOL CHEM, V262, P7605; MANN KG, 1990, BLOOD, V76, P1; MANN KG, 1992, SEMIN HEMATOL, V29, P213; MORITA T, 1985, BIOCHEM BIOPH RES CO, V130, P841, DOI 10.1016/0006-291X(85)90493-0; MORITA T, 1991, J BIOCHEM, V110, P990, DOI 10.1093/oxfordjournals.jbchem.a123701; NAITO K, 1991, J BIOL CHEM, V266, P7353; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; RIBEIRO JMC, 1993, SCIENCE, V260, P539, DOI 10.1126/science.8386393; RIBEIRO JMC, 1987, ANNU REV ENTOMOL, V32, P463, DOI 10.1146/annurev.en.32.010187.002335; RIBEIRO JMC, 1995, BIOCHEM J, V308, P243, DOI 10.1042/bj3080243; SCHWALBE RA, 1989, J BIOL CHEM, V264, P20288; Sun JX, 1996, THROMB HAEMOSTASIS, V75, P573; Sun JX, 1998, INSECT BIOCHEM MOLEC, V28, P191, DOI 10.1016/S0965-1748(97)00115-X; Wojcik EGC, 1997, BIOCHEM J, V323, P629, DOI 10.1042/bj3230629; Yuda M, 1997, EUR J BIOCHEM, V249, P337, DOI 10.1111/j.1432-1033.1997.00337.x; Yuda Masao, 1996, Medical Entomology and Zoology, V47, P263; ZHONG DG, 1994, P NATL ACAD SCI USA, V91, P3574, DOI 10.1073/pnas.91.9.3574	29	34	38	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6636	6641		10.1074/jbc.275.9.6636	http://dx.doi.org/10.1074/jbc.275.9.6636			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692472	hybrid			2022-12-27	WOS:000085654400084
J	Ludowyke, RI; Holst, J; Mudge, LM; Sim, ATR				Ludowyke, RI; Holst, J; Mudge, LM; Sim, ATR			Transient translocation and activation of protein phosphatase 2A during mast cell secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA RBL-2H3 CELLS; SKELETAL-MUSCLE CELLS; FC-EPSILON-RI; KINASE-C; OKADAIC ACID; HISTAMINE-RELEASE; VACUOLE INHERITANCE; PHOSPHORYLATION; STIMULATION; RECEPTORS	Okadaic acid inhibits secretion from mast cells, suggesting a regulatory role for protein Ser/Thr phosphatases type I (PP1) and/or 2A (PP2A) in the secretory process. In unstimulated RBL-2H3 cells, okadaic acid pretreatment inhibited PP2A activity in both cytosol and membrane fractions, but inhibition of secretion correlated with inhibition of membrane-bound rather than cytosolic PP2A activity, Okadaic acid had very little effect on PPI activity. Stimulation of RBL-2H3 cells by antigen led to the activity and amount of PP2A in the membrane fraction increasing nearly 2-fold. In contrast, there was little change in the activity or distribution of PPI, Importantly, the translocation of PP2A was transient, coinciding with or marginally preceding the peak rate of secretion, suggesting a Link between PP2A translocation, activity, and secretion. Phorbol la-myristate 13-acetate plus the calcium ionophore A23187 induced a slower, prolonged rate of secretion that coincided with a similarly protracted translocation of PP2A to the membrane fraction. PP2A translocation is not the only event required for secretion as translocation was also induced by phorbol la-myristate 13-acetate, without resulting in secretion. These results indicate that increased protein dephosphorylation in the membrane fraction mediated by PP2A is required for mast cell secretion. To our knowledge, this is the first demonstration of a signal-mediated, rapid, transient translocation and activation of PP2A in membranes in any system.	Univ New S Wales, St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia; Univ Newcastle, Fac Med & Hlth Sci, Sch Biomed Sci, Discipline Med Biochem, Callaghan, NSW 2308, Australia	St Vincents Hospital Sydney; University of New South Wales Sydney; University of Newcastle	Ludowyke, RI (corresponding author), St Vincents Hosp, Ctr Immunol, Victoria St, Darlinghurst, NSW 2010, Australia.	r.ludowyke@efi.unsw.edu.au	Holst, Jeff/H-7634-2012	Holst, Jeff/0000-0002-0377-9318				Beaven MA, 1996, CURR OPIN IMMUNOL, V8, P766, DOI 10.1016/S0952-7915(96)80002-1; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BEGUM N, 1995, J BIOL CHEM, V270, P709, DOI 10.1074/jbc.270.2.709; Begum N, 1996, J BIOL CHEM, V271, P31166, DOI 10.1074/jbc.271.49.31166; BOTANA LM, 1992, AGENTS ACTIONS, V37, P1, DOI 10.1007/BF01987883; BRAUTIGAN DL, 1995, SEMIN CANCER BIOL, V6, P211, DOI 10.1006/scbi.1995.0028; Brockdorff J, 1997, TISSUE ANTIGENS, V49, P228, DOI 10.1111/j.1399-0039.1997.tb02743.x; COGHLAN VM, 1995, BIOCHEM SOC T, V23, P592, DOI 10.1042/bst0230592; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; Collins E, 1998, METH MOL B, V93, P79; CONRADT B, 1994, J CELL BIOL, V126, P99, DOI 10.1083/jcb.126.1.99; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; CUNHAMELO JR, 1989, J IMMUNOL, V143, P2617; ESTEVEZ MD, 1994, BIOCHEM PHARMACOL, V47, P591, DOI 10.1016/0006-2952(94)90194-5; Faux MC, 1997, J BIOL CHEM, V272, P17038, DOI 10.1074/jbc.272.27.17038; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; Guo ZH, 1998, CELL, V94, P537, DOI 10.1016/S0092-8674(00)81594-9; Hansra G, 1996, J BIOL CHEM, V271, P32785, DOI 10.1074/jbc.271.51.32785; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KAWASUGI K, 1995, CELL MOTIL CYTOSKEL, V31, P215, DOI 10.1002/cm.970310305; Kitani S, 1996, INT ARCH ALLERGY IMM, V110, P339, DOI 10.1159/000237326; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Lloyd HGE, 1998, PULM PHARMACOL THER, V11, P41, DOI 10.1006/pupt.1998.0113; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; Ludowyke RI, 1998, CELL BIOL INT, V22, P855, DOI 10.1006/cbir.1998.0332; Ludowyke RI, 1996, J IMMUNOL, V157, P5130; LUDOWYKE RI, 1994, CELL MOTIL CYTOSKEL, V29, P354, DOI 10.1002/cm.970290408; Mukhopadhyay S, 1998, J BIOL CHEM, V273, P30039, DOI 10.1074/jbc.273.45.30039; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PEACHELL PT, 1993, J IMMUNOL, V151, P3808; PFEIFFER JR, 1994, J IMMUNOL, V152, P270; Revan S, 1996, J BIOL CHEM, V271, P17114, DOI 10.1074/jbc.271.29.17114; SCHULMAN ES, 1993, CRIT REV IMMUNOL, V13, P35; SELDIN DC, 1985, P NATL ACAD SCI USA, V82, P3871, DOI 10.1073/pnas.82.11.3871; Sim ATR, 1998, NEUROCHEM RES, V23, P487, DOI 10.1023/A:1022422332404; SIM ATR, 1994, J NEUROCHEM, V62, P1552; SIM ATR, 1991, MOL NEUROBIOL, V5, P229, DOI 10.1007/BF02935548; SRINIVASAN M, 1994, J BIOL CHEM, V269, P12514; TAKEI M, 1993, J PHARM PHARMACOL, V45, P750, DOI 10.1111/j.2042-7158.1993.tb07102.x; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; WHITE KN, 1988, J IMMUNOL, V141, P942	47	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6144	6152		10.1074/jbc.275.9.6144	http://dx.doi.org/10.1074/jbc.275.9.6144			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692405	hybrid			2022-12-27	WOS:000085654400017
J	Trim, JE; Samra, SK; Arthur, MJP; Wright, MC; McAulay, M; Beri, R; Mann, DA				Trim, JE; Samra, SK; Arthur, MJP; Wright, MC; McAulay, M; Beri, R; Mann, DA			Upstream tissue inhibitor of metalloproteinases-1 (TIMP-1) element-1, a novel and essential regulatory DNA motif in the human TIMP-1 gene promoter, directly interacts with a 30-kDa nuclear protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-POTENTIATING ACTIVITY; EXTRACELLULAR-MATRIX; BIOLOGICAL FUNCTIONS; CELL APOPTOSIS; BINDING-SITES; VIRUS TYPE-1; B-CELLS; EXPRESSION; TRANSCRIPTION; MECHANISMS	Elevated expression of the tissue inhibitor of metalloproteinases-l (TIMP-1) protein and mRNA has been reported in human diseases including cancers and tissue fibrosis. Regulation of TIMP-1 gene expression is mainly mediated at the level of gene transcription and involves the activation of several well known transcription factors including those belonging to the AP-1, STAT, and Pea3/Ets families. In the current study, we have used DNase-l footprinting to identify a new regulatory element (5'-TGTGGTTTCCG-3') present in the human TIMP-1 gene promoter. Mutagenesis and transfection studies in culture-activated rat hepatic stellate cells and the human Jurkat T cell line demonstrated that the new element named upstream TIMP-1 element-1 (UTE-1) is essential for transcriptional activity of the human TIMP-1 promoter. Electrophoretic mobility shift assay studies revealed that UTE-1 can form protein-DNA complexes of distinct mobilities with nuclear extracts from a variety of mammalian cell types and showed that induction of a high mobility UTE-1 complex is associated with culture activation of freshly isolated rat hepatic stellate cells. A combination of W-cross-linking and Southwestern blotting techniques demonstrated that UTE I directly interacts with a 30-kDa nuclear protein that appears to be present in all cell types tested. We conclude that UTE-1 is a novel regulatory element that in combination with its cellular binding proteins may be an important component of the mechanisms controlling TIMP-1 expression in normal and pathological states.	Southampton Gen Hosp, Div Cell & Mol Med, Liver Res Grp, Southampton SO16 6YD, Hants, England; Zeneca Pharmaceut, Macclesfield SK10 4TG, Cheshire, England	University of Southampton	Mann, DA (corresponding author), Southampton Gen Hosp, Div Cell & Mol Med, Liver Res Grp, S Acad Block,Level D,Tremona Rd, Southampton SO16 6YD, Hants, England.			Wright, Matthew/0000-0003-3167-6743; Mann, Derek/0000-0003-0950-243X				Alexander CM, 1996, J CELL BIOL, V135, P1669, DOI 10.1083/jcb.135.6.1669; ARTHUR MJP, 1989, J CLIN INVEST, V84, P1076, DOI 10.1172/JCI114270; Bahr MJ, 1999, HEPATOLOGY, V29, P839, DOI 10.1002/hep.510290333; Batchelor WB, 1998, PROG CARDIOVASC DIS, V41, P35, DOI 10.1016/S0033-0620(98)80021-2; Benyon RC, 1996, GASTROENTEROLOGY, V110, P821, DOI 10.1053/gast.1996.v110.pm8608892; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Bugno M, 1995, NUCLEIC ACIDS RES, V23, P5041, DOI 10.1093/nar/23.24.5041; CAMPBELL CE, 1991, J BIOL CHEM, V266, P7199; Cawson T, 1998, MOL MED TODAY, V4, P130, DOI 10.1016/S1357-4310(97)01192-1; Clark IM, 1997, BIOCHEM J, V324, P611, DOI 10.1042/bj3240611; COULOMBE B, 1988, MOL CELL BIOL, V8, P3227, DOI 10.1128/MCB.8.8.3227; DENHARDT DT, 1993, PHARMACOL THERAPEUT, V59, P329, DOI 10.1016/0163-7258(93)90074-N; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doyle GAR, 1997, BIOCHEMISTRY-US, V36, P2492, DOI 10.1021/bi962161e; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; EDWARDS DR, 1996, J OBES RELAT META S3, V20, P9; Elsharkawy AM, 1999, HEPATOLOGY, V30, P761, DOI 10.1002/hep.510300327; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; GEWART DR, 1987, EMBO J, V6, P651; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Guedez L, 1998, BLOOD, V92, P1342, DOI 10.1182/blood.V92.4.1342.416k22_1342_1349; HAYAKAWA T, 1990, FEBS LETT, V268, P125, DOI 10.1016/0014-5793(90)80989-V; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; Iredale JP, 1996, HEPATOLOGY, V24, P176, DOI 10.1002/hep.510240129; IREDALE JP, 1995, CLIN SCI, V89, P75, DOI 10.1042/cs0890075; Jackson S. P., 1993, Gene transcription: a practical approach., P189; KOSSAKOWSKA AE, 1991, BLOOD, V77, P2475; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; MANSOOR A, 1997, MODERN PATHOL, V10, pA130; Mimori K, 1997, BRIT J CANCER, V76, P531, DOI 10.1038/bjc.1997.420; Newby AC, 1999, CARDIOVASC RES, V41, P345, DOI 10.1016/S0008-6363(98)00286-7; Ree AH, 1997, CLIN CANCER RES, V3, P1623; Reynolds J J, 1996, Oral Dis, V2, P70; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; StetlerStevenson M, 1997, BLOOD, V89, P1708, DOI 10.1182/blood.V89.5.1708.1708_1708_1715; UCHIJIMA M, 1994, J BIOL CHEM, V269, P14946; VanLint C, 1997, J VIROL, V71, P6113, DOI 10.1128/JVI.71.8.6113-6127.1997; Werb Z, 1998, ANN NY ACAD SCI, V857, P110, DOI 10.1111/j.1749-6632.1998.tb10111.x	43	49	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6657	6663		10.1074/jbc.275.9.6657	http://dx.doi.org/10.1074/jbc.275.9.6657			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692475	hybrid			2022-12-27	WOS:000085654400087
J	Yeow, WS; Au, WC; Juang, YT; Fields, CD; Dent, CL; Gewert, DR; Pitha, PM				Yeow, WS; Au, WC; Juang, YT; Fields, CD; Dent, CL; Gewert, DR; Pitha, PM			Reconstitution of virus-mediated expression of interferon alpha genes in human fibroblast cells by ectopic interferon regulatory factor-7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; DIFFERENTIAL EXPRESSION; A GENES; BETA ENHANCEOSOME; RESPONSE ELEMENT; PROMOTER REGION; IN-VIVO; IFN; ACTIVATION; INFECTION	Type I interferons constitute an important part of the innate immune response against viral infection. Unlike the expression of interferon (IFN) B gene, the expression of IFNA genes is restricted to the lymphoid cells, Both IFN regulatory factor 3 and 7 (IRF-3 and IRF-7) were suggested to play positive roles in these genes expression. However, their role in the differential expression of individual subtypes of human IFNA genes is unknown. Using various IFNA reporter constructs in transient transfection assay we found that overexpression of IRF-3 in virus infected 2FTGH cells selectively activated IFNA1 VRE, whereas IRF-7 was able to activate IFNA1, A2, and A4, The binding of recombinant IRF-7 and IRF-3 to these VREs correlated with their transcriptional activation. Nuclear proteins from infected and uninfected IRF-7 expressing 2FTGH cells formed multiple DNA-protein complexes with IFNA1 VRE, in which two unique DNA-protein complexes containing IRF-7 were detected, In 2FTGH cells, virus stimulated expression of IFNB gene but none of the IFNA genes. Reconstitution of IRF-7 synthesis in these cells resulted, upon virus infection, in the activation of seven endogenous IFNA genes in which IFNA1 predominated. These studies suggest that IRF-7 is a critical determinant for the induction of IFNA genes in infected cells.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21231 USA; Glaxo Wellcome Res & Dev, Beckenham BR3 3BS, Kent, England; QT Genet, Cambridge CB4 3PE, England	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; GlaxoSmithKline	Pitha, PM (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, 615 Orleans St, Baltimore, MD 21231 USA.			Yeow, Wen-Shuz/0000-0002-0436-9636	PHS HHS [A119737] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AU WC, 1993, J BIOL CHEM, V268, P24032; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; BISAT F, 1988, NUCLEIC ACIDS RES, V16, P6067, DOI 10.1093/nar/16.13.6067; Braganca J, 1997, J BIOL CHEM, V272, P22154, DOI 10.1074/jbc.272.35.22154; Burysek L, 1999, J VIROL, V73, P7334; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Cella M, 1999, NAT MED, V5, P919, DOI 10.1038/11360; DEMAEYER E, 1988, INTERFERONS OTHER CY; Dent CL, 1996, EUR J BIOCHEM, V236, P895, DOI 10.1111/j.1432-1033.1996.t01-1-00895.x; Dent CL, 1996, J INTERF CYTOK RES, V16, P99, DOI 10.1089/jir.1996.16.99; DIAZ MO, 1995, SEMIN VIROL, V6, P143, DOI 10.1006/smvy.1995.0019; Duncan GS, 1996, J EXP MED, V184, P2043, DOI 10.1084/jem.184.5.2043; Erlandsson L, 1998, CURR BIOL, V8, P223, DOI 10.1016/S0960-9822(98)70086-7; Escalante CR, 1998, NATURE, V391, P103, DOI 10.1038/34224; Fujii Y, 1999, EMBO J, V18, P5028, DOI 10.1093/emboj/18.18.5028; Genin P, 1995, NUCLEIC ACIDS RES, V23, P5055; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HISCOTT J, 1984, NUCLEIC ACIDS RES, V12, P3727, DOI 10.1093/nar/12.9.3727; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; HOSSHOMFELD A, 1989, VIROLOGY, V173, P539, DOI 10.1016/0042-6822(89)90566-7; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; KELLEY KA, 1985, NUCLEIC ACIDS RES, V13, P825, DOI 10.1093/nar/13.3.825; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lopez S, 1997, J BIOL CHEM, V272, P22788, DOI 10.1074/jbc.272.36.22788; LUND B, 1985, J INTERFERON RES, V5, P229, DOI 10.1089/jir.1985.5.229; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Marrack P, 1999, J EXP MED, V189, P521, DOI 10.1084/jem.189.3.521; Masumi A, 1999, MOL CELL BIOL, V19, P1810; MEGYERI K, 1995, MOL CELL BIOL, V15, P2207; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; RAJ NBK, 1988, J BIOL CHEM, V263, P8943; RAJ NBK, 1991, J BIOL CHEM, V266, P11360; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Salkowski CA, 1996, J IMMUNOL, V156, P3107; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Tamura Tomohiko, 1997, Leukemia (Basingstoke), V11, P439; UTSUMI J, 1992, INTERFERON PRINCIPLE, P107; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	51	83	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6313	6320		10.1074/jbc.275.9.6313	http://dx.doi.org/10.1074/jbc.275.9.6313			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692430	hybrid			2022-12-27	WOS:000085654400042
J	Bhakta, NR; Garcia, AM; Frank, EH; Grodzinsky, AJ; Morales, TI				Bhakta, NR; Garcia, AM; Frank, EH; Grodzinsky, AJ; Morales, TI			The insulin-like growth factors (IGFs) I and II bind to articular cartilage via the IGF-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN OSTEOARTHRITIC CHONDROCYTES; INCREASED EXPRESSION; SYNOVIAL-FLUID; HEPARIN; MATRIX; PROTEOGLYCANS; STIMULATION; COMPLEXES; EXPLANTS; IGFBP-4	Bovine articular cartilage discs (3 mm diameter x 400 mu m thick) were equilibrated in buffer containing I-125-insulin-like growth factor (IGF)-I (4 degrees C) +/- unlabeled IGF-I or IGF-II, Competition for binding to cartilage discs by each unlabeled IGF was concentration-dependent, with ED50 values for inhibition of I-125-IGF-I binding of 11 and 10 nM for IGF-I and -II, respectively, and saturation by 50 nM, By contrast, an analog of IGF-I with very low affinity for the insulin-like growth factor-binding proteins (IGF-BPs), des-(1-3)-IGF-I, was not competitive with I-125-IGF-I for cartilage binding even at 100-400 nM. Binding of the I-125-labeled IGF-II isoform to cartilage was competed for by unlabeled ICE-I or -II, with ED(50)s of 160 and 8 nM, respectively. This probably reflected the differential affinities of the endogenous IGF-BPs (IGF-BP-6 and -2) for IGF-II/IGF-I. Transport of I-125-IGF-I was also measured in an apparatus that allows diffusion only across the discs (400 mu m), by addition to one side and continuous monitoring of efflux on the other side. The time lag for transport of I-125-IGF was 266 min, an order of magnitude longer than the theoretical prediction for free diffusion in the matrix. I-125-IGF-I transport then reached a steady state rate (% efflux of total added I-125-IGF/unit time), which was subsequently accelerated similar to 2-fold by addition of an excess of unlabeled IGF-I, Taken together, these results indicate that IGF binding to cartilage, mostly through the IGF-BPs, regulates the transport of IC;Fs in articular cartilage, probably contributing to the control of their paracrine activities.	Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; MIT, Ctr Biomed Engn, Cambridge, MA 02139 USA; MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Morales, TI (corresponding author), Massachusetts Gen Hosp, Dept Orthopaed Surg, White Bldg R426, Boston, MA 02114 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033236] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR33236] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARAI T, 1994, J BIOL CHEM, V269, P20388; Arai T, 1996, ENDOCRINOLOGY, V137, P4571, DOI 10.1210/en.137.11.4571; Ballard FJ, 1996, INT J BIOCHEM CELL B, V28, P1085; Bastian SEP, 1997, J CELL PHYSIOL, V170, P290, DOI 10.1002/(SICI)1097-4652(199703)170:3<290::AID-JCP10>3.0.CO;2-J; CollettSolberg PF, 1996, ENDOCRIN METAB CLIN, V25, P591, DOI 10.1016/S0889-8529(05)70342-X; Crank J., 1975, MATH DIFFUSION; DORE S, 1994, ARTHRITIS RHEUM-US, V37, P253, DOI 10.1002/art.1780370215; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; Fowlkes JL, 1997, ENDOCRINOLOGY, V138, P2280, DOI 10.1210/en.138.6.2280; FRANCIS GL, 1993, BIOCHEM J, V293, P713, DOI 10.1042/bj2930713; Garcia AM, 1998, J ORTHOPAED RES, V16, P734, DOI 10.1002/jor.1100160616; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kang Y, 1998, J ORTHOPAED RES, V16, P551, DOI 10.1002/jor.1100160505; LORD APD, 1994, J ENDOCRINOL, V141, P505, DOI 10.1677/joe.0.1410505; LUYTEN FP, 1988, ARCH BIOCHEM BIOPHYS, V267, P416, DOI 10.1016/0003-9861(88)90047-1; MCQUILLAN DJ, 1986, BIOCHEM J, V240, P423, DOI 10.1042/bj2400423; MIDDLETON JFS, 1992, ANN RHEUM DIS, V51, P440, DOI 10.1136/ard.51.4.440; Morales TI, 1997, ARCH BIOCHEM BIOPHYS, V343, P164, DOI 10.1006/abbi.1997.0166; OH Y, 1993, ENDOCRINOLOGY, V132, P1337, DOI 10.1210/en.132.3.1337; OHARA BP, 1990, ANN RHEUM DIS, V49, P536, DOI 10.1136/ard.49.7.536; Olney RC, 1996, J CLIN ENDOCR METAB, V81, P1096, DOI 10.1210/jc.81.3.1096; Quinn TM, 1998, J CELL SCI, V111, P573; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; RECHLER MM, 1990, HDB EXPT PHARM, V95, P263; RHOGHANI M, 1991, J CLIN ENDOCR METAB, V73, P658; ROBERTSON JG, 1999, AM J PHYSIOL, V276, pE660; Russo VC, 1997, ENDOCRINOLOGY, V138, P4858, DOI 10.1210/en.138.11.4858; Schneiderman R, 1995, ARCH BIOCHEM BIOPHYS, V324, P159, DOI 10.1006/abbi.1995.9914; Schneiderman R, 1995, ARCH BIOCHEM BIOPHYS, V324, P173, DOI 10.1006/abbi.1995.9913; SUNDARRAJ N, 1995, J CELL SCI, V108, P2663; Tardif G, 1996, ARTHRITIS RHEUM, V39, P968, DOI 10.1002/art.1780390614; Tavera C, 1996, OSTEOARTHR CARTILAGE, V4, P263, DOI 10.1016/S1063-4584(05)80104-9; YANG IM, 1994, HDB ENDOCRINE RES TE, P181	33	57	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5860	5866		10.1074/jbc.275.8.5860	http://dx.doi.org/10.1074/jbc.275.8.5860			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681577	hybrid			2022-12-27	WOS:000085474500084
J	Pond, AL; Scheve, BK; Benedict, AT; Petrecca, K; Van Wagoner, DR; Shrier, A; Nerbonne, JM				Pond, AL; Scheve, BK; Benedict, AT; Petrecca, K; Van Wagoner, DR; Shrier, A; Nerbonne, JM			Expression of distinct ERG proteins in rat, mouse, and human heart - Relation to functional I-Kr channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG QT SYNDROME; RECTIFIER K+ CURRENT; HUMAN VENTRICULAR MYOCYTES; DELAYED RECTIFIER; POTASSIUM CHANNEL; CARDIAC-ARRHYTHMIA; 2 COMPONENTS; HERG; SUBUNITS; FAMILY	One form of inherited long QT syndrome, LQT2, results from mutations in HERG1, the human ether-a-go-go-related gene, which encodes a voltage-gated K+ channel alpha subunit. Heterologous expression of HERG1 gives rise to K+ currents that are similar (but not identical) to the rapid component of delayed rectification, I-Kr in cardiac myocytes, In addition, N-terminal splice variants of HERG1 and MERG1 (mouse ERG1) referred to as HERG1b and NIERG1b have been cloned and suggested to play roles in the generation of functional I-Kr channels. In the experiments here, antibodies generated against HERG1 were used to examine ERG1 protein expression in heart and in brain. In Western blots of extracts of QT-6 cells expressing HERG1, MERG1, dr RERG1 (rat ERG1) probed with antibodies targeted against the C terminus of HERG1, a single 155-kDa protein is identified, whereas a 95-kDa band is evident in blots of extracts from cells expressing MERG1b or HEBG1b. In immunoblots of fractionated rat (and mouse) brain and heart membrane proteins, however, two prominent high molecular mass proteins of 165 and 205 kDa were detected. Following treatment with glycopeptidase F, the 165- and 205-kDa proteins were replaced by two new bands at 175 and 130 kDa, suggesting that ERG1 is differentially glycosylated in rat/mouse brain and heart. In human heart, a single HERG1 protein with an apparent molecular mass of 145 kDa is evident. In rats, ERG1 protein (and I-Kr) expression is higher in atria than ventricles, whereas in humans, HERG1 expression is higher in ventricular, than atrial, tissue. Taken together, these results suggest that the N-terminal alternatively spliced variants of ERG1 (i.e. ERG1b) are not expressed at the protein level in rat, mouse, or human heart and that these variants do not, therefore, play roles in the generation of functional cardiac I-Kr channels.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada; Cleveland Clin Fdn, Cleveland, OH 44195 USA	Washington University (WUSTL); McGill University; Cleveland Clinic Foundation	Nerbonne, JM (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.		Van Wagoner, David R/C-6783-2008	Van Wagoner, David R/0000-0001-8250-9828; Pond, Amber/0000-0002-2836-889X				Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; ABRAHAMSSON C, 1994, CARDIOVASC RES, V28, P337, DOI 10.1093/cvr/28.3.337; ALTSCHULD R, 1980, J MOL CELL CARDIOL, V12, P1383, DOI 10.1016/0022-2828(80)90123-6; APKON M, 1991, J GEN PHYSIOL, V97, P973, DOI 10.1085/jgp.97.5.973; BARRY DM, 1995, CIRC RES, V77, P361, DOI 10.1161/01.RES.77.2.361; Barry DM, 1996, ANNU REV PHYSIOL, V58, P363, DOI 10.1146/annurev.ph.58.030196.002051; Bauer CK, 1998, RECEPTOR CHANNEL, V6, P19; Brahmajothi MV, 1997, CIRC RES, V81, P128, DOI 10.1161/01.RES.81.1.128; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; JIANG CA, 1994, NAT GENET, V8, P141, DOI 10.1038/ng1094-141; Keating MT, 1996, MEDICINE, V75, P1, DOI 10.1097/00005792-199601000-00001; KORN SJ, 1989, J GEN PHYSIOL, V94, P789, DOI 10.1085/jgp.94.5.789; Kupershmidt S, 1998, J BIOL CHEM, V273, P27231, DOI 10.1074/jbc.273.42.27231; LeesMiller JP, 1997, CIRC RES, V81, P719; Li GR, 1996, CIRC RES, V78, P689, DOI 10.1161/01.RES.78.4.689; LIU DW, 1995, CIRC RES, V76, P351, DOI 10.1161/01.RES.76.3.351; London B, 1997, CIRC RES, V81, P870; London B, 1998, BIOPHYS J, V74, pA26; MAIMONE MM, 1993, NEURON, V11, P53, DOI 10.1016/0896-6273(93)90270-2; MAYS DJ, 1995, J CLIN INVEST, V96, P382; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; Petrecca K, 1999, J PHYSIOL-LONDON, V515, P41, DOI 10.1111/j.1469-7793.1999.041ad.x; RODEN DM, 1995, J CARDIOVASC ELECTR, V6, P1023, DOI 10.1111/j.1540-8167.1995.tb00379.x; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SANGUINETTI MC, 1991, AM J PHYSIOL, V260, pH393, DOI 10.1152/ajpheart.1991.260.2.H393; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; SCHWARTZ PJ, 1975, AM HEART J, V89, P378, DOI 10.1016/0002-8703(75)90089-7; Shi WM, 1997, J NEUROSCI, V17, P9423; Snyders DJ, 1996, MOL PHARMACOL, V49, P949; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; VanWagoner DR, 1996, AM J PHYSIOL-HEART C, V271, pH937, DOI 10.1152/ajpheart.1996.271.3.H937; VELDKAMP MW, 1995, CIRCULATION, V92, P3497, DOI 10.1161/01.CIR.92.12.3497; WANG ZG, 1994, CARDIOVASC RES, V28, P1540, DOI 10.1093/cvr/28.10.1540; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Wymore RS, 1997, CIRC RES, V80, P261, DOI 10.1161/01.RES.80.2.261; Xu HD, 1996, J GEN PHYSIOL, V108, P405, DOI 10.1085/jgp.108.5.405; YANG T, 1995, CIRC RES, V77, P1246, DOI 10.1161/01.RES.77.6.1246; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061	42	129	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5997	6006		10.1074/jbc.275.8.5997	http://dx.doi.org/10.1074/jbc.275.8.5997			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681594	hybrid			2022-12-27	WOS:000085474500101
J	Sato, K; Homma, M				Sato, K; Homma, M			Functional reconstitution of the Na+-driven polar flagellar motor component of Vibrio alginolyticus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; PROTEIN TRANSLOCATION; ALKALOPHILIC BACILLUS; MEMBRANE TOPOLOGY; ROTATION; MOTILITY; SEQUENCE; COMPLEX; PROTON	The bacterial flagellar motor is a molecular machine that couples the influx of specific ions to the generation of the force necessary to drive rotation of the flagellar filament. Four integral membrane proteins, PomA, PomB, MotX, and MotY, have been suggested to be directly involved in torque generation of the Na+-driven polar flagellar motor of Vibrio alginolyticus. In the present study, we report the isolation of the functional component of the torque-generating unit. The purified protein complex appears to consist of PomA and PomB and contains neither MotX nor MotY. The PomA/B protein, reconstituted into proteoliposomes, catalyzed Na-22(+) influx in response to a potassium diffusion potential. Sodium uptake was abolished by the presence of Lif ions and phenamil, a sodium channel blocker. This is the first demonstration of a purification and functional reconstitution of the bacterial flagellar motor component involved in torque generation, in addition, this study demonstrates that the Nac-driven motor component, PomA and PomB, forms the Na+-conducting channel.	Nagoya Univ, Div Biol Sci, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University	Sato, K (corresponding author), Nagoya Univ, Div Biol Sci, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.	m47004a@nucc.cc.nagoya-u.ac.jp						AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; Asai Y, 1997, J BACTERIOL, V179, P5104, DOI 10.1128/jb.179.16.5104-5110.1997; Asai Y, 1999, J BACTERIOL, V181, P6332, DOI 10.1128/JB.181.20.6332-6338.1999; ATSUMI T, 1990, J BACTERIOL, V172, P1634, DOI 10.1128/jb.172.3.1634-1639.1990; BERG HC, 1995, BIOPHYS J, V68, pS163; BLAIR DF, 1990, CELL, V60, P439, DOI 10.1016/0092-8674(90)90595-6; BLAIR DF, 1991, J BACTERIOL, V173, P4049, DOI 10.1128/jb.173.13.4049-4055.1991; BLAIR DF, 1995, ANNU REV MICROBIOL, V49, P489, DOI 10.1146/annurev.mi.49.100195.002421; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CHUN SY, 1988, SCIENCE, V239, P276, DOI 10.1126/science.2447650; DEAN GE, 1984, J BACTERIOL, V159, P991, DOI 10.1128/JB.159.3.991-999.1984; DEMOT R, 1994, MOL MICROBIOL, V12, P333; DeRosier DJ, 1998, CELL, V93, P17, DOI 10.1016/S0092-8674(00)81141-1; FRANCIS NR, 1994, J MOL BIOL, V235, P1261, DOI 10.1006/jmbi.1994.1079; Garza AG, 1996, J MOL BIOL, V258, P270, DOI 10.1006/jmbi.1996.0249; GARZA AG, 1995, P NATL ACAD SCI USA, V92, P1970, DOI 10.1073/pnas.92.6.1970; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; IMAE Y, 1989, J BIOENERG BIOMEMBR, V21, P705, DOI 10.1007/BF00762688; IRIKURA VM, 1993, J BACTERIOL, V175, P802, DOI 10.1128/JB.175.3.802-810.1993; Jaques S, 1999, P NATL ACAD SCI USA, V96, P5740, DOI 10.1073/pnas.96.10.5740; KABACK HR, 1988, ANNU REV PHYSIOL, V50, P243; Kaim G, 1998, EMBO J, V17, P5887, DOI 10.1093/emboj/17.20.5887; Kojima S, 1999, J MOL BIOL, V285, P1537, DOI 10.1006/jmbi.1998.2377; LIU JZ, 1990, J BACTERIOL, V172, P5236, DOI 10.1128/jb.172.9.5236-5244.1990; Lloyd SA, 1996, J BACTERIOL, V178, P223, DOI 10.1128/jb.178.1.223-231.1996; MCCARTER LL, 1994, J BACTERIOL, V176, P5988, DOI 10.1128/jb.176.19.5988-5998.1994; MCCARTER LL, 1994, J BACTERIOL, V176, P4219, DOI 10.1128/jb.176.14.4219-4225.1994; MEISTER M, 1987, CELL, V49, P643, DOI 10.1016/0092-8674(87)90540-X; Muramoto K, 1998, MOL MICROBIOL, V29, P1191, DOI 10.1046/j.1365-2958.1998.00998.x; Okunishi I, 1996, J BACTERIOL, V178, P2409, DOI 10.1128/jb.178.8.2409-2415.1996; OOSAWA K, 1994, J BACTERIOL, V176, P3683, DOI 10.1128/JB.176.12.3683-3691.1994; Osborn M J, 1974, Methods Enzymol, V31, P642; RACKER E, 1979, ARCH BIOCHEM BIOPHYS, V198, P470, DOI 10.1016/0003-9861(79)90521-6; Sato K, 1998, SCIENCE, V281, P700, DOI 10.1126/science.281.5377.700; SHARP LL, 1995, BIOCHEMISTRY-US, V34, P9166, DOI 10.1021/bi00028a028; SOCKETT H, 1992, J BACTERIOL, V174, P793, DOI 10.1128/jb.174.3.793-806.1992; STADER J, 1986, J BACTERIOL, V166, P244, DOI 10.1128/jb.166.1.244-252.1986; STOLZ B, 1991, J BACTERIOL, V173, P7033, DOI 10.1128/jb.173.21.7033-7037.1991; SUGIYAMA S, 1988, J BIOL CHEM, V263, P8215; Tang H, 1996, J MOL BIOL, V261, P209, DOI 10.1006/jmbi.1996.0453; YAMAGUCHI S, 1986, J BACTERIOL, V166, P187, DOI 10.1128/jb.166.1.187-193.1986; Yorimitsu T, 1999, J BACTERIOL, V181, P5103, DOI 10.1128/JB.181.16.5103-5106.1999; ZHOU JD, 1995, J MOL BIOL, V251, P237, DOI 10.1006/jmbi.1995.0431; Zhou JD, 1998, P NATL ACAD SCI USA, V95, P6436, DOI 10.1073/pnas.95.11.6436	44	122	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5718	5722		10.1074/jbc.275.8.5718	http://dx.doi.org/10.1074/jbc.275.8.5718			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681557	hybrid			2022-12-27	WOS:000085474500064
J	Shirakata, Y; Komurasaki, T; Toyoda, H; Hanakawa, Y; Yamasaki, K; Tokumaru, S; Sayama, K; Hashimoto, K				Shirakata, Y; Komurasaki, T; Toyoda, H; Hanakawa, Y; Yamasaki, K; Tokumaru, S; Sayama, K; Hashimoto, K			Epiregulin, a novel member of the epidermal growth factor family, is an autocrine growth factor in normal human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR FAMILY; CARDIAC DEVELOPMENT; MESSENGER-RNA; MICE LACKING; PSORIATIC EPIDERMIS; NEUREGULIN RECEPTOR; STAT1 ACTIVATION; AUTO-INDUCTION; EGF RECEPTOR; FACTOR-ALPHA	Epiregulin is a new member of the epidermal growth factor (EGF) family purified from conditioned medium of NIH-3T3 clone T7. Some EGF family growth factors play essential roles in human keratinocytes in an autocrine manner. me show here that epiregulin is another autocrine growth factor for human keratinocytes. Epiregulin stimulated human keratinocyte proliferation under both subconfluent and confluent culture conditions in the absence of exogenous EGF family growth factors. Immunoprecipitation of [S-35]methionine-labeled conditioned medium revealed a S-kDa band corresponding to epiregulin. Northern blot analysis detected a 4.8-kilobase transcript of epiregulin, and the addition of epiregulin up-regulated epiregulin mRNA synthesis. Furthermore, an anti-epiregulin blocking antibody reduced DNA synthesis by 25%. Epiregulin up-regulated the mRNA levels of heparin-binding EGF-like growth factor (HB-EGF), amphiregulin, and TGF-alpha. In turn, the addition of EGF, RB-EGF, amphiregulin, and TGF-alpha increased epiregulin mRNA levels. These results demonstrate that epiregulin acts as an autocrine growth factor in human epidermal keratinocytes and is part of auto and cross-induction mechanisms involving HB-EGF, amphiregulin, and TGF-alpha. The mRNA expression profile resulting from induction of differentiation with high calcium and fetal calf serum revealed the differential expression of epiregulin, HB-EGF, amphiregulin, and TGP-alpha in keratinocytes. This indicates that these four growth factors have distinct, non-redundant biological functions.	Ehime Univ, Sch Med, Dept Dermatol, Shigenobu, Ehime 7910295, Japan; Taisho Pharmaceut Co Ltd, Mol Biol Lab, Med Res Labs, Omiya, Saitama 3308530, Japan	Ehime University; Taisho Pharmaceutical Holdings Co Ltd	Shirakata, Y (corresponding author), Ehime Univ, Sch Med, Dept Dermatol, Shigenobu, Ehime 7910295, Japan.	shirakat@m.ehime-u.ac.jp	Yamasaki, Kenshi/C-8905-2018	Yamasaki, Kenshi/0000-0002-5495-4956				ANSEL J, 1990, J INVEST DERMATOL, V94, pS101, DOI 10.1111/1523-1747.ep12876053; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Blauvelt A, 1996, J INVEST DERMATOL, V106, P1047, DOI 10.1111/1523-1747.ep12338641; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; COOK PW, 1992, CANCER RES, V52, P3224; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Erickson SL, 1997, DEVELOPMENT, V124, P4999; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; HASHIMOTO K, 1994, J BIOL CHEM, V269, P20060; Hashimoto Koji, 1992, Journal of Dermatology (Tokyo), V19, P648; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; Komurasaki T, 1997, ONCOGENE, V15, P2841, DOI 10.1038/sj.onc.1201458; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; NAGY IV, 1992, J INVEST DERMATOL, V99, P350; PIEPKORN M, 1995, J INVEST DERMATOL, V105, P802, DOI 10.1111/1523-1747.ep12326567; PITTELKOW MR, 1986, J INVEST DERMATOL, V86, P410, DOI 10.1111/1523-1747.ep12285684; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Riese DJ, 1998, J BIOL CHEM, V273, P11288, DOI 10.1074/jbc.273.18.11288; Riese DJ, 1996, ONCOGENE, V12, P345; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Stoll S, 1997, J CLIN INVEST, V100, P1271, DOI 10.1172/JCI119641; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Toyoda H, 1995, FEBS LETT, V377, P403, DOI 10.1016/0014-5793(95)01403-9; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; Toyoda H, 1997, BIOCHEM J, V326, P69, DOI 10.1042/bj3260069; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Yawalkar N, 1996, J INVEST DERMATOL, V106, P80, DOI 10.1111/1523-1747.ep12327985; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	48	129	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5748	5753		10.1074/jbc.275.8.5748	http://dx.doi.org/10.1074/jbc.275.8.5748			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681561	hybrid			2022-12-27	WOS:000085474500068
J	Matsui, I; Matsui, E; Sakai, Y; Kikuchi, H; Kawarabayasi, Y; Ura, H; Kawaguchi, S; Kuramitsu, S; Harata, K				Matsui, I; Matsui, E; Sakai, Y; Kikuchi, H; Kawarabayasi, Y; Ura, H; Kawaguchi, S; Kuramitsu, S; Harata, K			The molecular structure of hyperthermostable aromatic aminotransferase with novel substrate specificity from Pyrococcus horikoshii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID AMINOTRANSFERASE; ARCHAEBACTERIUM SULFOLOBUS-SOLFATARICUS; THERMOSTABLE ASPARTATE-AMINOTRANSFERASE; CYTOSOLIC ALANINE AMINOTRANSFERASE; RAT TYROSINE AMINOTRANSFERASE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURES; TRYPANOSOMA-CRUZI; ACTIVE-SITE	Aromatic amino acid aminotransferase (ArATPh), which has a melting temperature of 120 degrees C, is one of the most thermostable aminotransferases yet to be discovered. The crystal structure of this aminotransferase from the hyperthermophilic archaeon Pyrococcus horikoshii was determined to a resolution of 2.1 Angstrom ArATPh has a homodimer structure in which each subunit is composed of two domains, in a manner similar to other well characterized aminotransferases, By the least square fit after superposing on a mesophilic ArAT, the ArATPh molecule exhibits a large deviation of the main chain coordinates, three shortened alpha-helices, an elongated loop connecting two domains, and a long loop transformed from an alpha-helix, which are all factors that are likely to contribute to its hyperthermostability, The pyridine ring of the cofactor pyridoxal 5'-phosphate covalently binding to Lys(233) is stacked parallel to F121 on one side and interacts with the geminal dimethyl-CH/pi groups of Val(201) on the other side. This tight stacking against the pyridine ring probably contributes to the hyperthermostability of ArATPh, Compared with other ArATs, ArATPh has a novel substrate specificity, the order of preference being Tyr > Phe > Glu > Trp > His much greater than Met > Leu > Asp > Asn. Its relatively weak activity against Asp is due to lack of an arginine residue corresponding to Arg(292)* (where the asterisk indicates that this is a residues supplied by the other subunit of the dimer) in pig cytosolic aspartate aminotransferase. The enzyme recognizes the aromatic substrate by hydrophobic interaction with aromatic rings (Phe(121) and Tyr(59)*) and probably recognizes acidic substrates by a hydrophilic interaction involving a hydrogen bond network with Thr(264)*.	Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 305, Japan; Minist Int Trade & Ind, Natl Inst Technol & Evaluat, Shibuya Ku, Tokyo, Japan; Osaka Univ, Grad Sch Sci, Dept Biol, Toyonaka, Osaka 5600043, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Osaka University	Harata, K (corresponding author), Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 305, Japan.							ADAM MW, 1999, BIOTECHNOLOGY, V13, P662; ADAMS MWW, 1992, ADV INORG CHEM, V38, P341, DOI 10.1016/S0898-8838(08)60068-9; ANDERSSON SM, 1982, CLIN CHIM ACTA, V125, P117, DOI 10.1016/0009-8981(82)90188-7; ANDREOTTI G, 1995, BBA-PROTEIN STRUCT M, V1247, P90, DOI 10.1016/0167-4838(94)00211-X; BIROLO L, 1991, BIOCHIM BIOPHYS ACTA, V1080, P198, DOI 10.1016/0167-4838(91)90002-H; BONTEMPI EJ, 1993, MOL BIOCHEM PARASIT, V59, P253, DOI 10.1016/0166-6851(93)90223-K; BRUNGER AT, 1992, XPLOR VERSION 3 1 SY, P1; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURLEY SK, 1986, J AM CHEM SOC, V108, P7995, DOI 10.1021/ja00285a019; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; COWAN D, 1985, TRENDS BIOTECHNOL, V3, P68, DOI 10.1016/0167-7799(85)90080-0; COWAN DA, 1992, TRENDS BIOTECHNOL, V10, P315, DOI 10.1016/0167-7799(92)90257-V; Croocker PC, 1999, EXTREMOPHILES, V3, P3, DOI 10.1007/s007920050093; CUBELLIS MV, 1989, EUR J BIOCHEM, V186, P375, DOI 10.1111/j.1432-1033.1989.tb15219.x; FERSHT A, 1985, ENZYME STRUCTURE MEC, P311; GRANGE T, 1985, J MOL BIOL, V184, P347, DOI 10.1016/0022-2836(85)90386-9; HARGROVE JL, 1989, J BIOL CHEM, V264, P45; HAYASHI H, 1993, BIOCHEMISTRY-US, V32, P12229, DOI 10.1021/bi00096a036; INOUE K, 1988, J BIOCHEM-TOKYO, V104, P777, DOI 10.1093/oxfordjournals.jbchem.a122549; INOUE K, 1991, BIOCHEMISTRY-US, V30, P7796, DOI 10.1021/bi00245a019; ISHIGURO M, 1991, BIOCHEMISTRY-US, V30, P6048, DOI 10.1021/bi00238a031; ISHIGURO M, 1991, BIOCHEMISTRY-US, V30, P10451, DOI 10.1021/bi00107a013; Ishikawa K, 1998, J BIOL CHEM, V273, P17726, DOI 10.1074/jbc.273.28.17726; IWASAKI M, 1994, J BIOCHEM-TOKYO, V115, P156, DOI 10.1093/oxfordjournals.jbchem.a124293; Jensen RA, 1996, J BACTERIOL, V178, P2161, DOI 10.1128/jb.178.8.2161-2171.1996; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KARMEN A, 1955, J CLIN INVEST, V34, P126, DOI 10.1172/JCI103055; Kawaguchi S, 1997, J BIOCHEM-TOKYO, V122, P55; Kawarabayasi Y, 1998, DNA Res, V5, P147, DOI 10.1093/dnares/5.2.147; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; KIRSCH JF, 1984, J MOL BIOL, V174, P497, DOI 10.1016/0022-2836(84)90333-4; KLUMP H, 1992, J BIOL CHEM, V267, P22681; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; KURAMITSU S, 1985, J BIOCHEM, V97, P1259, DOI 10.1093/oxfordjournals.jbchem.a135173; KURAMITSU S, 1985, BIOCHEM BIOPH RES CO, V133, P134, DOI 10.1016/0006-291X(85)91851-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARINO G, 1988, J BIOL CHEM, V263, P12305; MEHTA PK, 1993, EUR J BIOCHEM, V214, P549, DOI 10.1111/j.1432-1033.1993.tb17953.x; MIYAZAWA K, 1994, J BIOCHEM, V115, P568, DOI 10.1093/oxfordjournals.jbchem.a124377; MONTEMARTINI M, 1993, BIOCHEM J, V292, P901, DOI 10.1042/bj2920901; Nei M., 1987, MOL EVOLUT GENET, P293; NISHIO M, 1995, TETRAHEDRON, V51, P8665, DOI 10.1016/0040-4020(94)01066-9; Okamoto A, 1996, J BIOCHEM-TOKYO, V119, P135; Okamoto A, 1998, J MOL BIOL, V280, P443, DOI 10.1006/jmbi.1998.1869; OKAMOTO A, 1994, J BIOCHEM, V116, P95, DOI 10.1093/oxfordjournals.jbchem.a124509; Oue S, 1997, J BIOCHEM-TOKYO, V121, P161; OVCHINNIKOV YA, 1973, FEBS LETT, V29, P31, DOI 10.1016/0014-5793(73)80008-0; PARK JB, 1991, J BIOL CHEM, V266, P19351; RETTENMEIER R, 1990, NUCLEIC ACIDS RES, V18, P3853, DOI 10.1093/nar/18.13.3853; Rhee S, 1997, J BIOL CHEM, V272, P17293, DOI 10.1074/jbc.272.28.17293; SON DY, 1992, PLANT MOL BIOL, V20, P705, DOI 10.1007/BF00046455; SPOLTER PD, 1963, J BIOL CHEM, V238, P2071; SUNG MH, 1990, J BACTERIOL, V172, P1345, DOI 10.1128/jb.172.3.1345-1351.1990; SUNG MH, 1991, J BIOL CHEM, V266, P2567; Taylor PP, 1998, TRENDS BIOTECHNOL, V16, P412, DOI 10.1016/S0167-7799(98)01240-2; TRACH KA, 1993, MOL MICROBIOL, V8, P69, DOI 10.1111/j.1365-2958.1993.tb01204.x; WATSON RJ, 1993, J BACTERIOL, V175, P1919, DOI 10.1128/JB.175.7.1919-1928.1993; XING RY, 1992, J BACTERIOL, V174, P541, DOI 10.1128/jb.174.2.541-548.1992	58	56	63	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4871	4879		10.1074/jbc.275.7.4871	http://dx.doi.org/10.1074/jbc.275.7.4871			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671523	hybrid			2022-12-27	WOS:000085378200049
J	Naya, FJ; Mercer, B; Shelton, J; Richardson, JA; Williams, RS; Olson, EN				Naya, FJ; Mercer, B; Shelton, J; Richardson, JA; Williams, RS; Olson, EN			Stimulation of slow skeletal muscle fiber gene expression by calcineurin in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSCRIPTIONAL PATHWAY; CYCLOSPORINE; ACTIVATION; PROTEINS; ELEMENTS; FAMILY; MYOD; MICE	Adult skeletal muscle fibers can be categorized into fast and slow twitch subtypes based on specialized contractile and metabolic properties and on distinctive patterns of muscle gene expression. Muscle fiber-type characteristics are dependent on the frequency of motor nerve stimulation and are thought to be controlled by calcium-dependent signaling. The calcium, calmodulin-dependent protein phosphatase, calcineurin, stimulates slow fiber-specific gene promoters in cultured skeletal muscle cells, and the calcineurin inhibitor, cyclosporin A inhibits slow fiber gene expression in vivo, suggesting a key role of calcineurin in activation of the slow muscle fiber phenotype, Calcineurin has also been shown to induce hypertrophy of cardiac muscle and to mediate the hypertrophic effects of insulin-like growth factor-1 on skeletal myocytes in vitro. To determine whether activated calcineurin was sufficient to induce slow fiber gene expression and hypertrophy in adult skeletal muscle in vivo, we created transgenic mice that expressed activated calcineurin under control of the muscle creatine kinase enhancer. These mice exhibited an increase in slow muscle fibers, but no evidence for skeletal muscle hypertrophy, These results demonstrate that calcineurin activation is sufficient to induce the slow fiber gene regulatory program in vivo and suggest that additional signals are required for skeletal muscle hypertrophy.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; BROOKE MH, 1970, ARCH NEUROL-CHICAGO, V23, P369, DOI 10.1001/archneur.1970.00480280083010; Calvo S, 1999, MOL CELL BIOL, V19, P515; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CHIN ER, 1996, PHYSIOLOGIST, V39, pA75; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Dunn SE, 1999, J BIOL CHEM, V274, P21908, DOI 10.1074/jbc.274.31.21908; Esser K, 1999, J BIOL CHEM, V274, P12095, DOI 10.1074/jbc.274.17.12095; GOY JJ, 1989, LANCET, V1, P1446; Hughes SM, 1998, CURR BIOL, V8, pR892, DOI 10.1016/S0960-9822(07)00554-4; HUGHES SM, 1993, DEVELOPMENT, V118, P1137; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; Liu SF, 1997, EMBO J, V16, P143, DOI 10.1093/emboj/16.1.143; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Nakayama M, 1996, MOL CELL BIOL, V16, P2408; O'Mahoney JV, 1998, MOL CELL BIOL, V18, P6641, DOI 10.1128/MCB.18.11.6641; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PETTE D, 1992, REV PHYSIOL BIOCH P, V120, P115, DOI 10.1007/BFb0036123; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rawls A, 1998, DEVELOPMENT, V125, P2349; SALMONS S, 1976, NATURE, V263, P30, DOI 10.1038/263030a0; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; WESTERBLAD H, 1991, J GEN PHYSIOL, V98, P615, DOI 10.1085/jgp.98.3.615; WILLIAMS RS, 1986, J BIOL CHEM, V261, P376; [No title captured]	29	319	334	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4545	4548		10.1074/jbc.275.7.4545	http://dx.doi.org/10.1074/jbc.275.7.4545			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671477	hybrid			2022-12-27	WOS:000085378200003
J	Prasad, SVN; Esposito, G; Mao, L; Koch, WJ; Rockman, HA				Prasad, SVN; Esposito, G; Mao, L; Koch, WJ; Rockman, HA			G beta gamma-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; ADRENERGIC-RECEPTOR KINASE; P70 S6 KINASE; CARDIAC-HYPERTROPHY; PHOSPHATIDYLINOSITOL 3-KINASE; COUPLED RECEPTORS; LIPID PRODUCTS; SPECIFICITY; EXPRESSION; SURVIVAL	Activation of phosphoinositide 3-kinases is coupled to both phosphotyrosine/growth factor and G protein-coupled receptors. We explored the role of phosphoinositide 3-kinase activation in myocardium during in vivo pressure overload hypertrophy in mice. Cytosolic extracts from wild type hypertrophied hearts showed a selective increase in the phosphoinositide 3-kinase gamma isoform, To address the role of G protein-coupled receptor-mediated activation of phosphoinositide 3-kinase, we used transgenic mice with cardiac-specific overexpression of a G beta gamma sequestering peptide. Extracts from hypertrophied transgenic hearts showed complete loss of phosphoinositide 3-kinase activation, indicating a G beta gamma dependent process. To determine the class of G; proteins that contribute G beta gamma dimers for in vivo phosphoinositide 3-kinase activation, two strategies were used: 1) transgenic mice with cardiac-specific overexpression of a G, inhibitor peptide and 2) pertussis toxin treatment prior to pressure overload in wild type mice. Pressure overloaded G(q) inhibitor transgenic mice showed a complete absence of phosphoinositide 3-kinase activation, whereas pretreatment with pertussis toxin showed ro bust phosphoinositide S-kinase activation. Taken together, these data demonstrate that activation of the phosphoinositide 3-kinase during in vivo pressure overload hypertrophy is G beta gamma-dependent and the G beta gamma dimers arise from stimulation of G(q)-coupled receptors.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA	Duke University; Duke University	Rockman, HA (corresponding author), Duke Univ, Med Ctr, Dept Med, CARL Bldg,Rm 226,DUMC 3104, Durham, NC 27710 USA.		Esposito, Giovanni/F-2880-2010	Esposito, Giovanni/0000-0003-0565-7127	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061690, R01HL056687, R37HL061690] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56687, HL61690] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Brown RA, 1999, J BIOL CHEM, V274, P14529, DOI 10.1074/jbc.274.21.14529; Choi DJ, 1997, J BIOL CHEM, V272, P17223, DOI 10.1074/jbc.272.27.17223; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; Laser M, 1998, J BIOL CHEM, V273, P24610, DOI 10.1074/jbc.273.38.24610; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P2505, DOI 10.1074/jbc.273.5.2505; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Metjian A, 1999, J BIOL CHEM, V274, P27943, DOI 10.1074/jbc.274.39.27943; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161	34	163	168	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4693	4698		10.1074/jbc.275.7.4693	http://dx.doi.org/10.1074/jbc.275.7.4693			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671499	hybrid			2022-12-27	WOS:000085378200025
J	Shahan, TA; Fawzi, A; Bellon, G; Monboisse, JC; Kefalides, NA				Shahan, TA; Fawzi, A; Bellon, G; Monboisse, JC; Kefalides, NA			Regulation of tumor cell chemotaxis by type IV collagen is mediated by a Ca2+-dependent mechanism requiring CD47 and the integrin alpha(v)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; CALCIUM-ENTRY; PROTEIN; ADHESION; MELANOMA; BINDING; FIBRONECTIN; MIGRATION; DOMAIN; CHAIN	Studies from our laboratories demonstrated that synthetic peptides from the non-collagenous (NC-1) domain of the (alpha 3 (IV) chain of type TV collagen (COL IV) enhanced tumor cell adhesion (Han, J., Ohno, N., Monboisse, J. C., Pasco, S., Borel, J. P., and Kefalides, N. A. (1997) J. Biol. Chem. 272, 20395-20401). We have isolated the receptors for the alpha 3(IV)185-203 peptide from melanoma and prostate tumor cells and identified them as CD47/integrin-associated protein and the integrin alpha(v)beta(3) (Shahan, T. A, Ziaie, Z., Pasco, S., Fawzi, A, Bellon, G., Monboisse, J. C., and Kefalides, N. A. (1999) Cancer Res. 59, 4584-4590). In the present study we have examined the effect of CD47 and the integrin alpha(v)beta(3) on in vitro tumor cell chemotaxis and Ca-i(2+) modulation in response to COL IV, from the anterior lens capsule (ALC-COL IV) and peptides from its NC-1 domain. COL TV as well as the alpha 3(IV) peptide promoted tumor cell chemotaxis with an immediate increase in intracellular [Ca2+]. Treating tumor cells with CD47 and integrin alpha(v)beta(3)-reactive antibodies reduced chemotaxis as well as the rise in [Ca2+](i) in response to ALC-COL IV or the alpha 3(IV)185-203 peptide but not to Engelbreth-Holm-Swarm-COL IV or fibronectin. The a3(IV)185-203 synthetic peptide stimulated an increase in calcium from intracellular stores exclusively, whereas ALC-COL IV, Engelbreth-Holm-Swarm-COL IV, and fibronectin stimulated Ca2+ flux from both internal and external stores. Furthermore, treatment of the cells with Ca2+ chelator bis-(O-aminophenoxyl)ethane-N,N,N',N' -tetraaceticacid-acetomethoxy ester inhibited chemotaxis toward both ALC-COL IV and the alpha 3(IV)185-203 peptide. These data indicate that CD47 and integrin alpha(v)beta(3) regulate tumor cell chemotaxis in response to COL IV and the alpha 3(IV)185-203 peptide through a Ca2+-dependent mechanism.	Univ Penn, City Sci Ctr, Connect Tissue Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Reims Champagne Ardenne, Lab Biochim Med & Biol Mol, CNRS, UPRESA 6021,IFR Biomol 53,UFR Med Reims, F-51095 Reims, France	University of Pennsylvania; University of Pennsylvania; Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne	Kefalides, NA (corresponding author), Univ Penn, City Sci Ctr, Connect Tissue Res Inst, 3624 Market St,5-E, Philadelphia, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007490, P01AR020553] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-29493] Funding Source: Medline; NIAMS NIH HHS [AR07490, AR-20553] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKIYAMA SK, 1995, CANCER METAST REV, V14, P173, DOI 10.1007/BF00690290; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BRINKER JM, 1985, COLLAGEN REL RES, V5, P233; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; DOWDY S, 1983, STAT RES, P32; Eble JA, 1996, J BIOL CHEM, V271, P30964, DOI 10.1074/jbc.271.48.30964; FALK W, 1988, J IMMUNOL METHODS, V33, P33239; FENG LL, 1994, J BIOL CHEM, V269, P2342; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; GODFRAIND T, 1986, PHARMACOL REV, V38, P321; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; Han J, 1997, J BIOL CHEM, V272, P20395, DOI 10.1074/jbc.272.33.20395; Herlyn M, 1990, Adv Cancer Res, V54, P213, DOI 10.1016/S0065-230X(08)60812-X; HERLYN M, 1990, CANCER METAST REV, V9, P101, DOI 10.1007/BF00046337; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISHIBASHI Y, 1994, J EXP MED, V180, P1225, DOI 10.1084/jem.180.4.1225; KEFALIDES NA, 1994, KIDNEY INT, V43, P94; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; Klominek J, 1997, INT J CANCER, V72, P1034, DOI 10.1002/(SICI)1097-0215(19970917)72:6<1034::AID-IJC19>3.0.CO;2-4; LEINONEN A, 1994, J BIOL CHEM, V269, P26172; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; OURA EB, 1998, MICROSC RES TECHNIQ, V43, P265; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; SAVARESE DMF, 1992, J BIOL CHEM, V267, P21928; SCHWARTZ MA, 1993, J BIOL CHEM, V268, P19931; SENIOR RM, 1992, J CLIN INVEST, V90, P2251, DOI 10.1172/JCI116111; Shahan TA, 1999, CANCER RES, V59, P4584; Smith TW, 1996, MELANOMA RES, V6, P351, DOI 10.1097/00008390-199610000-00002; TEJERINA T, 1993, EUR J PHARMACOL, V239, P75, DOI 10.1016/0014-2999(93)90978-Q; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; VANSTRIJP JAG, 1993, J IMMUNOL, V151, P3324; Wang XQ, 1998, MOL BIOL CELL, V9, P865, DOI 10.1091/mbc.9.4.865; WISDOM BJ, 1992, CONNECT TISSUE RES, V27, P225, DOI 10.3109/03008209209006998	38	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4796	4802		10.1074/jbc.275.7.4796	http://dx.doi.org/10.1074/jbc.275.7.4796			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671513	hybrid			2022-12-27	WOS:000085378200039
J	Wu, LW; Mayo, LD; Dunbar, JD; Kessler, KM; Baerwald, MR; Jaffe, EA; Wang, DF; Warren, RS; Donner, DB				Wu, LW; Mayo, LD; Dunbar, JD; Kessler, KM; Baerwald, MR; Jaffe, EA; Wang, DF; Warren, RS; Donner, DB			Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MAJOR BINDING-SITE; TYROSINE KINASE; PERMEABILITY FACTOR; PHOSPHATIDYLINOSITOL 3'-KINASE; DEVELOPMENTAL EXPRESSION; PHOSPHORYLATION SITES; PLC-GAMMA; IN-VIVO; FLT-1	This study was initiated to identify signaling proteins used by the receptors for vascular endothelial cell growth factor KDR/FlK1, and Flt1, Two-hybrid cloning and immunoprecipitation from human umbilical vein endothelial cells (HUVEC) showed that KDR binds to and promotes the tyrosine phosphorylation of phospholipase C gamma (PLC gamma), Neither placental growth factor, which activates Flt1, epidermal growth factor (EGF), or fibroblast growth factor (FGF) induced tyrosine phosphorylation of PLC gamma, indicating that KDR is uniquely important to PLC gamma activation in HUVEC, By signaling through KDR, VEGF promoted the tyrosine phosphorylation of focal adhesion kinase, induced activation of Akt, protein kinase C epsilon (PKC epsilon), mitogen-activated protein kinase (MAPK), and promoted thymidine incorporation into DNA VEGF activates PLC gamma, PKC epsilon, and phosphatidylinositol 3-kinase independently of one another. MEK, PLC gamma, and to a lesser extent PKC, are in the pathway through which KDR activates MAPK. PLC gamma or PKC inhibitors did not affect FGF- or EGF-mediated MAPK activation. MAPK/ERK kinase inhibition diminished VEGF-, FGF-, and EGF-promoted thymidine incorporation into DNA, However, blockade of PKC diminished thymidine incorporation into DNA induced by VEGF but not FGF or EGF. Signaling through KDR/Flk1 activates signaling pathways not utilized by other mitogens to induce proliferation of HUVEC.	Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Interfaith Med Ctr, Dept Med, Brooklyn, NY 11238 USA; Cornell Univ, Med Ctr, New York, NY 10021 USA; SUNY Hlth Sci Ctr, Brooklyn, NY 11203 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Cornell University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of California System; University of California San Francisco	Donner, DB (corresponding author), Indiana Univ, Sch Med, Walther Oncol Ctr, 1044 W Walnut St, Indianapolis, IN 46202 USA.	ddonner@IUPUI.edu	Wu, Li-Wha/AAH-7768-2021	Wu, Li-Wha/0000-0001-7010-6220; Baerwald, Melinda/0000-0001-7462-5212	NCI NIH HHS [CA 84018, CA 73023, CA 67891] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073023, R01CA067891, R55CA067891] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BREIER G, 1992, DEVELOPMENT, V114, P521; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CONNOLLY DT, 1991, J CELL BIOCHEM, V47, P219, DOI 10.1002/jcb.240470306; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V240, P635, DOI 10.1006/bbrc.1997.7719; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Igarashi K, 1998, BIOCHEM BIOPH RES CO, V246, P95, DOI 10.1006/bbrc.1998.8578; Ito N, 1998, J BIOL CHEM, V273, P23410, DOI 10.1074/jbc.273.36.23410; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KIM J, 1993, NATURE, V262, P841; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lu G, 1996, CIRC RES, V79, P611, DOI 10.1161/01.RES.79.3.611; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MONACCI WT, 1993, AM J PHYSIOL, V264, pC995, DOI 10.1152/ajpcell.1993.264.4.C995; PARK JE, 1994, J BIOL CHEM, V269, P25646; Parrizas M, 1997, J BIOL CHEM, V272, P154; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; Sawano A, 1997, BIOCHEM BIOPH RES CO, V238, P487, DOI 10.1006/bbrc.1997.7327; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1986, CANCER RES, V46, P5629; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; Strawn LM, 1996, CANCER RES, V56, P3540; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; TATRAI A, 1994, BBA-MOL CELL RES, V1224, P575, DOI 10.1016/0167-4889(94)90296-8; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; Wellner M, 1999, ARTERIOSCL THROM VAS, V19, P178, DOI 10.1161/01.ATV.19.1.178; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	55	252	263	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5096	5103		10.1074/jbc.275.7.5096	http://dx.doi.org/10.1074/jbc.275.7.5096			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671553	hybrid			2022-12-27	WOS:000085378200079
J	Zuo, SJ; Bermudez, V; Zhang, G; Kelman, Z; Hurwitz, J				Zuo, SJ; Bermudez, V; Zhang, G; Kelman, Z; Hurwitz, J			Structure and activity associated with multiple forms of Schizosaccharomyces pombe DNA polymerase delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; CELL NUCLEAR ANTIGEN; SACCHAROMYCES-CEREVISIAE; REPLICATION INVITRO; EPSILON; INITIATION; SUBUNIT; STRAND; ALPHA; PURIFICATION	DNA polymerase delta (Pol delta) isolated from Schizosaccharomyces pombe (sp) consists of at least four subunits, Pol3, Cdc1, Cdc27, and Cdm1, We have reconstituted the four-subunit complex by simultaneously expressing these polypeptides in baculovirus-infected insect cells. The properties of the purified cloned spPol delta were identical to the native spPol delta isolated from S, pombe cells. In addition, we also isolated a three-subunit complex containing Pol3, Cdc1, and Cdm1, Both three- and four-subunit complexes required replication factor C and proliferating cell nuclear antigen for DNA replication. However, in the presence of low levels of polymerase complexes, the three-subunit complex was less efficient than the four-subunit complex in supporting DNA replication. The inefficient synthesis of DNA by the three-subunit complex can be remedied by the addition of Cdc27, the subunit missing in the three-subunit complex. Gel filtration analysis demonstrated that the three-subunit complex is a monomer of the heterotrimer (Pol3, Cdc1, and Cdm1) and that the four-subunit complex is a dimer of the heterotetramer (Pol3, Cdc1, Cdc27, and Cdm1), similar to the structure of native spPol delta, We have further shown that Cdc1 and Cdc27 interact to form a heterodimeric complex. Gel filtration studies indicate that the structure of this complex is dimeric, These observations suggest that the Cdc27 subunit may play an important role contributing to the dimerization of Pol delta.	Mem Sloan Kettering Canc Ctr, Grad Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Hurwitz, J (corresponding author), Mem Sloan Kettering Canc Ctr, Grad Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.	j-hurwitz@ski.mskcc.org			NIGMS NIH HHS [GM58559] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; CONAWAY RC, 1982, P NATL ACAD SCI-BIOL, V79, P2523, DOI 10.1073/pnas.79.8.2523; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; Gould KL, 1998, GENETICS, V149, P1221; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; JIANG YQ, 1995, ARCH BIOCHEM BIOPHYS, V320, P297, DOI 10.1016/0003-9861(95)90013-6; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MacNeill SA, 1996, EMBO J, V15, P4613, DOI 10.1002/j.1460-2075.1996.tb00839.x; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MELENDY T, 1991, J BIOL CHEM, V266, P1942; MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; NASMYTH K, 1981, MOL GEN GENET, V146, P167; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; Reynolds N, 1998, CURR GENET, V34, P250, DOI 10.1007/s002940050394; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; SURIMOTO T, 1990, NATURE, V346, P534; Tanaka H, 1999, MOL CELL BIOL, V19, P1038; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x; Zuo SJ, 1997, P NATL ACAD SCI USA, V94, P11244, DOI 10.1073/pnas.94.21.11244	42	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5153	5162		10.1074/jbc.275.7.5153	http://dx.doi.org/10.1074/jbc.275.7.5153			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671561	hybrid			2022-12-27	WOS:000085378200087
J	Oda, M; Sakitani, K; Kaibori, M; Inoue, T; Kamiyama, Y; Okumura, T				Oda, M; Sakitani, K; Kaibori, M; Inoue, T; Kamiyama, Y; Okumura, T			Vicinal dithiol-binding agent, phenylarsine oxide, inhibits inducible nitric-oxide synthase gene expression at a step of nuclear factor-kappa B DNA binding in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED RAT HEPATOCYTES; HEAT-SHOCK RESPONSE; TYROSINE PHOSPHORYLATION; MOLECULAR-CLONING; IN-VITRO; T-CELLS; PROTEIN; TRANSCRIPTION; ACTIVATION; INTERLEUKIN-1-BETA	Inflammatory cytokine interleukin 1 beta induces inducible nitric-oxide synthase (iNOS) mRNA and its protein, which are followed by increasing the production of nitric oxide, in primary cultures of rat hepatocytes. Nuclear factor-kappa B (NF-kappa B), an important transcription factor for iNOS gene expression, is also activated and translocated to the nucleus. In the present study, we found that vicinal dithiol-binding agent, phenylarsine oxide (PAO), inhibited the induction of iNOS protein and mRNA as well as the release of nitrite (nitric oxide metabolite) into the culture medium. Simultaneous addition of a vicinal dithiol compound, 2,3-dimercaptopropanol, with PAO completely abolished these inhibitions. PAO could not prevent either degradation of an inhibitory protein, I kappa B, of NF-kappa B or translocation of NF-kappa B to the nucleus, However, electrophoretic mobility shift assay demonstrated that PAO decreased the interaction between NF-kappa B and its binding consensus oligonucleotide. Transfection experiments with iNOS promoter-luciferase construct revealed that PAO inhibited NF-kappa B binding to DNA These results indicate that PAO inhibits iNOS gene expression at a step of NF-kappa B binding to DNA by modifying its vicinal dithiol moiety, which may play a crucial role for the iNOS regulation in hepatocytes.	Kansai Med Univ, Dept Med Chem, Moriguchi, Osaka 5708506, Japan; Kansai Med Univ, Dept Surg 1, Moriguchi, Osaka 5708506, Japan; Kansai Med Univ, Dept Internal Med 3, Moriguchi, Osaka 5708506, Japan	Kansai Medical University; Kansai Medical University; Kansai Medical University	Okumura, T (corresponding author), Kansai Med Univ, Dept Med Chem, 10-15 Fumizonocho, Moriguchi, Osaka 5708506, Japan.							Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; Beck KF, 1996, FEBS LETT, V394, P263, DOI 10.1016/0014-5793(96)00966-0; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; deVera ME, 1996, SURGERY, V120, P144, DOI 10.1016/S0039-6060(96)80281-9; deVera ME, 1996, HEPATOLOGY, V24, P1238; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Eberhardt W, 1996, BIOCHEM BIOPH RES CO, V223, P752, DOI 10.1006/bbrc.1996.0968; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GELLER DA, 1995, J IMMUNOL, V155, P4890; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HORIUTI Y, 1991, CELL STRUCT FUNCT, V16, P203, DOI 10.1247/csf.16.203; ISLAM F, 1991, ARCH BIOCHEM BIOPHYS, V289, P161, DOI 10.1016/0003-9861(91)90456-S; Kaibori M, 1999, J HEPATOL, V30, P1138, DOI 10.1016/S0168-8278(99)80270-0; KALEF E, 1993, ANAL BIOCHEM, V212, P325, DOI 10.1006/abio.1993.1337; KANEMAKI T, 1993, PROSTAGLANDINS, V45, P459, DOI 10.1016/0090-6980(93)90122-N; Kim IY, 1997, P NATL ACAD SCI USA, V94, P12904, DOI 10.1073/pnas.94.24.12904; Kitade H, 1996, HEPATOLOGY, V23, P797, DOI 10.1002/hep.510230421; Kitade H, 1996, BBA-MOL CELL RES, V1311, P20, DOI 10.1016/0167-4889(95)00188-3; KNOWLES RG, 1990, BIOCHEM J, V270, P833, DOI 10.1042/bj2700833; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LEVENSON RM, 1989, J BIOL CHEM, V264, P19984; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Nunokawa Y, 1996, BIOCHEM BIOPH RES CO, V223, P347, DOI 10.1006/bbrc.1996.0897; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; NUSSLER AK, 1992, J EXP MED, V176, P261, DOI 10.1084/jem.176.1.261; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171, DOI 10.1002/jlb.54.2.171; NUSSLER AK, 1993, BIOCHEM BIOPH RES CO, V194, P826, DOI 10.1006/bbrc.1993.1896; ONEILL LAJ, 1995, BBA-MOL CELL RES, V1266, P31, DOI 10.1016/0167-4889(94)00217-3; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Sakitani K, 1998, GENES CELLS, V3, P321, DOI 10.1046/j.1365-2443.1998.00193.x; Sakitani K, 1997, HEPATOLOGY, V25, P416; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shumilla JA, 1998, ARCH BIOCHEM BIOPHYS, V349, P356, DOI 10.1006/abbi.1997.0470; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; Spitsin SV, 1997, MOL MED, V3, P315, DOI 10.1007/BF03401810; SPITZER JA, 1994, HEPATOLOGY, V19, P217, DOI 10.1002/hep.1840190132; STADLER J, 1991, AM J PHYSIOL, V260, P910; Tewes F, 1997, EUR J IMMUNOL, V27, P3015, DOI 10.1002/eji.1830271139; Vos TA, 1999, HEPATOLOGY, V29, P421, DOI 10.1002/hep.510290231; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; ZAHLER WL, 1968, J BIOL CHEM, V243, P716	50	59	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4369	4373		10.1074/jbc.275.6.4369	http://dx.doi.org/10.1074/jbc.275.6.4369			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660607	hybrid			2022-12-27	WOS:000085288800091
J	Patel, BN; Dunn, RJ; David, S				Patel, BN; Dunn, RJ; David, S			Alternative RNA splicing generates a glycosylphosphatidylinositol-anchored form of ceruloplasmin in mammalian brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; IRON UPTAKE; GENE-EXPRESSION; PLASMA-PROTEINS; ACERULOPLASMINEMIA; CELLS; PHOSPHATIDYLINOSITOL; METABOLISM; RETINA; ORIGIN	Ceruloplasmin is a copper containing ferroxidase that is essential for normal iron homeostasis. Whereas ceruloplasmin in plasma is produced and secreted by hepatocytes, in the brain a glycosylphosphatidylinositol (GPI)-anchored form of ceruloplasmin is expressed on the surface of astrocytes, By using a cDNA cloning approach, we have now determined that the GPI-anchored form of ceruloplasmin is generated by alternative RNA splicing. The splicing occurs downstream of exon 18 and replaces the C-terminal 5 amino acids of the secreted form with an alternative 30 amino acids that signal GPI anchor addition. RNase protection analysis demonstrates that the GPI-anchored form is the major form in the brain, whereas the secreted form predominates in the liver. Individuals with aceruloplasminemia, a hereditary deficiency of ceruloplasmin, have severe iron deposition in a number of organs, including the brain where it results-in neurodegeneration. Therefore, this novel GPI-anchored form of ceruloplasmin is likely to play an important role in iron metabolism in the central nervous system.	Montreal Gen Hosp, Res Inst, Ctr Res Neurosci, Montreal, PQ H3G 1A4, Canada; McGill Univ, Montreal, PQ H3G 1A4, Canada	McGill University; McGill University	David, S (corresponding author), Montreal Gen Hosp, Res Inst, Ctr Res Neurosci, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.							ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BELL JE, 1991, NEUROPATH APPL NEURO, V17, P441, DOI 10.1111/j.1365-2990.1991.tb00748.x; Bothwell TH, 1998, SEMIN HEMATOL, V35, P55; Bottai D, 1997, J COMP NEUROL, V389, P65, DOI 10.1002/(SICI)1096-9861(19971208)389:1<65::AID-CNE5>3.0.CO;2-C; DAIMON M, 1995, BIOCHEM BIOPH RES CO, V208, P1028, DOI 10.1006/bbrc.1995.1437; DeSilva DM, 1996, PHYSIOL REV, V76, P31, DOI 10.1152/physrev.1996.76.1.31; FLEMING RE, 1990, J BIOL CHEM, V265, P7701; GAITSKHOKI V S, 1990, Biokhimiya, V55, P927; GERLACH M, 1994, J NEUROCHEM, V63, P793, DOI 10.1046/j.1471-4159.1994.63030793.x; GUTTERIDGE JMC, 1992, ANN NEUROL S, V32, P16; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Klomp LWJ, 1996, HUM MOL GENET, V5, P1989, DOI 10.1093/hmg/5.12.1989; Klomp LWJ, 1996, J CLIN INVEST, V98, P207, DOI 10.1172/JCI118768; KOOYMAN DL, 1995, SCIENCE, V269, P89, DOI 10.1126/science.7541557; KOSCHINSKY ML, 1986, P NATL ACAD SCI USA, V83, P5086, DOI 10.1073/pnas.83.14.5086; Levin LA, 1998, INVEST OPHTH VIS SCI, V39, P157; Lindley PF, 1997, J BIOL INORG CHEM, V2, P454, DOI 10.1007/s007750050156; LISANTI MP, 1991, J CELL SCI, V99, P637; LOW MG, 1985, NATURE, V318, P62, DOI 10.1038/318062a0; MITTAL B, 1994, MOL CELL NEUROSCI, V5, P63, DOI 10.1006/mcne.1994.1006; Miyajima H, 1997, ANN NEUROL, V41, P404, DOI 10.1002/ana.410410318; Miyajima H, 1998, NEUROLOGY, V51, P1188, DOI 10.1212/WNL.51.4.1188; MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761; MOLLGARD K, 1988, DEV BIOL, V128, P207, DOI 10.1016/0012-1606(88)90283-7; OSAKI S, 1966, J BIOL CHEM, V241, P2746; Patel BN, 1997, J BIOL CHEM, V272, P20185, DOI 10.1074/jbc.272.32.20185; RICHARDSON DR, 1995, BBA-MOL CELL RES, V1269, P105, DOI 10.1016/0167-4889(95)00096-B; ROSKAMS A, 1990, J NEUROSCI RES, V31, P421; ROYLE NJ, 1987, SOMAT CELL MOLEC GEN, V13, P285, DOI 10.1007/BF01535211; Sambrook J., 2002, MOL CLONING LAB MANU; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; THOMAS T, 1989, DEV BIOL, V134, P38, DOI 10.1016/0012-1606(89)90076-6; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; YANG FM, 1990, J BIOL CHEM, V265, P10780; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; Young SP, 1997, FEBS LETT, V411, P93, DOI 10.1016/S0014-5793(97)00478-X; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	38	160	169	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4305	4310		10.1074/jbc.275.6.4305	http://dx.doi.org/10.1074/jbc.275.6.4305			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660599	hybrid			2022-12-27	WOS:000085288800083
J	Reidt, U; Reuter, K; Achsel, T; Ingelfinger, D; Luhrmann, R; Ficner, R				Reidt, U; Reuter, K; Achsel, T; Ingelfinger, D; Luhrmann, R; Ficner, R			Crystal structure of the human U4/U6 small nuclear ribonucleoprotein particle-specific SnuCyp-20, a nuclear cyclophilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; ESCHERICHIA-COLI; BINDING DOMAIN; CYCLOSPORINE-A; 90KD PROTEINS; BRUGIA-MALAYI; BETA-GAMMA; COMPLEX; RESOLUTION; REFINEMENT	The cyclophilin SnuCyp-20 is a specific component of the human U4/U6 small nuclear ribonucleoprotein particle involved in the nuclear splicing of pre-mRNA. It stably associates with the U4/U6-60kD and -90kD proteins, the human orthologues of the Saccharomyces cerevisiae Prp4 and Prp3 splicing factors. We have determined the crystal structure of SnuCyp-20 art 2.0-Angstrom resolution by molecular replacement. Tbe structure of SnuCyp-20 closely resembles that of human cyclophilin A (hCypA), In particular, the catalytic centers of SnuCyp-20 and hCypA superimpose perfectly, which is reflected by the observed peptidyl-prolyl-cis/trans-isomerase activity of SnuCyp-20. The surface properties of both proteins, however, differ significantly. Apart from seven additional amino-terminal residues, the insertion of five amino acids in the loop alpha 1-beta 3 and of one amino acid in the loop alpha 2-beta 8 changes the conformations of both loops. The enlarged loop alpha 1-beta 3 is involved in the formation of a wide cleft with predominantly hydrophobic character, We propose that this enlarged loop is required for the interaction with the U4/U6-60kD protein.	Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany; Max Planck Inst Biophys Chem, Abt Zellulare Biochem, D-37070 Gottingen, Germany	Philipps University Marburg; Max Planck Society	Ficner, R (corresponding author), Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany.	ficner@imt.uni-marburg.de		Reuter, Klaus/0000-0003-3673-7971				Ayadi L, 1998, J MOL BIOL, V284, P673, DOI 10.1006/jmbi.1998.2183; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; BRUNGER A, 1993, XPLOR VERSION 3 1; Burge CB, 1999, RNA WORLD, P525; CLUBB RT, 1994, BIOCHEMISTRY-US, V33, P2761, DOI 10.1021/bi00176a004; Edwards KJ, 1997, J MOL BIOL, V271, P258, DOI 10.1006/jmbi.1997.1151; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299; Horowitz DS, 1997, RNA, V3, P1374; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KE HM, 1993, P NATL ACAD SCI USA, V90, P11850, DOI 10.1073/pnas.90.24.11850; KE HM, 1992, J MOL BIOL, V228, P539, DOI 10.1016/0022-2836(92)90841-7; Konno M, 1996, J MOL BIOL, V256, P897, DOI 10.1006/jmbi.1996.0136; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lauber J, 1997, RNA, V3, P926; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mikol V, 1998, PROTEIN SCI, V7, P1310, DOI 10.1002/pro.5560070606; MIKOL V, 1994, P NATL ACAD SCI USA, V91, P5183, DOI 10.1073/pnas.91.11.5183; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Reuter K, 1999, J MOL BIOL, V294, P515, DOI 10.1006/jmbi.1999.3258; Reuter K, 1999, ACTA CRYSTALLOGR D, V55, P888, DOI 10.1107/S0907444998016151; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Taylor P, 1998, FEBS LETT, V425, P361, DOI 10.1016/S0014-5793(98)00264-6; Teigelkamp S, 1998, RNA, V4, P127; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Will CL, 1997, CURR OPIN CELL BIOL, V9, P320, DOI 10.1016/S0955-0674(97)80003-8; Zhao YD, 1997, STRUCTURE, V5, P139, DOI 10.1016/S0969-2126(97)00172-X	35	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7439	7442		10.1074/jbc.275.11.7439	http://dx.doi.org/10.1074/jbc.275.11.7439			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713041	Green Published, hybrid			2022-12-27	WOS:000085913300001
J	Ruiz-Velasco, N; Guerrero-Esteo, M; Briskin, MJ; Teixido, J				Ruiz-Velasco, N; Guerrero-Esteo, M; Briskin, MJ; Teixido, J			The alpha(4) integrin subunit Tyr(187) has a key role in alpha(4)beta(7)-dependent cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONOBESE DIABETIC MICE; MUCOSAL VASCULAR ADDRESSIN; LIGAND-BINDING; IN-VIVO; T-CELLS; CIRCULATING LYMPHOCYTES; ALPHA-4-BETA-1 VLA-4; MONOCLONAL-ANTIBODY; FUNCTIONAL-ROLE; BETA-7 SUBUNIT	The integrin alpha(4)beta(7) is the cell adhesion receptor for the mucosal vascular addressin MAdCAM-1, and this interaction is dominant in lymphocyte homing to Peyer's patch high endothelial venules, and plays key roles in lymphocyte recruitment at sites of inflammation. To identify alpha(4) subunit amino acids important for alpha(4)beta(7)/MAd-CAM-1 interaction, we expressed mutant alpha(4) and wild type beta(7) chains in K562 cells and analyzed the effect of the mutations on cell adhesion to a soluble MAdCAM-1 (sMAdCAM-1-Ig), Transfectants expressing mutated alpha(4) at Tyr(187) displayed a substantial decrease in adhesion to this ligand, which was associated with a reduced alpha(4)beta(7)/sMAdCAM-1-Ig interaction, as determined by soluble binding assays. Addition of Mn2+ to the adhesion assays did not restore the impaired adhesion. Mutations at alpha(4) Gln(152)Asp(153) also affected transfectant adhesion to sMAdCAM-1-Ig, but did not involve an alteration of alpha(4)beta(7)/MAdCAM-1 binding, and adhesion was restored by Mn2+. Instead, mutations at alpha(4) Asn(123)Glu(124) did not affect this adhesion. Mutation of alpha(4) Tyr(187) abolished alpha(4)beta(7)-mediated cell adhesion to CS-1/fibronectin, an additional ligand for alpha(4)beta(7), while alpha(4) Gln(152)Asp(153) transfectant mutants showed a reduced adhesion, These results identify alpha(4), Tyr(187) as a key residue during receptor alpha(4)beta(7)/ligand interactions, indicating that it plays important roles in alpha(4)beta(7)-mediated leukocyte adhesion, and provide a potential target for therapeutic intervention in several inflammatory pathologies.	CSIC, Ctr Invest Biol, Dept Immunol, E-28006 Madrid, Spain; LeukoSite Inc, Cambridge, MA 02142 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Teixido, J (corresponding author), CSIC, Ctr Invest Biol, Dept Immunol, Velazquez 144, E-28006 Madrid, Spain.		Teixidó, Joaquin/J-8543-2014					Abitorabi MA, 1997, J CELL BIOL, V139, P563, DOI 10.1083/jcb.139.2.563; ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; CAMPANERO MR, 1992, EUR J IMMUNOL, V22, P3111, DOI 10.1002/eji.1830221213; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; CERFBENSUSSAN N, 1992, EUR J IMMUNOL, V22, P273, DOI 10.1002/eji.1830220140; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; ERLE DJ, 1994, J IMMUNOL, V153, P517; FAVEEUW C, 1994, J IMMUNOL, V152, P5969; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HAMANN A, 1994, J IMMUNOL, V152, P3282; HANNINEN A, 1993, J CLIN INVEST, V92, P2509, DOI 10.1172/JCI116859; Hanninen A, 1998, J IMMUNOL, V160, P6018; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Hesterberg PE, 1996, GASTROENTEROLOGY, V111, P1373, DOI 10.1053/gast.1996.v111.pm8898653; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HU MCT, 1992, P NATL ACAD SCI USA, V89, P8254, DOI 10.1073/pnas.89.17.8254; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; LAZAROVITS AI, 1984, J IMMUNOL, V133, P1857; LEMKE H, 1978, NATURE, V271, P249, DOI 10.1038/271249a0; LOBB RR, 1994, J CLIN INVEST, V94, P1722, DOI 10.1172/JCI117519; MOULD AP, 1994, J BIOL CHEM, V269, P27224; MOULD AP, 1990, J BIOL CHEM, V265, P4020; Munoz M, 1997, BIOCHEM J, V327, P727, DOI 10.1042/bj3270727; Munoz M, 1996, J BIOL CHEM, V271, P2696, DOI 10.1074/jbc.271.5.2696; NAKACHE M, 1989, NATURE, V337, P179, DOI 10.1038/337179a0; Picarella D, 1997, J IMMUNOL, V158, P2099; POSTIGO AA, 1993, J IMMUNOL, V151, P2471; PULIDO R, 1991, J BIOL CHEM, V266, P10241; ROBERTS K, 1993, EUR J IMMUNOL, V23, P1630, DOI 10.1002/eji.1830230735; Rott LS, 1996, J IMMUNOL, V156, P3727; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1342; Schechner JS, 1999, LAB INVEST, V79, P601; SCHIFFER SG, 1995, J BIOL CHEM, V270, P14270, DOI 10.1074/jbc.270.24.14270; SCHWEIGHOFFER T, 1993, J IMMUNOL, V151, P717; Shyjan AM, 1996, J IMMUNOL, V156, P2851; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; SRIRAMARAO P, 1994, J IMMUNOL, V153, P4238; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TEIXIDO J, 1992, J BIOL CHEM, V267, P1786; Tidswell M, 1997, J IMMUNOL, V159, P1497; Viney JL, 1996, J IMMUNOL, V157, P2488; Wagner N, 1996, NATURE, V382, P366, DOI 10.1038/382366a0; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; Yin ZN, 1999, BLOOD, V93, P1221; YUAN Q, 1990, INT IMMUNOL, V2, P1097, DOI 10.1093/intimm/2.11.1097; YUAN Q, 1992, J BIOL CHEM, V267, P7352	55	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7052	7059		10.1074/jbc.275.10.7052	http://dx.doi.org/10.1074/jbc.275.10.7052			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702270	hybrid, Green Published			2022-12-27	WOS:000085809600050
J	Vaz, FM; Fouchier, SW; Ofman, R; Sommer, M; Wanders, RJA				Vaz, FM; Fouchier, SW; Ofman, R; Sommer, M; Wanders, RJA			Molecular and biochemical characterization of rat gamma-trimethylaminobutyraldehyde dehydrogenase and evidence for the involvement of human aldehyde-dehydrogenase 9 in carnitine biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BUTYROBETAINE HYDROXYLASE; CULTURED FIBROBLASTS; TISSUE DISTRIBUTION; 3RD ISOZYME; BETAINE; AMINOBUTYRALDEHYDE; LIVER; PURIFICATION; METABOLISM; ACID	The penultimate step in carnitine biosynthesis is mediated by gamma-trimethylaminobutyraldehyde dehydrogenase (EC 1.2.1.47), a cytosolic NAD(+)-dependent aldehyde dehydrogenase that converts gamma-trimethylaminobutyraldehyde into gamma-butyrobetaine. This enzyme was purified from rat liver, and two internal peptide fragments were sequenced by Edman degradation. The peptide sequences were used to search the Expressed Sequence Tag data base, which led to the identification of a rat cDNA containing an open reading frame of 1485 base pairs encoding a polypeptide of 494 amino acids with a calculated molecular mass of 55 kDa, Expression of the coding sequence in Escherichia coli confirmed that the cDNA encodes gamma-trimethylaminobutyraldehyde dehydrogenase. The previously identified human aldehyde dehydrogenase 9 (Ee 1.2.1.19) has 92% identity with rat trimethylaminobutyraldehyde dehydrogenase and has been reported to convert substrates that resemble gamma-trimethylaminobutyraldehyde. When aldehyde dehydrogenase 9 was expressed in E. coli, it exhibited high trimethylaminobutyraldehyde dehydrogenase activity. Furthermore, comparison of the enzymatic characteristics of the heterologously expressed human and rat dehydrogenases with those of purified rat liver trimethylaminobutyraldehyde dehydrogenase revealed that the three enzymes have highly similar substrate specificities. In addition, the highest V-max/K-m values were obtained with gamma-trimethylaminobutyraldehyde as substrate. This indicates that human aldehyde dehydrogenase 9 is the gamma-trimethylaminobutyraldehyde dehydrogenase, which functions in carnitine biosynthesis.	Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Clin Chem,Lab Genet Metab Dis, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Pediat,Lab Genet Metab Dis, NL-1100 DE Amsterdam, Netherlands	Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Wanders, RJA (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Clin Chem, Lab Genet Metab Dis F0 224, POB 22700, NL-1100 DE Amsterdam, Netherlands.		Fouchier, Sigrid/A-8310-2011	Vaz, Frederic/0000-0002-9048-1041				AMBROZIAK W, 1988, AGENTS ACTIONS, V23, P311, DOI 10.1007/BF02142573; AMBROZIAK W, 1991, COMP BIOCHEM PHYS B, V100, P321, DOI 10.1016/0305-0491(91)90382-N; ARIGA N, 1971, ANAL BIOCHEM, V43, P446, DOI 10.1016/0003-2697(71)90274-0; Barak AJ, 1996, ALCOHOL, V13, P395, DOI 10.1016/0741-8329(96)00030-4; BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMER J, 1983, PHYSIOL REV, V63, P1420, DOI 10.1152/physrev.1983.63.4.1420; CARON PC, 1988, BIOCHEM J, V251, P559, DOI 10.1042/bj2510559; CHERN MK, 1995, BIOCHEM BIOPH RES CO, V213, P561, DOI 10.1006/bbrc.1995.2168; ENGLARD S, 1979, FEBS LETT, V102, P297, DOI 10.1016/0014-5793(79)80022-8; ENGLARD S, 1978, ARCH BIOCHEM BIOPHYS, V190, P361, DOI 10.1016/0003-9861(78)90287-4; GRUNEWALD RW, 1995, KIDNEY INT, V48, P1714, DOI 10.1038/ki.1995.469; HULSE JD, 1980, J BIOL CHEM, V255, P1146; Izaguirre G, 1997, COMP BIOCHEM PHYS B, V118, P59, DOI 10.1016/S0305-0491(97)00022-9; JAKOBS BS, 1995, BIOCHEM BIOPH RES CO, V213, P1035, DOI 10.1006/bbrc.1995.2232; JAKOBY WB, 1959, J BIOL CHEM, V234, P2145; Johansson K, 1998, PROTEIN SCI, V7, P2106, DOI 10.1002/pro.5560071007; KAUFMAN RA, 1977, J BIOL CHEM, V252, P7437; Kikonyogo A, 1996, BIOCHEM J, V316, P317, DOI 10.1042/bj3160317; KURYS G, 1989, J BIOL CHEM, V264, P4715; KURYS G, 1993, EUR J BIOCHEM, V218, P311, DOI 10.1111/j.1432-1033.1993.tb18379.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin SW, 1996, GENOMICS, V34, P376, DOI 10.1006/geno.1996.0300; LINDSTEDT G, 1970, J BIOL CHEM, V245, P4178; LINDSTEDT G, 1982, SCAND J CLIN LAB INV, V42, P477; PETRONINI PG, 1992, BIOCHEM J, V282, P69, DOI 10.1042/bj2820069; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; REBOUCHE CJ, 1982, FED PROC, V41, P2848; REBOUCHE CJ, 1980, BIOCHIM BIOPHYS ACTA, V630, P22, DOI 10.1016/0304-4165(80)90133-6; RIZZO WB, 1991, J CLIN INVEST, V88, P1643, DOI 10.1172/JCI115478; Vaz FM, 1998, BIOCHEM BIOPH RES CO, V250, P506, DOI 10.1006/bbrc.1998.9343; Verhoeven NM, 1998, J LIPID RES, V39, P66; Yoshida A, 1998, EUR J BIOCHEM, V251, P549, DOI 10.1046/j.1432-1327.1998.2510549.x; ZASPEL BJ, 1980, BIOCHIM BIOPHYS ACTA, V631, P192, DOI 10.1016/0304-4165(80)90067-7	34	58	64	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7390	7394		10.1074/jbc.275.10.7390	http://dx.doi.org/10.1074/jbc.275.10.7390			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702312	hybrid			2022-12-27	WOS:000085809600092
J	Camerer, E; Gjernes, E; Wiiger, M; Pringle, S; Prydz, H				Camerer, E; Gjernes, E; Wiiger, M; Pringle, S; Prydz, H			Binding of Factor VIIa to tissue factor on keratinocytes induces gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; GROWTH-FACTOR; BLOOD-COAGULATION; ENDOTHELIAL-CELLS; KINASE PATHWAY; UP-REGULATION; MIGRATION; UROKINASE; CA2+; KERATINIZATION	Binding of the zymogen serine protease Factor VII (FVII) to its cellular cofactor tissue factor (TF) triggers blood coagulation. Several recent reports have suggested that the formation of this complex may serve additional functions. We have used cDNA arrays to study differential gene expression in response to the interaction of activated FVII (FVIIa) with TF on a human keratinocyte cell line, Of 931 mRNA species observed up to 6 h after FVIIa (10 nM) addition, 24 were significantly up-regulated in what may resemble a wound-type response. Responders included mRNA species coding for transcription regulators (c-fos, egr-1, ETR101, BTEB2, c-myc, fra-1, and tristetraproline), growth factors (amphiregulin, hbEGF, CTGF, and FGF-5), proinflammatory cytokines (IL-1 beta, IL-8, LIF, and MIP2 alpha), proteins involved in cellular reorganization/migration (RhoE, uPAR, and collagenases 1 and 3), and others (PAI-2, cyclophilin, GADD45, Jagged1, and prostaglandin E-2 receptor). The transcriptional response to FVIIa was abrogated by antibodies to TF and left unaffected by hirudin, The pattern of genes induced suggests that the FVIIa.TF complex may play an active role in early wound repair as well as hemostasis. The former is a novel function ascribed to the complex that may also be contributing to the pathophysiology of unwarranted TF expression.	Univ Oslo, Biotechnol Ctr Oslo, N-0349 Oslo, Norway	University of Oslo	Prydz, H (corresponding author), Biotechnol Ctr Oslo, Gaustadalleen 21, N-0371 Oslo, Norway.		Camerer, Eric/K-4161-2017	Camerer, Eric/0000-0002-6271-7125				Babic AM, 1999, MOL CELL BIOL, V19, P2958; BASTIEN L, 1994, J BIOL CHEM, V269, P11873; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Breitkreutz D, 1998, EUR J CELL BIOL, V75, P273, DOI 10.1016/S0171-9335(98)80123-4; BREITKREUTZ D, 1993, DIFFERENTIATION, V54, P201, DOI 10.1111/j.1432-0436.1993.tb01602.x; Camerer E, 1996, THROMB RES, V81, P1, DOI 10.1016/0049-3848(95)00209-X; Camerer E, 1996, J BIOL CHEM, V271, P29034, DOI 10.1074/jbc.271.46.29034; Camerer E, 1999, J BIOL CHEM, V274, P32225, DOI 10.1074/jbc.274.45.32225; Chang AW, 1998, ARTERIOSCL THROM VAS, V18, P1855, DOI 10.1161/01.ATV.18.12.1855; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; Dieckgraefe BK, 1999, AM J PHYSIOL-GASTR L, V276, pG322, DOI 10.1152/ajpgi.1999.276.2.G322; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Giordano FJ, 1996, NAT MED, V2, P534, DOI 10.1038/nm0596-534; Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299; Guasch RM, 1998, MOL CELL BIOL, V18, P4761, DOI 10.1128/MCB.18.8.4761; HASTY KA, 1987, J BIOL CHEM, V262, P10048; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; JANG YS, 1995, CIRCULATION, V92, P3041, DOI 10.1161/01.CIR.92.10.3041; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Koster R, 1996, AM J PATHOL, V149, P1871; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lai WS, 1999, MOL CELL BIOL, V19, P4311; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Muller M, 1999, EXP CELL RES, V248, P136, DOI 10.1006/excr.1999.4395; Oemar BS, 1997, ARTERIOSCL THROM VAS, V17, P1483, DOI 10.1161/01.ATV.17.8.1483; Ollivier V, 1998, BLOOD, V91, P2698, DOI 10.1182/blood.V91.8.2698.2698_2698_2703; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; PATTERSON PH, 1994, P NATL ACAD SCI USA, V91, P7833, DOI 10.1073/pnas.91.17.7833; PAWAR S, 1995, J CELL PHYSIOL, V165, P556, DOI 10.1002/jcp.1041650314; Pendurthi UR, 1997, P NATL ACAD SCI USA, V94, P12598, DOI 10.1073/pnas.94.23.12598; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Poulsen LK, 1998, J BIOL CHEM, V273, P6228, DOI 10.1074/jbc.273.11.6228; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; RAO LVM, 1992, CANCER METAST REV, V11, P249; Reinartz J, 1996, EXP CELL RES, V223, P91, DOI 10.1006/excr.1996.0061; Ritchie H, 1999, THROMB HAEMOSTASIS, V81, P96; RIVERS RPA, 1975, BRIT J HAEMATOL, V30, P311, DOI 10.1111/j.1365-2141.1975.tb00547.x; ROMER J, 1994, J INVEST DERMATOL, V102, P519, DOI 10.1111/1523-1747.ep12373187; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; ROTTINGEN JA, 1995, J BIOL CHEM, V270, P4650, DOI 10.1074/jbc.270.9.4650; Ruf W, 1996, Curr Opin Hematol, V3, P379; SAKAI T, 1989, J BIOL CHEM, V264, P9980; Sato Y, 1997, THROMB HAEMOSTASIS, V78, P1138; Shigemori C, 1998, THROMB HAEMOSTASIS, V80, P894; Stoll S, 1997, J CLIN INVEST, V100, P1271, DOI 10.1172/JCI119641; Taniguchi T, 1998, CANCER RES, V58, P4461; Taubman MB, 1997, THROMB HAEMOSTASIS, V78, P200; Taylor FB, 1998, BLOOD, V91, P1609, DOI 10.1182/blood.V91.5.1609.1609_1609_1615; VITA N, 1993, EUR CYTOKINE NETW, V4, P197; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; ZAHN X, 1988, MOL CELL BIOL, V8, P3487; ZANG Y, 1994, J CLIN INVEST, V94, P1320	57	161	171	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6580	6585		10.1074/jbc.275.9.6580	http://dx.doi.org/10.1074/jbc.275.9.6580			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692465	hybrid			2022-12-27	WOS:000085654400077
J	Kawamura, Y; Arakawa, K; Maeshima, M; Yoshida, S				Kawamura, Y; Arakawa, K; Maeshima, M; Yoshida, S			Tissue specificity of E subunit isoforms of plant vacuolar H+-ATPase and existence of isotype enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRASSULACEAN ACID METABOLISM; VESICLE PROTON PUMP; CATALYTIC-A-SUBUNIT; V-TYPE ATPASE; MESEMBRYANTHEMUM-CRYSTALLINUM; B-SUBUNIT; FUNCTIONAL EXPRESSION; TRANSLOCATING ATPASES; POLYACRYLAMIDE GELS; MESSENGER-RNA	Immunoblot analyses and partial amino acid sequencings revealed that both the 40- (E1) and 37-kDa (E2) subunits of V-ATPase in the pea epicotyl were E subunit isoforms. Similarly, both the 35- (D1) and 29-kDa (D2) subunits were D subunit isoforms, although the similarity of the amino acid sequences is still unknown. In immunoblot analyses, two or three E subunit isoforms with molecular masses ranging from 29 to 40 kDa were detected in other plants. Two isotypes of V-ATPase from the pea epicotyl were separated by ion exchange chromatography and had subunit compositions differing only in the ratio of E1 and E2. There was a difference in the V-max and K-m of ATP hydrolysis between the two isotypes. E1 was scarcely detected in crude membrane fractions from the leaf and cotyledon, while E2 was detected in fractions from all of the tissues examined. The compositions of D subunit isoforms in the leaf and epicotyl were different, and the vacuolar membrane in the leaf did not contain D2. The efficiency of H+ pumping activity in the vacuolar membrane of the leaf was higher than that of the epicotyl. The results suggest that the presence of the isoforms of D and E subunits is characteristic to plants and that the isoforms are closely related to the enzymatic properties.	Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Biochem Lab, Nagoya, Aichi 4648601, Japan	Hokkaido University; Nagoya University	Arakawa, K (corresponding author), Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan.	keita-ar@pop.lowtem.hokudai.ac.jp	Arakawa, Keita/C-2535-2012; Maeshima, Masayoshi/D-3073-2013	Maeshima, Masayoshi/0000-0002-1611-5481; Kawamura, Yukio/0000-0002-1498-5352				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARAI H, 1988, J BIOL CHEM, V263, P8796; Bauerle C, 1998, PLANT PHYSIOL, V117, P859, DOI 10.1104/pp.117.3.859; BERKELMAN T, 1994, PLANT PHYSIOL, V104, P287, DOI 10.1104/pp.104.1.287; BERNASCONI P, 1990, J BIOL CHEM, V265, P17428; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMBERGER C, 1992, PLANTA, V188, P575, DOI 10.1007/BF00197051; Crider BP, 1997, J BIOL CHEM, V272, P10721; DIETZ KJ, 1995, PLANT J, V8, P521, DOI 10.1046/j.1365-313X.1995.8040521.x; Dietz KJ, 1996, BBA-BIOMEMBRANES, V1281, P134, DOI 10.1016/0005-2736(96)00044-2; DIETZ KJ, 1996, PLANT PHYSIOL, V111, P652; GLUCK S, 1987, J BIOL CHEM, V262, P15780; GOGARTEN JP, 1992, PLANT CELL, V4, P851; GRAHAM LA, 1995, J BIOL CHEM, V270, P15037, DOI 10.1074/jbc.270.25.15037; Harlow E., 1988, ANTIBODIES LAB MANUA; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; HERNANDO N, 1995, P NATL ACAD SCI USA, V92, P6087, DOI 10.1073/pnas.92.13.6087; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HODGES TK, 1972, P NATL ACAD SCI USA, V69, P3307, DOI 10.1073/pnas.69.11.3307; Hotsubo K, 1997, PLANT COLD HARDINESS, P237; KIM W, 1997, PLANT PHYSIOL, V115, P314; Kluge C, 1999, BBA-BIOMEMBRANES, V1419, P105, DOI 10.1016/S0005-2736(99)00055-3; KONDO M, 1991, ELECTROPHORESIS, V12, P685, DOI 10.1002/elps.1150120918; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XH, 1999, PLANT J, V17, P19, DOI 10.1046/j.1365-313X.1999.00345.x; Lu Yu-Ping, 1997, Plant Physiology (Rockville), V114, P194; MAGNOTTA S, 1997, PLANT PHYSIOL, V115, P1730; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MATSUURAENDO C, 1990, EUR J BIOCHEM, V187, P745, DOI 10.1111/j.1432-1033.1990.tb15362.x; MATSUURAENDO C, 1992, PLANT PHYSIOL, V100, P718, DOI 10.1104/pp.100.2.718; Muller ML, 1997, J BIOL CHEM, V272, P12762, DOI 10.1074/jbc.272.19.12762; Muller ML, 1999, J BIOL CHEM, V274, P10706, DOI 10.1074/jbc.274.16.10706; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PALMGREN MG, 1990, PLANT PHYSIOL, V94, P882, DOI 10.1104/pp.94.3.882; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PERERA IY, 1995, PLANT MOL BIOL, V29, P227, DOI 10.1007/BF00043648; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; RATAJCZAK R, 1994, PLANT CELL ENVIRON, V17, P1101, DOI 10.1111/j.1365-3040.1994.tb02008.x; Rouquie D, 1998, FEBS LETT, V437, P287, DOI 10.1016/S0014-5793(98)01252-6; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; SZE H, 1985, ANNU REV PLANT PHYS, V36, P175, DOI 10.1146/annurev.pp.36.060185.001135; TAIZ L, 1992, J EXP BIOL, V172, P113; Tomashek JJ, 1997, J BIOL CHEM, V272, P16618, DOI 10.1074/jbc.272.26.16618; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANHILLE B, 1993, J BIOL CHEM, V268, P7075; WANG ZQ, 1990, J BIOL CHEM, V265, P21957; Xie XS, 1996, J BIOL CHEM, V271, P30980; YOSHIDA S, 1989, PLANT PHYSIOL, V89, P634, DOI 10.1104/pp.89.2.634	57	27	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6515	6522		10.1074/jbc.275.9.6515	http://dx.doi.org/10.1074/jbc.275.9.6515			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692456	hybrid			2022-12-27	WOS:000085654400068
J	Hippler, M; Biehler, K; Krieger-Liszkay, A; van Dillewjin, J; Rochaix, JD				Hippler, M; Biehler, K; Krieger-Liszkay, A; van Dillewjin, J; Rochaix, JD			Limitation in electron transfer in photosystem I donor side mutants of Chlamydomonas reinhardtii - Lethal photo-oxidative damage in high light is overcome in a suppressor strain deficient in the assembly of the light harvesting complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL-PROTEIN COMPLEX; THERMO-LUMINESCENCE; THYLAKOID MEMBRANE; PHOTOINHIBITORY TREATMENTS; CHLORELLA-VULGARIS; BINDING-PROTEINS; CYTOCHROME C(6); WILD-TYPE; PHOTOSYNTHESIS; PLASTOCYANIN	Strains of Chlamydomonas reinhardtii lacking the PsaF gene or containing the mutation K23Q within the N-terminal part of PsaF are sensitive to high light (>400 mu E m(-2) s(-1)) under aerobic conditions. In vitro experiments indicate that the sensitivity to high light of the isolated photosystem I (PSI) complex from wild type and from PsaF mutants is similar. In vivo measurements of photochemical quenching and oxygen evolution show that impairment of the donor side of PSI in the PsaF mutants leads to a diminished linear electron transfer and/or a decrease of photosystem II (PSII) activity in high light. Thermoluminescence measurements indicate that the PSII reaction center is directly affected under photo-oxidative stress when the rate of electron transfer becomes limiting in the PsaF-deficient strain and in the PsaF mutant K23Q. We have isolated a high light-resistant PsaF-deficient suppressor strain that has a high chlorophyll alb ratio and is affected in the assembly of light-harvesting complex. These results indicate that under high light a functionally intact donor side of PSI is essential for protection of C. reinhardtii against photo-oxidative damage when the photosystems are properly connected to their light-harvesting antennae.	Univ Geneva, Dept Mol Biol, CH-1211 Geneva, Switzerland; Univ Geneva, Dept Plant Biol, CH-1211 Geneva, Switzerland; Univ Freiburg, Inst Biol 2, Lehrstuhl Biochem Pflanzen, D-79104 Freiburg, Germany; Univ Kaiserslautern, FB Biol, D-67653 Kaiserslautern, Germany	University of Geneva; University of Geneva; University of Freiburg; University of Kaiserslautern	Rochaix, JD (corresponding author), Univ Geneva, Dept Mol Biol, 30 Quai Ernest Ansermet, CH-1211 Geneva, Switzerland.		Rochaix, Jean-David/ABC-5243-2020	Michael, Hippler/0000-0001-9670-6101; Krieger-Liszkay, Anja/0000-0001-7141-4129				Andree S, 1998, PLANT PHYSIOL, V116, P1053, DOI 10.1104/pp.116.3.1053; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; ASADA K, 1994, FROM MOL MECH FIELD, P129; Asada Kozi, 1996, V5, P123; AUCHINCLOSS AH, 1992, J BIOL CHEM, V267, P10439; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; Baroli I, 1998, PLANTA, V205, P288, DOI 10.1007/s004250050323; BASSI R, 1992, J BIOL CHEM, V267, P25714; BONAVENTURA C, 1969, BIOCHIM BIOPHYS ACTA, V189, P366, DOI 10.1016/0005-2728(69)90168-6; Bossmann B, 1997, PHOTOSYNTH RES, V52, P127, DOI 10.1023/A:1005823711838; Bossmann B, 1999, PLANTA, V207, P551, DOI 10.1007/s004250050517; BRIANTAIS JM, 1992, PHOTOSYNTH RES, V31, P1, DOI 10.1007/BF00049531; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; CHUNAEV AS, 1991, PHOTOSYNTHETICA, V25, P291; CHUNAEV AS, 1987, PHOTOSYNTHETICA, V21, P301; CLINE K, 1986, J BIOL CHEM, V261, P4804; Delosme R, 1996, BBA-BIOENERGETICS, V1273, P150, DOI 10.1016/0005-2728(95)00143-3; DEMETER S, 1984, BIOCHIM BIOPHYS ACTA, V764, P24, DOI 10.1016/0005-2728(84)90136-1; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; ESCOUBAS JM, 1995, P NATL ACAD SCI USA, V92, P10237, DOI 10.1073/pnas.92.22.10237; FARAH J, 1995, EMBO J, V14, P4976, DOI 10.1002/j.1460-2075.1995.tb00180.x; FARINEAU J, 1990, BIOCHIM BIOPHYS ACTA, V1016, P357, DOI 10.1016/0005-2728(90)90169-5; FRANKLIN AE, 1993, J BIOL CHEM, V268, P22175; GONG H, 1991, J BIOL CHEM, V266, P21293; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HARRISON MA, 1992, PLANT CELL PHYSIOL, V33, P627; Hippler M, 1999, J BIOL CHEM, V274, P4180, DOI 10.1074/jbc.274.7.4180; Hippler M, 1997, BIOCHEMISTRY-US, V36, P6343, DOI 10.1021/bi970082c; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; Hippler M, 1998, P NATL ACAD SCI USA, V95, P7339, DOI 10.1073/pnas.95.13.7339; Hippler M, 1996, EMBO J, V15, P6374, DOI 10.1002/j.1460-2075.1996.tb01028.x; HOOBER JK, 1990, PLANT PHYSIOL, V92, P419, DOI 10.1104/pp.92.2.419; HORTON P, 1994, PLANT PHYSIOL, V106, P415, DOI 10.1104/pp.106.2.415; HOYERHANSEN G, 1988, PLANTA, V173, P12, DOI 10.1007/BF00394481; HUANG LQ, 1992, PLANT PHYSIOL, V99, P247, DOI 10.1104/pp.99.1.247; Huner NPA, 1998, TRENDS PLANT SCI, V3, P224, DOI 10.1016/S1360-1385(98)01248-5; IMBAULT P, 1988, GENE, V73, P397, DOI 10.1016/0378-1119(88)90504-5; JANSSON S, 1994, BIOCHIM BIOPHYS ACTA, V1194, P1; JOLIOT P, 1986, BIOCHIM BIOPHYS ACTA, V849, P211, DOI 10.1016/0005-2728(86)90027-7; KATOH S, 1962, J BIOCHEM-TOKYO, V51, P32, DOI 10.1093/oxfordjournals.jbchem.a127497; Kozaki A, 1996, NATURE, V384, P557, DOI 10.1038/384557a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEY AC, 1982, BIOCHIM BIOPHYS ACTA, V680, P95, DOI 10.1016/0005-2728(82)90320-6; MAXWELL DP, 1995, PLANT PHYSIOL, V107, P687, DOI 10.1104/pp.107.3.687; MEHLER AH, 1951, ARCH BIOCHEM BIOPHYS, V33, P65, DOI 10.1016/0003-9861(51)90082-3; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; MICHEL H, 1983, BIOCHIM BIOPHYS ACTA, V725, P417, DOI 10.1016/0005-2728(83)90182-2; MURATA N, 1969, BIOCHIM BIOPHYS ACTA, V172, P242, DOI 10.1016/0005-2728(69)90067-X; NELSON JAE, 1994, MOL CELL BIOL, V14, P4011, DOI 10.1128/MCB.14.6.4011; OHAD I, 1988, BIOCHIM BIOPHYS ACTA, V933, P288, DOI 10.1016/0005-2728(88)90036-9; OQUIST G, 1993, PLANTA, V189, P150, DOI 10.1007/BF00201355; PETER GF, 1991, J BIOL CHEM, V266, P16745; PLUMLEY FG, 1995, PLANT CELL, V7, P689, DOI 10.2307/3870172; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; PRASIL O, 1992, PHOTOSYSTEMS STRUCTU, P295, DOI DOI 10.1016/B978-0-444-89440-3.50017-5; RUTHERFORD AW, 1982, BIOCHIM BIOPHYS ACTA, V682, P457, DOI 10.1016/0005-2728(82)90061-5; RYRIE IJ, 1983, EUR J BIOCHEM, V131, P149, DOI 10.1111/j.1432-1033.1983.tb07242.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHREIBER U, 1986, PHOTOSYNTH RES, V9, P261, DOI 10.1007/BF00029749; SMITH BM, 1990, PLANT PHYSIOL, V93, P1433, DOI 10.1104/pp.93.4.1433; SOMERVILLE CR, 1986, ANNU REV PLANT PHYS, V37, P467, DOI 10.1146/annurev.arplant.37.1.467; SPREITZER RJ, 1981, PLANT PHYSIOL, V67, P565, DOI 10.1104/pp.67.3.565; SPREITZER RJ, 1993, ANNU REV PLANT PHYS, V44, P411, DOI 10.1146/annurev.pp.44.060193.002211; STIEHL HH, 1969, Z NATURFORSCH PT B, VB 24, P1588; SULTEMEYER D, 1993, PLANTA, V189, P235; TAKAHASHI Y, 1991, EMBO J, V10, P2033, DOI 10.1002/j.1460-2075.1991.tb07733.x; TERAO T, 1988, PLANT CELL PHYSIOL, V29, P825; VANMIEGHEM FJE, 1989, BIOCHIM BIOPHYS ACTA, V977, P207, DOI 10.1016/S0005-2728(89)80073-8; VASS I, 1992, P NATL ACAD SCI USA, V89, P1408, DOI 10.1073/pnas.89.4.1408; VASS I, 1988, Z NATURFORSCH C, V43, P871; WHITE MJ, 1987, EUR J BIOCHEM, V165, P531, DOI 10.1111/j.1432-1033.1987.tb11471.x; WOLLMAN FA, 1982, BIOCHIM BIOPHYS ACTA, V680, P352, DOI 10.1016/0005-2728(82)90149-9; XU QA, 1994, J BIOL CHEM, V269, P3205; YALOVSKY S, 1992, P NATL ACAD SCI USA, V89, P5616, DOI 10.1073/pnas.89.12.5616; ZER H, 1994, J BIOL CHEM, V269, P17670	76	32	37	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5852	5859		10.1074/jbc.275.8.5852	http://dx.doi.org/10.1074/jbc.275.8.5852			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681576	hybrid, Green Published			2022-12-27	WOS:000085474500083
J	Soundar, S; Danek, BL; Colman, RF				Soundar, S; Danek, BL; Colman, RF			Identification by mutagenesis of arginines in the substrate binding site of the porcine NADP-dependent isocitrate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG-HEART; ESCHERICHIA-COLI; ACTIVE-SITE; ENZYME; PHOSPHORYLATION; EXPRESSION; SEQUENCE	Pig heart mitochondrial NADP-dependent isocitrate dehydrogenase is the most extensively studied among the mammalian isocitrate dehydrogenases. The crystal structure of Escherichia cell isocitrate dehydpogenase and sequence alignment of porcine with E. coli isocitrate dehydrogenase suggests that the porcine Arg(101), Arg(110), Arg(120), and Arg(133) are candidates for roles in substrate binding. The four arginines were separately mutated to glutamine using a polymerase chain reaction method. Wild type and mutant enzymes were each expressed in E. coli, isolated as maltose binding fusion proteins, then cleaved with thrombin, and purified to yield homogeneous porcine isocitrate dehydrogenase. The R120Q mutant has a specific activity, as well as K-m values for isocitrate, Mn2+, and NADP(+) similar to wild type enzyme, indicating that Arg(120) is not needed for function. The specific activities of R101Q, R110Q, and R133Q are 1.73, 1.30, and 19.7 mu mols/min/mg, respectively, as compared with 39.6 units/mg for wild type enzyme. The R110Q and R133Q enzymes exhibit K-m values for isocitrate that are increased more than 400- and 165-fold, respectively, as compared with wild type. The K-m values for Mn2+, but not for NADP(+), are also elevated indicating that binding of the metal-isocitrate complex is impaired in these mutants. It is proposed that the positive charges of Arg(110) and Arg(133) normally strengthen the binding of the negatively charged isocitrate by electrostatic attraction. The R101Q mutant shows smaller, but significant increases in the K-m values for isocitrate and Mn2+; however, the marked decrease in k(cat) suggests a role for Arg(101) in catalysis The V-max of wild type enzyme depends on the ionized form of an enzymic group of pK 5.5, and this pK(aes) is similar for the R101Q and R120Q enzymes. In contrast, the pK(aes) for R110Q and R133Q enzymes increases to 6.4 and 7.4, respectively, indicating that the positive charges of Arg(110) and Arg(133) normally lower the pK of the nearby catalytic base to facilitate its ionization. These results may be understood in terms of the structure of the porcine NADP-specific isocitrate dehydrogenase generated by the Insight Modeler Program, based on the x-ray coordinates of the E. coli enzyme.	Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA	University of Delaware	Colman, RF (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.				NIDDK NIH HHS [DK 39075] Funding Source: Medline; NIGMS NIH HHS [T32 GM 08550] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008550] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY JM, 1985, BIOCHEMISTRY-US, V24, P5367, DOI 10.1021/bi00341a015; BLACKSHEAR PJ, 1984, METHOD ENZYMOL, V104, P237; COLMAN RF, 1973, J BIOL CHEM, V248, P8137; COLMAN RF, 1968, J BIOL CHEM, V243, P2454; COLMAN RF, 1969, BIOCHEM BIOPH RES CO, V34, P528, DOI 10.1016/0006-291X(69)90414-8; COLMAN RF, 1983, PEPTIDE PROTEIN REV, V1, P41; DEAN AM, 1990, SCIENCE, V249, P1044, DOI 10.1126/science.2204110; DEAN AM, 1989, J BIOL CHEM, V264, P20482; EHRLICH RS, 1977, BIOCHEMISTRY-US, V16, P3378, DOI 10.1021/bi00634a014; EHRLICH RS, 1987, BIOCHEMISTRY-US, V26, P3461, DOI 10.1021/bi00386a032; GODSKY NB, 1999, FASEB J, V13, pA1444; HASELBECK RJ, 1992, BIOCHEMISTRY-US, V31, P6219, DOI 10.1021/bi00142a007; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; Jennings GT, 1997, BIOCHEMISTRY-US, V36, P13743, DOI 10.1021/bi970916r; JOHANSON RA, 1981, ARCH BIOCHEM BIOPHYS, V207, P9, DOI 10.1016/0003-9861(81)90002-3; KELLY JH, 1981, J BIOL CHEM, V256, P330; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; SOUNDAR S, 1993, J BIOL CHEM, V268, P5264; Soundar S, 1996, PROTEIN EXPRES PURIF, V8, P305, DOI 10.1006/prep.1996.0105; SOUNDAR S, 1999, PROTEIN SCI S1, V8, P138; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9310, DOI 10.1021/bi00087a008; TAO BY, 1994, PCR TECHNOLOGY CURRE, P74; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422	25	29	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5606	5612		10.1074/jbc.275.8.5606	http://dx.doi.org/10.1074/jbc.275.8.5606			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681542	hybrid			2022-12-27	WOS:000085474500049
J	Burr, AHJ; Hunt, P; Wagar, DR; Dewilde, S; Blaxter, ML; Vanfleteren, JR; Moens, L				Burr, AHJ; Hunt, P; Wagar, DR; Dewilde, S; Blaxter, ML; Vanfleteren, JR; Moens, L			A hemoglobin with an optical function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEMATODE MERMIS-NIGRESCENS; AMINO-ACID-SEQUENCES; ASCARIS HEMOGLOBIN; ANGSTROM RESOLUTION; GENE-EXPRESSION; GLOBIN GENES; FLAVOHEMOGLOBIN; EVOLUTION; MYOGLOBIN; PROTEIN	Hemoglobins are best known as oxygen transport proteins. Here we describe a hemoglobin from the parasitic nematode Mermis nigrescens (Mn-GLB-E) that has an optical, light shadowing function. The protein accumulates to high concentration as intracellular crystals in the ocellus of mature phototactic adult females while also being expressed at low concentration in other tissues. It differs in sequence and expression pattern from Mn-GLB-B, a second Mermis globin. It retains the structure and oxygen-binding and light-absorbing properties typical of nematode hemoglobins. As such, recruitment to a shadowing role in the eye appears to have occurred by changes in expression without modification of biochemistry. Both globins are coded by genes interrupted by two introns at the conserved positions B12.2 and G7.0, which is in agreement with the 3exon/2intron pattern model of globin gene evolution.	Univ Instelling Antwerp, Dept Biochem, B-2610 Antwerp, Belgium; Simon Fraser Univ, Dept Biol Sci, Burnaby, BC V5A 1S6, Canada; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Univ Ghent, Dept Biol, B-9000 Ghent, Belgium	University of Antwerp; Simon Fraser University; University of Edinburgh; Ghent University	Moens, L (corresponding author), Univ Instelling Antwerp, Dept Biochem, Univ Pl 1, B-2610 Antwerp, Belgium.	lmoens@uia.ua.ac.be	Hunt, Peter W/H-3545-2013; Blaxter, Mark L/B-4113-2010; Blaxter, Mark/O-2535-2019	Hunt, Peter W/0000-0001-5679-2404; Blaxter, Mark L/0000-0003-2861-949X; Burr, A. H. Jay/0000-0002-1065-2956				Altschul SF, 1996, METHOD ENZYMOL, V266, P460; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; Batschelet E., 1981, CIRCULAR STAT BIOL; Blaxter ML, 1998, NATURE, V392, P71, DOI 10.1038/32160; BLAXTER ML, 1993, PARASITOL TODAY, V9, P353, DOI 10.1016/0169-4758(93)90082-Q; BLAXTER ML, 1994, MOL BIOCHEM PARASIT, V68, P1, DOI 10.1016/0166-6851(94)00127-8; Bolognesi M, 1997, PROG BIOPHYS MOL BIO, V68, P29, DOI 10.1016/S0079-6107(97)00017-5; Burr A. H., 1984, PHOTORECEPTION VISIO, P131; BURR AH, 1975, BIOCHIM BIOPHYS ACTA, V405, P404, DOI 10.1016/0005-2795(75)90105-1; BURR AH, 1975, J ULTRA MOL STRUCT R, V51, P1, DOI 10.1016/S0022-5320(75)80003-7; BURR AH, 1979, J COMP PHYSIOL, V134, P85, DOI 10.1007/BF00610280; BURR AH, 1989, PHOTOCHEM PHOTOBIOL, V49, P89, DOI 10.1111/j.1751-1097.1989.tb04082.x; BURR AH, 1985, BIOPHYS J, V47, P527, DOI 10.1016/S0006-3495(85)83947-3; BURR AHJ, 1990, J COMP PHYSIOL A, V167, P245; BURR AHJ, 1990, J COMP PHYSIOL A, V167, P257; Christie JR, 1937, J AGRIC RES, V55, P0353; COBB NA, 1926, J PARASITOL, V8, P66; COUTURE M, 1994, MOL GEN GENET, V243, P185, DOI 10.1007/BF00280316; CRAWFORD MJ, 1995, J BIOL CHEM, V270, P6991, DOI 10.1074/jbc.270.12.6991; CROLL NA, 1975, COMP BIOCHEM PHYS A, V51, P139, DOI 10.1016/0300-9629(75)90426-0; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; DEBAERE I, 1992, P NATL ACAD SCI USA, V89, P4638, DOI 10.1073/pnas.89.10.4638; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; Dewilde S, 1996, J BIOL CHEM, V271, P19865, DOI 10.1074/jbc.271.33.19865; Dewilde S, 1998, J BIOL CHEM, V273, P32467, DOI 10.1074/jbc.273.49.32467; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; DIGGS LW, 1954, BLOOD, V9, P1172, DOI 10.1182/blood.V9.12.1172.1172; DIKSHIT RP, 1992, ARCH BIOCHEM BIOPHYS, V293, P241, DOI 10.1016/0003-9861(92)90391-9; DIXON B, 1992, J MOL EVOL, V35, P131, DOI 10.1007/BF00183224; ELLENBY C, 1966, COMP BIOCHEM PHYSIOL, V19, P871, DOI 10.1016/0010-406X(66)90442-7; ELLENBY C, 1964, NATURE, V202, P615, DOI 10.1038/202615a0; Ermler U, 1995, EMBO J, V14, P6067, DOI 10.1002/j.1460-2075.1995.tb00297.x; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; GILLESGONZALEZ MA, 1995, BIOCHEMISTRY-US, V34, P232, DOI 10.1021/bi00001a027; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; GO M, 1995, TRACING BIOL EVOLUTI; Hardison R, 1998, J EXP BIOL, V201, P1099; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; Harosi FI, 1998, BIOL BULL-US, V195, P5, DOI 10.2307/1542769; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HIRSCH RE, 1985, BLOOD, V66, P775; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; JENSEN EO, 1981, NATURE, V291, P677, DOI 10.1038/291677a0; KAO WY, 1994, J MOL EVOL, V38, P241; KAPP OH, 1995, PROTEIN SCI, V4, P2179, DOI 10.1002/pro.5560041024; KLOEK AP, 1994, J BIOL CHEM, V269, P2377; Lamy JN, 1996, CHEM REV, V96, P3113, DOI 10.1021/cr9600058; LEWIN R, 1984, SCIENCE, V226, P328, DOI 10.1126/science.226.4672.328; Long MY, 1995, P NATL ACAD SCI USA, V92, P12495, DOI 10.1073/pnas.92.26.12495; MACNICHOL EF, 1978, SCIENCE, V200, P549, DOI 10.1126/science.644317; Moens L, 1996, MOL BIOL EVOL, V13, P324, DOI 10.1093/oxfordjournals.molbev.a025592; NAG TC, 1995, J ELECTRON MICROSC, V44, P405; PIATIGORSKY J, 1991, SCIENCE, V252, P1078, DOI 10.1126/science.252.5009.1078; Piatigorsky J, 1998, PROG RETIN EYE RES, V17, P145, DOI 10.1016/S1350-9462(97)00004-9; RIGGS AF, 1991, AM ZOOL, V31, P535; Sharon-Friling R, 1998, MOL CELL BIOL, V18, P2067, DOI 10.1128/MCB.18.4.2067; SHERMAN DR, 1992, P NATL ACAD SCI USA, V89, P11696, DOI 10.1073/pnas.89.24.11696; SIDDIQUI IA, 1970, J ULTRA MOL STRUCT R, V32, P558, DOI 10.1016/S0022-5320(70)80028-4; Suzuki T, 1998, CELL MOL LIFE SCI, V54, P979, DOI 10.1007/s000180050227; Trotman CNA, 1998, TRENDS GENET, V14, P132, DOI 10.1016/S0168-9525(98)01400-0; VANDEPEER Y, 1993, COMPUT APPL BIOSCI, V9, P177; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; VASUDEVAN SG, 1991, MOL GEN GENET, V226, P49, DOI 10.1007/BF00273586; VINOGRADOV SN, 1993, COMP BIOCHEM PHYS B, V106, P1, DOI 10.1016/0305-0491(93)90002-M; WITTENBERG BA, 1987, P NATL ACAD SCI USA, V84, P7503, DOI 10.1073/pnas.84.21.7503; Wittenberg J.B., 1992, Advances in Comparative and Environmental Physiology, V13, P59; WITTENBERG JB, 1995, BIOL BULL, V188, P5, DOI 10.2307/1542061; WITTENBERG JB, 1990, ANNU REV BIOPHYS BIO, V19, P217; WITTENBERG JB, 1985, B BIOL SOC WASH, V6, P301; YAMAUCHI K, 1992, BIOCHIM BIOPHYS ACTA, V1171, P81, DOI 10.1016/0167-4781(92)90142-M; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224; ZHAO XF, 1995, J BIOL CHEM, V270, P20763, DOI 10.1074/jbc.270.35.20763; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015	74	26	30	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4810	4815		10.1074/jbc.275.7.4810	http://dx.doi.org/10.1074/jbc.275.7.4810			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671515	Green Submitted, hybrid			2022-12-27	WOS:000085378200041
J	Butt, E; Bernhardt, M; Smolenski, A; Kotsonis, P; Frohlich, LG; Sickmann, A; Meyer, HE; Lohmann, SM; Schmidt, HHHW				Butt, E; Bernhardt, M; Smolenski, A; Kotsonis, P; Frohlich, LG; Sickmann, A; Meyer, HE; Lohmann, SM; Schmidt, HHHW			Endothelial nitric-oxide synthase (type III) is activated and becomes calcium independent upon phosphorylation by cyclic nucleotide-dependent protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; VASODILATOR-STIMULATED PHOSPHOPROTEIN; FLUID SHEAR-STRESS; TYROSINE PHOSPHORYLATION; BINDING DOMAIN; I-BETA; EXPRESSION; CELLS; IDENTIFICATION; CALMODULIN	Endothelial nitric-oxide synthase (NOS-III) is defined as being strictly dependent on Ca2+/calmodulin (CaM) for activity, although NO release from endothelial cells has been reported to also occur at intracellular free Ca2+ levels that are substimulatory for the purified enzyme. We demonstrate here that NOS-III, but neither NOS-I nor -II, is rapidly and strongly activated and phosphorylated on both Ser and Thr in the presence of cGMP-dependent protein kinase II (cGK II) and the catalytic subunit of cAMP-dependent protein kinase (cAK) in vitro. Phosphopeptide analysis by mass spectrometry identified Ser(1177), as well as Ser(633) which is situated in a recently defined CaM autoinhibitory domain within the flavin-binding region of human NOS-III, Phosphoamino acid analysis identified a putative phosphorylation site at Thr(495) in the CaM-binding domain. Importantly, both cAK and cGK phosphorylation of NOS-III in vitro caused a highly reproducible partial (10-20%) NOS-III activation which was independent of Ca2+/CaM, and as much as a 4-fold increase in V-max in the presence of Ca2+/CaM. cAK stimulation in intact endothelial cells also increased both Ca2+/CaM-independent and -dependent activation of NOS-III. These data collectively provide new evidence for cAK and cGK stimulation of both Ca2+/CaM-independent and -dependent NOS-III activity, and suggest possible cross-talk between the NO and prostaglandin I, pathways and a positive feedback mechanism for NO/cGMP signaling.	Med Univ Clin, Inst Clin Biochem & Pathobiochem, D-97080 Wurzburg, Germany; Univ Wurzburg, Dept Pharmacol & Toxicol, D-97078 Wurzburg, Germany; Ruhr Univ Bochum, Inst Physiol Chem, Prot Struct Lab, D-44780 Bochum, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Wurzburg; University of Wurzburg; Ruhr University Bochum	Butt, E (corresponding author), Med Univ Clin, Inst Clin Biochem & Pathobiochem, Josef Schneider Str 2, D-97080 Wurzburg, Germany.		Schmidt, Harald HHW/B-1549-2008; Sickmann, Albert/A-1010-2011	Schmidt, Harald HHW/0000-0003-0419-5549; Sickmann, Albert/0000-0002-2388-5265; Smolenski, Albert/0000-0001-9210-9406				Ayajiki K, 1996, CIRC RES, V78, P750, DOI 10.1161/01.RES.78.5.750; Belhassen L, 1997, J BIOL CHEM, V272, P11198; Birks EJ, 1997, CORONARY ARTERY DIS, V8, P389, DOI 10.1097/00019501-199706000-00007; Bommel HM, 1998, J BIOL CHEM, V273, P33142, DOI 10.1074/jbc.273.50.33142; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BUTT E, 1994, J BIOL CHEM, V269, P14509; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Corson MA, 1996, CIRC RES, V79, P984, DOI 10.1161/01.RES.79.5.984; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; DINERMAN JL, 1994, NEUROPHARMACOLOGY, V33, P1245, DOI 10.1016/0028-3908(94)90023-X; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; DRAIJER R, 1995, CIRC RES, V77, P897, DOI 10.1161/01.RES.77.5.897; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Etter EF, 1996, P NATL ACAD SCI USA, V93, P5368, DOI 10.1073/pnas.93.11.5368; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Fleming I, 1998, CIRC RES, V82, P686, DOI 10.1161/01.RES.82.6.686; Fleming I, 1999, CARDIOVASC RES, V43, P532, DOI 10.1016/S0008-6363(99)00094-2; Fleming I, 1999, P NATL ACAD SCI USA, V96, P1123, DOI 10.1073/pnas.96.3.1123; Fox SW, 1998, BONE, V23, P1, DOI 10.1016/S8756-3282(98)00070-2; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Gambaryan S, 1996, J CLIN INVEST, V98, P662, DOI 10.1172/JCI118837; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GRAIER WF, 1992, BIOCHEM J, V288, P345, DOI 10.1042/bj2880345; HOFMANN H, 1995, BIOCHEMISTRY-US, V34, P13443, DOI 10.1021/bi00041a023; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; POHLER D, 1995, FEBS LETT, V374, P419, DOI 10.1016/0014-5793(95)01168-E; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Reif A, 1999, J BIOL CHEM, V274, P24921, DOI 10.1074/jbc.274.35.24921; Ruan J, 1996, J BIOL CHEM, V271, P22679, DOI 10.1074/jbc.271.37.22679; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Sase K, 1997, TRENDS CARDIOVAS MED, V7, P28, DOI 10.1016/S1050-1738(96)00121-1; UHLER MD, 1993, J BIOL CHEM, V268, P13586; Vaandrager AB, 1997, J BIOL CHEM, V272, P4195, DOI 10.1074/jbc.272.7.4195; Vaandrager AB, 1998, P NATL ACAD SCI USA, V95, P1466, DOI 10.1073/pnas.95.4.1466; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; WALTER U, 1980, J BIOL CHEM, V255, P3757	54	239	251	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5179	5187		10.1074/jbc.275.7.5179	http://dx.doi.org/10.1074/jbc.275.7.5179			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671564	hybrid			2022-12-27	WOS:000085378200090
J	Chessler, SD; Lernmark, A				Chessler, SD; Lernmark, A			Alternative splicing of GAD67 results in the synthesis of a third form of glutamic-acid decarboxylase in human islets and other non-neural tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; DIFFERENTIAL EXPRESSION; CHILDHOOD IDDM; GENE; RAT; ANTIBODIES; ISOFORM; CELLS; MOUSE; AUTOANTIBODIES	Two forms of glutamic-acid decarboxylase (GAD) have been identified in mammalian tissues: a 65-kDa form (GAD65) and a 67-kDa form (GAD67). Alternate splicing produces one or two smaller variants of GAD67 in the brain of embryonic mice and rats. Additionally, a short, heretofore unidentified transcript homologous to GAD67 has been detected in human testis RNA. Because GAD, the enzyme responsible for gamma-aminobutyric acid production and a key autoantigen in type I diabetes, has unclear function in non-neural tissue, it is important to understand its pattern of expression. Unlike GAD65, GAD67 is not produced in human pancreatic islets, Here, we describe a novel splice variant of GAD67 that is produced in human islets, testis, adrenal cortex, and perhaps other endocrine tissues, but not in brain. This transcript directs the synthesis of a protein without GAD enzymatic activity: GAD25. A unique peptide sequence at the carboxyl terminus of GAD25 is highly conserved between mice, rats, and humans. We conclude that humans produce a third form of GAD in non-neural tissues and that human islets, although they do not synthesize full-length GAD67, do express this shortened variant.	Univ Washington, HSB, Robert H Williams Lab, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Chessler, SD (corresponding author), Univ Washington, HSB, Robert H Williams Lab, Dept Med, POB 357710, Seattle, WA 98195 USA.		Lernmark, Åke/F-8140-2015	Lernmark, Åke/0000-0003-1735-0499	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026190, P30DK017047] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53004, DK17047, R01 DK026190, DK26190] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOND RW, 1990, P NATL ACAD SCI USA, V87, P8771, DOI 10.1073/pnas.87.22.8771; Bosma PT, 1999, MOL BIOL EVOL, V16, P397, DOI 10.1093/oxfordjournals.molbev.a026120; CRAM DS, 1995, ENDOCRINOLOGY, V136, P1111, DOI 10.1210/en.136.3.1111; EDELHOFF S, 1993, GENOMICS, V17, P93, DOI 10.1006/geno.1993.1288; Falorni A, 1996, DIABETOLOGIA, V39, P1091; FAULKNERJONES BE, 1993, ENDOCRINOLOGY, V133, P2962, DOI 10.1210/en.133.6.2962; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRUBIN CE, 1994, DIABETOLOGIA, V37, P344, DOI 10.1007/BF00408469; HAGOPIAN WA, 1993, ENDOCRINOLOGY, V132, P2674, DOI 10.1210/en.132.6.2674; HONEYMAN MC, 1993, J EXP MED, V177, P535, DOI 10.1084/jem.177.2.535; KARLSEN AE, 1991, P NATL ACAD SCI USA, V88, P8337, DOI 10.1073/pnas.88.19.8337; KAUFMAN DL, 1992, J CLIN INVEST, V89, P283, DOI 10.1172/JCI115573; KIM J, 1993, DIABETES, V42, P1799, DOI 10.2337/diabetes.42.12.1799; KOBAYASHI Y, 1987, J NEUROSCI, V7, P2768; KRIEGER NR, 1979, J NEUROCHEM, V33, P299, DOI 10.1111/j.1471-4159.1979.tb11732.x; Lernmark A, 1996, J INTERN MED, V240, P259, DOI 10.1046/j.1365-2796.1996.27859000.x; LI LS, 1995, J HISTOCHEM CYTOCHEM, V43, P53, DOI 10.1177/43.1.7822765; Madden TL, 1996, METHOD ENZYMOL, V266, P131; Mally MI, 1996, DIABETES, V45, P496, DOI 10.2337/diabetes.45.4.496; MILLER LP, 1978, J NEUROCHEM, V30, P361, DOI 10.1111/j.1471-4159.1978.tb06538.x; PERSSON H, 1990, MOL CELL BIOL, V10, P4701, DOI 10.1128/MCB.10.9.4701; PETERSEN JS, 1993, DIABETES, V42, P484, DOI 10.2337/diabetes.42.3.484; Roep BO, 1999, J AUTOIMMUN, V13, P267, DOI 10.1006/jaut.1999.0312; SEISSLER J, 1993, J CLIN INVEST, V92, P1394, DOI 10.1172/JCI116714; SEISSLER J, 1994, AUTOIMMUNITY, V19, P231, DOI 10.3109/08916939409071348; Solimena M, 1998, DIABETES METAB REV, V14, P227, DOI 10.1002/(SICI)1099-0895(1998090)14:3<227::AID-DMR215>3.0.CO;2-E; SZABO G, 1994, MOL CELL BIOL, V14, P7535, DOI 10.1128/MCB.14.11.7535; Szabo G, 1996, DNA CELL BIOL, V15, P1081, DOI 10.1089/dna.1996.15.1081; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; von Boehmer H, 1999, SCIENCE, V284, P1135; Yoon JW, 1999, SCIENCE, V284, P1183, DOI 10.1126/science.284.5417.1183	32	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5188	5192		10.1074/jbc.275.7.5188	http://dx.doi.org/10.1074/jbc.275.7.5188			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671565	hybrid			2022-12-27	WOS:000085378200091
J	Ciriolo, MR; De Martino, A; Lafavia, E; Rossi, L; Carri, MT; Rotilio, G				Ciriolo, MR; De Martino, A; Lafavia, E; Rossi, L; Carri, MT; Rotilio, G			Cu,Zn-superoxide dismutase-dependent apoptosis induced by nitric oxide in neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; CYTOCHROME-C RELEASE; SUPEROXIDE-DISMUTASE; MEDIATED APOPTOSIS; CDK INHIBITOR; PEROXYNITRITE; DEATH; ACTIVATION; CLEAVAGE; COPPER	Nitric oxide (NO) challenge to human neuroblastoma cells (SH-SY5Y) ultimately results in apoptosis, Tumor suppressor protein p53 and cell cycle inhibitor p21 accumulate as an early sign of S-nitrosoglutathione-mediated toxicity. Cytochrome c release from mitochondria and caspase 3 activation also occurred. Cells transfected with either wild type (WT) or mutant (G93A) Cu,Zn-superoxide dismutase (Cu,Zn-SOD) produced comparable amounts of nitrite/nitrate but showed different degree of apoptosis, G93A cells were the most affected and WT cells the most protected; however, Cu,Zn-SOD content of these two cell lines was a-fold the SH-SY5Y cells under both resting and treated conditions. We linked decreased susceptibility of the WT cells to higher and more stable Bcl-2 and decreased reactive oxygen species. Conversely, we linked G93A susceptibility to increased reactive oxygen species production since simultaneous administration of S-nitrosoglutathione and copper chelators protects from apoptosis, Furthermore, G93A cells showed a significant decrease of Bcl-2 expression and, as target of NO-derived radicals, showed lower cytochrome c oxidase activity. These results demonstrate that resistance to NO-mediated apoptosis is strictly related to the level and integrity of Cu,Zn-SOD and that the balance between reactive nitrogen and reactive oxygen species regulates neuroblastoma apoptosis.	Univ G dAnnunzio, Dept Biomed Sci, I-66100 Chieti, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; IRCCS, I-00178 Rome, Italy; Ctr Neurobiol Sperimentale Mondino Tor Vergata S, I-00178 Rome, Italy	G d'Annunzio University of Chieti-Pescara; University of Rome Tor Vergata	Ciriolo, MR (corresponding author), Univ G dAnnunzio, Dept Biomed Sci, Via Vestini, I-66100 Chieti, Italy.	Ciriolo@bio.uniroma2.it	Ciriolo, Maria Rosa/K-6572-2016; Carri, Maria Teresa/K-5480-2016	Ciriolo, Maria Rosa/0000-0002-7863-9029; Carri, Maria Teresa/0000-0002-1789-1546				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Beckman J. S., 1996, NITRIC OXIDE PRINCIP; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; Bonfoco E, 1996, NEUROREPORT, V8, P273, DOI 10.1097/00001756-199612200-00054; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Brockhaus F, 1999, BIOCHEM J, V338, P295, DOI 10.1042/0264-6021:3380295; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Brune B, 1997, J BIOL CHEM, V272, P7253, DOI 10.1074/jbc.272.11.7253; Carri MT, 1997, FEBS LETT, V414, P365, DOI 10.1016/S0014-5793(97)01051-X; CIRIOLO MR, 1994, J BIOL CHEM, V269, P25783; Ciriolo MR, 1997, J BIOL CHEM, V272, P2700, DOI 10.1074/jbc.272.5.2700; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ESTEVEZ AG, 1995, J NEUROCHEM, V65, P1543; FISCELLA M, 1993, ONCOGENE, V8, P1519; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; Gabbianelli R, 1999, J NEUROCHEM, V73, P1175, DOI 10.1046/j.1471-4159.1999.0731175.x; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Ghibelli L, 1999, FASEB J, V13, P2031, DOI 10.1096/fasebj.13.14.2031; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; Inoue K, 1999, J BIOL CHEM, V274, P27069, DOI 10.1074/jbc.274.38.27069; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kim YM, 1999, CIRC RES, V84, P253, DOI 10.1161/01.RES.84.3.253; Kitamura Y, 1998, NEUROCHEM INT, V32, P93, DOI 10.1016/S0197-0186(97)00029-6; Leist M, 1998, EXP CELL RES, V239, P183, DOI 10.1006/excr.1997.4026; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Melkova Z, 1997, FEBS LETT, V403, P273, DOI 10.1016/S0014-5793(97)00065-3; Messmer UK, 1996, J BIOL CHEM, V271, P20192, DOI 10.1074/jbc.271.33.20192; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MONCADA S, 1991, PHARMACOL REV, V43, P109; Morrison BM, 1999, BRAIN RES REV, V29, P121, DOI 10.1016/S0165-0173(98)00049-6; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Patel BN, 1997, J BIOL CHEM, V272, P20185, DOI 10.1074/jbc.272.32.20185; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; RADI R, 1991, J BIOL CHEM, V266, P4244; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; RIGO A, 1975, ANAL BIOCHEM, V68, P1, DOI 10.1016/0003-2697(75)90672-7; ROSSI L, 1994, BIOCHEM BIOPH RES CO, V203, P1028, DOI 10.1006/bbrc.1994.2285; Rota C, 1999, J BIOL CHEM, V274, P28161, DOI 10.1074/jbc.274.40.28161; Rubin LL, 1997, BRIT MED BULL, V53, P617; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; Schmidt H. H. W., 1996, METHODS NITRIC OXIDE, P491; Sharpe MA, 1998, J BIOL CHEM, V273, P30961, DOI 10.1074/jbc.273.47.30961; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; STEINKUHLER C, 1991, J BIOL CHEM, V266, P24580; Szabo C, 1996, FEBS LETT, V381, P82, DOI 10.1016/0014-5793(96)00087-7; Tamatani M, 1998, J NEUROCHEM, V71, P1588; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Troy CM, 1996, J NEUROSCI, V16, P253; Uehara T, 1999, J NEUROCHEM, V72, P196, DOI 10.1046/j.1471-4159.1999.0720196.x; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	66	97	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5065	5072		10.1074/jbc.275.7.5065	http://dx.doi.org/10.1074/jbc.275.7.5065			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671549	hybrid			2022-12-27	WOS:000085378200075
J	Lin, X; Mattjus, P; Pike, HM; Windebank, AJ; Brown, RE				Lin, X; Mattjus, P; Pike, HM; Windebank, AJ; Brown, RE			Cloning and expression of glycolipid transfer protein from bovine and porcine brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR PROTEIN; PIG BRAIN; VEGETATIVE INCOMPATIBILITY; NEUTRAL GLYCOSPHINGOLIPIDS; GLUCOSYLCERAMIDE SYNTHASE; FILAMENTOUS FUNGI; HET-C; PURIFICATION; MEMBRANES; CELLS	Glycolipid transfer protein (GLTP) is a small (23-24 kDa), basic protein (pI congruent to 9.0) that accelerates the intermembrane transfer of various glycolipids. Here, we report the first cloning of cDNAs that encode the bovine and porcine GLTPs, The cDNA open reading frame for bovine GLTP was constructed by bridge-overlapping extension polymerase chain reaction (PCR) after obtaining partial coding cDNA clones by hot start, seminested, and rapid amplification of cDNA ends-PCR. The cDNA open reading frame for porcine GLTP was constructed by reverse transcriptase-PCR, The encoded amino acid sequences in the full-length bovine and porcine cDNAs were identical, consisting of 209 amino acid residues, and were nearly the same as the published sequence determined by Edman degradation. The cDNA encoded one additional amino acid at the N terminus (methionine), arginine at positions 10 and 200 instead of lysine, and threonine at position 65 instead of alanine, Expression of GLTP-cDNA in Escherichia coli using pGEX-6P-1 vector resulted in glutathione S-transferase (GST)GLTP fusion protein. Regulation of growth and induction conditions led to --50% of expressed fusion protein being soluble and active. Proteolytic cleavage of GST-GLTP fusion protein (bound to GST-Sepharose) and affinity purification resulted in fully active GLTP. Northern blot analyses of bovine tissues showed a single transcript of similar to 2.2 kilobases and the following hierarchy of mRNA levels: cerebrum > kidney > spleen congruent to lung congruent to cerebellum > liver > heart muscle. Reverse transcriptase-PCR analyses of mRNA levels supported the Northern blot results.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	University of Minnesota System; Mayo Clinic; Mayo Clinic	Brown, RE (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	reb@maroon.tc.umn.edu	Mattjus, Peter/ABE-3596-2021; Mattjus, Peter/AAQ-7531-2021	Mattjus, Peter/0000-0001-8991-5933; Brown, Rhoderick/0000-0002-7337-3604	NIGMS NIH HHS [R01-GM45928, R01 GM045928, R01 GM045928-08, R01 GM045928-07] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045928] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE A, 1989, BIOCHIM BIOPHYS ACTA, V985, P38, DOI 10.1016/0005-2736(89)90100-4; ABE A, 1990, J BIOL CHEM, V265, P9634; ABE A, 1985, J BIOL CHEM, V260, P1231; ABE A, 1989, BIOCHIM BIOPHYS ACTA, V985, P45, DOI 10.1016/0005-2736(89)90101-6; BANKAITIS WA, 1996, PHOSPHOLIPID TRANSFE, P51; BEGUERET J, 1994, TRENDS GENET, V10, P441, DOI 10.1016/0168-9525(94)90115-5; BLOJ B, 1981, J BIOL CHEM, V256, P5988; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN RE, 1990, BIOCHIM BIOPHYS ACTA, V1044, P77, DOI 10.1016/0005-2760(90)90221-I; BROWN RE, 1985, CHEM PHYS LIPIDS, V38, P79, DOI 10.1016/0009-3084(85)90059-3; Brown RE, 1998, J CELL SCI, V111, P1; BROWN RE, 1988, J CELL BIOL, V107, pA2045; CHEN WS, 1995, ONCOL REP, V2, P5; CONZELMANN E, 1982, EUR J BIOCHEM, V123, P455, DOI 10.1111/j.1432-1033.1982.tb19789.x; DATTA SC, 1988, LIPIDS, V23, P508, DOI 10.1007/BF02535529; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; GAMMON CM, 1987, BIOCHEMISTRY-US, V26, P6239, DOI 10.1021/bi00393a043; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; Ichikawa S, 1998, TRENDS CELL BIOL, V8, P198, DOI 10.1016/S0962-8924(98)01249-5; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kolter T, 1998, BRAIN PATHOL, V8, P79; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lin X, 1999, MOL BIOL CELL, V10, p175A; Mahuran DJ, 1998, BBA-LIPID LIPID MET, V1393, P1, DOI 10.1016/S0005-2760(98)00057-5; MARSH NL, 1995, J CLIN INVEST, V95, P2903, DOI 10.1172/JCI117997; Mattjus P, 1999, ANAL BIOCHEM, V268, P297, DOI 10.1006/abio.1998.3065; MATTJUS P, 2000, IN PRESS BIOCHEMISTR; METZ RJ, 1982, J BIOL CHEM, V257, P2901; METZ RJ, 1980, J BIOL CHEM, V255, P4463; Moreau P, 1998, PROG LIPID RES, V37, P371, DOI 10.1016/S0163-7827(98)00016-2; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Okazaki T, 1998, CELL SIGNAL, V10, P685, DOI 10.1016/S0898-6568(98)00035-7; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SASAKI T, 1990, EXPERIENTIA, V46, P611, DOI 10.1007/BF01939700; Sasaki T, 1990, Subcell Biochem, V16, P113; SAUPE S, 1994, P NATL ACAD SCI USA, V91, P5927, DOI 10.1073/pnas.91.13.5927; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; SOEDA S, 1993, J BIOL CHEM, V268, P18519; VOGEL A, 1991, EUR J BIOCHEM, V200, P591, DOI 10.1111/j.1432-1033.1991.tb16222.x; Wirtz KWA, 1997, BIOCHEM J, V324, P353, DOI 10.1042/bj3240353; Wu J, 1998, P NATL ACAD SCI USA, V95, P12398, DOI 10.1073/pnas.95.21.12398; YAMADA K, 1985, J BIOL CHEM, V260, P4615; YAMADA K, 1986, BIOCHIM BIOPHYS ACTA, V879, P345	47	54	57	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5104	5110		10.1074/jbc.275.7.5104	http://dx.doi.org/10.1074/jbc.275.7.5104			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671554	Green Accepted, hybrid			2022-12-27	WOS:000085378200080
J	Feder, R; Dagan, A; Mor, A				Feder, R; Dagan, A; Mor, A			Structure-activity relationship study of antimicrobial dermaseptin S4 showing the consequences of peptide oligomerization on selective cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-MEMBRANES; MOLECULAR-BASIS; FROG-SKIN; ANTIBIOTICS; ANALOGS; DESIGN; S3	To understand how peptide organization in aqueous solution might affect the activity of antimicrobial peptides, the potency of various dermaseptin S4 analogs was assessed against human red blood cells (RBC), protozoa, and several Gram-negative bacteria. Dermaseptin 54 had weak antibacterial activity but potent hemolytic or antiprotozoan effects. K4K20-S4 was 2-3 fold more potent against protozoa and RBC, yet K4K20-S4 was more potent by 2 orders of magnitude against bacteria. K-4-S4 had similar behavior as K4K20-S4, but K-20-S4 and analogous negative charge substitutions were as active as dermaseptin 54 or had reduced activity. Binding experiments suggested that potency enhancement was not the result of increased affinity to target cells. In contrast, potency correlated well with aggregation properties. Fluorescence studies indicated that K-20-S4 and all negative charge substitutions were as aggregated as dermaseptin S4, whereas K-4-S4 and K4K20-S4 were clearly less aggregated. Overall, the data indicated that N-terminal domain interaction between dermaseptin 54 monomers is responsible for the peptide's oligomerization in solution and, hence, for its limited spectrum of action. Moreover, bell-shaped dose-response profiles obtained with bacteria but not with protozoa or RBC implied that aggregation can have dramatic consequences on antibacterial activity. Based on these results, we tested the feasibility of selectivity reversal in the activity of dermaseptin 54, Tampering with the composition of the hydrophobic domains by reducing hydrophobicity or by increasing the net positive charge affected dramatically the peptide's activity and resulted in various analogs that displayed potent antibacterial activity but reduced hemolytic activity. Among these, maximal antibacterial activity was displayed by a 15-mer version that was more potent by 2 orders of magnitude compared with native dermaseptin 54, These results emphasize the notion that peptide-based antibiotics represent a highly modular synthetic antimicrobial system and provide indications of how the peptide's physico-chemical properties affect potency and selectivity.	Hebrew Univ Jerusalem, Wolfson Ctr Appl Struct Biol, Lab Antimicrobial Peptides Invest, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Mor, A (corresponding author), Hebrew Univ Jerusalem, Wolfson Ctr Appl Struct Biol, Lab Antimicrobial Peptides Invest, IL-91904 Jerusalem, Israel.							BESSALLE R, 1993, J MED CHEM, V36, P1203, DOI 10.1021/jm00061a011; BLONDELLE SE, 1992, BIOCHEMISTRY-US, V31, P12688, DOI 10.1021/bi00165a020; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Coote PJ, 1998, ANTIMICROB AGENTS CH, V42, P2160, DOI 10.1128/AAC.42.9.2160; De Lucca AJ, 1998, MED MYCOL, V36, P291, DOI 10.1080/02681219880000461; EPAND RM, 1995, BIOPOLYMERS, V37, P319, DOI 10.1002/bip.360370504; FROHLICH DR, 1991, INT J PEPT PROT RES, V37, P2; Ghosh JK, 1997, J BIOL CHEM, V272, P31609, DOI 10.1074/jbc.272.50.31609; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; HERNANDEZ C, 1992, EUR J CELL BIOL, V59, P414; Jouenne T, 1998, J ANTIMICROB CHEMOTH, V42, P87, DOI 10.1093/jac/42.1.87; KYTE J, 1982, J MOL BIOL, V157, P106; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P3423, DOI 10.1021/bi00010a034; MOR A, 1994, BIOCHEMISTRY-US, V33, P6642, DOI 10.1021/bi00187a034; MOR A, 1994, J BIOL CHEM, V269, P1934; MOR A, 1994, J BIOL CHEM, V269, P31635; MOR A, 1994, EUR J BIOCHEM, V219, P145, DOI 10.1111/j.1432-1033.1994.tb19924.x; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; STRAHILEVITZ J, 1994, BIOCHEMISTRY-US, V33, P10951, DOI 10.1021/bi00202a014; ZASLOFF M, 1988, P NATL ACAD SCI USA, V85, P910, DOI 10.1073/pnas.85.3.910	23	158	168	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4230	4238		10.1074/jbc.275.6.4230	http://dx.doi.org/10.1074/jbc.275.6.4230			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660589	hybrid			2022-12-27	WOS:000085288800073
J	Cissel, DS; Beaven, MA				Cissel, DS; Beaven, MA			Disruption of Raf-1/heat shock protein 90 complex and Raf signaling by dexamethasone in mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; KAPPA-B ACTIVITY; FC-EPSILON-RI; NUCLEAR FACTOR; IGE RECEPTOR; KINASE; ACTIVATION; ALPHA; PATHWAY; HSP90	Antigen stimulation of mast cells via the IgE receptor, Fc epsilon RI, results in the recruitment of the cytosolic tyrosine kinase, Syk, and the activation of various signaling cascades. One of these, the extracellular signal-regulated kinase (ERK2) cascade, is inhibited by low concentrations of the immunosuppressant drug, dexamethasone, probably at a step prior to the activation of Raf-1 (Rider, L. G., Hirasawa, N., Santini, F., and Beaven, M. A. (1996) J. Immunol. 157, 2374-2380). We now show that treatment of cultured RBL-2H3 mast cells with nanomolar concentrations of dexamethasone causes dissociation of the Raf-1 heat shock protein 90 (Hsp90) complex. Raf-1 bereft of this protein fails to associate with the membrane or Ras in antigen-stimulated cells. Upstream events such as the Syk-dependent phosphorylation of Shc, the engagement of Shc with the adapter protein, Grb2, and the activation of Ras itself are unaffected. interestingly, the counterpart of Raf-1 in the c-Jun N-terminal kinase (JNK) cascade, MEKK-1 (mitogen-activated protein kinase/ERK kinase), is similarly associated with Hsp90 and this association as well as the activation of MEKK-1 are disrupted by dexamethasone treatment. Disruption of the ERK and JNK cascades at the level of Raf-1 and MEKK-1 could account for the inhibitory action of dexamethasone on the generation of inflammatory mediators in stimulated mast cells.	NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Beaven, MA (corresponding author), NHLBI, Lab Mol Immunol, NIH, Bldg 10,Rm 8N109, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000990, Z01HL000990] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Baumgartner RA, 1996, J IMMUNOL, V157, P1625; Cato ACB, 1996, BIOESSAYS, V18, P371, DOI 10.1002/bies.950180507; Coss MC, 1998, CELL GROWTH DIFFER, V9, P41; CUENOD BJ, 1996, J BIOL CHEM, V271, P16268; DRESKIN SC, 1989, J IMMUNOL, V142, P4407; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; Hirasawa N, 1998, J IMMUNOL, V161, P4939; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; JONES SVP, 1991, FEBS LETT, V289, P47, DOI 10.1016/0014-5793(91)80905-I; Kanno T, 1996, J IMMUNOL, V157, P5277; Kimura T, 1997, J BIOL CHEM, V272, P13991, DOI 10.1074/jbc.272.21.13991; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Louvion JF, 1998, MOL BIOL CELL, V9, P3071, DOI 10.1091/mbc.9.11.3071; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; OSullivan BT, 1997, BIOL PSYCHIAT, V41, P574, DOI 10.1016/S0006-3223(96)00094-7; Pelletier C, 1998, J IMMUNOL, V161, P4768; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; PRIESCHL EE, 1995, J IMMUNOL, V155, P4963; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; Rider LG, 1996, J IMMUNOL, V157, P2374; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Sternberg PW, 1998, CELL, V95, P447, DOI 10.1016/S0092-8674(00)81612-8; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; vanderStraten A, 1997, EMBO J, V16, P1961, DOI 10.1093/emboj/16.8.1961; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355; Zhang C, 1997, J BIOL CHEM, V272, P13397, DOI 10.1074/jbc.272.20.13397; Zhang C, 1997, J IMMUNOL, V158, P4968; Ziogas A, 1998, J BIOL CHEM, V273, P24108, DOI 10.1074/jbc.273.37.24108	37	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7066	7070		10.1074/jbc.275.10.7066	http://dx.doi.org/10.1074/jbc.275.10.7066			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702272	hybrid			2022-12-27	WOS:000085809600052
J	Emoto, M; Klarlund, JK; Waters, SB; Hu, V; Buxton, JM; Chawla, A; Czech, MP				Emoto, M; Klarlund, JK; Waters, SB; Hu, V; Buxton, JM; Chawla, A; Czech, MP			A role for phospholipase D in GLUT4 glucose transporter translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; NASCENT SECRETORY VESICLES; PROTEIN-KINASE; PLASMA-MEMBRANE; RAT ADIPOCYTES; PHOSPHOINOSITIDE 3-KINASE; INSULIN STIMULATION; SIGNAL-TRANSDUCTION; 3T3-L1 ADIPOCYTES	Based on recent studies showing that phospholipase D (PLD)1 is associated with intracellular membranes and promotes membrane budding from the trans-Golgi, we tested its possible role in the membrane trafficking of GLUT4 glucose transporters. Using immunofluorescence confocal microscopy, expressed Myc epitope-tagged PLD1 was found to associate with intracellular vesicular structures by a mechanism that requires its N-terminal pleckstrin homology domain, partial co-localization with expressed GLUT4 fused to green fluorescent protein in both 3T3-L1 adipocytes and Chinese hamster ovary cells was evident. Furthermore, microinjection of purified FED into cultured adipocytes markedly potentiated the effect of a submaximal concentration of insulin to stimulate GLUT4 translocation to cell surface membranes. Insulin stimulated PLD activity in cells expressing high levels of insulin receptors but no such insulin effect was detected in 3T3-L1 adipocytes, Taken together, these results are consistent with the hypothesis that PLD1 associated with GLUT4-containing membranes acts in a constitutive manner to promote the mechanism of GLUT4 translocation by insulin.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01655 USA; Metabolex Inc, Hayward, CA 94545 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Czech, MP (corresponding author), Univ Massachusetts, Med Ctr, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.	Michael.Czech@umassmed.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030898, R01DK030898] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30898] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashery U, 1999, P NATL ACAD SCI USA, V96, P1094, DOI 10.1073/pnas.96.3.1094; AUGERT G, 1988, J BIOL CHEM, V263, P3600; Bae YS, 1999, J LEUKOCYTE BIOL, V65, P241, DOI 10.1002/jlb.65.2.241; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bottomley MJ, 1998, BBA-MOL CELL BIOL L, V1436, P165, DOI 10.1016/S0005-2760(98)00141-6; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Charron MJ, 1999, J BIOL CHEM, V274, P3253, DOI 10.1074/jbc.274.6.3253; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Chen YG, 1996, J BIOL CHEM, V271, P5297, DOI 10.1074/jbc.271.10.5297; Coffer PJ, 1998, BIOCHEM J, V335, P1; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Cox D, 1999, J BIOL CHEM, V274, P1240, DOI 10.1074/jbc.274.3.1240; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Hinchliffe KA, 1998, BBA-MOL CELL BIOL L, V1436, P87, DOI 10.1016/S0005-2760(98)00140-4; HOULE, 1999, BIOCHIM BIOPHYS ACTA, V1439, P135; Irvine R, 1998, CURR BIOL, V8, pR557, DOI 10.1016/S0960-9822(07)00360-0; Jones AT, 1997, BIOCHEM BIOPH RES CO, V236, P285, DOI 10.1006/bbrc.1997.6962; Jones D, 1999, BBA-MOL CELL BIOL L, V1439, P229, DOI 10.1016/S1388-1981(99)00097-9; Karnam P, 1997, J BIOL CHEM, V272, P6136, DOI 10.1074/jbc.272.10.6136; Katan M, 1999, FEBS LETT, V452, P36, DOI 10.1016/S0014-5793(99)00531-1; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Kusner DJ, 1999, J IMMUNOL, V162, P2266; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Meier KE, 1999, BBA-MOL CELL BIOL L, V1439, P199, DOI 10.1016/S1388-1981(99)00095-5; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Morris AJ, 1997, ANAL BIOCHEM, V252, P1, DOI 10.1006/abio.1997.2299; Moss J, 1999, MOL CELL BIOCHEM, V193, P153, DOI 10.1023/A:1006993000870; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; OKADA T, 1994, J BIOL CHEM, V269, P3568; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shome K, 1997, CURR BIOL, V7, P387, DOI 10.1016/S0960-9822(06)00186-2; Spang A, 1998, P NATL ACAD SCI USA, V95, P11199, DOI 10.1073/pnas.95.19.11199; Stamnes M, 1998, P NATL ACAD SCI USA, V95, P13676, DOI 10.1073/pnas.95.23.13676; Standaert ML, 1996, BIOCHEM J, V313, P1039, DOI 10.1042/bj3131039; Tolias KF, 1999, CHEM PHYS LIPIDS, V98, P69, DOI 10.1016/S0009-3084(99)00019-5; Venkateswarlu K, 1998, BIOCHEM J, V335, P139, DOI 10.1042/bj3350139; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Vollenweider P, 1997, ENDOCRINOLOGY, V138, P4941, DOI 10.1210/en.138.11.4941; Wang QH, 1999, MOL CELL BIOL, V19, P4008; WHITE MF, 1994, J BIOL CHEM, V269, P1; Wilkie N, 1996, J BIOL CHEM, V271, P32447, DOI 10.1074/jbc.271.50.32447; YANG J, 1993, J BIOL CHEM, V268, P4600	59	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7144	7151		10.1074/jbc.275.10.7144	http://dx.doi.org/10.1074/jbc.275.10.7144			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702282	hybrid			2022-12-27	WOS:000085809600062
J	Strassheim, D; Porter, RA; Phelps, SH; Williams, CL				Strassheim, D; Porter, RA; Phelps, SH; Williams, CL			Unique in vivo associations with SmgGDS and RhoGDI and different guanine nucleotide exchange activities exhibited by RhoA, dominant negative RhoA(Asn-19) and activated RhoA(Val-14)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; SIGNALING PATHWAYS; FAMILY PROTEINS; RAS P21; KINASE; GDP; IDENTIFICATION; TRANSLOCATION; DISSOCIATION; PROMOTER	We compared the in vivo characteristics of hemagglutinin (HA)-tagged RhoA, dominant negative RhoA(Asn-19) and activated RhoA(Val-14) stably expressed in Chinese hamster ovary (CHO) cells. Proteins co-precipitating with these HA-tagged GTPases were identified by peptide sequencing or by Western blotting. Dominant negative RhoA(Asn-19) co-precipitates with the guanine nucleotide exchange factor (GEF) SmgGDS but does not detectably interact with other expressed GEFs, such as Ost or Dbl, SmgGDS co-precipitates minimally with wild-type RhoA and does not detectably associate with RhoA(Val-14). The guanine nucleotide dissociation inhibitor RhoGDI co-precipitates with RhoA, and to a lesser extent with RhoA(Val-14), but does not detectably co-precipitate with RhoA(Asn-19). Wild-type RhoA is predominantly in the [P-32]GDP-bound form, RhoA(Val-14) is predominantly in the [P-32]GTP-bound form, and negligible levels of [P-32]GDP or [P-32]GTP are bound to RhoA(Asn-19) in P-32-labeled cells. Immunofluorescence analyses indicate that HA-RhoA(Asn-19) is excluded from the nucleus and cell junctions. Microinjection of SmgGDS cDNA into CHO cells stably expressing HA-RhoA causes HA-RhoA to be excluded from the nucleus and cell junctions, similar to the distribution of RhoA(Asn-19). Our findings indicate that the expression of RhoA(Asn-19) may specifically inhibit signaling pathways that rely upon the SmgGDS-dependent activation of RhoA.	Guthrie Res Inst, Mol Pharmacol Lab, Sayre, PA 18840 USA		Williams, CL (corresponding author), Guthrie Res Inst, Mol Pharmacol Lab, Sayre, PA 18840 USA.		STRASSHEIM, DEREK/AHB-1158-2022					Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; Baldassare JJ, 1997, J BIOL CHEM, V272, P4911, DOI 10.1074/jbc.272.8.4911; CHUANG TH, 1994, BIOCHEM J, V303, P761, DOI 10.1042/bj3030761; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FUJIOKA H, 1992, J BIOL CHEM, V267, P926; GIBBS JB, 1995, METHOD ENZYMOL, V255, P118; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Iouzalen N, 1998, BIOCHEM BIOPH RES CO, V250, P359, DOI 10.1006/bbrc.1998.9336; ITOH T, 1991, BIOCHEM BIOPH RES CO, V177, P1319, DOI 10.1016/0006-291X(91)90685-Z; JENO P, 1995, ANAL BIOCHEM, V224, P75, DOI 10.1006/abio.1995.1010; KAWAMURA M, 1993, BIOCHEM BIOPH RES CO, V190, P832, DOI 10.1006/bbrc.1993.1124; Lorenzi MV, 1999, ONCOGENE, V18, P4742, DOI 10.1038/sj.onc.1202851; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; ORITA S, 1993, J BIOL CHEM, V268, P25542; PATERSON H, 1995, METHOD ENZYMOL, V256, P162; PIZON V, 1994, J CELL SCI, V107, P1661; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954; Ruiz-Velasco V, 1998, J PHYSIOL-LONDON, V513, P761, DOI 10.1111/j.1469-7793.1998.761ba.x; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; Shimizu K, 1996, J BIOL CHEM, V271, P27013, DOI 10.1074/jbc.271.43.27013; Strassheim D, 1999, J BIOL CHEM, V274, P18675, DOI 10.1074/jbc.274.26.18675; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Williams CL, 1996, BIOCHEM PHARMACOL, V51, P707, DOI 10.1016/S0006-2952(95)02393-3; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	31	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6699	6702		10.1074/jbc.275.10.6699	http://dx.doi.org/10.1074/jbc.275.10.6699			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702222	hybrid			2022-12-27	WOS:000085809600002
J	Bastian, S; Pruneau, D; Loillier, B; Robert, C; Bonnafous, JC; Paquet, JL				Bastian, S; Pruneau, D; Loillier, B; Robert, C; Bonnafous, JC; Paquet, JL			Identification of a key region of kinin B-1 receptor for high affinity binding of peptide antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRADYKININ B2 RECEPTOR; 7TH TRANSMEMBRANE DOMAIN; ANGIOTENSIN-II RECEPTOR; 2 AMINO-ACIDS; SIGNAL-TRANSDUCTION; HUMAN B1; PHOSPHOLIPASE-C; POINT MUTATION; TERMINUS; INTERNALIZATION	To investigate the molecular basis for the specificity of ligand recognition in human kinin B-1 (B1R) and B-2 (B2R) receptors, we constructed a series of chimeric receptors by progressively replacing, from the N to the C terminus, the human B2R domains by their B-1 counterparts. The chimeric construct possessing the C-terminal tail and the transmembrane domain VII (TM VII) of the B2R (construct 6) displayed 7- and 20 fold decreased affinities for the B-1 agonist [H-3]desArg(10)-kallidin (desArg(10)-KD) and the B-1 antagonist [H-3]desArg(10)-[Leu(9)]KD respectively, as compared with the wild-type B1R. Moreover, the substitution of the B-1 TM VII by its B-2 homologue TM increased the affinity for the pseudopeptide antagonists, Hoe140 and NPC 567, High affinity for desArg(10)-KD binding was fully regained when the B-2 residue Thr(287) was replaced in construct 6 by the corresponding B-1 Leu(294) residue. When the B-2 residue Tyr(295) was exchanged with the corresponding B-1 Phe(302), high affinity binding for both agonist and antagonist was recovered. Moreover, the L294T and F302Y mutant B1R exhibited 69- and 6.5-fold increases, respectively, in their affinities for the B-2 receptor antagonist, Hoe140. Therefore we proposed that Leu(294) and Phe(302) residues, which may not be directly involved in the binding of B1R ligands and, hence, their Thr(287) and Tyr(295) B-2 counterparts, are localized in a receptor region, which plays a pivotal role in the binding selectivity of the peptide or pseudopeptide kinin ligands.	Ctr Rech Labs Fournier, F-21121 Daix, France; INSERM, U439, F-34090 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Bastian, S (corresponding author), Ctr Rech Labs Fournier, 50 Route Dijon, F-21121 Daix, France.							Abd Alla S., 1996, J BIOL CHEM, V271, P1748; ADHAM N, 1994, NEUROPHARMACOLOGY, V33, P387, DOI 10.1016/0028-3908(94)90068-X; Bastian S, 1997, BRIT J PHARMACOL, V122, P393, DOI 10.1038/sj.bjp.0701380; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Fathy DB, 1998, J BIOL CHEM, V273, P12210, DOI 10.1074/jbc.273.20.12210; Faussner A, 1998, J BIOL CHEM, V273, P2617, DOI 10.1074/jbc.273.5.2617; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; HALL JM, 1992, PHARMACOL THERAPEUT, V56, P131, DOI 10.1016/0163-7258(92)90016-S; Herzig MCS, 1996, J BIOL CHEM, V271, P29746, DOI 10.1074/jbc.271.47.29746; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HOCK FJ, 1991, BRIT J PHARMACOL, V102, P769, DOI 10.1111/j.1476-5381.1991.tb12248.x; Jarnagin K, 1996, J BIOL CHEM, V271, P28277, DOI 10.1074/jbc.271.45.28277; KAUPMANN K, 1995, EMBO J, V14, P727, DOI 10.1002/j.1460-2075.1995.tb07051.x; Leeb T, 1997, J BIOL CHEM, V272, P311; Marceau F, 1998, PHARMACOL REV, V50, P357; MARIE J, 1994, J BIOL CHEM, V269, P20815; MENKE JG, 1994, J BIOL CHEM, V269, P21583; MOROHASHI H, 1995, J LEUKOCYTE BIOL, V57, P180, DOI 10.1002/jlb.57.1.180; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4417, DOI 10.1073/pnas.91.10.4417; NOVOTNY EA, 1994, BIOCHEM BIOPH RES CO, V201, P523, DOI 10.1006/bbrc.1994.1733; OKSENBERG D, 1992, NATURE, V360, P161, DOI 10.1038/360161a0; Pease JE, 1998, J BIOL CHEM, V273, P19972, DOI 10.1074/jbc.273.32.19972; Prado GN, 1997, J BIOL CHEM, V272, P14638, DOI 10.1074/jbc.272.23.14638; Prado GN, 1998, J BIOL CHEM, V273, P33548, DOI 10.1074/jbc.273.50.33548; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; REGOLI D, 1980, PHARMACOL REV, V32, P1; Satoh S, 1999, BIOCHEM BIOPH RES CO, V255, P164, DOI 10.1006/bbrc.1998.0161; Shyu JF, 1996, J BIOL CHEM, V271, P31127, DOI 10.1074/jbc.271.49.31127; STEWART JM, 1991, BRADYKININ ANTAGONIS, P51; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUCKER AL, 1994, J BIOL CHEM, V269, P27900; Wirth K J, 1992, Agents Actions Suppl, V38 ( Pt 2), P406	36	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6107	6113		10.1074/jbc.275.9.6107	http://dx.doi.org/10.1074/jbc.275.9.6107			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692400	hybrid			2022-12-27	WOS:000085654400012
J	Anderson, AE; Adams, JP; Qian, Y; Cook, RG; Pfaffinger, PJ; Sweatt, JD				Anderson, AE; Adams, JP; Qian, Y; Cook, RG; Pfaffinger, PJ; Sweatt, JD			Kv4.2 phosphorylation by cyclic AMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIENT OUTWARD CURRENTS; GLUTATHIONE-S-TRANSFERASE; SQUID GIANT-AXON; K+ CHANNEL; POTASSIUM CHANNEL; PYRAMIDAL NEURONS; SUBTHRESHOLD POTENTIALS; SINGLE CHANNEL; EXPRESSION; BRAIN	Recent evidence suggests that K+ channels composed of Kv4.2 alpha-subunits underlie a transient current in hippocampal CA1 neurons and ventricular myocytes, and activation of the cAMP second messenger cascade has been shown to modulate this transient current. We determined if Kv4.2 alpha-subunits were directly phosphorylated by cAMP-dependent protein kinase (PKA). The intracellular domains of the amino and carboxyl termini of Kv4.2 were expressed as glutathione S-transferase fusion protein constructs; we observed that both of these fusion proteins were substrates for PKA in vitro. By using phosphopeptide mapping and amino acid sequencing, we identified PHA phosphorylation sites on the amino- and carboxyl-terminal fusion proteins corresponding to Thr(38) and Ser(552), respectively, within the Kv4.2 sequence. Kinetic characterization of the PKA sites demonstrated phosphorylation kinetics comparable to Kemptide. To evaluate PKA site phosphorylation in situ, phospho-selective antisera for each of the sites were generated. By using COS-7 cells expressing an EGFP-Kv4.2 fusion protein, we observed that stimulation of the endogenous PKA cascade resulted in an increase in phosphorylation of Thr(38) and Ser(552) within Kv4.2 in the intact cell. We also observed modulation of PKA phosphorylation at these sites within Kv4.2 in hippocampal area CA1. These results provide insight into likely sites of regulation of Kv4.2 by PKA.	Baylor Coll Med, Dept Pediat & Neurol, Houston, TX 77030 USA; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Anderson, AE (corresponding author), Feigin Ctr, BCM, Cain Fdn Labs, MC 3-6365,6621 Fannin St, Houston, TX 77030 USA.	aander@cns.neusc.bcm.tmc.edu		Sweatt, J. David/0000-0003-3567-485X				Alonso G, 1997, NEUROSCIENCE, V77, P617; Anderson A. E., 1997, Society for Neuroscience Abstracts, V23, P1394; Anderson A. E., 1998, Society for Neuroscience Abstracts, V24, P7; BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; Barry DM, 1998, CIRC RES, V83, P560, DOI 10.1161/01.RES.83.5.560; CHABALA LD, 1993, J GEN PHYSIOL, V102, P713, DOI 10.1085/jgp.102.4.713; CHANDY KG, 1995, HDB RECEPTORS CHANNE; CHEN SJ, 1993, BIOCHEMISTRY-US, V32, P1032, DOI 10.1021/bi00055a006; COHEN IS, 1986, HEART CARDIOVASCULAR, P637; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DIXON JE, 1994, CIRC RES, V75, P252, DOI 10.1161/01.RES.75.2.252; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FURUKAWA T, 1990, CIRC RES, V67, P1287, DOI 10.1161/01.RES.67.5.1287; GESCHWIND HJ, 1984, J AM COLL CARDIOL, V4, P216, DOI 10.1016/S0735-1097(84)80205-3; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; Hille B., 1992, IONIC CHANNELS EXCIT, V2 ed, P115; Hoffman DA, 1997, NATURE, V387, P869, DOI 10.1038/43119; Hoffman DA, 1998, J NEUROSCI, V18, P3521; HOGER JH, 1991, NEURON, V6, P227, DOI 10.1016/0896-6273(91)90358-7; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; Johns DC, 1997, J BIOL CHEM, V272, P31598, DOI 10.1074/jbc.272.50.31598; Jonas EA, 1996, CURR OPIN NEUROBIOL, V6, P318, DOI 10.1016/S0959-4388(96)80114-0; KACZMAREK L, 1992, BEHAV NEURAL BIOL, V57, P263, DOI 10.1016/0163-1047(92)90276-A; Levitan IB, 1991, NEURON CELL MOL BIOL; LIU DW, 1993, CIRC RES, V72, P671, DOI 10.1161/01.RES.72.3.671; MADISON DV, 1986, J PHYSIOL-LONDON, V372, P245, DOI 10.1113/jphysiol.1986.sp016007; Martina M, 1998, J NEUROSCI, V18, P8111; Nakamura TY, 1997, AM J PHYSIOL-HEART C, V273, pH1775, DOI 10.1152/ajpheart.1997.273.4.H1775; PAK MD, 1991, P NATL ACAD SCI USA, V88, P4386, DOI 10.1073/pnas.88.10.4386; PAYET MD, 1992, J BIOL CHEM, V267, P18270; PEROZO E, 1991, J GEN PHYSIOL, V98, P19, DOI 10.1085/jgp.98.1.19; PEROZO E, 1991, J GEN PHYSIOL, V98, P1, DOI 10.1085/jgp.98.1.1; PEROZO E, 1990, NEURON, V5, P685, DOI 10.1016/0896-6273(90)90222-2; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; Roberson ED, 1999, J NEUROSCI, V19, P4337; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Serodio P, 1998, J NEUROPHYSIOL, V79, P1081, DOI 10.1152/jn.1998.79.2.1081; SERODIO P, 1994, J NEUROPHYSIOL, V72, P1516, DOI 10.1152/jn.1994.72.4.1516; Serodio P, 1996, J NEUROPHYSIOL, V75, P2174, DOI 10.1152/jn.1996.75.5.2174; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Williamson J R, 1976, Recent Adv Stud Cardiac Struct Metab, V9, P205	43	106	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5337	5346		10.1074/jbc.275.8.5337	http://dx.doi.org/10.1074/jbc.275.8.5337			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681507	hybrid			2022-12-27	WOS:000085474500014
J	Fu, LW; Miseta, A; Hunton, D; Marchase, RB; Bedwell, DM				Fu, LW; Miseta, A; Hunton, D; Marchase, RB; Bedwell, DM			Loss of the major isoform of phosphoglucomutase results in altered calcium homeostasis in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SECRETORY PATHWAY; PLASMA-MEMBRANE; CA-2+ INFLUX; ENDOPLASMIC-RETICULUM; INTRACELLULAR CALCIUM; CA2+ CONCENTRATIONS; XENOPUS OOCYTES; PMR1; CELLS; GENE	Phosphoglucomutase (PGM) is a key enzyme in glucose metabolism, where it catalyzes the interconversion of glucose 1-phosphate (Glc-1-P) and glucose 6-phosphate (Glc-6-P), In this study, we make the novel observation that PGM is also involved in the regulation of cellular Ca2+ homeostasis in Saccharomyces cerevisiae. When a strain lacking the major isoform of PGM (pgm2 Delta) was grown on media containing galactose as sole carbon source, its rate of Ca2+ uptake was 5-fold higher than an isogenic wild-type strain. This increased rate of Ca2+ uptake resulted in a 9-fold increase in the steady-state total cellular Ca2+ level. The fraction of cellular Ca2+ located in the exchangeable pool in the pgm2 Delta strain was found to be as large as the exchangeable fraction observed in wild-type cells, suggesting that the depletion of Golgi Ca2+ stores is not responsible for the increased rate of Ca2+ uptake. We also found that growth of the pgm2 Delta strain on galactose media is inhibited by 10 mu M cyclosporin A, suggesting that activation of the calmodulin/calcineurin signaling pathway is required to activate the Ca2+ transporters that sequester the increased cytosolic Ca2+ load caused by this high rate of Ca2+ uptake. We propose that these Ca2+-related alterations are attributable to a reduced metabolic flux between Glc-1-P and Glc-6-P due to a limitation of PGM enzymatic activity in the pgm2 Delta strain. Consistent with this hypothesis, we found that this "metabolic bottleneck" resulted in an 8-fold increase in the Glc-1-P level compared with the wild-type strain, while the Glc-6-P and ATP levels were normal. These results suggest that Glc-1-P (or a related metabolite) may participate in the control of Ca2+ uptake from the environment.	Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Bedwell, DM (corresponding author), Univ Alabama Birmingham, Dept Microbiol, Bevill Biomed Res Bldg,Rm 432,845 19th St S, Birmingham, AL 35294 USA.	dbedwell@uab.edu		Miseta, Attila/0000-0002-7984-3347; Fu, Karl/0000-0001-5386-9429; Bedwell, David/0000-0002-6605-818X				ALLEN DG, 1977, SCIENCE, V195, P996, DOI 10.1126/science.841325; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Batiza AF, 1996, J BIOL CHEM, V271, P23357, DOI 10.1074/jbc.271.38.23357; BEDWELL DM, 1987, MOL CELL BIOL, V7, P4038, DOI 10.1128/MCB.7.11.4038; BENEDETTI A, 1988, J BIOL CHEM, V263, P3466; BERGER W, 1984, HUM NEUROBIOL, V3, P163; BOLES E, 1994, EUR J BIOCHEM, V220, P83, DOI 10.1111/j.1432-1033.1994.tb18601.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; Chen PY, 1998, DIABETES, V47, P874, DOI 10.2337/diabetes.47.6.874; Csutora P, 1999, P NATL ACAD SCI USA, V96, P121, DOI 10.1073/pnas.96.1.121; CUNNINGHAM KW, 1994, J EXP BIOL, V196, P157; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; DUNN T, 1994, J BIOL CHEM, V269, P7273; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; EILAM Y, 1985, J GEN MICROBIOL, V131, P623; EILAM Y, 1990, J GEN MICROBIOL, V136, P861, DOI 10.1099/00221287-136-5-861; EILAM Y, 1990, J GEN MICROBIOL, V136, P2537, DOI 10.1099/00221287-136-12-2537; EILAM Y, 1987, J GEN MICROBIOL, V133, P1641; FINGER A, 1993, EUR J BIOCHEM, V218, P565, DOI 10.1111/j.1432-1033.1993.tb18410.x; FU DD, 1994, YEAST, V10, P515, DOI 10.1002/yea.320100411; FU LW, 1995, J BACTERIOL, V177, P3087, DOI 10.1128/jb.177.11.3087-3094.1995; Halachmi D, 1996, FEBS LETT, V392, P194, DOI 10.1016/0014-5793(96)00799-5; HALACHMI D, 1989, FEBS LETT, V256, P55, DOI 10.1016/0014-5793(89)81717-X; HARMSEN MM, 1993, GENE, V125, P115, DOI 10.1016/0378-1119(93)90318-W; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hiraiwa H, 1999, J BIOL CHEM, V274, P5532, DOI 10.1074/jbc.274.9.5532; HOFMANN M, 1994, EUR J BIOCHEM, V221, P741, DOI 10.1111/j.1432-1033.1994.tb18787.x; IIDA H, 1990, J BIOL CHEM, V265, P13391; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KILPATRICK L, 1990, J CLIN INVEST, V86, P196, DOI 10.1172/JCI114684; KIM HY, 1995, J BIOL CHEM, V270, P9706, DOI 10.1074/jbc.270.17.9706; Lapinskas PJ, 1996, MOL MICROBIOL, V21, P519, DOI 10.1111/j.1365-2958.1996.tb02561.x; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Miseta A, 1999, J BIOL CHEM, V274, P5939, DOI 10.1074/jbc.274.9.5939; Miseta A, 1999, FEBS LETT, V451, P132, DOI 10.1016/S0014-5793(99)00519-0; NAKAJIMASHIMADA J, 1991, P NATL ACAD SCI USA, V88, P6878, DOI 10.1073/pnas.88.15.6878; OH D, 1990, MOL CELL BIOO, V10, P3373; OHSUMI Y, 1988, J BACTERIOL, V170, P2676, DOI 10.1128/jb.170.6.2676-2682.1988; Pinton P, 1998, BIOFACTORS, V8, P243, DOI 10.1002/biof.5520080312; Pozos TC, 1996, MOL CELL BIOL, V16, P3730; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RANDRIAMAMPITA C, 1995, J BIOL CHEM, V270, P29, DOI 10.1074/jbc.270.1.29; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Sorin A, 1997, J BIOL CHEM, V272, P9895; THEVELEIN JM, 1995, TRENDS BIOCHEM SCI, V20, P3, DOI 10.1016/S0968-0004(00)88938-0; THOMAS D, 1995, J BIOL CHEM, V270, P6429, DOI 10.1074/jbc.270.12.6429; URIBE S, 1992, CELL CALCIUM, V13, P211, DOI 10.1016/0143-4160(92)90009-H; WILLIAMS RJP, 1990, ADV EXP MED BIOL, V269, P7	53	44	45	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5431	5440		10.1074/jbc.275.8.5431	http://dx.doi.org/10.1074/jbc.275.8.5431			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681519	hybrid			2022-12-27	WOS:000085474500026
J	Spier, AD; Lummis, SCR				Spier, AD; Lummis, SCR			The role of tryptophan residues in the 5-hydroxytryptamines receptor ligand binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; SITE-DIRECTED MUTAGENESIS; FUNCTIONAL EXPRESSION; SPLICE VARIANTS; ALPHA-SUBUNIT; MOLECULAR-CLONING; GLYCINE RECEPTOR; 5-HT3 RECEPTORS; AMINO-ACIDS; IDENTIFICATION	Aromatic amino acids are important components of the ligand binding site in the Cys loop family of ligand-gated ion channels. To examine the role of tryptophan residues in the ligand binding domain of the 5-hydroxytryptamine(3) (5-HT3) receptor, we used site-directed mutagenesis to change each of the eight N-terminal tryptophan residues in the 5-HT3A receptor subunit to tyrosine or serine, The mutants were expressed as homomeric 5-HT3A receptors in HEK293 cells and analyzed with radioligand binding, electrophysiology, and immnunocytochemistry. Mutation of Trp(90), Trp(183), and Trp(195) to tyrosine resulted in functional receptors, although with increased EC50 values (2-92-fold) to 5-HT3 receptor agonists, Changing these residues to serine either ablated function (Trp(90) and Trp(183)) gp resulted in a further increase in EC50 (Trp(195)). Mutation of residue Trp(60) had no effect on Ligand binding or receptor function, whereas mutation of Trp(95), Trp(102), Trp(121), and Trp(214) ablated ligand binding and receptor function, and all but one of the receptors containing these mutations were not expressed at the plasma membrane. We propose that Trp(90), Trp(183), and Trp(195) are intimately involved in Ligand binding, whereas Trp(95), Trp(102), Trp(121), and Trp(214) have a critical role in receptor structure or assembly.	MRC, Mol Biol Lab, Div Neurobiol, Cambridge CB2 2QH, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	MRC Laboratory Molecular Biology; University of Cambridge		s.lummis@mole.bio.cam.ac.uk						AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; Aprison MH, 1996, J NEUROSCI RES, V43, P127; AYLWIN ML, 1994, FEBS LETT, V349, P99, DOI 10.1016/0014-5793(94)00649-0; Belelli D, 1995, MOL PHARMACOL, V48, P1054; CHANGEUX JP, 1992, Q REV BIOPHYS, V25, P395, DOI 10.1017/S0033583500004352; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; COHEN JB, 1991, J BIOL CHEM, V266, P23354; CORRINGER PJ, 1995, J BIOL CHEM, V270, P11749, DOI 10.1074/jbc.270.20.11749; Davies PA, 1999, NATURE, V397, P359, DOI 10.1038/16941; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; GALZI JL, 1991, FEBS LETT, V294, P198, DOI 10.1016/0014-5793(91)80668-S; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GALZI JL, 1994, CURR OPIN STRUC BIOL, V4, P554, DOI 10.1016/S0959-440X(94)90218-6; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; Glitsch M, 1996, PFLUG ARCH EUR J PHY, V432, P134, DOI 10.1007/s004240050115; GOZLAN H, 1992, CENTRAL PERIPHERAL 5, P60; Hargreaves AC, 1996, MOL PHARMACOL, V50, P1284; HOPE AG, 1993, EUR J PHARM-MOLEC PH, V245, P187, DOI 10.1016/0922-4106(93)90128-V; Hucho F, 1996, EUR J BIOCHEM, V239, P539, DOI 10.1111/j.1432-1033.1996.0539u.x; ISENBERG KE, 1993, NEUROREPORT, V5, P121, DOI 10.1097/00001756-199311180-00006; KARLIN A, 1973, P NATL ACAD SCI USA, V70, P3636, DOI 10.1073/pnas.70.12.3636; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KUHSE J, 1993, NEURON, V11, P1049, DOI 10.1016/0896-6273(93)90218-G; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lankiewicz S, 1998, MOL PHARMACOL, V53, P202, DOI 10.1124/mol.53.2.202; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; MIQUEL MC, 1991, BIOCHEM PHARMACOL, V42, P1453, DOI 10.1016/0006-2952(91)90459-I; MISHINA M, 1985, NATURE, V313, P364, DOI 10.1038/313364a0; MIYAKE A, 1995, MOL PHARMACOL, V48, P407; SCHMIEDEN V, 1993, SCIENCE, V262, P256, DOI 10.1126/science.8211147; SEPULVEDA MI, 1991, BRIT J PHARMACOL, V104, P536, DOI 10.1111/j.1476-5381.1991.tb12464.x; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; Spier AD, 1999, MOL BRAIN RES, V67, P221; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; UETZ P, 1994, FEBS LETT, V339, P302, DOI 10.1016/0014-5793(94)80435-4; WERNER P, 1994, MOL BRAIN RES, V26, P233, DOI 10.1016/0169-328X(94)90095-7; Yan D, 1999, J BIOL CHEM, V274, P5537, DOI 10.1074/jbc.274.9.5537; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088	43	80	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5620	5625		10.1074/jbc.275.8.5620	http://dx.doi.org/10.1074/jbc.275.8.5620			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681544	hybrid			2022-12-27	WOS:000085474500051
J	Kipp, M; Schwab, BL; Przybylski, M; Nicotera, P; Fackelmayer, FO				Kipp, M; Schwab, BL; Przybylski, M; Nicotera, P; Fackelmayer, FO			Apoptotic cleavage of scaffold attachment factor A (SAF-A) by caspase-3 occurs at a noncanonical cleavage site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-MEDIATED APOPTOSIS; PROGRAMMED CELL-DEATH; NUCLEAR-MATRIX; IN-VIVO; BINDING-PROTEIN; HNRNP-U; DNA; FRAGMENTATION; MACHINERY; EVENTS	Members of the caspase family of cysteine proteases play essential roles in the disintegration of cellular architecture during apoptosis. Caspases have been grouped into subfamilies according to their preferred cleavage sites, with the "apoptotic executioner" caspase-3 as the prototype of DEXD-dependent proteases, We show here that caspase-3 is more tolerant to variations of the cleavage site than previously anticipated and present an example of a noncanonical recognition site that is efficiently cleaved by caspase-3 in vitro and in vivo, The new cleavage site was identified in human scaffold attachment factor A, one of the major scaffold attachment region DNA-binding proteins of human cells thought to be involved in nuclear architecture by fastening chromatin loops to a proteinaceous nuclear skeleton, the so-called nuclear matrix or scaffold. Using an amino-terminal recombinant construct of scaffold attachment factor A and recombinant caspase-3, we have mapped the cleavage site by matrix-assisted laser desorption ionization/time of flight mass spectrometry and Edman sequencing, We find that cleavage occurs after Asp-100 in a sequence context (SALD) that does not conform to the hitherto accepted DEXD consensus sequence of caspase-3. A point mutation, D100A, abrogates cleavage by recombinant caspase-3 in vitro and during apoptosis in vivo, confirming SALD as a novel caspase-3 cleavage site.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany; Univ Konstanz, Dept Chem, D-78457 Constance, Germany	University of Konstanz; University of Konstanz	Fackelmayer, FO (corresponding author), Univ Konstanz, Dept Biol, D-78457 Constance, Germany.	Frank.Fackelmayer@uni-konstanz.de						Buhler S, 1998, PROTEINS, P63; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; Casiano CA, 1996, J EXP MED, V184, P765, DOI 10.1084/jem.184.2.765; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Emoto Y, 1996, BLOOD, V87, P1990; FACKELMAYER FO, 1994, EUR J BIOCHEM, V221, P749, DOI 10.1111/j.1432-1033.1994.tb18788.x; FACKELMAYER FO, 1994, BIOCHEMISTRY-US, V33, P10416, DOI 10.1021/bi00200a024; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Gohring F, 1997, EMBO J, V16, P7361, DOI 10.1093/emboj/16.24.7361; Gohring F, 1997, BIOCHEMISTRY-US, V36, P8276, DOI 10.1021/bi970480f; Hsu HL, 1996, J CELL SCI, V109, P277; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Krammer P H, 1999, Adv Immunol, V71, P163; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Martelli AM, 1999, J CELL BIOCHEM, V72, P35, DOI 10.1002/(SICI)1097-4644(19990101)72:1<35::AID-JCB5>3.0.CO;2-S; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Mattern KA, 1996, J CELL BIOCHEM, V62, P275, DOI 10.1002/(SICI)1097-4644(199608)62:2<275::AID-JCB15>3.0.CO;2-K; Mattern KA, 1999, EXP CELL RES, V246, P461, DOI 10.1006/excr.1998.4267; McConnell KR, 1997, J IMMUNOL, V158, P2083; Mittl PRE, 1997, J BIOL CHEM, V272, P6539, DOI 10.1074/jbc.272.10.6539; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Przybylski M, 1995, ADV MASS SPECTROM, V13, P257; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; ROMIG H, 1992, EMBO J, V11, P3431, DOI 10.1002/j.1460-2075.1992.tb05422.x; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; THORNBERRY NA, 1994, METHOD ENZYMOL, V244, P615; Treuner K, 1999, NUCLEIC ACIDS RES, V27, P1499, DOI 10.1093/nar/27.6.1499; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Weaver VM, 1996, J CELL SCI, V109, P45; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618	40	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5031	5036		10.1074/jbc.275.7.5031	http://dx.doi.org/10.1074/jbc.275.7.5031			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671544	hybrid			2022-12-27	WOS:000085378200070
J	Novikova, EG; Reznik, SE; Varlamov, O; Fricker, LD				Novikova, EG; Reznik, SE; Varlamov, O; Fricker, LD			Carboxypeptidase Z is present in the regulated secretory pathway and extracellular matrix in cultured cells and in human tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPEMANN ORGANIZER; ATT-20 CELLS; FAMILY; ENZYME; PURIFICATION; EXPRESSION; ANTAGONIST; RECEPTORS; MUTATION; PROTEINS	Carboxypeptidase Z (CPZ) is a newly reported member of the metallocarboxypeptidase gene family, but unlike other members of this family, CPZ contains an N-terminal domain that has amino acid sequence similarity to Wnt-binding proteins. In order to gain insights as to the potential function of CPZ, the intracellular localization of this protein was determined in cell culture and in human tissues, When expressed in the AtT-20 mouse pituitary cell line, CPZ protein is routed to the regulated secretory pathway and secreted upon stimulation. A fraction of the secreted CPZ remains associated with the extracellular matrix. Endogenous CPZ in the PC12 rat pheochromocytoma cell line is also associated with the extracellular matrix. In human placenta, CPZ is present within invasive trophoblasts and in the surrounding extracellular space, indicating an association with extracellular matrix. CPZ is also present in amnion cells, but is not readily apparent in the extracellular matrix of this cell type. A human adenocarcinoma of the colon shows expression of CPZ in the extracellular matrix adjacent to malignant cells. Taken together, CPZ appears to be a component of the extracellular matrix in some cell types, where it may function in the binding of Wnt.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Fricker, LD (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004494, K02DA000194] Funding Source: NIH RePORTER; NIDA NIH HHS [K02 DA-00194, R01 DA-04494] Funding Source: Medline; NIDDK NIH HHS [R01 DK-51271] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Barrett A.J., 1998, HDB PROTEOLYTIC ENZY, P1318; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; FINCH PW, 1997, P NATL ACAD SCI USA, V94, P670; Fricker LD, 1996, J BIOL CHEM, V271, P30619, DOI 10.1074/jbc.271.48.30619; Fricker LD, 1999, TRENDS BIOCHEM SCI, V24, P390, DOI 10.1016/S0968-0004(99)01448-6; GREENE D, 1992, BIOCHEM J, V285, P613, DOI 10.1042/bj2850613; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; HORNBY PJ, 1993, NEUROENDOCRINOLOGY, V58, P555, DOI 10.1159/000126590; KLEIN RS, 1992, J NEUROCHEM, V58, P2011, DOI 10.1111/j.1471-4159.1992.tb10941.x; Kromer A, 1998, J CELL BIOL, V140, P1331, DOI 10.1083/jcb.140.6.1331; Lei YH, 1999, DNA CELL BIOL, V18, P175, DOI 10.1089/104454999315565; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Novikova EG, 1999, BIOCHEM BIOPH RES CO, V256, P564, DOI 10.1006/bbrc.1999.0378; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Salic AN, 1997, DEVELOPMENT, V124, P4739; SKIDGEL RA, 1989, J BIOL CHEM, V264, P2236; SKIDGEL RA, 1988, TRENDS PHARMACOL SCI, V9, P299, DOI 10.1016/0165-6147(88)90015-6; Song LX, 1997, J BIOL CHEM, V272, P10543; SONG LX, 1995, J BIOL CHEM, V270, P25007, DOI 10.1074/jbc.270.42.25007; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wang YS, 1996, J BIOL CHEM, V271, P4468; Werb Z, 1998, ANN NY ACAD SCI, V857, P110, DOI 10.1111/j.1749-6632.1998.tb10111.x; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Xin XN, 1998, DNA CELL BIOL, V17, P311, DOI 10.1089/dna.1998.17.311; Xin XN, 1998, DNA CELL BIOL, V17, P897, DOI 10.1089/dna.1998.17.897	30	28	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4865	4870		10.1074/jbc.275.7.4865	http://dx.doi.org/10.1074/jbc.275.7.4865			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671522	hybrid			2022-12-27	WOS:000085378200048
J	Russell, KS; Haynes, MP; Caulin-Glaser, T; Rosneck, J; Sessa, WC; Bender, JR				Russell, KS; Haynes, MP; Caulin-Glaser, T; Rosneck, J; Sessa, WC; Bender, JR			Estrogen stimulates heat shock protein 90 binding to endothelial nitric oxide synthase in human vascular endothelial cells - Effects on calcium sensitivity and NO release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUID SHEAR-STRESS; POSTMENOPAUSAL WOMEN; TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; REPLACEMENT THERAPY; MCF-7 CELLS; RECEPTOR; HSP90; GELDANAMYCIN; CALMODULIN	Estradiol (E-2) causes endothelium-dependent vasodilation, mediated, in part, by enhanced nitric oxide (NO) release. We have previously shown that E-2-induced activation of endothelial nitric oxide synthase (eNOS) reduces its calcium dependence. This pathway of eNOS activation is unique to a limited number of stimuli, including shear stress, the response to which is herbimycin-inhibitable. Consistent with this, herbimycin and geldanamycin pretreatment of human umbilical vein endothelial cells (HUVEC) abrogated E-2-stimulated NO release and cGMP production, respectively. These benzoquinone ansamycins are potent inhibitors of Hsp90 function, which has recently been shown to play a role in stimulus-dependent eNOS activation. As in response to shear, E-2 induced an Hsp90-eNOS association, peaking at 30 min and completely inhibited by the conventional estrogen receptor antagonist ICI 182,780, These findings suggest that Hsp90 plays an important role in the rapid, estrogen receptor-mediated modulation of eNOS activation by estrogen.	Yale Univ, Boyer Ctr Mol Med, Sch Med, Div Cardiovasc Med & Mol Cardiobiol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06536 USA	Yale University; Yale University	Bender, JR (corresponding author), Yale Univ, Boyer Ctr Mol Med, Sch Med, Div Cardiovasc Med & Mol Cardiobiol, 454C,295 Congress Ave, New Haven, CT 06536 USA.	jeffrey.bender@yale.edu	Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938	NHLBI NIH HHS [HL61782, HL61371] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL061371, R01HL061371, R56HL061782, R01HL061782] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmad S, 1999, BIOCHEM PHARMACOL, V58, P425, DOI 10.1016/S0006-2952(99)00125-2; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; Ayajiki K, 1996, CIRC RES, V78, P750, DOI 10.1161/01.RES.78.5.750; Best PJM, 1998, ANN INTERN MED, V128, P285, DOI 10.7326/0003-4819-128-4-199802150-00006; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; CaulinGlaser T, 1997, CIRC RES, V81, P885; Chen HS, 1997, ARCH BIOCHEM BIOPHYS, V348, P190, DOI 10.1006/abbi.1997.0398; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; Corson MA, 1996, CIRC RES, V79, P984, DOI 10.1161/01.RES.79.5.984; Devin-Leclerc J, 1998, MOL ENDOCRINOL, V12, P842, DOI 10.1210/me.12.6.842; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Fleming I, 1999, P NATL ACAD SCI USA, V96, P1123, DOI 10.1073/pnas.96.3.1123; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Guetta V, 1996, CIRCULATION, V93, P1928, DOI 10.1161/01.CIR.93.10.1928; Guetta V, 1997, CIRCULATION, V96, P2795, DOI 10.1161/01.CIR.96.9.2795; HAYASHI T, 1995, BIOCHEM BIOPH RES CO, V214, P847, DOI 10.1006/bbrc.1995.2364; Imthurn B, 1997, J CLIN ENDOCR METAB, V82, P388, DOI 10.1210/jc.82.2.388; Krueger JK, 1997, BIOCHEMISTRY-US, V36, P6017, DOI 10.1021/bi9702703; KUCHAN MJ, 1996, AM J PHYSIOL, V266, pC628; LANTINHERMOSO R, 1997, AM J PHYSIOL, V293, pL119; LEE CM, 1995, J BIOL CHEM, V270, P27403, DOI 10.1074/jbc.270.46.27403; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; MIGLIACCIO A, 1993, ONCOGENE, V8, P2183; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; PAPAPETROPOULOS A, 1994, HYPERTENSION, V23, P476, DOI 10.1161/01.HYP.23.4.476; PFAU S, 1995, J CELL BIOL, V128, P969, DOI 10.1083/jcb.128.5.969; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Richards RG, 1998, J BIOL CHEM, V273, P11962, DOI 10.1074/jbc.273.19.11962; Rubanyi GM, 1997, J CLIN INVEST, V99, P2429, DOI 10.1172/JCI119426; Segnitz B, 1997, J BIOL CHEM, V272, P18694, DOI 10.1074/jbc.272.30.18694; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; WERNERFELMAYER G, 1993, J BIOL CHEM, V268, P1842; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871	48	153	160	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5026	5030		10.1074/jbc.275.7.5026	http://dx.doi.org/10.1074/jbc.275.7.5026			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671543	hybrid			2022-12-27	WOS:000085378200069
J	Sims, KD; Straff, DJ; Robinson, MB				Sims, KD; Straff, DJ; Robinson, MB			Platelet-derived growth factor rapidly increases activity and cell surface expression of the EAAC1 subtype of glutamate transporter through activation of phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RAT ADIPOSE-CELLS; INSULIN-STIMULATED TRANSLOCATION; HUMAN DOPAMINE TRANSPORTER; CENTRAL-NERVOUS-SYSTEM; FACTOR-B-CHAIN; SIGNAL-TRANSDUCTION; GLUCOSE-UPTAKE; GLIOMA-CELLS; 3T3-L1 ADIPOCYTES	Na+-dependent glutamate transporters are the primary mechanism for removal of excitatory amino acids (EAAs) from the extracellular space of the central nervous system and influence both physiologic and pathologic effects of these compounds. Recent evidence suggests that the activity and cell surface expression of a neuronal subtype of glutamate transporter, EAAC1, are rapidly increased by direct activation of protein kinase C and are decreased by wortmannin, an inhibitor of phosphatidylinositol S-kinase (PI3-K), We hypothesized that this regulation could be analogous to insulin-induced stimulation of the GLUT4 subtype of glucose transporter, which is dependent upon activation of PIS-K, Using C6 glioma, a cell line that endogenously and selectively expresses EAAC1, we report that platelet-derived growth factor (PDGF) increased Na+-dependent L-[H-3]-glutamate transport activity within 30 min. This effect of PDGF was not due to a change in total cellular EAAC1 immunoreactivity but was instead correlated with an increase cell surface expression of EAAC1, as measured using a membrane impermeant biotinylation reagent combined with Western blotting. A decrease in nonbiotinylated intracellular EAAC1 was also observed. These studies suggest that PDGF causes a redistribution of EAAC1 from an intracellular compartment to the cell surface. These effects of PDGF were accompanied by a 35-fold increase in PI3-K activity and were blocked by the PIS-K inhibitors, wortmannin and LY 294002, but not by an inhibitor of protein kinase C, Other growth factors, including insulin, nerve growth factor, and epidermal growth factor had no effect on glutamate transport nor did they increase PI3-K activity. These studies suggest that, as is observed for insulin-mediated translocation of GLUT4, EAAC1 cell surface expression can be rapidly increased by PDGF through activation of PIS-K, It is possible that this PDGF-mediated increase in EAAC1 activity may contribute to the previously demonstrated neuroprotective effects of PDGF.	Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosci, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania	Robinson, MB (corresponding author), Abramson Pediat Res Ctr, Rm 502,3516 Civic Ctr Blvd, Philadelphia, PA 19104 USA.	robinson@pharm.med.upenn.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [F30MH011977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039011, R01NS029868] Funding Source: NIH RePORTER; NIMH NIH HHS [MH11977] Funding Source: Medline; NINDS NIH HHS [NS29868, NS39011] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abramovitch R, 1999, BRIT J CANCER, V79, P1392, DOI 10.1038/sj.bjc.6690223; Aledo JC, 1997, BIOCHEM J, V325, P727, DOI 10.1042/bj3250727; Apparsundaram S., 1997, Society for Neuroscience Abstracts, V23, P1132; Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P744; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Beckman ML, 1998, J NEUROSCI, V18, P6103; Beckman ML, 1999, J NEUROSCI, V19; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bernstein EM, 1999, J BIOL CHEM, V274, P889, DOI 10.1074/jbc.274.2.889; BISSELL MG, 1974, BRAIN RES, V82, P77, DOI 10.1016/0006-8993(74)90894-4; Brooks-Kayal AR, 1998, NEUROCHEM INT, V33, P95, DOI 10.1016/S0197-0186(98)00018-7; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; CASADO M, 1991, J NEUROCHEM, V57, P1185, DOI 10.1111/j.1471-4159.1991.tb08278.x; CASADO M, 1993, J BIOL CHEM, V268, P27313; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHENG B, 1995, J NEUROSCI, V15, P7095; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Conradt M, 1997, J NEUROCHEM, V68, P1244, DOI 10.1046/j.1471-4159.1997.68031244.x; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Davis KE, 1998, J NEUROSCI, V18, P2475; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Dowd LA, 1996, J NEUROCHEM, V67, P508, DOI 10.1046/j.1471-4159.1996.67020508.x; DREJER J, 1985, J NEUROCHEM, V45, P145, DOI 10.1111/j.1471-4159.1985.tb05486.x; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FRANCHIGAZZOLA R, 1994, FEBS LETT, V352, P109, DOI 10.1016/0014-5793(94)00929-5; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Furuta A, 1997, NEUROSCIENCE, V81, P1031, DOI 10.1016/S0306-4522(97)00252-2; Goya L, 1997, ADV EXP MED BIOL, V429, P249; Goya L, 1996, INT J DEV NEUROSCI, V14, P409, DOI 10.1016/S0736-5748(96)00026-3; Greene JG, 1996, PROG NEUROBIOL, V48, P613, DOI 10.1016/0301-0082(96)00006-8; HANPETER D, 1995, MOL MEMBR BIOL, V12, P263, DOI 10.3109/09687689509072426; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; HUTTON LA, 1992, J NEUROSCI RES, V32, P375, DOI 10.1002/jnr.490320309; IIHARA K, 1994, J CEREBR BLOOD F MET, V14, P818, DOI 10.1038/jcbfm.1994.102; Iihara K, 1996, J CEREBR BLOOD F MET, V16, P941, DOI 10.1097/00004647-199609000-00018; Iihara K, 1997, J CEREBR BLOOD F MET, V17, P1097, DOI 10.1097/00004647-199710000-00012; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; LAUNAY JM, 1994, AM J PHYSIOL, V266, pR526, DOI 10.1152/ajpregu.1994.266.2.R526; LONGUEMARE MC, 1995, J NEUROSCI RES, V40, P379, DOI 10.1002/jnr.490400312; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Malide D, 1997, J HISTOCHEM CYTOCHEM, V45, P1083, DOI 10.1177/002215549704500806; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Melikian H. E., 1998, Society for Neuroscience Abstracts, V24, P609; Mennerick S, 1998, J NEUROSCI, V18, P4490; MILLER KJ, 1994, J BIOL CHEM, V269, P27351; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; MUNIR M, 2000, IN PRESS NEUROCHEM I; NAKANISHI S, 1995, CELL SIGNAL, V7, P545, DOI 10.1016/0898-6568(95)00033-L; Nave BT, 1996, BIOCHEM J, V318, P203, DOI 10.1042/bj3180203; NISHIMURA H, 1994, BIOCHEM J, V302, P271, DOI 10.1042/bj3020271; Palos TP, 1999, J NEUROCHEM, V73, P1012, DOI 10.1046/j.1471-4159.1999.0731012.x; Palos TP, 1996, MOL BRAIN RES, V37, P297, DOI 10.1016/0169-328X(95)00331-L; Peghini P, 1997, EMBO J, V16, P3822, DOI 10.1093/emboj/16.13.3822; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; PISHAK MR, 1980, J NEUROCHEM, V34, P866, DOI 10.1111/j.1471-4159.1980.tb09659.x; Pristupa ZB, 1998, SYNAPSE, V30, P79, DOI 10.1002/(SICI)1098-2396(199809)30:1<79::AID-SYN10>3.3.CO;2-I; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; Quick MW, 1997, J NEUROSCI, V17, P2967; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; Rice JE, 1996, BIOCHEM SOC T, V24, P540, DOI 10.1042/bst0240540; Robinson M B, 1997, Adv Pharmacol, V37, P69; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; SASAHARA M, 1995, MOL BRAIN RES, V32, P63, DOI 10.1016/0169-328X(95)00060-6; SEGOVIA J, 1994, J NEUROCHEM, V63, P1218; Shashidharan P, 1997, BRAIN RES, V773, P139, DOI 10.1016/S0006-8993(97)00921-9; Shayakul C, 1997, AM J PHYSIOL-RENAL, V273, pF1023, DOI 10.1152/ajprenal.1997.273.6.F1023; Sims KD, 1999, CRIT REV NEUROBIOL, V13, P169, DOI 10.1615/CritRevNeurobiol.v13.i2.30; SMITS A, 1991, P NATL ACAD SCI USA, V88, P8159, DOI 10.1073/pnas.88.18.8159; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKEGAWA K, 1995, J CELL SCI, V108, P3745; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Valenzuela CF, 1995, MOL PHARMACOL, V48, P1099; Valenzuela CF, 1997, BRAIN RES REV, V24, P77; Valenzuela CF, 1996, J BIOL CHEM, V271, P16151, DOI 10.1074/jbc.271.27.16151; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOGT B, 1991, BIOCHEM J, V275, P597, DOI 10.1042/bj2750597; Wang LH, 1999, J BIOL CHEM, V274, P19246, DOI 10.1074/jbc.274.27.19246; WEI JW, 1991, INT J BIOCHEM, V23, P851, DOI 10.1016/0020-711X(91)90070-4; Yang H, 1999, J NEUROSCI, V19, P2413; Yeang HY, 1998, ANAL BIOCHEM, V265, P381; Zhang L, 1997, BIOCHEM PHARMACOL, V53, P677, DOI 10.1016/S0006-2952(96)00898-2; Zhang Wei, 1992, Neurological Research, V14, P397; ZORZANO A, 1989, J BIOL CHEM, V264, P12358; Zvelebil MJ, 1996, PHILOS T R SOC B, V351, P217, DOI 10.1098/rstb.1996.0019	97	101	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5228	5237		10.1074/jbc.275.7.5228	http://dx.doi.org/10.1074/jbc.275.7.5228			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671571	hybrid			2022-12-27	WOS:000085378200097
J	Suprynowicz, FA; Sparkowski, J; Baege, A; Schlegel, R				Suprynowicz, FA; Sparkowski, J; Baege, A; Schlegel, R			E5 oncoprotein mutants activate phosphoinositide 3-kinase independently of platelet-derived growth factor receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PAPILLOMAVIRUS SEQUENCES; SIMIAN SARCOMA-VIRUS; FACTOR-BETA RECEPTOR; MAP KINASE KINASE; NIH 3T3 CELLS; BOVINE PAPILLOMAVIRUS; PHOSPHATIDYLINOSITOL 3-KINASE; ONCOGENIC TRANSFORMATION; SIGNAL TRANSDUCTION; PLASMA-MEMBRANE	The E5 oncoprotein of bovine papillomavirus type 1 is a Golgi-resident, 44-amino acid polypeptide that can transform fibroblast cell lines by activating endogenous platelet-derived growth factor receptor beta (PDGF-R), However, the recent discovery of E5 mutants that exhibit strong transforming activity but minimal PDGF-R tyrosine phosphorylation indicates that E5 can potentially use additional signal transduction pathway(s) to transform cells. We now show that two classes of E5 mutants, despite poorly activating the PDGF-R, induce tyrosine phosphorylation and activation of phosphoinositide S-kinase (PI 3-K) and that this activation is resistant to a selective inhibitor of PDGF-R kinase activity, tyrphostin AG1296, Consistent with this independence from PDGF-R signaling, the E5 mutants fail to induce significant cell proliferation in the absence of PDGF, unlike wild-type E5 or the sis oncoprotein. Despite differences in growth factor requirements, however, both wild-type E5 and mutant E5 cell lines form colonies in agarose, Interestingly, activation of PI 3-K occurs without concomitant activation of the ras-dependent mitogen-activated protein kinase pathway. The known ability of constitutively activated PI 3-K to induce anchorage-independent cell proliferation suggests a mechanism by which the mutant E5 proteins transform cells.	Georgetown Univ, Med Ctr, Dept Pathol, Washington, DC 20007 USA	Georgetown University	Schlegel, R (corresponding author), Georgetown Univ, Med Ctr, Dept Pathol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.				NATIONAL CANCER INSTITUTE [R01CA053371] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA53371] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adduci AJ, 1999, J BIOL CHEM, V274, P10249, DOI 10.1074/jbc.274.15.10249; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1996, BIOCH BIOPHYS ACTA R, V1288, P11; CHEN EY, 1982, NATURE, V299, P529, DOI 10.1038/299529a0; COHEN BD, 1993, MOL CELL BIOL, V13, P6462, DOI 10.1128/MCB.13.10.6462; COHEN BD, 1993, J VIROL, V67, P5303, DOI 10.1128/JVI.67.9.5303-5311.1993; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; Downward J, 1997, ADV SEC MESS PHOSPH, V31, P1; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; DVORETZKY I, 1980, VIROLOGY, V103, P369, DOI 10.1016/0042-6822(80)90195-6; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Ghai J, 1996, P NATL ACAD SCI USA, V93, P12879, DOI 10.1073/pnas.93.23.12879; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOLDSTEIN DJ, 1994, J VIROL, V68, P4432, DOI 10.1128/JVI.68.7.4432-4441.1994; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klein O, 1998, J VIROL, V72, P8921, DOI 10.1128/JVI.72.11.8921-8932.1998; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; KOVALENKO M, 1994, CANCER RES, V54, P6106; Lai CC, 1998, P NATL ACAD SCI USA, V95, P15241, DOI 10.1073/pnas.95.26.15241; LANCASTER WD, 1982, MICROBIOL REV, V46, P191, DOI 10.1128/MMBR.46.2.191-207.1982; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIM PS, 1990, J INFECT DIS, V162, P1263, DOI 10.1093/infdis/162.6.1263; Lopez-Ilasaca M, 1998, BIOCHEM PHARMACOL, V56, P269, DOI 10.1016/S0006-2952(98)00059-8; LOWY DR, 1980, NATURE, V287, P72, DOI 10.1038/287072a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SOLTOFF SP, 1992, COLD SPRING HARB SYM, V57, P75, DOI 10.1101/SQB.1992.057.01.010; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SPARKOWSKI J, 1995, EMBO J, V14, P3055, DOI 10.1002/j.1460-2075.1995.tb07308.x; Sparkowski J, 1996, J VIROL, V70, P2420, DOI 10.1128/JVI.70.4.2420-2430.1996; SPARKOWSKI J, 1994, J VIROL, V68, P6120, DOI 10.1128/JVI.68.9.6120-6123.1994; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TADA A, 1989, J GEN VIROL, V70, P1593, DOI 10.1099/0022-1317-70-6-1593; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VELU TJ, 1989, J CELL BIOCHEM, V39, P153, DOI 10.1002/jcb.240390207; VOGEL LB, 1993, MOL CELL BIOL, V13, P7408, DOI 10.1128/MCB.13.12.7408; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YEE C, 1985, AM J PATHOL, V119, P361	58	25	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5111	5119		10.1074/jbc.275.7.5111	http://dx.doi.org/10.1074/jbc.275.7.5111			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671555	hybrid			2022-12-27	WOS:000085378200081
J	Thebault, S; Gachon, F; Lemasson, I; Devaux, C; Mesnard, JM				Thebault, S; Gachon, F; Lemasson, I; Devaux, C; Mesnard, JM			Molecular cloning of a novel human I-mfa domain-containing protein that differently regulates human T-cell leukemia virus type I and HIV-1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CREB-BINDING-PROTEIN; RNA-POLYMERASE-II; LONG TERMINAL REPEAT; AUG TRANSLATIONAL INITIATION; HTLV-1 TRANSACTIVATOR TAX; BHLH TRANSCRIPTION FACTOR; FIBROBLAST GROWTH-FACTOR; CAMP-RESPONSIVE ELEMENT; GENE-EXPRESSION	Regulation of viral genome expression is the result of complex cooperation between viral proteins and host cell factors. We report here the characterization of a novel cellular factor sharing homology with the specific cysteine-rich C-terminal domain of the basic helix-loop-helix repressor protein I-mfa, The synthesis of this new factor, called HIC for Human I-mfa domain-Containing protein, is controlled at the translational level by two different codons, an ATG and an upstream non-ATG translational initiator, allowing the production of two protein isoforms, p32 and p40, respectively. We show that the HIC protein isoforms present different subcellular localizations, p32 being mainly distributed throughout the cytoplasm, whereas p40 is targeted to the nucleolus. Moreover, in trying to understand the function of RIG, we have found that both isoforms stimulate in T-cells the expression of a luciferase reporter gene driven by the human T cell leukemia virus type I-long terminal repeat in the presence of the viral transactivator Tax. We demonstrate by mutagenesis that the I-mfa-like domain of HIC is involved in this regulation. Finally, we also show that HIC is able to down-regulate the luciferase expression from the human immunodeficiency virus type 1-long terminal repeat induced by the viral transactivator Tat, From these results, we propose that HIC and I-mfa represent two members of a new family of proteins regulating gene expression and characterized by a particular cysteine-rich C-terminal domain.	CNRS, CRBM, Inst Biol,UPR 1086, Lab Infect Retrovirales & Signalisat Cellulaire, F-34060 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Mesnard, JM (corresponding author), CNRS, CRBM, Inst Biol,UPR 1086, Lab Infect Retrovirales & Signalisat Cellulaire, 4 Blvd Henro IV, F-34060 Montpellier, France.		Gachon, Frederic/A-9289-2010; Gachon, Frédéric/H-3111-2019; Lemasson, Isabelle/N-1355-2013	Gachon, Frédéric/0000-0002-9279-9707; Mesnard, Jean-Michel/0000-0003-3344-5367				ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; Arnaud E, 1999, MOL CELL BIOL, V19, P505; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; Bantignies F, 1996, MOL CELL BIOL, V16, P2174; BEIMLING P, 1989, ONCOGENE, V4, P511; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; BOECK R, 1992, J VIROL, V66, P1765, DOI 10.1128/JVI.66.3.1765-1768.1992; BOECK R, 1994, EMBO J, V13, P3608, DOI 10.1002/j.1460-2075.1994.tb06668.x; Bonnard M, 1999, J IMMUNOL, V162, P1252; Botto JM, 1997, BIOCHEM J, V324, P389, DOI 10.1042/bj3240389; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; Caron C, 1997, P NATL ACAD SCI USA, V94, P3662, DOI 10.1073/pnas.94.8.3662; Chen CMA, 1996, CELL, V86, P731, DOI 10.1016/S0092-8674(00)80148-8; Chun RF, 1996, J BIOL CHEM, V271, P27888, DOI 10.1074/jbc.271.44.27888; Clemens KE, 1996, MOL CELL BIOL, V16, P4656; Colgin MA, 1998, J VIROL, V72, P9396, DOI 10.1128/JVI.72.11.9396-9399.1998; Coudronniere N, 1998, EUR J IMMUNOL, V28, P1445, DOI 10.1002/(SICI)1521-4141(199805)28:05<1445::AID-IMMU1445>3.0.CO;2-P; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DAVIDSON BL, 1994, HUM GENET, V93, P300, DOI 10.1007/BF00212027; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; Drabkin HJ, 1998, MOL CELL BIOL, V18, P5140, DOI 10.1128/MCB.18.9.5140; Firulli AB, 1998, NAT GENET, V18, P266, DOI 10.1038/ng0398-266; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; Gachon F, 1998, J VIROL, V72, P8332, DOI 10.1128/JVI.72.10.8332-8337.1998; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GITLIN SD, 1993, J VIROL, V67, P7307, DOI 10.1128/JVI.67.12.7307-7316.1993; Gratton S, 1998, J IMMUNOL, V161, P3551; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; HIRSCH I, 1990, VIROLOGY, V177, P759, DOI 10.1016/0042-6822(90)90544-2; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Imataka H, 1997, EMBO J, V16, P817, DOI 10.1093/emboj/16.4.817; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Kraut N, 1998, EMBO J, V17, P6276, DOI 10.1093/emboj/17.21.6276; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lemasson I, 1998, J BIOL CHEM, V273, P23598, DOI 10.1074/jbc.273.36.23598; Lemasson I, 1996, J IMMUNOL, V156, P859; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Mavankal G, 1996, P NATL ACAD SCI USA, V93, P2089, DOI 10.1073/pnas.93.5.2089; Miyoshi I., 1982, GANN MONOGR, V28, P219; Okamoto H, 1996, P NATL ACAD SCI USA, V93, P11575, DOI 10.1073/pnas.93.21.11575; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Reddy TR, 1997, ONCOGENE, V14, P2785, DOI 10.1038/sj.onc.1201119; Riley P, 1998, NAT GENET, V18, P271, DOI 10.1038/ng0398-271; ROSEN CA, 1987, P NATL ACAD SCI USA, V84, P4919, DOI 10.1073/pnas.84.14.4919; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; Semmes OJ, 1996, J BIOL CHEM, V271, P9730, DOI 10.1074/jbc.271.16.9730; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SODROSKI J, 1985, SCIENCE, V229, P74, DOI 10.1126/science.2990041; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; UITTENBOGAARD MN, 1994, J BIOL CHEM, V269, P22466; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; ZERBIB AC, 1994, J EXP MED, V179, P1973, DOI 10.1084/jem.179.6.1973	72	48	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4848	4857		10.1074/jbc.275.7.4848	http://dx.doi.org/10.1074/jbc.275.7.4848			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671520	Green Published, hybrid			2022-12-27	WOS:000085378200046
J	Yakhnin, AV; Trimble, JJ; Chiaro, CR; Babitzke, P				Yakhnin, AV; Trimble, JJ; Chiaro, CR; Babitzke, P			Effects of mutations in the L-tryptophan binding pocket of the trp RNA-binding attenuation protein of Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION ATTENUATION; LEADER RNA; OPERON; TRAP; EXPRESSION; BIOSYNTHESIS; MTRB	The Bacillus subtilis tryptophan biosynthetic genes are regulated by the trp RNA-binding attenuation protein (TRAP), Cooperative binding of L-tryptophan activates TRAP so that it can bind to RNA. The crystal structure revealed that L-tryptophan forms nine hydrogen bonds with various amino acid residues of TRAP, We performed site-directed mutagenesis to determine the importance of several of these hydrogen bonds in TRAP activation. We tested both alanine substitutions as well as substitutions more closely related to the natural amino acid at appropriate positions. Tryptophan binding mutations were identified in vivo having unchanged, reduced, or completely eliminated repression activity. Several of the in vivo defective TRAP mutants exhibited reduced affinity for tryptophan in vitro but did not interfere with RNA binding at saturating tryptophan concentrations. However, a 10-fold decrease in TRAP affinity for tryptophan led to an almost complete loss of regulation, whereas increased TRAP affinity for tryptophan had little or no effect on the in vivo regulatory activity of TRAP. One hydrogen bond was found to be dispensable for TRAP activity, whereas two others appear to be essential for TRAP function, Another mutant protein exhibited tryptophan-independent RNA binding activity. We also found that trp leader RNA increases the affinity of TRAP for tryptophan.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Babitzke, P (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.		Babitzke, Paul/AAL-3048-2020	Babitzke, Paul/0000-0003-2481-1062	NIGMS NIH HHS [R01 GM052840, GM52840] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052840] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; BABITZKE P, 1995, J BIOL CHEM, V270, P12452, DOI 10.1074/jbc.270.21.12452; BABITZKE P, 1992, J BACTERIOL, V174, P2059, DOI 10.1128/JB.174.7.2059-2064.1992; BABITZKE P, 1993, P NATL ACAD SCI USA, V90, P133, DOI 10.1073/pnas.90.1.133; BABITZKE P, 1994, J BIOL CHEM, V269, P16597; Babitzke P, 1997, MOL MICROBIOL, V26, P1, DOI 10.1046/j.1365-2958.1997.5541915.x; Du HS, 1998, J BIOL CHEM, V273, P20494, DOI 10.1074/jbc.273.32.20494; GOLLNICK P, 1990, P NATL ACAD SCI USA, V87, P8726, DOI 10.1073/pnas.87.22.8726; KURODA MI, 1988, J BACTERIOL, V170, P3080, DOI 10.1128/jb.170.7.3080-3088.1988; MERINO E, 1995, J BACTERIOL, V177, P6362, DOI 10.1128/jb.177.22.6362-6370.1995; Miller J.H., 1972, EXPT MOL GENETICS; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; SHIMOTSU H, 1986, J BACTERIOL, V166, P461, DOI 10.1128/jb.166.2.461-471.1986; Sudershana S, 1999, J BACTERIOL, V181, P5742, DOI 10.1128/JB.181.18.5742-5749.1999; SULLIVAN MA, 1984, GENE, V29, P21, DOI 10.1016/0378-1119(84)90161-6; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Yang M, 1997, J MOL BIOL, V270, P696, DOI 10.1006/jmbi.1997.1149	17	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4519	4524		10.1074/jbc.275.6.4519	http://dx.doi.org/10.1074/jbc.275.6.4519			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660627	hybrid			2022-12-27	WOS:000085288800111
J	Barth, P; Guillouard, I; Setif, P; Lagoutte, B				Barth, P; Guillouard, I; Setif, P; Lagoutte, B			Essential role of a single arginine of photosystem I in stabilizing the electron transfer complex with ferredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS SP PCC-6803; CYANOBACTERIUM SYNECHOCOCCUS SP; FLASH ABSORPTION-SPECTROSCOPY; CHEMICAL CROSS-LINKING; PSI-E SUBUNIT; BINDS FERREDOXIN; LINKED COMPLEX; AMINO-ACIDS; 2 SUBUNITS; REDUCTION	PsaE is one of the photosystem I subunits involved in ferredoxin binding, The central role of arginine 39 of this 8-kDa peripheral polypeptide has been established by a series of mutations. The neutral substitution R39Q leads to a 250-fold increase of the dissociation constant K-d of the photosystem I-ferredoxin complex, as large as the increase induced by PsaE deletion. At pH 8.0, this K-d value strongly depends on the charge of the residue substituting Arg-39: 0.22 mu M for wild type, 1.5 mu M for R39K, 56 mu M for R39Q, and more than 100 mu M for R39D. The consequences of arginine 39 substitution for the titratable histidine were analyzed as a function of pH, The K-d value of R39H is increased 140 times at pH 8.0 but only 5 times at pH 5.8, which is assigned to the protonation of histidine at low pH. In the mutant R39Q, the association rate of ferredoxin was decreased 3-fold compared with wild type, whereas an 80-fold increase is calculated for the dissociation rate. We propose that a major contribution of PsaE is to provide a prominent positive charge at position 39 for controlling the electrostatic interaction and lifetime of the complex with ferredoxin.	Ctr Etud Saclay, CEA, Dept Biol Cellulaire & Mol, Sect Bioenerget, F-91191 Gif Sur Yvette, France; Ctr Etud Saclay, CNRS, URA 2096, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS)	Lagoutte, B (corresponding author), Ctr Etud Saclay, CEA, Dept Biol Cellulaire & Mol, Sect Bioenerget, F-91191 Gif Sur Yvette, France.	lagouttb@dsvidf.cea.fr						ANDERSEN B, 1992, FEBS LETT, V311, P169, DOI 10.1016/0014-5793(92)81391-X; Barth P, 1998, BIOCHEMISTRY-US, V37, P16233, DOI 10.1021/bi981379t; BOEKEMA EJ, 1987, FEBS LETT, V217, P283, DOI 10.1016/0014-5793(87)80679-8; BOTTCHER B, 1992, BIOCHIM BIOPHYS ACTA, V1100, P125, DOI 10.1016/0167-4838(92)90544-N; BOTTIN H, 1992, BIOCHIM BIOPHYS ACTA, V1101, P48, DOI 10.1016/0167-4838(92)90465-P; CHITNIS PR, 1989, J BIOL CHEM, V264, P18374; CHITNIS PR, 1992, PLANT PHYSIOL, V99, P239, DOI 10.1104/pp.99.1.239; DEMARSAC NT, 1982, GENE, V20, P11; FALZONE CJ, 1994, BIOCHEMISTRY-US, V33, P6052, DOI 10.1021/bi00186a004; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; Fischer N, 1998, EMBO J, V17, P849, DOI 10.1093/emboj/17.4.849; FROMME P, 1994, BBA-BIOENERGETICS, V1187, P99, DOI 10.1016/0005-2728(94)90092-2; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; Golbeck JH, 1994, MOL BIOL CYANOBACTER, P319; Hanley J, 1996, BIOCHEMISTRY-US, V35, P8563, DOI 10.1021/bi960399x; Jacquot JP, 1997, FEBS LETT, V400, P293, DOI 10.1016/S0014-5793(96)01407-X; JANIN J, 1990, J BIOL CHEM, V265, P16027; Klukas O, 1999, J BIOL CHEM, V274, P7351, DOI 10.1074/jbc.274.11.7351; Kruip J, 1997, J BIOL CHEM, V272, P17061, DOI 10.1074/jbc.272.27.17061; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAGOUTTE B, 1992, EUR J BIOCHEM, V205, P1175, DOI 10.1111/j.1432-1033.1992.tb16888.x; LELONG C, 1995, BIOCHEMISTRY-US, V34, P14462, DOI 10.1021/bi00044a024; LELONG C, 1994, J BIOL CHEM, V269, P10034; Lelong C, 1996, EMBO J, V15, P2160, DOI 10.1002/j.1460-2075.1996.tb00569.x; Muhlenhoff U, 1996, EMBO J, V15, P488, DOI 10.1002/j.1460-2075.1996.tb00381.x; ROGNER M, 1990, J BIOL CHEM, V265, P6189; ROUSSEAU F, 1993, EMBO J, V12, P1755, DOI 10.1002/j.1460-2075.1993.tb05823.x; ROUSSEAU F, 1991, FEBS LETT, V260, P241; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schubert WD, 1998, J MOL BIOL, V280, P297, DOI 10.1006/jmbi.1998.1824; SETIF PQY, 1994, BIOCHEMISTRY-US, V33, P8495, DOI 10.1021/bi00194a014; SETIF PQY, 1995, BIOCHEMISTRY-US, V34, P9059, DOI 10.1021/bi00028a015; WEBER N, 1993, BIOCHIM BIOPHYS ACTA, V1143, P204, DOI 10.1016/0005-2728(93)90144-5; XU Q, 1994, J BIOL CHEM, V269, P21512; XU QA, 1994, PLANT PHYSIOL, V106, P617, DOI 10.1104/pp.106.2.617; ZANETTI G, 1987, EUR J BIOCHEM, V169, P143, DOI 10.1111/j.1432-1033.1987.tb13591.x; ZHAO J, 1993, MOL MICROBIOL, V9, P183, DOI 10.1111/j.1365-2958.1993.tb01680.x; ZILBER AL, 1988, PLANT PHYSIOL, V88, P810, DOI 10.1104/pp.88.3.810; ZILBER AL, 1992, PLANT PHYSIOL, V99, P901, DOI 10.1104/pp.99.3.901	39	37	39	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7030	7036		10.1074/jbc.275.10.7030	http://dx.doi.org/10.1074/jbc.275.10.7030			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702267	hybrid			2022-12-27	WOS:000085809600047
J	Di Marco, S; Rizzi, M; Volpari, C; Walsh, MA; Narjes, F; Colarusso, S; De Francesco, R; Matassa, VG; Sollazzo, M				Di Marco, S; Rizzi, M; Volpari, C; Walsh, MA; Narjes, F; Colarusso, S; De Francesco, R; Matassa, VG; Sollazzo, M			Inhibition of the hepatitis C virus NS3/4A protease - The crystal structures of two protease-inhibitor complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-BINDING SITE; ANGSTROM RESOLUTION; PEPTIDE; TRYPSIN; AMIDINOPHENYLPYRUVATE; REFINEMENT; THROMBIN; THERAPY	The hepatitis C virus NS3 protein contains a serine protease domain with a chymotrypsin-like fold, which is a target for development of therapeutics. We report the crystal structures of this domain complexed with NS4A cofactor and with two potent, reversible covalent inhibitors spanning the P1-P4 residues. Both inhibitors bind in an extended backbone conformation, forming an antiparallel beta-sheet with one enzyme beta-strand. The P1 residue contributes most to the binding energy, whereas P2-P4 side chains are partially solvent exposed. The structures do not show notable rearrangements of the active site upon inhibitor binding. These results are significant for the development of antivirals.	Ist Ric Biol Mol P Angeletti, Dept Biotechnol, I-00040 Rome, Italy; Ist Ric Biol Mol P Angeletti, Dept Biochem, I-00040 Rome, Italy; Ist Ric Biol Mol P Angeletti, Dept Med Chem, I-00040 Rome, Italy; Univ Piemonte Orientale, Dipartimento Sci Tecnol Farm, I-28100 Novara, Italy	Merck & Company; Merck & Company; Merck & Company; University of Eastern Piedmont Amedeo Avogadro	Sollazzo, M (corresponding author), Ist Ric Biol Mol P Angeletti, Dept Biotechnol, Via Pontina Km 30-600, I-00040 Rome, Italy.	sollazzo@irbm.it	De Francesco, Raffaele/J-6003-2012; Walsh, Martin A/I-1566-2013; Di Marco, Stefania -/C-3859-2009	De Francesco, Raffaele/0000-0001-8754-5123; Walsh, Martin A/0000-0001-5683-1151; Narjes, Frank/0000-0002-3104-7771				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barbato G, 1999, J MOL BIOL, V289, P371, DOI 10.1006/jmbi.1999.2745; Bartenschlager R, 1997, INTERVIROLOGY, V40, P378, DOI 10.1159/000150570; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHEN ZG, 1995, ARCH BIOCHEM BIOPHYS, V322, P198, DOI 10.1006/abbi.1995.1452; DeFrancesco R, 1996, BIOCHEMISTRY-US, V35, P13282, DOI 10.1021/bi9616458; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Ingallinella P, 1998, BIOCHEMISTRY-US, V37, P8906, DOI 10.1021/bi980314n; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Kuhn P, 1998, BIOCHEMISTRY-US, V37, P13446, DOI 10.1021/bi9813983; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; Martin TW, 1999, NAT STRUCT BIOL, V6, P403, DOI 10.1038/8195; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Narjes F, 2000, BIOCHEMISTRY-US, V39, P1849, DOI 10.1021/bi9924260; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Steinkuhler C, 1998, BIOCHEMISTRY-US, V37, P8899, DOI 10.1021/bi980313v; TANIZAWA K, 1985, BIOL CHEM H-S, V366, P871, DOI 10.1515/bchm3.1985.366.2.871; Urbani A, 1999, BIOCHEMISTRY-US, V38, P5206, DOI 10.1021/bi982773u; WALTER J, 1983, H-S Z PHYSIOL CHEM, V364, P949, DOI 10.1515/bchm2.1983.364.2.949; WEILAND O, 1994, FEMS MICROBIOL REV, V14, P279, DOI 10.1016/0168-6445(94)90044-2; Yan YW, 1998, PROTEIN SCI, V7, P837	25	109	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7152	7157		10.1074/jbc.275.10.7152	http://dx.doi.org/10.1074/jbc.275.10.7152			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702283	hybrid			2022-12-27	WOS:000085809600063
J	Du, Y; Tsai, S; Keller, JR; Williams, SC				Du, Y; Tsai, S; Keller, JR; Williams, SC			Identification of an interleukin-3-regulated aldoketo reductase gene in myeloid cells which may function in autocrine regulation of myelopoiesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTOR; COLONY-STIMULATING FACTOR; REPRESENTATIONAL DIFFERENCE ANALYSIS; MESSENGER-RNA EXPRESSION; TRANSCRIPTION FACTOR; RAT-LIVER; C/EBP-EPSILON; GRANULOCYTIC DIFFERENTIATION; NEUTROPHIL DIFFERENTIATION; ALDEHYDE REDUCTASE	The EML hematopoietic progenitor cell line is a model system for studying molecular events regulating myeloid commitment and terminal differentiation. We used representational difference analysis to identify genes that are expressed differentially during myeloid differentiation of EML cells. One gene (named mAKRa) encoded a novel member of the aldoketo reductase (AKR) superfamily of cytosolic NAD(P)(H)-dependent oxidoreductases. mAKRa mRNA was detected in murine hematopoietic tissues including bone marrow, spleen, and thymus. In myeloid cell lines, mAKRa was expressed at highest levels in cells representative of promyelocytes. mAKRa mRNA levels increased rapidly in response to interleukin-3 over the first 24 h of EML cell differentiation when the cells undergo lineage commitment and extensive proliferation, mAKRa mRNA levels decreased later in the differentiation process particularly when the EML cells were cultured with granulocyte/macrophage colony-stimulating factor and retinoic acid to induce terminal granulocytic maturation. mAKRa mRNA levels decreased during retinoic acid-induced terminal granulocytic differentiation of the MPRO promyelocyte cell line. AKRs act as molecular switches by catalyzing the interconversion or inactivation of bioactive molecules including steroids and prostaglandins. We propose that mAKRa may catalyze the production or catabolism of autocrine factors that promote the proliferation and/or lineage commitment of early myeloid progenitors.	Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, Lubbock, TX 79430 USA; Texas Tech Univ, Hlth Sci Ctr, Univ Med Ctr, SW Canc Ctr, Lubbock, TX 79430 USA; Mt Sinai Sch Med, New York, NY 10029 USA; NCI, Intramural Res Support Program, Sci Applicat Int Corp, Frederick Canc Res & Dev Ctr, Ft Detrick, MD 21702 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Williams, SC (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, 3601 4th St, Lubbock, TX 79430 USA.	Simon.Williams@ttmc.ttuhsc.edu	Keller, Jonathan R./O-6677-2018		NATIONAL CANCER INSTITUTE [ZIABC010001, Z01BC010001] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BASSET DE, 1995, TRENDS GENET, V11, P372, DOI 10.1016/S0168-9525(00)89109-X; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BROXMEYER HE, 1988, CRC CR REV ONCOL-HEM, V8, P173, DOI 10.1016/S1040-8428(88)80016-7; Broxmeyer HE, 1999, EXP HEMATOL, V27, P1113, DOI 10.1016/S0301-472X(99)00045-4; BUNCE CM, 1994, LEUKEMIA, V8, P595; Bunce CM, 1996, BBA-MOL CELL RES, V1311, P189, DOI 10.1016/0167-4889(96)00005-5; CARPER D, 1987, FEBS LETT, V220, P209, DOI 10.1016/0014-5793(87)80905-5; Chih DY, 1997, BLOOD, V90, P2987, DOI 10.1182/blood.V90.8.2987; Collins SJ, 1996, CURR TOP MICROBIOL, V211, P7; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; Desmond JC, 1999, BLOOD, V94, p256A; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Du CC, 1999, BLOOD, V94, P793, DOI 10.1182/blood.V94.2.793.414k43_793_802; Dupuis F, 1997, J LIPID MEDIAT CELL, V16, P117, DOI 10.1016/S0929-7855(97)00007-2; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Gotoh A, 1997, Curr Opin Hematol, V4, P3; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; IHLE JN, 1992, CHEM IMMUNOL, V51, P65; IHLE JN, 1981, J IMMUNOL, V126, P2184; Iwama A, 1998, NUCLEIC ACIDS RES, V26, P3034, DOI 10.1093/nar/26.12.3034; Jez JM, 1997, BIOCHEM J, V326, P625, DOI 10.1042/bj3260625; Jez JM, 1997, BIOCHEM PHARMACOL, V54, P639, DOI 10.1016/S0006-2952(97)84253-0; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Lawson ND, 1998, P NATL ACAD SCI USA, V95, P10129, DOI 10.1073/pnas.95.17.10129; Lawson ND, 1998, EXP HEMATOL, V26, P1178; LI CL, 1995, BLOOD, V85, P1472, DOI 10.1182/blood.V85.6.1472.bloodjournal8561472; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; METCALF D, 1993, BLOOD, V82, P3515; Mills KI, 1998, FEBS LETT, V440, P158, DOI 10.1016/S0014-5793(98)01435-5; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; Nalbant D, 1998, ENDOCRINOLOGY, V139, P272, DOI 10.1210/en.139.1.272; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; ONISHI Y, 1991, FEBS LETT, V283, P215, DOI 10.1016/0014-5793(91)80591-P; PAWLOWSKI JE, 1991, J BIOL CHEM, V266, P8820; PELUS LM, 1989, IMMUNOL RES, V8, P176, DOI 10.1007/BF02918143; PENNING TM, 1984, BIOCHEM J, V222, P601, DOI 10.1042/bj2220601; Penning TM, 1996, STEROIDS, V61, P508, DOI 10.1016/S0039-128X(96)00093-1; PEVNY L, 1995, DEVELOPMENT, V121, P163; Purton LE, 1999, BLOOD, V94, P483, DOI 10.1182/blood.V94.2.483.414k12_483_495; QIN KN, 1994, BIOCHEMISTRY-US, V33, P3223, DOI 10.1021/bi00177a012; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Scott LM, 1996, BLOOD, V88, P2517, DOI 10.1182/blood.V88.7.2517.bloodjournal8872517; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Sigurdsson F, 1997, SEMIN HEMATOL, V34, P303; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; TAKAHASHI M, 1993, GENE, V127, P249, DOI 10.1016/0378-1119(93)90728-L; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Weiler SR, 1999, BLOOD, V93, P527, DOI 10.1182/blood.V93.2.527.402k32_527_536; Williams SC, 1998, J BIOL CHEM, V273, P13493, DOI 10.1074/jbc.273.22.13493; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P6462, DOI 10.1073/pnas.94.12.6462; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	57	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6724	6732		10.1074/jbc.275.10.6724	http://dx.doi.org/10.1074/jbc.275.10.6724			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702227	hybrid			2022-12-27	WOS:000085809600007
J	Fjeld, CC; Rice, AE; Kim, Y; Gee, KR; Denu, JM				Fjeld, CC; Rice, AE; Kim, Y; Gee, KR; Denu, JM			Mechanistic basis for catalytic activation of mitogen-activated protein kinase phosphatase 3 by extracellular signal-regulated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL-SPECIFICITY PHOSPHATASE; TRANSITION-STATE STRUCTURES; TYROSINE-PHOSPHATASE; CRYSTAL-STRUCTURE; IN-VIVO; MAP; VHR; PURIFICATION; PATHWAYS; DOMAIN	The dual specificity mitogen-activated protein kinase phosphatase MKP3 has been shown to down-regulate mitogenic signaling through dephosphorylation of extracellular signal-regulated kinase (ERK), Camps et al, (Camps, RI., Nichols, A. Gillieron, C., Antonsson, B., Muda, M., Chabert, C., Boschert, U., and Arkinstall, S. (1998) Science 280, 1262-1265) had demonstrated that ERK binding to the noncatalytic amino-terminal domain of MKP3 can dramatically activate the phosphatase catalytic domain. The physical basis for this activation has not been established. Here, we provide detailed biochemical evidence that ERK activates MKP3 through the stabilization of the active phosphatase conformation, inducing closure of the catalytic "general acid" loop. In the closed conformation, this loop structure can participate efficiently in general acic/base catalysis, substrate binding, and transition-state stabilization. The pH activity profiles of ERK-activated MKP3 clearly indicated the involvement of general acid catalysis, a hallmark of protein-tyrosine phosphatase catalysis, In contrast, unactivated MKP3 did not display this enzymatic group as critical for the low activity form of the enzyme. Using a combination of Bronsted analyses, presteady-state and steady-state kinetics, we have isolated all catalytic steps in the reaction and have quantified the specific rate enhancement. Through protonation of the leaving group and transition-state stabilization, activated MKP3 catalyzes formation of the phosphoenzyme intermediate similar to 100-fold faster than unactivated enzyme. In addition, ERK-activated MKP3 catalyzes intermediate hydrolysis 5-6-fold more efficiently and binds ligands up to 19-fold more tightly. Consistent with ERK stabilizing the active conformation of MKP3, the chemical chaperone dimethyl sulfoxide was able to mimic this activation. A general protein-tyrosine phosphatase regulatory mechanism involving the flexible general acid loop is discussed.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Mol Probes Inc, Eugene, OR 97402 USA	Oregon Health & Science University	Denu, JM (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NIGMS NIH HHS [GM59785-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059785, R37GM059785] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P886, DOI 10.1021/bi00118a034; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; FERREIRAPEREIRA A, 1994, J BIOL CHEM, V269, P12074; Fjeld CC, 1999, J BIOL CHEM, V274, P20336, DOI 10.1074/jbc.274.29.20336; Gee KR, 1999, ANAL BIOCHEM, V273, P41, DOI 10.1006/abio.1999.4202; Gottlin EB, 1996, J BIOL CHEM, V271, P27445, DOI 10.1074/jbc.271.44.27445; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; HENGGE AC, 1995, BIOCHEMISTRY-US, V34, P13982, DOI 10.1021/bi00043a003; Hengge AC, 1996, BIOCHEMISTRY-US, V35, P7084, DOI 10.1021/bi960255i; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Stewart AE, 1999, NAT STRUCT BIOL, V6, P174; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; WARD Y, 1994, NATURE, V367, P681; Wiland AM, 1996, J BIOL CHEM, V271, P33486, DOI 10.1074/jbc.271.52.33486; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	37	80	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6749	6757		10.1074/jbc.275.10.6749	http://dx.doi.org/10.1074/jbc.275.10.6749			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702230	hybrid			2022-12-27	WOS:000085809600010
J	Lali, FV; Hunt, AE; Turner, SJ; Foxwell, BMJ				Lali, FV; Hunt, AE; Turner, SJ; Foxwell, BMJ			The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; RECEPTOR-BETA-CHAIN; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; IL-2 RECEPTOR; PROLIFERATION; INTERLEUKIN-7; STIMULATION; AKT; SUPPRESSION	Pyridinyl imidazole inhibitors, particularly SB203580, have been widely used to elucidate the roles of p38 mitogen-activated protein (MAP) kinase (p38/HOG/SAPKII) in a wide array of biological systems. Studies by this group and others have shown that 8B203580 can have antiproliferative activity on cytokine-activated lymphocytes, However, we recently reported that the antiproliferative effects of 8B203580 were unrelated to p38 MAP kinase activity. This present study now shows that SB203580 can inhibit the key cell cycle event of retinoblastoma protein phosphorylation in interleukin-a-stimulated T cells. Studies on the proximal regulator of this event, the phosphatidylinositol 3-kinase/protein kinase B (PKB)(Akt/Rac) kinase pathway, showed that SB203580 blocked the phosphorylation and activation of PKB by inhibiting the PKB kinase, phosphoinositide-dependent protein kinase 1. The concentrations of SB203580 required to block PKB phosphorylation (IC,, 3-5 mu M) are only approximately 10-fold higher than those required to inhibit p38 MAP kinase (IC50 0.3-0.5 mu M). These data define a new activity for this drug and would suggest that extreme caution should be taken when interpreting data where SB203580 has been used at concentrations above 1-2 mu M.	Kennedy Inst Rheumatol, London W6 8LH, England	University of Oxford	Foxwell, BMJ (corresponding author), Kennedy Inst Rheumatol, 1 Aspenlea Rd, London W6 8LH, England.		Lali, Ferdinand/AAD-1946-2019; Ferdinand, Lali/AAH-4867-2020	Ferdinand, Lali/0000-0001-5890-9936				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Bacqueville D, 1998, BIOCHEM BIOPH RES CO, V244, P630, DOI 10.1006/bbrc.1997.7885; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Belham CM, 1997, CELL SIGNAL, V9, P109, DOI 10.1016/S0898-6568(96)00120-9; Bianchi M, 1996, J EXP MED, V183, P927, DOI 10.1084/jem.183.3.927; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; Cohen PS, 1996, P NATL ACAD SCI USA, V93, P3967, DOI 10.1073/pnas.93.9.3967; Crawley JB, 1996, EUR J IMMUNOL, V26, P2717, DOI 10.1002/eji.1830261125; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Crawley JB, 1996, J BIOL CHEM, V271, P16357, DOI 10.1074/jbc.271.27.16357; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; Dou QP, 1997, J CELL BIOCHEM, V64, P586; Dufner A, 1999, MOL CELL BIOL, V19, P4525; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; Hunt AE, 1999, J BIOL CHEM, V274, P7591, DOI 10.1074/jbc.274.11.7591; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MINAMI Y, 1994, J IMMUNOL, V152, P5680; Ozaki I, 1999, J BIOL CHEM, V274, P5310, DOI 10.1074/jbc.274.9.5310; Page TH, 1997, J IMMUNOL, V158, P5727; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WILLCOCKS JL, 1993, EUR J IMMUNOL, V23, P716, DOI 10.1002/eji.1830230322; Zhang J, 1999, J IMMUNOL, V162, P3819	40	265	267	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7395	7402		10.1074/jbc.275.10.7395	http://dx.doi.org/10.1074/jbc.275.10.7395			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702313	hybrid			2022-12-27	WOS:000085809600093
J	Nienaber, V; Wang, JY; Davidson, D; Henkin, J				Nienaber, V; Wang, JY; Davidson, D; Henkin, J			Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; PLASMINOGEN-ACTIVATOR; CRYSTAL-STRUCTURE; SELECTIVE-INHIBITION; CATALYTIC DOMAIN; BINDING-SITE; FACTOR-XA; METASTASIS; PROTEASE; MICE	Inhibition of urokinase has been shown to slow tumor growth and metastasis. To utilize structure-based drug design, human urokinase was re-engineered to provide a more optimal crystal form. The redesigned protein consists of residues ILe(16)-Lys(243) (in the chymotrypsin numbering system; for the urokinase numbering system it is ILe(159)-Lys(404)) and two point mutations, C122A and N145Q (C279A and N302Q). The protein yields crystals that diffract to ultra-high resolution at a synchrotron source. The native structure has been refined to 1.5 Angstrom resolution. This new crystal form contains an accessible active site that facilitates compound soaking, which was used to determine the co-crystal structures of urokinase in complex with the small molecule inhibitors amiloride, 4-iodo-benzo(b)thiophene-2-carboxamidine and phenylguanidine at 2.0-2.2 Angstrom resolution. All three inhibitors bind at the primary binding pocket of urokinase, The structures of amiloride and 4-iodo-benzo(b)thiophene-2-carboxamidine also reveal that each of their halogen atoms are bound at a novel structural subsite adjacent to the primary binding pocket. This site consists of residues Gly(218), Ser(146), and Cys(191)-Cys(220) and the side chain of Lys(143). This pocket could be utilized in future drug design efforts. Crystal structures of these three inhibitors in complex with urokinase reveal strategies for the design of more potent nonpeptidic urokinase inhibitors.	Abbott Labs, Dept Biol Struct, Abbott Pk, IL 60064 USA; Abbott Labs, Dept Canc Res, Abbott Pk, IL 60064 USA	Abbott Laboratories; Abbott Laboratories	Nienaber, V (corresponding author), Abbott Labs, Dept Biol Struct, D46Y-AP10-LL,100 Abbott Pk Rd, Abbott Pk, IL 60064 USA.	vicki.nienaber@abbott.com		Davidson, Donald/0000-0002-8669-9814				Alonso DF, 1996, BREAST CANCER RES TR, V40, P209, DOI 10.1007/BF01806809; Alonso DF, 1998, ANTICANCER RES, V18, P4499; ASTEDT B, 1995, FIBRINOLYSIS, V9, P175, DOI 10.1016/S0268-9499(95)80008-5; BABA WI, 1968, CLIN PHARMACOL THER, V9, P318; Banerji A, 1998, CANCER LETT, V129, P15, DOI 10.1016/S0304-3835(98)00090-1; BANNER DW, 1991, J BIOL CHEM, V266, P20085; Barlow G H, 1976, Methods Enzymol, V45, P239; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BIRKTOFT JJ, 1972, J MOL BIOL, V68, P187, DOI 10.1016/0022-2836(72)90210-0; BLOW DM, 1976, ACCOUNTS CHEM RES, V9, P145, DOI 10.1021/ar50100a004; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1990, EUR J BIOCHEM, V193, P175, DOI 10.1111/j.1432-1033.1990.tb19320.x; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; Bridges A J, 1993, Bioorg Med Chem, V1, P403, DOI 10.1016/S0968-0896(00)82150-1; BROWNER MF, 1995, BIOCHEMISTRY-US, V34, P6602, DOI 10.1021/bi00020a004; BRUNGER A, 1993, XPLOR VERSION 3 1; Chand P, 1997, J MED CHEM, V40, P4030, DOI 10.1021/jm970479e; DAS J, 1995, BIOORGAN MED CHEM, V3, P999, DOI 10.1016/0968-0896(95)00104-O; Duffy M J, 1990, Blood Coagul Fibrinolysis, V1, P681; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; Evens DM, 1998, CLIN EXP METASTAS, V16, P353; HENDERSON R, 1970, Journal of Molecular Biology, V54, P341, DOI 10.1016/0022-2836(70)90434-1; Jankun J, 1997, CANCER RES, V57, P559; KOBAYASHI H, 1994, THROMB HAEMOSTASIS, V71, P474; KOHN EC, 1991, PHARMACOL THERAPEUT, V52, P235, DOI 10.1016/0163-7258(91)90011-A; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; LO KM, 1991, BIOCHIM BIOPHYS ACTA, V1088, P217; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Malikayil JA, 1997, BIOCHEMISTRY-US, V36, P1034, DOI 10.1021/bi9622231; Menegatti E, 1989, J Enzyme Inhib, V2, P249, DOI 10.3109/14756368909088478; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PRICE SR, 1995, CURR OPIN BIOTECH, V6, P425, DOI 10.1016/0958-1669(95)80072-7; QUAX PHA, 1990, CANCER RES, V50, P1488; Rabbani SA, 1995, INT J CANCER, V63, P840, DOI 10.1002/ijc.2910630615; Renatus M, 1997, J BIOL CHEM, V272, P21713, DOI 10.1074/jbc.272.35.21713; SCHMITT M, 1992, BIOL CHEM H-S, V373, P611, DOI 10.1515/bchm3.1992.373.2.611; Segel IH, 1975, ENZYME KINETICS BEHA; SHELDRICK GM, 1990, SHELX 97; SIGLER PB, 1966, J MOL BIOL, V15, P175, DOI 10.1016/S0022-2836(66)80219-X; SPRAGGON G, 1995, STRUCTURE, V3, P681, DOI 10.1016/S0969-2126(01)00203-9; STEITZ TA, 1969, J MOL BIOL, V46, P337, DOI 10.1016/0022-2836(69)90426-4; TOWLE MJ, 1993, CANCER RES, V53, P2553; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; VERLINDE CLMJ, 1994, STRUCTURE, V2, P577, DOI 10.1016/S0969-2126(00)00060-5; WANG JY, 1995, PROTEIN SCI, V4, P1758, DOI 10.1002/pro.5560040911; Xiao GW, 1999, P NATL ACAD SCI USA, V96, P3700, DOI 10.1073/pnas.96.7.3700; YANG H, 1990, J MED CHEM, V33, P2956, DOI 10.1021/jm00173a008	53	58	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7239	7248		10.1074/jbc.275.10.7239	http://dx.doi.org/10.1074/jbc.275.10.7239			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702294	hybrid			2022-12-27	WOS:000085809600074
J	Heckman, CA; Mehew, JW; Ying, GG; Introna, M; Golay, J; Boxer, LM				Heckman, CA; Mehew, JW; Ying, GG; Introna, M; Golay, J; Boxer, LM			A-Myb up-regulates bcl-2 through a Cdx binding site in t(14;18) lymphoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYB; TRANSCRIPTION FACTOR; B-MYB; BURKITTS-LYMPHOMA; CREB PROTEINS; V-MYB; EXPRESSION; GENE; APOPTOSIS; LINES	In follicular lymphoma, bcl-2 is translocated to the immunoglobulin heavy chain locus leading to deregulation of bcl-2 expression. We examined the role of Myb proteins in the regulation of bcl-2 expression in lymphoma cells. We showed that A-Myb up-regulates bcl-2 promoter activity. Northern and Western analyses demonstrated that A-Myb was expressed in the DHL-4 t(14; 18) cell line. In t(14;18) cells and mature B cells, A-Myb up-regulated bcl-2 expression, whereas B- and c-Myb had little effect on bcl-8 gene expression. Deletion analysis of the bcl-8 5'-region identified a region responsive to A-Myb in t(14;18) cells. A potential binding site for the Cdx homeodomain proteins was located in this sequence. Analysis of the A-Myb-responsive region by UV cross-linking experiments revealed that a 32-kDa protein formed a complex with this region, but direct binding by Myb proteins could not be demonstrated. A-Myb could be recovered along with Cdx2 when nuclear extracts were passed over the Cdx site. Mutagenesis of the Cdx binding site abolished binding by the 32-kDa protein and significantly reduced the ability of A-Myb to induce bcl-2 expression. A strong induction of bcl-2 P2 promoter activity was observed in cotransfection studies of DHL-4 cells with the A-Myb and Cdx2 expression vectors, and increased endogenous Bcl-2 protein expression was observed in B cells transfected with A-Myb and/or Cdx2 expression constructs.	Stanford Univ, Sch Med, Div Hematol, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Vet Affairs Palo Alto Hlth Care Syst, Ctr Mol Biol Med, Stanford, CA 94305 USA; Mario Negri Inst Pharmacol Res, Lab Mol Immunohematol, I-20157 Milan, Italy	Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Boxer, LM (corresponding author), Stanford Univ, Sch Med, Div Hematol, Dept Med, S-161, Stanford, CA 94305 USA.		Introna, Martino/AAA-5823-2019; Golay, Josee/AAA-4085-2022	Introna, Martino/0000-0001-6216-0892; Golay, Josee/0000-0002-7932-909X; Heckman, Caroline/0000-0002-4324-8706	NATIONAL CANCER INSTITUTE [R01CA056764, R56CA056764, R01CA071832] Funding Source: NIH RePORTER; NCI NIH HHS [CA56764, CA71832] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARSURA M, 1992, BLOOD, V79, P2708; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; CHANTRET I, 1988, CANCER RES, V48, P1936; Chase A, 1999, BLOOD, V93, P1025, DOI 10.1182/blood.V93.3.1025.403a20_1025_1031; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Drummond F, 1997, ANN HUM GENET, V61, P393, DOI 10.1017/S0003480097006465; Facchinetti V, 1997, BIOCHEM J, V324, P729, DOI 10.1042/bj3240729; FOOS G, 1993, ONCOGENE, V8, P1775; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Golay J, 1996, BLOOD, V87, P1900; Golay J, 1997, LEUKEMIA LYMPHOMA, V26, P271, DOI 10.3109/10428199709051776; GOLAY J, 1994, ONCOGENE, V9, P2469; GOLAY J, 1994, J IMMUNOL, V153, P543; Golay J, 1998, J IMMUNOL, V160, P2786; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; Grassilli E, 1999, CANCER RES, V59, P2451; GURFINKEL N, 1987, EUR J IMMUNOL, V17, P567, DOI 10.1002/eji.1830170421; Heckman C, 1997, J BIOL CHEM, V272, P19609, DOI 10.1074/jbc.272.31.19609; HEWITT SM, 1995, CANCER RES, V55, P5386; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; KENNEY SC, 1992, MOL CELL BIOL, V12, P136, DOI 10.1128/MCB.12.1.136; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; MIYASHITA T, 1994, CANCER RES, V54, P3131; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Phan SC, 1996, MOL CELL BIOL, V16, P2387; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Ying GG, 1997, J BIOL CHEM, V272, P24921, DOI 10.1074/jbc.272.40.24921; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310; Zhang F, 1997, MOL CELL BIOL, V17, P3272, DOI 10.1128/MCB.17.6.3272	38	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6499	6508		10.1074/jbc.275.9.6499	http://dx.doi.org/10.1074/jbc.275.9.6499			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692454	hybrid			2022-12-27	WOS:000085654400066
J	Rowlinson, SW; Crews, BC; Goodwin, DC; Schneider, C; Gierse, JK; Marnett, LJ				Rowlinson, SW; Crews, BC; Goodwin, DC; Schneider, C; Gierse, JK; Marnett, LJ			Spatial requirements for 15-(R)-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid synthesis within the cyclooxygenase active site of murine COX-2 - Why acetylated COX-1 does not synthesize 15-(R)-HETE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; H-2 SYNTHASE; ASPIRIN ACETYLATION; CRYSTAL-STRUCTURE; H SYNTHASE-1; INHIBITORS; EXPRESSION; MUTATION; AGENTS; REGION	The two isoforms of cyclooxygenase, COX-1 and COX-2, are acetylated by aspirin at Ser-530 and Ser-516, respectively, in the cyclooxygenase active site. Acetylated COX-2 is essentially a lipoxygenase, making 15-(R)-hydroxyeicosatetraenoic acid (18-HETE) and 11-(R)-hydroxyeicosatetraenoic acid (11-HETE), whereas acetylated COX-1 is unable to oxidize arachidonic acid to any products. Because the COX isoforms are structurally similar and share approximately 60% amino acid identity, we postulated that differences within the cyclooxygenase active sites must account for the inability of acetylated COX-1 to make 11- and 15-HETE. Residues Val-434, Arg-513, and Val-523 were predicted by comparison of the COX-1 and -2 crystal structures to account for spatial and flexibility differences observed ed between the COX isoforms. Site-directed mutagenesis of Val-434, Arg-513, and Val-523 in mouse COX-2 to their COX-I equivalents resulted in abrogation of 11- and 15-HETE production after aspirin treatment, confirming the hypothesis that these residues are the major isoform selectivity determinants regulating HETE production. The ability of aspirin-treated R513H mCOX-2 to make 15-HETE, although in reduced amounts, indicates that this residue is not an alternate binding site for the carboxylate of arachidonate and that it is not the only specificity determinant regulating HETE production. Further experiments were undertaken to ascertain whether the steric bulk imparted by the acetyl moiety on Ser-530 prevented the omega-end of arachidonic acid from binding within the top channel cavity in mCOX-2. Site directed mutagenesis was performed to change Val-228, which resides at the junction of the main cyclooxygenase channel and the top channel, and Gly-533, which is in the top channel, Both V228F and G533A produced wild type-like product profiles, but, upon acetylation, neither was able to make HETE products. This suggests that arachidonic acid orientates in a L-shaped binding configuration in the production of both prostaglandin and HETE products.	Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Biochem & Chem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Clin Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA; Monsanto Searle, St Louis, MO 63198 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Monsanto	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Biochem & Chem, 221 Kirkland Hall, Nashville, TN 37232 USA.			Goodwin, Douglas/0000-0002-7869-7704	NCI NIH HHS [CA68485, CA47479] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485, R35CA047479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; FU JY, 1990, J BIOL CHEM, V265, P16737; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; Goodwin DC, 1998, J BIOL CHEM, V273, P8903, DOI 10.1074/jbc.273.15.8903; Guo QP, 1996, J BIOL CHEM, V271, P19134, DOI 10.1074/jbc.271.32.19134; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HERSCHMAN HR, 1995, BIOESSAYS, V17, P1031, DOI 10.1002/bies.950171207; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Kalgutkar AS, 1998, SCIENCE, V280, P1268, DOI 10.1126/science.280.5367.1268; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; Loll PJ, 1996, BIOCHEMISTRY-US, V35, P7330, DOI 10.1021/bi952776w; LOLL PJ, 1995, NAT STRUCT BIOL, V2, P637, DOI 10.1038/nsb0895-637; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MANCINI JA, 1994, FEBS LETT, V342, P33, DOI 10.1016/0014-5793(94)80579-2; Marnett L. J., 1991, PEROXIDASES CHEM BIO, V1, P293; MASFERRER JL, 1990, J CLIN INVEST, V86, P1375, DOI 10.1172/JCI114850; ONEILL GP, 1994, MOL PHARMACOL, V45, P245; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; Rieke CJ, 1999, J BIOL CHEM, V274, P17109, DOI 10.1074/jbc.274.24.17109; ROTH GJ, 1983, BIOCHEMISTRY-US, V22, P4672, DOI 10.1021/bi00289a010; Rowlinson SW, 1999, J BIOL CHEM, V274, P23305, DOI 10.1074/jbc.274.33.23305; Serhan CN, 1999, ADV EXP MED BIOL, V447, P133; SHIMOKAWA T, 1992, J BIOL CHEM, V267, P12387; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; Wong E, 1997, J BIOL CHEM, V272, P9280; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	31	66	69	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6586	6591		10.1074/jbc.275.9.6586	http://dx.doi.org/10.1074/jbc.275.9.6586			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692466	hybrid			2022-12-27	WOS:000085654400078
J	Schmidt, WK; Tam, A; Michaelis, S				Schmidt, WK; Tam, A; Michaelis, S			Reconstitution of the Ste24p-dependent N-terminal proteolytic step in yeast a-factor biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SACCHAROMYCES-CEREVISIAE; ALPHA-FACTOR; MECHANISM; STE24P; METHYLATION; PRENYLATION; PHEROMONE; PEPTIDE; PATHWAY	The yeast mating pheromone a-factor precursor contains an N-terminal extension and a C-terminal CAAX motif within which multiple posttranslational processing events occur. A recently discovered component in a-factor processing is Ste24p/Afc1p, a multispanning endoplasmic reticulum membrane protein that contains an HEXXH metalloprotease motif, Our in vivo genetic characterization of this protein has demonstrated roles for Ste24p in both the N-terminal and C-terminal proteolytic processing of the a-factor precursor. Here, we present evidence that the N-terminal proteolysis of the a-factor precursor P1 can be accurately reconstituted in vitro using yeast membranes. We show that this activity is dependent on Ste24p and is abolished by mutation of the Ste24p HEXYH metalloprotease motif or by mutation of the a-factor P1 substrate at a residue adjacent to the N-terminal P1 cleavage site. We also demonstrate that N-terminal proteolysis of the P1 a-factor precursor requires Zn2+ as a co-factor and can be inhibited by the addition of the metalloprotease inhibitor 1,10-orthophenanthroline, Our results are consistent with Ste24p itself being the P1-->P2 a-factor protease or a limiting activator of this activity. Interestingly, we also show that the human Ste24 homolog expressed in yeast can efficiently promote the N-terminal processing of a-factor in vivo and in vitro, thus establishing a-factor as a surrogate substrate in the absence of known human substrates, The results reported here, together with the previously reported in vitro reconstitution of Ste24p-dependent CAAX processing, provide a system for examining the potential bifunctional roles of yeast Ste24p and its homologs.	Johns Hopkins Univ, Sch Med, Dept Cell Biol & Anat, Baltimore, MD 21205 USA	Johns Hopkins University	Michaelis, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol & Anat, 725 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041223, F32GM018641] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41223, GM18641] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMES N, 1995, SCIENCE, V270, P464, DOI 10.1126/science.270.5235.464; AULD DS, 1995, METHOD ENZYMOL, V248, P228; BARRETT AJ, 1994, METHOD ENZYMOL, V244, P1; BENDER A, 1986, CELL, V47, P929, DOI 10.1016/0092-8674(86)90808-1; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Chen P, 1997, MOL BIOL CELL, V8, P1273, DOI 10.1091/mbc.8.7.1273; Chen P, 1997, J CELL BIOL, V136, P251, DOI 10.1083/jcb.136.2.251; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Freije JMP, 1999, GENOMICS, V58, P270, DOI 10.1006/geno.1999.5834; FujimuraKamada K, 1997, J CELL BIOL, V136, P271, DOI 10.1083/jcb.136.2.271; FULLER R, 1986, YEAST CELL BIOL, P461; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; Kumagai H, 1999, BBA-GEN SUBJECTS, V1426, P468, DOI 10.1016/S0304-4165(98)00170-6; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MICHAELIS S, 1992, ANTON LEEUW INT J G, V61, P115, DOI 10.1007/BF00580617; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; Otto JC, 1999, J BIOL CHEM, V274, P8379, DOI 10.1074/jbc.274.13.8379; Romano JD, 1998, MOL BIOL CELL, V9, P2231, DOI 10.1091/mbc.9.8.2231; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; Tam A, 1998, J CELL BIOL, V142, P635, DOI 10.1083/jcb.142.3.635; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	26	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6227	6233		10.1074/jbc.275.9.6227	http://dx.doi.org/10.1074/jbc.275.9.6227			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692417	hybrid			2022-12-27	WOS:000085654400029
J	Salojin, KV; Zhang, J; Meagher, C; Delovitch, TL				Salojin, KV; Zhang, J; Meagher, C; Delovitch, TL			ZAP-70 is essential for the T cell antigen receptor-induced plasma membrane targeting of SOS and Vav in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; PROTEIN-TYROSINE KINASE; NONOBESE DIABETIC MICE; GRB2 ADAPTER PROTEIN; SIGNAL-TRANSDUCTION; GENETIC-EVIDENCE; RAS ACTIVATION; SH2 DOMAINS; ZETA-CHAIN; PATHWAY	Translocation of the SOS and Vav GDP/GTP exchange factors proximal to Ras and Pac GTPases localized in the plasma membrane glycolipid-enriched microdomains is a pivotal step required for T cell antigen receptor-induced T cell activation. Here we demonstrate that the T cell antigen receptor xi-chain-associated ZAP-70 kinase and T cell antigen receptor xi-chain immunoreceptor tyrosine-based activation motifs are essential for the membrane recruitment of SOS and Vav. Plasma membrane targeting of SOS or Vav begins with the assembly of ZAP-70 with Grb-2 and SOS. The subsequent tyrosine phosphorylation of LAT (linker for activation of T cell) by ZAP-70 leads to a shift in equilibrium from the ZAP-70.Grb-2.SOS(Vav) complex to the (Vav)SOS.Grb-2.LAT complex. This shift results in the targeting of SOS and Vav into glycolipid-enriched microdomains and initiation of the Ras and Rac signaling cascades involved in T cell activation, proliferation, and cytokine production.	John P Robarts Res Inst, Autoimmun Diabet Grp, London, ON N6G 2V4, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6G 2V4, Canada; Univ Western Ontario, Dept Med, London, ON N6G 2V4, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Salojin, KV (corresponding author), John P Robarts Res Inst, Autoimmun Diabet Grp, 1400 Western Rd, London, ON N6G 2V4, Canada.		Zhang, Jian/A-2564-2008	Zhang, Jian/0000-0002-9523-5296				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DeSilva DR, 1997, CELL IMMUNOL, V180, P116, DOI 10.1006/cimm.1997.1182; Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Lanzavecchia A, 1999, CELL, V96, P1, DOI 10.1016/S0092-8674(00)80952-6; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; NEL AE, 1995, J BIOL CHEM, V270, P18428, DOI 10.1074/jbc.270.31.18428; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; RAMOSMORALES F, 1995, ONCOGENE, V11, P1665; RAPOPORT MJ, 1993, J EXP MED, V177, P1221, DOI 10.1084/jem.177.4.1221; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Salojin K, 1997, J EXP MED, V186, P887, DOI 10.1084/jem.186.6.887; Salojin KV, 1999, J IMMUNOL, V163, P844; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Shores EW, 1997, J EXP MED, V185, P893, DOI 10.1084/jem.185.5.893; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SloanLancaster J, 1997, J EXP MED, V186, P1713, DOI 10.1084/jem.186.10.1713; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yamasaki S, 1996, MOL CELL BIOL, V16, P7151; Zhang J, 1999, J IMMUNOL, V162, P3819; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	45	33	35	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5966	5975		10.1074/jbc.275.8.5966	http://dx.doi.org/10.1074/jbc.275.8.5966			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681590	hybrid			2022-12-27	WOS:000085474500097
J	Vallentin, A; Prevostel, C; Fauquier, T; Bonnefont, X; Joubert, D				Vallentin, A; Prevostel, C; Fauquier, T; Bonnefont, X; Joubert, D			Membrane targeting and cytoplasmic sequestration in the spatiotemporal localization of human protein kinase C alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; GREEN FLUORESCENT PROTEIN; BETA-SUBUNIT; INTERCELLULAR COMMUNICATION; INTRACELLULAR RECEPTOR; BINDING MOTIF; LIVING CELLS; TRANSLOCATION; DOMAIN; DESENSITIZATION	In order to map the molecular determinants that dictate the subcellular localization of human protein kinase C alpha (hPKC alpha), full-length and deletion mutants of hPKC alpha were tagged with the green fluorescent protein (GFP) and transiently expressed in GH3B6 cells. We found that upon thyrotropin-releasing hormone (TRH) or phorbol 12-myristate 13-acetate stimulation, hPKC alpha-GFP was localized exclusively in regions of cell-cell contacts. Surprisingly, PKC alpha failed to translocate in single cells despite the presence of TRH receptors, as attested by the TRH-induced rise in intracellular calcium concentration in these cells. TRH-stimulated translocation of hPKC alpha-GFP from the cytoplasm to cell-cell contacts was a biphasic process: a fast (measured in seconds) and transient phase, followed by a slower (approximately 1 hour) and long lasting phase. The latter and the translocation induced by phorbol 12-myristate 13-acetate absolutely required the N-terminal V1 region. In contrast to the full-length hPKC alpha, the N-terminal regulatory domain alone or associated with the V3 hinge region was spontaneously and uniformly localized at the plasma membrane of single and apposed cells. However, treatment with the calcium chelator BAPTA/AM induced a differential cytoplasmic/nuclear redistribution of the regulatory domain, depending on its association with V3, which suggests the existence of a mechanism controlling the cytoplasmic sequestration of inactive hPKC alpha and involving the V3 region. By using other deletion mutants, we were able to map the sequence required for this sequestration to the C2+V3 regions. This work points to the existence of a complex interplay between membrane targeting and cytoplasmic sequestration in the control of the spatiotemporal localization of hPKC alpha.	CNRS, INSERM, U469, F-34094 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Joubert, D (corresponding author), CNRS, INSERM, U469, 141 Rue Cardonille, F-34094 Montpellier 5, France.		BONNEFONT, Xavier/AAH-3882-2019; Prevostel, Corinne/AAO-1433-2020	BONNEFONT, Xavier/0000-0003-4778-4060; PREVOSTEL, Corinne/0000-0002-7553-087X; Fauquier, Teddy/0000-0003-1132-9402				Acs P, 1997, J BIOL CHEM, V272, P22148, DOI 10.1074/jbc.272.35.22148; Almholt K, 1999, BIOCHEM J, V337, P211, DOI 10.1042/0264-6021:3370211; Alvaro V, 1997, ONCOGENE, V14, P677, DOI 10.1038/sj.onc.1200880; Barak LS, 1999, J BIOL CHEM, V274, P7565, DOI 10.1074/jbc.274.11.7565; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BIRMAN P, 1989, ACTA ENDOCRINOL-COP, V121, P489, DOI 10.1530/acta.0.1210489; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; Guerineau NC, 1998, J BIOL CHEM, V273, P10389, DOI 10.1074/jbc.273.17.10389; HOUSE C, 1989, FEBS LETT, V249, P243, DOI 10.1016/0014-5793(89)80632-5; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Jansen LAM, 1996, CARCINOGENESIS, V17, P1527, DOI 10.1093/carcin/17.7.1527; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Johnson JE, 1997, J BIOL CHEM, V272, P30787, DOI 10.1074/jbc.272.49.30787; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBOLD E, 1994, CARCINOGENESIS, V15, P1265, DOI 10.1093/carcin/15.6.1265; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOSIOR M, 1995, J BIOL CHEM, V270, P25526, DOI 10.1074/jbc.270.43.25526; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; Prevostel C, 1998, BIOCHEM J, V334, P393, DOI 10.1042/bj3340393; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Rotenberg SA, 1998, J BIOL CHEM, V273, P2390, DOI 10.1074/jbc.273.4.2390; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Yu R, 1997, J BIOL CHEM, V272, P28301, DOI 10.1074/jbc.272.45.28301; Yu R, 1998, MOL ENDOCRINOL, V12, P737, DOI 10.1210/me.12.5.737	38	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					6014	6021		10.1074/jbc.275.8.6014	http://dx.doi.org/10.1074/jbc.275.8.6014			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681596	hybrid			2022-12-27	WOS:000085474500103
J	Yerushalmi, H; Schuldiner, S				Yerushalmi, H; Schuldiner, S			An essential glutamyl residue in EmrE, a multidrug antiporter from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE HELICES; COVALENT MODIFICATION; PROTEOLIPID SUBUNIT; H+-ATPASE; TRANSPORTER; PROTEINS; N,N'-DICYCLOHEXYLCARBODIIMIDE; MUTAGENESIS; FAMILY; EFFLUX	EmrE is an Escherichia coli 12-kDa protein that confers resistance to toxic compounds, by actively removing them in exchange with protons. The protein includes eight charged residues. Seven of these residues are located in the hydrophilic loops and can be replaced with either Cys or another amino acid bearing the same charge, without impairing transport activity. Glu-14 is the only charged residue in the membrane domain and is conserved in all the proteins of the family. We show here that this residue is the site of action of dicyclohexylcarbodiimide, a carbodiimide known to act in hydrophobic environments. When Glu-14 was replaced with either Cys or Asp, resistance was abolished. Whereas the E14C mutant displays no transport activity, the E14D protein shows efflux and exchange at rates about 30-50% that of the wild type. The maximal Delta pH-driven uptake rate of E14D is only 10% that of the wild type. The mutant shows a different pH profile in all the transport modes. Our results support the notion that Glu-14 is an essential part of a binding domain shared by substrates and protons but mutually exclusive in time. This notion provides the molecular basis for the obligatory exchange catalyzed by EmrE.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Schuldiner, S (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.		Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS016708, R01NS016708] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16708] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arkin IT, 1996, BIOCHEMISTRY-US, V35, P7233, DOI 10.1021/bi960094i; Edgar R, 1999, EMBO J, V18, P822, DOI 10.1093/emboj/18.4.822; Fillingame RH, 1997, J EXP BIOL, V200, P217; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRINIUS L, 1992, PLASMID, V27, P119, DOI 10.1016/0147-619X(92)90012-Y; GRINIUS L, 1994, J BIOL CHEM, V268, P29998; HERMOLIN J, 1989, J BIOL CHEM, V264, P3896; IGARASHI P, 1987, J BIOL CHEM, V262, P860; INOUE H, 1995, FEBS LETT, V363, P264, DOI 10.1016/0014-5793(95)00331-3; KIM YK, 1993, J PHARMACOL EXP THER, V266, P500; Mordoch SS, 1999, J BIOL CHEM, V274, P19480, DOI 10.1074/jbc.274.27.19480; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; NEGRIN RS, 1980, J BIOL CHEM, V255, P5643; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Paulsen IT, 1996, MOL MICROBIOL, V19, P1167, DOI 10.1111/j.1365-2958.1996.tb02462.x; Paulsen IT, 1996, P NATL ACAD SCI USA, V93, P3630, DOI 10.1073/pnas.93.8.3630; POURCHER T, 1993, J BIOL CHEM, V268, P3209; Sahin-Toth M, 1999, BIOCHEMISTRY-US, V38, P813, DOI 10.1021/bi982200h; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schuldiner S, 1997, J EXP BIOL, V200, P335; SEBALD W, 1980, P NATL ACAD SCI-BIOL, V77, P785, DOI 10.1073/pnas.77.2.785; SUCHI R, 1991, BIOCHEMISTRY-US, V30, P6490, DOI 10.1021/bi00240a020; VonHeijne G, 1996, PROG BIOPHYS MOL BIO, V66, P113, DOI 10.1016/S0079-6107(97)85627-1; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P7490; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; Yerushalmi H, 1996, J BIOL CHEM, V271, P31044, DOI 10.1074/jbc.271.49.31044; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6	29	114	116	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5264	5269		10.1074/jbc.275.8.5264	http://dx.doi.org/10.1074/jbc.275.8.5264			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681497	hybrid			2022-12-27	WOS:000085474500004
J	Asagoshi, K; Yamada, T; Terato, H; Ohyama, Y; Monden, Y; Arai, T; Nishimura, S; Aburatani, H; Lindahl, T; Ide, H				Asagoshi, K; Yamada, T; Terato, H; Ohyama, Y; Monden, Y; Arai, T; Nishimura, S; Aburatani, H; Lindahl, T; Ide, H			Distinct repair activities of human 7,8-dihydro-8 oxoguanine DNA glycosylase and formamidopyrimidine DNA glycosylase for formamidopyrimidine and 7,8-dihydro-8-oxoguanine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI FPG PROTEIN; APURINIC APYRIMIDINIC SITES; BASE-EXCISION-REPAIR; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; ENDONUCLEASE-III; SUBSTRATE-SPECIFICITY; MUTAGENIC SUBSTRATE; IONIZING-RADIATION; ABASIC SITES	7,8-Dihydro-8-oxoguanine (8-oxoG) and 2,6-diamino-4-hydroxyformamidopyrimidine (Fapy) are major DNA lesions formed by reactive oxygen species and are involved in mutagenic and/or lethal events in cells. Both lesions are repaired by human 7,8 dihydro-8-oxoguanine DNA glycosylase (hOGG1) and formamidopyrimidine DNA glycosylase (Fpg) in human and Escherichia coli cells, respectively. In the present study, the repair activities of hOGG1 and Fpg were compared using defined oligonucleotides containing 8-oxoG and a methylated analog of Fapy (me-Fapy) at the same site. The k(cat)/K-m values of hOGG1 for 8-oxoG and me-Fapy were comparable, and this was also the case for Fpg, However, the k(cat)/K-m values of hOGG1 for both lesions were approximately 80-fold lower than those of Fpg, Analysis of the Schiff base intermediate by NaBH4 trapping implied that lower substrate affinity and slower hydrolysis of the intermediate for hOGG1 than Fpg accounted for the difference. hOGG1 and Fpg showed distinct preferences of the base opposite 8-oxoG, with the activity differences being 19.8- (hOGG1) and 12-fold (Fpg) between the most and least preferred bases. Surprisingly, such preferences were almost abolished and less than a-fold for both enzymes when me-Fapy was a substrate, suggesting that, unlike 8-oxoG, me-Fapy is not subjected to paired base-dependent repair. The repair efficiency of me-Fapy randomly incorporated in M13 DNA varied at the sequence level, but orders of preferred and unpreferred repair sites were quite different for hOGG1 and Fpg. The distinctive activities of hOGG1 and Fpg including enzymatic parameters (k(cat)/K-m), paired base, and sequence context effects may originate from the differences in the inherent architecture of the DNA binding domain and catalytic mechanism of the enzymes.	Hiroshima Univ, Grad Sch Sci, Dept Math & Life Sci, Higashihiroshima 7398526, Japan; Banyu Tsukuba Res Inst, Merck Res Labs, Tsukuba, Ibaraki 3002611, Japan; Univ Tokyo, RCAST, Genomesci Div, Bunkyo Ku, Tokyo 1130033, Japan; Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England	Hiroshima University; Merck & Company; University of Tokyo	Ide, H (corresponding author), Hiroshima Univ, Grad Sch Sci, Dept Math & Life Sci, Higashihiroshima 7398526, Japan.	ideh@ipc.hiroshima-u.ac.jp		Terato, Hiroaki/0000-0002-7070-5263				Aburatani H, 1997, CANCER RES, V57, P2151; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; Bruner SD, 1998, CURR BIOL, V8, P393, DOI 10.1016/S0960-9822(98)70158-7; CASTAING B, 1993, NUCLEIC ACIDS RES, V21, P2899, DOI 10.1093/nar/21.12.2899; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHETSANGA CJ, 1981, BIOCHEMISTRY-US, V20, P5201, DOI 10.1021/bi00521a016; Cunningham RP, 1996, CURR BIOL, V6, P1230, DOI 10.1016/S0960-9822(96)00703-8; David SS, 1998, CHEM REV, V98, P1221, DOI 10.1021/cr980321h; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; Eide L, 1996, P NATL ACAD SCI USA, V93, P10735, DOI 10.1073/pnas.93.20.10735; Girard PM, 1997, NUCLEIC ACIDS RES, V25, P3204, DOI 10.1093/nar/25.16.3204; GRAVES R, 1992, CARCINOGENESIS, V13, P1455, DOI 10.1093/carcin/13.8.1455; Hang B, 1998, J BIOL CHEM, V273, P33406, DOI 10.1074/jbc.273.50.33406; Hatahet Z, 1998, P NATL ACAD SCI USA, V95, P8556, DOI 10.1073/pnas.95.15.8556; Hatahet Z, 1998, CONT CANC RES, P229; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; HAYASHIBARA KC, 1991, J AM CHEM SOC, V113, P5104, DOI 10.1021/ja00013a080; IDE H, 1993, BIOCHEM MOL BIOL INT, V31, P485; Karahalil B, 1998, NUCLEIC ACIDS RES, V26, P1228, DOI 10.1093/nar/26.5.1228; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Monden Y, 1999, BIOCHEM BIOPH RES CO, V258, P605, DOI 10.1006/bbrc.1999.0649; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; OCONNOR TR, 1988, NUCLEIC ACIDS RES, V16, P5879, DOI 10.1093/nar/16.13.5879; OCONNOR TR, 1993, J BIOL CHEM, V268, P9063; PAVLOV YI, 1994, BIOCHEMISTRY-US, V33, P4695, DOI 10.1021/bi00181a029; PEGG AE, 1984, CANCER INVEST, V2, P223, DOI 10.3109/07357908409104376; Rabow LE, 1997, BIOCHEMISTRY-US, V36, P5084, DOI 10.1021/bi963005a; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Senturker S, 1998, NUCLEIC ACIDS RES, V26, P5270, DOI 10.1093/nar/26.23.5270; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TUDEK B, 1992, NUCLEIC ACIDS RES, V20, P3079, DOI 10.1093/nar/20.12.3079; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; Ye N, 1998, J MOL BIOL, V284, P269, DOI 10.1006/jmbi.1998.2138; You HJ, 1998, BIOCHEMISTRY-US, V37, P6033, DOI 10.1021/bi973042h	43	112	113	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4956	4964		10.1074/jbc.275.7.4956	http://dx.doi.org/10.1074/jbc.275.7.4956			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671534	hybrid			2022-12-27	WOS:000085378200060
J	Janzik, I; Macheroux, P; Amrhein, N; Schaller, A				Janzik, I; Macheroux, P; Amrhein, N; Schaller, A			LeSBT1, a subtilase from tomato plants - Overexpression in insect cells, purification, and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHOGENESIS-RELATED PROTEINS; PROHORMONE CONVERTASES; SERINE PROTEINASE; PROPROTEIN CONVERTASE; PROTEASE; SUBTILISIN; CLEAVAGE; ACTIVATION; MATURATION; IDENTIFICATION	The cDNA of a tomato subtilase designated LeSBT1 was cloned from a tomato flower cDNA library. The deduced amino acid sequence indicated for LeSBT1 the structure of a prepro-protein targeted to the secretory pathway by virtue of an amino-terminal signal peptide. LeSBT1 was expressed in the baculovirus/insect cell system and a processed 73-kDa form of LeSBT1, lacking both signal peptide and prodomain, was purified to homogeneity from culture supernatants, This 73-kDa LeSBT1, however, lacked proteolytic activity. Zymogen activation to yield 68-kDa LeSBT1 required the additional processing of an amino-terminal autoinhibitory peptide in a strictly pH-dependent manner. Mature 68-kDa LeSBT1 showed highest activity at acidic pH consistent with its presumed localization in the apoplast of the plant cell. In comparison to other plant subtilases, LeSBT1 exhibited a narrower substrate specificity in that it cleaves only polypeptide substrates preferentially but not exclusively carboxyl-terminal of glutamine residues. The possible involvement of LeSBT1 in selective proprotein processing is discussed with reference to the related mammalian proprotein convertases.	ETH Zurich, Inst Plant Sci, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Schaller, A (corresponding author), ETH Zurich, Inst Plant Sci, LFW E51,Univ Str 2, CH-8092 Zurich, Switzerland.		Macheroux, Peter/AAB-5157-2019; Schaller, Andreas/AAC-1940-2020	Macheroux, Peter/0000-0002-0242-454X; Schaller, Andreas/0000-0001-6872-9576; Janzik, Ingar/0000-0003-4768-0202				Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BEAVIS RC, 1992, ORG MASS SPECTROM, V27, P156, DOI 10.1002/oms.1210270217; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; Bischoff M, 1996, PLANT MOL BIOL, V31, P69, DOI 10.1007/BF00020607; Boudreault A, 1998, PROTEIN EXPRES PURIF, V14, P353, DOI 10.1006/prep.1998.0964; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; Deinum J, 1998, BBA-PROTEIN STRUCT M, V1388, P386, DOI 10.1016/S0167-4838(98)00196-4; FISCHER W, 1989, PHYSIOL MOL PLANT P, V35, P67, DOI 10.1016/0885-5765(89)90008-8; Genetic Computer Group, 1994, PROGR MAN WISC PACK; Gensberg K, 1998, SEMIN CELL DEV BIOL, V9, P11, DOI 10.1006/scdb.1997.0196; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; Harlow E., 1988, ANTIBODIES LAB MANUA; Jiang LW, 1999, PLANT J, V18, P23, DOI 10.1046/j.1365-313X.1999.00424.x; Jorda L, 1999, J BIOL CHEM, V274, P2360, DOI 10.1074/jbc.274.4.2360; KANEDA M, 1975, J BIOCHEM, V78, P1287, DOI 10.1093/oxfordjournals.jbchem.a131026; Kervinen J, 1999, EMBO J, V18, P3947, DOI 10.1093/emboj/18.14.3947; KINAL H, 1995, PLANT CELL, V7, P677, DOI 10.1105/tpc.7.6.677; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamango NS, 1999, ARCH BIOCHEM BIOPHYS, V362, P275, DOI 10.1006/abbi.1998.1033; LEDUC R, 1992, J BIOL CHEM, V267, P14304; Lee AY, 1998, NAT STRUCT BIOL, V5, P866, DOI 10.1038/2306; LINDBERG I, 1994, MOL CELL NEUROSCI, V5, P263, DOI 10.1006/mcne.1994.1030; Maniatis T., 1989, MOL CLONING LAB MAN; Meichtry J, 1999, PLANT MOL BIOL, V39, P749, DOI 10.1023/A:1006193414434; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Muller L, 1997, J CELL BIOL, V139, P625, DOI 10.1083/jcb.139.3.625; Neuteboom LW, 1999, PLANT MOL BIOL, V39, P273, DOI 10.1023/A:1006104205959; Possee RD., 1992, BACULOVIRUS EXPRESSI; RIBEIRO A, 1995, PLANT CELL, V7, P785, DOI 10.1105/tpc.7.6.785; Rudenskaya GN, 1998, FEBS LETT, V437, P237, DOI 10.1016/S0014-5793(98)01243-5; RUDENSKAYA GN, 1995, PLANTA, V196, P174, DOI 10.1007/BF00193231; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; SCHALLER A, 1994, P NATL ACAD SCI USA, V91, P11802, DOI 10.1073/pnas.91.25.11802; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Seidah NG, 1999, P NATL ACAD SCI USA, V96, P1321, DOI 10.1073/pnas.96.4.1321; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; SHENNAN KIJ, 1995, J BIOL CHEM, V270, P1402, DOI 10.1074/jbc.270.3.1402; Siezen RJ, 1997, PROTEIN SCI, V6, P501; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Taylor AA, 1997, PLANT J, V12, P1261, DOI 10.1046/j.1365-313x.1997.12061261.x; Tornero P, 1996, P NATL ACAD SCI USA, V93, P6332, DOI 10.1073/pnas.93.13.6332; Tornero P, 1997, J BIOL CHEM, V272, P14412, DOI 10.1074/jbc.272.22.14412; Tornero P, 1996, PLANT J, V10, P315, DOI 10.1046/j.1365-313X.1996.10020315.x; UCHIKOBA T, 1995, J BIOCHEM-TOKYO, V117, P1126, DOI 10.1093/oxfordjournals.jbchem.a124817; VERA P, 1988, PLANT PHYSIOL, V87, P58, DOI 10.1104/pp.87.1.58; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; YAMAGATA H, 1994, J BIOL CHEM, V269, P32725; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509	51	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5193	5199		10.1074/jbc.275.7.5193	http://dx.doi.org/10.1074/jbc.275.7.5193			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671566	Green Published, hybrid			2022-12-27	WOS:000085378200092
J	Rafie-Kolpin, M; Chefalo, PJ; Hussain, Z; Hahn, J; Uma, S; Matts, RL; Chen, JJ				Rafie-Kolpin, M; Chefalo, PJ; Hussain, Z; Hahn, J; Uma, S; Matts, RL; Chen, JJ			Two heme-binding domains of heme-regulated eukaryotic initiation factor-2 alpha kinase - N terminus and kinase insertion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; DEPENDENT PROTEIN-KINASE; HISTIDINE-RICH GLYCOPROTEIN; EIF-2-ALPHA KINASE; TRANSLATIONAL CONTROL; IN-VIVO; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING	In heme deficiency, protein synthesis in reticulocytes is inhibited by activation of heme-regulated alpha-subunit of eukaryotic initiation factor-2 alpha (eIF-2 alpha) kinase (HRI). Previous studies indicate that HRI contains two distinct heme-binding sites per HRI monomer, To study the role of the N terminus in the heme regulation of HRI, two N-terminally truncated mutants, Meta and Met3 (deletion of the first 103 and 130 amino acids, respectively), were prepared. Meta and Met3 underwent autophosphorylation and phosphorylated eIF-2 alpha with a specific activity of approximately 50% of that of the wild type HRI, These mutants were significantly less sensitive to heme regulation both in vivo and in vitro. In addition, the heme contents of purified Meta and Met3 HRI were less than 5% of that of the wild type HRI, These results indicated that the N terminus was important but was not the only domain involved in the heme-binding and heme regulation of HRI, Heme binding of the individual HRI domains showed that both N terminus and kinase insertion were able to bind hemin, whereas the C terminus and the catalytic domains were not. Thus, both the N terminus and the kinase insertion, which are unique to HRI, are involved in the heme binding and the heme regulation of HRI.	Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	Harvard University; Massachusetts Institute of Technology (MIT); Oklahoma State University System; Oklahoma State University - Stillwater	Chen, JJ (corresponding author), Harvard Univ, MIT, Div Hlth Sci & Technol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.				NIDDK NIH HHS [DK-09773, DK-53223, R01 DK016272] Funding Source: Medline; NIEHS NIH HHS [ES-04299] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053223, F32DK009773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004299, R29ES004299] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arnoux P, 1999, NAT STRUCT BIOL, V6, P516; BARBER GN, 1991, BIOCHEMISTRY-US, V30, P10356, DOI 10.1021/bi00106a038; Borza DB, 1998, J BIOL CHEM, V273, P5493, DOI 10.1074/jbc.273.10.5493; Cai RR, 1998, J BIOL CHEM, V273, P11274, DOI 10.1074/jbc.273.18.11274; CHEFALO PJ, 1994, J BIOL CHEM, V269, P25788; Chefalo PJ, 1998, EUR J BIOCHEM, V258, P820, DOI 10.1046/j.1432-1327.1998.2580820.x; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P315, DOI 10.1073/pnas.88.2.315; CHEN JJ, 1989, J BIOL CHEM, V264, P9559; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; COSENTINO GP, 1995, P NATL ACAD SCI USA, V92, P9445, DOI 10.1073/pnas.92.21.9445; Craig AWB, 1996, J BIOL CHEM, V271, P24526, DOI 10.1074/jbc.271.40.24526; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DIALLINAS G, 1994, GENE, V143, P21, DOI 10.1016/0378-1119(94)90599-1; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; HINNEBUSCH AG, 1996, COLD SPRING HARBOR M, V30, P199; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; Jackson RJ, 1991, TRANSLATION EUKARYOT, P193; KATAGIRI M, 1987, BIOCHEM BIOPH RES CO, V149, P1070, DOI 10.1016/0006-291X(87)90517-1; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; Komar AA, 1997, J BIOL CHEM, V272, P10646; LATHROP JT, 1993, SCIENCE, V259, P522, DOI 10.1126/science.8424176; McCoubrey WK, 1997, J BIOL CHEM, V272, P12568, DOI 10.1074/jbc.272.19.12568; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; Miyatake H, 1999, ACTA CRYSTALLOGR D, V55, P1215, DOI 10.1107/S0907444999004047; Mohrle JJ, 1997, BIOCHEM J, V328, P677; MORGAN WT, 1985, BIOCHEMISTRY-US, V24, P1496, DOI 10.1021/bi00327a031; Olsen DS, 1998, GENETICS, V149, P1495; Ortega LG, 1996, VIROLOGY, V215, P31, DOI 10.1006/viro.1996.0004; PAL JK, 1991, BIOCHEMISTRY-US, V30, P2555, DOI 10.1021/bi00223a037; PATEL RC, 1994, J BIOL CHEM, V269, P18593; PATEL RC, 1995, P NATL ACAD SCI USA, V92, P8283, DOI 10.1073/pnas.92.18.8283; Patel RC, 1998, MOL CELL BIOL, V18, P7009, DOI 10.1128/MCB.18.12.7009; Patel RC, 1996, J BIOL CHEM, V271, P25657, DOI 10.1074/jbc.271.41.25657; Qiu HF, 1998, MOL CELL BIOL, V18, P2697, DOI 10.1128/MCB.18.5.2697; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Santoyo J, 1997, J BIOL CHEM, V272, P12544, DOI 10.1074/jbc.272.19.12544; SATOH T, 1994, P NATL ACAD SCI USA, V91, P8423, DOI 10.1073/pnas.91.18.8423; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Sullivan AD, 1996, PARASITOLOGY, V112, P285, DOI 10.1017/S003118200006580X; Taylor DR, 1996, MOL CELL BIOL, V16, P6295; TRIGGSRAINE BL, 1988, J BACTERIOL, V170, P4415, DOI 10.1128/jb.170.9.4415-4419.1988; TSUTSUI K, 1982, J BIOL CHEM, V257, P3925; Uma S, 1997, J BIOL CHEM, V272, P11648; Uma S, 2000, EUR J BIOCHEM, V267, P498, DOI 10.1046/j.1432-1327.2000.01021.x; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WEK SA, 1995, MOL CELL BIOL, V15, P4497; Wu SY, 1996, J BIOL CHEM, V271, P1756, DOI 10.1074/jbc.271.3.1756; YANG JM, 1992, J BIOL CHEM, V267, P20519; ZHANG L, 1995, EMBO J, V14, P313, DOI 10.1002/j.1460-2075.1995.tb07005.x	57	81	86	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5171	5178		10.1074/jbc.275.7.5171	http://dx.doi.org/10.1074/jbc.275.7.5171			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671563	hybrid			2022-12-27	WOS:000085378200089
J	Filoteo, AG; Enyedi, A; Verma, AK; Elwess, NL; Penniston, JT				Filoteo, AG; Enyedi, A; Verma, AK; Elwess, NL; Penniston, JT			Plasma membrane Ca2+ pump isoform 3f is weakly stimulated by calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAIN; SKELETAL-MUSCLE; CALCIUM-PUMP; KINASE; ATPASE; 4B; CA2+-ATPASE; ANTIBODIES; REGION; BRAIN	Isoform 3f of the plasma membrane Ca2+ pump is a major isoform of this pump in rat skeletal muscle. It has an unusual structure, with a short carboxyl-terminal regulatory region of only 33 residues when compared with the 77 to 124 residues found in the other isoforms, Also, whereas the regulatory regions of the other iso forms, downstream of the alternative splice, consist of two homologous groups, the sequence of 3f is not related to either group. A synthetic peptide representing the calmodulin binding domain of isoform 3f had a much lower calmodulin affinity (with a K-d of 15 nM) than the corresponding peptide of isoform 2b (K-d value was 0.2 nM). The characteristics of this domain were further studied by making chimeras of the 3f regulatory region with the catalytic core of isoform 4 and by making the full-length isoform 3f, Both constructs bound to calmodulin-Sepharose. The chimera was fully active without calmodulin, showing no stimulation of activity when calmodulin was added. The full-length isoform 3f was slightly activated by calmodulin, These data show that the regulatory region of isoform 3f is only a weak autoinhibitor of the enzyme, in contrast to the properties of all the other isoforms studied so far, Rather, this isoform is a special-purpose, constitutively active form of the enzyme, expressed primarily in skeletal muscle and as a minor isoform in brain.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Natl Inst Haematol & Immunol, H-1113 Budapest, Hungary	Mayo Clinic	Penniston, JT (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.		Enyedi, Agnes/N-9742-2013	Enyedi, Agnes/0000-0002-7366-9376	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835, R01GM055514] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28835, GM55514] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURK SE, 1992, J BIOL CHEM, V267, P19683; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; Caride AJ, 1999, J BIOL CHEM, V274, P35227, DOI 10.1074/jbc.274.49.35227; Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353; Elwess NL, 1997, J BIOL CHEM, V272, P17981, DOI 10.1074/jbc.272.29.17981; ENYEDI A, 1993, J BIOL CHEM, V268, P17120; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; Enyedi A, 1997, J BIOL CHEM, V272, P27525, DOI 10.1074/jbc.272.44.27525; Enyedi A, 1996, J BIOL CHEM, V271, P32461, DOI 10.1074/jbc.271.50.32461; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; Filoteo AG, 1997, J BIOL CHEM, V272, P23741, DOI 10.1074/jbc.272.38.23741; GRAF E, 1980, ARCH BIOCHEM BIOPHYS, V203, P719, DOI 10.1016/0003-9861(80)90231-3; GREEB J, 1989, J BIOL CHEM, V264, P18569; KEETON TP, 1993, J BIOL CHEM, V268, P2740; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; LINDBERG O, 1956, METHODS BIOCHEMICAL, P1; MCCORMICK DJ, 1987, J IMMUNOL, V139, P2615; Penniston JT, 1998, J MEMBRANE BIOL, V165, P101, DOI 10.1007/s002329900424; REDDY LG, 1999, BIOPHYS, V76, P99012; SEILER S, 1982, J BIOL CHEM, V257, P13862; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; TOROK K, 1994, BIOCHEMISTRY-US, V33, P12807, DOI 10.1021/bi00209a012; Verma AK, 1996, J BIOL CHEM, V271, P3714; Verma AK, 1999, J BIOL CHEM, V274, P527, DOI 10.1074/jbc.274.1.527; VERMA AK, 1994, J BIOL CHEM, V269, P1687	28	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4323	4328		10.1074/jbc.275.6.4323	http://dx.doi.org/10.1074/jbc.275.6.4323			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660601	hybrid			2022-12-27	WOS:000085288800085
J	Pignol, D; Ayvazian, L; Kerfelec, B; Timmins, P; Crenon, I; Hermoso, J; Fontecilla-Camps, JC; Chapus, C				Pignol, D; Ayvazian, L; Kerfelec, B; Timmins, P; Crenon, I; Hermoso, J; Fontecilla-Camps, JC; Chapus, C			Critical role of micelles in pancreatic lipase activation revealed by small angle neutron scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-SALT; TAURODEOXYCHOLATE MICELLES; CRYSTAL-STRUCTURE; HORSE COLIPASE; CO-LIPASE; PORCINE; COMPLEX; DETERGENTS; ADSORPTION; VESICLES	In the duodenum, pancreatic lipase (PL) develops its activity on triglycerides by binding to the bile-emulsified oil droplets in the presence of its protein cofactor pancreatic colipase (PC), The neutron crystal structure of a PC-PL-micelle complex (Hermoso, J,, Pignol, D,, Penel, S,, Roth, M,, Chapus, C,, and Fontecilla-Camps, J, C, (1997) EMBO J, 16, 5531-5536) has suggested that the stabilization of the enzyme in its active conformation and its adsorption to the emulsified oil droplets are mediated by a preformed lipase-colipase-micelle complex. Here, we correlate the ability of different amphypathic compounds to activate FL, with their association with PC-FL in solution, The method of small angle neutron scattering with D2O/H2O contrast variation was used to characterize a solution containing PC-FL complex and taurodeoxycholate micelles, The resulting radius of gyration (56 Angstrom) and the match point of the solution indicate the formation of a ternary complex that is similar to the one observed in the neutron crystal structure. In addition, we show that either bile salts, lysophospholipids, or nonionic detergents that form micelles with radii of gyration ranging from 13 to 26 Angstrom are able to bind to the PC-FL complex, whereas smaller micelles or nonmicellar compounds are not. This further supports the notion of a micelle size-dependent affinity process for lipase activation in vivo.	CNRS, CNR, Inst Biol Struct Jean Pierre Ebel, Cristallog & Cristallogenese Prot Lab, F-38027 Grenoble 1, France; UPR 9036 CNRS, Lab Bioenerget & Ingn Prot, F-13402 Marseille, France; Inst Max Von Laue Paul Langevin, Large Scale Struct Grp, F-38042 Grenoble, France; CSIC, Inst Rocasolano, Grp Cristalog Macromol & Biol Estruct, E-28006 Madrid, Spain	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Institut Laue-Langevin (ILL); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR)	Fontecilla-Camps, JC (corresponding author), CNRS, CNR, Inst Biol Struct Jean Pierre Ebel, Cristallog & Cristallogenese Prot Lab, 41 Rue Jules Horowitz, F-38027 Grenoble 1, France.		Hermoso, Juan/J-3433-2012	Hermoso, Juan/0000-0002-1862-8950; PIGNOL, David/0000-0002-8070-0319				BORGSTRO.B, 1973, EUR J BIOCHEM, V37, P60, DOI 10.1111/j.1432-1033.1973.tb02957.x; BOURNE Y, 1994, J MOL BIOL, V238, P709, DOI 10.1006/jmbi.1994.1331; CANIONI P, 1981, BIOCHIM BIOPHYS ACTA, V670, P305, DOI 10.1016/0005-2795(81)90101-X; CAREY MC, 1983, ANNU REV PHYSIOL, V45, P651, DOI 10.1146/annurev.ph.45.030183.003251; CHAPUS C, 1975, FEBS LETT, V58, P155, DOI 10.1016/0014-5793(75)80247-X; CHAPUS C, 1981, EUR J BIOCHEM, V115, P99; CHARLES M, 1975, EUR J BIOCHEM, V58, P555, DOI 10.1111/j.1432-1033.1975.tb02405.x; CHARLES M, 1980, J MOL BIOL, V139, P297, DOI 10.1016/0022-2836(80)90132-1; DONNER J, 1976, BIOCHEMISTRY-US, V15, P5413, DOI 10.1021/bi00669a031; EGELHAAF SU, 1994, J PHYS CHEM-US, V98, P8560, DOI 10.1021/j100085a041; EGLOFF MP, 1995, BIOCHEMISTRY-US, V34, P2571; GHOSH R, 1981, 81GH29T ILL; GRANON S, 1986, BIOCHIM BIOPHYS ACTA, V671, P54; Hermoso J, 1997, EMBO J, V16, P5531, DOI 10.1093/emboj/16.18.5531; Hermoso J, 1996, J BIOL CHEM, V271, P18007, DOI 10.1074/jbc.271.30.18007; HOFMANN AF, 1967, ANNU REV MED, V18, P333, DOI 10.1146/annurev.me.18.020167.002001; IBEL K, 1976, J APPL CRYSTALLOGR, V9, P296, DOI 10.1107/S0021889876011394; JACROT B, 1976, REP PROG PHYS, V39, P911, DOI 10.1088/0034-4885/39/10/001; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LOMBARDO D, 1989, J MOL BIOL, V205, P259, DOI 10.1016/0022-2836(89)90380-X; MCINTYRE JC, 1990, BIOCHEMISTRY-US, V29, P2092, DOI 10.1021/bi00460a019; MCINTYRE JC, 1987, BIOCHEM J, V245, P821, DOI 10.1042/bj2450821; PATTON JS, 1978, J BIOL CHEM, V253, P4195; PEDERSEN JS, 1995, J PHYS CHEM-US, V99, P1299, DOI 10.1021/j100004a033; SARI H, 1978, FEBS LETT, V95, P229, DOI 10.1016/0014-5793(78)81000-X; SARI H, 1975, BIOCHIMIE, V57, P1045, DOI 10.1016/S0300-9084(75)80360-9; SMALL DM, 1968, J AM OIL CHEM SOC, V45, P108, DOI 10.1007/BF02915334; TIMMINS P, 1994, BIOPHYS CHEM, V53, P27, DOI 10.1016/0301-4622(94)00073-5; VANDERMEERS A, 1975, FEBS LETT, V49, P334, DOI 10.1016/0014-5793(75)80779-4; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; VANTILBEURGH H, 1993, NATURE, V362, P812; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	32	42	42	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4220	4224		10.1074/jbc.275.6.4220	http://dx.doi.org/10.1074/jbc.275.6.4220			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660587	Green Published, hybrid			2022-12-27	WOS:000085288800071
J	Chang, M; Zhang, LS; Tam, JP; Sanders-Bush, E				Chang, M; Zhang, LS; Tam, JP; Sanders-Bush, E			Dissecting G protein-coupled receptor signaling pathways with membrane-permeable blocking peptides - Endogenous 5-HT2C receptors in choroid plexus epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; BETA-GAMMA-SUBUNITS; ADENOSINE A(1) RECEPTOR; PHOSDUCIN-LIKE PROTEIN; G-ALPHA-Q; XENOPUS OOCYTES; PHOSPHOLIPASE-C; MESSENGER-RNA; CORTICAL ASTROCYTES; SEROTONIN RECEPTORS	To determine the intracellular signaling mechanism of the 5-HT2C receptor endogenously expressed in choroid plexus epithelial cells, we implemented a strategy of targeted disruption of protein-protein interactions. This strategy entails the delivery of conjugated membrane-permeable peptides that disrupt domain interaction at specific steps in the signaling cascade. As proof of concept, two peptides targeted against receptor-G protein interaction domains mere examined. Only G(q)CT, which targets the receptor-G(q) protein interacting domain, disrupted 5-HT2C receptor-mediated phosphatidylinositide hydrolysis. G(s)CT, targeting the receptor-G(s) protein, disrupted beta 2 adrenergic receptor-mediated activation of cAMCP but not 5-HT2C receptor-mediated phosphatidylinositide hydrolysis, The peptide MPS-PLC beta 1M, mimicking the domain of phospholipase C beta 1 (PLC beta 1) interacting with active G alpha(q), also blocked 5-HT2C receptor activation. In contrast, peptides PLC beta 2M and Phos that bind 60 and sequester free G beta gamma subunits were ineffective at blocking 5-HT2C receptor-mediated phosphoinositol turnover. However, both peptides disrupted G beta gamma-mediated alpha(2A) adrenergic receptor activation of mitogen-activated protein kinase, These results provide the first direct demonstration that active G alpha(q) subunits mediate endogenous 5-HT2C receptor activation of PLC beta and that G beta gamma subunits released from G alpha(q) heterotrimeric proteins are not involved. Comparable results were obtained with metabotropic glutamate receptor 5 expressed in astrocytes. Thus, coqiugated, membrane-permeable peptides are effective tools for the dissection of intracellular signals.	Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Immunol & Microbiol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Sanders-Bush, E (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, 221 Kirkland Hall, Nashville, TN 37232 USA.		Tam, James P/A-2176-2011	Tam, James P/0000-0003-4433-198X	NCI NIH HHS [CA36544] Funding Source: Medline; NIMH NIH HHS [MH34007] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH034007, R01MH034007] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABE T, 1992, J BIOL CHEM, V267, P13361; Backstrom JR, 1997, J NEUROSCI METH, V77, P109, DOI 10.1016/S0165-0270(97)00102-7; BACKSTROM JR, 1995, MOL BRAIN RES, V33, P311, DOI 10.1016/0169-328X(95)00156-M; Balazs R, 1997, J NEUROCHEM, V69, P151; Balazs R, 1998, J NEUROCHEM, V70, P2446; BARKER EL, 1993, MOL PHARMACOL, V44, P725; BARKER EL, 1994, J BIOL CHEM, V269, P11687; Berg KA, 1998, ANN NY ACAD SCI, V861, P104, DOI 10.1111/j.1749-6632.1998.tb10180.x; Berg KA, 1998, MOL PHARMACOL, V54, P94, DOI 10.1124/mol.54.1.94; Berg KA, 1996, MOL PHARMACOL, V50, P1017; BURRIS KD, 1991, J PHARMACOL EXP THER, V258, P891; CANTON H, 1990, EUR J PHARMACOL, V191, P93, DOI 10.1016/0014-2999(90)94100-C; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CHEN Y, 1994, NEUROSCI LETT, V179, P100, DOI 10.1016/0304-3940(94)90944-X; CONN PJ, 1986, P NATL ACAD SCI USA, V83, P4086, DOI 10.1073/pnas.83.11.4086; DELAPENA P, 1995, J BIOL CHEM, V270, P3554, DOI 10.1074/jbc.270.8.3554; Dickenson JM, 1998, EUR J PHARMACOL, V355, P85, DOI 10.1016/S0014-2999(98)00468-3; FISONE G, 1995, J BIOL CHEM, V270, P2427, DOI 10.1074/jbc.270.6.2427; Gilchrist A, 1998, J BIOL CHEM, V273, P14912, DOI 10.1074/jbc.273.24.14912; GROTEWIEL MS, 1994, J PHARMACOL EXP THER, V271, P1122; HAMM HE, 1994, METHOD ENZYMOL, V237, P423; Hartman JL, 1996, J BIOL CHEM, V271, P22591, DOI 10.1074/jbc.271.37.22591; Heisler LK, 1998, ANN NY ACAD SCI, V861, P74, DOI 10.1111/j.1749-6632.1998.tb10175.x; HOGER JH, 1991, NEURON, V6, P227, DOI 10.1016/0896-6273(91)90358-7; HOYER D, 1994, PHARMACOL REV, V46, P157; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KAUFMAN MJ, 1995, J NEUROCHEM, V64, P199; KOTERA T, 1994, AM J PHYSIOL, V266, pC536, DOI 10.1152/ajpcell.1994.266.2.C536; Lin YZ, 1996, J BIOL CHEM, V271, P5305, DOI 10.1074/jbc.271.10.5305; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu XY, 1996, P NATL ACAD SCI USA, V93, P11819, DOI 10.1073/pnas.93.21.11819; LUBBERT H, 1987, P NATL ACAD SCI USA, V84, P4332, DOI 10.1073/pnas.84.12.4332; LUTTRELL LM, 1995, J BIOL CHEM, V270, P12984, DOI 10.1074/jbc.270.22.12984; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; MILLER S, 1995, J NEUROSCI, V15, P6103; MURTHY KS, 1995, MOL PHARMACOL, V47, P1172; Murthy KS, 1996, J BIOL CHEM, V271, P23458, DOI 10.1074/jbc.271.38.23458; Offermanns S, 1996, MOL ENDOCRINOL, V10, P566, DOI 10.1210/me.10.5.566; PANICKER MM, 1991, P NATL ACAD SCI USA, V88, P2560, DOI 10.1073/pnas.88.6.2560; PARK DG, 1993, J BIOL CHEM, V268, P3710; Parmentier ML, 1998, MOL PHARMACOL, V53, P778, DOI 10.1124/mol.53.4.778; PAZOS A, 1985, BRAIN RES, V346, P231, DOI 10.1016/0006-8993(85)90857-1; Peavy RD, 1998, J NEUROCHEM, V71, P603; PEROUTKA SJ, 1986, J NEUROCHEM, V47, P529; QUICK MW, 1994, J BIOL CHEM, V269, P30164; Sankaran B, 1998, J BIOL CHEM, V273, P7148, DOI 10.1074/jbc.273.12.7148; Schmidt M, 1996, MOL PHARMACOL, V50, P1038; Schroder S, 1997, FEBS LETT, V401, P243, DOI 10.1016/S0014-5793(96)01483-4; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; TAYLOR JM, 1994, CELL SIGNAL, V6, P841, DOI 10.1016/0898-6568(94)90017-5; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0; TSUTSUMI M, 1989, J BIOL CHEM, V264, P9626; Westphal RS, 1996, MOL PHARMACOL, V49, P474; Willins DL, 1999, NEUROSCIENCE, V91, P599, DOI 10.1016/S0306-4522(98)00653-8; WU DQ, 1993, J BIOL CHEM, V268, P3704; YAGALOFF KA, 1985, J NEUROSCI, V5, P3178; Zhang LS, 1998, P NATL ACAD SCI USA, V95, P9184, DOI 10.1073/pnas.95.16.9184; Zhang LS, 1996, ANAL BIOCHEM, V233, P87, DOI 10.1006/abio.1996.0011	59	81	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7021	7029		10.1074/jbc.275.10.7021	http://dx.doi.org/10.1074/jbc.275.10.7021			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702266	hybrid			2022-12-27	WOS:000085809600046
J	Rozzelle, JE; Dauber, DS; Todd, S; Kelley, R; Craik, CS				Rozzelle, JE; Dauber, DS; Todd, S; Kelley, R; Craik, CS			Macromolecular inhibitors of HIV-1 protease - Characterization of designed heterodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY; RETROVIRAL PROTEASES; WILD-TYPE; PROTEINS; MATURATION; EXPRESSION; DIMERIZATION; INTERFACE; STABILITY; PEPTIDES	Defective variants of human immunodeficiency virus type 1 (HIV-1) protease (HIV PR) have been engineered to inhibit wild-type (wt) PW PR activity. These variants were designed to promote the formation of heterodimers and to destabilize the formation of inactive variant homodimers of HIV-1 protease through substitutions at Asp-25, Ile-49, and Gly-50 (Babe, L, M., Rose, J., and Craik, C, S. (1995) Proc. Natl, Acad Sci. U.S.A. 92, 10069-10073; McPhee, F., Good, A. C., Kuntz, I. D., and Craik, C. S. (1996) Proc. Natl. Acad Sci. U.S.A. 93, 11477-11481). The mechanism of action of these dominant-negative inhibitors was established using recombinantly expressed defective monomers, The defective monomers were refolded in vitro in the presence of wt HIV PR and showed dose-dependent inhibition of proteolytic activity. This inhibition was shown to result from the formation of inactive heterodimers between defective and wt HIV PR monomers, Heterodimer formation was detected by (i) isolating refolded, inactive heterodimers using histidine-tagged defective monomers and (ii) isolating heterodimers from bacteria coexpressing both wt and defective variants of HIV PR. Single-chain variants of HIV PR, in which the C terminus of the wt HIV PR monomer was covalently tethered to the N terminus of the defective monomer, were also expressed and analyzed. Thermal denaturation of these single-chain heterodimers using differential scanning calorimetry revealed a 1.5-7.2 degrees C greater thermal stability than single-chain wt HIV PR, The thermodynamic trend shown by these three variants mirrors their relative inhibition in provirus transfection assays. These data support the model that the effects seen both in tissue culture and in vitro arise from an increase in stability conferred on these heterodimers by interface mutations and identifies heterodimer formation as their mechanism of inhibition.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA	University of California System; University of California San Francisco; Roche Holding; Genentech	Craik, CS (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	craik@cgl.ucaf.edu			NIGMS NIH HHS [GM56531] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM056531] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABE LM, 1995, P NATL ACAD SCI USA, V92, P10069, DOI 10.1073/pnas.92.22.10069; BABE LM, 1991, BIOCHEMISTRY-US, V30, P106, DOI 10.1021/bi00215a016; BABE LM, 1992, PROTEIN SCI, V1, P1244, DOI 10.1002/pro.5560011003; Bouras A, 1999, J MED CHEM, V42, P957, DOI 10.1021/jm9803976; DARKE PL, 1994, BIOCHEMISTRY-US, V33, P98, DOI 10.1021/bi00167a013; GRANT SK, 1992, BIOCHEMISTRY-US, V31, P9491, DOI 10.1021/bi00154a023; JORDAN SP, 1992, J BIOL CHEM, V267, P20028; Junker U, 1996, J VIROL, V70, P7765, DOI 10.1128/JVI.70.11.7765-7772.1996; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McPhee F, 1996, P NATL ACAD SCI USA, V93, P11477, DOI 10.1073/pnas.93.21.11477; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NEET KE, 1994, PROTEIN SCI, V3, P2167, DOI 10.1002/pro.5560031202; PICHUANTES S, 1989, PROTEINS, V6, P324, DOI 10.1002/prot.340060315; ROSE JR, 1993, J BIOL CHEM, V268, P11939; ROSE JR, 1995, J VIROL, V69, P2751; Rose RB, 1998, BIOCHEMISTRY-US, V37, P2607, DOI 10.1021/bi9716074; RUTENBER E, 1993, J BIOL CHEM, V268, P15343; SALTO R, 1994, J BIOL CHEM, V269, P10691; Sanchez-Ruiz J M, 1995, Subcell Biochem, V24, P133; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIGAL E, 1990, J BIOL CHEM, V265, P5113; Todd MJ, 1998, J MOL BIOL, V283, P475, DOI 10.1006/jmbi.1998.2090; TOMASSELLI AG, 1990, BIOCHEMISTRY-US, V29, P264, DOI 10.1021/bi00453a036; WEBER IT, 1990, J BIOL CHEM, V265, P10492; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; WONDRAK EM, 1991, FEBS LETT, V280, P347, DOI 10.1016/0014-5793(91)80328-Z; ZHANG ZY, 1991, J BIOL CHEM, V266, P15591; Zutshi R, 1997, J AM CHEM SOC, V119, P4841, DOI 10.1021/ja962496j	30	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7080	7086		10.1074/jbc.275.10.7080	http://dx.doi.org/10.1074/jbc.275.10.7080			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702274	hybrid			2022-12-27	WOS:000085809600054
J	Sela-Brown, A; Silver, J; Brewer, G; Naveh-Many, T				Sela-Brown, A; Silver, J; Brewer, G; Naveh-Many, T			Identification of AUF1 as a parathyroid hormone mRNA 3 '-untranslated region-binding protein that determines parathyroid hormone mRNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; IN-VITRO; PTH SECRETION; VITAMIN-D; PHOSPHATE; PHOSPHORUS; CALCIUM; CELLS; RATS	Parathyroid hormone (PTH) mRNA levels are posttranscriptionally increased by hypocalcemia and decreased by hypophosphatemia, and this is mediated by cytosolic proteins binding to the PTH mRNA 3'-untranslated region (UTR). The same proteins are also present in other tissues, such as brain, but only in the parathyroid is their binding regulated by calcium and phosphate. The function of the PTH mRNA 3'-UTR-binding proteins was studied using an in vitro degradation assay. Competition for the parathyroid-binding proteins by excess unlabeled 3'-UTR destabilized the full-length PTR transcript in this assay, indicating that these proteins protect the RNA from RNase activity. The PTH RNA 3'-UTR-binding proteins were purified by RNA affinity chromatography of rat brain S-100 extracts. The eluate from the column was enriched in PTH RNA 3'-UTR binding activity. Addition of eluate to the In vitro degradation assay with parathyroid protein extracts stabilized the PTH transcript. A major band from the eluate at 50 kDa was sequenced and was identical to AU-rich binding protein (AUF1). Recombinant AUF1 bound the full-length PTH mRNA and the 3'-UTR. Added recombinant AUF1 also stabilized the PTH transcript in the in vitro degradation assay. Our results show that AUF1 is a protein that binds to the PTH mRNA 3'-UTR and stabilizes the PTH transcript.	Hadassah Univ Hosp, Serv Nephrol, Minerva Ctr Calcium & Bone Metab, IL-91120 Jerusalem, Israel; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Serv Nephrol, Piscataway, NJ 08854 USA	Hebrew University of Jerusalem; Rutgers State University New Brunswick; Rutgers State University Medical Center	Naveh-Many, T (corresponding author), Hadassah Univ Hosp, Serv Nephrol, Minerva Ctr Calcium & Bone Metab, POB 12000, IL-91120 Jerusalem, Israel.				NATIONAL CANCER INSTITUTE [R01CA052443] Funding Source: NIH RePORTER; NCI NIH HHS [CA52443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almaden Y, 1996, J BONE MINER RES, V11, P970; Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Buzby JS, 1996, BLOOD, V88, P2889, DOI 10.1182/blood.V88.8.2889.bloodjournal8882889; Buzby JS, 1999, J BIOL CHEM, V274, P33973, DOI 10.1074/jbc.274.48.33973; Chkheidze AN, 1999, MOL CELL BIOL, V19, P4572; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; EPSTEIN E, 2000, IN PRESS J CLIN INVE, V105; HENDY GN, 1981, P NATL ACAD SCI-BIOL, V78, P7365, DOI 10.1073/pnas.78.12.7365; KEMPER B, 1986, CRIT REV BIOCHEM MOL, V19, P353, DOI 10.3109/10409238609082545; KILAV R, 1995, J CLIN INVEST, V96, P327, DOI 10.1172/JCI118038; Kiledjian M, 1997, MOL CELL BIOL, V17, P4870, DOI 10.1128/MCB.17.8.4870; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Moallem E, 1998, J BIOL CHEM, V273, P5253, DOI 10.1074/jbc.273.9.5253; NAVEHMANY T, 1990, J CLIN INVEST, V86, P1313, DOI 10.1172/JCI114840; NAVEHMANY T, 1995, J CLIN INVEST, V96, P1786, DOI 10.1172/JCI118224; Nielsen PK, 1996, NEPHROL DIAL TRANSPL, V11, P1762; RAJAGOPALAN LE, 1995, BLOOD, V86, P2551; Rajagopalan LE, 1997, PROG NUCLEIC ACID RE, V56, P257, DOI 10.1016/S0079-6603(08)61007-7; Silver Justin, 1996, P325; Slatopolsky E, 1996, J CLIN INVEST, V97, P2534, DOI 10.1172/JCI118701; Wilson GM, 1999, METHODS, V17, P74, DOI 10.1006/meth.1998.0709; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257	25	110	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7424	7429		10.1074/jbc.275.10.7424	http://dx.doi.org/10.1074/jbc.275.10.7424			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702317	hybrid			2022-12-27	WOS:000085809600097
J	Xu, Y; Kakhniashvili, DA; Gremse, DA; Wood, DO; Mayor, JA; Walters, DE; Kaplan, RS				Xu, Y; Kakhniashvili, DA; Gremse, DA; Wood, DO; Mayor, JA; Walters, DE; Kaplan, RS			The yeast mitochondrial citrate transport protein - Probing the roles of cysteines, Arg(181), and Arg(189) in transporter function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; FATTY-ACID SYNTHESIS; TRICARBOXYLATE CARRIER; LACTOSE PERMEASE; UNCOUPLING PROTEIN; ESCHERICHIA-COLI; RESIDUES; IDENTIFICATION; PURIFICATION; EXPRESSION	Utilizing site-directed mutagenesis in combination with chemical modification of mutated residues, we have studied the roles of cysteine and arginine residues in the mitochondrial citrate transport protein (CTP) from Saccharomyces cerevisiae. Our strategy consisted of the sequential replacement of each of the four endogenous cysteine residues with Ser or in the case of Cys(73) with Val. Wild-type and mutated forms of the CTP were overexpressed in Escherichia coli, purified, and reconstituted in phospholipid vesicles. During the sequential replacement of each Cys, the effects of both hydrophilic and hydrophobic sulfhydryl reagents were examined. The data indicate that Cys(73) and Cys(256) are primarily responsible for inhibition of the wild-type CTP by hydrophilic sulfhydryl reagents. Experiments conducted with triple Cys replacement mutants (i.e. Cys(192) being the only remaining Cys) indicated that sulfhydryl reagents no longer inhibit but in fact stimulate CTP function 2-3-fold. Following the simultaneous replacement of all four endogenous Cys, the functional properties of the resulting Cys-less CTP were shown to be quite similar to those of the wild-type protein. Finally, utilizing the Cys-less CTP as a template, the roles of Arg(181) and Arg(189), two positively charged residues located within transmembrane domain IV, in CTP function were examined. Replacement of either residue with a Cys abolishes function, whereas replacement with a Lys or a Cys that is subsequently covalently modified with (2-aminoethyl) methanethiosulfonate hydrobromide, a reagent that restores positive charge at this site, supports CTP function. The results clearly show that positive charge at these two positions is essential for CTP function, although the chemistry of the guanidinium residue is not. Finally, these studies: (i) definitely demonstrate that Cys residues do not play an important role in the mechanism of the CTP; (ii) prove the utility of the Cys-less CTP for studying structure/function relationships within this metabolically important protein; and (iii) have led to the hypothesis that the polar face of alpha-helical transmembrane domain IV, within which Arg(181), Arg(189), and Cys(192) are located, constitutes an essential portion of the citrate translocation pathway through the membrane.	Finch Univ Hlth Sci Chicago Med Sch, Dept Biochem & Mol Biol, N Chicago, IL 60064 USA; Univ S Alabama, Coll Med, Dept Pharmacol, Mobile, AL 36688 USA; Univ S Alabama, Coll Med, Dept Microbiol & Immunol, Mobile, AL 36688 USA	Chicago Medical School; University of South Alabama; University of South Alabama	Kaplan, RS (corresponding author), Finch Univ Hlth Sci Chicago Med Sch, Dept Biochem & Mol Biol, 3333 Gren Bay Rd, N Chicago, IL 60064 USA.		Mayor, June/AAP-1544-2021; Walters, D. Eric/C-9626-2010	Walters, D. Eric/0000-0002-1513-3522	NIGMS NIH HHS [GM-54642] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054642] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ARECHAGA I, 1993, BIOCHEM J, V296, P693, DOI 10.1042/bj2960693; BISACCIA F, 1990, BIOCHIM BIOPHYS ACTA, V1019, P250, DOI 10.1016/0005-2728(90)90201-E; BISACCIA F, 1989, BIOCHIM BIOPHYS ACTA, V977, P171, DOI 10.1016/S0005-2728(89)80068-4; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; Briggs C, 1999, BIOCHEMISTRY-US, V38, P5096, DOI 10.1021/bi982945n; BRUNENGR.H, 1973, FEBS LETT, V36, P130, DOI 10.1016/0014-5793(73)80353-9; CONOVER TE, 1987, TRENDS BIOCHEM SCI, V12, P88, DOI 10.1016/0968-0004(87)90042-9; DEWAR MJS, 1977, J AM CHEM SOC, V99, P4899, DOI 10.1021/ja00457a004; DUE AD, 1995, BIOCHEM BIOPH RES CO, V208, P590, DOI 10.1006/bbrc.1995.1379; ENDEMANN G, 1982, J BIOL CHEM, V257, P3434; Frillingos S, 1996, BIOCHEMISTRY-US, V35, P13363, DOI 10.1021/bi961453c; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; KAPLAN RS, 1990, J BIOL CHEM, V265, P13379; KAPLAN RS, 1995, J BIOL CHEM, V270, P4108, DOI 10.1074/jbc.270.8.4108; Muller V, 1996, BIOCHEMISTRY-US, V35, P16132, DOI 10.1021/bi960667r; PALMIERI F, 1972, EUR J BIOCHEM, V26, P587, DOI 10.1111/j.1432-1033.1972.tb01801.x; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROBINSON BH, 1971, EUR J BIOCHEM, V20, P65, DOI 10.1111/j.1432-1033.1971.tb01363.x; SAHINTOTH M, 1993, BIOCHEMISTRY-US, V32, P10027, DOI 10.1021/bi00089a019; Schroers A, 1997, J BIOL CHEM, V272, P10558; VANIWAARDEN PR, 1992, BIOCHIM BIOPHYS ACTA, V1113, P161, DOI 10.1016/0304-4157(92)90037-B; VANIWAARDEN PR, 1991, BIOCHEMISTRY-US, V30, P9595, DOI 10.1021/bi00104a005; WATSON JA, 1970, J BIOL CHEM, V245, P5993; Winkler E, 1997, BIOCHEMISTRY-US, V36, P148, DOI 10.1021/bi962178x; XU Y, 1995, BIOCHEM BIOPH RES CO, V207, P783, DOI 10.1006/bbrc.1995.1255; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0	28	48	52	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7117	7124		10.1074/jbc.275.10.7117	http://dx.doi.org/10.1074/jbc.275.10.7117			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702279	hybrid			2022-12-27	WOS:000085809600059
J	Chiang, GG; Sefton, BM				Chiang, GG; Sefton, BM			Phosphorylation of a Src kinase at the autophosphorylation site in the absence of Src kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PROTEIN-KINASE; SIGNAL-TRANSDUCTION; HYDROGEN-PEROXIDE; INTERMOLECULAR AUTOPHOSPHORYLATION; RETROVIRAL VECTORS; HOMOLOGY-2 DOMAIN; STRUCTURAL BASIS; C-SRC; ACTIVATION; LCK	Exposure of cells to oxidants increases the phosphorylation of the Src family tyrosine protein kinase Lck at Tyr-394, a conserved residue in the activation loop of the catalytic domain. Kinase-deficient Lck expressed in fibroblasts that do not express any endogenous Lck has been shown to be phosphorylated at Tyr-394 following H2O2 treatment to an extent indistinguishable from that seen with wild type Lck. This finding indicates that a kinase other than Lck itself is capable of phosphorylating Tyr-394. Because fibroblasts express other Src family members, it remained to be determined whether the phosphorylation of Tyr-394 was carried out by another Src family kinase or by an unrelated tyrosine protein kinase. We examined here whether Tyr-394 in kinase-deficient Lck was phosphorylated following exposure of cells devoid of endogenous Src family kinase activity to H2O2. Strikingly, treatment of such cells with H2O2 led to the phosphorylation of Tyr-394 to an extent identical to that seen with wild type Lck, demonstrating that Src family kinases are not required for H2O2-induced phosphorylation of Lck. Furthermore, this efficient phosphorylation of Lck at Tyr-394 in non lymphoid cells suggests the existence of an ubiquitous activator of Src family kinases.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	Salk Institute; University of California System; University of California San Diego	Chiang, GG (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Chiang, Gary/0000-0003-3004-7400	NCI NIH HHS [T32-CA09435, CA14195, CA42350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014195, T32CA009435, R01CA042350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOULET I, 1987, BIOCHEM BIOPH RES CO, V149, P56, DOI 10.1016/0006-291X(87)91604-4; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CASNELLIE JE, 1982, J BIOL CHEM, V257, P3877; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HAWLEY RG, 1994, GENE THER, V1, P136; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HURLEY TR, 1989, ONCOGENE, V4, P265; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LUO K, 1990, ONCOGENE, V5, P921; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; Rao GN, 1996, ONCOGENE, V13, P713; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SEFTON BM, 1991, ANNU REV CELL BIOL, V7, P257, DOI 10.1146/annurev.cellbio.7.1.257; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SOTIRELLIS N, 1995, J BIOL CHEM, V270, P29773; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; SULLIVAN SG, 1994, FREE RADICAL BIO MED, V16, P399, DOI 10.1016/0891-5849(94)90042-6; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; VERONOVA AF, 1984, MOL CELL BIOL, V4, P2705; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Yan SR, 1996, J BIOL CHEM, V271, P23464, DOI 10.1074/jbc.271.38.23464; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	54	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6055	6058		10.1074/jbc.275.9.6055	http://dx.doi.org/10.1074/jbc.275.9.6055			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692391	hybrid			2022-12-27	WOS:000085654400003
J	Penzes, P; Johnson, RC; Alam, MR; Kambampati, V; Mains, RE; Eipper, BA				Penzes, P; Johnson, RC; Alam, MR; Kambampati, V; Mains, RE; Eipper, BA			An isoform of Kalirin, a brain-specific GDP/GTP exchange factor, is enriched in the postsynaptic density fraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMIDATING MONOOXYGENASE; PEPTIDE-PROCESSING ENZYME; RHO-FAMILY GTPASES; SIGNALING PATHWAY; RAC GTPASE; MEMBRANE; PROTEIN; GROWTH; ACTIN; CONTAINS	Communication between membranes and the actin cytoskeleton is an important aspect of neuronal function, Regulators of actin cytoskeletal dynamics include the Rho-like small GTP-binding proteins and their exchange factors. Kalirin is a brain-specific protein, first identified through its interaction with peptidylglycine alpha-amidating monooxygenase. In this study, we cloned rat Kalirin-7, a 7-kilobase mRNA form of Kalirin, Kalirin-7 contains nine spectrin-like repeats, a Dbl homology domain, and a pleckstrin homology domain. We found that the majority of Kalirin-7 protein is associated with synaptosomal membranes, but a fraction is cytosolic, We also detected higher molecular weight Kalirin proteins. In rat cerebral cortex, Kalirin-7 is highly enriched in the postsynaptic density fraction. In primary cultures of neurons, Kalirin-7 is detected in spine-like structures, while other forms of Kalirin are visualized in the cell soma and throughout the neurites, Halirin-7 and its DM homology-pleckstrin homology domain induce formation of lamellipodia and membrane ruffling, when transiently expressed in fibroblasts, indicative of Rad activation. Using Rad, the DM homology-pleckstrin homology domain catalyzed the in vitro exchange of bound GDP with GTP, Kalirin-7 is the first guanine-nucleotide exchange factor identified in the postsynaptic density, where it is positioned optimally to regulate signal transduction pathways connecting membrane proteins and the actin cytoskeleton.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University	Eipper, BA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.	beipper@jhmi.edu	Penzes, Peter/L-3987-2016	Penzes, Peter/0000-0001-5449-1640	NIDA NIH HHS [DA-00266] Funding Source: Medline; NIDDK NIH HHS [DK-32948] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032948, R56DK032948, R01DK032948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Adam G, 1996, MOL BRAIN RES, V43, P246, DOI 10.1016/S0169-328X(96)00177-5; Alam MR, 1997, J BIOL CHEM, V272, P12667, DOI 10.1074/jbc.272.19.12667; Alam MR, 1996, J BIOL CHEM, V271, P28636, DOI 10.1074/jbc.271.45.28636; Albertinazzi C, 1998, J CELL BIOL, V142, P815, DOI 10.1083/jcb.142.3.815; Allison DW, 1998, J NEUROSCI, V18, P2423; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Cigola E, 1998, J NEUROSCI, V18, P7638; Colomer V, 1997, HUM MOL GENET, V6, P1519, DOI 10.1093/hmg/6.9.1519; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Ehler E, 1997, MOL CELL NEUROSCI, V9, P1, DOI 10.1006/mcne.1997.0602; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; GULLEY RL, 1981, J CELL BIOL, V91, P298, DOI 10.1083/jcb.91.1.298; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Mains RE, 1999, J BIOL CHEM, V274, P2929, DOI 10.1074/jbc.274.5.2929; Milgram SL, 1996, MOL ENDOCRINOL, V10, P837, DOI 10.1210/me.10.7.837; Milgram SL, 1997, J CELL SCI, V110, P695; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1989, ONCOGENE, V4, P1067; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Wheal HV, 1998, PROG NEUROBIOL, V55, P611, DOI 10.1016/S0301-0082(98)00026-4; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1	40	113	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6395	6403		10.1074/jbc.275.9.6395	http://dx.doi.org/10.1074/jbc.275.9.6395			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692441	hybrid			2022-12-27	WOS:000085654400053
J	Zou, ZQ; Gao, CL; Nagaich, AK; Connell, T; Saito, S; Moul, JW; Seth, P; Appella, E; Srivastava, S				Zou, ZQ; Gao, CL; Nagaich, AK; Connell, T; Saito, S; Moul, JW; Seth, P; Appella, E; Srivastava, S			p53 regulates the expression of the tumor suppressor gene maspin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; WILD-TYPE P53; PLASMINOGEN-ACTIVATOR; APOPTOSIS; GROWTH; TRANSCRIPTION; ANGIOGENESIS; CARCINOMA; ARREST; CYCLE	Maspin has been shown to inhibit tumor cell invasion and metastasis in breast tumor cells. Maspin expression was detected in normal breast and prostate epithelial cells, whereas tumor cells exhibited reduced or no expression. However, the regulatory mechanism of maspin expression remains unknown. We report here a rapid and robust induction of maspin expression in prostate cancer cells (LNCaP, DU145, and PC3) and breast tumor cells (MCF7) following wild type p53 expression from an adenovirus p53 expression vector (AdWTp53). p53 activates the maspin promoter by binding directly to the p53 consensus-binding site present in the maspin promoter. DNA-damaging agents and cytotoxic drugs induced endogenous maspin expression in cells containing the wild type p53, Maspin expression was refractory to the DNA-damaging agents in cells containing mutant p53, These results, combined with recent studies of the tumor metastasis suppressor gene KAI1 and plasminogen activator inhibitor 1 (PAI1), define a new category of molecular targets of p53 that have the potential to negatively regulate tumor invasion and/or metastasis.	Uniformed Serv Univ Hlth Sci, Dept Surg, Ctr Prostate Dis Res, Bethesda, MD 20814 USA; Walter Reed Army Med Ctr, Dept Surg, Urol Serv, Washington, DC 20307 USA; NCI, Med Breast Canc Sect, Med Branch, NIH, Bethesda, MD 20892 USA; NIH, Cell Biol Lab, Bethesda, MD 20892 USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA	Zou, ZQ (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Surg, Ctr Prostate Dis Res, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.				NATIONAL CANCER INSTITUTE [ZIABC005599, Z01BC005599] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bouvet M, 1998, CANCER RES, V58, P2288; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; EFFERT PJ, 1992, J UROLOGY, V147, P789, DOI 10.1016/S0022-5347(17)37387-1; Heidenberg HB, 1996, UROLOGY, V48, P971, DOI 10.1016/S0090-4295(96)00365-2; Jiang WG, 1997, BIOCHEM BIOPH RES CO, V237, P639, DOI 10.1006/bbrc.1997.7154; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207; KUNZ C, 1995, NUCLEIC ACIDS RES, V23, P3710, DOI 10.1093/nar/23.18.3710; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li JJ, 1998, CARCINOGENESIS, V19, P833, DOI 10.1093/carcin/19.5.833; Mashimo T, 1998, P NATL ACAD SCI USA, V95, P11307, DOI 10.1073/pnas.95.19.11307; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Shao ZM, 1998, EXP CELL RES, V241, P394, DOI 10.1006/excr.1998.4066; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; SRIVASTAVA S, 1993, ONCOGENE, V8, P2449; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	19	233	248	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6051	6054		10.1074/jbc.275.9.6051	http://dx.doi.org/10.1074/jbc.275.9.6051			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692390	hybrid			2022-12-27	WOS:000085654400002
J	Caira, F; Antonson, P; Pelto-Huikko, M; Treuter, E; Gustafsson, JA				Caira, F; Antonson, P; Pelto-Huikko, M; Treuter, E; Gustafsson, JA			Cloning and characterization of RAP250, a novel nuclear receptor coactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; RETINOID-X-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; ESTROGEN-RECEPTOR; PROTEIN; COMPLEX; HETERODIMERS; INTERACTS; SEQUENCE; BINDING	Ligand-induced transcriptional activation of gene expression by nuclear receptors is dependent on recruitment of coactivators as intermediary factors. The present work describes the cloning and characterization of RAP250, a novel human nuclear receptor coactivator. The results of in vitro and in vivo experiments indicate that the interaction of RAP250 with nuclear receptors is ligand-dependent or ligand-enhanced depending on the nuclear receptor and involves only one short LXXLL motif called nuclear receptor box, Transient transfection assays further demonstrate that RAP250 has a large intrinsic glutamine-rich activation domain and can significantly enhance the transcriptional activity of several nuclear receptors, acting as a coactivator. Interestingly, Northern blot and In situ hybridization analyses reveal that RAP250 is widely expressed with the highest expression in reproductive organs (testis, prostate and ovary) and brain. Together, our data suggest that RAP250 may play an important role in mammalian gene expression mediated by nuclear receptor.	Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden; Tampere Univ, Sch Med, Dept Dev Biol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Dept Pathol, FIN-33101 Tampere, Finland	Karolinska Institutet; Tampere University; Tampere University; Tampere University Hospital	Treuter, E (corresponding author), Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden.	eckardt.treuter@csb.ki.se		Treuter, Eckardt/0000-0002-4147-8989; Antonson, Per/0000-0001-9335-9941				Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Feltkamp D, 1999, J BIOL CHEM, V274, P10421, DOI 10.1074/jbc.274.15.10421; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Fondell JD, 1999, P NATL ACAD SCI USA, V96, P1959, DOI 10.1073/pnas.96.5.1959; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; KUNZLER M, 1994, EMBO J, V13, P641, DOI 10.1002/j.1460-2075.1994.tb06302.x; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Treuter E, 1999, J BIOL CHEM, V274, P6667, DOI 10.1074/jbc.274.10.6667; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Wiebel FF, 1997, MOL CELL BIOL, V17, P3977, DOI 10.1128/MCB.17.7.3977; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	36	117	124	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5308	5317		10.1074/jbc.275.8.5308	http://dx.doi.org/10.1074/jbc.275.8.5308			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681503	hybrid			2022-12-27	WOS:000085474500010
J	Ren, JS; Diprose, J; Warren, J; Esnouf, RM; Bird, LE; Ikemizu, S; Slater, M; Milton, J; Balzarini, J; Stuart, DI; Stammers, DK				Ren, JS; Diprose, J; Warren, J; Esnouf, RM; Bird, LE; Ikemizu, S; Slater, M; Milton, J; Balzarini, J; Stuart, DI; Stammers, DK			Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases - Structural and biochemical analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; POTENT NONNUCLEOSIDE INHIBITORS; THIOUREA DERIVATIVES; ANGSTROM RESOLUTION; DATA-COLLECTION; DESIGN; CRYSTALLOGRAPHY; MORTALITY; THERAPY; ANALOGS	Most non-nucleoside reverse transcriptase (RT) inhibitors are specific for HIV-1 RT and demonstrate minimal inhibition of HIV-2 RT. However, we report that members of the phenylethylthiazolylthiourea (PETT) series of non-nucleoside reverse transcriptase inhibitors showing high potency against HIV-1 RT have varying abilities to inhibit HIV-2 RT. Thus, PETT-1 inhibits HIV-1 RT with an IC50 of 6 nM but shows only weak inhibition of HIV-2 RT, whereas PETT-2 retains similar potency against HIV-1 RT (IC50 of 5 nM) and also inhibits HIV-2 RT (IC50 of 2.2 mu M). X-ray crystallographic structure determinations of PETT-1 and PETT-2 in complexes with HIV-1 RT reveal the compounds bind in an overall similar conformation albeit with some differences in their interactions with the protein. To investigate whether PETT-2 could be acting at a different site on HIV-2 RT (e.g. the dNTP or template primer binding site), we compared modes of inhibition for PETT-2 against HIV-1 and HIV-2 RT, PETT-2 was a noncompetitive inhibitor with respect to the dGTP substrate for both HIV-1 and HIV-2 RTs, PETT-2 was also a noncompetitive inhibitor with respect to a poly(rC).(dG) template primer for HIV-2 RT. These results are consistent with PETT-2 binding in corresponding pockets in both HIV-1 and HIV-2 RT with amino acid sequence differences in HIV-2 RT affecting the binding of PETT-2 compared with PETT-1.	Univ Oxford, Struct Biol Div, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Stevenage SG1 2NY, Herts, England; Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium; Univ Oxford, Oxford Ctr Mol Sci, Oxford OX1 3QT, England	University of Oxford; Wellcome Centre for Human Genetics; GlaxoSmithKline; KU Leuven; University of Oxford	Stammers, DK (corresponding author), Univ Oxford, Struct Biol Div, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.	dave@strubi.ox.ac.uk	Ren, Jingshan/AAT-7729-2021	Ren, Jingshan/0000-0003-4015-1404; Bird, Louise/0000-0002-9846-5716; Warren, Jonathan/0000-0003-1253-0853; Stuart, David/0000-0002-3426-4210				AHGREN C, 1995, ANTIMICROB AGENTS CH, V39, P1329, DOI 10.1128/AAC.39.6.1329; Brettle RP, 1998, INT J STD AIDS, V9, P80, DOI 10.1258/0956462981921729; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, XPLOR MANUAL VERSION; Cantrell AS, 1996, J MED CHEM, V39, P4261, DOI 10.1021/jm950639r; CLAVEL F, 1986, NATURE, V324, P691, DOI 10.1038/324691a0; DECLERCQ E, 1993, MED RES REV, V13, P229, DOI 10.1002/med.2610130303; DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X; DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407; ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HIZI A, 1991, J BIOL CHEM, V266, P6230; Hopkins AL, 1999, J MED CHEM, V42, P4500, DOI 10.1021/jm990192c; Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LOWE DM, 1988, BIOCHEMISTRY-US, V27, P8884, DOI 10.1021/bi00425a002; Mao C, 1999, BIOORG MED CHEM LETT, V9, P1593, DOI 10.1016/S0960-894X(99)00235-8; Mao C, 1998, BIOORG MED CHEM LETT, V8, P2213, DOI 10.1016/S0960-894X(98)00384-9; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; Milton J, 1998, BIOORG MED CHEM LETT, V8, P2623, DOI 10.1016/S0960-894X(98)00214-5; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X; Ren JS, 1998, BIOCHEMISTRY-US, V37, P14394, DOI 10.1021/bi981309m; Ren JS, 1999, J MED CHEM, V42, P3845, DOI 10.1021/jm990275t; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; Sahlberg C, 1998, BIOORG MED CHEM LETT, V8, P1511, DOI 10.1016/S0960-894X(98)00249-2; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SHIH CK, 1991, P NATL ACAD SCI USA, V88, P9878, DOI 10.1073/pnas.88.21.9878; STAMMERS DK, 1994, J MOL BIOL, V242, P586, DOI 10.1006/jmbi.1994.1604; STAMMERS DK, 1987, ARCH BIOCHEM BIOPHYS, V258, P413, DOI 10.1016/0003-9861(87)90362-6; STAMMERS DK, 1991, FEBS LETT, V283, P298, DOI 10.1016/0014-5793(91)80613-8; STAMMERS DK, 1992, EUR J BIOCHEM, V206, P437, DOI 10.1111/j.1432-1033.1992.tb16944.x; STUART DI, 1993, CURR OPIN STRUC BIOL, V3, P737, DOI 10.1016/0959-440X(93)90057-R; Vig R, 1998, BIOORGAN MED CHEM, V6, P1789, DOI 10.1016/S0968-0896(98)00108-4; Witvrouw M, 1999, AIDS, V13, P1477, DOI 10.1097/00002030-199908200-00006; Yang GZ, 1996, J ACQ IMMUN DEF SYND, V11, P326, DOI 10.1097/00042560-199604010-00002; YOUNG SD, 1995, ANTIMICROB AGENTS CH, V39, P2602, DOI 10.1128/AAC.39.12.2602; Zhang H, 1995, ANTIVIR RES, V28, P331, DOI 10.1016/0166-3542(95)00056-9	41	128	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5633	5639		10.1074/jbc.275.8.5633	http://dx.doi.org/10.1074/jbc.275.8.5633			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681546	hybrid			2022-12-27	WOS:000085474500053
J	Tachibana, H; Haruta, H; Ueda, K; Chiwata, T; Yamada, K				Tachibana, H; Haruta, H; Ueda, K; Chiwata, T; Yamada, K			Induction of light chain replacement in human plasma cells by caffeine is independent from both the upregulation of RAG protein expression and germ line transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-B-CELLS; RECOMBINATION-ACTIVATING GENE; V(D)J RECOMBINATION; CONCANAVALIN-A; HUMAN NEUTROPHILS; IN-VITRO; REARRANGEMENT; PHOSPHORYLATION; PHOSPHATASES; MECHANISM	When some human plasma cell lines are cultured with concanavalin A, the original light chain is replaced with another light chain which results from secondary VJ recombination (light chain shifting), We examined various intracellular factors involved in the induction of light chain shifting. Light chain shifting can be induced upon treatment with agents with phosphatase inhibitory activity such as caffeine and okadaic acid. Although the plasma cells used express both RAG-1 and RAG-2, the expression level of these proteins was not affected by caffeine or okadaic acid. Transcription of the germ line locus, which correlates to the locus activation for rearrangement, is also not influenced by phosphatase inhibition. However, the amount of signal broken-ended DMA intermediates generated during V(D)J rearrangement was shown to increase upon caffeine or okadaic acid treatment, The inhibitory activity of caffeine on phosphatase was the same as okadaic acid. However, caffeine exhibited much higher activity for VJ coding joint formation than okadaic acid. Therefore, although phosphatase inhibition might act, in part, on a mechanism by which V(D)J recombinase activity is regulated within the human plasma cells, other factor(s) are probably also involved in the process.	Kyushu Univ, Grad Sch, Div Bioresources & Bioenvironm Sci, Higashi Ku, Fukuoka 8128581, Japan	Kyushu University	Tachibana, H (corresponding author), Kyushu Univ, Grad Sch, Div Bioresources & Bioenvironm Sci, Higashi Ku, Hakozaki 6-10-1, Fukuoka 8128581, Japan.							BUTCHER RW, 1962, J BIOL CHEM, V237, P1244; CHUCHANA P, 1990, EUR J IMMUNOL, V20, P1317, DOI 10.1002/eji.1830200618; Constantinescu A, 1997, J EXP MED, V185, P609, DOI 10.1084/jem.185.4.609; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; HAIN J, 1993, CANCER RES, V53, P1507; Han SH, 1997, SCIENCE, V278, P301, DOI 10.1126/science.278.5336.301; Hertz M, 1998, NATURE, V394, P292, DOI 10.1038/28419; Hikida M, 1998, J EXP MED, V187, P795, DOI 10.1084/jem.187.5.795; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Kato M, 1991, Hum Antibodies Hybridomas, V2, P94; LARRICK JW, 1989, BIO-TECHNOL, V7, P934, DOI 10.1038/nbt0989-934; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LOCK RB, 1994, CANCER RES, V54, P4933; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P9324, DOI 10.1073/pnas.87.23.9324; MURAKAMI H, 1985, IN VITRO CELL DEV B, V21, P593; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OHTA S, 1992, EUR J BIOCHEM, V206, P895, DOI 10.1111/j.1432-1033.1992.tb16998.x; Papavasiliou F, 1997, SCIENCE, V278, P298, DOI 10.1126/science.278.5336.298; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SCHLISSEL MS, 1994, J IMMUNOL, V153, P1645; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; StanhopeBaker P, 1996, CELL, V85, P887, DOI 10.1016/S0092-8674(00)81272-6; TACCIOLI GE, 1995, CURR OPIN IMMUNOL, V7, P436, DOI 10.1016/0952-7915(95)80085-9; TACHIBANA H, 1994, J BIOL CHEM, V269, P29061; Tachibana H, 1999, BLOOD, V93, P198, DOI 10.1182/blood.V93.1.198.401k11_198_207; Tachibana H, 1996, J BIOL CHEM, V271, P17404, DOI 10.1074/jbc.271.29.17404; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TORNALETTI S, 1989, BIOCHIM BIOPHYS ACTA, V1007, P112, DOI 10.1016/0167-4781(89)90138-3; Wang WH, 1998, J IMMUNOL, V160, P1789; Weaver DT, 1997, NATURE, V388, P428, DOI 10.1038/41225; WenzelSeifert K, 1996, J LEUKOCYTE BIOL, V60, P345, DOI 10.1002/jlb.60.3.345; Williams SC, 1996, J MOL BIOL, V264, P220, DOI 10.1006/jmbi.1996.0636; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140	44	2	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5927	5933		10.1074/jbc.275.8.5927	http://dx.doi.org/10.1074/jbc.275.8.5927			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681585	hybrid			2022-12-27	WOS:000085474500092
J	Murakami, E; Ragsdale, SW				Murakami, E; Ragsdale, SW			Evidence for intersubunit communication during acetyl-CoA cleavage by the multienzyme CO dehydrogenase/acetyl-CoA synthase complex from Methanosarcina thermophila - Evidence that the beta subunit catalyzes C-C and C-S bond cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE DEHYDROGENASE; COENZYME-A SYNTHESIS; CLOSTRIDIUM-THERMOACETICUM; ENZYME COMPLEX; METAL CENTERS; DECARBONYLASE/SYNTHASE COMPLEX; ACETATE BIOSYNTHESIS; ALPHA-METALLOSUBUNIT; ACTIVE-SITE; CLUSTER	The carbon monoxide dehydrogenase/acetyl-CoA synthase (CODH/ACS) from Methanosarcina thermophila is part of a five-subunit complex consisting of alpha, beta, gamma, delta, and epsilon subunits, The multienzyme complex catalyzes the reversible oxidation of CO to CO,, transfer of the methyl group of acetyl-CoA to tetrahydromethanopterin (H4MPT), and acetyl-CoA synthesis from CO, CoA, and methyl-H4MPT, The alpha and epsilon subunits are required for CO oxidation, The gamma and delta subunits constitute a corrinoid iron-sulfur protein that is involved in the transmethylation reaction. This work focuses on the beta subunit. The isolated beta subunit contains significant amounts of nickel. When proteases truncate the beta subunit, causing the CODH/ACS complex to dissociate, the amount of intact beta subunit correlates directly with the EPR signal intensity of Cluster A and the activity of the CO/acetyl-CoA exchange reaction. Our results strongly indicate that the beta subunit harbors Cluster A, a NiFeS cluster, that is the active site of acetyl-CoA cleavage and assembly. Although the beta subunit is necessary, it is not sufficient for acetyl-CoA synthesis; interactions between the CODH and the ACS subunits are required for cleavage or synthesis of the C-C bond of acetyl-CoA We propose that these interactions include intramolecular electron transfer reactions between the CODH and ACS subunits.	Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Ragsdale, SW (corresponding author), Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA.				NIGMS NIH HHS [GM39451] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM039451, R01GM039451, R29GM039451] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBANAT DR, 1990, J BACTERIOL, V172, P7145, DOI 10.1128/jb.172.12.7145-7150.1990; ABBANAT DR, 1991, P NATL ACAD SCI USA, V88, P3272, DOI 10.1073/pnas.88.8.3272; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anderson ME, 1996, BIOCHEMISTRY-US, V35, P8371, DOI 10.1021/bi952902w; ANDERSON ME, 1994, BIOCHEMISTRY-US, V33, P8702, DOI 10.1021/bi00195a011; ANDERSON ME, 1993, J AM CHEM SOC, V115, P12204, DOI 10.1021/ja00078a085; ANDERSON ME, 1993, J INORGAN BIOCH, V51; Barondeau DP, 1997, J AM CHEM SOC, V119, P3959, DOI 10.1021/ja963597k; Bhaskar B, 1998, BIOCHEMISTRY-US, V37, P14491, DOI 10.1021/bi9812423; CLARK JE, 1982, J BACTERIOL, V151, P507, DOI 10.1128/JB.151.1.507-509.1982; Dai YR, 1998, ARCH MICROBIOL, V169, P525, DOI 10.1007/s002030050606; DeRose VJ, 1998, J AM CHEM SOC, V120, P8767, DOI 10.1021/ja9731480; ELLIOTT JI, 1978, ARCH BIOCHEM BIOPHYS, V190, P351, DOI 10.1016/0003-9861(78)90285-0; FAN CL, 1991, BIOCHEMISTRY-US, V30, P431, DOI 10.1021/bi00216a018; Ferry JG, 1999, FEMS MICROBIOL REV, V23, P13, DOI 10.1016/S0168-6445(98)00029-1; Fontecilla-Camps JC, 1999, ADV INORG CHEM, V47, P283, DOI 10.1016/S0898-8838(08)60081-1; GORST CM, 1991, J BIOL CHEM, V266, P20687; Grahame DA, 1996, BIOCHEMISTRY-US, V35, P593, DOI 10.1021/bi9511494; Grahame DA, 1996, J BIOL CHEM, V271, P8352, DOI 10.1074/jbc.271.14.8352; GRAHAME DA, 1991, J BIOL CHEM, V266, P22227; GRAHAME DA, 1987, J BIOL CHEM, V262, P3706; Hu ZG, 1996, J AM CHEM SOC, V118, P830, DOI 10.1021/ja9528386; JABLONSKI PE, 1993, J BIOL CHEM, V268, P325; JAUN B, 1990, HELV CHIM ACTA, V73, P2209, DOI 10.1002/hlca.19900730818; KERBY RL, 1992, J BACTERIOL, V174, P5284, DOI 10.1128/JB.174.16.5284-5294.1992; KRZYCKI JA, 1984, J BACTERIOL, V158, P231, DOI 10.1128/JB.158.1.231-237.1984; KUMAR M, 1993, J AM CHEM SOC, V115, P11646, DOI 10.1021/ja00077a093; LINDAHL PA, 1990, J BIOL CHEM, V265, P3873; LU WP, 1994, J BIOL CHEM, V269, P9736; MaupinFurlow J, 1996, J BACTERIOL, V178, P340, DOI 10.1128/jb.178.2.340-346.1996; MaupinFurlow JA, 1996, J BACTERIOL, V178, P6849, DOI 10.1128/jb.178.23.6849-6856.1996; Menon S, 1996, BIOCHEMISTRY-US, V35, P12119, DOI 10.1021/bi961014d; Menon S, 1998, BIOCHEMISTRY-US, V37, P5689, DOI 10.1021/bi9727996; Menon S, 1999, J BIOL CHEM, V274, P11513, DOI 10.1074/jbc.274.17.11513; RAGSDALE SW, 1982, BIOCHEM BIOPH RES CO, V108, P658, DOI 10.1016/0006-291X(82)90880-4; RAGSDALE SW, 1985, J BIOL CHEM, V260, P3970; RAGSDALE SW, 1983, BIOCHEM BIOPH RES CO, V115, P658, DOI 10.1016/S0006-291X(83)80195-8; Ragsdale SW, 1996, J BIOL INORG CHEM, V1, P489, DOI 10.1007/s007750050082; RAGSDALE SW, 1985, P NATL ACAD SCI USA, V82, P6811, DOI 10.1073/pnas.82.20.6811; Ragsdale SW, 1996, MICROBIAL GROWTH ON C(1) COMPOUNDS, P191; RAYBUCK SA, 1991, J BACTERIOL, V173, P929, DOI 10.1128/jb.173.2.929-932.1991; Russell WK, 1998, J AM CHEM SOC, V120, P7502, DOI 10.1021/ja981165z; Seravalli J, 1997, BIOCHEMISTRY-US, V36, P11241, DOI 10.1021/bi970590m; SHANMUGASUNDARAM T, 1988, Biofactors, V1, P147; Simianu M, 1998, BIOCHEMISTRY-US, V37, P10027, DOI 10.1021/bi9726483; STEPHENS PJ, 1989, J BIOL CHEM, V264, P16347; TERLESKY KC, 1987, J BIOL CHEM, V262, P15392; TERLESKY KC, 1986, J BACTERIOL, V168, P1053, DOI 10.1128/jb.168.3.1053-1058.1986; Thauer RK, 1998, MICROBIOL-UK, V144, P2377, DOI 10.1099/00221287-144-9-2377; XIA JQ, 1995, BIOCHEMISTRY-US, V34, P6037, DOI 10.1021/bi00018a005; Xia JQ, 1997, J AM CHEM SOC, V119, P8301, DOI 10.1021/ja971025+; XIA JQ, 1995, J AM CHEM SOC, V117, P7065, DOI 10.1021/ja00132a004; Xia JQ, 1996, J AM CHEM SOC, V118, P483, DOI 10.1021/ja952845u	53	17	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4699	4707		10.1074/jbc.275.7.4699	http://dx.doi.org/10.1074/jbc.275.7.4699			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671500	hybrid			2022-12-27	WOS:000085378200026
J	Phillips, NJ; Miller, TJ; Engstrom, JJ; Melaugh, W; McLaughlin, R; Apicella, MA; Gibson, BW				Phillips, NJ; Miller, TJ; Engstrom, JJ; Melaugh, W; McLaughlin, R; Apicella, MA; Gibson, BW			Characterization of chimeric lipopolysaccharides from Escherichia coli strain JM109 transformed with lipooligosaccharide synthesis genes (lsg) from Haemophilus influenzae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-KETO-3-DEOXYOCTULOSONIC ACID EPITOPE; CELL-SURFACE LIPOOLIGOSACCHARIDES; HEMOPHILUS-INFLUENZAE; B LIPOOLIGOSACCHARIDE; NEISSERIA-GONORRHOEAE; O-ANTIGEN; RFE-GENE; ACTINOBACILLUS-ACTINOMYCETEMCOMITANS; MOLECULAR ANALYSIS; MASS-SPECTROMETRY	previously, we reported the expression of chimeric lipopolysaccharides (LPS) in Escherichia coli strain JM109 (a K-12 strain) transformed with plasmids containing Haemophilus influenzae lipooligosaccharide synthesis genes (lsg) (Abu Kwaik, Y., McLaughlin, R. E., Apicella, M. A., and Spinola, S. M. (1991) Mol. Microbiol. 5, 2475-2480). In this current study, we have analyzed the O-deacylated LPS and free oligosaccharides from three transformants (designated pGEMLOS-4, pGEMLOS-5, and pGEMLOS-7) by matrix-assisted laser desorption ionization, electrospray ionization, and tandem mass spectrometry techniques, along with composition and linkage analyses. These data show that the chimeric LPS consist of the complete E, coli LPS core structure glycosylated on the 7-position of the non-reducing terminal branch heptose with oligosaccharides from H. influenzae. In pGEMLOS-7, the disaccharide Gal1-->3GlcNAc1--> is added, and in pGEMLOS-5, the structure is extended to Gal1-->4GlcNAc1-->3Gal1-->3GlcNAc1-->. PGEMLOS-5 LPS reacts positively with monoclonal antibody 3F11, an antibody that recognizes the terminal disaccharide of lacto-N-neotetraose. In pGEMLOS-4 LPS, the 3F11 epitope is apparently blocked by glycosylation on the 6-position of the terminal Gal with either Gal or GlcNAc, The biosynthesis of these chimeric LPS was found to be dependent on a functional wecA (formerly rfe) gene in E. coli, By using this carbohydrate expression system, we have been able to examine the functions of the lsg genes independent of the effects of other endogenous Haemophilus genes and expressed proteins.	Univ Calif San Francisco, Sch Pharm 926S, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol, Oklahoma City, OK 73104 USA; Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA	University of California System; University of California San Francisco; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Iowa	Gibson, BW (corresponding author), Univ Calif San Francisco, Sch Pharm 926S, Dept Pharmaceut Chem, 513 Parnassus Ave, San Francisco, CA 94143 USA.				NCRR NIH HHS [RR04112, RR01614] Funding Source: Medline; NIAID NIH HHS [AI24616] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004112, P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024616, R56AI024616, R37AI024616] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABUKWAIK Y, 1991, MOL MICROBIOL, V5, P2475, DOI 10.1111/j.1365-2958.1991.tb02092.x; ALEXANDER DC, 1994, J BACTERIOL, V176, P7079, DOI 10.1128/JB.176.22.7079-7084.1994; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Bozue JA, 1999, J BIOL CHEM, V274, P4106, DOI 10.1074/jbc.274.7.4106; BUGERT P, 1995, MOL MICROBIOL, V15, P917, DOI 10.1111/j.1365-2958.1995.tb02361.x; Comstock LE, 1999, INFECT IMMUN, V67, P3525, DOI 10.1128/IAI.67.7.3525-3532.1999; DARVEAU RP, 1983, J BACTERIOL, V155, P831, DOI 10.1128/JB.155.2.831-838.1983; FALICK AM, 1986, ANAL CHEM, V58, P1308, DOI 10.1021/ac00298a009; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Gibson BW, 1997, J AM SOC MASS SPECTR, V8, P645, DOI 10.1016/S1044-0305(97)00042-1; Gilbert M, 1996, J BIOL CHEM, V271, P28271, DOI 10.1074/jbc.271.45.28271; GOTSCHLICH EC, 1994, J EXP MED, V180, P2181, DOI 10.1084/jem.180.6.2181; Grunden AM, 1996, J BACTERIOL, V178, P735, DOI 10.1128/jb.178.3.735-744.1996; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HELANDER IM, 1988, EUR J BIOCHEM, V177, P483, DOI 10.1111/j.1432-1033.1988.tb14398.x; HOLST O, 1991, CARBOHYD RES, V215, P323, DOI 10.1016/0008-6215(91)84031-9; Hood DW, 1996, MOL MICROBIOL, V22, P951, DOI 10.1046/j.1365-2958.1996.01545.x; Jennings MP, 1995, MOL MICROBIOL, V18, P729, DOI 10.1111/j.1365-2958.1995.mmi_18040729.x; KIMURA A, 1987, INFECT IMMUN, V55, P1979, DOI 10.1128/IAI.55.9.1979-1986.1987; KIMURA A, 1986, INFECT IMMUN, V51, P69, DOI 10.1128/IAI.51.1.69-79.1986; KLENA JD, 1993, MOL MICROBIOL, V9, P393, DOI 10.1111/j.1365-2958.1993.tb01700.x; LARSON G, 1987, CARBOHYD RES, V161, P281, DOI 10.1016/S0008-6215(00)90085-5; LEE NG, 1995, J BIOL CHEM, V270, P27151, DOI 10.1074/jbc.270.45.27151; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; MANDRELL RE, 1992, INFECT IMMUN, V60, P1322, DOI 10.1128/IAI.60.4.1322-1328.1992; MAROLDA CL, 1995, J BACTERIOL, V177, P5539, DOI 10.1128/jb.177.19.5539-5546.1995; Masoud H, 1997, BIOCHEMISTRY-US, V36, P2091, DOI 10.1021/bi961989y; MCLAUGHLIN R, 1992, J BACTERIOL, V174, P6455, DOI 10.1128/JB.174.20.6455-6459.1992; MCLAUGHLIN R, 1994, J ENDOTOXIN RES, V1, P165; MEIERDIETER U, 1992, J BIOL CHEM, V267, P746; Nakano Y, 1998, BBA-GENE STRUCT EXPR, V1442, P409, DOI 10.1016/S0167-4781(98)00174-2; PHILLIPS NJ, 1990, BIOMED ENVIRON MASS, V19, P731, DOI 10.1002/bms.1200191112; Phillips NJ, 1996, BIOCHEMISTRY-US, V35, P5937, DOI 10.1021/bi960059b; PHILLIPS NJ, 1992, BIOCHEMISTRY-US, V31, P4515, DOI 10.1021/bi00133a019; PHILLIPS NJ, 1993, BIOCHEMISTRY-US, V32, P2003, DOI 10.1021/bi00059a017; PREHM P, 1976, EUR J BIOCHEM, V70, P171, DOI 10.1111/j.1432-1033.1976.tb10967.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER H, 1991, J EXP MED, V174, P1601, DOI 10.1084/jem.174.6.1601; SCHWEDA EKH, 1995, CARBOHYD RES, V272, P213, DOI 10.1016/0008-6215(95)00018-O; SCHWEDA EKH, 1993, CARBOHYD RES, V246, P319, DOI 10.1016/0008-6215(93)84043-6; SKURNIK M, 1995, MOL MICROBIOL, V17, P575, DOI 10.1111/j.1365-2958.1995.mmi_17030575.x; SPINOLA SM, 1990, INFECT IMMUN, V58, P1558, DOI 10.1128/IAI.58.6.1558-1564.1990; STEVENSON G, 1994, J BACTERIOL, V176, P4144, DOI 10.1128/JB.176.13.4144-4156.1994; Sunshine MG, 1997, J BACTERIOL, V179, P5521, DOI 10.1128/jb.179.17.5521-5533.1997; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; WANG G, 1993, J BACTERIOL, V175, P3031, DOI 10.1128/JB.175.10.3031-3042.1993; WEISER JN, 1992, MICROB PATHOGENESIS, V13, P335, DOI 10.1016/0882-4010(92)90077-2; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YAO Z, 1994, J BACTERIOL, V176, P4144; Yoshida Y, 1998, INFECT IMMUN, V66, P107, DOI 10.1128/IAI.66.1.107-114.1998; Zhang LJ, 1997, MOL MICROBIOL, V23, P63, DOI 10.1046/j.1365-2958.1997.1871558.x; ZWAHLEN A, 1986, MICROB PATHOGENESIS, V1, P465, DOI 10.1016/0882-4010(86)90008-2	52	26	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4747	4758		10.1074/jbc.275.7.4747	http://dx.doi.org/10.1074/jbc.275.7.4747			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671507	Green Published, hybrid			2022-12-27	WOS:000085378200033
J	Qin, YM; Haapalainen, AM; Kilpelainen, SH; Marttila, MS; Koski, MK; Glumoff, T; Novikov, DK; Hiltunen, JK				Qin, YM; Haapalainen, AM; Kilpelainen, SH; Marttila, MS; Koski, MK; Glumoff, T; Novikov, DK; Hiltunen, JK			Human peroxisomal multifunctional enzyme type 2 - Site-directed mutagenesis studies show the importance of two protic residues for 2-enoyl-CoA hydratase 2 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							17-BETA-HYDROXYSTEROID DEHYDROGENASE-IV; BIFUNCTIONAL PROTEIN-DEFICIENCY; FATTY-ACID OXIDATION; BETA-OXIDATION; RAT-LIVER; MOLECULAR-CLONING; D-3-HYDROXYACYL-COA DEHYDRATASE; ENOYL-COENZYME; NEW-GENERATION; COA HYDRATASE	beta-Oxidation of acyl-CoAs in mammalian peroxisomes can occur via either multifunctional enzyme type 1 (MFE-1) or type 2 (MFE-2), both of which catalyze the hydration of trans-2-enoyl-CoA and the dehydrogenation of 3-hydroxyacyl-CoA, but with opposite chiral specificity. Amino acid sequence alignment of the 2-enoyl-CoA hydratase 2 domain in human MFE-2 with other MFE-2s reveals conserved protic residues: Tyr-347, Glu-366, Asp-370, His-406, Glu-408, Tyr-410, Asp-490, Tyr-505, Asp-810, His-515, Asp-517, and His-532, To investigate their potential roles in catalysis, each residue was replaced by alanine in site-directed mutagenesis, and the resulting constructs were tested for complementation in a yeast. After additional screening, the wild type and noncomplementing E366A and D510A variants were expressed and characterized. The purified proteins have similar secondary structural elements, with the same subunit composition. The E366A variant had a k(cat)/K-m value 100 times lower than that of the wild type MFE-2 at pH 5, whereas the D510A variant was inactive. Asp-510 was imbedded in a novel hydratase 2 motif found in the hydratase 2 proteins. The data show that the hydratase 2 reaction catalyzed by MFE-2 requires two protic residues, Glu-366 and Asp-510, suggesting that their catalytic role may be equivalent to that of the two catalytic residues of hydratase 1.	Univ Oulu, Dept Biochem, FIN-90014 Oulun Yliopisto, Finland; Bioctr Oulu, FIN-90014 Oulun Yliopisto, Finland	Finland National Institute for Health & Welfare; University of Oulu	Hiltunen, JK (corresponding author), Univ Oulu, Dept Biochem, Box 3000, FIN-90014 Oulun Yliopisto, Finland.							ADAMSKI J, 1995, BIOCHEM J, V311, P437, DOI 10.1042/bj3110437; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; BAHNSON BJ, 1989, BIOCHEMISTRY-US, V28, P4173, DOI 10.1021/bi00436a008; BINSTOCK JF, 1981, METHOD ENZYMOL, V71, P401; Caira F, 1998, BIOCHEM J, V330, P1361, DOI 10.1042/bj3301361; DieuaideNoubhani M, 1996, EUR J BIOCHEM, V240, P660, DOI 10.1111/j.1432-1033.1996.0660h.x; DieuaideNoubhani M, 1997, BIOCHEM J, V325, P367, DOI 10.1042/bj3250367; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; Engel CK, 1996, EMBO J, V15, P5135, DOI 10.1002/j.1460-2075.1996.tb00897.x; FILPPULA SA, 1995, J BIOL CHEM, V270, P27453, DOI 10.1074/jbc.270.46.27453; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GREEN DE, 1954, BIOL REV, V29, P330, DOI 10.1111/j.1469-185X.1954.tb00599.x; GRUNSVEN EG, 1999, HUM MOL GENET, V8, P1509; He XY, 1997, BIOCHEMISTRY-US, V36, P11044, DOI 10.1021/bi970901t; HILTUNEN JK, 1992, J BIOL CHEM, V267, P6646; HILTUNEN JK, 1989, J BIOL CHEM, V264, P13536; Jiang LL, 1996, J BIOCHEM-TOKYO, V120, P624; Kiema TR, 1999, BIOCHEMISTRY-US, V38, P2991, DOI 10.1021/bi981646v; Kobayashi K, 1997, EXP EYE RES, V64, P719, DOI 10.1006/exer.1996.0262; Leenders F, 1996, J BIOL CHEM, V271, P5438, DOI 10.1074/jbc.271.10.5438; LEENDERS F, 1994, EUR J BIOCHEM, V222, P221, DOI 10.1111/j.1432-1033.1994.tb18860.x; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; LI JX, 1990, J BIOL CHEM, V265, P13629; LYNEN F, 1953, BIOCHIM BIOPHYS ACTA, V12, P299, DOI 10.1016/0006-3002(53)90149-8; MOHRIG JR, 1995, SCIENCE, V269, P527; MULLERNEWEN G, 1993, BIOCHEMISTRY-US, V32, P11405; Normand T, 1995, J STEROID BIOCHEM, V55, P541, DOI 10.1016/0960-0760(95)00204-9; NUTTLEY WM, 1988, GENE, V69, P171, DOI 10.1016/0378-1119(88)90428-3; POIRIER Y, 1995, BIO-TECHNOL, V13, P142, DOI 10.1038/nbt0295-142; Qin YM, 1999, J BIOL CHEM, V274, P28619, DOI 10.1074/jbc.274.40.28619; Qin YM, 1997, BIOCHEM J, V321, P21, DOI 10.1042/bj3210021; Qin YM, 1997, BIOCHEM J, V328, P377, DOI 10.1042/bj3280377; SCHULZ H, 1991, BIOCHIM BIOPHYS ACTA, V1081, P109, DOI 10.1016/0005-2760(91)90015-A; Suzuki Y, 1997, AM J HUM GENET, V61, P1153, DOI 10.1086/301599; THIERINGER R, 1991, J BIOL CHEM, V266, P13118; van Grunsven EG, 1998, P NATL ACAD SCI USA, V95, P2128, DOI 10.1073/pnas.95.5.2128; van Grunsven EG, 1999, AM J HUM GENET, V64, P99, DOI 10.1086/302180; VanVeldhoven PP, 1996, FEBS LETT, V388, P80, DOI 10.1016/0014-5793(96)00508-X; WATERSON RM, 1972, J BIOL CHEM, V247, P5258; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	41	39	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4965	4972		10.1074/jbc.275.7.4965	http://dx.doi.org/10.1074/jbc.275.7.4965			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671535	hybrid			2022-12-27	WOS:000085378200061
J	Makise, M; Mima, S; Tsuchiya, T; Mizushima, T				Makise, M; Mima, S; Tsuchiya, T; Mizushima, T			Identification of amino acids involved in the functional interaction between DnaA protein and acidic phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MUTATIONAL ANALYSIS; ESCHERICHIA-COLI CHROMOSOME; UNSATURATED FATTY-ACIDS; ATP-BINDING; IN-VITRO; INITIATION PROTEIN; REPLICATION; MUTANTS; CARDIOLIPIN; HYDROLYSIS	DnaA protein, the initiator of chromosomal DNA replication in Escherichia coli, seems to be regulated through its binding to acidic phospholipids, such as cardiolipin. In our previous paper (Hase, M., Yoshimi, T,Ishikawa, Y., Ohba, A., Guo, L., Mima, S., Makise, M., Yamaguchi, Y., Tsuchiya, T., and Mizushima, T, (1998) J, Biol, Chem. 273, 28651-28656), we found that mutant DnaA protein (DnaA431), in which three basic amino acids (Arg(360), Arg(364) and Lys(372)) were mutated to acidic amino acids showed a decreased ability to interact with cardiolipin in vitro, suggesting that DnaA protein binds to cardiolipin through an ionic interaction. In this study, we construct three mutant dnaA genes each with a single mutation and examined the function of the mutant proteins in vitro and in vivo. All mutant proteins maintained activities for DNA replication and ATP binding, A mutant protein in which Lys(372) was mutated to Glu showed the weakest interaction with cardiolipin among these three mutant proteins. Thus, Lys(372) seems to play an important role in the interaction between DnaA protein and acidic phospholipids. Plasmid complementation analyses revealed that all these mutant proteins, including DnaA431 could function as an initiator for chromosomal DNA replication in vivo.	Okayama Univ, Fac Pharmaceut Sci, Okayama 7008530, Japan; Japan Sci & Technol Corp, PRESTO, Okayama 7008530, Japan	Okayama University; Japan Science & Technology Agency (JST)	Mizushima, T (corresponding author), Okayama Univ, Fac Pharmaceut Sci, 1-1-1 Tsushima Naka, Okayama 7008530, Japan.	mizushima@pheasant.pharm.okayama-u.ac.jp						Carr KM, 1996, MOL MICROBIOL, V20, P1307, DOI 10.1111/j.1365-2958.1996.tb02649.x; CASTUMA CE, 1993, J BIOL CHEM, V268, P24665; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; Garner J, 1998, J BIOL CHEM, V273, P5167, DOI 10.1074/jbc.273.9.5167; Garner J, 1996, EMBO J, V15, P3477, DOI 10.1002/j.1460-2075.1996.tb00714.x; Hase M, 1998, J BIOL CHEM, V273, P28651, DOI 10.1074/jbc.273.44.28651; Hase M, 1998, J BIOCHEM-TOKYO, V123, P680; KATAYAMA T, 1995, J BIOL CHEM, V270, P9265, DOI 10.1074/jbc.270.16.9265; Katayama T, 1998, CELL, V94, P61, DOI 10.1016/S0092-8674(00)81222-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Kurokawa K, 1998, BIOCHEM BIOPH RES CO, V243, P90, DOI 10.1006/bbrc.1997.8069; LARK KG, 1969, J MOL BIOL, V42, P221, DOI 10.1016/0022-2836(69)90039-4; Mizushima T, 1997, EMBO J, V16, P3724, DOI 10.1093/emboj/16.12.3724; Mizushima T, 1998, J BIOL CHEM, V273, P20847, DOI 10.1074/jbc.273.33.20847; Mizushima T, 1996, J BIOL CHEM, V271, P3633; Mizushima T, 1996, J BIOL CHEM, V271, P25178, DOI 10.1074/jbc.271.41.25178; Mizushima T, 1997, J BIOL CHEM, V272, P21195, DOI 10.1074/jbc.272.34.21195; Mizushima T, 1996, MOL GEN GENET, V252, P212, DOI 10.1007/BF02173222; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SHINPUKU T, 1995, BIOCHEM BIOPH RES CO, V212, P84, DOI 10.1006/bbrc.1995.1939; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; Suzuki E, 1998, BIOL PHARM BULL, V21, P657; Suzuki E, 1998, MOL MICROBIOL, V28, P95, DOI 10.1046/j.1365-2958.1998.00777.x; WEIMING X, 1995, P NATL ACAD SCI USA, P783; Yamaguchi Y, 1999, BIOCHEM J, V340, P433, DOI 10.1042/0264-6021:3400433; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202	28	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4513	4518		10.1074/jbc.275.6.4513	http://dx.doi.org/10.1074/jbc.275.6.4513			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660626	hybrid			2022-12-27	WOS:000085288800110
J	Thommesen, L; Norsett, K; Sandvik, AK; Hofsli, E; Laegreid, A				Thommesen, L; Norsett, K; Sandvik, AK; Hofsli, E; Laegreid, A			Regulation of inducible cAMP early repressor expression by gastrin and cholecystokinin in the pancreatic cell line AR42J	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE ACTIVATION; NERVE GROWTH-FACTOR; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; PHOSPHOLIPASE-C; B RECEPTORS; TYROSINE PHOSPHORYLATION; INDUCED TRANSCRIPTION; CREB PHOSPHORYLATION; RESPONSIVE-ELEMENT	The CREM gene encodes both activators and repressors of cAMP-induced transcription. Inducible cAMP early repressor (ICER) isoforms are generated upon activation of an alternative, intronic promoter within the CREM gene. ICER is proposed to down-regulate both its own expression and the expression of other genes that contain cAMP-responsive elements such as a number of growth factors. Thus, ICER has been postulated to play a role in proliferation and differentiation. Here we show that ICER gene expression is induced by gastrin, cholecystokinin (CCK), and epidermal growth factor in AR42J cells. The time course of gastrin- and CCK-mediated ICER induction is rapid and transient, similar to forskolin- and phorbol la-myristate 13-acetate-induced ICER expression. The specific CCK-B receptor antagonist L740,093 blocks the gastrin but not the CCK response, indicating that both the CCK-B and the CCK-A receptor can mediate ICER gene activation. Noteworthy, CREB is constitutively phosphorylated at Ser-133 in AR42J cells, and ICER induction proceeds in the absence of increased CREB Ser(P)-133. Gastrin-mediated ICER induction was not reduced in the presence of the protein kinase A inhibitor H-89, indicating a protein kinase A-independent mechanism. This is the first report on ICER inducibility via G(q)/G(11) protein-coupled receptors.	Norwegian Univ Sci & Technol, Dept Physiol & Biomed Engn, N-7489 Trondheim, Norway	Norwegian University of Science & Technology (NTNU)	Laegreid, A (corresponding author), Norwegian Univ Sci & Technol, Dept Physiol & Biomed Engn, Med Tekn Senter, N-7005 Trondheim, Norway.	astridl@medisin.ntnu.no						BERTRAND V, 1994, INT J CANCER, V56, P427, DOI 10.1002/ijc.2910560324; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bodor J, 1996, P NATL ACAD SCI USA, V93, P3536, DOI 10.1073/pnas.93.8.3536; Bodor J, 1998, J BIOL CHEM, V273, P9544, DOI 10.1074/jbc.273.16.9544; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; BRENNA E, 1992, GUT, V33, P1303, DOI 10.1136/gut.33.10.1303; CHRISTOPHE J, 1994, AM J PHYSIOL, V266, pG963, DOI 10.1152/ajpgi.1994.266.6.G963; Dabrowski A, 1997, DIGESTION, V58, P361, DOI 10.1159/000201466; Dabrowski A, 1997, AM J PHYSIOL-CELL PH, V273, pC1472, DOI 10.1152/ajpcell.1997.273.5.C1472; Daulhac L, 1997, BIOCHEM J, V325, P383, DOI 10.1042/bj3250383; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; Dethloff LA, 1999, FOOD CHEM TOXICOL, V37, P105, DOI 10.1016/S0278-6915(98)00119-7; FINDIK D, 1995, J CELL BIOCHEM, V57, P12, DOI 10.1002/jcb.240570103; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Habener JF, 1995, VITAM HORM, V51, P1, DOI 10.1016/S0083-6729(08)61037-7; Houpt TA, 1997, BRAIN RES, V751, P143, DOI 10.1016/S0006-8993(96)01413-8; ISHIZUKA J, 1994, CANCER RES, V54, P2129; Korf HW, 1996, NATURWISSENSCHAFTEN, V83, P535; KowalskiChauvel A, 1996, J BIOL CHEM, V271, P26356, DOI 10.1074/jbc.271.42.26356; LAEGREID A, 1995, J BIOL CHEM, V270, P25418, DOI 10.1074/jbc.270.43.25418; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; LALLI E, 1994, J BIOL CHEM, V269, P17359; LALLI E, 1995, P NATL ACAD SCI USA, V92, P9633, DOI 10.1073/pnas.92.21.9633; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; MARINO CR, 1993, FEBS LETT, V316, P48, DOI 10.1016/0014-5793(93)81734-H; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Monaco L, 1997, ONCOGENE, V15, P2493, DOI 10.1038/sj.onc.1201636; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; PATEL S, 1994, MOL PHARMACOL, V46, P943; PIIPER A, 1997, AM J PHYSIOL, V272, P135; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; Ruchaud S, 1997, ONCOGENE, V15, P827, DOI 10.1038/sj.onc.1201248; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANDVIK AK, 1991, AM J PHYSIOL, V260, pG925, DOI 10.1152/ajpgi.1991.260.6.G925; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; SCEMAMA JL, 1989, AM J PHYSIOL, V256, pG846, DOI 10.1152/ajpgi.1989.256.5.G846; Seternes OM, 1999, MOL ENDOCRINOL, V13, P1071, DOI 10.1210/me.13.7.1071; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; Seva C, 1996, FEBS LETT, V378, P74, DOI 10.1016/0014-5793(95)01414-4; SEVA C, 1994, REGUL PEPTIDES, V52, P31, DOI 10.1016/0167-0115(94)90018-3; Seva C, 1997, BIOCHEM BIOPH RES CO, V238, P202, DOI 10.1006/bbrc.1997.7163; SEVA C, 1990, CANCER RES, V50, P5829; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; TANIGUCHI T, 1994, ONCOGENE, V9, P861; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THOMPSON HL, 1994, J BIOL CHEM, V269, P9486; Tinti C, 1996, J BIOL CHEM, V271, P25375, DOI 10.1074/jbc.271.41.25375; TODISCO A, 1995, J BIOL CHEM, V270, P28337; Todisco A, 1997, AM J PHYSIOL-GASTR L, V273, pG891, DOI 10.1152/ajpgi.1997.273.4.G891; WALDUM HL, 1995, DIGEST DIS, V13, P25, DOI 10.1159/000171484; WALKER WH, 1994, P NATL ACAD SCI USA, V91, P12423, DOI 10.1073/pnas.91.26.12423; Wang HL, 1997, J NEUROCHEM, V68, P1728; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; XIE HJ, 1995, J IMMUNOL, V154, P1717; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	64	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4244	4250		10.1074/jbc.275.6.4244	http://dx.doi.org/10.1074/jbc.275.6.4244			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660591	hybrid			2022-12-27	WOS:000085288800075
J	Bessho, T; Sancar, A				Bessho, T; Sancar, A			Human DNA damage checkpoint protein hRAD9 is a 3 ' to 5 ' exonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE RAD1(+); GENE; HOMOLOGS; LINKAGE	Human RAD9 protein (hRAD9) is a homolog of the fission yeast Rad9 protein, one of the six so-called checkpoint Rad proteins involved in the early steps of DNA damage checkpoint response in Schizosaccharomyces pombe. It has been shown previously that, in vivo, a highly modified form of hRAD9 makes a ternary complex with two other checkpoint Rad proteins, hRAD1 and hHUS1 (Volkmer, E., and Karnitz, L, M. (1999) J. Biol. Chem. 274, 567-570; St. Onge, R. P., Udell, C. M., Casselman, R., and Davey, S. (1999) Mel. Biol Cell. 10, 1985-1995), However, the function of this complex is not known at present. To help define the functions of checkpoint Rad proteins in humans, we expressed hRAD9 in Escherichia coli, purified the recombinant protein and characterized it. We found that hRAD9 is a 3' to 5' exonuclease and located the nuclease active site to the region between residues 51 and 91 of the 391-amino acid-long protein. Our results suggest that exonucleolytic processing of primary DNA lesion by hRAD9 may contribute to DNA damage checkpoint response in humans.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Sancar, A (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, Mary Ellen Jones Bldg,CB 7260, Chapel Hill, NC 27599 USA.	Aziz-Sancar@med.unc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berlyn MKB, 1998, MICROBIOL MOL BIOL R, V62, P814, DOI 10.1128/MMBR.62.3.814-984.1998; Brondello JM, 1999, MOL CELL BIOL, V19, P4262; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Freire R, 1998, GENE DEV, V12, P2560, DOI 10.1101/gad.12.16.2560; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Kondo T, 1999, MOL CELL BIOL, V19, P1136; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; THELEN MP, 1994, J BIOL CHEM, V269, P133; TORRERUIZ MA, 1998, EMBO J, V17, P2687; Udell CM, 1998, NUCLEIC ACIDS RES, V26, P3971, DOI 10.1093/nar/26.17.3971; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567	16	63	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7451	7454		10.1074/jbc.275.11.7451	http://dx.doi.org/10.1074/jbc.275.11.7451			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713044	hybrid			2022-12-27	WOS:000085913300004
J	Dinulescu, DM; Cone, RD				Dinulescu, DM; Cone, RD			Agouti and agouti-related protein: Analogies and contrasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							STIMULATING-HORMONE-RECEPTOR; MELANOCORTIN RECEPTOR; IN-VIVO; ECTOPIC EXPRESSION; MOLECULAR-CLONING; TRANSGENIC MICE; HUMAN HOMOLOG; GENE; OBESITY; ANTAGONIST		Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Cone, RD (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	cone@ohsu.edu						Broberger C, 1998, P NATL ACAD SCI USA, V95, P15043, DOI 10.1073/pnas.95.25.15043; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; Bures EJ, 1998, BIOCHEMISTRY-US, V37, P12172, DOI 10.1021/bi981082v; CONE RD, 2000, MELANOCORTIN RECEPTO; Cowley MA, 1999, NEURON, V24, P155, DOI 10.1016/S0896-6273(00)80829-6; Danforth C, 1927, J HERED, V18, P153, DOI 10.1093/oxfordjournals.jhered.a102826; Dinulescu DM, 1998, P NATL ACAD SCI USA, V95, P12707, DOI 10.1073/pnas.95.21.12707; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Fong TM, 1997, BIOCHEM BIOPH RES CO, V237, P629, DOI 10.1006/bbrc.1997.7200; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1993, J BIOL CHEM, V268, P8246; Graham M, 1997, NAT GENET, V17, P273, DOI 10.1038/ng1197-273; Gunn TM, 1999, NATURE, V398, P152, DOI 10.1038/18217; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; KHONG CK, 1999, END SOC ABSTR, P226; Kiefer LL, 1998, BIOCHEMISTRY-US, V37, P991, DOI 10.1021/bi971913h; KLEBIG ML, 1995, P NATL ACAD SCI USA, V92, P4728, DOI 10.1073/pnas.92.11.4728; KWON HY, 1994, P NATL ACAD SCI USA, V91, P9760, DOI 10.1073/pnas.91.21.9760; LANE PRISCILLA W., 1960, JOUR HEREDITY, V51, P228; LANE PW, 1960, MOUSE NEWS LETT, V22, P35; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MICHAUD EJ, 1994, P NATL ACAD SCI USA, V91, P2562, DOI 10.1073/pnas.91.7.2562; Miller KA, 1997, GENETICS, V146, P1407; Miltenberger RJ, 1999, P NATL ACAD SCI USA, V96, P8579, DOI 10.1073/pnas.96.15.8579; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; Nagle DL, 1999, NATURE, V398, P148, DOI 10.1038/18210; OLIVERA BM, 1991, J BIOL CHEM, V266, P22067; Ollmann MM, 1999, J BIOL CHEM, V274, P15837, DOI 10.1074/jbc.274.22.15837; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Ollmann MM, 1998, GENE DEV, V12, P316, DOI 10.1101/gad.12.3.316; Perry WL, 1996, GENETICS, V144, P255; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; Rosenfeld RD, 1998, BIOCHEMISTRY-US, V37, P16041, DOI 10.1021/bi981027m; Rossi M, 1998, ENDOCRINOLOGY, V139, P4428, DOI 10.1210/en.139.10.4428; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Silvers W. K., 1979, COAT COLORS MICE, P6; SILVERS WK, 1955, J EXP ZOOL, V130, P199, DOI 10.1002/jez.1401300203; Tota MR, 1999, BIOCHEMISTRY-US, V38, P897, DOI 10.1021/bi9815602; Vage DI, 1997, NAT GENET, V15, P311, DOI 10.1038/ng0397-311; VRIELING H, 1994, P NATL ACAD SCI USA, V91, P5667, DOI 10.1073/pnas.91.12.5667; WILLARD DH, 1995, BIOCHEMISTRY-US, V34, P12341, DOI 10.1021/bi00038a030; WILSON BD, 1995, HUM MOL GENET, V4, P223, DOI 10.1093/hmg/4.2.223; Yang YK, 1999, J BIOL CHEM, V274, P14100, DOI 10.1074/jbc.274.20.14100; Yang YK, 1997, MOL ENDOCRINOL, V11, P274, DOI 10.1210/me.11.3.274; Yang YK, 1999, MOL ENDOCRINOL, V13, P148, DOI 10.1210/me.13.1.148; YEN TT, 1994, FASEB J, V8, P479, DOI 10.1096/fasebj.8.8.8181666; Zemel MB, 1998, MOL CELL BIOCHEM, V188, P129, DOI 10.1023/A:1006880708475	48	101	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6695	6698		10.1074/jbc.275.10.6695	http://dx.doi.org/10.1074/jbc.275.10.6695			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702221	hybrid			2022-12-27	WOS:000085809600001
J	Fallon, EM; Liparoto, SF; Lee, KJ; Ciardelli, TL; Lauffenburger, DA				Fallon, EM; Liparoto, SF; Lee, KJ; Ciardelli, TL; Lauffenburger, DA			Increased endosomal sorting of ligand to recycling enhances potency of an interleukin-2 analog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; RECEPTOR-BETA-CHAIN; ALDESLEUKIN RECOMBINANT INTERLEUKIN-2; HUMAN-IMMUNODEFICIENCY-VIRUS; INTERFERON-GAMMA-PRODUCTION; CELL STIMULATORY FACTOR; PHARMACOLOGICAL PROPERTIES; CYTOPLASMIC DOMAINS; CLINICAL EFFICACY; BINDING	An interleukin-2 (IL-2) variant containing adjacent point mutations (L18M/L19S, termed 2D1) displaying binding affinity to the heterotrimeric IL-2 receptor similar to that of wild-type IL-2 (WT) had been previously found to surprisingly exhibit increased bioactivity in a peripheral blood lymphocyte proliferation assay. In order to provide an explanatory mechanism for this unexpected potency enhancement, we hypothesize that altered endocytic trafficking of the 2D1 variant might be responsible by increasing the number of ligand-receptor complexes. We demonstrate here that the internalization kinetics of 2D1 via the high affinity IL-2 receptor are equivalent to those of WT but that a significantly increased fraction of internalized 2D1 is sorted to recycling instead of to lysosomal degradation. We further find a reduced pH sensitivity of binding to IL-2 receptor alpha relative to IL-2 receptor beta compared with WT, which could be responsible for the altered sorting behavior of 2D1 in the acidic endosomal compartment. Accordingly, the 2D1 variant displays a half-life 36 h longer than that of IL-2 in T-lymphocyte culture at concentrations equal to the K-D of the IL-2 receptor. The extended half-life of intact 2D1 provides enhanced mitogenesis as compared with IL-2. In addition, 2D1 stimulates natural killer cells to a lesser degree than IL-2 at equal concentrations. We conclude that this IL-2 variant provides increased mitogenic stimulation that could not be easily predicted from its cell surface receptor binding affinity while minimizing undesired stimulation of natural killer cells. This concept of altering trafficking dynamics may offer a generalizable approach to generating improvements in the pharmacological efficacy of therapeutic cytokines.	MIT, Dept Chem Engn, Cambridge, MA 02139 USA; MIT, Biotechnol Proc Engn Ctr, Cambridge, MA 02139 USA; Vet Affairs Med Ctr, Res Serv, White River Jct, VT 05009 USA; Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); US Department of Veterans Affairs; Veterans Health Administration (VHA); Dartmouth College	Lauffenburger, DA (corresponding author), MIT, Dept Chem Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	lauffen@mit.edu			NIGMS NIH HHS [GM52858] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052858] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON PM, 1994, CLIN PHARMACOKINET, V27, P19, DOI 10.2165/00003088-199427010-00003; ARIMA N, 1992, J EXP MED, V176, P1265, DOI 10.1084/jem.176.5.1265; BERNDT WG, 1994, BIOCHEMISTRY-US, V33, P6571, DOI 10.1021/bi00187a026; Carson WE, 1997, EUR J IMMUNOL, V27, P354, DOI 10.1002/eji.1830270203; CHAN SH, 1992, J IMMUNOL, V148, P92; CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; DAVIS CG, 1987, NATURE, V326, P760, DOI 10.1038/326760a0; DEPPER JM, 1985, P NATL ACAD SCI USA, V82, P4230, DOI 10.1073/pnas.82.12.4230; DeSanctis JB, 1997, IMMUNOLOGY, V90, P526, DOI 10.1046/j.1365-2567.1997.00174.x; DUPREZ V, 1988, J BIOL CHEM, V263, P12860; FORSTEN KE, 1994, MOL IMMUNOL, V31, P739, DOI 10.1016/0161-5890(94)90148-1; French AR, 1996, BIOTECHNOL BIOENG, V51, P281, DOI 10.1002/(SICI)1097-0290(19960805)51:3<281::AID-BIT4>3.0.CO;2-9; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; FUJII M, 1986, J EXP MED, V163, P550, DOI 10.1084/jem.163.3.550; Ghezzi S, 1997, J BIOL REG HOMEOS AG, V11, P74; GILLIS S, 1978, J IMMUNOL, V120, P2027; GUTGSELL NS, 1994, J IMMUNOL, V153, P3899; HANDA K, 1983, J IMMUNOL, V130, P988; HEMAR A, 1995, J CELL BIOL, V129, P55, DOI 10.1083/jcb.129.1.55; HORI T, 1987, BLOOD, V70, P1069; Howard M, 1994, GUIDEBOOK CYTOKINES; Jacobson EL, 1996, P NATL ACAD SCI USA, V93, P10405, DOI 10.1073/pnas.93.19.10405; Jeal W, 1997, BIODRUGS, V7, P285, DOI 10.2165/00063030-199707040-00005; JOHNSON K, 1994, EUR CYTOKINE NETW, V5, P23; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; Khatri VP, 1998, J CLIN INVEST, V101, P1373, DOI 10.1172/JCI2038; Kinter A, 1996, IMMUNOL RES, V15, P1, DOI 10.1007/BF02918280; KORNBLUTH J, 1988, J IMMUNOL, V141, P3234; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; KUNG AHC, 1993, THERAPEUTIC PROTEINS; LANDGRAF B, 1989, J BIOL CHEM, V264, P816; LANDGRAF BE, 1991, PROTEINS, V9, P207, DOI 10.1002/prot.340090306; Lauffenburger DA, 1998, CHEM BIOL, V5, pR257, DOI 10.1016/S1074-5521(98)90110-7; LUND KA, 1990, J BIOL CHEM, V265, P15713; Metcalf D, 1995, HEMOPOIETIC COLONY S; MIYAKE Y, 1989, J BIOL CHEM, V264, P16584; Morelon E, 1998, J BIOL CHEM, V273, P22044, DOI 10.1074/jbc.273.34.22044; Myszka DG, 1996, PROTEIN SCI, V5, P2468, DOI 10.1002/pro.5560051209; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; Noble S, 1997, BIODRUGS, V7, P394, DOI 10.2165/00063030-199707050-00007; ONO M, 1994, EUR J CANCER, V30A, pS7; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; REDDY CC, 1994, BIOTECHNOL PROGR, V10, P377, DOI 10.1021/bp00028a006; Reddy CC, 1996, J CELL PHYSIOL, V166, P512, DOI 10.1002/(SICI)1097-4652(199603)166:3<512::AID-JCP6>3.0.CO;2-S; Reddy CC, 1996, NAT BIOTECHNOL, V14, P1696, DOI 10.1038/nbt1296-1696; SANA TR, 1994, BIOCHEMISTRY-US, V33, P5838, DOI 10.1021/bi00185a023; Smith KA, 1995, ANN NY ACAD SCI, V766, P263, DOI 10.1111/j.1749-6632.1995.tb26674.x; SMITH KA, 1985, P NATL ACAD SCI USA, V82, P864, DOI 10.1073/pnas.82.3.864; SMITH KA, 1993, BLOOD, V81, P1414; Smith KA, 1997, CANCER J SCI AM, V3, pS137; SMITH KA, 1989, ANNU REV CELL BIOL, V5, P397; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; Subtil A, 1998, EUR J BIOCHEM, V253, P525, DOI 10.1046/j.1432-1327.1998.2530525.x; Subtil A, 1997, J CELL BIOL, V136, P583, DOI 10.1083/jcb.136.3.583; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; Theze J, 1996, IMMUNOL TODAY, V17, P481, DOI 10.1016/0167-5699(96)10057-C; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Vial T, 1995, TOXICOLOGY, V105, P31, DOI 10.1016/0300-483X(95)03124-X; VLASVELD LT, 1994, CANCER TREAT REV, V20, P275, DOI 10.1016/0305-7372(94)90004-3; WHITTINGTON R, 1993, DRUGS, V46, P446, DOI 10.2165/00003495-199346030-00009; WHITTINGTON R, 1994, DRUGS, V27, P19; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WILLIAMS DP, 1988, NUCLEIC ACIDS RES, V16, P10453, DOI 10.1093/nar/16.22.10453; WU ZN, 1995, J BIOL CHEM, V270, P16045, DOI 10.1074/jbc.270.27.16045	67	42	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6790	6797		10.1074/jbc.275.10.6790	http://dx.doi.org/10.1074/jbc.275.10.6790			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702236	hybrid			2022-12-27	WOS:000085809600016
J	Park, JS; Kim, EJ; Kwon, HJ; Hwang, ES; Namkoong, SE; Um, SJ				Park, JS; Kim, EJ; Kwon, HJ; Hwang, ES; Namkoong, SE; Um, SJ			Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein - Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAPILLOMAVIRUS TYPE-16 E7; IFN-GAMMA; CLASS-I; GENE-EXPRESSION; JE GENE; TRANSCRIPTION; MHC; TRANSFORMATION; ACTIVATION; IRF-1	In studying biological roles of interferon regulatory factor (IRF)-1 tumor suppressor in cervical carcinogenesis, we found that HPV E7 is functionally associated with IRF-1. Binding assays indicate a physical interaction between IRF-1 and HPV E7 in vivo and in vitro, The carboxyl-terminal transactivation domain of IRF-1 was required for the interaction, Transient co-expression of E7 significantly inhibits the IRF-1-mediated activation of IFN-P promoter in NIH-3T3 cells. Co-transfection of E7 mutants reveals that the pRb-binding portion of E7 is necessary for the E7-mediated inactivation of IRF-1. It was next determined whether histone deacetylase (HDAC) is involved in the inactivation mechanism as recently suggested, where the carboxyl-terminal zinc finger domain of E7 associates with NURD complex containing HDAC. When trichostatin A, an inhibitor of HDAC, was treated, the repressing activity of E7 was released in a dose-dependent manner. Furthermore, the mutation of zinc finger abrogates such activity without effect on the interaction with IRF-1. These results suggest that RPV E7 interferes with the transactivation function of IRF-1 by recruiting HDAC to the promoter. The immune-promoting role of IRF-1 evokes the idea that our novel finding might be important for the elucidation of the E7-mediated immune evading mechanism that is frequently found in cervical cancer.	Sejong Univ, Dept Biosci & Biotechnol, Seoul 143747, South Korea; Catholic Univ, Coll Med, Dept Obstet & Gynecol, Seoul 137040, South Korea; Univ Seoul, Dept Life Sci, Seoul 130743, South Korea	Sejong University; Catholic University of Korea; University of Seoul	Um, SJ (corresponding author), Sejong Univ, Dept Biosci & Biotechnol, 98 Kunja Dong, Seoul 143747, South Korea.		권, 호정/AAS-3642-2021					Barnard P, 1999, VIROLOGY, V259, P305, DOI 10.1006/viro.1999.9771; Borchers A, 1999, ARCH VIROL, V144, P1539, DOI 10.1007/s007050050609; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; BROKAW JL, 1994, VIROLOGY, V205, P603, DOI 10.1006/viro.1994.1688; Chatterjee-Kishore M, 1998, J BIOL CHEM, V273, P16177, DOI 10.1074/jbc.273.26.16177; CROMME FV, 1994, BRIT J CANCER, V69, P1176, DOI 10.1038/bjc.1994.231; CROMME FV, 1993, BRIT J CANCER, V67, P1372, DOI 10.1038/bjc.1993.254; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; Hobart M, 1997, J IMMUNOL, V158, P4260; HUANG PS, 1993, MOL CELL BIOL, V13, P953, DOI 10.1128/MCB.13.2.953; JENSENDURR P, 1996, TRENDS GENET, V12, P270; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; Kleine-Lowinski K, 1999, INT J CANCER, V82, P6, DOI 10.1002/(SICI)1097-0215(19990702)82:1<6::AID-IJC2>3.0.CO;2-3; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; Min W, 1996, J IMMUNOL, V156, P3174; PFISTER H, 1987, ADV CANCER RES, V48, P113, DOI 10.1016/S0065-230X(08)60691-0; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Proffitt JA, 1997, FEBS LETT, V400, P141, DOI 10.1016/S0014-5793(96)01375-0; Riethdorf L, 1996, AM J PATHOL, V149, P1469; ROLLINS BJ, 1991, MOL CELL BIOL, V11, P3125, DOI 10.1128/MCB.11.6.3125; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Rose M. D., 1990, METHODS YEAST GENETI, P155; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; Schneider S, 1996, BIOTECHNIQUES, V20, P960; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Taniguchi T, 1997, BBA-REV CANCER, V1333, pM9, DOI 10.1016/S0304-419X(97)00014-0; TIMMERS HTM, 1989, J VIROL, V63, P1470, DOI 10.1128/JVI.63.3.1470-1473.1989; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Um S, 1998, J BIOL CHEM, V273, P20728, DOI 10.1074/jbc.273.33.20728; Valente AJ, 1998, J IMMUNOL, V161, P3719; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; vom Baur E, 1998, GENE DEV, V12, P1278, DOI 10.1101/gad.12.9.1278; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; WU EW, 1993, J BIOL, V67, P2404; Zhou ZHL, 1998, J IMMUNOL, V160, P3908; ZURHAUSEN H, 1928, BIOCHIM BIOPHYS ACTA, pF55	40	241	249	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6764	6769		10.1074/jbc.275.10.6764	http://dx.doi.org/10.1074/jbc.275.10.6764			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702232	hybrid			2022-12-27	WOS:000085809600012
J	Cain, K; Bratton, SB; Langlais, C; Walker, G; Brown, DG; Sun, XM; Cohen, GM				Cain, K; Bratton, SB; Langlais, C; Walker, G; Brown, DG; Sun, XM; Cohen, GM			Apaf-1 oligomerizes into biologically active similar to 700-kDa and inactive similar to 1.4-MDa apoptosome complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; CED-4; ACTIVATION; PROTEASES; RECEPTOR; CASPASES; DEATH; CELLS	Apaf-1, by binding to and activating caspase-9, plays a critical role in apoptosis. Oligomerization of Apaf-1, in the presence of dATP and cytochrome c, is required for the activation of caspase-9 and produces a caspase activating apoptosome complex. Reconstitution studies with recombinant proteins have indicated that the size of this complex is very large in the order of similar to 1.4 MDa. We now demonstrate that dATP activation of cell lysates results in the formation of two large Apaf-1-containing apoptosome complexes with M-r values of similar to 1.4 MDa and similar to 700 kDa. Kinetic analysis demonstrates that in vitro the similar to 700-kDa complex is produced more rapidly than the similar to 1.4 MDa complex and exhibits a much greater ability to activate effector caspases. Significantly, in human tumor monocytic cells undergoing apoptosis after treatment with either etoposide or N-tosyl-l-phenylalanyl chloromethyl ketone (TPCK), the similar to 700-kDa Apaf-1 containing apoptosome complex was predominately formed. This complex processed effector caspases. Thus, the similar to 700-kDa complex appears to be the correctly formed and biologically active apoptosome complex, which is assembled during apoptosis.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester	Cohen, GM (corresponding author), Univ Leicester, MRC, Toxicol Unit, Hodgkin Bldg,POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England.	gmc2@le.ac.uk	Cohen, Gerald M/A-1687-2008	Bratton, Shawn/0000-0003-2895-5020				ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUDEMAN DM, 1989, J NEUROSCI RES, V24, P184, DOI 10.1002/jnr.490240209; Hengartner MO, 1997, NATURE, V388, P714, DOI 10.1038/41873; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MacFarlane M, 1997, J CELL BIOL, V137, P469, DOI 10.1083/jcb.137.2.469; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Zhu HJ, 1997, CELL DEATH DIFFER, V4, P590, DOI 10.1038/sj.cdd.4400284; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	24	274	307	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6067	6070		10.1074/jbc.275.9.6067	http://dx.doi.org/10.1074/jbc.275.9.6067			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692394	hybrid			2022-12-27	WOS:000085654400006
J	Milutinovic, S; Knox, JD; Szyf, M				Milutinovic, S; Knox, JD; Szyf, M			DNA methyltransferase inhibition induces the transcription of the tumor suppressor p21(WAF1/CIP1/sdi1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINES; HISTONE DEACETYLASE; GENE-EXPRESSION; LUNG-CANCER; METHYLATION; BINDING; NEOPLASIA; INDUCTION; PATHWAY; CYCLE	Previous lines of evidence have shown that inhibition of DNA methyltransferase (MeTase) can arrest tumor cell growth; however, the mechanisms involved were not clear, In this manuscript we show that out of 16 known tumor suppressors and cell cycle regulators, the cyclin-dependent kinase inhibitor p21 is the only tumor suppressor induced in the human lung cancer cell line, A549, following inhibition of DNA MeTase by a novel DNA MeTase antagonist or antisense oligonucleotides. The rapid induction of p21 expression points to a mechanism that does not involve demethylation of p21 promoter. Consistent with this hypothesis, we show that part of the CpG island upstream of the endogenous p21 gene is unmethylated and that the expression of unmethylated p21 promoter luciferase reporter constructs is induced following inhibition of DNA MeTase. These results are consistent with the hypothesis that the level of DNA MeTase in a cell can control the expression of a nodal tumor suppressor by a mechanism that does not involve DNA methylation.	McGill Univ, Dept Pharmacol, Montreal, PQ H3G 1Y6, Canada	McGill University	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.							Araujo FD, 1998, MOL CELL BIOL, V18, P3475, DOI 10.1128/MCB.18.6.3475; Baylin SB, 1998, ADV CANCER RES, V72, P141; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; Bigey P, 1999, J BIOL CHEM, V274, P4594, DOI 10.1074/jbc.274.8.4594; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Esposito F, 1997, EUR J BIOCHEM, V245, P730, DOI 10.1111/j.1432-1033.1997.00730.x; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Fukuoka K, 1997, JPN J CANCER RES, V88, P1009, DOI 10.1111/j.1349-7006.1997.tb00322.x; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Gonzalgo ML, 1998, CANCER RES, V58, P1245; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Joseph B, 1998, J BIOL CHEM, V273, P20511, DOI 10.1074/jbc.273.32.20511; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Myohanen SK, 1998, CANCER RES, V58, P591; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; ROULEAU J, 1992, J BIOL CHEM, V267, P7368; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Szyf M, 1998, CANCER METAST REV, V17, P219, DOI 10.1023/A:1006023023787; SZYF M, 1991, J BIOL CHEM, V266, P10027; SZYF M, 1990, MOL ENDOCRINOL, V4, P1144, DOI 10.1210/mend-4-8-1144; SZYF M, 1998, CURR RES MOL THER, V1, P93; SZYF M, 1994, TRENDS PHARMACOL SCI, V7, P233; Tao L, 1997, J MOL BIOL, V273, P509, DOI 10.1006/jmbi.1997.1352; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wu J C, 1985, Prog Clin Biol Res, V198, P119; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Wu RC, 1997, J BIOL CHEM, V272, P29091, DOI 10.1074/jbc.272.46.29091; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; YISRAELI J, 1984, DNA METHYLATION BIOC, P353	49	99	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6353	6359		10.1074/jbc.275.9.6353	http://dx.doi.org/10.1074/jbc.275.9.6353			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692435	hybrid			2022-12-27	WOS:000085654400047
J	Sato, K; Inaba, M; Suwa, Y; Matsuu, A; Hikasa, Y; Ono, K; Kagota, K				Sato, K; Inaba, M; Suwa, Y; Matsuu, A; Hikasa, Y; Ono, K; Kagota, K			Inherited defects of sodium-dependent glutamate transport mediated by glutamate/aspartate transporter in canine red cells due to a decreased level of transporter protein expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; AMINO-ACID TRANSPORTER; RAT-BRAIN; HIGH K; CLONING; ERYTHROCYTES; ASPARTATE; MICE; NEURODEGENERATION; INCREASE	Canine red cells have a high affinity Na+/K+-dependent glutamate transporter. We herein demonstrate that this transport is mediated by the canine homologue of glutamate/aspartate transporter (GLAST), one of the glutamate transporter subtypes abundant in the central nervous system. me also demonstrate that GLAST is the most ubiquitous glutamate transporter among the transporter subtypes that hare been cloned to date. The GLAST protein content was extremely reduced in variant red cells, low glutamate transport (LGlut) red cells characterized by an inherited remarkable decrease in glutamate transport activity. All LGluT dogs carried a missense mutation of Gly(492) to Ser (G492S) in either the heterozygous or homozygous state. The GLAST protein with G-492S mutation was fully functional in glutamate transport in Xenopus oocytes. However, G492S GLAST exhibited a marked decrease in activity after the addition of cycloheximide, while the wild type showed no significant change, indicating that G492S GLAST was unstable compared with the wild-type transporter, Moreover, LGluT dogs, but not normal dogs, heterozygous for the G492S mutation showed a selective decrease in the accumulation of GLAST mRNA from the normal allele. Based on these findings, we conclude that a complicated heterologous combination of G492S mutation and some transcriptional defect contributes to the pathogenesis of the LGluT red cell phenotype.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Med Sci, Lab Vet Clin Pathobiol, Tokyo 1138657, Japan; Tottori Univ, Fac Agr, Dept Vet Internal Med, Tottori 6808553, Japan	University of Tokyo; Tottori University	Inaba, M (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Med Sci, Lab Vet Clin Pathobiol, Tokyo 1138657, Japan.		Sato, Kota/G-1129-2012; Inaba, Mutsumi/A-4878-2012					ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DENEKE SM, 1987, J APPL PHYSIOL, V63, P1966, DOI 10.1152/jappl.1987.63.5.1966; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FUJISE H, 1995, BBA-BIOMEMBRANES, V1239, P22, DOI 10.1016/0005-2736(95)00140-X; Grone A, 1996, AM J VET RES, V57, P254; Hagiwara T, 1996, GENOMICS, V33, P508, DOI 10.1006/geno.1996.0226; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Inaba M, 1996, J CLIN INVEST, V97, P1804, DOI 10.1172/JCI118610; INABA M, 1986, J BIOL CHEM, V261, P6099; INABA M, 1984, J BIOL CHEM, V259, P312; INOUE K, 1995, MOL BRAIN RES, V28, P343, DOI 10.1016/0169-328X(94)00244-9; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kanai Y, 1997, CURR OPIN CELL BIOL, V9, P565, DOI 10.1016/S0955-0674(97)80035-X; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P1207, DOI 10.1021/bi00600a011; KAWAKAMI H, 1994, BIOCHEM BIOPH RES CO, V199, P171, DOI 10.1006/bbrc.1994.1210; LEHRE KP, 1995, J NEUROSCI, V15, P1835; Lin CLG, 1998, NEURON, V20, P589, DOI 10.1016/S0896-6273(00)80997-6; MAEDE Y, 1989, BLOOD, V73, P312; MAEDE Y, 1985, J BIOL CHEM, V260, P3337; MAEDE Y, 1983, BLOOD, V61, P493; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Peghini P, 1997, EMBO J, V16, P3822, DOI 10.1093/emboj/16.13.3822; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; RAJENDRAN VM, 1987, AM J PHYSIOL, V252, pG33, DOI 10.1152/ajpgi.1987.252.1.G33; ROTHSTEIN JD, 1993, P NATL ACAD SCI USA, V90, P6591, DOI 10.1073/pnas.90.14.6591; SATO K, 1994, BBA-BIOMEMBRANES, V1195, P211, DOI 10.1016/0005-2736(94)90258-5; Schlag BD, 1998, MOL PHARMACOL, V53, P355, DOI 10.1124/mol.53.3.355; SCHNEIDER EG, 1980, J BIOL CHEM, V255, P7650; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TANAKA K, 1993, NEUROSCI LETT, V159, P183, DOI 10.1016/0304-3940(93)90829-A; Trotti D, 1999, NAT NEUROSCI, V2, P427, DOI 10.1038/8091; Trotti D, 1998, TRENDS PHARMACOL SCI, V19, P328, DOI 10.1016/S0165-6147(98)01230-9; Wahle S, 1996, J CELL BIOL, V135, P1867, DOI 10.1083/jcb.135.6.1867; Watase K, 1998, EUR J NEUROSCI, V10, P976, DOI 10.1046/j.1460-9568.1998.00108.x; YOUNG JD, 1977, MEMBRANE TRANSPORT R, P301; Zerangue N, 1996, J PHYSIOL-LONDON, V493, P419, DOI 10.1113/jphysiol.1996.sp021393	43	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6620	6627		10.1074/jbc.275.9.6620	http://dx.doi.org/10.1074/jbc.275.9.6620			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692470	hybrid			2022-12-27	WOS:000085654400082
J	Gurnell, M; Wentworth, JM; Agostini, M; Adams, M; Collingwood, TN; Provenzano, C; Browne, PO; Rajanayagam, O; Burris, TP; Schwabe, JW; Lazar, MA; Chatterjee, VKK				Gurnell, M; Wentworth, JM; Agostini, M; Adams, M; Collingwood, TN; Provenzano, C; Browne, PO; Rajanayagam, O; Burris, TP; Schwabe, JW; Lazar, MA; Chatterjee, VKK			A dominant-negative peroxisome proliferator-activated receptor gamma (PPAR gamma) mutant is a constitutive repressor and inhibits PPAR gamma-mediated adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; HIGH-AFFINITY LIGAND; 9-CIS RETINOIC ACID; TRANSACTIVATION DOMAIN; TRANSCRIPTION FACTOR; RESISTANCE SYNDROME; ESTROGEN-RECEPTOR; BETA-RECEPTOR; CO-REPRESSOR; X-RECEPTOR	The nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR gamma) promotes adipocyte differentiation, exerts atherogenic and anti-inflammatory effects in monocyte/macrophages, and is believed to mediate the insulin-sensitizing action of antidiabetic thiazolidinedione ligands. As no complete PPAR gamma antagonists have been described hitherto, we have constructed a dominant-negative mutant receptor to inhibit wild-type PPAR gamma action. Highly conserved hydrophobic and charged residues (Leu(468) and Glu(471)) in helix 12 of the ligand-binding domain were mutated to alanine. This compound PPAR gamma mutant retains ligand and DNA binding, but exhibits markedly reduced transactivation due to impaired coactivator (cAMP-response element-binding protein-binding protein and steroid receptor coactivator-l) recruitment. Unexpectedly, the mutant receptor silences basal gene transcription, recruits core pressors (the silencing mediator of retinoid and thyroid receptors and the nuclear corepressor) more avidly than wild-type PPAR gamma, and exhibits delayed ligand-dependent corepressor release, It is a powerful dominant-negative inhibitor of cotransfected wild-type receptor action. Furthermore, when expressed in primary human preadipocytes using a recombinant adenovirus, this PPAR gamma mutant blocks thiazolidinedione-induced differentiation, providing direct evidence that PPAR gamma mediates adipogenesis. Our observations suggest that, as in other mutant nuclear receptor contexts (acute promyelocytic leukemia, resistance to thyroid hormone), dominant-negative inhibition by PPAR gamma is linked to aberrant corepressor interaction. Adenoviral expression of this mutant receptor is a valuable means to antagonize PPAR gamma signaling.	Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; RW Johnson Pharmaceut Res Inst, Raritan, NJ 08869 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Pennsylvania; Johnson & Johnson; Johnson & Johnson USA; MRC Laboratory Molecular Biology	Chatterjee, VKK (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England.		Burris, Thomas/H-5078-2011; Burris, Thomas P/B-3886-2016; Lazar, Mitchell A/AAF-3738-2019; Schwabe, John WR/A-9132-2008	Burris, Thomas P/0000-0003-2922-4449; Schwabe, John WR/0000-0003-2865-4383; Chatterjee, Vengalil Krishna/0000-0002-2654-8854; Wentworth, John/0000-0002-5197-3529				Adams M, 1997, J CLIN INVEST, V100, P3149, DOI 10.1172/JCI119870; ADAMS M, 1994, J CLIN INVEST, V94, P506, DOI 10.1172/JCI117362; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Burris TP, 1999, MOL ENDOCRINOL, V13, P410, DOI 10.1210/me.13.3.410; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Collingwood TN, 1997, P NATL ACAD SCI USA, V94, P248, DOI 10.1073/pnas.94.1.248; COLLINGWOOD TN, 1994, MOL ENDOCRINOL, V8, P1262, DOI 10.1210/me.8.9.1262; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lin BC, 1997, MOL CELL BIOL, V17, P6131, DOI 10.1128/MCB.17.10.6131; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; Tagami T, 1998, MOL ENDOCRINOL, V12, P1888, DOI 10.1210/me.12.12.1888; TONE Y, 1994, J BIOL CHEM, V269, P31157; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Wentworth JM, 1999, GENE, V236, P315, DOI 10.1016/S0378-1119(99)00265-6; Yoh SM, 1997, MOL ENDOCRINOL, V11, P470, DOI 10.1210/me.11.4.470; Young PW, 1998, J PHARMACOL EXP THER, V284, P751; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	38	247	255	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5754	5759		10.1074/jbc.275.8.5754	http://dx.doi.org/10.1074/jbc.275.8.5754			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681562	hybrid			2022-12-27	WOS:000085474500069
J	Kanamori, H; Krieg, S; Mao, CJ; Di Pippo, VA; Wang, S; Zajchowski, DA; Shapiro, DJ				Kanamori, H; Krieg, S; Mao, CJ; Di Pippo, VA; Wang, S; Zajchowski, DA; Shapiro, DJ			Proteinase inhibitor 9, an inhibitor of granzyme B-mediated apoptosis, is a primary estrogen-inducible gene in human liver cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIOVASCULAR RISK-FACTORS; MESSENGER-RNA; CYTOTOXIC LYMPHOCYTES; POSTMENOPAUSAL WOMEN; RESPONSE ELEMENT; RECEPTOR; EXPRESSION; INDUCTION; PROTEASES; MECHANISMS	Although liver is an estrogen target tissue, the number of hepatic genes known to be directly induced by estrogen is very small. We identified proteinase inhibitor 9, or PI-9, as being rapidly and strongly induced by estrogen in an estrogen receptor-positive human liver cell line (HepG2-ER7), Since PI-9 mRNA was also induced by estrogen in a human liver biopsy sample, PI-9 is a genuine estrogen-regulated human gene. PI-9 is a potent inhibitor of granzyme B and of granzyme B-mediated apoptosis. Estrogens induced PI-9 mRNA within 2 h, PI-9 mRNA levels reached a plateau of 30-40-fold induction in 4 h, and induction was not blocked by cycloheximide, indicating that induction of PI-9 mRNA is a primary response. The antiestrogen trans-hydroxytamoxifen was a partial agonist for PI-9 mRNA induction, whereas the antiestrogen ICI 182,780 was a pure antagonist. Western blot analysis showed that estrogen strongly increases PI-9 protein levels. Inhibition of transcription with actinomycin D resulted in identical rates of PI-B mRNA decay in the presence and absence of estrogen, We isolated genomic clones containing the PI-9 promoter region, identified a putative transcription start site, and carried out transient transfections of PI-g-luciferase reporter gene constructs. The estrogen, moxestrol, elicited a robust induction from the PI-9-luciferase reporter, Mutational inactivation of three potential imperfect estrogen response elements in the PI-9 5'-flanking region had no effect on moxestrol estrogen receptor induction.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Tokyo, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan; Berlex Biosci, Dept Canc Res, Richmond, CA 94804 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Tokyo	Shapiro, DJ (corresponding author), Univ Illinois, Dept Biochem, 413 RAL,600 S Mathews Ave, Urbana, IL 61801 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016720] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-16720] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aste-Amezaga M, 1998, J IMMUNOL, V160, P5936; Atkinson EA, 1998, J BIOL CHEM, V273, P21261, DOI 10.1074/jbc.273.33.21261; ATTARDI B, 1993, MOL ENDOCRINOL, V7, P668, DOI 10.1210/me.7.5.668; Barkhem T, 1997, J STEROID BIOCHEM, V62, P53, DOI 10.1016/S0960-0760(97)00017-4; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; BROCK ML, 1983, CELL, V34, P207, DOI 10.1016/0092-8674(83)90151-4; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Darmon AJ, 1998, CRIT REV IMMUNOL, V18, P255, DOI 10.1615/CritRevImmunol.v18.i3.50; Dean DM, 1996, MOL ENDOCRINOL, V10, P1489, DOI 10.1210/me.10.12.1489; Froelich CJ, 1998, IMMUNOL TODAY, V19, P30, DOI 10.1016/S0167-5699(97)01184-5; Guidotti LG, 1999, SCIENCE, V284, P825, DOI 10.1126/science.284.5415.825; Harlow E., 1988, ANTIBODIES LAB MANUA; Hayashi J, 1998, ARCH INTERN MED, V158, P177, DOI 10.1001/archinte.158.2.177; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; IWAMURA K, 1979, ACTA HEPATO-GASTRO, V26, P267; IWAMURA K, 1976, Tokai Journal of Experimental and Clinical Medicine, V1, P41; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; Kanamori H, 1999, BIOTECHNIQUES, V26, P1018, DOI 10.2144/99266bm01; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; Krams S M, 1995, Transpl Immunol, V3, P162, DOI 10.1016/0966-3274(95)80043-3; KRATTENMACHER R, 1994, J STEROID BIOCHEM, V48, P207, DOI 10.1016/0960-0760(94)90146-5; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; LEE JH, 1995, DNA CELL BIOL, V14, P419, DOI 10.1089/dna.1995.14.419; LIPSETT MB, 1978, REPRODUCTIVE ENDOCRI, P80; LOVE RR, 1994, J NATL CANCER I, V86, P1534, DOI 10.1093/jnci/86.20.1534; Mattick S, 1997, J STEROID BIOCHEM, V60, P285, DOI 10.1016/S0960-0760(96)00198-7; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; Roger T, 1998, BIOCHEM J, V330, P429, DOI 10.1042/bj3300429; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SPRECHER CA, 1995, J BIOL CHEM, V270, P29854; Sun JR, 1996, J BIOL CHEM, V271, P27802, DOI 10.1074/jbc.271.44.27802; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; TAM SP, 1985, J BIOL CHEM, V260, P1670; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; ZAJCHOWSKI DA, 1991, MOL ENDOCRINOL, V5, P1613, DOI 10.1210/mend-5-11-1613; Zhang CC, 1999, MOL ENDOCRINOL, V13, P632, DOI 10.1210/me.13.4.632	39	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5867	5873		10.1074/jbc.275.8.5867	http://dx.doi.org/10.1074/jbc.275.8.5867			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681578	hybrid			2022-12-27	WOS:000085474500085
J	Lieb, B; Altenhein, B; Markl, J				Lieb, B; Altenhein, B; Markl, J			The sequence of a gastropod hemocyanin (HtH1 from Haliotis tuberculata)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KEYHOLE LIMPET HEMOCYANIN; OCTOPUS-DOFLEINI-HEMOCYANIN; SEPIA-OFFICINALIS HEMOCYANIN; AMINO-ACID-SEQUENCE; QUATERNARY STRUCTURE; FUNCTIONAL UNIT; IMMUNOELECTRON MICROSCOPY; ELECTRON-MICROSCOPY; HELIX-POMATIA; SUBUNIT	The eight functional units (FUs), a-h, of the hemocyanin isoform HtH1 from Haliotis tuberculata (Prosobranchia, Archaeogastropoda) have been sequenced via cDNA, which provides the first complete primary structure of a gastropod hemocyanin subunit, With 3404 amino acids (392 kDa) it is the largest polypeptide sequence ever obtained for a respiratory protein. The cDNA comprises 10,758 base pairs and includes the coding regions for a short signal peptide, the eight different functional units, a 3'-untranslated region of 478 base pairs, and a poly(A) tail. The predicted protein contains 13 potential sites for N-linked carbohydrates (one for HtH1-a, none for HtH1-c, and two each for the other six functional units). Multiple sequence alignments show that the fragment HtH1-abcdefg is structurally equivalent to the seven-FU subunit from Octopus hemocyanin, which is fundamental to our understanding of the quaternary structures of both hemocyanins, Using the fossil record of the gastropod-cephalopod split to calibrate a molecular clock, the origin of the molluscan hemocyanin from a single-FU protein was calculated as 753 +/- 68 million years ago. This fits recent paleontological evidence for the existence of rather large mollusc-like species in the late Precambrian.	Johannes Gutenberg Univ Mainz, Inst Zool, D-55099 Mainz, Germany	Johannes Gutenberg University of Mainz	Markl, J (corresponding author), Johannes Gutenberg Univ Mainz, Inst Zool, Saarstr 21, D-55099 Mainz, Germany.	JMarkl@uzomai.biologie.uni-mainz.de	Lieb, Bernhard/AFT-2157-2022					ALBRECHT U, 1995, VERH DTSCH ZOOL GES, V88, P156; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; Benton MJ, 1993, FOSS REC, P125; Cuff ME, 1998, J MOL BIOL, V278, P855, DOI 10.1006/jmbi.1998.1647; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DECLERCQ L, 1990, INVERTEBRATE DIOXYGEN CARRIERS, P131; DREXEL R, 1987, BIOL CHEM H-S, V368, P617, DOI 10.1515/bchm3.1987.368.1.617; Fedonkin MA, 1997, NATURE, V388, P868, DOI 10.1038/42242; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; Gebauer W, 1999, J STRUCT BIOL, V128, P280, DOI 10.1006/jsbi.1999.4198; GEBAUER W, 1994, ZOOL-ANAL COMPLEX SY, V98, P51; Gebauer W, 1999, ARCH BIOCHEM BIOPHYS, V372, P128, DOI 10.1006/abbi.1999.1478; GOULD SJ, 1993, BOOK LIFE, P1; Harris JR, 1999, MICRON, V30, P597, DOI 10.1016/S0968-4328(99)00036-0; Harris JR, 1998, MICRON, V29, P329, DOI 10.1016/S0968-4328(98)00019-5; HARRIS JR, 1993, J STRUCT BIOL, V111, P96, DOI 10.1006/jsbi.1993.1040; HARRIS JR, 2000, IN PRESS MICRON, V31; HERSKOVITS TT, 1991, COMP BIOCHEM PHYS B, V99, P19, DOI 10.1016/0305-0491(91)90003-V; Keller H, 1999, EUR J BIOCHEM, V264, P27, DOI 10.1046/j.1432-1327.1999.00564.x; LAMBERT O, 1994, J MOL BIOL, V238, P75, DOI 10.1006/jmbi.1994.1269; Lamy J, 1998, J MOL BIOL, V284, P1051, DOI 10.1006/jmbi.1998.2235; LAMY J, 1987, BIOCHEMISTRY-US, V26, P3509, DOI 10.1021/bi00386a039; Lieb B, 1999, EUR J BIOCHEM, V265, P134, DOI 10.1046/j.1432-1327.1999.00694.x; MANGUM CP, 1985, AM J PHYSIOL, V248, P505; MARKL J, 1991, NATURWISSENSCHAFTEN, V78, P512, DOI 10.1007/BF01131401; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; Miller KI, 1998, J MOL BIOL, V278, P827, DOI 10.1006/jmbi.1998.1648; Mouche F, 1999, J STRUCT BIOL, V127, P199, DOI 10.1006/jsbi.1999.4154; Orlova EV, 1997, J MOL BIOL, V271, P417, DOI 10.1006/jmbi.1997.1182; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; SIEZEN RJ, 1974, J MOL BIOL, V90, P77; Sohngen SM, 1997, EUR J BIOCHEM, V248, P602, DOI 10.1111/j.1432-1033.1997.00602.x; Stoeva S, 1997, COMP BIOCHEM PHYS B, V117, P101, DOI 10.1016/S0305-0491(96)00292-1; Stoeva S, 1999, BBA-PROTEIN STRUCT M, V1435, P94, DOI 10.1016/S0167-4838(99)00198-3; Swerdlow RD, 1996, COMP BIOCHEM PHYS B, V113, P537, DOI 10.1016/0305-0491(95)02091-8; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANHOLDE KE, 1991, J MOL BIOL, V217, P307, DOI 10.1016/0022-2836(91)90545-H; vanHolde KE, 1995, ADV PROTEIN CHEM, V47, P1, DOI 10.1016/S0065-3233(08)60545-8; WICHERTJES T, 1986, BIOCHIM BIOPHYS ACTA, V872, P183, DOI 10.1016/0167-4838(86)90270-0; XIN XQ, 1990, INVERTEBRATE DIOXYGEN CARRIERS, P113; Xun G, 1998, J MOL EVOL, V47, P369, DOI 10.1007/PL00013150	42	72	77	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5675	5681		10.1074/jbc.275.8.5675	http://dx.doi.org/10.1074/jbc.275.8.5675			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681551	hybrid			2022-12-27	WOS:000085474500058
J	Ukropec, JA; Hollinger, MK; Salva, SM; Woolkalis, MJ				Ukropec, JA; Hollinger, MK; Salva, SM; Woolkalis, MJ			SHP2 association with VE-cadherin complexes in human endothelial cells is regulated by thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; ALPHA-CATENIN; GROWTH-FACTOR; ADHESION MOLECULE-1; CYTOPLASMIC DOMAIN; PHOSPHORYLATION; PERMEABILITY; BINDING; INCREASE; RECEPTOR	Thrombin-mediated changes in endothelial cell adherens junctions modulate vascular permeability. We demonstrate that the nonreceptor protein-tyrosine phosphatase SHP2 co-precipitates with VE-cadherin complexes in confluent, quiescent human umbilical vein endothelial cells. Ligand-binding blots using a SHP2-glutathione S-transferase fusion peptide established that SHP2 associates selectively with beta-catenin in VE-cadherin complexes. Thrombin treatment of human umbilical vein endothelial cells promotes SHP2 tyrosine phosphorylation and dissociation from VE-cadherin complexes. The loss of SHP2 from the cadherin complexes correlates with a dramatic increase in the tyrosine phosphorylation of beta-catenin, gamma-catenin, and p120-catenin complexed with VE-cadherin. We propose that thrombin regulates the tyrosine phosphorylation of VE-cadherin-associated beta-catenin, gamma-catenin, and p120-catenin by modulating the quantity of SHP2 associated with VE-cadherin complexes. Such changes in adherens junction complex composition likely underlie thrombin-elicited alterations in endothelial monolayer permeability.	Thomas Jefferson Univ, Dept Physiol, Philadelphia, PA 19107 USA	Jefferson University	Woolkalis, MJ (corresponding author), Thomas Jefferson Univ, Dept Physiol, 411 Jefferson Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.	Marilyn.Woolkalis@mail.tju.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052132, R29HL052132] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52132] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Ellis CA, 1999, AM J PHYSIOL-CELL PH, V276, pC38, DOI 10.1152/ajpcell.1999.276.1.C38; Esser S, 1998, J CELL SCI, V111, P1853; GAITS F, 1995, BIOCHEM J, V311, P97, DOI 10.1042/bj3110097; GARCIA JGN, 1986, J CELL PHYSIOL, V128, P96, DOI 10.1002/jcp.1041280115; GERLACH MS, 1995, J BIOL CHEM, V270, P24635, DOI 10.1074/jbc.270.42.24635; Gilbert-McClain LI, 1998, J CELL BIOCHEM, V70, P141, DOI 10.1002/(SICI)1097-4644(19980701)70:1<141::AID-JCB14>3.0.CO;2-S; Gloor SM, 1997, BIOCHEM BIOPH RES CO, V239, P804, DOI 10.1006/bbrc.1997.7557; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Jackson DE, 1997, J BIOL CHEM, V272, P24868, DOI 10.1074/jbc.272.40.24868; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Lampugnani MG, 1997, J CELL SCI, V110, P2065; Masuda M, 1997, FEBS LETT, V408, P331, DOI 10.1016/S0014-5793(97)00457-2; Navarro P, 1998, J CELL BIOL, V140, P1475, DOI 10.1083/jcb.140.6.1475; Nieset JE, 1997, J CELL SCI, V110, P1013; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Ozawa M, 1998, J CELL BIOL, V142, P1605, DOI 10.1083/jcb.142.6.1605; Papkoff J, 1997, J BIOL CHEM, V272, P4536; Rabiet MJP, 1996, ARTERIOSCL THROM VAS, V16, P488, DOI 10.1161/01.ATV.16.3.488; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Shi S, 1998, ENDOTHELIUM-J ENDOTH, V6, P153, DOI 10.3109/10623329809072202; Sorby M, 1996, J BIOL CHEM, V271, P10963; STADDON JM, 1995, J CELL SCI, V108, P609; Takahashi K, 1997, ONCOGENE, V15, P71, DOI 10.1038/sj.onc.1201160; Tsukatani Y, 1997, J CELL PHYSIOL, V173, P54, DOI 10.1002/(SICI)1097-4652(199710)173:1<54::AID-JCP7>3.3.CO;2-G; Vogel W, 1996, CELL GROWTH DIFFER, V7, P1589; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779	33	186	189	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5983	5986		10.1074/jbc.275.8.5983	http://dx.doi.org/10.1074/jbc.275.8.5983			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681592	hybrid			2022-12-27	WOS:000085474500099
J	Clifford, GM; Londos, C; Kraemer, FB; Vernon, RG; Yeaman, SJ				Clifford, GM; Londos, C; Kraemer, FB; Vernon, RG; Yeaman, SJ			Translocation of hormone-sensitive lipase and perilipin upon lipolytic stimulation of rat adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; LIPID DROPLETS; ADENYLATE-CYCLASE; ADIPOSE-TISSUE; LEYDIG-CELLS; INSULIN; MECHANISM; PHOSPHORYLATION; METABOLISM	Adipocyte lipolysis was compared with hormone-sensitive lipase (HSL)/perilipin subcellular distribution and perilipin phosphorylation using Western blot analysis. Under basal conditions, HSL resided predominantly in the cytosol and unphosphorylated perilipin upon the lipid droplet. Upon lipolytic stimulation of adipocytes isolated from young rats with the beta-adrenergic agonist, isoproterenol, HSL translocated from the cytosol to the lipid droplet, but there was no movement of perilipin from the droplet to the cytosol; however, perilipin phosphorylation was observed. By contrast, upon lipolytic stimulation and perilipin phosphorylation in cells from more mature rats, there was no HSL translocation but a significant movement of perilipin away from the lipid droplet. Adipocytes from younger rats had markedly greater rates of lipolysis than those from the older rats. Thus high rates of lipolysis require translocation of HSL to the lipid droplet and translocation of HSL and perilipin can occur independently of each other. A loss of the ability to translocate HSL to the lipid droplet probably contributes to the diminished lipolytic response to catecholamines with age.	Univ Newcastle, Sch Med, Sch Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; NIDDK, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; Vet Affairs Palo Alto Hlth Care Syst, Dept Med, Palo Alto, CA 94304 USA; Hannah Res Inst, Ayr KA6 5HL, Scotland	Newcastle University - UK; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Yeaman, SJ (corresponding author), Univ Newcastle, Sch Med, Sch Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.		Kraemer, Fredric/AAC-3633-2019	Kraemer, Fredric/0000-0003-2468-7807	NIDDK NIH HHS [DK49705, DK46942] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049705, R01DK046942] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barber T., 1995, Molecular Biology of the Cell, V6, p437A; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; Clifford GM, 1998, FEBS LETT, V435, P125, DOI 10.1016/S0014-5793(98)01052-7; DAX EM, 1981, J LIPID RES, V22, P934; EGAN JJ, 1990, J BIOL CHEM, V265, P18769; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; Fong TH, 1996, J CELL BIOCHEM, V63, P366, DOI 10.1002/(SICI)1097-4644(19961201)63:3<366::AID-JCB12>3.0.CO;2-F; FREDRIKSON G, 1981, J BIOL CHEM, V256, P6311; GIUDICELLI Y, 1978, EUR J BIOCHEM, V90, P413, DOI 10.1111/j.1432-1033.1978.tb12619.x; GONZALEZ J, 1978, EXP AGING RES, V4, P455, DOI 10.1080/03610737808257169; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GRUEN R, 1980, METABOLISM, V29, P246, DOI 10.1016/0026-0495(80)90066-9; HONNOR RC, 1985, J BIOL CHEM, V260, P5130; KRAEMER FB, 1993, J LIPID RES, V34, P663; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Langin D, 1996, P NUTR SOC, V55, P93, DOI 10.1079/PNS19960013; LONDOS C, 1995, BIOCHEM SOC T, V23, P611, DOI 10.1042/bst0230611; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; MCGOWAN MW, 1983, CLIN CHEM, V29, P538; MOONEY RA, 1991, BIOCHEM J, V274, P433, DOI 10.1042/bj2740433; Morimoto C, 1997, J LIPID RES, V38, P132; NILSSON NO, 1980, FEBS LETT, V111, P125, DOI 10.1016/0014-5793(80)80776-9; OKUDA H, 1968, J BIOCHEM-TOKYO, V64, P377, DOI 10.1093/oxfordjournals.jbchem.a128905; OKUDA H, 1966, J BIOCHEM-TOKYO, V59, P438, DOI 10.1093/oxfordjournals.jbchem.a128324; RODBELL M, 1964, J BIOL CHEM, V239, P375; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; Shen WJ, 1999, P NATL ACAD SCI USA, V96, P5528, DOI 10.1073/pnas.96.10.5528; Smith GM, 1996, FEBS LETT, V396, P90, DOI 10.1016/0014-5793(96)01076-9; Souza SC, 1998, DIABETES, V47, P691, DOI 10.2337/diabetes.47.4.691; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Syu LJ, 1999, MOL CELL, V4, P109, DOI 10.1016/S1097-2765(00)80192-6; Wang SM, 1997, J CELL BIOCHEM, V67, P84, DOI 10.1002/(SICI)1097-4644(19971001)67:1<84::AID-JCB9>3.0.CO;2-S; WISE LS, 1978, J BIOL CHEM, V253, P2624; YEAMAN SJ, 1994, ADV ENZYME REGUL, V34, P355, DOI 10.1016/0065-2571(94)90022-1	34	188	202	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5011	5015		10.1074/jbc.275.7.5011	http://dx.doi.org/10.1074/jbc.275.7.5011			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671541	hybrid			2022-12-27	WOS:000085378200067
J	Magana, MM; Koo, SH; Towle, HC; Osborne, TF				Magana, MM; Koo, SH; Towle, HC; Osborne, TF			Different sterol regulatory element-binding protein-1 isoforms utilize distinct co-regulatory factors to activate the promoter for fatty acid synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; UPSTREAM STIMULATORY FACTOR; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; INSULIN REGULATION; CULTURED-CELLS; NF-Y; SP1; IDENTIFICATION; CARBOHYDRATE	Sterol regulatory element-binding proteins (SREBPs) activate genes of cholesterol and fatty acid metabolism. In each case, a ubiquitous co-regulatory factor that binds to a neighboring recognition site is also required for efficient promoter activation. It is likely that gene- and pathway-specific regulation by the separate SREBP isoforms is dependent on subtle differences in how the individual proteins function with specific co-regulators to activate gene expression. In the studies reported here we extend these observations significantly by demonstrating that SREBPs are involved in both sterol regulation and carbohydrate activation of the FAS promoter. We also demonstrate that the previously implicated Spl site is largely dispensable for sterol regulation in established cultured cells, whereas a CCAAT-binding factor/nuclear factor Y is critically important. In contrast, carbohydrate activation of the FAS promoter in primary hepatocytes is dependent upon SREBP and both the Spl and CCAAT-binding factor/nuclear factor Y sites. Because Ic is the predominant SREBP isoform expressed in hepatocytes and la is more abundant in sterol depleted established cell lines, this suggests that the different SREBP isoforms utilize distinct co-regulatory factors to activate target gene expression.	Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA 92697 USA; Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of California System; University of California Irvine; University of Minnesota System; University of Minnesota Twin Cities	Osborne, TF (corresponding author), Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA 92697 USA.		Koo, Seung-Hoi/E-2763-2015	Koo, Seung-Hoi/0000-0001-8769-2879	NHLBI NIH HHS [HL48044] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048044] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Athanikar JN, 1997, MOL CELL BIOL, V17, P5193, DOI 10.1128/MCB.17.9.5193; Bennett MK, 1999, J BIOL CHEM, V274, P13025, DOI 10.1074/jbc.274.19.13025; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dooley KA, 1999, J BIOL CHEM, V274, P5285, DOI 10.1074/jbc.274.9.5285; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Guan GM, 1997, J BIOL CHEM, V272, P10295; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kotzka J, 1998, BIOCHEM BIOPH RES CO, V249, P375, DOI 10.1006/bbrc.1998.9161; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Rangan VS, 1996, J BIOL CHEM, V271, P2307, DOI 10.1074/jbc.271.4.2307; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; SHIH HM, 1995, BIOTECHNIQUES, V18, P813; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Thewke DP, 1998, J BIOL CHEM, V273, P21402, DOI 10.1074/jbc.273.33.21402; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; Wang D, 1997, J BIOL CHEM, V272, P26367, DOI 10.1074/jbc.272.42.26367; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; Yokoyama C., 1993, CELL, V75, P185	35	131	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4726	4733		10.1074/jbc.275.7.4726	http://dx.doi.org/10.1074/jbc.275.7.4726			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671504	hybrid			2022-12-27	WOS:000085378200030
J	Muller-Newen, G; Kuster, A; Wijdenes, J; Schaper, F; Heinrich, PC				Muller-Newen, G; Kuster, A; Wijdenes, J; Schaper, F; Heinrich, PC			Studies on the interleukin-6-type cytokine signal transducer gp130 reveal a novel mechanism of receptor activation by monoclonal antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; COMPLEX; IL-6; EXPRESSION; BINDING; CLONING; ASSOCIATION; FAMILY; SITES; DIMERIZATION	The transmembrane glycoprotein gp130 belongs to the family of hematopoietic cytokine receptors. It represents the common signal transducing receptor component of the so called interleukin-6-type cytokines. For several cytokine receptors including gp130 it has been shown that receptor activation cannot only be achieved by the natural ligand but also by single monoclonal antibodies raised against the receptor ectodomain. These findings have been interpreted in a way that dimerization of cytokine receptors is sufficient for receptor activation, Here we show that the recently described gp130-activating antibody B-S12 actually consists of two different monoclonal antibodies. By subcloning of B-S12 the monoclonal antibodies B-S12-A5 and B-S12-G7 were obtained. The individual antibodies are biologically inactive, in combination they exert B-Sla-like activity on hepatoma cells. On Ba/F3 cells stably transfected with gp130 a combination of B-S12-G7 with another monoclonal gp130 antibody, B-P8, is required to stimulate proliferation. Using gp130 deletion mutants we show that all three antibodies map to domains 2 and 3 of gp130 which constitute the cytokine binding module. The individual antibodies inhibit activation of the signal transducer by interleukin-6 and interfere with binding of interleukin-6 to gp130, Interestingly, the combination of B-S12-G7 and a Fab fragment of B-PS retains biological activity. We conclude from our data that (i) the monoclonal antibodies activate gp130 by mimicking the natural ligand and (ii) enforcement of gp130 dimerization is not sufficient for receptor activation but additional conformational requirements have to be fulfilled.	Rhein Westfal TH Aachen, Inst Biochem, D-52074 Aachen, Germany; DIACLONE, F-25020 Besancon, France	RWTH Aachen University	Muller-Newen, G (corresponding author), Rhein Westfal TH Aachen, Inst Biochem, Pauwelsstr 30, D-52074 Aachen, Germany.	mueller-newen@RWTH-Aachen.de	Schaper, Fred/F-1403-2013	Schaper, Fred/0000-0002-8899-5414				AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; Autissier P, 1997, EUR J IMMUNOL, V27, P794, DOI 10.1002/eji.1830270331; Ballinger MD, 1998, NAT STRUCT BIOL, V5, P938, DOI 10.1038/2911; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Bravo J, 1998, EMBO J, V17, P1665, DOI 10.1093/emboj/17.6.1665; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Fourcin M, 1996, J BIOL CHEM, V271, P11756, DOI 10.1074/jbc.271.20.11756; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Grotzinger J, 1997, PROTEINS, V27, P96; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; Horsten U, 1997, J BIOL CHEM, V272, P23748, DOI 10.1074/jbc.272.38.23748; HORSTEN U, 1995, FEBS LETT, V360, P43, DOI 10.1016/0014-5793(95)00053-C; Kernebeck T, 1999, PROTEIN SCI, V8, P5; Kurth I, 1999, J IMMUNOL, V162, P1480; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; WIJDENES J, 1991, MOL IMMUNOL, V28, P1183, DOI 10.1016/0161-5890(91)90004-4; Wijdenes J, 1995, EUR J IMMUNOL, V25, P3474, DOI 10.1002/eji.1830251240; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YIN TG, 1993, J IMMUNOL, V151, P2555; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	44	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4579	4586		10.1074/jbc.275.7.4579	http://dx.doi.org/10.1074/jbc.275.7.4579			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671483	hybrid			2022-12-27	WOS:000085378200009
J	Hu, QH; Maity, SN				Hu, QH; Maity, SN			Stable expression of a dominant negative mutant of CCAAT binding factor/NF-Y in mouse fibroblast cells resulting in retardation of cell growth and inhibition of transcription of various cellular genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE-II; FACTOR CBF; NF-Y; SUBUNIT INTERACTION; FUNCTIONAL DOMAINS; MAMMALIAN-CELLS; MESSENGER-RNA; HISTONE FOLD; YEAST HAP5; B-SUBUNIT	The heterotrimeric CCAAT-binding factor CBF specifically interacts with the CCAAT motif present in the proximal promoters of numerous mammalian genes. To understand the in vivo function of CBF, a dominant negative mutant of CBF-B subunit that inhibits DNA binding of wild type CBF was stably expressed in mouse fibroblast cells under control of tetracycline-responsive promoter. Expression of the mutant CBF-B but not the wild-type CBF-B resulted in retardation of fibroblast cell growth. The analysis of cell growth using bromode-oxyuridine labeling showed that expression of the mutant CBF-B decreased the number of cells entering into S phase, and also delayed induction of S phase in the quiescent cells after serum stimulation, thus indicating that the inhibition of CBF binding prolonged the progression of S phase in fibroblasts. These results provide direct evidence for the first time that CBF is an important regulator of fibroblast growth. The inhibition of CBF binding reduced expression of various cellular genes including the alpha 2(1) collagen, E2F1, and topoisomerase II alpha genes which promoters contain the CEF-binding site. This result implied that expression of many other genes which promoters contain CBF-binding site was also decreased by the inhibition of CBF binding, and that the decreased expression of multiple cellular genes possibly caused the retardation of fibroblast cell growth.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Maity, SN (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Maity, Sankar/0000-0002-2387-6545	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR043660] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline; NIAMS NIH HHS [AR43660] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADACHI N, 1992, NUCLEIC ACIDS RES, V20, P5297, DOI 10.1093/nar/20.20.5297; Adachi N, 1997, BIOCHEM BIOPH RES CO, V230, P105, DOI 10.1006/bbrc.1996.5893; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; Bi WM, 1997, J BIOL CHEM, V272, P26562, DOI 10.1074/jbc.272.42.26562; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen HX, 1998, GENETICS, V148, P123; Coustry F, 1996, J BIOL CHEM, V271, P14485, DOI 10.1074/jbc.271.24.14485; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hasegawa T, 1996, NUCLEIC ACIDS RES, V24, P3253, DOI 10.1093/nar/24.16.3253; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Isaacs RJ, 1998, BBA-GENE STRUCT EXPR, V1400, P121, DOI 10.1016/S0167-4781(98)00131-6; Kim IS, 1996, MOL CELL BIOL, V16, P4003; LALANNE JL, 1987, NUCLEIC ACIDS RES, V15, P4990, DOI 10.1093/nar/15.12.4990; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; LI XY, 1992, NUCLEIC ACIDS RES, V20, P1087, DOI 10.1093/nar/20.5.1087; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Liang SG, 1998, J BIOL CHEM, V273, P31590, DOI 10.1074/jbc.273.47.31590; Lotan T, 1998, CELL, V93, P1195, DOI 10.1016/S0092-8674(00)81463-4; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P8286; Maity SN, 1996, METHOD ENZYMOL, V273, P217; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MAITY SN, 1998, TRENDS BIOCHEM SCI, V18, P459; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; McNabb DS, 1997, MOL CELL BIOL, V17, P7008, DOI 10.1128/MCB.17.12.7008; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; Niederreither K, 1995, MATRIX BIOL, V14, P705, DOI 10.1016/S0945-053X(05)80013-7; Sambrook J., 2002, MOL CLONING LAB MANU; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; TATE EH, 1983, CYTOMETRY, V4, P211, DOI 10.1002/cyto.990040304; TULCHINSKY EM, 1990, GENE, V87, P219, DOI 10.1016/0378-1119(90)90305-B; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1	45	61	63	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4435	4444		10.1074/jbc.275.6.4435	http://dx.doi.org/10.1074/jbc.275.6.4435			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660616	hybrid			2022-12-27	WOS:000085288800100
J	Mousseau, DD; Banville, D; L'Abbe, D; Bouchard, P; Shen, SH				Mousseau, DD; Banville, D; L'Abbe, D; Bouchard, P; Shen, SH			PILR alpha, a novel immunoreceptor tyrosine-based inhibitory motif-bearing protein, recruits SHP-1 upon tyrosine phosphorylation and is paired with the truncated counterpart PILR beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PROTEIN; HEMATOPOIETIC-CELLS; PHOSPHATASE PTP1C; SH2 DOMAINS; RECEPTOR; ACTIVATION; ASSOCIATION; BINDING; GENE; MACROPHAGES	SHP-1-mediated dephosphorylation of protein tyrosine residues is central to the regulation of several cell signaling pathways, the specificity of which is dictated by the intrinsic affinity of SH2 domains for the flanking sequences of phosphotyrosine residues. By using a modified yeast two-hybrid system and SHP-1 as bait, we have cloned a human cDNA, PILR alpha, encoding a 303-amino acid immunoglobulin-like transmembrane receptor bearing two cytoplasmic tyrosines positioned within an immunoreceptor tyrosine-based inhibitory motif, Substrate trapping in combination with pervanadate treatment of 293T cells confirms that PILR alpha associates with SHP-1 in vivo upon tyrosine phosphorylation. Mutation of the tyrosine residues in PILR alpha indicates the pivotal role of the Tyr-269 residue in recruiting SHP-1; Surface plasmon resonance analysis further suggests that the association between PILR alpha-Tyr-269 and SHP-1 is mediated primarily via the amino-terminal SH2 domain of the latter. Polymerase chain reaction amplification of cDNA in combination with genomic sequence analysis revealed a second gene, PILR beta, coding for a putative activating receptor as suggested by a truncated cytoplasmic tail and a charged lysine residue in its transmembrane region. The PILR alpha and PILR beta genes are localized to chromosome 7 which is in contrast with the mapping of known members of the inhibitory receptor superfamil.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada	National Research Council Canada; McGill University	Shen, SH (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.							Adachi M, 1996, CELL, V85, P15; Berg KL, 1998, ONCOGENE, V17, P2535, DOI 10.1038/sj.onc.1202203; Biassoni R, 1996, J EXP MED, V183, P645, DOI 10.1084/jem.183.2.645; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; Bruhns P, 1999, J IMMUNOL, V162, P3168; Burshtyn DN, 1997, TRENDS CELL BIOL, V7, P473, DOI 10.1016/S0962-8924(97)01167-7; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Burshtyn DN, 1999, J IMMUNOL, V162, P897; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Keegan K, 1996, ONCOGENE, V12, P1537; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KonKozlowski M, 1996, J BIOL CHEM, V271, P3856; Kuroiwa A, 1998, J BIOL CHEM, V273, P1070, DOI 10.1074/jbc.273.2.1070; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Meyaard L, 1997, IMMUNITY, V7, P283, DOI 10.1016/S1074-7613(00)80530-0; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; Olcese L, 1996, J IMMUNOL, V156, P4531; PAWSON T, 1995, NATURE, V373, P477, DOI 10.1038/373477a0; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; Tangye SG, 1999, J IMMUNOL, V162, P6981; Taylor LS, 1999, BLOOD, V94, P1790, DOI 10.1182/blood.V94.5.1790.417k16_1790_1796; TOWNLEY R, 1993, BIOCHEMISTRY-US, V32, P13414, DOI 10.1021/bi00212a006; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Vely F, 1997, J IMMUNOL, V159, P2075; Vely F, 1997, EUR J IMMUNOL, V27, P3010, DOI 10.1002/eji.1830271138; Wagtmann N, 1995, IMMUNITY, V3, P801, DOI 10.1016/1074-7613(95)90069-1; Wang LL, 1999, J IMMUNOL, V162, P1318; Yu ZB, 1998, J BIOL CHEM, V273, P3687, DOI 10.1074/jbc.273.6.3687	40	78	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4467	4474		10.1074/jbc.275.6.4467	http://dx.doi.org/10.1074/jbc.275.6.4467			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660620	hybrid			2022-12-27	WOS:000085288800104
J	Baumann, NA; Vidugiriene, J; Machamer, CE; Menon, AK				Baumann, NA; Vidugiriene, J; Machamer, CE; Menon, AK			Cell surface display and intracellular trafficking of free glycosylphosphatidylinositols in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; LEISHMANIA-MAJOR; VACCINIA VIRUS; GOLGI-COMPLEX; GLYCOINOSITOL PHOSPHOLIPIDS; ANCHOR BIOSYNTHESIS; GPI-ANCHOR; RAT-LIVER; PIG-A	In addition to serving as membrane anchors for cell surface proteins, glycosylphosphatidylinositols (GPIs) can be found abundantly as free glycolipids in mammalian cells. in this study we analyze the subcellular distribution and intracellular transport of metabolically radiolabeled GPIs in three different cell lines. We use a variety of membrane isolation techniques (subcellular fractionation, plasma membrane vesiculation to isolate pure plasma membrane fractions, and enveloped viruses to sample cellular membranes) to provide direct evidence that free GPIs are not confined to their site of synthesis, the endoplasmic reticulum, but can redistribute to populate other subcellular organelles. Over short labeling periods (2.5 h), radiolabeled GPIs were found at similar concentration in all subcellular fractions with the exception of a mitochondria-enriched fraction where GPI concentration was low. Pulse-chase experiments over extended chase periods showed that although the total amount of cellular radiolabeled GPIs decreased, the plasma membrane complement of labeled GPIs increased. GPIs at the plasma membrane were found to populate primarily the exoplasmic leaflet as detected using periodate oxidation of the cell surface, Transport of GPIs to the cell surface was inhibited by Brefeldin A and blocked at 15 degrees C, suggesting that GPIs are transported to the plasma membrane via a vesicular mechanism, The rate of transport of radiolabeled GPIs to the cell surface was found to be comparable with the rate of secretion of newly synthesized soluble proteins destined for the extracellular space.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Vilnius State Univ, Dept Biochem & Biophys, LT-2009 Vilnius, Lithuania; Johns Hopkins Univ, Sch Med, Dept Cell Biol & Anat, Baltimore, MD 21205 USA	University of Wisconsin System; University of Wisconsin Madison; Vilnius University; Johns Hopkins University	Menon, AK (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	menon@biochem.wisc.edu		Menon, Anant Kumar/0000-0001-6924-2698	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044375] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44375] Funding Source: Medline; NIGMS NIH HHS [GM55427] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1994, MOL BIOL CELL, P553; ARDAIL D, 1993, J BIOL CHEM, V268, P25985; BAUMANN NA, 1999, OLIGOSACCHARIDES CHE; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRAELL WA, 1988, ANAL BIOCHEM, V170, P328, DOI 10.1016/0003-2697(88)90638-0; BROWN RE, 1990, BIOCHIM BIOPHYS ACTA, V1044, P77, DOI 10.1016/0005-2760(90)90221-I; Cadd TL, 1997, BIOESSAYS, V19, P993, DOI 10.1002/bies.950191109; Cluett EB, 1997, MOL BIOL CELL, V8, P2233, DOI 10.1091/mbc.8.11.2233; Cluett EB, 1996, J CELL SCI, V109, P2121; DEEG MA, 1992, J BIOL CHEM, V267, P18581; DJAFARZADEH S, 1994, CHIMIA, V48, P401; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; Field MC, 1997, GLYCOBIOLOGY, V7, P161, DOI 10.1093/glycob/7.2.161-d; FRIES E, 1986, BIOCHEM J, V237, P33, DOI 10.1042/bj2370033; FRIES E, 1984, EMBO J, V3, P147, DOI 10.1002/j.1460-2075.1984.tb01775.x; Graham John M., 1993, V19, P1; GRIFFITHS G, 1984, J CELL BIOL, V98, P2133, DOI 10.1083/jcb.98.6.2133; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HIROSE S, 1992, J BIOL CHEM, V267, P16968; Ilgoutz SC, 1999, EMBO J, V18, P2746, DOI 10.1093/emboj/18.10.2746; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kohlwein SD, 1996, TRENDS CELL BIOL, V6, P260, DOI 10.1016/0962-8924(96)10025-8; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; MACALA LJ, 1983, J LIPID RES, V24, P1243; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCCONVILLE MJ, 1989, J BIOL CHEM, V264, P757; MCCONVILLE MJ, 1990, MOL BIOCHEM PARASIT, V38, P57, DOI 10.1016/0166-6851(90)90205-Z; MCCONVILLE MJ, 2000, IN PRESS MOL MEMBR B; Menon AK, 1997, BIOCHEM SOC T, V25, P861, DOI 10.1042/bst0250861; MENON AK, 1999, GPI ANCHORED BIOMOLE, P15; MENSAWILMOT K, 1994, J CELL BIOL, V124, P935, DOI 10.1083/jcb.124.6.935; MILLERPODRAZA H, 1982, BIOCHEMISTRY-US, V21, P3265, DOI 10.1021/bi00257a003; MORITA YS, 1999, IN PRESS OLIGOSACCHA; Nakamura N, 1997, J BIOL CHEM, V272, P15834, DOI 10.1074/jbc.272.25.15834; PESSIN JE, 1980, J BIOL CHEM, V255, P9044; PUOTI A, 1992, J BIOL CHEM, V267, P22673; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; Scheiffele P, 1999, J BIOL CHEM, V274, P2038, DOI 10.1074/jbc.274.4.2038; SCHMELZ M, 1994, J VIROL, V68, P130, DOI 10.1128/JVI.68.1.130-147.1994; SCOTT RE, 1976, SCIENCE, V194, P743, DOI 10.1126/science.982043; SHAROM FJ, 1985, CAN J BIOCHEM CELL B, V63, P1049, DOI 10.1139/o85-130; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; SHORE GC, 1977, J CELL BIOL, V72, P714, DOI 10.1083/jcb.72.3.714; Singh N, 1996, J BIOL CHEM, V271, P12879, DOI 10.1074/jbc.271.22.12879; SODEIK B, 1993, J CELL BIOL, V121, P521, DOI 10.1083/jcb.121.3.521; STEVENS VL, 1995, BIOCHEM J, V310, P361, DOI 10.1042/bj3100361; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; STROUS JAM, 1980, CELL, V22, P709, DOI 10.1016/0092-8674(80)90547-4; TAKEDA J, 1995, TRENDS BIOCHEM SCI, V20, P367, DOI 10.1016/S0968-0004(00)89078-7; TANK DW, 1982, J CELL BIOL, V92, P207, DOI 10.1083/jcb.92.1.207; TARTAKOFF AM, 1986, EMBO J, V5, P1477, DOI 10.1002/j.1460-2075.1986.tb04385.x; TROTTER PJ, 1994, BBA-LIPID LIPID MET, V1213, P241, DOI 10.1016/0005-2760(94)00073-5; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VAN GENDEREN IL, 1994, VIROLOGY, V200, P831, DOI 10.1006/viro.1994.1252; VAN MEER G, 1982, EMBO J, V1, P847, DOI 10.1002/j.1460-2075.1982.tb01258.x; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VANMEER G, 1994, SUBCELL BIOCH, V34, P1; VANTHOF W, 1995, J BIOL CHEM, V270, P24150; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333; Vidugiriene J, 1999, J BIOL CHEM, V274, P15203, DOI 10.1074/jbc.274.21.15203; Watanabe R, 1996, J BIOL CHEM, V271, P26868, DOI 10.1074/jbc.271.43.26868; Watanabe R, 1998, EMBO J, V17, P877, DOI 10.1093/emboj/17.4.877; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WILLIAMS DB, 1985, J CELL BIOL, V101, P725, DOI 10.1083/jcb.101.3.725	67	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7378	7389		10.1074/jbc.275.10.7378	http://dx.doi.org/10.1074/jbc.275.10.7378			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702311	hybrid			2022-12-27	WOS:000085809600091
J	Lee, D; Lee, B; Kim, J; Kim, DW; Choe, J				Lee, D; Lee, B; Kim, J; Kim, DW; Choe, J			cAMP response element-binding protein-binding protein binds to human papillomavirus E2 protein and activates E2-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE-T-ANTIGEN; ADENOVIRUS E1A; HISTONE ACETYLTRANSFERASE; REPLICATION FUNCTIONS; REMODELING FACTOR; IN-VITRO; TRANSACTIVATION DOMAIN; DNA-REPLICATION; TERMINAL DOMAIN; CBP	cAMP response element-binding protein-binding protein (CBP) is a eucaryotic transcriptional co-activator that contains multiple protein-protein interaction domains for association with various transcription factors, components of the basal transcriptional apparatus, and other co-activator proteins, Here, we report that CBP is also a co-activator of the human papillomavirus (HPV) E2 protein, which is a sequence-specific transcription/replication factor. We provide biochemical, genetic, and functional evidence that CBP binds directly to HPV E2 in vivo and in vitro and activates Ea-dependent transcription. Mutations in an amphipathic helix within HPV-18 E2 abolish its transcriptional activation properties and its ability to bind to CBP, Furthermore, the binding of CBP to E2 was shown to be necessary for Ea-dependent transcription. Interestingly, the histone acetyltransferase activity of CBP plays a role in CBP activation of Ea-dependent transcription.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Choe, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.		Choe, Joonho/F-3066-2011; Lee, Daeyoup/C-1653-2011	Lee, Daeyoup/0000-0003-2006-1823				Abroi A, 1996, J VIROL, V70, P6169, DOI 10.1128/JVI.70.9.6169-6179.1996; Alexiadis V, 1997, CHROMOSOMA, V105, P324; Alexiadis V, 1998, EMBO J, V17, P3428, DOI 10.1093/emboj/17.12.3428; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHOE J, 1989, J VIROL, V63, P1743, DOI 10.1128/JVI.63.4.1743-1755.1989; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cooper CS, 1998, VIROLOGY, V241, P312, DOI 10.1006/viro.1997.8941; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Desaintes C, 1999, ONCOGENE, V18, P4538, DOI 10.1038/sj.onc.1202818; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; ECKNER R, 1994, COLD SPRING HARB SYM, V59, P85, DOI 10.1101/SQB.1994.059.01.012; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Harris SF, 1999, SCIENCE, V284, P1673, DOI 10.1126/science.284.5420.1673; HAUGEN TH, 1988, EMBO J, V7, P4245, DOI 10.1002/j.1460-2075.1988.tb03322.x; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kovelman R, 1996, J VIROL, V70, P7549, DOI 10.1128/JVI.70.11.7549-7560.1996; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; Liu L, 1999, MOL CELL BIOL, V19, P1202; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; MATSUKURA T, 1986, J VIROL, V58, P979, DOI 10.1128/JVI.58.3.979-982.1986; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; MCBRIDE AA, 1988, EMBO J, V7, P533, DOI 10.1002/j.1460-2075.1988.tb02842.x; MCBRIDE AA, 1989, P NATL ACAD SCI USA, V86, P510, DOI 10.1073/pnas.86.2.510; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Recht J, 1999, EMBO J, V18, P229, DOI 10.1093/emboj/18.1.229; Roberts SM, 1997, GENETICS, V147, P451; Sakai H, 1996, J VIROL, V70, P1602, DOI 10.1128/JVI.70.3.1602-1611.1996; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; USHIKAI M, 1994, J VIROL, V68, P6655, DOI 10.1128/JVI.68.10.6655-6666.1994; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WINOKUR PL, 1992, EMBO J, V11, P4111, DOI 10.1002/j.1460-2075.1992.tb05504.x; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZIMMERMANN H, 1999, J VIROL, V73, P6029	59	76	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7045	7051		10.1074/jbc.275.10.7045	http://dx.doi.org/10.1074/jbc.275.10.7045			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702269	hybrid			2022-12-27	WOS:000085809600049
J	Mongiat, M; Taylor, K; Otto, J; Aho, S; Uitto, J; Whitelock, JM; Iozzo, RV				Mongiat, M; Taylor, K; Otto, J; Aho, S; Uitto, J; Whitelock, JM; Iozzo, RV			The protein core of the proteoglycan perlecan binds specifically to fibroblast growth factor-7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; MEDIATED CELL-ADHESION; COLON CARCINOMA-CELLS; BASEMENT-MEMBRANES; DOMAIN-III; FACTOR FAMILY; EXPRESSION; DIVERSITY; BIOSYNTHESIS; RECEPTOR	Perlecan is a multifaceted heparan sulfate proteoglycan that is expressed not only as an intrinsic constituent of basement membranes but also as a cell-surface and pericellular proteoglycan, Perlecan functions as a ligand reservoir for various growth factors that become stabilized against misfolding or proteolysis and acts as a co-receptor for basic fibroblast growth factor by augmenting high affinity binding and receptor activation. These biological properties are mediated by the heparan sulfate moiety, Rather little is known about the protein core's mediation of functions. We have recently discovered that fibroblast growth factor-7 (FGF7) binds to perlecan protein core and that exogenous perlecan efficiently reconstitutes FGF7 mitogenic activity in perlecan-deficient cells. In this report we examined the specific binding of FGF7 to various domains and subdomains of perlecan protein core. Using several experimental approaches including overlay protein assays, radioligand binding experiments, and the yeast two-hybrid system, me demonstrate that FGF7 binds specifically to the N-terminal half of domain III and to a lesser extent to domain V, with affinity constants in the range of 60 nM. Thus, perlecan protein core should be considered a novel biological ligand for FGF7, an interaction that could influence cancer growth and tissue remodeling.	Thomas Jefferson Univ, Jefferson Med Coll, JAH, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Commonwealth Sci & Ind Res Org Mol Sci, Sydney, NSW 2114, Australia	Jefferson University; Jefferson University; Jefferson University; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, JAH, Dept Pathol Anat & Cell Biol, Rm 249,1020 Locust St, Philadelphia, PA 19107 USA.		Iozzo, Renato/AAS-1980-2020; Mongiat, Maurizio/H-8297-2018	Mongiat, Maurizio/0000-0001-6509-0068; Whitelock, John/0000-0003-1835-802X; Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [R01 CA39481, R01 CA47282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, ANN NY ACAD SCI, V638, P62, DOI 10.1111/j.1749-6632.1991.tb49018.x; Adatia R, 1997, ANN ONCOL, V8, P1257, DOI 10.1023/A:1008243115385; Aho S, 1998, MATRIX BIOL, V17, P401, DOI 10.1016/S0945-053X(98)90100-7; Aviezer D, 1997, MOL CELL BIOL, V17, P1938, DOI 10.1128/MCB.17.4.1938; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BATTAGLIA C, 1993, EUR J CELL BIOL, V61, P92; BonnehBarkay D, 1997, J BIOL CHEM, V272, P12415, DOI 10.1074/jbc.272.19.12415; Brown JC, 1997, EUR J BIOCHEM, V250, P39, DOI 10.1111/j.1432-1033.1997.t01-1-00039.x; CHAKRAVARTI S, 1995, J BIOL CHEM, V270, P404, DOI 10.1074/jbc.270.1.404; COHEN IR, 1994, CANCER RES, V54, P5771; Conrad H. E., 1998, HEPARIN BINDING PROT; Faham S, 1998, CURR OPIN STRUC BIOL, V8, P578, DOI 10.1016/S0959-440X(98)80147-4; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; Gohring W, 1998, EUR J BIOCHEM, V255, P60, DOI 10.1046/j.1432-1327.1998.2550060.x; Goretzki L, 1999, J BIOL CHEM, V274, P16831, DOI 10.1074/jbc.274.24.16831; Hopf M, 1999, EUR J BIOCHEM, V259, P917, DOI 10.1046/j.1432-1327.1999.00127.x; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; IOZZO RV, 1989, J BIOL CHEM, V264, P2690; IOZZO RV, 1984, J CELL BIOL, V99, P403, DOI 10.1083/jcb.99.2.403; Kuo HJ, 1997, J BIOL CHEM, V272, P26522, DOI 10.1074/jbc.272.42.26522; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Milev P, 1998, J BIOL CHEM, V273, P21439, DOI 10.1074/jbc.273.34.21439; MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; SCHULZE B, 1995, EUR J BIOCHEM, V231, P551, DOI 10.1111/j.1432-1033.1995.tb20731.x; Schulze B, 1996, MATRIX BIOL, V15, P349, DOI 10.1016/S0945-053X(96)90138-9; Sharma B, 1998, J CLIN INVEST, V102, P1599, DOI 10.1172/JCI3793; TIMPL R, 1993, EXPERIENTIA, V49, P417, DOI 10.1007/BF01923586; VIGNY M, 1988, J CELL PHYSIOL, V137, P321, DOI 10.1002/jcp.1041370216; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; Whitelock JM, 1999, MATRIX BIOL, V18, P163, DOI 10.1016/S0945-053X(99)00014-1; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767; YURCHENCO PD, 1987, J BIOL CHEM, V262, P17668	36	121	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7095	7100		10.1074/jbc.275.10.7095	http://dx.doi.org/10.1074/jbc.275.10.7095			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702276	hybrid			2022-12-27	WOS:000085809600056
J	Provoda, CJ; Waring, MT; Buckley, KM				Provoda, CJ; Waring, MT; Buckley, KM			Evidence for a primary endocytic vesicle involved in synaptic vesicle biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; PC12 CELLS; IN-VITRO; TRANSFERRIN RECEPTOR; TARGETING SIGNAL; RAT-BRAIN; PATHWAYS; AMINOPEPTIDASE; MICROVESICLES; POPULATIONS	The regulated release of neurotransmitters at synapses is mediated by the fusion of neurotransmitter-filled synaptic vesicles with the plasma membrane. Continuous synaptic activity relies on the constant recycling of synaptic vesicle proteins into newly formed synaptic vesicles. At least two different mechanisms are presumed to mediate synaptic Vesicle biogenesis at the synapse as follows: direct retrieval of synaptic vesicle proteins and lipids from the plasma membrane, and indirect passage of synaptic vesicle proteins through an endosomal intermediate. We have identified a vesicle population with the characteristics of a primary endocytic vesicle responsible for the recycling of synaptic vesicle proteins through the indirect pathway. We find that synaptic vesicle proteins colocalize in this vesicle with a variety of proteins known to recycle from the plasma membrane through the endocytic pathway, in eluding three different glucose transporters, GLUT1, GLUT3, and GLUT4, and the transferrin receptor. These vesicles differ from "classical" synaptic vesicles in their size and their generic protein content, indicating that they do not discriminate between synaptic vesicle-specific proteins and other recycling proteins. We propose that these vesicles deliver synaptic vesicle proteins that have escaped internalization by the direct pathway to endosomes, where they are sorted from other recycling proteins and packaged into synaptic vesicles.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Buckley, KM (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.			Buckley, Kathleen/0000-0003-0283-4917	NINDS NIH HHS [NS27536] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027536] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Blagoveshchenskaya AD, 1999, J CELL BIOL, V145, P1419, DOI 10.1083/jcb.145.7.1419; CAMERON IL, 1993, CELL BIOL INT, V17, P93, DOI 10.1006/cbir.1993.1009; Clift-O'Grady L, 1998, METHODS, V16, P150, DOI 10.1006/meth.1998.0662; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; DESNOS C, 1995, J CELL BIOL, V130, P1041, DOI 10.1083/jcb.130.5.1041; GREEN SA, 1992, J CELL BIOL, V117, P47, DOI 10.1083/jcb.117.1.47; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; Grote E, 1996, J CELL BIOL, V132, P537, DOI 10.1083/jcb.132.4.537; Hannah MJ, 1999, ANNU REV CELL DEV BI, V15, P733, DOI 10.1146/annurev.cellbio.15.1.733; Haucke V, 1999, SCIENCE, V285, P1268, DOI 10.1126/science.285.5431.1268; HERMAN GA, 1994, P NATL ACAD SCI USA, V91, P12750, DOI 10.1073/pnas.91.26.12750; HUDSON AW, 1993, J CELL BIOL, V122, P579, DOI 10.1083/jcb.122.3.579; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Jeng CJ, 1998, J CELL BIOL, V140, P685, DOI 10.1083/jcb.140.3.685; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; Koenig JH, 1996, J CELL BIOL, V135, P797, DOI 10.1083/jcb.135.3.797; Lichtenstein Y, 1998, P NATL ACAD SCI USA, V95, P11223, DOI 10.1073/pnas.95.19.11223; Melikian HE, 1999, J NEUROSCI, V19, P7699; MUNDIGL O, 1994, CURR OPIN CELL BIOL, V6, P561, DOI 10.1016/0955-0674(94)90077-9; Murthy VN, 1998, NATURE, V392, P497, DOI 10.1038/33152; Norcott JP, 1996, J CELL BIOL, V134, P1229, DOI 10.1083/jcb.134.5.1229; Renick SE, 1999, J NEUROSCI, V19, P21, DOI 10.1523/JNEUROSCI.19-01-00021.1999; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; Schmidt A, 1998, METHODS, V16, P160, DOI 10.1006/meth.1998.0663; Schmidt A, 1997, J CELL BIOL, V137, P445, DOI 10.1083/jcb.137.2.445; Shi GY, 1998, J CELL BIOL, V143, P947, DOI 10.1083/jcb.143.4.947; Thoidis G, 1999, J BIOL CHEM, V274, P14062, DOI 10.1074/jbc.274.20.14062; Thoidis G, 1998, P NATL ACAD SCI USA, V95, P183, DOI 10.1073/pnas.95.1.183; URIU T, 1991, J NEUROCHEM, V56, P1548, DOI 10.1111/j.1471-4159.1991.tb02050.x; VERHEY KJ, 1993, J CELL BIOL, V123, P137, DOI 10.1083/jcb.123.1.137; Warren RA, 1998, J BIOL CHEM, V273, P17056, DOI 10.1074/jbc.273.27.17056; Wei ML, 1998, J CELL BIOL, V140, P565, DOI 10.1083/jcb.140.3.565	35	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7004	7012		10.1074/jbc.275.10.7004	http://dx.doi.org/10.1074/jbc.275.10.7004			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702264	hybrid			2022-12-27	WOS:000085809600044
J	Scott, S; Dorrington, R; Svetlov, V; Beeser, AE; Distler, M; Cooper, TG				Scott, S; Dorrington, R; Svetlov, V; Beeser, AE; Distler, M; Cooper, TG			Functional domain mapping and subcellular distribution of Dal82p in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN-CATABOLITE REPRESSION; UPSTREAM ACTIVATION SEQUENCES; ALLANTOIN SYSTEM GENES; TRANSCRIPTIONAL ACTIVATION; REGULATORY ELEMENTS; INDUCTION SEQUENCE; SHUTTLE VECTORS; PROTEIN-BINDING; FUSION PROTEINS; GATA FACTORS	Previous studies have shown that (i) Dal81p and Dal82p are required for allophanate-induced gene expression in Saccharomyces cerevisiae; (ii) the cis-acting element mediating the induced transcriptional response to allophanate is a dodecanucleotide, UISALL; and (iii) Dal82p binds specifically to UISALL. Here we show that Dal82p is localized to the nucleus and parallels movement of the DNA through the cell cycle. Deletion analysis of DAL82 identified and localized three functional domains. Electrophoretic mobility shift assays identified a peptide (consisting of Dal82p amino acids 1-85) that is sufficient to bind a DNA fragment containing UISALL. LexA-tethering experiments demonstrated that Dal82p is capable of mediating transcriptional activation. The activation domain consists of two parts: (i) an absolutely required core region (amino acids 66-99) and (ii) less well defined regions flanking residues 66-99 that are required for full wild-type levels of activation. The Dal82p C terminus contains a predicted coiled-coil motif that down-regulates Dal82p-mediated transcriptional activation.	Univ Tennessee, Dept Microbiol & Immunol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Cooper, TG (corresponding author), Univ Tennessee, Dept Microbiol & Immunol, Memphis, TN 38163 USA.			Cooper, Terrance G./0000-0002-7651-9963	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM035642, GM-35642] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALLEN JB, 1994, YEAST, V10, P1267, DOI 10.1002/yea.320101003; ANDRE B, 1995, NUCLEIC ACIDS RES, V23, P558, DOI 10.1093/nar/23.4.558; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BLINDER D, 1995, J BACTERIOL, V177, P4190, DOI 10.1128/jb.177.14.4190-4193.1995; BRICMONT PA, 1989, MOL CELL BIOL, V9, P3869, DOI 10.1128/MCB.9.9.3869; BRICMONT PA, 1991, MOL CELL BIOL, V11, P1161, DOI 10.1128/MCB.11.2.1161; BYSANI N, 1991, J BACTERIOL, V173, P4977, DOI 10.1128/jb.173.16.4977-4982.1991; CHISHOLM G, 1982, MOL CELL BIOL, V2, P1088, DOI 10.1128/MCB.2.9.1088; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Coffman JA, 1996, MOL CELL BIOL, V16, P847; Coffman JA, 1997, J BACTERIOL, V179, P3416, DOI 10.1128/jb.179.11.3416-3429.1997; COFFMAN JA, 1995, J BACTERIOL, V177, P6910, DOI 10.1128/jb.177.23.6910-6918.1995; Cooper T., 1982, MOL BIOL YEAST SACCH, P39, DOI DOI 10.1101/087969180.11B.39; COOPER TG, 1989, MOL CELL BIOL, V9, P5440, DOI 10.1128/MCB.9.12.5440; COOPER TG, 1983, J BACTERIOL, V155, P623, DOI 10.1128/JB.155.2.623-627.1983; COOPER TG, 1990, J BACTERIOL, V172, P1014, DOI 10.1128/jb.172.2.1014-1018.1990; Cooper TG, 1996, MYCOTA, V3, P139; CUNNINGHAM TS, 1993, J BACTERIOL, V175, P5851, DOI 10.1128/JB.175.18.5851-5861.1993; CUNNINGHAM TS, 1994, J BACTERIOL, V176, P4718, DOI 10.1128/JB.176.15.4718-4725.1994; Cunningham TS, 1996, J BACTERIOL, V178, P3470, DOI 10.1128/jb.178.12.3470-3479.1996; DAUGHERTY JR, 1993, J BACTERIOL, V175, P64, DOI 10.1128/JB.175.1.64-73.1993; DORRINGTON RA, 1993, NUCLEIC ACIDS RES, V21, P3777, DOI 10.1093/nar/21.16.3777; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; Galibert F, 1996, EMBO J, V15, P2031, DOI 10.1002/j.1460-2075.1996.tb00557.x; GENBAUFFE FS, 1986, MOL CELL BIOL, V6, P3954, DOI 10.1128/MCB.6.11.3954; GOLEMIS EA, 1996, CURRENT PROTOCOLS MO; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; HARTIG A, 1992, NUCLEIC ACIDS RES, V20, P5677, DOI 10.1093/nar/20.21.5677; Jarrett HW, 1998, J CHROMATOGR A, V803, P131, DOI 10.1016/S0021-9673(97)01257-0; Kunze I, 1999, BBA-BIOENERGETICS, V1410, P287, DOI 10.1016/S0005-2728(99)00006-7; LEMOINE Y, 1978, MOL GEN GENET, V166, P251, DOI 10.1007/BF00267616; LUCHE RM, 1990, MOL CELL BIOL, V10, P3884, DOI 10.1128/MCB.10.8.3884; Miller JH, 1972, EXPT MOL GENETICS, P403; MINEHART PL, 1991, MOL CELL BIOL, V11, P6216, DOI 10.1128/MCB.11.12.6216; MINEHART PL, 1992, J BACTERIOL, V174, P1828, DOI 10.1128/jb.174.6.1828-1836.1992; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; OLIVE MG, 1991, J BACTERIOL, V173, P255, DOI 10.1128/jb.173.1.255-261.1991; Park HD, 1999, J BACTERIOL, V181, P7052, DOI 10.1128/JB.181.22.7052-7064.1999; RAI R, 1988, J BACTERIOL, V170, P266, DOI 10.1128/jb.170.1.266-271.1988; RAI R, 1987, J BACTERIOL, V169, P3521, DOI 10.1128/jb.169.8.3521-3524.1987; RAI R, 1989, MOL CELL BIOL, V9, P602, DOI 10.1128/MCB.9.2.602; ROON RJ, 1968, J BIOL CHEM, V243, P5213; SIKORSKI RS, 1989, GENETICS, V122, P19; SoussiBoudekou S, 1997, MOL MICROBIOL, V23, P1157, DOI 10.1046/j.1365-2958.1997.3021665.x; STANBROUGH M, 1995, P NATL ACAD SCI USA, V92, P9450, DOI 10.1073/pnas.92.21.9450; Svetlov V, 1997, J BACTERIOL, V179, P7644, DOI 10.1128/jb.179.24.7644-7652.1997; Towbin H, 1992, Biotechnology, V24, P145; TUROSCY V, 1982, J BACTERIOL, V151, P1237, DOI 10.1128/JB.151.3.1237-1246.1982; VANVUUREN HJJ, 1991, J BACTERIOL, V173, P7186, DOI 10.1128/jb.173.22.7186-7195.1991; VISSERS S, 1989, EUR J BIOCHEM, V181, P357, DOI 10.1111/j.1432-1033.1989.tb14732.x; WHITNEY PA, 1973, J BIOL CHEM, V248, P6203; WIAME JM, 1985, ADV MICROB PHYSIOL, V26, P1, DOI 10.1016/S0065-2911(08)60394-X; YOO HS, 1991, GENE, V104, P55, DOI 10.1016/0378-1119(91)90464-M; YOO HS, 1989, MOL CELL BIOL, V9, P3231, DOI 10.1128/MCB.9.8.3231	55	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7198	7204		10.1074/jbc.275.10.7198	http://dx.doi.org/10.1074/jbc.275.10.7198			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702289	Green Published, hybrid, Green Accepted			2022-12-27	WOS:000085809600069
J	Xiao, Y; Metzl, M; Mueller, DM				Xiao, Y; Metzl, M; Mueller, DM			Partial uncoupling of the mitochondrial membrane by a heterozygous null mutation in the gene encoding the gamma- or delta-subunit of the yeast mitochondrial ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSILON-SUBUNITS; SYNTHASE; F1-ATPASE; ROTATION; F1; DISRUPTION; PROTEIN	Prior genetic studies indicated that the yeast mitochondrial ATP synthase can be assembled into enzyme complexes devoid of the gamma-, delta-, or epsilon-subunits (Lai-Zhang, J., Xiao, Y., and Mueller, D, M. (1999) EMBO J, 18, 58-64), These subunit-deficient complexes were postulated to uncouple the mitochondrial membrane thereby causing negative cellular phenotypes, This study provides bio chemical and additional genetic data that support this hypothesis. The genetic data indicate that in a diploid cell, a heterozygous deletion mutation in the gene encoding the gamma- or delta-subunit of the ATPase is semidominant negative due to a decrease in the gene number from 2 to 1, However, the heterozygous atp2 Delta mutation is epistatic to the heterozygous mutation in the gene encoding gamma or delta, suggesting that the semidominant negative effect is because of a gain of activity in the cells. Biochemical studies using mitochondria isolated from the yeast strains that are heterozygous for a mutation in gamma or delta indicate that the mitochondria are partially uncoupled. These results support the hypothesis that the negative phenotypes are caused by the formation of a gamma- or delta-less ATP synthase complex that is uncoupled.	Finch Univ Hlth Sci Chicago Med Sch, Dept Biochem & Mol Biol, N Chicago, IL 60064 USA	Chicago Medical School	Mueller, DM (corresponding author), Finch Univ Hlth Sci Chicago Med Sch, Dept Biochem & Mol Biol, 3333 Greenbay Rd, N Chicago, IL 60064 USA.	muellerd@mis.finchcms.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044412] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44412] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; BOYER PD, 1973, P NATL ACAD SCI USA, V70, P2837, DOI 10.1073/pnas.70.10.2837; Capaldi RA, 1996, J BIOENERG BIOMEMBR, V28, P397, DOI 10.1007/BF02113980; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Giraud MF, 1997, EUR J BIOCHEM, V245, P813, DOI 10.1111/j.1432-1033.1997.00813.x; GUELIN E, 1993, J BIOL CHEM, V268, P161; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hermolin J, 1999, J BIOL CHEM, V274, P17011, DOI 10.1074/jbc.274.24.17011; Jie LZ, 1999, EMBO J, V18, P58, DOI 10.1093/emboj/18.1.58; MUELLER DM, 1988, J BIOL CHEM, V263, P5634; MUKHOPADHYAY A, 1994, FEBS LETT, V343, P160, DOI 10.1016/0014-5793(94)80310-2; Nakamoto RK, 1996, J MEMBRANE BIOL, V151, P101, DOI 10.1007/s002329900061; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; PAUL MF, 1994, J BIOL CHEM, V269, P26158; PITTMAN D, 1960, GENETICS, V45, P1023; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Schulenberg B, 1997, EUR J BIOCHEM, V249, P134, DOI 10.1111/j.1432-1033.1997.t01-1-00134.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; ZHANG Y, 1994, J BIOL CHEM, V269, P10221	28	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6963	6968		10.1074/jbc.275.10.6963	http://dx.doi.org/10.1074/jbc.275.10.6963			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702258	hybrid			2022-12-27	WOS:000085809600038
J	de la Horra, C; Hernando, N; Lambert, G; Forster, I; Biber, J; Murer, H				de la Horra, C; Hernando, N; Lambert, G; Forster, I; Biber, J; Murer, H			Molecular determinants of pH sensitivity of the type IIa Na/P-i cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; NA+/H+ ANTIPORTER; PHOSPHATE-TRANSPORT; INORGANIC-PHOSPHATE; ESCHERICHIA-COLI; RAT-KIDNEY; EXPRESSION; OOCYTES; SENSOR; NHAA	Type II Na/P-i cotransporters play key roles in epithelial P-i transport and thereby contribute to overall P-i homeostasis, Renal proximal tubular brush border membrane expresses the IIa isoform, whereas the IIb isoform is preferentially expressed in small intestinal brush border membrane of mammals. IIa and Hb proteins are predicted to contain eight transmembrane domains with the N- and C-terminal tails facing the cytoplasm. They differ in their pH dependences: the activity of IIa increases at higher pH, whereas the Db shows no or a slightly opposite pH dependence. To determine the structural domains responsible for the difference in pH sensitivity, mouse IIa and IIb chimeras were constructed, and their pH dependence was characterized, A region between the fourth and fifth transmembrane domains was required for conferring pH sensitivity to the IIa-mediated Na/P-i cotransport. Sequence comparison (IIa versus IIb) of the third extracellular loops revealed a stretch of three charged amino acids in IIa (RER) replaced by uncharged residues in IIb (GNT). Introduction of the uncharged GNT sequence (by REK) in IIa abolished its pH dependence, whereas introduction of the charged REK stretch in Tm (by GNT) led to a pH dependence similar to IIa. These findings suggest that charged residues within the third extracellular loop are involved in the pH sensitivity of IIa Na/P-i cotransporter.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland	University of Zurich	Murer, H (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		IBIS, EPIDEMIOLOGIA/O-8791-2015	de la Horra Padilla, M Carmen/0000-0002-5787-6607; Forster, Ian/0000-0003-3087-9952				AMSTUTZ M, 1985, AM J PHYSIOL, V248, pF705, DOI 10.1152/ajprenal.1985.248.5.F705; Beck L, 1998, P NATL ACAD SCI USA, V95, P5372, DOI 10.1073/pnas.95.9.5372; Berndt T. J., 1992, KIDNEY PHYSL PATHOPH, P2511; BUSCH A, 1994, P NATL ACAD SCI USA, V91, P8205, DOI 10.1073/pnas.91.17.8205; CHENG L, 1981, J BIOL CHEM, V256, P1556; CROSS HS, 1990, MINER ELECTROL METAB, V16, P115; CUSTER M, 1994, AM J PHYSIOL, V266, pF767, DOI 10.1152/ajprenal.1994.266.5.F767; DANISI G, 1991, HDB PHYSL, V2, P232; DENNIS VW, 1992, RENAL PHYSL, P1785; Forster IC, 1999, AM J PHYSIOL-RENAL, V276, pF644, DOI 10.1152/ajprenal.1999.276.4.F644; Forster IC, 1999, J PHYSIOL-LONDON, V517, P327, DOI 10.1111/j.1469-7793.1999.0327t.x; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; HARTMANN CM, 1995, PFLUG ARCH EUR J PHY, V430, P830, DOI 10.1007/BF00386183; HAYES G, 1994, J BIOL CHEM, V269, P24143; Hilfiker H, 1998, P NATL ACAD SCI USA, V95, P14564, DOI 10.1073/pnas.95.24.14564; Lambert G, 1999, PFLUG ARCH EUR J PHY, V437, P972, DOI 10.1007/s004240050869; LAMBERT G, 1999, J GEN PHYSIOL, V114, P1; Lauf PK, 1998, CELL PHYSIOL BIOCHEM, V8, P46, DOI 10.1159/000016270; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; Murer H, 1998, CURR OPIN CELL BIOL, V10, P429, DOI 10.1016/S0955-0674(98)80054-9; Murer H, 1996, KIDNEY INT, V49, P1769, DOI 10.1038/ki.1996.264; Murer H, 1996, ANNU REV PHYSIOL, V58, P607, DOI 10.1146/annurev.physiol.58.1.607; Murer H, 1997, PFLUG ARCH EUR J PHY, V433, P379, DOI 10.1007/s004240050292; MURER H, 1992, KIDNEY PHYSL PATHOPH, P2481; Noumi T, 1997, J BIOCHEM-TOKYO, V121, P661; Oberbauer R, 1996, P NATL ACAD SCI USA, V93, P4903, DOI 10.1073/pnas.93.10.4903; Stroffekova K, 1998, AM J PHYSIOL-CELL PH, V275, pC1113, DOI 10.1152/ajpcell.1998.275.4.C1113; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WERNER A, 1990, J BIOL CHEM, V265, P12331; Zhang Y, 1996, J BIOL CHEM, V271, P5741, DOI 10.1074/jbc.271.10.5741	30	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6284	6287		10.1074/jbc.275.9.6284	http://dx.doi.org/10.1074/jbc.275.9.6284			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692425	hybrid, Green Accepted			2022-12-27	WOS:000085654400037
J	Herman, A; Bignon, C; Daniel, N; Grosclaude, J; Gertler, A; Djiane, J				Herman, A; Bignon, C; Daniel, N; Grosclaude, J; Gertler, A; Djiane, J			Functional heterodimerization of prolactin and growth hormone receptors by ovine placental lactogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRUNCATED RECOMBINANT ANALOGS; SITE-DIRECTED MUTAGENESIS; EXTRACELLULAR DOMAIN; SELECTIVE MODIFICATION; SOMATOGENIC ACTIVITY; MOLECULAR-CLONING; ESCHERICHIA-COLI; RAT HEPATOCYTES; KINASE-ACTIVITY; HEPATIC TISSUE	Although homo- or heterodimerization are common mechanisms for activation of cytokine receptors, crosstalk. between two distinct receptors in this superfamily has been never shown. Here we show a physiologically relevant example indicating that such an interaction does occurs, thus raising the hypothesis that heterodimerization between distinct cytokine receptors may be a novel mechanism contributing to the diversity of cytokine signaling. These findings were documented using both surface plasmon resonance and gel filtration experiments and show that ovine placental lactogen (PL) heterodimerizes the extracellular domains (ECDs) of ruminant growth hormone receptor (GHR) and prolactin receptor (PRLR). We also show that PL or PL analogues that exhibit little or no activity in cells transfected with PRLRs and no activity in cells transfected with ovine GHRs exhibit largely enhanced activity in cells cotransfected with both PRLRs and GHRs. Furthermore, chimeric receptors consisting of cytosolic and transmembrane part of ovine GHR or ovine PRLR and ECDs of human granulocyte-macrophage colony-stimulating factor receptor (GM-CSFR) alpha or beta were constructed. Upon transfection into Chinese hamster ovary cells along with reporter luciferase gene and stimulation by GM-CSF, a significant increase in luciferase activity occurred when GM-CCFR-alpha-PRLR and GM-CSFR-beta-GHR or GM-CSFR-alpha-GHR and GM-CSRR-beta-PRLR were cotransfected. In conclusion, we show that ovine PL is capable of functional heterodimerization of GHR and PRLR and that when their cytosolic parts, coupled to the ECD of GM-CSF receptors, are heterodimerized by GM-CSF, they are capable of transducing biological signal.	Hebrew Univ Jerusalem, Fac Agr, Inst Biochem Food Sci & Nutr, IL-76100 Rehovot, Israel; INRA, Unite Endocrinol Mol, F-78352 Jouy En Josas, France; INRA, Unite Virol & Immunol Mol, F-78352 Jouy En Josas, France	Hebrew University of Jerusalem; INRAE; UDICE-French Research Universities; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Gertler, A (corresponding author), Hebrew Univ Jerusalem, Fac Agr, Inst Biochem Food Sci & Nutr, POB 12, IL-76100 Rehovot, Israel.	gertler@agri.huji.ac.il						ADAMS TE, 1990, MOL CELL ENDOCRINOL, V73, P135, DOI 10.1016/0303-7207(90)90126-S; Anders RA, 1996, J BIOL CHEM, V271, P21758, DOI 10.1074/jbc.271.36.21758; Anders RA, 1996, J EUKARYOT MICROBIOL, V43, pS13, DOI 10.1111/j.1550-7408.1996.tb04954.x; ANTHONY RV, 1995, J ANIM SCI, V73, P1861; ANTHONY RV, 1995, J REPROD FERTIL, P83; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BIGNON C, 1994, J BIOL CHEM, V269, P3318; Bignon C, 1997, J MOL ENDOCRINOL, V19, P109, DOI 10.1677/jme.0.0190109; BIGNON C, 1993, BIOTECHNIQUES, V15, P243; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; BREIER BH, 1994, ENDOCRINOLOGY, V135, P919, DOI 10.1210/en.135.3.919; BYATT JC, 1991, J ENDOCRINOL, V130, P11, DOI 10.1677/joe.0.1300011; BYATT JC, 1986, J DAIRY SCI, V69, P2066, DOI 10.3168/jds.S0022-0302(86)80638-5; BYATT JC, 1992, J ENDOCRINOL, V132, P185, DOI 10.1677/joe.0.1320185; CHAN JSD, 1976, ENDOCRINOLOGY, V98, P65, DOI 10.1210/endo-98-1-65; COLOSI P, 1989, MOL ENDOCRINOL, V3, P1462, DOI 10.1210/mend-3-9-1462; Currie MJ, 1996, GROWTH REGULAT, V6, P123; DEVLIN RH, 1994, GEN COMP ENDOCR, V95, P31, DOI 10.1006/gcen.1994.1099; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FORSYTH IA, 1986, J DAIRY SCI, V69, P886, DOI 10.3168/jds.S0022-0302(86)80479-9; FREEMARK M, 1989, J CLIN INVEST, V83, P883, DOI 10.1172/JCI113972; FREEMARK M, 1984, AM J PHYSIOL, V246, pE21, DOI 10.1152/ajpendo.1984.246.1.E21; FREEMARK M, 1986, ENDOCRINOLOGY, V118, P613, DOI 10.1210/endo-118-2-613; FREEMARK M, 1986, AM J PHYSIOL, V251, pE328, DOI 10.1152/ajpendo.1986.251.3.E328; FREEMARK M, 1982, ENDOCRINOLOGY, V110, P2201, DOI 10.1210/endo-110-6-2201; FREEMARK M, 1989, ENDOCRINOLOGY, V125, P1504, DOI 10.1210/endo-125-3-1504; FRITZ H, 1965, Z PHYSL CHEM, V342, P253; GERTLER A, 1992, J BIOL CHEM, V267, P12655; Gertler A, 1996, J BIOL CHEM, V271, P24482, DOI 10.1074/jbc.271.40.24482; Goffin V, 1996, J BIOL CHEM, V271, P16573, DOI 10.1074/jbc.271.28.16573; Helman D, 1998, J BIOL CHEM, V273, P16067, DOI 10.1074/jbc.273.26.16067; Helman D, 1997, ENDOCRINOLOGY, V138, P4069, DOI 10.1210/en.138.10.4069; Herman A, 1999, J BIOL CHEM, V274, P7631, DOI 10.1074/jbc.274.12.7631; HURLEY TW, 1977, BIOCHEMISTRY-US, V16, P5598, DOI 10.1021/bi00644a033; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Kann G, 1999, J ENDOCRINOL, V160, P365, DOI 10.1677/joe.0.1600365; KLEMPT M, 1993, ENDOCRINOLOGY, V132, P1071, DOI 10.1210/en.132.3.1071; KRIVI GG, 1989, END SOC 71 ANN M JUN; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBRUN JJ, 1995, P NATL ACAD SCI USA, V92, P4031, DOI 10.1073/pnas.92.9.4031; MARTAL J, 1975, BIOCHEM BIOPH RES CO, V65, P770, DOI 10.1016/S0006-291X(75)80212-9; Min SH, 1996, GROWTH REGULAT, V6, P144; OGAWA E, 1995, J ENDOCRINOL, V145, P87, DOI 10.1677/joe.0.1450087; REDDY S, 1978, J ENDOCRINOL, V78, P59, DOI 10.1677/joe.0.0780059; Sakal E, 1998, J ENDOCRINOL, V159, P509, DOI 10.1677/joe.0.1590509; Sakal E, 1997, J ENDOCRINOL, V152, P317, DOI 10.1677/joe.0.1520317; SANDOWSKI Y, 1995, MOL CELL ENDOCRINOL, V115, P1, DOI 10.1016/0303-7207(95)03664-S; SCOTT P, 1992, MOL CELL ENDOCRINOL, V89, P47, DOI 10.1016/0303-7207(92)90210-W; SINGH K, 1992, ENDOCRINOLOGY, V130, P2758, DOI 10.1210/en.130.5.2758; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; STATEN NR, 1993, J BIOL CHEM, V268, P18467; TCHELET A, 1995, J ENDOCRINOL, V144, P393, DOI 10.1677/joe.0.1440393; Tchelet A, 1997, MOL CELL ENDOCRINOL, V130, P141, DOI 10.1016/S0303-7207(97)00084-1; VashdiElberg D, 1996, J BIOL CHEM, V271, P5558, DOI 10.1074/jbc.271.10.5558; VASHDIELBERG D, 1995, ENDOCRINOLOGY, V136, P1258, DOI 10.1210/en.136.3.1258; WARREN WC, 1990, J ENDOCRINOL, V126, P141, DOI 10.1677/joe.0.1260141; WELLS JA, 1995, BIO-TECHNOL, V13, P647, DOI 10.1038/nbt0795-647; WELLS JA, 1993, RECENT PROG HORM RES, V48, P253	60	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6295	6301		10.1074/jbc.275.9.6295	http://dx.doi.org/10.1074/jbc.275.9.6295			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692427	hybrid, Green Published			2022-12-27	WOS:000085654400039
J	Kireeva, ML; Komissarova, N; Waugh, DS; Kashlev, M				Kireeva, ML; Komissarova, N; Waugh, DS; Kashlev, M			The 8-nucleotide-long RNA : DNA hybrid is a primary stability determinant of the RNA polymerase II elongation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; TRANSCRIPTIONAL ARREST; SOLUTION CONFORMATION; TERNARY COMPLEXES; NASCENT RNA; INITIATION; INVITRO; SITE; PURIFICATION	The sliding clamp model of transcription processivity, based on extensive studies of Escherichia coli RNA polymerase, suggests that formation of a stable elongation complex requires two distinct nucleic acid components: an 8-9-nt transcript-template hybrid, and a DNA duplex immediately downstream from the hybrid. Here, we address the minimal composition of the processive elongation complex in the eukaryotes by developing a method for promoter-independent assembly of functional elongation complex of S. cerevisiae RNA polymerase II from synthetic DNA and RNA oligonucleotides, me show that only one of the nucleic acid components, the 8-nt RNA: DNA hybrid, is necessary for the formation of a stable elongation complex with RNA polymerase II. The double-strand DNA upstream and downstream of the hybrid does not affect stability of the elongation complex. This finding reveals a significant difference in processivity determinants of RNA polymerase II and E. coli RNA polymerase. In addition, using the imperfect RNA:DNA hybrid disturbed by the mismatches in the RNA, we show that nontemplate DNA strand may reduce the elongation complex stability via the reduction of the RNA:DNA hybrid length. The structure of a "minimal stable" elongation complex suggests a key role of the RNA:DNA hybrid in RNA polymerase II processivity.	NCI, Adv Biosci Labs Inc, Basic Res Program, Frederick Canc Res & Dev Ctr,NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Kashlev, M (corresponding author), NCI, Adv Biosci Labs Inc, Basic Res Program, Frederick Canc Res & Dev Ctr,NIH, Bldg 539,Room 222, Frederick, MD 21702 USA.	mkashlev@mail.ncifcrf.gov	Kireeva, Maria/B-4391-2018	Kireeva, Maria/0000-0003-0527-3182				Asturias FJ, 1997, J MOL BIOL, V272, P536, DOI 10.1006/jmbi.1997.1273; BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; CAI H, 1987, J BIOL CHEM, V262, P298; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; COPPOLA JA, 1984, J MOL BIOL, V178, P415, DOI 10.1016/0022-2836(84)90151-7; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; DEDRICK RL, 1985, BIOCHEMISTRY-US, V24, P2245, DOI 10.1021/bi00330a019; EBEL S, 1994, EUR J BIOCHEM, V220, P703, DOI 10.1111/j.1432-1033.1994.tb18671.x; Fu JH, 1999, CELL, V98, P799, DOI 10.1016/S0092-8674(00)81514-7; Gelles J, 1998, CELL, V93, P13, DOI 10.1016/S0092-8674(00)81140-X; GRACHEV MA, 1980, FEBS LETT, V115, P23, DOI 10.1016/0014-5793(80)80718-6; Gralla JD, 1996, METHOD ENZYMOL, V273, P99; Gu WG, 1996, P NATL ACAD SCI USA, V93, P6935, DOI 10.1073/pnas.93.14.6935; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; IZBAN MG, 1995, J BIOL CHEM, V270, P2290, DOI 10.1074/jbc.270.5.2290; JOHNSTON DE, 1977, RNA POLYM, P413; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KASHLEV MA, 1990, GENE, V130, P9; Keene RG, 1999, J BIOL CHEM, V274, P11526, DOI 10.1074/jbc.274.17.11526; Koleske AJ, 1996, METHOD ENZYMOL, V273, P176; KOLODZIEJ P, 1989, MOL CELL BIOL, V9, P5387, DOI 10.1128/MCB.9.12.5387; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Komissarova N, 1998, P NATL ACAD SCI USA, V95, P14699, DOI 10.1073/pnas.95.25.14699; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; LANE AN, 1993, EUR J BIOCHEM, V215, P297, DOI 10.1111/j.1432-1033.1993.tb18035.x; Liu MY, 1998, J BIOL CHEM, V273, P25541, DOI 10.1074/jbc.273.40.25541; Mavankal G, 1996, P NATL ACAD SCI USA, V93, P2089, DOI 10.1073/pnas.93.5.2089; Mooney RA, 1999, CELL, V98, P687, DOI 10.1016/S0092-8674(00)81483-X; Mote J, 1998, J BIOL CHEM, V273, P16843, DOI 10.1074/jbc.273.27.16843; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; Poglitsch CL, 1999, CELL, V98, P791, DOI 10.1016/S0092-8674(00)81513-5; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; ROE JH, 1984, J MOL BIOL, V176, P495, DOI 10.1016/0022-2836(84)90174-8; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Samkurashvili I, 1998, MOL CELL BIOL, V18, P5343, DOI 10.1128/MCB.18.9.5343; Samkurashvili I, 1996, J BIOL CHEM, V271, P23495, DOI 10.1074/jbc.271.38.23495; Shilatifard A, 1997, CURR OPIN GENET DEV, V7, P199, DOI 10.1016/S0959-437X(97)80129-3; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; TELESNITSKY A, 1989, BIOCHEMISTRY-US, V28, P5210, DOI 10.1021/bi00438a044; Tsao KL, 1996, GENE, V169, P59, DOI 10.1016/0378-1119(95)00762-8; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Xie Z, 1996, J BIOL CHEM, V271, P11043, DOI 10.1074/jbc.271.19.11043; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	47	174	176	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6530	6536		10.1074/jbc.275.9.6530	http://dx.doi.org/10.1074/jbc.275.9.6530			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692458	hybrid			2022-12-27	WOS:000085654400070
J	Munch-Petersen, B; Knecht, W; Lenz, C; Sondergaard, L; Piskur, J				Munch-Petersen, B; Knecht, W; Lenz, C; Sondergaard, L; Piskur, J			Functional expression of a multisubstrate deoxyribonucleoside kinase from Drosophila melanogaster and its C-terminal deletion mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; LACTOBACILLUS-ACIDOPHILUS R-26; HUMAN THYMIDINE KINASE-1; DEOXYCYTIDINE KINASE; DEOXYNUCLEOSIDE KINASES; SUBSTRATE-SPECIFICITY; LOCALIZATION; PROTEIN; TYPE-1; ENZYME	The occurrence of a deoxyribonucleoside kinase in Drosophila melanogaster (Dm-dNK) with remarkably broad substrate specificity has recently been indicated (Munch-Petersen, B., Piskur, J., and Sondergaard, L. (1998) J. Biol. Chem. 273, 3926-3931). To prove that the capacity to phosphorylate all four deoxyribonucleosides is in fact associated to one polypeptide chain, partially sequenced cDNA clones, originating from the Berkeley Drosophila genome sequencing project, were searched for homology with human deoxyribonucleoside kinases. The total sequence of one cDNA clone and the corresponding genomic DNA was determined and expressed in Escherichia coli as a glutathione S-transferase fusion protein. The purified and thrombin cleaved recombinant protein phosphorylated the four deoxyribonucleosides with high turnover and K-m values similar to those of the native Dm-dNK, as well as the four ribonucleosides and many therapeutical nucleoside analogs. Dm-dNK has apparently the same origin as the mammalian kinases, thymidine kinase 2, deoxycytidine kinase, deoxyguanosine kinase, and the herpesviral thymidine kinases, but it has a unique C terminus that seems to be important for catalytic activity and specificity. The C-terminal-20 amino acids were dispensable for phosphorylation of deoxyribonucleosides but necessary for full activity with purine ribonucleosides. Removal of the C-terminal 20 amino acids increased the specific activity 2-fold, but 99% of the activity was lost after removal of the C-terminal 30 amino acids.	Roskilde Univ, Dept Chem & Life Sci, DK-4000 Roskilde, Denmark; Tech Univ Denmark, Dept Microbiol, DK-2800 Lyngby, Denmark; Univ Copenhagen, Dept Genet, DK-1353 Copenhagen, Denmark	Roskilde University; Technical University of Denmark; University of Copenhagen	Munch-Petersen, B (corresponding author), Roskilde Univ, Dept Chem & Life Sci, POB 260, DK-4000 Roskilde, Denmark.							ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; BALASUBRAMANIAM NK, 1990, J GEN VIROL, V71, P2979, DOI 10.1099/0022-1317-71-12-2979; BARKHOLT V, 1989, ANAL BIOCHEM, V177, P318, DOI 10.1016/0003-2697(89)90059-6; Black ME, 1996, J GEN VIROL, V77, P1521, DOI 10.1099/0022-1317-77-7-1521; BLACK ME, 1990, BIOCHEM BIOPH RES CO, V169, P1080, DOI 10.1016/0006-291X(90)92005-K; BOHMAN C, 1988, BIOCHEMISTRY-US, V27, P4258, DOI 10.1021/bi00412a009; BROWN DG, 1995, NAT STRUCT BIOL, V2, P876, DOI 10.1038/nsb1095-876; Champness JN, 1998, PROTEINS, V32, P350, DOI 10.1002/(SICI)1097-0134(19980815)32:3<350::AID-PROT10>3.0.CO;2-8; Chang ZF, 1998, J BIOL CHEM, V273, P12095, DOI 10.1074/jbc.273.20.12095; CHEN MS, 1978, J BIOL CHEM, V253, P1325; ERIKSSON S, 1991, BIOCHEM BIOPH RES CO, V176, P586, DOI 10.1016/S0006-291X(05)80224-4; Evans JS, 1998, J GEN VIROL, V79, P2083, DOI 10.1099/0022-1317-79-9-2083; GENTRY GA, 1992, PHARMACOL THERAPEUT, V54, P319, DOI 10.1016/0163-7258(92)90006-L; HARRISON PT, 1991, J GEN VIROL, V72, P2583, DOI 10.1099/0022-1317-72-10-2583; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Horton P., 1996, P INT SYST MOL BIOL, V4, P109; IKEDA S, 1994, BIOCHEMISTRY-US, V33, P5328, DOI 10.1021/bi00183a041; Ives DH, 1998, PROG NUCLEIC ACID RE, V59, P205; IWATSUKI N, 1967, J MOL BIOL, V29, P155, DOI 10.1016/0022-2836(67)90187-8; JENSEN RA, 1976, ANNU REV MICROBIOL, V30, P409, DOI 10.1146/annurev.mi.30.100176.002205; Johansson M, 1996, GENOMICS, V38, P450, DOI 10.1006/geno.1996.0654; Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454; Johansson M, 1999, J BIOL CHEM, V274, P23814, DOI 10.1074/jbc.274.34.23814; Johansson M, 1997, P NATL ACAD SCI USA, V94, P11941, DOI 10.1073/pnas.94.22.11941; KIT S, 1985, MICROBIOL SCI, V2, P369; Munch-Petersen B, 1998, J BIOL CHEM, V273, P3926, DOI 10.1074/jbc.273.7.3926; MUNCHPETERSEN B, 1993, J BIOL CHEM, V268, P15621; MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032; MUNSCH N, 1982, EXPERIENTIA, V38, P1197, DOI 10.1007/BF01959738; OKAZAKI R, 1964, J BIOL CHEM, V239, P269; PEARSON WR, 1991, GENOMICS, V11, P635, DOI 10.1016/0888-7543(91)90071-L; Petty EM, 1996, CYTOGENET CELL GENET, V72, P319, DOI 10.1159/000134213; Schneider U, 1999, BIOCHEMISTRY-US, V38, P4620, DOI 10.1021/bi9827060; SHERMAN MY, 1992, EMBO J, V11, P71; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; SODERLUND JCF, 1995, ADV EXP MED BIOL, V370, P201; Valentin-Hansen P, 1978, Methods Enzymol, V51, P308; Wang L, 1999, FEBS LETT, V443, P170, DOI 10.1016/S0014-5793(98)01711-6; WANG LY, 1993, J BIOL CHEM, V268, P22847; Wang LY, 1996, FEBS LETT, V390, P39, DOI 10.1016/0014-5793(96)00623-0; Wild K, 1997, PROTEIN SCI, V6, P2097	42	75	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6673	6679		10.1074/jbc.275.9.6673	http://dx.doi.org/10.1074/jbc.275.9.6673			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692477	hybrid			2022-12-27	WOS:000085654400089
J	Borza, DB; Netzer, KO; Leinonen, A; Todd, P; Cervera, J; Saus, J; Hudson, BG				Borza, DB; Netzer, KO; Leinonen, A; Todd, P; Cervera, J; Saus, J; Hudson, BG			The goodpasture autoantigen - Identification of multiple cryptic epitopes on the NC1 domain of the alpha 3(IV) collagen chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Neuroradiology	MAY   18, 1998	PHILADELPHIA, PENNSYLVANIA	Amer Soc Neuroradiol			GLOMERULAR-BASEMENT-MEMBRANE; LINKED ALPORT SYNDROME; ANTI-GBM NEPHRITIS; IV COLLAGEN; RENAL-TRANSPLANTATION; GLOBULAR DOMAIN; ALPHA-CHAINS; ALLOANTIBODIES; ANTIBODIES; PATHOGENESIS	Goodpasture (GP) disease is an autoimmune disorder in which autoantibodies against the alpha 3(TV) chain of type TV collagen bind to the glomerular and alveolar basement membranes, causing progressive glomerulonephritis and pulmonary hemorrhage, Two major conformational epitope regions have been identified on the noncollagenous domain of type IV collagen (NC1 domain) of the alpha 3(IV) chain as residues 17-31 (E-A) and 127-141 (E-B) (Netzer, K.-O. et al. (1999) J. Biol. Chem. 274, 11267-11274), To determine whether these regions are two distinct epitopes or form a single epitope, three GP sera were fractionated by affinity chromatography on immobilized NC1 chimeras containing the E-A and/or the E-B region. Four subpopulations of GP antibodies with distinct epitope specificity for the alpha 3(IV)NC1 domain were thus separated and characterized. They were designated GP(A), GP(B), GP(AB) and GP(X), to reflect their reactivity with E-A only, E-B only, both regions, and neither, respectively. Hence, regions E-A and E-B encompass critical amino acids that constitute three distinct epitopes for GP(A), GP(B), and GP(AB) antibodies, respectively, whereas the epitope for GP, antibodies is located in a different unknown region. The GP(A) antibodies were consistently immunodominant, accounting for 60-65% of the total immunoreactivity to alpha 3(IV)NC1; thus, they probably play a major role in pathogenesis. Regions E-A and E-B are held in close proximity because they jointly form the epitope for Mab3, a monoclonal antibody that competes for binding with GP autoantibodies. All GP epitopes are sequestered in the hexamer configuration of the NC1 domain found in tissues and are inaccessible for antibody binding unless dissociation of the hexamer occurs, suggesting a possible mechanism for etiology of GP disease. GP antibodies have the capacity to extract alpha 3(IV)NC1 monomers, but not dimers, from native human glomerular basement membrane hexamers, a property that may be of fundamental importance for the pathogenesis of the disease.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Inst Invest Citol, Fdn Valenciana Invest Biomed, Valencia 46010, Spain	University of Kansas; University of Kansas Medical Center	Hudson, BG (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.		Borza, Dorin-Bogdan/AAF-2156-2020	Borza, Dorin-Bogdan/0000-0003-4568-279X; Hudson, Billy/0000-0002-5420-4100; Saus, Juan/0000-0003-2082-1597	NIDDK NIH HHS [DK 18381] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018381, R37DK018381] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brainwood D, 1998, KIDNEY INT, V53, P762, DOI 10.1046/j.1523-1755.1998.00794.x; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; Dehan P, 1996, NEPHROL DIAL TRANSPL, V11, P1983, DOI 10.1093/oxfordjournals.ndt.a027085; Dehan P, 1996, NEPHROL DIAL TRANSPL, V11, P2215, DOI 10.1093/oxfordjournals.ndt.a027139; DING J, 1994, KIDNEY INT, V45, P1504, DOI 10.1038/ki.1994.196; Gunwar S, 1998, J BIOL CHEM, V273, P8767, DOI 10.1074/jbc.273.15.8767; HARLOW E, 1988, ANTIBODIES LABORATOR, P311; HELLMARK T, 1994, KIDNEY INT, V46, P823, DOI 10.1038/ki.1994.338; Hellmark T, 1999, KIDNEY INT, V55, P936, DOI 10.1046/j.1523-1755.1999.055003936.x; HUDSON BG, 1992, KIDNEY INT, V42, P179, DOI 10.1038/ki.1992.276; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; JOHANSSON C, 1991, CONNECT TISSUE RES, V25, P229, DOI 10.3109/03008209109029159; JOHANSSON C, 1992, J BIOL CHEM, V267, P24533; KAHASI TZ, 1997, J BIOL CHEM, V272, P17023; Kalluri R, 1996, J BIOL CHEM, V271, P9062, DOI 10.1074/jbc.271.15.9062; KALLURI R, 1994, KIDNEY INT, V45, P721, DOI 10.1038/ki.1994.96; Kalluri R, 1997, J CLIN INVEST, V99, P2470, DOI 10.1172/JCI119431; KALLURI R, 1995, J AM SOC NEPHROL, V6, P1178; KLEPPEL MM, 1992, KIDNEY INT, V41, P1629, DOI 10.1038/ki.1992.235; Lane D., 1988, ANTIBODIES LAB MANUA, P579; Netzer KO, 1999, J BIOL CHEM, V274, P11267, DOI 10.1074/jbc.274.16.11267; PENADES JR, 1995, EUR J BIOCHEM, V229, P754, DOI 10.1111/j.1432-1033.1995.tb20524.x; Ryan JJ, 1998, CLIN EXP IMMUNOL, V113, P17, DOI 10.1046/j.1365-2249.1998.00623.x; Sado Y, 1998, KIDNEY INT, V53, P664, DOI 10.1046/j.1523-1755.1998.00795.x; SAUS J, 1988, J BIOL CHEM, V263, P13374; WEBER M, 1988, CLIN EXP IMMUNOL, V74, P289; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564; WIESLANDER J, 1987, CLIN EXP IMMUNOL, V69, P332; WILSON CB, 1986, KIDNEY, P800	29	102	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					6030	6037		10.1074/jbc.275.8.6030	http://dx.doi.org/10.1074/jbc.275.8.6030			8	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681598	hybrid			2022-12-27	WOS:000085474500105
J	Deng, J; Pan, RQ; Wu, R				Deng, J; Pan, RQ; Wu, R			Distinct roles for amino- and carboxyl-terminal sequences of SPRR1 protein in the formation of cross-linked envelopes of conducting airway epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH PROTEINS; HUMAN EPIDERMAL-KERATINOCYTES; CORNIFIED ENVELOPE; VITAMIN-A; EXPRESSION; INVOLUCRIN; LINKING; TRANSGLUTAMINASE; DIFFERENTIATION; COMPONENTS	The small proline-rich protein, SPRR1, is a marker gene whose expression in conducting airway epithelium is elevated under a variety of conditions that enhance squamous differentiation. The purpose of this study is to elucidate the nature of the SPRR1 sequence involved in cross-linked envelope formation in a tissue/cell type, such as conducting airway epithelium, that normally does not express squamous function except after injury or maintenance in culture, For this, a Flag-SPRR1 fusion protein expression system has been developed. Using the liposome-mediated gene transfer technique on passage 1 culture of human tracheobronchial epithelial (TBE) cells, the Flag-SPRR1 fusion protein can be expressed and detected immunologically by both anti-Flag and anti-SPRR1 antibodies. The incorporation of Flag-SPRR1 fusion protein into cross-linked envelopes can be demonstrated when transfected human passage 1 TEE cultures are treated with phorbol 12-myristate 13 acetate and high calcium (1.5 mM). By deletion and site-directed mutagenesis, two distinct roles of the amino and carboxyl-terminal sequences of SPRR1 have been demonstrated. First, we demonstrated that the aminoterminal sequence of SPRR1 protein is required for the incorporation of the fusion protein into cross-linked envelopes, whereas a deletion on the carboxyl-terminal region or on the middle repetitive unit has no effect. Interestingly, insertion of a 24-amino acid peptide of monkey MUC2 repetitive sequence in the amino-terminus of SPRR1 protein had a stimulatory effect. Site-directed mutagenesis on the following amino acid residues, Lys(7), Gln(88), and Lys(89), which were found previously to participate in the cross-linked envelope formation of keratinocytes, had no detrimental effect on the incorporation. However, mutations on Grin clusters, such as Gln(4)-Gln(6) and Gln(22)-Gln(25), had detrimental effects on the incorporation. These results suggest an amino-terminal sequence-dependent and multiple crosslinked sites for the incorporation of Flag-SPRR1 fusion protein into cross-linked envelopes of cultured human TEE cells. Second, we demonstrated that the carboxyl terminus of SPRR1 protein is required for a high level of Flag-fusion protein expression, A deletion in the carboxyl region or a mutation on the last lysine residue of the carboxyl end had a detrimental effect on the level of Flag-SPRR1 fusion protein expressed in transfected cells. In contrast, there was only a slight decrease in the level of expression if the amino-terminus was deleted. Interestingly, the efficiency for fusion protein to incorporate into cross-linked envelopes was elevated by the mutation at the carboxyl end. These results suggest distinct roles, perhaps coordinately, for both amino- and carboxyl-terminal sequences in the regulation of the life cycle of SPRR1 protein in cultured TEE cells.	Univ Calif Davis, Ctr Comparat Resp Biol & Med, Dept Internal Med & Vet Anat Physiol & Cell Biol, Davis, CA 95616 USA	University of California System; University of California Davis	Wu, R (corresponding author), Univ Calif Davis, Ctr Comparat Resp Biol & Med, Dept Internal Med & Vet Anat Physiol & Cell Biol, 1 Shields Ave, Davis, CA 95616 USA.	rwu@ucdavis.edu			NIEHS NIH HHS [ES09701, ES05707, ES06230] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009701, R01ES006230] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AN G, 1994, AM J RESP CELL MOL, V10, P546, DOI 10.1165/ajrcmb.10.5.8179918; BACKENDORF C, 1992, NAT GENET, V2, P91, DOI 10.1038/ng1092-91; BADEN HP, 1987, BIOCHIM BIOPHYS ACTA, V925, P63, DOI 10.1016/0304-4165(87)90148-6; CANDI E, 1995, J BIOL CHEM, V270, P26382, DOI 10.1074/jbc.270.44.26382; Candi E, 1999, J BIOL CHEM, V274, P7226, DOI 10.1074/jbc.274.11.7226; GANG A, 1992, AM J RESP CELL MOL, V7, P104, DOI 10.1165/ajrcmb/7.1.104; GIBBS S, 1993, GENOMICS, V16, P630, DOI 10.1006/geno.1993.1240; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HUANG TH, 1994, AM J RESP CELL MOL, V10, P192, DOI 10.1165/ajrcmb.10.2.7509163; Jarnik M, 1996, J CELL SCI, V109, P1381; Kartasova T, 1996, J INVEST DERMATOL, V106, P294, DOI 10.1111/1523-1747.ep12340741; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2204, DOI 10.1128/MCB.8.5.2204; KE Y, 1988, DIFFERENTIATION, V38, P60, DOI 10.1111/j.1432-0436.1988.tb00592.x; REICHERT U, 1993, MOL BIOL SKIN, P151; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROBINSON CB, 1991, J TISSUE CULTURE MET, V13, P95; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; SIMON M, 1984, CELL, V36, P827, DOI 10.1016/0092-8674(84)90032-1; Steinert PM, 1998, J BIOL CHEM, V273, P11758, DOI 10.1074/jbc.273.19.11758; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; Tesfaigzi J, 1996, AM J RESP CELL MOL, V14, P478, DOI 10.1165/ajrcmb.14.5.8624253; WU R, 1982, GROWTH CELLS HORMONA, P641; YANKASKAS JR, 1993, AM J PHYSIOL, V264, pC1219, DOI 10.1152/ajpcell.1993.264.5.C1219; ZETTERGREN JG, 1984, P NATL ACAD SCI-BIOL, V81, P238, DOI 10.1073/pnas.81.1.238	27	7	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5739	5747		10.1074/jbc.275.8.5739	http://dx.doi.org/10.1074/jbc.275.8.5739			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681560	hybrid			2022-12-27	WOS:000085474500067
J	Wang, HY; Lee, DHS; D'Andrea, MR; Peterson, PA; Shank, RP; Reitz, AB				Wang, HY; Lee, DHS; D'Andrea, MR; Peterson, PA; Shank, RP; Reitz, AB			beta-amyloid(1-42) binds to alpha 7 nicotinic acetylcholine receptor with high affinity - Implications for Alzheimer's disease pathology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; BETA-PEPTIDE; SCAVENGER RECEPTOR; NEUROTOXICITY; EXPRESSION; MICE; PLAQUES; RELEASE; CALCIUM; SLICES	Alzheimer's disease pathology is characterized by the presence of neuritic plaques and the loss of cholinergic neurons in the brain. The underlying mechanisms leading to these events are unclear, but the 42-amino acid beta-amyloid peptide (A beta(1-42)) is involved, Immunohistochemical studies on human sporadic Alzheimer's disease brains demonstrate that A beta(1-42) and a neuronal pentameric cation channel, the alpha 7 nicotinic acetylcholine receptor (alpha 7nAChR), are both present in neuritic plaques and co-localize in individual cortical neurons. Using human brain tissues and cells that overexpress either alpha 7nAChR or amyloid precursor protein as the starting material, A beta(1-42) and alpha 7nAChR can be co-immunoprecipitated by the respective specific antibodies, suggesting that they are tightly associated. The formation of the alpha 7nAChR.A beta(1-42) complex can be efficiently suppressed by AP,,, implying that this AP sequence region contains the binding epitope, Receptor binding experiments show that A beta(1-42) and alpha 7nAChR bind with high affinity, and this interaction can be inhibited by alpha 7nAChR ligands, Human neuroblastoma cells overexpressing alpha 7nAChR are readily killed by A beta(1-42) whereas alpha 7nAChR agonists such as nicotine and epibatidine offered protection. Because A beta(1-42) inhibits alpha 7nAChR-dependent calcium activation and acetylcholine release, two processes critically involved in memory and cognitive functions, and the distribution of alpha 7nAChR correlates with neuritic plaques in Alzheimer's disease brains, we propose that interaction of the alpha 7nAChR and A beta(1-42) is a pivotal mechanism involved in the pathophysiology of Alzheimer's disease.	RW Johnson Pharmaceut Res Inst, Spring House, PA 19477 USA	Johnson & Johnson; Johnson & Johnson USA	Lee, DHS (corresponding author), RW Johnson Pharmaceut Res Inst, Rm 345,Res Bldg,McKean & Welsh Rd, Spring House, PA 19477 USA.	dlee@prius.jnj.com			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH031862] Funding Source: NIH RePORTER; NIMH NIH HHS [MH31862] Funding Source: Medline; NINDS NIH HHS [NS31862] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alonso AD, 1997, P NATL ACAD SCI USA, V94, P298, DOI 10.1073/pnas.94.1.298; Auld DS, 1998, TRENDS NEUROSCI, V21, P43, DOI 10.1016/S0166-2236(97)01144-2; Ball M, 1997, NEUROBIOL AGING, V18, pS1, DOI 10.1016/s0197-4580(97)00057-2; Breese CR, 1997, J COMP NEUROL, V387, P385, DOI 10.1002/(SICI)1096-9861(19971027)387:3<385::AID-CNE5>3.0.CO;2-X; D'Andrea MR, 1998, J HISTOCHEM CYTOCHEM, V46, P157; ElKhoury J, 1996, NATURE, V382, P716; GrootKormelink PJ, 1997, FEBS LETT, V400, P309, DOI 10.1016/S0014-5793(96)01383-X; HEUILLET E, 1994, EUR J PHARM-MOLEC PH, V269, P139, DOI 10.1016/0922-4106(94)90080-9; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kar S, 1998, J NEUROCHEM, V70, P2179; KOWALL NW, 1992, NEUROBIOL AGING, V13, P537, DOI 10.1016/0197-4580(92)90053-Z; Li YX, 1999, BRAIN RES, V830, P218, DOI 10.1016/S0006-8993(99)01372-4; LINK CD, 1995, P NATL ACAD SCI USA, V92, P9368, DOI 10.1073/pnas.92.20.9368; MATTSON MP, 1997, ALZHEIMERS DIS REV, V2, P1; Maurice T, 1996, BRAIN RES, V706, P181, DOI 10.1016/0006-8993(95)01032-7; Munch G, 1998, J NEURAL TRANSM, V105, P439, DOI 10.1007/s007020050069; Nalbantoglu J, 1997, NATURE, V387, P500, DOI 10.1038/387500a0; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; PERRY EK, 1992, J CHEM NEUROANAT, V5, P399, DOI 10.1016/0891-0618(92)90056-V; Quik M, 1997, MOL PHARMACOL, V51, P499; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SEGUELA P, 1993, J NEUROSCI, V13, P596; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; WANG HY, 1994, J NEUROCHEM, V63, P1720; WANG HY, NEUROPEPDES, V33, P197; Yan SD, 1997, NATURE, V389, P689; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; ZHAO B, 1995, J NEUROSCI RES, V40, P261, DOI 10.1002/jnr.490400215	30	660	690	0	58	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5626	5632		10.1074/jbc.275.8.5626	http://dx.doi.org/10.1074/jbc.275.8.5626			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681545	hybrid			2022-12-27	WOS:000085474500052
J	Bubb, MR; Spector, I; Beyer, BB; Fosen, KM				Bubb, MR; Spector, I; Beyer, BB; Fosen, KM			Effects of jasplakinolide on the kinetics of actin polymerization - An explanation for certain in vivo observations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; PHALLOIDIN BINDING; HEAVY-MEROMYOSIN; CULTURED-CELLS; DYNAMICS; PROFILIN; GROWTH; THYMOSIN-BETA-4; INHIBITION; FILAMENTS	Jasplakinolide paradoxically stabilizes actin filaments in vitro, but in vivo it can disrupt actin filaments and induce polymerization of monomeric actin into amorphous masses. A detailed analysis of the effects of jasplakinolide on the kinetics of actin polymerization suggests a resolution to this paradox. Jasplakinolide markedly enhances the rate of actin filament nucleation. This increase corresponds to a change in the size of actin oligomer capable of nucleating filament growth from four to approximately three subunits, which is mechanistically consistent with the localization of the jasplakinolide-binding site at an interface of three actin subunits, Because jasplakinolide both decreases the amount of sequestered actin (by lowering the critical concentration of actin) and augments nucleation, the enhancement of polymerization by jasplakinolide is amplified in the presence of actin-monomer sequestering proteins such as thymosin beta(4). Overall, the kinetic parameters in vitro define the mechanism by which jasplakinolide induces polymerization of monomeric actin in vivo, Expected consequences of jasplakinolide function are consistent with the experimental observations and include de novo nucleation resulting in disordered polymeric actin and in insufficient monomeric actin to allow for remodeling of stress fibers.	Univ Florida, Dept Med, Gainesville, FL 32610 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University System of Florida; University of Florida; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Bubb, MR (corresponding author), Univ Florida, Dept Med, Box 100277, Gainesville, FL 32610 USA.							ATTRI AK, 1991, J BIOL CHEM, V266, P6815; BERSHADSKY AD, 1995, J CELL SCI, V108, P1183; BUBB MR, 1995, BIOCHEMISTRY-US, V34, P3921, DOI 10.1021/bi00012a008; BUBB MR, 1994, J BIOL CHEM, V269, P14869; CAO LG, 1993, J CELL BIOL, V123, P173, DOI 10.1083/jcb.123.1.173; Carlier MF, 1996, J BIOL CHEM, V271, P9231, DOI 10.1074/jbc.271.16.9231; De La Cruz EM, 1996, BIOCHEMISTRY-US, V35, P14054, DOI 10.1021/bi961047t; ESTES JE, 1981, BIOCHEMISTRY-US, V20, P708, DOI 10.1021/bi00507a006; GOLDSCHMIDTCLERMONT PJ, 1992, MOL BIOL CELL, V3, P1015, DOI 10.1091/mbc.3.9.1015; HEIDECKER M, 1995, BIOCHEMISTRY-US, V34, P11017, DOI 10.1021/bi00035a007; Holzinger A, 1997, CELL MOTIL CYTOSKEL, V38, P365, DOI 10.1002/(SICI)1097-0169(1997)38:4<365::AID-CM6>3.0.CO;2-2; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Krendel MF, 1999, CELL MOTIL CYTOSKEL, V43, P296, DOI 10.1002/(SICI)1097-0169(1999)43:4<296::AID-CM3>3.0.CO;2-U; KRISTOFFERSON D, 1980, J BIOL CHEM, V255, P8567; Lee E, 1998, CELL MOTIL CYTOSKEL, V39, P122, DOI 10.1002/(SICI)1097-0169(1998)39:2<122::AID-CM3>3.0.CO;2-8; LEWIS MS, 1963, BIOCHEMISTRY-US, V2, P34, DOI 10.1021/bi00901a008; LINDBERG U, 1988, BIOCHIM BIOPHYS ACTA, V967, P391, DOI 10.1016/0304-4165(88)90102-X; McGrath JL, 1998, BIOPHYS J, V75, P2070, DOI 10.1016/S0006-3495(98)77649-0; MONTAGUE C, 1983, J MUSCLE RES CELL M, V4, P95, DOI 10.1007/BF00711960; MURAMATSU N, 1988, ANAL BIOCHEM, V168, P345, DOI 10.1016/0003-2697(88)90328-4; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; OOSAWA F, 1975, THERMODYNAMICS POLYM, P47; PANTALONI D, 1985, P NATL ACAD SCI USA, V82, P7207, DOI 10.1073/pnas.82.21.7207; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; REICHERT A, 1994, FEBS LETT, V347, P247, DOI 10.1016/0014-5793(94)00551-6; RUSCHA MF, 1981, PREP BIOCHEM, V11, P351, DOI 10.1080/00327488108061774; SCHACHMAN HK, 1959, ULTRACENTRIFUGATION, P75; SENDEROWICZ AMJ, 1995, J NATL CANCER I, V87, P46, DOI 10.1093/jnci/87.1.46; Shurety W, 1998, MOL BIOL CELL, V9, P957, DOI 10.1091/mbc.9.4.957; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Spector I, 1999, MICROSC RES TECHNIQ, V47, P18, DOI 10.1002/(SICI)1097-0029(19991001)47:1<18::AID-JEMT3>3.0.CO;2-E; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Terry DR, 1997, J BIOL CHEM, V272, P7841, DOI 10.1074/jbc.272.12.7841; TOBACMAN LS, 1983, J BIOL CHEM, V258, P8806; Tsuyama S, 1997, INT J BIOCHEM CELL B, V29, P293, DOI 10.1016/S1357-2725(96)00097-0; WALSH TP, 1984, BIOCHEMISTRY-US, V23, P6099, DOI 10.1021/bi00320a030; WEBER A, 1992, BIOCHEMISTRY-US, V31, P6179, DOI 10.1021/bi00142a002; WEHLAND J, 1977, P NATL ACAD SCI USA, V74, P5613, DOI 10.1073/pnas.74.12.5613	38	412	420	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5163	5170		10.1074/jbc.275.7.5163	http://dx.doi.org/10.1074/jbc.275.7.5163			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671562	hybrid			2022-12-27	WOS:000085378200088
J	Chiarugi, P; Cirri, P; Taddei, L; Giannoni, E; Camici, G; Manao, G; Raugei, G; Ramponi, G				Chiarugi, P; Cirri, P; Taddei, L; Giannoni, E; Camici, G; Manao, G; Raugei, G; Ramponi, G			The low M-r protein-tyrosine phosphatase is involved in Rho-mediated cytoskeleton rearrangement after integrin and platelet-derived growth factor stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; ACTIN CYTOSKELETON; C-SRC; PHOSPHORYLATION; ADHESION; EXPRESSION; ANCHORAGE; ACTIVATION; RECEPTOR; E-CDK2	The low molecular weight protein-tyrosine phosphatase (LMW-PTP) is an enzyme that is involved in the early events of platelet-derived growth factor (PDGF) receptor signal transduction, In fact, LMW-PTP is able to specifically bind and dephosphorylate activated PDGF receptor, thus modulating PDGF-induced mitogenesis. In particular, LMW-PTP is involved in pathways that regulate the transcription of the immediately early genes myc and fos in response to growth factor stimulation. Recently, we have found that LMW-PTP exists constitutively in cytosolic and cytoskeleton-associated localization and that, after PDGF stimulation, c-Src is able to bind and phosphorylate LMW-PTP only in the cytoskeleton-associated fraction. As a consequence of its phosphorylation, LMW-PTP increases its catalytic activity about 20-fold, In this study, our interest was to investigate the role of LMW-PTP phosphorylation in cellular response to PDGF stimulation, To address this issue, we have transfected in NIH-3T3 cells a mutant form of LMW-PTP in which the c-Src phosphorylation sites (Tyr(131) and Tyr(132)) were mutated to alanine, We have established that LMW-PTP phosphorylation by c-Src after PDGF treatment strongly influences both cell adhesion and migration. In addition, we have discovered a new LMW-PTP substrate localized in the cytoskeleton that becomes tyrosine-phosphorylated after PDGF treatment: p190Rho-GAP, Hence, LMW-PTP plays multiple roles in PDGF receptor-mediated mitogenesis, since it can bind and dephosphorylate PDGF receptor, and, at the same time, the cytoskeleton-associated LMW-PTP, through the regulation of the p190Rho-GAP phosphorylation state, controls the cytoskeleton rearrangement in response to PDGF stimulation.	Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy	University of Florence	Ramponi, G (corresponding author), Univ Florence, Dipartimento Sci Biochim, Viale Morgagni 50, I-50134 Florence, Italy.	raugei@cesit1.unifi.it	Chiarugi, Paola/CDD-7988-2022; Giannoni, Elisa/AAE-2092-2020; Camici, Giovanni/H-1631-2018	Chiarugi, Paola/0000-0001-7655-2969; raugei, giovanni/0000-0003-1294-786X; Giannoni, Elisa/0000-0001-7136-1098; Camici, Giovanni/0000-0002-0523-0695				Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Bucciantini M, 1999, FEBS LETT, V456, P73, DOI 10.1016/S0014-5793(99)00828-5; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Chiarugi P, 1998, J BIOL CHEM, V273, P6776, DOI 10.1074/jbc.273.12.6776; CHIARUGI P, 1995, FEBS LETT, V372, P49, DOI 10.1016/0014-5793(95)00947-8; Cirri P, 1998, J BIOL CHEM, V273, P32522, DOI 10.1074/jbc.273.49.32522; CIRRI P, 1993, BIOCHIM BIOPHYS ACTA, V1161, P216, DOI 10.1016/0167-4838(93)90216-E; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Fincham VJ, 1999, J CELL SCI, V112, P947; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; RAMPONI G, 1994, ADV PROT PHOSPHATASE, V8, P1; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rigacci S, 1996, J BIOL CHEM, V271, P1278, DOI 10.1074/jbc.271.3.1278; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; Tailor P, 1997, J BIOL CHEM, V272, P5371, DOI 10.1074/jbc.272.9.5371; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Vincent S, 1999, EUR J CELL BIOL, V78, P539, DOI 10.1016/S0171-9335(99)80019-3; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	31	77	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4640	4646		10.1074/jbc.275.7.4640	http://dx.doi.org/10.1074/jbc.275.7.4640			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671492	hybrid			2022-12-27	WOS:000085378200018
J	Karki, S; Tokito, MK; Holzbaur, ELF				Karki, S; Tokito, MK; Holzbaur, ELF			A dynactin subunit with a highly conserved cysteine-rich motif interacts directly with Arp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-RELATED PROTEIN; CYTOPLASMIC DYNEIN; COMPLEX; ORGANIZATION; BINDING; ORGANELLES; ALIGNMENT; TRANSPORT; COMPONENT; REVEALS	Dynactin is a multisubunit complex and a required cofactor for most, or all, of the cellular processes powered by the microtubule-based motor cytoplasmic dynein. Using a dynein affinity column, the previously uncharacterized p62 subunit of dynactin was isolated and microsequenced. Two peptide sequences were used to clone human cDNAs encoding p62. Sequence analysis of the predicted human polypeptide of 53 kDa revealed a highly conserved pattern of eleven cysteine residues, eight of which fit the consensus sequence for a Zn2+-binding RING domain. We have characterized p62 as an integral component of 20 S dynactin by biochemical and immunocytochemical methods. Affinity chromatography experiments demonstrate that pea binds directly to the Arp1 subunit of dynactin, Immunocytochemistry with antibodies to p62 demonstrates that this polypeptide has a punctate cytoplasmic distribution as well as centrosomal distribution typical of dynactin, In transfected cells, overexpression of p62 did not disrupt microtubule organization or the integrity of the Golgi but did cause both cytosolic and nuclear distribution of the protein, suggesting that this polypeptide may be targeted to the nucleus at very high expression levels.	Univ Penn, Dept Anim Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Holzbaur, ELF (corresponding author), 143 Rosenthal Bldg,3800 Spruce St, Philadelphia, PA 19104 USA.				NIGMS NIH HHS [GM48661] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048661] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Burd CG, 1997, MOL BIOL CELL, V8, P1089, DOI 10.1091/mbc.8.6.1089; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; Holleran EA, 1998, INT REV CYTOL, V182, P69, DOI 10.1016/S0074-7696(08)62168-3; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; Karki S, 1997, J BIOL CHEM, V272, P5887, DOI 10.1074/jbc.272.9.5887; Karki S, 1998, J CELL BIOL, V142, P1023, DOI 10.1083/jcb.142.4.1023; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Sambrooks J, 1989, MOL CLONING LAB MANU; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHAFER DA, 1994, J CELL BIOL, V126, P403, DOI 10.1083/jcb.126.2.403; Starr DA, 1998, J CELL BIOL, V142, P763, DOI 10.1083/jcb.142.3.763; Steffen W, 1997, MOL BIOL CELL, V8, P2077, DOI 10.1091/mbc.8.10.2077; Tokito MK, 1996, MOL BIOL CELL, V7, P1167, DOI 10.1091/mbc.7.8.1167; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Vierula PJ, 1997, MOL MICROBIOL, V24, P331, DOI 10.1046/j.1365-2958.1997.3461704.x; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; WatermanStorer CM, 1997, P NATL ACAD SCI USA, V94, P12180, DOI 10.1073/pnas.94.22.12180	27	30	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4834	4839		10.1074/jbc.275.7.4834	http://dx.doi.org/10.1074/jbc.275.7.4834			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671518	hybrid			2022-12-27	WOS:000085378200044
J	Lynch, J; Suh, ER; Silberg, DG; Rulyak, S; Blanchard, N; Traber, PG				Lynch, J; Suh, ER; Silberg, DG; Rulyak, S; Blanchard, N; Traber, PG			The caudal-related homeodomain protein Cdx1 inhibits proliferation of intestinal epithelial cells by down-regulation of D-type cyclins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTASE-PHLORHIZIN HYDROLASE; HOMEOBOX GENE-EXPRESSION; TRANSCRIPTION; DIFFERENTIATION; ACTIVATION; PROMOTERS; SEQUENCE; ELEMENTS; CDX-2/3; BINDING	Gdx1 is a homeodomain transcription factor that regulates intestine-specific gene expression. Experimental evidence suggests that Cdx1 may be involved in cell cycle regulation, but its role is ill defined and the mechanisms have not been explored. We used stable transfection of inducible constructs and transient expression with a replication-deficient adenovirus to induce Cdx1 expression in rat IEC6 cells, a non-transformed intestinal epithelial cell line that does not express Cdx1 protein. Expression of Cdx1 markedly reduced proliferation of IEC6 cells with accumulation of cells in the G(0)/G(1) phase of the cell cycle. Cell cycle arrest was accompanied by an increase in the hypophosphorylated forms of the retinoblastoma protein (pRb) and the pRb-related p130 protein. Protein levels of multiple cyclin-dependent kinase inhibitors were either unchanged (p16, p18, p21, p27, and p57) or were not detected (p15 and p19), Most significantly, levels of cyclins D1 and D2 were markedly diminished with Cdx1 expression, but not cyclins D3, E, or the G(1) kinases, Additionally, cyclin-dependent kinase-4 activity was decreased in association with decreased cyclin D protein, We conclude that Cdx1 regulates intestinal epithelial cell proliferation by inhibiting progression through G(0)/G(1), most likely via modulation of cyclin D1 and D2 protein levels.	Univ Penn, Div Gastroenterol, Dept Med & Genet, Philadelphia, PA 19104 USA	University of Pennsylvania	Traber, PG (corresponding author), Hosp Univ Penn, 3400 Spruce St,100 Centrex, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK049210, P30DK050306, T32DK007066] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01-DK49210, T32-DK07066, P30-DK50306] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECK F, 1995, DEV DYNAM, V204, P219, DOI 10.1002/aja.1002040302; BONNER CA, 1995, GENOMICS, V28, P206, DOI 10.1006/geno.1995.1132; BOULIKAS T, 1993, J CELL BIOCHEM, V52, P14, DOI 10.1002/jcb.240520104; BRENT R, 1997, SHORT PROTOCOLS MOL; BURGLIN TR, 1994, COMPREHENSIVE CLASSI; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; Duluc I, 1997, J CELL SCI, V110, P1317; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; EE HC, 1995, AM J PATHOL, V147, P586; GAMER LW, 1993, MECH DEVELOP, V43, P71, DOI 10.1016/0925-4773(93)90024-R; GERTZENBERG RH, 1994, J CELL BIOCHEM, V55, P22; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; JAMES R, 1991, J BIOL CHEM, V266, P3246; JAMES R, 1994, J BIOL CHEM, V269, P15229; Jin TR, 1996, MOL CELL BIOL, V16, P19; Jin TR, 1997, MOL ENDOCRINOL, V11, P203, DOI 10.1210/me.11.2.203; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; Lambert M, 1996, EUR J BIOCHEM, V236, P778, DOI 10.1111/j.1432-1033.1996.00778.x; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; MEYER BI, 1993, DEVELOPMENT, V117, P191; PETERSON MG, 1988, EUR J BIOCHEM, V174, P417, DOI 10.1111/j.1432-1033.1988.tb14114.x; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Taylor JK, 1997, NUCLEIC ACIDS RES, V25, P2293, DOI 10.1093/nar/25.12.2293; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; Traber PG, 1996, ANNU REV PHYSIOL, V58, P275, DOI 10.1146/annurev.physiol.58.1.275; Trinh KY, 1999, J BIOL CHEM, V274, P6011, DOI 10.1074/jbc.274.9.6011; TROELSEN JT, 1994, FEBS LETT, V342, P297, DOI 10.1016/0014-5793(94)80520-2; TROELSEN JT, 1992, J BIOL CHEM, V267, P20407; Troelsen JT, 1997, BIOCHEM J, V322, P833, DOI 10.1042/bj3220833; Yang D, 1998, GASTROENTEROLOGY, V114, pA707, DOI 10.1016/S0016-5085(98)82902-8	38	58	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4499	4506		10.1074/jbc.275.6.4499	http://dx.doi.org/10.1074/jbc.275.6.4499			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660624	hybrid			2022-12-27	WOS:000085288800108
J	Marino, M; Zheng, G; Chiovato, L; Pinchera, A; Brown, D; Andrews, D; McCluskey, RT				Marino, M; Zheng, G; Chiovato, L; Pinchera, A; Brown, D; Andrews, D; McCluskey, RT			Role of megalin (gp330) in transcytosis of thyroglobulin by thyroid cells - A novel function in the control of thyroid hormone release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; EPITHELIAL-CELLS; SERUM THYROGLOBULIN; HEYMANN NEPHRITIS; FOLLICLE CELLS; POTENTIAL ROLE; GENE FAMILY; PROTEIN; COMPLEXES; BINDING	When thyroglobulin (Tg) is endocytosed by thyrocytes and transported to lysosomes, thyroid hormones (T4 and T3) are released. However, some internalized Tg is transcytosed intact into the bloodstream, thereby avoiding proteolytic cleavage. Here we show that megalin (gp330), a Tg receptor on thyroid cells, plays a role in Tg transcytosis. Following incubation with exogenous rat Tg at 37 degrees C, Fisher rat thyroid (FRTL-5) cells, a differentiated thyroid cell line, released T3 into the medium. However, when cells were incubated with Tg plus either of two megalin competitors, T3 release was increased, suggesting that Tg internalized by megalin bypassed the lysosomal pathway, possibly with release of undegraded Tg from cells. To assess this possibility, we performed experiments in which FRTL-5 cells were incubated with either unlabeled or I-125-labeled Tg at 37 degrees C to allow internalization, treated with heparin to remove cell surface-bound Tg, and further incubated at 37 degrees C to allow Tg release. Intact 330-kDa Tg was released into the medium, and the amount released was markedly reduced by megalin competitors. To investigate whether Tg release resulted from transcytosis, we studied FRTL-5 cells cultured as polarized layers with tight junctions on permeable filters in the upper chamber of dual chambered devices, Following the addition of Tg to the upper chamber and incubation at 37 degrees C, intact 330-kDa Tg was found in fluids collected from the lower chamber. The amount recovered was markedly reduced by megalin competitors, indicating that megalin mediates Tg transcytosis. We also studied Tg transcytosis in vivo, using a rat model of goiter induced by aminotriazole, in which increased release of thyrotropin induces massive colloid endocytosis, This was associated with increased megalin expression on thyrocytes and increased serum Tg levels, with reduced serum T3 levels, supporting the conclusion that megalin mediates Tg transcytosis. Tg transcytosis is a novel function of megalin, which usually transports ligands to lysosomes, Megalin-mediated transcytosis may regulate the extent of thyroid hormone release.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Pathol Res Lab, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Program Membrane Biol, Charlestown, MA 02129 USA; Univ Pisa, Dept Endocrinol, I-56124 Pisa, Italy	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University of Pisa	Marino, M (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Pathol Res Lab, 149 13th St, Charlestown, MA 02129 USA.	m.marino@endoc.med.unipi.it	Chiovato, Luca/K-6617-2016; chiovato, luca/AAC-9003-2019	Chiovato, Luca/0000-0001-7457-7353; 	NIDDK NIH HHS [DK 46301, DK42956] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK042956, R01DK046301, R01DK042956, R56DK042956] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aghini-Lombardi F, 1999, J CLIN ENDOCR METAB, V84, P561, DOI 10.1210/jc.84.2.561; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; Berndorfer U, 1996, J CLIN ENDOCR METAB, V81, P1918, DOI 10.1210/jc.81.5.1918; BERNIERVALENTIN F, 1990, J BIOL CHEM, V265, P17373; BERNIERVALENTIN F, 1991, ENDOCRINOLOGY, V129, P2194, DOI 10.1210/endo-129-4-2194; BIDEY SP, 1984, J ENDOCRINOL, V101, P269, DOI 10.1677/joe.0.1010269; BIDEY SP, 1988, J ENDOCRINOL, V119, P365, DOI 10.1677/joe.0.1190365; BRIX K, 1994, J CLIN INVEST, V93, P1388, DOI 10.1172/JCI117115; Brix K, 1997, HEPATOLOGY, V26, P1232; Brix K, 1996, ENDOCRINOLOGY, V137, P1963, DOI 10.1210/en.137.5.1963; BROWN D, 1988, J ELECTRON MICR TECH, V9, P145, DOI 10.1002/jemt.1060090204; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CAVE WT, 1975, J CLIN ENDOCR METAB, V41, P590, DOI 10.1210/jcem-41-3-590; Chun JT, 1999, EXP NEUROL, V157, P194, DOI 10.1006/exnr.1999.7052; CONSIGLIO E, 1979, J BIOL CHEM, V254, P5065; Czekay RP, 1997, MOL BIOL CELL, V8, P517, DOI 10.1091/mbc.8.3.517; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; de Vijlder JJM, 1999, EUR J ENDOCRINOL, V140, P7, DOI 10.1530/eje.0.1400007; DELANGE FM, 1996, WERNER INGBARS THYRO, P296; Descamps L, 1996, AM J PHYSIOL-HEART C, V270, pH1149, DOI 10.1152/ajpheart.1996.270.4.H1149; Druetta L, 1998, EUR J ENDOCRINOL, V139, P498, DOI 10.1530/eje.0.1390498; DUNN A, 1996, WERNER INGBARS THYRO, P81; DUNN JT, 1978, J CLIN ENDOCR METAB, V47, P861, DOI 10.1210/jcem-47-4-861; EDELHOCH H, 1978, WERNERS THYROID FUND, P98; ESQUIVEL PS, 1977, J EXP MED, V145, P1250, DOI 10.1084/jem.145.5.1250; FENZI GF, 1985, CLIN ENDOCRINOL, V23, P115, DOI 10.1111/j.1365-2265.1985.tb00205.x; Fillebeen C, 1999, J BIOL CHEM, V274, P7011, DOI 10.1074/jbc.274.11.7011; GARBI C, 1988, J CELL PHYSIOL, V135, P39, DOI 10.1002/jcp.1041350106; GENTILE F, 1992, BIOCHEM BIOPH RES CO, V186, P1185, DOI 10.1016/S0006-291X(05)81531-1; Giraud A, 1997, ENDOCRINOLOGY, V138, P2325, DOI 10.1210/en.138.6.2325; HANSEN SH, 1995, J BIOL CHEM, V270, P28425; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZOG V, 1987, EMBO J, V6, P555, DOI 10.1002/j.1460-2075.1987.tb04790.x; Hilpert J, 1999, J BIOL CHEM, V274, P5620, DOI 10.1074/jbc.274.9.5620; Jung FF, 1998, KIDNEY INT, V53, P358, DOI 10.1046/j.1523-1755.1998.00766.x; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KOSTROUCH Z, 1993, ENDOCRINOLOGY, V132, P2645, DOI 10.1210/en.132.6.2645; KOUNNAS MZ, 1994, ANN NY ACAD SCI, V737, P114, DOI 10.1111/j.1749-6632.1994.tb44305.x; LEMANSKY P, 1992, EUR J BIOCHEM, V209, P111, DOI 10.1111/j.1432-1033.1992.tb17267.x; LISSITZKY S, 1975, CLIN ENDOCRINOL, V4, P363, DOI 10.1111/j.1365-2265.1975.tb01545.x; Livolsi Virginia A., 1996, P497; Lundgren S, 1997, J HISTOCHEM CYTOCHEM, V45, P383, DOI 10.1177/002215549704500306; Marino M, 1999, J BIOL CHEM, V274, P12898, DOI 10.1074/jbc.274.18.12898; McKenzie J. Maxwell, 1996, P416; MIQUELIS R, 1987, J BIOL CHEM, V262, P15291; MOESTRUP SK, 1993, J BIOL CHEM, V268, P16564; Moestrup SK, 1996, P NATL ACAD SCI USA, V93, P8612, DOI 10.1073/pnas.93.16.8612; MOSTOV KE, 1985, CELL, V43, P389, DOI 10.1016/0092-8674(85)90166-7; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; MULCAHY RT, 1985, IN VITRO CELL DEV B, V21, P513, DOI 10.1007/BF02620844; Mziaut H, 1996, ENDOCRINOLOGY, V137, P1370, DOI 10.1210/en.137.4.1370; NITSCH L, 1989, INT CONGR SER, V818, P73; Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092-8674(00)80655-8; RABITO CA, 1986, AM J PHYSIOL, V251, pF978, DOI 10.1152/ajprenal.1986.251.6.F978; RAMANUJAM KS, 1991, J BIOL CHEM, V266, P13135; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; Raychowdhury R, 1996, AM J PATHOL, V148, P1613; ROMAGNOLI P, 1991, EXP CELL RES, V194, P202, DOI 10.1016/0014-4827(91)90355-X; ROUSSET B, 1991, MOL CELL ENDOCRINOL, V78, P89; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SCHNEIDER PB, 1964, ENDOCRINOLOGY, V64, P973; Spencer Carole A., 1996, P406; STEFANSSON S, 1995, J CELL SCI, V108, P2361; STRUM JM, 1971, LAB INVEST, V24, P1; VANHERLE AJ, 1979, NEW ENGL J MED, V301, P307, DOI 10.1056/NEJM197908093010605; VANHERLE AJ, 1979, NEW ENGL J MED, V301, P239, DOI 10.1056/NEJM197908023010504; VANUIJEN AJ, 1985, ENDOCRINOLOGY, V116, P114; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; Zheng G, 1998, ENDOCRINOLOGY, V139, P1462, DOI 10.1210/en.139.3.1462; ZHENG G, 1994, ANN NY ACAD SCI, V737, P154, DOI 10.1111/j.1749-6632.1994.tb44309.x; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321; ZIMMERMANBELSIN.T, 1999, THYROID, V5, P549; Zlokovic BV, 1996, P NATL ACAD SCI USA, V93, P4229, DOI 10.1073/pnas.93.9.4229; ZURZOLO C, 1991, J CELL SCI, V98, P65	76	83	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7125	7137		10.1074/jbc.275.10.7125	http://dx.doi.org/10.1074/jbc.275.10.7125			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702280	hybrid			2022-12-27	WOS:000085809600060
J	Pedram, A; Razandi, M; Kehrl, J; Levin, ER				Pedram, A; Razandi, M; Kehrl, J; Levin, ER			Natriuretic peptides inhibit G protein activation - Mediation through cross-talk between cyclic GMP-dependent protein kinase and regulators of G protein-signaling proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; HAMSTER OVARY CELLS; RGS PROTEINS; ASTROCYTE PROLIFERATION; PHYSIOLOGICAL-ROLE; COUPLED RECEPTORS; ALPHA-SUBUNITS; FAMILY; PATHWAYS; CGMP	Atrial natriuretic peptide (ANP) inhibits the proliferation of many cells, in part through interfering with signal transduction enacted by G protein-coupled growth factor receptors. Signaling interactions between ANP and the G protein-coupled growth factor receptor ligand, endothelin-3 (ET-3), regulate astrocyte proliferation at a very proximal but undefined point. Here, we find that ANP inhibits the ability of ET-3 to activate G alpha(q), and G alpha(i) in these cells. ANP stimulated the translocation of endogenous regulators of G protein-signaling (RGS) proteins 3 and 4 from the cytosol to the cell membrane, and enhanced their association with G alpha(q) and G alpha(i). ANP effects were significantly blocked by HS-142-1, an inhibitor of guanylate cyclase activation, or by ET-3, KT5823, an inhibitor of cyclic GRIP-dependent protein kinase (PKG) reversed the RGS translocation induced by ANP; conversely, expression of an active catalytic subunit of PKG-I, or 8-bromo-cyclic GMP stimulated RGS translocation, ANP caused the phosphorylation of both RGS proteins in a PKG-dependent fashion, and the expressed PKG tin the absence of ANP) also stimulated RGS phosphorylation. A novel cross-talk between PKG and RGS proteins is stimulated by ANP and leads to the increased translocation and association of RGS proteins with G alpha. The rapid inactivation of G proteins provides a mechanism by which ANP inhibits downstream signaling to the cell proliferation program.	Long Beach VA Med Ctr, Med Serv 111I, Div Endocrinol, Long Beach, CA 90822 USA; Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA; Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92717 USA; NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Levin, ER (corresponding author), Long Beach VA Med Ctr, Med Serv 111I, Div Endocrinol, 5901 E 7th St, Long Beach, CA 90822 USA.	elevin@pop.long-beach.va.gov	Kehrl, John/AAE-6292-2019; Levin, Ellis/J-5402-2013	Kehrl, John/0000-0002-6526-159X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030521] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-30521] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aquilla E, 1996, J BIOL CHEM, V271, P31572, DOI 10.1074/jbc.271.49.31572; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Chrisman TD, 1999, J BIOL CHEM, V274, P4293, DOI 10.1074/jbc.274.7.4293; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dey NB, 1998, CIRC RES, V82, P139; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1998, J BIOL CHEM, V273, P18405, DOI 10.1074/jbc.273.29.18405; Dulin NO, 1999, MOL CELL BIOL, V19, P714; GADBOIS DM, 1992, P NATL ACAD SCI USA, V89, P8626, DOI 10.1073/pnas.89.18.8626; GRIDER JR, 1993, AM J PHYSIOL, V264, pG334, DOI 10.1152/ajpgi.1993.264.2.G334; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LEVIN ER, 1990, J BIOL CHEM, V265, P10019; LINCOLN TM, 1989, PHARMACOL THERAPEUT, V41, P479, DOI 10.1016/0163-7258(89)90127-7; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MACMILLANCROW LA, 1994, BIOCHEM BIOPH RES CO, V201, P531, DOI 10.1006/bbrc.1994.1734; MATSUDA Y, 1993, CARDIOVASC DRUG REV, V11, P45, DOI 10.1111/j.1527-3466.1993.tb00266.x; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Pedram A, 1998, J BIOL CHEM, V273, P13966, DOI 10.1074/jbc.273.22.13966; PFEIFER A, 1995, J BIOL CHEM, V270, P9052, DOI 10.1074/jbc.270.16.9052; Prins BA, 1996, J BIOL CHEM, V271, P14156, DOI 10.1074/jbc.271.24.14156; Razandi M, 1996, AM J PHYSIOL-HEART C, V270, pH1342, DOI 10.1152/ajpheart.1996.270.4.H1342; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; Sugimoto T, 1996, J BIOL CHEM, V271, P544, DOI 10.1074/jbc.271.1.544; SUZUKI E, 1991, J HYPERTENS, V9, P927; TEI M, 1990, BIOCHEM BIOPH RES CO, V167, P413, DOI 10.1016/0006-291X(90)92038-2; Wang GR, 1998, P NATL ACAD SCI USA, V95, P4888, DOI 10.1073/pnas.95.9.4888; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924	46	55	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7365	7372		10.1074/jbc.275.10.7365	http://dx.doi.org/10.1074/jbc.275.10.7365			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702309	hybrid			2022-12-27	WOS:000085809600089
J	Gidwitz, S; Lyman, S; White, GC				Gidwitz, S; Lyman, S; White, GC			Expression and function of calcium binding domain chimeras of the integrins alpha(IIb) and alpha(5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; FIBRINOGEN GAMMA-CHAIN; LIGAND-BINDING; MONOCLONAL-ANTIBODY; GPIIB-IIIA; PLATELET INTEGRIN; CELL-ADHESION; GLANZMANN THROMBASTHENIA; SELECTIVE RECOGNITION; AFFINITY MODULATION	To further identify amino acid domains involved in the ligand binding specificity of alpha(IIb)beta(3), chimeras of the conserved calcium binding domains of alpha(IIb) and the alpha subunit of the fibronectin receptor alpha(5)beta(1) were constructed. Chimeras that replaced all four calcium binding domains, replaced all but the second calcium binding domain of alpha(IIb) with those of alpha(5), or deleted all four calcium binding domains were synthesized but not expressed on the cell surface. Additional chimeras exchanged subsets or all of the variant amino acids in the second calcium binding domain, a region implicated in ligand binding. Cell surface expression of each second calcium binding domain mutant complexed with beta(3) was observed. Each second calcium binding domain mutant was able to 1) bind to immobilized fibrinogen, 2) form fibrinogen-dependent aggregates after treatment with dithiothreitol, and 3) bind the activation-dependent antibody PAC1 after LIBS 6 treatment. Soluble fibrinogen binding studies suggested that there were only small changes in either the K-d or B-max of any mutant. We conclude that chimeras of alpha(IIb) containing the second calcium binding domain sequences of alpha(5) are capable of complexing with beta(3), that the complexes are expressed on the cell surface, and that mutant complexes are capable of binding both immobilized and soluble fibrinogen, suggesting that the second calcium binding domain does not determine ligand binding specificity.	Univ N Carolina, Dept Med, Div Hematol & Oncol, Ctr Thrombosis & Hemostasis, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Gidwitz, S (corresponding author), 932 Mary Ellen Jones Bldg,231H-CB 7035, Chapel Hill, NC 27599 USA.	gidwitz@med.unc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45100] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alemany M, 1996, BLOOD, V87, P592, DOI 10.1182/blood.V87.2.592.bloodjournal872592; ANDRIEUX A, 1991, J BIOL CHEM, V266, P14202; ANDRIEUX A, 1989, J BIOL CHEM, V264, P9258; ATKINSON RA, 1994, INT J PEPT PROT RES, V43, P563; BAJT ML, 1992, J BIOL CHEM, V267, P3789; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BLUMENSTEIN M, 1992, BIOCHEMISTRY-US, V31, P10692, DOI 10.1021/bi00159a008; BROWN PJ, 1988, EXP CELL RES, V177, P303, DOI 10.1016/0014-4827(88)90464-8; CALVETE JJ, 1991, BIOCHEM J, V274, P457, DOI 10.1042/bj2740457; CALVETE JJ, 1994, THROMB HAEMOSTASIS, V72, P1; CALVETE JJ, 1993, FEBS LETT, V335, P132, DOI 10.1016/0014-5793(93)80454-3; CHARO IF, 1991, J BIOL CHEM, V266, P1415; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; COOK JJ, 1992, BIOCHIM BIOPHYS ACTA, V1119, P312, DOI 10.1016/0167-4838(92)90219-4; DICKINSON CD, 1994, J MOL BIOL, V236, P1079, DOI 10.1016/0022-2836(94)90013-2; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GINSBERG MH, 1993, THROMB HAEMOSTASIS, V70, P87; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; GULINO D, 1992, J BIOL CHEM, V267, P1001; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; Kamata T, 1996, J BIOL CHEM, V271, P18610, DOI 10.1074/jbc.271.31.18610; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; Kunicki TJ, 1996, J BIOL CHEM, V271, P20315, DOI 10.1074/jbc.271.34.20315; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANZA F, 1992, J CLIN INVEST, V89, P1995, DOI 10.1172/JCI115808; LAROSE L, 1995, J BIOL CHEM, V270, P3858, DOI 10.1074/jbc.270.8.3858; LEV S, 1993, MOL CELL BIOL, V13, P2224, DOI 10.1128/MCB.13.4.2224; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; Loftus JC, 1996, J BIOL CHEM, V271, P2033, DOI 10.1074/jbc.271.4.2033; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LU X, 1994, BIOCHEM J, V34, P929; Lyman S, 1997, J BIOL CHEM, V272, P22538, DOI 10.1074/jbc.272.36.22538; MACINTYRE DE, 1974, BIOCHEM SOC T, V2, P873, DOI 10.1042/bst0020873; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; MAYO KH, 1990, BIOCHEMISTRY-US, V29, P3277, DOI 10.1021/bi00465a019; MCEVER RP, 1983, J BIOL CHEM, V258, P5269; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MORI H, 1993, PROTEIN SCI, V2, P1621, DOI 10.1002/pro.5560021008; NEWMAN PJ, 1993, THROMB HAEMOSTASIS, V69, P1017; NEWMAN PJ, 1985, BLOOD, V65, P227; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PFAFF M, 1994, J BIOL CHEM, V269, P20233; PFAFF M, 1994, CELL ADHES COMMUN, V2, P491, DOI 10.3109/15419069409014213; PHILLIPS DR, 1988, BLOOD, V71, P831; PIDARD D, 1986, BLOOD, V67, P604; PIDARD D, 1983, J BIOL CHEM, V258, P2582; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; ROCCO M, 1993, PROTEIN SCI, V2, P2154, DOI 10.1002/pro.5560021215; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SILVER SM, 1987, BLOOD, V69, P1031; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; Suehiro K, 1997, J BIOL CHEM, V272, P5360, DOI 10.1074/jbc.272.8.5360; TAUBENFELD SM, 1995, THROMB HAEMOSTASIS, V74, P923; TAYLOR DB, 1992, J BIOL CHEM, V267, P11729; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; TUCKWELL DS, 1994, CELL ADHES COMMUN, V2, P385, DOI 10.3109/15419069409004450; VIGNALI DAA, 1994, J EXP MED, V179, P1945, DOI 10.1084/jem.179.6.1945; Xia Z, 1996, BRIT J HAEMATOL, V93, P204, DOI 10.1046/j.1365-2141.1996.445980.x; Yao LJ, 1996, BIOCHEM J, V315, P161, DOI 10.1042/bj3150161; ZUCKER MB, 1984, THROMB HAEMOSTASIS, V51, P119	73	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6680	6688		10.1074/jbc.275.9.6680	http://dx.doi.org/10.1074/jbc.275.9.6680			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692478	hybrid			2022-12-27	WOS:000085654400090
J	Klenotic, PA; Carlos, JL; Samuelson, JC; Schuenemann, TA; Tschantz, WR; Paetzel, M; Strynadka, NCJ; Dalbey, RE				Klenotic, PA; Carlos, JL; Samuelson, JC; Schuenemann, TA; Tschantz, WR; Paetzel, M; Strynadka, NCJ; Dalbey, RE			The role of the conserved Box E residues in the active site of the Escherichia coli type I signal peptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEADER PEPTIDASE; CATALYTIC MECHANISM; MOLECULAR-CLONING; BACILLUS-SUBTILIS; PLASMA-MEMBRANE; PROTEIN; GENE; SERINE; IDENTIFICATION; SEQUENCE	Type I signal peptidases are integral membrane proteins that function to remove signal peptides from secreted and membrane proteins. These enzymes carry out catalysis using a serine/lysine dyad instead of the prototypical serine/histidine/aspartic acid triad found in most serine proteases. Site-directed scanning mutagenesis was used to obtain a qualitative assessment of which residues in the fifth conserved region, Box E, of the Escherichia coli signal peptidase I are critical for maintaining a functional enzyme, First, we find that there is no requirement for activity for a salt bridge between the invariant Asp-273 and the Arg-146 residues. In addition, we show that the conserved Ser-278 is required for optimal activity as well as conserved salt bridge partners Asp-280 and Arg-282. Finally, Gly-272 is essential for signal peptidase I activity, consistent with it being located within van der Waals proximity to Ser-278 and general base Lys-145 side-chain atoms. We propose that replacement of the hydrogen side chain of Gly-212 with a methyl group results in steric crowding perturbation of the active site conformation, and specifically, disruption of the Ser-90/Lys-145 hydrogen bond. A refined model is proposed for the catalytic dyad mechanism of signal peptidase I in which the general base Lys-145 is positioned by Ser-278, which in turn is held in place by Asp-280.	Ohio State Univ, Dept Chem, Columbus, OH 43210 USA; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University System of Ohio; Ohio State University; University of British Columbia	Dalbey, RE (corresponding author), Ohio State Univ, Dept Chem, 120 W 18th Ave, Columbus, OH 43210 USA.			Paetzel, Mark/0000-0002-7408-5487	NIGMS NIH HHS [GM 08512, GM 48805] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM048805, T32GM008512] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER RK, 1987, BIOCHEMISTRY-US, V26, P8561, DOI 10.1021/bi00400a010; BLACK MT, 1992, BIOCHEM J, V282, P539, DOI 10.1042/bj2820539; BLACK MT, 1993, J BACTERIOL, V175, P4957, DOI 10.1128/JB.175.16.4957-4961.1993; Bolhuis A, 1999, J BIOL CHEM, V274, P15865, DOI 10.1074/jbc.274.22.15865; CHATTERJEE S, 1995, J MOL BIOL, V245, P311, DOI 10.1006/jmbi.1994.0025; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; Cregg KM, 1996, J BACTERIOL, V178, P5712, DOI 10.1128/jb.178.19.5712-5718.1996; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; Dalbey RE, 1997, PROTEIN SCI, V6, P1129, DOI 10.1002/pro.5560060601; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; DATE T, 1981, P NATL ACAD SCI-BIOL, V78, P6106, DOI 10.1073/pnas.78.10.6106; FIKES JD, 1990, J BIOL CHEM, V265, P3417; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; INADA T, 1989, J BACTERIOL, V171, P585, DOI 10.1128/jb.171.1.585-587.1989; ITO K, 1980, J BIOL CHEM, V255, P2123; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; KEILER KC, 1995, J BIOL CHEM, V270, P28864, DOI 10.1074/jbc.270.48.28864; KUHN A, 1985, J BIOL CHEM, V260, P5914; KUO DW, 1993, ARCH BIOCHEM BIOPHYS, V303, P274, DOI 10.1006/abbi.1993.1283; Miller J.H., 1972, EXPT MOL GENETICS; Paetzel M, 1997, J BIOL CHEM, V272, P9994; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Paetzel M, 1997, TRENDS BIOCHEM SCI, V22, P28, DOI 10.1016/S0968-0004(96)10065-7; Peat TS, 1996, NATURE, V380, P727, DOI 10.1038/380727a0; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; ROLAND KL, 1990, J BIOL CHEM, V265, P12828; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; SHEN LM, 1991, BIOCHEMISTRY-US, V30, P11775, DOI 10.1021/bi00115a006; SMITH MC, 1988, J BIOL CHEM, V263, P7211; SUNG M, 1992, J BIOL CHEM, V267, P13154; TSCHANTZ WR, 1995, BIOCHEMISTRY-US, V34, P3935, DOI 10.1021/bi00012a010; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; TSCHANTZ WR, 1994, METHOD ENZYMOL, V244, P285; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VANDIJL JM, 1990, MOL GEN GENET, V223, P233, DOI 10.1007/BF00265059; VanValkenburgh C, 1999, J BIOL CHEM, V274, P11519, DOI 10.1074/jbc.274.17.11519; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WOLFE PB, 1983, J BIOL CHEM, V258, P2073; WOLFE PB, 1982, J BIOL CHEM, V257, P7898; YADEAU JT, 1989, J BIOL CHEM, V264, P2928; ZWIZINSKI C, 1980, J BIOL CHEM, V255, P7973	42	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6490	6498		10.1074/jbc.275.9.6490	http://dx.doi.org/10.1074/jbc.275.9.6490			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692453	hybrid			2022-12-27	WOS:000085654400065
J	Lin, BY; Ma, TL; Liu, JS; Kuo, SR; Jin, G; Broker, TR; Harper, JW; Chow, LT				Lin, BY; Ma, TL; Liu, JS; Kuo, SR; Jin, G; Broker, TR; Harper, JW; Chow, LT			HeLa cells are phenotypically limiting in cyclin E/CDK2 for efficient human papillomavirus DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE ALPHA-PRIMASE; E2 BINDING-SITES; E1 PROTEIN; DEPENDENT KINASES; EUKARYOTIC CELLS; TYPE-11 ORIGIN; T-ANTIGEN; VIRAL E1; S-PHASE; HELICASE	Human papillomaviral (HPV) origin-containing plasmids replicate efficiently in human 293 cells or cell extracts in the presence of HPV origin-recognition protein E2 and replication initiation protein E1, whereas cervical carcinoma-derived, HPV-18-positive HeLa cells or cell extracts support HPV DNA replication poorly. We recently showed that HPV-11 E1 interacts with cyclin/ cyclin-dependent kinase (cdk) complexes through an RXL motif and is a substrate for these kinases, E1 mutations in this motif or in candidate cdk phosphorylation sites are impaired in replication, suggesting a role for cdks in HPV replication. We now demonstrate that one limiting activity in HeLa cells is cyclin E/CDK2, Purified cyclin E/CDK2 or cyclin E/CDK3 complex, but not other cdks, partially complemented HeLa cell extracts. Cyclin E/CDK2 expression vectors also enhanced transient HPV replication in HeLa cells, HeLa cell-derived HPV-18 E1 protein is truncated at the carboxyl terminus but can associate with cyclin E/CDK2. This truncated E1 was replication-incompetent and inhibited cell-free HPV replication, These results indicate that Beta cells are phenotypically limiting in cyclin E/CDK2 for efficient HPV replication, most likely due to sequestration by the endogenous, defective HPV-18 E1 protein. Further analyses of the regulation of HPV E1 and HPV replication by cyclin E may shed light on the roles of cyclin E/CDK2 in cellular DNA replication.	Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Alabama System; University of Alabama Birmingham; Baylor College of Medicine	Chow, LT (corresponding author), Univ Alabama, Dept Biochem & Mol Genet, 1918 Univ Blvd, Birmingham, AL 35294 USA.			Harper, Jeffrey/0000-0002-6944-7236	NATIONAL CANCER INSTITUTE [R01CA083679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054137] Funding Source: NIH RePORTER; NCI NIH HHS [CA83679] Funding Source: Medline; NIGMS NIH HHS [GM54137] Funding Source: Medline; PHS HHS [C36200] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adams PD, 1996, MOL CELL BIOL, V16, P6623; Berg M, 1997, J VIROL, V71, P3853, DOI 10.1128/JVI.71.5.3853-3863.1997; BONNEANDREA C, 1995, J VIROL, V69, P2341, DOI 10.1128/JVI.69.4.2341-2350.1995; Cannella D, 1997, CHROMOSOMA, V105, P349; CHANG ZF, 1995, J BIOL CHEM, V270, P27374, DOI 10.1074/jbc.270.45.27374; CHIANG CM, 1992, P NATL ACAD SCI USA, V89, P5799, DOI 10.1073/pnas.89.13.5799; CHIANG CM, 1992, J VIROL, V66, P5224, DOI 10.1128/JVI.66.9.5224-5231.1992; Chow Louise T., 1997, P267; CHOW LT, 1994, INTERVIROLOGY, V37, P150, DOI 10.1159/000150373; Conger KL, 1999, J BIOL CHEM, V274, P2696, DOI 10.1074/jbc.274.5.2696; Connell-Crowley L, 1998, CURR BIOL, V8, P65, DOI 10.1016/S0960-9822(98)70021-1; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Cueille N, 1998, J VIROL, V72, P7255, DOI 10.1128/JVI.72.9.7255-7262.1998; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; Fouts ET, 1999, J BIOL CHEM, V274, P4447, DOI 10.1074/jbc.274.7.4447; Gibbs E, 1996, J BIOL CHEM, V271, P22847, DOI 10.1074/jbc.271.37.22847; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; Han YF, 1999, J VIROL, V73, P4899, DOI 10.1128/JVI.73.6.4899-4907.1999; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hofmann F, 1996, GENE DEV, V10, P851, DOI 10.1101/gad.10.7.851; INAGAKI Y, 1988, J VIROL, V62, P1640, DOI 10.1128/JVI.62.5.1640-1646.1988; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Jenkins O, 1996, J GEN VIROL, V77, P1805, DOI 10.1099/0022-1317-77-8-1805; KUO SR, 1994, J BIOL CHEM, V269, P24058; Lee KY, 1998, J VIROL, V72, P4911, DOI 10.1128/JVI.72.6.4911-4917.1998; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; Leone G, 1999, P NATL ACAD SCI USA, V96, P6626, DOI 10.1073/pnas.96.12.6626; Li HY, 1997, J VIROL, V71, P6479, DOI 10.1128/JVI.71.9.6479-6485.1997; LI R, 1994, P NATL ACAD SCI USA, V91, P7051, DOI 10.1073/pnas.91.15.7051; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; Liu JS, 1998, J BIOL CHEM, V273, P30704, DOI 10.1074/jbc.273.46.30704; LIU JS, 1995, J BIOL CHEM, V270, P27283, DOI 10.1074/jbc.270.45.27283; LU JZJ, 1993, J VIROL, V67, P7131, DOI 10.1128/JVI.67.12.7131-7139.1993; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Ma TL, 1999, P NATL ACAD SCI USA, V96, P382, DOI 10.1073/pnas.96.2.382; Masterson PJ, 1998, J VIROL, V72, P7407, DOI 10.1128/JVI.72.9.7407-7419.1998; MCVEY D, 1993, J VIROL, V67, P5206, DOI 10.1128/JVI.67.9.5206-5215.1993; MELENDY T, 1995, J VIROL, V69, P7857, DOI 10.1128/JVI.69.12.7857-7867.1995; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PARK P, 1994, P NATL ACAD SCI USA, V91, P8700, DOI 10.1073/pnas.91.18.8700; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; Sedman J, 1998, J VIROL, V72, P6893, DOI 10.1128/JVI.72.8.6893-6897.1998; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STENLUND A, 1996, DNA REPLICATION EUKA, P679; SVERDRUP F, 1995, J VIROL, V69, P1319, DOI 10.1128/JVI.69.2.1319-1323.1995; Swindle CS, 1999, J VIROL, V73, P1001, DOI 10.1128/JVI.73.2.1001-1009.1999; USTAV E, 1993, P NATL ACAD SCI USA, V90, P898, DOI 10.1073/pnas.90.3.898; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Voitenleitner C, 1999, MOL CELL BIOL, V19, P646; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Weisshart K, 1999, J VIROL, V73, P2201, DOI 10.1128/JVI.73.3.2201-2211.1999; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0; Zou NX, 1998, J VIROL, V72, P3436, DOI 10.1128/JVI.72.4.3436-3441.1998	60	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6167	6174		10.1074/jbc.275.9.6167	http://dx.doi.org/10.1074/jbc.275.9.6167			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692408	hybrid			2022-12-27	WOS:000085654400020
J	Nilsson, I; Witt, S; Kiefer, H; Mingarro, I; von Heijne, G				Nilsson, I; Witt, S; Kiefer, H; Mingarro, I; von Heijne, G			Distant downstream sequence determinants can control N-tail translocation during protein insertion into the endoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRANSMEMBRANE ORIENTATION; INDEPENDENT TRANSLOCATION; TOPOLOGICAL RULES; TERMINAL TAILS; SIGNAL; INTEGRATION; SEGMENTS; SITE; GLYCOSYLATION	We have studied the membrane insertion of ProW, an Escherichia coli inner membrane protein with seven transmembrane segments and a large periplasmic N-terminal tail, into endoplasmic reticulum (ER)-derived dog pancreas microsomes. Strikingly, significant levels of N-tail translocation is seen only when a minimum of four of the transmembrane segments are present; for constructs with fewer transmembrane segments, the N-tail remains mostly nontranslocated and the majority of the molecules adopt an "inverted" topology where normally nontranslocated parts are translocated and vice versa, N-tail translocation can also be promoted by shortening of the N-tail and by the addition of positively charged residues immediately downstream of the first transmembrane segment. We conclude that as many as four consecutive transmembrane segments may be collectively involved in determining membrane protein topology in the ER and that the effects of downstream sequence determinants may vary depending on the size and charge of the N-tail, We also provide evidence to suggest that the ProW N-tail is translocated across the ER membrane in a C-to-N-terminal direction.	Univ Stockholm, Dept Biochem, S-10691 Stockholm, Sweden	Stockholm University	von Heijne, G (corresponding author), Univ Stockholm, Dept Biochem, S-10691 Stockholm, Sweden.		Nilsson, IngMarie/H-2887-2012; Mingarro, Ismael/B-4745-2014; von Heijne, Gunnar/AAH-9389-2019; von Heijne, Gunnar/F-5576-2011	Mingarro, Ismael/0000-0002-1910-1229; von Heijne, Gunnar/0000-0002-4490-8569; Kiefer, Hans/0000-0002-8574-9867				BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; CAO GQ, 1994, EMBO J, V13, P4662, DOI 10.1002/j.1460-2075.1994.tb06789.x; Cristobal S, 1999, J BIOL CHEM, V274, P20068, DOI 10.1074/jbc.274.29.20068; DALBEY RE, 1995, TRENDS CELL BIOL, V5, P380, DOI 10.1016/S0962-8924(00)89079-0; Delgado-Partin VM, 1998, J BIOL CHEM, V273, P9927, DOI 10.1074/jbc.273.16.9927; Denzer AJ, 1995, EMBO J, V14, P6311, DOI 10.1002/j.1460-2075.1995.tb00321.x; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; Goder V, 1999, J CELL BIOL, V147, P257, DOI 10.1083/jcb.147.2.257; Haardt M, 1996, J BACTERIOL, V178, P5370, DOI 10.1128/jb.178.18.5370-5381.1996; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hegde RS, 1999, TRENDS CELL BIOL, V9, P132, DOI 10.1016/S0962-8924(99)01504-4; JOHANSSON M, 1993, MOL GEN GENET, V239, P251, DOI 10.1007/BF00281625; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LILJESTROM P, 1991, J VIROL, V65, P147; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; McMurry JL, 1999, J BIOL CHEM, V274, P6776, DOI 10.1074/jbc.274.10.6776; Mitsopoulos C, 1997, FEBS LETT, V419, P18, DOI 10.1016/S0014-5793(97)01413-0; Monne M, 1999, EUR J BIOCHEM, V263, P264, DOI 10.1046/j.1432-1327.1999.00498.x; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; Nakai T, 1999, J BIOL CHEM, V274, P23647, DOI 10.1074/jbc.274.33.23647; NILSSON I, 1993, J BIOL CHEM, V268, P5798; OLIVER J, 1995, FEBS LETT, V362, P126, DOI 10.1016/0014-5793(95)00223-V; Ota K, 1998, MOL CELL, V2, P495, DOI 10.1016/S1097-2765(00)80149-5; ROTHMAN JE, 1977, NATURE, V269, P775, DOI 10.1038/269775a0; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; SHAKINESHLEMAN SH, 1993, BIOCHEMISTRY-US, V32, P9465, DOI 10.1021/bi00087a026; van Geest M, 1999, J BIOL CHEM, V274, P2816, DOI 10.1074/jbc.274.5.2816; WALLIN E, 1995, PROTEIN ENG, V8, P693, DOI 10.1093/protein/8.7.693; WHITLEY P, 1995, J BIOL CHEM, V270, P29831; WHITLEY P, 1994, NAT STRUCT BIOL, V1, P858, DOI 10.1038/nsb1294-858; WHITLEY P, 1994, EMBO J, V13, P4653, DOI 10.1002/j.1460-2075.1994.tb06788.x; Whitley P, 1996, J BIOL CHEM, V271, P6241, DOI 10.1074/jbc.271.11.6241; Zhang JT, 1998, MOL BIOL CELL, V9, P853, DOI 10.1091/mbc.9.4.853; [No title captured]	40	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6207	6213		10.1074/jbc.275.9.6207	http://dx.doi.org/10.1074/jbc.275.9.6207			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692414	hybrid, Green Published			2022-12-27	WOS:000085654400026
J	Brown, SB; Clarke, MCH; Magowan, L; Sanderson, H; Savill, J				Brown, SB; Clarke, MCH; Magowan, L; Sanderson, H; Savill, J			Constitutive death of platelets leading to scavenger receptor-mediated phagocytosis - A caspase-independent cell clearance program	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL APOPTOSIS; P-SELECTIN; PHOSPHATIDYLSERINE EXTERNALIZATION; AGING NEUTROPHILS; IN-VITRO; RECOGNITION; EXPRESSION; MACROPHAGES; DOWNSTREAM; INHIBITION	Apoptosis is a physiological program for the deletion of cells in which caspases govern events leading to safe clearance by phagocytes. However, a growing weight of evidence now suggests that not all forms of programmed cell death are caspase-dependent. We now report a complete and constitutive but caspase-independent program for the specific phagocytic clearance of intact effete platelets, anucleated blood cells of critical importance in health and disease. Platelets aged in vitro not only exhibited increased expression of proapoptotic Bah and Bar but also evidenced constitutive diminution of function such as decreased aggregation to ADP, which was accelerated by culture in the absence of plasma. This abrogation of cell function in plasma-deprived platelets was associated with morphological and biochemical features similar to those of granulocyte apoptosis, that is, cytoplasmic condensation, plasma membrane changes including exposure of phosphatidylserine and the granule protein P-selectin, and recognition by phagocyte scavenger receptors. However, and in contrast with constitutive death of other inflammatory blood cells by apoptosis, these events were not affected by caspase inhibitors, nor was there evidence of caspase-3 activation either by hydrolysis of analog peptide substrates or Western blot analysis, serving to emphasize that neither programmed cell death nor clearance by phagocytes need involve caspases.	Royal Infirm, Dept Clin & Surg Sci Internal Med, Ctr Inflammat Res, Edinburgh EH3 9YW, Midlothian, Scotland; Univ Nottingham Hosp, Dept Med, Div Renal & Inflammatory Dis, Nottingham NG7 2UH, England; Univ Nottingham Hosp, Dept Med, Div Cardiovasc Med, Nottingham NG7 2UH, England	Royal Infirmary of Edinburgh; University of Nottingham; University of Nottingham	Brown, SB (corresponding author), Univ Edinburgh, Sch Med, Ctr Inflammat Res, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	Simon.Brown@ed.ac.uk	Brown, Simon/B-3006-2009	Clarke, Murray/0000-0002-8215-8885				Bazzoni F, 1999, INT J CLIN LAB RES, V29, P41, DOI 10.1007/s005990050061; Berger G, 1998, BLOOD, V92, P4446, DOI 10.1182/blood.V92.11.4446; BEVERS EM, 1989, BIOCHEMISTRY-US, V28, P2382, DOI 10.1021/bi00432a007; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; Brown SB, 1997, BIOCHEM J, V323, P233, DOI 10.1042/bj3230233; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; DEBRUIJNEADMIRAAL LG, 1992, BLOOD, V80, P134; Dibbert B, 1998, BLOOD, V92, P778, DOI 10.1182/blood.V92.3.778.415k38_778_783; DRANSFIELD I, 1995, BLOOD, V85, P3264, DOI 10.1182/blood.V85.11.3264.bloodjournal85113264; DRANSFIELD I, 1994, J IMMUNOL, V153, P1254; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fadeel B, 1998, BLOOD, V92, P4808, DOI 10.1182/blood.V92.12.4808.424k01_4808_4818; FADOK VA, 1992, J IMMUNOL, V148, P2207; Gilligan HM, 1996, J EXP MED, V184, P2231, DOI 10.1084/jem.184.6.2231; Gwag BJ, 1999, NEUROSCIENCE, V90, P1339, DOI 10.1016/S0306-4522(98)00508-9; Hart SP, 1997, J IMMUNOL, V159, P919; HASLETT C, 1985, AM J PATHOL, V119, P101; ISRAELS SJ, 1992, BLOOD, V80, P143; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; Knepper-Nicolai B, 1998, J BIOL CHEM, V273, P30530, DOI 10.1074/jbc.273.46.30530; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LEE A, 1993, J LEUKOCYTE BIOL, V54, P283, DOI 10.1002/jlb.54.4.283; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MACMILLAN DC, 1966, NATURE, V211, P140, DOI 10.1038/211140a0; Manfredini R, 1998, ANTISENSE NUCLEIC A, V8, P341, DOI 10.1089/oli.1.1998.8.341; MANGAN DF, 1991, J IMMUNOL, V146, P1541; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; Monney L, 1998, J BIOL CHEM, V273, P6121, DOI 10.1074/jbc.273.11.6121; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; MUSSON RA, 1983, AM J PATHOL, V111, P331; Naito M, 1997, BLOOD, V89, P2060, DOI 10.1182/blood.V89.6.2060; Platt N, 1996, P NATL ACAD SCI USA, V93, P12456, DOI 10.1073/pnas.93.22.12456; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; REN Y, 1995, J IMMUNOL, V154, P2366; Ren Y, 1998, CELL DEATH DIFFER, V5, P563, DOI 10.1038/sj.cdd.4400407; RINDER HM, 1991, BLOOD, V78, P1760; Savill J, 1998, NATURE, V392, P442, DOI 10.1038/33025; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Shcherbina A, 1999, BLOOD, V93, P4222, DOI 10.1182/blood.V93.12.4222.412k34_4222_4231; Squier MKT, 1997, J IMMUNOL, V158, P3690; STUART MJ, 1975, NEW ENGL J MED, V292, P1310, DOI 10.1056/NEJM197506192922502; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vanags DM, 1997, BRIT J HAEMATOL, V99, P824, DOI 10.1046/j.1365-2141.1997.4813284.x; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Weinmann P, 1999, BLOOD, V93, P3106; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHYTE MKB, 1993, J IMMUNOL, V150, P5124; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; Zauli G, 1997, BLOOD, V90, P2234; Zhuang JG, 1998, J BIOL CHEM, V273, P15628, DOI 10.1074/jbc.273.25.15628	58	145	155	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5987	5996		10.1074/jbc.275.8.5987	http://dx.doi.org/10.1074/jbc.275.8.5987			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681593	hybrid			2022-12-27	WOS:000085474500100
J	Wang, JB; Bauman, S; Colman, RF				Wang, JB; Bauman, S; Colman, RF			Probing subunit interactions in alpha class rat liver glutathione S-transferase with the photoaffinity label glutathionyl S-[4-(succinimidyl)benzophenone]	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; NUCLEOTIDE-SEQUENCE; ETHACRYNIC-ACID; AFFINITY LABEL; BINDING SITE; ACTIVE-SITE; PI; RESISTANCE; COMPLEX; MECHANISM	Glutathionyl S-[4-(succinimidyl)benzophenone] (GS-Succ-BP), an analogue of the product of glutathione and electrophilic substrate, acts as a photoaffinity label of dimeric rat liver glutathione S-transferase (GST), isoenzyme 1-1, A time-dependent loss of enzyme activity is observed upon irradiation of the enzyme with long wavelength UV light in the presence of the reagent. The initial rate of inactivation exhibits nonlinear dependence on the concentration of the reagent, characterized by an apparent dissociation constant of the enzyme-reagent complex (K-R) of 99 +/- 2 mu M and k(max) of 0.082 +/- 0.005 min(-1). Protection against this inactivation is provided by the electrophilic substrate (ethacrynic acid), electrophilic substrate analogue (dinitrophenol), and product analogues (S-hexylglutathione and p-nitrobenzylglutathione) but not by steroids (Delta(5)-androstene-3,17-dione and 17 beta-estradiol-3,17-disulfate). These results suggest that GS-Succ-BP binds and reacts with the enzyme within the xenobiotic substrate binding site, and this reaction site is distinct from the substrate and nonsubstrate steroid binding sites of the enzyme. About 1 mol of reagent is incorporated into I mol of enzyme dimer when the enzyme is completely inactivated, Met208 is the only amino acid target of the reagent, and modification of this residue in one enzyme subunit of the GST 1-1 dimer completely abolishes the enzyme activity of both subunits, In order to evaluate the role of subunit interactions in the Alpha class glutathione S-transferases, inactive GS-Succ-BP-modified GST 1-1 was mixed with unlabeled, active GST 2-2. The enzyme subunits were dissociated in dilute trifluoroacetic acid and then renatured at pH 7.8 and separated by chromatofocusing into GST 1-1, 1-2, and 2-2, The specific activities of the heterodimer toward several substrates indicate that the loss of catalytic activity in the unmodified subunit of the modified GST 1-1 is the indirect result of the interaction between the two enzyme subunits and that this subunit interaction is absent in the heterodimer GST 1-2.	Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA	University of Delaware	Colman, RF (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.				NATIONAL CANCER INSTITUTE [R01CA066561] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA66561] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACETO A, 1992, BIOCHEM J, V285, P241, DOI 10.1042/bj2850241; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; BARYCKI JJ, 1993, BIOCHEMISTRY-US, V32, P13002, DOI 10.1021/bi00211a008; Barycki JJ, 1997, ARCH BIOCHEM BIOPHYS, V345, P16, DOI 10.1006/abbi.1997.0244; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P432, DOI 10.1002/rcm.1290031207; BENSON AM, 1989, BIOCHEM J, V261, P1023, DOI 10.1042/bj2611023; BENSON AM, 1977, P NATL ACAD SCI USA, V74, P158, DOI 10.1073/pnas.74.1.158; Board PG, 1997, BIOCHEM J, V328, P929; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER J, 1976, ANAL BIOCHEM, V75, P674, DOI 10.1016/0003-2697(76)90129-9; Caccuri AM, 1999, J BIOL CHEM, V274, P19276, DOI 10.1074/jbc.274.27.19276; CAMERON AD, 1995, STRUCTURE, V3, P717, DOI 10.1016/S0969-2126(01)00206-4; DIRR HW, 1991, BIOCHEM BIOPH RES CO, V180, P294, DOI 10.1016/S0006-291X(05)81291-4; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; ERHARDT J, 1995, EUR J BIOCHEM, V230, P614; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hu LQ, 1997, PROTEIN SCI, V6, P43; HULBERT PB, 1983, J PHARM PHARMACOL, V35, P384, DOI 10.1111/j.2042-7158.1983.tb02962.x; IVANETICH KM, 1990, BIOCHEM PHARMACOL, V39, P1999, DOI 10.1016/0006-2952(90)90621-Q; JI XH, 1995, BIOCHEMISTRY-US, V34, P5317, DOI 10.1021/bi00016a003; Ji XH, 1997, BIOCHEMISTRY-US, V36, P9690, DOI 10.1021/bi970805s; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KAPLAN W, 1997, PROTEIN SCI, V6, P299; KATUSZ RM, 1991, BIOCHEMISTRY-US, V30, P11230, DOI 10.1021/bi00111a006; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P76; LAI HCJ, 1984, J BIOL CHEM, V259, P5536; LEWIS AD, 1988, P NATL ACAD SCI USA, V85, P8511, DOI 10.1073/pnas.85.22.8511; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; McHugh TE, 1996, J BIOL CHEM, V271, P27470, DOI 10.1074/jbc.271.44.27470; MCTIGUE MA, 1995, J MOL BIOL, V246, P21, DOI 10.1006/jmbi.1994.0061; Morrow CS, 1998, J BIOL CHEM, V273, P20114, DOI 10.1074/jbc.273.32.20114; Nieslanik BS, 1999, BIOCHEMISTRY-US, V38, P6971, DOI 10.1021/bi9829130; Oakley AJ, 1997, BIOCHEMISTRY-US, V36, P576, DOI 10.1021/bi962316i; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; Penefsky H S, 1979, Methods Enzymol, V56, P527; PICKETT CB, 1984, J BIOL CHEM, V259, P5182; PUCHALSKI RB, 1990, P NATL ACAD SCI USA, V87, P2443, DOI 10.1073/pnas.87.7.2443; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; SCHRAMM VL, 1984, J BIOL CHEM, V259, P714; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; Stevens JM, 1998, BIOCHEMISTRY-US, V37, P15534, DOI 10.1021/bi981044b; TELAKOWSKIHOPKINS CA, 1986, P NATL ACAD SCI USA, V83, P9393, DOI 10.1073/pnas.83.24.9393; Van der Aar EM, 1998, DRUG METAB REV, V30, P569, DOI 10.3109/03602539808996325; Wallace LA, 1998, BIOCHEMISTRY-US, V37, P5320, DOI 10.1021/bi972936z; Wang JB, 1996, PROTEIN SCI, V5, P1032; Wang JB, 1998, BIOCHEMISTRY-US, V37, P15671, DOI 10.1021/bi981381k; WANG YH, 1993, MICROW OPT TECHN LET, V6, P268, DOI 10.1002/mop.4650060417; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x	51	24	24	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5493	5503		10.1074/jbc.275.8.5493	http://dx.doi.org/10.1074/jbc.275.8.5493			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681528	hybrid			2022-12-27	WOS:000085474500035
J	Le, F; Stomski, F; Woodcock, JM; Lopez, AF; Gonda, TJ				Le, F; Stomski, F; Woodcock, JM; Lopez, AF; Gonda, TJ			The role of disulfide-linked dimerization in interleukin-3 receptor signaling and biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; COMMON BETA-SUBUNIT; ACTIVATED PROTEIN-KINASE; GM-CSF RECEPTOR; HEMATOPOIETIC-CELLS; ALPHA-CHAIN; TYROSINE PHOSPHORYLATION; EXPRESSION CLONING; CYTOPLASMIC DOMAIN; IL-5 RECEPTORS	Cysteine residues 86 and 91 of the beta subunit of the human interleukin (hIL)-3 receptor (h beta c) participate in disulfide-linked receptor subunit heterodimerization. This linkage is essential for receptor tyrosine phosphorylation, since the Cys-86 --> Ala (Mc4) and Cys-91 --> Ala (Mc5) mutations abolished both events. Here, we used these mutants to examine whether disulfide-linked receptor dimerization affects the biological and biochemical activities of the IL-3 receptor. Murine T cells expressing hIL-3R alpha and Mc4 or Mc5 did not proliferate in hIL-3, whereas cells expressing wild-type h beta c exhibited rapid proliferation. However, a small subpopulation of cells expressing each mutant could be selected for growth in IL-3, and these proliferated similarly to cells expressing wild-type h beta c, despite failing to undergo IL-3-stimulated h beta e tyrosine phosphorylation. The Mc4 and Mc5 mutations substantially reduced, but did not abrogate, IL-3-mediated anti-apoptotic activity in the unselected populations. Moreover, the mutations abolished IL-3-induced JAK2, STAT, and AKT activation in the unselected cells, whereas activation of these molecules in IL-3-selected cells was normal. In contrast, Mc4 and Mc5 showed a limited effect on activation of Erk1 and -2 in unselected cells. These data suggest that whereas disulfide-mediated cross-linking and h beta c tyrosine phosphorylation are normally important for receptor activation, alternative mechanisms can bypass these requirements.	Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia	Institute Medical & Veterinary Science Australia	Gonda, TJ (corresponding author), Inst Med & Vet Sci, Hanson Ctr Canc Res, Frome Rd, Adelaide, SA 5000, Australia.	tom.gonda@imvs.sa.gov.au	Lopez, Angel F/E-2260-2011	Lopez, Angel F/0000-0001-7430-0135; Woodcock, Joanna/0000-0001-5127-9687				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Bagley CJ, 1997, BLOOD, V89, P1471, DOI 10.1182/blood.V89.5.1471.1471_1471_1482; Barry SC, 1997, BLOOD, V89, P842, DOI 10.1182/blood.V89.3.842; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dorsch M, 1997, J EXP MED, V186, P1947, DOI 10.1084/jem.186.12.1947; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; Guthridge MA, 1998, STEM CELLS, V16, P301, DOI 10.1002/stem.160301; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; Itoh T, 1998, MOL CELL BIOL, V18, P742, DOI 10.1128/MCB.18.2.742; Jenkins BJ, 1998, BLOOD, V92, P1989, DOI 10.1182/blood.V92.6.1989; Jenkins BJ, 1999, J BIOL CHEM, V274, P8669, DOI 10.1074/jbc.274.13.8669; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LOPEZ AF, 1991, J BIOL CHEM, V266, P24741; MIURA Y, 1994, J BIOL CHEM, V269, P29962; MORTENSEN RM, 1991, P NATL ACAD SCI USA, V88, P7036, DOI 10.1073/pnas.88.16.7036; MUTO A, 1995, BIOCHEM BIOPH RES CO, V208, P368, DOI 10.1006/bbrc.1995.1347; Okuda K, 1997, BLOOD, V90, P4759, DOI 10.1182/blood.V90.12.4759.4759_4759_4766; OKUDA K, 1992, BLOOD, V79, P2880; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; Rui LY, 1999, P NATL ACAD SCI USA, V96, P7172, DOI 10.1073/pnas.96.13.7172; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; SAKAMAKI K, 1993, J BIOL CHEM, V268, P15833; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Schiemann WP, 1997, J BIOL CHEM, V272, P16631, DOI 10.1074/jbc.272.26.16631; Stomski FC, 1998, J BIOL CHEM, V273, P1192, DOI 10.1074/jbc.273.2.1192; Stomski FC, 1996, MOL CELL BIOL, V16, P3035; Sun Q, 1999, BLOOD, V94, P1943, DOI 10.1182/blood.V94.6.1943.418k04_1943_1951; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; Watanabe S, 1997, BLOOD, V89, P1197, DOI 10.1182/blood.V89.4.1197; Watanabe S, 1996, J ALLERGY CLIN IMMUN, V98, pS183, DOI 10.1016/S0091-6749(96)70065-9; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; Woodcock JM, 1997, BLOOD, V90, P3005, DOI 10.1182/blood.V90.8.3005; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	44	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					5124	5130		10.1074/jbc.275.7.5124	http://dx.doi.org/10.1074/jbc.275.7.5124			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671557	hybrid			2022-12-27	WOS:000085378200083
J	Venturi, M; Rimon, A; Gerchman, Y; Hunte, C; Padan, E; Michel, H				Venturi, M; Rimon, A; Gerchman, Y; Hunte, C; Padan, E; Michel, H			The monoclonal antibody 1F6 identifies a pH-dependent conformational change in the hydrophilic NH(2) terminus of NhaA Na(+)/H(+) antiporter of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; EXPRESSION; ADAPTATION; PROTEINS; LYSR; ANT	One of the most interesting properties of the NhaA Na(+)/H(+) antiporter of Escherichia coli is the strong regulation of its activity by pH, This regulation is accompanied by a conformational change that can be probed by digestion with trypsin and involves the hydrophilic loop connecting the transmembrane helices VIII-M, In the present work we show that a monoclonal antibody (mAb), 1F6, recognizes yet another domain of NhaA in a pH-dependent manner. This antibody binds NhaA at pH 8.5 but not at pH 4.5, whereas two other mAbs bind to NhaA independently of pH, The epitope of mAb 1F6 was located at the NH(2) terminus of NhaA by probing proteolytic fragments in Western blot analysis and amino acid sequencing. The antibody bound to the peptide HLHR-FFSS, starting at the third amino acid of NhaA. A synthetic peptide with this sequence was shown to bind mAb 1F6 both at acidic and alkaline pH suggesting that this peptide is accessible to mAb 1F6 in the native protein only at alkaline pH. Although slightly shifted to acidic pH, the pH profile of the binding of mAb 1F6 to the antiporter is similar to that of both the Na(+)/H(+) antiporter activity as well as to its sensitivity to trypsin, We thus suggest that these pH profiles reflect a pH-dependent conformational change, which leads to activation of the antiporter, Indeed, a replacement of Gly-338 by Ser (G338S), which alleviates the pH dependence of both the NhaA activity as well as its sensitivity to trypsin, affects in a similar pattern the binding of mAb 1F6 to NhaA. Furthermore, the binding site of mAb 1F6 is involved in the functioning of the antiporter as follows: a double Cys replacement H3C/H5C causes an acidic shift by half a pH unit in the pH dependence of the antiporter; N-ethylmaleimide, which does not inhibit the wild-type protein, inhibits H3C/H5C antiporter to an extent similar to that exerted by mAb 1F6.	Max Planck Inst Biophys, Abt Mol Membranbiol, D-60528 Frankfurt, Germany; Hebrew Univ Jerusalem, Div Microbial & Mol Ecol, IL-91904 Jerusalem, Israel	Max Planck Society; Hebrew University of Jerusalem	Michel, H (corresponding author), Max Planck Inst Biophys, Abt Mol Membranbiol, Heinrich Hoffmann Str 7, D-60528 Frankfurt, Germany.	venturi@mpibp-frankfurt.mpg.de	Gerchman, Yoram/F-5226-2015; Hunte, Carola/E-4071-2015; Gerchman, Yoram/H-4698-2019	Gerchman, Yoram/0000-0002-8637-9589; Hunte, Carola/0000-0002-0826-3986; 				BELLI SI, 1994, BIOCHEM J, V304, P75, DOI 10.1042/bj3040075; Carmel O, 1997, EMBO J, V16, P5922, DOI 10.1093/emboj/16.19.5922; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; Gerchman Y, 1999, J BIOL CHEM, V274, P24617, DOI 10.1074/jbc.274.35.24617; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; Inoue H, 1999, FEBS LETT, V443, P11, DOI 10.1016/S0014-5793(98)01652-4; KARPEL R, 1991, J BIOL CHEM, V266, P21753; KING SM, 1985, P NATL ACAD SCI USA, V82, P4717, DOI 10.1073/pnas.82.14.4717; Monnet C, 1999, J BIOL CHEM, V274, P3789, DOI 10.1074/jbc.274.6.3789; Olami Y, 1997, J BIOL CHEM, V272, P1761, DOI 10.1074/jbc.272.3.1761; PADAN E, 1989, J BIOL CHEM, V264, P20297; PADAN E, 1994, BBA-BIOENERGETICS, V1185, P129, DOI 10.1016/0005-2728(94)90204-6; Padan E, 1998, FEBS LETT, V441, P53, DOI 10.1016/S0014-5793(98)01524-5; Padan E, 1998, MICR EXTREM UNUSUAL, P163; PADAN E, 1992, ALKALI CATION TRANSP, P3; PETERS JH, 1990, MONOKLONALE ANTIKORP, P330; PINNER E, 1992, J BIOL CHEM, V267, P11064; RAHAVMANOR O, 1992, J BIOL CHEM, V267, P10433; Rimon A, 1998, J BIOL CHEM, V273, P26470, DOI 10.1074/jbc.273.41.26470; RIMON A, 1995, J BIOL CHEM, V270, P26813, DOI 10.1074/jbc.270.45.26813; Rothman A, 1996, J BIOL CHEM, V271, P32288, DOI 10.1074/jbc.271.50.32288; ROTHMAN A, 1997, BIOCHEMISTRY-US, V36, P14577; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schuldiner S., 1992, ALKALI CATION TRANSP, P25; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; TAGLICHT D, 1993, J BIOL CHEM, V268, P5382; WOLF A, 1994, J BIOL CHEM, V269, P23051; Zor T, 1996, ANAL BIOCHEM, V236, P302, DOI 10.1006/abio.1996.0171	29	50	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4734	4742		10.1074/jbc.275.7.4734	http://dx.doi.org/10.1074/jbc.275.7.4734			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671505	hybrid			2022-12-27	WOS:000085378200031
J	Cha, SH; Sekine, T; Kusuhara, H; Yu, E; Kim, JY; Kim, DK; Sugiyama, Y; Kanai, Y; Endou, H				Cha, SH; Sekine, T; Kusuhara, H; Yu, E; Kim, JY; Kim, DK; Sugiyama, Y; Kanai, Y; Endou, H			Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION TRANSPORTER; RAT-KIDNEY; FUNCTIONAL EXPRESSION; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; PROTEIN; BRAIN; LIVER; IDENTIFICATION; MECHANISMS	A cDNA encoding a novel multispecific organic anion transporter, OAT4, was isolated from a human kidney cDNA library, The OAT4 cDNA consisted of 2210 base pairs that encoded a 550-amino acid residue protein with 12 putative membrane-spanning domains. The amino acid sequence of OAT4 showed 38 to 44% identity to those of other members of the OAT family. Northern blot analysis revealed that OAT4 mRNA is abundantly expressed in the placenta as well as in the kidney. When expressed in Xenopus oocytes, OAT4 mediated the high affinity transport of estrone sulfate (K-m = 1.01 mu M) and dehydroepiandrosterone sulfate (K-m = 0.63 mu M) in a sodium-independent manner. OAT4 also mediated the transport of ochratoxin A. OAT4-mediated transport of estrone Sulfate was inhibited by several sulfate conjugates, such as p-nitrophenyl sulfate, alpha-naphthyl sulfate, beta-estradiol sulfate, and 4-methylumbelliferyl sulfate. By contrast, glucuronide conjugates showed little or no inhibitory effect on the OAT4-mediated transport of estrone sulfate. OAT4 interacted with chemically heterogeneous anionic compounds, such as nonsteroidal antiinflammatory drugs, diuretics, sulfobromophthalein, penicillin G, and bile salts, whereas tetraethylammonium, an organic cation, did not. OAT4 is the first member of the multispecific organic anion transporter family, which is expressed abundantly in the placenta. OAT4 might be responsible for the elimination and detoxification of harmful anionic substances from the fetus.	Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, Mitaka, Tokyo 1818611, Japan; Univ Tokyo, Dept Biopharmaceut, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	Kyorin University; University of Tokyo	Endou, H (corresponding author), Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan.							Allikmets R, 1998, CANCER RES, V58, P5337; Angeletti RH, 1997, P NATL ACAD SCI USA, V94, P283, DOI 10.1073/pnas.94.1.283; Apiwattanakul N, 1999, MOL PHARMACOL, V55, P847; Beaulieu E, 1997, BIOCHEM J, V326, P539, DOI 10.1042/bj3260539; Bradbury MWB, 1979, CONCEPT BLOOD BRAIN; BRANCHAUD CL, 1983, J CLIN ENDOCR METAB, V56, P761, DOI 10.1210/jcem-56-4-761; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; Hosoyamada M, 1999, AM J PHYSIOL-RENAL, V276, pF122, DOI 10.1152/ajprenal.1999.276.1.F122; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; Jariyawat S, 1999, J PHARMACOL EXP THER, V290, P672; Kekuda R, 1998, J BIOL CHEM, V273, P15971, DOI 10.1074/jbc.273.26.15971; Kusuhara H, 1999, J BIOL CHEM, V274, P13675, DOI 10.1074/jbc.274.19.13675; Kuze K, 1999, J BIOL CHEM, V274, P1519, DOI 10.1074/jbc.274.3.1519; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Li LQ, 1998, J BIOL CHEM, V273, P16184, DOI 10.1074/jbc.273.26.16184; LopezNieto CE, 1997, J BIOL CHEM, V272, P6471, DOI 10.1074/jbc.272.10.6471; Lu R, 1999, AM J PHYSIOL-RENAL, V276, pF295, DOI 10.1152/ajprenal.1999.276.2.F295; Matthews JC, 1998, AM J PHYSIOL-CELL PH, V274, pC603, DOI 10.1152/ajpcell.1998.274.3.C603; Moller J. V., 1983, PHARMACOL REV, V34, P315; Morgan DJ, 1997, CLIN EXP PHARMACOL P, V24, P869, DOI 10.1111/j.1440-1681.1997.tb02707.x; Mori K, 1997, FEBS LETT, V417, P371, DOI 10.1016/S0014-5793(97)01325-2; Noe B, 1997, P NATL ACAD SCI USA, V94, P10346, DOI 10.1073/pnas.94.19.10346; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; Pardridge WM., 1991, PEPTIDE DRUG DELIVER; PETZINGER E, 1994, REV PHYSIOL BIOCH P, V123, P47, DOI 10.1007/BFb0030903; Prasad PD, 1998, J BIOL CHEM, V273, P7501, DOI 10.1074/jbc.273.13.7501; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; Race JE, 1999, BIOCHEM BIOPH RES CO, V255, P508, DOI 10.1006/bbrc.1998.9978; Rapoport SI, 1976, BLOOD BRAIN BARRIER; Schomig E, 1998, FEBS LETT, V425, P79, DOI 10.1016/S0014-5793(98)00203-8; SCHUETZ JD, 1993, J CLIN INVEST, V92, P1018, DOI 10.1172/JCI116607; Sekine T, 1998, FEBS LETT, V429, P179, DOI 10.1016/S0014-5793(98)00585-7; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; SHIMADA H, 1987, AM J PHYSIOL, V253, pF795, DOI 10.1152/ajprenal.1987.253.5.F795; SHIN BC, 1997, ENDOCRINOLOGY, V138, P3397; SIMONSON GD, 1994, J CELL SCI, V107, P1065; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; Tojo A, 1999, J AM SOC NEPHROL, V10, P464; Tsuda M, 1999, J PHARMACOL EXP THER, V289, P1301; ULLRICH KJ, 1993, CLIN INVESTIGATOR, V71, P843; Ullrich KJ, 1997, J MEMBRANE BIOL, V158, P95, DOI 10.1007/s002329900247; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879, DOI 10.1248/bpb1978.4.879	44	329	340	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4507	4512		10.1074/jbc.275.6.4507	http://dx.doi.org/10.1074/jbc.275.6.4507			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660625	hybrid			2022-12-27	WOS:000085288800109
J	Falnes, PO; Ariansen, S; Sandvig, K; Olsnes, S				Falnes, PO; Ariansen, S; Sandvig, K; Olsnes, S			Requirement for prolonged action in the cytosol for optimal protein synthesis inhibition by diphtheria toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; A-FRAGMENT; LOW PH; INTRACELLULAR STABILITY; ENTRY; CELLS; MOLECULE; TRANSLOCATION; RIBOSYLATION	Diphtheria toxin A-fragment enters the cytosol of target cells, where it inhibits protein synthesis by catalyzing ADP-ribosylation of elongation factor 2 (EF-2). We have here analyzed toxin-induced protein synthesis inhibition in single cells by autoradiography and compared it with inhibition of protein synthesis in the whole cell culture. The data show that half-maximal protein synthesis inhibition in the whole cell population after a-short incubation time is achieved by partially inhibiting protein synthesis in basically all the cells, while half-maximal protein synthesis inhibition after a long incubation time is due to a complete protein synthesis block in about half the cells in the population. We have also compared stable and unstable A-fragment mutants with respect to the kinetics of cell intoxication. While the toxicity of the stable mutants increased with time, the unstable mutants showed a similar toxicity at early and late time points. When studying the kinetics of cell intoxication by toxins with short cytosolic half-life, we could not detect any recovery of protein synthesis at late time points when all the mutant A-fragments should be degraded. This indicates that the ADP-ribosylation of EF-2 cannot be reversed by an endogenous activity in the cells. The data indicate that entry of toxin into a cell is not associated with an immediate block in protein synthesis, and that prolonged action of single A-fragment molecules in the cytosol is sufficient to obtain complete protein synthesis inhibition at low toxin concentrations.	Norwegian Radium Hosp, Inst Canc Res, N-0310 Oslo, Norway	University of Oslo	Olsnes, S (corresponding author), Norwegian Radium Hosp, Inst Canc Res, N-0310 Oslo, Norway.		Falnes, Pål Ø./AAA-4581-2020	Falnes, Pal/0000-0001-8114-6025				CARROLL SF, 1986, BIOCHEMISTRY-US, V25, P2425, DOI 10.1021/bi00357a019; COLLIER RJ, 1971, J BIOL CHEM, V246, P1496; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; DRAZIN R, 1971, J BIOL CHEM, V246, P1504; DUMONT ME, 1988, J BIOL CHEM, V263, P2087; Falnes PO, 1998, EMBO J, V17, P615, DOI 10.1093/emboj/17.2.615; FALNES PO, 1995, BIOCHEMISTRY-US, V34, P11152, DOI 10.1021/bi00035a021; FALNES PO, 1994, J BIOL CHEM, V269, P8402; FENDRICK JL, 1992, EUR J BIOCHEM, V205, P25, DOI 10.1111/j.1432-1033.1992.tb16748.x; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HONJO T, 1971, J BIOL CHEM, V246, P4251; HUDSON TH, 1985, J BIOL CHEM, V260, P2675; JIANG JX, 1991, BIOCHEMISTRY-US, V30, P3857, DOI 10.1021/bi00230a008; LEE H, 1984, P NATL ACAD SCI-BIOL, V81, P2703, DOI 10.1073/pnas.81.9.2703; MCGILL S, 1989, EMBO J, V8, P2843, DOI 10.1002/j.1460-2075.1989.tb08431.x; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2518; SANDVIG K, 1984, J CELL BIOL, V98, P963, DOI 10.1083/jcb.98.3.963; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; STENMARK H, 1992, BIOCHEM J, V281, P619, DOI 10.1042/bj2810619; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Varshavsky A, 1995, COLD SPRING HARB SYM, V60, P461, DOI 10.1101/SQB.1995.060.01.051; YAMAIZUMI M, 1982, P NATL ACAD SCI-BIOL, V79, P461, DOI 10.1073/pnas.79.2.461; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5	24	27	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4363	4368		10.1074/jbc.275.6.4363	http://dx.doi.org/10.1074/jbc.275.6.4363			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660606	hybrid			2022-12-27	WOS:000085288800090
J	Mason, JM; Beattie, BK; Liu, QR; Dumont, DJ; Barber, DL				Mason, JM; Beattie, BK; Liu, QR; Dumont, DJ; Barber, DL			The SH2 inositol 5-phosphatase Ship1 is recruited in an SH2-dependent manner to the erythropoietin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; STAT5 ACTIVATION; POLYPHOSPHATE 5-PHOSPHATASE; PHOSPHATASE SHIP; PHOSPHATIDYLINOSITOL 3-KINASE; ERYTHROID PROGENITORS; INTRACELLULAR DOMAIN; HUMAN ERYTHROBLASTS; MULTIPLE CYTOKINES; MOLECULAR-CLONING	Ship1 ((S) under bar H2 (i) under bar nositol 5-(p) under bar hosphatase (1) under bar) has been shown to be a target of tyrosine phosphorylation downstream of cytokine and immunoregulatory receptors. In addition to its catalytic activity on phosphatidylinositol substrates, it can serve as an adaptor protein in binding Shc and Grb2. Erythropoietin (EPO), the primary regulator of erythropoiesis, has been shown to activate the tyrosine phosphorylation of Shc, resulting in recruitment of Grb2, However, the mechanism by which the erythropoietin receptor (EPO-R) recruits Shc remains unknown. EPO activates the tyrosine phosphorylation of Ship1, resulting in the interdependent recruitment of Shc and Grb2, Ship1 is recruited to the EPO-R in an SH2-dependent manner. Utilizing a panel of EPO-R deletion and tyrosine mutants, we have discovered remarkable redundancy in Ship1 recruitment. EPO-R Tyr(401) appears to be a major site of Ship1 binding; however, Tyr(429) and Tyr(431) can also serve to recruit Ship1, In addition, we have shown that EPO stimulates the formation of a ternary complex consisting of Ship1, Shc, and Grb2. Ship1 may modulate several discrete signal transduction pathways. EPO-dependent activation of ERK1/2 and protein kinase B (PKB)/Akt was examined utilizing a panel of EPO-R deletion mutants. Activation of ERK1/2 was observed in EPO-R Delta 99, which retains only the most proximal tyrosine, Tyr(343). In contrast, EPO-dependent PKB activation was observed in EPO-R Delta 43, but not in EPO-R Delta 99. It appears that EPO-dependent PKB activation is downstream of a region that indirectly couples to phosphatidylinositol 3-kinase.	Ontario Canc Inst, Div Cellular & Mol Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Amgen Inst, Toronto, ON M5G 2G1, Canada; Sunnybrook & Womens Hlth Sci Ctr, Div Canc Biol, Toronto, ON M4N 3MS, Canada; Toronto Gen Hosp, Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Barber, DL (corresponding author), Ontario Canc Inst, Div Cellular & Mol Biol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Barber, Dwayne/0000-0001-5528-8150				Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Barber DL, 1997, BLOOD, V89, P55, DOI 10.1182/blood.V89.1.55.55_55_64; BARBER DL, 1994, MOL CELL BIOL, V14, P2257, DOI 10.1128/MCB.14.4.2257; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; Bergelson S, 1998, J BIOL CHEM, V273, P2396, DOI 10.1074/jbc.273.4.2396; Cheung JY, 1997, BLOOD, V89, P92, DOI 10.1182/blood.V89.1.92.92_92_100; CHEUNG JY, 1992, J CLIN INVEST, V90, P1850, DOI 10.1172/JCI116061; Coffer PJ, 1998, BIOCHEM J, V335, P1; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAMEN JE, 1993, BLOOD, V82, P2296; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; Furukawa T., 1996, Blood, V88, p145A; Geier SJ, 1997, BLOOD, V89, P1876, DOI 10.1182/blood.V89.6.1876; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; HUANG LW, 1995, ONCOGENE, V11, P2097; Huber M, 1998, EMBO J, V17, P7311, DOI 10.1093/emboj/17.24.7311; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Kralovics R, 1997, BLOOD, V90, P2057, DOI 10.1182/blood.V90.5.2057; Kralovics R., 1995, Blood, V86, p18A; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; Liu L, 1997, J BIOL CHEM, V272, P8983; Liu Q, 1997, GENOMICS, V39, P109, DOI 10.1006/geno.1996.4374; Liu QR, 1998, BLOOD, V91, P2753, DOI 10.1182/blood.V91.8.2753.2753_2753_2759; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; MILLER BA, 1989, BLOOD, V73, P1188; MILLER BA, 1994, CELL CALCIUM, V16, P481, DOI 10.1016/0143-4160(94)90078-7; Miller BA, 1999, J BIOL CHEM, V274, P20465, DOI 10.1074/jbc.274.29.20465; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Odai H, 1997, BLOOD, V89, P2745, DOI 10.1182/blood.V89.8.2745; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; SOKOL L, 1995, BLOOD, V86, P15, DOI 10.1182/blood.V86.1.15.bloodjournal86115; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Zamorano J, 1998, J IMMUNOL, V161, P859; ZHU H, 1994, J BIOL CHEM, V269, P29943	56	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4398	4406		10.1074/jbc.275.6.4398	http://dx.doi.org/10.1074/jbc.275.6.4398			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660611	hybrid			2022-12-27	WOS:000085288800095
J	Sambrano, GR; Huang, W; Faruqi, T; Mahrus, S; Craik, C; Coughlin, SR				Sambrano, GR; Huang, W; Faruqi, T; Mahrus, S; Craik, C; Coughlin, SR			Cathepsin G activates protease-activated receptor-4 in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN RECEPTOR; P-SELECTIN; POLYMORPHONUCLEAR LEUKOCYTES; CELL-SURFACE; PROTEOLYTIC MECHANISM; CATALYTIC ACTIVITY; MOLECULAR-CLONING; DEFICIENT MICE; ANTIPROTEINASES; NEUTROPHILS	Of the four known protease-activated receptors (PARs), PARI and PARE are expressed by human platelets and mediate thrombin signaling. Whether these receptors are redundant, interact, or play at least partially distinct roles is unknown. It is possible that PAR1 and/or PAR4 might confer responsiveness to proteases other than thrombin. The neutrophil granule protease, cathepsin G, is known to cause platelet secretion and aggregation. We now report that this action of cathepsin G is mediated by PAR4. Cathepsin G triggered calcium mobilization in PAR4-transfected fibroblasts, PAR4-expressing Xenopus oocytes, and washed human platelets. An antibody raised against the PAR4 thrombin cleavage site blocked platelet activation by cathepsin G but not other agonists, Desensitization with a PAR4 activating peptide had a similar effect. By contrast, inhibition of PAR1 function had no effect on platelet responses to cathepsin G. When neutrophils were present, the neutrophil agonist fMet-Leu-Phe triggered calcium signaling in Fura-2-loaded platelets. Strikingly, this neutrophil-dependent platelet activation was blocked by the PAR4 antibody. These data show that PARI mediates platelet responses to cathepsin G and support the hypothesis that cathepsin G might mediate neutrophil-platelet interactions at sites of vascular injury or inflammation.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Coughlin, SR (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, HSE-1300,505 Parnassus Ave, San Francisco, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44907] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott RE, 1998, ARCH SURG-CHICAGO, V133, P1002, DOI 10.1001/archsurg.133.9.1002; Bernatowicz MS, 1996, J MED CHEM, V39, P4879, DOI 10.1021/jm960455s; BROZNA JP, 1990, SEMIN THROMB HEMOST, V16, P326, DOI 10.1055/s-2007-1002685; CERLETTI C, 1995, THROMB HAEMOSTASIS, V74, P218; CHEN J, 1994, J BIOL CHEM, V269, P16041; DELMASCHIO A, 1990, AM J PHYSIOL, V258, pH870, DOI 10.1152/ajpheart.1990.258.3.H870; EVANGELISTA V, 1993, BLOOD, V81, P2947; EVANGELISTA V, 1991, BLOOD, V77, P2379; Frenette PS, 1996, CELL, V84, P563, DOI 10.1016/S0092-8674(00)81032-6; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; LAROSA CA, 1994, J VASC SURG, V19, P306, DOI 10.1016/S0741-5214(94)70106-7; MOLINO M, 1992, BIOCHEM J, V288, P741, DOI 10.1042/bj2880741; MOLINO M, 1995, J BIOL CHEM, V270, P11168, DOI 10.1074/jbc.270.19.11168; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; NORMAN KE, 1995, BLOOD, V86, P4417, DOI 10.1182/blood.V86.12.4417.bloodjournal86124417; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; OWEN CA, 1995, J IMMUNOL, V155, P5803; OWEN CA, 1995, J CELL BIOL, V131, P775, DOI 10.1083/jcb.131.3.775; Owen CA, 1999, J LEUKOCYTE BIOL, V65, P137, DOI 10.1002/jlb.65.2.137; SELAK MA, 1990, BIOCHEM J, V266, P55, DOI 10.1042/bj2660055; SELAK MA, 1994, BIOCHEM J, V297, P269, DOI 10.1042/bj2970269; Si-Tahar M, 1997, J BIOL CHEM, V272, P11636; Subramaniam M, 1996, BLOOD, V87, P1238, DOI 10.1182/blood.V87.4.1238.bloodjournal8741238; Trejo J, 1996, J BIOL CHEM, V271, P21536, DOI 10.1074/jbc.271.35.21536; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Weksler BB, 1988, INFLAMMATION BASIC P, P543; Williams J W, 1979, Methods Enzymol, V63, P437; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; Yang SQ, 1998, J MOL BIOL, V279, P1001, DOI 10.1006/jmbi.1998.1749	33	267	274	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6819	6823		10.1074/jbc.275.10.6819	http://dx.doi.org/10.1074/jbc.275.10.6819			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702240	hybrid			2022-12-27	WOS:000085809600020
J	Schuler, M; Bossy-Wetzel, E; Goldstein, JC; Fitzgerald, P; Green, DR				Schuler, M; Bossy-Wetzel, E; Goldstein, JC; Fitzgerald, P; Green, DR			p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTANT; ENCODING HUMAN P53; P53-DEPENDENT APOPTOSIS; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; P53-MEDIATED APOPTOSIS; INTERACTING PROTEIN; CELL-DEATH; DNA-DAMAGE; IN-VIVO	The p53 tumor suppressor gene is critically involved in cell cycle regulation, DNA repair, and programmed cell death, Several lines of evidence suggest that p53 death signals lead to caspase activation; however, the mechanism of caspase activation by p53 still is unclear. Expressing wild type p53 by means of an adenoviral expression vector, we were able to induce apoptotic cell death, as characterized by morphological changes, phosphatidylserine externalization, and internucleosomal DNA fragmentation, in p53(null) Saos-2 cells. This cell death was accompanied by caspase activation as well as by cleavage of caspase substrates and was preceded by mitochondrial cytochrome c release. The addition of the broad-spectrum caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone (zVAD-fmk) directly after transduction almost completely prevented p53-induced apoptotic cell death but did not inhibit mitochondrial cytochrome c release. In contrast, N-acetylcysteine, even at high concentrations, could not prevent induction of programmed cell death by p53 expression. Cytosolic extracts from Saos-2 cells transduced with p53, but not from Saos-2 cells transduced with the empty adenoviral vector, contained a cytochrome c-releasing activity in vitro, which was still active in the presence of zVAD-fmk, When Bar was immunodepleted from the cytosolic extracts of p53 expressing cells before incubation with isolated mitochondria, the in vitro cytochrome c release was abolished. Thus, we could demonstrate in cells and in vitro that p53 activates the apoptotic machinery through induction of the release of cytochrome c from the mitochondrial intermembrane space. Furthermore, we provide in vitro evidence for the requirement of cytosolic Bar for this cytochrome c-releasing activity of p53 in Saos-2 cells.	La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA	La Jolla Institute for Immunology	Green, DR (corresponding author), La Jolla Inst Allergy & Immunol, Div Cellular Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	dgreen5240@aol.com	Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040646] Funding Source: NIH RePORTER; NCI NIH HHS [CA69831] Funding Source: Medline; NIAID NIH HHS [AI40646] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DELRUIZRUIZ MC, 1999, CELL DEATH DIFFER, V6, P271; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Fuchs EJ, 1997, CANCER RES, V57, P2550; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; HUYGHE BG, 1995, HUM GENE THER, V6, P1403, DOI 10.1089/hum.1995.6.11-1403; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Sheikh MS, 1998, CANCER RES, V58, P1593; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Westphal EM, 1999, CANCER RES, V59, P1485; WILLS KN, 1994, HUM GENE THER, V5, P1079, DOI 10.1089/hum.1994.5.9-1079; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu YJ, 1998, CANCER RES, V58, P4277; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	62	447	453	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					7337	7342		10.1074/jbc.275.10.7337	http://dx.doi.org/10.1074/jbc.275.10.7337			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702305	hybrid			2022-12-27	WOS:000085809600085
J	Cieslar, JH; Dobson, GP				Cieslar, JH; Dobson, GP			Free [ADP] and aerobic muscle work follow at least second order kinetics in rat gastrocnemius in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP HYDROLYSIS EQUILIBRIA; SKELETAL-MUSCLE; MAGNETIC-RESONANCE; CREATINE-KINASE; P-31 NMR; OXIDATIVE-PHOSPHORYLATION; MITOCHONDRIAL-FUNCTION; OXYGEN-CONSUMPTION; ADENYLATE KINASE; METABOLISM	The relationship between free cytosolic [ADP] land [P-i]) and steady-state aerobic muscle work in rat gastrocnemius muscle in vivo using P-31 NMR was investigated. Anesthetized rats were ventilated and placed in a custom-built cradle fitted with a force transducer that could be placed into a 7-tesla NMR magnet. Muscle work was induced by supramaximal sciatic nerve stimulation that activated all fibers, Muscles were stimulated at 0.1, 0.2, 0.3, 0.4, 0.5, 0.8, 1.0, and 2.0 Hz until twitch force, phosphocreatine, and P-i were unchanged between two consecutive spectra acquired in 4-min blocks (8-12 min), Parallel bench experiments were performed to measure total tissue glycogen, lactate, total creatine, and pyruvate in freeze-clamped muscles after 10 min of stimulation at each frequency. Up to 0.5 Hz, there was no significant change in muscle glycogen, lactate, and the lactate/pyruvate ratios between 8-12 min. At 0.8 Hz, there was a 17% fall in glycogen and a 65% rise in the muscle lactate with a concomitant fall in pH, Above this frequency, glycogen fell rapidly, lactate continued to rise, and ATP and pH declined. On the basis of these force and metabolic measurements, we estimated the maximal mitochondrial capacity (V-max) to be 0.8 Hz. Free [ADP] was then calculated at each submaximal workload from measuring all the reactants of the creatine kinase equilibrium after adjusting the K'(CK) to the muscle temp (30 degrees C), pH, and pMg, We show that ADP (and P-i) and tension-time integral follow a Pill relationship with at least a second order function. The K-0.5 values for free [ADP] and [P-i] were 48 mu M and 9 mM, respectively. Our data did not fit any form of the Michaelis-Menten equation. We therefore conclude that free cytosolic [ADP] and [P-i] could potentially control steady-state oxidative phosphorylation in skeletal muscle in vitro.	James Cook Univ N Queensland, Sch Biomol Sci, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia; James Cook Univ N Queensland, Sch Mol Sci, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia	James Cook University; James Cook University	Dobson, GP (corresponding author), James Cook Univ N Queensland, Sch Biomol Sci, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia.	geoffrey.dobson@jcu.edu.au						ARGOV Z, 1987, J APPL PHYSIOL, V63, P1428, DOI 10.1152/jappl.1987.63.4.1428; Arnold S, 1999, FEBS LETT, V443, P105, DOI 10.1016/S0014-5793(98)01694-9; Arnold S, 1997, EUR J BIOCHEM, V249, P350, DOI 10.1111/j.1432-1033.1997.t01-1-00350.x; Atkinson D, 1977, CELLULAR METABOLISM; BALABAN RS, 1990, AM J PHYSIOL, V258, pC377, DOI 10.1152/ajpcell.1990.258.3.C377; BALABAN RS, 1986, SCIENCE, V232, P1121, DOI 10.1126/science.3704638; BALABAN RS, 1993, CARDIAC MED RESONANC, V258, P93; BRAUNWALD E, 1971, AM J CARDIOL, V27, P416, DOI 10.1016/0002-9149(71)90439-5; BRINDLE KM, 1989, BIOCHEMISTRY-US, V28, P4887, DOI 10.1021/bi00437a054; CHANCE B, 1955, J BIOL CHEM, V217, P383; CHANCE B, 1985, P NATL ACAD SCI USA, V82, P8384, DOI 10.1073/pnas.82.24.8384; CHANCE B, 1986, P NATL ACAD SCI USA, V83, P9458, DOI 10.1073/pnas.83.24.9458; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; CHANCE B, 1988, MAGNETIC RESONANCE I, V2, P1501; Cieslar J, 1998, AM J PHYSIOL-REG I, V275, pR1530, DOI 10.1152/ajpregu.1998.275.5.R1530; ERECINSKA M, 1982, J MEMBRANE BIOL, V70, P1, DOI 10.1007/BF01871584; GOLDING EM, 1995, J EXP BIOL, V198, P1775; GOLDING EM, 1995, MAGNET RESON MED, V33, P467, DOI 10.1002/mrm.1910330403; HEINEMAN FW, 1990, ANNU REV PHYSIOL, V52, P523; Hochachka PW., 1994, MUSCLES MOL METABOLI; Jeneson JAL, 1997, MOL CELL BIOCHEM, V174, P17, DOI 10.1023/A:1006891420109; Jeneson JAL, 1998, AM J PHYSIOL-HEART C, V275, pH726, DOI 10.1152/ajpheart.1998.275.2.H726; Jeneson JAL, 1996, J BIOL CHEM, V271, P27995, DOI 10.1074/jbc.271.45.27995; KALCKAR HM, 1969, BIOL PHOSPHORYLATION; KATZ LA, 1987, FEBS LETT, V221, P270, DOI 10.1016/0014-5793(87)80939-0; KATZ LA, 1988, AM J PHYSIOL, V255, pH185, DOI 10.1152/ajpheart.1988.255.1.H185; KEMP GJ, 1994, MAGN RESON QUART, V10, P43; Kemp GJ, 1996, NMR BIOMED, V9, P261, DOI 10.1002/(SICI)1099-1492(199609)9:6<261::AID-NBM430>3.0.CO;2-B; Klingenberg M, 1970, Essays Biochem, V6, P119; KLINGENBERG M, 1969, ENERGY LEVEL METABOL, P119; KUSHMERICK MJ, 1992, AM J PHYSIOL, V263, pC598, DOI 10.1152/ajpcell.1992.263.3.C598; KUSHMERICK MJ, 1976, J PHYSIOL-LONDON, V254, P711, DOI 10.1113/jphysiol.1976.sp011254; LARDY HA, 1952, J BIOL CHEM, V195, P215; LOISELLE DS, 1982, AM J PHYSIOL, V243, pC242, DOI 10.1152/ajpcell.1982.243.5.C242; MEYER RA, 1988, AM J PHYSIOL, V254, pC548, DOI 10.1152/ajpcell.1988.254.4.C548; NIOKA S, 1992, J APPL PHYSIOL, V72, P521, DOI 10.1152/jappl.1992.72.2.521; PASSONEAU J, 1993, ENZYMATIC ANAL; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; PFAFF E, 1968, EUR J BIOCHEM, V6, P66, DOI 10.1111/j.1432-1033.1968.tb00420.x; PORTMAN MA, 1989, J CLIN INVEST, V83, P456, DOI 10.1172/JCI113904; Portman MA, 1998, AM J PHYSIOL-HEART C, V275, pH727; SARNOFF SJ, 1958, AM J PHYSIOL, V192, P148, DOI 10.1152/ajplegacy.1957.192.1.148; SHOUBRIDGE EA, 1984, BIOCHIM BIOPHYS ACTA, V805, P72, DOI 10.1016/0167-4889(84)90038-7; STAINSBY WN, 1982, FED PROC, V41, P185; Teague WE, 1996, J EXP BIOL, V199, P509; THOMPSON CH, 1995, J APPL PHYSIOL, V78, P2131, DOI 10.1152/jappl.1995.78.6.2131	46	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6129	6134		10.1074/jbc.275.9.6129	http://dx.doi.org/10.1074/jbc.275.9.6129			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692403	hybrid			2022-12-27	WOS:000085654400015
J	Strickland, E; Hakala, K; Thomas, PJ; DeMartino, GN				Strickland, E; Hakala, K; Thomas, PJ; DeMartino, GN			Recognition of misfolding proteins by PA700, the regulatory subcomplex of the 26 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; MOLECULAR CHAPERONE HSC70; NUCLEOTIDE-BINDING DOMAIN; ATP-DEPENDENT ACTIVATOR; CYSTIC-FIBROSIS; SACCHAROMYCES-CEREVISIAE; DELTA-F508 MUTATION; 20-S PROTEASOME; DNAK CHAPERONE; 20S PROTEASOME	The 26 S proteasome is a large protease complex that catalyzes the degradation of both native and misfolded proteins, These proteins are known to interact with PA700, the regulatory subcomplex of the 26 S proteasome, via a covalently attached polyubiquitin chain. Here we provide evidence for an additional ubiquitin-independent mode of substrate recognition by PA700. PA700 prevents the aggregation of three incompletely folded, nonubiquitinated substrates: the Delta F-508 mutant form of cystic fibrosis transmembrane regulator, nucleotide binding domain 1, insulin B chain, and citrate synthase. This function does not require ATP hydrolysis. The stoichiometry required for this function, the effect of PA700 on the lag phase of aggregation, and the temporal specificity of PA700 in this process all indicate that PA700 interacts with a subpopulation of non-native conformations that is either particularly aggregation-prone or nucleates misassociation reactions. The inhibition of off-pathway self-association reactions is also reflected in the ability of PA700 to promote refolding of citrate synthase. These results provide evidence that, in addition to binding polyubiquitin chains, PA700 contains a site(s) that recognizes and interacts with misfolded or partially denatured polypeptides. This feature supplies an additional level of substrate specificity to the 26 S proteasome and a means by which substrates are maintained in a soluble state until refolding or degradation is complete.	Univ Texas, SW Med Ctr, Program Mol Biophys, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Thomas, PJ (corresponding author), 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	thomas07@utsw.swmed.edu; gdemar@mednet.swmed.edu	Thomas, Philip J/F-7115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049835, R01DK046181, R56DK046181, R37DK049835] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46181, DK49835] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams GM, 1997, J MOL BIOL, V273, P646, DOI 10.1006/jmbi.1997.1334; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Clarke AR, 1996, CURR OPIN STRUC BIOL, V6, P43, DOI 10.1016/S0959-440X(96)80093-5; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DeMartino GN, 1996, J BIOL CHEM, V271, P3112, DOI 10.1074/jbc.271.6.3112; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; Hoffman L, 1996, J BIOL CHEM, V271, P32538, DOI 10.1074/jbc.271.51.32538; HOHFELD J, 1995, CELL, V83, P589; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Kominami K, 1997, MOL BIOL CELL, V8, P171, DOI 10.1091/mbc.8.1.171; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; Lee GJ, 1995, METHOD CELL BIOL, V50, P325, DOI 10.1016/S0091-679X(08)61040-7; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; MA CP, 1994, J BIOL CHEM, V269, P3539; MA CP, 1992, J BIOL CHEM, V267, P10515; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; Pak M, 1999, J BIOL CHEM, V274, P19316, DOI 10.1074/jbc.274.27.19316; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PIND S, 1994, J BIOL CHEM, V269, P12784; Qu BH, 1997, J BIOENERG BIOMEMBR, V29, P483, DOI 10.1023/A:1022439108101; Qu BH, 1996, J BIOL CHEM, V271, P7261, DOI 10.1074/jbc.271.13.7261; Rubin DM, 1998, EMBO J, V17, P4909, DOI 10.1093/emboj/17.17.4909; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; SRERE PA, 1961, J BIOL CHEM, V236, P2557; Strickland E, 1997, J BIOL CHEM, V272, P25421, DOI 10.1074/jbc.272.41.25421; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; THOMAS PJ, 1993, J BIOENERG BIOMEMBR, V25, P11, DOI 10.1007/BF00768063; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; WANG Z, 1992, PROTEIN SCI, V1, P522; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480	57	155	160	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5565	5572		10.1074/jbc.275.8.5565	http://dx.doi.org/10.1074/jbc.275.8.5565			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681537	hybrid			2022-12-27	WOS:000085474500044
J	Harris, T; Shahidullah, M; Ellingson, JS; Covarrubias, M				Harris, T; Shahidullah, M; Ellingson, JS; Covarrubias, M			General anesthetic action at an internal protein site involving the S4-S5 cytoplasmic loop of a neuronal K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; MOLECULAR-BASIS; INACTIVATION GATE; GLYCINE RECEPTORS; XENOPUS-OOCYTES; FOLDING PROBLEM; ALCOHOL; PORE; COOPERATIVITY; PREDICTION	The structural bases of general anesthetic action on a neuronal K+ channel were investigated using the series of homologous l-alkanols, electrophysiology, and mutational analysis. Domain swapping between dShaw2 (alkanol-sensitive) and hKv3.4 (alkanol-resistant) and site-directed mutagenesis demonstrated that a 13-amino acid cytoplasmic loop (S4-S5) determines the selective inhibition of native dShaw2 channels by l-alkanols, The S4-S5 loop may contribute to a receptor for both l-alkanols and the inactivation particle, because the enhanced l-alkanol sensitivity of hKv3.4 channels hosting S4-S5 mutations correlates directly with disrupted channel inactivation. Evidence of a discrete protein site was also obtained from the analysis of the relationship between potency and alkyl chain length, which begins to level off after 1-hexanol. Rapid application to the cytoplasmic side of inside-out membrane patches shows that the interaction between dShaw2 channels and l-alkanols equilibrates in <200 ms. By contrast, the equilibration time is >1000 fold slower when the drug is applied externally to outside-out membrane patches. The data strongly favor a mechanism of inhibition involving a discrete internal site for l-alkanols in dShaw2 K+ channels. A new working hypothesis proposes that l-alkanols lock dShaw2 channels in their closed conformation by a direct interaction at a crevice formed by the S4-S5 loop.	Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University	Covarrubias, M (corresponding author), Jefferson Med Coll, Dept Pathol Anat & Cell Biol, 1020 Locust St, Philadelphia, PA 19107 USA.	manuel.covarrubias@mail.tju.edu		Covarrubias, Manuel/0000-0002-0881-4143	NIAAA NIH HHS [AA10615] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010615] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Antz C, 1999, NAT STRUCT BIOL, V6, P146; Armstrong CM, 1997, J GEN PHYSIOL, V109, P523, DOI 10.1085/jgp.109.5.523; Ayer RK, 1997, J MEMBRANE BIOL, V157, P215; Beck EJ, 1998, J GEN PHYSIOL, V112, P71, DOI 10.1085/jgp.112.1.71; BELL GH, 1973, CHEM PHYS LIPIDS, V10, P1, DOI 10.1016/0009-3084(73)90036-4; Chu BS, 1997, ALCOHOL CLIN EXP RES, V21, P1103, DOI 10.1097/00000374-199709000-00025; Correa AM, 1998, AM J PHYSIOL-CELL PH, V275, pC1009, DOI 10.1152/ajpcell.1998.275.4.C1009; COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; COVARRUBIAS M, 1993, P NATL ACAD SCI USA, V90, P6957, DOI 10.1073/pnas.90.15.6957; COVARRUBIAS M, 1995, J BIOL CHEM, V270, P19408, DOI 10.1074/jbc.270.33.19408; Diamond I, 1997, PHYSIOL REV, V77, P1, DOI 10.1152/physrev.1997.77.1.1; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 1998, J STRUCT BIOL, V121, P263, DOI 10.1006/jsbi.1998.3962; Eckenhoff RG, 1996, P NATL ACAD SCI USA, V93, P2807, DOI 10.1073/pnas.93.7.2807; Eckenhoff RG, 1997, PHARMACOL REV, V49, P343; Forman SA, 1997, BIOPHYS J, V72, P2170, DOI 10.1016/S0006-3495(97)78860-X; FORMAN SA, 1995, MOL PHARMACOL, V48, P574; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Franks NP, 1997, NATURE, V389, P334, DOI 10.1038/38614; FRANKS NP, 1985, NATURE, V316, P349, DOI 10.1038/316349a0; Holmgren M, 1996, J GEN PHYSIOL, V108, P195, DOI 10.1085/jgp.108.3.195; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; Jerng HH, 1999, J GEN PHYSIOL, V113, P641, DOI 10.1085/jgp.113.5.641; Lacroix E, 1998, J MOL BIOL, V284, P173, DOI 10.1006/jmbi.1998.2145; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; MCCORMACK K, 1993, BIOPHYS J, V65, P1740, DOI 10.1016/S0006-3495(93)81202-5; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; MUNOZ V, 1994, NAT STRUCT BIOL, V1, P399, DOI 10.1038/nsb0694-399; MUNOZ V, 1995, CURR OPIN BIOTECH, V6, P382, DOI 10.1016/0958-1669(95)80066-2; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P949, DOI 10.1085/jgp.102.6.949; Peoples RW, 1996, ANNU REV PHARMACOL, V36, P185, DOI 10.1146/annurev.pa.36.040196.001153; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; RETTIG J, 1992, EMBO J, V11, P2473, DOI 10.1002/j.1460-2075.1992.tb05312.x; Richards CD, 1998, TOXICOL LETT, V101, P41, DOI 10.1016/S0378-4274(98)00163-5; Roux MJ, 1998, J GEN PHYSIOL, V111, P625, DOI 10.1085/jgp.111.5.625; Smith-Maxwell CJ, 1998, J GEN PHYSIOL, V111, P399, DOI 10.1085/jgp.111.3.399; Smith-Maxwell CJ, 1998, J GEN PHYSIOL, V111, P421, DOI 10.1085/jgp.111.3.421; TSUNODA S, 1995, J NEUROSCI, V15, P1741, DOI 10.1523/JNEUROSCI.15-03-01741.1995; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; Wick MJ, 1998, P NATL ACAD SCI USA, V95, P6504, DOI 10.1073/pnas.95.11.6504; Yu DH, 1996, MOL PHARMACOL, V50, P1010; Zhang L, 1997, BRIT J PHARMACOL, V120, P353, DOI 10.1038/sj.bjp.0700934	43	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4928	4936		10.1074/jbc.275.7.4928	http://dx.doi.org/10.1074/jbc.275.7.4928			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671530	hybrid			2022-12-27	WOS:000085378200056
J	MacManus, A; Ramsden, M; Murray, M; Henderson, Z; Pearson, HA; Campbell, VA				MacManus, A; Ramsden, M; Murray, M; Henderson, Z; Pearson, HA; Campbell, VA			Enhancement of Ca-45(2+) influx and voltage-dependent Ca2+ channel activity by beta-amyloid-(1-40) in rat cortical synaptosomes and cultured cortical neurons - Modulation by the proinflammatory cytokine interleukin-1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE NEURONS; AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; HIPPOCAMPAL-NEURONS; CALCIUM CHANNELS; PC12 CELLS; BETA; RELEASE; DEATH; INVOLVEMENT	beta-Amyloid protein is thought to underlie the neurodegeneration associated with Alzheimer's disease by inducing Ca2+-dependent apoptosis, Elevated neuronal expression of the proinflammatory cytokine interleukin-1 beta is an additional feature of neurodegeneration, and in this study we demonstrate that interleukin-1 beta modulates the effects of beta-amyloid on Ca2+ homeostasis in the rat cortex. beta-Amyloid-(1-40) (1 mu M) caused a significant increase in Ca-45(2+) influx into rat cortical synaptosomes via activation of L- and N-type voltage-dependent Ca2+ channels and also increased the amplitude of N- and P-type Ca2+ channel currents recorded from cultured cortical neurons. In contrast, interleukin-1 beta (5 ng/ml) reduced the Ca-45(2+) influx into cortical synaptosomes and inhibited Ca2+ channel activity in cultured cortical neurons. Furthermore, the stimulatory effects of beta-amyloid protein on Ca2+ influx were blocked following exposure to interleukin-1 beta, suggesting that interleukin-1 beta may govern neuronal responses to beta-amyloid by regulating Ca2+ homeostasis.	Univ Dublin Trinity Coll, Dept Physiol, Dublin 2, Ireland; Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England	Trinity College Dublin; University of Leeds	Campbell, VA (corresponding author), Univ Dublin Trinity Coll, Dept Physiol, Dublin 2, Ireland.							ARAUJO DM, 1992, BRAIN RES, V569, P140; ARIAS C, 1995, J NEUROSCI RES, V41, P561, DOI 10.1002/jnr.490410416; BOESS FG, 1990, J NEUROCHEM, V55, P230, DOI 10.1111/j.1471-4159.1990.tb08843.x; Bono F, 1999, FEBS LETT, V457, P93, DOI 10.1016/S0014-5793(99)01006-6; CACABELOS R, 1994, METHOD FIND EXP CLIN, V16, P141; Combs CK, 1999, J NEUROSCI, V19, P928; CUNNINGHAM AJ, 1996, NEUROSCI LETT, V203, P1; DArcangelo G, 1997, NEUROREPORT, V8, P2079, DOI 10.1097/00001756-199705260-00053; FUKUYAMA R, 1994, BRAIN RES, V667, P269, DOI 10.1016/0006-8993(94)91505-9; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Held B, 1998, PFLUG ARCH EUR J PHY, V436, P766, DOI 10.1007/s004240050700; Hu JG, 1998, BRAIN RES, V785, P195, DOI 10.1016/S0006-8993(97)01318-8; HU PS, 1993, ACTA PHYSIOL SCAND, V148, P115, DOI 10.1111/j.1748-1716.1993.tb09540.x; HUSTON E, 1995, NEUOSCIENCE, V68, P457; Jordan J, 1997, J NEUROCHEM, V68, P1612; Koppal T, 1998, BRAIN RES, V786, P270, DOI 10.1016/S0006-8993(97)01466-2; Li YP, 1996, BRAIN RES, V738, P196, DOI 10.1016/S0006-8993(96)00733-0; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Lorton D, 1997, MECH AGEING DEV, V94, P199, DOI 10.1016/S0047-6374(96)01847-7; Lorton D, 1996, J NEUROIMMUNOL, V67, P21, DOI 10.1016/S0165-5728(96)00030-6; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1994, NEUROBIOL AGING, V15, P121; Murray CA, 1997, NEUROBIOL AGING, V18, P343, DOI 10.1016/S0197-4580(97)80317-X; PATTERSON PH, 1995, CURR OPIN NEUROBIOL, V5, P642, DOI 10.1016/0959-4388(95)80070-0; PLATASALAMAN CR, 1994, EUR J PHARM-MOLEC PH, V266, P1, DOI 10.1016/0922-4106(94)90202-X; Price SA, 1998, NEUROREPORT, V9, P539; SABRIA J, 1995, J NEUROCHEM, V64, P2567; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P504; SHENG JG, 1995, NEUROPATH APPL NEURO, V21, P290, DOI 10.1111/j.1365-2990.1995.tb01063.x; Silei V, 1999, BRAIN RES, V818, P168, DOI 10.1016/S0006-8993(98)01272-4; Suo ZM, 1998, BRAIN RES, V807, P110, DOI 10.1016/S0006-8993(98)00780-X; Sweeney WA, 1997, NEUROBIOL LEARN MEM, V68, P97, DOI 10.1006/nlme.1997.3770; TRUMP BF, 1995, FASEB J, V9, P219, DOI 10.1096/fasebj.9.2.7781924; Ueda K, 1997, J NEUROCHEM, V68, P265; VASILAKOS JP, 1994, FEBS LETT, V354, P289, DOI 10.1016/0014-5793(94)01142-7; Wernyj RP, 1999, MOL BRAIN RES, V64, P69, DOI 10.1016/S0169-328X(98)00307-6; Yallampalli S, 1998, NEUROSCI LETT, V251, P105, DOI 10.1016/S0304-3940(98)00515-1	39	121	131	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4713	4718		10.1074/jbc.275.7.4713	http://dx.doi.org/10.1074/jbc.275.7.4713			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671502	hybrid			2022-12-27	WOS:000085378200028
J	Choy, HE				Choy, HE			The study of guanosine 5 '-diphosphate 3 '-diphosphate-mediated transcription regulation in vitro using a coupled transcription-translation system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID STARVATION; COLI RNA-POLYMERASE; ESCHERICHIA-COLI; STRINGENT CONTROL; RIBOSOMAL-RNA; PROMOTER STRENGTH; HISTIDINE OPERON; SALMONELLA-TYPHIMURIUM; RIBONUCLEIC-ACID; PROTEIN OPERONS	The effects of the "alarmone" guanosine 5'-diphosphate 3'-diphosphate (ppGpp) on regulation of the Salmonella typhimurium histindine operon and the Escherichia coli tRNA(leu) operon were analyzed in vitro using a DNA-dependent transcription-translation system, S-30. The expression of the hisG promoter is positively regulated by ppGpp, whereas that of the leuV promoter (of tRNA(leu)) is negatively regulated by ppGpp. In an attempt to understand the global regulatory mechanism of ppGpp control, interrelationship between ppGpp-dependent activation and repression of gene expression was examined using these promoters as models. It has been traditionally supposed that the ppGpp-dependent regulation, at least for the activation, is by a passive mode of control: the activation of gene expression by ppGpp is a consequence of the repression of stable RNA gene expression in the condition of RNA polymerase limiting. To test this model, the ppGpp-dependent regulations of both an activable promoter (hisGp) and a repressible promoter (leuVp) were determined in vitro simultaneously using a mixed template setup. The rationale for this exercise was to see whether the ppGpp-dependent activation and repression are inversely correlated in the in vitro condition in which RNA polymerase is limiting. No correlation was observed. It was concluded that the ppGpp-dependent activation is independent of the repression. Moreover, it was proposed that ppGpp-dependent activation and repression are mediated by titratable factors, each of which operate independently.	Dankook Univ, Coll Med, Dept Biochem, Anseo 29, San, South Korea	Dankook University	Choy, HE (corresponding author), Dankook Univ, Coll Med, Dept Biochem, Anseo 29, San, South Korea.	hyonchoy@anseo.dankook.ac.kr						ABOUD M, 1975, J BIOL CHEM, V250, P2189; ABOUD M, 1973, J BIOL CHEM, V248, P3356; BARACCHINI E, 1988, J BIOL CHEM, V263, P2597; Bartlett MS, 1998, J MOL BIOL, V279, P331, DOI 10.1006/jmbi.1998.1779; BAUER BF, 1988, GENE, V63, P123, DOI 10.1016/0378-1119(88)90551-3; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; CASHEL M, 1987, ESCHERICHIA COLI SAL, V2, P1410; Chatterji D, 1998, GENES CELLS, V3, P279, DOI 10.1046/j.1365-2443.1998.00190.x; Choy HE, 1997, BBA-GENE STRUCT EXPR, V1353, P61, DOI 10.1016/S0167-4781(97)00042-0; CHURCHWARD G, 1982, J BACTERIOL, V150, P572, DOI 10.1128/JB.150.2.572-581.1982; DaCosta XJ, 1997, J BACTERIOL, V179, P5211, DOI 10.1128/jb.179.16.5211-5217.1997; De Crombrugghe B, 1971, Nat New Biol, V231, P139; Figueroa-Bossi N, 1998, EMBO J, V17, P2359, DOI 10.1093/emboj/17.8.2359; FRIMAKOFF P, 1979, P NATL ACAD SCI USA, V76, P1726; GALLANT JA, 1979, ANNU REV GENET, V13, P393, DOI 10.1146/annurev.ge.13.120179.002141; HERNANDEZ VJ, 1995, J MOL BIOL, V252, P536; HIRSCHMAN J, 1985, P NATL ACAD SCI USA, V82, P7525, DOI 10.1073/pnas.82.22.7525; JENSEN KF, 1990, MICROBIOL REV, V54, P89, DOI 10.1128/MMBR.54.2.89-100.1990; KAJITANI M, 1983, NUCLEIC ACIDS RES, V11, P3873, DOI 10.1093/nar/11.12.3873; KAJITANI M, 1983, NUCLEIC ACIDS RES, V11, P671, DOI 10.1093/nar/11.3.671; KAJITANI M, 1984, J BIOL CHEM, V259, P1951; LAMOND AI, 1985, CELL, V40, P319, DOI 10.1016/0092-8674(85)90146-1; Lesley S A, 1995, Methods Mol Biol, V37, P265; LI SC, 1984, CELL, V38, P851, DOI 10.1016/0092-8674(84)90280-0; LITTLE R, 1983, J BACTERIOL, V155, P1162, DOI 10.1128/JB.155.3.1162-1170.1983; Maaloe O., 1979, BIOL REGUL DEV, V1, P487; MAALOE O, 1968, BIOCH RIBOSOME MESSE, P231; Maaloe O, 1969, DEVELOP BIOL       S, V3, P33; MARTIN RG, 1968, J MOL BIOL, P127; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MIZUSHIMASUGANO J, 1985, EMBO J, V4, P1053, DOI 10.1002/j.1460-2075.1985.tb03738.x; OHLESN KI, 1992, MOL MICROBIOL, V6, P2243; REDDY PS, 1995, MOL MICROBIOL, V15, P255, DOI 10.1111/j.1365-2958.1995.tb02240.x; RIGGS DL, 1986, P NATL ACAD SCI USA, V83, P9333, DOI 10.1073/pnas.83.24.9333; ROWLEY KB, 1993, J BACTERIOL, V175, P1309, DOI 10.1128/JB.175.5.1309-1315.1993; Sambrook J., 2002, MOL CLONING LAB MANU; SORENSEN MA, 1994, J MOL BIOL, V236, P441, DOI 10.1006/jmbi.1994.1156; STEPHENS JC, 1975, P NATL ACAD SCI USA, V72, P4389, DOI 10.1073/pnas.72.11.4389; TEDIN K, 1992, J BIOL CHEM, V267, P2337; TRAVERS AA, 1980, J MOL BIOL, V141, P91, DOI 10.1016/S0022-2836(80)80030-1; TRAVERS AA, 1980, J BACTERIOL, V141, P973, DOI 10.1128/JB.141.2.973-976.1980; TRAVERS AA, 1984, NUCLEIC ACIDS RES, V12, P2605, DOI 10.1093/nar/12.6.2605; VOGEL U, 1992, MOL MICROBIOL, V6, P2191, DOI 10.1111/j.1365-2958.1992.tb01393.x; Zhou YN, 1998, P NATL ACAD SCI USA, V95, P2908, DOI 10.1073/pnas.95.6.2908; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411	45	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6783	6789		10.1074/jbc.275.10.6783	http://dx.doi.org/10.1074/jbc.275.10.6783			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702235	hybrid			2022-12-27	WOS:000085809600015
J	Kay, L; Nicolay, K; Wieringa, B; Saks, V; Wallimann, T				Kay, L; Nicolay, K; Wieringa, B; Saks, V; Wallimann, T			Direct evidence for the control of mitochondrial respiration by mitochondrial creatine kinase in oxidative muscle cells in situ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-HEART MITOCHONDRIA; IN-VIVO; DYNAMIC COMPARTMENTATION; CELLULAR RESPIRATION; INTERMEMBRANE SPACE; ENERGY HOMEOSTASIS; ADENYLATE KINASE; MEMBRANE-BINDING; SKELETAL-MUSCLES; DEFICIENT MICE	The efficiency of stimulation of mitochondrial respiration in permeabilized muscle cells by ADP produced at different intracellular sites, e.g cytosolic or mitochondrial intermembrane space, was evaluated in wildtype and creatine kinase (CK)-deficient mice. To activate respiration by endogenous production of ADP in permeabilized cells, ATP was added either alone or together with creatine, In cardiac fibers, while ATP alone activated respiration to half of the maximal rate, creatine plus ATP increased the respiratory rate up to its maximum. To find out whether the stimulation by creatine is a consequence of extramitochondrial [ADP] increase, or whether it directly correlates with ADP generation by mitochondrial CK in the mitochondrial intermembrane space, an exogenous ADP-trap system was added to rephosphorylate all cytosolic ADP, Under these conditions, creatine plus ATP still increased the respiration rate by 2.5 times, compared with ATP alone, for the same extramitochondrial [ADP] of 14 mu M, Moreover, this stimulatory effect of creatine, observed in wild-type cardiac fibers disappeared in mitochondrial CK deficient, but not in cytosolic CK-deficient muscle. It is concluded that respiration rates can be dissociated from cytosolic [ADP], and ADP generated by mitochondrial CK is an important regulator of oxidative phosphorylation.	ETH Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland; Univ Utrecht, Image Sci Inst, Dept Expt Invivo NMR, NL-3584 CJ Utrecht, Netherlands; Univ Nijmegen, Fac Med Sci, Dept Cell Biol, NL-6500 HB Nijmegen, Netherlands; Univ Grenoble 1, Lab Bioenerget, F-38041 Grenoble 9, France	Swiss Federal Institutes of Technology Domain; ETH Zurich; Utrecht University; Radboud University Nijmegen; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Kay, L (corresponding author), ETH Honggerberg, Inst Cell Biol, HPM F44, CH-8093 Zurich, Switzerland.		Wallimann, Theo/C-6047-2008; Nicolay, Klaas/F-4192-2010; Wieringa, Berend/A-5346-2011	Wallimann, Theo/0000-0003-4957-5836; Wieringa, Berend/0000-0001-9192-8020; Nicolay, Klaas/0000-0002-4179-616X				BALABAN RS, 1989, MOL CELL BIOCHEM, V89, P191; BALABAN RS, 1986, SCIENCE, V232, P1121, DOI 10.1126/science.3704638; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Boehm E, 1998, J MOL CELL CARDIOL, V30, P901, DOI 10.1006/jmcc.1998.0692; BRDICZKA D, 1994, J BIOL CHEM, V269, P27640; BRDICZKA D, 1994, MOL CELL BIOCHEM, V133, P69, DOI 10.1007/BF01267948; CHANCE B, 1955, J BIOL CHEM, V217, P383; DICKINSON K, 1992, SCI TOOLS, V36, P6; Dzeja PP, 1998, MOL CELL BIOCHEM, V184, P169, DOI 10.1023/A:1006859632730; FritzWolf K, 1996, NATURE, V381, P341, DOI 10.1038/381341a0; Gellerich FN, 1998, EUR J BIOCHEM, V254, P172, DOI 10.1046/j.1432-1327.1998.2540172.x; GELLERICH FN, 1987, BIOCHIM BIOPHYS ACTA, V890, P117, DOI 10.1016/0005-2728(87)90012-0; GELLERICH FN, 1994, MOL CELL BIOCHEM, V133, P85, DOI 10.1007/BF01267949; KUSHMERICK MJ, 1992, AM J PHYSIOL, V263, pC598, DOI 10.1152/ajpcell.1992.263.3.C598; Kuznetsov AV, 1996, EUR J BIOCHEM, V241, P909, DOI 10.1111/j.1432-1033.1996.00909.x; Laterveer FD, 1997, MOL CELL BIOCHEM, V174, P43, DOI 10.1023/A:1006899621926; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; Minajeva A, 1996, PFLUG ARCH EUR J PHY, V432, P904, DOI 10.1007/s004240050214; OVADI J, 1995, CELL ARCHITECTURE ME, P1; ROJO M, 1991, J BIOL CHEM, V266, P20290; SAKS VA, 1985, J BIOL CHEM, V260, P7757; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P1, DOI 10.1007/BF01267942; SAKS VA, 1987, BIOCHIM BIOPHYS ACTA, V891, P138, DOI 10.1016/0005-2728(87)90005-3; SAKS VA, 1995, J MOL CELL CARDIOL, V27, P625, DOI 10.1016/S0022-2828(08)80056-9; Saks VA, 1998, MOL CELL BIOCHEM, V184, P81, DOI 10.1023/A:1006834912257; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; Schlattner U, 1998, MOL CELL BIOCHEM, V184, P125, DOI 10.1023/A:1006851330913; SCHNYDER T, 1990, J MOL BIOL, V216, P809, DOI 10.1016/S0022-2836(99)80002-3; Stachowiak O, 1998, MOL CELL BIOCHEM, V184, P141, DOI 10.1023/A:1006803431821; Stachowiak O, 1996, BIOCHEMISTRY-US, V35, P15522, DOI 10.1021/bi961838v; Steeghs K, 1998, MOL CELL BIOCHEM, V184, P183, DOI 10.1023/A:1006811717709; Steeghs K, 1997, J NEUROSCI METH, V71, P29, DOI 10.1016/S0165-0270(96)00124-0; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VEKSLER VI, 1995, J BIOL CHEM, V270, P19921, DOI 10.1074/jbc.270.34.19921; VEKSLER VI, 1987, BIOCHIM BIOPHYS ACTA, V892, P191, DOI 10.1016/0005-2728(87)90174-5; VENTURACLAPIER R, 1985, PFLUG ARCH EUR J PHY, V404, P157, DOI 10.1007/BF00585412; VIGNAIS PV, 1976, BIOCHIM BIOPHYS ACTA, V456, P1, DOI 10.1016/0304-4173(76)90007-0; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9; Yaffe MP, 1999, NAT CELL BIOL, V1, pE149, DOI 10.1038/14101; ZIMMERBERG J, 1986, NATURE, V323, P36, DOI 10.1038/323036a0	41	117	122	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6937	6944		10.1074/jbc.275.10.6937	http://dx.doi.org/10.1074/jbc.275.10.6937			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702255	hybrid, Green Published			2022-12-27	WOS:000085809600035
J	Mozzarelli, A; Peracchi, A; Rovegno, B; Dale, G; Rossi, GL; Dunn, MF				Mozzarelli, A; Peracchi, A; Rovegno, B; Dale, G; Rossi, GL; Dunn, MF			Effect of pH and monovalent cations on the formation of quinonoid intermediates of the tryptophan synthase alpha(2)beta(2) complex in solution and in the crystal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXINDOLYL-L-ALANINE; BIENZYME COMPLEX; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; ALPHA-SUBUNIT; INTERSUBUNIT COMMUNICATION; ALLOSTERIC INTERACTIONS; 3-DIMENSIONAL STRUCTURE; CONFORMATIONAL-CHANGES; CATALYTIC MECHANISM	Quinonoid intermediates play a key role in the catalytic mechanism of pyridoxal 5'-phosphate-dependent enzymes. Whereas the structures of other pyridoxal 5'-phosphate-bound intermediates have been determined, the structure of a quinonoid species has not yet been reported. Here, we investigate factors controlling the accumulation and stability of quinonoids formed at the beta-active site of tryptophan synthase both in solution and the crystal. The quinonoids were obtained by reacting the alpha-aminoacrylate Schiff base with different nucleophiles, focusing mainly on the substrate analogs indoline and beta-mercaptoethanol, In solution, both monovalent cations (Cs+ or Na+) and alkaline pH increase the apparent affinity of indoline and favor accumulation of the indoline quinonoid, A similar pH dependence is observed when beta-mercaptoethanol is used. As indoline and beta-mercaptoethanol exhibit very distinct ionization properties, this finding suggests that nucleophile binding and quinonoid stability are controlled by some ionizable protein residue(s). In the crystal, alkaline pH favors formation of the indoline quinonoid as in solution, but the effect of cations is markedly different. In the absence of monovalent metal ions the quinonoid species accumulates substantially, whereas in the presence of sodium ions the accumulation is modest, unless alpha-subunit Ligands are also present, alpha-Subunit Ligands not only favor the formation of the intermediate, but also reduce significantly its decay rate. These findings define experimental conditions suitable for the stabilization of the quinonoid species in the crystal, a critical prerequisite for the determination of the three-dimensional structure of this intermediate.	Univ Parma, Inst Biochem Sci, I-43100 Parma, Italy; Univ Parma, Natl Inst Phys Matter, I-43100 Parma, Italy; Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	University of Parma; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Parma; University of California System; University of California Riverside	Mozzarelli, A (corresponding author), Univ Parma, Inst Biochem Sci, Viale Sci, I-43100 Parma, Italy.	biochim@ipruniv.cce.unipr.it	Peracchi, Alessio/G-5167-2012; Peracchi, Alessio/Q-5173-2019; Mozzarelli, Andrea/C-3615-2014	Peracchi, Alessio/0000-0003-3254-4099; Peracchi, Alessio/0000-0003-3254-4099; Mozzarelli, Andrea/0000-0003-3762-0062	NIGMS NIH HHS [GM55749] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed SA, 1996, J BIOL CHEM, V271, P29100, DOI 10.1074/jbc.271.46.29100; AHMED SA, 1985, J BIOL CHEM, V260, P3716; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BRZOVIC PS, 1992, J BIOL CHEM, V267, P13028; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; DREWE WF, 1986, BIOCHEMISTRY-US, V25, P2494, DOI 10.1021/bi00357a032; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; DUNN MF, 1987, INDIAN J BIOCHEM BIO, V24, P44; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; GOLDBERG ME, 1967, BIOCHEMISTRY-US, V6, P2113, DOI 10.1021/bi00859a032; HOUBEN KF, 1990, BIOCHEMISTRY-US, V29, P2421, DOI 10.1021/bi00461a028; Hur O, 1996, BIOCHEMISTRY-US, V35, P7378, DOI 10.1021/bi960240k; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KIRSCHNER K, 1975, EUR J BIOCHEM, V60, P513, DOI 10.1111/j.1432-1033.1975.tb21030.x; KIRSCHNER K, 1991, BIOCHEMISTRY-US, V30, P472, DOI 10.1021/bi00216a024; Kirschner K., 1975, PROTEIN LIGAND INTER, P27, DOI [10.1515/9783110830811-006, DOI 10.1515/9783110830811-006]; LANE AN, 1983, EUR J BIOCHEM, V129, P571; LEJA CA, 1995, BIOCHEMISTRY-US, V34, P6552, DOI 10.1021/bi00019a037; METZLER CM, 1988, BIOCHEMISTRY-US, V27, P4923, DOI 10.1021/bi00413a050; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1968, BIOCHEMISTRY-US, V7, P2742, DOI 10.1021/bi00848a008; Miles EW, 1999, J BIOL CHEM, V274, P12193, DOI 10.1074/jbc.274.18.12193; MILES EW, 1980, BIOCH MED ASPECTS TR; MOZZARELLI A, 1989, J BIOL CHEM, V264, P15774; Mozzarelli A, 1996, ANNU REV BIOPH BIOM, V25, P343; Pan P, 1996, BIOCHEMISTRY-US, V35, P5002, DOI 10.1021/bi960033k; Pan P, 1997, TRENDS BIOCHEM SCI, V22, P22, DOI 10.1016/S0968-0004(96)10066-9; PERACCHI A, 1995, BIOCHEMISTRY-US, V34, P9459, DOI 10.1021/bi00029a022; Peracchi A, 1996, BIOCHEMISTRY-US, V35, P1872, DOI 10.1021/bi951889c; PHILLIPS RS, 1984, BIOCHEMISTRY-US, V23, P6228, DOI 10.1021/bi00320a052; Rhee S, 1998, J BIOL CHEM, V273, P8553, DOI 10.1074/jbc.273.15.8553; Rhee S, 1998, BIOCHEMISTRY-US, V37, P10653, DOI 10.1021/bi980779d; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; Rhee S, 1996, BIOCHEMISTRY-US, V35, P4211, DOI 10.1021/bi952506d; ROSSI GL, 1992, PHILOS T R SOC A, V340, P191, DOI 10.1098/rsta.1992.0060; ROY M, 1988, BIOCHEMISTRY-US, V27, P6698, DOI 10.1021/bi00418a009; ROY M, 1988, BIOCHEMISTRY-US, V27, P8661, DOI 10.1021/bi00423a023; Schnackerz KD, 1998, J BIOL CHEM, V273, P33247, DOI 10.1074/jbc.273.50.33247; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; STRAMBINI GB, 1992, BIOCHEMISTRY-US, V31, P7535, DOI 10.1021/bi00148a014; Vaccari S, 1996, BIOPHYS CHEM, V61, P9, DOI 10.1016/0301-4622(96)00020-8; Woehl E, 1999, BIOCHEMISTRY-US, V38, P7131, DOI 10.1021/bi982919p; Woehl E, 1999, BIOCHEMISTRY-US, V38, P7118, DOI 10.1021/bi982918x; WOEHL EU, 1995, BIOCHEMISTRY-US, V34, P9466, DOI 10.1021/bi00029a023; Yang LH, 1996, PROTEIN EXPRES PURIF, V8, P126, DOI 10.1006/prep.1996.0082; YANOFSKY C, 1972, ENZYMES, V7, P1	47	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2000	275	10					6956	6962		10.1074/jbc.275.10.6956	http://dx.doi.org/10.1074/jbc.275.10.6956			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	292RV	10702257	hybrid			2022-12-27	WOS:000085809600037
J	Huang, YQ; Li, JJ; Karpatkin, S				Huang, YQ; Li, JJ; Karpatkin, S			Thrombin inhibits tumor cell growth in association with up-regulation of p21(waf/cip1) and caspases via a p53-independent, STAT-1-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; RECEPTOR ACTIVATION; ENDOTHELIAL-CELLS; KINASE; MECHANISM; CANCER; PROLIFERATION; MITOGENESIS; EXPRESSION; APOPTOSIS	Thrombin, a multifunctional protein, has been found to be involved in cellular mitogenesis, tumor growth, and metastasis, in addition to its well known effects on the initiation of platelet aggregation and secretion and the conversion of fibrinogen to fibrin to form blood clots. These properties of thrombin rely on its action as a serine protease, which cleaves the N-terminal region of a 7-transmembrane G protein receptor (protease-activated receptor, PAR-1), thus exposing a tethered end hexapeptide sequence capable of activating its receptor. Little is known about its effect on genes that regulate the cell cycle. This study was undertaken to investigate the possible mechanisms by which thrombin regulates tumor cell growth in several tumor cell lines: human CHRF megakaryocyte, DU145 prostate, MDAMB231 and MCF7 breast, U3A fibrosarcoma, and 2 murine fibroblast cell lines, MEFp53(-/-) and CD STAT(-/-), We have found that thrombin under the conditions of culture employed inhibits cell growth by both up-regulation of p21(waf/cip1) and induction of caspases via its PAR-1 receptor. The increased expression of p21(waf/cip1) by thrombin was p53 independent, STAT1 dependent, and protein synthesis independent. This was associated with tyrosine phosphorylation of JAK2 and STAT1, and nuclear translocation of STAT1, Induction of apoptosis is also PAR-1-specific, STAT1-dependent, and associated with up-regulation of caspases 1, 2, and 3. Our study establishes, for the first time, a link between PAR-1 receptor activation with the STAT signal pathway, which leads to cell cycle control and apoptosis. This observation broadens our understanding of the mechanism of PAR-1 activation and its effect on cell growth, and could possibly lead to therapeutic approaches for the treatment of cancer.	NYU, Sch Med, New York, NY 10016 USA; Kaplan Canc Ctr, New York, NY 10016 USA	New York University	Huang, YQ (corresponding author), NYU, Sch Med, New York, NY 10016 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL013336] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-13336-27] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG DK, 1994, CANCER RES, V54, P5280; Blackhart BD, 1996, J BIOL CHEM, V271, P16466, DOI 10.1074/jbc.271.28.16466; CARNEY DH, 1978, CELL, V15, P1341, DOI 10.1016/0092-8674(78)90059-4; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Donovan FM, 1997, J NEUROSCI, V17, P5316; Dostal DE, 1997, J MOL CELL CARDIOL, V29, P2893, DOI 10.1006/jmcc.1997.0524; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; HARPER JW, 1993, CELL, V75, P805; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; KLEPFISH A, 1993, INT J CANCER, V53, P978; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Leonard WJ, 1996, NAT MED, V2, P968, DOI 10.1038/nm0996-968; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Molloy CJ, 1996, J CLIN INVEST, V97, P1173, DOI 10.1172/JCI118531; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; Nierodzik ML, 1998, BLOOD, V92, P3694, DOI 10.1182/blood.V92.10.3694.422k40_3694_3700; NIERODZIK ML, 1991, J CLIN INVEST, V87, P229, DOI 10.1172/JCI114976; NIERODZIK ML, 1992, CANCER RES, V92, P3267; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; RODRIGUEZLINARES B, 1994, FEBS LETT, V352, P335, DOI 10.1016/0014-5793(94)00983-X; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; Shapiro PS, 1996, J BIOL CHEM, V271, P5750, DOI 10.1074/jbc.271.10.5750; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; STOUFFER GA, 1993, AM J PHYSIOL, V265, pC806, DOI 10.1152/ajpcell.1993.265.3.C806; SUGAMA Y, 1992, J CELL BIOL, V119, P935, DOI 10.1083/jcb.119.4.935; TOOTHILL VJ, 1990, J IMMUNOL, V145, P283; Trejo J, 1996, J BIOL CHEM, V271, P21536, DOI 10.1074/jbc.271.35.21536; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEISS RH, 1993, J BIOL CHEM, V268, P5724; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	38	78	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6462	6468		10.1074/jbc.275.9.6462	http://dx.doi.org/10.1074/jbc.275.9.6462			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692450	hybrid			2022-12-27	WOS:000085654400062
J	Monteil, A; Chemin, J; Bourinet, E; Mennessier, G; Lory, P; Nargeot, J				Monteil, A; Chemin, J; Bourinet, E; Mennessier, G; Lory, P; Nargeot, J			Molecular and functional properties of the human alpha(1G) subunit that forms T-type calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNELS; CURRENTS; CELLS; NEURONS; EXPRESSION; CONDUCTANCE; ACTIVATION; INHIBITION; DEPLETION; MYOCYTES	We describe here several novel properties of the human alpha(1G) subunit that forms T-type calcium channels. The partial intron/exon structure of the corresponding gene CACNA1G was defined and several alpha(1G) isoforms were identified, especially two isoforms that exhibit a distinct III-IV loop: alpha(1G-a) and alpha(1G-b). Northern blot and dot blot analyses indicated that alpha(1G) mRNA is predominantly expressed in the brain, especially in thalamus, cerebellum, and substantia nigra. Additional experiments have also provided evidence that alpha(1G) mRNA is expressed at a higher level during fetal life in nonneuronal tissues (ie. kidney, heart, and lung). Functional expression in HEK 293 cells of a fall-length cDNA encoding the shortest a,, isoform identified to date, alpha(1G-b), resulted in transient, low threshold activated Ca2+ currents with the expected permeability ratio (I-Sr > I-Ca greater than or equal to I-Ba) and channel conductance (similar to 7 pS). These properties, together with slowly deactivating tail currents, are typical of those of native T-type Ca2+ channels, This alpha(1G)-related current was inhibited by mibefradil (IC50 = 2 mu M) and weakly blocked by Ni2+ ions (IC50 = 148 mu M) and amiloride (IC50 > 1 mM). We showed that steady state activation and inactivation properties of this current fan generate a "window current" in the range of -65 to -55 mV. Using neuronal action potential waveforms, we show that alpha(1G) channels produce a massive and sustained Ca2+ influx due to their slow deactivation properties. These latter properties would account for the specificity of Ca2+ influx via T-type channels that occurs in the range of physiological resting membrane potentials, differing considerably from the behavior of other Ca2+ channels.	IGH, CNRS, UPR 1142, F-34396 Montpellier 05, France; Univ Montpellier 2, CNRS, UMR 5825, F-34095 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Lory, P (corresponding author), IGH, CNRS, UPR 1142, 141 Rue Cardonille, F-34396 Montpellier 05, France.		Monteil, Arnaud/G-3113-2012	Monteil, Arnaud/0000-0003-1632-7318; LORY, philippe/0000-0002-1638-7604; chemin, jean/0000-0002-6089-5964; Nargeot, Joel/0000-0003-2893-5636; bourinet, emmanuel/0000-0001-8021-0419				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arnoult C, 1996, P NATL ACAD SCI USA, V93, P13004, DOI 10.1073/pnas.93.23.13004; Bean BP, 1998, NEURON, V20, P825, DOI 10.1016/S0896-6273(00)80463-8; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; Bourinet E, 1996, J NEUROSCI, V16, P4983; Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; COULTER DA, 1989, J PHYSIOL-LONDON, V414, P587, DOI 10.1113/jphysiol.1989.sp017705; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; Day ML, 1998, PFLUG ARCH EUR J PHY, V436, P834, DOI 10.1007/s004240050712; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; GU X, 1993, J NEUROSCI, V13, P4936; Guo W, 1998, J MOL CELL CARDIOL, V30, P1095, DOI 10.1006/jmcc.1998.0675; HAGIWARA N, 1988, J PHYSIOL-LONDON, V395, P233, DOI 10.1113/jphysiol.1988.sp016916; Huguenard JR, 1998, TRENDS NEUROSCI, V21, P451, DOI 10.1016/S0166-2236(98)01331-9; Huguenard JR, 1996, ANNU REV PHYSIOL, V58, P329, DOI 10.1146/annurev.physiol.58.1.329; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; Klugbauer N, 1999, PFLUG ARCH EUR J PHY, V437, P710, DOI 10.1007/s004240050836; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kuga T, 1996, CIRC RES, V79, P14, DOI 10.1161/01.RES.79.1.14; Lambert RC, 1997, J NEUROSCI, V17, P6621; Lee JH, 1999, BIOPHYS J, V76, pA408; Lee JH, 1999, J NEUROSCI, V19, P1912; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Leuranguer V, 1998, NEUROPHARMACOLOGY, V37, P701, DOI 10.1016/S0028-3908(98)00060-4; Martinez JM, 1996, GENOME RES, V6, P58, DOI 10.1101/gr.6.1.58; MCCOBB DP, 1991, NEURON, V7, P119, DOI 10.1016/0896-6273(91)90080-J; MILLER A, 1995, J NEUROPHYSIOL, V73, P2349, DOI 10.1152/jn.1995.73.6.2349; MISHRA SK, 1994, CIRC RES, V75, P144, DOI 10.1161/01.RES.75.1.144; Mouginot D, 1997, J NEUROSCI, V17, P160, DOI 10.1523/JNEUROSCI.17-01-00160.1997; NUSS HB, 1993, CIRC RES, V73, P777, DOI 10.1161/01.RES.73.4.777; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Randall AD, 1997, NEUROPHARMACOLOGY, V36, P879, DOI 10.1016/S0028-3908(97)00086-5; ROHWEDEL J, 1994, DEV BIOL, V164, P87, DOI 10.1006/dbio.1994.1182; Rossier MF, 1996, ENDOCRINOLOGY, V137, P4817, DOI 10.1210/en.137.11.4817; SELF DA, 1994, J VASC RES, V31, P359, DOI 10.1159/000159064; Serrano JR, 1999, J GEN PHYSIOL, V114, P185, DOI 10.1085/jgp.114.2.185; SWANDULLA D, 1988, J GEN PHYSIOL, V92, P197, DOI 10.1085/jgp.92.2.197; Talley EM, 1999, J NEUROSCI, V19, P1895; Tegner J, 1999, J NEUROPHYSIOL, V81, P1318, DOI 10.1152/jn.1999.81.3.1318; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toyota M, 1999, CANCER RES, V59, P4535; TSAKIRIDOU E, 1995, J NEUROSCI, V15, P3110, DOI 10.1523/jneurosci.15-04-03110.1995; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; WANG Z, 1993, AM J PHYSIOL, V265, pC1239, DOI 10.1152/ajpcell.1993.265.5.C1239; Williams ME, 1999, J NEUROCHEM, V72, P791, DOI 10.1046/j.1471-4159.1999.0720791.x; XU XP, 1992, J PHYSIOL-LONDON, V454, P657, DOI 10.1113/jphysiol.1992.sp019285; XU Y, 1994, ISMB, V2, P376; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zamponi GW, 1996, J MEMBRANE BIOL, V151, P77, DOI 10.1007/s002329900059; ZHOU ZF, 1994, J MOL CELL CARDIOL, V26, P1211, DOI 10.1006/jmcc.1994.1139	54	192	205	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	2000	275	9					6090	6100		10.1074/jbc.275.9.6090	http://dx.doi.org/10.1074/jbc.275.9.6090			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	290AP	10692398	hybrid			2022-12-27	WOS:000085654400010
J	Arnold, JJ; Cameron, CE				Arnold, JJ; Cameron, CE			Poliovirus RNA-dependent RNA polymerase (3D(pol)) - Assembly of stable, elongation-competent complexes by using a symmetrical primer-template substrate (sym/sub)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS REVERSE-TRANSCRIPTASE; DNA-POLYMERASE; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; KINETIC-ANALYSIS; STEADY-STATE; NONNUCLEOSIDE INHIBITORS; NUCLEOTIDE INCORPORATION; KLENOW FRAGMENT; MECHANISM	Detailed studies of the kinetics and mechanism of nucleotide incorporation catalyzed by the RNA-dependent RNA polymerase from poliovirus, 3D(pol), have been Limited by the inability to assemble elongation complexes that permit activity to be monitored by extension of end-labeled primers. We have solved this problem by employing a short, symmetrical, heteropolymeric RNA primer-template that we refer to as "sym/sub." Formation of 3D(pol)-sym/sub complexes is slow owing to a slow rate of association (0.1 mu M-1 s(-1)) of 3D(pol) and sym/sub and a slow isomerization (0.076 s(-1)) of the 3D(pol)-sym/sub complex that is a prerequisite for catalytic competence of this complex. Complex assembly is stoichiometric under conditions in which competing reactions, such as enzyme inactivation, are eliminated. Inactivation of 3D(pol) occurs at a maximal rate of 0.051 s(-1) at 22 degrees C in reaction buffer lacking nucleotide. At this temperature, ATP protects 3D(pol) against inactivation with a K-0.5 of 37 mu M. Once formed, 3D(pol)-sym/sub elongation complexes are stable (t(1/2) = 2 h at 22 degrees C) and appear to contain only a single polymerase monomer, In the presence of Mg2+, AMP, 2'-dAMP, and 3'-dAMP are incorporated into sym/sub by 3D(pol) at rates of 72, 0.6, and 1 s(-1), respectively. After incorporation of AMP, 3D(pol)-sym/sub product complexes have a half-life of 8 h at 22 degrees C. The stability of 3D(pol)-sym/sub complexes is temperature-dependent. At 30 degrees C, there is a 2-8-fold decrease in complex stability. Complex dissociation is the rate-limiting step for primer utilization. 3D(pol) dissociates from the end of template at a rate 10-fold faster than from internal positions. The sym/sub system will facilitate mechanistic analysis of 3D(pol) and permit a direct kinetic and thermodynamic comparison of the RNA-dependent RNA polymerase to the other classes of nucleic acid polymerases.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Cameron, CE (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	cec9@psu.edu			NCI NIH HHS [CA75118] Funding Source: Medline; NIAID NIH HHS [AI45818] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA075118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045818] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arnold JJ, 1999, J BIOL CHEM, V274, P2706, DOI 10.1074/jbc.274.5.2706; Arnold JJ, 1999, J BIOL CHEM, V274, P37060, DOI 10.1074/jbc.274.52.37060; Astatke M, 1998, P NATL ACAD SCI USA, V95, P3402, DOI 10.1073/pnas.95.7.3402; Beckman MTL, 1998, J BIOL CHEM, V273, P6724, DOI 10.1074/jbc.273.12.6724; Benkovic SJ, 1995, METHOD ENZYMOL, V262, P257; Bolten R, 1998, J VIROL, V72, P8578, DOI 10.1128/JVI.72.11.8578-8585.1998; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; Carroll SS, 1996, METHOD ENZYMOL, V275, P365; DECLERCQ E, 1994, ANN NY ACAD SCI, V724, P438; DIAMOND SE, 1994, J VIROL, V68, P863, DOI 10.1128/JVI.68.2.863-876.1994; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; ELION GB, 1983, J ANTIMICROB CHEMOTH, V12, P9, DOI 10.1093/jac/12.suppl_B.9; ENSOUF R, 1995, NAT STRUCT BIOL, V2, P303; FENG JY, 1909, BIOCHEMISTRUY, V5, P55; Gohara DW, 1999, PROTEIN EXPRES PURIF, V17, P128, DOI 10.1006/prep.1999.1100; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Huang Y, 1997, BIOCHEMISTRY-US, V36, P8231, DOI 10.1021/bi962674l; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14064, DOI 10.1021/bi9713862; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOONIN EV, 1991, J GEN VIROL, V72, P2197, DOI 10.1099/0022-1317-72-9-2197; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; REARDON JE, 1993, J BIOL CHEM, V268, P8743; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; RICHARDS OC, 1992, J BIOL CHEM, V267, P17141; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; RUECKERT RR, 1996, FIELDS VIROLOGY, V1, P609; Serra MJ, 1995, METHOD ENZYMOL, V259, P242; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; Spence RA, 1996, BIOCHEMISTRY-US, V35, P1054, DOI 10.1021/bi952058+; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; ZINNEN S, 1994, J BIOL CHEM, V269, P24195	44	114	116	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5329	5336		10.1074/jbc.275.8.5329	http://dx.doi.org/10.1074/jbc.275.8.5329			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681506	hybrid			2022-12-27	WOS:000085474500013
J	Gong, CX; Lidsky, T; Wegiel, J; Zuck, L; Grundke-Iqbal, I; Iqbal, K				Gong, CX; Lidsky, T; Wegiel, J; Zuck, L; Grundke-Iqbal, I; Iqbal, K			Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain - Implications for neurofibrillary degeneration in Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; RABBIT-SKELETAL-MUSCLE; ABNORMAL PHOSPHORYLATION; OKADAIC ACID; MAP KINASE; BIOLOGICAL-ACTIVITY; CELL-CYCLE; RAT-BRAIN; FETAL-TAU; DEPHOSPHORYLATION	Hyperphosphorylated tau, which is the major protein of the neurofibrillary tangles in Alzheimer's disease brain, is most probably the result of an imbalance of tau kinase and phosphatase activities in the affected neurons. By using metabolically competent rat brain slices as a model, we found that selective inhibition of protein phosphatase 2A by okadaic acid induced an Alzheimer-like hyperphosphorylation and accumulation of tau, The hyperphosphorylated tau had a reduced ability to bind to microtubules and to promote microtubule assembly in vitro. Immunocytochemical staining revealed hyperphosphorylated tau accumulation in pyramidal neurons in cornu ammonis and in neocortical neurons, The topography of these changes recalls the distribution of neurofibrillary tangles in Alzheimer's disease brain. Selective inhibition of protein phosphatase 2B with cyclosporin A did not have any significant effect on tan phosphorylation, accumulation, or function. These studies suggest that protein phosphatase 2A participates in regulation of tau phosphorylation, processing, and function in vivo. A down-regulation of protein phosphatase 2A activity can lead to Alzheimer-like abnormal hyperphosphorylation of tau.	New York State Inst Basic Res Dev Disabil, Staten Isl, NY 10314 USA	Institute for Basic Research in Developmental Disabilities	Iqbal, K (corresponding author), New York State Inst Basic Res Dev Disabil, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	kiqbal@mail.con2.com			NIA NIH HHS [AG05892, AG08076, AG14875] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R03AG014875, R01AG005892, R01AG008076] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AITKEN A, 1982, EUR J BIOCHEM, V126, P235, DOI 10.1111/j.1432-1033.1982.tb06771.x; Alger B.E., 1984, BRAIN SLICES, P381; Alonso AD, 1997, P NATL ACAD SCI USA, V94, P298, DOI 10.1073/pnas.94.1.298; Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Blanquet PR, 1998, NEUROSCIENCE, V86, P739, DOI 10.1016/S0306-4522(98)00087-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARDENAS AM, 1995, BBA-BIOMEMBRANES, V1234, P255, DOI 10.1016/0005-2736(94)00283-U; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COHEN P, 1973, EUR J BIOCHEM, V34, P1, DOI 10.1111/j.1432-1033.1973.tb02721.x; COHEN P, 1988, METHOD ENZYMOL, V159, P427; DREWES G, 1993, FEBS LETT, V336, P425, DOI 10.1016/0014-5793(93)80850-T; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; EASOM RA, 1988, BIOCHEM J, V329, P283; GARVER TD, 1995, MOL PHARMACOL, V47, P745; GOEDERT M, 1995, J NEUROCHEM, V65, P2804; Goedert M, 1997, FEBS LETT, V409, P57, DOI 10.1016/S0014-5793(97)00483-3; GOEDERT M, 1992, FEBS LETT, V312, P95, DOI 10.1016/0014-5793(92)81418-L; GONG CX, 1994, NEUROSCIENCE, V61, P765, DOI 10.1016/0306-4522(94)90400-6; GONG CX, 1995, J NEUROCHEM, V65, P732, DOI 10.1046/j.1471-4159.1995.65020732.x; Gong CX, 1996, BRAIN RES, V741, P95, DOI 10.1016/S0006-8993(96)00904-3; GONG CX, 1994, FEBS LETT, V341, P94, DOI 10.1016/0014-5793(94)80247-5; GONG CX, 1994, J NEUROCHEM, V62, P803; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; GRUNDKEIQBAL I, 1988, MOL BRAIN RES, V4, P43, DOI 10.1016/0169-328X(88)90017-4; HALPAIN S, 1995, NEUROPROTOCOLS COMPA, P46; HARRIS KA, 1993, ANN NEUROL, V33, P77, DOI 10.1002/ana.410330113; HASEGAWA M, 1993, J NEUROCHEM, V60, P2068, DOI 10.1111/j.1471-4159.1993.tb03491.x; HYMAN BT, 1984, SCIENCE, V225, P1168, DOI 10.1126/science.6474172; Iqbal K, 1998, J NEURAL TRANSM-SUPP, P169; IQBAL K, 1989, P NATL ACAD SCI USA, V86, P5646, DOI 10.1073/pnas.86.14.5646; IQBAL K, 1994, FEBS LETT, V349, P104, DOI 10.1016/0014-5793(94)00650-4; ISHIGURO K, 1993, FEBS LETT, V325, P167, DOI 10.1016/0014-5793(93)81066-9; Jicha GA, 1999, J NEUROSCI, V19, P7486, DOI 10.1523/JNEUROSCI.19-17-07486.1999; Kayyali US, 1997, J NEUROCHEM, V68, P1668; KOPKE E, 1993, J BIOL CHEM, V268, P24374; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Liao H, 1998, J BIOL CHEM, V273, P21901, DOI 10.1074/jbc.273.34.21901; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LIPTON P, 1995, J NEUROSCI METH, V59, P151, DOI 10.1016/0165-0270(94)00205-U; LIU WK, 1993, J NEUROSCI RES, V34, P371, DOI 10.1002/jnr.490340315; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; MalchiodiAlbedi F, 1997, J NEUROSCI RES, V48, P425, DOI 10.1002/(SICI)1097-4547(19970601)48:5<425::AID-JNR4>3.0.CO;2-G; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; MAWALDEWAN M, 1994, J BIOL CHEM, V269, P30981; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Merrick SE, 1996, J BIOL CHEM, V271, P5589, DOI 10.1074/jbc.271.10.5589; MORISHIMAKAWASHIMA M, 1995, NEUROBIOL AGING, V16, P379, DOI 10.1016/0197-4580(95)00032-A; Namboodiripad AN, 1996, AM J PHYSIOL-CELL PH, V270, pC449, DOI 10.1152/ajpcell.1996.270.2.C449; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; PEI JJ, 1994, BRAIN RES, V655, P70, DOI 10.1016/0006-8993(94)91598-9; SAITO T, 1995, FEBS LETT, V376, P238, DOI 10.1016/0014-5793(95)01292-0; SCHONTHAL A, 1992, NEW BIOL, V4, P16; Sengupta A, 1998, ARCH BIOCHEM BIOPHYS, V357, P299, DOI 10.1006/abbi.1998.0813; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SINGH TJ, 1995, J NEUROCHEM, V64, P1420; Sironi JJ, 1998, FEBS LETT, V436, P471, DOI 10.1016/S0014-5793(98)01185-5; SLOBODA RD, 1979, BIOCHEMISTRY-US, V18, P48, DOI 10.1021/bi00568a008; Sontag E, 1999, J BIOL CHEM, V274, P25490, DOI 10.1074/jbc.274.36.25490; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; STANTON PK, 1984, J NEUROSCI, V4, P3080; Tanaka T, 1998, FEBS LETT, V426, P248, DOI 10.1016/S0014-5793(98)00346-9; TANAKA T, 1993, METHOD FIND EXP CLIN, V15, P77; VULLIET R, 1992, J BIOL CHEM, V267, P22570; WANG JZ, 1995, J BIOL CHEM, V270, P4854, DOI 10.1074/jbc.270.9.4854; Wang JZ, 1996, MOL BRAIN RES, V38, P200, DOI 10.1016/0169-328X(95)00316-K; Xie HQ, 1998, BRAIN RES, V798, P173, DOI 10.1016/S0006-8993(98)00407-7; YAMAMOTO H, 1995, J BIOCHEM-TOKYO, V118, P1224, DOI 10.1093/oxfordjournals.jbchem.a125011	78	367	405	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5535	5544		10.1074/jbc.275.8.5535	http://dx.doi.org/10.1074/jbc.275.8.5535			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681533	hybrid			2022-12-27	WOS:000085474500040
J	Olivier, C; Auguste, P; Chabbert, M; Lelievre, E; Chevalier, S; Gascan, H				Olivier, C; Auguste, P; Chabbert, M; Lelievre, E; Chevalier, S; Gascan, H			Identification of a gp130 cytokine receptor critical site involved in oncostatin M response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-INHIBITORY FACTOR; COLONY-STIMULATING FACTOR; CILIARY NEUROTROPHIC FACTOR; IL-6 SIGNAL TRANSDUCER; HIGH-AFFINITY BINDING; SEVERE COMBINED IMMUNODEFICIENCY; COMMON BETA-CHAIN; MOLECULAR-CLONING; LIGAND-BINDING; MONOCLONAL-ANTIBODIES	Gp130 cytokine receptor is involved in the formation of multimeric functional receptors for interleukin-6 (IL-6), IL-11, leukemia inhibitory factor (LIF), oncostatin Rf (OSM), ciliary neurotrophic factor, and cardiotrophin-1. Cloning of the epitope recognized by an OSM-neutralizing anti-gp130 monoclonal antibody identified a portion of gp130 receptor localized in the EF loop of the cytokine binding domain. Site-directed mutagenesis of the corresponding region was carried out by alanine substitution of residues 186-198. To generate type 1 or type 2 OSM receptors, gp130 mutants were expressed together with either LIF receptor beta or OSM receptor beta. When positions Val-189/Tyr-190 and Phe-191/Val-192 were alanine-substituted, Scatchard analyses indicated a complete abrogation of OSM binding to both type receptors. Interestingly, binding of LIF to type 1 receptor was not affected, corroborating the notion that in this case gp130 mostly behaves as a converter protein rather than a binding receptor. The present study demonstrates that positions 189-192 of gp130 cytokine binding domain are essential for OSM binding to both gp130/LIF receptor beta and gp130/OSM receptor beta heterocomplexes.	CHU Angers, INSERM E 9928, F-49033 Angers, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers	Gascan, H (corresponding author), CHU Angers, INSERM 9928, 4 Rue Larrey, F-49033 Angers, France.		Chabbert, Marie/K-1245-2015; Lelievre, Eric/M-2878-2015; OLIVIER, Christophe/L-1598-2015	lelievre, eric/0000-0002-4132-4023; Auguste, Patrick/0000-0003-1485-0295				Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; Bagley CJ, 1997, BLOOD, V89, P1471, DOI 10.1182/blood.V89.5.1471.1471_1471_1482; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Bravo J, 1998, EMBO J, V17, P1665, DOI 10.1093/emboj/17.6.1665; Chevalier S, 1996, J BIOL CHEM, V271, P14764, DOI 10.1074/jbc.271.25.14764; Chevalier S, 1995, ANN NY ACAD SCI, V762, P482; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CORNELIS S, 1995, EMBO J, V14, P3395, DOI 10.1002/j.1460-2075.1995.tb07345.x; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; Hammacher A, 1998, J BIOL CHEM, V273, P22701, DOI 10.1074/jbc.273.35.22701; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HOESS RH, 1994, J IMMUNOL, V153, P722; Horsten U, 1997, J BIOL CHEM, V272, P23748, DOI 10.1074/jbc.272.38.23748; IMLER JL, 1992, EMBO J, V11, P2047, DOI 10.1002/j.1460-2075.1992.tb05262.x; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; ISHII N, 1994, J IMMUNOL, V153, P1310; Kalai M, 1997, BLOOD, V89, P1319, DOI 10.1182/blood.V89.4.1319; Kernebeck T, 1999, PROTEIN SCI, V8, P5; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kurth I, 1999, J IMMUNOL, V162, P1480; LADNER C, 1995, TRENDS BIOTECHNOL, V13, P426; Layton JE, 1997, J BIOL CHEM, V272, P29735, DOI 10.1074/jbc.272.47.29735; LEARY AG, 1990, BLOOD, V75, P1960; Leonard WJ, 1996, ANNU REV MED, V47, P229; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Middleton SA, 1996, J BIOL CHEM, V271, P14045, DOI 10.1074/jbc.271.24.14045; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; Owczarek CM, 1997, J BIOL CHEM, V272, P23976, DOI 10.1074/jbc.272.38.23976; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; Raskin N, 1998, J IMMUNOL, V161, P3474; Robledo O, 1996, J NEUROCHEM, V66, P1391; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; THOMA B, 1994, J BIOL CHEM, V269, P6215; WANG HM, 1992, J BIOL CHEM, V267, P979; WARE CB, 1995, DEVELOPMENT, V121, P1283; Wijdenes J, 1995, EUR J IMMUNOL, V25, P3474, DOI 10.1002/eji.1830251240; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; Woodcock JM, 1996, J BIOL CHEM, V271, P25999, DOI 10.1074/jbc.271.42.25999; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; Yamasaki K, 1997, NAT STRUCT BIOL, V4, P498, DOI 10.1038/nsb0697-498; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YIN TG, 1993, J IMMUNOL, V151, P2555	63	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5648	5656		10.1074/jbc.275.8.5648	http://dx.doi.org/10.1074/jbc.275.8.5648			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681548	hybrid			2022-12-27	WOS:000085474500055
J	Park, SG; Cha, MK; Jeong, W; Kim, IH				Park, SG; Cha, MK; Jeong, W; Kim, IH			Distinct physiological functions of thiol peroxidase isoenzymes in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL TYROSINE KINASE; MEMBRANE H+-ATPASE; PAG GENE-PRODUCT; ANTIOXIDANT PROTEIN; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; CONSERVED CYSTEINE; INDUCED ACTIVATION; ESCHERICHIA-COLI; YEAST	A new type of peroxidase ("thiol peroxidase"; TPx) having cysteine as the primary site of catalysis has been discovered from prokaryotes to eukaryotes. In addition to two yeast TPx isoforms (TSA I and TSA II/AHPC1) previously described, three additional TPx homologues were identified by analysis of the open reading frame data base for Saccharomyces cerevisiae, Three novel isoforms showed a distinct thiol peroxidase activity supported by thioredoxin, and appeared to be distinctively localized in cytoplasm, mitochondria, and nucleus. Each isoform was named after its subcellular localization such as cytoplasmic TPx I (cTPx I or TSA I), cTPx II, cTPx III (TSA II/AHPC1), mitochondrial TPx (mTPx), and nuclear TPx (nTPx). Their transcriptional activities suggest that cTPx I and cTPx III are the most predominant isoforms among the five type isoforms. Transcriptional activities of TPx isoenzymes during yeast Life span were quite different from each other. Unlike other TPx null mutants, cTPx I null mutant was hypersensitive to various oxidants except for 4-nitroquinoline N-oxide. The null mutant was more resistant toward 4-nitroquinoline N-oxide and acidic culture than its wild type. The severe growth retardation of cTPx II mutant resulted in accumulation of G(1)-phased cells. Based on kinetic properties of five isoforms, their subcellular localizations, and distinct physiology of each null mutant, we discussed the physiological functions of five types of TPx isoenzymes in yeast throughout the full growth cycle.	Paichai Univ, Dept Biochem, Nat Creat Res Initiat Ctr Antioxidant Prot, Seo Gu, Taejon 302735, South Korea	Pai Chai University	Kim, IH (corresponding author), Paichai Univ, Dept Biochem, Nat Creat Res Initiat Ctr Antioxidant Prot, Seo Gu, 439-6 Doma-2-Dong, Taejon 302735, South Korea.		Kim, Il-Han/W-1401-2019					BRANDAO RL, 1994, BBA-MOL CELL RES, V1223, P117, DOI 10.1016/0167-4889(94)90080-9; Cha MK, 1998, J BIOCHEM MOL BIOL, V31, P409; Cha MK, 1996, J BIOCHEM MOL BIOL, V29, P236; Cha MK, 1996, J BACTERIOL, V178, P5610, DOI 10.1128/jb.178.19.5610-5614.1996; CHA MK, 1995, J BIOL CHEM, V270, P28635, DOI 10.1074/jbc.270.48.28635; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Coleman ST, 1997, J BIOL CHEM, V272, P23224, DOI 10.1074/jbc.272.37.23224; DERISI JL, 1997, SCIENCE, V278, P880; ERASO P, 1987, FEBS LETT, V224, P187, DOI 10.1016/0014-5793(87)80445-3; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Guthrie C, 1991, METHODS ENZYMOL, V194; Halliwell B, 1989, PRODUCTION RADICAL D; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; KAIN SR, 1995, BIOTECHNIQUES, V19, P650; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM KW, 1988, J BIOL CHEM, V263, P4704; KWON SJ, 1994, BIOCHEM BIOPH RES CO, V201, P8, DOI 10.1006/bbrc.1994.1662; Lee J, 1999, J BIOL CHEM, V274, P4537, DOI 10.1074/jbc.274.8.4537; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; LIM YS, 1993, BIOCHEM BIOPH RES CO, V192, P273, DOI 10.1006/bbrc.1993.1410; LIM YS, 1994, GENE, V140, P279, DOI 10.1016/0378-1119(94)90558-4; LIM YS, 1994, BIOCHEM BIOPH RES CO, V199, P199, DOI 10.1006/bbrc.1994.1214; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; Miller J.H., 1972, EXPT MOL GENETICS; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Prosperi MT, 1998, FEBS LETT, V423, P39, DOI 10.1016/S0014-5793(98)00057-X; Sambrook J., 2002, MOL CLONING LAB MANU; Saran M, 1997, INT J RADIAT BIOL, V72, P745, DOI 10.1080/095530097142906; SCHERENS B, 1993, YEAST, V9, P1355, DOI 10.1002/yea.320091210; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SIGLER K, 1991, BIOCHEM INT, V23, P861; Singer MS, 1998, GENETICS, V150, P613; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; Wemmie JA, 1997, J BIOL CHEM, V272, P7908, DOI 10.1074/jbc.272.12.7908; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; WOLFF SP, 1994, METHOD ENZYMOL, V233, P182	43	190	207	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2000	275	8					5723	5732		10.1074/jbc.275.8.5723	http://dx.doi.org/10.1074/jbc.275.8.5723			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	286XQ	10681558	hybrid			2022-12-27	WOS:000085474500065
J	Hell, K; Tzagoloff, A; Neupert, W; Stuart, RA				Hell, K; Tzagoloff, A; Neupert, W; Stuart, RA			Identification of Cox20p, a novel protein involved in the maturation and assembly of cytochrome oxidase subunit 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL-MEMBRANE SYSTEM; SACCHAROMYCES-CEREVISIAE; C-OXIDASE; NUCLEAR GENE; INTERMEMBRANE SPACE; N-TERMINI; PET GENES; YEAST; EXPRESSION; CLONING	We have identified Cox20p, a 23.8-kDa protein of the mitochondrial inner membrane that is involved in the biogenesis of the yeast cytochrome oxidase complex. Cytochrome oxidase subunit 2 (Cox2p) accumulates as a precursor in cox20 mutants, suggesting a defect in bio genesis of this mitochondrially encoded protein. The inability of cox20 mutants to process the subunit 2 precursor (pCox2p) is not due to impaired export of the protein across the inner membrane or to an inactive Imp1p/Imp2p peptidase. Rather, Cox20p specifically binds the newly synthesized pCox2p, a step required to present the exported pCox2p as a substrate to the Imp1p peptidase, All of the endogenous pCox2p accumulated in an Delta imp1 mutant, and a small fraction of Cox2p in wild type yeast, is detected in a complex with Cox20p, Following maturation Cox2p remained associated with Cox20p, prior to assembling into the cytochrome oxidase complex. We propose that Cox20p acts as a membrane-bound chaperone necessary for cleavage of pCox2p and for interaction of the mature protein with other subunits of cytochrome oxidase in a later step of the assembly process.	Univ Munich, Inst Physiol Chem, D-80336 Munich, Germany; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	University of Munich; Columbia University	Stuart, RA (corresponding author), Marquette Univ, Dept Biol, Milwaukee, WI 53201 USA.	rosemary.stuart@marquette.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050187] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM050187, GM50187] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN SH, 1992, J BIOL CHEM, V267, P7386; Altamura N, 1996, FEBS LETT, V382, P111, DOI 10.1016/0014-5793(96)00165-2; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arnold I, 1998, J BIOL CHEM, V273, P1469, DOI 10.1074/jbc.273.3.1469; BAUER M, 1994, MOL GEN GENET, V245, P272, DOI 10.1007/BF00290106; BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; BISSON R, 1982, J BIOL CHEM, V257, P6716; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; CAPALDI RA, 1990, ARCH BIOCHEM BIOPHYS, V280, P252, DOI 10.1016/0003-9861(90)90327-U; Church C, 1996, J BIOL CHEM, V271, P18499, DOI 10.1074/jbc.271.31.18499; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; Douglas M, 1979, Methods Enzymol, V56, P58; Esser K, 1996, MOL GEN GENET, V252, P437, DOI 10.1007/s004380050248; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x; Glerum DM, 1997, J BIOL CHEM, V272, P19088, DOI 10.1074/jbc.272.30.19088; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; GLERUM DM, 1995, J BIOL CHEM, V270, P15585, DOI 10.1074/jbc.270.26.15585; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; GLICK BS, 1993, PROTEIN SCI, V2, P1901, DOI 10.1002/pro.5560021112; GRIVELL LA, 1995, CRIT REV BIOCHEM MOL, V30, P121, DOI 10.3109/10409239509085141; HAHNE K, 1994, CELL, V79, P829, DOI 10.1016/0092-8674(94)90072-8; Harlow E, 1988, ANTIBODIES LABORATOR, P521; He SC, 1997, MOL BIOL CELL, V8, P1449, DOI 10.1091/mbc.8.8.1449; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; HERRMANN JM, 1995, J BIOL CHEM, V270, P27079, DOI 10.1074/jbc.270.45.27079; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee CM, 1999, J BIOL CHEM, V274, P20937, DOI 10.1074/jbc.274.30.20937; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASON TL, 1973, J BIOL CHEM, V248, P1346; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MCEWEN JE, 1985, J BACTERIOL, V161, P831, DOI 10.1128/JB.161.3.831-835.1985; MCEWEN JE, 1993, CURR GENET, V23, P9, DOI 10.1007/BF00336742; Meyer W, 1997, BIOL CHEM, V378, P1373, DOI 10.1515/bchm.1997.378.11.1373; MURTIF VL, 1985, P NATL ACAD SCI USA, V82, P5617, DOI 10.1073/pnas.82.17.5617; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; Poyton Robert O., 1992, Trends in Cell Biology, V2, P369, DOI 10.1016/0962-8924(92)90049-S; PRATJE E, 1986, EMBO J, V5, P1313, DOI 10.1002/j.1460-2075.1986.tb04361.x; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; SEVARINO KA, 1980, P NATL ACAD SCI-BIOL, V77, P142, DOI 10.1073/pnas.77.1.142; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1986, J BIOL CHEM, V261, P7163; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; van Dyck L, 1998, GENE DEV, V12, P1515, DOI 10.1101/gad.12.10.1515; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x	58	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4571	4578		10.1074/jbc.275.7.4571	http://dx.doi.org/10.1074/jbc.275.7.4571			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671482	hybrid			2022-12-27	WOS:000085378200008
J	Angelo, RG; Rubin, CS				Angelo, RG; Rubin, CS			Characterization of structural features that mediate the tethering of Caenorhabditis elegans protein kinase A to a novel A kinase anchor protein - Insights into the anchoring of PKAI isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT RII; AFFINITY BINDING-PROTEIN; A-KINASE; II-BETA; MOLECULAR CHARACTERIZATION; CA2+ CHANNELS; C-ELEGANS; EXPRESSION; CLONING; CELLS	Caenorhabditis elegans protein kinase A (PKAI(CE)) is tethered to organelles in vivo. A unique A kinase anchor protein (AKAP(CE)) avidly binds the RI-like regulatory subunits (R-CE) of PKAI(CE) and stringently discriminates against RII alpha and RII beta subunits, the preferred ligands for classical AKAPs, We elucidated structural features that stabilize AKAP(CE).R-CE complexes and confer atypical R isoform specificity on the anchor protein. Three large aliphatic amino acids (Leu(236), Ile(248), and Leu(252)) in the tethering domain of AKAP(CE) (residues 236-255) are crucial for ligation of R-CE. Their side chains apparently generate a precisely configured hydrophobic binding pocket that accommodates an apolar surface on RCE dimers, Basic residues (His(254)-Arg(255)-Lys(256)) at the C terminus of the tethering site set an upper limit on affinity for R-CE. A central dipeptide (phe(243)-Ser(244)) contributes critical and distinctive properties of the tethering site. Ser(244) is essential for selective binding of R-CE and exclusion of RII isoforms, The aromatic hydrophobic character of phe(243) ensures maximal R-CE binding activity, thereby supporting a "gatekeeper" function of Ser(244). Substitution of phe(243)-Ser(244) With Leu-Val generated an RII-specific AKAP. R-CE and RII subunits contain similar dimerization domains. AKAP-binding domains of R-CE (residues 23-47) and RII differ markedly in size, amino acid sequence, and docking specificity. Four hydrophobic residues (Cys(23), Val(27), Ile(32), and Cys(44)) in R-CE are crucial for avid binding with AKAP(CE), whereas side chains from Leu(20), Leu(35), Val(36), Ile(40), and Ile(41) have little impact on complex formation. Tyr(26) is embedded in the docking domain, but its aromatic ring is required for R-CE-R-CE dimerization. Residues 236-255 in AKAP(CE) also constitute a binding site for mammalian RI alpha. RI alpha (PKAI alpha) is tightly sequestered by AKAP(CE) in vitro (K-D = similar to 10 10 nM) and in the environment of intact cells. The tethering domain of AKAP(CE) provides a molecular module for manipulating intracellular localization of RI and elucidating functions of anchored PKAI in eukaryotes.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Atran Labs, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Rubin, CS (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Atran Labs, 1300 Morris Pk Ave,F-229, Bronx, NY 10461 USA.				NIGMS NIH HHS [GM07620, GM57660] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057660] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angelo R, 1998, J BIOL CHEM, V273, P14633, DOI 10.1074/jbc.273.23.14633; Banky P, 1998, J BIOL CHEM, V273, P35048, DOI 10.1074/jbc.273.52.35048; BEEBE SJ, 1994, SEMIN CANCER BIOL, V5, P285; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BUBIS J, 1987, J BIOL CHEM, V262, P14961; Burton KA, 1997, P NATL ACAD SCI USA, V94, P11067, DOI 10.1073/pnas.94.20.11067; CARR DW, 1991, J BIOL CHEM, V266, P14188; CARRERA A, 1994, DEV BIOL, V165, P272, DOI 10.1006/dbio.1994.1252; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; DURGERIAN S, 1989, J BIOL CHEM, V264, P9807; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Feliciello A, 1996, J BIOL CHEM, V271, P25350, DOI 10.1074/jbc.271.41.25350; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; Gray PC, 1998, CURR OPIN NEUROBIOL, V8, P330, DOI 10.1016/S0959-4388(98)80057-3; GROSS RE, 1990, J BIOL CHEM, V265, P6896; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Han JD, 1997, J BIOL CHEM, V272, P26611, DOI 10.1074/jbc.272.42.26611; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hausken ZE, 1996, J BIOL CHEM, V271, P29016, DOI 10.1074/jbc.271.46.29016; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HOFMANN F, 1977, J BIOL CHEM, V252, P1441; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; Huang LJS, 1999, J CELL BIOL, V145, P951, DOI 10.1083/jcb.145.5.951; ImaizumiScherrer T, 1996, J CELL BIOL, V134, P1241, DOI 10.1083/jcb.134.5.1241; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; LAND M, 1994, J BIOL CHEM, V269, P9234; Leon DA, 1997, J BIOL CHEM, V272, P28431, DOI 10.1074/jbc.272.45.28431; Lester LB, 1997, P NATL ACAD SCI USA, V94, P14942, DOI 10.1073/pnas.94.26.14942; Lester LB, 1996, J BIOL CHEM, V271, P9460, DOI 10.1074/jbc.271.16.9460; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; Li Z, 1999, J BIOL CHEM, V274, P27191, DOI 10.1074/jbc.274.38.27191; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; LU XY, 1990, J BIOL CHEM, V265, P3293; Miki E, 1998, J BIOL CHEM, V273, P34384, DOI 10.1074/jbc.273.51.34384; Miki K, 1999, J BIOL CHEM, V274, P29057, DOI 10.1074/jbc.274.41.29057; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Moos J, 1998, MOL REPROD DEV, V50, P79, DOI 10.1002/(SICI)1098-2795(199805)50:1&lt;79::AID-MRD10&gt;3.0.CO;2-T; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; Rossi EA, 1999, J BIOL CHEM, V274, P27201, DOI 10.1074/jbc.274.38.27201; RUBIN CS, 1973, P NATL ACAD SCI USA, V70, P3735, DOI 10.1073/pnas.70.12.3735; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; Sternberg PW, 1998, TRENDS GENET, V14, P466, DOI 10.1016/S0168-9525(98)01592-3; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Witczak O, 1999, EMBO J, V18, P1858, DOI 10.1093/emboj/18.7.1858	58	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4351	4362		10.1074/jbc.275.6.4351	http://dx.doi.org/10.1074/jbc.275.6.4351			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660605	hybrid			2022-12-27	WOS:000085288800089
J	Brenneisen, P; Wenk, J; Wlaschek, M; Krieg, T; Scharffetter-Kochanek, K				Brenneisen, P; Wenk, J; Wlaschek, M; Krieg, T; Scharffetter-Kochanek, K			Activation of p70 ribosomal protein S6 kinase is an essential step in the DNA damage-dependent signaling pathway responsible for the ultraviolet B-mediated increase in interstitial collagenase (MMP-1) and stromelysin-1 (MMP-3) protein levels in human dermal fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; SKIN IN-VIVO; GROWTH-FACTOR; MATRIX-METALLOPROTEINASES; ATAXIA-TELANGIECTASIA; GEL-ELECTROPHORESIS; PYRIMIDINE DIMERS; RADICAL FORMATION; OZONE DEPLETION; GENE-EXPRESSION	Ultraviolet B (UVB) irradiation has been shown to stimulate the expression of matrix-degrading metalloproteinases via generation of DNA damage and/or reactive oxygen species. Matrix-degrading metalloproteinases promote UVB-triggered detrimental long term effects like cancer formation and premature skin aging. Here, we were interested in identifying components of the signal transduction pathway that causally link UVB-mediated DNA damage and induction of matrix-degrading metalloproteinase (MMP)-1/interstitial collagenase and MMP-3/stromelysin-1 in human dermal fibroblasts in vitro. The activity of p70 ribosomal S6 kinase, a downstream target of the FK506-binding protein- 12/rapamycin-associated protein kinase (FRAP) kinase (RAFT1, mTOR), was identified to be 4.8 +/- 0.8-fold, and MMP-1 and MMP-3 protein levels 2.4- and 11.5-fold increased upon UVB irradiation compared with mock-irradiated controls, The FRAP kinase inhibitor rapamycin and the DNA repair inhibitor aphidicolin significantly suppressed the UVB-mediated increase in p70 ribosomal S6 kinase activity by 50-65% and MMP-1 and MMP-3 protein levels by 34-68% and 42-88% compared with UVB-irradiated fibroblasts, By contrast, the interleukin-1 beta-mediated increase in MMP-1 and MMP-3 protein levels could not be suppressed by rapamycin, Collectively, our data suggest that the FRAP-controlled p70 ribosomal S6 kinase is an essential component of a DNA damage-dependent, but not of the interleukin-1/cell membrane receptor-dependent signaling.	Univ Cologne, Dept Dermatol, D-50924 Cologne, Germany	University of Cologne	Scharffetter-Kochanek, K (corresponding author), Univ Cologne, Dept Dermatol, Joseph Stelzmann Str 9, D-50924 Cologne, Germany.	karin.scharffetter@uni-koeln.de		Scharffetter-Kochanek, Karin/0000-0002-9655-685X				Aho S, 1997, EUR J BIOCHEM, V247, P503, DOI 10.1111/j.1432-1033.1997.00503.x; Ahrens C, 1997, P NATL ACAD SCI USA, V94, P6837, DOI 10.1073/pnas.94.13.6837; ALTMEYER A, 1993, CYTOKINE, V5, P133, DOI 10.1016/1043-4666(93)90052-7; Anderson R.R., 1993, CLIN PHOTOMEDICINE, P19; ANGEL P, 1985, J CELL BIOCHEM, V29, P351, DOI 10.1002/jcb.240290408; Averbeck D, 1998, PHOTOCHEM PHOTOBIOL, V68, P289, DOI 10.1111/j.1751-1097.1998.tb09683.x; BAYREUTHER K, 1992, ARCH GERONTOL GERIAT, P47, DOI 10.1016/S0167-4943(05)80006-8; Blattner C, 1998, ONCOGENE, V16, P2827, DOI 10.1038/sj.onc.1201827; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Brenneisen P, 1996, PHOTOCHEM PHOTOBIOL, V64, P649, DOI 10.1111/j.1751-1097.1996.tb03119.x; Brenneisen P, 1998, J BIOL CHEM, V273, P5279, DOI 10.1074/jbc.273.9.5279; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BRULS WAG, 1984, PHOTOCHEM PHOTOBIOL, V40, P485, DOI 10.1111/j.1751-1097.1984.tb04622.x; CERUTTI PA, 1994, LANCET, V344, P862, DOI 10.1016/S0140-6736(94)92832-0; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; CLINGEN PH, 1995, PHOTOCHEM PHOTOBIOL, V61, P163, DOI 10.1111/j.1751-1097.1995.tb03955.x; CONCA W, 1989, J CLIN INVEST, V83, P1753, DOI 10.1172/JCI114077; CRAWFORD HC, 1994, INVAS METAST, V14, P234; CRUTZEN PJ, 1992, NATURE, V356, P104, DOI 10.1038/356104a0; DARMIENTO J, 1995, MOL CELL BIOL, V15, P5732; DARR D, 1994, J INVEST DERMATOL, V102, P671, DOI 10.1111/1523-1747.ep12374036; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Drouin R, 1997, PHOTOCHEM PHOTOBIOL, V66, P719, DOI 10.1111/j.1751-1097.1997.tb03213.x; Dumont FJ, 1995, LIFE SCI, V58, P373, DOI 10.1016/0024-3205(95)02233-3; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; Fisher GJ, 1998, J CLIN INVEST, V101, P1432, DOI 10.1172/JCI2153; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Fisher GJ, 1997, NEW ENGL J MED, V337, P1419, DOI 10.1056/NEJM199711133372003; Fisher GJ, 1999, PHOTOCHEM PHOTOBIOL, V69, P154, DOI 10.1111/j.1751-1097.1999.tb03268.x; FLEISCHMAJER R, 1981, J INVEST DERMATOL, V76, P400, DOI 10.1111/1523-1747.ep12520933; FREEMAN SE, 1986, ANAL BIOCHEM, V158, P119, DOI 10.1016/0003-2697(86)90599-3; GILCHREST BA, 1989, J AM ACAD DERMATOL, V21, P610, DOI 10.1016/S0190-9622(89)70227-9; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; HANAWALT PC, 1991, MUTAT RES, V247, P203, DOI 10.1016/0027-5107(91)90016-H; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; Herrmann G, 1993, Exp Dermatol, V2, P92, DOI 10.1111/j.1600-0625.1993.tb00015.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hjertvik M, 1998, MUTAT RES-DNA REPAIR, V407, P87, DOI 10.1016/S0921-8777(97)00062-1; ITO K, 1992, BIOCHEMISTRY-US, V31, P11606, DOI 10.1021/bi00161a046; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; JURKIEWICZ BA, 1994, PHOTOCHEM PHOTOBIOL, V59, P1, DOI 10.1111/j.1751-1097.1994.tb04993.x; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; KEYSE SM, 1993, CANC BIOL, V4, P19; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Kleijn M, 1996, FEBS LETT, V396, P165, DOI 10.1016/0014-5793(96)01097-6; KOIVUKANGAS V, 1994, ACTA DERM-VENEREOL, V74, P279; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVIN MF, 1995, TRENDS BIOCHEM SCI, V20, P382, DOI 10.1016/S0968-0004(00)89083-0; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MAJMUDAR G, 1994, MOL CARCINOGEN, V9, P17, DOI 10.1002/mc.2940090105; MASAKI H, 1995, BIOCHEM BIOPH RES CO, V206, P474, DOI 10.1006/bbrc.1995.1067; MATSUNAGA T, 1993, PHOTOCHEM PHOTOBIOL, V57, P934, DOI 10.1111/j.1751-1097.1993.tb02952.x; Mount DW, 1996, NATURE, V383, P763, DOI 10.1038/383763a0; NOVAKHOFER I, 1984, J BIOL CHEM, V259, P5995; Perez S., 1995, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V189, P453; Petit-Frere C, 1998, J INVEST DERMATOL, V111, P354, DOI 10.1038/sj.jid.5602962; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; RYDBERG B, 1994, RADIAT RES, V139, P133, DOI 10.2307/3578657; Sawamura D, 1996, ARCH DERMATOL RES, V288, P628, DOI 10.1007/s004030050115; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; SIRUM KL, 1989, BIOCHEMISTRY-US, V28, P8691, DOI 10.1021/bi00448a004; Slaper H, 1996, NATURE, V384, P256, DOI 10.1038/384256a0; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEWART MJ, 1994, BIOESSAYS, V16, P809, DOI 10.1002/bies.950161107; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; SUTHERLAND JC, 1991, BIOTECHNIQUES, V10, P492; Tedesco AC, 1997, BRAZ J MED BIOL RES, V30, P561, DOI 10.1590/S0100-879X1997000500002; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; TERADA N, 1993, J BIOL CHEM, V268, P12062; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; Yarosh D, 1999, PHOTOCHEM PHOTOBIOL, V69, p44S; Yarosh Daniel B., 1998, Photochemistry and Photobiology, V67, p59S	84	84	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4336	4344		10.1074/jbc.275.6.4336	http://dx.doi.org/10.1074/jbc.275.6.4336			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660603	hybrid			2022-12-27	WOS:000085288800087
J	Saphire, ACS; Guan, TL; Schirmer, EC; Nemerow, GR; Gerace, L				Saphire, ACS; Guan, TL; Schirmer, EC; Nemerow, GR; Gerace, L			Nuclear import adenovirus DNA in vitro involves the nuclear protein import pathway and hsc70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN-70; PORE COMPLEX; TRANSPORT; CELLS; INHIBITION; RECEPTOR; RAN/TC4; REQUIRES; SIGNALS; ENTRY	Adenovirus, a respiratory virus with a double-stranded DNA genome, replicates in the nuclei of mammalian cells. We have developed a cytosol-dependent in vitro assay utilizing adenovirus nucleocapsids to examine the requirements for adenovirus docking to the nuclear pore complex and for DNA import into the nucleus. Our assay reveals that adenovirus DNA import is blocked by a competitive excess of classical protein nuclear localization sequences and other inhibitors of nuclear protein import and indicates that this process is dependent on hsc70, Previous work revealed that the hexon (coat) protein of adenovirus is the only major protein on the surface of the adenovirus nucleocapsid that docks at the nuclear pore complex. This, together with our finding that in vitro nuclear import of hexon is inhibited by an excess of classical nuclear localization sequences, suggests a role for the hexon protein in adenovirus DNA import. However, recombinant transport factors that are sufficient for hexon import in permeabilized cells do not support DNA import, indicating that there are other as yet unidentified factors required for this process.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Gerace, L (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd,IMM 10, La Jolla, CA 92037 USA.	lgerace@scripps.edu		Schirmer, Eric/0000-0003-2635-1338	NHLBI NIH HHS [HL54352] Funding Source: Medline; NIGMS NIH HHS [GM41955] Funding Source: Medline; PHS HHS [EI38948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041955] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; CEPKO CL, 1982, CELL, V31, P407, DOI 10.1016/0092-8674(82)90134-9; Clarkson WD, 1997, J MOL BIOL, V272, P716, DOI 10.1006/jmbi.1997.1255; DALES S, 1973, VIROLOGY, V56, P465, DOI 10.1016/0042-6822(73)90050-0; Dingwall C, 1998, METHOD CELL BIOL, V53, P517; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; GERACE L, 1992, Current Opinion in Cell Biology, V4, P637, DOI 10.1016/0955-0674(92)90083-O; Greber UF, 1997, EMBO J, V16, P5998, DOI 10.1093/emboj/16.19.5998; GREBER UF, 1993, CELL, V75, P477, DOI 10.1016/0092-8674(93)90382-Z; GUAN TL, 1995, MOL BIOL CELL, V6, P1591, DOI 10.1091/mbc.6.11.1591; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Kann M, 1997, J VIROL, V71, P1310, DOI 10.1128/JVI.71.2.1310-1316.1997; LANGERSAFER PR, 1982, P NATL ACAD SCI-BIOL, V79, P4381, DOI 10.1073/pnas.79.14.4381; LAVER WG, 1969, VIROLOGY, V39, P599, DOI 10.1016/0042-6822(69)90111-1; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NIEWIAROWSKA J, 1992, EXP CELL RES, V201, P408, DOI 10.1016/0014-4827(92)90290-O; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; ONEILL RE, 1995, J BIOL CHEM, V270, P22701, DOI 10.1074/jbc.270.39.22701; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; PATTERSON S, 1986, VACCINE, V4, P79, DOI 10.1016/0264-410X(86)90042-3; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; PUVIONDUTILLEUL F, 1995, MICROSC RES TECHNIQ, V31, P22, DOI 10.1002/jemt.1070310104; Robbins PD, 1998, TRENDS BIOTECHNOL, V16, P35, DOI 10.1016/S0167-7799(97)01137-2; Shenk Thomas, 1996, P979; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; STANDIFORD DM, 1992, J CELL BIOL, V118, P991, DOI 10.1083/jcb.118.5.991; STEWART PL, 1993, EMBO J, V12, P2589, DOI 10.1002/j.1460-2075.1993.tb05919.x; Sweet DJ, 1996, J CELL BIOL, V133, P971, DOI 10.1083/jcb.133.5.971; VANOOSTRUM J, 1985, J VIROL, V56, P439, DOI 10.1128/JVI.56.2.439-448.1985; WARIS M, 1987, J CHROMATOGR, V397, P321, DOI 10.1016/S0021-9673(01)85015-9; WICKHAM TJ, 1994, J CELL BIOL, V127, P257, DOI 10.1083/jcb.127.1.257; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; YAMADA M, 1993, J VIROL, V67, P119, DOI 10.1128/JVI.67.1.119-130.1993; YANG J, 1994, MOL CELL BIOL, V14, P5088, DOI 10.1128/MCB.14.8.5088; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	40	113	116	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4298	4304		10.1074/jbc.275.6.4298	http://dx.doi.org/10.1074/jbc.275.6.4298			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660598	hybrid			2022-12-27	WOS:000085288800082
